@prefix skos: . @prefix owl: . @prefix rdfs: . @prefix xsd: . @prefix umls: . a owl:Ontology ; rdfs:comment "RDF Version of the UMLS ontology PDQ; converted with the UMLS2RDF tool (https://github.com/ncbo/umls2rdf), developed by the NCBO project." ; rdfs:label "PDQ" ; owl:imports ; owl:versionInfo "2015AB" . a owl:Class ; skos:prefLabel """Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000038281"""^^xsd:string ; skos:altLabel """GLO-GM2-LE-MUC1-TF-TN-KLH"""@eng ; ; """10891"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935834"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GPI-0100/MUC-2-Globo H-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000038280"""^^xsd:string ; skos:altLabel """GPI 0100/MUC2-GLO H-KLH"""@eng ; ; ; """2003-12-01"""^^xsd:string ; """10890"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935833"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/PSA prostate cancer vaccine"""@eng ; skos:notation """CDR0000038283"""^^xsd:string ; skos:altLabel """IL-12/PSA VAC"""@eng ; ; ; """10893"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935836"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH conjugate vaccine/QS21"""@eng ; skos:notation """CDR0000038282"""^^xsd:string ; skos:altLabel """GLO-GM2-LE-MUC1-TF-TN-KLH/QS 21"""@eng ; ; ; """10892"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935835"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/dexamethasone/prednisolone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038285"""^^xsd:string ; skos:altLabel """ARA-C/DM/DNR/PRDL/TG/VCR"""@eng ; ; ; ; ; ; ; """10895"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935838"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/mercaptopurine/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000038284"""^^xsd:string ; skos:altLabel """CF/MP/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; """10894"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935837"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin/dexamethasone/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000038287"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DM/DNR/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; ; ; """10897"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935840"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/prednisolone/prednisone"""@eng ; skos:notation """CDR0000038286"""^^xsd:string ; skos:altLabel """MTX/PRDL/PRED"""@eng ; ; ; ; """10896"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935839"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valganciclovir"""@eng ; skos:notation """CDR0000038289"""^^xsd:string ; skos:altLabel """Valcyte"""@eng , """VGCV"""@eng ; skos:definition """A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38289&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38289&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2629\" NCI Thesaurus)"""@eng ; ; ; """10899"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2629"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0969586"""^^xsd:string ; umls:cui """C0909381"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/mercaptopurine/methotrexate/prednisolone"""@eng ; skos:notation """CDR0000038288"""^^xsd:string ; skos:altLabel """CF/MP/MTX/PRDL"""@eng ; ; ; ; ; """10898"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935841"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MART-1 antigen/Montanide ISA-51/recombinant interleukin-7"""@eng ; skos:notation """CDR0000388007"""^^xsd:string ; skos:altLabel """gp100/IL-7/ISA-51/MART-1"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2004-08-17"""^^xsd:string ; """2004-08-24"""^^xsd:string ; umls:cui """C1541607"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole"""@eng ; skos:notation """CDR0000039229"""^^xsd:string ; skos:altLabel """Persantine"""@eng , """2,2',2'',2''''-[(4,8-Dipiperidinopyrimido-[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol"""@eng , """DP"""@eng ; skos:definition """A synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties. Dipyridamole inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate (cAMP), and inhibiting the stimulation of platelet aggregation by agents such as platelet activating factor and collagen. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39229&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39229&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C445\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """1851"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58-32-2"""^^xsd:string ; """515776"""^^xsd:string ; """C445"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0012582"""^^xsd:string ; umls:cui """C0700020"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I inverted papilloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040758"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus inverted papilloma, stage I"""@eng , """inverted papilloma of the paranasal sinus and nasal cavity, stage I"""@eng , """paranasal sinus and nasal cavity inverted papilloma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """3705"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; umls:cui """C0280404"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I midline lethal granuloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040759"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus midline lethal granuloma, stage I"""@eng , """midline lethal granuloma of the paranasal sinus and nasal cavity, stage I"""@eng , """paranasal sinus and nasal cavity midline lethal granuloma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3708"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280405"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III squamous cell carcinoma of the larynx"""@eng ; skos:notation """CDR0000040750"""^^xsd:string ; skos:altLabel """laryngeal squamous cell carcinoma, stage III"""@eng , """squamous cell carcinoma of the larynx, stage III"""@eng , """epidermoid carcinoma of the larynx, stage III"""@eng , """larynx squamous cell carcinoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3698"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280397"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III verrucous carcinoma of the larynx"""@eng ; skos:notation """CDR0000040751"""^^xsd:string ; skos:altLabel """laryngeal verrucous carcinoma, stage III"""@eng , """larynx verrucous carcinoma, stage III"""@eng , """verrucous carcinoma of the larynx, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3699"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280398"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III anal cancer"""@eng ; skos:notation """CDR0000040752"""^^xsd:string ; skos:altLabel """anus cancer, stage III"""@eng , """anal cancer, stage III"""@eng , """stage III anus cancer"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """37"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278501"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV squamous cell carcinoma of the larynx"""@eng ; skos:notation """CDR0000040753"""^^xsd:string ; skos:altLabel """larynx squamous cell carcinoma, metastatic"""@eng , """laryngeal squamous cell carcinoma, stage IV"""@eng , """metastatic squamous cell carcinoma of the larynx"""@eng , """epidermoid carcinoma of the larynx, stage IV"""@eng , """squamous cell carcinoma of the larynx, stage IV"""@eng , """epidermoid carcinoma of the larynx, metastatic"""@eng , """laryngeal squamous cell carcinoma, metastatic"""@eng , """larynx squamous cell carcinoma, stage IV"""@eng , """squamous cell carcinoma of the larynx, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3700"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280399"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV verrucous carcinoma of the larynx"""@eng ; skos:notation """CDR0000040754"""^^xsd:string ; skos:altLabel """laryngeal verrucous carcinoma, metastatic"""@eng , """larynx verrucous carcinoma, stage IV"""@eng , """metastatic verrucous carcinoma of the larynx"""@eng , """verrucous carcinoma of the larynx, stage IV"""@eng , """laryngeal verrucous carcinoma, stage IV"""@eng , """larynx verrucous carcinoma, metastatic"""@eng , """verrucous carcinoma of the larynx, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3701"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280400"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent squamous cell carcinoma of the larynx"""@eng ; skos:notation """CDR0000040755"""^^xsd:string ; skos:altLabel """laryngeal squamous cell carcinoma, recurrent"""@eng , """epidermoid carcinoma of the larynx, recurrent"""@eng , """squamous cell carcinoma of the larynx, recurrent"""@eng , """larynx squamous cell carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3702"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280401"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent verrucous carcinoma of the larynx"""@eng ; skos:notation """CDR0000040756"""^^xsd:string ; skos:altLabel """verrucous carcinoma of the larynx, recurrent"""@eng , """laryngeal verrucous carcinoma, recurrent"""@eng , """larynx verrucous carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3703"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280402"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I squamous cell carcinoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040757"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity squamous cell carcinoma, stage I"""@eng , """epidermoid carcinoma of the paranasal sinus and nasal cavity, stage I"""@eng , """squamous cell carcinoma of the paranasal sinus and nasal cavity, stage I"""@eng , """nasal cavity and paranasal sinus squamous cell carcinoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3704"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280403"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMB-1 immunotoxin"""@eng ; skos:notation """CDR0000043265"""^^xsd:string ; skos:altLabel """immunotoxin LMB-1"""@eng , """B3-NLysPE38"""@eng , """LMB-1"""@eng ; skos:definition """A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region. LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors. The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43265&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43265&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2499\" NCI Thesaurus)"""@eng ; """7763"""^^xsd:string ; """C2499"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """651311"""^^xsd:string ; umls:cui """C0796420"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/dexamethasone"""@eng ; skos:notation """CDR0000043264"""^^xsd:string ; skos:altLabel """CLB/DM"""@eng ; ; ; """7755"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796417"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """budesonide"""@eng ; skos:notation """CDR0000043267"""^^xsd:string ; """7776"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0054201"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """B43-PAP immunotoxin"""@eng ; skos:notation """CDR0000043266"""^^xsd:string ; skos:altLabel """anti-CD19 immunotoxin"""@eng , """B43-PAP"""@eng ; """2004-04-09"""^^xsd:string ; """7774"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796424"""^^xsd:string ; umls:cui """C1527162"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """patent blue V dye"""@eng ; skos:notation """CDR0000043261"""^^xsd:string ; skos:altLabel """dye, patent blue V"""@eng , """Patent Blue V"""@eng , """dye, patent blue violet"""@eng , """patent blue violet dye"""@eng ; ; """2002-11-19"""^^xsd:string ; """7748"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0070139"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nelarabine"""@eng ; skos:notation """CDR0000043260"""^^xsd:string ; skos:altLabel """Arranon"""@eng , """2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine"""@eng , """GW506U78"""@eng , """2-Amino, 6-Methoxypurine Arabinoside"""@eng , """506U78"""@eng ; skos:definition """An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43260&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43260&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1704\" NCI Thesaurus)"""@eng ; ; ; """7747"""^^xsd:string ; """C1704"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """52611"""^^xsd:string ; """686673"""^^xsd:string ; """2006-08-31"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1615581"""^^xsd:string ; umls:cui """C0907349"""^^xsd:string ; umls:cui """C0759671"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/dexamethasone/idarubicin"""@eng ; skos:notation """CDR0000043263"""^^xsd:string ; skos:altLabel """CLB/DM/IDA"""@eng ; ; ; ; """7754"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796416"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/fludarabine/topotecan"""@eng ; skos:notation """CDR0000043262"""^^xsd:string ; skos:altLabel """ARA-C/FAMP/TOPO"""@eng ; ; ; ; """7753"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796415"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fibrosarcomatous osteosarcoma"""@eng ; skos:notation """CDR0000039884"""^^xsd:string ; skos:altLabel """osteogenic sarcoma, fibroblastic"""@eng , """osteosarcoma, fibrosarcomatous"""@eng , """fibroblastic osteogenic sarcoma"""@eng , """osteogenic sarcoma, fibrosarcomatous"""@eng , """fibrosarcomatous osteogenic sarcoma"""@eng , """sarcoma, osteogenic fibroblastic"""@eng , """osteosarcoma, fibroblastic"""@eng , """fibroblastic osteosarcoma"""@eng ; rdfs:subClassOf ; """2565"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279602"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chondrosarcomatous osteosarcoma"""@eng ; skos:notation """CDR0000039885"""^^xsd:string ; skos:altLabel """osteosarcoma, chondrosarcomatous"""@eng , """sarcoma, osteogenic, chondrosarcomatous"""@eng , """osteogenic sarcoma, chondrosarcomatous"""@eng , """chondrosarcomatous osteogenic sarcoma"""@eng , """osteosarcoma, chondroblastic"""@eng , """chondroblastic osteogenic sarcoma"""@eng , """osteogenic sarcoma, chondroblastic"""@eng , """chondroblastic osteosarcoma"""@eng ; rdfs:subClassOf ; """2566"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279603"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nafarelin"""@eng ; skos:notation """CDR0000039886"""^^xsd:string ; skos:altLabel """NFRL"""@eng ; """2567"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0064906"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """osteoblastic osteosarcoma"""@eng ; skos:notation """CDR0000039887"""^^xsd:string ; skos:altLabel """osteoblastic osteogenic sarcoma"""@eng , """osteogenic sarcoma, osteoblastic"""@eng , """osteosarcoma, osteoblastic"""@eng , """sarcoma, osteogenic osteoblastic"""@eng ; rdfs:subClassOf ; """2568"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1704328"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/filgrastim"""@eng ; skos:notation """CDR0000043269"""^^xsd:string ; skos:altLabel """ARA-C/DNR/G-CSF"""@eng ; ; ; ; """7781"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796426"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/melphalan"""@eng ; skos:notation """CDR0000043268"""^^xsd:string ; skos:altLabel """ARA-C/L-PAM/VP-16"""@eng ; ; ; ; """7780"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796425"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TdT negative childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039882"""^^xsd:string ; skos:altLabel """ALL, TdT negative, childhood"""@eng , """ALL, pediatric TdT negative"""@eng , """TdT negative pediatric acute lymphocytic leukemia"""@eng , """TdT negative childhood acute lymphocytic leukemia"""@eng , """ALL, childhood TdT negative"""@eng , """acute lymphocytic leukemia, childhood TdT negative"""@eng , """leukemia, childhood acute lymphocytic TdT negative"""@eng , """TdT negative acute lymphocytic leukemia, childhood"""@eng , """TdT negative ALL, childhood"""@eng , """pediatric ALL, TdT negative"""@eng , """TdT negative lymphocytic leukemia, acute childhood"""@eng , """TdT negative childhood ALL"""@eng , """childhood ALL, TdT negative"""@eng , """leukemia, pediatric acute lymphocytic TdT negative"""@eng , """acute lymphoblastic leukemia, childhood TdT negative"""@eng , """ALL, TdT negative, pediatric"""@eng ; rdfs:subClassOf ; """2563"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279600"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TdT positive childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039883"""^^xsd:string ; skos:altLabel """childhood ALL, TdT positive"""@eng , """TdT positive lymphocytic leukemia, acute childhood"""@eng , """leukemia, pediatric acute lymphocytic TdT positive"""@eng , """acute lymphocytic leukemia, childhood TdT positive"""@eng , """TdT positive acute lymphocytic leukemia, childhood"""@eng , """ALL, pediatric TdT positive"""@eng , """acute lymphoblastic leukemia, childhood TdT positive"""@eng , """TdT positive childhood ALL"""@eng , """TdT positive ALL, childhood"""@eng , """ALL, TdT positive, pediatric"""@eng , """ALL, TdT positive, childhood"""@eng , """TdT positive pediatric acute lymphocytic leukemia"""@eng , """ALL, childhood TdT positive"""@eng , """pediatric ALL, TdT positive"""@eng , """TdT positive childhood acute lymphocytic leukemia"""@eng , """leukemia, childhood acute lymphocytic TdT positive"""@eng ; rdfs:subClassOf ; """2564"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279601"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """losoxantrone"""@eng ; skos:notation """CDR0000041809"""^^xsd:string ; skos:altLabel """CI-941"""@eng , """DuP 941"""@eng , """CI941"""@eng , """CI 941"""@eng , """biantrazole"""@eng , """DuP-941"""@eng ; ; ; ; """4994"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0969814"""^^xsd:string ; umls:cui """C0245032"""^^xsd:string ; umls:cui """C0950689"""^^xsd:string ; umls:cui """C0629098"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/leucovorin calcium/PALA"""@eng ; skos:notation """CDR0000041808"""^^xsd:string ; skos:altLabel """CF/FUDR/PALA"""@eng ; ; ; ; """4993"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281384"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium glucarate"""@eng ; skos:notation """CDR0000041803"""^^xsd:string ; skos:altLabel """Antacidin"""@eng , """Calcium Saccharate"""@eng , """Calcium D-Glucarate"""@eng , """CGT"""@eng , """2,3,4,5-tetrahydroxy-1,6- dioxido-hexane-1,6-dione, Calcium"""@eng , """Calcium D-Saccharate"""@eng , """Saccharated Lime"""@eng ; skos:definition """The calcium salt form of glucaric acid, a natural substance found in many fruits and vegetables, with potential anti-cancer property. The active metabolite of calcium glucarate, D-Glucaro-1,4-Lactone in vivo, is an inhibitor of beta-Glucuronidase, an enzyme found in certain bacteria reside in the human gut. One of the key processes in which human body eliminates toxic chemicals as well as hormones (such as estrogen) is by attaching glucuronic acid to them in the liver and then excreting the complex in the bile. When beta-glucuronidase breaks the bond, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Thereby, supplementing calcium glucarate may suppress the developments of hormone-dependent cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41803&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41803&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C335\" NCI Thesaurus)"""@eng ; """4989"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C335"""^^xsd:string ; """122011"""^^xsd:string ; """5793-88-4"""^^xsd:string ; umls:cui """C0771997"""^^xsd:string ; umls:cui """C0006698"""^^xsd:string ; umls:cui """C1572555"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edatrexate/paclitaxel"""@eng ; skos:notation """CDR0000041802"""^^xsd:string ; skos:altLabel """EDAM/TAX"""@eng ; ; ; """4988"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281380"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/merbarone"""@eng ; skos:notation """CDR0000041801"""^^xsd:string ; skos:altLabel """G-CSF/MERB"""@eng ; ; ; """4987"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281379"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetirizine"""@eng ; skos:notation """CDR0000041800"""^^xsd:string ; """4986"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0055147"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/quinine"""@eng ; skos:notation """CDR0000041807"""^^xsd:string ; skos:altLabel """QUIN/TAX"""@eng ; ; ; """4992"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281383"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gallium nitrate"""@eng ; skos:notation """CDR0000041806"""^^xsd:string ; skos:altLabel """5-FU/GAN"""@eng ; ; ; """4991"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281382"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/ifosfamide/interferon alfa"""@eng ; skos:notation """CDR0000041805"""^^xsd:string ; skos:altLabel """BLEO/CDDP/IFF/IFN-A"""@eng ; ; ; ; ; """4990"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338167"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """morphine sulfate"""@eng ; skos:notation """CDR0000041804"""^^xsd:string ; skos:altLabel """Kadian"""@eng , """Oramorph SR"""@eng , """MORPH"""@eng , """MS Contin"""@eng , """MSir"""@eng , """Statex SR"""@eng , """Roxanol"""@eng , """Infumorph"""@eng ; ; ; """2006-11-29"""^^xsd:string ; """C669"""^^xsd:string ; """499"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700789"""^^xsd:string ; umls:cui """C0700788"""^^xsd:string ; umls:cui """C0700655"""^^xsd:string ; umls:cui """C0700790"""^^xsd:string ; umls:cui """C0700786"""^^xsd:string ; umls:cui """C0700785"""^^xsd:string ; umls:cui """C0026549"""^^xsd:string ; umls:cui """C0066814"""^^xsd:string ; umls:cui """C0919266"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040101"""^^xsd:string ; skos:altLabel """hypopharyngeal cancer, stage I"""@eng , """hypopharynx cancer, stage I"""@eng ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2851"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279799"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000256402"""^^xsd:string ; skos:altLabel """CF/CPT-11/FLAVO/5-FU"""@eng ; ; ; ; ; """2002-07-16"""^^xsd:string ; """11372"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327736"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyroxamide"""@eng ; skos:notation """CDR0000256405"""^^xsd:string ; skos:altLabel """Suberoyl-3-aminopyridineamide Hydroxamic Acid"""@eng ; skos:definition """A synthetic derivative of hydroxamic acid with antineoplastic properties, Pyroxamide inhibits histone deacetylases involved in transcription; induces hyperacetylation of core histones, modulating chromatin structure and affecting transcription of some genes that inhibit tumor growth; and induces growth arrest and apoptosis. Pyroxamide is used in clinical studies for cancer chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256405&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256405&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2801\" NCI Thesaurus)"""@eng ; """11374"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2801"""^^xsd:string ; """696085"""^^xsd:string ; """382180-17-8"""^^xsd:string ; umls:cui """C0966748"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/ixabepilone"""@eng ; skos:notation """CDR0000256404"""^^xsd:string ; skos:altLabel """BMS 247550/dFdC"""@eng ; ; ; """2004-01-08"""^^xsd:string ; """11373"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327737"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/sorafenib"""@eng ; skos:notation """CDR0000440037"""^^xsd:string ; skos:altLabel """17-AAG/SFN"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-06"""^^xsd:string ; """2005-07-15"""^^xsd:string ; umls:cui """C1831672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/nitrocamptothecin"""@eng ; skos:notation """CDR0000038029"""^^xsd:string ; skos:altLabel """9-NC/VP-16"""@eng ; ; ; """10544"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879576"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IM-862/irinotecan"""@eng ; skos:notation """CDR0000038028"""^^xsd:string ; skos:altLabel """CPT-11/IM 862"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """10543"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879575"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adrenocortical carcinoma"""@eng ; skos:notation """CDR0000038759"""^^xsd:string ; skos:altLabel """stage I adrenocortical cancer"""@eng , """carcinoma, adrenocortical stage I"""@eng , """adrenocortical carcinoma, stage I"""@eng ; rdfs:subClassOf ; """adrenocortical carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1199"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0678050"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adrenocortical carcinoma"""@eng ; skos:notation """CDR0000038758"""^^xsd:string ; skos:altLabel """adrenal cortex cancer"""@eng , """carcinoma, adrenocortical"""@eng , """Adrenocortical carcinoma"""@eng , """adrenocortical cancer"""@eng , """adrenal cortical carcinoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1198"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346402"""^^xsd:string ; umls:cui """C0206686"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody M195"""@eng ; skos:notation """CDR0000038025"""^^xsd:string ; skos:altLabel """Y90 MOAB M195"""@eng , """M195"""@eng , """monoclonal antibody M195, yttrium Y 90"""@eng , """yttrium Y 90 MOAB M195"""@eng , """MOAB M195, yttrium Y 90"""@eng ; """10540"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879572"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin beta"""@eng ; skos:notation """CDR0000257861"""^^xsd:string ; skos:altLabel """EPOB"""@eng , """NeoRecormon"""@eng ; skos:definition """A recombinant therapeutic agent that is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257861&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257861&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26639\" NCI Thesaurus)"""@eng ; """11467"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26639"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0376540"""^^xsd:string ; umls:cui """C0357131"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/IM-862"""@eng ; skos:notation """CDR0000038027"""^^xsd:string ; skos:altLabel """5-FU/IM 862"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """10542"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879574"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/temozolomide"""@eng ; skos:notation """CDR0000038026"""^^xsd:string ; skos:altLabel """CCNU/TMZ"""@eng ; ; ; """10541"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879573"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/thalidomide"""@eng ; skos:notation """CDR0000038021"""^^xsd:string ; skos:altLabel """IFN-A/THAL"""@eng ; ; ; """10537"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879569"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 metaiodobenzylguanidine"""@eng ; skos:notation """CDR0000038020"""^^xsd:string ; skos:altLabel """131 I-MIBG"""@eng , """Meta-Iodobenzylguanidine"""@eng , """MIBG"""@eng , """I131-MIBG"""@eng , """I 131 Metaiodobenzylguanidine"""@eng ; skos:definition """An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Meta-iodobenzylguanidine localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38020&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38020&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C970\" NCI Thesaurus)"""@eng ; ; ; ; """10536"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """77679-27-7"""^^xsd:string ; """C970"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C3467948"""^^xsd:string ; umls:cui """C0047506"""^^xsd:string ; umls:cui """C0879568"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/gemcitabine/vinorelbine"""@eng ; skos:notation """CDR0000038023"""^^xsd:string ; skos:altLabel """dFdC/LipoDox/VNB"""@eng ; ; ; ; """10539"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879571"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tipifarnib/topotecan"""@eng ; skos:notation """CDR0000038022"""^^xsd:string ; skos:altLabel """R115777/TOPO"""@eng ; ; ; """2002-09-11"""^^xsd:string ; """10538"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879570"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anetholtrithione"""@eng ; skos:notation """CDR0000042828"""^^xsd:string ; """6627"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0002937"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """computed tomography"""@eng ; skos:notation """CDR0000042829"""^^xsd:string ; skos:altLabel """tomography, computed"""@eng ; rdfs:subClassOf ; """6628"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0040405"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human hyaluronidase"""@eng ; skos:notation """CDR0000486735"""^^xsd:string ; skos:altLabel """rHuPH20"""@eng , """Chemophase"""@eng ; skos:definition """A human recombinant form of the naturally occurring human enzyme hyaluronidase with potential chemoadjuvant activity. Upon local administration, recombinant human hyaluronidase hydrolyzes hyaluronic acid, a glucosaminoglycan responsible for the viscosity of the interstitial barrier. The digestion of hyaluronic acid lowers the viscosity in the interstitial space, thereby increasing permeability and facilitating local penetration of chemotherapeutic agents into cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486735&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486735&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61504\" NCI Thesaurus)"""@eng ; """C61504"""^^xsd:string ; """2006-10-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831846"""^^xsd:string ; umls:cui """C1720035"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AG-024322"""@eng ; skos:notation """CDR0000459491"""^^xsd:string ; skos:definition """A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2 and 4), enzymes that regulate cell cycle progression. Inhibition of CDK may result in cell cycle arrest, induction of apoptosis, and inhibition of DNA replication and tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459491&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459491&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52182\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C52182"""^^xsd:string ; """2006-07-26"""^^xsd:string ; umls:cui """C1706655"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/epirubicin/vincristine"""@eng ; skos:notation """CDR0000042569"""^^xsd:string ; skos:altLabel """CBDCA/EPI/VCR"""@eng ; ; ; ; """6251"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392992"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """camptothecin-polymer conjugate IT-101"""@eng ; skos:notation """CDR0000489507"""^^xsd:string ; skos:altLabel """IT-101"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831896"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """parathyroid hormone"""@eng ; skos:notation """CDR0000489119"""^^xsd:string ; skos:altLabel """Parathyrin"""@eng , """Parathormone"""@eng , """PTH"""@eng ; skos:definition """Encoded by human PTH Gene (Parathyroid Hormone Family), secreted (parathyroid cells) 115-aa 13-kDa (precursor) Parathyroid Hormone elevates blood Ca2+ levels by dissolving the salts in bone and preventing renal excretion. PTH defects cause familial isolated hypoparathyroidism. (NCI) Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489119&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489119&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C41027\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """C41027"""^^xsd:string ; umls:cui """C0030520"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TdT positive adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039880"""^^xsd:string ; skos:altLabel """acute lymphoblastic leukemia, adult TdT positive"""@eng , """TdT positive acute lymphocytic leukemia, adult"""@eng , """ALL, TdT positive, adult"""@eng , """TdT positive adult ALL"""@eng , """leukemia, adult acute lymphocytic TdT positive"""@eng , """TdT positive lymphocytic leukemia, acute adult"""@eng , """ALL, adult TdT positive"""@eng , """adult ALL, TdT positive"""@eng , """TdT positive ALL, adult"""@eng , """TdT positive adult acute lymphocytic leukemia"""@eng , """acute lymphocytic leukemia, adult TdT positive"""@eng ; rdfs:subClassOf ; """2561"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279598"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/gemcitabine/paclitaxel"""@eng ; skos:notation """CDR0000393195"""^^xsd:string ; skos:altLabel """CTX/dFdC/DOX/TAX"""@eng ; ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541369"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/VNP40101M"""@eng ; skos:notation """CDR0000334924"""^^xsd:string ; skos:altLabel """ARA-C/VNP-40101M"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328055"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Jin Fu Kang"""@eng ; skos:notation """CDR0000484642"""^^xsd:string ; skos:definition """A traditional Chinese herbal medicine with potential antineoplastic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484642&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484642&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61316\" NCI Thesaurus)"""@eng ; """C61316"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831812"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular cancer"""@eng ; skos:notation """CDR0000038579"""^^xsd:string ; skos:altLabel """testicle cancer"""@eng , """testis cancer"""@eng , """Testicular cancer"""@eng , """carcinoma of the testis"""@eng , """cancer of the testis"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1121"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0677483"""^^xsd:string ; umls:cui """C0153594"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium carbonate/cholecalciferol"""@eng ; skos:notation """CDR0000042823"""^^xsd:string ; skos:altLabel """CACO3/VIT-D"""@eng ; ; ; """6622"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1632844"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """telomerase peptide vaccine GV1001"""@eng ; skos:notation """CDR0000502114"""^^xsd:string ; skos:altLabel """PrimoVax"""@eng , """GV1001"""@eng ; """2006-08-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831944"""^^xsd:string ; umls:cui """C1831943"""^^xsd:string ; umls:cui """C1831942"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/interleukin-12"""@eng ; skos:notation """CDR0000042561"""^^xsd:string ; skos:altLabel """gp100/IFA/IL-12"""@eng ; ; ; ; """6242"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392984"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/interleukin-2"""@eng ; skos:notation """CDR0000042560"""^^xsd:string ; skos:altLabel """gp100/IFA/IL-2"""@eng ; ; ; ; """6241"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392983"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spinal cord neurofibroma"""@eng ; skos:notation """CDR0000526260"""^^xsd:string ; rdfs:subClassOf ; """precancerous/nonmalignant condition"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C1336047"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/gemtuzumab ozogamicin/idarubicin"""@eng ; skos:notation """CDR0000350368"""^^xsd:string ; skos:altLabel """ARA-C/CMA-676/IDA"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2003-12-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328133"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/oblimersen"""@eng ; skos:notation """CDR0000301924"""^^xsd:string ; skos:altLabel """CTX/G3139"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327956"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """18F-fluoromisonidazole"""@eng ; skos:notation """CDR0000458064"""^^xsd:string ; skos:altLabel """18F-misonidazole"""@eng , """18F-MISO"""@eng ; skos:definition """A radiofluorinated 2-nitroimidazole derivate with hypoxia-specific tracer activity. Misonidazole is reduced under hypoxic conditions and in reduced form covalently binds to macromolecules in hypoxic cells. 18F (fluorine-18) radiofluorination of misonidazole to form 18F-fluoromisonidazole allows radioisotopic imaging of reduced misonidazole bound to macromolecules in hypoxic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=458064&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=458064&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52180\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C52180"""^^xsd:string ; umls:cui """C1710834"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polysaccharide-K"""@eng ; skos:notation """CDR0000039574"""^^xsd:string ; skos:altLabel """PSK"""@eng , """Krestin"""@eng , """Psk"""@eng , """Glycoproteins"""@eng ; skos:definition """Protein-bound polysaccharide from the mushroom Coriolus versicolor (Shitake); a biological response modifier with antitumor activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39574&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39574&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1204\" NCI Thesaurus)"""@eng ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2228"""^^xsd:string ; """C1204"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1962943"""^^xsd:string ; umls:cui """C0072522"""^^xsd:string ; umls:cui """C0017968"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyrazofurin"""@eng ; skos:notation """CDR0000039575"""^^xsd:string ; skos:altLabel """pyrazomycin"""@eng , """Compound 47599"""@eng , """Beta-Pyrazomycin"""@eng , """1H-Pyrazole-5-carboxamide, 4-Hydroxy-3-beta-D-ribofuranosyl- (9CI)"""@eng , """Pyrazole, -3-Carboxamide, 4-Hydroxy-5-beta-L-ribofuranosyl"""@eng , """Pirazofurin"""@eng , """47599"""@eng , """4-Hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide"""@eng ; skos:definition """A nucleoside analog. Pyrazofurin potently inhibits orotidine 5'-monophosphate (OMP) decarboxylase, thereby interfering with de novo synthesis of uridine nucleotides and resulting in cytotoxicity. This agent also causes a rapid depletion of the pyrimidine deoxynucleotide pool, thereby inhibiting DNA synthesis and cell replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39575&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39575&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1208\" NCI Thesaurus)"""@eng ; """2230"""^^xsd:string ; """12100"""^^xsd:string ; """30868-30-5"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C1208"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """143095"""^^xsd:string ; umls:cui """C1524065"""^^xsd:string ; umls:cui """C0072661"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/lomustine/mechlorethamine"""@eng ; skos:notation """CDR0000039576"""^^xsd:string ; skos:altLabel """CCNU/DOX/NM"""@eng , """NAC"""@eng ; ; ; ; """2231"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279378"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-interleukin-2"""@eng ; skos:notation """CDR0000039577"""^^xsd:string ; skos:altLabel """polyethylene glycol-modified recombinant interleukin-2"""@eng , """PEG-IL-2"""@eng ; skos:definition """A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39577&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39577&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1304\" NCI Thesaurus)"""@eng ; ; """2232"""^^xsd:string ; """3646"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1304"""^^xsd:string ; umls:cui """C0083036"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000039570"""^^xsd:string ; skos:altLabel """MF"""@eng , """5-FU/MITO"""@eng ; ; ; """2224"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279374"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etanidazole"""@eng ; skos:notation """CDR0000041248"""^^xsd:string ; skos:altLabel """CBDCA/CTX/SR-2508"""@eng ; ; ; ; """4321"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280842"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/melphalan/prednisone"""@eng ; skos:notation """CDR0000039572"""^^xsd:string ; skos:altLabel """BCNU/CTX/L-PAM/PRED"""@eng , """MCBP"""@eng ; ; ; ; ; """2226"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279375"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039573"""^^xsd:string ; skos:altLabel """MOP"""@eng , """NM/PCB/VCR"""@eng ; ; ; ; """2227"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066785"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon consensus, methionyl"""@eng ; skos:notation """CDR0000041245"""^^xsd:string ; skos:altLabel """Recombinant methionyl human consensus interferon"""@eng , """r-metHuIFN-Con1"""@eng , """methionyl interferon consensus"""@eng ; """4318"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """C2369"""^^xsd:string ; umls:cui """C0164613"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 14G2A"""@eng ; skos:notation """CDR0000041244"""^^xsd:string ; skos:altLabel """14G2A"""@eng , """14G2A, monoclonal antibody"""@eng , """MOAB 14G2A"""@eng , """antibody 14G2A, monoclonal"""@eng ; skos:definition """A murine monoclonal antibody directed against the ganglioside GD2 with potential antineoplastic activity. Monoclonal antibody 14G2A binds to the ganglioside GD2 and induces antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41244&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41244&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2368\" NCI Thesaurus)"""@eng ; ; ; """4317"""^^xsd:string ; """3204"""^^xsd:string ; """C2368"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """624345"""^^xsd:string ; umls:cui """C0280838"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody 14G2A"""@eng ; skos:notation """CDR0000041247"""^^xsd:string ; skos:altLabel """IL-2/MOAB 14G2A"""@eng ; ; ; """4320"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280841"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dihydro-5-azacytidine"""@eng ; skos:notation """CDR0000041246"""^^xsd:string ; skos:altLabel """CDDP/DHAC"""@eng ; ; ; """4319"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280840"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyrimethamine"""@eng ; skos:notation """CDR0000039578"""^^xsd:string ; skos:altLabel """Daraprim"""@eng ; skos:definition """A synthetic derivative of ethyl-pyrimidine with potent antimalarial properties. Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR). DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins. This agent is often used in combination with other antimalarials for the treatment of uncomplicated falciparum malaria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39578&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39578&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C788\" NCI Thesaurus)"""@eng ; """2233"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58-14-0"""^^xsd:string ; """C788"""^^xsd:string ; """3061"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0034283"""^^xsd:string ; umls:cui """C0591326"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/semustine"""@eng ; skos:notation """CDR0000039579"""^^xsd:string ; skos:altLabel """MAD"""@eng , """DOX/MeCCNU"""@eng ; ; ; """2234"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279380"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/prednisone"""@eng ; skos:notation """CDR0000041243"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/PRED"""@eng ; ; ; ; ; """4316"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280837"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/interleukin-2"""@eng ; skos:notation """CDR0000041242"""^^xsd:string ; skos:altLabel """BC-G/IL-2"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """4315"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280836"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706"""@eng ; skos:notation """CDR0000391228"""^^xsd:string ; skos:altLabel """AMG-706"""@eng ; skos:definition """An orally bioavailable multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=391228&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=391228&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48374\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """2004-09-25"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """C48374"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541476"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lip basal cell carcinoma"""@eng ; skos:notation """CDR0000040039"""^^xsd:string ; skos:altLabel """basal cell carcinoma, lip"""@eng ; rdfs:subClassOf ; """2774"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279739"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-275183/pemetrexed disodium"""@eng ; skos:notation """CDR0000425375"""^^xsd:string ; skos:altLabel """BMS 275183/LY231514"""@eng ; ; ; """2005-03-11"""^^xsd:string ; """2005-03-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541528"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TSH secreting adenoma"""@eng ; skos:notation """CDR0000040035"""^^xsd:string ; skos:altLabel """adenoma, TSH secreting"""@eng ; rdfs:subClassOf ; """2761"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279735"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pituitary eosinophilic adenoma"""@eng ; skos:notation """CDR0000040034"""^^xsd:string ; skos:altLabel """adenoma, eosinophilic, pituitary"""@eng , """pituitary adenoma, eosinophilic"""@eng , """adenoma, growth hormone secreting"""@eng , """growth hormone secreting adenoma"""@eng , """eosinophilic adenoma, pituitary"""@eng ; rdfs:subClassOf ; """2759"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279734"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-grade salivary gland carcinoma"""@eng ; skos:notation """CDR0000040037"""^^xsd:string ; skos:altLabel """salivary gland carcinoma, low grade"""@eng , """cancer of the salivary gland, low grade"""@eng , """carcinoma of the salivary gland, low grade"""@eng , """low-grade salivary gland cancer"""@eng , """salivary gland cancer, low grade"""@eng ; rdfs:subClassOf ; """2772"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279737"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pituitary chromophobe adenoma"""@eng ; skos:notation """CDR0000040036"""^^xsd:string ; skos:altLabel """chromophobe adenoma, pituitary"""@eng , """adenoma, chromophobe, pituitary"""@eng ; rdfs:subClassOf ; """2763"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0001432"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pituitary basophilic adenoma"""@eng ; skos:notation """CDR0000040031"""^^xsd:string ; skos:altLabel """ACTH secreting adenoma"""@eng , """adenoma, ACTH secreting"""@eng , """basophilic adenoma, pituitary"""@eng , """adenoma, basophilic, pituitary"""@eng ; rdfs:subClassOf ; """2756"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1306214"""^^xsd:string ; umls:cui """C0001431"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic alpha cell adenoma"""@eng ; skos:notation """CDR0000040030"""^^xsd:string ; skos:altLabel """adenoma, glucagon secreting"""@eng , """adenoma, alpha cell, pancreatic"""@eng , """adenoma, glucagon producing"""@eng , """glucagon producing adenoma"""@eng , """glucagon secreting adenoma"""@eng , """adenoma, pancreatic alpha cell"""@eng ; rdfs:subClassOf ; """2755"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279730"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prolactin secreting adenoma"""@eng ; skos:notation """CDR0000040033"""^^xsd:string ; skos:altLabel """adenoma, prolactin secreting"""@eng ; rdfs:subClassOf ; """2758"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0033375"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic alpha cell carcinoma"""@eng ; skos:notation """CDR0000040032"""^^xsd:string ; skos:altLabel """glucagon producing carcinoma"""@eng , """glucagon secreting carcinoma"""@eng , """carcinoma, glucagon secreting"""@eng , """carcinoma, pancreatic alpha cell"""@eng , """carcinoma, alpha cell, pancreatic"""@eng , """carcinoma, glucagon producing"""@eng ; rdfs:subClassOf ; """2757"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334282"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxycodone hydrochloride"""@eng ; skos:notation """CDR0000508980"""^^xsd:string ; skos:altLabel """4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride"""@eng , """OxyContin"""@eng , """Roxicodone"""@eng ; skos:definition """The hydrochloride salt of oxycodone, a methylether of oxymorphone and semisynthetic opioid agonist with analgesic and antitussive properties. Oxycodone binds to mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opiates. In addition to analgesia and a depressive effect on the cough center in the medulla, this agent may cause euphoria, anxiolysis, miosis, sedation, physical dependence, constipation, and respiratory depression, depending on dosage and variations in individual metabolism. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=508980&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=508980&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48010\" NCI Thesaurus)"""@eng ; """124-90-3"""^^xsd:string ; """2006-09-15"""^^xsd:string ; """C48010"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0722364"""^^xsd:string ; umls:cui """C0282274"""^^xsd:string ; umls:cui """C0723149"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biostim"""@eng ; skos:notation """CDR0000039167"""^^xsd:string ; ; ; """1787"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0053640"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """povidone-iodine"""@eng ; skos:notation """CDR0000039166"""^^xsd:string ; skos:altLabel """Betadine"""@eng , """iodine povidone topical"""@eng , """Betadine topical"""@eng , """PVP-Iodine"""@eng ; """1786"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0032857"""^^xsd:string ; umls:cui """C3215443"""^^xsd:string ; umls:cui """C0699524"""^^xsd:string ; umls:cui """C0699525"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bromocriptine mesylate"""@eng ; skos:notation """CDR0000039165"""^^xsd:string ; skos:altLabel """BRCR"""@eng ; ; ; """Drug/agent"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """1785"""^^xsd:string ; """C317"""^^xsd:string ; umls:cui """C0546852"""^^xsd:string ; umls:cui """C0006230"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ubenimex"""@eng ; skos:notation """CDR0000039164"""^^xsd:string ; skos:altLabel """bestatin"""@eng , """NK 421"""@eng ; """1784"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0053355"""^^xsd:string ; umls:cui """C1523998"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood medulloblastoma"""@eng ; skos:notation """CDR0000041638"""^^xsd:string ; skos:altLabel """cerebellar PNET, childhood"""@eng , """pediatric cerebellar primitive neuroectodermal tumor"""@eng , """Brain tumor, child: Medulloblastoma"""@eng , """medulloblastoma, childhood"""@eng , """medulloblastoma, pediatric"""@eng , """childhood infratentorial primitive neuroectodermal tumor"""@eng , """infratentorial primitive neuroectodermal tumor, pediatric"""@eng , """PNET, pediatric cerebellar"""@eng , """childhood cerebellar PNET"""@eng , """PNET, cerebellar, pediatric"""@eng , """pediatric medulloblastoma"""@eng , """cerebellar, pediatric, PNET"""@eng , """primitive neuroectodermal tumor, pediatric cerebellar"""@eng , """primitive neuroectodermal tumor, pediatric infratentorial"""@eng , """pediatric infratentorial PNET"""@eng , """pediatric cerebellar PNET"""@eng , """primitive neuroectodermal tumor, childhood infratentorial"""@eng , """infratentorial primitive neuroectodermal tumor, childhood"""@eng , """cerebellar primitive neuroectodermal tumor, pediatric"""@eng , """pediatric infratentorial primitive neuroectodermal tumor"""@eng , """infratentorial PNET, pediatric"""@eng , """cerebellar PNET, pediatric"""@eng , """PNET, childhood infratentorial"""@eng , """infratentorial, pediatric, PNET"""@eng , """childhood cerebellar primitive neuroectodermal tumor"""@eng , """PNET, infratentorial, childhood"""@eng , """PNET, pediatric infratentorial"""@eng , """childhood infratentorial PNET"""@eng , """cerebellar, childhood, PNET"""@eng , """cerebellar primitive neuroectodermal tumor, childhood"""@eng , """PNET, infratentorial, pediatric"""@eng , """PNET, childhood cerebellar"""@eng , """infratentorial, childhood, PNET"""@eng , """primitive neuroectodermal tumor, childhood cerebellar"""@eng , """PNET, cerebellar, childhood"""@eng , """infratentorial PNET, childhood"""@eng ; rdfs:subClassOf ; """2003-05-22"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """48"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278510"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triazinate"""@eng ; skos:notation """CDR0000039162"""^^xsd:string ; skos:altLabel """ethanesulfonic acid compound with 3-((2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenoxy)methyl)-N,N-dimethylben zamide (1:1)"""@eng , """BAF"""@eng , """TZT"""@eng , """benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI)"""@eng , """Baker's antifol"""@eng , """ethanesulfonic acid compound"""@eng , """ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(8CI)"""@eng , """Baker's Antifolate"""@eng , """Bakers antifol"""@eng , """ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride"""@eng , """Bakers Antifolate"""@eng , """ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(9CI)"""@eng , """Soluble Baker's Antifol"""@eng , """alpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-trizin-1(2H)-yl)phenoxy)-N,N-dimethyl-m-toluamide ethanesulfonic acid"""@eng ; skos:definition """A synthetic dihydrotriazine derivative with antineoplastic properties. As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis. Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39162&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39162&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1258\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1782"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """127755"""^^xsd:string ; """41191-04-2"""^^xsd:string ; """C1258"""^^xsd:string ; """9789"""^^xsd:string ; """139105"""^^xsd:string ; umls:cui """C0950301"""^^xsd:string ; umls:cui """C1135158"""^^xsd:string ; umls:cui """C0077008"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diaziquone"""@eng ; skos:notation """CDR0000039161"""^^xsd:string ; skos:altLabel """aziridinylbenzoquinone"""@eng , """1,4-cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester"""@eng , """carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI)"""@eng , """1,4-cyclohexadiene-1,4-dicarbamic acid,2,5-bis(1-aziridinyl)-3,6-dioxo,-diethyl ester"""@eng , """CI-904"""@eng , """[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester"""@eng , """2,5-bis(1-aziridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone"""@eng , """Aziridinylbenzoquinone carbamic acid"""@eng , """AZQ"""@eng , """Aziridinyl Benzoquinone"""@eng , """2,5-bis(1-aciridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone"""@eng , """2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamic acid diethyl ester"""@eng , """2,5-diaziridinyl-3,6-bis(ethoxycarbonyl-amino)-1,4-benzoquinone"""@eng ; skos:definition """A synthetic bifunctional quinone derivative with potential antineoplastic activity. Diaziquone alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. This agent can also form free radicals, thereby initiating DNA damage via DNA strand breaks. Due to its lipophilicity, diaziquone readily crosses the blood brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39161&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39161&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1363\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1781"""^^xsd:string ; """C1363"""^^xsd:string ; """16707"""^^xsd:string ; """182986"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """57998-68-2"""^^xsd:string ; umls:cui """C0113600"""^^xsd:string ; umls:cui """C0109747"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azlocillin"""@eng ; skos:notation """CDR0000039160"""^^xsd:string ; skos:altLabel """Azlin"""@eng ; """1780"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0701435"""^^xsd:string ; umls:cui """C0004499"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-3/melphalan"""@eng ; skos:notation """CDR0000041634"""^^xsd:string ; skos:altLabel """IL-3/L-PAM"""@eng ; ; ; """4796"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281245"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edatrexate/ifosfamide"""@eng ; skos:notation """CDR0000041635"""^^xsd:string ; skos:altLabel """EDAM/IFF"""@eng ; ; ; """4797"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281246"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/tretinoin"""@eng ; skos:notation """CDR0000041636"""^^xsd:string ; skos:altLabel """ATRA/CDDP/VP-16"""@eng ; ; ; ; """4798"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281247"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cisplatin/cytarabine/dexamethasone/etoposide"""@eng ; skos:notation """CDR0000041637"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CDDP/DM/VP-16"""@eng ; ; ; ; ; ; """4799"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281248"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related primary CNS lymphoma"""@eng ; skos:notation """CDR0000041630"""^^xsd:string ; skos:altLabel """primary CNS lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """AIDS-related lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4792"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281241"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000041631"""^^xsd:string ; skos:altLabel """AIDS-associated diffuse large cell lymphoma"""@eng , """diffuse large cell lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """4793"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281242"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bruceantin"""@eng ; skos:notation """CDR0000039169"""^^xsd:string ; skos:altLabel """Picras-3-en-21-oic Acid, 15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11, 12-trihydroxy-2,16-dioxo-, Methyl Ester, (11.beta.,12.alpha,15.beta.(E))"""@eng , """[11Beta,12alpha,15beta(E)]-15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxopicras-3-en-21-oic Acid Methyl Ester"""@eng , """2H-3, 11c-(Epoxymethano)phenanthro[10,1-bc]pyran, Picras-3-en-21-oic Acid Derivative"""@eng ; skos:definition """A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica. Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis. Bruceantin also has antiamoebic and antimalarial activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39169&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39169&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1025\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """13613"""^^xsd:string ; """41451-75-6"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """165563"""^^xsd:string ; """C1025"""^^xsd:string ; umls:cui """C0054160"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bromodeoxyuridine"""@eng ; skos:notation """CDR0000039168"""^^xsd:string ; skos:altLabel """broxuridine"""@eng , """5-bromodeoxyuridine"""@eng ; """2006-11-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1788"""^^xsd:string ; """C318"""^^xsd:string ; umls:cui """C0006233"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/flutamide/leuprolide"""@eng ; skos:notation """CDR0000410698"""^^xsd:string ; skos:altLabel """FLUT/LEUP/PS-341"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541435"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/bortezomib/goserelin"""@eng ; skos:notation """CDR0000410694"""^^xsd:string ; skos:altLabel """CDX/PS-341/ZDX"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541432"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/bortezomib/leuprolide"""@eng ; skos:notation """CDR0000410696"""^^xsd:string ; skos:altLabel """CDX/LEUP/PS-341"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541433"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/flutamide/goserelin"""@eng ; skos:notation """CDR0000410697"""^^xsd:string ; skos:altLabel """FLUT/PS-341/ZDX"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541434"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp96-Ig fusion protein-expressing non-small cell lung cancer cell vaccine"""@eng ; skos:notation """CDR0000473873"""^^xsd:string ; skos:altLabel """gp96-Ig fusion protein vaccine"""@eng ; skos:definition """A cancer vaccine consisting of irradiated non-small cell lung cancer cells, manipulated to express and secrete heat shock protein gp96-Ig fusion protein, with potential antineoplastic activity. Vaccination with gp96-Ig fusion protein-expressing non-small cell lung cancer cell vaccine may elicit a cytotoxic T cell response against non-small lung cancer cells. Monomorphic heat shock protein gp96 participates in the major histocompatibility complex class I-restricted antigen presentation pathway. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473873&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473873&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073\" NCI Thesaurus)"""@eng ; """C61073"""^^xsd:string ; """2006-07-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831778"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-A3/HPV 16 peptide vaccine"""@eng ; skos:notation """CDR0000478746"""^^xsd:string ; skos:altLabel """MAGE-A3 HPV-16 Peptide Vaccine"""@eng ; skos:definition """A multi-epitope \"Trojan antigen\" (\"TA\") construct vaccine consisting of human melanoma antigen A3 (MAGE-A3) and human papillomavirus (HPV) 16 peptide epitopes linked by the furin-sensitive linker RVKR (arginine-serine-lysine-arginine peptide) with immunostimulatory and antitumor activities. The TA construct enters the cytoplasm of antigen-presenting cells (APC) and is processed by the endoplasmic reticulum (ER) and the trans-Golgi network (TGN), where the endopeptidase furin releases the epitopes from the RVKR linker and, together with various exopeptidases, generates MHC class I-binding peptides. Expressed on the cell surfaces of APC, these MHC class I-binding peptides stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that display the same peptide epitopes on their cell surfaces. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=478746&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=478746&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61088\" NCI Thesaurus)"""@eng ; """2006-04-07"""^^xsd:string ; """C61088"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-28"""^^xsd:string ; umls:cui """C1831802"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bacitracin/clotrimazole/gentamicin"""@eng ; skos:notation """CDR0000042859"""^^xsd:string ; skos:altLabel """BAC/CLOT/GM"""@eng ; ; ; ; """6669"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677793"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bacitracin"""@eng ; skos:notation """CDR0000042858"""^^xsd:string ; skos:altLabel """BAC"""@eng ; ; """6668"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0004599"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/exemestane"""@eng ; skos:notation """CDR0000038562"""^^xsd:string ; skos:altLabel """CDX/PNU 155971"""@eng ; ; ; """11193"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134586"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """magnetic resonance spectroscopic imaging"""@eng ; skos:notation """CDR0000038563"""^^xsd:string ; rdfs:subClassOf ; """11194"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1522706"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lenalidomide"""@eng ; skos:notation """CDR0000038564"""^^xsd:string ; skos:altLabel """CDC-501"""@eng , """IMiD-1"""@eng , """CC5013"""@eng , """CC 5013"""@eng , """Revlimid"""@eng , """CC-5013"""@eng ; skos:definition """A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38564&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38564&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2668\" NCI Thesaurus)"""@eng ; ; ; ; ; """TRD"""^^xsd:string ; """11195"""^^xsd:string ; """C2668"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C1134588"""^^xsd:string ; umls:cui """C1144149"""^^xsd:string ; umls:cui """C1328651"""^^xsd:string ; umls:cui """C1135145"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """goserelin/raloxifene"""@eng ; skos:notation """CDR0000038565"""^^xsd:string ; skos:altLabel """RALOX/ZDX"""@eng ; ; ; """11196"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134589"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dalteparin/gemcitabine"""@eng ; skos:notation """CDR0000038566"""^^xsd:string ; skos:altLabel """DAL/dFdC"""@eng ; ; ; """11197"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134590"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bupropion hydrochloride"""@eng ; skos:notation """CDR0000038567"""^^xsd:string ; skos:altLabel """(+-)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone Hydrochloride"""@eng , """BUP"""@eng , """Zyban"""@eng , """Amfebutamone"""@eng , """BW 323U66"""@eng , """Wellbutrin"""@eng , """1-Propanone, 1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-"""@eng ; skos:definition """The hydrochloride salt of an aminoketone antidepressant. The molecular mechanism of the antidepressant effect of bupropion is unknown. This agent does not inhibit monoamine oxidase and, compared to classical tricyclic antidepressants, is a weak blocker of the neuronal uptake of serotonin and norepinephrine. Buproprion also weakly inhibits the neuronal re-uptake of dopamine. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38567&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38567&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1317\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """34911-55-2"""^^xsd:string ; """34841-39-9 (old RN)"""^^xsd:string ; """170811"""^^xsd:string ; """C1317"""^^xsd:string ; """11198"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0085208"""^^xsd:string ; umls:cui """C0751626"""^^xsd:string ; umls:cui """C0085934"""^^xsd:string ; umls:cui """C0700563"""^^xsd:string ; umls:cui """C1524101"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rofecoxib"""@eng ; skos:notation """CDR0000038568"""^^xsd:string ; skos:altLabel """4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone"""@eng , """Vioxx"""@eng , """MK 966"""@eng ; skos:definition """A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38568&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38568&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1832\" NCI Thesaurus)"""@eng ; """11199"""^^xsd:string ; """162011-90-7"""^^xsd:string ; """C1832"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0762662"""^^xsd:string ; umls:cui """C0766718"""^^xsd:string ; umls:cui """C0876768"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000042850"""^^xsd:string ; skos:altLabel """CBDCA/CTX/DOX"""@eng ; ; ; ; """6660"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677787"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/gemcitabine"""@eng ; skos:notation """CDR0000042853"""^^xsd:string ; skos:altLabel """dFdC/DOX"""@eng ; ; ; """6663"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677788"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine"""@eng ; skos:notation """CDR0000042852"""^^xsd:string ; skos:altLabel """CAPE"""@eng , """Ro 09-1978/000"""@eng , """5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine"""@eng , """Xeloda"""@eng ; skos:definition """A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42852&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42852&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1794\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """6662"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """154361-50-9"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """C1794"""^^xsd:string ; """712807"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0724419"""^^xsd:string ; umls:cui """C0671970"""^^xsd:string ; umls:cui """C1527087"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gemcitabine/leucovorin calcium"""@eng ; skos:notation """CDR0000042855"""^^xsd:string ; skos:altLabel """CF/dFdC/5-FU"""@eng ; ; ; ; """6665"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677790"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 chimeric monoclonal antibody G-250"""@eng ; skos:notation """CDR0000042854"""^^xsd:string ; skos:altLabel """iodine I 131 MOAB G-250"""@eng , """iodine I 131 MOAB G250"""@eng , """iodine I 131 monoclonal antibody G-250"""@eng , """I 131 Monoclonal Antibody G-250"""@eng , """iodine I 131 monoclonal antibody G250"""@eng ; skos:definition """A radioimmunoconjugate comprised of the chimeric monoclonal antibody G-250 conjugated with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 chimeric monoclonal antibody G-250 binds to G-250, a renal-cell carcinoma-associated antigen, delivering cytotoxic iodine I 131 specifically to renal cell carcinoma cells that express G-250. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42854&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42854&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2449\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """6664"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """C2449"""^^xsd:string ; umls:cui """C0677789"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/lomustine/procarbazine"""@eng ; skos:notation """CDR0000042857"""^^xsd:string ; skos:altLabel """CCNU/CTX/PCB/VP-16"""@eng ; ; ; ; ; """6667"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677792"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arzoxifene hydrochloride"""@eng ; skos:notation """CDR0000042856"""^^xsd:string ; skos:altLabel """LY353381.HCl"""@eng , """SERM-3"""@eng , """LY353381 Hydrochloride"""@eng , """2-(4-Methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thiophene-6-ol hydrochloride"""@eng ; skos:definition """The hydrochloride salt of arzoxifene, a synthetic aromatic derivative with anti-estrogenic properties. Arzoxifene binds to estrogen receptors as a mixed estrogen agonist/antagonist. In comparison to other selective estrogen receptor modulators (SERMs), arzoxifene exhibits greater bioavailability and higher anti-estrogenic potency in the breast than raloxifene; it exhibits reduced estrogenicity in the uterus compared with either tamoxifen or raloxifene. This agent may have beneficial effects on bone and the cardiovascular system. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42856&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42856&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2460\" NCI Thesaurus)"""@eng ; """6666"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2460"""^^xsd:string ; umls:cui """C1527089"""^^xsd:string ; umls:cui """C0950979"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phosphaturic mesenchymal tumor"""@eng ; skos:notation """CDR0000433506"""^^xsd:string ; rdfs:subClassOf ; """2005-05-20"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """2005-05-16"""^^xsd:string ; umls:cui """C1831619"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/tipifarnib"""@eng ; skos:notation """CDR0000433053"""^^xsd:string ; skos:altLabel """R115777/VP-16"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-03"""^^xsd:string ; umls:cui """C1831612"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pulmonary complications management"""@eng ; skos:notation """CDR0000433509"""^^xsd:string ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2005-05-16"""^^xsd:string ; """2005-05-20"""^^xsd:string ; umls:cui """C1831620"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/interleukin-12/MART-1 antigen"""@eng ; skos:notation """CDR0000042252"""^^xsd:string ; skos:altLabel """IFA/IL-12/MART-1"""@eng ; ; ; ; """5500"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281755"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """barium sulfate"""@eng ; skos:notation """CDR0000483042"""^^xsd:string ; skos:definition """The sulfate salt of barium, an alkaline, divalent metal. Barium sulfate is quite insoluble in water, and is used as a radiopaque agent to diagnose gastrointestinal medical conditions. Barium sulfate is taken by mouth or given rectally. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=483042&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=483042&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28859\" NCI Thesaurus)"""@eng ; """2006-05-05"""^^xsd:string ; """C28859"""^^xsd:string ; """2006-06-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0004754"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epratuzumab/rituximab"""@eng ; skos:notation """CDR0000271206"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/MOAB LL2"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327878"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/satraplatin"""@eng ; skos:notation """CDR0000043098"""^^xsd:string ; skos:altLabel """BMS-182751/PRED"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """7492"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678095"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/etoposide"""@eng ; skos:notation """CDR0000043099"""^^xsd:string ; skos:altLabel """LipoDox/VP-16"""@eng ; ; ; """7493"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678096"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral cancer prevention"""@eng ; skos:notation """CDR0000043096"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """7490"""^^xsd:string ; umls:cui """C0678094"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irofulven"""@eng ; skos:notation """CDR0000043097"""^^xsd:string ; skos:altLabel """MGI 114"""@eng , """HMAF"""@eng , """MGI-114"""@eng , """Hydroxymethylacylfulvene"""@eng , """6-hydroxymethylacylfulvene"""@eng , """(R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one"""@eng ; skos:definition """A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens. Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43097&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43097&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1717\" NCI Thesaurus)"""@eng ; """7491"""^^xsd:string ; """683863"""^^xsd:string ; """158440-71-2"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1717"""^^xsd:string ; """55804"""^^xsd:string ; umls:cui """C0532362"""^^xsd:string ; umls:cui """C0950968"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium salicylate"""@eng ; skos:notation """CDR0000043094"""^^xsd:string ; skos:altLabel """salsalate"""@eng , """salicylate"""@eng , """Na-Sal"""@eng , """salicylic acid"""@eng , """Disalcid"""@eng , """Benzoic acid, 2-hydroxy-, monosodium salt"""@eng ; skos:definition """The sodium salt of salicylic acid. As a nonsteroidal anti-inflammatory drug (NSAID), sodium salicylate irreversibly acetylates cyclooxygenases I and II, thereby inhibiting prostaglandin synthesis and associated inflammation and pain. This agent may also activate mitogen-activated protein kinase (p38MAPK), thereby inducing apoptosis in cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43094&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43094&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C834\" NCI Thesaurus)"""@eng ; """7480"""^^xsd:string ; """54-21-7"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """49171"""^^xsd:string ; """C834"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0036075"""^^xsd:string ; umls:cui """C0702072"""^^xsd:string ; umls:cui """C0037549"""^^xsd:string ; umls:cui """C0036079"""^^xsd:string ; umls:cui """C0073983"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody A33"""@eng ; skos:notation """CDR0000043095"""^^xsd:string ; skos:altLabel """131I-labeled MOAB A33"""@eng ; """2003-10-07"""^^xsd:string ; """7489"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678093"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/paclitaxel"""@eng ; skos:notation """CDR0000043092"""^^xsd:string ; skos:altLabel """5-FU/TAX"""@eng ; ; ; """7476"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678091"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/fludarabine"""@eng ; skos:notation """CDR0000043093"""^^xsd:string ; skos:altLabel """BRYO/FAMP"""@eng ; ; ; """7477"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678092"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/QS21/tyrosinase peptide"""@eng ; skos:notation """CDR0000043090"""^^xsd:string ; skos:altLabel """gp100/QS 21/TYRP"""@eng ; ; ; ; """7474"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678089"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000043091"""^^xsd:string ; skos:altLabel """gp100/GM-CSF/TYRP"""@eng ; ; ; ; """7475"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678090"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/interferon alfa/prednisone/vincristine"""@eng ; skos:notation """CDR0000039769"""^^xsd:string ; skos:altLabel """I-COPA"""@eng , """CTX/DOX/IFN-A/PRED/VCR"""@eng ; ; ; ; ; ; """2430"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338105"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine"""@eng ; skos:notation """CDR0000039768"""^^xsd:string ; skos:altLabel """DTIC"""@eng , """WR-139007"""@eng , """5-(dimethyltriazeno)imidazole-4-carboxamide"""@eng , """Dacarbazina"""@eng , """DIC"""@eng , """Dimethyl Triazeno Imidazol Carboxamide"""@eng , """Dimethyl Triazeno Imidazole Carboxamide"""@eng , """1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-"""@eng , """Dacarbazine - DTIC"""@eng , """Dakarbazin"""@eng , """Dimethyl (triazeno) imidazolecarboxamide"""@eng , """Detimedac"""@eng , """5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide"""@eng , """Imidazole Carboxamide Dimethyltriazeno"""@eng , """Biocarbazine"""@eng , """dimethyl-triazeno-imidazole carboxamide"""@eng , """Deticene"""@eng , """DTIC-Dome"""@eng , """Dacarbazina Almirall"""@eng , """Dacatic"""@eng , """Imidazole Carboxamide"""@eng , """Asercit"""@eng , """5-(3-3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide"""@eng , """Fauldetic"""@eng ; skos:definition """A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39768&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39768&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C411\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """243"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """45388"""^^xsd:string ; """C411"""^^xsd:string ; """3188"""^^xsd:string ; """4342-03-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511712"""^^xsd:string ; umls:cui """C0010927"""^^xsd:string ; umls:cui """C0699717"""^^xsd:string ; umls:cui """C1511709"""^^xsd:string ; umls:cui """C0728898"""^^xsd:string ; umls:cui """C0392206"""^^xsd:string ; umls:cui """C1511711"""^^xsd:string ; umls:cui """C1511710"""^^xsd:string ; umls:cui """C1521710"""^^xsd:string ; umls:cui """C1521711"""^^xsd:string ; umls:cui """C0728896"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piroxicam"""@eng ; skos:notation """CDR0000039761"""^^xsd:string ; skos:altLabel """Feldene"""@eng , """4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboximide-1,1-dioxide"""@eng , """PXM"""@eng ; skos:definition """A nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39761&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39761&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C751\" NCI Thesaurus)"""@eng ; ; ; """2423"""^^xsd:string ; """666076"""^^xsd:string ; """C751"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """36322-90-4"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0687717"""^^xsd:string ; umls:cui """C0031990"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nabilone"""@eng ; skos:notation """CDR0000039760"""^^xsd:string ; skos:altLabel """Cesamet"""@eng , """Cpd 109514"""@eng ; skos:definition """A synthetic cannabinoid and dibenzopyrane derivative with anti-emetic activity. Although the mechanism of action has not been fully elucidated yet, it has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39760&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39760&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1171\" NCI Thesaurus)"""@eng ; """2422"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """56496-90-3"""^^xsd:string ; """C1171"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0969772"""^^xsd:string ; umls:cui """C1263104"""^^xsd:string ; umls:cui """C0068333"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spiroplatin"""@eng ; skos:notation """CDR0000039763"""^^xsd:string ; skos:altLabel """TNO-6"""@eng , """Cis-1,1-diamino-methylcyclohexane sulfato-platinum"""@eng ; skos:definition """A synthetic derivative of cyclohexane sulfatoplatinum with antineoplastic properties. Spiroplatin induces DNA cross-links, thereby inhibiting DNA replication and RNA and protein synthesis. Similar to other platinum compounds, this agent has been shown to be mutagenic and carcinogenic. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39763&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39763&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1234\" NCI Thesaurus)"""@eng ; """2425"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1234"""^^xsd:string ; """311056"""^^xsd:string ; """74790-08-2"""^^xsd:string ; umls:cui """C0075022"""^^xsd:string ; umls:cui """C0950614"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel"""@eng ; skos:notation """CDR0000039762"""^^xsd:string ; skos:altLabel """[2aR-[2a Alpha,4beta,4a beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"""@eng , """TAX"""@eng , """Praxel"""@eng , """Taxol"""@eng , """Asotax"""@eng , """Anzatax"""@eng , """5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine"""@eng , """Bristaxol"""@eng , """Taxol Konzentrat"""@eng ; skos:definition """A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39762&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39762&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1411\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2424"""^^xsd:string ; """33069-62-4"""^^xsd:string ; """125973"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """22850"""^^xsd:string ; """C1411"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """673089"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0678133"""^^xsd:string ; umls:cui """C1518840"""^^xsd:string ; umls:cui """C0144576"""^^xsd:string ; umls:cui """C1518839"""^^xsd:string ; umls:cui """C1518838"""^^xsd:string ; umls:cui """C1518837"""^^xsd:string ; umls:cui """C1518836"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyridoxine hydrochloride"""@eng ; skos:notation """CDR0000039765"""^^xsd:string ; skos:altLabel """B6 vitamin"""@eng , """vitamin B6"""@eng , """Hexa-Betalin"""@eng , """Beesix"""@eng , """VIT-B6"""@eng , """vitamin-B6"""@eng ; ; """2006-11-29"""^^xsd:string ; """2427"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48030"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0087162"""^^xsd:string ; umls:cui """C0701074"""^^xsd:string ; umls:cui """C0701075"""^^xsd:string ; umls:cui """C0700496"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trimetrexate glucuronate"""@eng ; skos:notation """CDR0000039764"""^^xsd:string ; skos:altLabel """2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline mono-D-glucuronate"""@eng , """TMTX"""@eng , """Neutrexin"""@eng , """TMQ"""@eng ; skos:definition """A lipid soluble methotrexate derivative with potential antineoplastic activity. Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis. Trimetrexate glucuronate also exhibits antiviral activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39764&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39764&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1265\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """2426"""^^xsd:string ; """82952-64-5"""^^xsd:string ; """23250"""^^xsd:string ; """C1265"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """352122"""^^xsd:string ; """27505"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0085176"""^^xsd:string ; umls:cui """C0699968"""^^xsd:string ; umls:cui """C0077209"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/fluorouracil"""@eng ; skos:notation """CDR0000039767"""^^xsd:string ; skos:altLabel """CTX/EPI/5-FU"""@eng , """FEC 100"""@eng , """FEC"""@eng ; ; ; ; """2429"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0060133"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """decitabine/idarubicin"""@eng ; skos:notation """CDR0000039766"""^^xsd:string ; skos:altLabel """DAC/IDA"""@eng , """5-AZA-dCyd/IDA"""@eng ; ; ; """2428"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279499"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/dacarbazine/tamoxifen"""@eng ; skos:notation """CDR0000041036"""^^xsd:string ; skos:altLabel """BCNU/CDDP/DTIC/TMX"""@eng ; ; ; ; ; """4076"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0914674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/dacarbazine"""@eng ; skos:notation """CDR0000041037"""^^xsd:string ; skos:altLabel """BCNU/CDDP/DTIC"""@eng ; ; ; ; """4077"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280646"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/mercaptopurine/methotrexate/prednisolone/teniposide/vincristine"""@eng ; skos:notation """CDR0000041034"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MP/MTX/PRDL/VCR/VM-26"""@eng ; ; ; ; ; ; ; ; """4074"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280643"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/dexamethasone/ifosfamide/methotrexate/thioguanine/vindesine"""@eng ; skos:notation """CDR0000041035"""^^xsd:string ; skos:altLabel """DAVA/DM/DNR/IFF/MTX/TG"""@eng ; ; ; ; ; ; ; """4075"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280644"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000041032"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DOX/VCR"""@eng ; ; ; ; ; ; ; """4072"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280641"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041033"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MP/MTX"""@eng ; ; ; ; ; ; """4073"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280642"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/prednisone/procarbazine/sargramostim/vincristine"""@eng ; skos:notation """CDR0000041030"""^^xsd:string ; skos:altLabel """GM-CSF/NM/PCB/PRED/VCR"""@eng ; ; ; ; ; ; """4070"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280639"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041031"""^^xsd:string ; skos:altLabel """ASP/DNR/PRDL/VCR"""@eng ; ; ; ; ; """4071"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280640"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/tamoxifen"""@eng ; skos:notation """CDR0000041038"""^^xsd:string ; skos:altLabel """CDDP/TMX"""@eng ; ; ; """4078"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280647"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine/mitoguazone"""@eng ; skos:notation """CDR0000041039"""^^xsd:string ; skos:altLabel """DFMO/MGBG"""@eng ; ; ; """4079"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280648"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, small cell lung cancer"""@eng ; skos:notation """CDR0000040206"""^^xsd:string ; skos:altLabel """small cell lung cancer cellular diagnosis"""@eng , """oat cell lung cancer, cellular diagnosis"""@eng ; rdfs:subClassOf ; """2998"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279902"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/interferon alfa"""@eng ; skos:notation """CDR0000040207"""^^xsd:string ; skos:altLabel """DHAD/IFN-A"""@eng ; ; ; """2999"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338108"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, salivary gland cancer"""@eng ; skos:notation """CDR0000040204"""^^xsd:string ; skos:altLabel """salivary gland cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2996"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279900"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, rectal cancer"""@eng ; skos:notation """CDR0000040205"""^^xsd:string ; skos:altLabel """rectal cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2997"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279901"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000040202"""^^xsd:string ; skos:altLabel """chronic lymphocytic leukemia cellular diagnosis"""@eng , """CLL cellular diagnosis"""@eng ; rdfs:subClassOf ; """2994"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279898"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000040203"""^^xsd:string ; skos:altLabel """chronic myelogenous leukemia cellular diagnosis"""@eng , """CML cellular diagnosis"""@eng ; rdfs:subClassOf ; """2995"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279899"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000040200"""^^xsd:string ; skos:altLabel """childhood rhabdomyosarcoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2992"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279896"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/cyclophosphamide/interleukin-2"""@eng ; skos:notation """CDR0000040201"""^^xsd:string ; skos:altLabel """BC-G/CTX/IL-2"""@eng ; ; ; ; """2003-10-29"""^^xsd:string ; """2993"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279897"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040208"""^^xsd:string ; skos:altLabel """adult Hodgkins lymphoma"""@eng , """adult HD"""@eng , """lymphoma, Hodgkin's, adult"""@eng , """adult Hodgkins disease"""@eng , """Lymphoma, Hodgkin's lymphoma, adult"""@eng , """HD, adult"""@eng , """adult Hodgkin disease"""@eng , """Hodgkin's disease, adult"""@eng , """adult Hodgkin lymphoma"""@eng , """Hodgkin's lymphoma, adult"""@eng , """adult Hodgkin's disease"""@eng ; rdfs:subClassOf ; """2003-01-16"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220597"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lung cancer"""@eng ; skos:notation """CDR0000040209"""^^xsd:string ; rdfs:subClassOf ; """2002-10-15"""^^xsd:string ; """30"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0684249"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody Hu3S193"""@eng ; skos:notation """CDR0000340956"""^^xsd:string ; skos:altLabel """Y90 MOAB Hu3S193"""@eng ; skos:definition """A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=340956&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=340956&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38678\" NCI Thesaurus)"""@eng ; """2003-10-25"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C38678"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328082"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iseganan HCl oral solution"""@eng ; skos:notation """CDR0000038389"""^^xsd:string ; skos:altLabel """Protegrin"""@eng , """IB-367 rinse"""@eng ; """11009"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135119"""^^xsd:string ; umls:cui """C1527211"""^^xsd:string ; umls:cui """C1527212"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NPI-2358"""@eng ; skos:notation """CDR0000488984"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62444"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1741609"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oligonucleotide SPC2996"""@eng ; skos:notation """CDR0000485272"""^^xsd:string ; skos:altLabel """SPC2996 oligonucleotide"""@eng ; skos:definition """A synthetic antisense oligonucleotide against Bcl-2 messenger RNA with potential antitumor activity. Oligonucleotide SPC2996 binds to and inactivates Bcl-2 mRNA, thereby inhibiting the expression of Bcl-2 protein, promoting tumor cell apoptosis, and potentially enhancing the efficacy of standard cytotoxic chemotherapy. Linked to tumor drug resistance, the antiapoptotic protein Bcl-2 is upregulated in several types of cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485272&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485272&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61325\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-10"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """C61325"""^^xsd:string ; umls:cui """C1831825"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """A-007"""@eng ; skos:notation """CDR0000485274"""^^xsd:string ; skos:altLabel """4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone"""@eng ; skos:definition """The phenylhydrazone 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone formulated as a topical agent with immunomodulating and potential antineoplastic activities. Applied topically as a 0.25% gel, A-007 may stimulate a local immune response against human papillomavirus (HPV)-induced cervical intraepithelial neoplasia (CIN). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485274&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485274&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61305\" NCI Thesaurus)"""@eng ; """C61305"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """2006-05-11"""^^xsd:string ; umls:cui """C0385861"""^^xsd:string ; umls:cui """C0385862"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VCL-CB01 vaccine"""@eng ; skos:notation """CDR0000485276"""^^xsd:string ; skos:definition """A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485276&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485276&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61327\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-11"""^^xsd:string ; """C61327"""^^xsd:string ; """2006-05-11"""^^xsd:string ; umls:cui """C1831826"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melan-A VLP vaccine"""@eng ; skos:notation """CDR0000506112"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831836"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LY573636"""@eng ; skos:notation """CDR0000506118"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-24"""^^xsd:string ; umls:cui """C1831958"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transgenic lymphocyte immunization vaccine"""@eng ; skos:notation """CDR0000315736"""^^xsd:string ; skos:altLabel """TLI vaccine"""@eng ; skos:definition """A vaccine consisting of a preparation of allogeneic lymphocytes that encode a gene for telomerase. In transgenic lymphocyte immunization, the transgenic cells are infused into the patient, where they serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315736&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315736&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38720\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """C38720"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327996"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic polypeptide tumor"""@eng ; skos:notation """CDR0000038988"""^^xsd:string ; skos:altLabel """pancreatic multiple hormonal syndrome"""@eng , """interacinar cell pancreatic polypeptide tumor"""@eng , """multiple hormonal syndrome, pancreatic"""@eng ; rdfs:subClassOf ; """2004-10-18"""^^xsd:string ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1547"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1882278"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/lomustine/vincristine"""@eng ; skos:notation """CDR0000039450"""^^xsd:string ; skos:altLabel """CCVV"""@eng , """CCNU/CTX/VCR/VP-16"""@eng ; ; ; ; ; """2085"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0257084"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA-TRICOM vaccine/sargramostim"""@eng ; skos:notation """CDR0000428320"""^^xsd:string ; skos:altLabel """fPSA-TRI/GM-CSF"""@eng ; ; ; """2005-04-07"""^^xsd:string ; """2005-04-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541546"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fruit and vegetable extracts"""@eng ; skos:notation """CDR0000315883"""^^xsd:string ; skos:altLabel """Juice Plus"""@eng ; skos:definition """Extracts from fruits and vegetables that contain fiber, vitamins, minerals, and other natural substances with antioxidant, lipid-lowering, and antiproliferative properties. Used in chemoprevention therapy, these extracts may prevent the development or recurrence of cancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315883&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315883&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38707\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38707"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328003"""^^xsd:string ; umls:cui """C1328004"""^^xsd:string ; umls:tui """T168"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dasatinib"""@eng ; skos:notation """CDR0000315885"""^^xsd:string ; skos:altLabel """BMS-354825"""@eng , """Sprycel"""@eng ; skos:definition """An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315885&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315885&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38713\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38713"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1455147"""^^xsd:string ; umls:cui """C1723829"""^^xsd:string ; umls:cui """C1328005"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """splenic marginal zone lymphoma"""@eng ; skos:notation """CDR0000372809"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0349632"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/topotecan"""@eng ; skos:notation """CDR0000042079"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/TOPO"""@eng ; ; ; ; """5313"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281611"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclosporine/paclitaxel"""@eng ; skos:notation """CDR0000042078"""^^xsd:string ; skos:altLabel """CBDCA/CYSP/TAX"""@eng ; ; ; ; """5312"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281610"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mitoxantrone/prednisolone/vincristine"""@eng ; skos:notation """CDR0000042077"""^^xsd:string ; skos:altLabel """CTX/DHAD/PRDL/VCR"""@eng ; ; ; ; ; """5311"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281609"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult neurofibrosarcoma"""@eng ; skos:notation """CDR0000042076"""^^xsd:string ; skos:altLabel """malignant neurolemma, adult"""@eng , """schwannoma, malignant, adult"""@eng , """malignant schwannoma, adult"""@eng , """neurogenic sarcoma, adult"""@eng , """sarcoma, neurogenic, adult"""@eng , """sarcoma, neurofibro-, adult"""@eng , """neurolemma, malignant, adult"""@eng , """neurofibrosarcoma, adult"""@eng ; rdfs:subClassOf ; """531"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278622"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/paclitaxel"""@eng ; skos:notation """CDR0000042075"""^^xsd:string ; skos:altLabel """L-PAM/TAX"""@eng ; ; ; """5308"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281608"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """homoharringtonine/interferon alfa"""@eng ; skos:notation """CDR0000042074"""^^xsd:string ; skos:altLabel """HH/IFN-A"""@eng ; ; ; """5307"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338186"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant viral vaccine"""@eng ; skos:notation """CDR0000042073"""^^xsd:string ; skos:altLabel """vaccine, recombinant viral"""@eng ; ; rdfs:subClassOf ; """5305"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281606"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone marrow ablation with stem cell support"""@eng ; skos:notation """CDR0000042072"""^^xsd:string ; ; rdfs:subClassOf ; ; ; ; ; """5304"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281605"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """graft versus tumor induction"""@eng ; skos:notation """CDR0000042071"""^^xsd:string ; skos:altLabel """graft versus host disease induction"""@eng ; ; rdfs:subClassOf ; """5303"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281604"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/gemcitabine/oxaliplatin"""@eng ; skos:notation """CDR0000434417"""^^xsd:string ; skos:altLabel """dFdC/L-OHP/MOAB VEGF"""@eng ; ; ; ; """2005-05-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-23"""^^xsd:string ; umls:cui """C1831628"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gallium nitrate/paclitaxel"""@eng ; skos:notation """CDR0000042110"""^^xsd:string ; skos:altLabel """GAN/TAX"""@eng ; ; ; """5346"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281635"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/gallium nitrate/paclitaxel"""@eng ; skos:notation """CDR0000042111"""^^xsd:string ; skos:altLabel """GAN/G-CSF/TAX"""@eng ; ; ; ; """5347"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281636"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/thiotepa"""@eng ; skos:notation """CDR0000042112"""^^xsd:string ; skos:altLabel """TAX/TSPA"""@eng ; ; ; """5348"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281637"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """O6-benzylguanine"""@eng ; skos:notation """CDR0000042113"""^^xsd:string ; skos:altLabel """06-Benzylguanine"""@eng , """O-6-Benzylguanine"""@eng , """BG"""@eng , """O(6)-Benzylguanine"""@eng , """06-Benzyl Guanine"""@eng ; skos:definition """A guanine analogue with antineoplastic activity. O(6)-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42113&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42113&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1306\" NCI Thesaurus)"""@eng ; ; ; ; ; """5349"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """45789"""^^xsd:string ; """19916-73-5"""^^xsd:string ; """C1306"""^^xsd:string ; """637037"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0083812"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/O6-benzylguanine"""@eng ; skos:notation """CDR0000042114"""^^xsd:string ; skos:altLabel """BCNU/BG"""@eng ; ; ; """5350"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281639"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/didanosine/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000042115"""^^xsd:string ; skos:altLabel """CTX/ddI/DOX/VP-16"""@eng ; ; ; ; ; """5351"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281640"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imipenem"""@eng ; skos:notation """CDR0000042116"""^^xsd:string ; skos:altLabel """imipemide"""@eng , """MK-0787"""@eng ; skos:definition """A broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. Imipenem binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis. Imipenem has the greatest affinity for PBP 1A, 1B, and 2, and its lethal effect is related to binding to PBP 2 and 1B. This antibiotic is active against a wide range of gram-positive and gram-negative organisms and is stable in the presence of beta-lactamases. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42116&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42116&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C570\" NCI Thesaurus)"""@eng ; """5352"""^^xsd:string ; """717864"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C570"""^^xsd:string ; """74431-23-5"""^^xsd:string ; umls:cui """C0020933"""^^xsd:string ; umls:cui """C0729073"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bexarotene"""@eng ; skos:notation """CDR0000042117"""^^xsd:string ; skos:altLabel """3-methyl TTNEB"""@eng , """Targretin"""@eng , """LGD1069"""@eng , """4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid"""@eng ; skos:definition """A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42117&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42117&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1635\" NCI Thesaurus)"""@eng ; ; ; ; """5353"""^^xsd:string ; """C1635"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """153559-49-0"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0765273"""^^xsd:string ; umls:cui """C0300770"""^^xsd:string ; umls:cui """C0813158"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute minimally differentiated myeloid leukemia (M0)"""@eng ; skos:notation """CDR0000042118"""^^xsd:string ; skos:altLabel """M0 adult acute minimally differentiated myeloid leukemia"""@eng , """M0 leukemia, adult acute"""@eng , """adult acute M0 leukemia"""@eng ; rdfs:subClassOf ; """5354"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281641"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute minimally differentiated myeloid leukemia (M0)"""@eng ; skos:notation """CDR0000042119"""^^xsd:string ; skos:altLabel """pediatric acute M0 leukemia"""@eng , """pediatric acute minimally differentiated myeloid leukemia (M0)"""@eng , """M0 childhood acute minimally differentiated myeloid leukemia"""@eng , """M0 pediatric acute minimally differentiated myeloid leukemia"""@eng , """M0 leukemia, pediatric acute"""@eng , """M0 leukemia, childhood acute"""@eng , """childhood acute M0 leukemia"""@eng ; rdfs:subClassOf ; """5355"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281642"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/letrozole"""@eng ; skos:notation """CDR0000410777"""^^xsd:string ; skos:altLabel """LTZ/SC-58635"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541441"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/capecitabine/gemcitabine"""@eng ; skos:notation """CDR0000410776"""^^xsd:string ; skos:altLabel """CAPE/dFdC/MOAB VEGF"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541440"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/PI-88"""@eng ; skos:notation """CDR0000410774"""^^xsd:string ; skos:altLabel """PI 88/TXT"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541439"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000288825"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED/PS-341/VCR/VP-16"""@eng ; ; ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-02-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327921"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """musculoskeletal complications management"""@eng ; skos:notation """CDR0000474305"""^^xsd:string ; skos:altLabel """complications management, musculoskeletal"""@eng , """management, musculoskeletal complications"""@eng ; rdfs:subClassOf owl:Thing ; ; """Supportive care modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831785"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent small intestine cancer"""@eng ; skos:notation """CDR0000038757"""^^xsd:string ; skos:altLabel """small intestine cancer, recurrent"""@eng , """recurrent small bowel cancer"""@eng , """small bowel cancer, recurrent"""@eng ; rdfs:subClassOf ; """small intestine cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1196"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854788"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult primary liver cancer"""@eng ; skos:notation """CDR0000038756"""^^xsd:string ; skos:altLabel """hepatoma, adult primary"""@eng , """Liver cancer, adult primary"""@eng , """liver cancer, adult primary"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1195"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220630"""^^xsd:string ; umls:cui """C0279607"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent extrahepatic bile duct cancer"""@eng ; skos:notation """CDR0000038755"""^^xsd:string ; skos:altLabel """extrahepatic bile duct cancer, recurrent"""@eng , """bile duct cancer, recurrent extrahepatic"""@eng ; rdfs:subClassOf ; """extrahepatic bile duct cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1194"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278812"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan/leucovorin calcium/panitumumab"""@eng ; skos:notation """CDR0000257863"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/MOAB ABX-EGF"""@eng ; ; ; ; ; """2004-10-11"""^^xsd:string ; """11468"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541168"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/methylprednisolone"""@eng ; skos:notation """CDR0000043308"""^^xsd:string ; skos:altLabel """MTX/MePRDL"""@eng ; ; ; """7835"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796460"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/melphalan"""@eng ; skos:notation """CDR0000043309"""^^xsd:string ; skos:altLabel """CBDCA/L-PAM"""@eng ; ; ; """7836"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796461"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043306"""^^xsd:string ; skos:altLabel """ASP/MP/MTX/VCR"""@eng ; ; ; ; ; """7833"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796458"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mercaptopurine/methotrexate/prednisone"""@eng ; skos:notation """CDR0000043307"""^^xsd:string ; skos:altLabel """ARA-C/MP/MTX/PRED"""@eng ; ; ; ; ; """7834"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796459"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/busulfan/cyclophosphamide"""@eng ; skos:notation """CDR0000043304"""^^xsd:string ; skos:altLabel """ATG/BU/CTX"""@eng ; ; ; ; """7831"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000043305"""^^xsd:string ; skos:altLabel """ASP/DHAD/DM/VP-16"""@eng ; ; ; ; ; """7832"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796457"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2 liposome/polyvalent melanoma vaccine"""@eng ; skos:notation """CDR0000043302"""^^xsd:string ; skos:altLabel """IFN-A/IL-2 LIPO/POLYMELVAC"""@eng ; ; ; ; """7821"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796454"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bronchoalveolar cell lung cancer"""@eng ; skos:notation """CDR0000043303"""^^xsd:string ; skos:altLabel """bronchioloalveolar carcinoma"""@eng , """lung cancer, bronchoalveolar cell"""@eng , """bronchoalveolar carcinoma"""@eng ; rdfs:subClassOf ; """7822"""^^xsd:string ; """2005-01-07"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007120"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/rituximab"""@eng ; skos:notation """CDR0000043300"""^^xsd:string ; skos:altLabel """DM/MOAB IDEC-C2B8"""@eng ; ; ; """7819"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extrahepatic bile duct cancer"""@eng ; skos:notation """CDR0000038752"""^^xsd:string ; skos:altLabel """Extrahepatic bile duct cancer"""@eng , """bile duct cancer, extrahepatic"""@eng , """Klatskin tumor (bile duct bifurcation)"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1191"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206702"""^^xsd:string ; umls:cui """C0153453"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glycyrrhizin"""@eng ; skos:notation """CDR0000041799"""^^xsd:string ; skos:altLabel """glycyrrhetic acid"""@eng , """glycyrrhetinic acid"""@eng ; """4985"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0017986"""^^xsd:string ; umls:cui """C0061751"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thioguanine/tiazofurin"""@eng ; skos:notation """CDR0000041798"""^^xsd:string ; skos:altLabel """TCAR/TG"""@eng ; ; ; """4984"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281378"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/17-N-allylamino-17-demethoxygeldanamycin"""@eng ; skos:notation """CDR0000257866"""^^xsd:string ; skos:altLabel """17-AAG/CDDP/dFdC"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """11469"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327790"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """respiratory papillomas"""@eng ; skos:notation """CDR0000041793"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2003-05-22"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4976"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281373"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminocamptothecin"""@eng ; skos:notation """CDR0000041792"""^^xsd:string ; skos:altLabel """9-amino-camptothecin"""@eng , """9-amino-20-camptothecin"""@eng , """9-AC"""@eng , """9-aminocamptothecin"""@eng , """9-amino-CPT"""@eng , """9-amino-20(S)-camptothecin"""@eng , """9AC"""@eng ; skos:definition """A water-insoluble camptothecin derivative. Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages. Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41792&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41792&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1488\" NCI Thesaurus)"""@eng ; ; """4975"""^^xsd:string ; """86639-63-6"""^^xsd:string ; """603071"""^^xsd:string ; """41083"""^^xsd:string ; """C1488"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0214192"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000041791"""^^xsd:string ; skos:altLabel """CBDCA/IFF/VCR/VP-16"""@eng ; ; ; ; ; """4974"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281371"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/thiotepa/vincristine"""@eng ; skos:notation """CDR0000041790"""^^xsd:string ; skos:altLabel """DM/MTX/TSPA/VCR"""@eng ; ; ; ; ; """4973"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281370"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/fludarabine"""@eng ; skos:notation """CDR0000041797"""^^xsd:string ; skos:altLabel """FAMP/G-CSF"""@eng ; ; ; """4983"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281377"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/cytarabine/sargramostim"""@eng ; skos:notation """CDR0000041796"""^^xsd:string ; skos:altLabel """ARA-C/BU/CTX/GM-CSF"""@eng ; ; ; ; ; """4981"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281376"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """differentiation therapy"""@eng ; skos:notation """CDR0000041795"""^^xsd:string ; skos:altLabel """therapy, differentiation"""@eng ; ; rdfs:subClassOf ; """4979"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281375"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pressor support"""@eng ; skos:notation """CDR0000041794"""^^xsd:string ; ; rdfs:subClassOf ; """4978"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0281374"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liposomal oxaliplatin"""@eng ; skos:notation """CDR0000500373"""^^xsd:string ; skos:altLabel """Aroplatin"""@eng , """liposomal NDDP"""@eng ; """TRD"""^^xsd:string ; """2006-08-06"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1517906"""^^xsd:string ; umls:cui """C0125061"""^^xsd:string ; umls:cui """C1831940"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenretinide/tretinoin"""@eng ; skos:notation """CDR0000043243"""^^xsd:string ; skos:altLabel """ATRA/HPR"""@eng ; ; ; """7709"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796398"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/hydrocortisone/leucovorin calcium"""@eng ; skos:notation """CDR0000043242"""^^xsd:string ; skos:altLabel """ARA-C/CF/CTX/HC"""@eng ; ; ; ; ; """7708"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796397"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 125"""@eng ; skos:notation """CDR0000043241"""^^xsd:string ; skos:altLabel """I-125"""@eng , """125-Iodine"""@eng , """Iodine I-125"""@eng ; skos:definition """A radioactive isotope of iodine, a nonmetallic element of the halogen group. With a half-life of 60 days, iodine 125 occurs naturally and can be produced artificially. This agent has both therapeutic and diagnostic uses, particularly in thyroid disease. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43241&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43241&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1841\" NCI Thesaurus)"""@eng ; ; """7707"""^^xsd:string ; """C1841"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796396"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/recombinant human thrombopoietin"""@eng ; skos:notation """CDR0000043240"""^^xsd:string ; skos:altLabel """ARA-C/IDA/rhTPO"""@eng ; ; ; ; """7706"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796395"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/gemcitabine"""@eng ; skos:notation """CDR0000043247"""^^xsd:string ; skos:altLabel """CBDCA/dFdC"""@eng ; ; ; """7731"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796403"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/idarubicin/lomustine"""@eng ; skos:notation """CDR0000043246"""^^xsd:string ; skos:altLabel """CCNU/DM/IDA"""@eng ; ; ; ; """7730"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796402"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/prednisolone"""@eng ; skos:notation """CDR0000043245"""^^xsd:string ; skos:altLabel """L-PAM/PRDL"""@eng ; ; ; """7729"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796401"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acitretin"""@eng ; skos:notation """CDR0000043244"""^^xsd:string ; skos:altLabel """(All-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid"""@eng , """Etretin"""@eng , """Neotigason"""@eng , """Ro-10-1670"""@eng , """Soriatane"""@eng , """Ro 10-1670"""@eng , """Trimethylmethoxyphenyl-retinoic acid"""@eng ; skos:definition """An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties. Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells. This agent may also inhibit tumor angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43244&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43244&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C985\" NCI Thesaurus)"""@eng ; """7710"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """55079-83-9"""^^xsd:string ; """C985"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733550"""^^xsd:string ; umls:cui """C0050559"""^^xsd:string ; umls:cui """C0678135"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp209-2M antigen/incomplete Freund's adjuvant/interleukin-2"""@eng ; skos:notation """CDR0000043249"""^^xsd:string ; skos:altLabel """gp209-2M/IFA/IL-2"""@eng ; ; ; ; """7733"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796405"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/sargramostim"""@eng ; skos:notation """CDR0000043248"""^^xsd:string ; skos:altLabel """G-CSF/GM-CSF"""@eng ; ; ; """7732"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796404"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/doxorubicin/melphalan"""@eng ; skos:notation """CDR0000041861"""^^xsd:string ; skos:altLabel """ABCM"""@eng , """BCNU/CTX/DOX/L-PAM"""@eng ; ; ; ; ; """5073"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0165053"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/interferon alfa/zidovudine"""@eng ; skos:notation """CDR0000041860"""^^xsd:string ; skos:altLabel """BU/CTX/IFN-A/ZDV"""@eng ; ; ; ; ; """5072"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338174"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000041863"""^^xsd:string ; skos:altLabel """CDDP/CF/5-FU/VP-16"""@eng ; ; ; ; ; """5075"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281429"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clodronate"""@eng ; skos:notation """CDR0000041862"""^^xsd:string ; skos:altLabel """CLOD"""@eng , """Difosfonal"""@eng , """CL2MDP"""@eng , """Loron"""@eng , """Mebonat"""@eng , """Bonefos"""@eng , """Clasteon"""@eng , """Clodronic Acid Disodium Salt"""@eng , """Clodronate Disodium"""@eng , """Dichloromethylene Diphosphonate"""@eng , """Ossiten"""@eng ; skos:definition """A nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate disodium binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41862&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41862&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1418\" NCI Thesaurus)"""@eng ; ; """5074"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """713466"""^^xsd:string ; """C1418"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1516659"""^^xsd:string ; umls:cui """C0591741"""^^xsd:string ; umls:cui """C0012081"""^^xsd:string ; umls:cui """C1516661"""^^xsd:string ; umls:cui """C1516660"""^^xsd:string ; umls:cui """C0282130"""^^xsd:string ; umls:cui """C1516662"""^^xsd:string ; umls:cui """C0162357"""^^xsd:string ; umls:cui """C0008994"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extramedullary plasmacytoma"""@eng ; skos:notation """CDR0000041865"""^^xsd:string ; skos:altLabel """plasmacytoma, extramedullary"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """508"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278619"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/melphalan"""@eng ; skos:notation """CDR0000041864"""^^xsd:string ; skos:altLabel """IFF/L-PAM/VP-16"""@eng ; ; ; ; """5077"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281430"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interleukin-1-alpha"""@eng ; skos:notation """CDR0000041867"""^^xsd:string ; skos:altLabel """CDDP/IL-1A"""@eng ; ; ; """5081"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281431"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oltipraz"""@eng ; skos:notation """CDR0000041866"""^^xsd:string ; skos:altLabel """OPZ"""@eng ; ; """5080"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0069456"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/interleukin-6/sargramostim"""@eng ; skos:notation """CDR0000041869"""^^xsd:string ; skos:altLabel """CBDCA/GM-CSF/IL-6/VP-16"""@eng ; ; ; ; ; """5083"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281433"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/etoposide/hydroxyurea"""@eng ; skos:notation """CDR0000041868"""^^xsd:string ; skos:altLabel """BCNU/CTX/HU/VP-16"""@eng ; ; ; ; ; """5082"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0297110"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """inositol"""@eng ; skos:notation """CDR0000305828"""^^xsd:string ; skos:altLabel """cis-1,2,3,5-trans-4,6-Cyclohexanehexol"""@eng , """myo-inositol"""@eng , """Cyclohexanehexol"""@eng ; skos:definition """A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305828&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305828&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28163\" NCI Thesaurus)"""@eng ; """2003-05-23"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28163"""^^xsd:string ; """87-89-8"""^^xsd:string ; umls:cui """C0021547"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/pemetrexed disodium"""@eng ; skos:notation """CDR0000305824"""^^xsd:string ; skos:altLabel """CBDCA/LY231514"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327967"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D1/3-MAGE-3-His fusion protein/SB-AS02B adjuvant"""@eng ; skos:notation """CDR0000256424"""^^xsd:string ; skos:altLabel """D1/3 MAGE3 HIS/SB AS02B"""@eng ; ; ; """2002-07-16"""^^xsd:string ; """11394"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327745"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SB-AS02B adjuvant"""@eng ; skos:notation """CDR0000256423"""^^xsd:string ; skos:altLabel """SB AS02B"""@eng ; skos:definition """A proprietary oil-in-water emulsion specifically designed for combining protein preparations used in vaccines. SB-AS02B adjuvant contains monophosphoryl lipid A and QS21, a saponin extracted from the South American tree Quillaja saponaria Molina. This agent may be used for formulating cancer-specific vaccine preparations such as those containing MAGE-3 melanoma protein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256423&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256423&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2810\" NCI Thesaurus)"""@eng ; ; """11392"""^^xsd:string ; """719275"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2810"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """10184"""^^xsd:string ; umls:cui """C1327744"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D1/3-MAGE-3-His fusion protein"""@eng ; skos:notation """CDR0000256422"""^^xsd:string ; skos:altLabel """D1/3-Mage-3 Fusion Protein (SB MAGE-3)"""@eng , """SB MAGE-3"""@eng , """D1/3 MAGE3 HIS"""@eng , """D1/3-Mage-3 Fusion Protein"""@eng ; skos:definition """A recombinant, chimeric protein derived from a melanoma antigenic epitope (MAGE-3) and recognized by specific cytotoxic T lymphocytes. MAGE-3, a human peptide epitope present in the cytosol of melanoma cells, may be expressed as the fusion protein D1/3-Mage-3; this fusion protein may boost antitumoral immune responses when used in a vaccine formulation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256422&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256422&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2748\" NCI Thesaurus)"""@eng ; ; ; """11393"""^^xsd:string ; """719274"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2748"""^^xsd:string ; """10184"""^^xsd:string ; umls:cui """C1327743"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fludarabine"""@eng ; skos:notation """CDR0000037936"""^^xsd:string ; skos:altLabel """CBDCA/FAMP"""@eng ; ; ; """10355"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AFP gene hepatocellular carcinoma vaccine/Montanide ISA-51"""@eng ; skos:notation """CDR0000037937"""^^xsd:string ; skos:altLabel """AFP GENE VAC/ISA-51"""@eng ; ; """10357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879483"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/azacitidine"""@eng ; skos:notation """CDR0000037934"""^^xsd:string ; skos:altLabel """AZA/WR-2721"""@eng ; ; ; """10353"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879480"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/SU5416"""@eng ; skos:notation """CDR0000037935"""^^xsd:string ; skos:altLabel """SU-5416/TAX"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10354"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879481"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/paclitaxel"""@eng ; skos:notation """CDR0000037932"""^^xsd:string ; skos:altLabel """CAPE/TAX"""@eng ; ; ; """10351"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879478"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone/rituximab"""@eng ; skos:notation """CDR0000037933"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/MOAB IDEC-C2B8"""@eng ; ; ; ; ; """10352"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879479"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III vulvar cancer"""@eng ; skos:notation """CDR0000037930"""^^xsd:string ; skos:altLabel """stage III vulva cancer"""@eng , """vulva cancer, stage III"""@eng , """vulvar cancer, stage III"""@eng , """stage III carcinoma of the vulva"""@eng , """cancer of the vulva, stage III"""@eng , """stage III cancer of the vulva"""@eng , """carcinoma of the vulva, stage III"""@eng ; rdfs:subClassOf ; """vulvar cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1035"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854962"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel/estramustine"""@eng ; skos:notation """CDR0000037931"""^^xsd:string ; skos:altLabel """CBDCA/EM/TXT"""@eng ; ; ; ; """10350"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879477"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/pyrazoloacridine"""@eng ; skos:notation """CDR0000038003"""^^xsd:string ; skos:altLabel """CBDCA/PZA"""@eng ; ; ; """10498"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879550"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-human chorionic gonadotropin vaccine/gemcitabine"""@eng ; skos:notation """CDR0000038002"""^^xsd:string ; skos:altLabel """ANTI-HCG VAC/dFdC"""@eng ; ; ; """10497"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879549"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-human chorionic gonadotropin vaccine"""@eng ; skos:notation """CDR0000038001"""^^xsd:string ; skos:definition """A peptide vaccine consisting of the whole or partial beta subunit of human chorionic gonadotrophin hormone (hCG) linked to an adjuvant carrier of bacterial or viral origin, with anti-fertility property. Anti-hCG vaccine blocks the activity of hCG which is naturally produced by the trophectoderm of the pre-implantation embryo within a few days of fertilization. hCG is required for the maintenance of the corpus luteum in the ovary thus ensuring its continued production of progesterone, which is required for the successful completion of implantation of the blastocyst. Without progesterone, the corpus luteum regresses, and menstruation occurs. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38001&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38001&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28719\" NCI Thesaurus)"""@eng ; ; """10496"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28719"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C0879548"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/temozolomide"""@eng ; skos:notation """CDR0000038000"""^^xsd:string ; skos:altLabel """CPT-11/TMZ"""@eng ; ; ; """10495"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/irinotecan/SU5416"""@eng ; skos:notation """CDR0000038007"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/SU-5416"""@eng ; ; ; ; """2003-10-29"""^^xsd:string ; """10501"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879553"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000038006"""^^xsd:string ; skos:altLabel """CF/MTX"""@eng ; ; ; """10500"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879552"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ras peptide cancer vaccine/sargramostim"""@eng ; skos:notation """CDR0000037938"""^^xsd:string ; skos:altLabel """GM-CSF/RAS PEP VAC"""@eng ; ; ; """10358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879276"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HuM291"""@eng ; skos:notation """CDR0000038004"""^^xsd:string ; skos:altLabel """HuM291"""@eng , """HUM291 [Anti-CD3 Antibody]"""@eng , """Anti-CD3 Antibody"""@eng , """Anti CD3"""@eng , """MOAB HuM291"""@eng ; skos:definition """A humanized monoclonal antibody deficient in Fc receptor binding directed against CD3 on the surfaces of T cells. Monoclonal antibody HuM291 binds to the CD3 portion of the CD3:TCR (T-cell receptor) complex expressed on the surface of T cells, resulting in apoptosis of antigen-activated T cells., Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38004&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38004&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2229\" NCI Thesaurus)"""@eng ; """10499"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """711007"""^^xsd:string ; """C2229"""^^xsd:string ; """8928"""^^xsd:string ; umls:cui """C0879551"""^^xsd:string ; umls:cui """C3887822"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plasmid DNA encoding human interleukin-12"""@eng ; skos:notation """CDR0000489352"""^^xsd:string ; skos:altLabel """pIL-12"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-15"""^^xsd:string ; """2006-06-09"""^^xsd:string ; umls:cui """C0879338"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody 3F8"""@eng ; skos:notation """CDR0000042680"""^^xsd:string ; skos:altLabel """I 131 Monoclonal Antibody 3F8"""@eng , """I131-MOAB-3F8"""@eng , """iodine I 131 MOAB 3F8"""@eng ; skos:definition """A radioimmunoconjugate consisting of 3F8, a murine anti-GD2 ganglioside monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic properties. Using monoclonal antibody 3F8 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing GD2. GD2 is a ganglioside which is overexpressed in malignant melanoma, neuroblastoma, and small cell carcinoma of the lung. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42680&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42680&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2431\" NCI Thesaurus)"""@eng ; """6465"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C2431"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393072"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous Epstein-Barr virus-specific cytotoxic T lymphocytes"""@eng ; skos:notation """CDR0000042681"""^^xsd:string ; skos:altLabel """Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes"""@eng , """EBV CTL"""@eng , """EBV-specific CTL"""@eng ; skos:definition """A preparation of lymphocytes harvested from a patient with an Epstein-Barr virus (EBV)-positive tumor. Ex vivo, the lymphocytes are activated against EBV-specific antigens and then returned to the patient, where they mount a specific immune response against EBV-positive tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42681&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42681&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28842\" NCI Thesaurus)"""@eng ; ; """2006-08-18"""^^xsd:string ; """C28842"""^^xsd:string ; """10567"""^^xsd:string ; """6466"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393073"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp96 heat shock protein-peptide complex"""@eng ; skos:notation """CDR0000042682"""^^xsd:string ; skos:altLabel """Autologous gp96 Heat Shock Protein Peptide Complex Vaccine"""@eng , """Heat Shock Protein Peptide Complex-96"""@eng , """HSP gp96-Peptide Complex"""@eng , """gp96 HSP-Peptide Complex"""@eng , """heat shock protein-peptide complex, gp96"""@eng , """HSPPC-96"""@eng , """Oncophage"""@eng ; skos:definition """An autologous cancer vaccine derived from tumor-specific gp96 heat shock proteins. Heat shock proteins chaperone peptides through the endoplasmic reticulum, are key regulators of dendritic cell maturation, migration and antigen processing, and are involved in T-cell activation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42682&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42682&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2432\" NCI Thesaurus)"""@eng ; """6467"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """C2432"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1764850"""^^xsd:string ; umls:cui """C0393074"""^^xsd:string ; umls:cui """C0935952"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMB-7 immunotoxin"""@eng ; skos:notation """CDR0000042683"""^^xsd:string ; skos:altLabel """HB21(Fv)PE40"""@eng , """LMB-7 (Single-Chain Immunotoxin)"""@eng , """B3(Fv)-PE38 Immunotoxin"""@eng , """B3(Fv)-PE38"""@eng , """immunotoxin LMB-7"""@eng ; skos:definition """A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells. The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42683&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42683&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1619\" NCI Thesaurus)"""@eng ; """6468"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """658931"""^^xsd:string ; """659639"""^^xsd:string ; """C1619"""^^xsd:string ; """5863"""^^xsd:string ; umls:cui """C0296314"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sabarubicin"""@eng ; skos:notation """CDR0000042684"""^^xsd:string ; skos:altLabel """MEN 10755"""@eng , """MEN-10755"""@eng ; """C1706"""^^xsd:string ; """6470"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; umls:cui """C0393075"""^^xsd:string ; umls:cui """C0664590"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/vindesine"""@eng ; skos:notation """CDR0000042685"""^^xsd:string ; skos:altLabel """BLEO/DAVA/DOX"""@eng ; ; ; ; """6471"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393076"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil-uracil/leucovorin calcium"""@eng ; skos:notation """CDR0000042687"""^^xsd:string ; skos:altLabel """Orzel"""@eng , """CF/UFT"""@eng ; ; ; """6473"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393078"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bizelesin"""@eng ; skos:notation """CDR0000042688"""^^xsd:string ; skos:altLabel """U-77779"""@eng , """benzo(1,2-b:4,3-b')dipyrrol-4-ol,6,6'-(carbonylbis(imino-1H-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-,(S-(R*,R*))"""@eng ; skos:definition """A synthetic cyclopropylpyrroloindole antineoplastic antibiotic. Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis. Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42688&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42688&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1472\" NCI Thesaurus)"""@eng ; """6474"""^^xsd:string ; """C1472"""^^xsd:string ; """44170"""^^xsd:string ; """129655-21-6"""^^xsd:string ; """615291"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """51724"""^^xsd:string ; umls:cui """C0209891"""^^xsd:string ; umls:cui """C0147481"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """psiCRIP-MFG-S-TK1-67"""@eng ; skos:notation """CDR0000042689"""^^xsd:string ; """6475"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393079"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/sorafenib"""@eng ; skos:notation """CDR0000406595"""^^xsd:string ; skos:altLabel """MOAB VEGF/SFN"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541410"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/gefitinib"""@eng ; skos:notation """CDR0000330111"""^^xsd:string ; skos:altLabel """SC-58635/ZD 1839"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328040"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lapatinib/paclitaxel"""@eng ; skos:notation """CDR0000371599"""^^xsd:string ; skos:altLabel """GW-572016/TAX"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-08-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541245"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XL820"""@eng ; skos:notation """CDR0000452042"""^^xsd:string ; skos:altLabel """XL820-001"""@eng ; skos:definition """An orally available, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL820 simultaneously inhibits the RTKs VEGF, KIT and PDGF. In tumor models of breast carcinomas, gliomas and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452042&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452042&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49090\" NCI Thesaurus)"""@eng ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C49090"""^^xsd:string ; """2005-10-14"""^^xsd:string ; umls:cui """C1710687"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegylated interferon alfa/temozolomide"""@eng ; skos:notation """CDR0000038492"""^^xsd:string ; skos:altLabel """PEG-IFNA/TMZ"""@eng ; ; ; """11111"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134526"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant fowlpox-CEA-MUC-1-TRICOM vaccine"""@eng ; skos:notation """CDR0000385667"""^^xsd:string ; skos:altLabel """PANVAC-F"""@eng , """fCEA-MUC-1-TRI"""@eng , """fowlpox-CEA-MUC-1-TRICOM vaccine"""@eng ; skos:definition """A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385667&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385667&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29316\" NCI Thesaurus)"""@eng ; ; ; ; """TRD"""^^xsd:string ; """2004-08-30"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """C29316"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1515687"""^^xsd:string ; umls:cui """C1541350"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/rituximab/temozolomide"""@eng ; skos:notation """CDR0000301904"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/MTX/TMZ"""@eng ; ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327955"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palonosetron hydrochloride"""@eng ; skos:notation """CDR0000486366"""^^xsd:string ; skos:altLabel """1H-Benz(de)isoquinolin-1-one, 2-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, Monohydrochloride,(3aS)-"""@eng , """RS 25259-197"""@eng , """Aloxi"""@eng ; skos:definition """The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic properties. Palonosetron competitively blocks the action of serotonin at 5-HT3 receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486366&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486366&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47650\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """135729-62-3"""^^xsd:string ; """C47650"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """2006-06-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0288369"""^^xsd:string ; umls:cui """C1310734"""^^xsd:string ; umls:cui """C1310735"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nystatin"""@eng ; skos:notation """CDR0000039512"""^^xsd:string ; skos:altLabel """Mycostatin"""@eng , """O-V Statin"""@eng , """Nystex"""@eng ; """2146"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0028741"""^^xsd:string ; umls:cui """C0699474"""^^xsd:string ; umls:cui """C0699475"""^^xsd:string ; umls:cui """C0699477"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/teniposide"""@eng ; skos:notation """CDR0000039513"""^^xsd:string ; skos:altLabel """MTX/VM-26"""@eng ; ; ; """2147"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279331"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zinostatin"""@eng ; skos:notation """CDR0000039510"""^^xsd:string ; skos:altLabel """vinostatin"""@eng , """neocarzinostatin"""@eng , """NCS"""@eng ; skos:definition """An enediyne antineoplastic antibiotic hybrid containing an aminoglycoside chromophore. Zinostatin is isolated from the bacterium Streptomyces carzinostaticus. The aminoglycoside component of zinostatin intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-strand breaks in DNA and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39510&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39510&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C682\" NCI Thesaurus)"""@eng ; """2144"""^^xsd:string ; """10905"""^^xsd:string ; """C682"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9014-02-2"""^^xsd:string ; """69856"""^^xsd:string ; umls:cui """C0027597"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """N-methylformamide"""@eng ; skos:notation """CDR0000039511"""^^xsd:string ; skos:altLabel """NMF"""@eng , """X 188"""@eng , """Formamide, N-methyl"""@eng , """EK 7011"""@eng , """N-MF"""@eng , """monomethylformamide"""@eng , """formylmethylamine"""@eng ; skos:definition """A water-soluble organic solvent. As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39511&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39511&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1163\" NCI Thesaurus)"""@eng ; """2145"""^^xsd:string ; """3051"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """123-39-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """20515"""^^xsd:string ; """C1163"""^^xsd:string ; umls:cui """C0066373"""^^xsd:string ; umls:cui """C1522004"""^^xsd:string ; umls:cui """C1522003"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/prednisone/tamoxifen/vincristine"""@eng ; skos:notation """CDR0000039516"""^^xsd:string ; skos:altLabel """CTX/5-FU/MTX/PRED/TMX/VCR"""@eng , """CMFVP(T)"""@eng ; ; ; ; ; ; ; """2150"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279333"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cyclophosphamide/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039517"""^^xsd:string ; skos:altLabel """CTX/DOX/HMM/PRED/VCR"""@eng , """CHHOP"""@eng ; ; ; ; ; ; """2153"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279335"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039514"""^^xsd:string ; skos:altLabel """COMA-A"""@eng , """ARA-C/CTX/DOX/MTX/VCR"""@eng ; ; ; ; ; ; """2149"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066953"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin"""@eng ; skos:notation """CDR0000039515"""^^xsd:string ; skos:altLabel """Cis-platinum II Diamine Dichloride"""@eng , """Cis-diamminedichloro Platinum (II)"""@eng , """cis-diammine-dichloroplatinum"""@eng , """Peyrone's Salt"""@eng , """Platiblastin-S"""@eng , """Platinol-AQ"""@eng , """Platiran"""@eng , """Briplatin"""@eng , """Platinex"""@eng , """Platosin"""@eng , """Placis"""@eng , """Platinol"""@eng , """Platistin"""@eng , """Platinol-AQ VHA Plus"""@eng , """Cis-diamminedichloroplatinum"""@eng , """CPDD"""@eng , """Cis-dichloroammine Platinum (II)"""@eng , """Platinoxan"""@eng , """cis-DDP"""@eng , """CDDP"""@eng , """cis-platinum II"""@eng , """Cismaplat"""@eng , """CACP"""@eng , """Cysplatyna"""@eng , """DDP"""@eng , """Citosin"""@eng , """Abiplatin"""@eng , """cisplatinum"""@eng , """Platinum, Diaminedichloro-, cis- (8CI)"""@eng , """Citoplatino"""@eng , """Cisplatyl"""@eng , """Platinol- AQ"""@eng , """PDD"""@eng , """Platinum Diamminodichloride"""@eng , """Neoplatin"""@eng , """Lederplatin"""@eng , """(SP-4-2)-Diamminedichloroplatinum"""@eng , """Cisplatina"""@eng , """Peyrone's Chloride"""@eng , """Platamine"""@eng , """Blastolem"""@eng , """cis-platinum"""@eng , """Platiblastin"""@eng , """Metaplatin"""@eng , """Cis-platinous Diamine Dichloride"""@eng ; skos:definition """An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39515&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39515&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C376\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """215"""^^xsd:string ; """119875"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """C376"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """15663-27-1"""^^xsd:string ; """8041"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1516573"""^^xsd:string ; umls:cui """C1516570"""^^xsd:string ; umls:cui """C1145694"""^^xsd:string ; umls:cui """C1516569"""^^xsd:string ; umls:cui """C1516568"""^^xsd:string ; umls:cui """C0008838"""^^xsd:string ; umls:cui """C1516566"""^^xsd:string ; umls:cui """C1516565"""^^xsd:string ; umls:cui """C1516564"""^^xsd:string ; umls:cui """C1516563"""^^xsd:string ; umls:cui """C1516562"""^^xsd:string ; umls:cui """C1516572"""^^xsd:string ; umls:cui """C0699666"""^^xsd:string ; umls:cui """C1516567"""^^xsd:string ; umls:cui """C0950644"""^^xsd:string ; umls:cui """C1516575"""^^xsd:string ; umls:cui """C1516571"""^^xsd:string ; umls:cui """C0699648"""^^xsd:string ; umls:cui """C1516576"""^^xsd:string ; umls:cui """C1516574"""^^xsd:string ; umls:cui """C0722652"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interferon alfa/melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000041263"""^^xsd:string ; skos:altLabel """CTX/IFN-A/L-PAM/PRED/VCR"""@eng ; ; ; ; ; ; """4336"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338136"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/quinine/verapamil/vincristine"""@eng ; skos:notation """CDR0000041262"""^^xsd:string ; skos:altLabel """DM/DOX/QUIN/VCR/VPAM"""@eng ; ; ; ; ; ; """4335"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280852"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/cyclophosphamide/misonidazole"""@eng ; skos:notation """CDR0000039518"""^^xsd:string ; skos:altLabel """CHIPS"""@eng , """CDDP/CTX/HMM/MNI"""@eng ; ; ; ; ; """2154"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279336"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/methotrexate/procarbazine"""@eng ; skos:notation """CDR0000039519"""^^xsd:string ; skos:altLabel """CCNU/MTX/PCB"""@eng , """CMP"""@eng ; ; ; ; """2156"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054385"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, ovarian low malignant potential tumor"""@eng ; skos:notation """CDR0000041267"""^^xsd:string ; skos:altLabel """ovarian low malignant potential tumor, cellular diagnosis"""@eng ; rdfs:subClassOf ; """4340"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280857"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of the vulva"""@eng ; skos:notation """CDR0000041266"""^^xsd:string ; skos:altLabel """vulva, squamous cell carcinoma of the"""@eng ; rdfs:subClassOf ; """4339"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280856"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone metastases prevention/treatment"""@eng ; skos:notation """CDR0000041265"""^^xsd:string ; skos:altLabel """prevention, bone metastases"""@eng , """prevention of bone metastases"""@eng , """treatment, bone metastases"""@eng , """treatment of bone metastases"""@eng ; """Cancer therapy modality"""^^xsd:string ; """2006-03-03"""^^xsd:string ; """4338"""^^xsd:string ; umls:cui """C0280855"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/monoclonal antibody 3F8"""@eng ; skos:notation """CDR0000041264"""^^xsd:string ; skos:altLabel """CBDCA/MOAB 3F8/VP-16"""@eng ; ; ; ; """4337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280854"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular choriocarcinoma and seminoma"""@eng ; skos:notation """CDR0000040019"""^^xsd:string ; skos:altLabel """testicular cancer, choriocarcinoma and seminoma"""@eng , """choriocarcinoma and seminoma, testicular"""@eng , """testicular seminoma and choriocarcinoma"""@eng , """testis cancer, seminoma and choriocarcinoma"""@eng , """testicular cancer, seminoma and choriocarcinoma"""@eng , """seminoma and choriocarcinoma of the testis"""@eng , """testis cancer, choriocarcinoma and seminoma"""@eng , """testicle cancer, choriocarcinoma and seminoma"""@eng ; rdfs:subClassOf ; """2745"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279720"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic beta islet cell adenoma"""@eng ; skos:notation """CDR0000040018"""^^xsd:string ; skos:altLabel """insulin secreting adenoma"""@eng , """insulin producing adenoma"""@eng , """adenoma, pancreatic beta islet cell"""@eng , """islet cell, beta, pancreatic adenoma"""@eng , """beta islet cell adenoma, pancreatic"""@eng ; rdfs:subClassOf ; """2744"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279719"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """picibanil"""@eng ; skos:notation """CDR0000489137"""^^xsd:string ; skos:altLabel """OK-432"""@eng ; """C745"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """39325-01-4"""^^xsd:string ; umls:cui """C0918027"""^^xsd:string ; umls:cui """C0031875"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular embryonal carcinoma and seminoma"""@eng ; skos:notation """CDR0000040012"""^^xsd:string ; skos:altLabel """embryonal carcinoma and seminoma, testicular"""@eng , """testis cancer, seminoma and embryonal carcinoma"""@eng , """seminoma and embryonal carcinoma of the testis"""@eng , """testicular cancer, embryonal carcinoma and seminoma"""@eng , """testicular seminoma and embryonal carcinoma"""@eng , """testis cancer, embryonal carcinoma and seminoma"""@eng , """testicle cancer, embryonal carcinoma and seminoma"""@eng , """testicular cancer, seminoma and embryonal carcinoma"""@eng ; rdfs:subClassOf ; """2738"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279713"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular embryonal carcinoma and yolk sac tumor with seminoma"""@eng ; skos:notation """CDR0000040011"""^^xsd:string ; skos:altLabel """testicular cancer, embryonal carcinoma and yolk sac tumor with seminoma"""@eng , """yolk sac tumor with seminoma and embryonal carcinoma of the testis"""@eng , """embryonal carcinoma and yolk sac tumor with seminoma, testicular"""@eng , """testicular yolk sac tumor with seminoma and embryonal carcinoma"""@eng , """testicular cancer, yolk sac tumor with seminoma and embryonal carcinoma"""@eng , """testis cancer, yolk sac tumor with seminoma and embryonal carcinoma"""@eng , """testis cancer, embryonal carcinoma and yolk sac tumor with seminoma"""@eng , """testicle cancer, yolk sac tumor with seminoma and embryonal carcinoma"""@eng ; rdfs:subClassOf ; """2737"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279712"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular embryonal carcinoma and yolk sac tumor"""@eng ; skos:notation """CDR0000040010"""^^xsd:string ; skos:altLabel """testis cancer, yolk sac tumor and embryonal carcinoma"""@eng , """yolk sac tumor and embryonal carcinoma of the testis"""@eng , """testicle cancer, yolk sac tumor and embryonal carcinoma"""@eng , """testicular cancer, yolk sac tumor and embryonal carcinoma"""@eng , """testicular yolk sac tumor and embryonal carcinoma"""@eng , """testicular cancer, embryonal carcinoma and yolk sac tumor"""@eng , """embryonal carcinoma and yolk sac tumor, testicular"""@eng , """testis cancer, embryonal carcinoma and yolk sac tumor"""@eng ; rdfs:subClassOf ; """2736"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279711"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular choriocarcinoma and teratoma"""@eng ; skos:notation """CDR0000040017"""^^xsd:string ; skos:altLabel """choriocarcinoma and teratoma, testicular"""@eng , """testicular teratoma and choriocarcinoma"""@eng , """testicle cancer, choriocarcinoma and teratoma"""@eng , """testicular cancer, teratoma and choriocarcinoma"""@eng , """testis cancer, teratoma and choriocarcinoma"""@eng , """testicular cancer, choriocarcinoma and teratoma"""@eng , """testis cancer, choriocarcinoma and teratoma"""@eng , """teratoma and choriocarcinoma of the testis"""@eng ; rdfs:subClassOf ; """2743"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279718"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular choriocarcinoma and embryonal carcinoma"""@eng ; skos:notation """CDR0000040016"""^^xsd:string ; skos:altLabel """choriocarcinoma and embryonal carcinoma of the testis"""@eng , """testicular cancer, choriocarcinoma and embryonal carcinoma"""@eng , """testis cancer, choriocarcinoma and embryonal carcinoma"""@eng , """testicular cancer, embryonal carcinoma and choriocarcinoma"""@eng , """embryonal carcinoma and choriocarcinoma, testicular"""@eng , """testis cancer, embryonal carcinoma and choriocarcinoma"""@eng , """testicle cancer, choriocarcinoma and embryonal carcinoma"""@eng ; rdfs:subClassOf ; """2742"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279717"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hemoptysis"""@eng ; skos:notation """CDR0000516015"""^^xsd:string ; rdfs:subClassOf ; """2006-10-22"""^^xsd:string ; """2006-10-24"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0019079"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular yolk sac tumor and teratoma with seminoma"""@eng ; skos:notation """CDR0000040014"""^^xsd:string ; skos:altLabel """testis cancer, yolk sac tumor and teratoma with seminoma"""@eng , """teratoma with seminoma and yolk sac tumor of the testis"""@eng , """testicular teratoma with seminoma and yolk sac tumor"""@eng , """testicle cancer, teratoma with seminoma and yolk sac tumor"""@eng , """testis cancer, teratoma with seminoma and yolk sac tumor"""@eng , """testicular cancer, teratoma with seminoma and yolk sac tumor"""@eng , """testicular cancer, yolk sac tumor and teratoma with seminoma"""@eng , """yolk sac tumor and teratoma with seminoma, testicular"""@eng ; rdfs:subClassOf ; """2740"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279715"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult intermediate grade NHL"""@eng ; skos:notation """CDR0000039064"""^^xsd:string ; skos:altLabel """intermediate grade adult non-Hodgkin's lymphoma"""@eng , """NHL, adult intermediate grade"""@eng , """adult NHL, intermediate grade"""@eng , """non-Hodgkin's lymphoma, adult intermediate grade"""@eng , """lymphoma, adult intermediate grade non-Hodgkin's"""@eng ; """2005-01-21"""^^xsd:string ; """1649"""^^xsd:string ; umls:cui """C0279076"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """previously treated childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000043389"""^^xsd:string ; skos:altLabel """childhood rhabdomyosarcoma, previously treated"""@eng , """rhabdomyosarcoma, previously treated, childhood"""@eng , """previously treated pediatric rhabdomyosarcoma"""@eng , """pediatric rhabdomyosarcoma, previously treated"""@eng ; rdfs:subClassOf ; """childhood rhabdomyosarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7941"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796528"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lovastatin"""@eng ; skos:notation """CDR0000041658"""^^xsd:string ; skos:altLabel """Mevacor"""@eng , """Mevinolin"""@eng , """(2S)-2-Methylbutanoic Acid, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl Ester"""@eng , """Monacolin K"""@eng , """Lovastatin Sodium"""@eng ; skos:definition """A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering activity and potential antineoplastic activity. Lovastatin is hydrolyszed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in the cholesterol biosynthesis. In addition, this agent may inhibit tumor cell proliferation and reduce tumor cell invasiveness, thereby decreasing tumor metastatic potential; induce tumor cell apoptosis, possibly by inhibiting protein geranylgeranylation and; arrest cells in the G1 phase of the cell cycle, an effect that sensitizes tumor cells to the cytotoxic effects of ionizing radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41658&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41658&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C620\" NCI Thesaurus)"""@eng ; """4820"""^^xsd:string ; """C620"""^^xsd:string ; """633781"""^^xsd:string ; """46181"""^^xsd:string ; """75330-75-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0728780"""^^xsd:string ; umls:cui """C0024027"""^^xsd:string ; umls:cui """C1708744"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior adjuvant chemotherapy"""@eng ; skos:notation """CDR0000041659"""^^xsd:string ; """4821"""^^xsd:string ; umls:cui """C0281265"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/procarbazine/vincristine"""@eng ; skos:notation """CDR0000041652"""^^xsd:string ; skos:altLabel """PCB/VCR/VP-16"""@eng ; ; ; ; """4814"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281262"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/etoposide/mechlorethamine/prednisone/vinblastine/vincristine"""@eng ; skos:notation """CDR0000041653"""^^xsd:string ; skos:altLabel """BLEO/DOX/NM/PRED/VBL/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """4815"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0297109"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000041650"""^^xsd:string ; skos:altLabel """BLEO/DOX/VCR/VP-16"""@eng , """DBVE"""@eng ; ; ; ; ; """4811"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281259"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/epirubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000041651"""^^xsd:string ; skos:altLabel """CDDP/EPI/MTX/VBL"""@eng ; ; ; ; ; """4813"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065453"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mivobulin isethionate"""@eng ; skos:notation """CDR0000041656"""^^xsd:string ; skos:altLabel """CI-980"""@eng ; ; """4818"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C1357"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0109740"""^^xsd:string ; umls:cui """C0796310"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel"""@eng ; skos:notation """CDR0000041657"""^^xsd:string ; skos:altLabel """TXT"""@eng , """RP56976"""@eng , """[2aR-[2a Alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"""@eng , """Taxotere"""@eng , """N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol"""@eng , """RP 56976"""@eng ; skos:definition """A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41657&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41657&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1526\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4819"""^^xsd:string ; """628503"""^^xsd:string ; """114977-28-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """40466"""^^xsd:string ; """C1526"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733872"""^^xsd:string ; umls:cui """C0699967"""^^xsd:string ; umls:cui """C1527020"""^^xsd:string ; umls:cui """C0246415"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """smoking cessation intervention"""@eng ; skos:notation """CDR0000041654"""^^xsd:string ; ; rdfs:subClassOf ; """4816"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C1692317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thymopentin"""@eng ; skos:notation """CDR0000041655"""^^xsd:string ; skos:altLabel """Immunox"""@eng , """Timunox"""@eng , """N-(N-(N-(N(2)-L-Arginyl-L-Lysyl)-L-alpha-Aspartyl)-L-Valyl)-L-Tyrosine"""@eng , """Mepentil"""@eng , """Sintomodulina"""@eng ; skos:definition """A synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41655&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41655&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1294\" NCI Thesaurus)"""@eng ; """4817"""^^xsd:string ; """39678"""^^xsd:string ; """C1294"""^^xsd:string ; """69558-55-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """645363"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0918006"""^^xsd:string ; umls:cui """C0080225"""^^xsd:string ; umls:cui """C1831597"""^^xsd:string ; umls:cui """C1515436"""^^xsd:string ; umls:cui """C1515435"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody ACA125 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000299488"""^^xsd:string ; skos:altLabel """VaccinOvar"""@eng ; skos:definition """A murine immunoglobulin G1 (IgG1) monoclonal anti-idiotype antibody (ACA125). Vaccination with monoclonal antibody ACA125 anti-idiotype vaccine may stimulate the host immune system to mount an antibody response and subsequent antibody-dependent cell-mediated cytotoxicity response against CA125 positive tumor cells, thereby decreasing tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299488&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299488&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26449\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2003-03-24"""^^xsd:string ; """2003-03-18"""^^xsd:string ; """C26449"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832044"""^^xsd:string ; umls:cui """C1328701"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes/interleukin-2/MOv-gamma chimeric receptor gene"""@eng ; skos:notation """CDR0000271911"""^^xsd:string ; skos:altLabel """ALLOLYMPH/IL-2/MOv-gCR"""@eng ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-01-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327892"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000271916"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-01-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327893"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/etanercept"""@eng ; skos:notation """CDR0000437893"""^^xsd:string ; skos:altLabel """ATG/ETN"""@eng ; ; ; """2005-06-20"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831659"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/mycophenolate mofetil"""@eng ; skos:notation """CDR0000042877"""^^xsd:string ; skos:altLabel """CYSP/MMF"""@eng ; ; ; """6690"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677809"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/L-leucovorin"""@eng ; skos:notation """CDR0000042304"""^^xsd:string ; skos:altLabel """CDDP/5-FU/L-CF"""@eng ; ; ; ; """5552"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338233"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetracycline hydrochloride"""@eng ; skos:notation """CDR0000042307"""^^xsd:string ; skos:altLabel """TETRA"""@eng , """Achromycin"""@eng ; skos:definition """The hydrochloride salt of tetracycline, a broad-spectrum naphthacene antibiotic, produced semisynthetically from chlortetracycline, an antibiotic isolated from the Streptomyces aureofaciens. In bacteria, tetracycline hydrochloride blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis and bacterial cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42307&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42307&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48020\" NCI Thesaurus)"""@eng ; ; ; """5555"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """C48020"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0740484"""^^xsd:string ; umls:cui """C0546879"""^^xsd:string ; umls:cui """C0039644"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/melphalan"""@eng ; skos:notation """CDR0000042306"""^^xsd:string ; skos:altLabel """DM/L-PAM"""@eng ; ; ; """5554"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338234"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vector Ad-p53"""@eng ; skos:notation """CDR0000042873"""^^xsd:string ; skos:altLabel """p53 adenoviral vector"""@eng , """Ad-p53"""@eng , """adenovirus p53 construct"""@eng , """Ad-p53 vector"""@eng ; """2006-10-09"""^^xsd:string ; """6686"""^^xsd:string ; umls:cui """C0677806"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edetate calcium disodium"""@eng ; skos:notation """CDR0000042300"""^^xsd:string ; skos:altLabel """EDTA calcium"""@eng , """EDTA"""@eng ; ; """5547"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0006692"""^^xsd:string ; umls:cui """C0013618"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human chorionic gonadotropin/staphage lysate"""@eng ; skos:notation """CDR0000042303"""^^xsd:string ; skos:altLabel """LDI-100"""@eng , """HCG/SPL"""@eng ; ; ; """5551"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338232"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfacon-1"""@eng ; skos:notation """CDR0000042870"""^^xsd:string ; skos:altLabel """Advaferon"""@eng , """Recombinant methionyl human consensus interferon"""@eng , """Recombinant Consensus Interferon"""@eng , """r-metHuIFN-Con1"""@eng , """methionyl interferon consensus"""@eng , """interferon consensus, methionyl"""@eng , """Interferon Consensus, Methionyl"""@eng , """consensus interferon"""@eng , """CIFN"""@eng , """methionyl-interferon-consensus"""@eng , """Infergen"""@eng , """IFN Alfacon-1"""@eng ; skos:definition """An analogue of consensus interferon which contains an additional methionyl amino acid residue. Consensus interferon (also known as interferon alfacon-1, rCon-IFN, and CIFN) is a genetically engineered synthetic interferon created from the most common amino acid sequences from the naturally occurring alpha interferons. Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42870&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42870&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1766\" NCI Thesaurus)"""@eng ; """6683"""^^xsd:string ; """118390-30-0"""^^xsd:string ; """2006-08-16"""^^xsd:string ; """C1766"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1512830"""^^xsd:string ; umls:cui """C0721063"""^^xsd:string ; umls:cui """C0164613"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """omeprazole"""@eng ; skos:notation """CDR0000042309"""^^xsd:string ; skos:altLabel """H168/68"""@eng , """OMEP"""@eng , """Prilosec"""@eng , """5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole"""@eng , """Losec"""@eng ; skos:definition """A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic properties and does not antagonize histamine H2 receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42309&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42309&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C716\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """5557"""^^xsd:string ; """C716"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591742"""^^xsd:string ; umls:cui """C0028978"""^^xsd:string ; umls:cui """C0700777"""^^xsd:string ; umls:cui """C1764845"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clarithromycin"""@eng ; skos:notation """CDR0000042308"""^^xsd:string ; skos:altLabel """Abbott-56268"""@eng , """CLARITH"""@eng , """6-O-Methylerythromycin"""@eng , """Biaxin"""@eng ; skos:definition """A semisynthetic 14-membered ring macrolide antibiotic. Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms. Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42308&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42308&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1054\" NCI Thesaurus)"""@eng ; ; ; """5556"""^^xsd:string ; """C1054"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """81103-11-9"""^^xsd:string ; """643733"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0055856"""^^xsd:string ; umls:cui """C0701281"""^^xsd:string ; umls:cui """C0701282"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/interleukin-2/MART-1 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000042879"""^^xsd:string ; skos:altLabel """gp100/IFA/IL-2/MART-1/TYRP"""@eng ; ; ; ; ; ; """6692"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677811"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/MART-1 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000042878"""^^xsd:string ; skos:altLabel """gp100/IFA/MART-1/TYRP"""@eng ; ; ; ; ; """6691"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677810"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult subependymal giant cell astrocytoma"""@eng ; skos:notation """CDR0000530662"""^^xsd:string ; skos:altLabel """subependymal giant cell astrocytoma, adult"""@eng , """astrocytoma, adult subependymal giant cell"""@eng ; rdfs:subClassOf ; """2007-01-11"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C1832033"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, transitional cell cancer of the renal pelvis and ureter"""@eng ; skos:notation """CDR0000040659"""^^xsd:string ; skos:altLabel """cancer of the renal pelvis and ureter stage"""@eng , """carcinoma of the renal pelvis and ureter stage"""@eng , """transitional cell carcinoma of the renal pelvis and ureter stage"""@eng ; rdfs:subClassOf ; """3571"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280282"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """regional transitional cell cancer of the renal pelvis and ureter"""@eng ; skos:notation """CDR0000040658"""^^xsd:string ; skos:altLabel """transitional cell cancer of the renal pelvis and ureter, regional"""@eng , """carcinoma of the renal pelvis and ureter, regional"""@eng , """cancer of the renal pelvis and ureter, regional"""@eng ; rdfs:subClassOf ; """transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3570"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280281"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040655"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MTX/VCR"""@eng ; ; ; ; ; ; """3567"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280278"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000040654"""^^xsd:string ; skos:altLabel """CAF/TsAVbH"""@eng , """CTX/DOX/5-FU/FXM/TSPA/VBL"""@eng ; ; ; ; ; ; """3566"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280277"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, prostate cancer"""@eng ; skos:notation """CDR0000040657"""^^xsd:string ; skos:altLabel """prostate cancer stage"""@eng ; rdfs:subClassOf ; """3569"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280280"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate"""@eng ; skos:notation """CDR0000040656"""^^xsd:string ; skos:altLabel """CMFH"""@eng , """CTX/5-FU/FXM/MTX"""@eng ; ; ; ; """3568"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280279"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/thiotepa"""@eng ; skos:notation """CDR0000040651"""^^xsd:string ; skos:altLabel """TSPA/WR-2721"""@eng ; ; ; """3563"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human chorionic gonadotropin"""@eng ; skos:notation """CDR0000040650"""^^xsd:string ; skos:altLabel """HCG"""@eng ; ; """2006-11-27"""^^xsd:string ; """C528"""^^xsd:string ; """356"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1527152"""^^xsd:string ; umls:cui """C1141639"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mitoxantrone/prednisone/vincristine"""@eng ; skos:notation """CDR0000040653"""^^xsd:string ; skos:altLabel """CTX/DHAD/PRED/VCR"""@eng , """CNOP"""@eng ; ; ; ; ; """3565"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280276"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mopidamol"""@eng ; skos:notation """CDR0000040652"""^^xsd:string ; skos:altLabel """RA-233"""@eng , """Rapenton"""@eng ; """3564"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0917703"""^^xsd:string ; umls:cui """C0026523"""^^xsd:string ; umls:cui """C0917704"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/FR901228"""@eng ; skos:notation """CDR0000405924"""^^xsd:string ; skos:altLabel """FLAVO/FR 901228"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541402"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/sorafenib"""@eng ; skos:notation """CDR0000405926"""^^xsd:string ; skos:altLabel """IFN-A/SFN"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541403"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/irinotecan/oxaliplatin"""@eng ; skos:notation """CDR0000405927"""^^xsd:string ; skos:altLabel """CPT-11/L-OHP/MOAB VEFG"""@eng ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541404"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenretinide/lonafarnib"""@eng ; skos:notation """CDR0000415997"""^^xsd:string ; skos:altLabel """HPR/SCH 66336"""@eng ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541491"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """demineralized bone matrix"""@eng ; skos:notation """CDR0000476316"""^^xsd:string ; skos:altLabel """DBM"""@eng ; skos:definition """Demineralized allograft bone with osteoinductive activity. Demineralizedbone matrices are prepared by acid extraction of allograftbone, resulting in loss of most of the mineralized componentbut retention of collagen and noncollagenous proteins, includinggrowth factors.The efficacy of a demineralizedbone matrix (DBM) as a bone-graft substitute or extender may be related to the total amount of bone morphogeneticprotein (BMP) present, and the ratios of the different BMPspresent. BMPs belong to the transforming growth factor (TGF) superfamily of proteins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476316&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476316&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61085\" NCI Thesaurus)"""@eng ; """2006-04-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61085"""^^xsd:string ; """2006-07-26"""^^xsd:string ; umls:cui """C1832069"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Traumeel S"""@eng ; skos:notation """CDR0000360844"""^^xsd:string ; skos:altLabel """TRS"""@eng ; skos:definition """Diluted extracts isolated from plants and minerals, including belladonna, arnica, St. Johns wort, and Echinacea. As a homeopathic mouth rinse preparation, Traumeel S exhibits antiinflammatory activity; the mechanism of action has not been fully elucidated. This agent may reduce the severity and duration of treatment-related stomatitis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=360844&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=360844&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38683\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """C38683"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0968917"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoricoxib"""@eng ; skos:notation """CDR0000462092"""^^xsd:string ; skos:altLabel """L-791456"""@eng , """Arcoxia"""@eng , """MK-0663"""@eng , """5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine"""@eng ; skos:definition """A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic ,and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462092&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462092&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=\" NCI Thesaurus)"""@eng ; """2006-01-25"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1530229"""^^xsd:string ; umls:cui """C0972314"""^^xsd:string ; umls:cui """C1097007"""^^xsd:string ; umls:cui """C1130504"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neurotoxicity attenuation"""@eng ; skos:notation """CDR0000039747"""^^xsd:string ; skos:altLabel """attenuation, neurotoxicity"""@eng ; ; rdfs:subClassOf ; """2409"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0279496"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leukapheresis"""@eng ; skos:notation """CDR0000039746"""^^xsd:string ; """2408"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0023416"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progestin therapy"""@eng ; skos:notation """CDR0000039745"""^^xsd:string ; skos:altLabel """therapy, progestin"""@eng ; ; rdfs:subClassOf ; """2407"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen therapy"""@eng ; skos:notation """CDR0000039744"""^^xsd:string ; skos:altLabel """therapy, estrogen"""@eng ; ; rdfs:subClassOf ; """2406"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279494"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """androgen therapy"""@eng ; skos:notation """CDR0000039743"""^^xsd:string ; skos:altLabel """therapy, androgen"""@eng ; ; rdfs:subClassOf ; """2405"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial stromal sarcoma"""@eng ; skos:notation """CDR0000041019"""^^xsd:string ; skos:altLabel """stromal sarcoma, endometrial"""@eng ; rdfs:subClassOf ; """4059"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206630"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine trihydrate"""@eng ; skos:notation """CDR0000039741"""^^xsd:string ; skos:altLabel """Ethyol"""@eng , """S-2-(3-Aminopropylamino)ethylphosphorothioic Acid"""@eng , """YM-08310"""@eng , """Aminopropylaminoethylthiophosphoric Acid"""@eng , """WR-2721"""@eng , """APAETP"""@eng , """gammaphos"""@eng , """2-[(3-Aminopropyl)amino]ethanethiol Dihydrogen Phosphate Ester"""@eng , """S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid"""@eng , """ethiofos"""@eng ; skos:definition """The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39741&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39741&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C488\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """18318"""^^xsd:string ; """C488"""^^xsd:string ; """296961"""^^xsd:string ; """20537-88-6"""^^xsd:string ; """2402"""^^xsd:string ; umls:cui """C1706792"""^^xsd:string ; umls:cui """C0591467"""^^xsd:string ; umls:cui """C0729078"""^^xsd:string ; umls:cui """C0015020"""^^xsd:string ; umls:cui """C0729079"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """warfarin"""@eng ; skos:notation """CDR0000039740"""^^xsd:string ; skos:altLabel """1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone"""@eng , """4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one"""@eng , """Panwarfin"""@eng , """Compound 42"""@eng , """WARF"""@eng , """WARF Compound 42"""@eng , """3-(Alpha-acetonylbenzyl)-4-hydroxycoumarin"""@eng , """Athrombin-K"""@eng , """Coumadin"""@eng , """3-Alpha-phenyl-beta-acetylethyl-4-hydroxycoumarin"""@eng , """Co-Rax"""@eng , """Rodex"""@eng ; skos:definition """A synthetic anticoagulant. Warfarin appears to inhibit the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39740&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39740&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C945\" NCI Thesaurus)"""@eng ; ; """2401"""^^xsd:string ; """C945"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """59813"""^^xsd:string ; """81-81-2"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0917972"""^^xsd:string ; umls:cui """C0043031"""^^xsd:string ; umls:cui """C0699129"""^^xsd:string ; umls:cui """C1527323"""^^xsd:string ; umls:cui """C1520123"""^^xsd:string ; umls:cui """C1520122"""^^xsd:string ; umls:cui """C0699130"""^^xsd:string ; umls:cui """C1520121"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV uterine sarcoma"""@eng ; skos:notation """CDR0000041014"""^^xsd:string ; skos:altLabel """uterine sarcoma, metastatic"""@eng , """uterine sarcoma, stage IV"""@eng , """metastatic uterine sarcoma"""@eng ; rdfs:subClassOf ; """uterine sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4054"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280627"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent uterine sarcoma"""@eng ; skos:notation """CDR0000041015"""^^xsd:string ; skos:altLabel """uterine sarcoma, recurrent"""@eng ; rdfs:subClassOf ; """uterine sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4055"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280628"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, uterine sarcoma"""@eng ; skos:notation """CDR0000041016"""^^xsd:string ; skos:altLabel """uterine sarcoma, cellular diagnosis"""@eng ; rdfs:subClassOf ; """4056"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280629"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uterine carcinosarcoma"""@eng ; skos:notation """CDR0000041017"""^^xsd:string ; skos:altLabel """Mullerian sarcoma, uterine mixed"""@eng , """mixed Mullerian sarcoma, uterine"""@eng , """Mullerian tumor, uterine mixed"""@eng , """uterine mixed Mullerian sarcoma"""@eng , """carcinosarcoma, uterine"""@eng ; rdfs:subClassOf ; """4057"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280630"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood choroid plexus tumor"""@eng ; skos:notation """CDR0000041010"""^^xsd:string ; skos:altLabel """choroid plexus carcinoma, childhood"""@eng , """brain tumor, pediatric choroid plexus"""@eng , """childhood brain tumor, choroid plexus"""@eng , """central nervous system tumor, choroid plexus, childhood"""@eng , """pediatric brain tumor, choroid plexus"""@eng , """CNS tumor, childhood choroid plexus"""@eng , """CNS tumor, pediatric choroid plexus"""@eng , """childhood choroid plexus carcinoma"""@eng , """pediatric choroid plexus tumor"""@eng , """brain tumor, childhood choroid plexus"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4050"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1510426"""^^xsd:string ; umls:cui """C0280623"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I uterine sarcoma"""@eng ; skos:notation """CDR0000041011"""^^xsd:string ; skos:altLabel """uterine sarcoma, stage I"""@eng ; rdfs:subClassOf ; """uterine sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4051"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280624"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II uterine sarcoma"""@eng ; skos:notation """CDR0000041012"""^^xsd:string ; skos:altLabel """uterine sarcoma, stage II"""@eng ; rdfs:subClassOf ; """uterine sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4052"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280625"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide"""@eng ; skos:notation """CDR0000039748"""^^xsd:string ; skos:altLabel """Endoxan"""@eng , """Cytophosphane"""@eng , """Ledoxina"""@eng , """CPM"""@eng , """N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-Oxide"""@eng , """WR-138719"""@eng , """Neosar"""@eng , """N,N-bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate"""@eng , """Mitoxan"""@eng , """2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate"""@eng , """Cyclophosphamid monohydrate"""@eng , """Cyclostin"""@eng , """Zytoxan"""@eng , """Syklofosfamid"""@eng , """Clafen"""@eng , """Claphene"""@eng , """CP monohydrate"""@eng , """N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic acid intramolecular ester monohydrate"""@eng , """N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate"""@eng , """2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate"""@eng , """Cyclophosphanum"""@eng , """Endoxana"""@eng , """Genoxal"""@eng , """Cicloxal"""@eng , """Sendoxan"""@eng , """N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate"""@eng , """Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate"""@eng , """Cycloblastin"""@eng , """Asta B 518"""@eng , """Cyclophosphamidum"""@eng , """Enduxan"""@eng , """CYCLO-cell"""@eng , """B-518"""@eng , """bis(2-chloroethyl)phosphamide cyclic propanolamide ester monohydrate"""@eng , """Ciclofosfamida"""@eng , """Ciclofosfamide"""@eng , """N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate"""@eng , """Fosfaseron"""@eng , """Carloxan"""@eng , """2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide monohydrate"""@eng , """Cyclophospham"""@eng , """Cyclophosphan"""@eng , """Cyclostine"""@eng , """Cytophosphan"""@eng , """Procytox"""@eng , """CTX"""@eng , """1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate"""@eng , """N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate"""@eng , """Cycloblastine"""@eng , """2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide"""@eng , """Cytoxan"""@eng ; skos:definition """A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39748&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39748&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C405\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """241"""^^xsd:string ; """26271"""^^xsd:string ; """C405"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """4173"""^^xsd:string ; """7089"""^^xsd:string ; """6055-19-2 (monohydrate)"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """50-18-0 (anhydrous form)"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511592"""^^xsd:string ; umls:cui """C1511594"""^^xsd:string ; umls:cui """C1511591"""^^xsd:string ; umls:cui """C1511589"""^^xsd:string ; umls:cui """C0887682"""^^xsd:string ; umls:cui """C0699320"""^^xsd:string ; umls:cui """C1522705"""^^xsd:string ; umls:cui """C3495431"""^^xsd:string ; umls:cui """C0699318"""^^xsd:string ; umls:cui """C1511585"""^^xsd:string ; umls:cui """C0699322"""^^xsd:string ; umls:cui """C0701108"""^^xsd:string ; umls:cui """C0701109"""^^xsd:string ; umls:cui """C1511584"""^^xsd:string ; umls:cui """C0701107"""^^xsd:string ; umls:cui """C1511586"""^^xsd:string ; umls:cui """C1511587"""^^xsd:string ; umls:cui """C0699319"""^^xsd:string ; umls:cui """C0699321"""^^xsd:string ; umls:cui """C0010583"""^^xsd:string ; umls:cui """C0699323"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040228"""^^xsd:string ; skos:altLabel """childhood Hodgkins disease"""@eng , """childhood Hodgkins lymphoma"""@eng , """Hodgkin's lymphoma, childhood"""@eng , """Hodgkin's disease, childhood"""@eng , """pediatric Hodgkin's disease"""@eng , """childhood Hodgkin disease"""@eng , """Lymphoma, Hodgkin's lymphoma, child"""@eng , """lymphoma, Hodgkin's, childhood"""@eng , """childhood Hodgkin lymphoma"""@eng , """pediatric HD"""@eng , """HD, childhood"""@eng , """childhood HD"""@eng , """childhood Hodgkin's disease"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2003-01-16"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3043"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220644"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040229"""^^xsd:string ; skos:altLabel """childhood HD, stage I"""@eng , """stage I Hodgkin's disease, childhood"""@eng , """HD, stage I, childhood"""@eng , """Hodgkin's lymphoma, stage I, childhood"""@eng , """stage I childhood Hodgkin's disease"""@eng , """stage I pediatric Hodgkin's disease"""@eng , """HD, childhood, stage I"""@eng , """pediatric Hodgkin's disease, stage I"""@eng , """stage I childhood HD"""@eng , """Hodgkin's disease, childhood, stage I"""@eng , """lymphoma, stage I childhood Hodgkin's"""@eng , """childhood Hodgkin's lymphoma, stage I"""@eng , """pediatric HD, stage I"""@eng ; rdfs:subClassOf ; """2003-01-10"""^^xsd:string ; """childhood Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3044"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279915"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """goserelin"""@eng ; skos:notation """CDR0000040224"""^^xsd:string ; skos:altLabel """Zoladex"""@eng , """ICI-118630"""@eng , """6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide"""@eng , """ZDX"""@eng ; skos:definition """A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40224&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40224&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1374\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3035"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """65807-02-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1374"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0120107"""^^xsd:string ; umls:cui """C0701275"""^^xsd:string ; umls:cui """C0149473"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent urethral cancer"""@eng ; skos:notation """CDR0000040225"""^^xsd:string ; skos:altLabel """urethral cancer, recurrent"""@eng ; rdfs:subClassOf ; """urethral cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3036"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279912"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/vinblastine"""@eng ; skos:notation """CDR0000040226"""^^xsd:string ; skos:altLabel """DP/VBL"""@eng ; ; ; """3041"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279913"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/interferon alfa"""@eng ; skos:notation """CDR0000041489"""^^xsd:string ; skos:altLabel """CLB/IFN-A"""@eng ; ; ; """4645"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338154"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """merbarone"""@eng ; skos:notation """CDR0000040220"""^^xsd:string ; skos:altLabel """MERB"""@eng ; ; """3029"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0127565"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitozolomide"""@eng ; skos:notation """CDR0000040221"""^^xsd:string ; """3030"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0066618"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """naproxen"""@eng ; skos:notation """CDR0000040222"""^^xsd:string ; skos:altLabel """RS-3540"""@eng , """Naprosyn"""@eng , """6-Methoxy-alpha-methyl-2-naphthaleneacetic Acid"""@eng , """d-2-(6-Methoxy-2-naphthyl)propionic Acid"""@eng ; skos:definition """A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40222&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40222&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C680\" NCI Thesaurus)"""@eng ; """3032"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """22204-53-1"""^^xsd:string ; """C680"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700017"""^^xsd:string ; umls:cui """C0027396"""^^xsd:string ; umls:cui """C1764836"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """probenecid"""@eng ; skos:notation """CDR0000040223"""^^xsd:string ; skos:altLabel """Benemid"""@eng , """PROB"""@eng , """SK-Probenecid"""@eng ; skos:definition """A benzoic acid derivative with antihyperuricemic property. Probenecid competitively inhibits the active reabsorption of urate at the proximal tubule in the kidney thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. In addition, probenecid modulates the transport of organic acids and acidic drugs at the proximal and distal renal tubule, thereby increasing the drug serum concentration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40223&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40223&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C772\" NCI Thesaurus)"""@eng ; ; """3033"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """18786"""^^xsd:string ; """C772"""^^xsd:string ; """57-66-9"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591159"""^^xsd:string ; umls:cui """C0033209"""^^xsd:string ; umls:cui """C0729110"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interferon alfa-2b"""@eng ; skos:notation """CDR0000462279"""^^xsd:string ; skos:altLabel """Alfatronol"""@eng , """Intron A"""@eng , """Heberon Alfa"""@eng , """interferon alpha-2b"""@eng , """Urifron"""@eng , """Viraferon"""@eng , """Glucoferon"""@eng , """interferon alfa-2B"""@eng , """IFN alpha-2B"""@eng ; skos:definition """A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462279&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462279&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1953\" NCI Thesaurus)"""@eng ; """C1953"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-28"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0751600"""^^xsd:string ; umls:cui """C0592253"""^^xsd:string ; umls:cui """C0021735"""^^xsd:string ; umls:cui """C1514785"""^^xsd:string ; umls:cui """C1514784"""^^xsd:string ; umls:cui """C1514787"""^^xsd:string ; umls:cui """C1514786"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CHP-NY-ESO-1 peptide vaccine"""@eng ; skos:notation """CDR0000489132"""^^xsd:string ; skos:altLabel """cholesterol-bearing hydrophobized pullulan NY-ESO-1 protein"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831881"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III melanoma"""@eng ; skos:notation """CDR0000038836"""^^xsd:string ; skos:altLabel """stage III cutaneous melanoma"""@eng , """melanoma, cutaneous stage III"""@eng , """melanoma, stage III"""@eng , """cutaneous melanoma, stage III"""@eng ; rdfs:subClassOf ; """melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1305"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278882"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV melanoma"""@eng ; skos:notation """CDR0000038837"""^^xsd:string ; skos:altLabel """cutaneous melanoma, stage IV"""@eng , """metastatic cutaneous melanoma"""@eng , """melanoma, cutaneous stage IV"""@eng , """melanoma, metastatic"""@eng , """metastatic melanoma"""@eng , """melanoma, cutaneous metastatic"""@eng , """cutaneous melanoma, metastatic"""@eng , """melanoma, stage IV"""@eng , """stage IV cutaneous melanoma"""@eng ; rdfs:subClassOf ; """melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1306"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278883"""^^xsd:string ; umls:cui """C1321872"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I melanoma"""@eng ; skos:notation """CDR0000038834"""^^xsd:string ; skos:altLabel """stage I cutaneous melanoma"""@eng , """melanoma, cutaneous stage I"""@eng , """melanoma, stage I"""@eng , """cutaneous melanoma, stage I"""@eng ; rdfs:subClassOf ; """melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1303"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278880"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II melanoma"""@eng ; skos:notation """CDR0000038835"""^^xsd:string ; skos:altLabel """stage II cutaneous melanoma"""@eng , """melanoma, stage II"""@eng , """melanoma, cutaneous stage II"""@eng , """cutaneous melanoma, stage II"""@eng ; rdfs:subClassOf ; """melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1304"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278881"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast cancer"""@eng ; skos:notation """CDR0000038832"""^^xsd:string ; skos:altLabel """Breast cancer, female"""@eng ; ; ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """13"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0006142"""^^xsd:string ; umls:cui """C0235653"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melanoma"""@eng ; skos:notation """CDR0000038833"""^^xsd:string ; skos:altLabel """Skin cancer, melanoma"""@eng , """cutaneous melanoma"""@eng , """melanoma, cutaneous"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1302"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0025202"""^^xsd:string ; umls:cui """C0151779"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult glioblastoma"""@eng ; skos:notation """CDR0000038830"""^^xsd:string ; skos:altLabel """central nervous system tumor, astrocytoma, grade IV adult"""@eng , """CNS tumor, grade IV adult astrocytoma"""@eng , """brain tumor, adult glioblastoma multiforme"""@eng , """adult glioblastoma multiforme"""@eng , """glioblastoma multiforme, adult"""@eng , """CNS tumor, adult grade IV astrocytoma"""@eng , """adult CNS tumor, glioblastoma multiforme"""@eng , """astrocytoma, grade IV adult"""@eng , """brain tumor, adult grade IV astrocytoma"""@eng , """adult brain tumor, glioblastoma multiforme"""@eng , """grade IV adult astrocytoma"""@eng , """CNS tumor, adult glioblastoma multiforme"""@eng , """glioblastoma, adult"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1296"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278878"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000038831"""^^xsd:string ; skos:altLabel """childhood small non-cleaved cell lymphoma"""@eng , """lymphoma, small non-cleaved cell, childhood"""@eng , """small noncleaved cell lymphoma, childhood"""@eng , """pediatric SNC lymphoma"""@eng , """lymphoma, small noncleaved cell, childhood"""@eng , """pediatric small non-cleaved cell lymphoma"""@eng , """lymphoma, diffuse undifferentiated, childhood"""@eng , """childhood SNC lymphoma"""@eng , """small non-cleaved cell lymphoma, childhood"""@eng , """SNC lymphoma, childhood"""@eng , """DUL, childhood"""@eng , """diffuse undifferentiated lymphoma, childhood"""@eng ; rdfs:subClassOf ; """1297"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278879"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/GTI-2040"""@eng ; skos:notation """CDR0000335130"""^^xsd:string ; skos:altLabel """ARA-C/GTI2040"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent melanoma"""@eng ; skos:notation """CDR0000038838"""^^xsd:string ; skos:altLabel """melanoma, recurrent"""@eng , """cutaneous melanoma, recurrent"""@eng , """recurrent cutaneous melanoma"""@eng , """melanoma, cutaneous recurrent"""@eng ; rdfs:subClassOf ; """melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1307"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278884"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult low grade NHL"""@eng ; skos:notation """CDR0000038839"""^^xsd:string ; skos:altLabel """NHL, adult, low grade"""@eng , """adult NHL, low grade"""@eng , """non-Hodgkin's lymphoma, adult, low grade"""@eng , """low grade non-Hodgkin's lymphoma, adult"""@eng , """lymphoma, adult low grade non-Hodgkin's"""@eng ; """2005-01-21"""^^xsd:string ; """1308"""^^xsd:string ; umls:cui """C0278885"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult erythroleukemia (M6a)"""@eng ; skos:notation """CDR0000377684"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541339"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """apaziquone"""@eng ; skos:notation """CDR0000042095"""^^xsd:string ; skos:altLabel """3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol"""@eng , """Eoquin"""@eng , """Neoquin"""@eng , """E09"""@eng ; skos:definition """A bioreductive prodrug and novel analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone alkylates DNA after actvation to its active metabolite in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. This agent may selectively sensitize hypoxic tumor cells to radiocytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42095&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42095&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1087\" NCI Thesaurus)"""@eng ; """5330"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C1087"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0095568"""^^xsd:string ; umls:cui """C1831599"""^^xsd:string ; umls:cui """C1707848"""^^xsd:string ; umls:cui """C1707849"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-6/sargramostim"""@eng ; skos:notation """CDR0000042094"""^^xsd:string ; skos:altLabel """GM-CSF/IL-6"""@eng ; ; ; """5329"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281625"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/etoposide/methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042097"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MTX/PRED/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """5332"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281627"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/fluorouracil/hydroxyurea/interferon alfa"""@eng ; skos:notation """CDR0000042096"""^^xsd:string ; skos:altLabel """5-FU/G-CSF/HU/IFN-A"""@eng ; ; ; ; ; """5331"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338187"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/goserelin/methotrexate/tamoxifen"""@eng ; skos:notation """CDR0000042091"""^^xsd:string ; skos:altLabel """CTX/5-FU/MTX/TMX/ZDX"""@eng ; ; ; ; ; ; """5326"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281622"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gossypol"""@eng ; skos:notation """CDR0000505287"""^^xsd:string ; skos:altLabel """2,2'-bis[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]"""@eng , """2,2'-bis[1,6,7-Trihydroxy-4-methyl-5-isopropyl-8-aldehydonaphthalene"""@eng , """Cottonseed Meal Toxin"""@eng , """AT-101"""@eng , """1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3-3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarboxaldehyde"""@eng , """Gossypol (Racemic)"""@eng , """1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde"""@eng ; skos:definition """An orally-active polyphenolic aldehyde with potential antineoplastic activity. Derived primarily from unrefined cottonseed oil, gossypol induces cell cycle arrest at the G0/G1 phase, thereby inhibiting DNA replication and inducing apoptosis. This agent also inhibits cell-signaling enzymes, resulting in inhibition of cell growth, and may act as a male contraceptive. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=505287&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=505287&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C529\" NCI Thesaurus)"""@eng ; """2006-08-24"""^^xsd:string ; """56817"""^^xsd:string ; """303-45-7"""^^xsd:string ; """C529"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831824"""^^xsd:string ; umls:cui """C0018096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/goserelin/tamoxifen"""@eng ; skos:notation """CDR0000042093"""^^xsd:string ; skos:altLabel """CTX/DOX/TMX/ZDX"""@eng ; ; ; ; ; """5328"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281624"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/leuprolide/tamoxifen"""@eng ; skos:notation """CDR0000042092"""^^xsd:string ; skos:altLabel """CTX/DOX/LEUP/TMX"""@eng ; ; ; ; ; """5327"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281623"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/interferon gamma"""@eng ; skos:notation """CDR0000041249"""^^xsd:string ; skos:altLabel """CYSP/IFN-G"""@eng ; ; ; """4322"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280843"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """roxithromycin"""@eng ; skos:notation """CDR0000042099"""^^xsd:string ; skos:altLabel """Rulide"""@eng , """RU 965"""@eng , """RXM"""@eng , """roxitromycine"""@eng , """RU 28965"""@eng ; """5334"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0750742"""^^xsd:string ; umls:cui """C0750743"""^^xsd:string ; umls:cui """C0750744"""^^xsd:string ; umls:cui """C0035891"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/tumor necrosis factor"""@eng ; skos:notation """CDR0000042098"""^^xsd:string ; skos:altLabel """L-PAM/TNF"""@eng ; ; ; """5333"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281628"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminobenzoate potassium"""@eng ; skos:notation """CDR0000039571"""^^xsd:string ; skos:altLabel """Potaba"""@eng , """potassium para-aminobenzoate"""@eng , """potassium p-aminobenzoate"""@eng ; skos:definition """The potassium salt form of aminobenzoate, with anti-inflammatory and antifibrotic activities. Aminobenzoate potassium increases oxygen uptake at the tissue level and may enhance monoamine oxidase (MAO) activity, which requires oxygen as a substrate. Enhanced MAO activity maybe accountable for the prevention or regression of fibrosis, which may occur due to too much serotonin or too little MAO activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39571&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39571&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1736\" NCI Thesaurus)"""@eng ; """2225"""^^xsd:string ; """C1736"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-15"""^^xsd:string ; umls:cui """C0032820"""^^xsd:string ; umls:cui """C0543464"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-NY-ESO-1 vaccine/vaccinia-NY-ESO-1 vaccine"""@eng ; skos:notation """CDR0000428316"""^^xsd:string ; skos:altLabel """rF-NY-ESO-1/rV-NY-ESO-1"""@eng ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541544"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """herpes simplex thymidine kinase"""@eng ; skos:notation """CDR0000037895"""^^xsd:string ; skos:altLabel """HSVtk"""@eng ; """10303"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879457"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/megestrol"""@eng ; skos:notation """CDR0000041241"""^^xsd:string ; skos:altLabel """CDDP/MEG/VP-16"""@eng ; ; ; ; """4314"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280835"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000041240"""^^xsd:string ; skos:altLabel """CDDP/DOX/GM-CSF/VP-16"""@eng ; ; ; ; ; """4313"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280834"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/suramin"""@eng ; skos:notation """CDR0000367302"""^^xsd:string ; skos:altLabel """5-FU/SUR"""@eng ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541226"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland acinic cell tumor"""@eng ; skos:notation """CDR0000040038"""^^xsd:string ; skos:altLabel """acinic cell tumor, salivary gland"""@eng ; rdfs:subClassOf ; """2773"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279738"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell endodermal sinus tumor"""@eng ; skos:notation """CDR0000040488"""^^xsd:string ; skos:altLabel """yolk sac carcinoma, ovarian germ cell"""@eng , """endodermal sinus tumor, ovarian germ cell"""@eng , """ovarian germ cell yolk sac carcinoma"""@eng ; rdfs:subClassOf ; """3376"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346188"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lung metastases"""@eng ; skos:notation """CDR0000040826"""^^xsd:string ; skos:altLabel """cancer with pulmonary metastases"""@eng , """lung, metastatic cancer to"""@eng , """cancer, metastatic to lung"""@eng , """metastatic cancer to lung"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3855"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0153676"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liver metastases"""@eng ; skos:notation """CDR0000040827"""^^xsd:string ; skos:altLabel """metastatic cancer to liver"""@eng , """liver, metastatic cancer to"""@eng , """cancer, metastatic to liver"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3856"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0494165"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """site, metastatic cancer"""@eng ; skos:notation """CDR0000040824"""^^xsd:string ; skos:altLabel """metastatic cancer site"""@eng ; rdfs:subClassOf ; """3853"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280457"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult tumors metastatic to brain"""@eng ; skos:notation """CDR0000040825"""^^xsd:string ; skos:altLabel """metastatic cancer to brain"""@eng , """cancer, metastatic to brain"""@eng , """brain metastases"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3854"""^^xsd:string ; """2005-04-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """adult brain tumor"""^^xsd:string ; umls:cui """C0220650"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/paclitaxel"""@eng ; skos:notation """CDR0000040822"""^^xsd:string ; skos:altLabel """CDDP/TAX"""@eng ; ; ; """3851"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280455"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """respiratory and cerebral stimulants"""@eng ; skos:notation """CDR0000040823"""^^xsd:string ; rdfs:subClassOf ; """3852"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C1277064"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """caffeine/cisplatin/cytarabine"""@eng ; skos:notation """CDR0000040820"""^^xsd:string ; skos:altLabel """CAC"""@eng , """ARA-C/CAF/CDDP"""@eng ; ; ; ; """3849"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280453"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium/sargramostim"""@eng ; skos:notation """CDR0000040821"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/5-FU/GM-CSF"""@eng ; ; ; ; ; ; """3850"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280454"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone metastases"""@eng ; skos:notation """CDR0000040828"""^^xsd:string ; skos:altLabel """cancer, metastatic to bone"""@eng , """metastatic cancer to bone"""@eng , """bone, metastatic cancer to"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3857"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0153690"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin metastases"""@eng ; skos:notation """CDR0000040829"""^^xsd:string ; skos:altLabel """skin, metastatic cancer to"""@eng , """metastatic cancer to skin"""@eng , """cancer, metastatic to skin"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3858"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0153687"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dextromethorphan/morphine"""@eng ; skos:notation """CDR0000043324"""^^xsd:string ; skos:altLabel """DEX/MORPH"""@eng ; ; ; """7860"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796475"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SarCNU"""@eng ; skos:notation """CDR0000043325"""^^xsd:string ; skos:definition """An alkylating chloroethylnitrosourea with antineoplastic activity. Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43325&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43325&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C963\" NCI Thesaurus)"""@eng ; """7861"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C963"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0045644"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """substance abuse disorder"""@eng ; skos:notation """CDR0000043326"""^^xsd:string ; skos:altLabel """disorder, substance abuse"""@eng , """drug abuse"""@eng , """disorder, drug abuse"""@eng , """substance abuse"""@eng ; rdfs:subClassOf ; """7863"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0013146"""^^xsd:string ; umls:cui """C0740858"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """osteosarcoma/malignant fibrous histiocytoma of bone"""@eng ; skos:notation """CDR0000043327"""^^xsd:string ; rdfs:subClassOf ; """7864"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0796476"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethylxanthenone acetic acid"""@eng ; skos:notation """CDR0000043320"""^^xsd:string ; skos:altLabel """Dimethyloxoxanthene Acetic Acid"""@eng , """5,6-MexXAA"""@eng , """DMXAA"""@eng , """AS1404"""@eng , """5,6-Dimethylxanthenone-4-Acetic Acid"""@eng ; skos:definition """A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Dimethylxanthenone acetic acid induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43320&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43320&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2504\" NCI Thesaurus)"""@eng ; ; """7847"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C2504"""^^xsd:string ; umls:cui """C2930490"""^^xsd:string ; umls:cui """C1831616"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000043321"""^^xsd:string ; skos:altLabel """CBDCA/IFF/VP-16/WR-2721"""@eng ; ; ; ; ; """7857"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BL22 immunotoxin"""@eng ; skos:notation """CDR0000043322"""^^xsd:string ; skos:altLabel """BL22 Immunotoxin [RFB4(dsFv) - PE38"""@eng , """BL22"""@eng , """RFB4(dsFv)-PE38 immunotoxin"""@eng , """Anti-CD22 Recombinant Immunotoxin BL22"""@eng , """immunotoxin BL22"""@eng ; skos:definition """A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity. BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells. The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43322&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43322&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1842\" NCI Thesaurus)"""@eng ; """7858"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """10994"""^^xsd:string ; """8099"""^^xsd:string ; """691237"""^^xsd:string ; """11082"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1842"""^^xsd:string ; """11062"""^^xsd:string ; umls:cui """C0796473"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/methotrexate"""@eng ; skos:notation """CDR0000043323"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MTX"""@eng ; ; ; ; """7859"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796474"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 3p"""@eng ; skos:notation """CDR0000043328"""^^xsd:string ; rdfs:subClassOf ; """7865"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796477"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer genetics"""@eng ; skos:notation """CDR0000043329"""^^xsd:string ; skos:altLabel """genetics of cancer"""@eng ; """2002-10-16"""^^xsd:string ; """7866"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0694768"""^^xsd:string ; umls:tui """T091"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 DOTA-biotin"""@eng ; skos:notation """CDR0000365680"""^^xsd:string ; skos:altLabel """90Y-DOTA-biotin"""@eng ; """2004-04-23"""^^xsd:string ; """2004-04-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677849"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CC49-streptavidin conjugate"""@eng ; skos:notation """CDR0000365681"""^^xsd:string ; skos:altLabel """CC49 fusion protein"""@eng , """CC49Fusion"""@eng ; """2004-04-23"""^^xsd:string ; """2004-04-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541221"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BW A773U"""@eng ; skos:notation """CDR0000040798"""^^xsd:string ; """3762"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0280441"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dideoxyadenosine"""@eng ; skos:notation """CDR0000040799"""^^xsd:string ; skos:altLabel """ddA"""@eng , """2',3'-Dideoxyadenosine"""@eng , """6-Amino-9-(2''3'-dideoxy-beta-D-glycero-pentofuranosyl)purine"""@eng ; skos:definition """A synthetic nucleoside analogue of deoxyadenosine and a prodrug of didanosine in which the 3' hydroxyl group on the ribose moiety is replaced by a hydrogen atom. Dideoxyadenosine competitively inhibits adenylyl cyclase, thereby reducing levels of cyclic adenosine monophosphate (cAMP). By inhibiting cAMP-mediated gene activation in tumor cells, this agent may retard tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40799&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40799&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C429\" NCI Thesaurus)"""@eng ; """3763"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C429"""^^xsd:string ; """7332"""^^xsd:string ; """30971"""^^xsd:string ; """4279"""^^xsd:string ; """95943"""^^xsd:string ; """83-05-6"""^^xsd:string ; """112-18-5"""^^xsd:string ; """6698-26-6"""^^xsd:string ; """4097-22-7"""^^xsd:string ; umls:cui """C0012131"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pefloxacin"""@eng ; skos:notation """CDR0000040794"""^^xsd:string ; skos:altLabel """PEF"""@eng ; ; """3758"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0030771"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penicillin V potassium"""@eng ; skos:notation """CDR0000040795"""^^xsd:string ; skos:altLabel """penV"""@eng , """Pen-Vee"""@eng ; ; """3759"""^^xsd:string ; """C730"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-21"""^^xsd:string ; umls:cui """C0700553"""^^xsd:string ; umls:cui """C0700986"""^^xsd:string ; umls:cui """C0030840"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pefloxacin/penicillin V"""@eng ; skos:notation """CDR0000040796"""^^xsd:string ; skos:altLabel """PEF/penV"""@eng ; ; ; """3760"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280439"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """catheter management"""@eng ; skos:notation """CDR0000040797"""^^xsd:string ; skos:altLabel """management of catheter"""@eng , """catheter use/management"""@eng , """intravenous catheter care"""@eng ; ; rdfs:subClassOf ; """3761"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280440"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interferon alfa/prednisone"""@eng ; skos:notation """CDR0000040790"""^^xsd:string ; skos:altLabel """CPI"""@eng , """CTX/IFN-A/PRED"""@eng ; ; ; ; """3754"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338117"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piroxantrone"""@eng ; skos:notation """CDR0000040791"""^^xsd:string ; skos:altLabel """Piroxantrone HCl"""@eng , """oxanthrazole"""@eng , """oxantrazole"""@eng , """Anthra(1,9-cd)pyrazol-6(2H)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)"""@eng , """PD-111815"""@eng , """CI-942"""@eng ; skos:definition """An anthrapyrazole antineoplastic antibiotic. Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40791&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40791&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1182\" NCI Thesaurus)"""@eng ; ; ; """29720"""^^xsd:string ; """C1182"""^^xsd:string ; """349174"""^^xsd:string ; """91441-23-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C0069736"""^^xsd:string ; umls:cui """C1522210"""^^xsd:string ; umls:cui """C0701493"""^^xsd:string ; umls:cui """C1522209"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-1-beta"""@eng ; skos:notation """CDR0000040793"""^^xsd:string ; skos:altLabel """Catabolin"""@eng , """IL-1B"""@eng , """Recombinant Interleukin-1-beta"""@eng , """IL-1-b"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to the endogenous protein cytokine interleukin 1 (IL-1)-beta. Produced by monocytes and activated macrophages, endogenous mature IL-1 is generated through proteolytic cleavage by proteases such as IL-1-beta converting enzyme (ICE). This agent promotes angiogenesis, fibroblast proliferation, and neutrophil chemotaxis; it also regulates the functions of lymphocytes and epithelial cells and is involved in the 'acute phase response' to infection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40793&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40793&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C585\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """3757"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C585"""^^xsd:string ; umls:cui """C0021753"""^^xsd:string ; umls:cui """C1522432"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel"""@eng ; skos:notation """CDR0000043229"""^^xsd:string ; skos:altLabel """CBDCA/TXT"""@eng ; ; ; """7694"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796387"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Fc-gamma receptor III"""@eng ; skos:notation """CDR0000043228"""^^xsd:string ; rdfs:subClassOf ; """7693"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796386"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/oxaliplatin/vatalanib"""@eng ; skos:notation """CDR0000329910"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/PTK-787"""@eng ; ; ; ; ; """2003-08-24"""^^xsd:string ; """2004-08-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328037"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastric cancer prevention"""@eng ; skos:notation """CDR0000043221"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """7686"""^^xsd:string ; umls:cui """C0796382"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flt3 ligand/gp100 antigen/incomplete Freund's adjuvant/MART-1 antigen/tyrosinase"""@eng ; skos:notation """CDR0000043220"""^^xsd:string ; skos:altLabel """Flt3L/gp100/IFA/MART-1/TYR"""@eng ; ; ; ; ; """7685"""^^xsd:string ; """2006-08-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796381"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor replication error analysis"""@eng ; skos:notation """CDR0000043223"""^^xsd:string ; rdfs:subClassOf ; """7688"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796384"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GPX-100"""@eng ; skos:notation """CDR0000043222"""^^xsd:string ; skos:altLabel """13-deoxydoxorubicin"""@eng ; skos:definition """An analogue of the anthracycline antineoplastic antibiotic doxorubicin. GPX-100 intercalates DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. GPX-100 was designed to be a non-cardiotoxic anthracycline antibiotic. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43222&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43222&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2494\" NCI Thesaurus)"""@eng ; """7687"""^^xsd:string ; """C2494"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-07"""^^xsd:string ; umls:cui """C0796383"""^^xsd:string ; umls:cui """C1521804"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor necrosis factor alpha"""@eng ; skos:notation """CDR0000043225"""^^xsd:string ; rdfs:subClassOf ; """7690"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1456820"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mannose-binding lectin"""@eng ; skos:notation """CDR0000043224"""^^xsd:string ; skos:altLabel """mannose binding lectin"""@eng ; rdfs:subClassOf ; """7689"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1417054"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Fc-gamma receptor II"""@eng ; skos:notation """CDR0000043227"""^^xsd:string ; rdfs:subClassOf ; """7692"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1414553"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-10"""@eng ; skos:notation """CDR0000043226"""^^xsd:string ; """7691"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0085295"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/etoposide"""@eng ; skos:notation """CDR0000041849"""^^xsd:string ; skos:altLabel """EM/VP-16"""@eng ; ; ; """5060"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281417"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-B4 blocked ricin immunotoxin"""@eng ; skos:notation """CDR0000041848"""^^xsd:string ; skos:altLabel """MOAB anti-B4-bR"""@eng , """monoclonal antibody anti-B4 blocked ricin"""@eng , """anti-B4 blocked ricin, monoclonal antibody"""@eng ; """5054"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-30"""^^xsd:string ; """C2380"""^^xsd:string ; umls:cui """C0763109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000041847"""^^xsd:string ; skos:altLabel """DM/DOX/PRED/VCR"""@eng ; ; ; ; ; """5031"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281415"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/prednisone/quinine/vincristine"""@eng ; skos:notation """CDR0000041846"""^^xsd:string ; skos:altLabel """DM/DOX/PRED/QUIN/VCR"""@eng ; ; ; ; ; ; """5030"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281414"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PDGFR inhibitor CP-868,596"""@eng ; skos:notation """CDR0000518325"""^^xsd:string ; skos:altLabel """CP-868,596"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-03"""^^xsd:string ; umls:cui """C2987647"""^^xsd:string ; umls:cui """C1831982"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malignant fibrous histiocytoma of bone"""@eng ; skos:notation """CDR0000041844"""^^xsd:string ; rdfs:subClassOf ; """5028"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0740479"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/procarbazine/vincristine"""@eng ; skos:notation """CDR0000041843"""^^xsd:string ; skos:altLabel """CTX/PCB/VCR"""@eng ; ; ; ; """5027"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281411"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/leuprolide/zoledronate"""@eng ; skos:notation """CDR0000362084"""^^xsd:string ; skos:altLabel """DOX/LEUP/ZOLE"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541199"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/tretinoin"""@eng ; skos:notation """CDR0000041841"""^^xsd:string ; skos:altLabel """ATRA/G-CSF"""@eng ; ; ; """5025"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281409"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydralazine/interferon alfa"""@eng ; skos:notation """CDR0000041840"""^^xsd:string ; skos:altLabel """hydralazine/IFN-A"""@eng ; ; ; """5024"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338171"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic eosinophilic leukemia"""@eng ; skos:notation """CDR0000276487"""^^xsd:string ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """chronic myeloproliferative disorders"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0346421"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic neutrophilic leukemia"""@eng ; skos:notation """CDR0000276485"""^^xsd:string ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """chronic myeloproliferative disorders"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0023481"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tryptophanase"""@eng ; skos:notation """CDR0000041124"""^^xsd:string ; skos:altLabel """TDO2"""@eng , """TRPO"""@eng , """Tryptophan 2,3-Dioxygenase"""@eng , """Tryptophan Pyrrolase"""@eng , """L-tryptophanase"""@eng , """TPH2"""@eng , """Tryptophan Oxygenase"""@eng , """Tryptamin 2,3-Dioxygenase"""@eng ; skos:definition """Encoded by human TDO2 Gene, 406-aa 48-kDa Tryptophanase is a homotetramer that may bind protoheme IV involved in tryptophan catabolism with broad specificity towards tryptamine and derivatives including tryptophan, 5-hydroxytryptophan, and serotonin. (NCI) Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41124&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41124&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C17218\" NCI Thesaurus)"""@eng ; """4199"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C17218"""^^xsd:string ; umls:cui """C0041256"""^^xsd:string ; umls:cui """C0041260"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038227"""^^xsd:string ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10834"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862226"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetra-O-methyl nordihydroguaiaretic acid"""@eng ; skos:notation """CDR0000472205"""^^xsd:string ; skos:altLabel """M4N"""@eng , """EM-1421"""@eng ; """2006-03-10"""^^xsd:string ; """C61441"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; umls:cui """C1831769"""^^xsd:string ; umls:cui """C0654036"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transdermal estrogen"""@eng ; skos:notation """CDR0000472200"""^^xsd:string ; skos:altLabel """EstroGel"""@eng ; skos:definition """A transdermal formulation containing the synthetic form of estradiol, the most potent, endogenously produced estrogen. Upon topical administration, estradiol diffuses through the cell membrane and binds to and activates specific intracellular estrogen receptors located on estrogen-responsive tissues, including the reproductive tract, breast, pituitary, hypothalamus, liver, and bone. The activated ligand-receptor complex binds to estrogen response elements on DNA and promotes the transcription of genes involved in the functioning of the female reproductive system and secondary sex characteristics. In addition, estradiol inhibits the pituitary secretion of the gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=472200&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=472200&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61440\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-10-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-10"""^^xsd:string ; """C61440"""^^xsd:string ; umls:cui """C1831768"""^^xsd:string ; umls:cui """C1330258"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 531"""@eng ; skos:notation """CDR0000459753"""^^xsd:string ; skos:altLabel """Amgen Megakaryopoiesis Protein 2"""@eng ; skos:definition """A recombinant protein with megakarypoiesis stimulating activity. AMG 531 mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TPO-R stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459753&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459753&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52183\" NCI Thesaurus)"""@eng ; """C52183"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C2364481"""^^xsd:string ; umls:cui """C1505595"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 glass microspheres"""@eng ; skos:notation """CDR0000038672"""^^xsd:string ; skos:altLabel """TheraSphere"""@eng ; skos:definition """An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90. When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38672&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38672&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38679\" NCI Thesaurus)"""@eng ; """11317"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38679"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135147"""^^xsd:string ; umls:cui """C1134675"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PR-171"""@eng ; skos:notation """CDR0000459751"""^^xsd:string ; skos:definition """An epoxomicin derivate with potential antineoplastic activity. PR-171 irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459751&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459751&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52196\" NCI Thesaurus)"""@eng ; """2006-09-11"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C52196"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1709429"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/GTI-2040/prednisone"""@eng ; skos:notation """CDR0000374992"""^^xsd:string ; skos:altLabel """GTI2040/PRED/TXT"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541309"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EKB-569"""@eng ; skos:notation """CDR0000352165"""^^xsd:string ; skos:altLabel """EKB 569"""@eng ; skos:definition """A 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352165&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352165&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2713\" NCI Thesaurus)"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2713"""^^xsd:string ; """2006-08-02"""^^xsd:string ; umls:cui """C0961045"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent Merkel cell carcinoma"""@eng ; skos:notation """CDR0000038245"""^^xsd:string ; skos:altLabel """Merkel cell carcinoma, recurrent"""@eng ; rdfs:subClassOf ; """neuroendocrine carcinoma of the skin"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10851"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0935808"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III Merkel cell carcinoma"""@eng ; skos:notation """CDR0000038244"""^^xsd:string ; skos:altLabel """Merkel cell carcinoma, stage III"""@eng ; rdfs:subClassOf ; """neuroendocrine carcinoma of the skin"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10850"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0935807"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Wobe-Mugos E"""@eng ; skos:notation """CDR0000038247"""^^xsd:string ; skos:altLabel """Wobe-Mugos"""@eng ; ; """10853"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935809"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BBR 3464"""@eng ; skos:notation """CDR0000038246"""^^xsd:string ; skos:altLabel """BBR-3464"""@eng , """BBR3464"""@eng ; """10852"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0756613"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I Merkel cell carcinoma"""@eng ; skos:notation """CDR0000038241"""^^xsd:string ; skos:altLabel """Merkel cell carcinoma, stage I"""@eng ; rdfs:subClassOf ; """neuroendocrine carcinoma of the skin"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10848"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0935805"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Merkel cell carcinoma"""@eng ; skos:notation """CDR0000038240"""^^xsd:string ; skos:altLabel """Merkel cell cancer"""@eng , """MCC"""@eng , """carcinoma, Merkel cell"""@eng ; rdfs:subClassOf ; """10847"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007129"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III penile cancer"""@eng ; skos:notation """CDR0000038243"""^^xsd:string ; skos:altLabel """penile cancer, stage III"""@eng , """penis cancer, stage III"""@eng ; rdfs:subClassOf ; """penile cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1085"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854967"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II Merkel cell carcinoma"""@eng ; skos:notation """CDR0000038242"""^^xsd:string ; skos:altLabel """Merkel cell carcinoma, stage II"""@eng ; rdfs:subClassOf ; """neuroendocrine carcinoma of the skin"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10849"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0935806"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/gemcitabine/paclitaxel"""@eng ; skos:notation """CDR0000038677"""^^xsd:string ; skos:altLabel """CTX/dFdC/EPI/TAX"""@eng ; ; ; ; ; """11329"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thalidomide/topotecan"""@eng ; skos:notation """CDR0000038249"""^^xsd:string ; skos:altLabel """THAL/TOPO"""@eng ; ; ; """10857"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935811"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/prednisone/Wobe-Mugos E"""@eng ; skos:notation """CDR0000038248"""^^xsd:string ; skos:altLabel """L-PAM/PRED/Wobe-Mugos"""@eng ; ; ; ; """10854"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935810"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/megestrol"""@eng ; skos:notation """CDR0000038920"""^^xsd:string ; skos:altLabel """AGT/MEG"""@eng ; ; ; """1428"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278965"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbamazepine"""@eng ; skos:notation """CDR0000042418"""^^xsd:string ; skos:altLabel """Tegretol"""@eng , """5H-Dibenz(b,f)azepine-5-carboxamide"""@eng , """Epitol"""@eng ; skos:definition """A tricyclic compound chemically related to tricyclic antidepressants (TCA) with anticonvulsant and analgesic properties. Carbamazepine exerts its anticonvulsant activity by reducing polysynaptic responses and blocking post-tetanic potentiation. Its analgesic activity is not understood; however, carbamazepine is commonly used to treat pain associated with trigeminal neuralgia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42418&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42418&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C341\" NCI Thesaurus)"""@eng ; """5690"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """169864"""^^xsd:string ; """298-46-4"""^^xsd:string ; """C341"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0006949"""^^xsd:string ; umls:cui """C0700087"""^^xsd:string ; umls:cui """C0700667"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oblimersen/paclitaxel"""@eng ; skos:notation """CDR0000037918"""^^xsd:string ; skos:altLabel """G3139/TAX"""@eng ; ; ; """10332"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879470"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/gemcitabine"""@eng ; skos:notation """CDR0000037919"""^^xsd:string ; skos:altLabel """dFdC/MOAB C225"""@eng ; ; ; """10333"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879471"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MMP"""@eng ; skos:notation """CDR0000037914"""^^xsd:string ; rdfs:subClassOf ; """10329"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919336"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I vulvar cancer"""@eng ; skos:notation """CDR0000037915"""^^xsd:string ; skos:altLabel """stage I cancer of the vulva"""@eng , """vulvar cancer, stage I"""@eng , """cancer of the vulva, stage I"""@eng , """carcinoma of the vulva, stage I"""@eng , """vulva cancer, stage I"""@eng , """stage I carcinoma of the vulva"""@eng , """stage I vulva cancer"""@eng ; rdfs:subClassOf ; """vulvar cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1033"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854960"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PI-3 kinase"""@eng ; skos:notation """CDR0000037916"""^^xsd:string ; rdfs:subClassOf ; """10330"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919338"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ILX-295501"""@eng ; skos:notation """CDR0000037917"""^^xsd:string ; skos:altLabel """ILX295501"""@eng , """ILX 295501"""@eng ; """2003-10-28"""^^xsd:string ; """10331"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879469"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 vulvar cancer"""@eng ; skos:notation """CDR0000037910"""^^xsd:string ; skos:altLabel """vulva cancer, stage 0"""@eng , """stage 0 vulva cancer"""@eng , """stage 0 cancer of the vulva"""@eng , """vulvar cancer, stage 0"""@eng , """vulvar cancer in situ"""@eng , """carcinoma of the vulva, stage 0"""@eng , """stage 0 carcinoma of the vulva"""@eng , """carcinoma in situ of the vulva"""@eng , """cancer of the vulva, stage 0"""@eng ; rdfs:subClassOf ; """vulvar cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1032"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278729"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HER-2"""@eng ; skos:notation """CDR0000037912"""^^xsd:string ; rdfs:subClassOf ; """10327"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0242957"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CSF1-R"""@eng ; skos:notation """CDR0000037913"""^^xsd:string ; rdfs:subClassOf ; """10328"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879468"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/Candida albicans skin test reagent/CD40-ligand/gp100 antigen/interferon gamma/interleukin-4/MART-1 antigen/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000038061"""^^xsd:string ; skos:altLabel """ADC/CASTA/CD40-L/GM-CSF/gp100/IFN-G/IL-4/MART-1/TYRP"""@eng ; ; ; ; ; ; ; ; ; ; """10597"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879602"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """insulinoma"""@eng ; skos:notation """CDR0000038792"""^^xsd:string ; skos:altLabel """islet cell insulinoma"""@eng , """pancreatic insulinoma"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1243"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0021670"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent testicular cancer"""@eng ; skos:notation """CDR0000038791"""^^xsd:string ; skos:altLabel """relapsed carcinoma of the testis"""@eng , """testicle cancer, recurrent"""@eng , """recurrent or refractory testicular cancer"""@eng , """testicular cancer, refractory"""@eng , """testis cancer, relapsed"""@eng , """refractory cancer of the testis"""@eng , """carcinoma of the testis, recurrent"""@eng , """recurrent testis cancer"""@eng , """testicular cancer, relapsed"""@eng , """testicle cancer, relapsed"""@eng , """cancer of the testis, relapsed"""@eng , """recurrent carcinoma of the testis"""@eng , """refractory testis cancer"""@eng , """testicular cancer, recurrent"""@eng , """refractory testicular cancer"""@eng , """cancer of the testis, recurrent"""@eng , """carcinoma of the testis, relapsed"""@eng , """refractory carcinoma of the testis"""@eng , """relapsed testicular cancer"""@eng , """cancer of the testis, refractory"""@eng , """testis cancer, recurrent"""@eng , """recurrent cancer of the testis"""@eng , """relapsed testis cancer"""@eng , """testis cancer, refractory"""@eng , """carcinoma of the testis, refractory"""@eng , """relapsed cancer of the testis"""@eng , """testicle cancer, refractory"""@eng ; rdfs:subClassOf ; """testicular cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1240"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278841"""^^xsd:string ; umls:cui """C1377904"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000038062"""^^xsd:string ; skos:altLabel """CAPE/MOAB HER2/TAX"""@eng ; ; ; ; """10598"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879603"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rV-B7.1 vaccine/vaccinia-PSA vaccine"""@eng ; skos:notation """CDR0000038065"""^^xsd:string ; skos:altLabel """rV-B7.1/VPSA"""@eng ; ; ; """2004-11-03"""^^xsd:string ; """10601"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879604"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IVA vaginal cancer"""@eng ; skos:notation """CDR0000038064"""^^xsd:string ; skos:altLabel """vaginal cancer, stage IVA"""@eng , """stage IVA cancer of the vagina"""@eng , """stage IVA carcinoma of the vagina"""@eng , """stage IVA vagina cancer"""@eng , """cancer of the vagina, stage IVA"""@eng , """carcinoma of the vagina, stage IVA"""@eng , """vagina cancer, stage IVA"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1060"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278744"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/idarubicin"""@eng ; skos:notation """CDR0000038067"""^^xsd:string ; skos:altLabel """DM/IDA"""@eng ; ; ; """10604"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935662"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody Hu3S193"""@eng ; skos:notation """CDR0000038066"""^^xsd:string ; skos:altLabel """In 111 MOAB Hu3S193"""@eng ; """10603"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879605"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arginine butyrate/ganciclovir"""@eng ; skos:notation """CDR0000038069"""^^xsd:string ; skos:altLabel """BW-B759U/L-arginine"""@eng ; ; ; """10608"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935664"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/temozolomide/vincristine"""@eng ; skos:notation """CDR0000038068"""^^xsd:string ; skos:altLabel """CBDCA/TMZ/VCR"""@eng ; ; ; ; """10607"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935663"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noninvasive thymoma and thymic carcinoma"""@eng ; skos:notation """CDR0000038799"""^^xsd:string ; skos:altLabel """non-invasive thymoma"""@eng , """noninvasive thymoma"""@eng ; rdfs:subClassOf ; """thymoma and thymic carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1250"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278847"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """invasive thymoma and thymic carcinoma"""@eng ; skos:notation """CDR0000038798"""^^xsd:string ; skos:altLabel """invasive thymoma"""@eng ; rdfs:subClassOf ; """thymoma and thymic carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1249"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278846"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue"""@eng ; skos:notation """CDR0000372812"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0242647"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nodal marginal zone B-cell lymphoma"""@eng ; skos:notation """CDR0000372811"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0855139"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/docetaxel/estramustine/leuprolide"""@eng ; skos:notation """CDR0000357873"""^^xsd:string ; skos:altLabel """CDX/EM/LEUP/TXT"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541571"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ex vivo-expanded HER2-specific T cells"""@eng ; skos:notation """CDR0000459973"""^^xsd:string ; skos:definition """T cells specific for the human epidermal growth factor receptor 2 (HER2) with potential immunopotentiating activity. T cells directed against HER2, overexpressed on many tumor cells, are collected from HER2-expressing tumor tissue, expanded ex vivo and, then re-introduced in the patient. Re-introduction of ex vivo-expanded HER2-specific T cells may enhance the cytotoxic T cell response against tumor cells overexpressing HER2, resulting in inhibition of tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459973&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459973&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52192\" NCI Thesaurus)"""@eng ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C52192"""^^xsd:string ; umls:cui """C1708270"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human anti-TGF-beta monoclonal antibody GC1008"""@eng ; skos:notation """CDR0000530302"""^^xsd:string ; skos:altLabel """GC1008"""@eng ; """2007-01-16"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832030"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glycopeptide antibiotic"""@eng ; skos:notation """CDR0000468927"""^^xsd:string ; skos:definition """One of a class of antibiotics originally isolated from plant and soil bacteria with structures containing either a glycosylated cyclic or polycyclic nonribosomal peptide. These antibiotics inhibit the cell wall structure of susceptible organisms (principally Gram-positive cocci) by inhibiting peptidoglycan synthesis.First-generation glycopeptide antibiotics include vancomycin, teicoplanin, and ramoplanin; second-generation semi-synthetic glycopeptide antibiotics include oritavancin, dalbavancin, and telavancin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468927&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468927&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61101\" NCI Thesaurus)"""@eng ; """2006-07-18"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61101"""^^xsd:string ; umls:cui """C0162724"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Clostridium novyi-NT spores"""@eng ; skos:notation """CDR0000502157"""^^xsd:string ; skos:altLabel """C. novyi-NT spores"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-13"""^^xsd:string ; umls:cui """C1831945"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L523S DNA vaccine"""@eng ; skos:notation """CDR0000353188"""^^xsd:string ; skos:altLabel """L523S-DNA"""@eng ; ; """2004-01-23"""^^xsd:string ; """2004-01-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328162"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinblastine"""@eng ; skos:notation """CDR0000042951"""^^xsd:string ; skos:altLabel """vincaleukoblastine"""@eng , """Velban"""@eng , """Vincaleucoblastine"""@eng , """VLB"""@eng , """Velsar"""@eng , """VBL"""@eng ; skos:definition """A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42951&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42951&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C930\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """713"""^^xsd:string ; """C930"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """865-21-4"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0042670"""^^xsd:string ; umls:cui """C0919392"""^^xsd:string ; umls:cui """C0728761"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000039682"""^^xsd:string ; skos:altLabel """BLEO/PCB/VBL"""@eng , """VPB"""@eng ; ; ; ; """2336"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039683"""^^xsd:string ; skos:altLabel """ARA-C/DOX/MP/PRED/VCR"""@eng ; ; ; ; ; ; """2337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279463"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039680"""^^xsd:string ; skos:altLabel """VMF"""@eng , """5-FU/MTX/VCR"""@eng ; ; ; ; """2334"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078399"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/sargramostim"""@eng ; skos:notation """CDR0000039681"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/GM-CSF"""@eng ; ; ; ; ; """2335"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279461"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/doxorubicin/lomustine/prednisone"""@eng ; skos:notation """CDR0000039686"""^^xsd:string ; skos:altLabel """AB-DIC"""@eng , """BLEO/CCNU/DOX/DTIC/PRED"""@eng ; ; ; ; ; ; """2340"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0081426"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate"""@eng ; skos:notation """CDR0000039687"""^^xsd:string ; skos:altLabel """CDDP/DOX/MTX"""@eng , """AMDDP"""@eng ; ; ; ; """2341"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0300200"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/gp100 antigen/MAGE-3/MART-1 antigen/Melan-A/NY-ESO-B/QS21/tyrosinase peptide"""@eng ; skos:notation """CDR0000257354"""^^xsd:string ; skos:altLabel """flu/gp100/MAGE3/MART-1/MEL-A/NY ESO-B/QS 21/TYRP"""@eng ; ; ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """11450"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327766"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/doxorubicin"""@eng ; skos:notation """CDR0000039685"""^^xsd:string ; skos:altLabel """ABCX"""@eng , """BLEO/CDDP/DOX"""@eng ; ; ; ; """2339"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279465"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/fluorouracil/vinblastine"""@eng ; skos:notation """CDR0000039688"""^^xsd:string ; skos:altLabel """CDDP/DOX/5-FU/VBL"""@eng , """FUVAC"""@eng ; ; ; ; ; """2342"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279468"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin/mercaptopurine"""@eng ; skos:notation """CDR0000039689"""^^xsd:string ; skos:altLabel """ARA-C/DOX/MP"""@eng ; ; ; ; """2343"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279469"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/mitolactol/prednisone"""@eng ; skos:notation """CDR0000039538"""^^xsd:string ; skos:altLabel """DMFP"""@eng , """DBD/5-FU/MTX/PRED"""@eng ; ; ; ; ; """2185"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279356"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rV-B7.1 vaccine"""@eng ; skos:notation """CDR0000037779"""^^xsd:string ; skos:altLabel """Recombinant Vaccinia-B7.1"""@eng , """Recombinant Vaccinia-B7.1 Vaccine"""@eng , """rV-B7 (Recomb Vaccinia/B7)"""@eng , """rV-B7.1"""@eng ; skos:definition """A recombinant vaccinia virus encoding the T-cell co-stimulatory molecule B7-1. Co-administration of recombinant vaccinia-B7.1 and a tumor-associated antigen in a cancer vaccine may enhance tumor-associated antigen-specific T-cell responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37779&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37779&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2237\" NCI Thesaurus)"""@eng ; ; ; """10135"""^^xsd:string ; """8202"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """8397"""^^xsd:string ; """C2237"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """699018"""^^xsd:string ; umls:cui """C0879372"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluoxymesterone/mitolactol/vincristine"""@eng ; skos:notation """CDR0000039530"""^^xsd:string ; skos:altLabel """DBD/DOX/FXM/VCR"""@eng , """DAVCH"""@eng ; ; ; ; """2173"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057164"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluoxymesterone/mitolactol/mitoxantrone/tamoxifen"""@eng ; skos:notation """CDR0000039531"""^^xsd:string ; skos:altLabel """D(DHAD)TH"""@eng , """DBD/DHAD/FXM/TMX"""@eng ; ; ; ; """2174"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279349"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dianhydrogalactitol/doxorubicin"""@eng ; skos:notation """CDR0000039532"""^^xsd:string ; skos:altLabel """DAP-II"""@eng , """CDDP/DAG/DOX"""@eng ; ; ; ; """2175"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279350"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ancitabine hydrochloride/daunorubicin/mercaptopurine/prednisolone"""@eng ; skos:notation """CDR0000039533"""^^xsd:string ; skos:altLabel """DCCMP"""@eng , """CYC/DNR/MP/PRDL"""@eng ; ; ; ; ; """2177"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279351"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluoxymesterone/mitolactol/tamoxifen/vincristine"""@eng ; skos:notation """CDR0000039534"""^^xsd:string ; skos:altLabel """DAVTH"""@eng , """DBD/DOX/FXM/TMX/VCR"""@eng ; ; ; ; ; """2178"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0164415"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluoxymesterone/methotrexate/mitolactol/tamoxifen/vincristine"""@eng ; skos:notation """CDR0000039535"""^^xsd:string ; skos:altLabel """DAVTHML"""@eng , """DBD/DOX/FXM/MTX/TMX/VCR"""@eng ; ; ; ; ; ; """2179"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279353"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dianhydrogalactitol/etoposide"""@eng ; skos:notation """CDR0000039536"""^^xsd:string ; skos:altLabel """DV"""@eng , """DAG/VP-16"""@eng ; ; ; """2180"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279354"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/cytarabine/daunorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039537"""^^xsd:string ; skos:altLabel """DZAPO"""@eng , """ARA-C/AZA/DNR/PRED/VCR"""@eng ; ; ; ; ; ; """2182"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279355"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody OKT3/tumor necrosis factor"""@eng ; skos:notation """CDR0000041201"""^^xsd:string ; skos:altLabel """IL-2/MOAB OKT3/TNF"""@eng ; ; ; ; """4274"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338199"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody OKT3"""@eng ; skos:notation """CDR0000041200"""^^xsd:string ; skos:altLabel """IL-2/MOAB OKT3"""@eng ; ; ; """4273"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338198"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/etoposide/methylprednisolone"""@eng ; skos:notation """CDR0000041203"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/MePRDL/VP-16"""@eng ; ; ; ; ; """4276"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280807"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2/monoclonal antibody OKT3/tumor necrosis factor"""@eng ; skos:notation """CDR0000041202"""^^xsd:string ; skos:altLabel """CTX/IL-2/MOAB OKT3/TNF"""@eng ; ; ; ; ; """4275"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338200"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Re-186 hydroxyethylidene diphosphonate"""@eng ; skos:notation """CDR0000041205"""^^xsd:string ; skos:altLabel """rhenium-186 HEDP"""@eng , """Re-186 HEDP"""@eng , """rhenium-186 hydroxyethylidene diphosphonate"""@eng ; """4278"""^^xsd:string ; """C1562"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0280809"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin integrity changes secondary to cutaneous metastases"""@eng ; skos:notation """CDR0000041204"""^^xsd:string ; skos:altLabel """cutaneous metastases, local care of"""@eng , """local care of cutaneous metastases"""@eng ; rdfs:subClassOf ; """4277"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280808"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/interferon alfa"""@eng ; skos:notation """CDR0000041207"""^^xsd:string ; skos:altLabel """CDDP/CTX/IFN-A"""@eng ; ; ; ; """4280"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338132"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/mitoxantrone"""@eng ; skos:notation """CDR0000041206"""^^xsd:string ; skos:altLabel """CBDCA/DHAD"""@eng ; ; ; """4279"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280810"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sleep disorders"""@eng ; skos:notation """CDR0000041209"""^^xsd:string ; skos:altLabel """disturbances, sleep"""@eng , """disorders, sleep"""@eng , """sleep disturbances"""@eng ; rdfs:subClassOf ; """4282"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0851578"""^^xsd:string ; umls:cui """C0037317"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/melphalan"""@eng ; skos:notation """CDR0000041208"""^^xsd:string ; skos:altLabel """CBDCA/L-PAM/VP-16"""@eng ; ; ; ; """4281"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280812"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """domperidone"""@eng ; skos:notation """CDR0000040071"""^^xsd:string ; skos:altLabel """KW 5338"""@eng , """Motilium"""@eng , """R 33,812"""@eng ; """2813"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0878021"""^^xsd:string ; umls:cui """C0878022"""^^xsd:string ; umls:cui """C0013015"""^^xsd:string ; umls:cui """C0700011"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piritrexim"""@eng ; skos:notation """CDR0000040070"""^^xsd:string ; skos:altLabel """BW-301U"""@eng , """6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"""@eng , """Piritrexim Isethionate"""@eng , """2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine"""@eng , """6-[(2,5-Dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine"""@eng ; skos:definition """A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40070&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40070&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1031\" NCI Thesaurus)"""@eng ; ; ; """2812"""^^xsd:string ; """72732-56-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1031"""^^xsd:string ; """351521"""^^xsd:string ; umls:cui """C1522061"""^^xsd:string ; umls:cui """C0054332"""^^xsd:string ; umls:cui """C0701495"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040073"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MTX/VCR"""@eng , """COMLA"""@eng ; ; ; ; ; """2815"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0082890"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/misonidazole"""@eng ; skos:notation """CDR0000040072"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/MNI"""@eng , """M-CAP"""@eng ; ; ; ; ; """2814"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279772"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/lomustine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040075"""^^xsd:string ; skos:altLabel """CCNU/CTX/MTX/VCR"""@eng , """CyMOC"""@eng ; ; ; ; ; """2817"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054929"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040074"""^^xsd:string ; skos:altLabel """COMLA-Plus"""@eng , """ARA-C/BLEO/CTX/DOX/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """2816"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279774"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000040077"""^^xsd:string ; skos:altLabel """CDDP/DOX/VP-16"""@eng , """PAV"""@eng ; ; ; ; """2819"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0058890"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/methotrexate"""@eng ; skos:notation """CDR0000040076"""^^xsd:string ; skos:altLabel """MADIT"""@eng , """ARA-C/DM/MTX"""@eng ; ; ; ; """2818"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279776"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/ascorbic acid/dexamethasone/thalidomide"""@eng ; skos:notation """CDR0000430890"""^^xsd:string ; skos:altLabel """AS2O3/DM/THAL/VIT-C"""@eng ; ; ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-04-28"""^^xsd:string ; umls:cui """C1831608"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/ascorbic acid/dexamethasone"""@eng ; skos:notation """CDR0000430891"""^^xsd:string ; skos:altLabel """AS2O3/DM/VIT-C"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-04-28"""^^xsd:string ; """2005-05-23"""^^xsd:string ; umls:cui """C1831609"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/selenium"""@eng ; skos:notation """CDR0000430892"""^^xsd:string ; skos:altLabel """CPT-11/SEL"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-04-28"""^^xsd:string ; """2005-05-23"""^^xsd:string ; umls:cui """C1831610"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cisplatin/etoposide"""@eng ; skos:notation """CDR0000355764"""^^xsd:string ; skos:altLabel """CDDP/MOAB VEGF/VP-16"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328198"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diffusion tensor imaging"""@eng ; skos:notation """CDR0000526227"""^^xsd:string ; rdfs:subClassOf ; """2006-12-12"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-12-18"""^^xsd:string ; umls:cui """C1537007"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laser scanning cytometry"""@eng ; skos:notation """CDR0000526225"""^^xsd:string ; rdfs:subClassOf ; """2006-12-18"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C1449707"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transient myeloproliferative disorder"""@eng ; skos:notation """CDR0000525750"""^^xsd:string ; skos:altLabel """TMD"""@eng ; rdfs:subClassOf ; """2006-12-08"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """2006-12-05"""^^xsd:string ; umls:cui """C1834582"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """xerostomia"""@eng ; skos:notation """CDR0000530108"""^^xsd:string ; skos:altLabel """dry mouth"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2007-01-09"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C0043352"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lometrexol"""@eng ; skos:notation """CDR0000041670"""^^xsd:string ; skos:altLabel """6R-5,10-Dideazatetrahydrofolate"""@eng , """LMTX"""@eng , """Pyrido[2,3-d]pyrimidine, L-glutamic acid derivative (9CI)"""@eng , """(6R)-DDATHF"""@eng , """L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (R)-"""@eng , """L-Glutamic acid, N-(4-(2-((6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-"""@eng ; skos:definition """A folate analog antimetabolite with antineoplastic activity. As the 6R diastereomer of 5,10-dideazatetrahydrofolate, lometrexol inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation. The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41670&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41670&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C979\" NCI Thesaurus)"""@eng ; ; ; """4833"""^^xsd:string ; """660025"""^^xsd:string ; """46981"""^^xsd:string ; """C979"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """106400-81-1"""^^xsd:string ; umls:cui """C0048852"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide"""@eng ; skos:notation """CDR0000041671"""^^xsd:string ; skos:altLabel """Temodal"""@eng , """RP-46161"""@eng , """CCRG-81045"""@eng , """TMZ"""@eng , """SCH 52365"""@eng , """M and B 39831"""@eng , """M & B 39831"""@eng , """8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one"""@eng , """imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-"""@eng , """3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide"""@eng , """Methazolastone"""@eng , """Temodar"""@eng ; skos:definition """A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41671&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41671&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1244\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4834"""^^xsd:string ; """85622-93-1"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """362856"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """42084"""^^xsd:string ; """C1244"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0076080"""^^xsd:string ; umls:cui """C1524087"""^^xsd:string ; umls:cui """C0108742"""^^xsd:string ; umls:cui """C0876179"""^^xsd:string ; umls:cui """C0701506"""^^xsd:string ; umls:cui """C0126551"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041672"""^^xsd:string ; skos:altLabel """CF/MP/MTX"""@eng ; ; ; ; """4835"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281272"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041673"""^^xsd:string ; skos:altLabel """ASP/MP/MTX"""@eng ; ; ; ; """4836"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281273"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/mitomycin"""@eng ; skos:notation """CDR0000041674"""^^xsd:string ; skos:altLabel """CF/5-FU/MITO"""@eng ; ; ; ; """4837"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/thymidine"""@eng ; skos:notation """CDR0000041675"""^^xsd:string ; skos:altLabel """CBDCA/TDR"""@eng ; ; ; """4838"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/topotecan"""@eng ; skos:notation """CDR0000041676"""^^xsd:string ; skos:altLabel """TOPO/VP-16"""@eng ; ; ; """4839"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281276"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/floxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000041677"""^^xsd:string ; skos:altLabel """CF/DM/FUDR"""@eng ; ; ; ; """4840"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281277"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cyclophosphamide"""@eng ; skos:notation """CDR0000041678"""^^xsd:string ; skos:altLabel """CTX/WR-2721"""@eng ; ; ; """4841"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281278"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000041679"""^^xsd:string ; skos:altLabel """CYSP/DHAD/VP-16"""@eng ; ; ; ; """4842"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281279"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/temsirolimus"""@eng ; skos:notation """CDR0000434598"""^^xsd:string ; skos:altLabel """BRYO/CCI-779"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-19"""^^xsd:string ; umls:cui """C1831633"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diphenhydramine hydrochloride"""@eng ; skos:notation """CDR0000039163"""^^xsd:string ; skos:altLabel """Benadryl"""@eng , """Eldadryl"""@eng , """SK-Diphenhydramine"""@eng , """Bendylate"""@eng ; skos:definition """The hydrochloride salt form of diphenhydramine, an ethanolamine and first-generation histamine antagonist with anti-allergic activity. Diphenhydramine hydrochloride competitively blocks H1receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries, and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39163&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39163&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C300\" NCI Thesaurus)"""@eng ; """1783"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33299"""^^xsd:string ; """C300"""^^xsd:string ; """147-24-0"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700901"""^^xsd:string ; umls:cui """C1527343"""^^xsd:string ; umls:cui """C0004963"""^^xsd:string ; umls:cui """C0700899"""^^xsd:string ; umls:cui """C0700902"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041639"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """4800"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/pemetrexed disodium"""@eng ; skos:notation """CDR0000434621"""^^xsd:string ; skos:altLabel """LY231514/MOAB VEGF"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-20"""^^xsd:string ; umls:cui """C1831634"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fludarabine/thalidomide/topotecan"""@eng ; skos:notation """CDR0000269712"""^^xsd:string ; skos:altLabel """CBDCA/FAMP/THAL/TOPO"""@eng ; ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327860"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/HER-2/neu peptide vaccine"""@eng ; skos:notation """CDR0000424410"""^^xsd:string ; skos:altLabel """ADC/HER-2"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541522"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/imatinib mesylate"""@eng ; skos:notation """CDR0000269719"""^^xsd:string ; skos:altLabel """AS203/STI571"""@eng ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327861"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000041633"""^^xsd:string ; skos:altLabel """small noncleaved cell lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """4795"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1720008"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042323"""^^xsd:string ; skos:altLabel """DM/DOX/PEG-ASP/VCR"""@eng ; ; ; ; ; """5571"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338243"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/methylprednisolone"""@eng ; skos:notation """CDR0000042322"""^^xsd:string ; skos:altLabel """CYSP/MePRDL"""@eng ; ; ; """5570"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338242"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/dexamethasone/thiotepa"""@eng ; skos:notation """CDR0000042321"""^^xsd:string ; skos:altLabel """BU/DM/TSPA"""@eng ; ; ; ; """5569"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338241"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Shwachman-Diamond syndrome"""@eng ; skos:notation """CDR0000285969"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0272170"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-CEA vaccine"""@eng ; skos:notation """CDR0000042326"""^^xsd:string ; skos:altLabel """ALVAC-CEA"""@eng ; ; """5576"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338246"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """denileukin diftitox"""@eng ; skos:notation """CDR0000042325"""^^xsd:string ; skos:altLabel """DAB389 interleukin-2"""@eng , """ONTAK"""@eng , """DAB(389)IL-2"""@eng , """Interleukin-2 Fusion Protein"""@eng , """LY335348"""@eng , """DAB389-IL2"""@eng , """DAB389IL-2"""@eng , """DAB(389)-Interleukin-2"""@eng , """DAB389IL2"""@eng , """Interleukin-2 Fusion Toxin"""@eng , """DAB389 interleukin-2 immunotoxin"""@eng ; skos:definition """A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42325&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42325&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1476\" NCI Thesaurus)"""@eng ; ; """5575"""^^xsd:string ; """2006-05-16"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1476"""^^xsd:string ; """714744"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0211023"""^^xsd:string ; umls:cui """C0722264"""^^xsd:string ; umls:cui """C0917978"""^^xsd:string ; umls:cui """C0717670"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042324"""^^xsd:string ; skos:altLabel """DM/PEG-ASP/VCR"""@eng ; ; ; ; """5573"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338244"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """9-cis-retinoic acid/interferon alfa"""@eng ; skos:notation """CDR0000042329"""^^xsd:string ; skos:altLabel """9-CRA/IFN-A"""@eng ; ; ; """5579"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338247"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pemetrexed disodium"""@eng ; skos:notation """CDR0000042328"""^^xsd:string ; skos:altLabel """LY231514"""@eng , """ALIMTA"""@eng , """Multitargeted Antifolate"""@eng , """MTA"""@eng , """LY 231514"""@eng , """L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)"""@eng , """N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt"""@eng ; skos:definition """A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42328&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42328&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1533\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; """5578"""^^xsd:string ; """137281-23-3"""^^xsd:string ; """150399-23-8 (disodium)"""^^xsd:string ; """C1533"""^^xsd:string ; """698037"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0936142"""^^xsd:string ; umls:cui """C0251353"""^^xsd:string ; umls:cui """C0210657"""^^xsd:string ; umls:cui """C1101816"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral cavity adenoid cystic carcinoma"""@eng ; skos:notation """CDR0000040679"""^^xsd:string ; skos:altLabel """adenoid cystic carcinoma, oral cavity"""@eng ; rdfs:subClassOf ; """3593"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280311"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral cavity mucoepidermoid carcinoma"""@eng ; skos:notation """CDR0000040678"""^^xsd:string ; skos:altLabel """mucoepidermoid carcinoma, oral cavity"""@eng ; rdfs:subClassOf ; """3592"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280309"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia with t(16;16)(p13;q22)"""@eng ; skos:notation """CDR0000377659"""^^xsd:string ; ; ; ; ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-18"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541332"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040673"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity cancer cellular diagnosis"""@eng , """nasal cavity and paranasal sinus cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """3588"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280295"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040672"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity cancer stage"""@eng , """nasal cavity and paranasal sinus cancer stage"""@eng ; rdfs:subClassOf ; """3587"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280294"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytogenetic abnormalities, adult acute myeloid leukemia"""@eng ; skos:notation """CDR0000377654"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-18"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541330"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040670"""^^xsd:string ; skos:altLabel """hypopharyngeal cancer cellular diagnosis"""@eng , """hypopharynx cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """3585"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280292"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral cavity verrucous carcinoma"""@eng ; skos:notation """CDR0000040677"""^^xsd:string ; skos:altLabel """verrucous carcinoma, oral cavity"""@eng ; rdfs:subClassOf ; """3591"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280306"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lip and oral cavity squamous cell carcinoma"""@eng ; skos:notation """CDR0000040676"""^^xsd:string ; skos:altLabel """oral cavity and lip squamous cell carcinoma"""@eng , """squamous cell carcinoma, lip and oral cavity"""@eng , """epidermoid carcinoma, lip and oral cavity"""@eng ; rdfs:subClassOf ; """3590"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280297"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydatidiform mole"""@eng ; skos:notation """CDR0000040675"""^^xsd:string ; skos:altLabel """hydatidiform mole GTT"""@eng , """GTT, hydatidiform mole"""@eng , """molar pregnancy"""@eng , """hydatid mole"""@eng , """gestational trophoblastic tumor, hydatidiform mole"""@eng , """chorionic tumor"""@eng , """trophoblastic tumor GTT"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """gestational trophoblastic tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """359"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0020217"""^^xsd:string ; umls:cui """C1135868"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040674"""^^xsd:string ; skos:altLabel """Hodgkin's lymphoma stage, childhood"""@eng , """childhood Hodgkin's disease stage"""@eng , """stage, childhood Hodgkin's disease"""@eng , """Hodgkin's disease stage, childhood"""@eng ; rdfs:subClassOf ; """2003-01-14"""^^xsd:string ; """3589"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280296"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IB cervical cancer"""@eng ; skos:notation """CDR0000038478"""^^xsd:string ; skos:altLabel """stage IB uterine cervix cancer"""@eng , """uterine cervical cancer, stage IB"""@eng , """carcinoma of the cervix, stage IB"""@eng , """cervical cancer, stage IB"""@eng , """stage IB cervix cancer"""@eng , """stage IB cancer of the cervix"""@eng , """uterine cervix cancer, stage IB"""@eng , """stage IB carcinoma of the cervix"""@eng , """cancer of the cervix, stage IB"""@eng , """cervix cancer, stage IB"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """111"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278582"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000038479"""^^xsd:string ; skos:altLabel """lymphocytic leukemia, stage II chronic"""@eng , """leukemia, stage II chronic lymphocytic"""@eng , """chronic lymphocytic leukemia, stage II"""@eng , """CLL, stage II"""@eng ; rdfs:subClassOf ; """chronic lymphocytic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1110"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854803"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neuroepithelial tumor of the kidney"""@eng ; skos:notation """CDR0000038476"""^^xsd:string ; skos:altLabel """NETK"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """11098"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1134517"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cBR96-doxorubicin immunoconjugate"""@eng ; skos:notation """CDR0000038477"""^^xsd:string ; skos:altLabel """BMS-182248-01"""@eng , """BMS-182248"""@eng , """SGN-15"""@eng , """DOX-MOAB BR96"""@eng , """cBR96-doxorubicin conjugate"""@eng , """cBR96-DOX"""@eng ; ; ; """11099"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134650"""^^xsd:string ; umls:cui """C1522478"""^^xsd:string ; umls:cui """C0295526"""^^xsd:string ; umls:cui """C0295525"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood spinal cord tumors"""@eng ; skos:notation """CDR0000038474"""^^xsd:string ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """11096"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1134515"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood rhabdoid tumor of the central nervous system"""@eng ; skos:notation """CDR0000038475"""^^xsd:string ; rdfs:subClassOf ; """11097"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1134516"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """2-methoxyestradiol"""@eng ; skos:notation """CDR0000038472"""^^xsd:string ; skos:altLabel """(17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol"""@eng , """2ME2"""@eng , """2-ME"""@eng , """Panzem"""@eng , """2-Methoxy Estradiol"""@eng ; skos:definition """An orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38472&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38472&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C965\" NCI Thesaurus)"""@eng ; """11094"""^^xsd:string ; """62972"""^^xsd:string ; """362-07-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """659853"""^^xsd:string ; """C965"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135121"""^^xsd:string ; umls:cui """C0046319"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gefitinib/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000038473"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/ZD 1839"""@eng ; ; ; ; ; """2002-10-10"""^^xsd:string ; """11095"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/monoclonal antibody Ch14.18/sargramostim"""@eng ; skos:notation """CDR0000038470"""^^xsd:string ; skos:altLabel """13-CRA/GM-CSF/MOAB Ch14.18"""@eng ; ; ; ; """11092"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134512"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/isotretinoin/monoclonal antibody Ch14.18"""@eng ; skos:notation """CDR0000038471"""^^xsd:string ; skos:altLabel """13-CRA/IL-2/MOAB Ch14.18"""@eng ; ; ; ; """11093"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134513"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MART-1:27-35 peptide vaccine"""@eng ; skos:notation """CDR0000476336"""^^xsd:string ; skos:definition """A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476336&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476336&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2775\" NCI Thesaurus)"""@eng ; """7474"""^^xsd:string ; """5909"""^^xsd:string ; """C2775"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """6123"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """672643"""^^xsd:string ; """2006-07-19"""^^xsd:string ; umls:cui """C1831795"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100:209-217(210M) peptide vaccine"""@eng ; skos:notation """CDR0000476335"""^^xsd:string ; skos:altLabel """G9 209-2M"""@eng , """gp100:209-217(210M)"""@eng ; skos:definition """A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210 designed to improve immunogenicity. Vaccination with gp100:209-217(210M) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing gp100. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476335&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476335&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49022\" NCI Thesaurus)"""@eng ; """C49022"""^^xsd:string ; """683472"""^^xsd:string ; """2006-07-19"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """11152"""^^xsd:string ; """8709"""^^xsd:string ; """11024"""^^xsd:string ; """6123"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7474"""^^xsd:string ; umls:cui """C1711108"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Pycnogenol"""@eng ; skos:notation """CDR0000353158"""^^xsd:string ; skos:altLabel """PYC"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0072642"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ZD-6126"""@eng ; skos:notation """CDR0000353153"""^^xsd:string ; skos:altLabel """ZD6126"""@eng , """ZD 6126"""@eng ; ; """Drug/agent"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """C2736"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C1122629"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clofarabine/cytarabine/idarubicin"""@eng ; skos:notation """CDR0000353152"""^^xsd:string ; skos:altLabel """ARA-C/CAFdA/IDA"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328156"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clofarabine/idarubicin"""@eng ; skos:notation """CDR0000353151"""^^xsd:string ; skos:altLabel """CAFdA/IDA"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328155"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clofarabine/cytarabine"""@eng ; skos:notation """CDR0000353150"""^^xsd:string ; skos:altLabel """ARA-C/CAFdA"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328154"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CRS-100"""@eng ; skos:notation """CDR0000487160"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """C62409"""^^xsd:string ; umls:cui """C1831855"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """shark cartilage"""@eng ; skos:notation """CDR0000304435"""^^xsd:string ; skos:altLabel """Benefin"""@eng , """Cartilade"""@eng ; skos:definition """A nutritional supplement gleaned from the exoskeleton of the shark. Shark cartilage inhibits metalloproteinases (MMPs) and possesses antiangiogenic and antimetastatic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304435&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304435&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2318\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2003-04-23"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C2318"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0281563"""^^xsd:string ; umls:cui """C1519299"""^^xsd:string ; umls:cui """C1135152"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/tamoxifen"""@eng ; skos:notation """CDR0000041078"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/TMX"""@eng ; ; ; ; ; """4117"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280682"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/thiotepa"""@eng ; skos:notation """CDR0000041079"""^^xsd:string ; skos:altLabel """DHAD/TSPA"""@eng ; ; ; """4118"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/melphalan/misonidazole/prednisone"""@eng ; skos:notation """CDR0000041072"""^^xsd:string ; skos:altLabel """BCNU/CTX/L-PAM/MNI/PRED"""@eng ; ; ; ; ; ; """4111"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280676"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/hydroxyurea"""@eng ; skos:notation """CDR0000041073"""^^xsd:string ; skos:altLabel """ARA-C/HU"""@eng ; ; ; """4112"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280677"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aromatase inhibition"""@eng ; skos:notation """CDR0000041070"""^^xsd:string ; skos:altLabel """inhibition, aromatase"""@eng ; ; rdfs:subClassOf ; """4109"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041071"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4110"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280675"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000041076"""^^xsd:string ; skos:altLabel """CTX/IL-2/TIL"""@eng ; ; ; ; """4115"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280680"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/thiotepa"""@eng ; skos:notation """CDR0000041077"""^^xsd:string ; skos:altLabel """DOX/5-FU/TSPA"""@eng ; ; ; ; """4116"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280681"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/hydroxyurea"""@eng ; skos:notation """CDR0000041074"""^^xsd:string ; skos:altLabel """5-FU/HU"""@eng ; ; ; """4113"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280678"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/misonidazole"""@eng ; skos:notation """CDR0000041075"""^^xsd:string ; skos:altLabel """L-PAM/MNI"""@eng ; ; ; """4114"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280679"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HPA-23"""@eng ; skos:notation """CDR0000040248"""^^xsd:string ; """3076"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0122297"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cisplatin/irinotecan"""@eng ; skos:notation """CDR0000369696"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/MOAB VEGF"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-04-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541235"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """posterior urethral cancer"""@eng ; skos:notation """CDR0000040242"""^^xsd:string ; skos:altLabel """urethral cancer, posterior"""@eng ; rdfs:subClassOf ; """urethral cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3063"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279931"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urethral cancer associated with invasive bladder cancer"""@eng ; skos:notation """CDR0000040243"""^^xsd:string ; skos:altLabel """urethral carcinoma associated with invasive bladder cancer"""@eng ; rdfs:subClassOf ; """urethral cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3064"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279932"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant macrophage colony-stimulating factor"""@eng ; skos:notation """CDR0000040240"""^^xsd:string ; skos:altLabel """macrophage colony-stimulating factor"""@eng , """macrophage colony stimulating factor"""@eng , """M-CSF"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-11-29"""^^xsd:string ; """C1290"""^^xsd:string ; """3056"""^^xsd:string ; umls:cui """C1524095"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anterior urethral cancer"""@eng ; skos:notation """CDR0000040241"""^^xsd:string ; skos:altLabel """urethral cancer, anterior"""@eng ; rdfs:subClassOf ; """urethral cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3062"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279930"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor necrosis factor therapy"""@eng ; skos:notation """CDR0000040246"""^^xsd:string ; skos:altLabel """therapy, tumor necrosis factor"""@eng , """therapy, TNF"""@eng ; ; rdfs:subClassOf ; """3074"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279936"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diethyldithiocarbamate"""@eng ; skos:notation """CDR0000040247"""^^xsd:string ; skos:altLabel """diethyldithione"""@eng , """Diethylcarbamodithioic Acid"""@eng , """diethyldithiocarbaminic acid"""@eng , """DDTC"""@eng , """DTC"""@eng , """Diethyldione"""@eng , """Imuthiol"""@eng , """DIECA"""@eng , """diethyldithiocarbamic acid"""@eng ; skos:definition """A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40247&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40247&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C432\" NCI Thesaurus)"""@eng ; ; ; """3075"""^^xsd:string ; """147-84-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C432"""^^xsd:string ; """29744"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0012194"""^^xsd:string ; umls:cui """C0086154"""^^xsd:string ; umls:cui """C0878291"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/mitomycin/vindesine"""@eng ; skos:notation """CDR0000040244"""^^xsd:string ; skos:altLabel """BEMP"""@eng , """BLEO/CDDP/DAVA/MITO"""@eng ; ; ; ; ; """3067"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279933"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/etoposide/lomustine"""@eng ; skos:notation """CDR0000040245"""^^xsd:string ; skos:altLabel """CCNU/CLB/VP-16"""@eng , """CEC"""@eng ; ; ; ; """3070"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279934"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dynamic contrast-enhanced magnetic resonance imaging"""@eng ; skos:notation """CDR0000492734"""^^xsd:string ; skos:altLabel """DCE-MRI"""@eng ; rdfs:subClassOf ; """2006-07-07"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-06-27"""^^xsd:string ; umls:cui """C1831914"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cathepsin K inhibitor MK0822"""@eng ; skos:notation """CDR0000531150"""^^xsd:string ; skos:altLabel """MK0822"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C1832045"""^^xsd:string ; umls:cui """C1832046"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/methotrexate/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000315771"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/MOAB IDEC-C2B8/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328001"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisolone/rituximab/vincristine"""@eng ; skos:notation """CDR0000315770"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB IDEC-C2B8/PRDL/VCR"""@eng ; ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328000"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/rituximab/vincristine"""@eng ; skos:notation """CDR0000315772"""^^xsd:string ; skos:altLabel """BLEO/CTX/DHAD/MOAB IDEC-C2B8/PRDL/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328002"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyproheptadine"""@eng ; skos:notation """CDR0000315774"""^^xsd:string ; skos:altLabel """cyproheptadine hydrochloride"""@eng , """Periactin"""@eng ; skos:definition """The hydrochloride salt of a synthetic methyl-piperidine derivative with antihistaminic and anti-serotoninergic properties. Cyproheptadine competes with free histamine (HA) for binding at HA-receptor sites, thereby competitively antagonizing histamine stimulation of HA-receptors in the gastrointestinal tract, large blood vessels, and bronchial smooth muscle. This agent also competes with free serotonin for binding at serotonin receptor sites. Cyproheptadine exhibits anticholinergic and sedative properties and has been shown to stimulate appetite and weight gain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315774&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315774&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28949\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """2003-06-17"""^^xsd:string ; """C28949"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0010620"""^^xsd:string ; umls:cui """C0031017"""^^xsd:string ; umls:cui """C0354872"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iris melanoma"""@eng ; skos:notation """CDR0000038818"""^^xsd:string ; skos:altLabel """melanoma, uveal, anterior"""@eng , """iris intraocular melanoma"""@eng , """melanoma, iris"""@eng , """melanoma, anterior uveal"""@eng , """anterior uveal melanoma"""@eng , """intraocular melanoma, iris"""@eng , """melanoma, intraocular, iris"""@eng , """uveal melanoma, anterior"""@eng ; rdfs:subClassOf ; """intraocular melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1280"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0346373"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciliary body and choroid melanoma, small size"""@eng ; skos:notation """CDR0000038819"""^^xsd:string ; skos:altLabel """melanoma, intraocular ciliary body and choroid small size"""@eng , """melanoma, posterior uveal, small size"""@eng , """uveal melanoma, posterior, small size"""@eng , """small size ciliary body and choroid melanoma"""@eng , """intraocular melanoma ciliary body and choroid, small size"""@eng , """posterior uveal melanoma, small size"""@eng ; rdfs:subClassOf ; """intraocular melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1281"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278867"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prolactin-producing pituitary tumor"""@eng ; skos:notation """CDR0000038814"""^^xsd:string ; skos:altLabel """prolactin producing pituitary tumor"""@eng , """pituitary tumor, prolactin producing"""@eng ; rdfs:subClassOf ; """pituitary tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1276"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278863"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """growth hormone-producing pituitary tumor"""@eng ; skos:notation """CDR0000038815"""^^xsd:string ; skos:altLabel """growth hormone producing pituitary tumor"""@eng , """pituitary tumor, growth hormone producing"""@eng ; rdfs:subClassOf ; """pituitary tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1277"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278864"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent pituitary tumor"""@eng ; skos:notation """CDR0000038816"""^^xsd:string ; skos:altLabel """pituitary tumor, recurrent"""@eng ; rdfs:subClassOf ; """pituitary tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1278"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278865"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intraocular melanoma"""@eng ; skos:notation """CDR0000038817"""^^xsd:string ; skos:altLabel """melanoma, intraocular"""@eng , """ocular melanoma"""@eng , """Eye cancer, intraocular melanoma"""@eng , """uveal melanoma"""@eng , """melanoma, ocular"""@eng , """melanoma, uveal"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1279"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220633"""^^xsd:string ; umls:cui """C0558356"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent thyroid cancer"""@eng ; skos:notation """CDR0000038810"""^^xsd:string ; skos:altLabel """thyroid cancer, recurrent"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1261"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278861"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Kaposi's sarcoma"""@eng ; skos:notation """CDR0000038811"""^^xsd:string ; skos:altLabel """sarcoma, multiple hemorrhagic"""@eng , """multiple hemorrhagic sarcoma"""@eng , """sarcoma, Kaposi's"""@eng , """Skin cancer, Kaposi's sarcoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1271"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0036220"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pituitary tumor"""@eng ; skos:notation """CDR0000038812"""^^xsd:string ; skos:altLabel """pituitary adenoma, functioning"""@eng , """tumor, pituitary"""@eng , """nonfunctioning pituitary adenoma"""@eng , """pituitary adenoma, nonfunctioning"""@eng , """Pituitary tumor"""@eng , """functioning pituitary adenoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1273"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0338078"""^^xsd:string ; umls:cui """C0854486"""^^xsd:string ; umls:cui """C0032019"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ACTH-producing pituitary tumor"""@eng ; skos:notation """CDR0000038813"""^^xsd:string ; skos:altLabel """Cushing's syndrome"""@eng , """Cushing's disease"""@eng , """ACTH producing pituitary tumor"""@eng , """pituitary tumor, ACTH-producing"""@eng ; rdfs:subClassOf ; """pituitary tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1274"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0221406"""^^xsd:string ; umls:cui """C0278862"""^^xsd:string ; umls:cui """C0010481"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/cyclosporine/paclitaxel"""@eng ; skos:notation """CDR0000042525"""^^xsd:string ; skos:altLabel """CBDCA/CTX/CYSP/TAX"""@eng ; ; ; ; ; """6156"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392957"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ifosfamide/paclitaxel"""@eng ; skos:notation """CDR0000042524"""^^xsd:string ; skos:altLabel """CBDCA/IFF/TAX"""@eng , """IC-T"""@eng ; ; ; ; """6155"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392956"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody A33"""@eng ; skos:notation """CDR0000042527"""^^xsd:string ; skos:altLabel """A33"""@eng , """MOAB A33"""@eng , """A33 monoclonal antibody"""@eng ; skos:definition """A humanized monoclonal antibody (MoAb) directed against A33 antigen with potential antineoplastic activity. A33 antigen, expressed in 95% of primary and metastatic colorectal carcinomas, is a transmembrane glycoprotein of the immunoglobulin superfamily. Conjugated MoAb A33 can be used in combination with other chemotherapy agents for treatment of colorectal cancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42527&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42527&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2410\" NCI Thesaurus)"""@eng ; """6158"""^^xsd:string ; """C2410"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-16"""^^xsd:string ; umls:cui """C0392959"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/cyclosporine/paclitaxel"""@eng ; skos:notation """CDR0000042526"""^^xsd:string ; skos:altLabel """CDDP/CTX/CYSP/TAX"""@eng ; ; ; ; ; """6157"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392958"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/pegaspargase/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042521"""^^xsd:string ; skos:altLabel """ARA-C/PEG-ASP/TG/VCR"""@eng ; ; ; ; ; """6144"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392953"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/idarubicin/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042520"""^^xsd:string ; skos:altLabel """CTX/DM/IDA/PEG-ASP/VCR"""@eng ; ; ; ; ; ; """6143"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392952"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody Me1-14 F(ab')2"""@eng ; skos:notation """CDR0000042523"""^^xsd:string ; skos:altLabel """MOAB Me1-14 F(ab')2"""@eng , """Me1-14 F(ab')2"""@eng , """Me1-14 F(ab')2 monoclonal antibody"""@eng ; skos:definition """The F(ab)2 fragment of Me1-14, a murine IgG2a monoclonal antibody directed against proteoglycan chondroitin sulfate-associated protein expressed by gliomas and melanomas. By binding to proteoglycan chondroitin sulfate-associated protein, monoclonal antibody Me1-14 F(ab')2 conjugated to a radioisotope may localize gliomas and melanomas when used as a tracer in radioimaging applications; in radioimmunotherapeutic applications, this agent conjugated to a radioisotope may be used to deliver targeted radiotoxicity to these tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42523&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42523&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2409\" NCI Thesaurus)"""@eng ; """6146"""^^xsd:string ; """C2409"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-30"""^^xsd:string ; umls:cui """C0392955"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042522"""^^xsd:string ; skos:altLabel """PEG-ASP/VCR"""@eng ; ; ; """6145"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392954"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CEP-2563 dihydrochloride"""@eng ; skos:notation """CDR0000042529"""^^xsd:string ; skos:altLabel """CEP-2563"""@eng ; """6165"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0392960"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nitrocamptothecin"""@eng ; skos:notation """CDR0000042528"""^^xsd:string ; skos:altLabel """9-Nitro-20 (S-)Camptothecin"""@eng , """Camptogen"""@eng , """Rubitecan"""@eng , """9-nitrocamptothecin"""@eng , """RFS 2000"""@eng , """9NC"""@eng , """9-NC"""@eng , """Orathecin"""@eng , """9-nitro-CPT"""@eng ; skos:definition """A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties. Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42528&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42528&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1485\" NCI Thesaurus)"""@eng ; ; ; """6164"""^^xsd:string ; """91421-42-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """603070"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """C1485"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1519114"""^^xsd:string ; umls:cui """C1101755"""^^xsd:string ; umls:cui """C1519115"""^^xsd:string ; umls:cui """C0213800"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alpha-lipoic acid"""@eng ; skos:notation """CDR0000440740"""^^xsd:string ; skos:altLabel """thioctic acid"""@eng ; """2005-07-12"""^^xsd:string ; """2005-07-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0023791"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 386"""@eng ; skos:notation """CDR0000423474"""^^xsd:string ; """2005-03-04"""^^xsd:string ; """2005-03-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541521"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AEE788/everolimus"""@eng ; skos:notation """CDR0000426487"""^^xsd:string ; skos:altLabel """AEE-788/RAD"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541535"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CG7870"""@eng ; skos:notation """CDR0000423472"""^^xsd:string ; skos:altLabel """CG-7870"""@eng ; ; """2005-03-04"""^^xsd:string ; """2005-03-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541519"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CG7870/docetaxel"""@eng ; skos:notation """CDR0000423473"""^^xsd:string ; skos:altLabel """CG-7870/TXT"""@eng ; ; ; """2005-03-04"""^^xsd:string ; """2005-03-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541520"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/lumiliximab/rituximab"""@eng ; skos:notation """CDR0000423470"""^^xsd:string ; skos:altLabel """CTX/FAMP/MOAB IDEC-152/MOAB IDEC-C2B8"""@eng ; ; ; ; ; """2005-03-04"""^^xsd:string ; """2005-03-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541518"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tyrosinase-related protein-2"""@eng ; skos:notation """CDR0000038407"""^^xsd:string ; skos:altLabel """Recombinant Tyrosinase-Related Protein-2"""@eng , """TRP-2"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to an endogenous non-mutated melanocyte differentiation antigen expressed by both normal and malignant melanocytes. Vaccinations with recombinant tyrosinase-related protein-2 may elicit an antitumoral cytotoxic T-cell response against tumor cells and some normal cells that express tyrosinase-related protein-2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38407&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38407&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38682\" NCI Thesaurus)"""@eng ; ; ; """11025"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C38682"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1527209"""^^xsd:string ; umls:cui """C0114832"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/iodine I 131 tositumomab/prednisone/vincristine"""@eng ; skos:notation """CDR0000038154"""^^xsd:string ; skos:altLabel """CTX/DOX/I131-MOAB-B1/PRED/VCR"""@eng ; ; ; ; ; ; """10734"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935736"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000038157"""^^xsd:string ; skos:altLabel """CF/5-FU/PS-341"""@eng ; ; ; ; """2002-11-19"""^^xsd:string ; """10737"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935739"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SS1(dsFv)-PE38 immunotoxin"""@eng ; skos:notation """CDR0000038156"""^^xsd:string ; skos:definition """A recombinant immunotoxin consisting of the single chain anti-mesothelin monoclonal antibody SS1(dsFv) linked to Pseudomonas exotoxin PE-38. The monoclonal antibody moiety of the agent binds to cells that express mesothelin, a cell surface glycoprotein which may be overexpressed in ovarian cancer, mesotheliomas, and some squamous cell carcinomas; after internalization, the exotoxin moiety inactivates eukaryotic translation elongation factor 2, thereby disrupting tumor cell protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38156&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38156&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2609\" NCI Thesaurus)"""@eng ; """10736"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9052"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C2609"""^^xsd:string ; umls:cui """C1258770"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/gemcitabine/ifosfamide"""@eng ; skos:notation """CDR0000358901"""^^xsd:string ; skos:altLabel """dFdC/DOX/IFF"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541578"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/ifosfamide"""@eng ; skos:notation """CDR0000358902"""^^xsd:string ; skos:altLabel """CDDP/dFdC/IFF"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541579"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody BrE-3/yttrium Y 90 monoclonal antibody BrE-3"""@eng ; skos:notation """CDR0000038151"""^^xsd:string ; skos:altLabel """In 111 MOAB BrE-3/Y 90 MOAB BrE-3"""@eng ; ; ; """10731"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935733"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Aurora kinase inhibitor R763"""@eng ; skos:notation """CDR0000522734"""^^xsd:string ; skos:altLabel """R763"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-17"""^^xsd:string ; umls:cui """C1831988"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody BrE-3"""@eng ; skos:notation """CDR0000038150"""^^xsd:string ; skos:altLabel """monoclonal antibody BrE-3, indium In 111"""@eng , """In 111 monoclonal antibody BrE-3"""@eng , """indium In 111 MOAB BrE-3"""@eng , """In 111 MOAB BrE-3"""@eng , """MOAB BrE-3, indium In 111"""@eng , """BrE-3 monoclonal antibody, indium In 111"""@eng ; skos:definition """A humanized monoclonal antibody conjugated to the imaging radioisotope (indium-111). This radioimmunoconjugate binds to the breast epithelial mucin antigen, which is found primarily on breast cancer cells, permitting radioimmmuno-localization of mucin-positive tumor cells and an estimate of radiation dosimetry prior to administration of cytotoxic radiotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38150&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38150&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2608\" NCI Thesaurus)"""@eng ; ; """10730"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2608"""^^xsd:string ; umls:cui """C0935732"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/fludarabine/rituximab"""@eng ; skos:notation """CDR0000407237"""^^xsd:string ; skos:altLabel """17-AAG/FAMP/MOAB IDEC-C2B8"""@eng ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541411"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000038401"""^^xsd:string ; skos:altLabel """lymphoma, diffuse large cell, adult"""@eng , """large cell lymphoma, diffuse, adult"""@eng , """diffuse large cell lymphoma, adult"""@eng , """DL lymphoma, adult"""@eng , """adult DL lymphoma"""@eng , """DHL, adult"""@eng , """histiocytic lymphoma, diffuse, adult"""@eng , """diffuse histiocytic lymphoma, adult"""@eng , """lymphoma, diffuse histiocytic, adult"""@eng ; rdfs:subClassOf ; """1102"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278762"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/SCIO-469"""@eng ; skos:notation """CDR0000407548"""^^xsd:string ; skos:altLabel """PS-341/SCIO 469"""@eng ; ; ; """2004-11-19"""^^xsd:string ; """2004-11-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541418"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/epirubicin/paclitaxel"""@eng ; skos:notation """CDR0000038152"""^^xsd:string ; skos:altLabel """CBDCA/EPI/TAX/WR-2721"""@eng ; ; ; ; ; """10732"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935734"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent renal cell cancer"""@eng ; skos:notation """CDR0000043694"""^^xsd:string ; skos:altLabel """renal cell cancer, recurrent"""@eng , """kidney cancer, recurrent"""@eng , """hypernephroma, recurrent"""@eng , """recurrent renal cell carcinoma"""@eng , """renal cell carcinoma, recurrent"""@eng , """recurrent hypernephroma"""@eng , """recurrent kidney cancer"""@eng ; rdfs:subClassOf ; """renal cell cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """941"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278679"""^^xsd:string ; umls:cui """C0862435"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized parathyroid cancer"""@eng ; skos:notation """CDR0000043695"""^^xsd:string ; skos:altLabel """carcinoma of the parathyroid, localized"""@eng , """localized parathyroid carcinoma"""@eng , """cancer of the parathyroid, localized"""@eng , """parathyroid cancer, localized"""@eng , """parathyroid carcinoma, localized"""@eng ; rdfs:subClassOf ; """parathyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """943"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278680"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic parathyroid cancer"""@eng ; skos:notation """CDR0000043696"""^^xsd:string ; skos:altLabel """parathyroid cancer, metastatic"""@eng , """parathyroid carcinoma, metastatic"""@eng , """cancer of the parathyroid, metastatic"""@eng , """carcinoma of the parathyroid, metastatic"""@eng , """metastatic parathyroid carcinoma"""@eng ; rdfs:subClassOf ; """parathyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """944"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278681"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methylmercaptopurine riboside/PALA"""@eng ; skos:notation """CDR0000043697"""^^xsd:string ; skos:altLabel """5-FU/MMPR/PALA"""@eng ; ; ; ; """945"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278682"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II renal cell cancer"""@eng ; skos:notation """CDR0000043690"""^^xsd:string ; skos:altLabel """kidney cancer, stage II"""@eng , """renal cell cancer, stage II"""@eng , """stage II renal cell carcinoma"""@eng , """hypernephroma, stage II"""@eng , """stage II hypernephroma"""@eng , """stage II kidney cancer"""@eng , """renal cell carcinoma, stage II"""@eng ; rdfs:subClassOf ; """renal cell cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """938"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278676"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III renal cell cancer"""@eng ; skos:notation """CDR0000043691"""^^xsd:string ; skos:altLabel """stage III renal cell carcinoma"""@eng , """stage III kidney cancer"""@eng , """renal cell carcinoma, stage III"""@eng , """stage III hypernephroma"""@eng , """hypernephroma, stage III"""@eng , """kidney cancer, stage III"""@eng , """renal cell cancer, stage III"""@eng ; rdfs:subClassOf ; """renal cell cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """939"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278677"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV esophageal cancer"""@eng ; skos:notation """CDR0000043692"""^^xsd:string ; skos:altLabel """metastatic esophageal cancer"""@eng , """esophageal cancer, stage IV"""@eng , """esophagus cancer, metastatic"""@eng , """esophagus cancer, stage IV"""@eng , """esophageal cancer, metastatic"""@eng ; rdfs:subClassOf ; """esophageal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """94"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278562"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV renal cell cancer"""@eng ; skos:notation """CDR0000043693"""^^xsd:string ; skos:altLabel """renal cell carcinoma, metastatic"""@eng , """kidney cancer, metastatic"""@eng , """metastatic renal cell cancer"""@eng , """metastatic hypernephroma"""@eng , """metastatic renal cell carcinoma"""@eng , """renal cell cancer, metastatic"""@eng , """stage IV hypernephroma"""@eng , """stage IV renal cell carcinoma"""@eng , """renal cell carcinoma, stage IV"""@eng , """kidney cancer, stage IV"""@eng , """hypernephroma, stage IV"""@eng , """metastatic kidney cancer"""@eng , """renal cell cancer, stage IV"""@eng , """stage IV kidney cancer"""@eng , """hypernephroma, metastatic"""@eng ; rdfs:subClassOf ; """renal cell cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """940"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0813175"""^^xsd:string ; umls:cui """C0278678"""^^xsd:string ; umls:cui """C0862448"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/interleukin-2"""@eng ; skos:notation """CDR0000043698"""^^xsd:string ; skos:altLabel """DOX/IL-2"""@eng ; ; ; """946"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent parathyroid cancer"""@eng ; skos:notation """CDR0000043699"""^^xsd:string ; skos:altLabel """recurrent parathyroid carcinoma"""@eng , """parathyroid carcinoma, recurrent"""@eng , """cancer of the parathyroid, recurrent"""@eng , """carcinoma of the parathyroid, recurrent"""@eng , """parathyroid cancer, recurrent"""@eng ; rdfs:subClassOf ; """parathyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """949"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278684"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/cisplatin/fluorouracil"""@eng ; skos:notation """CDR0000445429"""^^xsd:string ; skos:altLabel """CDDP/5-FU/MOAB C225"""@eng ; ; ; ; """2005-08-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-18"""^^xsd:string ; umls:cui """C1831717"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """secondary acute myeloid leukemia"""@eng ; skos:notation """CDR0000040808"""^^xsd:string ; skos:altLabel """secondary acute non-lymphocytic leukemia"""@eng , """acute myeloid leukemia, secondary"""@eng , """acute non-lymphocytic leukemia, secondary"""@eng , """secondary acute non-lymphoblastic leukemia"""@eng , """secondary AML"""@eng , """secondary acute nonlymphoblastic leukemia"""@eng , """non-lymphocytic leukemia, secondary acute"""@eng , """nonlymphoblastic leukemia, secondary acute"""@eng , """acute non-lymphoblastic leukemia, secondary"""@eng , """acute nonlymphocytic leukemia, secondary"""@eng , """myelogenous leukemia, secondary acute"""@eng , """secondary acute nonlymphocytic leukemia"""@eng , """nonlymphocytic leukemia, secondary acute"""@eng , """secondary acute myelogenous leukemia"""@eng , """secondary ANLL"""@eng , """acute myelogenous leukemia, secondary"""@eng , """myeloid leukemia, secondary acute"""@eng , """non-lymphoblastic leukemia, secondary acute"""@eng , """acute nonlymphoblastic leukemia, secondary"""@eng ; rdfs:subClassOf ; """3772"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280449"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extragonadal germ cell tumor"""@eng ; skos:notation """CDR0000040809"""^^xsd:string ; skos:altLabel """Extragonadal germ cell tumor"""@eng , """germ cell tumor, extragonadal"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3773"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0262963"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/etoposide/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000040804"""^^xsd:string ; skos:altLabel """VAIE"""@eng , """DACT/IFF/VCR/VP-16"""@eng ; ; ; ; ; """3768"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280445"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate/tamoxifen"""@eng ; skos:notation """CDR0000040805"""^^xsd:string ; skos:altLabel """CMFTH"""@eng , """CTX/5-FU/FXM/MTX/TMX"""@eng ; ; ; ; ; """3769"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280446"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000040806"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/5-FU"""@eng ; ; ; ; ; """3770"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280447"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/melphalan/teniposide"""@eng ; skos:notation """CDR0000040807"""^^xsd:string ; skos:altLabel """CDDP/L-PAM/VM-26"""@eng , """VMP"""@eng ; ; ; ; """3771"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280448"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uridine"""@eng ; skos:notation """CDR0000040800"""^^xsd:string ; skos:altLabel """Urd"""@eng , """UR"""@eng ; skos:definition """A nucleoside consisting of uracil and D-ribose and a component of RNA. Uridine has been studied as a rescue agent to reduce the toxicities associated with 5-fluorouracil (5-FU), thereby allowing the administration of higher doses of 5-FU in chemotherapy regimens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40800&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40800&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C922\" NCI Thesaurus)"""@eng ; """3764"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """30252"""^^xsd:string ; """58-96-8"""^^xsd:string ; """20256"""^^xsd:string ; """C922"""^^xsd:string ; umls:cui """C0041984"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000040801"""^^xsd:string ; skos:altLabel """DACT/IFF/VCR"""@eng , """VAI"""@eng ; ; ; ; """3765"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083089"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/vincristine"""@eng ; skos:notation """CDR0000040802"""^^xsd:string ; skos:altLabel """VB"""@eng , """BO"""@eng , """BLEO/VCR"""@eng ; ; ; """3766"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280443"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/vinblastine"""@eng ; skos:notation """CDR0000040803"""^^xsd:string ; skos:altLabel """VB-IV"""@eng , """BLEO/VBL"""@eng ; ; ; """3767"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280444"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etanidazole"""@eng ; skos:notation """CDR0000039026"""^^xsd:string ; skos:altLabel """CTX/SR-2508"""@eng ; ; ; """1596"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279043"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """OXi-104"""@eng ; skos:notation """CDR0000043343"""^^xsd:string ; skos:altLabel """OXi 104"""@eng ; ; """2003-10-23"""^^xsd:string ; """7888"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796491"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/triptorelin"""@eng ; skos:notation """CDR0000043340"""^^xsd:string ; skos:altLabel """FLUT/TRIP"""@eng ; ; ; """7877"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796488"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/methotrexate/mitomycin"""@eng ; skos:notation """CDR0000039025"""^^xsd:string ; skos:altLabel """MITO/MTX/VP-16"""@eng ; ; ; ; """1595"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279042"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 3"""@eng ; skos:notation """CDR0000043346"""^^xsd:string ; rdfs:subClassOf ; """7890"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008666"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/quinidine"""@eng ; skos:notation """CDR0000039023"""^^xsd:string ; skos:altLabel """DOX/QND/VP-16"""@eng ; ; ; ; """1590"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279040"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/OXi-104"""@eng ; skos:notation """CDR0000043344"""^^xsd:string ; skos:altLabel """CDDP/OXi 104"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """7889"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """insulin"""@eng ; skos:notation """CDR0000043345"""^^xsd:string ; """789"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0021641"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/ras peptide cancer vaccine"""@eng ; skos:notation """CDR0000043348"""^^xsd:string ; skos:altLabel """IL-2/ras pep vac"""@eng ; ; ; """7896"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hu14.18-IL2 fusion protein"""@eng ; skos:notation """CDR0000043349"""^^xsd:string ; skos:altLabel """EMD 273063"""@eng , """Hu 14.18/IL - 2 Fusion Protein"""@eng , """hu14.18-IL2"""@eng ; skos:definition """A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43349&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43349&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2509\" NCI Thesaurus)"""@eng ; """2006-08-25"""^^xsd:string ; """721298"""^^xsd:string ; """C2509"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7897"""^^xsd:string ; umls:cui """C1529682"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/vinblastine"""@eng ; skos:notation """CDR0000039028"""^^xsd:string ; skos:altLabel """IFN-A/VBL"""@eng ; ; ; """1599"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338084"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III breast cancer"""@eng ; skos:notation """CDR0000039029"""^^xsd:string ; skos:altLabel """breast cancer, stage III"""@eng ; rdfs:subClassOf ; """2003-06-16"""^^xsd:string ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """16"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278487"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovulatory agent"""@eng ; skos:notation """CDR0000039259"""^^xsd:string ; rdfs:subClassOf ; """1890"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279161"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Burkitt's lymphoma"""@eng ; skos:notation """CDR0000039258"""^^xsd:string ; skos:altLabel """lymphoma, Burkitt's"""@eng , """Burkitt's tumor"""@eng , """NHL, Burkitt's"""@eng , """non-Hodgkin's lymphoma, Burkitt's"""@eng ; rdfs:subClassOf ; """189"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0006413"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 11q23"""@eng ; skos:notation """CDR0000043207"""^^xsd:string ; rdfs:subClassOf ; """7650"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796367"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 11q"""@eng ; skos:notation """CDR0000043206"""^^xsd:string ; rdfs:subClassOf ; """7649"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796366"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 11"""@eng ; skos:notation """CDR0000043205"""^^xsd:string ; rdfs:subClassOf ; """7648"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008653"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 8p22"""@eng ; skos:notation """CDR0000043204"""^^xsd:string ; rdfs:subClassOf ; """7647"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796365"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 17p12"""@eng ; skos:notation """CDR0000043203"""^^xsd:string ; rdfs:subClassOf ; """7646"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796364"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 7q31"""@eng ; skos:notation """CDR0000043202"""^^xsd:string ; rdfs:subClassOf ; """7645"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796363"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 5q31"""@eng ; skos:notation """CDR0000043201"""^^xsd:string ; rdfs:subClassOf ; """7644"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796362"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 7q"""@eng ; skos:notation """CDR0000043200"""^^xsd:string ; rdfs:subClassOf ; """7643"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796361"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """microsatellite instability"""@eng ; skos:notation """CDR0000043209"""^^xsd:string ; rdfs:subClassOf ; """7652"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796369"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clonality"""@eng ; skos:notation """CDR0000043208"""^^xsd:string ; rdfs:subClassOf ; """7651"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796368"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/docetaxel/prednisone/thalidomide"""@eng ; skos:notation """CDR0000388010"""^^xsd:string ; skos:altLabel """MOAB VEGF/PRED/THAL/TXT"""@eng ; ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541608"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent grade I lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000378006"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C1541448"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent grade II lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000378007"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C1541449"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood grade III lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000378005"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541447"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anesthesia"""@eng ; skos:notation """CDR0000467902"""^^xsd:string ; ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C0002903"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """observation"""@eng ; skos:notation """CDR0000467903"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0700325"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """kyphoplasty"""@eng ; skos:notation """CDR0000467900"""^^xsd:string ; ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C1455863"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """long-term effects secondary to cancer therapy in adults"""@eng ; skos:notation """CDR0000467906"""^^xsd:string ; rdfs:subClassOf ; """2006-02-06"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C1831740"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cardiovascular complications"""@eng ; skos:notation """CDR0000467907"""^^xsd:string ; rdfs:subClassOf ; """2006-02-10"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0161816"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal complications management"""@eng ; skos:notation """CDR0000467905"""^^xsd:string ; skos:altLabel """complications management, gastrointestinal"""@eng , """management, gastrointestinal complications"""@eng ; ; ; rdfs:subClassOf ; ; ; """2006-02-10"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-03-03"""^^xsd:string ; umls:cui """C1831739"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent laryngeal cancer"""@eng ; skos:notation """CDR0000040115"""^^xsd:string ; skos:altLabel """larynx cancer, recurrent"""@eng , """laryngeal cancer, recurrent"""@eng ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2877"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279818"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent penile cancer"""@eng ; skos:notation """CDR0000038263"""^^xsd:string ; skos:altLabel """penis cancer, recurrent"""@eng , """penile cancer, recurrent"""@eng ; rdfs:subClassOf ; """penile cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1087"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854964"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palivizumab"""@eng ; skos:notation """CDR0000038262"""^^xsd:string ; skos:altLabel """PALI"""@eng , """Synagis"""@eng ; ; """10869"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0723567"""^^xsd:string ; umls:cui """C0672596"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trastuzumab/vinorelbine"""@eng ; skos:notation """CDR0000038261"""^^xsd:string ; skos:altLabel """MOAB HER2/VNB"""@eng ; ; ; """10868"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935819"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenosine triphosphate"""@eng ; skos:notation """CDR0000038260"""^^xsd:string ; """10867"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0001480"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000038267"""^^xsd:string ; skos:altLabel """CF/5-FU/TXT"""@eng ; ; ; ; """10873"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935821"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palivizumab/ribavirin"""@eng ; skos:notation """CDR0000038266"""^^xsd:string ; skos:altLabel """PALI/RIBA"""@eng ; ; ; """10872"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935908"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """topotecan/ZD9331"""@eng ; skos:notation """CDR0000038265"""^^xsd:string ; skos:altLabel """TOPO/ZD 9331"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """10871"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935820"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ZD9331"""@eng ; skos:notation """CDR0000038264"""^^xsd:string ; skos:altLabel """ZD 9331"""@eng ; ; """2003-10-23"""^^xsd:string ; """10870"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0299046"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Detox-B adjuvant/ras peptide cancer vaccine"""@eng ; skos:notation """CDR0000038269"""^^xsd:string ; skos:altLabel """DETOXB/ras pep vac"""@eng ; ; ; """10875"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935822"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Huang Lian"""@eng ; skos:notation """CDR0000038268"""^^xsd:string ; skos:altLabel """Coptis chinesis"""@eng ; """10874"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0696725"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000040548"""^^xsd:string ; skos:altLabel """adult small noncleaved cell lymphoma, stage IV"""@eng , """metastatic adult small noncleaved cell lymphoma"""@eng , """adult small noncleaved cell lymphoma, metastatic"""@eng , """stage IV adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3444"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280179"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/paclitaxel/thalidomide"""@eng ; skos:notation """CDR0000363901"""^^xsd:string ; skos:altLabel """EM/TAX/THAL"""@eng ; ; ; ; """2004-04-01"""^^xsd:string ; """2004-03-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541213"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim-fetal liver tyrosine kinase-3 fusion protein/gp100 antigen/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000037978"""^^xsd:string ; skos:altLabel """G-CSF-Flt3K fusion protein/gp100/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; """10397"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium Tc 99m human serum albumin colloid"""@eng ; skos:notation """CDR0000037979"""^^xsd:string ; """10398"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879625"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I vaginal cancer"""@eng ; skos:notation """CDR0000038049"""^^xsd:string ; skos:altLabel """vaginal cancer, stage I"""@eng , """cancer of the vagina, stage I"""@eng , """stage I vagina cancer"""@eng , """stage I cancer of the vagina"""@eng , """vagina cancer, stage I"""@eng , """carcinoma of the vagina, stage I"""@eng , """stage I carcinoma of the vagina"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1057"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278741"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """therapeutic autologous dendritic cells"""@eng ; skos:notation """CDR0000038048"""^^xsd:string ; skos:altLabel """ADC"""@eng , """autologous dendritic cells"""@eng ; skos:definition """A population of a type of antigen-presenting cell (APC), the dendritic cell (DC), harvested from a patient and grown in vitro in the presence of tumor-associated antigens (TAAs) derived from the patient's tumor (a technique known as 'pulsing') and then injected back into the patient; autologous DCs so manipulated may stimulate a specific cell-mediated antitumoral cytotoxicity. DCs derived from a patient may also be fused with the patient's tumor cells in vitro to combine sustained tumor antigen expression with the antigen-presenting and immunostimulatory capacities of DCs; when injected back into the patient, these autologous DC-tumor cell hybrids (fusion cells) may stimulate an active antitumoral immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38048&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38048&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2594\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2006-09-27"""^^xsd:string ; """C2594"""^^xsd:string ; """10568"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879593"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/fludarabine/tretinoin"""@eng ; skos:notation """CDR0000037972"""^^xsd:string ; skos:altLabel """ARA-C/ATRA/FAMP"""@eng ; ; ; ; """10390"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879510"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palladium Pd 103"""@eng ; skos:notation """CDR0000038046"""^^xsd:string ; skos:altLabel """Pd 103"""@eng , """Palladium 103"""@eng ; skos:definition """A radioisotope of the metal palladium used in brachytherapy implants or 'seed'. With a half-life of 17 days, palladium 103 administered with brachytherapy allows continuous, tumor-site specific low-energy irradiation to the tumor cell population while sparing normal adjacent tissues from radiotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38046&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38046&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2550\" NCI Thesaurus)"""@eng ; """10566"""^^xsd:string ; """C2550"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0303566"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/tretinoin"""@eng ; skos:notation """CDR0000037970"""^^xsd:string ; skos:altLabel """ARA-C/ATRA/DNR/VP-16"""@eng ; ; ; ; ; """10388"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879508"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/gemcitabine"""@eng ; skos:notation """CDR0000038044"""^^xsd:string ; skos:altLabel """dFdC/LipoDox"""@eng ; ; ; """10564"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879589"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/topotecan"""@eng ; skos:notation """CDR0000038043"""^^xsd:string ; skos:altLabel """ARA-C/CTX/TOPO"""@eng ; ; ; ; """10563"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879588"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin liposomal"""@eng ; skos:notation """CDR0000038042"""^^xsd:string ; skos:altLabel """ARA-C/Daunoxome"""@eng ; ; ; """10562"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879587"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/gemtuzumab ozogamicin"""@eng ; skos:notation """CDR0000038041"""^^xsd:string ; skos:altLabel """ARA-C/CMA-676"""@eng ; ; ; """10561"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879586"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostatic acid phosphatase-sargramostim fusion protein"""@eng ; skos:notation """CDR0000038040"""^^xsd:string ; skos:altLabel """PA2024"""@eng ; skos:definition """A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38040&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38040&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2548\" NCI Thesaurus)"""@eng ; """10560"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2548"""^^xsd:string ; umls:cui """C0879585"""^^xsd:string ; umls:cui """C1527179"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alum adjuvant/gp100 antigen/interleukin-12/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000038560"""^^xsd:string ; skos:altLabel """ALUM/gp100/IL-12/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; ; """11191"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134584"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """apixaban"""@eng ; skos:notation """CDR0000484444"""^^xsd:string ; skos:altLabel """BMS-562247"""@eng ; skos:definition """An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484444&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484444&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61308\" NCI Thesaurus)"""@eng ; """2006-07-06"""^^xsd:string ; """2006-05-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61308"""^^xsd:string ; umls:cui """C1831808"""^^xsd:string ; umls:cui """C1831809"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-12/MART-1 antigen/Montanide ISA-51/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000038561"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/IL-12/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; ; """11192"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134585"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade I lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000039049"""^^xsd:string ; rdfs:subClassOf ; """2004-06-22"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1621"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0279065"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody PTI-6D2"""@eng ; skos:notation """CDR0000529286"""^^xsd:string ; skos:altLabel """PTI-6D2"""@eng ; """2007-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832014"""^^xsd:string ; umls:cui """C1832013"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CSL360"""@eng ; skos:notation """CDR0000529287"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1832015"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temoporfin"""@eng ; skos:notation """CDR0000042851"""^^xsd:string ; skos:altLabel """Foscan"""@eng ; """6661"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0379149"""^^xsd:string ; umls:cui """C0701505"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIB cervical cancer"""@eng ; skos:notation """CDR0000038569"""^^xsd:string ; skos:altLabel """carcinoma of the cervix, stage IIB"""@eng , """stage IIB cancer of the cervix"""@eng , """uterine cervical cancer, stage IIB"""@eng , """stage IIB cervix cancer"""@eng , """uterine cervix cancer, stage IIB"""@eng , """cervical cancer, stage IIB"""@eng , """cervix cancer, stage IIB"""@eng , """stage IIB uterine cervix cancer"""@eng , """cancer of the cervix, stage IIB"""@eng , """stage IIB carcinoma of the cervix"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """112"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278583"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """renal complications management"""@eng ; skos:notation """CDR0000354476"""^^xsd:string ; skos:altLabel """kidney complications management"""@eng ; rdfs:subClassOf ; """2004-01-23"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C1328179"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GI-4000 vaccine"""@eng ; skos:notation """CDR0000486259"""^^xsd:string ; skos:definition """A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity. Upon administration, GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras. This may lead to a destruction of cancer cells expressing a Ras mutation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486259&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486259&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61489\" NCI Thesaurus)"""@eng ; """2006-05-19"""^^xsd:string ; """C61489"""^^xsd:string ; """2006-10-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831831"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amoxicillin/ciprofloxacin"""@eng ; skos:notation """CDR0000429575"""^^xsd:string ; skos:altLabel """AMOX/CPFX"""@eng ; ; ; """2005-04-15"""^^xsd:string ; """2005-04-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541559"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D17S50"""@eng ; skos:notation """CDR0000257379"""^^xsd:string ; rdfs:subClassOf ; """2002-08-16"""^^xsd:string ; """11420"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327773"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABI-007/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000429570"""^^xsd:string ; skos:altLabel """ABI 007/CTX/DOX"""@eng ; ; ; ; """2005-04-15"""^^xsd:string ; """2005-04-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541557"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """degarelix"""@eng ; skos:notation """CDR0000441235"""^^xsd:string ; skos:altLabel """N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide"""@eng , """FE200486"""@eng ; skos:definition """A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=441235&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=441235&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48385\" NCI Thesaurus)"""@eng ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-08-05"""^^xsd:string ; """C48385"""^^xsd:string ; umls:cui """C0971731"""^^xsd:string ; umls:cui """C1455035"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 11D10 anti-idiotype vaccine/monoclonal antibody GD2 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000257372"""^^xsd:string ; skos:altLabel """MOAB 11D10 VAC/MOAB GD2 VAC"""@eng , """TriAb/TriGem"""@eng ; ; ; """2003-06-10"""^^xsd:string ; """11413"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327767"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pilocarpine hydrochloride"""@eng ; skos:notation """CDR0000042876"""^^xsd:string ; skos:altLabel """pilocarpine"""@eng , """Salagen"""@eng ; skos:definition """The hydrochloride salt of a natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract. When applied topically to the eye, this agent stimulates the sphincter pupillae to contract, resulting in miosis; stimulates the ciliary muscle to contract, resulting in spasm of accomodation; and may cause a transitory rise in intraocular pressure followed by a more persistent fall due to opening of the trabecular meshwork and an increase in the outflow of aqueous humor. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42876&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42876&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """6689"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-04-03"""^^xsd:string ; umls:cui """C0699930"""^^xsd:string ; umls:cui """C0770456"""^^xsd:string ; umls:cui """C0031923"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CDKNA2A"""@eng ; skos:notation """CDR0000257374"""^^xsd:string ; rdfs:subClassOf ; """2002-08-16"""^^xsd:string ; """11414"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327768"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/thiotepa"""@eng ; skos:notation """CDR0000257375"""^^xsd:string ; skos:altLabel """MTX/TSPA"""@eng ; ; ; """2002-08-16"""^^xsd:string ; """11416"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327769"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/temsirolimus"""@eng ; skos:notation """CDR0000257376"""^^xsd:string ; skos:altLabel """CCI-779/IFN-A"""@eng ; ; ; """2005-05-05"""^^xsd:string ; """11417"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327770"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D5S346"""@eng ; skos:notation """CDR0000257377"""^^xsd:string ; rdfs:subClassOf ; """2002-08-16"""^^xsd:string ; """11418"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327771"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult myxopapillary ependymoma"""@eng ; skos:notation """CDR0000041191"""^^xsd:string ; skos:altLabel """myxopapillary ependymoma, adult"""@eng , """adult well-differentiated ependymoma"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult ependymal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4264"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C3887518"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """well-differentiated mildly and moderately anaplastic astrocytoma, adult"""@eng ; skos:notation """CDR0000041190"""^^xsd:string ; skos:altLabel """astrocytoma, adult well-differentiated mildly and moderately anaplastic"""@eng , """anaplastic astrocytoma, adult well-differentiated mildly and moderately"""@eng ; """2004-06-15"""^^xsd:string ; """4263"""^^xsd:string ; umls:cui """C0280784"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """well-differentiated oligodendroglioma, adult"""@eng ; skos:notation """CDR0000041193"""^^xsd:string ; skos:altLabel """oligodendroglioma, adult well-differentiated"""@eng ; """2004-06-18"""^^xsd:string ; """4266"""^^xsd:string ; umls:cui """C0280789"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult anaplastic ependymoma"""@eng ; skos:notation """CDR0000041192"""^^xsd:string ; skos:altLabel """anaplastic ependymoma, adult"""@eng , """adult malignant ependymoma"""@eng , """malignant ependymoma, adult"""@eng , """ependymoma, adult malignant"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult ependymal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4265"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280787"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed gliomas"""@eng ; skos:notation """CDR0000041195"""^^xsd:string ; skos:altLabel """gliomas, mixed"""@eng , """glial tumors, mixed"""@eng , """adult oligoastrocytoma"""@eng , """adult anaplastic oligoastrocytoma"""@eng , """tumors, mixed glial"""@eng , """mixed glial tumors"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4268"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1542126"""^^xsd:string ; umls:cui """C0259783"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult anaplastic oligodendroglioma"""@eng ; skos:notation """CDR0000041194"""^^xsd:string ; skos:altLabel """anaplastic oligodendroglioma, adult"""@eng , """oligodendroglioma, adult anaplastic"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """4267"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult oligodendroglial tumors"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280790"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult central nervous system germ cell tumor"""@eng ; skos:notation """CDR0000041197"""^^xsd:string ; skos:altLabel """adult mixed germ cell tumors"""@eng , """adult yolk sac tumor"""@eng , """central nervous system germ cell tumor, adult"""@eng , """intracranial germ cell tumors, adult"""@eng , """germ cell tumors, adult intracranial"""@eng , """tumors, adult intracranial germ cell"""@eng , """adult CNS teratoma"""@eng , """adult CNS embryonal carcinoma"""@eng , """adult intracranial germ cell tumor"""@eng , """adult CNS choriocarcinoma"""@eng , """adult CNS germinoma"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4270"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1370503"""^^xsd:string ; umls:cui """C1370506"""^^xsd:string ; umls:cui """C1370505"""^^xsd:string ; umls:cui """C1370504"""^^xsd:string ; umls:cui """C0280796"""^^xsd:string ; umls:cui """C1370508"""^^xsd:string ; umls:cui """C1332221"""^^xsd:string ; umls:cui """C1541762"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult pineal parenchymal tumor"""@eng ; skos:notation """CDR0000041196"""^^xsd:string ; skos:altLabel """pineal parenchymal tumor, adult"""@eng , """parenchymal tumor, adult pineal"""@eng , """Brain tumor, adult: Pineal parenchymal tumors"""@eng , """tumor, adult pineal parenchymal"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """4269"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """2005-04-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280794"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """primary central nervous system lymphoma"""@eng ; skos:notation """CDR0000041199"""^^xsd:string ; skos:altLabel """Primary CNS lymphoma"""@eng , """primary CNS lymphoma"""@eng , """CNS lymphoma, primary"""@eng , """central nervous system lymphoma, primary"""@eng , """lymphoma, primary CNS"""@eng , """lymphoma, primary central nervous system"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4272"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280803"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/semustine/streptozocin/vincristine"""@eng ; skos:notation """CDR0000039336"""^^xsd:string ; skos:altLabel """MOF-STREP"""@eng , """5-FU/MeCCNU/SZC/VCR"""@eng ; ; ; ; ; """1972"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066687"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/type, adult brain tumor"""@eng ; skos:notation """CDR0000040581"""^^xsd:string ; skos:altLabel """adult brain tumor stage"""@eng ; rdfs:subClassOf ; """3481"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280204"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interferon alfa/interleukin-2/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000040580"""^^xsd:string ; skos:altLabel """CTX/IFN-A/IL-2/TIL"""@eng ; ; ; ; ; """3480"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338114"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, malignant mesothelioma"""@eng ; skos:notation """CDR0000040583"""^^xsd:string ; skos:altLabel """malignant mesothelioma stage"""@eng ; rdfs:subClassOf ; """3483"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280206"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/methotrexate/sargramostim"""@eng ; skos:notation """CDR0000040582"""^^xsd:string ; skos:altLabel """DOX/5-FU/GM-CSF/MTX"""@eng ; ; ; ; ; """3482"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280205"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adult primary liver cancer"""@eng ; skos:notation """CDR0000040585"""^^xsd:string ; skos:altLabel """adult primary liver cancer stage"""@eng ; rdfs:subClassOf ; """3485"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280208"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/prednisone/vincristine"""@eng ; skos:notation """CDR0000039334"""^^xsd:string ; skos:altLabel """ASP/CTX/PRED/VCR"""@eng ; ; ; ; ; """1970"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279203"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, metastatic squamous neck cancer with occult primary"""@eng ; skos:notation """CDR0000040587"""^^xsd:string ; skos:altLabel """metastatic squamous neck cancer with occult primary stage"""@eng ; rdfs:subClassOf ; """3487"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280210"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, melanoma"""@eng ; skos:notation """CDR0000040586"""^^xsd:string ; skos:altLabel """melanoma stage"""@eng ; rdfs:subClassOf ; """3486"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280209"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/sargramostim/thiotepa"""@eng ; skos:notation """CDR0000040589"""^^xsd:string ; skos:altLabel """CBDCA/CTX/GM-CSF/TSPA"""@eng ; ; ; ; ; """3489"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280212"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000040588"""^^xsd:string ; skos:altLabel """adult soft tissue sarcoma stage"""@eng ; rdfs:subClassOf ; """3488"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280211"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisolone/rituximab/vincristine"""@eng ; skos:notation """CDR0000441233"""^^xsd:string ; skos:altLabel """CTX/MOAB IDEC-C2B8/PRDL/VCR"""@eng ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-05"""^^xsd:string ; """2005-07-25"""^^xsd:string ; umls:cui """C1831692"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000373801"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541289"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liposomal daunorubicin citrate"""@eng ; skos:notation """CDR0000037796"""^^xsd:string ; skos:altLabel """liposomal daunorubicin"""@eng , """DaunoXome"""@eng , """daunorubicin liposomal"""@eng ; skos:definition """A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37796&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37796&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2213\" NCI Thesaurus)"""@eng ; ; ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """10155"""^^xsd:string ; """C2213"""^^xsd:string ; umls:cui """C0592528"""^^xsd:string ; umls:cui """C0717668"""^^xsd:string ; umls:cui """C0724567"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 4B5 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000037797"""^^xsd:string ; skos:altLabel """4B5 monoclonal antibody anti-idiotype vaccine"""@eng , """MOAB 4B5"""@eng , """MOAB 4B5 anti-idiotype vaccine"""@eng ; ; ; """10156"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879386"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/rebeccamycin analogue"""@eng ; skos:notation """CDR0000037794"""^^xsd:string ; skos:altLabel """CDDP/REBECCA"""@eng ; ; ; """10153"""^^xsd:string ; """2004-09-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879384"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ISIS 2503"""@eng ; skos:notation """CDR0000037795"""^^xsd:string ; skos:altLabel """ISIS-2503"""@eng , """ISIS2503"""@eng , """H-RAS Antisense"""@eng ; skos:definition """A synthetic oligodeoxynucleotide. Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the oncogene H-Ras. ISIS 2503 selectively inhibits the expression of H-Ras, and may inhibit the growth of some Ras-dependent tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37795&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37795&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2024\" NCI Thesaurus)"""@eng ; ; """10154"""^^xsd:string ; """718878"""^^xsd:string ; """2006-12-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2024"""^^xsd:string ; umls:cui """C1527185"""^^xsd:string ; umls:cui """C0879385"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-377,202"""@eng ; skos:notation """CDR0000037792"""^^xsd:string ; skos:altLabel """L-377202"""@eng ; skos:definition """A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin. This complex is hydrolyzed by the enzyme prostate-specific antigen (PSA), resulting in the formation of doxorubicin and leucine-doxorubicin. Selective targeting of these drugs to prostate tumor cells occurs because the hydrolyzing PSA enzyme is localized to the prostate gland. Doxorubicin and leucine-doxorubicin intercalate into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. These agents also produce toxic free-radical intermediates and interact with cell membrane lipids causing lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37792&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37792&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1853\" NCI Thesaurus)"""@eng ; """10151"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1853"""^^xsd:string ; umls:cui """C0879383"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rosiglitazone"""@eng ; skos:notation """CDR0000037793"""^^xsd:string ; skos:altLabel """BRL49653"""@eng , """(+/-)-5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, ( Z )-2-Butenedioate (1:1)"""@eng , """ROS"""@eng , """Avandia"""@eng , """rosiglitazone maleate"""@eng ; skos:definition """An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37793&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37793&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2583\" NCI Thesaurus)"""@eng ; ; """10152"""^^xsd:string ; """C2583"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0875967"""^^xsd:string ; umls:cui """C0795660"""^^xsd:string ; umls:cui """C0289313"""^^xsd:string ; umls:cui """C0289314"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methylprednisolone/mitoxantrone/vincristine"""@eng ; skos:notation """CDR0000041229"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/MePRDL/VCR"""@eng ; ; ; ; ; """4302"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280824"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/oxaliplatin"""@eng ; skos:notation """CDR0000037791"""^^xsd:string ; skos:altLabel """GemOx"""@eng , """dFdC/L-OHP"""@eng ; ; ; """10150"""^^xsd:string ; """2004-07-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879382"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EMLA"""@eng ; skos:notation """CDR0000041227"""^^xsd:string ; skos:altLabel """Eutectic Mixture of Local Anesthetics"""@eng , """lidocaine-prilocaine"""@eng ; """4300"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0617623"""^^xsd:string ; umls:cui """C0059079"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I non-small cell lung cancer"""@eng ; skos:notation """CDR0000041226"""^^xsd:string ; skos:altLabel """NSCLC, Stage I"""@eng , """stage I NSCLC"""@eng , """lung cancer, nonsmall cell, stage I"""@eng , """lung cancer, non-oat cell, stage I"""@eng , """nonsmall cell lung cancer, stage I"""@eng , """non-oat cell lung cancer, stage I"""@eng , """stage I nonsmall cell lung cancer"""@eng , """non-small cell lung cancer, stage I"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """43"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278504"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylphenidate hydrochloride"""@eng ; skos:notation """CDR0000041225"""^^xsd:string ; skos:altLabel """Ritalin Hydrochloride"""@eng , """alpha-Phenyl-2-piperidineacetic Acid Methyl Ester"""@eng , """d-methylphenidate"""@eng , """Ritalin"""@eng , """alpha-Phenyl-2-piperidineacetic Acid Methyl Ester Hydrochloride"""@eng , """Concerta"""@eng ; skos:definition """The hydrochloride salt of a synthetic central nervous system stimulant. Methylphenidate appears to activate the brain stem arousal system and cortex to produce its stimulant effect and, in some clinical settings, may improve cognitive function. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41225&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41225&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C646\" NCI Thesaurus)"""@eng ; """298-59-9 (hydrochloride)"""^^xsd:string ; """113-45-1"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C646"""^^xsd:string ; """4299"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0939301"""^^xsd:string ; umls:cui """C0700545"""^^xsd:string ; umls:cui """C0728759"""^^xsd:string ; umls:cui """C1709012"""^^xsd:string ; umls:cui """C0025810"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nimodipine/vincristine"""@eng ; skos:notation """CDR0000041224"""^^xsd:string ; skos:altLabel """NIMO/VCR"""@eng ; ; ; """4298"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280823"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized unresectable neuroblastoma"""@eng ; skos:notation """CDR0000041223"""^^xsd:string ; skos:altLabel """neuroblastoma, localized unresectable"""@eng ; rdfs:subClassOf ; """neuroblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4297"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280822"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041222"""^^xsd:string ; skos:altLabel """DACT/DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """4296"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280821"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alum adjuvant/monoclonal antibody 4B5 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000037798"""^^xsd:string ; skos:altLabel """ALUM/MOAB 4B5"""@eng ; ; ; """10157"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879387"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 4B5 anti-idiotype vaccine/sargramostim"""@eng ; skos:notation """CDR0000037799"""^^xsd:string ; skos:altLabel """GM-CSF/MOAB 4B5"""@eng ; ; ; """10158"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879388"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buthionine sulfoximine/melphalan"""@eng ; skos:notation """CDR0000040059"""^^xsd:string ; skos:altLabel """BSO/L-PAM"""@eng ; ; ; """2800"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279762"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leuprolide acetate"""@eng ; skos:notation """CDR0000040058"""^^xsd:string ; skos:altLabel """Enantone"""@eng , """Procren"""@eng , """Lupron Depot-Ped"""@eng , """Enanton"""@eng , """Lupron Depot-4 Month"""@eng , """Lucrin Depot"""@eng , """Leuprorelin"""@eng , """Leuprorelin Acetate"""@eng , """Abbott 43818"""@eng , """Prostap"""@eng , """Ginecrin"""@eng , """6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)"""@eng , """Lupron Depot"""@eng , """Viadur"""@eng , """Abbott-43818"""@eng , """Lucrin"""@eng , """Enantone-Gyn"""@eng , """Lupron Depot-3 Month"""@eng , """Leuplin"""@eng , """TAP-144"""@eng , """Uno-Enantone"""@eng , """Lupron"""@eng , """6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig)"""@eng , """LEUP"""@eng , """A-43818"""@eng , """Trenantone"""@eng , """Carcinil"""@eng , """Procrin"""@eng ; skos:definition """The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40058&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40058&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1319\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """74381-53-6 (acetate)"""^^xsd:string ; """25379"""^^xsd:string ; """377526"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C1319"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2798"""^^xsd:string ; """53714-56-0"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517841"""^^xsd:string ; umls:cui """C1517840"""^^xsd:string ; umls:cui """C0524775"""^^xsd:string ; umls:cui """C0701459"""^^xsd:string ; umls:cui """C1517838"""^^xsd:string ; umls:cui """C1517839"""^^xsd:string ; umls:cui """C0876209"""^^xsd:string ; umls:cui """C0721462"""^^xsd:string ; umls:cui """C1517830"""^^xsd:string ; umls:cui """C1517831"""^^xsd:string ; umls:cui """C1517836"""^^xsd:string ; umls:cui """C1517837"""^^xsd:string ; umls:cui """C1517834"""^^xsd:string ; umls:cui """C1517835"""^^xsd:string ; umls:cui """C0085272"""^^xsd:string ; umls:cui """C1517833"""^^xsd:string ; umls:cui """C0701461"""^^xsd:string ; umls:cui """C0701460"""^^xsd:string ; umls:cui """C0700596"""^^xsd:string ; umls:cui """C0086550"""^^xsd:string ; umls:cui """C1517829"""^^xsd:string ; umls:cui """C1517828"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progesterone receptor positive"""@eng ; skos:notation """CDR0000040057"""^^xsd:string ; skos:altLabel """positive progesterone receptor"""@eng , """PR+"""@eng ; """2796"""^^xsd:string ; umls:cui """C0279759"""^^xsd:string ; umls:tui """T034"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen receptor status unknown"""@eng ; skos:notation """CDR0000040056"""^^xsd:string ; skos:altLabel """unknown status, estrogen receptor"""@eng ; """2795"""^^xsd:string ; umls:cui """C0279758"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fatigue assessment/management"""@eng ; skos:notation """CDR0000040055"""^^xsd:string ; skos:altLabel """assessment/management, fatigue"""@eng ; ; rdfs:subClassOf ; """2794"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0279757"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen receptor negative"""@eng ; skos:notation """CDR0000040054"""^^xsd:string ; skos:altLabel """ER-"""@eng , """negative estrogen receptor"""@eng ; """2793"""^^xsd:string ; umls:cui """C0279756"""^^xsd:string ; umls:tui """T034"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/melphalan"""@eng ; skos:notation """CDR0000040053"""^^xsd:string ; skos:altLabel """AMA"""@eng , """ARA-C/L-PAM"""@eng ; ; ; """2792"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279755"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """suramin"""@eng ; skos:notation """CDR0000040052"""^^xsd:string ; skos:altLabel """sodium suramin"""@eng , """Fourneau 309"""@eng , """309 F"""@eng , """Moranyl"""@eng , """Naganin"""@eng , """Germanin"""@eng , """Antrypol"""@eng , """Naganine"""@eng , """SUR"""@eng , """Bayer 205"""@eng ; skos:definition """A polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40052&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40052&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C853\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2791"""^^xsd:string ; """29340"""^^xsd:string ; """C853"""^^xsd:string ; """145-63-1"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """24534"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0038880"""^^xsd:string ; umls:cui """C0813205"""^^xsd:string ; umls:cui """C0878167"""^^xsd:string ; umls:cui """C0878166"""^^xsd:string ; umls:cui """C0878169"""^^xsd:string ; umls:cui """C0878168"""^^xsd:string ; umls:cui """C0878170"""^^xsd:string ; umls:cui """C0878171"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen receptor positive"""@eng ; skos:notation """CDR0000040051"""^^xsd:string ; skos:altLabel """positive estrogen receptor"""@eng , """ER+"""@eng ; """2790"""^^xsd:string ; umls:cui """C0279754"""^^xsd:string ; umls:tui """T034"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """postmenopausal"""@eng ; skos:notation """CDR0000040050"""^^xsd:string ; """2789"""^^xsd:string ; umls:cui """C0232970"""^^xsd:string ; umls:tui """T079"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valproic acid"""@eng ; skos:notation """CDR0000350047"""^^xsd:string ; skos:altLabel """VA"""@eng , """Di-n-propylacetic Acid"""@eng , """2-Propylvaleric Acid"""@eng , """Depakene"""@eng , """Novo-Valproic"""@eng , """Valproate"""@eng , """Valproate Sodium"""@eng , """Ergenyl"""@eng , """Alti-Valproic"""@eng , """2-Propylpentanoic Acid"""@eng ; skos:definition """A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities. In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350047&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350047&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29536\" NCI Thesaurus)"""@eng ; ; """2003-12-23"""^^xsd:string ; """99-66-1"""^^xsd:string ; """93819"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C29536"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328121"""^^xsd:string ; umls:cui """C1328122"""^^xsd:string ; umls:cui """C0700659"""^^xsd:string ; umls:cui """C0700661"""^^xsd:string ; umls:cui """C0037567"""^^xsd:string ; umls:cui """C0080356"""^^xsd:string ; umls:cui """C0042291"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-12/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043597"""^^xsd:string ; skos:altLabel """gp100/IL-12/ISA-51/TYRP"""@eng ; ; ; ; """8879"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879306"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/floxuridine/leucovorin calcium/SCH-58500"""@eng ; skos:notation """CDR0000043596"""^^xsd:string ; skos:altLabel """CF/DM/FUDR/SCH 58500"""@eng ; ; ; ; ; """2003-10-22"""^^xsd:string ; """8877"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/HPV-16 E7(12-20) peptide vaccine/Montanide ISA-51"""@eng ; skos:notation """CDR0000043595"""^^xsd:string ; skos:altLabel """gp100/HPV16E7 (12-20)/ISA-51"""@eng ; ; ; """8876"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/peptide 946 melanoma vaccine/tetanus peptide melanoma vaccine"""@eng ; skos:notation """CDR0000043594"""^^xsd:string ; skos:altLabel """ISA-51/p946/Tet p"""@eng ; ; ; """8875"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879302"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/mitoxantrone"""@eng ; skos:notation """CDR0000043593"""^^xsd:string ; skos:altLabel """DHAD/TXT"""@eng ; ; ; """8874"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879303"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/peptide 946-tetanus peptide conjugate melanoma vaccine"""@eng ; skos:notation """CDR0000043592"""^^xsd:string ; skos:altLabel """ISA-51/p946-Tet p"""@eng ; ; """8873"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879302"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/peptide 946 melanoma vaccine"""@eng ; skos:notation """CDR0000043591"""^^xsd:string ; skos:altLabel """ISA-51/p946"""@eng ; ; """8872"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879301"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MART-1 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000043590"""^^xsd:string ; skos:altLabel """ISA-51/MART-1"""@eng ; ; """8871"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879300"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043599"""^^xsd:string ; skos:altLabel """ISA-51/VHL peptide"""@eng ; ; """8881"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879308"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/Montanide ISA-51/sargramostim/tetanus peptide melanoma vaccine/tyrosinase peptide"""@eng ; skos:notation """CDR0000043598"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/ISA-51/Tet p/TYRP"""@eng ; ; ; ; ; """8880"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879307"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000042871"""^^xsd:string ; skos:altLabel """CBDCA/CTX/WR-2721"""@eng ; ; ; ; """6684"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677805"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior estrogen therapy"""@eng ; skos:notation """CDR0000040090"""^^xsd:string ; skos:altLabel """estrogen therapy, prior"""@eng ; """2838"""^^xsd:string ; umls:cui """C0279788"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042758"""^^xsd:string ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6555"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677728"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, recurrent adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042756"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6553"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677726"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent or aggressive adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042757"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """6554"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0677727"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent mantle cell lymphoma"""@eng ; skos:notation """CDR0000042755"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6552"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677725"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, stage IV adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042752"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6549"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677722"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, recurrent adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042753"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6550"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677723"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV mantle cell lymphoma"""@eng ; skos:notation """CDR0000042751"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6548"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677721"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/phenoxodiol"""@eng ; skos:notation """CDR0000389212"""^^xsd:string ; skos:altLabel """NV-06/TAX"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541358"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II inverted papilloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040762"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity inverted papilloma, stage II"""@eng , """nasal cavity and paranasal sinus inverted papilloma, stage II"""@eng , """inverted papilloma of the paranasal sinus and nasal cavity, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Cancer stage"""^^xsd:string ; """3712"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; umls:cui """C0280408"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/methotrexate/mycophenolate mofetil/tacrolimus"""@eng ; skos:notation """CDR0000269773"""^^xsd:string ; skos:altLabel """ATG/FK506/MMF/MTX"""@eng ; ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327864"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/rituximab"""@eng ; skos:notation """CDR0000269777"""^^xsd:string ; skos:altLabel """CTX/FAMP/MOAB IDEC-C2B8"""@eng ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327865"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dapsone"""@eng ; skos:notation """CDR0000494629"""^^xsd:string ; skos:altLabel """Bis(4-aminophenyl)sulfone"""@eng , """Dumitone"""@eng , """DDS"""@eng , """Avlosulfon"""@eng , """1358F"""@eng , """4,4'-Sulfonylbisbenzeneamine"""@eng , """4,4'-Sulfonyldianiline"""@eng , """Croysulfone"""@eng , """Undolac"""@eng , """Sulphadione"""@eng , """Sulfona-Mae"""@eng , """Eporal"""@eng , """Novophone"""@eng , """4,4'-Sulfonylbisbenzamine"""@eng , """Diphenasone"""@eng , """DADPS"""@eng , """Disulone"""@eng ; skos:definition """A synthetic derivative of diamino-sulfone with anti-mycobacterial and anti-malarial properties. A structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=494629&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=494629&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C415\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """80-08-0"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """C415"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """6091"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511721"""^^xsd:string ; umls:cui """C1511722"""^^xsd:string ; umls:cui """C1511723"""^^xsd:string ; umls:cui """C0010980"""^^xsd:string ; umls:cui """C1527112"""^^xsd:string ; umls:cui """C0729116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/vinorelbine"""@eng ; skos:notation """CDR0000042349"""^^xsd:string ; skos:altLabel """TAX/VNB"""@eng ; ; ; """5601"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338263"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/melatonin"""@eng ; skos:notation """CDR0000042348"""^^xsd:string ; skos:altLabel """IL-2/MLT"""@eng ; ; ; """5600"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338262"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000042341"""^^xsd:string ; skos:altLabel """CTX/DM/DNR/VCR"""@eng ; ; ; ; ; """5594"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338257"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/losoxantrone/paclitaxel"""@eng ; skos:notation """CDR0000042340"""^^xsd:string ; skos:altLabel """DuP-941/G-CSF/TAX"""@eng ; ; ; ; """5592"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338256"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/paclitaxel"""@eng ; skos:notation """CDR0000042343"""^^xsd:string ; skos:altLabel """IFN-A/IL-2/TAX"""@eng ; ; ; ; """5596"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338259"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/thioguanine"""@eng ; skos:notation """CDR0000042342"""^^xsd:string ; skos:altLabel """ARA-C/IDA/TG"""@eng ; ; ; ; """5595"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338258"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/interferon alfa/interleukin-2/paclitaxel"""@eng ; skos:notation """CDR0000042345"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/IFN-A/IL-2/TAX"""@eng ; ; ; ; ; ; """5598"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338261"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/tretinoin"""@eng ; skos:notation """CDR0000042344"""^^xsd:string ; skos:altLabel """ATRA/MP/MTX"""@eng ; ; ; ; """5597"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338260"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent non-small cell lung cancer"""@eng ; skos:notation """CDR0000042347"""^^xsd:string ; skos:altLabel """non-small cell lung cancer, recurrent"""@eng , """recurrent NSCLC"""@eng , """recurrent nonsmall cell lung cancer"""@eng , """nonsmall cell lung cancer, recurrent"""@eng , """lung cancer, non-oat cell, recurrent"""@eng , """lung cancer, nonsmall cell, recurrent"""@eng , """non-oat cell lung cancer, recurrent"""@eng , """NSCLC, recurrent"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """56"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278517"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melatonin"""@eng ; skos:notation """CDR0000042346"""^^xsd:string ; skos:altLabel """Therapeutic Melatonin"""@eng , """MLT"""@eng , """Circadin"""@eng ; skos:definition """A recombinant therapeutic analog of melatonin, a natural serotonin-derived indole with antioxidant properties. Melatonin hormone synthesis occurs in the pineal gland and depends on beta-adrenergic receptor function. Melatonin is involved in numerous biological functions: circadian rhythm, sleep, stress response, aging, and immunity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42346&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42346&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C632\" NCI Thesaurus)"""@eng ; ; """5599"""^^xsd:string ; """73-31-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """56423"""^^xsd:string ; """C632"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0025219"""^^xsd:string ; umls:cui """C1710381"""^^xsd:string ; umls:cui """C1527137"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Newcastle disease virus"""@eng ; skos:notation """CDR0000257613"""^^xsd:string ; """2002-10-19"""^^xsd:string ; """2002-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0027984"""^^xsd:string ; umls:tui """T005"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laetrile"""@eng ; skos:notation """CDR0000257611"""^^xsd:string ; skos:altLabel """Laetrille"""@eng ; skos:definition """Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants. Over the years the meaning of laetrile has changed. There are now preparations called Laetrile where amygdalin is the major constituent. Laetrile and amygdalin are often used interchangeably, but are different agents. Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin. Both metabolites may possess antineoplastic properties. Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness. It is not approved for use in the United States. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257611&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257611&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29149\" NCI Thesaurus)"""@eng ; """2002-10-19"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """C29149"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0878244"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Cancell"""@eng ; skos:notation """CDR0000257610"""^^xsd:string ; skos:altLabel """JS-101"""@eng , """Crocinic acid"""@eng , """JS-114"""@eng , """Jim's Juice"""@eng , """Entelev"""@eng , """Cantron"""@eng , """126-F"""@eng , """Radic"""@eng , """Sheridan's Formula"""@eng ; """2002-10-19"""^^xsd:string ; """2002-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0656932"""^^xsd:string ; umls:cui """C0656933"""^^xsd:string ; umls:cui """C0656934"""^^xsd:string ; umls:cui """C0656935"""^^xsd:string ; umls:cui """C0656936"""^^xsd:string ; umls:cui """C0656937"""^^xsd:string ; umls:cui """C1328661"""^^xsd:string ; umls:cui """C1328660"""^^xsd:string ; umls:cui """C1328658"""^^xsd:string ; umls:cui """C1328659"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000040611"""^^xsd:string ; skos:altLabel """stage, childhood acute lymphocytic leukemia"""@eng , """childhood acute lymphocytic leukemia stage"""@eng ; rdfs:subClassOf ; """3512"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280235"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/thalidomide"""@eng ; skos:notation """CDR0000377675"""^^xsd:string ; skos:altLabel """PS-341/THAL"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541336"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/type, childhood brain tumor"""@eng ; skos:notation """CDR0000040613"""^^xsd:string ; skos:altLabel """pediatric brain tumor stage"""@eng , """childhood brain tumor stage"""@eng ; rdfs:subClassOf ; """3515"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280238"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/WX-UK1"""@eng ; skos:notation """CDR0000377677"""^^xsd:string ; skos:altLabel """CAPE/WX UK1"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541337"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized transitional cell cancer of the renal pelvis and ureter"""@eng ; skos:notation """CDR0000040615"""^^xsd:string ; skos:altLabel """transitional cell cancer of the renal pelvis and ureter, localized"""@eng , """cancer of the renal pelvis and ureter, localized"""@eng , """carcinoma of the renal pelvis and ureter, localized"""@eng ; rdfs:subClassOf ; """transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3518"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280240"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood liver cancer"""@eng ; skos:notation """CDR0000040614"""^^xsd:string ; skos:altLabel """childhood liver cancer stage"""@eng ; rdfs:subClassOf ; """3517"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280239"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, rectal cancer"""@eng ; skos:notation """CDR0000040617"""^^xsd:string ; skos:altLabel """rectal cancer stage"""@eng ; rdfs:subClassOf ; """3521"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280242"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/cell type, childhood non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040616"""^^xsd:string ; skos:altLabel """childhood non-Hodgkin's lymphoma, stage"""@eng ; rdfs:subClassOf ; """3520"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280241"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, retinoblastoma"""@eng ; skos:notation """CDR0000040619"""^^xsd:string ; skos:altLabel """retinoblastoma stage"""@eng ; rdfs:subClassOf ; """3523"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280244"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000040618"""^^xsd:string ; skos:altLabel """childhood rhabdomyosarcoma, stage"""@eng , """childhood rhabdomyosarcoma stage"""@eng , """rhabdomyosarcoma, childhood, stage"""@eng ; rdfs:subClassOf ; """3522"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280243"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/thalidomide"""@eng ; skos:notation """CDR0000377679"""^^xsd:string ; skos:altLabel """CDDP/CTX/DM/DOX/THAL/VP-16"""@eng ; ; ; ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1512081"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EKB-569/temsirolimus"""@eng ; skos:notation """CDR0000405966"""^^xsd:string ; skos:altLabel """CCI-779/EKB 569"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """2005-05-05"""^^xsd:string ; umls:cui """C1541405"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000038454"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/MOAB VEGF"""@eng ; ; ; ; ; """11071"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134498"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/tirapazamine"""@eng ; skos:notation """CDR0000038455"""^^xsd:string ; skos:altLabel """CTX/DOX/SR-4233"""@eng ; ; ; ; """11072"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134499"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CC49-delta CH2"""@eng ; skos:notation """CDR0000038456"""^^xsd:string ; skos:altLabel """Monoclonal Antibody HCC49DCH2"""@eng , """MOAB CC49-deltaCH2"""@eng , """MoAb HuCC49DeltaCH2"""@eng , """MOAB HCC49DCH2"""@eng ; skos:definition """A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72). TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38456&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38456&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2698\" NCI Thesaurus)"""@eng ; """11073"""^^xsd:string ; """9260"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2698"""^^xsd:string ; """696081"""^^xsd:string ; umls:cui """C1134500"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/monoclonal antibody 105AD7 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000038457"""^^xsd:string ; skos:altLabel """BC-G/MOAB 105AD7"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """11074"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134501"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/temozolomide/thiotepa"""@eng ; skos:notation """CDR0000038450"""^^xsd:string ; skos:altLabel """CBDCA/TMZ/TSPA"""@eng ; ; ; ; """11068"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134496"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """apolizumab"""@eng ; skos:notation """CDR0000038451"""^^xsd:string ; skos:altLabel """1D1O Anti-lymphoma Antibody"""@eng , """MoAb Hu1D10"""@eng , """Monoclonal Antibody Hu1D10"""@eng , """Monoclonal antibody 1D10"""@eng , """Remitogen"""@eng , """MOAB 1D10"""@eng ; skos:definition """A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38451&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38451&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2228\" NCI Thesaurus)"""@eng ; ; """11069"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """9968"""^^xsd:string ; """C2228"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """710066"""^^xsd:string ; """8308"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1531285"""^^xsd:string ; umls:cui """C1122758"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allopurinol"""@eng ; skos:notation """CDR0000038452"""^^xsd:string ; skos:altLabel """1,5-Dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one"""@eng , """Sigapurol"""@eng , """Zyloprim"""@eng , """4-Hydroxypyrazolo[3,4-d]pyrimidine"""@eng , """ALLO"""@eng , """1H-Pyrazolo[3,4-d]pyrimidin-4-ol"""@eng ; skos:definition """A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38452&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38452&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C224\" NCI Thesaurus)"""@eng ; ; ; """1107"""^^xsd:string ; """2005-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C224"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0002144"""^^xsd:string ; umls:cui """C1765317"""^^xsd:string ; umls:cui """C0701096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CI-994/gemcitabine"""@eng ; skos:notation """CDR0000037896"""^^xsd:string ; skos:altLabel """CI 994/dFdC"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10306"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879458"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """psoralen"""@eng ; skos:notation """CDR0000037899"""^^xsd:string ; skos:altLabel """S-59"""@eng ; """10309"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0766140"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethynyluracil/fluorouracil/oxaliplatin"""@eng ; skos:notation """CDR0000037898"""^^xsd:string ; skos:altLabel """776C85/5-FU/L-OHP"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """10308"""^^xsd:string ; umls:cui """C0879460"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-2-KLH vaccine"""@eng ; skos:notation """CDR0000042967"""^^xsd:string ; skos:altLabel """vaccine, MUC-2-KLH"""@eng , """MUC-2-KLH"""@eng ; ; """7199"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677979"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alum adjuvant/monoclonal antibody 105AD7 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000038458"""^^xsd:string ; skos:altLabel """ALUM/MOAB 105AD7"""@eng ; ; ; """11075"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentostatin/rituximab"""@eng ; skos:notation """CDR0000038459"""^^xsd:string ; skos:altLabel """DCF/MOAB IDEC-C2B8"""@eng ; ; ; """11076"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/thiotepa/topotecan"""@eng ; skos:notation """CDR0000042963"""^^xsd:string ; skos:altLabel """CBDCA/TOPO/TSPA"""@eng ; ; ; ; """7195"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677976"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/fluorouracil"""@eng ; skos:notation """CDR0000042962"""^^xsd:string ; skos:altLabel """5-FU/TXT"""@eng ; ; ; """7194"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677975"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/vincristine"""@eng ; skos:notation """CDR0000041050"""^^xsd:string ; skos:altLabel """DACT/VCR"""@eng ; ; ; """4090"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280659"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000041051"""^^xsd:string ; skos:altLabel """DACT/DOX/VCR"""@eng ; ; ; ; """4091"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280660"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor infiltrating lymphocyte therapy"""@eng ; skos:notation """CDR0000041052"""^^xsd:string ; skos:altLabel """TIL"""@eng , """therapy, tumor infiltrating lymphocyte"""@eng ; ; rdfs:subClassOf ; """4092"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280661"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radiation enteritis"""@eng ; skos:notation """CDR0000041053"""^^xsd:string ; rdfs:subClassOf ; """4093"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0259795"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin"""@eng ; skos:notation """CDR0000041054"""^^xsd:string ; skos:altLabel """CDDP/WR-2721"""@eng ; ; ; """4094"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280662"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chloroquinoxaline sulfonamide"""@eng ; skos:notation """CDR0000041055"""^^xsd:string ; skos:altLabel """CQS"""@eng , """Benzenesulfonamide, 4-amino-N-(5-chloro-2-quinoxalinyl)-"""@eng , """chlorosulfaquinoxaline"""@eng , """Chlorsulfaquinoxaline"""@eng ; skos:definition """A chlorinated heterocyclic sulfanilamide with potential antineoplastic activity and potential immunosuppressive activity. Chloroquinoxaline sulfonamide poisons topoisomerase II alpha and topoisomerase II beta, thereby causing double-stranded breaks in DNA, accumulation of unrepaired DNA, and apoptosis. This agent also exhibits lymphotoxicity by inhibiting lymphocyte activation in a cell cycle-specific manner. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41055&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41055&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C982\" NCI Thesaurus)"""@eng ; """4095"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """32123"""^^xsd:string ; """339004"""^^xsd:string ; """97919-22-7"""^^xsd:string ; """C982"""^^xsd:string ; umls:cui """C0049111"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """midazolam hydrochloride"""@eng ; skos:notation """CDR0000041056"""^^xsd:string ; skos:altLabel """Versed"""@eng , """midazolam"""@eng , """8-Chloro-6-(2-fluorophenyl)-1-Methyl- 4H- Imidazo(1,5a)(1,4)Benzodiazepine"""@eng ; skos:definition """The hydrochloride salt of a short-acting benzodiazepine derivative with an imidazole structure and anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam binds to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS), resulting in increases in the opening of chloride channels, membrane hyperpolarization, and the inhibitory effect of GABA. This agent may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41056&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41056&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C654\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """C654"""^^xsd:string ; """4096"""^^xsd:string ; """2006-05-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0026056"""^^xsd:string ; umls:cui """C0700457"""^^xsd:string ; umls:cui """C0042553"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim"""@eng ; skos:notation """CDR0000041057"""^^xsd:string ; skos:altLabel """Recombinant Methionyl Human Granulocyte Colony Stimulating Factor"""@eng , """Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor"""@eng , """granulocyte colony-stimulating factor"""@eng , """r-metHuG-CSF"""@eng , """G-CSF"""@eng , """G CSF"""@eng , """granulocyte colony stimulating factor"""@eng , """Neupogen"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41057&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41057&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1474\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4097"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1474"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """121181-53-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733468"""^^xsd:string ; umls:cui """C0210630"""^^xsd:string ; umls:cui """C0079459"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/mitoxantrone/vinblastine"""@eng ; skos:notation """CDR0000041058"""^^xsd:string ; skos:altLabel """CCNU/DHAD/VBL"""@eng ; ; ; ; """4098"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280663"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/metoclopramide/midazolam"""@eng ; skos:notation """CDR0000041059"""^^xsd:string ; skos:altLabel """DM/MCP/midazolam"""@eng , """MDM"""@eng ; ; ; ; """4099"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280664"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000040260"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/VBL"""@eng , """M-CAVE"""@eng ; ; ; ; ; """3089"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279944"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer screening"""@eng ; skos:notation """CDR0000040261"""^^xsd:string ; skos:altLabel """early cancer detection"""@eng , """screening"""@eng , """cancer detection, early"""@eng ; """2002-10-17"""^^xsd:string ; """3092"""^^xsd:string ; umls:cui """C0199230"""^^xsd:string ; umls:cui """C2607925"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone/suramin"""@eng ; skos:notation """CDR0000040262"""^^xsd:string ; skos:altLabel """HC/SUR"""@eng ; ; ; """3093"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279945"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040263"""^^xsd:string ; skos:altLabel """adult NHL stage"""@eng , """adult non-Hodgkin's lymphoma stage"""@eng ; rdfs:subClassOf ; """3098"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279948"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I gastric cancer"""@eng ; skos:notation """CDR0000040264"""^^xsd:string ; skos:altLabel """gastric cancer, stage I"""@eng , """stomach cancer, stage I"""@eng ; rdfs:subClassOf ; """gastric cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """31"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278495"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, low grade, stage I adult"""@eng ; skos:notation """CDR0000040265"""^^xsd:string ; skos:altLabel """NHL, low grade, stage I adult"""@eng , """adult non-Hodgkin's lymphoma, low grade, stage I"""@eng , """adult NHL, stage I, low grade"""@eng , """low-grade, stage I adult NHL"""@eng , """lymphoma, low grade, stage I adult non-Hodgkin's"""@eng ; """2005-01-21"""^^xsd:string ; """3102"""^^xsd:string ; umls:cui """C0279951"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000040266"""^^xsd:string ; skos:altLabel """small lymphocytic lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3103"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """small lymphocytic lymphoma"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0855098"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000040267"""^^xsd:string ; skos:altLabel """stage I follicular small cleaved cell lymphoma"""@eng , """follicular small cleaved cell lymphoma, stage I"""@eng , """stage I grade I follicular small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3105"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279954"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000040268"""^^xsd:string ; skos:altLabel """stage I grade II follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma, stage I"""@eng , """stage I follicular mixed cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3106"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279955"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000040269"""^^xsd:string ; skos:altLabel """stage I grade III follicular large cell lymphoma"""@eng , """stage I follicular large cell lymphoma"""@eng , """follicular large cell lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3107"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279956"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100:280-288(288V) peptide vaccine"""@eng ; skos:notation """CDR0000492712"""^^xsd:string ; skos:definition """A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492712&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492712&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49042\" NCI Thesaurus)"""@eng ; """683473"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """C49042"""^^xsd:string ; """7474"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """6123"""^^xsd:string ; umls:cui """C1831910"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colloidal gold-bound tumor necrosis factor"""@eng ; skos:notation """CDR0000492715"""^^xsd:string ; skos:altLabel """Aurimmune"""@eng , """colloidal gold-bound recombinant human tumor necrosis factor"""@eng , """colloidal gold-bound rhTNF"""@eng , """colloidal gold-bound TNF"""@eng , """CYT-6091"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-20"""^^xsd:string ; """C62538"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831912"""^^xsd:string ; umls:cui """C1831913"""^^xsd:string ; umls:cui """C1831911"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039440"""^^xsd:string ; skos:altLabel """CCNU-OP"""@eng , """CCNU/PRED/VCR"""@eng ; ; ; ; """2075"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279300"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lexatumumab"""@eng ; skos:notation """CDR0000528015"""^^xsd:string ; skos:altLabel """HGS-ETR2"""@eng , """monoclonal antibody HGS-ETR2"""@eng , """anti-TRAIL receptor 2 monoclonal antibody HGS-ETR2"""@eng ; """2006-12-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C2742502"""^^xsd:string ; umls:cui """C1721684"""^^xsd:string ; umls:cui """C1721685"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/paclitaxel/pegfilgrastim"""@eng ; skos:notation """CDR0000315750"""^^xsd:string ; skos:altLabel """CDDP/5-FU/GCSF-SD01/TAX"""@eng ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327999"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """18F-FHBG"""@eng ; skos:notation """CDR0000488475"""^^xsd:string ; skos:altLabel """9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine"""@eng ; """Drug/agent"""^^xsd:string ; """C62533"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """2006-06-02"""^^xsd:string ; umls:cui """C1453307"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EC145"""@eng ; skos:notation """CDR0000488470"""^^xsd:string ; """C62525"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; umls:cui """C1831870"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/thioguanine"""@eng ; skos:notation """CDR0000038878"""^^xsd:string ; skos:altLabel """DM/MTX/TG"""@eng ; ; ; ; """1367"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278918"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/doxorubicin/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038879"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DOX/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; """1368"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278919"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide"""@eng ; skos:notation """CDR0000038872"""^^xsd:string ; skos:altLabel """ADE"""@eng , """ARA-C/DNR/VP-16"""@eng ; ; ; ; """1361"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057163"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/lomustine"""@eng ; skos:notation """CDR0000038873"""^^xsd:string ; skos:altLabel """BLEO/CCNU"""@eng ; ; ; """1362"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278913"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/fluorouracil"""@eng ; skos:notation """CDR0000038870"""^^xsd:string ; skos:altLabel """FACP"""@eng , """CDDP/CTX/DOX/5-FU"""@eng ; ; ; ; ; """136"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054607"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TAC-101"""@eng ; skos:notation """CDR0000350384"""^^xsd:string ; skos:altLabel """TAC 101"""@eng ; skos:definition """A retinobenzoic acid with potential antineoplastic activity. TAC-101 inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest. This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350384&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350384&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38684\" NCI Thesaurus)"""@eng ; """2004-01-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38684"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C0675838"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000038876"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/MTX"""@eng ; ; ; ; ; """1365"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278916"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038877"""^^xsd:string ; skos:altLabel """ASP/MTX/PRED/VCR"""@eng ; ; ; ; ; """1366"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278917"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/floxuridine"""@eng ; skos:notation """CDR0000038874"""^^xsd:string ; skos:altLabel """DOX/FUDR"""@eng ; ; ; """1363"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278914"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038875"""^^xsd:string ; skos:altLabel """ASP/DNR/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """1364"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278915"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-grade childhood cerebral astrocytoma"""@eng ; skos:notation """CDR0000042503"""^^xsd:string ; skos:altLabel """supratentorial astrocytoma, childhood"""@eng , """grade I childhood cerebral astrocytoma"""@eng , """brain tumor, childhood cerebral astrocytoma"""@eng , """CNS tumor, pediatric cerebral astrocytoma"""@eng , """astrocytoma, pediatric cerebral"""@eng , """childhood cerebral astrocytoma"""@eng , """childhood cerebral astrocytoma, low-grade"""@eng , """low grade childhood cerebral glioma"""@eng , """pediatric brain tumor, cerebral astrocytoma"""@eng , """central nervous system tumor, cerebral astrocytoma, childhood"""@eng , """astrocytoma, childhood cerebral"""@eng , """pediatric supratentorial astrocytoma"""@eng , """CNS tumor, childhood cerebral astrocytoma"""@eng , """cerebral astrocytoma, childhood"""@eng , """childhood brain tumor, cerebral astrocytoma"""@eng , """childhood CNS tumor, cerebral astrocytoma"""@eng , """grade II childhood cerebral astrocytoma"""@eng , """brain tumor, pediatric cerebral astrocytoma"""@eng , """pediatric CNS tumor, cerebral astrocytoma"""@eng , """childhood supratentorial astrocytoma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood cerebral astrocytoma/malignant glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """608"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338072"""^^xsd:string ; umls:cui """C0338070"""^^xsd:string ; umls:cui """C0338071"""^^xsd:string ; umls:cui """C0278628"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """octreotide pamoate/tamoxifen"""@eng ; skos:notation """CDR0000042502"""^^xsd:string ; skos:altLabel """SMS 201-995 pa/TMX"""@eng ; ; ; """6066"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392936"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/deoxycytidine"""@eng ; skos:notation """CDR0000042501"""^^xsd:string ; skos:altLabel """ARA-C/dC"""@eng ; ; ; """6065"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392935"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """deoxycytidine"""@eng ; skos:notation """CDR0000042500"""^^xsd:string ; skos:altLabel """dC"""@eng ; ; """6064"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0011485"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atypical chronic myeloid leukemia"""@eng ; skos:notation """CDR0000335175"""^^xsd:string ; skos:altLabel """aCML"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2003-09-24"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """myelodysplastic/myeloproliferative diseases"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1292772"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """myelodysplastic/myeloproliferative disease, unclassifiable"""@eng ; skos:notation """CDR0000335177"""^^xsd:string ; skos:altLabel """MDS/MPD-U"""@eng ; rdfs:subClassOf ; """2003-09-24"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """myelodysplastic/myeloproliferative diseases"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1328061"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pruritus"""@eng ; skos:notation """CDR0000042504"""^^xsd:string ; skos:altLabel """itching"""@eng ; rdfs:subClassOf ; """609"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0033774"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CT-2584"""@eng ; skos:notation """CDR0000042509"""^^xsd:string ; skos:altLabel """CT2584"""@eng , """CT 2584"""@eng , """Apra"""@eng ; """6121"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0539091"""^^xsd:string ; umls:cui """C0718617"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human thrombopoietin"""@eng ; skos:notation """CDR0000042508"""^^xsd:string ; skos:altLabel """rhTPO"""@eng , """recombinant human TPO"""@eng , """thrombopoietin, recombinant human"""@eng ; ; """6118"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0392939"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """galiximab/rituximab"""@eng ; skos:notation """CDR0000285687"""^^xsd:string ; skos:altLabel """MOAB IDEC-114/MOAB IDEC-C2B8"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-16"""^^xsd:string ; """2003-02-21"""^^xsd:string ; umls:cui """C1327912"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """galiximab"""@eng ; skos:notation """CDR0000285686"""^^xsd:string ; skos:altLabel """MOAB IDEC-114"""@eng , """Monoclonal Antibody IDEC-114"""@eng , """anti-B7-1"""@eng , """anti-CD80"""@eng , """MOAB anti-CD80"""@eng , """monoclonal antibody anti-CD80"""@eng ; skos:definition """A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. IDEC-114 monoclonal antibody binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285686&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285686&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26447\" NCI Thesaurus)"""@eng ; ; """2006-08-07"""^^xsd:string ; """C26447"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2003-02-21"""^^xsd:string ; umls:cui """C1098262"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000285685"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/MOAB C225"""@eng ; ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327910"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II squamous cell carcinoma of the lip and oral cavity"""@eng ; skos:notation """CDR0000040700"""^^xsd:string ; skos:altLabel """epidermoid carcinoma of the lip and oral cavity, stage II"""@eng , """oral cavity and lip squamous cell carcinoma, stage II"""@eng , """squamous cell carcinoma of the lip and oral cavity, stage II"""@eng , """lip and oral cavity squamous cell carcinoma, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3639"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280348"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Eg5 inhibitor AZD4877"""@eng ; skos:notation """CDR0000522717"""^^xsd:string ; skos:altLabel """AZD4877"""@eng ; """2006-11-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1879525"""^^xsd:string ; umls:cui """C1831986"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """minocycline-EDTA"""@eng ; skos:notation """CDR0000509172"""^^xsd:string ; skos:altLabel """M-EDTA"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-15"""^^xsd:string ; umls:cui """C1831960"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hyperbaric oxygen"""@eng ; skos:notation """CDR0000039479"""^^xsd:string ; skos:definition """Oxygen that is administered at a higher pressure compared to standard (i.e. sea-level) atmospheric pressure. Administration of oxygen under hyperbaric conditions enhances the delivery of oxygen to hypoxic tumor cells, thereby increasing their sensitivity to radiation and chemotherapy. In addition, hyperbaric oxygen may improve the healing of radiation-induced injuries by improving oxygen delivery to damaged tissue. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39479&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39479&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2351\" NCI Thesaurus)"""@eng ; """2113"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """C2351"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0279328"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydromorphone hydrochloride"""@eng ; skos:notation """CDR0000039478"""^^xsd:string ; skos:altLabel """Novolauden"""@eng , """Hydrostat"""@eng , """Dilaudid"""@eng , """Laudicon"""@eng , """Hymorphan"""@eng , """hydromorphon"""@eng , """Dimorphone"""@eng , """dihydromorphinone"""@eng , """Dilaudid HP"""@eng ; """TRD"""^^xsd:string ; """2006-11-21"""^^xsd:string ; """2112"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0012306"""^^xsd:string ; umls:cui """C0700533"""^^xsd:string ; umls:cui """C0701971"""^^xsd:string ; umls:cui """C0023130"""^^xsd:string ; umls:cui """C1512538"""^^xsd:string ; umls:cui """C0728755"""^^xsd:string ; umls:cui """C1512536"""^^xsd:string ; umls:cui """C1512537"""^^xsd:string ; umls:cui """C0719907"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/oblimersen"""@eng ; skos:notation """CDR0000301884"""^^xsd:string ; skos:altLabel """dFdC/G3139"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327952"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine"""@eng ; skos:notation """CDR0000039475"""^^xsd:string ; skos:altLabel """ENT-50852"""@eng , """hexamethylmelamine"""@eng , """HMM"""@eng , """Hemel"""@eng , """Hexastat"""@eng , """HXM"""@eng , """Hexinawas"""@eng , """WR-95704"""@eng , """N,N,N',N',N\",N\"-hexamethyl-1,3,5-triazine-2,4,6-triamine"""@eng , """N,n,n',N\"N\"-hexamethyl-1,3,5,-triazine-2,4,6,-triamine"""@eng , """Hexaloids"""@eng , """RB-1515"""@eng , """Hexalen"""@eng , """2,4,6-tris(dimethylamino)-s-triazine"""@eng ; skos:definition """A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity. Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39475&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39475&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C544\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2109"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """954"""^^xsd:string ; """C544"""^^xsd:string ; """13875"""^^xsd:string ; """645-05-6"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0019453"""^^xsd:string ; umls:cui """C1522393"""^^xsd:string ; umls:cui """C0733617"""^^xsd:string ; umls:cui """C1448360"""^^xsd:string ; umls:cui """C1522394"""^^xsd:string ; umls:cui """C0594753"""^^xsd:string ; umls:cui """C1448359"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """haloperidol"""@eng ; skos:notation """CDR0000039474"""^^xsd:string ; skos:altLabel """R-1625"""@eng , """McN-JR-1625"""@eng , """Haldol"""@eng , """4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone"""@eng ; skos:definition """A phenylbutylpiperadine derivative with antipsychotic, neuroleptic and antiemetic effects. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. The antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39474&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39474&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C537\" NCI Thesaurus)"""@eng ; """2108"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """170973"""^^xsd:string ; """52-86-8"""^^xsd:string ; """C537"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591585"""^^xsd:string ; umls:cui """C0699382"""^^xsd:string ; umls:cui """C0700677"""^^xsd:string ; umls:cui """C0018546"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hycanthone"""@eng ; skos:notation """CDR0000039477"""^^xsd:string ; skos:altLabel """Etrenol"""@eng , """HYC"""@eng , """Hycanthone mesylate"""@eng ; skos:definition """A thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. Hycanthone interferes with parasite nerve function, resulting in parasite paralysis and death. This agent also intercalates into DNA and inhibits RNA synthesis in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39477&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39477&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C550\" NCI Thesaurus)"""@eng ; """2111"""^^xsd:string ; """C550"""^^xsd:string ; """134434"""^^xsd:string ; """11712"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3105-97-3"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0063050"""^^xsd:string ; umls:cui """C1328672"""^^xsd:string ; umls:cui """C0020207"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """homoharringtonine"""@eng ; skos:notation """CDR0000039476"""^^xsd:string ; skos:altLabel """Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)"""@eng , """Ceflatonin"""@eng , """HH"""@eng , """Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)"""@eng , """HHT"""@eng ; skos:definition """A cytotoxic plant alkaloid isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Homoharringtonine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39476&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39476&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1127\" NCI Thesaurus)"""@eng ; ; ; ; ; """2110"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1127"""^^xsd:string ; """19125"""^^xsd:string ; """26833-87-4"""^^xsd:string ; """105"""^^xsd:string ; """141633"""^^xsd:string ; """2006-08-25"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0062941"""^^xsd:string ; umls:cui """C1512487"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/semustine/vincristine"""@eng ; skos:notation """CDR0000039471"""^^xsd:string ; skos:altLabel """COMB"""@eng , """BLEO/CTX/MeCCNU/VCR"""@eng ; ; ; ; ; """2105"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279325"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/prednisone/tamoxifen"""@eng ; skos:notation """CDR0000039470"""^^xsd:string ; skos:altLabel """CMFPT"""@eng , """CTX/5-FU/MTX/PRED/TMX"""@eng ; ; ; ; ; ; """2104"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055986"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039473"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/MTX/PRED/VCR"""@eng , """CMFP-VA"""@eng ; ; ; ; ; ; ; """2107"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279327"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/melphalan/vincristine"""@eng ; skos:notation """CDR0000039472"""^^xsd:string ; skos:altLabel """CTX/DOX/L-PAM/VCR"""@eng , """CONPADRI-I"""@eng ; ; ; ; ; """2106"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 antiferritin immunoglobulin"""@eng ; skos:notation """CDR0000040362"""^^xsd:string ; skos:altLabel """I 131-antiferritin IgG"""@eng , """I 131-AFI"""@eng , """immunoglobulin, iodine I 131 antiferritin"""@eng , """I131-AFI"""@eng ; """3218"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0280029"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000440029"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB IDEC-C2B8/PRED/rhuMAb VEGF/VCR"""@eng ; ; ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-06"""^^xsd:string ; """2005-07-15"""^^xsd:string ; umls:cui """C1831671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized gallbladder cancer"""@eng ; skos:notation """CDR0000038748"""^^xsd:string ; skos:altLabel """gallbladder cancer, localized"""@eng ; rdfs:subClassOf ; """gallbladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1187"""^^xsd:string ; """2004-12-14"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278806"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unresectable gallbladder cancer"""@eng ; skos:notation """CDR0000038749"""^^xsd:string ; skos:altLabel """gallbladder cancer, unresectable"""@eng ; rdfs:subClassOf ; """gallbladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1188"""^^xsd:string ; """2004-12-14"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278807"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Gonzalez regimen"""@eng ; skos:notation """CDR0000441094"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2005-07-23"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """2005-07-18"""^^xsd:string ; umls:cui """C1831689"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/fludarabine"""@eng ; skos:notation """CDR0000257897"""^^xsd:string ; skos:altLabel """FAMP/MOAB CD52"""@eng ; ; ; """2002-09-12"""^^xsd:string ; """11474"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327792"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thymic carcinoma"""@eng ; skos:notation """CDR0000331691"""^^xsd:string ; skos:altLabel """type C thymoma"""@eng ; rdfs:subClassOf ; """2003-08-24"""^^xsd:string ; """2003-08-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0205969"""^^xsd:string ; umls:cui """C1322286"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """combined thymoma"""@eng ; skos:notation """CDR0000331693"""^^xsd:string ; rdfs:subClassOf ; """2003-08-24"""^^xsd:string ; """2003-08-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1328043"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/prednisone/vincristine"""@eng ; skos:notation """CDR0000040868"""^^xsd:string ; skos:altLabel """COPB"""@eng , """COP-BLEO"""@eng , """CPOB"""@eng , """BLEO/CTX/PRED/VCR"""@eng ; ; ; ; ; """3906"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056272"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/interleukin-2"""@eng ; skos:notation """CDR0000040869"""^^xsd:string ; skos:altLabel """CDDP/5-FU/IL-2"""@eng ; ; ; ; """3907"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """APC8015 vaccine"""@eng ; skos:notation """CDR0000038038"""^^xsd:string ; skos:altLabel """Provenge"""@eng , """PAP-pulsed dendritic cells"""@eng , """PAP-loaded dendritic cells"""@eng , """Sipuleucel-T"""@eng , """APC 8015"""@eng ; skos:definition """A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38038&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38038&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1985\" NCI Thesaurus)"""@eng ; ; """10559"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1985"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135133"""^^xsd:string ; umls:cui """C0879584"""^^xsd:string ; umls:cui """C1706668"""^^xsd:string ; umls:cui """C1135134"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-small cell lung cancer"""@eng ; skos:notation """CDR0000040862"""^^xsd:string ; skos:altLabel """NSCLC"""@eng , """nonsmall cell lung cancer"""@eng , """lung cancer, nonsmall cell"""@eng , """Lung cancer, non-small cell"""@eng , """non-oat cell lung cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """39"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007131"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interferon"""@eng ; skos:notation """CDR0000040863"""^^xsd:string ; skos:altLabel """IFN"""@eng , """human fibroblast interferon"""@eng , """human leukocyte interferon"""@eng , """human lymphoblastoid interferon"""@eng ; """C584"""^^xsd:string ; """390"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1522537"""^^xsd:string ; umls:cui """C0021747"""^^xsd:string ; umls:cui """C0733469"""^^xsd:string ; umls:cui """C0733470"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """m-azidopyrimethamine"""@eng ; skos:notation """CDR0000040860"""^^xsd:string ; skos:altLabel """MZP"""@eng ; skos:definition """An antifolate derived from diaminopyrimidine with cytotoxic properties. With a mechanism of action similar to that of methotrexate (MTX), m-azidopyrimethamine blocks tetrahydrofolate synthesis, resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. This agent is more lipophilic but less potent than MTX. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40860&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40860&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2366\" NCI Thesaurus)"""@eng ; """3898"""^^xsd:string ; """382050"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2366"""^^xsd:string ; umls:cui """C0280485"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ImuVert"""@eng ; skos:notation """CDR0000040861"""^^xsd:string ; skos:altLabel """Serratia marcescens extract"""@eng ; """3899"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1524034"""^^xsd:string ; umls:cui """C0063444"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040866"""^^xsd:string ; skos:altLabel """COP-BLAM"""@eng , """BLEO/CTX/DOX/PCB/PRED/VCR"""@eng , """CAP-BOP"""@eng ; ; ; ; ; ; ; """3904"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056273"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040867"""^^xsd:string ; skos:altLabel """CAVPB"""@eng , """BACOP"""@eng , """CHOP-BLEO"""@eng , """CA-BOP"""@eng , """BLEO/CTX/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """3905"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055599"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/cyclophosphamide/dactinomycin/vinblastine"""@eng ; skos:notation """CDR0000040864"""^^xsd:string ; skos:altLabel """BLEO/CDDP/CTX/DACT/VBL"""@eng , """VAB-6"""@eng , """VAB-V"""@eng ; ; ; ; ; ; """3902"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280488"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide"""@eng ; skos:notation """CDR0000040865"""^^xsd:string ; skos:altLabel """BEP"""@eng , """BLEO/CDDP/VP-16"""@eng , """PEB"""@eng , """PVP-16B"""@eng ; ; ; ; """3903"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053334"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estradiol/norethindrone"""@eng ; skos:notation """CDR0000043368"""^^xsd:string ; skos:altLabel """ESDL/NORETHIN"""@eng ; ; ; """7915"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1527331"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temsirolimus"""@eng ; skos:notation """CDR0000043369"""^^xsd:string ; skos:altLabel """CCI-779"""@eng , """Rapamycin Analog"""@eng , """Rapamycin Analog CCI-779"""@eng , """CCI-779 Rapamycin Analog"""@eng , """42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin"""@eng , """Cell Cycle Inhibitor 779"""@eng ; skos:definition """An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43369&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43369&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1844\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """61010"""^^xsd:string ; """162635-04-3"""^^xsd:string ; """7917"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C1844"""^^xsd:string ; """683864"""^^xsd:string ; umls:cui """C1707080"""^^xsd:string ; umls:cui """C0796512"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiestrogen therapy"""@eng ; skos:notation """CDR0000039008"""^^xsd:string ; skos:altLabel """therapy, antiestrogen"""@eng ; ; rdfs:subClassOf ; """1571"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0854638"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """replacement therapy"""@eng ; skos:notation """CDR0000039009"""^^xsd:string ; skos:altLabel """therapy, replacement"""@eng ; ; rdfs:subClassOf ; """1572"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279033"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III endometrial cancer"""@eng ; skos:notation """CDR0000038741"""^^xsd:string ; skos:altLabel """uterine cancer, stage III"""@eng , """endometrial cancer, stage III"""@eng , """stage III uterine cancer"""@eng , """endometrial carcinoma, stage III"""@eng , """stage III cancer of the endometrium"""@eng , """stage III carcinoma of the endometrium"""@eng , """cancer of the endometrium, stage III"""@eng , """carcinoma of the endometrium, stage III"""@eng ; rdfs:subClassOf ; """endometrial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1180"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278800"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/cyclophosphamide/thiotepa"""@eng ; skos:notation """CDR0000043360"""^^xsd:string ; skos:altLabel """CBDCA/CTX/TSPA/WR-2721"""@eng ; ; ; ; ; """7906"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796504"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IVA pancreatic cancer"""@eng ; skos:notation """CDR0000043361"""^^xsd:string ; skos:altLabel """pancreatic cancer, stage IVA"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7907"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1168204"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IVB pancreatic cancer"""@eng ; skos:notation """CDR0000043362"""^^xsd:string ; skos:altLabel """pancreatic cancer, stage IVB"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7908"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1168206"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioisotope therapy"""@eng ; skos:notation """CDR0000039007"""^^xsd:string ; skos:altLabel """therapy, isotope, radioactive"""@eng , """radioactive isotope therapy"""@eng ; ; ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """1569"""^^xsd:string ; umls:cui """C0203608"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000043364"""^^xsd:string ; skos:altLabel """IDEC In2B8"""@eng , """IDEC-In2B8"""@eng , """In111 ibritumomab tiuxetan"""@eng , """In 111 Ibritumomab Tiuxetan"""@eng ; skos:definition """A targeted radioimmunoconjugate composed of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by a chelator (tiuxetan) to the imaging radioisotope indium-111. This radioimmunoconjugate binds to CD20-positive cells, permitting radioimmuno-localization of CD20-positive cell biodistribution. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43364&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43364&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2579\" NCI Thesaurus)"""@eng ; ; ; """7910"""^^xsd:string ; """C2579"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """950023"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C1527183"""^^xsd:string ; umls:cui """C0796508"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IDEC-In2B8/rituximab"""@eng ; skos:notation """CDR0000043365"""^^xsd:string ; skos:altLabel """IDEC-In2B8/MOAB IDEC-C2B8"""@eng ; ; ; """7911"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """syngeneic bone marrow transplantation"""@eng ; skos:notation """CDR0000039002"""^^xsd:string ; skos:altLabel """transplantation, syngeneic bone marrow"""@eng , """bone marrow transplantation, syngeneic"""@eng ; ; rdfs:subClassOf ; """1563"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279026"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/oxaliplatin"""@eng ; skos:notation """CDR0000043367"""^^xsd:string ; skos:altLabel """5-FU/L-OHP"""@eng ; ; ; """7914"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/etoposide"""@eng ; skos:notation """CDR0000041735"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DM/VP-16"""@eng ; ; ; ; ; """4906"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281322"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/dexamethasone/ifosfamide/mercaptopurine/methotrexate/vindesine"""@eng ; skos:notation """CDR0000041734"""^^xsd:string ; skos:altLabel """ASP/DAVA/DM/DNR/IFF/MP/MTX"""@eng ; ; ; ; ; ; ; ; """4905"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281321"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/teniposide"""@eng ; skos:notation """CDR0000041737"""^^xsd:string ; skos:altLabel """ARA-C/IDA/VM-26"""@eng ; ; ; ; """4909"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281324"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/doxorubicin/etoposide/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000041736"""^^xsd:string ; skos:altLabel """DACT/DOX/IFF/VCR/VP-16"""@eng ; ; ; ; ; ; """4908"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281323"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """physiotherapy"""@eng ; skos:notation """CDR0000041731"""^^xsd:string ; ; rdfs:subClassOf ; """4901"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0949766"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiangiogenesis therapy"""@eng ; skos:notation """CDR0000041730"""^^xsd:string ; ; rdfs:subClassOf ; """4900"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281318"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041733"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DNR/MP/MTX/VCR"""@eng ; ; ; ; ; ; ; ; """4904"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281320"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/doxorubicin/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000041732"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DNR/DOX/MP/VCR"""@eng ; ; ; ; ; ; ; ; """4903"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281319"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-1 KLH vaccine"""@eng ; skos:notation """CDR0000038032"""^^xsd:string ; skos:altLabel """MUC-1-KLH VAC"""@eng ; ; """10547"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879579"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic GM-CSF-secreting breast cancer vaccine/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000392728"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF BREAST VAC"""@eng ; ; ; ; """2004-09-17"""^^xsd:string ; """2004-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541367"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/paclitaxel"""@eng ; skos:notation """CDR0000041739"""^^xsd:string ; skos:altLabel """CYSP/TAX"""@eng ; ; ; """4910"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281325"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plicamycin"""@eng ; skos:notation """CDR0000041738"""^^xsd:string ; skos:altLabel """mithramycin"""@eng , """A-2371"""@eng , """Mithracin"""@eng , """Mithracine"""@eng , """PA-144"""@eng , """MTH"""@eng , """Mith"""@eng , """Aureolic acid"""@eng ; skos:definition """An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41738&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41738&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C658\" NCI Thesaurus)"""@eng ; """491"""^^xsd:string ; """24559"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C658"""^^xsd:string ; """18378-89-7"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """915"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0702002"""^^xsd:string ; umls:cui """C0702003"""^^xsd:string ; umls:cui """C0702001"""^^xsd:string ; umls:cui """C0026234"""^^xsd:string ; umls:cui """C1514184"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-1 KLH vaccine/QS21"""@eng ; skos:notation """CDR0000038033"""^^xsd:string ; skos:altLabel """MUC-1-KLH VAC/QS 21"""@eng ; ; ; """10548"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879580"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small intestine leiomyosarcoma"""@eng ; skos:notation """CDR0000038746"""^^xsd:string ; skos:altLabel """small bowel leiomyosarcoma"""@eng , """leiomyosarcoma, small intestine"""@eng ; rdfs:subClassOf ; """small intestine cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1185"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0920305"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gallbladder cancer"""@eng ; skos:notation """CDR0000038747"""^^xsd:string ; skos:altLabel """Gallbladder cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1186"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153452"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/GTI-2040"""@eng ; skos:notation """CDR0000343780"""^^xsd:string ; skos:altLabel """GTI2040/TXT"""@eng ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328099"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/oblimersen"""@eng ; skos:notation """CDR0000347069"""^^xsd:string ; skos:altLabel """ARA-C/G3139"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """2003-11-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328115"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor-draining lymph node lymphocyte therapy"""@eng ; skos:notation """CDR0000041883"""^^xsd:string ; ; rdfs:subClassOf ; """5097"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281444"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cryosurgery"""@eng ; skos:notation """CDR0000041882"""^^xsd:string ; skos:altLabel """cryotherapy"""@eng ; ; rdfs:subClassOf ; """5096"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0010408"""^^xsd:string ; umls:cui """C0010412"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edatrexate/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000041881"""^^xsd:string ; skos:altLabel """EDAM/G-CSF/TAX"""@eng ; ; ; ; """5094"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281443"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/paclitaxel"""@eng ; skos:notation """CDR0000041880"""^^xsd:string ; skos:altLabel """EM/TAX"""@eng ; ; ; """5093"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-3/interleukin-6"""@eng ; skos:notation """CDR0000041887"""^^xsd:string ; skos:altLabel """IL-3/IL-6"""@eng ; ; ; """5103"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281445"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000041886"""^^xsd:string ; skos:altLabel """CAMP"""@eng , """AMSA/CTX/VP-16"""@eng ; ; ; ; """510"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278621"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic osteosarcoma"""@eng ; skos:notation """CDR0000041885"""^^xsd:string ; skos:altLabel """metastatic osteogenic sarcoma"""@eng , """osteosarcoma, metastatic"""@eng , """sarcoma, metastatic osteogenic"""@eng , """osteogenic sarcoma, metastatic"""@eng ; rdfs:subClassOf ; """osteosarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """51"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278512"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/methotrexate/PALA/triacetyluridine"""@eng ; skos:notation """CDR0000041889"""^^xsd:string ; skos:altLabel """CF/5-FU/MTX/PALA/TAU"""@eng ; ; ; ; ; ; """5105"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281447"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/milodistim"""@eng ; skos:notation """CDR0000041888"""^^xsd:string ; skos:altLabel """CBDCA/IFF/PIXY321/VP-16"""@eng ; ; ; ; ; """5104"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281446"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypnosis"""@eng ; skos:notation """CDR0000470289"""^^xsd:string ; rdfs:subClassOf ; """Preventative intervention/procedure"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """2006-02-23"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0020587"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """protein expression"""@eng ; skos:notation """CDR0000474415"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """Diagnostic test/procedure"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1171362"""^^xsd:string ; umls:tui """T045"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine"""@eng ; skos:notation """CDR0000442270"""^^xsd:string ; skos:altLabel """HPV 16/18 L1 VLP/AS04 VAC"""@eng ; skos:definition """A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=442270&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=442270&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48395\" NCI Thesaurus)"""@eng ; """2005-08-05"""^^xsd:string ; """C48395"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-27"""^^xsd:string ; umls:cui """C1708391"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fully human anti-alpha-v integrin monoclonal antibody"""@eng ; skos:notation """CDR0000473196"""^^xsd:string ; skos:altLabel """Human Anti-Alpha-V Integrin Monoclonal Antibody"""@eng , """CNTO 95"""@eng ; skos:definition """A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with antiangiogenic and antitumor activities. Fully human anti-alpha-v integrin monoclonal antibody competitively binds to and blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth. Integrins facilitatethe adhesion of stimulated endothelial cells to the extracellular matrix (ECM); trigger the secretion of ECM-rearranging proteases and; propagatesignaling events that promote the survival and differentiation ofcells in newly formed vasculature. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473196&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473196&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61070\" NCI Thesaurus)"""@eng ; """C61070"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831772"""^^xsd:string ; umls:cui """C1452279"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I mantle cell lymphoma"""@eng ; skos:notation """CDR0000042713"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6507"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677683"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/docetaxel/estramustine/goserelin"""@eng ; skos:notation """CDR0000357941"""^^xsd:string ; skos:altLabel """CDX/LEUP/TXT/ZDX"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541572"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody KW-2871"""@eng ; skos:notation """CDR0000467926"""^^xsd:string ; skos:definition """A low-fucose, human-mouse chimeric IgG1 monoclonal antibody directed against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, with potential antineoplastic activity. Monoclonal antibody KW-2871 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. This agent is prepared by fusing murine immunoglobulin (Ig) light and heavy variable regions derived from the murine IgG3 antibody KM-641 to a human constant (Fc) region. The low fucose content of the oligosaccharide side chains of this antibody may enhance binding of the antibody Fc region to lymphocyte Fc receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467926&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467926&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61095\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """C61095"""^^xsd:string ; """2006-07-17"""^^xsd:string ; umls:cui """C1831744"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Angelica sinensis extract"""@eng ; skos:notation """CDR0000467927"""^^xsd:string ; skos:altLabel """dong quai"""@eng ; skos:definition """An herbal extract derived from the root of the plant Angelica sinensis with possible antiinflammatory, antispasmodic, vasodilatory, estrogenic, and antitumor activities. Angelica sinensis contains volatile oils, including safrole, isosafrole, and n-butylphthalide; coumarin derivatives, including psoralens, bergapten, osthol, imperatorin, and oxypeucedanin; and ferulic acid. The coumarin derivatives in this agent may vasodilate and relax smooth muscle and may exhibit additive anticoagulant effects. Ferulic acid, a phenolic phytochemical present in plant cell walls, may neutralize free radicals such as reactive oxygen species.In addition, Angelica sinensis extract has been shown to inhibit the growth and induce apoptosis of glioblastoma mutltiforme brain tumor cells through p53-dependent and p53-independent pathways. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467927&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467927&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60817\" NCI Thesaurus)"""@eng ; """2006-02-10"""^^xsd:string ; """C60817"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-11"""^^xsd:string ; umls:cui """C1122975"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypertonic saline"""@eng ; skos:notation """CDR0000467928"""^^xsd:string ; skos:altLabel """HTS"""@eng ; skos:definition """Any solution of sodium chloride (NaCl) in water with a concentration of NaCl higher than physiologic (0.9% w/v). When administered in vivo, hypertonic saline (HTS) exhbits several physiological effects beneficial to cerebral injury including: 1) osmotic and vasoregulatory - by promoting the flow of excess water from cerebral tissue to the blood via osmosis and decreasing edema in the vascular endothelium of injured tissues, thus lowering vascular resistance and allowing more blood flow; 2) hemodymanic - by effectively expanding plasma volume; 3) immunomodulatory - by preventing leukocytes from becoming activated and adhering to injured neurons and; 4) neurochemical - by counteracting detrimental excitatory amino acids through the normalization of neuronal cell membranes and by restoration of normal electrolyte and neurotransmitter levels in brain cells, and normal cell volumes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467928&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467928&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60814\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-14"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """C60814"""^^xsd:string ; umls:cui """C0036085"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ferrous sulfate"""@eng ; skos:notation """CDR0000467929"""^^xsd:string ; skos:altLabel """Iron(II) Sulfate"""@eng ; skos:definition """A sulfate salt of mineral iron formulated for oral administration and used as a dietary supplement, ferrous sulfate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is a component of many enzymes such as catalase, peroxidase, and cytochromes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467929&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467929&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29049\" NCI Thesaurus)"""@eng ; """2006-02-10"""^^xsd:string ; """7720-78-7"""^^xsd:string ; """C29049"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0060282"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/tamoxifen"""@eng ; skos:notation """CDR0000038209"""^^xsd:string ; skos:altLabel """TMX/TXT"""@eng ; ; ; """10810"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935785"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute myeloid leukemia/other myeloid malignancies"""@eng ; skos:notation """CDR0000038208"""^^xsd:string ; skos:altLabel """myeloid leukemia, pediatric acute"""@eng , """acute non-lymphoblastic leukemia, childhood"""@eng , """nonlymphoblastic leukemia, childhood acute"""@eng , """acute nonlymphoblastic leukemia, pediatric"""@eng , """leukemia, pediatric acute myeloid"""@eng , """leukemia, pediatric acute nonlymphoblastic"""@eng , """pediatric leukemia, acute myelogenous"""@eng , """Leukemia, acute myeloid (AML), child"""@eng , """myelogenous leukemia, pediatric acute"""@eng , """acute nonlymphocytic leukemia, childhood"""@eng , """pediatric acute nonlymphoblastic leukemia"""@eng , """non-lymphoblastic leukemia, childhood acute"""@eng , """acute non-lymphoblastic leukemia, pediatric"""@eng , """acute nonlymphocytic leukemia, pediatric"""@eng , """pediatric ANLL"""@eng , """childhood ANLL"""@eng , """leukemia, childhood acute non-lymphoblastic"""@eng , """pediatric leukemia, acute myeloid"""@eng , """pediatric leukemia, acute nonlymphoblastic"""@eng , """leukemia, pediatric acute nonlymphocytic"""@eng , """myeloid leukemia, childhood acute"""@eng , """childhood acute non-lymphoblastic leukemia"""@eng , """acute non-lymphocytic leukemia, childhood"""@eng , """leukemia, childhood acute myeloid"""@eng , """acute myelogenous leukemia, pediatric"""@eng , """childhood acute nonlymphoblastic leukemia"""@eng , """ANLL, childhood"""@eng , """pediatric acute non-lymphoblastic leukemia"""@eng , """childhood leukemia, acute nonlymphocytic"""@eng , """AML, pediatric"""@eng , """pediatric AML"""@eng , """leukemia, childhood acute non-lymphocytic"""@eng , """childhood leukemia, acute non-lymphocytic"""@eng , """pediatric acute non-lymphocytic leukemia"""@eng , """pediatric leukemia, acute nonlymphocytic"""@eng , """pediatric acute myelocytic leukemia"""@eng , """acute myelocytic leukemia, childhood"""@eng , """myelogenous leukemia, childhood acute"""@eng , """leukemia, childhood acute nonlymphoblastic"""@eng , """acute myeloid leukemia, pediatric"""@eng , """leukemia, pediatric acute myelogenous"""@eng , """acute myelogenous leukemia, childhood"""@eng , """pediatric acute myeloid leukemia"""@eng , """ANLL, pediatric"""@eng , """childhood leukemia, acute non-lymphoblastic"""@eng , """childhood leukemia, acute nonlymphoblastic"""@eng , """acute non-lymphocytic leukemia, pediatric"""@eng , """myelocytic leukemia, childhood acute"""@eng , """childhood acute nonlymphocytic leukemia"""@eng , """pediatric leukemia, acute non-lymphocytic"""@eng , """childhood acute myelogenous leukemia"""@eng , """nonlymphoblastic leukemia, pediatric acute"""@eng , """nonlymphocytic leukemia, childhood acute"""@eng , """nonlymphocytic leukemia, pediatric acute"""@eng , """non-lymphocytic leukemia, childhood acute"""@eng , """childhood leukemia, acute myelogenous"""@eng , """leukemia, pediatric acute non-lymphocytic"""@eng , """pediatric leukemia, acute non-lymphoblastic"""@eng , """pediatric acute nonlymphocytic leukemia"""@eng , """AML, childhood"""@eng , """leukemia, pediatric acute non-lymphoblastic"""@eng , """acute nonlymphoblastic leukemia, childhood"""@eng , """childhood leukemia, acute myeloid"""@eng , """pediatric acute myelogenous leukemia"""@eng , """childhood acute non-lymphocytic leukemia"""@eng , """non-lymphoblastic leukemia, pediatric acute"""@eng , """acute myeloid leukemia, childhood"""@eng , """childhood acute myelocytic leukemia"""@eng , """leukemia, childhood acute myelogenous"""@eng , """non-lymphocytic leukemia, pediatric acute"""@eng , """childhood AML"""@eng , """leukemia, childhood acute nonlymphocytic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2002-09-12"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1081"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1321871"""^^xsd:string ; umls:cui """C0220621"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EGFR antisense DNA"""@eng ; skos:notation """CDR0000038201"""^^xsd:string ; skos:definition """A synthetic sequence of DNA constructed in the antisense orientation to a sequence of DNA in epidermal growth factor receptor (EGFR), a member of the erbB gene family. EGFR antisense DNA suppresses the expression of EGFR by tumor cells, thereby inhibiting tumor cell proliferation and decreasing tumor growth. This agent also appears to reduce the invasiveness of certain breast cancer cells. Members of the erbB gene family are overexpressed in many cancers and play roles in carcinogenesis and the regulation of cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38201&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38201&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2617\" NCI Thesaurus)"""@eng ; ; ; ; """10802"""^^xsd:string ; """C2617"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-01"""^^xsd:string ; umls:cui """C0935778"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/imatinib mesylate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038200"""^^xsd:string ; skos:altLabel """DNR/PRED/STI571/VCR"""@eng ; ; ; ; ; """10801"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935777"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DC-chol liposomes/EGFR antisense DNA"""@eng ; skos:notation """CDR0000038203"""^^xsd:string ; skos:altLabel """DC-CHOL LIP/EGFR antiDNA"""@eng ; ; ; """10804"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935780"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DC-chol liposomes"""@eng ; skos:notation """CDR0000038202"""^^xsd:string ; skos:altLabel """DC-CHOL LIP"""@eng ; ; """10803"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935779"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol/paclitaxel"""@eng ; skos:notation """CDR0000038205"""^^xsd:string ; skos:altLabel """CALTROL/TAX"""@eng ; ; ; """10806"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935782"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/irinotecan"""@eng ; skos:notation """CDR0000038204"""^^xsd:string ; skos:altLabel """CBDCA/CPT-11"""@eng ; ; ; """10805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935781"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/tamoxifen"""@eng ; skos:notation """CDR0000038207"""^^xsd:string ; skos:altLabel """EPI/TMX"""@eng ; ; ; """10809"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935784"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/fluorouracil-uracil/leucovorin calcium"""@eng ; skos:notation """CDR0000038206"""^^xsd:string ; skos:altLabel """CF/UFT/VP-16"""@eng ; ; ; ; """10808"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935783"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edrecolomab/sargramostim"""@eng ; skos:notation """CDR0000042284"""^^xsd:string ; skos:altLabel """GM-CSF/MOAB 17-1A"""@eng ; ; ; """5530"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338221"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tretinoin liposome"""@eng ; skos:notation """CDR0000042285"""^^xsd:string ; skos:altLabel """All-trans-retinoic acid liposomal"""@eng , """L-ATRA"""@eng , """Atragen"""@eng , """Tretinoin Liposomal"""@eng , """liposomal all-trans-retinoic acid"""@eng , """liposomal tretinoin"""@eng , """AR-623"""@eng ; skos:definition """An intravenous formulation of tretinoin (vitamin A acid or all-trans retinoic acid) encased in liposomes. Tretinoin is a naturally occurring retinoic acid agent that binds to and activates retinoic acid receptors (RAR), effecting changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of carcinogenesis. This agent also inhibits telomerase, leading to telomere shortening and eventual apoptosis of certain tumor cell types. Liposome encapsulation extends the half-life of intravenously administered tretinoin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42285&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42285&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2398\" NCI Thesaurus)"""@eng ; ; ; ; ; """5531"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C2398"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328678"""^^xsd:string ; umls:cui """C0338222"""^^xsd:string ; umls:cui """C1331605"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody 2B1"""@eng ; skos:notation """CDR0000042286"""^^xsd:string ; skos:altLabel """MoAb 2B1 Bispecific"""@eng , """2B1 Bispecific MAb"""@eng , """2B1 antibody, bispecific"""@eng , """BsAb 2B1"""@eng , """2B1"""@eng , """2B1 Bispecific Murine MAb"""@eng ; skos:definition """A monoclonal antibody with potential antineoplastic activity. Specific for both the immunoglobulin G (IgG) receptor CD16 and c-erbB-2, bispecific antibody 2B1 may enhance cellular immune responses against c-erbB-2-positive cells, resulting in increased tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42286&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42286&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2399\" NCI Thesaurus)"""@eng ; """5532"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """673928"""^^xsd:string ; """C2399"""^^xsd:string ; """6002"""^^xsd:string ; umls:cui """C0338223"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone/tretinoin liposome"""@eng ; skos:notation """CDR0000042287"""^^xsd:string ; skos:altLabel """DHAD/L-ATRA/VP-16"""@eng ; ; ; ; """5533"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338224"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interferon alfa"""@eng ; skos:notation """CDR0000042280"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IFN-A"""@eng ; ; ; ; """5526"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338217"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042281"""^^xsd:string ; skos:altLabel """ARA-C/CTX/TG/VCR"""@eng ; ; ; ; ; """5527"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338218"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000042282"""^^xsd:string ; skos:altLabel """CTX/DNR/PEG-ASP/PRED/VCR"""@eng ; ; ; ; ; ; """5528"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338219"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042283"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/PEG-ASP/VCR"""@eng ; ; ; ; ; ; """5529"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338220"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/tretinoin liposome"""@eng ; skos:notation """CDR0000042288"""^^xsd:string ; skos:altLabel """ARA-C/L-ATRA"""@eng ; ; ; """5534"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338225"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """staphage lysate"""@eng ; skos:notation """CDR0000042289"""^^xsd:string ; ; """5535"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0075166"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """esterified estrogens"""@eng ; skos:notation """CDR0000443633"""^^xsd:string ; skos:altLabel """Estratab"""@eng , """Menest"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-08-12"""^^xsd:string ; """2005-08-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0721660"""^^xsd:string ; umls:cui """C0717752"""^^xsd:string ; umls:cui """C0662514"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intestinal adenocarcinoma of the stomach"""@eng ; skos:notation """CDR0000039918"""^^xsd:string ; skos:altLabel """stomach cancer, intestinal adenocarcinoma"""@eng , """gastric cancer, intestinal adenocarcinoma"""@eng , """stomach, intestinal adenocarcinoma of the"""@eng ; rdfs:subClassOf ; """2599"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279633"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039919"""^^xsd:string ; skos:altLabel """leukemia, acute lymphoblastic, pediatric"""@eng , """lymphocytic leukemia, acute, pediatric"""@eng , """acute lymphocytic leukemia, pediatric"""@eng , """childhood acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, childhood"""@eng , """ALL, childhood"""@eng , """acute lymphocytic leukemia, childhood"""@eng , """Leukemia, acute lymphocytic (ALL), child"""@eng , """leukemia, acute lymphocytic, childhood"""@eng , """pediatric acute lymphocytic leukemia"""@eng , """ALL, pediatric"""@eng , """lymphocytic leukemia, acute, childhood"""@eng , """lymphoblastic leukemia, acute, pediatric"""@eng , """childhood leukemia, acute lymphocytic"""@eng , """lymphoblastic leukemia, acute, childhood"""@eng , """pediatric ALL"""@eng , """childhood leukemia, acute lymphoblastic"""@eng , """leukemia, acute lymphocytic, pediatric"""@eng , """pediatric leukemia, acute lymphocytic"""@eng , """childhood ALL"""@eng , """acute lymphoblastic leukemia, pediatric"""@eng , """leukemia, acute lymphoblastic, childhood"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """26"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023452"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute basophilic leukemia"""@eng ; skos:notation """CDR0000039916"""^^xsd:string ; skos:altLabel """basophilic leukemia, adult acute"""@eng , """acute basophilic leukemia, adult"""@eng , """leukemia, adult acute basophilic"""@eng ; rdfs:subClassOf ; """2597"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279631"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute megakaryoblastic leukemia (M7)"""@eng ; skos:notation """CDR0000039917"""^^xsd:string ; skos:altLabel """M7 adult acute megakaryocytic leukemia"""@eng , """acute megakaryocytic leukemia, adult"""@eng , """leukemia, adult acute megakaryocytic"""@eng , """megakaryocytic leukemia, adult acute"""@eng ; rdfs:subClassOf ; """2004-06-21"""^^xsd:string ; """2598"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279632"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute monoblastic leukemia (M5a)"""@eng ; skos:notation """CDR0000039914"""^^xsd:string ; skos:altLabel """adult acute M5a leukemia"""@eng , """adult acute poorly differentiated monoblastic leukemia"""@eng , """monoblastic leukemia, adult acute"""@eng , """leukemia, adult acute monoblastic"""@eng , """M5a adult acute poorly differentiated monocytic leukemia"""@eng , """acute monoblastic leukemia, adult"""@eng , """M5a leukemia, adult acute"""@eng ; rdfs:subClassOf ; ; ; """2004-06-21"""^^xsd:string ; """2595"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279629"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute eosinophilic leukemia"""@eng ; skos:notation """CDR0000039915"""^^xsd:string ; skos:altLabel """leukemia, adult acute eosinophilic"""@eng , """acute eosinophilic leukemia, adult"""@eng , """eosinophilic leukemia, adult acute"""@eng ; rdfs:subClassOf ; """2596"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279630"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myelomonocytic leukemia (M4)"""@eng ; skos:notation """CDR0000039912"""^^xsd:string ; skos:altLabel """acute myelomonocytic leukemia, adult"""@eng , """myelomonocytic leukemia, adult acute"""@eng , """leukemia, adult acute myelomonocytic"""@eng , """adult acute myelomonoblastic leukemia"""@eng , """myelomonoblastic leukemia, adult acute"""@eng , """adult acute M4 leukemia"""@eng , """AMMoL, adult"""@eng , """M4 leukemia, adult acute"""@eng , """acute myelomonoblastic leukemia, adult"""@eng , """adult AMML"""@eng , """adult AMMoL"""@eng , """AMML, adult"""@eng , """M4 adult acute myelomonocytic leukemia"""@eng ; rdfs:subClassOf ; ; ; ; """2593"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279627"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the esophagus"""@eng ; skos:notation """CDR0000039913"""^^xsd:string ; skos:altLabel """esophagus cancer, adenocarcinoma"""@eng , """esophageal cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2594"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279628"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute promyelocytic leukemia (M3)"""@eng ; skos:notation """CDR0000039910"""^^xsd:string ; skos:altLabel """adult acute progranulocytic leukemia"""@eng , """progranulocytic leukemia, adult acute"""@eng , """APL, adult"""@eng , """adult APL"""@eng , """promyelocytic leukemia, adult acute"""@eng , """acute promyelocytic leukemia, adult"""@eng , """acute progranulocytic leukemia, adult"""@eng , """M3 leukemia, adult acute"""@eng , """leukemia, adult acute promyelocytic"""@eng , """adult acute M3 leukemia"""@eng , """M3 adult acute promyelocytic leukemia"""@eng ; rdfs:subClassOf ; ; """2591"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279625"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of the esophagus"""@eng ; skos:notation """CDR0000039911"""^^xsd:string ; skos:altLabel """squamous cell esophageal cancer"""@eng , """esophageal cancer, squamous cell"""@eng , """esophagus cancer, squamous cell"""@eng , """squamous cell esophagus cancer"""@eng ; rdfs:subClassOf ; """2592"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279626"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent vulvar cancer"""@eng ; skos:notation """CDR0000037950"""^^xsd:string ; skos:altLabel """cancer of the vulva, recurrent"""@eng , """carcinoma of the vulva, recurrent"""@eng , """recurrent vulva cancer"""@eng , """vulva cancer, recurrent"""@eng , """recurrent carcinoma of the vulva"""@eng , """vulvar cancer, recurrent"""@eng , """recurrent cancer of the vulva"""@eng ; rdfs:subClassOf ; """vulvar cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1037"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278734"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/flt3 ligand/milodistim/sargramostim"""@eng ; skos:notation """CDR0000037951"""^^xsd:string ; skos:altLabel """Flt3L/G-CSF/GM-CSF/PIXY321"""@eng ; ; ; ; ; """10370"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879491"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody MDX447"""@eng ; skos:notation """CDR0000037952"""^^xsd:string ; skos:altLabel """MDX-447"""@eng , """EMD 82633"""@eng , """BsAb MDX447"""@eng ; skos:definition """An antibody with potential antineoplastic activity. Specific for both the high-affinity immunoglobulin G (IgG) receptor CD64 and epidermal growth factor receptor (EGFR), bispecific antibody MDX447 may enhance cellular immune responses against EGFR positive cells, resulting in increased tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37952&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37952&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2207\" NCI Thesaurus)"""@eng ; ; """10371"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2207"""^^xsd:string ; umls:cui """C0879492"""^^xsd:string ; umls:cui """C1527214"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody MDX447/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000037953"""^^xsd:string ; skos:altLabel """BsAb MDX447/LAK"""@eng ; ; ; """10372"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/SU5416"""@eng ; skos:notation """CDR0000037954"""^^xsd:string ; skos:altLabel """DOX/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10373"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879494"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/efaproxiral"""@eng ; skos:notation """CDR0000037955"""^^xsd:string ; skos:altLabel """BCNU/RSR13"""@eng ; ; ; """2002-12-23"""^^xsd:string ; """10374"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/mitoxantrone/vinorelbine"""@eng ; skos:notation """CDR0000037956"""^^xsd:string ; skos:altLabel """DHAD/EM/VNB"""@eng ; ; ; ; """10375"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879496"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/isotretinoin/paclitaxel"""@eng ; skos:notation """CDR0000037957"""^^xsd:string ; skos:altLabel """13-CRA/IFN-A/TAX"""@eng ; ; ; ; """10376"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879497"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/irinotecan"""@eng ; skos:notation """CDR0000037958"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/5-FU"""@eng ; ; ; ; """10377"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879498"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide phosphate/melphalan/topotecan"""@eng ; skos:notation """CDR0000037959"""^^xsd:string ; skos:altLabel """ETOP/L-PAM/TOPO"""@eng ; ; ; ; """10378"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879499"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/mitomycin/mitoxantrone"""@eng ; skos:notation """CDR0000361813"""^^xsd:string ; skos:altLabel """DHAD/MITO/MTX"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541191"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/mitoxantrone"""@eng ; skos:notation """CDR0000361812"""^^xsd:string ; skos:altLabel """DHAD/MTX"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541190"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nadroparin calcium"""@eng ; skos:notation """CDR0000483128"""^^xsd:string ; skos:altLabel """nadroparin"""@eng , """Fraxiparine"""@eng ; skos:definition """A low molecular weight heparin (LMWH) composed of a heterogeneous mixture of sulfated polysaccharide glycosaminoglycan chains obtained by depolymerisation of porcine mucosal sodium heparin, extraction/purification and conversion to the calcium salt. Nadroparin binds to antithrombin III (ATIII) and inhibits the activity of activated factor X (factor Xa), thereby inhibiting the final common pathway of the coagulation cascade and preventing the formation of a cross-linked fibrin clot. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=483128&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=483128&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61320\" NCI Thesaurus)"""@eng ; """C61320"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-05"""^^xsd:string ; """2006-07-06"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0206232"""^^xsd:string ; umls:cui """C0878354"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/gefitinib"""@eng ; skos:notation """CDR0000433202"""^^xsd:string ; skos:altLabel """CAPE/ZD 1839"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-05"""^^xsd:string ; umls:cui """C1831617"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/fluorouracil"""@eng ; skos:notation """CDR0000368790"""^^xsd:string ; skos:altLabel """5-FU/MOAB C225"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-04-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541234"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T900607"""@eng ; skos:notation """CDR0000271169"""^^xsd:string ; skos:altLabel """T607"""@eng , """T900607 sodium"""@eng ; skos:definition """A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271169&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271169&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26674\" NCI Thesaurus)"""@eng ; """2003-01-26"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C26674"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327873"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ticilimumab"""@eng ; skos:notation """CDR0000448620"""^^xsd:string ; skos:altLabel """anti-CTLA4 human monoclonal antibody CP-675,206"""@eng , """CP-675,206"""@eng ; skos:definition """A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Ticilimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=448620&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=448620&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49085\" NCI Thesaurus)"""@eng ; """C49085"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-18"""^^xsd:string ; """2005-09-23"""^^xsd:string ; umls:cui """C2351038"""^^xsd:string ; umls:cui """C1948073"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-582664"""@eng ; skos:notation """CDR0000462556"""^^xsd:string ; skos:definition """A vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. BMS-582664 strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462556&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462556&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53397\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """C53397"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-28"""^^xsd:string ; umls:cui """C1701190"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000039646"""^^xsd:string ; skos:altLabel """DOX/VCR/VP-16"""@eng , """VAV"""@eng ; ; ; ; """2301"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078136"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/melphalan/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039647"""^^xsd:string ; skos:altLabel """COMPADRI-V"""@eng , """CTX/DOX/L-PAM/MTX/VCR"""@eng ; ; ; ; ; ; """2302"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279432"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast cancer in situ"""@eng ; skos:notation """CDR0000039644"""^^xsd:string ; skos:altLabel """in situ breast cancer"""@eng , """stage 0 breast cancer"""@eng , """breast cancer, stage 0"""@eng ; rdfs:subClassOf ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """23"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0154084"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/lomustine/methotrexate"""@eng ; skos:notation """CDR0000039645"""^^xsd:string ; skos:altLabel """CHEXM"""@eng , """CCNU/HMM/MTX"""@eng ; ; ; ; """2300"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279430"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/tumor necrosis factor"""@eng ; skos:notation """CDR0000039642"""^^xsd:string ; skos:altLabel """DACT/TNF"""@eng ; ; ; """2298"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279428"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000039643"""^^xsd:string ; skos:altLabel """CDDP/CF/DOX/5-FU"""@eng ; ; ; ; ; """2299"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279429"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/cyclophosphamide/fluorouracil"""@eng ; skos:notation """CDR0000039640"""^^xsd:string ; skos:altLabel """CDDP/CTX/5-FU/HMM"""@eng , """CHEX-UP"""@eng ; ; ; ; ; """2295"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279427"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """folic acid"""@eng ; skos:notation """CDR0000039641"""^^xsd:string ; skos:altLabel """FA"""@eng ; skos:definition """A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to and purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39641&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39641&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C510\" NCI Thesaurus)"""@eng ; ; ; ; ; """2296"""^^xsd:string ; """C510"""^^xsd:string ; """2006-06-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0016410"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000039648"""^^xsd:string ; skos:altLabel """VBMCP"""@eng , """BCNU/CTX/L-PAM/PRED/VCR"""@eng ; ; ; ; ; ; """2303"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/ethinyl estradiol/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000039649"""^^xsd:string ; skos:altLabel """CALF-E"""@eng , """CF/CTX/DOX/ethinyl estradiol/5-FU"""@eng ; ; ; ; ; ; """2304"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279434"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP2D6"""@eng ; skos:notation """CDR0000322898"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1332830"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pazopanib"""@eng ; skos:notation """CDR0000476479"""^^xsd:string ; skos:altLabel """GW786034"""@eng ; skos:definition """A novel small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476479&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476479&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60779\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C60779"""^^xsd:string ; """2006-04-07"""^^xsd:string ; umls:cui """C1831796"""^^xsd:string ; umls:cui """C1327963"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorodopamine F 18"""@eng ; skos:notation """CDR0000363614"""^^xsd:string ; skos:altLabel """18-FDP"""@eng , """18F-fluorodopamine"""@eng , """F-18 fluorodopamine"""@eng , """18 FDP"""@eng ; """2004-03-24"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541202"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody G250"""@eng ; skos:notation """CDR0000373829"""^^xsd:string ; skos:altLabel """Monoclonal Antibody G-250"""@eng , """cG250"""@eng , """Rencarex"""@eng , """WX-G250"""@eng , """MOAB G250"""@eng ; skos:definition """A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, monoclonal antibody G250 (mAb G250) may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373829&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373829&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1960\" NCI Thesaurus)"""@eng ; """2004-05-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1960"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1709068"""^^xsd:string ; umls:cui """C3146299"""^^xsd:string ; umls:cui """C0540128"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """everolimus/gefitinib"""@eng ; skos:notation """CDR0000373823"""^^xsd:string ; skos:altLabel """RAD/ZD 1839"""@eng ; skos:definition """A chemotherapy drug combination consisting of everolimus and gefitinib. Everolimus is a proliferation inhibitor with immunosuppressive and anti-angiogenic properties. Gefitinib is a epidermal growth factor receptor (EGFR) inhibitor with anti-angiogenic activity. This combination chemotherapy may result in increased tumor cell death compared to the use of either agent alone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373823&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373823&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48388\" NCI Thesaurus)"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C48388"""^^xsd:string ; umls:cui """C1541292"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-MUC-1 vaccine/vaccinia-TRICOM vaccine"""@eng ; skos:notation """CDR0000339874"""^^xsd:string ; skos:altLabel """rV-MUC-1/rV-TRICOM"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328073"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim/vaccinia-MUC-1 vaccine/vaccinia-TRICOM vaccine"""@eng ; skos:notation """CDR0000339875"""^^xsd:string ; skos:altLabel """GM-CSF/rV-MUC-1/rV-TRICOM"""@eng ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328074"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/soblidotin"""@eng ; skos:notation """CDR0000339876"""^^xsd:string ; skos:altLabel """dFdC/TZT1027"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328075"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant vaccinia-MUC-1 vaccine"""@eng ; skos:notation """CDR0000339873"""^^xsd:string ; skos:altLabel """rV-MUC-1"""@eng , """Recombinant Vaccina V-MUC-1 Vaccine"""@eng , """Recombinant Vaccinia MUC-1"""@eng , """vaccinia-MUC-1 vaccine"""@eng ; skos:definition """A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=339873&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=339873&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2732\" NCI Thesaurus)"""@eng ; ; ; """2006-09-25"""^^xsd:string ; """2003-10-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """8066"""^^xsd:string ; """694449"""^^xsd:string ; """C2732"""^^xsd:string ; """9710"""^^xsd:string ; umls:cui """C1328072"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/interleukin-2"""@eng ; skos:notation """CDR0000299437"""^^xsd:string ; skos:altLabel """IL-2/MOAB CTLA-4"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2003-09-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327942"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/GM.CD40L cell vaccine"""@eng ; skos:notation """CDR0000430850"""^^xsd:string ; skos:altLabel """ATCV/GM.CD40L"""@eng ; ; ; """2005-04-27"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831607"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood solid tumor"""@eng ; skos:notation """CDR0000039053"""^^xsd:string ; skos:altLabel """solid tumor, childhood"""@eng , """pediatric solid tumor"""@eng ; rdfs:subClassOf ; """1632"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279068"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/topotecan"""@eng ; skos:notation """CDR0000041709"""^^xsd:string ; skos:altLabel """TAX/TOPO"""@eng ; ; ; """4878"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer prevention vaccine"""@eng ; skos:notation """CDR0000491925"""^^xsd:string ; rdfs:subClassOf ; """2006-06-22"""^^xsd:string ; """2006-06-22"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C1831900"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunosuppression"""@eng ; skos:notation """CDR0000491927"""^^xsd:string ; rdfs:subClassOf ; """2006-06-22"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-06-22"""^^xsd:string ; umls:cui """C0021079"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """topoisomerase II inhibitor RTA 744"""@eng ; skos:notation """CDR0000491929"""^^xsd:string ; skos:altLabel """RTA-744"""@eng , """RTA 744"""@eng ; skos:definition """An anthracycline derivative with potential antitumor activity. RTA 744 intercalates into DNA and interrupts topoisomerase II activity, thereby inhibits DNA replication and repair, as well as RNA and protein synthesis. Unlike other anthracycline derivatives, RTA 744 crosses the blood-brain barrier and reaches therapeutic levels in the brain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491929&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491929&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61568\" NCI Thesaurus)"""@eng ; """2006-09-19"""^^xsd:string ; """2006-06-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61568"""^^xsd:string ; umls:cui """C1831901"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vitamin B12"""@eng ; skos:notation """CDR0000530928"""^^xsd:string ; skos:altLabel """cyanocobalamin"""@eng ; skos:definition """An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine, Vitamin B12 (cyanocobalamin) is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=530928&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=530928&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C939\" NCI Thesaurus)"""@eng ; """2007-01-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C939"""^^xsd:string ; umls:cui """C0042845"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erb-38 immunotoxin"""@eng ; skos:notation """CDR0000042875"""^^xsd:string ; skos:altLabel """erb-38"""@eng ; skos:definition """A bivalent fusion protein consisting of disulfide-stabilized Fv fragments of an anti-HER2 (erbB2) monoclonal antibody (e23) and a truncated version of the M(r) 38 fragment of Pseudomonas exotoxin that lacks the toxin's cell binding domain. ERB-38 immunotoxin binds specifically to cells that overexpress HER2, the antigenic target of the monoclonal antibody; the exotoxin portion of the immunotoxin then lyses the cells bound by the antibody portion. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42875&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42875&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2453\" NCI Thesaurus)"""@eng ; """6688"""^^xsd:string ; """7373"""^^xsd:string ; """2006-12-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """683039"""^^xsd:string ; """C2453"""^^xsd:string ; umls:cui """C0677808"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antimetabolite"""@eng ; skos:notation """CDR0000038991"""^^xsd:string ; rdfs:subClassOf ; """155"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003376"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """brachytherapy"""@eng ; skos:notation """CDR0000038990"""^^xsd:string ; skos:altLabel """therapy, low-LET implant"""@eng , """low-LET implant therapy"""@eng ; ; rdfs:subClassOf ; """1549"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279015"""^^xsd:string ; umls:cui """C0006098"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90-DOTA-chimeric monoclonal antibody cG250"""@eng ; skos:notation """CDR0000465788"""^^xsd:string ; skos:altLabel """90Y-DOTA-cG250"""@eng , """Yttrium Y 90 DOTA Chimeric Monoclonal Antibody cG250"""@eng ; skos:definition """A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465788&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465788&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53409\" NCI Thesaurus)"""@eng ; """2006-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """C53409"""^^xsd:string ; umls:cui """C1710703"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-LET electron therapy"""@eng ; skos:notation """CDR0000038992"""^^xsd:string ; skos:altLabel """therapy, low-LET electron"""@eng ; ; rdfs:subClassOf ; """1550"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279016"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed high-low LET therapy"""@eng ; skos:notation """CDR0000038995"""^^xsd:string ; skos:altLabel """therapy, mixed high-low LET"""@eng ; ; rdfs:subClassOf ; """1553"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279019"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/epratuzumab/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000406589"""^^xsd:string ; skos:altLabel """DOX/MOAB LL2/PEG-ASP/PRED/VCR"""@eng ; ; ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541409"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-specific immune-modulator therapy"""@eng ; skos:notation """CDR0000038997"""^^xsd:string ; skos:altLabel """therapy, non-specific immune-modulator"""@eng , """immune-modulator therapy, non-specific"""@eng ; ; rdfs:subClassOf ; """1556"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279021"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor cell derivative vaccine"""@eng ; skos:notation """CDR0000038996"""^^xsd:string ; skos:altLabel """tumor vacc"""@eng , """vaccine, tumor cell derivative"""@eng ; ; rdfs:subClassOf ; """1555"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279020"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chemosensitization/potentiation"""@eng ; skos:notation """CDR0000038999"""^^xsd:string ; skos:altLabel """potentiation/chemosensitization"""@eng ; """1560"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279023"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """in vitro-treated bone marrow transplantation"""@eng ; skos:notation """CDR0000038998"""^^xsd:string ; skos:altLabel """monoclonal antibody treated bone marrow transplantation"""@eng , """bone marrow transplantation, in vitro-treated"""@eng , """transplantation, in vitro-treated bone marrow"""@eng , """antibody treated bone marrow transplantation"""@eng ; ; rdfs:subClassOf ; """1559"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279022"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic cancer"""@eng ; skos:notation """CDR0000041702"""^^xsd:string ; skos:altLabel """Metastatic cancer"""@eng , """cancer, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """487"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C2939420"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levamisole hydrochloride"""@eng ; skos:notation """CDR0000039058"""^^xsd:string ; skos:altLabel """Ergamisole"""@eng , """Ketrax"""@eng , """Tramisol"""@eng , """LEV"""@eng , """Trimisol"""@eng ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C610"""^^xsd:string ; """1642"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0023556"""^^xsd:string ; umls:cui """C0733385"""^^xsd:string ; umls:cui """C0733383"""^^xsd:string ; umls:cui """C0733387"""^^xsd:string ; umls:cui """C0733386"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alpha-1,3-galactosyltransferase-expressing allogeneic pancreatic tumor cell vaccine"""@eng ; skos:notation """CDR0000475734"""^^xsd:string ; skos:altLabel """Alpha-Gal Pancreatic Cancer Vaccine"""@eng , """Hyperacute-Pancreatic Cancer Vaccine"""@eng ; skos:definition """A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with antitumor activity. Vaccination results in murine alpha-1,3-galactosyltransferase-mediated expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell \"xenograft\"; these foreign alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell xenograft. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies (naturally occur against gut flora) that bind the foreign alpha-gal epitopes, resulting in the rapid activation of complement and antibody-dependent cell-mediated cytotoxicity (ADCC). The host immune system then attacks pancreatic cancer cells, preexistent to vaccination and with cell membrane epitopes unmodified by alpha-gal, resulting in ADCC and tumor growth inhibition or reduction. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475734&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475734&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61082\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-21"""^^xsd:string ; """2006-03-24"""^^xsd:string ; """C61082"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831790"""^^xsd:string ; umls:cui """C1831791"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nuclear magnetic resonance"""@eng ; skos:notation """CDR0000042774"""^^xsd:string ; skos:altLabel """NMR"""@eng ; rdfs:subClassOf ; """6573"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0024485"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/topotecan"""@eng ; skos:notation """CDR0000042775"""^^xsd:string ; skos:altLabel """TOPO/WR-2721"""@eng ; ; ; """6574"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677737"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium Tc 99m dextran"""@eng ; skos:notation """CDR0000042776"""^^xsd:string ; """6575"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0076028"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """marimastat/tamoxifen"""@eng ; skos:notation """CDR0000042777"""^^xsd:string ; skos:altLabel """BB-2516/TMX"""@eng ; """6576"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677738"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """reverse transcriptase-polymerase chain reaction"""@eng ; skos:notation """CDR0000042770"""^^xsd:string ; skos:altLabel """RT-PCR"""@eng ; rdfs:subClassOf ; """6568"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0599161"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polymerase chain reaction"""@eng ; skos:notation """CDR0000042771"""^^xsd:string ; skos:altLabel """PCR"""@eng ; rdfs:subClassOf ; """6570"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0032520"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autoradiography"""@eng ; skos:notation """CDR0000042772"""^^xsd:string ; rdfs:subClassOf ; """6571"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0004400"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """electrophoresis, polyacrylamide gel"""@eng ; skos:notation """CDR0000042773"""^^xsd:string ; rdfs:subClassOf ; """6572"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0013862"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/fluorouracil"""@eng ; skos:notation """CDR0000042778"""^^xsd:string ; skos:altLabel """CDDP/5-FU/WR-2721"""@eng ; ; ; ; """6577"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677739"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VX-853"""@eng ; skos:notation """CDR0000042779"""^^xsd:string ; skos:altLabel """VX 853"""@eng ; ; """2003-10-23"""^^xsd:string ; """6578"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677740"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/TLK286"""@eng ; skos:notation """CDR0000355722"""^^xsd:string ; skos:altLabel """CBDCA/TLK-286"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328191"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/TLK286"""@eng ; skos:notation """CDR0000355720"""^^xsd:string ; skos:altLabel """LipoDox/TLK-286"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328190"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ZD4054"""@eng ; skos:notation """CDR0000355727"""^^xsd:string ; skos:definition """An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. ZD4054 binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355727&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355727&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48430\" NCI Thesaurus)"""@eng ; """2004-02-20"""^^xsd:string ; """C48430"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C1328193"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegylated arginine deiminase"""@eng ; skos:notation """CDR0000355725"""^^xsd:string ; skos:altLabel """ADI-PEG 20"""@eng , """ADI-PEG"""@eng ; """2004-02-20"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328192"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """type AB thymoma"""@eng ; skos:notation """CDR0000331488"""^^xsd:string ; skos:altLabel """mixed thymoma"""@eng ; rdfs:subClassOf ; """2003-08-24"""^^xsd:string ; """2003-08-20"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1266092"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lenalidomide/rituximab"""@eng ; skos:notation """CDR0000393606"""^^xsd:string ; skos:altLabel """CC 5013/MOAB IDEC-C2B8"""@eng ; ; ; """2004-10-25"""^^xsd:string ; """2004-09-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541375"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/pravastatin"""@eng ; skos:notation """CDR0000424451"""^^xsd:string ; skos:altLabel """ARA-C/IDA/PRAV"""@eng ; ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541523"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pravastatin"""@eng ; skos:notation """CDR0000424450"""^^xsd:string ; skos:altLabel """Pravachol"""@eng , """pravastatin sodium"""@eng , """PRAV"""@eng ; skos:definition """A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=424450&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=424450&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29375\" NCI Thesaurus)"""@eng ; ; """2005-03-24"""^^xsd:string ; """C29375"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0085542"""^^xsd:string ; umls:cui """C0700763"""^^xsd:string ; umls:cui """C0700474"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sputum cytology"""@eng ; skos:notation """CDR0000038184"""^^xsd:string ; """10767"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0551076"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylnaltrexone"""@eng ; skos:notation """CDR0000437863"""^^xsd:string ; skos:altLabel """N-methylnaltrexone bromide"""@eng , """MNTX"""@eng , """17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium"""@eng ; skos:definition """A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=437863&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=437863&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48403\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """C48403"""^^xsd:string ; """2006-08-29"""^^xsd:string ; umls:cui """C0066411"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peldesine"""@eng ; skos:notation """CDR0000042367"""^^xsd:string ; skos:altLabel """BCX-34"""@eng ; """5621"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0535443"""^^xsd:string ; umls:cui """C0338278"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Maxzide"""@eng ; skos:notation """CDR0000042366"""^^xsd:string ; """5620"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0127096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-11"""@eng ; skos:notation """CDR0000042365"""^^xsd:string ; skos:altLabel """rhIL-11"""@eng , """Adipogenesis Inhibitory Factor"""@eng , """Recombinant Human Interleukin-11"""@eng , """Oprelvekin"""@eng , """Neumega"""@eng , """IL-11"""@eng , """Inform"""@eng , """Interleukin-11-Recombinant"""@eng , """Interleukin 11"""@eng , """Recombinant Interleukin-11"""@eng , """Therapeutic Interleukin-11"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42365&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42365&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1303\" NCI Thesaurus)"""@eng ; ; ; ; """5619"""^^xsd:string ; """145941-26-0"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1303"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0537668"""^^xsd:string ; umls:cui """C0083031"""^^xsd:string ; umls:cui """C0537670"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/octreotide pamoate"""@eng ; skos:notation """CDR0000042364"""^^xsd:string ; skos:altLabel """5-FU/SMS 201-995 pa"""@eng ; ; ; """5618"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338277"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/dexamethasone"""@eng ; skos:notation """CDR0000042363"""^^xsd:string ; skos:altLabel """DM/DNR"""@eng ; ; ; """5617"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338276"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/methotrexate"""@eng ; skos:notation """CDR0000042362"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MTX"""@eng ; ; ; ; """5616"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin"""@eng ; skos:notation """CDR0000042361"""^^xsd:string ; skos:altLabel """CTX/DNR"""@eng ; ; ; """5615"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/losoxantrone"""@eng ; skos:notation """CDR0000042360"""^^xsd:string ; skos:altLabel """DOX/DuP-941"""@eng ; ; ; """5613"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338273"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane/doxorubicin/paclitaxel"""@eng ; skos:notation """CDR0000042369"""^^xsd:string ; skos:altLabel """ADR-529/DOX/TAX"""@eng ; ; ; ; """5623"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338280"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """9-cis-retinoic acid/tamoxifen"""@eng ; skos:notation """CDR0000042368"""^^xsd:string ; skos:altLabel """9-CRA/TMX"""@eng ; ; ; """5622"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338279"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000041632"""^^xsd:string ; skos:altLabel """AIDS-associated immunoblastic large cell lymphoma"""@eng , """immunoblastic large cell lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """4794"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1720728"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, vaginal cancer"""@eng ; skos:notation """CDR0000040639"""^^xsd:string ; skos:altLabel """vaginal cancer stage"""@eng ; rdfs:subClassOf ; """3548"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280264"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thiotepa/vinblastine"""@eng ; skos:notation """CDR0000040638"""^^xsd:string ; skos:altLabel """TSPA/VBL"""@eng ; ; ; """3547"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280263"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, urethral cancer"""@eng ; skos:notation """CDR0000040637"""^^xsd:string ; skos:altLabel """urethral cancer stage"""@eng ; rdfs:subClassOf ; """3546"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280262"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, extrahepatic bile duct cancer"""@eng ; skos:notation """CDR0000040636"""^^xsd:string ; skos:altLabel """extrahepatic bile duct cancer, stage"""@eng ; rdfs:subClassOf ; """3545"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280261"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040635"""^^xsd:string ; skos:altLabel """CHOD"""@eng , """CTX/DM/DOX/VCR"""@eng ; ; ; ; ; """3544"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0082139"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, Ewing's sarcoma/primitive neuroepitelial tumor"""@eng ; skos:notation """CDR0000040634"""^^xsd:string ; skos:altLabel """Ewing's sarcoma, stage"""@eng ; rdfs:subClassOf ; """3543"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280259"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/cell type, thyroid cancer"""@eng ; skos:notation """CDR0000040633"""^^xsd:string ; skos:altLabel """thyroid cancer stage"""@eng ; rdfs:subClassOf ; """3541"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280258"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, esophageal cancer"""@eng ; skos:notation """CDR0000040632"""^^xsd:string ; skos:altLabel """esophageal cancer, stage"""@eng ; rdfs:subClassOf ; """3540"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280257"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, testicular cancer"""@eng ; skos:notation """CDR0000040631"""^^xsd:string ; skos:altLabel """testicular cancer stage"""@eng ; rdfs:subClassOf ; """3539"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280256"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, endometrial cancer"""@eng ; skos:notation """CDR0000040630"""^^xsd:string ; skos:altLabel """endometrial carcinoma, stage"""@eng , """endometrial cancer, stage"""@eng , """cancer of the endometrium, stage"""@eng ; rdfs:subClassOf ; """3538"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280255"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/fluorouracil/hydroxyurea"""@eng ; skos:notation """CDR0000443025"""^^xsd:string ; skos:altLabel """5-FU/HU/TXT"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-04"""^^xsd:string ; """2005-08-05"""^^xsd:string ; umls:cui """C1831698"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sunscreen lotion"""@eng ; skos:notation """CDR0000510282"""^^xsd:string ; """2006-09-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0784979"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sunless tanning lotion"""@eng ; skos:notation """CDR0000510283"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-23"""^^xsd:string ; umls:cui """C1831963"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fondaparinux sodium"""@eng ; skos:notation """CDR0000510285"""^^xsd:string ; skos:altLabel """decasodium salt"""@eng , """Arixtra"""@eng , """alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate)"""@eng ; skos:definition """The sodium salt form of fondaparinux, a synthetic glucopyranoside with antithrombotic activity. Fondaparinux sodium selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=510285&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=510285&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47539\" NCI Thesaurus)"""@eng ; """C47539"""^^xsd:string ; """114870-03-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-23"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1099664"""^^xsd:string ; umls:cui """C1099665"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/vincristine"""@eng ; skos:notation """CDR0000041948"""^^xsd:string ; skos:altLabel """ASP/VCR"""@eng ; ; ; """5170"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281498"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/methotrexate"""@eng ; skos:notation """CDR0000041949"""^^xsd:string ; skos:altLabel """DP/MTX"""@eng ; ; ; """5172"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281499"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/vinorelbine"""@eng ; skos:notation """CDR0000041946"""^^xsd:string ; skos:altLabel """CDDP/VNB"""@eng ; ; ; """5169"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281497"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan"""@eng ; skos:notation """CDR0000041947"""^^xsd:string ; skos:altLabel """Busulfex"""@eng , """Tetramethylene Bis(methanesulfonate)"""@eng , """Mitosan"""@eng , """Methanesulfonic Acid Tetramethylene Ester"""@eng , """Mylecytan"""@eng , """GT-41"""@eng , """Myeloleukon"""@eng , """CB-2041"""@eng , """BU"""@eng , """1,4-Di(methanesulfonyloxy)butane"""@eng , """1,4-Butanediol Dimethylsulfonate"""@eng , """Myleran"""@eng , """Mielucin"""@eng , """Myelosan"""@eng , """Sulfabutin"""@eng , """Busulfanum"""@eng , """Misulban"""@eng , """Myeleukon"""@eng , """BUS"""@eng , """WR-19508"""@eng , """Bussulfam"""@eng , """1,4-Bis(methanesulfonoxy)butane"""@eng , """Glyzophrol"""@eng , """busulphan"""@eng , """1,4-Bitanediol Dimethanesulfonate Esters"""@eng , """BSF"""@eng , """1,4-Di(methylsulfonyloxy)butane"""@eng ; skos:definition """A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties. Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA. Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41947&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41947&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C321\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """517"""^^xsd:string ; """55-98-1"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C321"""^^xsd:string ; """750"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135149"""^^xsd:string ; umls:cui """C0728928"""^^xsd:string ; umls:cui """C0728924"""^^xsd:string ; umls:cui """C0700015"""^^xsd:string ; umls:cui """C0728926"""^^xsd:string ; umls:cui """C0939273"""^^xsd:string ; umls:cui """C1522695"""^^xsd:string ; umls:cui """C1522692"""^^xsd:string ; umls:cui """C1511348"""^^xsd:string ; umls:cui """C1522691"""^^xsd:string ; umls:cui """C0728927"""^^xsd:string ; umls:cui """C0006463"""^^xsd:string ; umls:cui """C1511349"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indomethacin/interleukin-2/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000041944"""^^xsd:string ; skos:altLabel """IL-2/Indomethacin/LAK"""@eng ; ; ; ; """5167"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxyurea/tretinoin"""@eng ; skos:notation """CDR0000041945"""^^xsd:string ; skos:altLabel """ATRA/HU"""@eng ; ; ; """5168"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281496"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/ifosfamide"""@eng ; skos:notation """CDR0000041942"""^^xsd:string ; skos:altLabel """ARA-C/IFF"""@eng ; ; ; """5164"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/indomethacin/interleukin-2/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000041943"""^^xsd:string ; skos:altLabel """CTX/IL-2/Indomethacin/TIL"""@eng ; ; ; ; ; """5166"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281494"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methotrexate"""@eng ; skos:notation """CDR0000041940"""^^xsd:string ; skos:altLabel """CTX/MTX"""@eng ; ; ; """5162"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281491"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/dacarbazine/thymidine"""@eng ; skos:notation """CDR0000041941"""^^xsd:string ; skos:altLabel """BCNU/DTIC/TDR"""@eng ; ; ; ; """5163"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/trastuzumab"""@eng ; skos:notation """CDR0000038432"""^^xsd:string ; skos:altLabel """MOAB HER2/ZD 1839"""@eng ; ; ; """2002-10-10"""^^xsd:string ; """11049"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134483"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/strontium chloride Sr 89"""@eng ; skos:notation """CDR0000038433"""^^xsd:string ; skos:altLabel """DOX/Sr89"""@eng ; ; ; """11050"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134484"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """folic acid/lometrexol/paclitaxel"""@eng ; skos:notation """CDR0000038430"""^^xsd:string ; skos:altLabel """FA/LMTX/TAX"""@eng ; ; ; ; """11047"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """teicoplanin"""@eng ; skos:notation """CDR0000038431"""^^xsd:string ; skos:altLabel """Targocid"""@eng , """Teichomycin"""@eng ; skos:definition """A glycopeptide antibiotic complex isolated from the bacterium Actinoplanes teichomyceticus. Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38431&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38431&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1412\" NCI Thesaurus)"""@eng ; """11048"""^^xsd:string ; """C1412"""^^xsd:string ; """61036-62-2"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0145106"""^^xsd:string ; umls:cui """C0678137"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/ifosfamide/methotrexate/trastuzumab"""@eng ; skos:notation """CDR0000038436"""^^xsd:string ; skos:altLabel """CDDP/DOX/IFF/MOAB HER2/MTX/VP-16"""@eng ; ; ; ; ; ; ; """11053"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134487"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """weight changes"""@eng ; skos:notation """CDR0000038437"""^^xsd:string ; rdfs:subClassOf ; """11054"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0005911"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin/ifosfamide/SU5416"""@eng ; skos:notation """CDR0000038434"""^^xsd:string ; skos:altLabel """DOX/DTIC/IFF/SU-5416"""@eng ; ; ; ; ; """2003-10-29"""^^xsd:string ; """11051"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134485"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate/trastuzumab"""@eng ; skos:notation """CDR0000038435"""^^xsd:string ; skos:altLabel """CDDP/DOX/MOAB HER2/MTX"""@eng ; ; ; ; ; """11052"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LY353381.HCl"""@eng ; skos:notation """CDR0000042943"""^^xsd:string ; skos:altLabel """LY 353381.HCl"""@eng , """LY-353381.HCl"""@eng ; """2006-10-09"""^^xsd:string ; """6979"""^^xsd:string ; umls:cui """C0950979"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine"""@eng ; skos:notation """CDR0000042942"""^^xsd:string ; skos:altLabel """ARA-C/CDDP"""@eng ; ; ; """693"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278635"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gene"""@eng ; skos:notation """CDR0000042941"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """6902"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0017337"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/methotrexate"""@eng ; skos:notation """CDR0000042940"""^^xsd:string ; skos:altLabel """PBM"""@eng , """BLEO/CDDP/MTX"""@eng ; ; ; ; """69"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065764"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multiple myeloma"""@eng ; skos:notation """CDR0000042947"""^^xsd:string ; skos:altLabel """myeloma, multiple"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """7017"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; umls:cui """C0026764"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000042946"""^^xsd:string ; skos:altLabel """BLEO/CDDP/MTX/VBL"""@eng ; ; ; ; ; """70"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0164192"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042945"""^^xsd:string ; skos:altLabel """metastatic adult Hodgkin's disease"""@eng , """adult Hodgkin's disease, stage IV"""@eng , """lymphoma, metastatic adult Hodgkin's"""@eng , """adult HD, stage IV"""@eng , """lymphoma, stage IV adult Hodgkin's"""@eng , """HD, metastatic, adult"""@eng , """Hodgkin's lymphoma, metastatic, adult"""@eng , """stage IV adult Hodgkin's disease"""@eng , """HD, stage IV, adult"""@eng , """adult HD, metastatic"""@eng , """stage IV adult HD"""@eng , """Hodgkin's lymphoma, stage IV, adult"""@eng , """Hodgkin's disease, metastatic, adult"""@eng , """HD, adult, metastatic"""@eng , """HD, adult, stage IV"""@eng , """Hodgkin's disease, stage IV, adult"""@eng , """adult Hodgkin's disease, metastatic"""@eng ; rdfs:subClassOf ; """2003-01-14"""^^xsd:string ; """adult Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278473"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triptorelin"""@eng ; skos:notation """CDR0000042944"""^^xsd:string ; skos:altLabel """6-D-Tryptophan-LH-RH"""@eng , """6-D-Tryptophanluteinizing Hormone-releasing Factor"""@eng , """Detryptoreline"""@eng , """AY-25650"""@eng , """Decapeptyl"""@eng , """CL-118,532"""@eng , """TRIP"""@eng , """D-TRP-6-LHRH"""@eng ; skos:definition """A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42944&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42944&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1267\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """699"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """57773-63-4"""^^xsd:string ; """C1267"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701191"""^^xsd:string ; umls:cui """C0701190"""^^xsd:string ; umls:cui """C0077275"""^^xsd:string ; umls:cui """C2745954"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ad5CMV-p53 gene"""@eng ; skos:notation """CDR0000043016"""^^xsd:string ; skos:altLabel """RPR/INGN-201"""@eng , """Ad-p53"""@eng , """Ad5CMV-p53"""@eng , """Ad5CMV p53 gene"""@eng , """INGN 201"""@eng , """INGN-201"""@eng , """Adeno-p53"""@eng , """Adenovirus p53"""@eng , """ADVEXIN"""@eng ; skos:definition """A replication-defective adenoviral-CMV vector that encodes a wild-type p53 gene. Ad5CMV-p53 induces tumor cells that have been transfected with the vector to produce wild-type p53, a tumor suppressor gene that is deleted or mutated in a significant number of cancers. In transfected tumor cells, the wild-type p-53 gene product exerts an antitumor effect by blocking cell cycle progression at the G1/S regulation point, activating DNA repair proteins in the presence of DNA damage, and initiating apoptosis when DNA damage is irreparable. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43016&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43016&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2471\" NCI Thesaurus)"""@eng ; ; ; ; """7294"""^^xsd:string ; """C2471"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """7135"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135129"""^^xsd:string ; umls:cui """C0678021"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyproterone/luteinizing hormone-releasing factor"""@eng ; skos:notation """CDR0000043017"""^^xsd:string ; skos:altLabel """CPTR/LHRH"""@eng ; ; ; """7296"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678022"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/fluorouracil"""@eng ; skos:notation """CDR0000043014"""^^xsd:string ; skos:altLabel """CDDP/5-FU/TXT"""@eng ; ; ; ; """7292"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678019"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000043015"""^^xsd:string ; skos:altLabel """CDDP/CTX/VP-16/WR-2721"""@eng ; ; ; ; ; """7293"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678020"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """omeprazole/porfimer sodium"""@eng ; skos:notation """CDR0000043012"""^^xsd:string ; skos:altLabel """DHE/OMEP"""@eng ; ; ; """7284"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678018"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/etoposide/ifosfamide/methotrexate/rituximab"""@eng ; skos:notation """CDR0000299571"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/IFF/MOAB IDEC-C2B8/MTX/VP-16"""@eng ; ; ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327947"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liposomal-NDDP"""@eng ; skos:notation """CDR0000043010"""^^xsd:string ; skos:altLabel """L-NDDP"""@eng ; """C1383"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7280"""^^xsd:string ; """2006-09-18"""^^xsd:string ; umls:cui """C0125061"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mycophenolate mofetil/tacrolimus"""@eng ; skos:notation """CDR0000043011"""^^xsd:string ; skos:altLabel """FK506/MMF"""@eng ; ; ; """7283"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678017"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMB-9 immunotoxin"""@eng ; skos:notation """CDR0000043018"""^^xsd:string ; skos:altLabel """immunotoxin LMB-9"""@eng , """LMB-9"""@eng , """B3 (dsFv)-PE38"""@eng ; skos:definition """A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to attack adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43018&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43018&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2472\" NCI Thesaurus)"""@eng ; """7297"""^^xsd:string ; """691236"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """7697"""^^xsd:string ; """C2472"""^^xsd:string ; umls:cui """C0678023"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """octreotide/prednisone"""@eng ; skos:notation """CDR0000043019"""^^xsd:string ; skos:altLabel """PRED/SSTN"""@eng ; ; ; """7298"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678024"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood subependymal giant cell astrocytoma"""@eng ; skos:notation """CDR0000530750"""^^xsd:string ; skos:altLabel """astrocytoma, childhood subependymal giant cell"""@eng , """subependymal giant cell astrocytoma, childhood"""@eng ; rdfs:subClassOf ; """Cancer diagnosis"""^^xsd:string ; """2007-01-11"""^^xsd:string ; """2007-01-16"""^^xsd:string ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; umls:cui """C1832034"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tuberous sclerosis complex"""@eng ; skos:notation """CDR0000530751"""^^xsd:string ; """2007-01-11"""^^xsd:string ; """Genetic condition"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C0041341"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CD30 antibody-drug conjugate SGN-35"""@eng ; skos:notation """CDR0000530758"""^^xsd:string ; skos:altLabel """anti-CD30 ADC SGN-35"""@eng , """antibody-drug conjugate SGN-35"""@eng , """SGN-35"""@eng ; """2007-01-16"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832035"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """siplizumab"""@eng ; skos:notation """CDR0000346499"""^^xsd:string ; skos:altLabel """MEDI-507"""@eng , """anti-CD2 monoclonal antibody"""@eng ; skos:definition """A monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346499&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346499&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38685\" NCI Thesaurus)"""@eng ; ; """2003-11-20"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38685"""^^xsd:string ; umls:cui """C1310928"""^^xsd:string ; umls:cui """C1328709"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent squamous cell carcinoma of the oropharynx"""@eng ; skos:notation """CDR0000040729"""^^xsd:string ; skos:altLabel """oropharynx squamous cell carcinoma, recurrent"""@eng , """epidermoid carcinoma of the oropharynx, recurrent"""@eng , """squamous cell carcinoma of the oropharynx, recurrent"""@eng , """oropharyngeal squamous cell carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3671"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280376"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMO2"""@eng ; skos:notation """CDR0000043183"""^^xsd:string ; rdfs:subClassOf ; """7626"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0380093"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus encoding rat Her-2/neu"""@eng ; skos:notation """CDR0000488459"""^^xsd:string ; """C62527"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831867"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ixabepilone (oral)"""@eng ; skos:notation """CDR0000486610"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135132"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038850"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MTX/PRED/TG/VCR"""@eng ; ; ; ; ; ; ; ; """1340"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278895"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/hydroxyurea"""@eng ; skos:notation """CDR0000042568"""^^xsd:string ; skos:altLabel """CDDP/HU"""@eng ; ; ; """6250"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392991"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ipomeanol"""@eng ; skos:notation """CDR0000038852"""^^xsd:string ; skos:altLabel """4-ipomeanol"""@eng , """1-(3-furanyl)-4-hydroxy-1-pentanone"""@eng ; skos:definition """A natural toxic furan isolated from a fungus-infected sweet potato (Ipomoea batatas) with potential antineoplastic activity. Ipomeanol is activated by mixed function oxidases in vivo to its epoxide form, an alkylating agent that covalently binds cell macromolecules. This agent causes cell death by a p53-independent mechanism. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38852&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38852&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C976\" NCI Thesaurus)"""@eng ; """1342"""^^xsd:string ; """32954-58-8"""^^xsd:string ; """349438"""^^xsd:string ; """C976"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """31371"""^^xsd:string ; umls:cui """C0048420"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nimustine"""@eng ; skos:notation """CDR0000038853"""^^xsd:string ; skos:altLabel """ACNU 50"""@eng , """Nidran"""@eng , """ACNU"""@eng , """Nimustine Hydrochloride"""@eng , """N'-[4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea"""@eng ; skos:definition """A nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38853&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38853&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C693\" NCI Thesaurus)"""@eng ; """1343"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """C693"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1518327"""^^xsd:string ; umls:cui """C1518326"""^^xsd:string ; umls:cui """C0771987"""^^xsd:string ; umls:cui """C0028096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/thiotepa"""@eng ; skos:notation """CDR0000038854"""^^xsd:string ; skos:altLabel """CDDP/TSPA"""@eng ; ; ; """1344"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278898"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin"""@eng ; skos:notation """CDR0000038855"""^^xsd:string ; skos:altLabel """ARA-C/DOX"""@eng ; ; ; """1345"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050343"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000038856"""^^xsd:string ; skos:altLabel """CPC"""@eng , """CBDCA/CDDP/CTX"""@eng ; ; ; ; """1346"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278900"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/levamisole"""@eng ; skos:notation """CDR0000038857"""^^xsd:string ; skos:altLabel """CF/5-FU/LEV"""@eng ; ; ; ; """1347"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278901"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038858"""^^xsd:string ; skos:altLabel """ASP/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """1348"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278902"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/doxorubicin/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000038859"""^^xsd:string ; skos:altLabel """ASP/DOX/MP/PRED/VCR"""@eng ; ; ; ; ; ; """1349"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278903"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-2/MART-1 antigen"""@eng ; skos:notation """CDR0000042563"""^^xsd:string ; skos:altLabel """gp100/IL-2/MART-1"""@eng ; ; ; ; """6245"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392986"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentetic acid calcium"""@eng ; skos:notation """CDR0000042562"""^^xsd:string ; skos:altLabel """calcium pentetic acid"""@eng , """Ca-DTPA"""@eng , """calcium-pentetic acid"""@eng , """Trisodium Calcium Diethylenetriaminepentaacetate"""@eng , """Ditripentat-Heyl"""@eng , """Pentetate Calcium Trisodium"""@eng , """Calcium Trisodium DTPA"""@eng , """calcium-DTPA"""@eng , """Calcium Trisodium Pentetate"""@eng , """calcium DTPA"""@eng ; skos:definition """A synthetic chelating agent related to EDTA. Pentetic acid calcium chelates with the metallic radioisotopic moieties of unbound, extracellular radioimmunotherapeutic agents, resulting in higher specific tumor cell binding of radioimmunotherpeutic agents, and so improved tumor cell radiocytotoxicity, while sparing normal cells and tissues from the radiocytotoxic effects of these agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42562&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42562&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1710\" NCI Thesaurus)"""@eng ; """6244"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C1710"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0520458"""^^xsd:string ; umls:cui """C1518953"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/hydroxyurea"""@eng ; skos:notation """CDR0000042565"""^^xsd:string ; skos:altLabel """CDDP/HU/VP-16"""@eng ; ; ; ; """6247"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392988"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/hydroxyurea/vinblastine"""@eng ; skos:notation """CDR0000042564"""^^xsd:string ; skos:altLabel """CDDP/HU/VBL"""@eng ; ; ; ; """6246"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392987"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/hydroxyurea/vindesine"""@eng ; skos:notation """CDR0000042567"""^^xsd:string ; skos:altLabel """CDDP/DAVA/HU"""@eng ; ; ; ; """6249"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392990"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/hydroxyurea/vinorelbine"""@eng ; skos:notation """CDR0000042566"""^^xsd:string ; skos:altLabel """CDDP/HU/VNB"""@eng ; ; ; ; """6248"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392989"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/oblimersen"""@eng ; skos:notation """CDR0000258241"""^^xsd:string ; skos:altLabel """G3139/STI571"""@eng ; ; ; """2002-10-07"""^^xsd:string ; """11482"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327798"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valacyclovir"""@eng ; skos:notation """CDR0000257236"""^^xsd:string ; skos:altLabel """Valtrex"""@eng ; skos:definition """A synthetic valyl ester derivative of acyclovir, the antiviral valacyclovir is an acyclovir prodrug that, after metabolization, inhibits viral DNA replication through interference with thymidine kinase. It is used in the management of herpes simplex and varicella zoster infections, as well as prophylactically for human cytomegalovirus infections. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28235\" NCI Thesaurus)"""@eng ; """10591"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-04"""^^xsd:string ; """C28235"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0592245"""^^xsd:string ; umls:cui """C0249458"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ro 50-3821"""@eng ; skos:notation """CDR0000339378"""^^xsd:string ; skos:altLabel """methoxy polyethylene glycol epoetin beta"""@eng , """methoxypolyethylene glycol epoetin beta"""@eng ; skos:definition """A pegylated form of recombinant human erythropoietin, a glycosylated protein naturally produced in the kidney that stimulates erythrocyte production in the bone marrow. Methoxypolyethylene glycol epoetin beta may reverse anemias induced by cancer therapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=339378&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=339378&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38687\" NCI Thesaurus)"""@eng ; """2003-10-25"""^^xsd:string ; """C38687"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328706"""^^xsd:string ; umls:cui """C1328071"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/hydroxyurea"""@eng ; skos:notation """CDR0000039459"""^^xsd:string ; skos:altLabel """FAMP/HU"""@eng ; ; ; """2093"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279314"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide/lomustine"""@eng ; skos:notation """CDR0000039458"""^^xsd:string ; skos:altLabel """CCNU/DOX/IFF"""@eng , """CIA"""@eng ; ; ; ; """2092"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279313"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """moxalactam"""@eng ; skos:notation """CDR0000039507"""^^xsd:string ; skos:altLabel """Latamoxef"""@eng , """Moxam"""@eng ; """2141"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0026651"""^^xsd:string ; umls:cui """C1527142"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/sargramostim/vincristine"""@eng ; skos:notation """CDR0000039453"""^^xsd:string ; skos:altLabel """GM-CSF/PRED/VCR"""@eng ; ; ; ; """2088"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279310"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000039452"""^^xsd:string ; skos:altLabel """DOX/DTIC/GM-CSF/IFF"""@eng ; ; ; ; ; """2087"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279309"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/prednisone"""@eng ; skos:notation """CDR0000039451"""^^xsd:string ; skos:altLabel """CTX/5-FU/PRED"""@eng , """CFP"""@eng ; ; ; ; """2086"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055162"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 3F8"""@eng ; skos:notation """CDR0000041259"""^^xsd:string ; skos:altLabel """MOAB 3F8"""@eng , """anti-Ganglioside (GD2) Monoclonal Antibody 3F8"""@eng , """3F8 Monoclonal Antibody"""@eng , """3F8"""@eng ; skos:definition """A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41259&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41259&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2370\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """4332"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """C2370"""^^xsd:string ; umls:cui """C0280849"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/sargramostim"""@eng ; skos:notation """CDR0000039457"""^^xsd:string ; skos:altLabel """GM-CSF/L-PAM"""@eng ; ; ; """2091"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279312"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/interleukin-2"""@eng ; skos:notation """CDR0000039456"""^^xsd:string ; skos:altLabel """CDDP/CTX/IL-2/VP-16"""@eng ; ; ; ; ; """2090"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279311"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chemotherapy"""@eng ; skos:notation """CDR0000039455"""^^xsd:string ; skos:altLabel """chemo"""@eng ; rdfs:subClassOf owl:Thing ; """209"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C3665472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hepsulfam"""@eng ; skos:notation """CDR0000039454"""^^xsd:string ; skos:altLabel """1,7-Heptanediyl Ester Sulfamic Acid"""@eng ; skos:definition """A bisulfamic ester which is similar in structure to busulfan and belongs to the family of drugs known as alkylsulfonate alkylating agents. Hepsulfam forms covalent linkages with nucleophilic centers in DNA, resulting in depurination, base miscoding, strand scission, DNA-DNA and DNA-protein cross-linking, and cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39454&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39454&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1123\" NCI Thesaurus)"""@eng ; """2089"""^^xsd:string ; """96892-57-8"""^^xsd:string ; """C1123"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """32057"""^^xsd:string ; """329680"""^^xsd:string ; umls:cui """C0062540"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/interferon alfa"""@eng ; skos:notation """CDR0000041256"""^^xsd:string ; skos:altLabel """CBDCA/IFN-A"""@eng ; ; ; """4329"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338135"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nafazatrom"""@eng ; skos:notation """CDR0000039508"""^^xsd:string ; skos:altLabel """Bay g 6575"""@eng , """Bay-g 6575"""@eng ; """2142"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0053025"""^^xsd:string ; umls:cui """C0950386"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """selective internal radiation therapy"""@eng ; skos:notation """CDR0000523462"""^^xsd:string ; skos:altLabel """SIRT"""@eng ; rdfs:subClassOf ; """2006-11-28"""^^xsd:string ; """2006-12-01"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831994"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim/rituximab"""@eng ; skos:notation """CDR0000339375"""^^xsd:string ; skos:altLabel """CTX/G-CSF/MOAB IDEC-C2B8"""@eng ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-09-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328070"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/gemcitabine"""@eng ; skos:notation """CDR0000367368"""^^xsd:string ; skos:altLabel """17-AAG/dFdC"""@eng ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541228"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/thiotepa"""@eng ; skos:notation """CDR0000040840"""^^xsd:string ; skos:altLabel """TMF"""@eng , """5-FU/MTX/TSPA"""@eng ; ; ; ; """3869"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0244554"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, myelodysplastic syndromes"""@eng ; skos:notation """CDR0000040841"""^^xsd:string ; skos:altLabel """myelodysplastic syndromes cellular diagnosis"""@eng ; rdfs:subClassOf ; """3870"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280466"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluconazole"""@eng ; skos:notation """CDR0000040842"""^^xsd:string ; skos:altLabel """alpha-(2,4-difluorophenyl)-alpha- (1,2,4-triazol-1-ylmethyl)-1,2, 4- triazole-1-ethanol"""@eng , """FCZ"""@eng , """Diflucan"""@eng ; skos:definition """A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40842&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40842&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C500\" NCI Thesaurus)"""@eng ; ; """3871"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """86386-73-4"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C500"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0016277"""^^xsd:string ; umls:cui """C0699601"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoguazone/mitoxantrone/vinblastine"""@eng ; skos:notation """CDR0000040843"""^^xsd:string ; skos:altLabel """(MV)2"""@eng , """DHAD/MGBG/VBL/VP-16"""@eng ; ; ; ; ; """3872"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280467"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent transitional cell cancer of the renal pelvis and ureter"""@eng ; skos:notation """CDR0000040844"""^^xsd:string ; skos:altLabel """carcinoma of the renal pelvis and ureter, recurrent"""@eng , """transitional cell cancer of the renal pelvis and ureter, recurrent"""@eng , """cancer of the renal pelvis and ureter, recurrent"""@eng ; rdfs:subClassOf ; """transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3873"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280468"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cloacogenic carcinoma of the anus"""@eng ; skos:notation """CDR0000040845"""^^xsd:string ; skos:altLabel """anus cancer, cloacogenic carcinoma"""@eng , """anal cancer, cloacogenic carcinoma"""@eng ; rdfs:subClassOf ; """3874"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334273"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """basaloid carcinoma of the anus"""@eng ; skos:notation """CDR0000040846"""^^xsd:string ; skos:altLabel """anus cancer, basaloid carcinoma"""@eng , """anal cancer, basaloid carcinoma"""@eng ; rdfs:subClassOf ; """3875"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280470"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trimethoprim"""@eng ; skos:notation """CDR0000040847"""^^xsd:string ; skos:altLabel """TMP"""@eng , """Trimpex"""@eng , """Proloprim"""@eng ; """3876"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0728764"""^^xsd:string ; umls:cui """C0733453"""^^xsd:string ; umls:cui """C0041041"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """heparin"""@eng ; skos:notation """CDR0000040848"""^^xsd:string ; skos:altLabel """Lipo-Hepin"""@eng , """Calciparine"""@eng , """Hep-Lock"""@eng ; """3877"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0019134"""^^xsd:string ; umls:cui """C0700893"""^^xsd:string ; umls:cui """C0700892"""^^xsd:string ; umls:cui """C1176302"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-grade childhood cerebral astrocytoma"""@eng ; skos:notation """CDR0000040849"""^^xsd:string ; skos:altLabel """CNS tumor, grade IV childhood astrocytoma"""@eng , """childhood brain tumor, glioblastoma multiforme"""@eng , """pediatric anaplastic astrocytoma"""@eng , """central nervous system tumor, astrocytoma, grade III childhood"""@eng , """astrocytoma, childhood anaplastic"""@eng , """CNS tumor, childhood glioblastoma multiforme"""@eng , """CNS tumor, grade III childhood astrocytoma"""@eng , """astrocytoma, grade IV childhood"""@eng , """pediatric cerebral astrocytoma, high-grade"""@eng , """brain tumor, childhood grade III astrocytoma"""@eng , """glioblastoma multiforme, childhood"""@eng , """brain tumor, childhood grade IV astrocytoma"""@eng , """grade IV childhood astrocytoma"""@eng , """grade III childhood supratentorial astrocytoma"""@eng , """CNS tumor, childhood grade IV astrocytoma"""@eng , """grade III childhood cerebral astrocytoma"""@eng , """anaplastic astrocytoma, childhood"""@eng , """childhood cerebral astrocytoma, high-grade"""@eng , """brain tumor, childhood glioblastoma multiforme"""@eng , """childhood anaplastic astrocytoma"""@eng , """childhood glioblastoma multiforme"""@eng , """childhood brain tumor, grade III astrocytoma"""@eng , """high grade childhood supratentorial astrocytoma"""@eng , """astrocytoma, grade III childhood"""@eng , """childhood CNS tumor, childhood grade III astrocytoma"""@eng , """childhood CNS tumor, glioblastoma multiforme"""@eng , """childhood malignant cerebral astrocytoma"""@eng , """central nervous system tumor, astrocytoma, grade IV childhood"""@eng , """CNS tumor, childhood grade III astrocytoma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood cerebral astrocytoma/malignant glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3882"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280474"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/thalidomide"""@eng ; skos:notation """CDR0000363628"""^^xsd:string ; skos:altLabel """DTIC/THAL"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541205"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exatecan mesylate"""@eng ; skos:notation """CDR0000043386"""^^xsd:string ; skos:altLabel """Exatecan"""@eng , """DX 8951f"""@eng , """DX-8951f"""@eng ; skos:definition """A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43386&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43386&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1679\" NCI Thesaurus)"""@eng ; ; """7938"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1679"""^^xsd:string ; """2006-08-02"""^^xsd:string ; umls:cui """C0965941"""^^xsd:string ; umls:cui """C0809953"""^^xsd:string ; umls:cui """C0935945"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glufanide disodium"""@eng ; skos:notation """CDR0000043387"""^^xsd:string ; skos:altLabel """IM 862"""@eng , """IM-862"""@eng , """IM862"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """7939"""^^xsd:string ; """C2558"""^^xsd:string ; umls:cui """C0076603"""^^xsd:string ; umls:cui """C2364019"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000039068"""^^xsd:string ; skos:altLabel """ARA-C/MP/MTX"""@eng ; ; ; ; """1654"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279080"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic phase chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000039069"""^^xsd:string ; skos:altLabel """chronic granulocytic leukemia, chronic phase"""@eng , """chronic phase CGL"""@eng , """myelocytic leukemia, chronic phase"""@eng , """CGL, chronic phase"""@eng , """CML, chronic phase"""@eng , """leukemia, chronic myelogenous, chronic phase"""@eng , """chronic myelocytic leukemia, chronic phase"""@eng , """myelogenous leukemia, chronic phase"""@eng , """chronic myelogenous leukemia, chronic phase"""@eng , """granulocytic leukemia, chronic phase"""@eng , """chronic phase CML"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """chronic myelogenous leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1655"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0023474"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/doxorubicin/tamoxifen"""@eng ; skos:notation """CDR0000043382"""^^xsd:string ; skos:altLabel """DOX/TMX/TXT"""@eng ; ; ; ; """7934"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796522"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/docetaxel/doxorubicin/tamoxifen"""@eng ; skos:notation """CDR0000043383"""^^xsd:string ; skos:altLabel """CTX/DOX/TMX/TXT"""@eng ; ; ; ; ; """7935"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796523"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """menopausal symptoms"""@eng ; skos:notation """CDR0000043380"""^^xsd:string ; skos:altLabel """symptoms, menopausal"""@eng ; rdfs:subClassOf ; """7932"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0236075"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """menopausal symptoms attenuation"""@eng ; skos:notation """CDR0000043381"""^^xsd:string ; ; rdfs:subClassOf ; ; """7933"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0796521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant soluble human CD4 protein"""@eng ; skos:notation """CDR0000039062"""^^xsd:string ; skos:altLabel """rCD4"""@eng ; skos:definition """A recombinant human soluble CD4 with antiviral activity. Recombinant human soluble CD4 has the amino terminus but not the T-cell binding domain of the endogenous CD4 antigen. This soluble CD4 protein competitively binds to envelope glycoprotein (gp120) of human immunodeficiency virus (HIV) resulting in inhibition of interaction between gp120 and the endogenous CD4 antigen, thereby blocking viral recognition of CD4 and subsequent entry of HIV into CD4 bearing cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39062&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39062&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2342\" NCI Thesaurus)"""@eng ; """1647"""^^xsd:string ; """C2342"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0279074"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/prednisone"""@eng ; skos:notation """CDR0000039063"""^^xsd:string ; skos:altLabel """CMFP"""@eng , """CTX/5-FU/MTX/PRED"""@eng ; ; ; ; ; """1648"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055985"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000039060"""^^xsd:string ; skos:altLabel """CMF"""@eng , """CTX/5-FU/MTX"""@eng ; ; ; ; """1644"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0950521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atvogen"""@eng ; skos:notation """CDR0000039061"""^^xsd:string ; skos:altLabel """Poly(Inosinic Acid) Poly(Cytidylic(12), Uridylic)Acid"""@eng , """Ampligen"""@eng ; skos:definition """A synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Atvogen acts through a number of pathways to stimulate intracellular antiviral activity of the immune system: it stimulates interferon production; activates the oligoadenylate synthase-RNase L pathway; stimulates natural killer cell activity; and acts as a non-mitogenic stimulator of the immune system. This agent also inhibits replication of human immunodeficiency virus (HIV) in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39061&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39061&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1011\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """1646"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1011"""^^xsd:string ; umls:cui """C1434913"""^^xsd:string ; umls:cui """C0051764"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/etoposide"""@eng ; skos:notation """CDR0000039066"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/VP-16"""@eng , """ACE"""@eng , """APE"""@eng ; ; ; ; """1652"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279078"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult high grade NHL"""@eng ; skos:notation """CDR0000039067"""^^xsd:string ; skos:altLabel """non-Hodgkin's lymphoma, adult high grade"""@eng , """high grade non-Hodgkin's lymphoma, adult"""@eng , """lymphoma, adult high grade non-Hodgkin's"""@eng , """NHL, adult high grade"""@eng , """adult NHL, high grade"""@eng ; """2005-01-21"""^^xsd:string ; """1653"""^^xsd:string ; umls:cui """C0279079"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """c-myb antisense oligonucleotide G4460"""@eng ; skos:notation """CDR0000043388"""^^xsd:string ; skos:altLabel """LR3001"""@eng , """G4460"""@eng ; """Drug/agent"""^^xsd:string ; """C1541"""^^xsd:string ; """7940"""^^xsd:string ; """2007-01-23"""^^xsd:string ; umls:cui """C0253788"""^^xsd:string ; umls:cui """C1831626"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hairy cell leukemia"""@eng ; skos:notation """CDR0000039065"""^^xsd:string ; skos:altLabel """Leukemia, hairy cell"""@eng , """leukemia, hairy cell"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1651"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023443"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/cladribine"""@eng ; skos:notation """CDR0000041713"""^^xsd:string ; skos:altLabel """2-CdA/CLB"""@eng ; ; ; """4884"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281307"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine/piroxicam"""@eng ; skos:notation """CDR0000041712"""^^xsd:string ; skos:altLabel """DFMO/PXM"""@eng ; ; ; """4883"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281306"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stomach cancer screening"""@eng ; skos:notation """CDR0000041711"""^^xsd:string ; skos:altLabel """early detection of stomach cancer"""@eng , """gastric cancer early detection"""@eng , """early detection of gastric cancer"""@eng , """gastric cancer screening"""@eng , """screening for stomach cancer"""@eng , """stomach cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4880"""^^xsd:string ; umls:cui """C0281305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calusterone"""@eng ; skos:notation """CDR0000041710"""^^xsd:string ; skos:altLabel """7 Beta, 17 Alpha-dimethyltestosterone"""@eng , """U-22,550"""@eng , """Androst-4-en-3-one, 17.beta.-hydroxy-7.beta.,17-dimethyl- (8CI)"""@eng , """17 Beta-OH-7 beta, 17 alpha-dimethyl-androst-4-ene-3-one"""@eng , """Androst-4-en-3-one, 7.beta., 17.alpha.-dimethyl-17.beta.-hydroxy-"""@eng , """17-Beta-hydroxy-7-beta, 17-dimethylandrost-4-ene-3-one"""@eng , """Androst-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7.beta.17.beta.)- (9CI)"""@eng , """Methosarb"""@eng , """Dimethyltestosterone"""@eng ; skos:definition """A 17-alkylated orally active androgenic steroid. Calusterone may alter the metabolism of estradiol and reduce estrogen production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41710&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41710&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C337\" NCI Thesaurus)"""@eng ; """488"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C337"""^^xsd:string ; """17021-26-0"""^^xsd:string ; """88536"""^^xsd:string ; """4401"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1305846"""^^xsd:string ; umls:cui """C0006790"""^^xsd:string ; umls:cui """C0649942"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/interleukin-3"""@eng ; skos:notation """CDR0000041717"""^^xsd:string ; skos:altLabel """ARA-C/DNR/IL-3/VP-16"""@eng ; ; ; ; ; """4888"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281310"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinfosiltine"""@eng ; skos:notation """CDR0000041716"""^^xsd:string ; skos:altLabel """S 12363"""@eng ; """4887"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281309"""^^xsd:string ; umls:cui """C0084429"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone/mitoxantrone"""@eng ; skos:notation """CDR0000041715"""^^xsd:string ; skos:altLabel """DHAD/HC"""@eng ; ; ; """4886"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281308"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan hydrochloride"""@eng ; skos:notation """CDR0000041714"""^^xsd:string ; skos:altLabel """Campto"""@eng , """(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione"""@eng , """Camptothecin-11"""@eng , """7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin"""@eng , """U-101440E"""@eng , """Camptosar"""@eng , """irinotecan"""@eng , """[1,4'-bipiperidine]-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester"""@eng , """CPT-11"""@eng , """(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate"""@eng , """Irinotecan HCl"""@eng ; skos:definition """The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41714&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41714&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1381\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """100286-90-6"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """616348"""^^xsd:string ; """C1381"""^^xsd:string ; """42459"""^^xsd:string ; """2006-05-18"""^^xsd:string ; """4885"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701186"""^^xsd:string ; umls:cui """C0123931"""^^xsd:string ; umls:cui """C0594375"""^^xsd:string ; umls:cui """C0701188"""^^xsd:string ; umls:cui """C0701187"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate"""@eng ; skos:notation """CDR0000041719"""^^xsd:string ; skos:altLabel """Metrotex"""@eng , """Lumexon"""@eng , """Trixilem"""@eng , """Emthexate"""@eng , """Lantarel"""@eng , """Fauldexato"""@eng , """4-Amino-10-methylfolic Acid"""@eng , """Folex"""@eng , """Abitrexate"""@eng , """Novatrex"""@eng , """Texate"""@eng , """Methoblastin"""@eng , """amethopterin"""@eng , """Methotrexate LPF"""@eng , """Alpha-Methopterin"""@eng , """MTX"""@eng , """N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid"""@eng , """Mexate"""@eng , """Methotrexatum"""@eng , """Mexate-AQ"""@eng , """Folex PFS"""@eng , """Emtexate"""@eng , """Maxtrex"""@eng , """Brimexate"""@eng , """Metotrexato"""@eng , """WR-19039"""@eng , """Metex"""@eng , """4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid"""@eng , """Farmitrexat"""@eng , """Medsatrexate"""@eng , """Tremetex"""@eng , """Ledertrexate"""@eng , """methotrexate methylaminopterin"""@eng , """Rheumatrex"""@eng , """Emthexat"""@eng , """Trexeron"""@eng , """CL-14377"""@eng ; skos:definition """An antimetabolite with antineoplastic and immunomodulating properties. Methotrxate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41719&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41719&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C642\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """489"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4291"""^^xsd:string ; """7723"""^^xsd:string ; """740"""^^xsd:string ; """59-05-2"""^^xsd:string ; """C642"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0025677"""^^xsd:string ; umls:cui """C1513214"""^^xsd:string ; umls:cui """C1513212"""^^xsd:string ; umls:cui """C1513213"""^^xsd:string ; umls:cui """C1513210"""^^xsd:string ; umls:cui """C1513211"""^^xsd:string ; umls:cui """C0701379"""^^xsd:string ; umls:cui """C1527141"""^^xsd:string ; umls:cui """C1527140"""^^xsd:string ; umls:cui """C0591758"""^^xsd:string ; umls:cui """C0720499"""^^xsd:string ; umls:cui """C1161371"""^^xsd:string ; umls:cui """C1513201"""^^xsd:string ; umls:cui """C1513200"""^^xsd:string ; umls:cui """C1513203"""^^xsd:string ; umls:cui """C1513202"""^^xsd:string ; umls:cui """C1513205"""^^xsd:string ; umls:cui """C1513204"""^^xsd:string ; umls:cui """C1513207"""^^xsd:string ; umls:cui """C1513206"""^^xsd:string ; umls:cui """C1513209"""^^xsd:string ; umls:cui """C1513208"""^^xsd:string ; umls:cui """C1513195"""^^xsd:string ; umls:cui """C1513194"""^^xsd:string ; umls:cui """C1513197"""^^xsd:string ; umls:cui """C1513196"""^^xsd:string ; umls:cui """C0205839"""^^xsd:string ; umls:cui """C1513198"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rhizoxin"""@eng ; skos:notation """CDR0000041718"""^^xsd:string ; skos:altLabel """WF-1360"""@eng ; skos:definition """A macrocyclic lactone. Rhizoxin binds to tubulin and inhibits microtubule assembly, thereby inducing cytotoxicity. This agent also may inhibit endothelial cell-induced angiogenic activity, which may result in decreased tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41718&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41718&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1218\" NCI Thesaurus)"""@eng ; """4889"""^^xsd:string ; """90996-54-6"""^^xsd:string ; """C1218"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """47008"""^^xsd:string ; """332598"""^^xsd:string ; umls:cui """C0950626"""^^xsd:string ; umls:cui """C0073184"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """visilizumab"""@eng ; skos:notation """CDR0000038685"""^^xsd:string ; skos:altLabel """Nuvion"""@eng ; """11339"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135148"""^^xsd:string ; umls:cui """C3887822"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ad5CMV-p53 gene/docetaxel"""@eng ; skos:notation """CDR0000038684"""^^xsd:string ; skos:altLabel """Ad5CMV-p53/TXT"""@eng ; ; ; """11338"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134690"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tissue oxygen measurement"""@eng ; skos:notation """CDR0000474380"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-03-16"""^^xsd:string ; umls:cui """C1831787"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hemiasterlin analog E7974"""@eng ; skos:notation """CDR0000447049"""^^xsd:string ; skos:altLabel """E7974"""@eng ; skos:definition """An analog of the sponge-derived anti-microtubule tripeptide hemiasterlin with antimitotic and potential antineoplastic activities. Hemiasterlin analog E7974 binds to the Vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly; depolymerization of exsiting microtubules; inhibition of mitosis; and inhibition of cellular proliferation. This agent may have more affinity for the beta-3 tubulin isotype. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=447049&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=447049&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49083\" NCI Thesaurus)"""@eng ; """2005-09-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C49083"""^^xsd:string ; """2006-08-25"""^^xsd:string ; umls:cui """C1708344"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038226"""^^xsd:string ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10833"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862221"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038225"""^^xsd:string ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10832"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862216"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038224"""^^xsd:string ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10831"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862211"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038223"""^^xsd:string ; rdfs:subClassOf ; """10830"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0862196"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I penile cancer"""@eng ; skos:notation """CDR0000038222"""^^xsd:string ; skos:altLabel """penile cancer, stage I"""@eng , """penis cancer, stage I"""@eng ; rdfs:subClassOf ; """penile cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1083"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854965"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody ABX-CBL"""@eng ; skos:notation """CDR0000038221"""^^xsd:string ; skos:altLabel """MOAB ABX-CBL"""@eng , """ABX-CBL"""@eng ; """10829"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935795"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/autologous tumor cell vaccine/sargramostim"""@eng ; skos:notation """CDR0000038220"""^^xsd:string ; skos:altLabel """ADC/ATCV/GM-CSF"""@eng ; ; ; ; """10828"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935794"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bronchoalveolar lavage"""@eng ; skos:notation """CDR0000038229"""^^xsd:string ; """10836"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1535502"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038228"""^^xsd:string ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10835"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862200"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute erythroleukemia (M6)"""@eng ; skos:notation """CDR0000039934"""^^xsd:string ; skos:altLabel """M6 pediatric acute erythroleukemia"""@eng , """pediatric acute erythroleukemia"""@eng , """erythroleukemia, childhood acute"""@eng , """M6 childhood acute erythroleukemia"""@eng , """M6 leukemia, childhood acute"""@eng , """acute erythroleukemia, childhood"""@eng , """pediatric acute M6 leukemia"""@eng , """leukemia, childhood acute erythro-"""@eng , """childhood acute M6 leukemia"""@eng , """leukemia, pediatric acute erythro-"""@eng ; rdfs:subClassOf ; """2614"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279647"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute eosinophilic leukemia"""@eng ; skos:notation """CDR0000039935"""^^xsd:string ; skos:altLabel """pediatric acute eosinophilic leukemia"""@eng , """acute eosinophilic leukemia, childhood"""@eng , """leukemia, childhood acute eosinophilic"""@eng , """eosinophilic leukemia, childhood acute"""@eng ; rdfs:subClassOf ; """2615"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279648"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute basophilic leukemia"""@eng ; skos:notation """CDR0000039936"""^^xsd:string ; skos:altLabel """basophilic leukemia, childhood acute"""@eng , """pediatric acute basophilic leukemia"""@eng , """acute basophilic leukemia, childhood"""@eng , """leukemia, childhood acute basophilic"""@eng ; rdfs:subClassOf ; """2616"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279649"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute megakaryocytic leukemia (M7)"""@eng ; skos:notation """CDR0000039937"""^^xsd:string ; skos:altLabel """megakaryocytic leukemia, childhood acute"""@eng , """pediatric acute megakaryocytic leukemia"""@eng , """M7 pediatric acute megakaryocytic leukemia"""@eng , """leukemia, childhood acute megakaryocytic"""@eng , """acute megakaryocytic leukemia, childhood"""@eng , """M7 childhood acute megakaryocytic leukemia"""@eng ; rdfs:subClassOf ; """2617"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279650"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoma simplex of the colon"""@eng ; skos:notation """CDR0000039930"""^^xsd:string ; skos:altLabel """colon, anaplastic adenocarcinoma of the"""@eng , """anaplastic adenocarcinoma of the colon"""@eng , """undifferentiated adenocarcinoma of the colon"""@eng , """colon, carcinoma simplex of the"""@eng , """colon, undifferentiated adenocarcinoma of the"""@eng ; rdfs:subClassOf ; """2610"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C2355642"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute myelomonocytic leukemia (M4)"""@eng ; skos:notation """CDR0000039931"""^^xsd:string ; skos:altLabel """myelomonoblastic leukemia, childhood acute"""@eng , """AMMoL, pediatric"""@eng , """AMMoL, childhood"""@eng , """M4 leukemia, childhood acute"""@eng , """childhood AMMoL"""@eng , """childhood acute M4 leukemia"""@eng , """pediatric AMML"""@eng , """acute myelomonocytic leukemia, childhood"""@eng , """leukemia, childhood acute myelomonocytic"""@eng , """AMML, pediatric"""@eng , """myelomonocytic leukemia, childhood acute"""@eng , """acute myelomonoblastic leukemia, childhood"""@eng , """pediatric AMMoL"""@eng , """pediatric acute myelomonocytic leukemia"""@eng , """childhood AMML"""@eng , """AMML, childhood"""@eng , """M4 childhood acute myelomonocytic leukemia"""@eng , """pediatric acute M4 leukemia"""@eng , """childhood AMML M4"""@eng ; rdfs:subClassOf ; """2611"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279644"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute poorly differentiated monocytic leukemia (M5a)"""@eng ; skos:notation """CDR0000039932"""^^xsd:string ; skos:altLabel """M5a pediatric acute monocytic leukemia without differentiation"""@eng , """monoblastic leukemia, childhood acute"""@eng , """leukemia, pediatric acute monoblastic"""@eng , """childhood acute monoblastic leukemia"""@eng , """pediatric acute monocytic leukemia without differentiation"""@eng , """childhood acute M5a leukemia"""@eng , """childhood AMOL, poorly differentiated"""@eng , """M5a childhood acute poorly differentiated monocytic leukemia"""@eng , """pediatric acute poorly differentiated monocytic leukemia"""@eng , """pediatric acute M5a leukemia"""@eng , """acute monocytic leukemia without differentiation, childhood"""@eng , """M5a childhood acute monocytic leukemia without differentiation"""@eng , """pediatric acute monoblastic leukemia"""@eng , """leukemia, childhood acute monocytic without differentiation"""@eng , """acute monoblastic leukemia, childhood"""@eng , """childhood acute monocytic leukemia without differentiation"""@eng , """pediatric AMOL, poorly differentiated"""@eng , """M5a leukemia, childhood acute"""@eng ; rdfs:subClassOf ; """2612"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279645"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute differentiated monocytic leukemia (M5b)"""@eng ; skos:notation """CDR0000039933"""^^xsd:string ; skos:altLabel """childhood acute monocytic leukemia with differentiation"""@eng , """leukemia, childhood acute monocytic with differentiation"""@eng , """M5b pediatric acute monocytic leukemia with differentiation"""@eng , """pediatric acute differentiated monocytic leukemia"""@eng , """childhood AMOL, differentiated"""@eng , """M5b childhood acute monocytic leukemia with differentiation"""@eng , """acute monocytic leukemia with differentiation, childhood"""@eng , """M5b leukemia, childhood acute"""@eng , """pediatric acute M5b leukemia"""@eng , """M5b childhood AMOL, differentiated"""@eng , """monocytic leukemia with differentiation, childhood acute"""@eng , """pediatric acute monocytic leukemia with differentiation"""@eng , """pediatric AMOL, differentiated"""@eng , """childhood acute M5b leukemia"""@eng ; rdfs:subClassOf ; """2613"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279646"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the rectum"""@eng ; skos:notation """CDR0000039938"""^^xsd:string ; skos:altLabel """rectal cancer, adenocarcinoma"""@eng , """rectum, adenocarcinoma of the"""@eng , """rectal, adenocarcinoma of the"""@eng , """rectum cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2618"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0149978"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the gallbladder"""@eng ; skos:notation """CDR0000039939"""^^xsd:string ; skos:altLabel """gallbladder, adenocarcinoma of the"""@eng , """gallbladder cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2619"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279651"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral fludarabine phosphate"""@eng ; skos:notation """CDR0000486428"""^^xsd:string ; skos:altLabel """Oral Fludarabine Phosphate"""@eng , """SH T 586"""@eng , """Fludara Oral"""@eng ; """Drug/agent"""^^xsd:string ; """C64338"""^^xsd:string ; """2007-01-15"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831839"""^^xsd:string ; umls:cui """C1831840"""^^xsd:string ; umls:cui """C1831841"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lutetium Lu 177 monoclonal antibody CC49"""@eng ; skos:notation """CDR0000038083"""^^xsd:string ; skos:altLabel """Lu177 MOAB CC49"""@eng ; ; ; """10628"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935675"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody CC49"""@eng ; skos:notation """CDR0000038082"""^^xsd:string ; skos:altLabel """Y90 MOAB CC49"""@eng ; ; """10627"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935674"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/phenylbutyrate/sargramostim"""@eng ; skos:notation """CDR0000038081"""^^xsd:string ; skos:altLabel """DM/GM-CSF/PBA"""@eng ; ; ; ; """10625"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/MAGE-12 peptide vaccine/Montanide ISA-51"""@eng ; skos:notation """CDR0000038080"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/MAGE-12"""@eng ; ; ; """10623"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/paclitaxel/yttrium Y 90 monoclonal antibody CC49"""@eng ; skos:notation """CDR0000038087"""^^xsd:string ; skos:altLabel """IFN-A/TAX/Y90 MOAB CC49"""@eng ; ; ; ; """10631"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935678"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/lutetium Lu 177 monoclonal antibody CC49/topotecan"""@eng ; skos:notation """CDR0000038086"""^^xsd:string ; skos:altLabel """IFN-A/Lu177 MOAB CC49/TOPO"""@eng ; ; ; ; """10630"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935677"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radiation therapy"""@eng ; skos:notation """CDR0000038085"""^^xsd:string ; skos:altLabel """radiotherapy"""@eng , """irradiation"""@eng , """therapy, radiation"""@eng ; rdfs:subClassOf owl:Thing ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1063"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; umls:cui """C1522449"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/lutetium Lu 177 monoclonal antibody CC49/paclitaxel"""@eng ; skos:notation """CDR0000038084"""^^xsd:string ; skos:altLabel """IFN-A/Lu177 MOAB CC49/TAX"""@eng ; ; ; ; """10629"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935676"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-275291/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000038089"""^^xsd:string ; skos:altLabel """BMS 275291/CBDCA/TAX"""@eng ; ; ; ; """2003-10-07"""^^xsd:string ; """10633"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935679"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-275291"""@eng ; skos:notation """CDR0000038088"""^^xsd:string ; skos:altLabel """D2163"""@eng , """BMS 275291"""@eng , """N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide"""@eng ; skos:definition """A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. BMS-275291 selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38088&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38088&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1875\" NCI Thesaurus)"""@eng ; ; ; """10632"""^^xsd:string ; """713763"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """62573"""^^xsd:string ; """259188-38-0"""^^xsd:string ; """C1875"""^^xsd:string ; """2006-07-27"""^^xsd:string ; umls:cui """C0935902"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Fanconi's anemia"""@eng ; skos:notation """CDR0000285961"""^^xsd:string ; skos:altLabel """FA"""@eng ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0015625"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dyskeratosis congenita"""@eng ; skos:notation """CDR0000285967"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0265965"""^^xsd:string ; umls:tui """T019"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Diamond-Blackfan anemia"""@eng ; skos:notation """CDR0000285964"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1260899"""^^xsd:string ; umls:tui """T019"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioimmunotherapy"""@eng ; skos:notation """CDR0000042070"""^^xsd:string ; ; rdfs:subClassOf ; ; rdfs:subClassOf ; """5302"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0085101"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/suramin"""@eng ; skos:notation """CDR0000271142"""^^xsd:string ; skos:altLabel """SUR/TAX"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327872"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/methotrexate"""@eng ; skos:notation """CDR0000039668"""^^xsd:string ; skos:altLabel """MTX/VP-16"""@eng , """VMC"""@eng ; ; ; """2323"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/triazinate"""@eng ; skos:notation """CDR0000039669"""^^xsd:string ; skos:altLabel """FAT"""@eng , """DOX/5-FU/TZT"""@eng ; ; ; ; """2324"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279453"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/sargramostim"""@eng ; skos:notation """CDR0000039664"""^^xsd:string ; skos:altLabel """ARA-C/ASP/GM-CSF"""@eng ; ; ; ; """2319"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279448"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000039665"""^^xsd:string ; skos:altLabel """FAMP"""@eng , """CDDP/DOX/5-FU/MITO"""@eng ; ; ; ; ; """2320"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0060058"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000039666"""^^xsd:string ; skos:altLabel """CDDP/IFN-A/IL-2"""@eng ; ; ; ; """2321"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338099"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute monocytic leukemia (M5)"""@eng ; skos:notation """CDR0000039667"""^^xsd:string ; skos:altLabel """leukemia, childhood acute monocytic"""@eng , """M5 childhood AMOL"""@eng , """monocytic leukemia, childhood acute"""@eng , """childhood AMOL"""@eng , """acute monocytic leukemia, childhood"""@eng , """M5 pediatric acute monocytic leukemia"""@eng , """AMOL, pediatric"""@eng , """pediatric acute monocytic leukemia"""@eng , """pediatric AMOL"""@eng , """M5 childhood acute monocytic leukemia"""@eng , """AMOL, childhood"""@eng ; rdfs:subClassOf ; """2322"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279451"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039660"""^^xsd:string ; skos:altLabel """CTX/MP/PRED/VCR"""@eng , """VEMP"""@eng ; ; ; ; ; """2315"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279444"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/mitomycin/streptozocin"""@eng ; skos:notation """CDR0000039661"""^^xsd:string ; skos:altLabel """FAM-S"""@eng , """DOX/5-FU/MITO/SZC"""@eng ; ; ; ; ; """2316"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0207828"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexrazoxane/doxorubicin/fluorouracil"""@eng ; skos:notation """CDR0000039662"""^^xsd:string ; skos:altLabel """ADR-529/CTX/DOX/5-FU"""@eng ; ; ; ; ; """2317"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279446"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/mitomycin/triazinate"""@eng ; skos:notation """CDR0000039663"""^^xsd:string ; skos:altLabel """FAM-T"""@eng , """DOX/5-FU/MITO/TZT"""@eng ; ; ; ; ; """2318"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279447"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/sargramostim"""@eng ; skos:notation """CDR0000041155"""^^xsd:string ; skos:altLabel """DOX/GM-CSF"""@eng ; ; ; """4228"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280753"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CB10-277"""@eng ; skos:notation """CDR0000041154"""^^xsd:string ; skos:altLabel """1-p-carboxy-3,3-dimethylphenyltriazine"""@eng ; skos:definition """A synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties. Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41154&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41154&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2367\" NCI Thesaurus)"""@eng ; """4227"""^^xsd:string ; """C2367"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """208107"""^^xsd:string ; umls:cui """C0284098"""^^xsd:string ; umls:cui """C0088835"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000041157"""^^xsd:string ; skos:altLabel """CBDCA/DOX/VCR/VP-16"""@eng ; ; ; ; ; """4230"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280755"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/ifosfamide"""@eng ; skos:notation """CDR0000041156"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/IFF"""@eng ; ; ; ; """4229"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280754"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/prochlorperazine"""@eng ; skos:notation """CDR0000041151"""^^xsd:string ; skos:altLabel """DOX/PCPZ"""@eng ; ; ; """4224"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280750"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cytarabine/etoposide"""@eng ; skos:notation """CDR0000041150"""^^xsd:string ; skos:altLabel """ARA-C/BU/VP-16"""@eng ; ; ; ; """4223"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280749"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fosquidone"""@eng ; skos:notation """CDR0000041153"""^^xsd:string ; skos:altLabel """GR-63178A"""@eng , """GR63178A"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """4226"""^^xsd:string ; """C1371"""^^xsd:string ; umls:cui """C1831596"""^^xsd:string ; umls:cui """C0118171"""^^xsd:string ; umls:cui """C0950804"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/fludarabine"""@eng ; skos:notation """CDR0000041152"""^^xsd:string ; skos:altLabel """ARA-C/FAMP"""@eng ; ; ; """4225"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280751"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/mechlorethamine/vincristine"""@eng ; skos:notation """CDR0000041159"""^^xsd:string ; skos:altLabel """CBDCA/NM/VCR/VP-16"""@eng ; ; ; ; ; """4232"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280757"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/vincristine"""@eng ; skos:notation """CDR0000041158"""^^xsd:string ; skos:altLabel """NM/VCR"""@eng ; ; ; """4231"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280756"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, high grade, stage IV adult"""@eng ; skos:notation """CDR0000040545"""^^xsd:string ; skos:altLabel """high-grade, metastatic adult non-Hodgkin's lymphoma"""@eng , """NHL, high grade, stage IV adult"""@eng , """non-Hodgkin's lymphoma, high grade, metastatic adult"""@eng , """adult non-Hodgkin's lymphoma, high grade, stage IV"""@eng , """high-grade, metastatic adult NHL"""@eng , """NHL, high grade, metastatic adult"""@eng , """adult NHL, stage IV, high grade"""@eng , """lymphoma, high grade, metastatic adult non-Hodgkin's"""@eng , """adult NHL, metastatic, high grade"""@eng , """adult non-Hodgkin's lymphoma, high grade, metastatic"""@eng , """lymphoma, high grade, stage IV adult non-Hodgkin's"""@eng , """high-grade, stage IV adult NHL"""@eng ; """2005-01-21"""^^xsd:string ; """3441"""^^xsd:string ; umls:cui """C0280176"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000040544"""^^xsd:string ; skos:altLabel """adult diffuse large cell lymphoma, stage IV"""@eng , """adult diffuse large cell lymphoma, metastatic"""@eng , """metastatic adult diffuse large cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3440"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280175"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000040547"""^^xsd:string ; skos:altLabel """metastatic adult lymphoblastic lymphoma"""@eng , """adult lymphoblastic lymphoma, stage IV"""@eng , """adult lymphoblastic lymphoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3443"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280178"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000040546"""^^xsd:string ; skos:altLabel """metastatic adult immunoblastic large cell lymphoma"""@eng , """adult immunoblastic large cell lymphoma, stage IV"""@eng , """adult immunoblastic large cell lymphoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3442"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280177"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000040541"""^^xsd:string ; skos:altLabel """follicular large cell lymphoma, metastatic"""@eng , """metastatic follicular large cell lymphoma"""@eng , """follicular large cell lymphoma, stage IV"""@eng , """stage IV grade III follicular large cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3437"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280172"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, intermediate grade, stage IV adult"""@eng ; skos:notation """CDR0000040540"""^^xsd:string ; skos:altLabel """NHL, intermediate grade, stage IV adult"""@eng , """intermediate-grade, metastatic adult NHL"""@eng , """adult non-Hodgkin's lymphoma, intermediate grade, stage IV"""@eng , """intermediate-grade, metastatic adult non-Hodgkin's lymphoma"""@eng , """lymphoma, intermediate grade, stage IV adult non-Hodgkin's"""@eng , """NHL, intermediate grade, metastatic adult"""@eng , """adult NHL, metastatic, intermediate grade"""@eng , """non-Hodgkin's lymphoma, intermediate grade, metastatic adult"""@eng , """adult non-Hodgkin's lymphoma, intermediate grade, metastatic"""@eng , """adult NHL, stage IV, intermediate grade"""@eng , """lymphoma, intermediate grade, metastatic adult non-Hodgkin's"""@eng , """intermediate-grade, stage IV adult NHL"""@eng ; """2005-01-21"""^^xsd:string ; """3436"""^^xsd:string ; umls:cui """C0280171"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000040543"""^^xsd:string ; skos:altLabel """adult diffuse mixed cell lymphoma, stage IV"""@eng , """metastatic adult diffuse mixed cell lymphoma"""@eng , """adult diffuse mixed cell lymphoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3439"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280174"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000040542"""^^xsd:string ; skos:altLabel """metastatic adult diffuse small cleaved cell lymphoma"""@eng , """adult diffuse small cleaved cell lymphoma, stage IV"""@eng , """adult diffuse small cleaved cell lymphoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3438"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280173"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/gemtuzumab ozogamicin"""@eng ; skos:notation """CDR0000380923"""^^xsd:string ; skos:altLabel """CMA-676/CYSP"""@eng ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541343"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """relapsed adult non-Hodgkin's lymphoma, low grade"""@eng ; skos:notation """CDR0000040549"""^^xsd:string ; skos:altLabel """non-Hodgkin's lymphoma, low grade, recurrent adult"""@eng , """low-grade, relapsed adult non-Hodgkin's lymphoma"""@eng , """adult non-Hodgkin's lymphoma, low grade, recurrent"""@eng , """NHL, low grade, relapsed adult"""@eng , """low-grade, recurrent adult NHL"""@eng , """low-grade, relapsed adult NHL"""@eng , """adult NHL, recurrent, low grade"""@eng , """recurrent adult NHL, low grade"""@eng , """relapsed adult NHL, low grade"""@eng , """recurrent adult non-Hodgkin's lymphoma, low grade"""@eng , """NHL, low grade, recurrent adult"""@eng , """non-Hodgkin's lymphoma, low grade, relapsed adult"""@eng , """adult NHL, relapsed, low grade"""@eng , """adult non-Hodgkin's lymphoma, low grade, relapsed"""@eng ; """2005-01-21"""^^xsd:string ; """3445"""^^xsd:string ; umls:cui """C0280180"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-glucan/isotretinoin/monoclonal antibody 3F8/sargramostim"""@eng ; skos:notation """CDR0000380927"""^^xsd:string ; skos:altLabel """b-GLUC/13-CRA/GM-CSF/MOAB 3F8"""@eng ; ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541346"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """FR901228/rituximab"""@eng ; skos:notation """CDR0000380924"""^^xsd:string ; skos:altLabel """FR 901228/MOAB IDEC-C2B8"""@eng ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541344"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-glucan/monoclonal antibody 3F8/sargramostim"""@eng ; skos:notation """CDR0000380925"""^^xsd:string ; skos:altLabel """b-GLUC/GM-CSF/MOAB 3F8"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541345"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """opioid growth factor"""@eng ; skos:notation """CDR0000428488"""^^xsd:string ; skos:altLabel """OGF"""@eng , """[Met5]-enkephalin"""@eng , """INNO-105"""@eng ; skos:definition """An endogenous pentapeptide with potential antineoplastic and antiangiogenic activities. Opioid growth factor (OGF) binds to and activates the opioid growth factor receptor (OGFr), present on some tumor cells and vascular cells, thereby inhibiting tumor cell proliferation and angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428488&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428488&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48413\" NCI Thesaurus)"""@eng ; """2005-04-23"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48413"""^^xsd:string ; umls:cui """C1831605"""^^xsd:string ; umls:cui """C1541553"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody hA20"""@eng ; skos:notation """CDR0000428486"""^^xsd:string ; skos:altLabel """MOAB hA20"""@eng ; skos:definition """A monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Monoclonal antibody hA20 (mAb hA20) is a fully humanized antibody that targets the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, mAb hA20 triggers a complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in cells overexpressing CD20. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428486&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428486&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48406\" NCI Thesaurus)"""@eng ; """2005-04-23"""^^xsd:string ; """C48406"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-30"""^^xsd:string ; umls:cui """C1541551"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rituximab/temsirolimus"""@eng ; skos:notation """CDR0000428487"""^^xsd:string ; skos:altLabel """CCI-779/MOAB IDEC-C2B8"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-05-05"""^^xsd:string ; """2005-04-23"""^^xsd:string ; umls:cui """C1541552"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/melphalan/prednisone"""@eng ; skos:notation """CDR0000428485"""^^xsd:string ; skos:altLabel """L-PAM/PRED/PS-341"""@eng ; ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541550"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium fluoride"""@eng ; skos:notation """CDR0000039598"""^^xsd:string ; skos:definition """An inorganic salt of fluoride used topically or in municipal water fluoridation systems to prevent dental caries. Fluoride appears to bind to calcium ions in the hydroxyapatite of surface tooth enamel, preventing corrosion of tooth enamel by acids. This agent may also inhibit acid production by commensal oral bacteria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39598&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39598&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C832\" NCI Thesaurus)"""@eng ; """2253"""^^xsd:string ; """77385"""^^xsd:string ; """C832"""^^xsd:string ; """7681-49-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0037508"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/lomustine/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039599"""^^xsd:string ; skos:altLabel """POCC"""@eng , """CCNU/CTX/PCB/VCR"""@eng ; ; ; ; ; """2254"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0071317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rifampin"""@eng ; skos:notation """CDR0000039592"""^^xsd:string ; skos:altLabel """RIF"""@eng , """Rifadin"""@eng , """L-5103"""@eng , """Rimactane"""@eng ; ; """2003-08-04"""^^xsd:string ; """2247"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0699924"""^^xsd:string ; umls:cui """C0699925"""^^xsd:string ; umls:cui """C0733661"""^^xsd:string ; umls:cui """C0035608"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039593"""^^xsd:string ; skos:altLabel """CCNU/PCB/VCR"""@eng , """PCV"""@eng ; ; ; ; """2248"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0070167"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zorubicin"""@eng ; skos:notation """CDR0000039590"""^^xsd:string ; skos:altLabel """Zorubicin Hydrochloride"""@eng , """daunorubicin benzoylhydrazone hydrochloride"""@eng , """benzoyl hydrazone daunorubicin"""@eng , """RP-22050"""@eng , """Benzoic Acid Hydrazide 3-Hydrazone with Daunorubicin"""@eng , """rubidazone"""@eng , """(2S-cis)-Benzoic Acid[1-[4-[3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3-naphthacenyl]ethylidene]hydrazide"""@eng , """Zorubicine"""@eng , """RP 22050"""@eng , """RBZ"""@eng ; skos:definition """A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39590&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39590&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1458\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """2245"""^^xsd:string ; """54083-22-6"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """12942"""^^xsd:string ; """164011"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1458"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0206788"""^^xsd:string ; umls:cui """C0073688"""^^xsd:string ; umls:cui """C1744634"""^^xsd:string ; umls:cui """C0701497"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/melphalan"""@eng ; skos:notation """CDR0000039591"""^^xsd:string ; skos:altLabel """PF"""@eng , """5-FU/L-PAM"""@eng ; ; ; """2246"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279387"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039596"""^^xsd:string ; skos:altLabel """PIP"""@eng , """MP/MTX/VCR"""@eng ; ; ; ; """2251"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279391"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian mixed epithelial carcinoma"""@eng ; skos:notation """CDR0000039597"""^^xsd:string ; skos:altLabel """epithelial carcinoma, ovarian mixed"""@eng , """mixed ephithelial carcinoma, ovarian"""@eng ; rdfs:subClassOf ; """2252"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279392"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/melphalan"""@eng ; skos:notation """CDR0000039594"""^^xsd:string ; skos:altLabel """PAF"""@eng , """DOX/5-FU/L-PAM"""@eng ; ; ; ; """2249"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279389"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """shionogi"""@eng ; skos:notation """CDR0000039595"""^^xsd:string ; """2250"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0949111"""^^xsd:string ; umls:tui """T093"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/MS-275"""@eng ; skos:notation """CDR0000403149"""^^xsd:string ; skos:altLabel """13-CRA/MS 275"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-10-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541389"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040093"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer, stage II"""@eng , """oral cavity and lip cancer, stage II"""@eng ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2842"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279791"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040092"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer, stage I"""@eng , """oral cavity and lip cancer, stage I"""@eng ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2841"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279790"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040091"""^^xsd:string ; skos:altLabel """Lip and oral cavity cancer"""@eng , """oral cavity and lip cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2840"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220641"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """14C BMS-275183"""@eng ; skos:notation """CDR0000487486"""^^xsd:string ; skos:altLabel """[14C] BMS-275183"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62553"""^^xsd:string ; umls:cui """C1831856"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/mitomycin/vincristine"""@eng ; skos:notation """CDR0000040097"""^^xsd:string ; skos:altLabel """MVPF"""@eng , """CDDP/5-FU/MITO/VCR"""@eng ; ; ; ; ; """2847"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279795"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040096"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer, recurrent"""@eng , """oral cavity and lip cancer, recurrent"""@eng ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2845"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279794"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040095"""^^xsd:string ; skos:altLabel """metastatic lip and oral cavity cancer"""@eng , """oral cavity and lip cancer, metastatic"""@eng , """oral cavity and lip cancer, stage IV"""@eng , """lip and oral cavity cancer, stage IV"""@eng , """lip and oral cavity cancer, metastatic"""@eng ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2844"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279793"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040094"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer, stage III"""@eng , """oral cavity and lip cancer, stage III"""@eng ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2843"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279792"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior antiestrogen therapy"""@eng ; skos:notation """CDR0000040099"""^^xsd:string ; skos:altLabel """antiestrogen therapy, prior"""@eng ; """2849"""^^xsd:string ; umls:cui """C0279797"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/melphalan/tamoxifen"""@eng ; skos:notation """CDR0000040098"""^^xsd:string ; skos:altLabel """DOX/5-FU/L-PAM/TMX"""@eng , """PAFT"""@eng ; ; ; ; ; """2848"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279796"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """seliciclib"""@eng ; skos:notation """CDR0000511023"""^^xsd:string ; """2006-10-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1609861"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """depigmentation therapy"""@eng ; skos:notation """CDR0000039005"""^^xsd:string ; skos:altLabel """therapy, depigmentation"""@eng ; """1567"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279029"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/fowlpox-PSA-TRICOM vaccine/goserelin/sargramostim"""@eng ; skos:notation """CDR0000428223"""^^xsd:string ; skos:altLabel """CDX/fPSA-TRI/GM-CSF/ZDX"""@eng ; ; ; ; ; """2005-04-07"""^^xsd:string ; """2005-03-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541541"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """STAT"""@eng ; skos:notation """CDR0000258384"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11505"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1335960"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """STAT3"""@eng ; skos:notation """CDR0000258386"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11500"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1367307"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KIT"""@eng ; skos:notation """CDR0000258381"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11504"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1416655"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """STAT1"""@eng ; skos:notation """CDR0000258383"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11499"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1335872"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cytarabine/idarubicin"""@eng ; skos:notation """CDR0000043033"""^^xsd:string ; skos:altLabel """ARA-C/IDA/WR-2721"""@eng ; ; ; ; """7343"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678038"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PV701"""@eng ; skos:notation """CDR0000258388"""^^xsd:string ; skos:altLabel """PV-701"""@eng , """PV 701"""@eng ; skos:definition """An attenuated, replication-competent, oncolytic strain of Newcastle disease virus. PV701 selectively lyses tumor cells. The selectivity of this agent is related to defects in the interferon-mediated antiviral response found in tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258388&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258388&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2799\" NCI Thesaurus)"""@eng ; """11509"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C2799"""^^xsd:string ; """9929"""^^xsd:string ; """700553"""^^xsd:string ; umls:cui """C1327815"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 9"""@eng ; skos:notation """CDR0000258389"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11493"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008672"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MEK inhibitor AZD6244"""@eng ; skos:notation """CDR0000532294"""^^xsd:string ; skos:altLabel """AZD6244"""@eng , """ARRY-142886"""@eng ; """2007-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541456"""^^xsd:string ; umls:cui """C1832054"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, stage I adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042712"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6506"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677682"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/etanidazole"""@eng ; skos:notation """CDR0000041649"""^^xsd:string ; skos:altLabel """CBDCA/IFF/SR-2508/VP-16"""@eng ; ; ; ; ; """4810"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281258"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/fluorouracil"""@eng ; skos:notation """CDR0000042710"""^^xsd:string ; skos:altLabel """EPI/5-FU"""@eng ; ; ; """6504"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935658"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, contiguous stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042716"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6510"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677686"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000042717"""^^xsd:string ; skos:altLabel """contiguous stage II grade I follicular small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6511"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677687"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, stage I adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042714"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6508"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677684"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """butocin"""@eng ; skos:notation """CDR0000039171"""^^xsd:string ; skos:altLabel """benin"""@eng , """butocine"""@eng ; """1791"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0054258"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000042718"""^^xsd:string ; skos:altLabel """contiguous stage II grade II follicular mixed cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6512"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677688"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000042719"""^^xsd:string ; skos:altLabel """contiguous stage II grade III follicular large cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6513"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677689"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cefamandole"""@eng ; skos:notation """CDR0000039178"""^^xsd:string ; skos:altLabel """cephamandole"""@eng ; """1798"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0007541"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drotrecogin alfa"""@eng ; skos:notation """CDR0000354474"""^^xsd:string ; skos:altLabel """Xigris![REGISTERED SIGN]!"""@eng , """Xigris®"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1100687"""^^xsd:string ; umls:cui """C1170000"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """kidney transplantation"""@eng ; skos:notation """CDR0000354477"""^^xsd:string ; ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-01-23"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0022671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ceftazidime sodium"""@eng ; skos:notation """CDR0000039179"""^^xsd:string ; skos:altLabel """Fortaz"""@eng ; ; """TRD"""^^xsd:string ; """1799"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C355"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C0700859"""^^xsd:string ; umls:cui """C0724548"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fulvestrant/trastuzumab"""@eng ; skos:notation """CDR0000445586"""^^xsd:string ; skos:altLabel """ICI 182780/MOAB HER2"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-23"""^^xsd:string ; """2005-08-24"""^^xsd:string ; umls:cui """C1831720"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/oxaliplatin/suberoylanilide hydroxamic acid"""@eng ; skos:notation """CDR0000445585"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/SAHA"""@eng ; ; ; ; ; """2005-08-23"""^^xsd:string ; """2005-08-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831719"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E1M184V peptide vaccine"""@eng ; skos:notation """CDR0000509253"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-15"""^^xsd:string ; umls:cui """C1831962"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous lung dysplasia"""@eng ; skos:notation """CDR0000437889"""^^xsd:string ; skos:altLabel """bronchial dysplasia"""@eng ; rdfs:subClassOf ; """2005-06-25"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """2005-06-17"""^^xsd:string ; umls:cui """C1336084"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DTGM fusion protein"""@eng ; skos:notation """CDR0000043449"""^^xsd:string ; skos:altLabel """fusion protein, DTGM"""@eng , """DTGM"""@eng ; """8628"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796606"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood ependymoma"""@eng ; skos:notation """CDR0000043448"""^^xsd:string ; skos:altLabel """CNS tumor, childhood ependymoma"""@eng , """brain tumor, ependymoma, childhood"""@eng , """Brain tumor, child: Ependymoma"""@eng , """brain tumor, childhood ependymoma"""@eng , """CNS tumor, ependymoma, childhood"""@eng , """ependymoma, childhood"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """8627"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1851584"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox virus vaccine vector/interleukin-2"""@eng ; skos:notation """CDR0000043445"""^^xsd:string ; skos:altLabel """FOWLVAC/IL-2"""@eng ; ; ; """8624"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796602"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox virus vaccine vector"""@eng ; skos:notation """CDR0000043444"""^^xsd:string ; skos:altLabel """FOWLVAC"""@eng ; skos:definition """A recombinant fowlpox virus-based vaccine vector designed to express various tumor-associated peptide antigens. Strong CD8 cytotoxic T cell responses may be induced after prolonged immunization with fowlpox virus vaccines and have been associated with tumor regression. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43444&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43444&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48390\" NCI Thesaurus)"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """C48390"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """8623"""^^xsd:string ; umls:cui """C0796601"""^^xsd:string ; umls:cui """C1704761"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """apomine"""@eng ; skos:notation """CDR0000043447"""^^xsd:string ; skos:altLabel """SR45023A"""@eng , """SR-45023A"""@eng , """SR 45023A"""@eng ; """2003-10-22"""^^xsd:string ; """8626"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1527108"""^^xsd:string ; umls:cui """C0919349"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/vincristine/VX-710"""@eng ; skos:notation """CDR0000043446"""^^xsd:string ; skos:altLabel """DOX/VCR/VX 710"""@eng ; ; ; ; """2003-10-23"""^^xsd:string ; """8625"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796603"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KSA-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000043441"""^^xsd:string ; skos:altLabel """KSA-KLH"""@eng ; ; """8602"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796598"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KSA glycoprotein"""@eng ; skos:notation """CDR0000043440"""^^xsd:string ; skos:altLabel """KSA"""@eng ; ; """8601"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0903677"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KSA-KLH conjugate vaccine/QS21"""@eng ; skos:notation """CDR0000043443"""^^xsd:string ; skos:altLabel """KSA-KLH/QS 21"""@eng ; ; ; """8604"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796600"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KSA glycoprotein/QS21"""@eng ; skos:notation """CDR0000043442"""^^xsd:string ; skos:altLabel """KSA/QS 21"""@eng ; ; ; """8603"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796599"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Gerson therapy"""@eng ; skos:notation """CDR0000453793"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2005-10-24"""^^xsd:string ; """2005-10-20"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C1831723"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/perflubron"""@eng ; skos:notation """CDR0000041964"""^^xsd:string ; skos:altLabel """CTX/PFOB"""@eng ; ; ; """5189"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281512"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/topotecan"""@eng ; skos:notation """CDR0000041965"""^^xsd:string ; skos:altLabel """CBDCA/TOPO"""@eng ; ; ; """5190"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281513"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/topotecan"""@eng ; skos:notation """CDR0000041966"""^^xsd:string ; skos:altLabel """ARA-C/TOPO"""@eng ; ; ; """5191"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/filgrastim/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000041967"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/5-FU/G-CSF"""@eng ; ; ; ; ; ; """5192"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281515"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/tretinoin"""@eng ; skos:notation """CDR0000041960"""^^xsd:string ; skos:altLabel """ATRA/BRYO"""@eng ; ; ; """5184"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/hydroxyurea/leucovorin calcium"""@eng ; skos:notation """CDR0000041961"""^^xsd:string ; skos:altLabel """CF/FUDR/HU"""@eng ; ; ; ; """5185"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281510"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/hydroxyurea"""@eng ; skos:notation """CDR0000041962"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/HU"""@eng ; ; ; ; """5186"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """perflubron"""@eng ; skos:notation """CDR0000041963"""^^xsd:string ; skos:altLabel """perfluorooctylbromide"""@eng , """PFOB"""@eng , """Imagent"""@eng ; skos:definition """A synthetic radiopaque liquid form of perfluorooctyl bromide. Used as a contrast agent for magnetic resonance imaging (MRI), perflubron is also used as a liquid ventilation agent to improve pulmonary gas exchange and lung compliance and may be used in surgery to reduce or eliminate the need for donor blood. Ventilation with perfluorocarbon fluid improves lung function in conditions involving surfactant deficiency and dysfunction, including respiratory distress syndrome and adult respiratory distress syndrome. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41963&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41963&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1422\" NCI Thesaurus)"""@eng ; ; """5187"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """423-55-2"""^^xsd:string ; """C1422"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0993621"""^^xsd:string ; umls:cui """C0162922"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/interferon alfa/pentostatin"""@eng ; skos:notation """CDR0000041968"""^^xsd:string ; skos:altLabel """DCF/IFF/IFN-A"""@eng ; ; ; ; """5194"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338179"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/monoclonal antibody CC49"""@eng ; skos:notation """CDR0000041969"""^^xsd:string ; skos:altLabel """IFN-A/MOAB CC49"""@eng ; ; ; """5195"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338180"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interventional radiology"""@eng ; skos:notation """CDR0000042921"""^^xsd:string ; rdfs:subClassOf ; """6755"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0344093"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial cancer prevention"""@eng ; skos:notation """CDR0000042920"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """6754"""^^xsd:string ; umls:cui """C0677841"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/cisplatin"""@eng ; skos:notation """CDR0000042923"""^^xsd:string ; skos:altLabel """CDDP/MOAB C225"""@eng ; ; ; """6757"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677842"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphography"""@eng ; skos:notation """CDR0000042922"""^^xsd:string ; rdfs:subClassOf ; """6756"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0024290"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/fludarabine"""@eng ; skos:notation """CDR0000042925"""^^xsd:string ; skos:altLabel """FAMP/WR-2721"""@eng ; ; ; """6759"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677844"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/fluorouracil"""@eng ; skos:notation """CDR0000042924"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/VP-16"""@eng ; ; ; ; """6758"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677843"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """staphylococcal enterotoxin A"""@eng ; skos:notation """CDR0000042927"""^^xsd:string ; skos:altLabel """SEA"""@eng ; """6760"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0059385"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """therapeutic testosterone"""@eng ; skos:notation """CDR0000042926"""^^xsd:string ; skos:altLabel """Mertestate"""@eng , """Testosterone"""@eng , """Delta4-Androsten-17beta-ol-3-one"""@eng , """Trans-Testosterone"""@eng , """Testoderm"""@eng , """Delatestryl"""@eng , """Testostroval-PA"""@eng , """(17Beta)-17-hydroxyandrost-4-en-3-one"""@eng , """Testolin"""@eng , """testosterone"""@eng , """Androtardyl"""@eng , """Malogen"""@eng , """Virosterone"""@eng , """Testostroval"""@eng , """Reposo-TMD"""@eng , """Testro AQ"""@eng , """testosterone enanthate"""@eng , """TESTO"""@eng ; skos:definition """A synthetic form of the endogenous androgenic steroid testosterone. Due to rapid metabolism by the liver, therapeutic testosterone is generally administered as an ester derivative. This agent and its derivatives promote the maintenance of male sex characteristics. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42926&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42926&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C862\" NCI Thesaurus)"""@eng ; ; ; """2006-09-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9700"""^^xsd:string ; """57-85-2 (propionate)"""^^xsd:string ; """676"""^^xsd:string ; """58-22-0"""^^xsd:string ; """C862"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0723656"""^^xsd:string ; umls:cui """C1515403"""^^xsd:string ; umls:cui """C0723655"""^^xsd:string ; umls:cui """C1515405"""^^xsd:string ; umls:cui """C1515404"""^^xsd:string ; umls:cui """C0076189"""^^xsd:string ; umls:cui """C0039601"""^^xsd:string ; umls:cui """C0723659"""^^xsd:string ; umls:cui """C0701001"""^^xsd:string ; umls:cui """C0701000"""^^xsd:string ; umls:cui """C0733491"""^^xsd:string ; umls:cui """C0733489"""^^xsd:string ; umls:cui """C0719723"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flt3 ligand/gp100 antigen"""@eng ; skos:notation """CDR0000042929"""^^xsd:string ; skos:altLabel """Flt3L/gp100"""@eng ; ; ; """6763"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677845"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant flt3 ligand"""@eng ; skos:notation """CDR0000042928"""^^xsd:string ; skos:altLabel """Mobist"""@eng , """Flt3L"""@eng , """flt3 ligand"""@eng , """Flt3-ligand"""@eng ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """6761"""^^xsd:string ; """C1714"""^^xsd:string ; umls:cui """C1522457"""^^xsd:string ; umls:cui """C0935953"""^^xsd:string ; umls:cui """C0249989"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000043038"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/TAX/WR-2721"""@eng ; ; ; ; ; """7357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678043"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/interleukin-11/sargramostim"""@eng ; skos:notation """CDR0000043039"""^^xsd:string ; skos:altLabel """ARA-C/DNR/GM-CSF/IL-11"""@eng ; ; ; ; ; """7358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678044"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000043034"""^^xsd:string ; skos:altLabel """5-FU/TMTX"""@eng ; ; ; """7345"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678039"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ONYX-015"""@eng ; skos:notation """CDR0000043035"""^^xsd:string ; skos:altLabel """E1B-Attenuated Adenovirus"""@eng , """CI-1042"""@eng , """E1B 55kDa mutant adenovirus dl1520"""@eng ; skos:definition """An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43035&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43035&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2830\" NCI Thesaurus)"""@eng ; ; """7353"""^^xsd:string ; """C2830"""^^xsd:string ; """688653"""^^xsd:string ; """7872"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678040"""^^xsd:string ; umls:tui """T005"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/ONYX-015"""@eng ; skos:notation """CDR0000043036"""^^xsd:string ; skos:altLabel """CDDP/5-FU/ONYX-015"""@eng ; ; ; ; """7354"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678041"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/thiotepa/topotecan"""@eng ; skos:notation """CDR0000043037"""^^xsd:string ; skos:altLabel """DHAD/TOPO/TSPA"""@eng ; ; ; ; """7355"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678042"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/tirapazamine"""@eng ; skos:notation """CDR0000043030"""^^xsd:string ; skos:altLabel """CTX/SR-4233"""@eng ; ; ; """7331"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678036"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dendritic cell-CEA peptide vaccine"""@eng ; skos:notation """CDR0000043031"""^^xsd:string ; skos:altLabel """Dendritic Cell CEA Peptide Vaccine"""@eng , """CEA peptide-pulsed dendritic cell vaccine"""@eng , """Vaccine, dendritic cell-CEA peptide"""@eng , """CEA peptide-pulsed DC vaccine"""@eng , """Dendritic cell-carcinoembryonic antigen peptide vaccine"""@eng ; skos:definition """A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43031&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43031&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2473\" NCI Thesaurus)"""@eng ; """7332"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C2473"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678037"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/thiotepa"""@eng ; skos:notation """CDR0000043032"""^^xsd:string ; skos:altLabel """L-PAM/TSPA"""@eng , """MELT"""@eng ; ; ; """734"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050572"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/methylprednisolone/tacrolimus"""@eng ; skos:notation """CDR0000429484"""^^xsd:string ; skos:altLabel """FK506/MePRDL/MOAB CD52"""@eng ; ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541555"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/melphalan"""@eng ; skos:notation """CDR0000257920"""^^xsd:string ; skos:altLabel """CTX/FAMP/L-PAM"""@eng ; ; ; ; """2002-09-12"""^^xsd:string ; """11476"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327796"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human mannose-binding lectin"""@eng ; skos:notation """CDR0000520344"""^^xsd:string ; skos:altLabel """rhMBL"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-06"""^^xsd:string ; umls:cui """C0065661"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/trastuzumab"""@eng ; skos:notation """CDR0000037855"""^^xsd:string ; skos:altLabel """LipoDox/MOAB HER2"""@eng ; ; ; """10259"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879426"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/fluorouracil/hydroxyurea"""@eng ; skos:notation """CDR0000038419"""^^xsd:string ; skos:altLabel """5-FU/HU/MOAB VEGF"""@eng ; ; ; ; """11036"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134475"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """panitumumab"""@eng ; skos:notation """CDR0000037857"""^^xsd:string ; skos:altLabel """Vectibix"""@eng , """monoclonal antibody ABX-EGF"""@eng , """MOAB ABX-EGF"""@eng , """ABX-EGF monoclonal antibody"""@eng , """ABX-EGF"""@eng ; skos:definition """A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37857&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37857&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1857\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """10260"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1857"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0879427"""^^xsd:string ; umls:cui """C1743549"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thiamine"""@eng ; skos:notation """CDR0000037856"""^^xsd:string ; skos:altLabel """vit B1"""@eng , """vitamin B1"""@eng , """thiamin"""@eng , """vitamin-B1"""@eng , """B1 vitamin"""@eng ; skos:definition """A heat-labile and water-soluble essential vitamin, belonging to the vitamin B family, with antioxidant, erythropoietic, mood modulating, and glucose-regulating activities. Thiamine reacts with adenosine triphosphate (ATP) to form an active coenzyme, thiamine pyrophosphate. Thiamine pyrophosphate is necessary for the actions of pyruvate dehydrogenase and alpha-ketoglutarate in carbohydrate metabolism and for the actions of transketolase, an enzyme that plays an important role in the pentose phosphate pathway. Thiamine plays a key role in intracellular glucose metabolism and may inhibit the action of glucose and insulin on arterial smooth muscle cell proliferation. Thiamine may also protect against lead toxicity by inhibiting lead-induced lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37856&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37856&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C874\" NCI Thesaurus)"""@eng ; """1026"""^^xsd:string ; """59-43-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C874"""^^xsd:string ; umls:cui """C0039840"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/oblimersen"""@eng ; skos:notation """CDR0000037851"""^^xsd:string ; skos:altLabel """CPT-11/G3139"""@eng ; ; ; """10254"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879423"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """B43-genistein immunoconjugate"""@eng ; skos:notation """CDR0000037850"""^^xsd:string ; """10253"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879422"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody BrE-3"""@eng ; skos:notation """CDR0000038148"""^^xsd:string ; skos:altLabel """MOAB BrE-3, yttrium Y 90"""@eng , """Y90 monoclonal antibody BrE-3"""@eng , """BrE-3 monoclonal antibody, yttrium Y 90"""@eng , """Y90 MOAB BrE-3"""@eng , """yttrium Y 90 MOAB BrE-3"""@eng , """monoclonal antibody BrE-3, yttrium Y 90"""@eng ; skos:definition """A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38148&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38148&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2607\" NCI Thesaurus)"""@eng ; ; """10729"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C2607"""^^xsd:string ; umls:cui """C0935731"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-214662"""@eng ; skos:notation """CDR0000037852"""^^xsd:string ; skos:altLabel """BMS214662"""@eng , """BMS 214662"""@eng ; skos:definition """A nonsedating benzodiazepine derivative with antineoplastic activity. BMS-214662 inhibits the enzyme farnesyl protein transferase, resulting in apoptosis of tumor cells. Farnesyl protein transferase modifies several proteins posttranslationally (farnesylation), including Ras, an oncoprotein implicated in the pathogenesis of many human tumors. BMS-214662 may also reverse the malignant phenotype of H-Ras-transformed cells. This agent has been shown to be active against tumor cells with and without Ras mutations. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37852&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37852&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1856\" NCI Thesaurus)"""@eng ; ; ; """10255"""^^xsd:string ; """C1856"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879424"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methyl-5-aminolevulinate"""@eng ; skos:notation """CDR0000038410"""^^xsd:string ; skos:altLabel """Metvix"""@eng ; """11028"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135142"""^^xsd:string ; umls:cui """C1134467"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/flavopiridol"""@eng ; skos:notation """CDR0000038411"""^^xsd:string ; skos:altLabel """CBDCA/FLAVO"""@eng ; ; ; """11029"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134468"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/irinotecan"""@eng ; skos:notation """CDR0000038144"""^^xsd:string ; skos:altLabel """CPT-11/FLAVO"""@eng ; ; ; """10724"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935729"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 105AD7 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000038413"""^^xsd:string ; skos:altLabel """105AD7"""@eng , """MOAB 105AD7"""@eng ; skos:definition """A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38413&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38413&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2648\" NCI Thesaurus)"""@eng ; ; ; """11030"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2648"""^^xsd:string ; """2006-08-29"""^^xsd:string ; umls:cui """C1134469"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/thalidomide"""@eng ; skos:notation """CDR0000037859"""^^xsd:string ; skos:altLabel """THAL/TXT"""@eng ; ; ; """10263"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879429"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/irinotecan"""@eng ; skos:notation """CDR0000037858"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/WR-2721"""@eng ; ; ; ; """10261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879428"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """renal cell cancer"""@eng ; skos:notation """CDR0000038140"""^^xsd:string ; skos:altLabel """renal cell carcinoma"""@eng , """Kidney (renal cell) cancer"""@eng , """kidney cancer"""@eng , """hypernephroma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1070"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007134"""^^xsd:string ; umls:cui """C0279702"""^^xsd:string ; umls:cui """C0740457"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ascorbic acid/selenium/vitamin E"""@eng ; skos:notation """CDR0000038141"""^^xsd:string ; skos:altLabel """SEL/VIT-C/VIT-E"""@eng ; ; ; ; """10700"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935724"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/doxorubicin"""@eng ; skos:notation """CDR0000357347"""^^xsd:string ; skos:altLabel """3AP/DOX"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328216"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV pancreatic cancer"""@eng ; skos:notation """CDR0000042547"""^^xsd:string ; skos:altLabel """pancreatic cancer, stage IV"""@eng , """pancreatic cancer, metastatic"""@eng , """stage IV pancreas cancer"""@eng , """pancreas cancer, stage IV"""@eng , """metastatic pancreatic cancer"""@eng , """metastatic pancreas cancer"""@eng , """pancreas cancer, metastatic"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """62"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1167725"""^^xsd:string ; umls:cui """C0346976"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penicillamine"""@eng ; skos:notation """CDR0000042546"""^^xsd:string ; skos:altLabel """Alpha-amino-beta-methyl-beta-mercaptobutyric Acid"""@eng , """Depamine"""@eng , """Kelatin"""@eng , """Perdolat"""@eng , """3-Mercapto-D-valine"""@eng , """D-Mercaptovaline"""@eng , """Cupripen"""@eng , """Cuprimine"""@eng , """Beta-thiovaline"""@eng , """Sufortan"""@eng , """D-Penicillamine"""@eng , """Depen"""@eng , """Atamir"""@eng , """Beta,Beta-dimethylcysteine"""@eng , """Trolovol"""@eng , """Metalcaptase"""@eng , """Cuprenil"""@eng , """Mercaptyl"""@eng , """Distamine"""@eng , """Pendramine"""@eng ; skos:definition """A beta dimethyl analog of the amino acid cysteine. As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion. Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42546&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42546&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C729\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """6198"""^^xsd:string ; """52-67-5"""^^xsd:string ; """81549"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """C729"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699484"""^^xsd:string ; umls:cui """C0719754"""^^xsd:string ; umls:cui """C0591393"""^^xsd:string ; umls:cui """C0699483"""^^xsd:string ; umls:cui """C0030817"""^^xsd:string ; umls:cui """C0025536"""^^xsd:string ; umls:cui """C1518948"""^^xsd:string ; umls:cui """C0591958"""^^xsd:string ; umls:cui """C1518943"""^^xsd:string ; umls:cui """C1518942"""^^xsd:string ; umls:cui """C1518947"""^^xsd:string ; umls:cui """C1518946"""^^xsd:string ; umls:cui """C1518945"""^^xsd:string ; umls:cui """C1518944"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cidofovir"""@eng ; skos:notation """CDR0000042545"""^^xsd:string ; skos:altLabel """Vistide"""@eng , """CDV"""@eng , """HPMPC"""@eng , """1(3-hydroxy-2-phosphonomethoxypropyl) Cytosine"""@eng ; skos:definition """A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42545&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42545&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1600\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """6196"""^^xsd:string ; """113852-37-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1600"""^^xsd:string ; umls:cui """C0286078"""^^xsd:string ; umls:cui """C0286079"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enalapril maleate"""@eng ; skos:notation """CDR0000042544"""^^xsd:string ; skos:altLabel """Enacard"""@eng , """Vasotec"""@eng , """Renitec"""@eng ; """TRD"""^^xsd:string ; """6194"""^^xsd:string ; """2006-11-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C468"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0600128"""^^xsd:string ; umls:cui """C0728763"""^^xsd:string ; umls:cui """C0700916"""^^xsd:string ; umls:cui """C0700452"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tesmilifene"""@eng ; skos:notation """CDR0000042543"""^^xsd:string ; skos:altLabel """DPPE"""@eng , """DHPE"""@eng ; ; ; ; """2005-01-10"""^^xsd:string ; """6190"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1704341"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diethylhomospermine"""@eng ; skos:notation """CDR0000042542"""^^xsd:string ; skos:altLabel """N1,N14-diethylhomospermine"""@eng , """DEHSPM"""@eng , """N1N14-diethylhomospermine"""@eng ; """6189"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0067118"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """crotoxin"""@eng ; skos:notation """CDR0000042541"""^^xsd:string ; skos:altLabel """CT"""@eng ; """6188"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0010377"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anastrozole"""@eng ; skos:notation """CDR0000042540"""^^xsd:string ; skos:altLabel """Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile"""@eng , """2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)"""@eng , """ANAS"""@eng , """ICI-D1033"""@eng , """Arimidex"""@eng , """ZD-1033"""@eng ; skos:definition """A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, anastrozole may inhibit tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42540&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42540&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1607\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """6187"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """120511-73-1"""^^xsd:string ; """C1607"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """719344"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0290882"""^^xsd:string ; umls:cui """C0290883"""^^xsd:string ; umls:cui """C0878174"""^^xsd:string ; umls:cui """C0733865"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/ifosfamide/mitomycin/sargramostim"""@eng ; skos:notation """CDR0000042549"""^^xsd:string ; skos:altLabel """CDDP/DOX/GM-CSF/IFF/MITO"""@eng ; ; ; ; ; ; """6204"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392973"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/ifosfamide/mitomycin"""@eng ; skos:notation """CDR0000042548"""^^xsd:string ; skos:altLabel """CDDP/DOX/IFF/MITO"""@eng , """I-MAP"""@eng ; ; ; ; ; """6203"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392972"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/cisplatin/fluorouracil"""@eng ; skos:notation """CDR0000038418"""^^xsd:string ; skos:altLabel """CDDP/5-FU/SC-58635"""@eng ; ; ; ; """11035"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134474"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CBE-11"""@eng ; skos:notation """CDR0000426420"""^^xsd:string ; skos:altLabel """hCBE-11"""@eng , """MOAB CBE-11"""@eng ; """2005-03-18"""^^xsd:string ; """2005-03-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541533"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bowel obstruction management"""@eng ; skos:notation """CDR0000037854"""^^xsd:string ; skos:altLabel """constipation, impaction, and bowel obstruction management"""@eng ; ; rdfs:subClassOf ; """10257"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0879425"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TG4010"""@eng ; skos:notation """CDR0000037853"""^^xsd:string ; skos:altLabel """MVA-MUC1-IL2™"""@eng , """MVA-MUC1-IL2![TRADE MARK SIGN]!"""@eng ; """2003-10-23"""^^xsd:string ; """10256"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328239"""^^xsd:string ; umls:cui """C0879624"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """advanced malignant mesothelioma"""@eng ; skos:notation """CDR0000038149"""^^xsd:string ; skos:altLabel """malignant mesothelioma, advanced"""@eng , """advanced mesothelial sarcoma"""@eng , """mesothelial sarcoma, advanced"""@eng , """mesothelioma, malignant, advanced"""@eng ; rdfs:subClassOf ; """malignant mesothelioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1073"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278752"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clear cell sarcoma of the kidney"""@eng ; skos:notation """CDR0000038146"""^^xsd:string ; skos:altLabel """kidney clear cell sarcoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """10727"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334488"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody F19"""@eng ; skos:notation """CDR0000043384"""^^xsd:string ; skos:altLabel """F19 monoclonal antibody"""@eng ; """7936"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796524"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rhabdoid tumor of the kidney"""@eng ; skos:notation """CDR0000038147"""^^xsd:string ; skos:altLabel """kidney rhabdoid tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """10728"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0854917"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000038412"""^^xsd:string ; skos:altLabel """lymphoma, immunoblastic large cell, adult"""@eng , """immunoblastic large cell lymphoma, adult"""@eng , """large cell lymphoma, adult immunoblastic"""@eng , """adult IBL lymphoma"""@eng , """IBL lymphoma, adult"""@eng ; rdfs:subClassOf ; """1103"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278763"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/vindesine"""@eng ; skos:notation """CDR0000039431"""^^xsd:string ; skos:altLabel """PEV"""@eng , """VEP"""@eng , """CDDP/DAVA/VP-16"""@eng ; ; ; ; """2066"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1321916"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/lomustine"""@eng ; skos:notation """CDR0000039430"""^^xsd:string ; skos:altLabel """CAC"""@eng , """CCNU/CTX/DOX"""@eng ; ; ; ; """2065"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279290"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim/zidovudine"""@eng ; skos:notation """CDR0000039433"""^^xsd:string ; skos:altLabel """GM-CSF/ZDV"""@eng ; ; ; """2068"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279293"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interleukin-2"""@eng ; skos:notation """CDR0000039432"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IL-2"""@eng ; ; ; ; """2067"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279292"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/mitomycin"""@eng ; skos:notation """CDR0000039435"""^^xsd:string ; skos:altLabel """5-FU/IFN-A/MITO"""@eng ; ; ; ; """2070"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338093"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/semustine"""@eng ; skos:notation """CDR0000039434"""^^xsd:string ; skos:altLabel """CF/5-FU/MeCCNU"""@eng ; ; ; ; """2069"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279294"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyrazine diazohydroxide"""@eng ; skos:notation """CDR0000039437"""^^xsd:string ; skos:altLabel """PZDH"""@eng , """pyrazinamine, N-nitroso-, sodium salt"""@eng , """pyrazine-2-diazohydroxide"""@eng , """pyrazineamine, N-nitroso-, sodium salt"""@eng ; skos:definition """A congener of pyridine 2-diazohydroxide. Pyrazine diazohydroxide forms DNA adducts via the reactive pyrazine diazonium ion, thereby inhibiting DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39437&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39437&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1207\" NCI Thesaurus)"""@eng ; """2072"""^^xsd:string ; """361456"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33930"""^^xsd:string ; """C1207"""^^xsd:string ; """103829-56-7"""^^xsd:string ; umls:cui """C0072657"""^^xsd:string ; umls:cui """C1524064"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/ifosfamide"""@eng ; skos:notation """CDR0000041369"""^^xsd:string ; skos:altLabel """BLEO/CDDP/IFF"""@eng ; ; ; ; """4440"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053662"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/sargramostim"""@eng ; skos:notation """CDR0000039439"""^^xsd:string ; skos:altLabel """CBDCA/CTX/GM-CSF"""@eng ; ; ; ; """2074"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279299"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malignant mesothelioma"""@eng ; skos:notation """CDR0000038142"""^^xsd:string ; skos:altLabel """Mesothelioma"""@eng , """mesothelial sarcoma"""@eng , """mesothelioma, malignant"""@eng , """sarcoma, mesothelial"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1071"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0025500"""^^xsd:string ; umls:cui """C0334513"""^^xsd:string ; umls:cui """C0345967"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/tamoxifen"""@eng ; skos:notation """CDR0000041364"""^^xsd:string ; skos:altLabel """DTIC/TMX"""@eng ; ; ; """4435"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280933"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/interferon alfa"""@eng ; skos:notation """CDR0000041365"""^^xsd:string ; skos:altLabel """DTIC/IFN-A"""@eng ; ; ; """4436"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338147"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethylbusulfan/etoposide"""@eng ; skos:notation """CDR0000041362"""^^xsd:string ; skos:altLabel """DMB/VP-16"""@eng ; ; ; """4433"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280931"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041363"""^^xsd:string ; skos:altLabel """CTX/DOX/PRDL/VCR"""@eng ; ; ; ; ; """4434"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078042"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/filgrastim"""@eng ; skos:notation """CDR0000041360"""^^xsd:string ; skos:altLabel """CTX/DOX/G-CSF"""@eng ; ; ; ; """4431"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280929"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/vinblastine"""@eng ; skos:notation """CDR0000041361"""^^xsd:string ; skos:altLabel """DOX/VBL"""@eng ; ; ; """4432"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280930"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/suberoylanilide hydroxamic acid"""@eng ; skos:notation """CDR0000437143"""^^xsd:string ; skos:altLabel """PS-341/SAHA"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-14"""^^xsd:string ; """2005-06-17"""^^xsd:string ; umls:cui """C1831651"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody F19"""@eng ; skos:notation """CDR0000043385"""^^xsd:string ; """7937"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796525"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/MS-275"""@eng ; skos:notation """CDR0000409555"""^^xsd:string ; skos:altLabel """AZA/MS 275"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """2004-11-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541420"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/oblimersen"""@eng ; skos:notation """CDR0000038416"""^^xsd:string ; skos:altLabel """CTX/FAMP/G3139"""@eng ; ; ; ; """11033"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adrenocortical suppressant"""@eng ; skos:notation """CDR0000040378"""^^xsd:string ; rdfs:subClassOf ; """3239"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280044"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinca alkaloid"""@eng ; skos:notation """CDR0000040379"""^^xsd:string ; rdfs:subClassOf ; """3240"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0042672"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immuno-therapeutic agent"""@eng ; skos:notation """CDR0000040376"""^^xsd:string ; rdfs:subClassOf ; """3237"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0876248"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imidazole carboxamide derivative"""@eng ; skos:notation """CDR0000040377"""^^xsd:string ; rdfs:subClassOf ; """3238"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280043"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glucocorticoid"""@eng ; skos:notation """CDR0000040374"""^^xsd:string ; rdfs:subClassOf ; """3235"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0017710"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/cisplatin"""@eng ; skos:notation """CDR0000038417"""^^xsd:string ; skos:altLabel """3AP/CDDP"""@eng ; """11034"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134473"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyrimidine antagonist"""@eng ; skos:notation """CDR0000040372"""^^xsd:string ; rdfs:subClassOf ; """3233"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280039"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """holmium Ho 166 DOTMP/melphalan"""@eng ; skos:notation """CDR0000437141"""^^xsd:string ; skos:altLabel """166Ho-DOTMP/L-PAM"""@eng ; ; ; """2005-06-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831650"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """folic acid antagonist"""@eng ; skos:notation """CDR0000040370"""^^xsd:string ; rdfs:subClassOf ; """3231"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0016411"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """purine antagonist"""@eng ; skos:notation """CDR0000040371"""^^xsd:string ; rdfs:subClassOf ; """3232"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280038"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MART-1 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000043636"""^^xsd:string ; skos:altLabel """gp100/MART-1/TYRP"""@eng ; ; ; ; """8921"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879342"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/vinorelbine"""@eng ; skos:notation """CDR0000043637"""^^xsd:string ; skos:altLabel """CBDCA/VNB"""@eng ; ; ; """8936"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879344"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/p53 peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000043634"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/p53 VAC"""@eng ; ; ; """8919"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879340"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin"""@eng ; skos:notation """CDR0000043635"""^^xsd:string ; skos:altLabel """KOS-953"""@eng , """CNF1010"""@eng , """17-Allylamino-17-demethoxygeldanamycin"""@eng , """17-AAG"""@eng , """17-N-Allylamino-17-demethoxy geldanamycin"""@eng , """17-N-allylamino-17-demethoxy geldanamycin"""@eng , """17-Demethoxy-17-(2-propenylamino)geldanamycin"""@eng , """17-Allyl-aminogeldanamycin"""@eng , """17-Allylamino-17-demethoxy-geldanamycin"""@eng , """17-(Allylamino)-17-demethoxygeldanamycin"""@eng ; skos:definition """A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. 17-allylamino-17-demethoxygeldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43635&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43635&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37899\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """8920"""^^xsd:string ; """57966"""^^xsd:string ; """330507"""^^xsd:string ; """75747-14-7"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """C37899"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1541784"""^^xsd:string ; umls:cui """C1710806"""^^xsd:string ; umls:cui """C0675974"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12 gene"""@eng ; skos:notation """CDR0000043632"""^^xsd:string ; skos:altLabel """plasmid DNA encoding human interleukin-12"""@eng , """plasmid IL-12"""@eng , """IL-12 gene"""@eng , """pIL-12"""@eng ; skos:definition """The DNA sequence that encodes the protein cytokine interleukin-12 (IL-12). When introduced as the complementary DNA (cDNA) form into tumor cells by, for example, a genetically engineered adenovirus vector, the transfected IL-12 cDNA expresses IL-12 which activates antitumoral natural killer (NK) cells and CD8+ T-cells and stimulates the secretion of interferon-gamma (IFN-gamma), potentially inhibiting tumor cell metastasis. This gene therapy may also result in IL-12-mediated inhibition of vascular endothelial growth factor (VEGF) and enhancement of matrix metalloproteinases (MMPs). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43632&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43632&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2222\" NCI Thesaurus)"""@eng ; ; """8917"""^^xsd:string ; """2007-01-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2222"""^^xsd:string ; umls:cui """C0879338"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """p53 peptide vaccine"""@eng ; skos:notation """CDR0000043633"""^^xsd:string ; skos:altLabel """P53 (264-272) peptide vaccine and tumor-specific mutant p53 peptide vaccine"""@eng , """p53 VAC"""@eng , """individualized mutant p53 peptide-pulsed cultured autologous dendritic cell vaccine"""@eng ; skos:definition """A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43633&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43633&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1986\" NCI Thesaurus)"""@eng ; ; ; """8918"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C1986"""^^xsd:string ; umls:cui """C0879339"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131"""@eng ; skos:notation """CDR0000043630"""^^xsd:string ; skos:altLabel """Iodotrope"""@eng , """Iodotope"""@eng , """I 131"""@eng ; skos:definition """A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43630&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43630&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1639\" NCI Thesaurus)"""@eng ; """8915"""^^xsd:string ; """C1639"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517591"""^^xsd:string ; umls:cui """C0303029"""^^xsd:string ; umls:cui """C1328689"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood medulloblastoma"""@eng ; skos:notation """CDR0000043631"""^^xsd:string ; skos:altLabel """childhood medulloblastoma, stage"""@eng ; rdfs:subClassOf ; """8916"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0879337"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polyvalent melanoma vaccine"""@eng ; skos:notation """CDR0000043301"""^^xsd:string ; skos:altLabel """POLYMELVAC"""@eng , """Canvaxin"""@eng , """Polyvalent Melanoma Cell Vaccine"""@eng , """PMCV"""@eng ; skos:definition """A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43301&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43301&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1633\" NCI Thesaurus)"""@eng ; ; ; """7820"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C1633"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0299555"""^^xsd:string ; umls:cui """C1143122"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gemcitabine/paclitaxel"""@eng ; skos:notation """CDR0000043638"""^^xsd:string ; skos:altLabel """dFdC/5-FU/TAX"""@eng ; ; ; ; """8937"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879345"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CD40-ligand"""@eng ; skos:notation """CDR0000043639"""^^xsd:string ; skos:altLabel """TRAP ligand"""@eng , """CD40-L"""@eng , """gp39"""@eng , """gp39 cytokine"""@eng , """T-cell antigen gp39"""@eng , """Recombinant CD40-Ligand"""@eng , """CD40L"""@eng , """CD154"""@eng , """TNF-related activation protein"""@eng , """CD154 antigen"""@eng , """rhu CD40L"""@eng , """T-BAM"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to CD40-ligand. CD40-ligand, also known as CD40L/TRAP and CD154, is a type II membrane protein which binds to CD40, a cell surface receptor that belongs to the tumor necrosis factor receptor family; CD40 is expressed on B lymphocytes, monocytes, dendritic cells (DC), hematopoietic progenitors, endothelial cells and epithelial cells. Recombinant CD40-ligand may be used to activate DC ex vivo via CD40 binding; CD40-ligand-activated DC may provide or augment a protective antitumor immunity when administered in dendritic cell cancer vaccines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43639&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43639&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1437\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """8938"""^^xsd:string ; """C1437"""^^xsd:string ; """9593"""^^xsd:string ; """696600"""^^xsd:string ; """147205-72-9"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C1527003"""^^xsd:string ; umls:cui """C0167627"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cutaneous leiomyoma"""@eng ; skos:notation """CDR0000279893"""^^xsd:string ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """2003-02-20"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346064"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II marginal zone lymphoma"""@eng ; skos:notation """CDR0000371896"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541264"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II marginal zone lymphoma"""@eng ; skos:notation """CDR0000371897"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541265"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """marginal zone lymphoma"""@eng ; skos:notation """CDR0000371894"""^^xsd:string ; skos:altLabel """Marginal zone lymphoma"""@eng ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-28"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1367654"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I marginal zone lymphoma"""@eng ; skos:notation """CDR0000371895"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541263"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trifluridine"""@eng ; skos:notation """CDR0000039240"""^^xsd:string ; skos:altLabel """2'-Deoxy-5-trifluoromethyluridine"""@eng , """F3TdR"""@eng , """triflorothymidine"""@eng ; skos:definition """A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39240&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39240&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C905\" NCI Thesaurus)"""@eng ; """1862"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """70-00-8"""^^xsd:string ; """C905"""^^xsd:string ; """75520"""^^xsd:string ; """3953"""^^xsd:string ; umls:cui """C0040987"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000371898"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541266"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000371899"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541267"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039040"""^^xsd:string ; skos:altLabel """ASP/CTX/DNR/PRED/VCR"""@eng ; ; ; ; ; ; """1612"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/thioguanine"""@eng ; skos:notation """CDR0000039041"""^^xsd:string ; skos:altLabel """ARA-C/CTX/TG"""@eng ; ; ; ; """1613"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1510469"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/carmustine/thioguanine"""@eng ; skos:notation """CDR0000039042"""^^xsd:string ; skos:altLabel """ARA-C/ASP/BCNU/TG"""@eng ; ; ; ; ; """1614"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279058"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/cytarabine/daunorubicin/hydroxyurea/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039043"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/CTX/DNR/HU/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; """1615"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279059"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039044"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MTX/PRED/TG/VCR"""@eng ; ; ; ; ; ; ; """1616"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039045"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DOX/MTX/PRED/TG/VCR"""@eng ; ; ; ; ; ; ; ; """1617"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053538"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine"""@eng ; skos:notation """CDR0000039046"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP"""@eng ; ; ; ; """1618"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279062"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039047"""^^xsd:string ; skos:altLabel """CTX/DNR/PRED/VCR"""@eng ; ; ; ; ; """1619"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678241"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphomatoid granulomatosis (grades I and II)"""@eng ; skos:notation """CDR0000039048"""^^xsd:string ; skos:altLabel """lethal midline reticulosis"""@eng ; rdfs:subClassOf ; """2004-06-22"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1620"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C0018197"""^^xsd:string ; umls:cui """C0024307"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/goserelin"""@eng ; skos:notation """CDR0000041770"""^^xsd:string ; skos:altLabel """CDX/ZDX"""@eng ; ; ; """4951"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281353"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/thiotepa"""@eng ; skos:notation """CDR0000041773"""^^xsd:string ; skos:altLabel """BCNU/CDDP/TSPA"""@eng ; ; ; ; """4954"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281356"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/floxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000041772"""^^xsd:string ; skos:altLabel """CDDP/CF/FUDR"""@eng ; ; ; ; """4953"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281355"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leuprolide/suramin"""@eng ; skos:notation """CDR0000041775"""^^xsd:string ; skos:altLabel """LEUP/SUR"""@eng ; ; ; """4956"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281358"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000041774"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/CTX/VP-16"""@eng ; ; ; ; ; """4955"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281357"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ketoconazole/paclitaxel"""@eng ; skos:notation """CDR0000041777"""^^xsd:string ; skos:altLabel """KCZ/TAX"""@eng ; ; ; """4958"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281360"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/leuprolide"""@eng ; skos:notation """CDR0000041776"""^^xsd:string ; skos:altLabel """AGT/LEUP"""@eng ; ; ; """4957"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281359"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transforming growth factor-alpha-pseudomonas exotoxin-40"""@eng ; skos:notation """CDR0000041531"""^^xsd:string ; skos:altLabel """TP-40"""@eng ; """4692"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0247342"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fermented wheat germ extract"""@eng ; skos:notation """CDR0000529839"""^^xsd:string ; skos:altLabel """FWGE"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1832024"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/fowlpox-CEA-MUC-1-TRICOM vaccine/vaccinia-CEA-MUC-1-TRICOM vaccine"""@eng ; skos:notation """CDR0000415564"""^^xsd:string ; skos:altLabel """ADC/fCEA-MUC-1-TRI/vCEA-MUC-1-TRI"""@eng ; ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """osteoporosis"""@eng ; skos:notation """CDR0000041530"""^^xsd:string ; rdfs:subClassOf ; """4691"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0029456"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/tesmilifene"""@eng ; skos:notation """CDR0000415568"""^^xsd:string ; skos:altLabel """CTX/DPPE/EPI"""@eng ; ; ; ; """2005-01-13"""^^xsd:string ; """2005-01-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541487"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sleep disorders therapy"""@eng ; skos:notation """CDR0000041536"""^^xsd:string ; ; rdfs:subClassOf ; """4697"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0281168"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """remifentanil hydrochloride"""@eng ; skos:notation """CDR0000461218"""^^xsd:string ; skos:altLabel """Ultiva"""@eng , """1-Piperidinepropanoic Acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-, Methyl Ester, Monohydrochloride"""@eng ; skos:definition """The hydrochloride salt form of remifentanil, a synthetic anilidopiperidine derivative and short-acting opiate agonist with analgesic and anesthetic properties. Remifentanil selectively binds to and activates the mu-opioid receptor, thereby producing analgesia, respiratory depression, miosis, reduced gastrointestinal motility, and euphoria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461218&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461218&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47702\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """132539-07-2"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C47702"""^^xsd:string ; umls:cui """C0771827"""^^xsd:string ; umls:cui """C0594510"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/cytarabine/idarubicin"""@eng ; skos:notation """CDR0000390236"""^^xsd:string ; skos:altLabel """ARA-C/AS2O3/IDA"""@eng ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-08-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541361"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen peptide 1-6D/Montanide ISA-51"""@eng ; skos:notation """CDR0000269492"""^^xsd:string ; skos:altLabel """CEA PEP 1-6D/ISA-51"""@eng ; ; """2002-12-21"""^^xsd:string ; """2002-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327853"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen peptide 1-6D/sargramostim"""@eng ; skos:notation """CDR0000269493"""^^xsd:string ; skos:altLabel """CEA PEP 1-6D/GM-CSF"""@eng ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327854"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fulvestrant/tipifarnib"""@eng ; skos:notation """CDR0000363600"""^^xsd:string ; skos:altLabel """ICI 182780/R115777"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541200"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegylated paclitaxel"""@eng ; skos:notation """CDR0000363602"""^^xsd:string ; skos:altLabel """PEG-paclitaxel"""@eng ; """2004-03-24"""^^xsd:string ; """2004-03-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541201"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 iodocholesterol"""@eng ; skos:notation """CDR0000363603"""^^xsd:string ; skos:altLabel """I-131 iodocholesterol"""@eng ; """2004-03-24"""^^xsd:string ; """2004-03-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0304983"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """familial adenomatous polyposis (APC)"""@eng ; skos:notation """CDR0000042839"""^^xsd:string ; skos:altLabel """FAP"""@eng ; ; rdfs:subClassOf ; """6640"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Genetic condition"""^^xsd:string ; """2006-08-02"""^^xsd:string ; umls:cui """C0032580"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000040554"""^^xsd:string ; skos:altLabel """relapsed follicular large cell lymphoma"""@eng , """recurrent grade III follicular large cell lymphoma"""@eng , """follicular large cell lymphoma, recurrent"""@eng , """follicular large cell lymphoma, relapsed"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3450"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280185"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000040555"""^^xsd:string ; skos:altLabel """adult diffuse small cleaved cell lymphoma, relapsed"""@eng , """diffuse small cleaved cell lymphoma, adult, recurrent"""@eng , """relapsed adult diffuse small cleaved cell lymphoma"""@eng , """adult diffuse small cleaved cell lymphoma, recurrent"""@eng , """diffuse small cleaved cell lymphoma, recurrent, adult"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3451"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280186"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """11C topotecan"""@eng ; skos:notation """CDR0000454314"""^^xsd:string ; skos:definition """A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata radiolabeled with carbon 11 (11C) with antineoplastic and radiotracer properties. During the S phase of the cell cycle, topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Quantitation of 11C topotecan accumulated in tumor tissues by positron emission tomography (PET) may help predict responses to topotecan therapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454314&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454314&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49172\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C49172"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """2005-10-24"""^^xsd:string ; umls:cui """C1711433"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel/pegfilgrastim"""@eng ; skos:notation """CDR0000405881"""^^xsd:string ; skos:altLabel """CBDCA/GCSF-SD01/TXT"""@eng ; ; ; ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541401"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian mucinous cystadenocarcinoma"""@eng ; skos:notation """CDR0000039952"""^^xsd:string ; skos:altLabel """cystadenocarcinoma, mucinous, ovarian"""@eng , """ovary cancer, mucinous cystadenocarcinoma"""@eng , """cystadenocarcinoma, ovarian mucinous"""@eng , """ovarian cancer, mucinous cystadenocarcinoma"""@eng , """mucinous cystadenocarcinoma of the ovary"""@eng , """cystadenocarcinoma of the ovary, mucinous"""@eng ; rdfs:subClassOf ; """2645"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279665"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian endometrioid adenocarcinoma"""@eng ; skos:notation """CDR0000039953"""^^xsd:string ; skos:altLabel """ovary cancer, endometrioid adenocarcinoma"""@eng , """adenocarcinoma of the ovary, endometrioid"""@eng , """ovarian cancer, endometrioid adenocarcinoma"""@eng , """endometrioid adenocarcinoma of the ovary"""@eng ; rdfs:subClassOf ; """2648"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346163"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian serous cystadenocarcinoma"""@eng ; skos:notation """CDR0000039950"""^^xsd:string ; skos:altLabel """ovary cancer, serous cystadenocarcinoma"""@eng , """cystadenocarcinoma of the ovary, serous"""@eng , """ovarian cancer, serous cystadenocarcinoma"""@eng , """serous cystadenocarcinoma of the ovary"""@eng ; rdfs:subClassOf ; """2641"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279663"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian mucinous cystadenoma with proliferating activity"""@eng ; skos:notation """CDR0000039951"""^^xsd:string ; skos:altLabel """mucinous cystadenoma with proliferating activity of the ovary"""@eng , """cystadenoma with proliferating activity, mucinous, ovarian"""@eng , """cystadenoma with proliferating activity, ovarian mucinous"""@eng , """ovary cancer, mucinous cystadenoma with proliferating activity"""@eng , """cystadenoma with proliferating activity of the ovary, mucinous"""@eng , """ovarian cancer, mucinous cystadenoma with proliferating activity"""@eng ; rdfs:subClassOf ; """2644"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279664"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaginal adenocarcinoma"""@eng ; skos:notation """CDR0000039956"""^^xsd:string ; skos:altLabel """vaginal cancer, adenocarcinoma"""@eng , """adenocarcinoma of the vagina"""@eng , """vagina cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2653"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279668"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaginal clear cell adenocarcinoma"""@eng ; skos:notation """CDR0000039957"""^^xsd:string ; skos:altLabel """vaginal cancer, clear cell adenocarcinoma"""@eng , """adenocarcinoma, clear cell, vaginal"""@eng , """clear cell adenocarinoma of the vagina"""@eng , """vagina cancer, clear cell adenocarcinoma"""@eng ; rdfs:subClassOf ; """2654"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238517"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian clear cell cystadenocarcinoma"""@eng ; skos:notation """CDR0000039954"""^^xsd:string ; skos:altLabel """ovarian mesonephroid cystadenocarcinoma"""@eng , """mesonephroid cystadenocarcinoma, ovarian"""@eng , """cystadenocarcinoma, clear cell, ovarian"""@eng , """ovarian cancer, mesonephroid cystadenocarcinoma"""@eng , """ovary cancer, mesonephroid cystadenocarcinoma"""@eng , """cystadenocarcinoma, mesonephroid, ovarian"""@eng , """ovary cancer, clear cell cystadenocarcinoma"""@eng , """ovarian cancer, clear cell cystadenocarcinoma"""@eng , """cystadenocarcinoma of the ovary, clear cell"""@eng , """clear cell cystadenocarcinoma of the ovary"""@eng ; rdfs:subClassOf ; """2651"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279667"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaginal squamous cell carcinoma"""@eng ; skos:notation """CDR0000039955"""^^xsd:string ; skos:altLabel """vaginal cancer, epidermoid cell carcinoma"""@eng , """squamous cell carcinoma of the vagina"""@eng , """carcinoma, squamous cell, vaginal"""@eng , """carcinoma, epidermoid cell, vaginal"""@eng , """epidermoid carcinoma of the vagina"""@eng , """vagina cancer, squamous cell carcinoma"""@eng , """vaginal cancer, squamous cell carcinoma"""@eng , """vagina cancer, epidermoid cell carcinoma"""@eng ; rdfs:subClassOf ; """2652"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238518"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sulindac/tamoxifen"""@eng ; skos:notation """CDR0000327787"""^^xsd:string ; skos:altLabel """SULIN/TMX"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328032"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Paget's disease of the vulva"""@eng ; skos:notation """CDR0000039959"""^^xsd:string ; skos:altLabel """vulva, Paget's disease of the"""@eng ; rdfs:subClassOf ; """2660"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1275217"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rifampin/tetracycline"""@eng ; skos:notation """CDR0000327783"""^^xsd:string ; skos:altLabel """RIF/TETRA"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328031"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dihydrotestosterone"""@eng ; skos:notation """CDR0000511037"""^^xsd:string ; skos:altLabel """DHT"""@eng , """Androstanolone"""@eng , """(5alpha,17beta)-17-Hydroxyandrostan-3-one"""@eng ; skos:definition """The most potent androgen, required for sex development. Dihydrotestosterone is synthesized from testosterone in the prostate gland, testes, hair follicles and adrenal glands by 5-alpha reductase. Dihydrotestosterone exerts its action similar to testosterone, which binds to and activates specific nuclear androgen receptors. After translocation into the nucleus, the activated hormone-receptor complex binds to the androgen response elements on the DNA and activates gene expressions that are required for sex development. Dihydrotestosterone is responsible for the formation of male primary sex characteristics and most male secondary sex characteristics during puberty, such as muscular growth, facial and body hair growth, and deepening of the voice. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=511037&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=511037&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29619\" NCI Thesaurus)"""@eng ; """2006-10-05"""^^xsd:string ; """C29619"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0038148"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SH U04722"""@eng ; skos:notation """CDR0000511038"""^^xsd:string ; """2006-10-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831964"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DHA-paclitaxel/gemcitabine"""@eng ; skos:notation """CDR0000271127"""^^xsd:string ; skos:altLabel """dFdC/DHA-TAX"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327871"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """needle biopsy"""@eng ; skos:notation """CDR0000482232"""^^xsd:string ; skos:altLabel """aspiration biopsy"""@eng , """puncture biopsy"""@eng ; rdfs:subClassOf ; """Diagnostic test/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C0936232"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 7"""@eng ; skos:notation """CDR0000043199"""^^xsd:string ; rdfs:subClassOf ; """7642"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008670"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Intron A"""@eng ; skos:notation """CDR0000448847"""^^xsd:string ; """2005-09-16"""^^xsd:string ; """C1953"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0751600"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CDDO"""@eng ; skos:notation """CDR0000453589"""^^xsd:string ; skos:altLabel """2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid"""@eng ; skos:definition """A synthetic, triterpenoid compound with anticancer and anti-inflammatory activities. CDDO blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3, an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453589&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453589&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48382\" NCI Thesaurus)"""@eng ; """2005-10-24"""^^xsd:string ; """C48382"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C0762434"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZD0530"""@eng ; skos:notation """CDR0000453588"""^^xsd:string ; skos:definition """An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. AZD0530 is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and their effects on cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, AZD0530 inhibits Src kinase-mediated osteoclast bone resorption. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453588&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453588&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48378\" NCI Thesaurus)"""@eng ; """C48378"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-10-24"""^^xsd:string ; """2006-07-27"""^^xsd:string ; umls:cui """C1706679"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorescent in situ hybridization (FISH)"""@eng ; skos:notation """CDR0000043193"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """7636"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0162789"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """miscellaneous antineoplastic hormone and synthetic substitute"""@eng ; skos:notation """CDR0000039303"""^^xsd:string ; rdfs:subClassOf ; """1937"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279177"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """comparative genomic analysis"""@eng ; skos:notation """CDR0000043191"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """7634"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796358"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 17"""@eng ; skos:notation """CDR0000043190"""^^xsd:string ; rdfs:subClassOf ; """7633"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008659"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 8"""@eng ; skos:notation """CDR0000043197"""^^xsd:string ; rdfs:subClassOf ; """7640"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008671"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000043196"""^^xsd:string ; skos:altLabel """childhood rhabdomyosarcoma, recurrent"""@eng , """rhabdomyosarcoma, recurrent childhood"""@eng , """recurrent pediatric rhabdomyosarcoma"""@eng , """pediatric rhabdomyosarcoma, recurrent"""@eng ; rdfs:subClassOf ; """childhood rhabdomyosarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """764"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278649"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 5"""@eng ; skos:notation """CDR0000043195"""^^xsd:string ; rdfs:subClassOf ; """7639"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008668"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """duct cell adenocarcinoma of the pancreas"""@eng ; skos:notation """CDR0000039302"""^^xsd:string ; skos:altLabel """pancreas cancer, duct cell adenocarcinoma"""@eng , """adenocarcinoma, duct cell, pancreatic"""@eng , """pancreatic cancer, duct cell adenocarcinoma"""@eng ; rdfs:subClassOf ; """1935"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279176"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sucralfate"""@eng ; skos:notation """CDR0000039608"""^^xsd:string ; skos:altLabel """Carafate"""@eng ; """2263"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0740157"""^^xsd:string ; umls:cui """C0038633"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039609"""^^xsd:string ; skos:altLabel """T-MOP"""@eng , """MTX/PRED/TG/VCR"""@eng ; ; ; ; ; """2264"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279397"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant adenovirus-hIFN-beta"""@eng ; skos:notation """CDR0000038609"""^^xsd:string ; skos:altLabel """Ad-hIFN-beta"""@eng , """BG00001"""@eng ; skos:definition """A recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38609&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38609&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28550\" NCI Thesaurus)"""@eng ; """11237"""^^xsd:string ; """2006-05-31"""^^xsd:string ; """C28550"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134622"""^^xsd:string ; umls:cui """C1527241"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/doxorubicin/mitomycin/sargramostim"""@eng ; skos:notation """CDR0000038605"""^^xsd:string ; skos:altLabel """CDDP/DOX/DTIC/GM-CSF/MITO"""@eng ; ; ; ; ; ; """11233"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134619"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epothilone D"""@eng ; skos:notation """CDR0000038604"""^^xsd:string ; skos:altLabel """(4S-(4R*,7S,8R*,9R*,13Z,16R*(E)))-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)oxacyclohexadec-13-ene-2,6-dione"""@eng , """KOS 862"""@eng , """desoxyepothilone B"""@eng , """KOS-862"""@eng , """12,13-Deoxyepothilone B"""@eng ; skos:definition """A natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38604&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38604&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2672\" NCI Thesaurus)"""@eng ; """11232"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2672"""^^xsd:string ; """189453-10-9"""^^xsd:string ; """703147"""^^xsd:string ; umls:cui """C1328652"""^^xsd:string ; umls:cui """C0962559"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """post-transplant lymphoproliferative disorder"""@eng ; skos:notation """CDR0000038607"""^^xsd:string ; skos:altLabel """PTLD"""@eng ; rdfs:subClassOf ; """11235"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0432487"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic GM-CSF-secreting breast cancer vaccine/cyclophosphamide/interferon alfa"""@eng ; skos:notation """CDR0000398146"""^^xsd:string ; skos:altLabel """CTX/GM-CSF BREAST VAC/IFN-A"""@eng ; ; ; ; """2004-10-25"""^^xsd:string ; """2004-10-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541385"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/mitomycin/streptozocin"""@eng ; skos:notation """CDR0000039606"""^^xsd:string ; skos:altLabel """SMF"""@eng , """5-FU/MITO/SZC"""@eng ; ; ; ; """2261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0082637"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lidocaine"""@eng ; skos:notation """CDR0000039607"""^^xsd:string ; skos:altLabel """2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide"""@eng , """2-Diethylamino-2',6'-acetoxylidide"""@eng , """Xylocitin"""@eng , """Cuivasil"""@eng , """Leostesin"""@eng , """Duncaine"""@eng , """Rucaina"""@eng , """Lidothesin"""@eng , """Xylocaine"""@eng , """Xylotox"""@eng , """Omega-diethylamino-2,6-dimethylacetanilide"""@eng , """Lignocaine"""@eng ; skos:definition """A synthetic aminoethylamide with local anesthetic and antiarrhythmic properties. Lidocaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the ionic fluxes required for the initiation and conduction of impulses and effecting local anesthesia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39607&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39607&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C614\" NCI Thesaurus)"""@eng ; """2262"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C614"""^^xsd:string ; """137-58-6"""^^xsd:string ; """40030"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0023660"""^^xsd:string ; umls:cui """C0702203"""^^xsd:string ; umls:cui """C0592275"""^^xsd:string ; umls:cui """C1517869"""^^xsd:string ; umls:cui """C1517868"""^^xsd:string ; umls:cui """C1517872"""^^xsd:string ; umls:cui """C1517870"""^^xsd:string ; umls:cui """C1517871"""^^xsd:string ; umls:cui """C0699094"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """corticotropin/cyclophosphamide"""@eng ; skos:notation """CDR0000038603"""^^xsd:string ; skos:altLabel """CCTROP/CTX"""@eng ; ; ; """11231"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134618"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/filgrastim/mitoxantrone"""@eng ; skos:notation """CDR0000038602"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/G-CSF"""@eng ; ; ; ; """11230"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134617"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/methotrexate/pentamidine/sargramostim/vincristine/zidovudine"""@eng ; skos:notation """CDR0000041173"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF/MTX/PAD/VCR/VP-16/ZDV"""@eng ; ; ; ; ; ; ; ; ; """4246"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280768"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/interleukin-2/sargramostim"""@eng ; skos:notation """CDR0000041454"""^^xsd:string ; skos:altLabel """CDDP/CTX/GM-CSF/IL-2/VP-16"""@eng ; ; ; ; ; ; """4524"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281002"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/fluorouracil/leucovorin calcium/zidovudine"""@eng ; skos:notation """CDR0000041171"""^^xsd:string ; skos:altLabel """CF/DP/5-FU/ZDV"""@eng ; ; ; ; ; """4244"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280766"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/interleukin-1-beta"""@eng ; skos:notation """CDR0000041170"""^^xsd:string ; skos:altLabel """CBDCA/IL-1B/VP-16"""@eng ; ; ; ; """4243"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280765"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin/sargramostim"""@eng ; skos:notation """CDR0000041177"""^^xsd:string ; skos:altLabel """CBDCA/DOX/GM-CSF"""@eng ; ; ; ; """4250"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280772"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin"""@eng ; skos:notation """CDR0000041176"""^^xsd:string ; skos:altLabel """CBDCA/DOX"""@eng ; ; ; """4249"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280771"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine/lomustine/procarbazine/vincristine"""@eng ; skos:notation """CDR0000041175"""^^xsd:string ; skos:altLabel """CCNU/DFMO/PCB/VCR"""@eng ; ; ; ; ; """4248"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280770"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peripheral blood stem cell transplantation"""@eng ; skos:notation """CDR0000041174"""^^xsd:string ; skos:altLabel """PBSC transplantation"""@eng , """PBPC transplantation"""@eng , """transplantation, peripheral blood stem cell"""@eng , """peripheral blood progenitor cell transplantation"""@eng ; ; rdfs:subClassOf ; """4247"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0242602"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000041179"""^^xsd:string ; skos:altLabel """DM/DNR/VCR"""@eng ; ; ; ; """4252"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280774"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/lomustine/vincristine"""@eng ; skos:notation """CDR0000041178"""^^xsd:string ; skos:altLabel """CCNU/CDDP/VCR"""@eng ; ; ; ; """4251"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280773"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ketoconazole/metronidazole"""@eng ; skos:notation """CDR0000041456"""^^xsd:string ; skos:altLabel """KCZ/METRO/VP-16"""@eng ; ; ; ; """4526"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281004"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """codeine phosphate"""@eng ; skos:notation """CDR0000040563"""^^xsd:string ; skos:altLabel """Codeine Phosphate"""@eng ; """3461"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C383"""^^xsd:string ; """2006-11-22"""^^xsd:string ; umls:cui """C0009217"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PI-88"""@eng ; skos:notation """CDR0000339562"""^^xsd:string ; skos:altLabel """PI 88"""@eng ; skos:definition """A sulfated oligosaccharide. PI-88 inhibits heparanase activity and heparan sulfate binding to fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), resulting in decreased tumor proliferation, inhibition of angiogenesis, and inhibition of metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=339562&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=339562&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38690\" NCI Thesaurus)"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38690"""^^xsd:string ; umls:cui """C1533712"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000040561"""^^xsd:string ; skos:altLabel """adult small noncleaved cell lymphoma, recurrent"""@eng , """small noncleaved cell lymphoma, adult, recurrent"""@eng , """relapsed adult small noncleaved cell lymphoma"""@eng , """small noncleaved cell lymphoma, recurrent, adult"""@eng , """adult small noncleaved cell lymphoma, relapsed"""@eng , """recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3457"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280192"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/etoposide/ketoconazole/metronidazole"""@eng ; skos:notation """CDR0000041457"""^^xsd:string ; skos:altLabel """DP/KCZ/METRO/VP-16"""@eng ; ; ; ; ; """4527"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281005"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """heroin"""@eng ; skos:notation """CDR0000040567"""^^xsd:string ; """3466"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0011892"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim"""@eng ; skos:notation """CDR0000040566"""^^xsd:string ; skos:altLabel """GM-CSF"""@eng , """GM CSF"""@eng , """Leukine"""@eng , """Prokine"""@eng , """Sagramostim"""@eng , """granulocyte-macrophage colony stimulating factor"""@eng , """granulocyte macrophage colony-stimulating factor"""@eng , """granulocyte-macrophage colony-stimulating factor"""@eng , """rhu GM-CFS"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to endogenous human GM-CSF. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40566&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40566&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1492\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3465"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C1492"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """123774-72-1"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701499"""^^xsd:string ; umls:cui """C0701500"""^^xsd:string ; umls:cui """C0079460"""^^xsd:string ; umls:cui """C0216231"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ganciclovir"""@eng ; skos:notation """CDR0000040565"""^^xsd:string ; skos:altLabel """2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one"""@eng , """Nordeoxyguanosine"""@eng , """Cymevan"""@eng , """9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine"""@eng , """2'-Nor-2'-deoxyguanosine"""@eng , """BW-B 759U"""@eng , """BW-B759U"""@eng , """DHPG"""@eng , """Virgan"""@eng , """2'NDG"""@eng , """BW 759U"""@eng ; skos:definition """A synthetic guanine derivative with antiviral activity. As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40565&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40565&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C517\" NCI Thesaurus)"""@eng ; ; ; ; """3464"""^^xsd:string ; """C517"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """82410-32-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517437"""^^xsd:string ; umls:cui """C0701311"""^^xsd:string ; umls:cui """C0017066"""^^xsd:string ; umls:cui """C1517438"""^^xsd:string ; umls:cui """C0701310"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fazarabine"""@eng ; skos:notation """CDR0000040564"""^^xsd:string ; skos:altLabel """1,3, 5-Triazin-2(1H)-one, 4-Amino-1-beta-D- arabinofuranosyl- (9CI)"""@eng , """1-Beta-D-arabinofuranosyl-5-azacytosine"""@eng , """Ara AC"""@eng , """ARA-AC"""@eng , """Kymarabine"""@eng ; skos:definition """An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40564&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40564&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1096\" NCI Thesaurus)"""@eng ; ; """3463"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """65886-71-7"""^^xsd:string ; """29722"""^^xsd:string ; """C1096"""^^xsd:string ; """281272"""^^xsd:string ; umls:cui """C0060103"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ketorolac"""@eng ; skos:notation """CDR0000040569"""^^xsd:string ; skos:definition """A synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic and antipyretic properties. Ketorolac, a non-selective inhibitor of the cyclo-oxygenase (COX) enzyme, prevents the synthesis of prostaglandins and thromboxanes from arachidonic acid. COX enzymes exist in two isoforms; inhibition of the COX-2 enzyme produces the anti-inflammatory and analgesic whereas, inhibition of the COX-1 enzyme is associated with gastrointestinal side effects, nephrotoxicity and platelet de-aggregatory effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40569&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40569&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1219\" NCI Thesaurus)"""@eng ; """3468"""^^xsd:string ; """74103-06-3 (racemic)"""^^xsd:string ; """66635-83-4"""^^xsd:string ; """C1219"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0073631"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IMREG-1"""@eng ; skos:notation """CDR0000040568"""^^xsd:string ; skos:altLabel """IMREG 1"""@eng ; """3467"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0063442"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ammonium tetrathiomolybdate"""@eng ; skos:notation """CDR0000467218"""^^xsd:string ; skos:altLabel """ATTM"""@eng , """ATM"""@eng , """TM"""@eng , """tetrathiomolybdate"""@eng ; """2006-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0076339"""^^xsd:string ; umls:cui """C0103097"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/levamisole"""@eng ; skos:notation """CDR0000041452"""^^xsd:string ; skos:altLabel """IL-2/LEV"""@eng ; ; ; """4522"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281000"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/interleukin-1-alpha"""@eng ; skos:notation """CDR0000041453"""^^xsd:string ; skos:altLabel """CBDCA/IFF/IL-1A/VP-16"""@eng ; ; ; ; ; """4523"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281001"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/filgrastim/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000041289"""^^xsd:string ; skos:altLabel """CDDP/DOX/G-CSF/MTX/VBL"""@eng ; ; ; ; ; ; """4362"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280877"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000041288"""^^xsd:string ; skos:altLabel """BLEO/CDDP/IFF/VP-16"""@eng ; ; ; ; ; """4361"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280876"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cetuximab"""@eng ; skos:notation """CDR0000373863"""^^xsd:string ; skos:altLabel """CBDCA/MOAB C225"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541294"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/GW572016"""@eng ; skos:notation """CDR0000373862"""^^xsd:string ; skos:altLabel """CAPE/GW-572016"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541293"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SB-AS15 adjuvant"""@eng ; skos:notation """CDR0000373865"""^^xsd:string ; skos:altLabel """SB AS15"""@eng ; skos:definition """A vaccine adjuvant containing CpG 7909, monophosphoryl lipid, and QS-21 with potential antineoplastic and immunostimulatory activities. CpG 7909 is a synthetic 24-mer oligonucleotide containing 3 CpG motifs that selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens. Monophosphoryl lipid is a detoxified derivative of lipid A, a component of Salmonella minnesota lipopolysaccharide (LPS); this agent may enhance humoral and cellular responses to various antigens. QS-21 is a purified, naturally occurring saponin derived from the South American tree Quillaja saponaria Molina and exhibits various immunostimulatory activities. Combinations of monophosphoryl lipid and QS-21 may be synergistic in inducing humoral and cellular immune responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373865&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373865&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48421\" NCI Thesaurus)"""@eng ; ; """2004-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48421"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C1541296"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/gemcitabine/vinblastine"""@eng ; skos:notation """CDR0000373864"""^^xsd:string ; skos:altLabel """dFdC/DOX//VBL"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541295"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allopurinol/rasburicase"""@eng ; skos:notation """CDR0000373867"""^^xsd:string ; skos:altLabel """ALLO/SR29142"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541298"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D1/3-MAGE-3-His fusion protein/SB-AS15 adjuvant"""@eng ; skos:notation """CDR0000373866"""^^xsd:string ; skos:altLabel """D1/3 MAGE3 HIS/SB AS15"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541297"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Eucerin"""@eng ; skos:notation """CDR0000041281"""^^xsd:string ; """4354"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0164056"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000041280"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/GM-CSF/VP-16"""@eng ; ; ; ; ; """4353"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280869"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/carboplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000041283"""^^xsd:string ; skos:altLabel """CBDCA/CTX/HMM"""@eng ; ; ; ; """4356"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280871"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/epirubicin"""@eng ; skos:notation """CDR0000041282"""^^xsd:string ; skos:altLabel """CLB/EPI"""@eng ; ; ; """4355"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280870"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone"""@eng ; skos:notation """CDR0000041285"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/MTX/PRED"""@eng ; ; ; ; ; ; """4358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280873"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/interferon alfa/mitomycin"""@eng ; skos:notation """CDR0000041284"""^^xsd:string ; skos:altLabel """FUDR/IFN-A/MITO"""@eng ; ; ; ; """4357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338139"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/melphalan"""@eng ; skos:notation """CDR0000041287"""^^xsd:string ; skos:altLabel """CTX/L-PAM"""@eng ; ; ; """4360"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280875"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/fluorouracil/methotrexate/prednisone"""@eng ; skos:notation """CDR0000041286"""^^xsd:string ; skos:altLabel """CDDP/CTX/5-FU/MTX/PRED"""@eng ; ; ; ; ; ; """4359"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280874"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000341569"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/SC-58635"""@eng ; ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328088"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypopharyngeal cancer"""@eng ; skos:notation """CDR0000038955"""^^xsd:string ; skos:altLabel """hypopharynx cancer"""@eng , """Hypopharyngeal cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1500"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153398"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II breast cancer"""@eng ; skos:notation """CDR0000038954"""^^xsd:string ; skos:altLabel """breast cancer, stage II"""@eng ; rdfs:subClassOf ; """2003-06-16"""^^xsd:string ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """15"""^^xsd:string ; """progesterone receptor status unknown"""^^xsd:string ; """premenopausal"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """estrogen receptor status unknown"""^^xsd:string ; """estrogen receptor positive"""^^xsd:string ; """bilateral breast cancer"""^^xsd:string ; """no positive axillary nodes"""^^xsd:string ; """estrogen receptor negative"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """1 or more positive axillary node"""^^xsd:string ; """performance status 2"""^^xsd:string ; """progesterone receptor negative"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """postmenopausal"""^^xsd:string ; """progesterone receptor positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278486"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000038957"""^^xsd:string ; skos:altLabel """lymphoma, non-Hodgkin's"""@eng , """NHL"""@eng ; rdfs:subClassOf ; """1514"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0024305"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic leukemia"""@eng ; skos:notation """CDR0000038956"""^^xsd:string ; skos:altLabel """leukemia, chronic"""@eng ; rdfs:subClassOf ; """1513"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1279296"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent salivary gland cancer"""@eng ; skos:notation """CDR0000038951"""^^xsd:string ; skos:altLabel """salivary gland cancer, recurrent"""@eng ; rdfs:subClassOf ; """salivary gland cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1460"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278993"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV salivary gland cancer"""@eng ; skos:notation """CDR0000038950"""^^xsd:string ; skos:altLabel """metastatic salivary gland cancer"""@eng , """salivary gland cancer, stage IV"""@eng , """salivary gland cancer, metastatic"""@eng ; rdfs:subClassOf ; """salivary gland cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1459"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278992"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult angiosarcoma"""@eng ; skos:notation """CDR0000038953"""^^xsd:string ; skos:altLabel """adult hemangiosarcoma"""@eng , """angiosarcoma, adult"""@eng , """hemangiosarcoma, adult"""@eng , """adult, angiosarcoma"""@eng , """sarcoma, angio-, adult"""@eng ; rdfs:subClassOf ; """148"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278592"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acute leukemia"""@eng ; skos:notation """CDR0000038952"""^^xsd:string ; skos:altLabel """leukemia, acute"""@eng ; rdfs:subClassOf ; """1474"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0085669"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SU014813"""@eng ; skos:notation """CDR0000486831"""^^xsd:string ; skos:definition """An orally-active, tyrosine kinase receptor inhibitor with potential antitumor activity. SU014813 binds to and inhibits the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-Kit and Fms-related tyrosine kinase 3 (Flt-3). This leads to an inhibition of cellular proliferation and angiogenesis and an induction of apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486831&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486831&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61507\" NCI Thesaurus)"""@eng ; """C61507"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-12"""^^xsd:string ; """2006-05-23"""^^xsd:string ; umls:cui """C1831849"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endocrine cancer"""@eng ; skos:notation """CDR0000038959"""^^xsd:string ; rdfs:subClassOf ; ; """1516"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153658"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """brain tumor"""@eng ; skos:notation """CDR0000038958"""^^xsd:string ; skos:altLabel """brain cancer"""@eng ; ; ; ; rdfs:subClassOf ; """2002-10-15"""^^xsd:string ; """1515"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0006118"""^^xsd:string ; umls:cui """C0153633"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T4N5 liposomal lotion"""@eng ; skos:notation """CDR0000042482"""^^xsd:string ; skos:altLabel """bacteriophage T4 endonuclease V in liposomal lotion"""@eng , """Dimericine"""@eng ; skos:definition """A topical lotion that contains the enzyme T4-bacteriophage endonuclease V encapsulated within liposomes. With topical liposomal delivery, the DNA repair enzyme T4-bacteriophage endonuclease V is transported into skin cells, where the enzyme enters cell nuclei and binds to and incises pyrimidine dimers, thereby catalyzing the first reaction step of the cellular excision repair pathway for removing DNA replication-inhibiting pyrimidine dimers produced within duplex DNA through exposure to ultraviolet (UV) irradiation. In vitro and in vivo studies in indicate that T4N5 liposomes increases repair of DNA damage caused by UV irradiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42482&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42482&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2408\" NCI Thesaurus)"""@eng ; """5998"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C2408"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0392927"""^^xsd:string ; umls:cui """C1710278"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042483"""^^xsd:string ; skos:altLabel """lymphoma, stage III adult Hodgkin's"""@eng , """stage III adult HD"""@eng , """Hodgkin's lymphoma, stage III, adult"""@eng , """adult Hodgkin's disease, stage III"""@eng , """HD, stage III, adult"""@eng , """stage III adult Hodgkin's disease"""@eng , """HD, adult, stage III"""@eng , """adult HD, stage III"""@eng , """Hodgkin's disease, stage III, adult"""@eng ; rdfs:subClassOf ; """2003-01-10"""^^xsd:string ; """adult Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278472"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """depression"""@eng ; skos:notation """CDR0000042480"""^^xsd:string ; rdfs:subClassOf ; """5992"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0812393"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cladribine/etoposide"""@eng ; skos:notation """CDR0000042481"""^^xsd:string ; skos:altLabel """2-CdA/VP-16"""@eng ; ; ; """5997"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392926"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Cockayne syndrome"""@eng ; skos:notation """CDR0000042486"""^^xsd:string ; """2003-06-19"""^^xsd:string ; """6004"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0009207"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone"""@eng ; skos:notation """CDR0000042487"""^^xsd:string ; skos:altLabel """Prednicen-M"""@eng , """Decorton"""@eng , """Ofisolona"""@eng , """Prednidib"""@eng , """Panafcort"""@eng , """Deltadehydrocortisone"""@eng , """Deltacortene"""@eng , """Prednilonga"""@eng , """Predeltin"""@eng , """Meticorten"""@eng , """DeCortin"""@eng , """Dacortin"""@eng , """Panasol-S"""@eng , """Promifen"""@eng , """Prednicort"""@eng , """Adasone"""@eng , """Prednisonum"""@eng , """PRD"""@eng , """Delta(1)-Cortisone"""@eng , """Predicor"""@eng , """Deltacortisone"""@eng , """Meprosona-F"""@eng , """Metacortandracin"""@eng , """Sk-Prednisone"""@eng , """Servisone"""@eng , """Deltra"""@eng , """Predniment"""@eng , """Paracort"""@eng , """Deltison"""@eng , """Deltasone"""@eng , """Liquid Pred"""@eng , """Delta-Dome"""@eng , """Decortisyl"""@eng , """Sterapred"""@eng , """17,21-Dihydroxypregna-1,4-diene-3,11,20-trione"""@eng , """Orasone"""@eng , """Cortancyl"""@eng , """PRED"""@eng , """1;2-Dehydrocortisone"""@eng , """Prednitone"""@eng , """Econosone"""@eng , """Predicorten"""@eng , """Lisacort"""@eng ; skos:definition """A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42487&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42487&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C770\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """601"""^^xsd:string ; """C770"""^^xsd:string ; """10023"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3574"""^^xsd:string ; """53-03-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0723447"""^^xsd:string ; umls:cui """C1514369"""^^xsd:string ; umls:cui """C1514368"""^^xsd:string ; umls:cui """C0728769"""^^xsd:string ; umls:cui """C0740150"""^^xsd:string ; umls:cui """C0740154"""^^xsd:string ; umls:cui """C0914041"""^^xsd:string ; umls:cui """C0591330"""^^xsd:string ; umls:cui """C1514375"""^^xsd:string ; umls:cui """C1514376"""^^xsd:string ; umls:cui """C1514377"""^^xsd:string ; umls:cui """C1514370"""^^xsd:string ; umls:cui """C1514371"""^^xsd:string ; umls:cui """C1514372"""^^xsd:string ; umls:cui """C1514373"""^^xsd:string ; umls:cui """C0722741"""^^xsd:string ; umls:cui """C1514378"""^^xsd:string ; umls:cui """C1514379"""^^xsd:string ; umls:cui """C0740149"""^^xsd:string ; umls:cui """C0740145"""^^xsd:string ; umls:cui """C0740144"""^^xsd:string ; umls:cui """C0740146"""^^xsd:string ; umls:cui """C0728770"""^^xsd:string ; umls:cui """C0728771"""^^xsd:string ; umls:cui """C0740143"""^^xsd:string ; umls:cui """C1328254"""^^xsd:string ; umls:cui """C1514381"""^^xsd:string ; umls:cui """C1514380"""^^xsd:string ; umls:cui """C1514383"""^^xsd:string ; umls:cui """C1514382"""^^xsd:string ; umls:cui """C1514384"""^^xsd:string ; umls:cui """C0032952"""^^xsd:string ; umls:cui """C1256257"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II pancreatic cancer"""@eng ; skos:notation """CDR0000042484"""^^xsd:string ; skos:altLabel """pancreas cancer, stage II"""@eng , """stage II pancreas cancer"""@eng , """pancreatic cancer, stage II"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """60"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1167721"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/tacrolimus"""@eng ; skos:notation """CDR0000042485"""^^xsd:string ; skos:altLabel """FK506/PRED"""@eng ; ; ; """6000"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392928"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HSP"""@eng ; skos:notation """CDR0000042488"""^^xsd:string ; skos:altLabel """70 kD heat-shock protein"""@eng , """HSP70-kD"""@eng , """70 kD heat shock protein"""@eng ; """6019"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C0243043"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """70-kD heat-shock protein/MUC-1 antigen"""@eng ; skos:notation """CDR0000042489"""^^xsd:string ; skos:altLabel """HSP70-kD/MUC-1"""@eng ; ; """6020"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-18"""^^xsd:string ; umls:cui """C0392929"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/trastuzumab"""@eng ; skos:notation """CDR0000426427"""^^xsd:string ; skos:altLabel """CAPE/MOAB HER2"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541534"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000042738"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6532"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796293"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000042739"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6533"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677709"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/sorafenib"""@eng ; skos:notation """CDR0000393784"""^^xsd:string ; skos:altLabel """dFdC/SFN"""@eng ; ; ; """2004-10-25"""^^xsd:string ; """2004-09-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541376"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, noncontiguous stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042730"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6524"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677700"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000042731"""^^xsd:string ; skos:altLabel """noncontiguous stage II grade I follicular small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6525"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677701"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000042732"""^^xsd:string ; skos:altLabel """noncontiguous stage II grade II follicular mixed cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6526"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677702"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000042733"""^^xsd:string ; skos:altLabel """noncontiguous stage II grade III follicular large cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6527"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677703"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oncolytic adenovirus encoding GM-CSF"""@eng ; skos:notation """CDR0000434519"""^^xsd:string ; skos:altLabel """CG0070"""@eng ; skos:definition """A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434519&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434519&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-08-20"""^^xsd:string ; """2005-05-20"""^^xsd:string ; umls:cui """C1709316"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II mantle cell lymphoma"""@eng ; skos:notation """CDR0000042735"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6529"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677705"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, noncontiguous stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042736"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6530"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677706"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000042737"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6531"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677707"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/CMV pp65 peptide"""@eng ; skos:notation """CDR0000273710"""^^xsd:string ; skos:altLabel """ADC/CMV-PEP"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327896"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/omeprazole"""@eng ; skos:notation """CDR0000423353"""^^xsd:string ; skos:altLabel """OMEP/PS-341"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541517"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ferumoxtran-10"""@eng ; skos:notation """CDR0000423355"""^^xsd:string ; skos:altLabel """Ultrasmall Particulate Iron Oxide"""@eng , """Sinerem"""@eng , """USPIO"""@eng , """Combidex"""@eng , """AMI-227"""@eng , """G-53425"""@eng ; skos:definition """A synthetic ultrasmall superparamagnetic iron oxide composed of dextran-coated iron oxide nanoparticles (also known as 'ultrasmall particulate iron oxides' or USPIO). Ferumoxtran-10, which accumulates in non-cancerous lymphatic tissue, is used as a molecular resonance imaging (MRI) contrast agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=423355&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=423355&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38140\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2005-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C38140"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0386367"""^^xsd:string ; umls:cui """C0754268"""^^xsd:string ; umls:cui """C0386370"""^^xsd:string ; umls:cui """C1541650"""^^xsd:string ; umls:cui """C0172518"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """citalopram hydrobromide"""@eng ; skos:notation """CDR0000500063"""^^xsd:string ; skos:altLabel """(![PLUS-MINUS SIGN]!)-1-(3-dimethylaminopropyl)-1- (4-fluorophenyl)-1,3 dihydroisobenzofuran-5-carbonitrile, HBr"""@eng , """Celexa"""@eng , """(±)-1-(3-dimethylaminopropyl)-1- (4-fluorophenyl)-1,3 dihydroisobenzofuran-5-carbonitrile, HBr"""@eng ; skos:definition """The orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), citalopram selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=500063&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=500063&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28932\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-06"""^^xsd:string ; """C28932"""^^xsd:string ; umls:cui """C0719199"""^^xsd:string ; umls:cui """C0724555"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """F-18 16 alpha-fluoroestradiol"""@eng ; skos:notation """CDR0000500062"""^^xsd:string ; skos:altLabel """F-18 FES"""@eng ; """2006-08-06"""^^xsd:string ; """2006-09-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62541"""^^xsd:string ; umls:cui """C1831937"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """titanium dioxide/zinc oxide sunscreen cream SPF 60"""@eng ; skos:notation """CDR0000500066"""^^xsd:string ; skos:altLabel """Vanicream Sunscreen SPF 60"""@eng ; """2006-08-06"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831938"""^^xsd:string ; umls:cui """C1831939"""^^xsd:string ; umls:tui """T167"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enzastaurin hydrochloride"""@eng ; skos:notation """CDR0000269069"""^^xsd:string ; skos:altLabel """LY-317615"""@eng , """3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione Dihydrochloride"""@eng ; skos:definition """The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269069&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269069&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26658\" NCI Thesaurus)"""@eng ; ; """Drug/agent"""^^xsd:string ; """2002-11-24"""^^xsd:string ; """C26658"""^^xsd:string ; """2006-05-19"""^^xsd:string ; umls:cui """C1765315"""^^xsd:string ; umls:cui """C1615613"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/gemtuzumab ozogamicin/idarubicin"""@eng ; skos:notation """CDR0000269068"""^^xsd:string ; skos:altLabel """ARA-C/CMA-676/IDA/VP-16"""@eng ; ; ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327829"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ginseng"""@eng ; skos:notation """CDR0000269063"""^^xsd:string ; skos:altLabel """Panax ginseng"""@eng ; skos:definition """The aromatic root of perennial herbs of the Panax genus used in Chinese traditional medicine. Ginseng is classified as an adaptogenic herb with multiple effects, many of them regulatory in nature. It contains a complex mixture of saponins, ginsenosides and panaxosides, and is available as a nutritional supplement. Although the mechanism of action is unclear, Ginseng is reported to enhance the immune system and reduce fatigue. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269063&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269063&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26651\" NCI Thesaurus)"""@eng ; """2002-11-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C26651"""^^xsd:string ; umls:cui """C1119918"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/doxorubicin"""@eng ; skos:notation """CDR0000269065"""^^xsd:string ; skos:altLabel """DOX/MOAB VEGF"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327827"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transferrin-CRM107"""@eng ; skos:notation """CDR0000269064"""^^xsd:string ; skos:altLabel """TransMID"""@eng , """HN66000"""@eng , """Tf-CRM107"""@eng , """HN-66000"""@eng ; skos:definition """A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269064&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269064&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26676\" NCI Thesaurus)"""@eng ; """2002-11-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26676"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0912205"""^^xsd:string ; umls:cui """C1328693"""^^xsd:string ; umls:cui """C1327826"""^^xsd:string ; umls:cui """C1527221"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexmethylphenidate"""@eng ; skos:notation """CDR0000269067"""^^xsd:string ; skos:altLabel """Focalin"""@eng , """d-MPH"""@eng , """dexmethylphenidate hydrochloride"""@eng ; """2002-11-24"""^^xsd:string ; """2002-11-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1170743"""^^xsd:string ; umls:cui """C1170283"""^^xsd:string ; umls:cui """C1169997"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000269066"""^^xsd:string ; skos:altLabel """GM-CSF/vCEA-TRI"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327828"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine"""@eng ; skos:notation """CDR0000474021"""^^xsd:string ; skos:definition """A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474021&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474021&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61076\" NCI Thesaurus)"""@eng ; """C61076"""^^xsd:string ; """2006-07-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831781"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liver transplantation"""@eng ; skos:notation """CDR0000474023"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-17"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; umls:cui """C0023911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """organ transplantation"""@eng ; skos:notation """CDR0000474022"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C0029216"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine"""@eng ; skos:notation """CDR0000474024"""^^xsd:string ; skos:altLabel """Autologous Dendritic Cell and Tumor mRNA Human CD40L Vaccine"""@eng ; skos:definition """A cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474024&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474024&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61077\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """C61077"""^^xsd:string ; """2006-07-24"""^^xsd:string ; umls:cui """C1831782"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """placebo"""@eng ; skos:notation """CDR0000043469"""^^xsd:string ; skos:altLabel """PLCB"""@eng ; skos:definition """An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43469&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43469&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C753\" NCI Thesaurus)"""@eng ; ; """868"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C753"""^^xsd:string ; umls:cui """C0032042"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/interleukin-2/MART-1 antigen"""@eng ; skos:notation """CDR0000043468"""^^xsd:string ; skos:altLabel """gp100/IFA/IL-2/MART-1"""@eng ; ; ; ; ; """8677"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796634"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/dacarbazine/hydroxyurea"""@eng ; skos:notation """CDR0000039389"""^^xsd:string ; skos:altLabel """BHD"""@eng , """BCNU/DTIC/HU"""@eng ; ; ; ; """2024"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279252"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dapsone/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000039388"""^^xsd:string ; skos:altLabel """Dapsone/TMTX"""@eng ; ; ; """2023"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279251"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin"""@eng ; skos:notation """CDR0000039387"""^^xsd:string ; skos:altLabel """BP"""@eng , """BLEO/CDDP"""@eng ; ; ; """2022"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057191"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminopterin/leucovorin calcium"""@eng ; skos:notation """CDR0000043462"""^^xsd:string ; skos:altLabel """APGA/CF"""@eng ; ; ; """8663"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796626"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/vincristine"""@eng ; skos:notation """CDR0000043461"""^^xsd:string ; skos:altLabel """VCR/VP-16"""@eng ; ; ; """866"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278655"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000039384"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MP/VCR"""@eng ; ; ; ; ; ; """2019"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279247"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/MART-1 antigen"""@eng ; skos:notation """CDR0000043467"""^^xsd:string ; skos:altLabel """gp100/IFA/MART-1"""@eng ; ; ; ; """8676"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796633"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/vincristine"""@eng ; skos:notation """CDR0000043466"""^^xsd:string ; skos:altLabel """CBDCA/CTX/VCR"""@eng ; ; ; ; """8675"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796632"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/thiotepa/vincristine"""@eng ; skos:notation """CDR0000043465"""^^xsd:string ; skos:altLabel """CBDCA/TSPA/VCR"""@eng ; ; ; ; """8674"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796631"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/methotrexate/procarbazine"""@eng ; skos:notation """CDR0000039380"""^^xsd:string ; skos:altLabel """PRIME"""@eng , """IFF/MTX/PCB"""@eng ; ; ; ; """2015"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0071973"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/fludarabine/pixantrone/rituximab"""@eng ; skos:notation """CDR0000269680"""^^xsd:string ; skos:altLabel """BBR 2778/DM/FAMP/MOAB IDEC-C2B8"""@eng ; ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327857"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Juven"""@eng ; skos:notation """CDR0000269682"""^^xsd:string ; skos:definition """An orally bioavailable nutritional supplement. Juven contains the amino acids glutamine and arginine in addition to beta-hydroxy-beta-methylbutyrate (HMB). This agent may promote muscle protein synthesis and increase muscle mass. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269682&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269682&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26656\" NCI Thesaurus)"""@eng ; """2002-12-21"""^^xsd:string ; """C26656"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C0939574"""^^xsd:string ; umls:tui """T168"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/iodine I 131 metaiodobenzylguanidine/melphalan"""@eng ; skos:notation """CDR0000363810"""^^xsd:string ; skos:altLabel """CBDCA/I131-MIBG/L-PAM/VP-16"""@eng ; ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-03-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541211"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000041902"""^^xsd:string ; skos:altLabel """G-CSF/TAX/TOPO"""@eng ; ; ; ; """5120"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281458"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclosporine/doxorubicin"""@eng ; skos:notation """CDR0000041903"""^^xsd:string ; skos:altLabel """CDDP/CYSP/DOX"""@eng ; ; ; ; """5121"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281459"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neuroendocrine carcinoma of the skin"""@eng ; skos:notation """CDR0000041900"""^^xsd:string ; skos:altLabel """trabecular carcinoma of the skin"""@eng , """cutaneous APUDoma"""@eng , """endocrine carcinoma of the skin"""@eng , """small cell neuroepithelial tumor of the skin"""@eng , """Skin cancer, neuroendocrine carcinoma"""@eng , """cutaneous neuroendocrine tumor"""@eng , """primary small cell carcinoma of the skin"""@eng , """adult neuroblastoma of the skin"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5118"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007129"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/pyrazoloacridine"""@eng ; skos:notation """CDR0000041901"""^^xsd:string ; skos:altLabel """G-CSF/PZA"""@eng ; ; ; """5119"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281457"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/filgrastim/ifosfamide/interleukin-3"""@eng ; skos:notation """CDR0000041906"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/IFF/IL-3/VP-16"""@eng ; ; ; ; ; ; """5124"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/ifosfamide/interleukin-3/vinblastine"""@eng ; skos:notation """CDR0000041907"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/IFF/IL-3/VBL"""@eng ; ; ; ; ; ; """5125"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281463"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/pentoxifylline"""@eng ; skos:notation """CDR0000041904"""^^xsd:string ; skos:altLabel """CDDP/PTX"""@eng ; ; ; """5122"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281460"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/pegaspargase"""@eng ; skos:notation """CDR0000041905"""^^xsd:string ; skos:altLabel """MTX/PEG-ASP"""@eng ; ; ; """5123"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281461"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000041908"""^^xsd:string ; skos:altLabel """AIDS-associated lymphoblastic lymphoma"""@eng , """lymphoblastic lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """5126"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281464"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/prednisolone/vindesine"""@eng ; skos:notation """CDR0000041909"""^^xsd:string ; skos:altLabel """BLEO/CTX/DAVA/DOX/PRDL"""@eng ; ; ; ; ; ; """5127"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281465"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/iodine I 131 monoclonal antibody BC8"""@eng ; skos:notation """CDR0000439948"""^^xsd:string ; skos:altLabel """FAMP/I131 MOAB BC8"""@eng ; ; ; """2005-07-23"""^^xsd:string ; """2005-07-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831669"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/temsirolimus"""@eng ; skos:notation """CDR0000433189"""^^xsd:string ; skos:altLabel """CCI-779/OSI774"""@eng ; ; ; """2005-05-05"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831613"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prinomastat"""@eng ; skos:notation """CDR0000043058"""^^xsd:string ; skos:altLabel """Prinomastat/AG 3340"""@eng , """AG3340"""@eng , """(3S)-N-Hydroxy-2,2-dimethyl-4-{{4-(4-piridinyloxy)phenyl}sulfonyl}-3-thiomorpholinecarboxamide"""@eng ; skos:definition """A synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43058&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43058&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1811\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """7412"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1811"""^^xsd:string ; umls:cui """C0919273"""^^xsd:string ; umls:cui """C3467777"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/prinomastat"""@eng ; skos:notation """CDR0000043059"""^^xsd:string ; skos:altLabel """AG3340/CBDCA/TAX"""@eng ; ; ; ; """7413"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043052"""^^xsd:string ; skos:altLabel """BLEO/CTX/DM/DOX/MTX/VCR"""@eng , """M-BACOD"""@eng ; ; ; ; ; ; ; """74"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fulvestrant"""@eng ; skos:notation """CDR0000043053"""^^xsd:string ; skos:altLabel """ICI 182,780"""@eng , """ICI 182780"""@eng , """ICI182780"""@eng , """Faslodex"""@eng , """7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol"""@eng , """ZD9238"""@eng ; skos:definition """A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43053&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43053&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1379\" NCI Thesaurus)"""@eng ; ; ; ; ; """TRD"""^^xsd:string ; """7401"""^^xsd:string ; """2006-05-18"""^^xsd:string ; """C1379"""^^xsd:string ; """719276"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """129453-61-8"""^^xsd:string ; umls:cui """C0701491"""^^xsd:string ; umls:cui """C1522236"""^^xsd:string ; umls:cui """C0935916"""^^xsd:string ; umls:cui """C1123005"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """electroporation therapy"""@eng ; skos:notation """CDR0000043050"""^^xsd:string ; """7386"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0678054"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/tesmilifene"""@eng ; skos:notation """CDR0000043051"""^^xsd:string ; skos:altLabel """CTX/DPPE"""@eng ; ; ; """2005-01-10"""^^xsd:string ; """7391"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678055"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/methylprednisolone"""@eng ; skos:notation """CDR0000043056"""^^xsd:string ; skos:altLabel """BU/CTX/MePRDL"""@eng ; ; ; ; """7404"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678058"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exisulind"""@eng ; skos:notation """CDR0000043057"""^^xsd:string ; skos:altLabel """Aptosyn"""@eng , """1H-Indene-3-acetic Acid, 5-Fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene), (Z)"""@eng , """Sulindac Sulfone"""@eng , """FGN-1"""@eng , """(Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic Acid"""@eng ; skos:definition """An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone. Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43057&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43057&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1239\" NCI Thesaurus)"""@eng ; ; ; ; ; """7411"""^^xsd:string ; """59864-04-9"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """719619"""^^xsd:string ; """C1239"""^^xsd:string ; """59973-80-7 (cis)"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0953857"""^^xsd:string ; umls:cui """C0935917"""^^xsd:string ; umls:cui """C0075616"""^^xsd:string ; umls:cui """C1524086"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/anti-thymocyte globulin"""@eng ; skos:notation """CDR0000043054"""^^xsd:string ; skos:altLabel """ATG/BU/CTX"""@eng ; ; ; ; """7402"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """B-Raf inhibitor PLX4032"""@eng ; skos:notation """CDR0000528954"""^^xsd:string ; skos:altLabel """PLX4032"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1832009"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin-magnetic targeted carrier complex"""@eng ; skos:notation """CDR0000038388"""^^xsd:string ; skos:altLabel """MTC-DOX"""@eng , """DOX-MTC"""@eng ; skos:definition """Anthracycline antineoplastic antibiotic doxorubicin bound to microscopic beads of activated carbon and iron (magnetic targeted carriers). With placement of a magnet on the body surface overlying a tumor site, this carrier complex delivers doxorubicin directly to the tumor, thereby prolonging the duration of the therapeutic effects while decreasing its systemic toxicity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38388&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38388&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2644\" NCI Thesaurus)"""@eng ; """11008"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2644"""^^xsd:string ; """2006-08-01"""^^xsd:string ; umls:cui """C1134452"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/temozolomide/thalidomide"""@eng ; skos:notation """CDR0000257906"""^^xsd:string ; skos:altLabel """SC-58635/THAL/TMZ"""@eng ; ; ; ; """2002-10-01"""^^xsd:string ; """11471"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327793"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NF2"""@eng ; skos:notation """CDR0000043574"""^^xsd:string ; rdfs:subClassOf ; """8854"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0085114"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000038380"""^^xsd:string ; skos:altLabel """cutaneous T-cell lymphoma, relapsed"""@eng , """recurrent mycosis fungoides/Sezary syndrome"""@eng , """relapsed cutaneous T-cell lymphoma"""@eng , """mycosis fungoides/Sezary syndrome, recurrent"""@eng , """cutaneous T-cell lymphoma, recurrent"""@eng ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """110"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278580"""^^xsd:string ; umls:cui """C0862200"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000038381"""^^xsd:string ; skos:altLabel """lymphoma, follicular large cell"""@eng , """nodular histiocytic lymphoma"""@eng , """NHL"""@eng , """large cell follicular lymphoma"""@eng , """histiocytic nodular lymphoma"""@eng , """FL lymphoma"""@eng , """follicular large cell lymphoma"""@eng , """grade III follicular large cell lymphoma"""@eng , """lymphoma, nodular histiocytic"""@eng , """NH lymphoma"""@eng ; rdfs:subClassOf ; """2003-11-19"""^^xsd:string ; """1100"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0079745"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NQO"""@eng ; skos:notation """CDR0000038382"""^^xsd:string ; rdfs:subClassOf ; """11000"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1134711"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AHR"""@eng ; skos:notation """CDR0000038383"""^^xsd:string ; rdfs:subClassOf ; """11001"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0596123"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """UDPGT"""@eng ; skos:notation """CDR0000038384"""^^xsd:string ; rdfs:subClassOf ; """11002"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1134448"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trivalent influenza vaccine"""@eng ; skos:notation """CDR0000038385"""^^xsd:string ; skos:altLabel """Flushield"""@eng , """Fluzone"""@eng , """Fluvirin"""@eng , """Influenza Vaccine"""@eng , """FluMist"""@eng ; skos:definition """A synthetic vaccine consisting of three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. This agent may be formulated for injection or intranasal administration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38385&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38385&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2643\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """11005"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """719208"""^^xsd:string ; """C2643"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0720489"""^^xsd:string ; umls:cui """C0720491"""^^xsd:string ; umls:cui """C1311943"""^^xsd:string ; umls:cui """C0770694"""^^xsd:string ; umls:cui """C0720492"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EGFR antisense DNA/sargramostim"""@eng ; skos:notation """CDR0000038386"""^^xsd:string ; skos:altLabel """EGFR antiDNA/GM-CSF"""@eng ; ; ; """11006"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134450"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/temozolomide"""@eng ; skos:notation """CDR0000257908"""^^xsd:string ; skos:altLabel """DTIC/TMZ"""@eng ; ; ; """2002-10-01"""^^xsd:string ; """11472"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327794"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegylated anti-GFR antibody fragment"""@eng ; skos:notation """CDR0000472077"""^^xsd:string ; skos:altLabel """Pegylated Anti-GRF Antibody Fragment"""@eng , """CDP 791"""@eng ; """2006-10-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-10"""^^xsd:string ; """C61438"""^^xsd:string ; umls:cui """C1831765"""^^xsd:string ; umls:cui """C1831766"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus-mediated human interleukin-12"""@eng ; skos:notation """CDR0000436005"""^^xsd:string ; skos:altLabel """Ad.hIL-12"""@eng , """adenovirus-interleukin-12"""@eng ; """2005-06-08"""^^xsd:string ; """2005-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831638"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ixabepilone/trastuzumab"""@eng ; skos:notation """CDR0000352312"""^^xsd:string ; skos:altLabel """BMS 247550/CBDCA/MOAB HER2"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328152"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/octreotide"""@eng ; skos:notation """CDR0000038164"""^^xsd:string ; skos:altLabel """DOX/SSTN"""@eng ; ; ; """10744"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935743"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Benzoporphyrin Derivative Monoacid Ring A"""@eng ; skos:notation """CDR0000038165"""^^xsd:string ; skos:altLabel """Visudyne"""@eng , """VERT"""@eng , """BPD-MA"""@eng ; """10745"""^^xsd:string ; """129497-78-5"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """C1014"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0876212"""^^xsd:string ; umls:cui """C0387288"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Detox-B adjuvant/verteporfin"""@eng ; skos:notation """CDR0000038166"""^^xsd:string ; skos:altLabel """DETOXB/VERT"""@eng ; """10746"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-02"""^^xsd:string ; umls:cui """C0935744"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ceramide"""@eng ; skos:notation """CDR0000038167"""^^xsd:string ; skos:altLabel """N-Acyl Sphingosine"""@eng , """Ceramide (lipids)"""@eng ; skos:definition """One of a number of a class of sphingolipids, N-acyl derivatives with long chains. Ceramide is the core molecule for the synthesis of sphingomyelin, an essential lipid for myelination and neurotransmission; it may function as a second messenger to stimulate differentiation, inhibit proliferation, and induce apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38167&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38167&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C359\" NCI Thesaurus)"""@eng ; """10747"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C359"""^^xsd:string ; """104404-17-3"""^^xsd:string ; """720500"""^^xsd:string ; umls:cui """C0007745"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tariquidar"""@eng ; skos:notation """CDR0000037877"""^^xsd:string ; skos:altLabel """XR9576"""@eng ; skos:definition """An anthranilamide derivative with multidrug resistance properties. Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs. Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37877&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37877&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2246\" NCI Thesaurus)"""@eng ; ; ; ; ; """10280"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2246"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C0910984"""^^xsd:string ; umls:cui """C0879444"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/doxorubicin HCl liposome/trastuzumab"""@eng ; skos:notation """CDR0000037876"""^^xsd:string ; skos:altLabel """LipoDox/MOAB HER2/TXT"""@eng ; ; ; ; """10279"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879443"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/paclitaxel/teniposide"""@eng ; skos:notation """CDR0000037875"""^^xsd:string ; skos:altLabel """IFF/TAX/VM-26"""@eng ; ; ; ; """10278"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/cyclophosphamide/epirubicin"""@eng ; skos:notation """CDR0000038163"""^^xsd:string ; skos:altLabel """CAPE/CTX/EPI"""@eng ; ; ; ; """10743"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935742"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hot flashes attenuation"""@eng ; skos:notation """CDR0000042907"""^^xsd:string ; ; rdfs:subClassOf ; """6739"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0677830"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hot flashes"""@eng ; skos:notation """CDR0000042906"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6738"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0600142"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tariquidar/vinorelbine"""@eng ; skos:notation """CDR0000037879"""^^xsd:string ; skos:altLabel """VNB/XR9576"""@eng ; ; ; """2004-04-12"""^^xsd:string ; """10282"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879445"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin-HPMA conjugate"""@eng ; skos:notation """CDR0000042904"""^^xsd:string ; skos:altLabel """HPMA-doxorubicin"""@eng , """doxorubicin-HPMA copolymer conjugate"""@eng , """P(GFLG)-ADR"""@eng , """doxorubicin-HPMA"""@eng , """PK1"""@eng ; skos:definition """A copolymer conjugate of the anthracycline antineoplastic antibiotic doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Conjugation with HPMA improves the therapeutic effects of doxorubicin, by promoting drug accumulation inside tumors, while decreasing systemic toxicity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42904&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42904&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1366\" NCI Thesaurus)"""@eng ; """6735"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1366"""^^xsd:string ; umls:cui """C0114882"""^^xsd:string ; umls:cui """C0701488"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-1 antigen/SB AS-2"""@eng ; skos:notation """CDR0000038168"""^^xsd:string ; skos:altLabel """MUC-1/SB AS-2"""@eng ; ; ; """10748"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935745"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/gemcitabine"""@eng ; skos:notation """CDR0000042902"""^^xsd:string ; skos:altLabel """CDDP/dFdC/WR-2721"""@eng ; ; ; ; """6733"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677827"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamoxifen citrate"""@eng ; skos:notation """CDR0000042901"""^^xsd:string ; skos:altLabel """Ledertam"""@eng , """PMS-Tamoxifen"""@eng , """Emblon"""@eng , """TMX"""@eng , """Dignotamoxi"""@eng , """Nourytam"""@eng , """Nolvadex"""@eng , """Tamax"""@eng , """Fentamox"""@eng , """(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)"""@eng , """Ebefen"""@eng , """Nolgen"""@eng , """Soltamox"""@eng , """Novo-Tamoxifen"""@eng , """Tamoxifeni Citras"""@eng , """Nolvadex-D"""@eng , """Tamaxin"""@eng , """Oncotam"""@eng , """Tamofen"""@eng , """Novofen"""@eng , """TAM"""@eng , """1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene"""@eng , """ICI 46,474"""@eng , """Lesporene"""@eng , """Genox"""@eng , """Oestrifen"""@eng , """(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine"""@eng , """Noltam"""@eng , """Zemide"""@eng , """(Z)-2-[4(1,2-diphenyl-1-butenyl)-phenoxyl]-N,N-dimethylethanamine"""@eng , """Gen-Tamoxifen"""@eng , """Apo-Tamox"""@eng , """Kessar"""@eng , """(Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate"""@eng , """Tamifen"""@eng , """Tamoxasta"""@eng , """Estroxyn"""@eng , """ICI-46474"""@eng , """Novaldex"""@eng , """Clonoxifen"""@eng , """Tamizam"""@eng , """tamoxifen"""@eng , """Jenoxifen"""@eng ; skos:definition """The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42901&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42901&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C855\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """673"""^^xsd:string ; """180973"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """10540-29-1"""^^xsd:string ; """54965-24-1 (citrate)"""^^xsd:string ; """C855"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1515197"""^^xsd:string ; umls:cui """C1515196"""^^xsd:string ; umls:cui """C1515195"""^^xsd:string ; umls:cui """C1515194"""^^xsd:string ; umls:cui """C1515193"""^^xsd:string ; umls:cui """C1515192"""^^xsd:string ; umls:cui """C1515191"""^^xsd:string ; umls:cui """C1515190"""^^xsd:string ; umls:cui """C0592159"""^^xsd:string ; umls:cui """C1515198"""^^xsd:string ; umls:cui """C0591901"""^^xsd:string ; umls:cui """C0591496"""^^xsd:string ; umls:cui """C0039286"""^^xsd:string ; umls:cui """C0919390"""^^xsd:string ; umls:cui """C1177006"""^^xsd:string ; umls:cui """C1515210"""^^xsd:string ; umls:cui """C1515211"""^^xsd:string ; umls:cui """C0700621"""^^xsd:string ; umls:cui """C1515188"""^^xsd:string ; umls:cui """C0591871"""^^xsd:string ; umls:cui """C1515189"""^^xsd:string ; umls:cui """C1515199"""^^xsd:string ; umls:cui """C1515207"""^^xsd:string ; umls:cui """C1515206"""^^xsd:string ; umls:cui """C1515205"""^^xsd:string ; umls:cui """C1515204"""^^xsd:string ; umls:cui """C1515203"""^^xsd:string ; umls:cui """C1515202"""^^xsd:string ; umls:cui """C1515201"""^^xsd:string ; umls:cui """C1515200"""^^xsd:string ; umls:cui """C0591441"""^^xsd:string ; umls:cui """C0079589"""^^xsd:string ; umls:cui """C1515209"""^^xsd:string ; umls:cui """C1515208"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/floxuridine"""@eng ; skos:notation """CDR0000042900"""^^xsd:string ; skos:altLabel """CDDP/FUDR"""@eng ; ; ; """6712"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677826"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/pegfilgrastim"""@eng ; skos:notation """CDR0000335445"""^^xsd:string ; skos:altLabel """CTX/DOX/GCSF-SD01"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328069"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/pegfilgrastim"""@eng ; skos:notation """CDR0000335444"""^^xsd:string ; skos:altLabel """GCSF-SD01/TAX"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328068"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/sargramostim"""@eng ; skos:notation """CDR0000041368"""^^xsd:string ; skos:altLabel """CTX/GM-CSF/VP-16"""@eng ; ; ; ; """4439"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280937"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """energy therapies"""@eng ; skos:notation """CDR0000372897"""^^xsd:string ; ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1516875"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/levamisole"""@eng ; skos:notation """CDR0000039436"""^^xsd:string ; skos:altLabel """5-FU/LEV"""@eng ; ; ; """2071"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279296"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """2-methoxyestradiol (nanocrystal colloidal dispersion)"""@eng ; skos:notation """CDR0000488412"""^^xsd:string ; skos:altLabel """Panzem NCD"""@eng ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831866"""^^xsd:string ; umls:cui """C1831865"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/gemcitabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000357362"""^^xsd:string ; skos:altLabel """CTX/dFdC/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328218"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000041366"""^^xsd:string ; skos:altLabel """DTIC/IFN-A/TMX"""@eng ; ; ; ; """4437"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338148"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/methotrexate/sargramostim/vincristine"""@eng ; skos:notation """CDR0000039438"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/GM-CSF/MTX/VCR"""@eng ; ; ; ; ; ; ; """2073"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279298"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """papaverine/phentolamine/prostaglandin E1"""@eng ; skos:notation """CDR0000360461"""^^xsd:string ; skos:altLabel """Triplemix"""@eng , """PAP/PGE1/PTM"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541582"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phentolamine mesylate"""@eng ; skos:notation """CDR0000360460"""^^xsd:string ; skos:altLabel """Regitine"""@eng , """PTM"""@eng , """2-[N-p'-Tolyl-N-(m'-hydroxyphenyl)aminomethyl]imidazoline"""@eng , """Vasomax"""@eng ; skos:definition """The mesylate salt of a synthetic imidazoline with alpha-adrenergic antagonist activity. As a competitive alpha-adrenergic antagonist, phentolamine binds to alpha-1 and alpha-2 receptors, resulting in a decrease in peripheral vascular resistance and vasodilatation. This agent also may block 5-hydroxytryptamine (5-HT) receptors and stimulate release of histamine from mast cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=360460&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=360460&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38691\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38691"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """50-60-2"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733398"""^^xsd:string ; umls:cui """C1541581"""^^xsd:string ; umls:cui """C0031448"""^^xsd:string ; umls:cui """C0136603"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mometasone furoate"""@eng ; skos:notation """CDR0000531049"""^^xsd:string ; skos:altLabel """(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione"""@eng , """Elocon"""@eng ; skos:definition """The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=531049&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=531049&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29268\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """C29268"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0066700"""^^xsd:string ; umls:cui """C0720180"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cBR96-doxorubicin immunoconjugate/gemcitabine"""@eng ; skos:notation """CDR0000285623"""^^xsd:string ; skos:altLabel """dFdC/SGN-15"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327907"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/filgrastim/vincristine"""@eng ; skos:notation """CDR0000371652"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/G-CSF/VCR/VP-16"""@eng ; ; ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541247"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Barrett's esophagus"""@eng ; skos:notation """CDR0000496926"""^^xsd:string ; rdfs:subClassOf ; """2006-07-20"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-07-23"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C0004763"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunological laboratory methods"""@eng ; skos:notation """CDR0000496927"""^^xsd:string ; skos:altLabel """laboratory methods, immunological"""@eng ; """2006-07-23"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0021060"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aprotinin bovine"""@eng ; skos:notation """CDR0000480388"""^^xsd:string ; skos:altLabel """Trasylol"""@eng ; skos:definition """A single chain polypeptide isolated from bovine lung with antifibrinolytic and anti-inflammatory activities. As a broad-spectrum serine protease inhibitor, aprotinin bovine competitively and reversibly inhibits the activity of a number of different esterases and proteases, including trypsin, chymotrypsin, kallikrein, plasmin, tissue plasminogen activator, and tissue and leukocytic proteinases, resulting in attenuation of the systemic inflammatory response (SIR), fibrinolysis, and thrombin generation. This agent also inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480388&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480388&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47402\" NCI Thesaurus)"""@eng ; """2006-04-14"""^^xsd:string ; """C47402"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0003641"""^^xsd:string ; umls:cui """C0592198"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/fludarabine/thiotepa"""@eng ; skos:notation """CDR0000409550"""^^xsd:string ; skos:altLabel """ATG/FAMP/TSPA"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-11-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541419"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """balloon-guided endoscopy"""@eng ; skos:notation """CDR0000527327"""^^xsd:string ; rdfs:subClassOf ; """2006-12-18"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-12-21"""^^xsd:string ; umls:cui """C1832008"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amiodarone/doxorubicin"""@eng ; skos:notation """CDR0000039419"""^^xsd:string ; skos:altLabel """amiodarone/DOX"""@eng ; ; ; """2054"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279280"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amiodarone/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000039418"""^^xsd:string ; skos:altLabel """amiodarone/DOX/VP-16"""@eng ; ; ; ; """2053"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279279"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/methotrexate/prednisone/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000039417"""^^xsd:string ; skos:altLabel """VTMAFP"""@eng , """DOX/5-FU/MTX/PRED/TSPA/VBL"""@eng ; ; ; ; ; ; ; """2052"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279278"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/piritrexim"""@eng ; skos:notation """CDR0000039416"""^^xsd:string ; skos:altLabel """DTIC/piritrexim"""@eng ; ; ; """2051"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279277"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039415"""^^xsd:string ; skos:altLabel """BOMB"""@eng , """DOX/MP/PRED/VCR"""@eng ; ; ; ; ; """2050"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279276"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/prednisone/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000039414"""^^xsd:string ; skos:altLabel """VTMFP"""@eng , """5-FU/MTX/PRED/TSPA/VBL"""@eng ; ; ; ; ; ; """2049"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/thiotepa"""@eng ; skos:notation """CDR0000039413"""^^xsd:string ; skos:altLabel """IL-2/TSPA"""@eng ; ; ; """2048"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/sargramostim"""@eng ; skos:notation """CDR0000039412"""^^xsd:string ; skos:altLabel """CTX/GM-CSF"""@eng ; ; ; """2047"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279273"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """teloxantrone hydrochoride"""@eng ; skos:notation """CDR0000039411"""^^xsd:string ; skos:altLabel """CI-937"""@eng , """DUP 937"""@eng , """Teloxantrone Hydrochloride"""@eng ; skos:definition """The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39411&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39411&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1520\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C1520"""^^xsd:string ; """2046"""^^xsd:string ; """2007-01-18"""^^xsd:string ; umls:cui """C0244822"""^^xsd:string ; umls:cui """C0701504"""^^xsd:string ; umls:cui """C0970561"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amiodarone hydrochloride"""@eng ; skos:notation """CDR0000039410"""^^xsd:string ; skos:altLabel """amiodarone"""@eng , """Cordarone"""@eng ; skos:definition """The hydrochloride salt of an iodine-rich benzofuran derivative with antiarrhythmic and vasodilatory activities. As a class III antiarrhythmic agent, amiodarone blocks the myocardial calcium, potassium and sodium channels in cardiac tissue, resulting in prolongation of the cardiac action potential and refractory period. In addition, this agent inhibits alpha- and beta-adrenergic receptors, resulting in a reduction in sympathetic stimulation of the heart, a negative chronotropic effect, and a decrease in myocardial oxygen demands. Amiodarone may cause vasodilation by stimulation of the release of nitric oxide and cyclooxygenase-dependent relaxing endothelial factors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39410&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39410&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C236\" NCI Thesaurus)"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """C236"""^^xsd:string ; """2045"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701076"""^^xsd:string ; umls:cui """C0002598"""^^xsd:string ; umls:cui """C0700442"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine"""@eng ; skos:notation """CDR0000041344"""^^xsd:string ; skos:altLabel """CTX/FAMP"""@eng ; ; ; """4416"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280920"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bladder irrigation"""@eng ; skos:notation """CDR0000041345"""^^xsd:string ; skos:altLabel """irrigation, bladder"""@eng ; """4417"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0194423"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cerebral edema management"""@eng ; skos:notation """CDR0000041346"""^^xsd:string ; skos:altLabel """edema, cerebral, management of"""@eng , """management of cerebral edema"""@eng , """edema, management of cerebral"""@eng , """cerebral edema, management of"""@eng ; ; rdfs:subClassOf ; """4418"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0150165"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """substituted urea"""@eng ; skos:notation """CDR0000040375"""^^xsd:string ; rdfs:subClassOf ; """3236"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280041"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """theophylline"""@eng ; skos:notation """CDR0000041340"""^^xsd:string ; skos:altLabel """Slo-bid"""@eng , """T-Phyl"""@eng , """Uniphyl"""@eng , """LaBID"""@eng , """Respbid"""@eng , """Theophylline Monohydrate"""@eng , """Theobid Duracap"""@eng , """Elixophyllin"""@eng , """Somophyllin-CRT"""@eng , """Theo-24"""@eng , """1,3-Dimethylxanthine Monohydrate"""@eng , """Constant-T"""@eng , """Slo-Phyllin"""@eng , """3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione"""@eng , """Theochron"""@eng , """Somophyllin-T"""@eng , """3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione Monohydrate"""@eng ; skos:definition """A natural alkaloid derivative of xanthine isolated from the plants Camellia sinensis and Coffea arabica. Theophylline appears to inhibit phosphodiesterase and prostaglandin production, regulate calcium flux and intracellular calcium distribution, and antagonize adenosine. Physiologically, this agent relaxes bronchial smooth muscle, produces vasodilation (except in cerebral vessels), stimulates the CNS, stimulates cardiac muscle, induces diuresis, and increases gastric acid secretion; it may also suppress inflammation and improve contractility of the diaphragm. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41340&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41340&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C872\" NCI Thesaurus)"""@eng ; """4412"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2066"""^^xsd:string ; """5967-84-0"""^^xsd:string ; """C872"""^^xsd:string ; """58-55-9 (anhydrous)"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0039771"""^^xsd:string ; umls:cui """C0700814"""^^xsd:string ; umls:cui """C0304443"""^^xsd:string ; umls:cui """C0700840"""^^xsd:string ; umls:cui """C0700841"""^^xsd:string ; umls:cui """C0700842"""^^xsd:string ; umls:cui """C0700843"""^^xsd:string ; umls:cui """C0700844"""^^xsd:string ; umls:cui """C0700845"""^^xsd:string ; umls:cui """C0700044"""^^xsd:string ; umls:cui """C0700838"""^^xsd:string ; umls:cui """C0700839"""^^xsd:string ; umls:cui """C0700831"""^^xsd:string ; umls:cui """C0700827"""^^xsd:string ; umls:cui """C0700825"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexniguldipine"""@eng ; skos:notation """CDR0000041341"""^^xsd:string ; skos:altLabel """B 859-35"""@eng , """B859-35"""@eng , """B 859 35"""@eng , """DNIG"""@eng , """B859 35"""@eng ; ; ; """4413"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0208704"""^^xsd:string ; umls:cui """C0285636"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/tipifarnib"""@eng ; skos:notation """CDR0000409579"""^^xsd:string ; skos:altLabel """ARA-C/DNR/R115777"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541421"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diaziquone/sargramostim"""@eng ; skos:notation """CDR0000041343"""^^xsd:string ; skos:altLabel """AZQ/GM-CSF"""@eng ; ; ; """4415"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280919"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphedema"""@eng ; skos:notation """CDR0000041348"""^^xsd:string ; rdfs:subClassOf ; """442"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0024236"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000041349"""^^xsd:string ; skos:altLabel """CF/5-FU/G-CSF"""@eng ; ; ; ; """4420"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280921"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """survivin inhibitor YM155"""@eng ; skos:notation """CDR0000476771"""^^xsd:string ; skos:altLabel """YM155"""@eng ; skos:definition """A novel proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via theextrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476771&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476771&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61091\" NCI Thesaurus)"""@eng ; """2006-08-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """C61091"""^^xsd:string ; umls:cui """C1831800"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anabolic androgen"""@eng ; skos:notation """CDR0000040373"""^^xsd:string ; rdfs:subClassOf ; """3234"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280040"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/vinblastine"""@eng ; skos:notation """CDR0000040354"""^^xsd:string ; skos:altLabel """VDP"""@eng , """CDDP/DTIC/VBL"""@eng ; ; ; ; """3210"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0285237"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antibody conjugate therapy"""@eng ; skos:notation """CDR0000040355"""^^xsd:string ; skos:altLabel """immunotoxin"""@eng , """therapy, antibody conjugate"""@eng ; ; rdfs:subClassOf ; """3211"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0021084"""^^xsd:string ; umls:cui """C0280026"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pimonidazole"""@eng ; skos:notation """CDR0000040356"""^^xsd:string ; skos:altLabel """ro 03-8799"""@eng ; """3212"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0950517"""^^xsd:string ; umls:cui """C0071072"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory anemia"""@eng ; skos:notation """CDR0000040357"""^^xsd:string ; rdfs:subClassOf ; """3213"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0002893"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentosan polysulfate sodium"""@eng ; skos:notation """CDR0000040350"""^^xsd:string ; skos:altLabel """PPS"""@eng , """Elmiron"""@eng , """Tavan SP-54"""@eng , """SP-54"""@eng , """Hemoclar"""@eng , """Fibrocid"""@eng ; skos:definition """The sodium salt of a semisynthetic heparin-like glucosaminoglycan. Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40350&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40350&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C946\" NCI Thesaurus)"""@eng ; """C946"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-23"""^^xsd:string ; """3202"""^^xsd:string ; """116001-96-8"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0524684"""^^xsd:string ; umls:cui """C0740028"""^^xsd:string ; umls:cui """C0740027"""^^xsd:string ; umls:cui """C0600293"""^^xsd:string ; umls:cui """C0600294"""^^xsd:string ; umls:cui """C0600295"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/vindesine"""@eng ; skos:notation """CDR0000040351"""^^xsd:string ; skos:altLabel """PACE"""@eng , """CDDP/CTX/DAVA/DOX"""@eng ; ; ; ; ; """3203"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280022"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/vindesine"""@eng ; skos:notation """CDR0000040352"""^^xsd:string ; skos:altLabel """CDDP/CTX/DAVA"""@eng , """PCE"""@eng ; ; ; ; """3204"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0246101"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000040353"""^^xsd:string ; skos:altLabel """MP/MTX/PRDL/VCR"""@eng , """POMP"""@eng ; ; ; ; ; """3206"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280024"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oligofructose-enriched inulin"""@eng ; skos:notation """CDR0000487522"""^^xsd:string ; skos:altLabel """Beneo Synergy 1"""@eng , """Synergy 1"""@eng ; skos:definition """A mixture of non-digestible carbohydrates, containing plant oligosaccharide inulin, and its breakdown product oligofructose, with potential antitumor, immunostimulating and prebiotic effects. Oligofructose-enriched inulin resists hydrolysis by intestinal digestive enzymes and is rapidly fermented in the colon into oligofructose. This provides a food source for colonic microbacteria, particularly bifidobacteria, thereby promoting beneficial bacterial growth and contributing to a protective colonic environment. In addition, this agent helps absorb calcium and magnesium from the gastrointestinal tract. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487522&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487522&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61598\" NCI Thesaurus)"""@eng ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61598"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831860"""^^xsd:string ; umls:cui """C1831859"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluphenazine hydrochloride"""@eng ; skos:notation """CDR0000487523"""^^xsd:string ; skos:altLabel """Prolixin"""@eng , """Permitil"""@eng ; skos:definition """The hydrochloride salt of fluphenazine, a phenothiazine with antipsychotic activity and potential antineoplastic activity. Fluphenazine blocks postsynaptic dopamine D2 receptors in the limbic system, cortical system and basal ganglia, resulting a reduction of schizophrenia-associated hallucinations and delusions. In addition, as a serotonin antagonist, this agent may inhibit lymphocyte and myeloma cell proliferation by blocking 5-hydroxytrptamine type 1B (5-HT type 1B) receptors for serotonin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487523&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487523&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47995\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """179197"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-30"""^^xsd:string ; """C47995"""^^xsd:string ; """146-56-5"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700567"""^^xsd:string ; umls:cui """C0722557"""^^xsd:string ; umls:cui """C0033390"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MART-1 antigen/Montanide ISA-51/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000043618"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; """8902"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flt3 ligand/gp100 antigen/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043619"""^^xsd:string ; skos:altLabel """Flt3L/gp100/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; """8903"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879327"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/sargramostim/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000043614"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/TRP-1"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """8899"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879323"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """esophageal cancer"""@eng ; skos:notation """CDR0000043615"""^^xsd:string ; skos:altLabel """esophagus cancer"""@eng , """Esophageal cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """89"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0546837"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043616"""^^xsd:string ; skos:altLabel """gp100/ISA-51/MART-1/TYRP"""@eng ; ; ; ; """8900"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879324"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-2/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043617"""^^xsd:string ; skos:altLabel """gp100/IL-2/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; """8901"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879325"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/Montanide ISA-51/sargramostim"""@eng ; skos:notation """CDR0000043610"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/ISA-51"""@eng ; ; ; """8895"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879319"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000043611"""^^xsd:string ; skos:altLabel """ISA-51/TRP-1"""@eng ; ; """2003-10-23"""^^xsd:string ; """8896"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879320"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/Montanide ISA-51/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000043612"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/TRP-1"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """8897"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879321"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/Montanide ISA-51/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000043613"""^^xsd:string ; skos:altLabel """IL-12/ISA-51/TRP-1"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """8898"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879322"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valsartan"""@eng ; skos:notation """CDR0000464172"""^^xsd:string ; skos:altLabel """CGP 48933"""@eng , """Diovan"""@eng , """N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine"""@eng , """L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-"""@eng ; skos:definition """An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464172&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464172&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47781\" NCI Thesaurus)"""@eng ; """2006-06-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """137862-53-4"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """C47781"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0216784"""^^xsd:string ; umls:cui """C0527644"""^^xsd:string ; umls:cui """C0719949"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine"""@eng ; skos:notation """CDR0000506045"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-24"""^^xsd:string ; umls:cui """C1831955"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polyphenon E"""@eng ; skos:notation """CDR0000506041"""^^xsd:string ; skos:definition """A defined, decaffeinated green tea polyphenol mixture isolated from the plant Camellia sinensis with antiviral and antioxidant activities. Polyphenon E may possess chemopreventive properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=506041&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=506041&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38689\" NCI Thesaurus)"""@eng ; """2006-08-24"""^^xsd:string ; """C38689"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0917976"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/oxaliplatin/trastuzumab"""@eng ; skos:notation """CDR0000038009"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/MOAB HER2"""@eng ; ; ; ; ; """10524"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879557"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/stem cell factor"""@eng ; skos:notation """CDR0000038008"""^^xsd:string ; skos:altLabel """IL-2/SCF"""@eng ; ; ; """10523"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879556"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/zosuquidar trihydrochloride"""@eng ; skos:notation """CDR0000257882"""^^xsd:string ; skos:altLabel """ARA-C/DNR/LY335979"""@eng ; ; ; ; """2002-09-12"""^^xsd:string ; """11470"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327791"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/leuprolide/nilutamide"""@eng ; skos:notation """CDR0000358327"""^^xsd:string ; skos:altLabel """ANAN/EM/LEUP/TXT"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541575"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone marrow ablation"""@eng ; skos:notation """CDR0000041757"""^^xsd:string ; rdfs:subClassOf ; """4933"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0281342"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/estramustine/etoposide"""@eng ; skos:notation """CDR0000041756"""^^xsd:string ; skos:altLabel """CDDP/EM/VP-16"""@eng ; ; ; ; """4931"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281341"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/paclitaxel"""@eng ; skos:notation """CDR0000041755"""^^xsd:string ; skos:altLabel """CDDP/5-FU/TAX"""@eng ; ; ; ; """4930"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281340"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/fludarabine/idarubicin"""@eng ; skos:notation """CDR0000041754"""^^xsd:string ; skos:altLabel """ARA-C/FAMP/IDA"""@eng ; ; ; ; """4929"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281339"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PSC 833/vinblastine"""@eng ; skos:notation """CDR0000041753"""^^xsd:string ; skos:altLabel """PSC-833/VBL"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """4928"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281338"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/suramin"""@eng ; skos:notation """CDR0000041752"""^^xsd:string ; skos:altLabel """AGT/SUR"""@eng ; ; ; """4927"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281337"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/tretinoin"""@eng ; skos:notation """CDR0000041751"""^^xsd:string ; skos:altLabel """ATRA/VP-16"""@eng ; ; ; """4926"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281336"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PSC 833"""@eng ; skos:notation """CDR0000041750"""^^xsd:string ; skos:altLabel """PSC-833"""@eng , """PSC833"""@eng , """6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic Acid]cyclosporin D"""@eng , """Cyclo((2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl)-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-me"""@eng , """Valspodar"""@eng , """Amdray"""@eng ; skos:definition """An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41750&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41750&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1405\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """4925"""^^xsd:string ; """41121"""^^xsd:string ; """648265"""^^xsd:string ; """121584-18-7"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C1405"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0139121"""^^xsd:string ; umls:cui """C1519948"""^^xsd:string ; umls:cui """C0753474"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/decitabine"""@eng ; skos:notation """CDR0000041759"""^^xsd:string ; skos:altLabel """CDDP/DAC"""@eng ; ; ; """4936"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281344"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult meningeal hemangiopericytoma"""@eng ; skos:notation """CDR0000041758"""^^xsd:string ; skos:altLabel """adult brain malignant hemangiopericytoma"""@eng , """meningeal hemangiopericytoma, adult"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult meningeal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4935"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541494"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000042189"""^^xsd:string ; skos:altLabel """pediatric small noncleaved cell lymphoma, stage I"""@eng , """small noncleaved cell lymphoma, childhood, stage I"""@eng , """lymphoma, stage I childhood small noncleaved cell"""@eng , """childhood small noncleaved cell lymphoma, stage I"""@eng , """stage I small noncleaved cell lymphoma, childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5429"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281700"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/prednisolone/vincristine"""@eng ; skos:notation """CDR0000038307"""^^xsd:string ; skos:altLabel """ARA-C/ASP/PRDL/VCR"""@eng ; ; ; ; ; """10921"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935856"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/doxorubicin/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000038308"""^^xsd:string ; skos:altLabel """ASP/DOX/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; """10922"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935857"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I cervical cancer"""@eng ; skos:notation """CDR0000038005"""^^xsd:string ; skos:altLabel """carcinoma of the cervix, stage I"""@eng , """cancer of the cervix, stage I"""@eng , """cervical cancer, stage I"""@eng , """uterine cervical cancer, stage I"""@eng , """cervix cancer, stage I"""@eng , """stage I carcinoma of the cervix"""@eng , """stage I cervix cancer"""@eng , """stage I cancer of the cervix"""@eng , """uterine cervix cancer, stage I"""@eng , """stage I uterine cervix cancer"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """105"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278575"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000038309"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DNR/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; ; """10923"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935858"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """protein tyrosine kinase inhibitor therapy"""@eng ; skos:notation """CDR0000037939"""^^xsd:string ; ; rdfs:subClassOf ; """10359"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0879484"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eculizumab"""@eng ; skos:notation """CDR0000415541"""^^xsd:string ; skos:altLabel """h5G1.1"""@eng , """monoclonal antibody anti-C5"""@eng , """Alexion"""@eng , """monoclonal antibody 5G1.1"""@eng ; skos:definition """A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415541&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415541&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48386\" NCI Thesaurus)"""@eng ; """2005-01-24"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C48386"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1959617"""^^xsd:string ; umls:cui """C1541483"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uterine leiomyomata"""@eng ; skos:notation """CDR0000279978"""^^xsd:string ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """2003-02-20"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0042133"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin HCl liposome/lenalidomide/vincristine"""@eng ; skos:notation """CDR0000393828"""^^xsd:string ; skos:altLabel """CC 5013/DM/LipoDox/VCR"""@eng ; ; ; ; ; """2004-10-25"""^^xsd:string ; """2004-09-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541377"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """delirium"""@eng ; skos:notation """CDR0000042226"""^^xsd:string ; rdfs:subClassOf ; """5472"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0011206"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody MDX-H210"""@eng ; skos:notation """CDR0000042227"""^^xsd:string ; skos:altLabel """520C9x22 bispecific antibody"""@eng , """bispecific antibody 520C9 x H22"""@eng , """bispecific antibody 520C9xH22"""@eng , """BsAb 520C9xH22"""@eng , """MDX-210"""@eng , """BsAb 520C9x22"""@eng , """MDX-H210"""@eng , """520C9xH22 bispecific antibody"""@eng , """bispecific antibody 520C9x22"""@eng , """antibody, bispecific 520C9xH22"""@eng , """520C9xH22 antibody, bispecific"""@eng ; ; ; """C1578"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """5473"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281736"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000042224"""^^xsd:string ; skos:altLabel """BLEO/CDDP/CTX/VP-16"""@eng ; ; ; ; ; """5470"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281734"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transitional care planning"""@eng ; skos:notation """CDR0000042225"""^^xsd:string ; rdfs:subClassOf ; """5471"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0281735"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/fluorouracil/interferon alfa/leucovorin calcium"""@eng ; skos:notation """CDR0000042222"""^^xsd:string ; skos:altLabel """CF/5-FU/IFN-A/VP-16"""@eng ; ; ; ; ; """5468"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338193"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nolatrexed dihydrochloride"""@eng ; skos:notation """CDR0000042223"""^^xsd:string ; skos:altLabel """Nolatrexed Hydrochloride"""@eng , """AG 337"""@eng , """3,4-Dihydro-2-amino-6-methyl-4-oxy-5-(4-pyridylthio)-quinazoline Dihydrochloride"""@eng , """Thymitaq"""@eng , """Nolatrexed"""@eng , """AG337"""@eng , """AG-337"""@eng ; skos:definition """A water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42223&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42223&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1577\" NCI Thesaurus)"""@eng ; ; """5469"""^^xsd:string ; """C1577"""^^xsd:string ; """147149-76-6"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0281733"""^^xsd:string ; umls:cui """C0796399"""^^xsd:string ; umls:cui """C0935948"""^^xsd:string ; umls:cui """C0389037"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """folic acid/lometrexol"""@eng ; skos:notation """CDR0000042220"""^^xsd:string ; skos:altLabel """FA/LMTX"""@eng ; ; ; """5465"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281730"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel"""@eng ; skos:notation """CDR0000042221"""^^xsd:string ; skos:altLabel """CDDP/TXT"""@eng ; ; ; """5467"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281731"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AG-013736/docetaxel"""@eng ; skos:notation """CDR0000422409"""^^xsd:string ; skos:altLabel """AG 013736/TXT"""@eng ; ; ; """2005-02-18"""^^xsd:string ; """2005-02-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/autologous dendritic cells/MART-1 antigen"""@eng ; skos:notation """CDR0000385552"""^^xsd:string ; skos:altLabel """ADC/MART-1/MOAB CTLA-4"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541594"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cetuximab/gemcitabine"""@eng ; skos:notation """CDR0000385553"""^^xsd:string ; skos:altLabel """dFdC/MOAB C225/MOAB VEGF"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541595"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/temozolomide"""@eng ; skos:notation """CDR0000042228"""^^xsd:string ; skos:altLabel """BCNU/TMZ"""@eng ; ; ; """5474"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281737"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/vinblastine"""@eng ; skos:notation """CDR0000042229"""^^xsd:string ; skos:altLabel """IL-2/VBL"""@eng ; ; ; """5477"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281738"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lanreotide"""@eng ; skos:notation """CDR0000405866"""^^xsd:string ; """2004-11-05"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1523"""^^xsd:string ; umls:cui """C0209211"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-599626"""@eng ; skos:notation """CDR0000391060"""^^xsd:string ; skos:definition """An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=391060&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=391060&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48380\" NCI Thesaurus)"""@eng ; """2004-09-25"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C48380"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541473"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide"""@eng ; skos:notation """CDR0000040998"""^^xsd:string ; skos:altLabel """CDDP/IFF"""@eng ; ; ; """4036"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280612"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/tumor necrosis factor"""@eng ; skos:notation """CDR0000040999"""^^xsd:string ; skos:altLabel """IL-2/TNF"""@eng ; ; ; """4037"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280613"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000040996"""^^xsd:string ; skos:altLabel """IFN-A/IL-2"""@eng ; ; ; """4034"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338121"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/methotrexate"""@eng ; skos:notation """CDR0000040997"""^^xsd:string ; skos:altLabel """CDDP/MTX"""@eng ; ; ; """4035"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280611"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/vincristine"""@eng ; skos:notation """CDR0000040994"""^^xsd:string ; skos:altLabel """CTX/EPI/VCR"""@eng , """FOC"""@eng ; ; ; ; """4032"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055157"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/epirubicin"""@eng ; skos:notation """CDR0000040995"""^^xsd:string ; skos:altLabel """CDDP/EPI"""@eng , """EP"""@eng ; ; ; """4033"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280609"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta carotene"""@eng ; skos:notation """CDR0000040992"""^^xsd:string ; skos:altLabel """Solatene"""@eng , """Lumitene"""@eng ; skos:definition """A naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities. As an anti-oxidant, beta carotene inhibits free-radical damage to DNA. This agent also induces cell differentiation and apoptosis of some tumor cell types, particularly in early stages of tumorigenesis, and enhances immune system activity by stimulating the release of natural killer cells, lymphocytes, and monocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40992&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40992&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1016\" NCI Thesaurus)"""@eng ; ; ; ; """4030"""^^xsd:string ; """7235-40-7"""^^xsd:string ; """62794"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """C1016"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0053396"""^^xsd:string ; umls:cui """C1831594"""^^xsd:string ; umls:cui """C0728799"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/epirubicin"""@eng ; skos:notation """CDR0000040993"""^^xsd:string ; skos:altLabel """CDDP/CTX/EPI"""@eng , """PEC"""@eng ; ; ; ; """4031"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055065"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood supratentorial primitive neuroectodermal tumors"""@eng ; skos:notation """CDR0000040990"""^^xsd:string ; skos:altLabel """pediatric primitive neuroectodermal tumor, supratentorial"""@eng , """pediatric pineocytoma"""@eng , """PNET, pediatric supratentorial"""@eng , """PNET, supratentorial, childhood"""@eng , """pediatric supratentorial PNET"""@eng , """pediatric pineal parenchymal tumor"""@eng , """neuroectodermal tumor, pediatric, primitive, supratentorial"""@eng , """supratentorial primitive neuroectodermal tumor, childhood"""@eng , """pediatric PNET, pineoblastoma"""@eng , """Brain tumor, child: PNET or pineal"""@eng , """pineocytoma, childhood"""@eng , """pediatric supratentorial primitive neuroectodermal tumor"""@eng , """supratentorial primitive neuroectodermal tumor, pediatric"""@eng , """pineoblastoma, childhood"""@eng , """childhood primitive neuroectodermal tumor, supratentorial"""@eng , """pediatric cerebral neuroblastoma"""@eng , """childhood pineocytoma"""@eng , """cerebral neuroblastoma, pediatric"""@eng , """childhood supratentorial PNET"""@eng , """pineal parenchymal tumor, childhood"""@eng , """childhood cerebral neuroblastoma"""@eng , """cerebral neuroblastoma, childhood"""@eng , """neuroectodermal tumor, childhood, primitive, supratentorial"""@eng , """neuroblastoma, pediatric cerebral"""@eng , """primitive neuroectodermal tumor, pediatric supratentorial"""@eng , """childhood PNET, pineoblastoma"""@eng , """PNET, childhood supratentorial"""@eng , """primitive neuroectodermal tumor, supratentorial, childhood"""@eng , """pediatric pineoblastoma"""@eng , """neuroblastoma, cerebral, pediatric"""@eng , """neuroblastoma, cerebral, childhood"""@eng , """childhood pineal parenchymal tumor"""@eng , """neuroblastoma, childhood cerebral"""@eng , """primitive neuroectodermal tumor, supratentorial, pediatric"""@eng , """childhood pineoblastoma"""@eng , """PNET, supratentorial, pediatric"""@eng , """primitive neuroectodermal tumor, childhood supratentorial"""@eng ; rdfs:subClassOf ; """2002-08-09"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4028"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280605"""^^xsd:string ; umls:cui """C3887519"""^^xsd:string ; umls:cui """C3887520"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metabolic abnormality assessment"""@eng ; skos:notation """CDR0000040991"""^^xsd:string ; skos:altLabel """metabolic assessment, abnormality"""@eng , """abnormal assessment of metabolism"""@eng , """metabolism studies"""@eng ; ; rdfs:subClassOf ; """4029"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280606"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/filgrastim/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000038599"""^^xsd:string ; skos:altLabel """G-CSF/TAX/TOPO/VP-16"""@eng ; ; ; ; ; """11228"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134616"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bupropion/nicotine"""@eng ; skos:notation """CDR0000038598"""^^xsd:string ; skos:altLabel """BUP/NIC"""@eng ; ; ; """11227"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134615"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/eflornithine"""@eng ; skos:notation """CDR0000038595"""^^xsd:string ; skos:altLabel """DFMO/SC-58635"""@eng ; ; ; """11224"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134612"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/trastuzumab"""@eng ; skos:notation """CDR0000038594"""^^xsd:string ; skos:altLabel """MOAB HER2/OSI774"""@eng ; ; ; """11223"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134611"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/thalidomide"""@eng ; skos:notation """CDR0000038597"""^^xsd:string ; skos:altLabel """DM/THAL"""@eng ; ; ; """11226"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134614"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """S-3304"""@eng ; skos:notation """CDR0000038596"""^^xsd:string ; skos:definition """An orally-agent agent with potential antineoplastic activity. S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38596&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38596&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2671\" NCI Thesaurus)"""@eng ; ; """11225"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2671"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C1134613"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gefitinib"""@eng ; skos:notation """CDR0000038591"""^^xsd:string ; skos:altLabel """CDDP/ZD 1839"""@eng ; ; ; """2002-10-10"""^^xsd:string ; """11220"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134608"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized resectable adult primary liver cancer"""@eng ; skos:notation """CDR0000038590"""^^xsd:string ; skos:altLabel """hepatoma, localized resectable adult primary"""@eng , """adult primary liver cancer, localized resectable"""@eng , """adult primary hepatoma, localized resectable"""@eng , """liver cancer, localized resectable adult primary"""@eng ; rdfs:subClassOf ; """adult primary liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1122"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278772"""^^xsd:string ; umls:cui """C1370857"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CI-1040"""@eng ; skos:notation """CDR0000038593"""^^xsd:string ; skos:altLabel """CI1040"""@eng ; """11222"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134610"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aspirin/folic acid"""@eng ; skos:notation """CDR0000038592"""^^xsd:string ; skos:altLabel """ASA/FA"""@eng ; ; ; """11221"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134609"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA-TRICOM vaccine"""@eng ; skos:notation """CDR0000305933"""^^xsd:string ; skos:altLabel """fPSA-TRI"""@eng ; skos:definition """A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA) and TRICOM, a combination of three immunostimulants (i.e., B7.1, ICAM-1, and LFA-3). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305933&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305933&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38708\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """2003-05-23"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38708"""^^xsd:string ; umls:cui """C1327972"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA-TRICOM vaccine/sargramostim/vaccinia-PSA-TRICOM vaccine"""@eng ; skos:notation """CDR0000305936"""^^xsd:string ; skos:altLabel """fPSA-TRI/GM-CSF/vPSA-TRI"""@eng ; ; ; ; """2003-05-23"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327975"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA-TRICOM vaccine/recombinant fowlpox GM-CSF vaccine/vaccinia-PSA-TRICOM vaccine"""@eng ; skos:notation """CDR0000305937"""^^xsd:string ; skos:altLabel """fPSA-TRI/rF-GM-CSF/vPSA-TRI"""@eng ; ; ; ; """2003-05-23"""^^xsd:string ; """2004-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327976"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-PSA-TRICOM vaccine"""@eng ; skos:notation """CDR0000305934"""^^xsd:string ; skos:altLabel """vPSA-TRI"""@eng , """vaccinia-prostate-specific antigen-TRICOM vaccine"""@eng ; skos:definition """A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305934&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305934&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38681\" NCI Thesaurus)"""@eng ; ; ; ; ; """2003-05-23"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C38681"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327973"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA-TRICOM vaccine/vaccinia-PSA-TRICOM vaccine"""@eng ; skos:notation """CDR0000305935"""^^xsd:string ; skos:altLabel """fPSA-TRI/vPSA-TRI"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327974"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/mycophenolate mofetil/prednisone"""@eng ; skos:notation """CDR0000380739"""^^xsd:string ; skos:altLabel """CYSP/MMF/PRED"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541587"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-interferon alfa-2b/sargramostim/thalidomide"""@eng ; skos:notation """CDR0000380733"""^^xsd:string ; skos:altLabel """GM-CSF/PEG-IFNA2b/THAL"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541586"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000039978"""^^xsd:string ; skos:altLabel """TsAVb"""@eng , """DOX/TSPA/VBL"""@eng ; ; ; ; """2684"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279686"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spindle cell intraocular melanoma"""@eng ; skos:notation """CDR0000039979"""^^xsd:string ; skos:altLabel """intraocular melanoma, spindle cell"""@eng , """melanoma, intraocular, spindle cell"""@eng , """melanoma, spindle cell intraocular"""@eng ; rdfs:subClassOf ; """2686"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279687"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sarcomatous mesothelioma"""@eng ; skos:notation """CDR0000039970"""^^xsd:string ; skos:altLabel """mesothelioma, sarcomatous"""@eng , """fibrous mesothelial sarcoma"""@eng , """mesothelial sarcoma, sarcomatous"""@eng , """fibrous mesothelioma"""@eng , """sarcomatous mesothelial sarcoma"""@eng , """sarcoma, mesothelial, sarcomatous"""@eng , """mesothelial sarcoma, fibrous"""@eng , """sarcoma, mesothelial, fibrous"""@eng , """mesothelioma, fibrous"""@eng ; rdfs:subClassOf ; """2675"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334513"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transitional cell carcinoma of the bladder"""@eng ; skos:notation """CDR0000039971"""^^xsd:string ; skos:altLabel """bladder cancer, transitional cell carcinoma"""@eng , """carcinoma, transitional cell, bladder"""@eng ; rdfs:subClassOf ; """2676"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279680"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of the bladder"""@eng ; skos:notation """CDR0000039972"""^^xsd:string ; skos:altLabel """carcinoma, squamous cell, bladder"""@eng , """bladder cancer, squamous cell carcinoma"""@eng ; rdfs:subClassOf ; """2677"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279681"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the bladder"""@eng ; skos:notation """CDR0000039973"""^^xsd:string ; skos:altLabel """adenocarcinoma, bladder"""@eng , """bladder cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2678"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279682"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """didemnin B"""@eng ; skos:notation """CDR0000039974"""^^xsd:string ; skos:altLabel """L-Tyrosine, N-[1-[N-[4-[[3-Hydroxy-4-[[N-[N-[1-(2-hydroxy-1-oxopropyl)- L-prolyl]-N-methyl-L-leucyl]-L-threonyl]amino-5-methyl-1-oxoheptyl]oxy]-2,5-dimethyl-1,3-dioxohexyl]-L-leucyl]- L-prolyl]-N,O-dimethyl-, .phi.-lactone (9CI)"""@eng , """1-Oxoheptyl]oxy]-2,5-dimethyl-1,3-dioxohexyl]-L-leucyl]- L-prolyl]-N,O-dimethyl-, .phi.-lactone (9CI)"""@eng , """didemnin"""@eng , """15H-Pyrrolol[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotri-cosine, Cyclic Peptide Deriv. (9CI)"""@eng ; skos:definition """A cyclic depsipeptide extracted from the Caribbean tunicate Trididemnum cyanophorum. Didemnin B activates caspase, thereby inducing apoptosis, and prevents eukaryotic elongation factor 2 (eEF-2)-dependent translocation, thereby inhibiting protein synthesis. This agent also has immunosuppressive and antiviral properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39974&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39974&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1364\" NCI Thesaurus)"""@eng ; """2679"""^^xsd:string ; """24505"""^^xsd:string ; """325319"""^^xsd:string ; """77327-05-0"""^^xsd:string ; """333841"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1364"""^^xsd:string ; umls:cui """C0936059"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitolactol/mitoxantrone/vincristine"""@eng ; skos:notation """CDR0000039975"""^^xsd:string ; skos:altLabel """D(DHAD)V"""@eng , """DBD/DHAD/VCR"""@eng ; ; ; ; """2681"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/dacarbazine/doxorubicin/mechlorethamine/vincristine"""@eng ; skos:notation """CDR0000039976"""^^xsd:string ; skos:altLabel """MADDOC"""@eng , """CDDP/CTX/DOX/DTIC/NM/VCR"""@eng ; ; ; ; ; ; ; """2682"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0126735"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/mechlorethamine/prednisone/procarbazine/vinblastine/vincristine"""@eng ; skos:notation """CDR0000039977"""^^xsd:string ; skos:altLabel """MOPP/ABV-Hybrid"""@eng , """BLEO/DOX/NM/PCB/PRED/VBL/VCR"""@eng ; ; ; ; ; ; ; ; """2683"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066790"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000039620"""^^xsd:string ; skos:altLabel """CDDP/CTX/5-FU/VCR"""@eng , """CO-5P"""@eng ; ; ; ; ; """2275"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279407"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil"""@eng ; skos:notation """CDR0000039621"""^^xsd:string ; skos:altLabel """CTX/5-FU"""@eng , """CF"""@eng ; ; ; """2276"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055160"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cyclophosphamide/methotrexate"""@eng ; skos:notation """CDR0000039622"""^^xsd:string ; skos:altLabel """CMH"""@eng , """CTX/HMM/MTX"""@eng ; ; ; ; """2277"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279409"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitoguazone/vinblastine"""@eng ; skos:notation """CDR0000039623"""^^xsd:string ; skos:altLabel """CVeM"""@eng , """CDDP/MGBG/VBL"""@eng ; ; ; ; """2278"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279410"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039624"""^^xsd:string ; skos:altLabel """CHOP-AMA"""@eng , """ARA-C/ASP/CTX/DOX/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """2279"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atvogen/interleukin-2"""@eng ; skos:notation """CDR0000039625"""^^xsd:string ; skos:altLabel """atvogen/IL-2"""@eng ; """Drug/agent combination"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """2280"""^^xsd:string ; umls:cui """C1831590"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/etoposide/sargramostim"""@eng ; skos:notation """CDR0000039626"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/GM-CSF/VP-16"""@eng ; ; ; ; ; """2281"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279413"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexrazoxane/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000039627"""^^xsd:string ; skos:altLabel """ADR-529/CTX/DOX/VCR"""@eng ; ; ; ; ; """2282"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279414"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/thiotepa/vincristine"""@eng ; skos:notation """CDR0000039628"""^^xsd:string ; skos:altLabel """BTOC"""@eng , """BCNU/CTX/TSPA/VCR"""@eng ; ; ; ; ; """2283"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279415"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMP2a-specific cytotoxic T-lymphocytes"""@eng ; skos:notation """CDR0000334454"""^^xsd:string ; skos:altLabel """LMP2A CTL"""@eng , """LMP2A-CTL"""@eng ; ; """2004-04-06"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2003-09-24"""^^xsd:string ; umls:cui """C1328049"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/leucovorin calcium"""@eng ; skos:notation """CDR0000041113"""^^xsd:string ; skos:altLabel """CF/5-FU/IFN-A"""@eng ; ; ; ; """4153"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338127"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000041112"""^^xsd:string ; skos:altLabel """IFN-A/IL-2/LAK"""@eng ; ; ; ; """4152"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338126"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian low malignant potential tumor"""@eng ; skos:notation """CDR0000041115"""^^xsd:string ; skos:altLabel """ovarian borderline malignant tumor"""@eng , """Ovarian low malignant potential tumor"""@eng , """ovarian tumors of low malignant potential"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """2003-05-22"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4155"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C3665489"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """embolization therapy"""@eng ; skos:notation """CDR0000041114"""^^xsd:string ; skos:altLabel """therapy, embolization"""@eng ; """4154"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0013931"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/sargramostim"""@eng ; skos:notation """CDR0000041117"""^^xsd:string ; skos:altLabel """GM-CSF/IL-2"""@eng ; ; ; """4157"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280714"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/sargramostim"""@eng ; skos:notation """CDR0000041116"""^^xsd:string ; skos:altLabel """GM-CSF/IFN-G"""@eng ; ; ; """4156"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280713"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/tumor necrosis factor"""@eng ; skos:notation """CDR0000040509"""^^xsd:string ; skos:altLabel """TNF/VP-16"""@eng ; ; ; """3405"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280140"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/ifosfamide"""@eng ; skos:notation """CDR0000040508"""^^xsd:string ; skos:altLabel """PIA"""@eng , """CDDP/DOX/IFF"""@eng ; ; ; ; """3404"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0063264"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/prednisone"""@eng ; skos:notation """CDR0000391173"""^^xsd:string ; skos:altLabel """PRED/TXT"""@eng ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541475"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell monodermal and highly specialized teratoma"""@eng ; skos:notation """CDR0000040501"""^^xsd:string ; skos:altLabel """monodermal and highly specialized teratoma, ovarian germ cell"""@eng , """teratoma, monodermal and highly specialized, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3390"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280134"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell mature teratoma"""@eng ; skos:notation """CDR0000040500"""^^xsd:string ; skos:altLabel """mature teratoma, ovarian germ cell"""@eng , """teratoma, mature, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3389"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280133"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/idoxuridine"""@eng ; skos:notation """CDR0000040503"""^^xsd:string ; skos:altLabel """BLEO/IUDR"""@eng ; ; ; """3399"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280136"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian mixed germ cell tumor"""@eng ; skos:notation """CDR0000040502"""^^xsd:string ; skos:altLabel """germ cell tumor, mixed, ovarian"""@eng , """mixed germ cell tumor, ovarian"""@eng ; rdfs:subClassOf ; """3398"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280135"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV gastric cancer"""@eng ; skos:notation """CDR0000040504"""^^xsd:string ; skos:altLabel """gastric cancer, stage IV"""@eng , """stomach cancer, metastatic"""@eng , """gastric cancer, metastatic"""@eng , """metastatic gastric cancer"""@eng , """stomach cancer, stage IV"""@eng ; rdfs:subClassOf ; """gastric cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """34"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278498"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/hydrocortisone/methotrexate"""@eng ; skos:notation """CDR0000040507"""^^xsd:string ; skos:altLabel """ARA-C/HC/MTX"""@eng , """MHA"""@eng ; ; ; ; """3403"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280138"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/vinblastine"""@eng ; skos:notation """CDR0000040506"""^^xsd:string ; skos:altLabel """EVA"""@eng , """DOX/VBL/VP-16"""@eng ; ; ; ; """3402"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0255874"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical Pap test"""@eng ; skos:notation """CDR0000467894"""^^xsd:string ; skos:altLabel """Pap test, cervical"""@eng ; rdfs:subClassOf ; """Diagnostic test/procedure"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0079104"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colon imaging studies"""@eng ; skos:notation """CDR0000467890"""^^xsd:string ; ; rdfs:subClassOf ; """2006-04-21"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1831736"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/rituximab"""@eng ; skos:notation """CDR0000043102"""^^xsd:string ; skos:altLabel """IL-2/MOAB IDEC-C2B8"""@eng ; ; ; """7496"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678099"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """infrared thermography"""@eng ; skos:notation """CDR0000467892"""^^xsd:string ; rdfs:subClassOf ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1831737"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Pap test"""@eng ; skos:notation """CDR0000467893"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0079104"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exercise intervention"""@eng ; skos:notation """CDR0000467899"""^^xsd:string ; rdfs:subClassOf ; ; rdfs:subClassOf ; """Preventative intervention/procedure"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C1831738"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000041779"""^^xsd:string ; skos:altLabel """NM/PCB/PRED/VCR"""@eng , """MOPP"""@eng ; ; ; ; ; """496"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066789"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 17q"""@eng ; skos:notation """CDR0000299020"""^^xsd:string ; rdfs:subClassOf ; """2003-03-24"""^^xsd:string ; """2003-03-14"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327938"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the pancreas"""@eng ; skos:notation """CDR0000041778"""^^xsd:string ; rdfs:subClassOf ; """4959"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281361"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/flavopiridol"""@eng ; skos:notation """CDR0000406005"""^^xsd:string ; skos:altLabel """DOX/FLAVO"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541407"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """image-guided radiation therapy"""@eng ; skos:notation """CDR0000470285"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-07"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-02-23"""^^xsd:string ; umls:cui """C3179062"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AL721"""@eng ; skos:notation """CDR0000038973"""^^xsd:string ; """1531"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C2979932"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unspecified childhood solid tumor, protocol specific"""@eng ; skos:notation """CDR0000038972"""^^xsd:string ; skos:altLabel """protocol specific, unspecified childhood solid tumor"""@eng , """childhood solid tumor, unspecified, protocol specific"""@eng , """Solid tumor, unspecified, child"""@eng , """pediatric solid tumor, unspecified, protocol specific"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1530"""^^xsd:string ; """childhood meningioma"""^^xsd:string ; """metastatic childhood soft tissue sarcoma"""^^xsd:string ; """stage 4S neuroblastoma"""^^xsd:string ; """recurrent tumors of the Ewing's family"""^^xsd:string ; """previously untreated childhood rhabdomyosarcoma"""^^xsd:string ; """recurrent childhood brain stem glioma"""^^xsd:string ; """recurrent childhood brain tumor"""^^xsd:string ; """localized osteosarcoma"""^^xsd:string ; """regional neuroblastoma"""^^xsd:string ; """stage III childhood liver cancer"""^^xsd:string ; """extraocular retinoblastoma"""^^xsd:string ; """disseminated neuroblastoma"""^^xsd:string ; """previously treated childhood rhabdomyosarcoma"""^^xsd:string ; """recurrent childhood liver cancer"""^^xsd:string ; """untreated childhood visual pathway glioma"""^^xsd:string ; """recurrent childhood medulloblastoma"""^^xsd:string ; """localized resectable neuroblastoma"""^^xsd:string ; """stage III Wilms' tumor"""^^xsd:string ; """untreated childhood brain stem glioma"""^^xsd:string ; """localized unresectable neuroblastoma"""^^xsd:string ; """stage I Wilms' tumor"""^^xsd:string ; """localized Ewing's sarcoma/primitive neuroectodermal tumor"""^^xsd:string ; """recurrent childhood rhabdomyosarcoma"""^^xsd:string ; """stage II childhood liver cancer"""^^xsd:string ; """untreated childhood cerebellar astrocytoma"""^^xsd:string ; """recurrent childhood ependymoma"""^^xsd:string ; """recurrent neuroblastoma"""^^xsd:string ; """pediatric germ cell tumor"""^^xsd:string ; """recurrent Ewing's sarcoma/primitive neuroectodermal tumor"""^^xsd:string ; """stage I childhood liver cancer"""^^xsd:string ; """stage IV Wilms' tumor"""^^xsd:string ; """intraocular retinoblastoma"""^^xsd:string ; """childhood supratentorial ependymoma"""^^xsd:string ; """metastatic Ewing's sarcoma/primitive neuroectodermal tumor"""^^xsd:string ; """metastatic tumors of the Ewing's family"""^^xsd:string ; """stage II Wilms' tumor"""^^xsd:string ; """untreated childhood medulloblastoma"""^^xsd:string ; """localized tumors of the Ewing's family"""^^xsd:string ; """untreated childhood visual pathway and hypothalamic glioma"""^^xsd:string ; """recurrent retinoblastoma"""^^xsd:string ; """recurrent osteosarcoma"""^^xsd:string ; """untreated childhood supratentorial primitive neuroectodermal tumors"""^^xsd:string ; """childhood oligodendroglioma"""^^xsd:string ; """recurrent childhood cerebellar astrocytoma"""^^xsd:string ; """recurrent childhood cerebral astrocytoma"""^^xsd:string ; """metastatic osteosarcoma"""^^xsd:string ; """Langerhans cell histiocytosis"""^^xsd:string ; """childhood infratentorial ependymoma"""^^xsd:string ; """recurrent childhood visual pathway and hypothalamic glioma"""^^xsd:string ; """low-grade childhood cerebral astrocytoma"""^^xsd:string ; """stage V Wilms' tumor"""^^xsd:string ; """recurrent childhood supratentorial primitive neuroectodermal tumors"""^^xsd:string ; """recurrent childhood visual pathway glioma"""^^xsd:string ; """childhood choroid plexus tumor"""^^xsd:string ; """nonmetastatic childhood soft tissue sarcoma"""^^xsd:string ; """childhood craniopharyngioma"""^^xsd:string ; """high-grade childhood cerebral astrocytoma"""^^xsd:string ; """childhood ependymoma"""^^xsd:string ; """recurrent Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """recurrent childhood soft tissue sarcoma"""^^xsd:string ; """childhood central nervous system germ cell tumor"""^^xsd:string ; """stage IV childhood liver cancer"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279002"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/sargramostim"""@eng ; skos:notation """CDR0000038971"""^^xsd:string ; skos:altLabel """ARA-C/GM-CSF"""@eng ; ; ; """1528"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279001"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interleukin-3"""@eng ; skos:notation """CDR0000038970"""^^xsd:string ; skos:altLabel """IL-3"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1527"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C588"""^^xsd:string ; """2006-11-21"""^^xsd:string ; umls:cui """C1527130"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000038977"""^^xsd:string ; skos:altLabel """CDDP/5-FU/MTX"""@eng ; ; ; ; """1535"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055981"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """evaluation of cancer risk factors"""@eng ; skos:notation """CDR0000038975"""^^xsd:string ; skos:altLabel """cancer risk factors evaluation"""@eng ; ; rdfs:subClassOf ; """1533"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0279005"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """folate-FITC"""@eng ; skos:notation """CDR0000489286"""^^xsd:string ; skos:altLabel """EC17"""@eng ; """2006-09-19"""^^xsd:string ; """C62479"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831885"""^^xsd:string ; umls:cui """C1831886"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/vincristine"""@eng ; skos:notation """CDR0000038979"""^^xsd:string ; skos:altLabel """CTX/ARA-C/VCR"""@eng ; ; ; ; """1537"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279008"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cytarabine/daunorubicin"""@eng ; skos:notation """CDR0000038978"""^^xsd:string ; skos:altLabel """AMSA/ARA-C/DNR"""@eng ; ; ; ; """1536"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279007"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 124 chimeric monoclonal antibody cG250"""@eng ; skos:notation """CDR0000465493"""^^xsd:string ; skos:definition """A radioimmunoconjugate comprised of the chimeric monoclonal antibody G-250 conjugated with iodine I 124 with potential imaging properties. The antibody moiety of iodine I 124 chimeric monoclonal antibody G-250 may bind to renal cell carcinoma cells that express the renal cell carcinoma-associated antigen G-250, allowing detection of tumor-localized iodine I 124 with diagnostic imaging. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465493&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465493&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53407\" NCI Thesaurus)"""@eng ; """C53407"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """2006-07-03"""^^xsd:string ; umls:cui """C1708573"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imiquimod/Montanide ISA-51/multi-epitope melanoma peptide vaccine/sargramostim/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000434536"""^^xsd:string ; skos:altLabel """GM-CSF/IMQ/ISA-51/MULTI-EP MP VAC/TET TOX PEP VAC"""@eng ; ; ; ; ; """2005-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-23"""^^xsd:string ; umls:cui """C1831630"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/galactomannan derivative"""@eng ; skos:notation """CDR0000355830"""^^xsd:string ; skos:altLabel """5-FU/GD"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328212"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dual Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406"""@eng ; skos:notation """CDR0000500041"""^^xsd:string ; skos:altLabel """INNO-406"""@eng , """NS-187"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-06"""^^xsd:string ; """2006-09-21"""^^xsd:string ; umls:cui """C2607225"""^^xsd:string ; umls:cui """C1831933"""^^xsd:string ; umls:cui """C1664222"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SOD1 inhibitor ATN-224"""@eng ; skos:notation """CDR0000500040"""^^xsd:string ; skos:altLabel """ATN-224"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-21"""^^xsd:string ; """2006-08-06"""^^xsd:string ; """C62514"""^^xsd:string ; umls:cui """C1831930"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant thyrotropin alfa"""@eng ; skos:notation """CDR0000481277"""^^xsd:string ; skos:altLabel """Thyrogen"""@eng ; skos:definition """A recombinant form of the human anterior pituitary glycoprotein thyroid stimulating hormone (TSH) with use in the diagnostic setting. With an amino acid sequence identical to that of human TSH, thyrotropin alfa binds to TSH receptors on normal thyroid epithelial cells or well-differentiated thyroid cancer cells, stimulating iodine uptake and organification, synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481277&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481277&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61322\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """C61322"""^^xsd:string ; umls:cui """C1831804"""^^xsd:string ; umls:cui """C0876183"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """essential thrombocythemia"""@eng ; skos:notation """CDR0000039361"""^^xsd:string ; skos:altLabel """thrombocythemia, essential"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1997"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0040028"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/vaccinia-5T4 antigen vaccine"""@eng ; skos:notation """CDR0000377544"""^^xsd:string ; skos:altLabel """IL-2/rV-5T4 VAC"""@eng ; ; """2004-06-23"""^^xsd:string ; """2006-08-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541329"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TroVax"""@eng ; skos:notation """CDR0000377543"""^^xsd:string ; skos:altLabel """rV-5T4 VAC"""@eng ; """2006-10-09"""^^xsd:string ; """2004-06-23"""^^xsd:string ; umls:cui """C1709858"""^^xsd:string ; umls:cui """C1541801"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/STA-4783"""@eng ; skos:notation """CDR0000377540"""^^xsd:string ; skos:altLabel """STA 4783/TAX"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541327"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """A6"""@eng ; skos:notation """CDR0000377541"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541900"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interleukin-2/leucovorin calcium"""@eng ; skos:notation """CDR0000039365"""^^xsd:string ; skos:altLabel """CF/5-FU/IL-2"""@eng ; ; ; ; """2000"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279228"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/doxorubicin/vinblastine"""@eng ; skos:notation """CDR0000039364"""^^xsd:string ; skos:altLabel """ABVD"""@eng , """BLEO/DOX/DTIC/VBL"""@eng , """ABDV"""@eng ; ; ; ; ; """20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050380"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000039367"""^^xsd:string ; skos:altLabel """CBDCA/IFF/VCR"""@eng ; ; ; ; """2002"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279230"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/sargramostim"""@eng ; skos:notation """CDR0000039366"""^^xsd:string ; skos:altLabel """CDDP/CTX/GM-CSF/VP-16"""@eng ; ; ; ; ; """2001"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279229"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000043405"""^^xsd:string ; skos:altLabel """ASP/DNR/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; """7962"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796543"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/lomustine/vincristine"""@eng ; skos:notation """CDR0000039360"""^^xsd:string ; skos:altLabel """PACCO"""@eng , """CCNU/CDDP/CTX/DOX/VCR"""@eng ; ; ; ; ; ; """1996"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant soluble T4"""@eng ; skos:notation """CDR0000039363"""^^xsd:string ; skos:altLabel """rsT4"""@eng ; """1999"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0210233"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody R24"""@eng ; skos:notation """CDR0000039362"""^^xsd:string ; skos:altLabel """R24"""@eng , """MOAB R24"""@eng ; skos:definition """An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells. Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39362&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39362&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2349\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """1998"""^^xsd:string ; """2380"""^^xsd:string ; """3802"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """608918"""^^xsd:string ; """C2349"""^^xsd:string ; """733504"""^^xsd:string ; umls:cui """C0279226"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ewing's family of tumors"""@eng ; skos:notation """CDR0000043409"""^^xsd:string ; skos:altLabel """sarcoma, Ewing's"""@eng , """neuroepithelioma, peripheral"""@eng , """Ewing's sarcoma"""@eng , """pPNET"""@eng , """PNET"""@eng , """peripheral primitive neuroectodermal tumor"""@eng , """peripheral neuroectodermal tumor"""@eng , """primitive neuroectodermal tumor"""@eng , """primitive neuroectodermal tumor (PNET)"""@eng , """Askin's tumor"""@eng , """primitive peripheral neuroectodermal tumor"""@eng , """primitive neuroectodermal tumor, peripheral"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7968"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C3489398"""^^xsd:string ; umls:cui """C0877849"""^^xsd:string ; umls:cui """C0684337"""^^xsd:string ; umls:cui """C0206663"""^^xsd:string ; umls:cui """C0553580"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """perifosine"""@eng ; skos:notation """CDR0000043408"""^^xsd:string ; skos:altLabel """octadecylphosphopiperidine"""@eng , """Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate"""@eng , """4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt"""@eng , """D21266"""@eng , """D-21266"""@eng ; skos:definition """An orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43408&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43408&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1727\" NCI Thesaurus)"""@eng ; """7967"""^^xsd:string ; """157716-52-4"""^^xsd:string ; """C1727"""^^xsd:string ; """639966"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58156"""^^xsd:string ; """2006-09-08"""^^xsd:string ; umls:cui """C0754570"""^^xsd:string ; umls:cui """C0538860"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/melphalan/tamoxifen"""@eng ; skos:notation """CDR0000039369"""^^xsd:string ; skos:altLabel """PFT"""@eng , """5-FU/L-PAM/TMX"""@eng ; ; ; ; """2004"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279232"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/prednisone"""@eng ; skos:notation """CDR0000039368"""^^xsd:string ; skos:altLabel """BLEO/DOX/PRED"""@eng , """BAP"""@eng ; ; ; ; """2003"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279231"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/keyhole limpet hemocyanin/Montanide ISA-51"""@eng ; skos:notation """CDR0000386166"""^^xsd:string ; skos:altLabel """gp100/ISA-51/KLH"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541354"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interleukin-18"""@eng ; skos:notation """CDR0000386168"""^^xsd:string ; skos:altLabel """IL-18"""@eng , """SB-485232"""@eng ; """Drug/agent"""^^xsd:string ; """C1680"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """2004-08-24"""^^xsd:string ; umls:cui """C0383327"""^^xsd:string ; umls:cui """C1527127"""^^xsd:string ; umls:cui """C1541887"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel/zoledronate"""@eng ; skos:notation """CDR0000386169"""^^xsd:string ; skos:altLabel """CBDCA/TXT/ZOLE"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541355"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/fludarabine/melphalan/thiotepa"""@eng ; skos:notation """CDR0000420822"""^^xsd:string ; skos:altLabel """FAMP/L-PAM/MOAB CD52/TSPA"""@eng ; ; ; ; ; """2005-02-18"""^^xsd:string ; """2005-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541501"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adenoid cystic carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040699"""^^xsd:string ; skos:altLabel """adenoid cystic carcinoma of the oral cavity, stage I"""@eng , """oral cavity adenoid cystic carcinoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3638"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280347"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I mucoepidermoid carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040698"""^^xsd:string ; skos:altLabel """mucoepidermoid carcinoma of the oral cavity, stage I"""@eng , """oral cavity mucoepidermoid carcinoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3637"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280346"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paranasal sinus and nasal cavity esthesioneuroblastoma"""@eng ; skos:notation """CDR0000040691"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus esthesioneuroblastoma"""@eng , """esthesioneuroblastoma, paranasal sinus and nasal cavity"""@eng ; rdfs:subClassOf ; """3623"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206717"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood brain stem glioma"""@eng ; skos:notation """CDR0000040690"""^^xsd:string ; skos:altLabel """gliosarcoma, childhood brain stem"""@eng , """brain tumor, brain stem glioma, childhood"""@eng , """pediatric brainstem glioma"""@eng , """pediatric brain tumor, brainstem glioma"""@eng , """pediatric brain stem glioma"""@eng , """brainstem glioma, pediatric"""@eng , """glioma, childhood brain stem"""@eng , """mixed glioma, childhood brain stem"""@eng , """glioma, pediatric brain stem"""@eng , """CNS tumor, childhood brain stem glioma"""@eng , """pediatric CNS tumor, brainstem glioma"""@eng , """brain tumor, childhood, brainstem glioma"""@eng , """gliosarcoma, childhood brainstem"""@eng , """CNS tumor, brain stem glioma, childhood"""@eng , """childhood brain stem mixed glioma"""@eng , """glioma, pediatric brainstem"""@eng , """CNS tumor, brainstem glioma, childhood"""@eng , """childhood CNS tumor, brainstem glioma"""@eng , """childhood brainstem glioma"""@eng , """brain stem glioma, pediatric"""@eng , """childhood brain tumor, brainstem glioma"""@eng , """brain tumor, pediatric, brainstem glioma"""@eng , """childhood brainstem mixed glioma"""@eng , """childhood brainstem gliosarcoma"""@eng , """brain tumor, brainstem glioma, childhood"""@eng , """brain stem glioma, childhood"""@eng , """mixed glioma, childhood brainstem"""@eng , """glioma, childhood brainstem"""@eng , """Brain tumor, child: Brain stem glioma"""@eng , """central nervous system tumor, brainstem glioma, childhood"""@eng , """brainstem glioma, childhood"""@eng , """CNS tumor, childhood brainstem glioma"""@eng , """childhood brain tumor, brain stem glioma"""@eng , """childhood brain stem gliosarcoma"""@eng , """CNS tumor, pediatric brainstem glioma"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """362"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278600"""^^xsd:string ; umls:cui """C3887517"""^^xsd:string ; umls:cui """C3887516"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ondansetron"""@eng ; skos:notation """CDR0000040693"""^^xsd:string ; skos:altLabel """GR-C507/75"""@eng , """Zofran"""@eng , """GR-38032F"""@eng , """GR 38032F"""@eng , """GR38032F"""@eng ; skos:definition """A carbazole derivative with antiemetic activity. As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40693&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40693&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1119\" NCI Thesaurus)"""@eng ; ; """3630"""^^xsd:string ; """C1119"""^^xsd:string ; """665799"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """99614-02-5"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0061851"""^^xsd:string ; umls:cui """C0733434"""^^xsd:string ; umls:cui """C0733437"""^^xsd:string ; umls:cui """C0206046"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colony-stimulating factor therapy"""@eng ; skos:notation """CDR0000040692"""^^xsd:string ; skos:altLabel """therapy, colony stimulating factor"""@eng , """colony stimulating factor therapy"""@eng ; ; rdfs:subClassOf ; """3629"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280342"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I squamous cell carcinoma of the lip and oral cavity"""@eng ; skos:notation """CDR0000040695"""^^xsd:string ; skos:altLabel """lip and oral cavity squamous cell carcinoma, stage I"""@eng , """oral cavity and lip squamous cell carcinoma, stage I"""@eng , """squamous cell carcinoma of the lip and oral cavity, stage I"""@eng , """epidermoid carcinoma of the lip and oral cavity, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3634"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280343"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult T-cell leukemia/lymphoma"""@eng ; skos:notation """CDR0000040694"""^^xsd:string ; skos:altLabel """HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """leukemia/lymphoma, adult T-cell"""@eng , """T-cell leukemia/lymphoma, adult"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3631"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023493"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I verrucous carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040697"""^^xsd:string ; skos:altLabel """oral cavity verrucous carcinoma, stage I"""@eng , """verrucous carcinoma of the oral cavity, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3636"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280345"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I basal cell carcinoma of the lip"""@eng ; skos:notation """CDR0000040696"""^^xsd:string ; skos:altLabel """basal cell carcinoma of the lip, stage I"""@eng , """lip basal cell carcinoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3635"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280344"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-tumor necrosis factor therapy"""@eng ; skos:notation """CDR0000041928"""^^xsd:string ; skos:altLabel """anti-TNF therapy"""@eng , """anti-TNF-alpha therapy"""@eng ; ; rdfs:subClassOf ; """5149"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281481"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant stem cell factor"""@eng ; skos:notation """CDR0000041929"""^^xsd:string ; skos:altLabel """r-metHuSCF"""@eng , """Ancestim"""@eng , """SCF"""@eng , """recombinant human methionyl stem cell factor"""@eng ; ; ; """5151"""^^xsd:string ; """C1410"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-05"""^^xsd:string ; umls:cui """C1526982"""^^xsd:string ; umls:cui """C0538777"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/paclitaxel/thiotepa"""@eng ; skos:notation """CDR0000041920"""^^xsd:string ; skos:altLabel """DHAD/TAX/TSPA"""@eng ; ; ; ; """5140"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281473"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/ciprofloxacin/cyclophosphamide/pentoxifylline"""@eng ; skos:notation """CDR0000041921"""^^xsd:string ; skos:altLabel """BU/CPFX/CTX/PTX"""@eng ; ; ; ; ; """5141"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281474"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/melphalan/thiotepa"""@eng ; skos:notation """CDR0000041922"""^^xsd:string ; skos:altLabel """BU/L-PAM/TSPA"""@eng , """BuMelT"""@eng ; ; ; ; """5142"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281475"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/ciprofloxacin/melphalan/pentoxifylline/thiotepa"""@eng ; skos:notation """CDR0000041923"""^^xsd:string ; skos:altLabel """BU/CPFX/L-PAM/PTX/TSPA"""@eng ; ; ; ; ; ; """5143"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281476"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lung cancer screening"""@eng ; skos:notation """CDR0000041924"""^^xsd:string ; skos:altLabel """early detection of lung cancer"""@eng , """lung cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """5144"""^^xsd:string ; umls:cui """C0281477"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian cancer screening"""@eng ; skos:notation """CDR0000041925"""^^xsd:string ; skos:altLabel """ovarian cancer early detection"""@eng , """early detection of ovarian cancer"""@eng ; """2002-10-17"""^^xsd:string ; """5145"""^^xsd:string ; umls:cui """C0281478"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """primary systemic amyloidosis"""@eng ; skos:notation """CDR0000041926"""^^xsd:string ; skos:altLabel """amyloidosis, primary systemic"""@eng , """amyloidosis"""@eng , """systemic amyloidosis, primary"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """5146"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281479"""^^xsd:string ; umls:cui """C0002726"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboxypeptidase-G2/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000041927"""^^xsd:string ; skos:altLabel """CF/CPG2/MTX"""@eng ; ; ; ; """5147"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281480"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetanus peptide melanoma vaccine"""@eng ; skos:notation """CDR0000042978"""^^xsd:string ; skos:altLabel """Tet p"""@eng ; skos:definition """A vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42978&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42978&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2468\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """7230"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C2468"""^^xsd:string ; umls:cui """C0677989"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/interleukin-12/tyrosinase peptide"""@eng ; skos:notation """CDR0000043070"""^^xsd:string ; skos:altLabel """gp100/IFA/IL-12/TYRP"""@eng ; ; ; ; ; """7434"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678069"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/tyrosinase peptide"""@eng ; skos:notation """CDR0000043071"""^^xsd:string ; skos:altLabel """gp100/IFA/TYRP"""@eng ; ; ; ; """7435"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678070"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Tn(c)-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000043072"""^^xsd:string ; skos:altLabel """Tn(c)-KLH"""@eng ; ; """7436"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678071"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """QS21/Tn(c)-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000043073"""^^xsd:string ; skos:altLabel """QS 21/Tn(c)-KLH"""@eng ; ; ; """7437"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678072"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acetaminophen/acetylcysteine/carmustine"""@eng ; skos:notation """CDR0000043074"""^^xsd:string ; skos:altLabel """ACMP/BCNU/NAC"""@eng ; ; ; ; """7438"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678073"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acetaminophen/acetylcysteine"""@eng ; skos:notation """CDR0000043075"""^^xsd:string ; skos:altLabel """ACMP/NAC"""@eng ; ; ; """7439"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678074"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """promegapoietin"""@eng ; skos:notation """CDR0000043076"""^^xsd:string ; skos:altLabel """SC 71858"""@eng , """SC-71858"""@eng , """PMP"""@eng ; ; """7440"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678075"""^^xsd:string ; umls:cui """C1328686"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/promegapoietin"""@eng ; skos:notation """CDR0000043077"""^^xsd:string ; skos:altLabel """G-CSF/PMP"""@eng ; ; ; """7441"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678076"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/topotecan"""@eng ; skos:notation """CDR0000043078"""^^xsd:string ; skos:altLabel """LipoDox/TOPO"""@eng ; ; ; """7442"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678077"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/iodine I 131 tositumomab"""@eng ; skos:notation """CDR0000043079"""^^xsd:string ; skos:altLabel """CTX/I131-MOAB-B1/VP-16"""@eng ; ; ; ; """7445"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678078"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D-cycloserine"""@eng ; skos:notation """CDR0000469006"""^^xsd:string ; skos:altLabel """Tisomycin"""@eng , """3-Isoxazolidinone, 4-amino-, d-"""@eng , """Oxamycin"""@eng , """(+)-4-Amino-3-isoxazolidinone"""@eng , """Seromycin"""@eng ; skos:definition """An analogue of the amino acid D-alanine with broad-spectrum antibiotic and glycinergic activities. D-cycloserine interferes with bacterial cell wall synthesis by competitively inhibiting two enzymes, L-alanine racemase and D-alanine:D-alanine ligase, thereby impairing peptidoglycan formation necessary for bacterial cell wall synthesis. This agent may be bactericidal or bacteriostatic, depending on its concentration at the infection site and the susceptibility of the organism. In addition, D-cycloserine is an excitatory amino acid and partial agonist at the glycine binding site of the NMDA receptor in the central nervous system (CNS); binding to the central NMDA receptor may result in amelioration of neuropathic pain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469006&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469006&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47466\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """154851"""^^xsd:string ; """68-41-7"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """C47466"""^^xsd:string ; umls:cui """C0701966"""^^xsd:string ; umls:cui """C0815039"""^^xsd:string ; umls:cui """C0010590"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/docetaxel/doxorubicin"""@eng ; skos:notation """CDR0000038366"""^^xsd:string ; skos:altLabel """DOX/MOAB VEGF/TXT"""@eng ; ; ; ; """10986"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935900"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TLK286"""@eng ; skos:notation """CDR0000038367"""^^xsd:string ; skos:altLabel """TELCYTA"""@eng , """TLK-286"""@eng ; skos:definition """A modified glutathione analog. TLK286 is selectively activated by glutathione S-Transferase P1-1 into an alkylating metabolite which forms covalent linkages with nucleophillic centers in tumor cell DNA, thereby inducing a cellular stress response and cytotoxicity, and decreasing tumor proliferation. S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38367&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38367&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2641\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """10987"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2641"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1258106"""^^xsd:string ; umls:cui """C1506936"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel/trastuzumab"""@eng ; skos:notation """CDR0000038364"""^^xsd:string ; skos:altLabel """CBDCA/MOAB HER2/TXT"""@eng ; ; ; ; """10984"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935898"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/trastuzumab"""@eng ; skos:notation """CDR0000038365"""^^xsd:string ; skos:altLabel """CDDP/MOAB HER2/TXT"""@eng ; ; ; ; """10985"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935899"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """telomerase: 540-548 peptide vaccine"""@eng ; skos:notation """CDR0000038362"""^^xsd:string ; skos:altLabel """TEL540-548"""@eng , """Telomerase:540-548 Peptide"""@eng ; skos:definition """A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development; its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38362&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38362&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2640\" NCI Thesaurus)"""@eng ; ; ; ; """10982"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """720002"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C2640"""^^xsd:string ; umls:cui """C0935896"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/Montanide ISA-51/telomerase: 540-548 peptide vaccine"""@eng ; skos:notation """CDR0000038363"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/TEL540-548"""@eng ; ; ; """10983"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935897"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038360"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """10980"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935894"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000038361"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/MOAB IDEC-C2B8/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """10981"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935895"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin-epinephrine/paclitaxel"""@eng ; skos:notation """CDR0000038368"""^^xsd:string ; skos:altLabel """CBDCA/MPI 5010/TAX"""@eng ; ; ; ; """10988"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anastrozole/trastuzumab"""@eng ; skos:notation """CDR0000038369"""^^xsd:string ; skos:altLabel """ANAS/MOAB HER2"""@eng ; ; ; """10989"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134443"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """limited stage small cell lung cancer"""@eng ; skos:notation """CDR0000037819"""^^xsd:string ; skos:altLabel """small cell lung cancer, limited stage"""@eng , """oat cell lung cancer, limited stage"""@eng , """SCLC, limited stage"""@eng , """lung cancer, limited stage small cell"""@eng , """limited stage SCLC"""@eng ; rdfs:subClassOf ; """small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1021"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278725"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tositumomab"""@eng ; skos:notation """CDR0000037818"""^^xsd:string ; skos:altLabel """Anti-CD20 Antibody"""@eng , """anti-B1"""@eng , """MOAB anti-B1"""@eng , """monoclonal antibody anti-B1"""@eng , """anti-B1 monoclonal antibody"""@eng ; skos:definition """A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells. Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37818&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37818&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2543\" NCI Thesaurus)"""@eng ; """10209"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2543"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0879399"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III multiple myeloma"""@eng ; skos:notation """CDR0000037811"""^^xsd:string ; skos:altLabel """multiple myeloma, stage III"""@eng , """plasma cell neoplasm, stage III"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """1018"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278724"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II multiple myeloma"""@eng ; skos:notation """CDR0000037810"""^^xsd:string ; skos:altLabel """multiple myeloma, stage II"""@eng , """plasma cell neoplasm, stage II"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """1017"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; umls:cui """C0278723"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000037813"""^^xsd:string ; skos:altLabel """metastatic cutaneous T-cell lymphoma"""@eng , """cutaneous T-cell lymphoma, stage IV"""@eng , """stage IV mycosis fungoides/Sezary syndrome"""@eng , """cutaneous T-cell lymphoma, metastatic"""@eng , """mycosis fungoides/Sezary syndrome, stage IV"""@eng ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """102"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862226"""^^xsd:string ; umls:cui """C0278572"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rifabutin"""@eng ; skos:notation """CDR0000037812"""^^xsd:string ; skos:altLabel """Mycobutin"""@eng ; skos:definition """A semisynthetic ansamycin antibiotic with potent antimycobacterial properties. Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37812&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37812&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1408\" NCI Thesaurus)"""@eng ; """1019"""^^xsd:string ; """72559-06-9"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1408"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733659"""^^xsd:string ; umls:cui """C0140575"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/cyclosporine"""@eng ; skos:notation """CDR0000037815"""^^xsd:string ; skos:altLabel """ATG/CYSP"""@eng ; ; ; """10202"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879398"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """didanosine"""@eng ; skos:notation """CDR0000037814"""^^xsd:string ; skos:altLabel """Videx EC"""@eng , """Videx"""@eng , """dideoxyinosine"""@eng , """Didanosine EC"""@eng , """ddI"""@eng , """2',3'-Dideoxyinosine"""@eng ; skos:definition """A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37814&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37814&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C431\" NCI Thesaurus)"""@eng ; ; ; ; """1020"""^^xsd:string ; """35782"""^^xsd:string ; """612049"""^^xsd:string ; """31714"""^^xsd:string ; """33746"""^^xsd:string ; """69655-05-6"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C431"""^^xsd:string ; """33134"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0012133"""^^xsd:string ; umls:cui """C0939526"""^^xsd:string ; umls:cui """C0592249"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sexuality and reproductive issues"""@eng ; skos:notation """CDR0000037817"""^^xsd:string ; rdfs:subClassOf ; """10207"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0036915"""^^xsd:string ; umls:tui """T053"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """smoking cessation and continued risk in cancer patients"""@eng ; skos:notation """CDR0000037816"""^^xsd:string ; rdfs:subClassOf ; """10203"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0879623"""^^xsd:string ; umls:tui """T078"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90-DOTA-tyr3-octreotide"""@eng ; skos:notation """CDR0000038102"""^^xsd:string ; skos:altLabel """Y-90-SMT487"""@eng , """Y90-DOTA-tyr3-octreotide"""@eng , """OctreoTher"""@eng ; skos:definition """A radiotherapeutic agent consisting of an analogue of the octapeptide octreotide (SMT 487) chelated to the radioisotope yttrium-90. Yttrium Y 90-DOTA-tyr3-octreotide binds to somatostatin receptor-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38102&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38102&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2601\" NCI Thesaurus)"""@eng ; """10656"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2601"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328662"""^^xsd:string ; umls:cui """C2003893"""^^xsd:string ; umls:cui """C0935692"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """QS21/ras peptide cancer vaccine"""@eng ; skos:notation """CDR0000038103"""^^xsd:string ; skos:altLabel """QS 21/ras pep vac"""@eng ; ; ; """10657"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935693"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vincristine sulfate liposomes"""@eng ; skos:notation """CDR0000038100"""^^xsd:string ; skos:altLabel """ONCO-TCS"""@eng , """liposomal vincristine"""@eng , """vincristine liposomal"""@eng ; """10653"""^^xsd:string ; """2004-03-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1519992"""^^xsd:string ; umls:cui """C1519991"""^^xsd:string ; umls:cui """C0935690"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphoma prevention, AIDS-related"""@eng ; skos:notation """CDR0000038101"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """10655"""^^xsd:string ; umls:cui """C0935691"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """regional gastrointestinal carcinoid tumor"""@eng ; skos:notation """CDR0000038106"""^^xsd:string ; skos:altLabel """gastrointestinal carcinoid tumor, regional"""@eng ; rdfs:subClassOf ; """gastrointestinal carcinoid tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1066"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278748"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/trastuzumab"""@eng ; skos:notation """CDR0000038107"""^^xsd:string ; skos:altLabel """MOAB HER2/SC-58635"""@eng ; ; ; """10660"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935696"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine in ethanol"""@eng ; skos:notation """CDR0000038104"""^^xsd:string ; skos:altLabel """DTI-015"""@eng ; """10658"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328663"""^^xsd:string ; umls:cui """C0935694"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/SU5416"""@eng ; skos:notation """CDR0000038105"""^^xsd:string ; skos:altLabel """IFN-A/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10659"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935695"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/SU5416"""@eng ; skos:notation """CDR0000038108"""^^xsd:string ; skos:altLabel """CBDCA/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10661"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935697"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """donepezil hydrochloride"""@eng ; skos:notation """CDR0000038109"""^^xsd:string ; skos:altLabel """Aricept"""@eng , """DONEP"""@eng , """Donepezil"""@eng ; skos:definition """The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity. This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38109&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38109&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2603\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """120011-70-3"""^^xsd:string ; """10662"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2603"""^^xsd:string ; umls:cui """C0771848"""^^xsd:string ; umls:cui """C0527315"""^^xsd:string ; umls:cui """C0527316"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """conjugated estrogens/progesterone"""@eng ; skos:notation """CDR0000357305"""^^xsd:string ; skos:altLabel """EST/PRG"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328215"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MDX-060 monoclonal antibody"""@eng ; skos:notation """CDR0000301900"""^^xsd:string ; skos:altLabel """MDX-060"""@eng ; skos:definition """A monoclonal antibody with potential antineoplastic activity. MDX-060 is a fully humanized antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily found on activated lymphocytes. CD30 is over-expressed in various lymphoproliferative disorders, Hodgkin's disease and other lymphomas, and other cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301900&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301900&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26441\" NCI Thesaurus)"""@eng ; """2003-04-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """C26441"""^^xsd:string ; umls:cui """C1327954"""^^xsd:string ; umls:cui """C3202976"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nedaplatin"""@eng ; skos:notation """CDR0000468844"""^^xsd:string ; skos:altLabel """platinum, diammine(hydroxy-kappaO)acetato(2-)-kappaO)-, (SP-4-3)-"""@eng ; skos:definition """A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468844&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468844&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61099\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-17"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """C61099"""^^xsd:string ; umls:cui """C0093999"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cell/adenovirus HER-2 vaccine"""@eng ; skos:notation """CDR0000468842"""^^xsd:string ; skos:altLabel """Adenovirus-transduced HER-2/neu Autologous Dendritic Cell Vaccine"""@eng ; skos:definition """A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, autologous dendritic cell/adenovirus HER-2 vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth.HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468842&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468842&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61098\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-03"""^^xsd:string ; """C61098"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C1831756"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Lactobacillus rhamnosus GG"""@eng ; skos:notation """CDR0000468840"""^^xsd:string ; skos:altLabel """Gefilus"""@eng , """Culturelle"""@eng , """LGG"""@eng ; skos:definition """A live specific strain of the species, Lactobacillus rhamnosus (a subspecies of Lactobacillus casei) with probiotic properties. When administered orally, Lactobacillus rhamnosus GG adheres to the mucous membrane of the intestine and may help to restore the balance of the GI microflora; promote gut-barrier functions; diminish the production of carcinogenic compounds by other intestinal bacteria; and activate the innate immuneresponse and enhance adaptive immunity, especially during infections. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468840&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468840&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61097\" NCI Thesaurus)"""@eng ; """2006-07-17"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61097"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1629836"""^^xsd:string ; umls:cui """C1832078"""^^xsd:string ; umls:cui """C1831754"""^^xsd:string ; umls:cui """C1831755"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T007"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """F-18 fluoroethyltyrosine"""@eng ; skos:notation """CDR0000467177"""^^xsd:string ; skos:altLabel """O-(2-[F 18]fluoroethyl)-1-tyrosine"""@eng , """Fluoroethyltyrosine F18"""@eng , """F-18 FET"""@eng , """18F-FET"""@eng ; skos:definition """An amino acid analog radiolabeled with fluorine F 18, a positron emitting isotope, used as a tracer in positron emission tomography (PET). Reflecting the increased amino acid transport capacity of tumor cells, F-18 fluroethyltyrosine (F-18 FET) is actively taken up in tumor cells via amino acid transport system L, but is neither incorporated into proteins nor readily degraded, resulting in high intracellular concentrations of this imaging agent. Radiolableled amino acid-based agents are useful in PET brain tumor imaging because F-18 fluoro-deoxyglucose (F-18 FDG), commonly used in PET tumor imaging, is relatively insensitive for detecting tumors in the brain due the high levels of glycolytic metabolism in the normal cortex and to a lesser extent in white matter. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467177&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467177&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60818\" NCI Thesaurus)"""@eng ; """2006-07-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """C60818"""^^xsd:string ; umls:cui """C1831729"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """topotecan/UCN-01"""@eng ; skos:notation """CDR0000257256"""^^xsd:string ; skos:altLabel """TOPO/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """11423"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327761"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phosphorodiamidate morpholino oligomer AVI-4126"""@eng ; skos:notation """CDR0000496940"""^^xsd:string ; skos:altLabel """AVI-4126"""@eng , """PMO AVI-4126"""@eng ; """C62518"""^^xsd:string ; """2006-09-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-25"""^^xsd:string ; umls:cui """C1450425"""^^xsd:string ; umls:cui """C1831927"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/etanercept"""@eng ; skos:notation """CDR0000383247"""^^xsd:string ; skos:altLabel """AS203/ETN"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-07-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541460"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """casopitant mesylate"""@eng ; skos:notation """CDR0000476572"""^^xsd:string ; skos:altLabel """GW679769"""@eng , """casopitant"""@eng ; skos:definition """The mesylate salt of a centrally-acting neurokinin 1 (NK1) receptor antagonist with antidepressant and antiemetic activities. Casopitant competitively binds to and blocks the activity of the NK1 receptor, thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in antiemetic effects. SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK1 receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476572&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476572&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61086\" NCI Thesaurus)"""@eng ; """2006-04-07"""^^xsd:string ; """C61086"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-21"""^^xsd:string ; umls:cui """C2347566"""^^xsd:string ; umls:cui """C1831797"""^^xsd:string ; umls:cui """C1831798"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/erlotinib/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000409775"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/MOAB VEGF/OSI774"""@eng ; ; ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541429"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine"""@eng ; skos:notation """CDR0000476576"""^^xsd:string ; skos:altLabel """Gardasil"""@eng ; skos:definition """A non-infectious recombinant, quadrivalent vaccine prepared from the highly purifiedvirus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, appear to be mediated by the development of humoral immuneresponses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476576&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=476576&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61087\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-08-04"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """C61087"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1721787"""^^xsd:string ; umls:cui """C1831799"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexverapamil"""@eng ; skos:notation """CDR0000041269"""^^xsd:string ; skos:altLabel """R verapamil"""@eng , """R-verapamil"""@eng , """R-Verapamil Hydrochloride"""@eng ; skos:definition """The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41269&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41269&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1563\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """4342"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """C1563"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """34790"""^^xsd:string ; umls:cui """C0280858"""^^xsd:string ; umls:cui """C1527029"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RG 12915"""@eng ; skos:notation """CDR0000041268"""^^xsd:string ; skos:altLabel """RG12915"""@eng , """RG-12915"""@eng ; """4341"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0246228"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody R24/sargramostim"""@eng ; skos:notation """CDR0000041322"""^^xsd:string ; skos:altLabel """GM-CSF/MOAB R24"""@eng ; ; ; """4395"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280903"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/piroxantrone"""@eng ; skos:notation """CDR0000041323"""^^xsd:string ; skos:altLabel """G-CSF/PXT"""@eng ; ; ; """4396"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280904"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil/procarbazine"""@eng ; skos:notation """CDR0000041320"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/PCB"""@eng ; ; ; ; """4393"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280901"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/zidovudine"""@eng ; skos:notation """CDR0000041321"""^^xsd:string ; skos:altLabel """CF/5-FU/ZDV"""@eng ; ; ; ; """4394"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280902"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000041326"""^^xsd:string ; skos:altLabel """CDDP/5-FU/IFN-A"""@eng ; ; ; ; """4399"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338146"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II non-small cell lung cancer"""@eng ; skos:notation """CDR0000041327"""^^xsd:string ; skos:altLabel """non-small cell lung cancer, stage II"""@eng , """lung cancer, non-oat cell, stage II"""@eng , """NSCLC, stage II"""@eng , """nonsmall cell lung cancer, stage II"""@eng , """stage II NSCLC"""@eng , """non-oat cell lung cancer, stage II"""@eng , """lung cancer, nonsmall cell, stage II"""@eng , """stage II nonsmall cell lung cancer"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """44"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278505"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/paclitaxel"""@eng ; skos:notation """CDR0000041324"""^^xsd:string ; skos:altLabel """DOX/TAX"""@eng ; ; ; """4397"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280905"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000041325"""^^xsd:string ; skos:altLabel """DOX/G-CSF/TAX"""@eng ; ; ; ; """4398"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280906"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/dexamethasone/etoposide/methotrexate/thiotepa/vincristine"""@eng ; skos:notation """CDR0000041328"""^^xsd:string ; skos:altLabel """CTX/DM/DNR/MTX/TSPA/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """4400"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280908"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/etoposide/methotrexate/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000041329"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MePRDL/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4401"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280909"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """analgesic and antipyretic"""@eng ; skos:notation """CDR0000040332"""^^xsd:string ; rdfs:subClassOf ; """3175"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280004"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000040333"""^^xsd:string ; skos:altLabel """CTX/PCB/PRED/VBL"""@eng , """CVPP"""@eng ; ; ; ; ; """3176"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056634"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone"""@eng ; skos:notation """CDR0000040330"""^^xsd:string ; skos:altLabel """CP"""@eng , """CTX/PRED"""@eng ; ; ; """3173"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280003"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antidepressant"""@eng ; skos:notation """CDR0000040331"""^^xsd:string ; rdfs:subClassOf ; """3174"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003289"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """central nervous system drug"""@eng ; skos:notation """CDR0000040336"""^^xsd:string ; skos:altLabel """CNS drug"""@eng ; rdfs:subClassOf owl:Thing ; """3179"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0007680"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cardiovascular drug"""@eng ; skos:notation """CDR0000040337"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3183"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0007220"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000040334"""^^xsd:string ; skos:altLabel """BLEO/CDDP/DOX/VP-16"""@eng , """EBAP"""@eng ; ; ; ; ; """3177"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280006"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/floxuridine/mitomycin"""@eng ; skos:notation """CDR0000040335"""^^xsd:string ; skos:altLabel """DOX/FUDR/MITO"""@eng , """FAM"""@eng ; ; ; ; """3178"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280007"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/dactinomycin/methotrexate"""@eng ; skos:notation """CDR0000040338"""^^xsd:string ; skos:altLabel """CLB/DACT/MTX"""@eng , """MAC"""@eng ; ; ; ; """3184"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083360"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/methotrexate"""@eng ; skos:notation """CDR0000040339"""^^xsd:string ; skos:altLabel """MAC"""@eng , """CTX/DACT/MTX"""@eng ; ; ; ; """3185"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065465"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 chimeric monoclonal antibody 806"""@eng ; skos:notation """CDR0000487509"""^^xsd:string ; skos:altLabel """111-Indium-ch806"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62407"""^^xsd:string ; umls:cui """C1831858"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000043678"""^^xsd:string ; skos:altLabel """adult soft tissue sarcoma, recurrent"""@eng , """soft tissue sarcoma, adult, recurrent"""@eng , """sarcoma, adult soft tissue, recurrent"""@eng ; rdfs:subClassOf ; """adult soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """926"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278665"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/interleukin-2"""@eng ; skos:notation """CDR0000043679"""^^xsd:string ; skos:altLabel """IFN-G/IL-2"""@eng ; ; ; """927"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278666"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II esophageal cancer"""@eng ; skos:notation """CDR0000043672"""^^xsd:string ; skos:altLabel """esophagus cancer, stage II"""@eng , """esophageal cancer, stage II"""@eng ; rdfs:subClassOf ; """esophageal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """92"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278560"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000043673"""^^xsd:string ; skos:altLabel """STS, adult"""@eng , """adult STS"""@eng , """sarcoma, adult soft tissue"""@eng , """Soft tissue sarcoma, adult"""@eng , """soft tissue sarcoma, adult"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """921"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220613"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000043670"""^^xsd:string ; skos:altLabel """non-Hodgkin's lymphoma, childhood"""@eng , """childhood NHL"""@eng , """Non-Hodgkin's lymphoma, child"""@eng , """lymphoma, non-Hodgkin's, childhood"""@eng , """pediatric NHL"""@eng , """pediatric non-Hodgkin's lymphoma"""@eng , """NHL, childhood"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """915"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220612"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """teniposide"""@eng ; skos:notation """CDR0000043671"""^^xsd:string ; skos:altLabel """4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside"""@eng , """VM-26"""@eng , """Thenvlidene-Lignan-P"""@eng , """PTG"""@eng , """EPT"""@eng , """[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"""@eng , """Vumon"""@eng , """VM26"""@eng , """4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside)"""@eng , """Thenylidene-Lignan-P"""@eng , """Vehem"""@eng ; skos:definition """A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43671&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43671&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C857\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """917"""^^xsd:string ; """122819"""^^xsd:string ; """C857"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """29767-20-2"""^^xsd:string ; """2006-12-28"""^^xsd:string ; """9336"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0039512"""^^xsd:string ; umls:cui """C0733482"""^^xsd:string ; umls:cui """C0728981"""^^xsd:string ; umls:cui """C0733481"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000043676"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, stage III"""@eng , """soft tissue sarcoma, adult, stage III"""@eng , """adult soft tissue sarcoma, stage III"""@eng ; rdfs:subClassOf ; """2003-06-18"""^^xsd:string ; """adult soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """924"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278663"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000043677"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, metastatic"""@eng , """sarcoma, adult soft tissue, stage IV"""@eng , """soft tissue sarcoma, adult, stage IV"""@eng , """adult soft tissue sarcoma, stage IV"""@eng ; rdfs:subClassOf ; """adult soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """925"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278664"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000043674"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, stage I"""@eng , """adult soft tissue sarcoma, stage I"""@eng , """soft tissue sarcoma, adult, stage I"""@eng ; rdfs:subClassOf ; """2003-06-18"""^^xsd:string ; """adult soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """922"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278661"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000043675"""^^xsd:string ; skos:altLabel """adult soft tissue sarcoma, stage II"""@eng , """soft tissue sarcoma, adult, stage II"""@eng , """sarcoma, adult soft tissue, stage II"""@eng ; rdfs:subClassOf ; """2003-06-18"""^^xsd:string ; """adult soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """923"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278662"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG-7909/Melan-A/Montanide ISA-51"""@eng ; skos:notation """CDR0000441010"""^^xsd:string ; skos:altLabel """CpG-7909/ISA-51/MEL-A"""@eng ; ; """2005-07-14"""^^xsd:string ; """2005-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831682"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG-7909/Melan-A/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000441011"""^^xsd:string ; skos:altLabel """CpG-7909/ISA-51/MEL-A/TYRP"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-15"""^^xsd:string ; """2005-07-14"""^^xsd:string ; umls:cui """C1831683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG-7909/MART-1 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000441012"""^^xsd:string ; skos:altLabel """CpG-7909/ISA-51/MART-1"""@eng ; ; ; """2005-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-14"""^^xsd:string ; umls:cui """C1831684"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG-7909/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000441013"""^^xsd:string ; skos:altLabel """CpG-7909/ISA-51/MART-1/TYRP"""@eng ; ; ; ; """2005-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-14"""^^xsd:string ; umls:cui """C1831685"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-10.A2/Melan-A/Montanide ISA-51/NY-ESO-1 peptide vaccine"""@eng ; skos:notation """CDR0000441016"""^^xsd:string ; skos:altLabel """ISA-51/MAGE10.A2/MEL-A/NY-ESO-1 peptide"""@eng ; ; ; """2005-07-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-15"""^^xsd:string ; umls:cui """C1831686"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Melan-A/Montanide ISA-51"""@eng ; skos:notation """CDR0000441017"""^^xsd:string ; skos:altLabel """ISA-51/MEL-A"""@eng ; """2005-07-15"""^^xsd:string ; """2005-07-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831687"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetracycline antibiotic"""@eng ; skos:notation """CDR0000470241"""^^xsd:string ; skos:altLabel """Tetracycline Antibiotics"""@eng , """Tetracyclines"""@eng ; skos:definition """Any of a group of broad spectrum naphthacene antibiotics isolated from various species of Streptomyces or produced semisynthetically. In bacteria, tetracycline antibiotics block binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470241&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470241&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1595\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C1595"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C1744619"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular yolk sac tumor and teratoma"""@eng ; skos:notation """CDR0000040013"""^^xsd:string ; skos:altLabel """testicle cancer, teratoma and yolk sac tumor"""@eng , """testicular teratoma and yolk sac tumor"""@eng , """testicular cancer, yolk sac tumor and teratoma"""@eng , """testis cancer, yolk sac tumor and teratoma"""@eng , """teratoma and yolk sac tumor of the testis"""@eng , """yolk sac tumor and teratoma, testicular"""@eng , """testicular cancer, teratoma and yolk sac tumor"""@eng , """testis cancer, teratoma and yolk sac tumor"""@eng ; rdfs:subClassOf ; """2739"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279714"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim plasmid DNA melanoma vaccine adjuvant"""@eng ; skos:notation """CDR0000042679"""^^xsd:string ; skos:altLabel """GM-CSF plasmid DNA melanoma vaccine adjuvant"""@eng ; skos:definition """A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42679&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42679&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2430\" NCI Thesaurus)"""@eng ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """6464"""^^xsd:string ; """C2430"""^^xsd:string ; umls:cui """C0393071"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim plasmid DNA sarcoma vaccine"""@eng ; skos:notation """CDR0000042678"""^^xsd:string ; skos:altLabel """GM-CSF plasmid DNA sarcoma vaccine"""@eng ; """6463"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393070"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tanomastat"""@eng ; skos:notation """CDR0000042675"""^^xsd:string ; skos:altLabel """BAY 12-9566"""@eng ; ; ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C1705"""^^xsd:string ; """6460"""^^xsd:string ; umls:cui """C0393069"""^^xsd:string ; umls:cui """C1515213"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitomycin C"""@eng ; skos:notation """CDR0000042674"""^^xsd:string ; skos:altLabel """mitomycin-C"""@eng , """NCI-C04706"""@eng , """Mutamycin"""@eng , """MITO"""@eng , """MITO-C"""@eng , """Mitocin-C"""@eng , """MTC"""@eng , """MITC"""@eng ; skos:definition """A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42674&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42674&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1820\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """646"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """C1820"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0702051"""^^xsd:string ; umls:cui """C0702049"""^^xsd:string ; umls:cui """C0002475"""^^xsd:string ; umls:cui """C1522440"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nandrolone decanoate"""@eng ; skos:notation """CDR0000042677"""^^xsd:string ; skos:altLabel """Deca-Durabolin"""@eng ; skos:definition """The decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42677&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42677&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1172\" NCI Thesaurus)"""@eng ; """6462"""^^xsd:string ; """C1172"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """360-70-3"""^^xsd:string ; umls:cui """C0068395"""^^xsd:string ; umls:cui """C0701192"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glufosfamide"""@eng ; skos:notation """CDR0000042676"""^^xsd:string ; skos:altLabel """D 19575"""@eng , """D-19575"""@eng ; ; """6461"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0294271"""^^xsd:string ; umls:cui """C0912322"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PA-1-STK ovarian carcinoma vaccine"""@eng ; skos:notation """CDR0000042671"""^^xsd:string ; """6457"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393067"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tocladesine"""@eng ; skos:notation """CDR0000042670"""^^xsd:string ; skos:altLabel """ICN-1256"""@eng , """c-AMP"""@eng , """8-chloro-cyclic adnenosine monophosphate"""@eng , """8-chloroadenosine 3',5' monophosphate"""@eng , """8-chloro-cyclic AMP"""@eng , """cAMP"""@eng , """adenazole"""@eng ; """6446"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0050063"""^^xsd:string ; umls:cui """C0935946"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma during pregnancy"""@eng ; skos:notation """CDR0000042673"""^^xsd:string ; skos:altLabel """pregnancy, non-Hodgkin's lymphoma during"""@eng , """NHL during pregnancy"""@eng ; rdfs:subClassOf ; """6459"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0393068"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benzydamine hydrochloride"""@eng ; skos:notation """CDR0000042672"""^^xsd:string ; skos:altLabel """Difflam"""@eng , """Tantum"""@eng , """benzydamine HCl"""@eng ; skos:definition """An indazole non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-edema properties. Unlike other NSAIDs, benzydamine hydrochloride does not inhibit cyclooxygenases (COX) but stabilizes membranes, resulting in local anesthesia; inhibits the production of pro-inflammatory cytokines; inhibits the generation of reactive oxygen species by neutrophils; inhibits leukocyte aggregation and adhesion; and exhibits antimicrobial properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42672&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42672&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1581\" NCI Thesaurus)"""@eng ; """6458"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C1581"""^^xsd:string ; """132-69-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511108"""^^xsd:string ; umls:cui """C0282070"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """synthetic melanoma-associated antigens vaccine"""@eng ; skos:notation """CDR0000445465"""^^xsd:string ; skos:definition """A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445465&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445465&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48639\" NCI Thesaurus)"""@eng ; """C48639"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """2005-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1710270"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E7080"""@eng ; skos:notation """CDR0000445461"""^^xsd:string ; skos:definition """A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445461&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445461&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48636\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """2005-08-24"""^^xsd:string ; """C48636"""^^xsd:string ; umls:cui """C1711372"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular choriocarcinoma and yolk sac tumor"""@eng ; skos:notation """CDR0000040015"""^^xsd:string ; skos:altLabel """testis cancer, choriocarcinoma and yolk sac tumor"""@eng , """testicle cancer, choriocarcinoma and yolk sac tumor"""@eng , """testicular cancer, yolk sac tumor and choriocarcinoma"""@eng , """yolk sac tumor and choriocarcinoma, testicular"""@eng , """testis cancer, yolk sac tumor and choriocarcinoma"""@eng , """testicular cancer, choriocarcinoma and yolk sac tumor"""@eng , """choriocarcinoma and yolk sac tumor of the testis"""@eng ; rdfs:subClassOf ; """2741"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279716"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine"""@eng ; skos:notation """CDR0000445463"""^^xsd:string ; skos:definition """A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445463&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445463&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48638\" NCI Thesaurus)"""@eng ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-08-24"""^^xsd:string ; """C48638"""^^xsd:string ; umls:cui """C1709860"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """851B gel"""@eng ; skos:notation """CDR0000445462"""^^xsd:string ; skos:definition """A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445462&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445462&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48637\" NCI Thesaurus)"""@eng ; """2006-07-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-08-24"""^^xsd:string ; """C48637"""^^xsd:string ; umls:cui """C1711061"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Fas/Fas ligand gene"""@eng ; skos:notation """CDR0000363640"""^^xsd:string ; rdfs:subClassOf ; """2004-03-24"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1541209"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine/interleukin-2"""@eng ; skos:notation """CDR0000387970"""^^xsd:string ; skos:altLabel """HLA-A2A3-FGF5-ISA51/IL-2"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2005-07-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1832067"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ATN-161"""@eng ; skos:notation """CDR0000459774"""^^xsd:string ; skos:definition """A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for integrin alpha5beta1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. Integrin alpha5beta1 is expressed on endothelial cells and plays a crucial role in endothelial cell adhesion and migration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459774&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459774&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52185\" NCI Thesaurus)"""@eng ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C52185"""^^xsd:string ; umls:cui """C1706674"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian cancer peptide vaccine"""@eng ; skos:notation """CDR0000387973"""^^xsd:string ; skos:altLabel """OC-PEP-VAC"""@eng ; skos:definition """A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=387973&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=387973&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48414\" NCI Thesaurus)"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C48414"""^^xsd:string ; umls:cui """C1541605"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/ovarian cancer peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000387974"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/OC-PEP-VAC"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541606"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel albumin-stabilized nanoparticle formulation"""@eng ; skos:notation """CDR0000038690"""^^xsd:string ; skos:altLabel """Abraxane"""@eng , """ABI-007"""@eng , """Albumin-Stabilized Nanoparticle Paclitaxel"""@eng , """nab-paclitaxel"""@eng , """ABI 007"""@eng , """Nanoparticle Paclitaxel"""@eng , """ABI007"""@eng ; skos:definition """A Cremophor ELP-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of Cremophor ELP and permits the administration of larger doses of this agent, which would be toxic in a Cremophor ELP-containing formulation due to Cremophor ELP's toxicity profile. Cremophor ELP is a nonionic solubilizer made by reacting castor oil with ethylene oxide in a molar ratio of 1:35, followed by a purification step. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38690&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38690&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2688\" NCI Thesaurus)"""@eng ; ; ; ; ; """Drug/agent"""^^xsd:string ; """11348"""^^xsd:string ; """C2688"""^^xsd:string ; """2006-11-01"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1564985"""^^xsd:string ; umls:cui """C1134696"""^^xsd:string ; umls:cui """C1527223"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/dacarbazine/interferon alfa/interleukin-2/tamoxifen"""@eng ; skos:notation """CDR0000042208"""^^xsd:string ; skos:altLabel """BCNU/CDDP/DTIC/IFN-A/IL-2/TMX"""@eng ; ; ; ; ; ; ; """5448"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338192"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/MART-1 antigen"""@eng ; skos:notation """CDR0000042209"""^^xsd:string ; skos:altLabel """IFA/MART-1"""@eng ; ; ; """5449"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281720"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone/placebo"""@eng ; skos:notation """CDR0000042204"""^^xsd:string ; skos:altLabel """HC/PLCB"""@eng ; ; ; """5444"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281715"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MART-1 antigen"""@eng ; skos:notation """CDR0000042205"""^^xsd:string ; skos:altLabel """MART-1"""@eng , """Antigen SK29-AA"""@eng , """MART1"""@eng , """Melan A"""@eng , """MLANA"""@eng , """MART-1 Tumor Antigen"""@eng , """Antigen LB39-AA"""@eng , """Melan-A"""@eng , """Melan-A Protein"""@eng , """Melanoma Antigen Recognized by T-Cells 1"""@eng , """MLANA Protein"""@eng ; skos:definition """A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42205&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42205&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28724\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5445"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28724"""^^xsd:string ; umls:cui """C1522481"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxyurea/pentoxifylline"""@eng ; skos:notation """CDR0000042206"""^^xsd:string ; skos:altLabel """HU/PTX"""@eng ; ; ; """5446"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281717"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/isotretinoin/leuprolide"""@eng ; skos:notation """CDR0000042207"""^^xsd:string ; skos:altLabel """13-CRA/FLUT/LEUP"""@eng ; ; ; ; """5447"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281718"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dihydrosphingosine"""@eng ; skos:notation """CDR0000042200"""^^xsd:string ; skos:altLabel """CDDP/safingol"""@eng ; ; ; """5440"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281711"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ketoconazole"""@eng ; skos:notation """CDR0000042201"""^^xsd:string ; skos:altLabel """DOX/KCZ"""@eng ; ; ; """5441"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281712"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/idarubicin/thioguanine"""@eng ; skos:notation """CDR0000042202"""^^xsd:string ; skos:altLabel """ARA-C/DM/IDA/TG/VP-16"""@eng , """IDA DCTER"""@eng ; ; ; ; ; ; """5442"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281713"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042203"""^^xsd:string ; skos:altLabel """CDDP/CTX/G-CSF/TAX"""@eng ; ; ; ; ; """5443"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281714"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radiation fibrosis"""@eng ; skos:notation """CDR0000269238"""^^xsd:string ; skos:altLabel """fibrosis, radiation-induced"""@eng ; rdfs:subClassOf ; """2002-11-24"""^^xsd:string ; """2002-11-22"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C2350622"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/fluorouracil/interferon alfa/sargramostim"""@eng ; skos:notation """CDR0000269239"""^^xsd:string ; skos:altLabel """AL/5-FU/GM-CSF/IFN-A"""@eng ; ; ; ; ; """2002-12-04"""^^xsd:string ; """2002-11-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327847"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cystoscopy"""@eng ; skos:notation """CDR0000269233"""^^xsd:string ; rdfs:subClassOf ; """2002-11-24"""^^xsd:string ; """2002-11-22"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0010702"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/methotrexate/temozolomide"""@eng ; skos:notation """CDR0000405846"""^^xsd:string ; skos:altLabel """CF/MTX/TMZ"""@eng ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541393"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/methotrexate/rituximab/temozolomide"""@eng ; skos:notation """CDR0000405845"""^^xsd:string ; skos:altLabel """CF/MOAB IDEC-C2B8/MTX/TMZ"""@eng ; ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541392"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylmercaptopurine riboside"""@eng ; skos:notation """CDR0000039497"""^^xsd:string ; skos:altLabel """6-(methylthio) inosine"""@eng , """9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl-, dihydrate"""@eng , """methylthioinosine"""@eng , """6-(methylthio)purine ribonucleoside"""@eng , """6-MMPR"""@eng , """beta-D-ribosyl-6-methylthiopurine"""@eng , """6-methyl MP riboside"""@eng , """6-methylthioinosine"""@eng , """MMPR"""@eng , """6-(methylmercapto)purine ribonucleoside"""@eng , """purine-6-thiol,6-methyl-9-ribofuranosyl"""@eng , """6-methylmercaptopurine riboside"""@eng , """SQ 21977"""@eng , """9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl- (8CI 9CI)"""@eng , """9H-purine, 6-(methylthio)-9beta-D-ribofuranosyl"""@eng , """6-(methylthio)purine riboside"""@eng , """NCI-C04784"""@eng ; skos:definition """A purine derivative with antineoplastic and anti-angiogenic properties. 6-methylmercaptopurine riboside (6-MMPR) inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39497&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39497&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2352\" NCI Thesaurus)"""@eng ; ; ; """2130"""^^xsd:string ; """924"""^^xsd:string ; """2818"""^^xsd:string ; """40774"""^^xsd:string ; """19524"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """342-69-8"""^^xsd:string ; """C2352"""^^xsd:string ; umls:cui """C0025828"""^^xsd:string ; umls:cui """C1521811"""^^xsd:string ; umls:cui """C1521810"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bromelain"""@eng ; skos:notation """CDR0000459959"""^^xsd:string ; skos:altLabel """Bromelase"""@eng , """EC 3.4.22.33"""@eng , """Pineapple Enzyme"""@eng ; skos:definition """A proteolytic enzyme obtained from the pineapple plant that cleaves sulhydryl groups. The enzyme is adsorbed intact through the gastrointestinal tract and has demonstrated therapeutic benefit. Bromelain has the ability to modulate cytokines, and has also demonstrated anti-inflammatory activity, immune response activity, and fibrinolytic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459959&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459959&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28134\" NCI Thesaurus)"""@eng ; """2006-12-15"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28134"""^^xsd:string ; umls:cui """C0006217"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioulnar synostosis"""@eng ; skos:notation """CDR0000285988"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0158761"""^^xsd:string ; umls:tui """T019"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """myelocerebellar disorder"""@eng ; skos:notation """CDR0000285989"""^^xsd:string ; skos:altLabel """ataxia-pancytopenia syndrome"""@eng ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1327919"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Pearson marrow-pancreas syndrome"""@eng ; skos:notation """CDR0000285984"""^^xsd:string ; skos:altLabel """Pearson's syndrome"""@eng ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0342784"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Revesz syndrome"""@eng ; skos:notation """CDR0000285985"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1327916"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """WT limb-blood syndrome"""@eng ; skos:notation """CDR0000285986"""^^xsd:string ; skos:altLabel """WT syndrome"""@eng ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1327917"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IVIC syndrome"""@eng ; skos:notation """CDR0000285987"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1327918"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Hodgkin's antigens-GM-CSF-expressing cell vaccine"""@eng ; skos:notation """CDR0000445421"""^^xsd:string ; skos:altLabel """KGEL vaccine"""@eng ; skos:definition """An allogeneic vaccine consisting of Hodgkin's lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene, with potential antineoplastic activity. Upon vaccination, Hodgkin's antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin's lymphoma associated antigens, resulting in tumor cell lysis. In addition, this vaccine secretes GM-CSF, thereby potentiating the CTL response against the Hodgkin's lymphoma-associated antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445421&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=445421&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61592\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C61592"""^^xsd:string ; """2005-08-18"""^^xsd:string ; """2005-08-19"""^^xsd:string ; umls:cui """C1831712"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/gefitinib/trastuzumab"""@eng ; skos:notation """CDR0000373961"""^^xsd:string ; skos:altLabel """MOAB HER2/TXT/ZD 1839"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541303"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """c-raf antisense oligonucleotide liposome"""@eng ; skos:notation """CDR0000419645"""^^xsd:string ; skos:altLabel """liposome-encapsulated c-raf antisense oligodeoxynucleotide"""@eng , """liposomal c-raf antisense oligonucleotide"""@eng , """LErafAON"""@eng , """c-raf antisense oligodeoxynucleotide liposome"""@eng ; """2005-02-04"""^^xsd:string ; """2005-01-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1436330"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706/cisplatin/gemcitabine/panitumumab"""@eng ; skos:notation """CDR0000419640"""^^xsd:string ; skos:altLabel """AMG-706/CDDP/dFdC/MOAB ABX-EGF"""@eng ; ; ; ; ; """2005-02-04"""^^xsd:string ; """2005-01-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541498"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cortisone"""@eng ; skos:notation """CDR0000039198"""^^xsd:string ; skos:altLabel """CORT"""@eng , """Cortogen Acetate"""@eng ; """1820"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338088"""^^xsd:string ; umls:cui """C0010137"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ancitabine hydrochloride"""@eng ; skos:notation """CDR0000039199"""^^xsd:string ; skos:altLabel """cycloCMP hydrochloride"""@eng , """6H-furo(2',3':4,5)oxazolo(3,2-a)pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-,(2R(2alpha,3beta,3a beta,9a beta))"""@eng , """Ancid"""@eng , """cyclocytidine hydrochloride"""@eng , """Cyclo-C"""@eng , """Ancytabine Hydrochloride"""@eng , """Ancitabine"""@eng , """cyclocytidine"""@eng , """U-33, 624A"""@eng , """cyclocytidine HCL"""@eng ; skos:definition """A derivative of cytarbine (ara-C). Although ancitabine's mechanism of action is unclear, it may inhibit DNA polymerase via competitive inhibition of deoxycytidine triphosphatase, resulting in inhibition of DNA replication; this agent may also incorporate into DNA and RNA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39199&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39199&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C403\" NCI Thesaurus)"""@eng ; ; """1822"""^^xsd:string ; """9781"""^^xsd:string ; """C403"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """145668"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0010557"""^^xsd:string ; umls:cui """C0877817"""^^xsd:string ; umls:cui """C1310603"""^^xsd:string ; umls:cui """C0917970"""^^xsd:string ; umls:cui """C0917971"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/fluorouracil"""@eng ; skos:notation """CDR0000039196"""^^xsd:string ; skos:altLabel """ACFUCY"""@eng , """CTX/DACT/5-FU"""@eng ; ; ; ; """1815"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eye cancer"""@eng ; skos:notation """CDR0000039197"""^^xsd:string ; skos:altLabel """ocular cancer"""@eng ; rdfs:subClassOf ; ; """1819"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0496836"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anaxirone"""@eng ; skos:notation """CDR0000039194"""^^xsd:string ; skos:altLabel """triglycidylurazol"""@eng , """TGU"""@eng ; """C950"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1813"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C0043767"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """novobiocin"""@eng ; skos:notation """CDR0000039195"""^^xsd:string ; skos:altLabel """NBC"""@eng ; ; ; """1814"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0028458"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000039192"""^^xsd:string ; skos:altLabel """FAC-M"""@eng , """CTX/DOX/5-FU/MTX"""@eng ; ; ; ; ; """1811"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054554"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pibenzimol"""@eng ; skos:notation """CDR0000039193"""^^xsd:string ; skos:altLabel """Phenol, p-[5-[5-(4-methyl-1-piperazinyl)-2-benzimidazolyl]-2- benzimidazolyl]-, Trihydrochloride"""@eng , """HOE 33258"""@eng , """Phenol, 4-(5-(4-methyl-1-piperazinyl)(2,5'-bi-1H-benzimidazol)-2'-yl)-, Trihydrochloride"""@eng , """bisbenzimidazole"""@eng , """Pibenzimol Hydrochloride"""@eng , """Pibenzimol Hydrocholoride"""@eng , """Hoechst dye 33258"""@eng , """Hoechst 33258"""@eng ; skos:definition """A fluorescent dye of benzimidazole derivative. Pibenzimol binds to AT-specific sites in the minor groove of duplex DNA and inhibits topoisomerase I, and DNA polymerase, thereby preventing DNA replication. This agent prolongs the G2 phase of the cell cycle and initiates apoptosis in tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39193&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39193&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C546\" NCI Thesaurus)"""@eng ; """1812"""^^xsd:string ; """322921"""^^xsd:string ; """C546"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """23268"""^^xsd:string ; """23491-45-4"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C2350231"""^^xsd:string ; umls:cui """C0878435"""^^xsd:string ; umls:cui """C0019832"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/vincristine"""@eng ; skos:notation """CDR0000039190"""^^xsd:string ; skos:altLabel """CTX/VCR/VP-16"""@eng ; ; ; ; """1809"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0252347"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Corynebacterium parvum"""@eng ; skos:notation """CDR0000039191"""^^xsd:string ; skos:altLabel """CPAR"""@eng , """Coparvax"""@eng , """C. parvum"""@eng ; """1810"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0056278"""^^xsd:string ; umls:cui """C0033477"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T007"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/prednisone"""@eng ; skos:notation """CDR0000257064"""^^xsd:string ; skos:altLabel """CTX/PRED/VP-16"""@eng ; ; ; ; """2002-08-07"""^^xsd:string ; """11404"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327752"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methoxsalen"""@eng ; skos:notation """CDR0000039499"""^^xsd:string ; skos:altLabel """Geralen"""@eng , """Mopsoralen"""@eng , """Oxsoralen-Ultra"""@eng , """Geroxalen"""@eng , """8-MOP"""@eng , """Uvadex"""@eng , """8-methoxypsoralen"""@eng , """Deltasoralen"""@eng , """Dermox"""@eng , """Methoxypsoralen"""@eng , """Ultramop"""@eng , """Puvasoralen"""@eng , """Ammoidin"""@eng , """Oxsoralen"""@eng , """9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one"""@eng , """Meladinine"""@eng , """Metoxaleno"""@eng , """Meladinina"""@eng , """Xanthotoxin"""@eng ; skos:definition """A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties. As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39499&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39499&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C643\" NCI Thesaurus)"""@eng ; """2132"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """45923"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """C643"""^^xsd:string ; """298-81-7"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1513215"""^^xsd:string ; umls:cui """C0025684"""^^xsd:string ; umls:cui """C0740123"""^^xsd:string ; umls:cui """C1513219"""^^xsd:string ; umls:cui """C0740127"""^^xsd:string ; umls:cui """C1513222"""^^xsd:string ; umls:cui """C1513223"""^^xsd:string ; umls:cui """C1513220"""^^xsd:string ; umls:cui """C1513218"""^^xsd:string ; umls:cui """C1513217"""^^xsd:string ; umls:cui """C1513216"""^^xsd:string ; umls:cui """C0939735"""^^xsd:string ; umls:cui """C1513221"""^^xsd:string ; umls:cui """C0722357"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody 8H9"""@eng ; skos:notation """CDR0000380753"""^^xsd:string ; skos:altLabel """iodine I 131 MOAB 8H9"""@eng ; skos:definition """A radioimmunoconjugate consisting of 8H9, a murine IgG1 anti-tenascin monoclonal antibody, radiolabeled with iodine 131 (I 131) with radioimaging and radioimmunotherapeutic properties. Monoclonal antibody 8H9 radiolabeled with I 131 may be used to radioimage and/or destroy tumor cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=380753&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=380753&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48400\" NCI Thesaurus)"""@eng ; """2004-07-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C48400"""^^xsd:string ; umls:cui """C1541591"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human lactoferrin"""@eng ; skos:notation """CDR0000394101"""^^xsd:string ; skos:altLabel """rhLF"""@eng ; """2004-10-25"""^^xsd:string ; """2004-10-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541381"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/bortezomib"""@eng ; skos:notation """CDR0000394103"""^^xsd:string ; skos:altLabel """17-AAG/PS-341"""@eng ; ; ; """2004-10-25"""^^xsd:string ; """2004-10-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541382"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """renal cell adenocarcinoma"""@eng ; skos:notation """CDR0000039996"""^^xsd:string ; skos:altLabel """kidney cancer, renal cell adenocarcinoma"""@eng , """adenocarcinoma of the kidney"""@eng , """renal adenocarcinoma"""@eng ; rdfs:subClassOf ; """2722"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007134"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """renal clear cell carcinoma"""@eng ; skos:notation """CDR0000039997"""^^xsd:string ; skos:altLabel """carcinoma, clear cell, renal"""@eng , """clear cell carcinoma of the kidney"""@eng , """kidney cancer, clear cell carcinoma"""@eng ; rdfs:subClassOf ; """2723"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279702"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """parathyroid mixed cell type adenoma"""@eng ; skos:notation """CDR0000039994"""^^xsd:string ; skos:altLabel """mixed cell type adenoma, parathyroid"""@eng ; rdfs:subClassOf ; """2718"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279701"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penile squamous cell carcinoma"""@eng ; skos:notation """CDR0000039995"""^^xsd:string ; skos:altLabel """penile cancer, squamous cell carcinoma"""@eng , """squamous cell carcinoma, penile"""@eng , """epidermoid carcinoma of the penis"""@eng , """penile epidermoid carcinoma"""@eng , """penis cancer, epidermoid carcinoma"""@eng , """epidermoid carcinoma, penile"""@eng , """penile cancer, epidermoid carcinoma"""@eng , """squamous cell carcinoma of the penis"""@eng , """penis cancer, squamous cell carcinoma"""@eng ; rdfs:subClassOf ; """2721"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238348"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """parathyroid chief cell adenoma"""@eng ; skos:notation """CDR0000039992"""^^xsd:string ; skos:altLabel """chief cell adenoma of the parathyroid"""@eng ; rdfs:subClassOf ; """2715"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334320"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """parathyroid transitional clear cell adenoma"""@eng ; skos:notation """CDR0000039993"""^^xsd:string ; skos:altLabel """transitional clear cell adenoma of the parathyroid"""@eng ; rdfs:subClassOf ; """2717"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279700"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hexamethylene bisacetamide"""@eng ; skos:notation """CDR0000039990"""^^xsd:string ; skos:altLabel """Acetamide, N,N'-hexamethylenebis-"""@eng , """Hexamethylenediacetamide"""@eng , """N,N'-1,6-Hexanediylbisacetamide"""@eng , """HMBA"""@eng , """Acetamide, N,N'-1, 6-hexanediylbis-"""@eng , """N,N'-Hexamethylenebisacetamide"""@eng , """N, N'-Diacetylhexamethylenediamine"""@eng , """Hexamethylenebisacetamide"""@eng ; skos:definition """A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines. Its precise mechanism of action is unknown. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39990&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39990&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1125\" NCI Thesaurus)"""@eng ; ; """2712"""^^xsd:string ; """3073-59-4"""^^xsd:string ; """95580"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """24942"""^^xsd:string ; """C1125"""^^xsd:string ; umls:cui """C0062641"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide/sodium thiosulfate"""@eng ; skos:notation """CDR0000346888"""^^xsd:string ; skos:altLabel """CBDCA/CTX/STS/VP-16"""@eng ; ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-11-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328111"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """renal granular cell carcinoma"""@eng ; skos:notation """CDR0000039998"""^^xsd:string ; skos:altLabel """kidney cancer, granular cell carcinoma"""@eng , """carcinoma, granular cell, renal"""@eng , """granular cell carcinoma of the kidney"""@eng ; rdfs:subClassOf ; """2724"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279703"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """type B1 thymoma"""@eng ; skos:notation """CDR0000039999"""^^xsd:string ; skos:altLabel """lymphocyte-rich thymoma"""@eng , """predominantly cortical thymoma"""@eng , """organoid thymoma"""@eng , """lymphocytic thymoma"""@eng ; rdfs:subClassOf ; """2003-08-20"""^^xsd:string ; """2725"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1266094"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/lymphokine-activated killer cells/monoclonal antibody R24"""@eng ; skos:notation """CDR0000041137"""^^xsd:string ; skos:altLabel """IL-2/LAK/MOAB R24"""@eng ; ; ; ; """4211"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280737"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000041136"""^^xsd:string ; skos:altLabel """CDDP/IFN-A/TMX"""@eng ; ; ; ; """4210"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338129"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/thiotepa"""@eng ; skos:notation """CDR0000041135"""^^xsd:string ; skos:altLabel """CF/5-FU/TSPA"""@eng ; ; ; ; """4209"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280735"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-glucan"""@eng ; skos:notation """CDR0000038642"""^^xsd:string ; skos:altLabel """b-GLUC"""@eng , """Immucell WGP"""@eng ; skos:definition """A polysaccharide isolated from the cell walls of bacteria, plants, and fungi with immunostimulant and antineoplastic activities. In a solubilized form, beta-glucan binds to a lectin site within complement receptor 3 (CR3) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to complement 3 (iC3b)-coated tumors. Thus, the attachment of beta-glucan to CR3 of circulating leukocytes simulates leukocytes to kill iC3b-coated tumor cells in the same way as they kill iC3b-coated yeast. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38642&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38642&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2678\" NCI Thesaurus)"""@eng ; ; ; ; ; """11289"""^^xsd:string ; """2006-05-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2678"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1134651"""^^xsd:string ; umls:cui """C1832061"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-2-Globo H-KLH conjugate vaccine/QS21"""@eng ; skos:notation """CDR0000038645"""^^xsd:string ; skos:altLabel """MUC2-GLO H-KLH/QS 21"""@eng ; ; ; """2003-12-01"""^^xsd:string ; """11291"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134653"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-glucan/monoclonal antibody 3F8"""@eng ; skos:notation """CDR0000038644"""^^xsd:string ; skos:altLabel """b-GLUC/MOAB 3F8"""@eng ; ; ; """11290"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134652"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/mitoxantrone"""@eng ; skos:notation """CDR0000041131"""^^xsd:string ; skos:altLabel """CBDCA/CTX/DHAD"""@eng ; ; ; ; """4205"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280731"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/dactinomycin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041130"""^^xsd:string ; skos:altLabel """BCNU/CTX/DACT/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """4204"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280730"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-10.A2"""@eng ; skos:notation """CDR0000038649"""^^xsd:string ; skos:altLabel """MAGE10.A2"""@eng ; skos:definition """A synthetic nonapeptide derived from a melanoma-associated antigen. Vaccination with MAGE-10.A2 may stimulate a host cytotoxic T-cell response against tumor cells that express the melanoma-associated antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38649&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38649&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2681\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """11295"""^^xsd:string ; """C2681"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; umls:cui """C1134715"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/Melan-A/NA17-A/tyrosinase peptide"""@eng ; skos:notation """CDR0000038648"""^^xsd:string ; skos:altLabel """gp100/MEL-A/NA17A/TYRP"""@eng ; ; ; ; """11294"""^^xsd:string ; """2006-08-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134656"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/thiotepa"""@eng ; skos:notation """CDR0000041139"""^^xsd:string ; skos:altLabel """CTX/TSPA/VP-16"""@eng ; ; ; ; """4213"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280739"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/melphalan/prednisone"""@eng ; skos:notation """CDR0000041138"""^^xsd:string ; skos:altLabel """IFN-A/L-PAM/PRED"""@eng ; ; ; ; """4212"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338130"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, intermediate grade, stage III adult"""@eng ; skos:notation """CDR0000040527"""^^xsd:string ; skos:altLabel """adult non-Hodgkin's lymphoma, intermediate grade, stage III"""@eng , """NHL, intermediate grade, stage III adult"""@eng , """intermediate-grade, stage III adult NHL"""@eng , """lymphoma, intermediate grade, stage III adult non-Hodgkin's"""@eng , """adult NHL, stage III, intermediate grade"""@eng ; """2005-01-21"""^^xsd:string ; """3423"""^^xsd:string ; umls:cui """C0280158"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000040526"""^^xsd:string ; skos:altLabel """stage III follicular mixed cell lymphoma"""@eng , """stage III grade II follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3422"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280157"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000040525"""^^xsd:string ; skos:altLabel """stage III follicular small cleaved cell lymphoma"""@eng , """stage III grade I follicular small cleaved cell lymphoma"""@eng , """follicular small cleaved cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3421"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280156"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000040524"""^^xsd:string ; skos:altLabel """small lymphocytic lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3420"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """small lymphocytic lymphoma"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0855100"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, low grade, stage III adult"""@eng ; skos:notation """CDR0000040523"""^^xsd:string ; skos:altLabel """adult non-Hodgkin's lymphoma, low grade, stage III"""@eng , """NHL, low grade, stage III adult"""@eng , """lymphoma, low grade, stage III adult non-Hodgkin's"""@eng , """adult NHL, stage III, low grade"""@eng , """low-grade, stage III adult NHL"""@eng ; """2005-01-21"""^^xsd:string ; """3419"""^^xsd:string ; umls:cui """C0280154"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000040522"""^^xsd:string ; skos:altLabel """stage II adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng , """adult small noncleaved cell lymphoma, stage II"""@eng , """stage II adult small noncleaved cell lymphoma"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3418"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280153"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000040521"""^^xsd:string ; skos:altLabel """adult lymphoblastic lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3417"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280152"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000040520"""^^xsd:string ; skos:altLabel """adult immunoblastic large cell lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3416"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280151"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000040529"""^^xsd:string ; skos:altLabel """adult diffuse small cleaved cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3425"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280160"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000040528"""^^xsd:string ; skos:altLabel """stage III follicular large cell lymphoma"""@eng , """follicular large cell lymphoma, stage III"""@eng , """stage III grade III follicular large cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3424"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280159"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CC-8490"""@eng ; skos:notation """CDR0000346082"""^^xsd:string ; skos:altLabel """SPC8490"""@eng ; skos:definition """A benzopyran with potential antineoplastic activity. CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346082&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346082&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38711\" NCI Thesaurus)"""@eng ; """2003-11-20"""^^xsd:string ; """C38711"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328106"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial adenocarcinoma"""@eng ; skos:notation """CDR0000039958"""^^xsd:string ; skos:altLabel """uterine cancer, adenocarcinoma"""@eng , """uterus cancer, adenocarcinoma"""@eng , """adenocarcinoma of the uterus"""@eng , """uterine corpus cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2659"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0700207"""^^xsd:string ; umls:cui """C1153706"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/topotecan"""@eng ; skos:notation """CDR0000299004"""^^xsd:string ; skos:altLabel """CDDP/TOPO/VP-16"""@eng ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327935"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/irinotecan"""@eng ; skos:notation """CDR0000299005"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/VP-16"""@eng ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327936"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/methylprednisolone/rituximab/vincristine"""@eng ; skos:notation """CDR0000299000"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/MePRDL/MTX/MOAB IDEC-C2B8/VCR"""@eng ; ; ; ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327931"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rasburicase"""@eng ; skos:notation """CDR0000299001"""^^xsd:string ; skos:altLabel """SR29142"""@eng , """recombinant urate oxidase"""@eng , """NK-631"""@eng , """SR-29142"""@eng , """Elitek"""@eng , """SR 29142"""@eng , """Urate Oxidase"""@eng ; skos:definition """A recombinant urate oxidase enzyme isolated from a genetically-modified strain of Saccharomyces cerevisae. Urate oxidase catalyzes the oxidation of uric acid to the excretable mebolite allantoin, a molecule that is 5-10 times more water-soluble than uric acid. An enzyme that occurs endogenously in most mammals, urate oxidase is not found in humans. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299001&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299001&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2404\" NCI Thesaurus)"""@eng ; ; ; ; """2003-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C2404"""^^xsd:string ; """671264"""^^xsd:string ; """721631"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1812640"""^^xsd:string ; umls:cui """C1170248"""^^xsd:string ; umls:cui """C0937932"""^^xsd:string ; umls:cui """C0338290"""^^xsd:string ; umls:cui """C0041931"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/rasburicase/vincristine"""@eng ; skos:notation """CDR0000299002"""^^xsd:string ; skos:altLabel """CTX/PRED/SR29142/VCR"""@eng ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327933"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methylprednisolone/rasburicase/vincristine"""@eng ; skos:notation """CDR0000299003"""^^xsd:string ; skos:altLabel """CTX/MePRDL/SR29142/VCR"""@eng ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327934"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HIV positive"""@eng ; skos:notation """CDR0000038919"""^^xsd:string ; skos:altLabel """HIV+"""@eng ; """1426"""^^xsd:string ; umls:cui """C0019699"""^^xsd:string ; umls:tui """T034"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """active peptic ulcer disease/GI bleeding"""@eng ; skos:notation """CDR0000038918"""^^xsd:string ; """1424"""^^xsd:string ; umls:cui """C0278963"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """performance status 2"""@eng ; skos:notation """CDR0000038911"""^^xsd:string ; skos:altLabel """PS2"""@eng , """Karnofsky 60-70"""@eng ; """1413"""^^xsd:string ; umls:cui """C0278956"""^^xsd:string ; umls:tui """T081"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior interferon therapy"""@eng ; skos:notation """CDR0000038910"""^^xsd:string ; """1410"""^^xsd:string ; umls:cui """C0278953"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """performance status 4"""@eng ; skos:notation """CDR0000038913"""^^xsd:string ; skos:altLabel """PS4"""@eng , """Karnofsky 20-30"""@eng ; """1415"""^^xsd:string ; umls:cui """C0278958"""^^xsd:string ; umls:tui """T081"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """performance status 3"""@eng ; skos:notation """CDR0000038912"""^^xsd:string ; skos:altLabel """PS3"""@eng , """Karnofsky 40-50"""@eng ; """1414"""^^xsd:string ; umls:cui """C0278957"""^^xsd:string ; umls:tui """T081"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """congestive heart failure"""@eng ; skos:notation """CDR0000038915"""^^xsd:string ; skos:altLabel """CHF"""@eng ; """1421"""^^xsd:string ; umls:cui """C0018802"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """history of myocardial infarction within 6 months"""@eng ; skos:notation """CDR0000038914"""^^xsd:string ; skos:altLabel """MI"""@eng ; """1420"""^^xsd:string ; umls:cui """C0278960"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """New York Heart Association class III/IV"""@eng ; skos:notation """CDR0000038917"""^^xsd:string ; skos:altLabel """NYHA III/IV"""@eng ; """1423"""^^xsd:string ; umls:cui """C0278962"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arrhythmias requiring therapy"""@eng ; skos:notation """CDR0000038916"""^^xsd:string ; """1422"""^^xsd:string ; umls:cui """C0278961"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/paclitaxel"""@eng ; skos:notation """CDR0000042446"""^^xsd:string ; skos:altLabel """TAX/WR-2721"""@eng ; ; ; """5767"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338346"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/isotretinoin"""@eng ; skos:notation """CDR0000042447"""^^xsd:string ; skos:altLabel """CDDP/13-CRA"""@eng ; ; ; """5768"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338347"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """7-cyanoquinocarcinol"""@eng ; skos:notation """CDR0000042444"""^^xsd:string ; skos:altLabel """DX-52-1"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-05"""^^xsd:string ; """C1611"""^^xsd:string ; """5764"""^^xsd:string ; umls:cui """C1527053"""^^xsd:string ; umls:cui """C0294165"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/dacarbazine"""@eng ; skos:notation """CDR0000042445"""^^xsd:string ; skos:altLabel """BC-G/DTIC"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """5765"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338345"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MDL 101731"""@eng ; skos:notation """CDR0000042442"""^^xsd:string ; skos:altLabel """MDL101731"""@eng ; """5762"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C0969834"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """marimastat"""@eng ; skos:notation """CDR0000042443"""^^xsd:string ; skos:altLabel """BB-2516"""@eng , """(2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid"""@eng , """(2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid"""@eng , """TA-2516"""@eng , """Marimastat BB-2516"""@eng , """Marimistat"""@eng ; skos:definition """An orally-active synthetic hydroxamate with potential antineoplastic activity. Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42443&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42443&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1652\" NCI Thesaurus)"""@eng ; ; ; """5763"""^^xsd:string ; """689451"""^^xsd:string ; """719333"""^^xsd:string ; """154039-60-8"""^^xsd:string ; """C1652"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338344"""^^xsd:string ; umls:cui """C0663405"""^^xsd:string ; umls:cui """C1523974"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood medulloblastoma"""@eng ; skos:notation """CDR0000042440"""^^xsd:string ; skos:altLabel """pediatric infratentorial PNET, recurrent"""@eng , """recurrent primitive neuroectodermal tumor, childhood infratentorial"""@eng , """PNET, cerebellar, pediatric, recurrent"""@eng , """recurrent childhood cerebellar primitive neuroectodermal tumor"""@eng , """recurrent pediatric infratentorial PNET"""@eng , """recurrent primitive neuroectodermal tumor, pediatric cerebellar"""@eng , """childhood infratentorial primitive neuroectodermal tumor, recurrent"""@eng , """recurrent primitive neuroectodermal tumor, childhood cerebellar"""@eng , """recurrent cerebellar, childhood, PNET"""@eng , """recurrent childhood cerebellar PNET"""@eng , """medulloblastoma, childhood, recurrent"""@eng , """recurrent cerebellar primitive neuroectodermal tumor, childhood"""@eng , """recurrent infratentorial PNET, childhood"""@eng , """recurrent PNET, childhood cerebellar"""@eng , """PNET, childhood cerebellar, recurrent"""@eng , """recurrent infratentorial, pediatric, PNET"""@eng , """recurrent pediatric cerebellar primitive neuroectodermal tumor"""@eng , """recurrent infratentorial primitive neuroectodermal tumor, childhood"""@eng , """recurrent cerebellar PNET, pediatric"""@eng , """recurrent cerebellar primitive neuroectodermal tumor, pediatric"""@eng , """recurrent PNET, pediatric infratentorial"""@eng , """medulloblastoma, pediatric, recurrent"""@eng , """recurrent cerebellar, pediatric, PNET"""@eng , """PNET, pediatric cerebellar, recurrent"""@eng , """PNET, infratentorial, childhood, recurrent"""@eng , """recurrent PNET, pediatric cerebellar"""@eng , """recurrent childhood infratentorial primitive neuroectodermal tumor"""@eng , """recurrent PNET, infratentorial, pediatric"""@eng , """PNET, cerebellar, childhood, recurrent"""@eng , """pediatric cerebellar PNET, recurrent"""@eng , """recurrent pediatric cerebellar PNET"""@eng , """childhood medulloblastoma, recurrent"""@eng , """recurrent PNET, childhood infratentorial"""@eng , """recurrent cerebellar PNET, childhood"""@eng , """childhood infratentorial PNET, recurrent"""@eng , """recurrent infratentorial, childhood, PNET"""@eng , """recurrent pediatric medulloblastoma"""@eng , """childhood cerebellar PNET, recurrent"""@eng , """PNET, pediatric infratentorial, recurrent"""@eng , """recurrent childhood infratentorial PNET"""@eng , """recurrent infratentorial PNET, pediatric"""@eng , """recurrent infratentorial primitive neuroectodermal tumor, pediatric"""@eng , """recurrent pediatric infratentorial primitive neuroectodermal tumor"""@eng , """PNET, infratentorial, pediatric, recurrent"""@eng , """recurrent PNET, infratentorial, childhood"""@eng , """recurrent primitive neuroectodermal tumor, pediatric infratentorial"""@eng , """pediatric medulloblastoma, recurrent"""@eng , """PNET, childhood infratentorial, recurrent"""@eng , """recurrent medulloblastoma, pediatric"""@eng , """recurrent medulloblastoma, childhood"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood medulloblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5760"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338342"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bexarotene/interferon alfa"""@eng ; skos:notation """CDR0000042441"""^^xsd:string ; skos:altLabel """IFN-A/LGD1069"""@eng ; ; ; """5761"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338343"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cyclosporine/cytarabine/daunorubicin"""@eng ; skos:notation """CDR0000042448"""^^xsd:string ; skos:altLabel """ARA-C/CTX/CYSP/DNR"""@eng ; ; ; ; ; """5769"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338348"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/mitoxantrone/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000042449"""^^xsd:string ; skos:altLabel """CTX/DHAD/PEG-ASP/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; """5770"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338349"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000371750"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541260"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000258329"""^^xsd:string ; skos:altLabel """CF/FLAVO/5-FU"""@eng ; ; ; ; """2002-10-09"""^^xsd:string ; """11487"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327803"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/FR901228/rituximab"""@eng ; skos:notation """CDR0000357440"""^^xsd:string ; skos:altLabel """FAMP/FR 901228/MOAB IDEC-C2B8"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328220"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/sargramostim/telomerase: 540-548 peptide vaccine"""@eng ; skos:notation """CDR0000357442"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/TEL540-548"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328221"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethyl sulfoxide/imiquimod/multi-epitope melanoma peptide vaccine/sargramostim/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000434553"""^^xsd:string ; skos:altLabel """DMSO/GM-CSF/IMQ/MULTI-EP MP VAC/TET TOX PEP VAC"""@eng ; ; ; ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-19"""^^xsd:string ; umls:cui """C1831632"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethyl sulfoxide/multi-epitope melanoma peptide vaccine/sargramostim/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000434552"""^^xsd:string ; skos:altLabel """DMSO/GM-CSF/MULTI-EP MP VAC/TET TOX PEP VAC"""@eng ; ; ; ; ; """2005-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-23"""^^xsd:string ; umls:cui """C1831631"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood nasal type extranodal NK/T-cell lymphoma"""@eng ; skos:notation """CDR0000489006"""^^xsd:string ; skos:altLabel """angiocentric T-cell lymphoma"""@eng , """childhood nasal type extranodal natural killer/T-cell lymphoma"""@eng ; rdfs:subClassOf ; """2006-06-02"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-05-31"""^^xsd:string ; umls:cui """C1879280"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult nasal type extranodal NK/T-cell lymphoma"""@eng ; skos:notation """CDR0000489005"""^^xsd:string ; skos:altLabel """angiocentric T-cell lymphoma"""@eng , """adult nasal type extranodal natural killer/T-cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """2006-05-31"""^^xsd:string ; """2006-06-02"""^^xsd:string ; umls:cui """C1879279"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aplastic anemia"""@eng ; skos:notation """CDR0000489004"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-05-31"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C0002874"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/Montanide ISA-51/NY-ESO-1 peptide vaccine"""@eng ; skos:notation """CDR0000355814"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/NY-ESO-1 peptide"""@eng ; ; ; """2005-06-29"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328203"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/oblimersen/prednisolone/rituximab/vincristine"""@eng ; skos:notation """CDR0000355815"""^^xsd:string ; skos:altLabel """CTX/DOX/G3139/MOAB IDEC-C2B8/PRDL/VCR"""@eng ; ; ; ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328204"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/prednisone/sirolimus"""@eng ; skos:notation """CDR0000355816"""^^xsd:string ; skos:altLabel """CYSP/PRED/SLM"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328205"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/sirolimus/tacrolimus"""@eng ; skos:notation """CDR0000355817"""^^xsd:string ; skos:altLabel """FK506/PRED/SLM"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328206"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/imatinib mesylate"""@eng ; skos:notation """CDR0000355818"""^^xsd:string ; skos:altLabel """STI571/TXT"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328207"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/cytarabine"""@eng ; skos:notation """CDR0000407377"""^^xsd:string ; skos:altLabel """17-AAG/ARA-C"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541412"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-deazauridine"""@eng ; skos:notation """CDR0000039208"""^^xsd:string ; skos:altLabel """2(1H)-pyridinone, 4-hydroxy-1-beta-D-ribofuranosyl"""@eng , """DAU"""@eng , """4-hydroxy-1-(beta-D-ribopentofuranosyl)-2-pyridone"""@eng , """deazauridine"""@eng ; skos:definition """A synthetic analogue of nucleoside uridine lacking a ring nitrogen in the 3-position. 3-deazauridine inhibits cytidine synthase, thereby reducing intracellular levels of cytidine and deoxycytidine and disrupting DNA and RNA synthesis. This agent may trigger apoptosis and enhance differentiation of neoplastic cells.. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39208&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39208&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C193\" NCI Thesaurus)"""@eng ; """1830"""^^xsd:string ; """126849"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """23205-42-7"""^^xsd:string ; """12540"""^^xsd:string ; """C193"""^^xsd:string ; umls:cui """C0000399"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dehydroemetine"""@eng ; skos:notation """CDR0000039209"""^^xsd:string ; """1831"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0011184"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metoprine"""@eng ; skos:notation """CDR0000039206"""^^xsd:string ; skos:altLabel """DDMP"""@eng , """BW 197U"""@eng ; skos:definition """A diaminopyrimidine folate antagonist with potential antineoplastic activity. Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39206&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39206&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1161\" NCI Thesaurus)"""@eng ; """1829"""^^xsd:string ; """19494"""^^xsd:string ; """7364"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7761-45-7"""^^xsd:string ; """C1161"""^^xsd:string ; umls:cui """C1524044"""^^xsd:string ; umls:cui """C0066142"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide"""@eng ; skos:notation """CDR0000039207"""^^xsd:string ; skos:altLabel """Demethyl Epipodophyllotoxin Ethylidine Glucoside"""@eng , """4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside"""@eng , """VePesid"""@eng , """EPEG"""@eng , """VP 16-213"""@eng , """VP-16"""@eng , """VP-16-213"""@eng , """VP-16213"""@eng , """9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one"""@eng , """Lastet"""@eng , """epipodophyllotoxin"""@eng ; skos:definition """A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39207&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39207&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C491\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """183"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33419-42-0"""^^xsd:string ; """C491"""^^xsd:string ; """141540"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """9197"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1516981"""^^xsd:string ; umls:cui """C0733688"""^^xsd:string ; umls:cui """C0733689"""^^xsd:string ; umls:cui """C0015133"""^^xsd:string ; umls:cui """C0086243"""^^xsd:string ; umls:cui """C0700191"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """danazol"""@eng ; skos:notation """CDR0000039204"""^^xsd:string ; skos:altLabel """Winobanin"""@eng , """Bonzol"""@eng , """Danocrine"""@eng , """17Alpha-ethynyl-17beta-hydroxy-4-androsteno[2,3-d]isoxazole"""@eng , """Win-17757"""@eng , """Cyclomen"""@eng , """(17Alpha)-pregna-2,4-dien-20-yno[2,3-d]-isoxazol-17-ol"""@eng , """Danol"""@eng , """Danoval"""@eng , """Chronogyn"""@eng , """Ladogal"""@eng , """DAN"""@eng , """1-Ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-cyclopental[7,8]phenanthro[3,2-d]isoxazol-1-ol"""@eng ; skos:definition """A synthetic androgen derived from ethinyl testosterone. Danazol indirectly reduces estrogen production by decreasing pituitary secretion of follicle-stimulating hormone and luteinizing hormone, and binds to sex hormone receptors in target tissues, thereby exhibiting antiestrogenic, anabolic and weakly androgenic effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39204&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39204&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C414\" NCI Thesaurus)"""@eng ; ; ; """1827"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """17230-88-5"""^^xsd:string ; """C414"""^^xsd:string ; """270916"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733889"""^^xsd:string ; umls:cui """C0733892"""^^xsd:string ; umls:cui """C1511718"""^^xsd:string ; umls:cui """C1527277"""^^xsd:string ; umls:cui """C0813502"""^^xsd:string ; umls:cui """C0010961"""^^xsd:string ; umls:cui """C1511717"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin-DNA complex"""@eng ; skos:notation """CDR0000039205"""^^xsd:string ; skos:altLabel """DNR-DNA"""@eng , """daunomycin-DNA complex"""@eng ; """1828"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0057158"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytembena"""@eng ; skos:notation """CDR0000039202"""^^xsd:string ; skos:altLabel """MBBA"""@eng , """sodium bromebrate"""@eng , """CTB"""@eng ; """1825"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0893303"""^^xsd:string ; umls:cui """C0111753"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyproterone acetate"""@eng ; skos:notation """CDR0000039203"""^^xsd:string ; skos:altLabel """Androcur"""@eng , """chloro-6-hydroxy-17 alpha methylene-1 alpha, 2 alpha pregnadiene-4,6 dione-3, 20 acetate"""@eng , """Cyprostat"""@eng , """SH 714"""@eng , """Dianette"""@eng , """cyproterone"""@eng , """CPTR"""@eng , """Cyprone"""@eng , """6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate"""@eng , """3'H-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-"""@eng ; skos:definition """The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39203&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39203&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1059\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """C1059"""^^xsd:string ; """1826"""^^xsd:string ; """2006-07-11"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591364"""^^xsd:string ; umls:cui """C0591314"""^^xsd:string ; umls:cui """C0056855"""^^xsd:string ; umls:cui """C0010621"""^^xsd:string ; umls:cui """C0701102"""^^xsd:string ; umls:cui """C1511602"""^^xsd:string ; umls:cui """C0699709"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cycloleucine"""@eng ; skos:notation """CDR0000039200"""^^xsd:string ; skos:altLabel """ACP"""@eng , """CB-1639"""@eng , """CL"""@eng , """1-aminocyclopentanecarboxylic acid"""@eng , """ACPC"""@eng , """1-Aminocyclopentane"""@eng , """CYL"""@eng ; skos:definition """A synthetic amino acid derivative of cyclopentanecarboxylic acid, cycloleucine displays immunosuppressive, antineoplastic, and cytostatic properties. Believed to act in vivo as a valine antagonist and an NMDA receptor antagonist acting at the glycine site, cycloleucine is a competitive inhibitor of many enzymes, such as methionine adenosyltransferase (S-adenosylmethionine biosynthesis). Toxicity is correlated with a block of nucleic acid methylation; cell cycle progression; and DNA, RNA and protein biosynthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39200&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39200&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C404\" NCI Thesaurus)"""@eng ; """1823"""^^xsd:string ; """C404"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """1026"""^^xsd:string ; """52-52-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0728841"""^^xsd:string ; umls:cui """C0010575"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine"""@eng ; skos:notation """CDR0000039201"""^^xsd:string ; skos:altLabel """SangCya"""@eng , """Sandimmune"""@eng , """27-400"""@eng , """CsA"""@eng , """ciclosporin"""@eng , """Sandimmun"""@eng , """Neoral"""@eng , """cyclosporin A"""@eng , """OL 27-400"""@eng , """cyclosporin"""@eng , """CYSP"""@eng ; skos:definition """A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39201&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39201&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C406\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1824"""^^xsd:string ; """290193"""^^xsd:string ; """59865-13-3"""^^xsd:string ; """C406"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522536"""^^xsd:string ; umls:cui """C0699605"""^^xsd:string ; umls:cui """C0699604"""^^xsd:string ; umls:cui """C0878526"""^^xsd:string ; umls:cui """C0010592"""^^xsd:string ; umls:cui """C0723210"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent rectal cancer"""@eng ; skos:notation """CDR0000043429"""^^xsd:string ; skos:altLabel """recurrent rectum cancer"""@eng , """rectum cancer, recurrent"""@eng , """rectal cancer, recurrent"""@eng ; rdfs:subClassOf ; """rectal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """83"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278554"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood craniopharyngioma"""@eng ; skos:notation """CDR0000043428"""^^xsd:string ; skos:altLabel """childhood brain tumor, craniopharyngioma"""@eng , """CNS tumor, pediatric craniopharyngioma"""@eng , """brain tumor, pediatric craniopharyngioma"""@eng , """CNS tumor, childhood craniopharyngioma"""@eng , """pediatric CNS tumor, craniopharyngioma"""@eng , """central nervous system tumor, craniopharyngioma, childhood"""@eng , """craniopharyngioma, childhood"""@eng , """brain tumor, childhood craniopharyngioma"""@eng , """brain tumor, craniopharyngioma, childhood"""@eng , """craniopharyngioma, pediatric"""@eng , """childhood CNS tumor, craniopharyngioma"""@eng , """pediatric brain tumor, craniopharyngioma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """828"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278652"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone"""@eng ; skos:notation """CDR0000043427"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED"""@eng , """CAP"""@eng ; ; ; ; """822"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278651"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood supratentorial ependymoma"""@eng ; skos:notation """CDR0000043426"""^^xsd:string ; skos:altLabel """ependymoma, pediatric supratentorial"""@eng , """pediatric CNS tumor supratentorial ependymoma"""@eng , """childhood supratentorial ependymoblastoma"""@eng , """CNS tumor, pediatric supratentorial ependymoma"""@eng , """brain tumor, supratentorial ependymoma, childhood"""@eng , """pediatric brain tumor, supratentorial ependymoma"""@eng , """brain tumor, childhood supratentorial ependymoma"""@eng , """childhood cerebral ependymoma"""@eng , """childhood brain tumor, supratentorial ependymoma"""@eng , """childhood CNS tumor, supratentorial ependymoma"""@eng , """central nervous system tumor, supratentorial ependymoma, childhood"""@eng , """brain tumor, pediatric supratentorial ependymoma"""@eng , """supratentorial ependymoblastoma, childhood"""@eng , """supratentorial ependymoma, childhood"""@eng , """ependymoblastoma, childhood supratentorial"""@eng , """CNS tumor, childhood supratentorial ependymoma"""@eng , """ependymoma, childhood supratentorial"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood ependymoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """821"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278650"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent colon cancer"""@eng ; skos:notation """CDR0000043425"""^^xsd:string ; skos:altLabel """colon cancer, recurrent"""@eng ; rdfs:subClassOf ; """colon cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """82"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278553"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acute myeloid leukemia"""@eng ; skos:notation """CDR0000043424"""^^xsd:string ; skos:altLabel """ANLL"""@eng , """leukemia, acute nonlymphocytic"""@eng , """acute nonlymphocytic leukemia"""@eng , """AML"""@eng , """leukemia, acute myeloid"""@eng ; rdfs:subClassOf ; """818"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023467"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acute lymphocytic leukemia"""@eng ; skos:notation """CDR0000043423"""^^xsd:string ; skos:altLabel """ALL"""@eng , """leukemia, acute lymphocytic"""@eng ; rdfs:subClassOf ; """816"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023449"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV rectal cancer"""@eng ; skos:notation """CDR0000043422"""^^xsd:string ; skos:altLabel """rectal cancer, Dukes D"""@eng , """rectal cancer, stage IV"""@eng , """rectal cancer, metastatic"""@eng , """metastatic rectal cancer"""@eng , """stage IV rectum cancer"""@eng , """rectum cancer, metastatic"""@eng , """Astler-Coller D rectal cancer"""@eng , """Dukes D rectal cancer"""@eng , """rectum cancer, stage IV"""@eng , """rectal cancer, Astler-Coller D"""@eng , """metastatic rectum cancer"""@eng , """rectum cancer, Dukes D"""@eng , """rectum cancer, Astler-Coller D"""@eng ; rdfs:subClassOf ; """rectal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """81"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0861772"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hyperthermia"""@eng ; skos:notation """CDR0000043421"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; """806"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0203597"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III rectal cancer"""@eng ; skos:notation """CDR0000043420"""^^xsd:string ; skos:altLabel """rectal cancer, stage III"""@eng , """rectum cancer, stage III"""@eng , """stage III rectum cancer"""@eng , """Dukes C rectal cancer"""@eng , """rectum cancer, Dukes C"""@eng , """rectal cancer, Dukes C"""@eng ; rdfs:subClassOf ; """rectal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """80"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278545"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041498"""^^xsd:string ; skos:altLabel """DM/MP/MTX/VCR"""@eng ; ; ; ; ; """4654"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281127"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/filgrastim"""@eng ; skos:notation """CDR0000041499"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/G-CSF"""@eng ; ; ; ; ; """4655"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281128"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide/methotrexate"""@eng ; skos:notation """CDR0000039341"""^^xsd:string ; skos:altLabel """DOX/IFF/MTX"""@eng ; ; ; ; """1977"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279209"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/tamoxifen"""@eng ; skos:notation """CDR0000039340"""^^xsd:string ; skos:altLabel """CTX/DOX/TMX"""@eng , """ACT"""@eng ; ; ; ; """1976"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279208"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/melphalan/thalidomide"""@eng ; skos:notation """CDR0000375588"""^^xsd:string ; skos:altLabel """CDDP/CTX/DM/DOX/L-PAM/PS-341/THAL/VP-16"""@eng ; ; ; ; ; ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541312"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/ifosfamide/methotrexate"""@eng ; skos:notation """CDR0000039346"""^^xsd:string ; skos:altLabel """AIM"""@eng , """ASP/IFF/MTX"""@eng ; ; ; ; """1982"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279214"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/piritrexim"""@eng ; skos:notation """CDR0000039345"""^^xsd:string ; skos:altLabel """MTX/Piritrexim"""@eng ; ; ; """1981"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279213"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin"""@eng ; skos:notation """CDR0000039344"""^^xsd:string ; skos:altLabel """AP"""@eng , """CDDP/DOX"""@eng ; ; ; """1980"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279212"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041490"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MP/MTX/VCR"""@eng ; ; ; ; ; ; """4646"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281119"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/mercaptopurine/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000041491"""^^xsd:string ; skos:altLabel """ARA-C/MP/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; """4647"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281120"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000041492"""^^xsd:string ; skos:altLabel """DM/DOX/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; """4648"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281121"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/doxorubicin/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041493"""^^xsd:string ; skos:altLabel """ASP/DM/DOX/MP/MTX/VCR"""@eng ; ; ; ; ; ; ; """4649"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281122"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041494"""^^xsd:string ; skos:altLabel """ASP/DM/DOX/MTX/VCR"""@eng ; ; ; ; ; ; """4650"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281123"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041495"""^^xsd:string ; skos:altLabel """ASP/DM/MP/MTX/VCR"""@eng ; ; ; ; ; ; """4651"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281124"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/mercaptopurine/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000041496"""^^xsd:string ; skos:altLabel """DM/DOX/MP/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; ; """4652"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281125"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/mercaptopurine/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000041497"""^^xsd:string ; skos:altLabel """DM/MP/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; """4653"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281126"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel vitamin E-based emulsion formulation"""@eng ; skos:notation """CDR0000474798"""^^xsd:string ; skos:altLabel """Tocosol Paclitaxel"""@eng , """S-8184"""@eng ; skos:definition """A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). The vitamin-E based emulsion allows bolus infusion without steroid premedication and may diminish hypersensitivity reactions; tumor tissue may be passively targeted due to preferential deposition of emulsion particles while an emulsion formulation component inhibits the P-glycoprotein drug efflux pump. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474798&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474798&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61079\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """C61079"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """2006-11-01"""^^xsd:string ; umls:cui """C1541153"""^^xsd:string ; umls:cui """C1541793"""^^xsd:string ; umls:cui """C1541188"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/pemetrexed disodium"""@eng ; skos:notation """CDR0000420842"""^^xsd:string ; skos:altLabel """DOX/LY231514"""@eng ; ; ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541506"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/motexafin gadolinium"""@eng ; skos:notation """CDR0000420843"""^^xsd:string ; skos:altLabel """CDDP/PCI-0120/TXT"""@eng ; ; ; ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody IDEC-159"""@eng ; skos:notation """CDR0000420841"""^^xsd:string ; skos:altLabel """MOAB IDEC-159"""@eng ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541505"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SB-497115"""@eng ; skos:notation """CDR0000420847"""^^xsd:string ; skos:altLabel """SB497115"""@eng , """SB 497115"""@eng ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541509"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ARQ 501/gemcitabine"""@eng ; skos:notation """CDR0000420844"""^^xsd:string ; skos:altLabel """ARQ-501/dFdC"""@eng ; ; ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541508"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/fludarabine/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000276583"""^^xsd:string ; skos:altLabel """EPOCH-F/R"""@eng , """CTX/DOX/FAMP/MOAB IDEC-C2B8/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327899"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/squalamine lactate"""@eng ; skos:notation """CDR0000038348"""^^xsd:string ; skos:altLabel """CBDCA/MSI-1256F"""@eng ; ; ; """10967"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/toremifene"""@eng ; skos:notation """CDR0000038349"""^^xsd:string ; skos:altLabel """FLUT/TOR"""@eng ; ; ; """10968"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935888"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000038344"""^^xsd:string ; skos:altLabel """CBDCA/MOAB VEGF/TAX"""@eng ; ; ; ; """10963"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935884"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/isotretinoin"""@eng ; skos:notation """CDR0000038345"""^^xsd:string ; skos:altLabel """13-CRA/DM"""@eng ; ; ; """10964"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935885"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/exisulind"""@eng ; skos:notation """CDR0000038346"""^^xsd:string ; skos:altLabel """FGN-1/TXT"""@eng ; ; ; """10965"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935886"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/irinotecan"""@eng ; skos:notation """CDR0000038347"""^^xsd:string ; skos:altLabel """CPT-11/EPI"""@eng ; ; ; """10966"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935887"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody Ch14.18"""@eng ; skos:notation """CDR0000038340"""^^xsd:string ; skos:altLabel """IL-2/MOAB Ch14.18"""@eng ; ; ; """10959"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935880"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MOv-gamma chimeric receptor gene"""@eng ; skos:notation """CDR0000038341"""^^xsd:string ; skos:altLabel """MOv-gamma"""@eng ; skos:definition """A recombinant engineered chimeric gene derived from the murine gene encoding the variable region of monoclonal antibody MOv18 against folate-binding protein, which is often overexpressed in human ovarian cancer cells, and the gene encoding the Fc receptor for the gamma subunit of human IgG and IgE. Peripheral blood lymphocytes expressing the MOv-gamma gene may be used in the immunotherapeutic treatment of ovarian cancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38341&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38341&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2638\" NCI Thesaurus)"""@eng ; ; ; """10960"""^^xsd:string ; """C2638"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """673412"""^^xsd:string ; umls:cui """C0935881"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antisense therapy"""@eng ; skos:notation """CDR0000038342"""^^xsd:string ; """10961"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0935882"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/epirubicin"""@eng ; skos:notation """CDR0000038343"""^^xsd:string ; skos:altLabel """CBDCA/EPI"""@eng ; ; ; """10962"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935883"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide/vatalanib"""@eng ; skos:notation """CDR0000442408"""^^xsd:string ; skos:altLabel """PTK-787/TMZ"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-12"""^^xsd:string ; """2005-08-02"""^^xsd:string ; umls:cui """C1831696"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intraductal breast carcinoma"""@eng ; skos:notation """CDR0000039839"""^^xsd:string ; skos:altLabel """ductal carcinoma in situ"""@eng , """ductal carcinoma in situ of the breast"""@eng , """DCIS of the breast"""@eng , """ductal cancer in situ of the breast"""@eng , """in situ ductal breast carcinoma"""@eng , """intraductal breast cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2518"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007124"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ductal breast carcinoma"""@eng ; skos:notation """CDR0000039838"""^^xsd:string ; rdfs:subClassOf ; """2517"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1527349"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Philadelphia chromosome negative chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000039835"""^^xsd:string ; skos:altLabel """CML, Philadelphia chromosome negative"""@eng , """Ph1 negative CML"""@eng , """CGL, Philadelphia chromosome negative"""@eng , """myelocytic leukemia, chronic, Philadelphia chromosome negative"""@eng , """chronic myelogenous leukemia, Philadelphia chromosome negative"""@eng , """granulocytic leukemia, chronic, Philadelphia chromosome negative"""@eng , """chronic myelocytic leukemia, Philadelphia chromosome negative"""@eng , """Ph' negative chronic myelogenous leukemia"""@eng , """Ph1 negative chronic myelogenous leukemia"""@eng , """chronic granulocytic leukemia, Philadelphia chromosome negative"""@eng , """myelogenous leukemia, chronic, Philadelphia chromosome negative"""@eng ; rdfs:subClassOf ; """2514"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279549"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult malignant mesenchymoma"""@eng ; skos:notation """CDR0000039834"""^^xsd:string ; skos:altLabel """malignant mesenchymoma, adult"""@eng , """mesenchymoma, malignant, adult"""@eng ; rdfs:subClassOf ; """2513"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279548"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the lung"""@eng ; skos:notation """CDR0000039837"""^^xsd:string ; skos:altLabel """lung, adenocarcinoma of the"""@eng , """non-oat cell adenocarcinoma of the lung"""@eng , """lung cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2516"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0152013"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult rhabdomyosarcoma"""@eng ; skos:notation """CDR0000039836"""^^xsd:string ; skos:altLabel """sarcoma, adult rhabdo-"""@eng , """rhabdomyosarcoma, adult"""@eng ; rdfs:subClassOf ; """2515"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279550"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult epithelioid sarcoma"""@eng ; skos:notation """CDR0000039831"""^^xsd:string ; skos:altLabel """sarcoma, epithelioid, adult"""@eng , """epithelioid sarcoma, adult"""@eng ; rdfs:subClassOf ; """2510"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279545"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult alveolar soft-part sarcoma"""@eng ; skos:notation """CDR0000039830"""^^xsd:string ; skos:altLabel """alveolar soft-part sarcoma, adult"""@eng , """sarcoma, alveolar soft-part, adult"""@eng , """soft-part sarcoma, alveolar, adult"""@eng ; rdfs:subClassOf ; """2509"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279544"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult malignant hemangiopericytoma"""@eng ; skos:notation """CDR0000039833"""^^xsd:string ; skos:altLabel """malignant hemangiopericytoma, adult"""@eng , """hemangiopericytoma, malignant, adult"""@eng ; rdfs:subClassOf ; """2512"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279547"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult malignant fibrous histiocytoma"""@eng ; skos:notation """CDR0000039832"""^^xsd:string ; skos:altLabel """fibrous histiocytoma, malignant, adult"""@eng , """histiocytoma, malignant fibrous, adult"""@eng , """malignant fibrous histiocytoma, adult"""@eng ; rdfs:subClassOf ; """2511"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279546"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000040556"""^^xsd:string ; skos:altLabel """adult diffuse mixed cell lymphoma, recurrent"""@eng , """diffuse mixed cell lymphoma, recurrent, adult"""@eng , """relapsed adult diffuse mixed cell lymphoma"""@eng , """adult diffuse mixed cell lymphoma, relapsed"""@eng , """diffuse mixed cell lymphoma, adult, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3452"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280187"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/ISIS 2503"""@eng ; skos:notation """CDR0000038128"""^^xsd:string ; skos:altLabel """dFdC/ISIS-2503"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """10688"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935714"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/oxaliplatin"""@eng ; skos:notation """CDR0000037836"""^^xsd:string ; skos:altLabel """L-OHP/TXT"""@eng ; ; ; """10239"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879411"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000037835"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DNR/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """10238"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879410"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisone"""@eng ; skos:notation """CDR0000037834"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/MTX/PRED"""@eng ; ; ; ; ; ; """10237"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879409"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000037833"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DNR/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """10236"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879408"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000037832"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DNR/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; """10235"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879407"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/methotrexate/rituximab"""@eng ; skos:notation """CDR0000298997"""^^xsd:string ; skos:altLabel """ARA-C/MOAB IDEC-C2B8/MTX/VP-16"""@eng ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327929"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP"""@eng ; skos:notation """CDR0000037830"""^^xsd:string ; skos:altLabel """3-aminopyridine-2-carboxaldehyde thiosemicarbazone"""@eng , """Triapine"""@eng , """3AP"""@eng , """OCX-191"""@eng ; skos:definition """A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37830&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37830&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2242\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """10220"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """663249"""^^xsd:string ; """236392-56-6"""^^xsd:string ; """C2242"""^^xsd:string ; """68338"""^^xsd:string ; """2006-07-25"""^^xsd:string ; umls:cui """C0879610"""^^xsd:string ; umls:cui """C0210403"""^^xsd:string ; umls:cui """C2004325"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000298999"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/MePRDL/MTX/VCR"""@eng ; ; ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327930"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan"""@eng ; skos:notation """CDR0000038121"""^^xsd:string ; skos:altLabel """CPT-11/5-FU"""@eng ; ; ; """10678"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935708"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/oblimersen"""@eng ; skos:notation """CDR0000038122"""^^xsd:string ; skos:altLabel """G3139/TXT"""@eng ; ; ; """10679"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935709"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bladder cancer screening"""@eng ; skos:notation """CDR0000038123"""^^xsd:string ; skos:altLabel """bladder cancer early detection"""@eng , """early detection of bladder cancer"""@eng ; """2002-10-17"""^^xsd:string ; """10681"""^^xsd:string ; umls:cui """C2937274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/tirapazamide"""@eng ; skos:notation """CDR0000038124"""^^xsd:string ; skos:altLabel """CDDP/SR-4233/VP-16"""@eng ; ; ; ; """10683"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935711"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/prinomastat"""@eng ; skos:notation """CDR0000038125"""^^xsd:string ; skos:altLabel """AG3340/TAX"""@eng ; ; ; """10684"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935712"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polysialic acid"""@eng ; skos:notation """CDR0000037839"""^^xsd:string ; skos:altLabel """POLYSIALIC"""@eng ; ; ; """10241"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0071677"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/docetaxel"""@eng ; skos:notation """CDR0000037838"""^^xsd:string ; skos:altLabel """CDDP/TXT/WR-2721"""@eng ; ; ; ; """10240"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879412"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus-interferon gamma TG1042"""@eng ; skos:notation """CDR0000530060"""^^xsd:string ; skos:altLabel """TG1042"""@eng , """Ad-IFNg"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C1832029"""^^xsd:string ; umls:cui """C1832028"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neoadjuvant therapy"""@eng ; skos:notation """CDR0000334860"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """2003-09-08"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0600558"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """coenzyme Q10/vitamin E"""@eng ; skos:notation """CDR0000334866"""^^xsd:string ; skos:altLabel """CoQ10/VIT-E"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328051"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ablative endocrine surgery"""@eng ; skos:notation """CDR0000039004"""^^xsd:string ; skos:altLabel """surgery, ablative endocrine"""@eng ; ; ; ; ; ; rdfs:subClassOf ; """1566"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279028"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethicone/polymer barrier cream"""@eng ; skos:notation """CDR0000468738"""^^xsd:string ; skos:altLabel """CDBC"""@eng , """Cavilon Durable Barrier Cream"""@eng ; """2006-07-11"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831750"""^^xsd:string ; umls:cui """C1831749"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glycerin cream (10%)"""@eng ; skos:notation """CDR0000468739"""^^xsd:string ; skos:altLabel """Sorbolene"""@eng ; """2006-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831751"""^^xsd:string ; umls:cui """C1831752"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cilengitide"""@eng ; skos:notation """CDR0000037844"""^^xsd:string ; skos:altLabel """EMD 121974"""@eng , """cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-N-methyl-L-valyl)"""@eng , """EMD121974"""@eng , """EMD-121974"""@eng ; skos:definition """A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37844&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37844&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1834\" NCI Thesaurus)"""@eng ; """10246"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """59073"""^^xsd:string ; """C1834"""^^xsd:string ; """707544"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C0971473"""^^xsd:string ; umls:cui """C0764377"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast duct lavage"""@eng ; skos:notation """CDR0000335409"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """2003-09-17"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1328067"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 18"""@eng ; skos:notation """CDR0000043198"""^^xsd:string ; rdfs:subClassOf ; """7641"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008660"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lestaurtinib"""@eng ; skos:notation """CDR0000367053"""^^xsd:string ; skos:altLabel """KT-5555"""@eng , """CEP-701"""@eng , """CEP701"""@eng , """CEP 701"""@eng , """SPM-924"""@eng ; skos:definition """An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=367053&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=367053&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48402\" NCI Thesaurus)"""@eng ; """2006-08-28"""^^xsd:string ; """2004-04-23"""^^xsd:string ; """C48402"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541677"""^^xsd:string ; umls:cui """C0767947"""^^xsd:string ; umls:cui """C0767948"""^^xsd:string ; umls:cui """C1832060"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/interferon alfa"""@eng ; skos:notation """CDR0000041308"""^^xsd:string ; skos:altLabel """ARA-C/IFN-A"""@eng ; ; ; """4381"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338142"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/interferon alfa"""@eng ; skos:notation """CDR0000041309"""^^xsd:string ; skos:altLabel """FAMP/IFN-A"""@eng ; ; ; """4382"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338143"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/tariquidar"""@eng ; skos:notation """CDR0000339958"""^^xsd:string ; skos:altLabel """TXT/XR9576"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328077"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DNA ploidy analysis"""@eng ; skos:notation """CDR0000043192"""^^xsd:string ; rdfs:subClassOf ; """7635"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796359"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interleukin-2/leucovorin calcium/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000041300"""^^xsd:string ; skos:altLabel """CF/5-FU/IL-2/LAK"""@eng ; ; ; ; ; """4373"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280883"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/interleukin-1-alpha"""@eng ; skos:notation """CDR0000041301"""^^xsd:string ; skos:altLabel """CBDCA/IL-1A"""@eng ; ; ; """4374"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280884"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000041302"""^^xsd:string ; skos:altLabel """CBDCA/GM-CSF/IFF/VP-16"""@eng ; ; ; ; ; """4375"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280885"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/leuprolide"""@eng ; skos:notation """CDR0000041303"""^^xsd:string ; skos:altLabel """CDDP/CTX/LEUP"""@eng ; ; ; ; """4376"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280886"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/interleukin-2/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000041304"""^^xsd:string ; skos:altLabel """IFN-G/IL-2/TIL"""@eng ; ; ; ; """4377"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280887"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ranpirnase"""@eng ; skos:notation """CDR0000041305"""^^xsd:string ; skos:altLabel """P-30"""@eng , """P30"""@eng , """P-30 protein"""@eng , """Onconase"""@eng , """P30 protein"""@eng ; skos:definition """A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens. Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41305&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41305&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1183\" NCI Thesaurus)"""@eng ; ; ; """4378"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C1183"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """196488-72-9"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0069919"""^^xsd:string ; umls:cui """C1522172"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody R24"""@eng ; skos:notation """CDR0000041306"""^^xsd:string ; skos:altLabel """IL-2/MOAB R24"""@eng ; ; ; """4379"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280888"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000041307"""^^xsd:string ; skos:altLabel """5-FU/IFN-A/IL-2"""@eng ; ; ; ; """4380"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338141"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """narcotic analgesic"""@eng ; skos:notation """CDR0000040318"""^^xsd:string ; rdfs:subClassOf ; """3159"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0027409"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """miscellaneous analgesic"""@eng ; skos:notation """CDR0000040319"""^^xsd:string ; rdfs:subClassOf ; """3160"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002771"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-dose chemotherapy"""@eng ; skos:notation """CDR0000334702"""^^xsd:string ; rdfs:subClassOf ; """2003-09-24"""^^xsd:string ; """2003-09-08"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1328050"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood malignant mesenchymoma"""@eng ; skos:notation """CDR0000040310"""^^xsd:string ; skos:altLabel """pediatric malignant mesenchymoma"""@eng , """malignant mesenchymoma, childhood"""@eng , """mesenchymoma, malignant, childhood"""@eng ; rdfs:subClassOf ; """3150"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279991"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benznidazole"""@eng ; skos:notation """CDR0000040311"""^^xsd:string ; ; """3151"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0053230"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegaspargase"""@eng ; skos:notation """CDR0000040312"""^^xsd:string ; skos:altLabel """Polyethylene Glycol-L-Asparaginase"""@eng , """(Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase"""@eng , """PEG-Asparaginase"""@eng , """PEGLA"""@eng , """PEG-L-Asparaginase(K-H)"""@eng , """PEG-L-asparaginase"""@eng , """Oncaspar"""@eng , """PEG-ASP"""@eng , """L-Asparaginase with Polyethylene Glycol"""@eng ; skos:definition """A complex of polyethylene glycol conjugated with L-asparaginase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40312&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40312&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1200\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3152"""^^xsd:string ; """624239"""^^xsd:string ; """644954"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4056"""^^xsd:string ; """C1200"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """3777"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0728753"""^^xsd:string ; umls:cui """C0071568"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """retinyl acetate"""@eng ; skos:notation """CDR0000040313"""^^xsd:string ; skos:altLabel """Retinol Acetate"""@eng , """vitamin A acetate"""@eng ; skos:definition """A naturally-occurring fatty acid ester form of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Retinyl acetate binds to and activates retinoid receptors, inducing cell differentiation and decreasing cell proliferation. This agent also inhibits carcinogen-induced neoplastic transformation in some cancer cell types and exhibits immunomodulatory properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40313&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40313&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1216\" NCI Thesaurus)"""@eng ; """3153"""^^xsd:string ; """122760"""^^xsd:string ; """127-47-9"""^^xsd:string ; """C1216"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """122045"""^^xsd:string ; umls:cui """C0073109"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dacarbazine/dactinomycin/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040314"""^^xsd:string ; skos:altLabel """VACAD"""@eng , """CTX/DACT/DOX/DTIC/VCR"""@eng ; ; ; ; ; ; """3155"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279993"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/zidovudine"""@eng ; skos:notation """CDR0000040315"""^^xsd:string ; skos:altLabel """IFN-A/ZDV"""@eng ; ; ; """3156"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338111"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """other narcotic analgesic"""@eng ; skos:notation """CDR0000040316"""^^xsd:string ; rdfs:subClassOf ; """3157"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279995"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """morphine and morphine derivative"""@eng ; skos:notation """CDR0000040317"""^^xsd:string ; rdfs:subClassOf ; """3158"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279996"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enzyme activation therapy"""@eng ; skos:notation """CDR0000487561"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """2006-05-25"""^^xsd:string ; umls:cui """C1831862"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/melphalan"""@eng ; skos:notation """CDR0000037848"""^^xsd:string ; skos:altLabel """DACT/L-PAM"""@eng ; ; ; """10250"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879420"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000037849"""^^xsd:string ; skos:altLabel """CTX/DOX//MOAB IDEC-C2B8/PRED/VCR/VP-16"""@eng , """EPOCH-R"""@eng ; ; ; ; ; ; ; """10251"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879421"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxaliplatin/paclitaxel"""@eng ; skos:notation """CDR0000043650"""^^xsd:string ; skos:altLabel """L-OHP/TAX"""@eng ; ; ; """8949"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879353"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 LL2 IgG"""@eng ; skos:notation """CDR0000043651"""^^xsd:string ; skos:altLabel """In111 LL2 IgG"""@eng ; """8950"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879621"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/goserelin/mitoxantrone/prednisone"""@eng ; skos:notation """CDR0000043652"""^^xsd:string ; skos:altLabel """CDX/DHAD/PRED/ZDX"""@eng ; ; ; ; ; """8951"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879354"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/keyhole limpet hemocyanin/sargramostim"""@eng ; skos:notation """CDR0000043653"""^^xsd:string ; skos:altLabel """ATCV/GM-CSF/KLH"""@eng ; ; ; ; """8952"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879355"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/vaccine-sensitized draining lymph node cells"""@eng ; skos:notation """CDR0000043654"""^^xsd:string ; skos:altLabel """IL-2/VDLN"""@eng ; ; ; """8953"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879356"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccine-sensitized draining lymph node cells"""@eng ; skos:notation """CDR0000043655"""^^xsd:string ; skos:altLabel """vDLN cells"""@eng ; skos:definition """Cells isolated from lymph nodes from patients, and activated in vitro to generate tumor-specific effector T cells. Lymph nodes in the lymphatics draining tumors often contain T cells that are immunologically sensitized but functionally deficient. Vaccine-sensitized draining lymph node cells are prepared by isolating these lymphocytes in vitro and stimulating them with cytokines to differentiate into mature effector cells. Vaccine-draining lymph node cells may also be produced by pharmacological activation of lymph node-derived lymphocytes with drugs such as ionomycin or with bacterial toxin; these activated lymphocytes may be expanded in culture with cytokines such as interleukin-2 prior to infusion into the patient. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43655&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43655&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2542\" NCI Thesaurus)"""@eng ; ; """8954"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C2542"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879357"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HER-2/neu peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000043656"""^^xsd:string ; skos:altLabel """GM-CSF/HER-2"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """8955"""^^xsd:string ; umls:cui """C0879358"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rituximab/yttrium Y 90 ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000043657"""^^xsd:string ; skos:altLabel """IDEC-Y2B8/MOAB IDEC-C2B8"""@eng ; ; ; """8956"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879359"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ONYX Liquid Embolic System"""@eng ; skos:notation """CDR0000043658"""^^xsd:string ; skos:altLabel """ONYX"""@eng , """ethylene-vinyl alcohol copolymer"""@eng , """Embolyx E"""@eng ; """8957"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879360"""^^xsd:string ; umls:cui """C0059816"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zosuquidar trihydrochloride"""@eng ; skos:notation """CDR0000043659"""^^xsd:string ; skos:altLabel """LY335979"""@eng ; skos:definition """A difluorocyclopropyl quinoline. Zosuquidar trihydrochloride binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43659&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43659&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2225\" NCI Thesaurus)"""@eng ; ; ; """8958"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C2225"""^^xsd:string ; """950008"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0380527"""^^xsd:string ; umls:cui """C0528372"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/dexamethasone/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000350092"""^^xsd:string ; skos:altLabel """DM/DNR/PEG-ASP/VCR"""@eng ; ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328126"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/methotrexate/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000350091"""^^xsd:string ; skos:altLabel """ARA-C/DNR/MTX/PEG-ASP/PRED/VCR"""@eng ; ; ; ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328125"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/dexamethasone/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000350090"""^^xsd:string ; skos:altLabel """ARA-C/DM/DNR/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328124"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pioglitazone hydrochloride"""@eng ; skos:notation """CDR0000398145"""^^xsd:string ; skos:altLabel """Actos"""@eng ; skos:definition """The hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=398145&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=398145&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29367\" NCI Thesaurus)"""@eng ; """2006-05-05"""^^xsd:string ; """C29367"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2004-10-25"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0872972"""^^xsd:string ; umls:cui """C0875954"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/prednisone/vincristine/zorubicin"""@eng ; skos:notation """CDR0000039603"""^^xsd:string ; skos:altLabel """ARA-C/PRED/VCR/RBZ"""@eng , """ROAP"""@eng ; ; ; ; ; """2258"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279394"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Maalox"""@eng ; skos:notation """CDR0000039600"""^^xsd:string ; """2255"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0065461"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/temozolomide"""@eng ; skos:notation """CDR0000038606"""^^xsd:string ; skos:altLabel """IFN-A/TMZ"""@eng ; ; ; """11234"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134620"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """osteoporosis management"""@eng ; skos:notation """CDR0000470267"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-16"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C1831758"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized unresectable adult primary liver cancer"""@eng ; skos:notation """CDR0000038601"""^^xsd:string ; skos:altLabel """adult primary liver cancer, localized unresectable"""@eng , """adult primary hepatoma, localized unresectable"""@eng , """liver cancer, localized unresectable adult primary"""@eng , """hepatoma, localized unresectable adult primary"""@eng ; rdfs:subClassOf ; """adult primary liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1123"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278773"""^^xsd:string ; umls:cui """C1370858"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethinyl estradiol/norgestrel"""@eng ; skos:notation """CDR0000038600"""^^xsd:string ; skos:altLabel """EE/NORGES"""@eng , """Lo/Ovral"""@eng ; ; ; """11229"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0717763"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/zorubicin"""@eng ; skos:notation """CDR0000039604"""^^xsd:string ; skos:altLabel """RUBIDIC"""@eng , """DTIC/RBZ"""@eng ; ; ; """2259"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279395"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiprolactin therapy"""@eng ; skos:notation """CDR0000041520"""^^xsd:string ; ; rdfs:subClassOf ; """4676"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281149"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spirogermanium"""@eng ; skos:notation """CDR0000039605"""^^xsd:string ; skos:altLabel """S 99 A"""@eng , """2-[3-(Dimethyl-amino)propyl]-8,8-diethyl-2-aza-8-germaspiro[4,5]decane"""@eng , """8,8-Diethyl-N,N-dimethyl-3-aza-8-germaspiro[4,5]decane-2-propanamine"""@eng , """Spiro-32"""@eng , """Spirogermanium Compound"""@eng , """Spirogermanium HCl"""@eng , """2-Aza-8-germaspiro[4.5]decane-2-propanamine, 8, 8-diethyl-N,N-dimethyl-, Dihydrochloride"""@eng , """Spirogermanium Hydrochloride"""@eng , """SPG"""@eng ; skos:definition """A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39605&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39605&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1232\" NCI Thesaurus)"""@eng ; """2260"""^^xsd:string ; """C1232"""^^xsd:string ; """18616"""^^xsd:string ; """41992-23-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """192965"""^^xsd:string ; umls:cui """C0075018"""^^xsd:string ; umls:cui """C1524077"""^^xsd:string ; umls:cui """C0954126"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PRX302"""@eng ; skos:notation """CDR0000517173"""^^xsd:string ; skos:altLabel """PSA-PAH1"""@eng ; """Drug/agent"""^^xsd:string ; """2006-10-24"""^^xsd:string ; umls:cui """C1831975"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/topotecan"""@eng ; skos:notation """CDR0000042659"""^^xsd:string ; skos:altLabel """BCNU/TOPO"""@eng ; ; ; """6411"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393058"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/paclitaxel/tirapazamine"""@eng ; skos:notation """CDR0000042658"""^^xsd:string ; skos:altLabel """CDDP/SR-4233/TAX"""@eng ; ; ; ; """6410"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393057"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/methotrexate/sargramostim/vincristine"""@eng ; skos:notation """CDR0000041172"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4245"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280767"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DetoxPC"""@eng ; skos:notation """CDR0000042653"""^^xsd:string ; skos:altLabel """Detox PC"""@eng , """DetoxPC adjuvant"""@eng , """Detox PC adjuvant"""@eng ; skos:definition """A detoxified, nonspecific immunostimulant consisting of a combination of the active monophosphoryl lipid A component of lipopolysaccharide (LPS) isolated from the bacterium Salmonella minnesota combined with a residue of the cell wall of the bacterium Mycobacterium phlei. Detox-PC differs from Detox adjuvant and Detox-B in that Detox-PC contains egg phosphatidylcholine and alpha-tocopherol. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42653&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42653&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2425\" NCI Thesaurus)"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """6391"""^^xsd:string ; """688197"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2425"""^^xsd:string ; umls:cui """C0393052"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 3H1 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000042652"""^^xsd:string ; skos:altLabel """3H1 anti-idiotype vaccine"""@eng , """CEA-Vac"""@eng , """CeaVac"""@eng , """MOAB 3H1 anti-idiotype vaccine"""@eng , """MOAB 3H1"""@eng ; skos:definition """A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42652&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42652&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2424\" NCI Thesaurus)"""@eng ; ; """6390"""^^xsd:string ; """C2424"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """720063"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0935951"""^^xsd:string ; umls:cui """C0393051"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cemadotin hydrochloride"""@eng ; skos:notation """CDR0000042651"""^^xsd:string ; skos:altLabel """LU 103793"""@eng , """LU103793"""@eng , """LU-103793"""@eng ; """6389"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; umls:cui """C0299746"""^^xsd:string ; umls:cui """C1527058"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methionine C 11"""@eng ; skos:notation """CDR0000042650"""^^xsd:string ; skos:altLabel """methionine C11"""@eng ; skos:definition """A synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42650&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42650&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1534\" NCI Thesaurus)"""@eng ; """6388"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """C1534"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0252667"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin"""@eng ; skos:notation """CDR0000042657"""^^xsd:string ; skos:altLabel """Roaccutan"""@eng , """Oratane"""@eng , """Accure"""@eng , """Accutane"""@eng , """Cistane"""@eng , """13-cis-vitamin A acid"""@eng , """Retinoicacid-13-cis"""@eng , """Neovitamin A Acid"""@eng , """13-cis-retinoic acid"""@eng , """Isotrexin"""@eng , """Roacutan"""@eng , """Neovitamin A"""@eng , """Isotretinoinum"""@eng , """Ro 4-3780"""@eng , """Isotrex"""@eng , """13-cis-Retinoate"""@eng , """Roaccutane"""@eng , """cis-retinoic acid"""@eng , """Ro-4-3780"""@eng , """13-cis Retinoic Acid"""@eng , """3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)2cis-4-trans-6-trans-8-trans-nonatetraenoic Acid"""@eng , """3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic Acid"""@eng , """13-CRA"""@eng ; skos:definition """A naturally-occurring retinoic acid with potential antineoplastic activity and teratogenic properties. 13-cis retinoic acid binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42657&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42657&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C603\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """641"""^^xsd:string ; """28104"""^^xsd:string ; """4759-48-2"""^^xsd:string ; """329481"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """C603"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0022265"""^^xsd:string ; umls:cui """C1517609"""^^xsd:string ; umls:cui """C1521727"""^^xsd:string ; umls:cui """C0701216"""^^xsd:string ; umls:cui """C0592073"""^^xsd:string ; umls:cui """C0594487"""^^xsd:string ; umls:cui """C0699581"""^^xsd:string ; umls:cui """C0301727"""^^xsd:string ; umls:cui """C1517612"""^^xsd:string ; umls:cui """C1517610"""^^xsd:string ; umls:cui """C1517611"""^^xsd:string ; umls:cui """C0731265"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/filgrastim/ifosfamide/mesna"""@eng ; skos:notation """CDR0000042656"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/IFF/MSA"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """6409"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ifosfamide/mesna"""@eng ; skos:notation """CDR0000042655"""^^xsd:string ; skos:altLabel """CBDCA/IFF/MSA"""@eng ; ; ; ; """6408"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393055"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neuroblastoma screening"""@eng ; skos:notation """CDR0000042654"""^^xsd:string ; skos:altLabel """neuroblastoma early detection"""@eng , """early detection of neuroblastoma"""@eng ; """2002-10-17"""^^xsd:string ; """6393"""^^xsd:string ; umls:cui """C0393053"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XK469R"""@eng ; skos:notation """CDR0000440966"""^^xsd:string ; skos:definition """The racemic form of a synthetic quinoxaline phenoxypropionic acid derivative with antineoplastic properties. XK469R selectively inhibits topoisomerase II by stabilizing the enzyme-DNA intermediates in which topoisomerase subunits are covalently linked to DNA through 5-phosphotyrosyl linkages, thereby interfering with DNA repair and replication, RNA and protein synthesis. This agent possesses unusual solid tumor selectivity and activity against multidrug-resistant cancer cells. XK469R is more water soluble and active than the pure isomers, R(+)XK469 and S(-)XK469. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=440966&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=440966&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2825\" NCI Thesaurus)"""@eng ; """C2825"""^^xsd:string ; """2005-07-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0765292"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diethylnorspermine"""@eng ; skos:notation """CDR0000375649"""^^xsd:string ; skos:altLabel """N1, N11-diethylnorspermine"""@eng , """DENSPM"""@eng ; """2004-06-23"""^^xsd:string ; """2004-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0067116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mycophenolate mofetil"""@eng ; skos:notation """CDR0000445228"""^^xsd:string ; skos:altLabel """CTX/MMF"""@eng ; ; ; """2005-08-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; umls:cui """C1831706"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ascorbic acid/beta carotene/garlic/selenium/vitamin E"""@eng ; skos:notation """CDR0000445227"""^^xsd:string ; skos:altLabel """ajo/Beta CT/SEL/VIT-C/VIT-E"""@eng ; ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-15"""^^xsd:string ; """2005-08-19"""^^xsd:string ; umls:cui """C1831705"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ascorbic acid/beta carotene/selenium/vitamin E"""@eng ; skos:notation """CDR0000445226"""^^xsd:string ; skos:altLabel """Beta CT/SEL/VIT-C/VIT-E"""@eng ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """2005-08-15"""^^xsd:string ; umls:cui """C1831704"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amoxicillin/omeprazole"""@eng ; skos:notation """CDR0000445225"""^^xsd:string ; skos:altLabel """AMOX/OMEP"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """2005-08-15"""^^xsd:string ; umls:cui """C1831703"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/NY-ESO-1 peptide vaccine"""@eng ; skos:notation """CDR0000322807"""^^xsd:string ; skos:altLabel """ISA-51/NY-ESO-1 peptide"""@eng ; ; """2003-07-26"""^^xsd:string ; """2003-07-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328024"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/tirapazamine"""@eng ; skos:notation """CDR0000322809"""^^xsd:string ; skos:altLabel """CDDP/SR-4233/VP-16"""@eng ; ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935711"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pertuzumab"""@eng ; skos:notation """CDR0000322808"""^^xsd:string ; skos:altLabel """MOAB 2C4"""@eng , """rhuMAb 2C4"""@eng , """rhuMAb-2C4"""@eng , """monoclonal antibody 2C4"""@eng , """rhuMAb2C4"""@eng , """Omnitarg"""@eng ; skos:definition """A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322808&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322808&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38692\" NCI Thesaurus)"""@eng ; ; """2003-07-26"""^^xsd:string ; """C38692"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328025"""^^xsd:string ; umls:cui """C1456449"""^^xsd:string ; umls:cui """C1434409"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040132"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity cancer, recurrent"""@eng , """nasal cavity and paranasal sinus cancer, recurrent"""@eng ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2897"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279832"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AG-013736"""@eng ; skos:notation """CDR0000352181"""^^xsd:string ; skos:altLabel """AG 013736"""@eng ; skos:definition """An orally bioavailable tyrosine kinase inhibitor. AG-013736 inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352181&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352181&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38718\" NCI Thesaurus)"""@eng ; ; """2004-01-23"""^^xsd:string ; """C38718"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328149"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult non-Hodgkin's lymphoma grade"""@eng ; skos:notation """CDR0000040562"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """3460"""^^xsd:string ; umls:cui """C0280193"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/tipifarnib"""@eng ; skos:notation """CDR0000352189"""^^xsd:string ; skos:altLabel """CAPE/R115777"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328150"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/lomustine/vincristine"""@eng ; skos:notation """CDR0000042268"""^^xsd:string ; skos:altLabel """BOLD"""@eng , """BLEO/CCNU/DTIC/VCR"""@eng ; ; ; ; ; """5515"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338207"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/interferon alfa/lomustine/vincristine"""@eng ; skos:notation """CDR0000042269"""^^xsd:string ; skos:altLabel """BLEO/CCNU/DTIC/IFN-A/VCR"""@eng ; ; ; ; ; ; """5516"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338208"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oophorectomy"""@eng ; skos:notation """CDR0000042262"""^^xsd:string ; skos:altLabel """ovariectomy"""@eng ; ; rdfs:subClassOf ; """551"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0029936"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000042263"""^^xsd:string ; skos:altLabel """CF/TMTX"""@eng ; ; ; """5510"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281765"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine (liposomal)"""@eng ; skos:notation """CDR0000042260"""^^xsd:string ; skos:altLabel """DepoFoam encapsulated cytarabine"""@eng , """DTC 101"""@eng , """DepoFoam"""@eng , """Encapsulated Cytarabine"""@eng , """Liposomal Cytarabine"""@eng , """DepoCyte"""@eng , """DepoCyt"""@eng ; skos:definition """A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42260&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42260&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2388\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """5508"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2388"""^^xsd:string ; """715320"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517907"""^^xsd:string ; umls:cui """C1328677"""^^xsd:string ; umls:cui """C0795597"""^^xsd:string ; umls:cui """C1517908"""^^xsd:string ; umls:cui """C0677882"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Daflon 500"""@eng ; skos:notation """CDR0000042261"""^^xsd:string ; skos:altLabel """D500"""@eng ; """5509"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281764"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/trastuzumab"""@eng ; skos:notation """CDR0000042266"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB HER2"""@eng ; ; ; ; """5513"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338205"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant"""@eng ; skos:notation """CDR0000042267"""^^xsd:string ; skos:altLabel """gp100/IFA"""@eng ; ; ; """5514"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338206"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody 520C9xH22/filgrastim"""@eng ; skos:notation """CDR0000042264"""^^xsd:string ; skos:altLabel """BsAb 520C9xH22/G-CSF"""@eng ; ; ; """5511"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281766"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trastuzumab"""@eng ; skos:notation """CDR0000042265"""^^xsd:string ; skos:altLabel """Anti-erbB2 Monoclonal Antibody"""@eng , """HER2 monoclonal antibody"""@eng , """monoclonal antibody c-erb-2"""@eng , """Anti-ERB-2"""@eng , """Herceptin"""@eng , """MOAB HER2"""@eng , """monoclonal antibody HER2"""@eng , """Anti-HER2/c-erbB2 Monoclonal Antibody"""@eng , """rhuMAb HER2"""@eng , """Anti-c-erbB2 Monoclonal Antibody"""@eng , """anti-c-erB-2"""@eng , """Anti-p185-HER2"""@eng ; skos:definition """A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42265&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42265&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1647\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """5512"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """688097"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C1647"""^^xsd:string ; """6667"""^^xsd:string ; umls:cui """C0728747"""^^xsd:string ; umls:cui """C0338204"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/epoetin alfa"""@eng ; skos:notation """CDR0000405822"""^^xsd:string ; skos:altLabel """AS2O3/EPO"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541391"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atorvastatin"""@eng ; skos:notation """CDR0000460239"""^^xsd:string ; skos:altLabel """Lipitor"""@eng , """CI-981"""@eng , """(betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid"""@eng , """Atorvastatin Calcium"""@eng , """(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid"""@eng ; skos:definition """A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460239&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460239&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28837\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C28837"""^^xsd:string ; """134523-00-5"""^^xsd:string ; """134523-03-8 (calcium)"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0082029"""^^xsd:string ; umls:cui """C0593906"""^^xsd:string ; umls:cui """C0286650"""^^xsd:string ; umls:cui """C0286651"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-fungal HSP90 human recombinant monoclonal antibody"""@eng ; skos:notation """CDR0000460238"""^^xsd:string ; skos:altLabel """Mycograb"""@eng ; """TRD"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831725"""^^xsd:string ; umls:cui """C1739735"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000306483"""^^xsd:string ; skos:altLabel """CF/MP/MTX/VCR"""@eng ; ; ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327985"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/pegaspargase/thioguanine/vincristine"""@eng ; skos:notation """CDR0000306480"""^^xsd:string ; skos:altLabel """ARA-C/CF/CTX/DM/DNR/MP/MTX/PEG-ASP/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327984"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multicentric Castleman's disease"""@eng ; skos:notation """CDR0000404334"""^^xsd:string ; skos:altLabel """multicentric angiofollicular lymphoid hyperplasia"""@eng , """Castleman's disease, multicentric"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-11-22"""^^xsd:string ; """2005-01-24"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C1334815"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unicentric Castleman's disease"""@eng ; skos:notation """CDR0000404333"""^^xsd:string ; skos:altLabel """angiofollicular lymphoid hyperplasia"""@eng , """Castleman's disease, unicentric"""@eng , """giant lymph node hyperplasia"""@eng ; rdfs:subClassOf ; """2004-11-22"""^^xsd:string ; """2005-01-24"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0017531"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CDK inhibitor R547"""@eng ; skos:notation """CDR0000529189"""^^xsd:string ; skos:altLabel """R547"""@eng , """cyclin-dependent kinase inhibitor R547"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; """2007-01-02"""^^xsd:string ; umls:cui """C1832011"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/rituximab"""@eng ; skos:notation """CDR0000043256"""^^xsd:string ; skos:altLabel """CTX/MOAB IDEC-C2B8"""@eng ; ; ; """7743"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796410"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/mitoxantrone/prednisone"""@eng ; skos:notation """CDR0000043257"""^^xsd:string ; skos:altLabel """EM/DHAD/PRED/TXT"""@eng ; ; ; ; ; """7744"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796411"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/dexamethasone/doxorubicin/thalidomide"""@eng ; skos:notation """CDR0000437235"""^^xsd:string ; skos:altLabel """DM/DOX/PS-341/THAL"""@eng ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-17"""^^xsd:string ; """2005-06-15"""^^xsd:string ; umls:cui """C1831653"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisapride"""@eng ; skos:notation """CDR0000041689"""^^xsd:string ; """4851"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0072916"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/vinblastine"""@eng ; skos:notation """CDR0000041688"""^^xsd:string ; skos:altLabel """EM/VBL"""@eng ; ; ; """4850"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281287"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/vincristine/zidovudine"""@eng ; skos:notation """CDR0000041685"""^^xsd:string ; skos:altLabel """CTX/DOX/VCR/VP-16/ZDV"""@eng ; ; ; ; ; ; """4848"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281285"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/topotecan"""@eng ; skos:notation """CDR0000041684"""^^xsd:string ; skos:altLabel """CDDP/TOPO"""@eng ; ; ; """4847"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281284"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic disease"""@eng ; skos:notation """CDR0000041687"""^^xsd:string ; skos:altLabel """mets"""@eng , """metastasize"""@eng , """metastasis"""@eng ; """485"""^^xsd:string ; umls:cui """C2939420"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/paclitaxel"""@eng ; skos:notation """CDR0000041686"""^^xsd:string ; skos:altLabel """CTX/TAX"""@eng ; ; ; """4849"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281286"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/cytarabine/daunorubicin"""@eng ; skos:notation """CDR0000041681"""^^xsd:string ; skos:altLabel """ARA-C/CYSP/DNR"""@eng ; ; ; ; """4844"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281281"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/didanosine/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000041680"""^^xsd:string ; skos:altLabel """CTX/ddI/DOX/VCR/VP-16"""@eng ; ; ; ; ; ; """4843"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281280"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drug resistance inhibition"""@eng ; skos:notation """CDR0000041683"""^^xsd:string ; skos:altLabel """multi-drug resistance inhibition"""@eng ; """4846"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0677911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/hydroxyurea"""@eng ; skos:notation """CDR0000041682"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/HU"""@eng ; ; ; ; """4845"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281282"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """7-hydroxystaurosporine"""@eng ; skos:notation """CDR0000042305"""^^xsd:string ; skos:altLabel """8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)"""@eng , """UCN-01"""@eng , """7-hydroxy-staurosporine"""@eng , """UCN 01"""@eng ; skos:definition """A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42305&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42305&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1271\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """49169"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """638850"""^^xsd:string ; """112953-11-4"""^^xsd:string ; """5553"""^^xsd:string ; """C1271"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0077681"""^^xsd:string ; umls:cui """C0950721"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/interleukin-12/MART-1 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000042888"""^^xsd:string ; skos:altLabel """gp100/IFA/IL-12/MART-1/TYRP"""@eng ; ; ; ; ; ; """6700"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677816"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/interleukin-2/tyrosinase peptide"""@eng ; skos:notation """CDR0000042889"""^^xsd:string ; skos:altLabel """IFA/IL-2/TYRP"""@eng ; ; ; ; """6701"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677817"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Haemophilus influenzae b vaccine"""@eng ; skos:notation """CDR0000042886"""^^xsd:string ; skos:altLabel """Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-OMP)"""@eng , """PedvaxHIB"""@eng , """Haemophilus b oligosaccharide conjugate vacccine"""@eng , """HibTITER"""@eng , """Haemophilus b conjugate vaccine"""@eng , """ActHIB"""@eng , """Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-T)"""@eng , """Hib TITER vaccine"""@eng ; skos:definition """A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42886&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42886&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1126\" NCI Thesaurus)"""@eng ; """6699"""^^xsd:string ; """722399"""^^xsd:string ; """C1126"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """126161-67-9"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1524027"""^^xsd:string ; umls:cui """C0717811"""^^xsd:string ; umls:cui """C0731347"""^^xsd:string ; umls:cui """C0722529"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cytarabine"""@eng ; skos:notation """CDR0000042887"""^^xsd:string ; skos:altLabel """AMSA/ARA-C"""@eng ; ; ; """67"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278525"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """COL-3"""@eng ; skos:notation """CDR0000042884"""^^xsd:string ; skos:altLabel """4-Dimethlyamino Sancycline"""@eng , """4-Dimethlyaminosancycline"""@eng , """4-dedimethylamino sancycline"""@eng , """Metastat"""@eng , """6-deoxy-6-demethyl-4-dedimethylaminotetracycline"""@eng , """COL 3"""@eng , """CMT-3"""@eng , """6-deoxy, 6-demethyl, 4-de-dimethylamino tetracycline"""@eng ; skos:definition """A chemically-modified tetracycline with potential antineoplastic activity. COL-3 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42884&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42884&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2454\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2003-10-29"""^^xsd:string ; """6697"""^^xsd:string ; """15866-90-7"""^^xsd:string ; """C2454"""^^xsd:string ; """54600"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """683551"""^^xsd:string ; umls:cui """C1328685"""^^xsd:string ; umls:cui """C3179296"""^^xsd:string ; umls:cui """C2937290"""^^xsd:string ; umls:cui """C2979988"""^^xsd:string ; umls:cui """C3179297"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pneumococcal polyvalent vaccine"""@eng ; skos:notation """CDR0000042885"""^^xsd:string ; skos:altLabel """Pnu-Imune 23"""@eng , """Pneumovax 23"""@eng ; """6698"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """C1643"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0307311"""^^xsd:string ; umls:cui """C0947642"""^^xsd:string ; umls:cui """C0305065"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bismuth subcitrate/metronidazole/omeprazole/tetracycline"""@eng ; skos:notation """CDR0000042882"""^^xsd:string ; skos:altLabel """BISSUBCIT/METRO/OMEP/TETRA"""@eng ; ; ; ; ; """6695"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677813"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amoxicillin/clarithromycin/omeprazole"""@eng ; skos:notation """CDR0000042883"""^^xsd:string ; skos:altLabel """AMOX/CLARITH/OMEP"""@eng ; ; ; ; """6696"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677814"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/MART-1 antigen/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000042880"""^^xsd:string ; skos:altLabel """GM-CSF/GP100/IFA/MART-1/TYRP"""@eng ; ; ; ; ; ; """6693"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677812"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bismuth subcitrate"""@eng ; skos:notation """CDR0000042881"""^^xsd:string ; skos:altLabel """BISSUBCIT"""@eng ; ; """6694"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0106556"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminocamptothecin colloidal dispersion"""@eng ; skos:notation """CDR0000042874"""^^xsd:string ; """6687"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677807"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edetate calcium disodium/interferon alfa/monoclonal antibody CC49"""@eng ; skos:notation """CDR0000042301"""^^xsd:string ; skos:altLabel """EDTA/IFN-A/MOAB CC49"""@eng ; ; ; ; """5548"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338231"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """misoprostol"""@eng ; skos:notation """CDR0000042872"""^^xsd:string ; skos:altLabel """Cytotec"""@eng , """(11alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxo-prost-13-en-1-oic Acid Methyl Ester"""@eng , """SC-29333"""@eng , """Methyl (11alpha,13E)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oate"""@eng ; """6685"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591321"""^^xsd:string ; umls:cui """C0795730"""^^xsd:string ; umls:cui """C0085174"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000043135"""^^xsd:string ; skos:altLabel """ASP/MTX/PRDL/VCR"""@eng ; ; ; ; ; """7574"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796318"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BAY 12-9566/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000043134"""^^xsd:string ; skos:altLabel """BAY129566/CF/5-FU"""@eng ; ; ; ; """7573"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hepatitis B antigen peptide"""@eng ; skos:notation """CDR0000043137"""^^xsd:string ; skos:altLabel """HBsAg"""@eng , """peptide, hepatitis B antigen"""@eng ; ; """7576"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796320"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-12"""@eng ; skos:notation """CDR0000043136"""^^xsd:string ; skos:altLabel """IFN-A/IL-12"""@eng ; ; ; """7575"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796319"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """xeroderma pigmentosum"""@eng ; skos:notation """CDR0000043131"""^^xsd:string ; """2002-09-10"""^^xsd:string ; """7570"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0043346"""^^xsd:string ; umls:tui """T019"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil"""@eng ; skos:notation """CDR0000043130"""^^xsd:string ; skos:altLabel """Arumel"""@eng , """FU"""@eng , """Fluouracil"""@eng , """Ro-2-9757"""@eng , """Adrucil"""@eng , """Cytosafe"""@eng , """AccuSite"""@eng , """Flurablastin"""@eng , """Fluoroplex"""@eng , """Efudex"""@eng , """5Fluracil"""@eng , """Timazin"""@eng , """5-Fluoro-2,4(1H,3H)-pyrimidinedione"""@eng , """Efurix"""@eng , """Ribofluor"""@eng , """Fluracil"""@eng , """5-FU"""@eng , """5-Fluracil"""@eng , """Actino-Hermal"""@eng , """Fiverocil"""@eng , """Flurox"""@eng , """5-fluorouracil"""@eng , """Fluroblastin"""@eng , """2,4-Dioxo-5-fluoropyrimidine"""@eng , """5fluorouracil"""@eng , """Fluoro Uracil"""@eng , """Fluril"""@eng , """Fluracedyl"""@eng , """5FU"""@eng ; skos:definition """An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43130&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43130&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C505\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """757"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """19893"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """51-21-8"""^^xsd:string ; """C505"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699372"""^^xsd:string ; umls:cui """C0699375"""^^xsd:string ; umls:cui """C0699374"""^^xsd:string ; umls:cui """C1517233"""^^xsd:string ; umls:cui """C1522717"""^^xsd:string ; umls:cui """C1517225"""^^xsd:string ; umls:cui """C1522715"""^^xsd:string ; umls:cui """C1522716"""^^xsd:string ; umls:cui """C1517227"""^^xsd:string ; umls:cui """C1517226"""^^xsd:string ; umls:cui """C0594005"""^^xsd:string ; umls:cui """C1517224"""^^xsd:string ; umls:cui """C1517230"""^^xsd:string ; umls:cui """C1517231"""^^xsd:string ; umls:cui """C1517232"""^^xsd:string ; umls:cui """C0016360"""^^xsd:string ; umls:cui """C1527295"""^^xsd:string ; umls:cui """C1517229"""^^xsd:string ; umls:cui """C1517228"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BAY 12-9566/doxorubicin"""@eng ; skos:notation """CDR0000043133"""^^xsd:string ; skos:altLabel """BAY129566/DOX"""@eng ; ; ; """7572"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796316"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/methotrexate/thioguanine"""@eng ; skos:notation """CDR0000043132"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MTX/TG"""@eng ; ; ; ; ; """7571"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796315"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laparoscopic surgery"""@eng ; skos:notation """CDR0000042302"""^^xsd:string ; skos:altLabel """surgery, laparoscopic"""@eng , """laparoscopy-assisted surgery"""@eng ; ; rdfs:subClassOf ; """5550"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0751429"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/gemcitabine/melphalan"""@eng ; skos:notation """CDR0000043139"""^^xsd:string ; skos:altLabel """BCNU/dFdC/L-PAM"""@eng ; ; ; ; """7580"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796322"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen peptide 1/hepatitis B antigen peptide"""@eng ; skos:notation """CDR0000043138"""^^xsd:string ; skos:altLabel """CAP-1/HBsAg"""@eng ; ; ; """7577"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796321"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/epratuzumab/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000299454"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB IDEC-C2B8/MOAB LL2/PRED/VCR"""@eng ; ; ; ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327943"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/methotrexate"""@eng ; skos:notation """CDR0000039316"""^^xsd:string ; skos:altLabel """IFF/MTX/VP-16"""@eng , """IMVP-16"""@eng ; ; ; ; """1952"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0063445"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mitomycin"""@eng ; skos:notation """CDR0000039318"""^^xsd:string ; skos:altLabel """DOX/MITO"""@eng , """MA"""@eng ; ; ; """1954"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279188"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult giant cell glioblastoma"""@eng ; skos:notation """CDR0000377342"""^^xsd:string ; skos:altLabel """giant cell glioblastoma, adult"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541316"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult gliosarcoma"""@eng ; skos:notation """CDR0000377343"""^^xsd:string ; skos:altLabel """gliosarcoma, adult"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541317"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ferumoxytol"""@eng ; skos:notation """CDR0000377345"""^^xsd:string ; skos:definition """A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron. In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=377345&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=377345&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38138\" NCI Thesaurus)"""@eng ; """2004-06-23"""^^xsd:string ; """C38138"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-07"""^^xsd:string ; umls:cui """C0060274"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/carmustine/mitomycin"""@eng ; skos:notation """CDR0000039319"""^^xsd:string ; skos:altLabel """BCNU/HMM/MITO"""@eng , """MiCH"""@eng ; ; ; ; """1955"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279189"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone/etoposide/sargramostim"""@eng ; skos:notation """CDR0000041261"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/GM-CSF/VP-16"""@eng ; ; ; ; ; ; """4334"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280851"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethanol"""@eng ; skos:notation """CDR0000446576"""^^xsd:string ; skos:altLabel """Absolute Ethanol"""@eng , """Methylcarbinol"""@eng , """ethyl alcohol"""@eng , """Alcohol"""@eng ; skos:definition """A colorless organic liquid also known as ethyl alcohol or grain alcohol. Ethanol's primary physiologic effects involve the central nervous system. Depending on the dose delivered, ethanol behaves as an anxiolytic, a depressant, or a general anesthetic. Ethanol-induced immunosuppression involves dysregulation of CD4+ T cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446576&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446576&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C216\" NCI Thesaurus)"""@eng ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-09-09"""^^xsd:string ; """C216"""^^xsd:string ; umls:cui """C0001962"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/ethacrynic acid"""@eng ; skos:notation """CDR0000041424"""^^xsd:string ; skos:altLabel """CLB/EA"""@eng ; ; ; """4496"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280976"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium Tc 94m sestamibi"""@eng ; skos:notation """CDR0000373868"""^^xsd:string ; skos:definition """A radioconjugate consisting of sestamibi labeled with the positron-emitting isotope Tc 94m. Sestamibi is a synthetic molecule of the isonitrile family that diffuses through cell membranes and may preferentially accumulate within mitochondria. Technetium Tc 94m sestamibi may be used in tumor-imaging studies utilizing positron emission tomography (PET). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373868&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=373868&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48423\" NCI Thesaurus)"""@eng ; """2004-06-23"""^^xsd:string ; """C48423"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C1541299"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory plasma cell neoplasm"""@eng ; skos:notation """CDR0000041876"""^^xsd:string ; skos:altLabel """plasma cell neoplasm, recurrent"""@eng , """recurrent plasma cell neoplasm"""@eng , """plasma cell neoplasm, refractory"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """509"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; umls:cui """C1370446"""^^xsd:string ; umls:cui """C0278620"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/tamoxifen"""@eng ; skos:notation """CDR0000041260"""^^xsd:string ; skos:altLabel """DNR/TMX"""@eng ; ; ; """4333"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280850"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SN2310"""@eng ; skos:notation """CDR0000518315"""^^xsd:string ; """2006-11-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831980"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/fludarabine/rituximab"""@eng ; skos:notation """CDR0000299063"""^^xsd:string ; skos:altLabel """FAMP/FLAVO/MOAB IDEC-C2B8"""@eng ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327940"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sunitinib malate"""@eng ; skos:notation """CDR0000299061"""^^xsd:string ; skos:altLabel """sunitinib"""@eng , """Sutent"""@eng , """SU11248"""@eng , """SU011248"""@eng , """5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide)"""@eng ; skos:definition """The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299061&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299061&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26673\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """2003-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C26673"""^^xsd:string ; umls:cui """C1176020"""^^xsd:string ; umls:cui """C1176021"""^^xsd:string ; umls:cui """C1698963"""^^xsd:string ; umls:cui """C1700685"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/filgrastim/ifosfamide/leucovorin calcium/methotrexate/rituximab/vincristine"""@eng ; skos:notation """CDR0000038669"""^^xsd:string ; skos:altLabel """ARA-C/CF/DM/G-CSF/IFF/MOAB IDEC-C2B8/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; ; ; """11313"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/ketoconazole"""@eng ; skos:notation """CDR0000038668"""^^xsd:string ; skos:altLabel """KCZ/TXT"""@eng ; ; ; """11312"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/sulindac"""@eng ; skos:notation """CDR0000038667"""^^xsd:string ; skos:altLabel """SULIN/TXT"""@eng ; ; ; """11311"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134670"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/celecoxib/gefitinib"""@eng ; skos:notation """CDR0000038666"""^^xsd:string ; skos:altLabel """CAPE/SC-58635/ZD 1839"""@eng ; ; ; ; """2002-10-10"""^^xsd:string ; """11310"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134669"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-LET photon therapy"""@eng ; skos:notation """CDR0000038665"""^^xsd:string ; skos:altLabel """therapy, low-LET photon"""@eng ; ; rdfs:subClassOf ; """1131"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0278778"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/thalidomide"""@eng ; skos:notation """CDR0000038664"""^^xsd:string ; skos:altLabel """CPT-11/THAL"""@eng ; ; ; """11309"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134668"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-275291/zoledronate"""@eng ; skos:notation """CDR0000038663"""^^xsd:string ; skos:altLabel """BMS 275291/ZOLE"""@eng ; ; ; """2003-10-07"""^^xsd:string ; """11308"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/oblimersen"""@eng ; skos:notation """CDR0000038662"""^^xsd:string ; skos:altLabel """ARA-C/DNR/G3139"""@eng ; ; ; ; """11307"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134666"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG 7909/trastuzumab"""@eng ; skos:notation """CDR0000038661"""^^xsd:string ; skos:altLabel """CpG-7909/MOAB HER2"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """11306"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134665"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG 7909"""@eng ; skos:notation """CDR0000038660"""^^xsd:string ; skos:altLabel """ProMune"""@eng , """CpG-7909"""@eng , """PF-3512676"""@eng ; skos:definition """A synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. CpG 7909 selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38660&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38660&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28580\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """11305"""^^xsd:string ; """C28580"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-18"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C2000258"""^^xsd:string ; umls:cui """C1134664"""^^xsd:string ; umls:cui """C1436331"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult extraskeletal chondrosarcoma"""@eng ; skos:notation """CDR0000038937"""^^xsd:string ; skos:altLabel """chondrosarcoma, adult extraskeletal"""@eng , """extraskeletal chondrosarcoma, adult"""@eng ; rdfs:subClassOf ; """1446"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278982"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 hypopharyngeal cancer"""@eng ; skos:notation """CDR0000038936"""^^xsd:string ; skos:altLabel """hypopharyngeal cancer, stage 0"""@eng , """hypopharynx cancer, stage 0"""@eng ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1445"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0347100"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 laryngeal cancer"""@eng ; skos:notation """CDR0000038935"""^^xsd:string ; skos:altLabel """laryngeal cancer, stage 0"""@eng , """stage 0 larynx cancer"""@eng , """larynx cancer, stage 0"""@eng ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1444"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0154069"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 oropharyngeal cancer"""@eng ; skos:notation """CDR0000038934"""^^xsd:string ; skos:altLabel """oropharyngeal cancer, stage 0"""@eng , """oropharynx cancer, stage 0"""@eng ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1443"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0347099"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038933"""^^xsd:string ; skos:altLabel """nasopharynx cancer, stage 0"""@eng , """nasopharyngeal cancer, stage 0"""@eng ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1442"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0347096"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000038932"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus cancer, stage 0"""@eng , """paranasal sinus and nasal cavity cancer, stage 0"""@eng ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1440"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278975"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """screening/prevention, cancer"""@eng ; skos:notation """CDR0000038931"""^^xsd:string ; skos:altLabel """cancer screening/prevention"""@eng , """prevention/detection, cancer"""@eng , """prevention/screening, cancer"""@eng , """cancer prevention/screening"""@eng , """cancer prevention/detection"""@eng , """early detection and prevention of cancer"""@eng ; """2002-10-17"""^^xsd:string ; """1439"""^^xsd:string ; umls:cui """C0278974"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin/methotrexate/prednisone/teniposide/vincristine"""@eng ; skos:notation """CDR0000038930"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DNR/MTX/PRED/VCR/VM-26"""@eng ; ; ; ; ; ; ; ; """1437"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278973"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/methylprednisolone/prednisone"""@eng ; skos:notation """CDR0000042464"""^^xsd:string ; skos:altLabel """CYSP/MePRDL/PRED"""@eng ; ; ; ; """5808"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338362"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/trastuzumab"""@eng ; skos:notation """CDR0000042465"""^^xsd:string ; skos:altLabel """CTX/EPI/MOAB HER2"""@eng ; ; ; ; """5855"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338363"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000042466"""^^xsd:string ; skos:altLabel """MOAB HER2/TAX"""@eng ; ; ; """5856"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338364"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cognitive/functional effects"""@eng ; skos:notation """CDR0000042467"""^^xsd:string ; rdfs:subClassOf ; """5898"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0935657"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000042460"""^^xsd:string ; skos:altLabel """BCNU/IFN-A/TMX"""@eng ; ; ; ; """5804"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338358"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/carboplatin/cisplatin/vincristine"""@eng ; skos:notation """CDR0000042461"""^^xsd:string ; skos:altLabel """C-BOP"""@eng , """BLEO/CBDCA/CDDP/VCR"""@eng ; ; ; ; ; """5805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338359"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/etoposide/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000042462"""^^xsd:string ; skos:altLabel """CTX/DM/MP/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; """5806"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338360"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin/ifosfamide/mesna"""@eng ; skos:notation """CDR0000042463"""^^xsd:string ; skos:altLabel """MAID"""@eng , """DOX/DTIC/IFF/MSA"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """5807"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338361"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000258309"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/OSI774"""@eng ; ; ; ; ; """2002-10-08"""^^xsd:string ; """11485"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327801"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GVAX pancreatic cancer vaccine"""@eng ; skos:notation """CDR0000368623"""^^xsd:string ; skos:altLabel """GM-CSF gene transduced allogeneic pancreatic cancer vaccine"""@eng ; """2004-05-28"""^^xsd:string ; """2004-04-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541231"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """screening for liver cancer"""@eng ; skos:notation """CDR0000043406"""^^xsd:string ; skos:altLabel """hepatocellular cancer, screening for"""@eng , """liver cancer, screening for"""@eng ; """2002-10-17"""^^xsd:string ; """7965"""^^xsd:string ; umls:cui """C0796544"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/O6-benzylguanine"""@eng ; skos:notation """CDR0000373889"""^^xsd:string ; skos:altLabel """BG/IFF"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541300"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetrorelix"""@eng ; skos:notation """CDR0000042798"""^^xsd:string ; """6598"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0209366"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lisofylline"""@eng ; skos:notation """CDR0000042799"""^^xsd:string ; skos:altLabel """LSF"""@eng , """CT-1501R"""@eng ; """6599"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-09"""^^xsd:string ; umls:cui """C0243902"""^^xsd:string ; umls:cui """C0243901"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """molecular diagnostic methods"""@eng ; skos:notation """CDR0000042792"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """6591"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0949688"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paroxetine hydrochloride"""@eng ; skos:notation """CDR0000042793"""^^xsd:string ; skos:altLabel """Paxil"""@eng ; skos:definition """The hydrochloride salt form of paroxetine, a phenylpiperidine derivative and a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Inhibition of serotonin recycling enhances serotonergic function through serotonin accumulation in the synaptic cleft, resulting in long-term desensitization and downregulation of 5HT1 (serotonin) receptors and leading to symptomatic relief of depressive illness. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42793&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42793&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1837\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """6592"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """78246-49-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1837"""^^xsd:string ; umls:cui """C0771019"""^^xsd:string ; umls:cui """C0376414"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of the skin"""@eng ; skos:notation """CDR0000042790"""^^xsd:string ; skos:altLabel """cancer of the skin, squamous cell"""@eng , """carcinoma of the skin, squamous cell"""@eng , """carcinoma, squamous cell, skin"""@eng , """skin cancer, squamous cell"""@eng , """carcinoma, epidermoid, skin"""@eng , """skin cancer, epidermoid carcinoma"""@eng , """epidermoid carcinoma of the skin"""@eng ; rdfs:subClassOf ; """skin cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """659"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0553723"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunological diagnostic methods"""@eng ; skos:notation """CDR0000042791"""^^xsd:string ; skos:altLabel """diagnostic methods, immunological"""@eng ; rdfs:subClassOf owl:Thing ; """6590"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0677746"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tomography, emission computed, single photon"""@eng ; skos:notation """CDR0000042796"""^^xsd:string ; skos:altLabel """SPECT imaging"""@eng ; rdfs:subClassOf ; """6596"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0040399"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mycophenolate mofetil"""@eng ; skos:notation """CDR0000042797"""^^xsd:string ; skos:altLabel """MMF"""@eng , """Cellcept"""@eng ; skos:definition """The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties. Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis. In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides. MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42797&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42797&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1468\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; """6597"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """950009"""^^xsd:string ; """2006-08-31"""^^xsd:string ; """C1468"""^^xsd:string ; """128794-94-5"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0592558"""^^xsd:string ; umls:cui """C0209368"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/mesna/topotecan"""@eng ; skos:notation """CDR0000042794"""^^xsd:string ; skos:altLabel """IFF/MSA/TOPO/VP-16"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """6593"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677749"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EGFR/HER2 inhibitor AV-412"""@eng ; skos:notation """CDR0000513167"""^^xsd:string ; skos:altLabel """AV-412"""@eng ; """Drug/agent"""^^xsd:string ; """2006-10-14"""^^xsd:string ; umls:cui """C3537165"""^^xsd:string ; umls:cui """C1831969"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100-fowlpox vaccine"""@eng ; skos:notation """CDR0000491988"""^^xsd:string ; skos:definition """A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic activity. The expression of gp100 may generate a cellular immune response to melanoma cells; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491988&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491988&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2761\" NCI Thesaurus)"""@eng ; """2006-06-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2761"""^^xsd:string ; """673927"""^^xsd:string ; """6909"""^^xsd:string ; umls:cui """C1515625"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Boswellia serrata extract"""@eng ; skos:notation """CDR0000452040"""^^xsd:string ; skos:definition """A standardized extract derived from the plant Boswellia serrata of the family Burseraceae with anti-inflammatory activity. Boswellia serrata extract contains terpenoid boswellic acids, which are potent inhibitors of 5-lipoxygenase activity and, so, leukotriene synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452040&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452040&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49089\" NCI Thesaurus)"""@eng ; """2006-01-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C49089"""^^xsd:string ; """2005-10-14"""^^xsd:string ; umls:cui """C0873038"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diazooxonorleucine"""@eng ; skos:notation """CDR0000039224"""^^xsd:string ; skos:altLabel """DON"""@eng , """6-diazo-5-oxo-L-norleucine"""@eng ; """2006-11-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1846"""^^xsd:string ; """C427"""^^xsd:string ; umls:cui """C0012020"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dinitrochlorobenzene"""@eng ; skos:notation """CDR0000039225"""^^xsd:string ; skos:altLabel """DNCB"""@eng ; """1847"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0012460"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dromostanolone propionate"""@eng ; skos:notation """CDR0000039226"""^^xsd:string ; skos:altLabel """Drolban"""@eng , """dromostanolone"""@eng , """Masterone"""@eng , """DSP"""@eng , """drostanolone propionate"""@eng ; """1848"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0603194"""^^xsd:string ; umls:cui """C0058758"""^^xsd:string ; umls:cui """C0603196"""^^xsd:string ; umls:cui """C0058753"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """droperidol"""@eng ; skos:notation """CDR0000039227"""^^xsd:string ; skos:altLabel """Inapsine"""@eng ; skos:definition """A butyrophenone with anti-emetic, sedative and anti-anxiety properties. Although the exact mechanism through which droperidol exerts its effects is unknown, droperidol may block dopamine receptors in the chemoreceptor trigger zone (CTZ), which may lead to its anti-emetic effect. This agent may also bind to postsynaptic gamma-aminobutyric acid (GABA) receptors in the central nervous system (CNS), which increases the inhibitory effect of GABA and leads to sedative and anti-anxiety activities. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39227&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39227&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C458\" NCI Thesaurus)"""@eng ; """1849"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """169874"""^^xsd:string ; """C458"""^^xsd:string ; """548-73-2"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699335"""^^xsd:string ; umls:cui """C0013136"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dihydro-5-azacytidine"""@eng ; skos:notation """CDR0000039220"""^^xsd:string ; skos:altLabel """DHAC"""@eng , """5,6-dihydro-5-azacytidine hydrochloride"""@eng , """5,6-dihydro-5-azacytidine HCl"""@eng , """1,3,5-triazin-2(1H)-one, 4-amino-3, 6-dihydro-1-beta-D-ribofuranosyl monohydrochloride"""@eng ; skos:definition """A synthetic nucleoside analogue of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39220&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39220&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C980\" NCI Thesaurus)"""@eng ; ; """1842"""^^xsd:string ; """19672"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """62488-57-7"""^^xsd:string ; """C980"""^^xsd:string ; """264880"""^^xsd:string ; umls:cui """C0952659"""^^xsd:string ; umls:cui """C0048906"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethylbusulfan"""@eng ; skos:notation """CDR0000039221"""^^xsd:string ; skos:altLabel """DMM"""@eng , """Dimethyl Myleran"""@eng , """Dimethylmyleran"""@eng , """DMB"""@eng , """Dimethyl-Myleran"""@eng ; skos:definition """An aliphatic analogue of busulfan with potential antineoplastic activity. As an alkylating agent, dimethylbusulfan induces neutropenia and has been shown to exhibit antitumor effects in some animal models. Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39221&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39221&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1073\" NCI Thesaurus)"""@eng ; ; """1843"""^^xsd:string ; """180543"""^^xsd:string ; """180542"""^^xsd:string ; """55-93-6"""^^xsd:string ; """23890"""^^xsd:string ; """C1073"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """180541"""^^xsd:string ; umls:cui """C0058272"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethyl sulfoxide"""@eng ; skos:notation """CDR0000039222"""^^xsd:string ; skos:altLabel """SQ-9453"""@eng , """Dromisol"""@eng , """Sulfinylbismethane"""@eng , """Domoso"""@eng , """Demasorb"""@eng , """Demeso"""@eng , """DMSO"""@eng ; skos:definition """A polar organic solvent. DMSO is a free radical scavenger that has been used to treat extravasation damage caused by anthracycline-based chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39222&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39222&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C437\" NCI Thesaurus)"""@eng ; ; ; """1844"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """763"""^^xsd:string ; """C437"""^^xsd:string ; """3211"""^^xsd:string ; """67-68-5"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0729119"""^^xsd:string ; umls:cui """C0729118"""^^xsd:string ; umls:cui """C0012403"""^^xsd:string ; umls:cui """C0729125"""^^xsd:string ; umls:cui """C0729122"""^^xsd:string ; umls:cui """C0729121"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atomoxetine hydrochloride"""@eng ; skos:notation """CDR0000475797"""^^xsd:string ; skos:altLabel """(-)-N-methyl-gamma(2-methylphenoxy)benzenepropamine Hydrochloride"""@eng , """(-)-N -methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride"""@eng , """Strattera"""@eng ; skos:definition """The hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft; the effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475797&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475797&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47405\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C47405"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """2006-03-24"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1176420"""^^xsd:string ; umls:cui """C1170741"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/isoniazid"""@eng ; skos:notation """CDR0000041515"""^^xsd:string ; skos:altLabel """BC-G/INH"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """4671"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281144"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/edatrexate"""@eng ; skos:notation """CDR0000041514"""^^xsd:string ; skos:altLabel """CBDCA/EDAM"""@eng ; ; ; """4670"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281143"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hexamethylene bisacetamide/tretinoin"""@eng ; skos:notation """CDR0000041517"""^^xsd:string ; skos:altLabel """ATRA/HMBA"""@eng ; ; ; """4673"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281146"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/edatrexate"""@eng ; skos:notation """CDR0000041516"""^^xsd:string ; skos:altLabel """CDDP/EDAM"""@eng ; ; ; """4672"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281145"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trifluoperazine/verapamil"""@eng ; skos:notation """CDR0000041511"""^^xsd:string ; skos:altLabel """TFPZ/VPAM"""@eng ; ; ; """4667"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281140"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-1-alpha/interleukin-2"""@eng ; skos:notation """CDR0000041510"""^^xsd:string ; skos:altLabel """IL-1A/IL-2"""@eng ; ; ; """4666"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281139"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/trifluoperazine/vinblastine/verapamil"""@eng ; skos:notation """CDR0000041513"""^^xsd:string ; skos:altLabel """DOX/trifluoperazine/VBL/VPAM"""@eng ; ; ; ; ; """4669"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281142"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/filgrastim"""@eng ; skos:notation """CDR0000041512"""^^xsd:string ; skos:altLabel """DOX/G-CSF"""@eng ; ; ; """4668"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281141"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CD7 immunotoxin"""@eng ; skos:notation """CDR0000042641"""^^xsd:string ; skos:altLabel """immunotoxin, anti CD7"""@eng , """immunotoxin, anti-CD7"""@eng , """anti CD7 immunotoxin"""@eng ; """6371"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677668"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """itraconazole/PKC412"""@eng ; skos:notation """CDR0000383190"""^^xsd:string ; skos:altLabel """ICZ/PKC 412"""@eng ; ; """2004-08-24"""^^xsd:string ; """2006-08-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541459"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immune globulin"""@eng ; skos:notation """CDR0000040109"""^^xsd:string ; skos:altLabel """Sandoglobulin"""@eng , """Venoglobulin-S"""@eng , """Gammagard S/D"""@eng , """Gammar-P"""@eng , """Panglobulin"""@eng , """Therapeutic Immune Globulin"""@eng , """Venoglobulin-I"""@eng , """IG"""@eng , """Immune Globulin Intravenous"""@eng , """IgIV"""@eng , """Gamimune N"""@eng , """WinRho SDF"""@eng , """BayGam"""@eng , """Immune Globulin IV"""@eng , """Polygam S/D"""@eng , """Therapeutic Immunoglobulin"""@eng , """Recombinant Immune Globulin"""@eng , """Iveegam EN"""@eng ; skos:definition """A preparation of plasma proteins derived from the pooled plasma of adult donors. Largely comprised of IgG antibodies, therapeutic immune globulin provides passive immunization by increasing the recipient's serum levels of circulating antibodies. IgG antibodies have multiple functions, including binding to and neutralizing bacterial toxins; opsonization of pathogens; activation of complement; and suppression of pathogenic cytokines and phagocytes through binding to CD5, interleukin-1a (IL-1a), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and T-cell receptors. Therapeutic immune globulin may diminish pathogenic mechanisms in some autoimmune diseases by binding to and inhibiting the activity of autoantibodies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40109&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40109&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2701\" NCI Thesaurus)"""@eng ; ; ; """2870"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """621996"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """C2701"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1170359"""^^xsd:string ; umls:cui """C0087152"""^^xsd:string ; umls:cui """C0722702"""^^xsd:string ; umls:cui """C1135151"""^^xsd:string ; umls:cui """C0724402"""^^xsd:string ; umls:cui """C1527233"""^^xsd:string ; umls:cui """C0722468"""^^xsd:string ; umls:cui """C0021027"""^^xsd:string ; umls:cui """C0086333"""^^xsd:string ; umls:cui """C0086952"""^^xsd:string ; umls:cui """C0162507"""^^xsd:string ; umls:cui """C0085297"""^^xsd:string ; umls:cui """C1515379"""^^xsd:string ; umls:cui """C0875969"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell lung cancer"""@eng ; skos:notation """CDR0000040108"""^^xsd:string ; skos:altLabel """lung cancer, squamous cell"""@eng , """lung cancer, epidermoid"""@eng , """epidermoid lung cancer"""@eng , """non-oat cell lung cancer, squamous cell"""@eng ; rdfs:subClassOf ; """287"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0149782"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040105"""^^xsd:string ; skos:altLabel """hypopharynx cancer, recurrent"""@eng , """hypopharyngeal cancer, recurrent"""@eng ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2855"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279803"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040104"""^^xsd:string ; skos:altLabel """hypopharynx cancer, stage IV"""@eng , """metastatic hypopharyngeal cancer"""@eng , """hypopharyngeal cancer, metastatic"""@eng , """hypopharynx cancer, metastatic"""@eng , """hypopharyngeal cancer, stage IV"""@eng ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2854"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1510473"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dihydrolenperone"""@eng ; skos:notation """CDR0000040107"""^^xsd:string ; skos:altLabel """Dihydro-lenperone"""@eng , """1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]-"""@eng ; skos:definition """A butyrophenone that has been investigated for antineoplastic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40107&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40107&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1463\" NCI Thesaurus)"""@eng ; """2869"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C1463"""^^xsd:string ; """26634"""^^xsd:string ; """38077-12-2"""^^xsd:string ; """343513"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0208317"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior LHRH agonist therapy"""@eng ; skos:notation """CDR0000040106"""^^xsd:string ; skos:altLabel """LHRH agonist therapy, prior"""@eng ; """2856"""^^xsd:string ; umls:cui """C0279804"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hemophagocytic lymphohistiocytosis"""@eng ; skos:notation """CDR0000486910"""^^xsd:string ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C0024291"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior progestin therapy"""@eng ; skos:notation """CDR0000040100"""^^xsd:string ; skos:altLabel """progestin therapy, prior"""@eng ; """2850"""^^xsd:string ; umls:cui """C0279798"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040103"""^^xsd:string ; skos:altLabel """hypopharyngeal cancer, stage III"""@eng , """hypopharynx cancer, stage III"""@eng ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2853"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279801"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040102"""^^xsd:string ; skos:altLabel """hypopharyngeal cancer, stage II"""@eng , """hypopharynx cancer, stage II"""@eng ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2852"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279800"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II marginal zone lymphoma"""@eng ; skos:notation """CDR0000371959"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541272"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/hydroxyurea/leucovorin calcium"""@eng ; skos:notation """CDR0000039329"""^^xsd:string ; skos:altLabel """CF/5-FU/HU"""@eng ; ; ; ; """1965"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279198"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039328"""^^xsd:string ; skos:altLabel """DOX/MTX/PRED/VCR"""@eng , """M-HOP"""@eng ; ; ; ; ; """1964"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279197"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/etoposide/mitomycin"""@eng ; skos:notation """CDR0000039321"""^^xsd:string ; skos:altLabel """CDDP/HMM/MITO/VP-16"""@eng , """MEPH"""@eng ; ; ; ; ; """1957"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065958"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/mitomycin"""@eng ; skos:notation """CDR0000039320"""^^xsd:string ; skos:altLabel """MAC"""@eng , """CTX/DOX/MITO"""@eng ; ; ; ; """1956"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279190"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/mitomycin"""@eng ; skos:notation """CDR0000039323"""^^xsd:string ; skos:altLabel """CDDP/DOX/MITO"""@eng , """MAP"""@eng ; ; ; ; """1959"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065713"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/vinblastine"""@eng ; skos:notation """CDR0000039322"""^^xsd:string ; skos:altLabel """ABV"""@eng , """BLEO/DOX/VBL"""@eng ; ; ; ; """1958"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078137"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039325"""^^xsd:string ; skos:altLabel """MOAD"""@eng , """ASP/DM/MTX/VCR"""@eng ; ; ; ; ; """1961"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279194"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-4"""@eng ; skos:notation """CDR0000039324"""^^xsd:string ; skos:altLabel """T-Cell Growth Factor 2"""@eng , """IL-4"""@eng , """B-Cell Stimulatory Factor 1"""@eng , """MCGF 2"""@eng , """Recombinant Interleukin-4"""@eng , """B-Cell Growth Factor"""@eng , """BCSF 1"""@eng , """B-Cell Stimulating Factor"""@eng , """Mast Cell Growth Factor-2"""@eng , """BCGF"""@eng , """B Cell Proliferating Factor"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-4 (IL-4). Produced primarily by activated T-cells, IL-4 binds to and activates its cell-surface receptor, stimulating the proliferation and differentiation of activated B-cells and enhancing their ability to present antigens to T-cells. As a potential immunotherapeutic agent, recombinant IL-4 also augments the effects of other cytokines on dendritic cells (DC), cytotoxic T lymphocytes (CTL), and tumor-infiltrating lymphocytes (TIL). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39324&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39324&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C589\" NCI Thesaurus)"""@eng ; ; ; ; """1960"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """618085"""^^xsd:string ; """207137-56-2"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C589"""^^xsd:string ; umls:cui """C1522540"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone/doxorubicin"""@eng ; skos:notation """CDR0000039327"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/DOX"""@eng ; ; ; ; ; """1963"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279196"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/novobiocin"""@eng ; skos:notation """CDR0000039326"""^^xsd:string ; skos:altLabel """CDDP/NBC"""@eng ; ; ; """1962"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279195"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentostatin/sargramostim"""@eng ; skos:notation """CDR0000041476"""^^xsd:string ; skos:altLabel """DCF/GM-CSF"""@eng ; ; ; """4547"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281021"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/diethyldithiocarbamate"""@eng ; skos:notation """CDR0000041477"""^^xsd:string ; skos:altLabel """CBDCA/DTC"""@eng ; ; ; """4548"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281022"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interleukin-6"""@eng ; skos:notation """CDR0000041474"""^^xsd:string ; skos:altLabel """IL-6"""@eng , """Sigosix"""@eng , """interleukin 6"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """4545"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C591"""^^xsd:string ; """2006-11-21"""^^xsd:string ; umls:cui """C1527132"""^^xsd:string ; umls:cui """C0878479"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/medroxyprogesterone/quinine"""@eng ; skos:notation """CDR0000041475"""^^xsd:string ; skos:altLabel """CTX/DOX/MPA/QUIN/VP-16"""@eng ; ; ; ; ; ; """4546"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281020"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody L6"""@eng ; skos:notation """CDR0000041472"""^^xsd:string ; skos:altLabel """L6"""@eng , """MOAB L6"""@eng ; skos:definition """A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells. This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41472&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41472&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2372\" NCI Thesaurus)"""@eng ; ; """4543"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2990"""^^xsd:string ; """C2372"""^^xsd:string ; umls:cui """C0281019"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idarubicin/tretinoin"""@eng ; skos:notation """CDR0000041470"""^^xsd:string ; skos:altLabel """ATRA/IDA"""@eng ; ; ; """4541"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281017"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idarubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041471"""^^xsd:string ; skos:altLabel """IDA/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """4542"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281018"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levamisole/tamoxifen"""@eng ; skos:notation """CDR0000041478"""^^xsd:string ; skos:altLabel """LEV/TMX"""@eng ; ; ; """4549"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281023"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/idoxuridine/leucovorin calcium/PALA"""@eng ; skos:notation """CDR0000041479"""^^xsd:string ; skos:altLabel """CF/5-FU/IUDR/PALA"""@eng ; ; ; ; ; """4550"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281024"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PSA:154-163(155L) peptide vaccine"""@eng ; skos:notation """CDR0000430384"""^^xsd:string ; skos:altLabel """PSA PEP VAC"""@eng ; skos:definition """A cancer vaccine comprised of a synthetic peptide with an amino acid sequence corresponding to positions 154-163 of the amino acid sequence for prostate-specific antigen (PSA) with a leucine substitution at position 155. Upon administration, PSA:154-163(155L) peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=430384&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=430384&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29338\" NCI Thesaurus)"""@eng ; """2006-09-11"""^^xsd:string ; """C29338"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-04-23"""^^xsd:string ; umls:cui """C1541563"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/PSA peptide vaccine"""@eng ; skos:notation """CDR0000430385"""^^xsd:string ; skos:altLabel """ISA-51/PSA PEP VAC"""@eng ; """2005-04-23"""^^xsd:string ; """2005-04-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541564"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine"""@eng ; skos:notation """CDR0000465181"""^^xsd:string ; skos:altLabel """autologous EBV-transformed B-lymphoblastoid cell vaccine"""@eng ; skos:definition """A cell-based vaccine composed of autologous lymphoblastoid B cells activated against Epstein-Barr virus (EBV) in vitro with potential immunoprotective activity. Upon prophylactic administration, this vaccine may stimulate specific cytotoxic T-lymphocyte (CTL) and antibody responses against EBV-transformed B cells, thereby preventing an EBV-induced post-transplantation lymphoproliferative disorder. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465181&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465181&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53443\" NCI Thesaurus)"""@eng ; """C53443"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-30"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C1711248"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Candida albicans skin test reagent"""@eng ; skos:notation """CDR0000038060"""^^xsd:string ; ; """10596"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879601"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hepatic complications"""@eng ; skos:notation """CDR0000532304"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2007-01-22"""^^xsd:string ; """2007-01-25"""^^xsd:string ; umls:cui """C1832055"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SU5416/thalidomide"""@eng ; skos:notation """CDR0000038328"""^^xsd:string ; skos:altLabel """SU-5416/THAL"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10948"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935873"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AG2037"""@eng ; skos:notation """CDR0000038329"""^^xsd:string ; skos:definition """A water soluble antifolate with anti-proliferative activity. AG2037 inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38329&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38329&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2633\" NCI Thesaurus)"""@eng ; """10949"""^^xsd:string ; """C2633"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935874"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/vinorelbine"""@eng ; skos:notation """CDR0000038322"""^^xsd:string ; skos:altLabel """MOAB VEGF/VNB"""@eng ; ; ; """10940"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935867"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel liposome"""@eng ; skos:notation """CDR0000038323"""^^xsd:string ; skos:altLabel """LEP"""@eng , """liposome-encapsulated paclitaxel"""@eng , """PNU-93914"""@eng ; """10941"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328670"""^^xsd:string ; umls:cui """C0935868"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ampicillin sodium/sulbactam sodium"""@eng ; skos:notation """CDR0000500377"""^^xsd:string ; skos:altLabel """Unasyn"""@eng ; skos:definition """A combination formulation of the sodium salts of the antibiotic ampicillin and the beta-lactamase inhibitor sulbactam with antibacterial activity. Ampicillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. The sulbactam component irreversibly binds to bacterial beta-lactamase at or near its active site, thereby interfering with substrate binding and inhibiting bacterial metabolism of penicillin and cephalosporin beta-lactam antibiotics, effectively extending their antibiotic spectrum to include many beta-lactam-resistant bacteria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=500377&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=500377&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28823\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """C28823"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-06"""^^xsd:string ; umls:cui """C1510875"""^^xsd:string ; umls:cui """C0147814"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vitamin E"""@eng ; skos:notation """CDR0000038321"""^^xsd:string ; skos:altLabel """dl-alpha tocopheryl acetate"""@eng , """3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol"""@eng , """5,7,8-Trimethyltocol"""@eng , """d-alpha-Tocopherol"""@eng , """(+/-)-alpha-Tocopherol"""@eng , """vitamin-E"""@eng , """VIT-E"""@eng , """E vitamin"""@eng , """VIT E"""@eng ; skos:definition """A natural fat-soluble antioxidant with potential chemopreventive activity. Also known as tocopherol, vitamin E ameliorates free-radical damage to biological membranes, protecting polyunsaturated fatty acids (PUFA) within membrane phospholipids and within circulating lipoproteins. Peroxyl radicals react 1000-fold faster with vitamin E than with PUFA. In the case of oxygen free radical-mediated tumorigenesis, vitamin E may be chemopreventive. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38321&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38321&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C942\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """1094"""^^xsd:string ; """20812"""^^xsd:string ; """1406-18-4"""^^xsd:string ; """C942"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0042874"""^^xsd:string ; umls:cui """C0994472"""^^xsd:string ; umls:cui """C0969677"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cytarabine/dexamethasone/etoposide/melphalan"""@eng ; skos:notation """CDR0000038326"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/DM/L-PAM/VP-16"""@eng ; ; ; ; ; ; """10946"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935871"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide phosphate/melphalan"""@eng ; skos:notation """CDR0000038327"""^^xsd:string ; skos:altLabel """CBDCA/ETOP/L-PAM"""@eng ; ; ; ; """10947"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935872"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/oblimersen"""@eng ; skos:notation """CDR0000038324"""^^xsd:string ; skos:altLabel """CBDCA/G3139/VP-16"""@eng ; ; ; ; """10942"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935869"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel poliglumex"""@eng ; skos:notation """CDR0000038325"""^^xsd:string ; skos:altLabel """polyglutamic acid paclitaxel"""@eng , """polyglutamate paclitaxel"""@eng , """paclitaxel-polyglutamate polymer"""@eng , """CT-2103"""@eng , """Poly-L-Glutamic acid-Paclitaxel Conjugate"""@eng , """Xyotax"""@eng , """PG-TXL"""@eng ; skos:definition """The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38325&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38325&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1795\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """10945"""^^xsd:string ; """C1795"""^^xsd:string ; umls:cui """C1702776"""^^xsd:string ; umls:cui """C0935965"""^^xsd:string ; umls:cui """C1328240"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bowel preparation"""@eng ; skos:notation """CDR0000481372"""^^xsd:string ; """2006-04-17"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-04-20"""^^xsd:string ; umls:cui """C0455052"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000039819"""^^xsd:string ; skos:altLabel """BCNU/CTX/VP-16"""@eng , """CBV"""@eng ; ; ; ; """2497"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054917"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039818"""^^xsd:string ; skos:altLabel """AMSA-OAP"""@eng , """AMSA/ARA-C/PRED/VCR"""@eng ; ; ; ; ; """2496"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0051766"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """medroxyprogesterone"""@eng ; skos:notation """CDR0000039813"""^^xsd:string ; skos:altLabel """Depo-Provera"""@eng , """17Alpha-hydroxy-6alpha-methylprogesterone"""@eng , """MPA"""@eng , """(6Alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione"""@eng , """6Alpha-methyl-4-pregnen-17alpha-ol-3,20-dione"""@eng , """medroxyprogesterone acetate"""@eng , """Provera Dosepak"""@eng , """Provera"""@eng , """6Alpha-methyl-17alpha-hydroxyprogesterone"""@eng , """Curretab"""@eng ; skos:definition """A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39813&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39813&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C629\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """249"""^^xsd:string ; """27408"""^^xsd:string ; """C629"""^^xsd:string ; """520-85-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0065864"""^^xsd:string ; umls:cui """C0025147"""^^xsd:string ; umls:cui """C0699704"""^^xsd:string ; umls:cui """C0699702"""^^xsd:string ; umls:cui """C0699700"""^^xsd:string ; umls:cui """C0338069"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T203"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trilostane"""@eng ; skos:notation """CDR0000039812"""^^xsd:string ; skos:altLabel """4,5-Epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile"""@eng , """2Alpha-cyano-4alpha,5alpha-epoxyandrostan-17beta-ol-3-one"""@eng , """WIN 24,540"""@eng , """Modrenal"""@eng , """(4Alpha,5alpha,17beta)-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile"""@eng , """WIN 24540"""@eng , """Desopan"""@eng , """Modrastane"""@eng ; skos:definition """A synthetic derivative of androstane with adrenocortical suppressive properties. Trilostane reversibly inhibits 3 beta-hydroxysteroid dehydrogenase delta 5-4 isomerase in the adrenal cortex, resulting in the decreased synthesis of mineralocorticoids and glucocorticoids and the decreased conversion of pregnenolone to progesterone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39812&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39812&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1263\" NCI Thesaurus)"""@eng ; """2489"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1263"""^^xsd:string ; """13647-35-3"""^^xsd:string ; """2006-12-19"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0950274"""^^xsd:string ; umls:cui """C1519649"""^^xsd:string ; umls:cui """C0591818"""^^xsd:string ; umls:cui """C0077144"""^^xsd:string ; umls:cui """C1955821"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide"""@eng ; skos:notation """CDR0000039811"""^^xsd:string ; skos:altLabel """Flutacan"""@eng , """Flutan"""@eng , """Prostacur"""@eng , """Grisetin"""@eng , """Fluken"""@eng , """Flutaplex"""@eng , """Euflex"""@eng , """Chimax"""@eng , """Flutabene"""@eng , """Prostica"""@eng , """4'-Nitro-3'-trifluoromethylisobutyranilide"""@eng , """Eulexin"""@eng , """Tecnoflut"""@eng , """Apimid"""@eng , """Testotard"""@eng , """FLUT"""@eng , """Profamid"""@eng , """2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide"""@eng , """Oncosal"""@eng , """Tafenil"""@eng , """Sch 13521"""@eng , """Eulexine"""@eng , """Drogenil"""@eng , """Fugerel"""@eng , """Flutamin"""@eng , """Flulem"""@eng , """Flutamex"""@eng , """Flucinome"""@eng , """Prostogenat"""@eng , """Flugerel"""@eng , """Prostadirex"""@eng , """Alpha,alpha,alpha-trifluoro-2-methy-4'-nitro-m-propionotoluidide"""@eng , """Fluta-Gry"""@eng , """Flucinom"""@eng , """Niftolid"""@eng ; skos:definition """A toluidine derivative and nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39811&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39811&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C509\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2488"""^^xsd:string ; """25378"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C509"""^^xsd:string ; """215876"""^^xsd:string ; """13311-84-7"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """147834"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700681"""^^xsd:string ; umls:cui """C1517245"""^^xsd:string ; umls:cui """C0591412"""^^xsd:string ; umls:cui """C1517263"""^^xsd:string ; umls:cui """C1517262"""^^xsd:string ; umls:cui """C1517261"""^^xsd:string ; umls:cui """C1517260"""^^xsd:string ; umls:cui """C1517267"""^^xsd:string ; umls:cui """C1517266"""^^xsd:string ; umls:cui """C1517265"""^^xsd:string ; umls:cui """C1517264"""^^xsd:string ; umls:cui """C0595574"""^^xsd:string ; umls:cui """C1517249"""^^xsd:string ; umls:cui """C1517248"""^^xsd:string ; umls:cui """C1522370"""^^xsd:string ; umls:cui """C0016384"""^^xsd:string ; umls:cui """C1522368"""^^xsd:string ; umls:cui """C1517258"""^^xsd:string ; umls:cui """C1517259"""^^xsd:string ; umls:cui """C1517256"""^^xsd:string ; umls:cui """C1517257"""^^xsd:string ; umls:cui """C1517254"""^^xsd:string ; umls:cui """C1517255"""^^xsd:string ; umls:cui """C1517252"""^^xsd:string ; umls:cui """C1517253"""^^xsd:string ; umls:cui """C1517250"""^^xsd:string ; umls:cui """C1517251"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drug modulation"""@eng ; skos:notation """CDR0000039810"""^^xsd:string ; skos:altLabel """modulation, drug"""@eng ; """2487"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279532"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """myelodysplastic syndromes"""@eng ; skos:notation """CDR0000039817"""^^xsd:string ; skos:altLabel """myelodysplasia"""@eng , """preleukemia"""@eng , """Myelodysplastic syndromes"""@eng , """dysmyelopoiesis"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2495"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C3463824"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pheochromocytoma"""@eng ; skos:notation """CDR0000039816"""^^xsd:string ; skos:altLabel """Pheochromocytoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2494"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0031511"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/methotrexate/mitomycin"""@eng ; skos:notation """CDR0000039815"""^^xsd:string ; skos:altLabel """M-FAM"""@eng , """DOX/5-FU/MITO/MTX"""@eng ; ; ; ; ; """2493"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279534"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biostim/doxorubicin/etoposide/prednisone"""@eng ; skos:notation """CDR0000039814"""^^xsd:string ; skos:altLabel """Biostim/DOX/PRED/VP-16"""@eng ; ; ; ; ; """2490"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279533"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hyperfractionated radiation therapy"""@eng ; skos:notation """CDR0000493007"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-06-29"""^^xsd:string ; """2006-07-07"""^^xsd:string ; umls:cui """C1831915"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/fludarabine/rituximab"""@eng ; skos:notation """CDR0000436065"""^^xsd:string ; skos:altLabel """FAMP/MOAB IDEC-C2B8/PS-341"""@eng ; ; ; ; """2005-06-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-06-06"""^^xsd:string ; umls:cui """C1831643"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000038490"""^^xsd:string ; skos:altLabel """chronic lymphocytic leukemia, stage III"""@eng , """leukemia, stage III chronic lymphocytic"""@eng , """lymphocytic leukemia, stage III chronic"""@eng , """CLL, stage III"""@eng ; rdfs:subClassOf ; """chronic lymphocytic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1111"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278769"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody anti-alpha V beta 3 integrin"""@eng ; skos:notation """CDR0000038491"""^^xsd:string ; skos:altLabel """Abegrin"""@eng , """Vitaxin"""@eng , """monoclonal antibody anti-avb3 integrin"""@eng , """MOAB anti-avb3 integrin"""@eng , """humanized monoclonal antibody LM609"""@eng , """MOAB anti-alpha V beta 3 integrin"""@eng , """Medi 522"""@eng , """MEDI-522"""@eng ; skos:definition """A humanized monoclonal IgG1 antibody directed against the vitronectin receptor alpha v beta 3 integrin. Humanized monoclonal antibody LM609 blocks the binding of ligands, such as vitronectin, to alpha v beta 3 integrin, resulting in inhibition of angiogenesis and metastasis. Alpha v beta 3 integrin is a cell adhesion and signaling receptor that is expressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38491&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38491&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38723\" NCI Thesaurus)"""@eng ; ; ; ; ; """TRD"""^^xsd:string ; """11110"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38723"""^^xsd:string ; umls:cui """C3536945"""^^xsd:string ; umls:cui """C1832066"""^^xsd:string ; umls:cui """C3536946"""^^xsd:string ; umls:cui """C1135124"""^^xsd:string ; umls:cui """C0675593"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ketamine hydrochloride"""@eng ; skos:notation """CDR0000452041"""^^xsd:string ; skos:altLabel """Ketalar"""@eng ; skos:definition """The hydrochloride salt of a synthetic nonbarbiturate anesthetic derivative of cyclohexanone. Although its mechanism of action is not well understood, ketamine appears to block NMDA receptors (N-methyl-D-aspartate) and may interact with sigma receptors, thereby reducing pain perception and inducing sedation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452041&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452041&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29142\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C29142"""^^xsd:string ; """2005-10-14"""^^xsd:string ; umls:cui """C0700541"""^^xsd:string ; umls:cui """C0022613"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/docetaxel"""@eng ; skos:notation """CDR0000038493"""^^xsd:string ; skos:altLabel """MOAB VEGF/TXT"""@eng ; ; ; """11112"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134527"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NY-ESO-1 peptide vaccine"""@eng ; skos:notation """CDR0000038494"""^^xsd:string ; skos:altLabel """NY-ESO-1 peptide"""@eng , """ESO-1 Peptide Vaccine"""@eng ; skos:definition """A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38494&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38494&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2657\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """11113"""^^xsd:string ; """C2657"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134528"""^^xsd:string ; umls:cui """C0935757"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NY-ESO-1 peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000038495"""^^xsd:string ; skos:altLabel """GM-CSF/NY-ESO-1 peptide"""@eng ; ; ; """11114"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134529"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multivitamins/soy protein isolate"""@eng ; skos:notation """CDR0000038496"""^^xsd:string ; skos:altLabel """MULTIVIT/SOY"""@eng ; ; ; """11115"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134530"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 lipiodol"""@eng ; skos:notation """CDR0000038497"""^^xsd:string ; skos:altLabel """I 131 lipiodol"""@eng , """Lipiocis"""@eng ; skos:definition """A cytotoxic radioconjugate consisting of lipiodol, an iodinated ethyl ester derived from poppy seed oil, labeled with iodine 131 (I-131). I-131 Lipiodol accumulates in hepatocellular carcinoma and hepatoblastoma tumor cells, resulting in targeted cytotoxicity to tumor cells while sparing surrounding normal cells and tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38497&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38497&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2696\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """11116"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C2696"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1527224"""^^xsd:string ; umls:cui """C1512605"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ertumaxomab"""@eng ; skos:notation """CDR0000038498"""^^xsd:string ; skos:altLabel """CD3-HER2neu MOAB"""@eng , """MOAB anti-CD3 x anti-HER-2-neu"""@eng , """anti-CD3 x anti-HER-2-neu bispecific monoclonal antibody"""@eng ; skos:definition """A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth. Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38498&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38498&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2658\" NCI Thesaurus)"""@eng ; ; """C2658"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-28"""^^xsd:string ; """11117"""^^xsd:string ; umls:cui """C1723386"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CD3 x anti-HER-2-neu bispecific monoclonal antibody/autologous lymphocytes/interleukin-2/sargramostim"""@eng ; skos:notation """CDR0000038499"""^^xsd:string ; skos:altLabel """AL/CD3-HER2neu MOAB/GM-CSF/IL-2"""@eng ; ; ; ; ; """11118"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134532"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PV-10"""@eng ; skos:notation """CDR0000463937"""^^xsd:string ; skos:altLabel """Provecta"""@eng ; skos:definition """An injectable ten percent solution of rose bengal disodium, an iodinated fluorescein derivative, with potential antineoplastic and radiosensitizing activities. When injected into tumor tissue, PV-10 specifically targets and concentrates in tumor cells, producing cytotoxic singlet oxygen when exposed to ionizing radiation. In addition, PV-10 may stimulate an anti-tumor immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463937&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463937&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53412\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-06-30"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """C53412"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1709443"""^^xsd:string ; umls:cui """C1709444"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/prednisone/YM598"""@eng ; skos:notation """CDR0000270683"""^^xsd:string ; skos:altLabel """DHAD/PRED/YM-598"""@eng ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327869"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """YM598"""@eng ; skos:notation """CDR0000270682"""^^xsd:string ; skos:altLabel """YM-598"""@eng ; skos:definition """An orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=270682&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=270682&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26678\" NCI Thesaurus)"""@eng ; ; """2003-01-26"""^^xsd:string ; """2006-12-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26678"""^^xsd:string ; umls:cui """C1175067"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/docetaxel"""@eng ; skos:notation """CDR0000368454"""^^xsd:string ; skos:altLabel """MOAB C225/TXT"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-04-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541230"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/polyglutamate paclitaxel"""@eng ; skos:notation """CDR0000270688"""^^xsd:string ; skos:altLabel """CBDCA/CT-2103"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327870"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039420"""^^xsd:string ; skos:altLabel """ARA-C/MTX/VCR"""@eng , """CAMELEON"""@eng ; ; ; ; """2055"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279281"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """loxoribine"""@eng ; skos:notation """CDR0000041358"""^^xsd:string ; skos:altLabel """RWJ 21757"""@eng ; """4429"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0950788"""^^xsd:string ; umls:cui """C0209660"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dextran sulfate sodium"""@eng ; skos:notation """CDR0000038928"""^^xsd:string ; """1435"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0079225"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """secondary myelofibrosis"""@eng ; skos:notation """CDR0000514484"""^^xsd:string ; rdfs:subClassOf ; """2006-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-10-13"""^^xsd:string ; """chronic myeloproliferative disorders"""^^xsd:string ; umls:cui """C0242006"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """terephthalamidine"""@eng ; skos:notation """CDR0000041351"""^^xsd:string ; skos:altLabel """1,4-Benzenedicarboximidamide"""@eng ; skos:definition """A derivative of the phthalanilide compounds. Terephthalamidine belongs to a family of compounds which appear to reversibly bind to the minor groove of the DNA double helix but not intercalate DNA. This agent also has been suggested to form ionic complexes with many biological components in vitro, including nucleic acids, proteins and lipids. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41351&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41351&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1245\" NCI Thesaurus)"""@eng ; """4422"""^^xsd:string ; """57155"""^^xsd:string ; """15411-54-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """C1245"""^^xsd:string ; umls:cui """C0076116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine"""@eng ; skos:notation """CDR0000041350"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DOX/TG/VCR"""@eng ; ; ; ; ; ; ; ; """4421"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280922"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """renal failure"""@eng ; skos:notation """CDR0000529777"""^^xsd:string ; rdfs:subClassOf ; """2007-01-03"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C0035078"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/ZD6474"""@eng ; skos:notation """CDR0000271334"""^^xsd:string ; skos:altLabel """TXT/ZD-6474"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327880"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell embryonal carcinoma"""@eng ; skos:notation """CDR0000040489"""^^xsd:string ; skos:altLabel """embryonal carcinoma, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3377"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280122"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/erlotinib"""@eng ; skos:notation """CDR0000271336"""^^xsd:string ; skos:altLabel """MOAB VEGF/OSI774"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327881"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040480"""^^xsd:string ; skos:altLabel """lymphoma, stage II, adult non-Hodgkin's"""@eng , """stage II adult NHL"""@eng , """adult non-Hodgkin's lymphoma, stage II"""@eng , """non-Hodgkin's lymphoma, stage II adult"""@eng , """NHL, stage II adult"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3366"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280115"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040481"""^^xsd:string ; skos:altLabel """stage III adult NHL"""@eng , """adult non-Hodgkin's lymphoma, stage III"""@eng , """non-Hodgkin's lymphoma, stage III adult"""@eng , """lymphoma, stage III, adult non-Hodgkin's"""@eng , """NHL, stage III adult"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3367"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280116"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040482"""^^xsd:string ; skos:altLabel """lymphoma, metastatic, adult non-Hodgkin's"""@eng , """NHL, metastatic adult"""@eng , """metastatic adult non-Hodgkin's lymphoma"""@eng , """adult non-Hodgkin's lymphoma, metastatic"""@eng , """NHL, stage IV adult"""@eng , """adult non-Hodgkin's lymphoma, stage IV"""@eng , """lymphoma, stage IV, adult non-Hodgkin's"""@eng , """non-Hodgkin's lymphoma, stage IV adult"""@eng , """stage IV adult NHL"""@eng , """non-Hodgkin's lymphoma, metastatic adult"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3368"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280117"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """infection prophylaxis/management"""@eng ; skos:notation """CDR0000040483"""^^xsd:string ; skos:altLabel """management, infection prophylaxis"""@eng ; ; ; rdfs:subClassOf ; ; """3369"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280118"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uterine sarcoma"""@eng ; skos:notation """CDR0000040484"""^^xsd:string ; skos:altLabel """uterine corpus cancer, sarcoma"""@eng , """Uterine sarcoma"""@eng , """endometrial sarcoma"""@eng , """sarcoma of the uterus"""@eng , """uterine cancer, sarcoma"""@eng , """sarcoma, endometrial"""@eng , """uterus cancer, sarcoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3371"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C2959547"""^^xsd:string ; umls:cui """C0338113"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """supportive care/therapy"""@eng ; skos:notation """CDR0000040485"""^^xsd:string ; skos:altLabel """care/therapy, supportive"""@eng , """therapy, supportive"""@eng ; rdfs:subClassOf owl:Thing ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3372"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0344211"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040486"""^^xsd:string ; skos:altLabel """ovarian germ cell tumor cellular diagnosis"""@eng ; rdfs:subClassOf ; """3374"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280119"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell dysgerminoma"""@eng ; skos:notation """CDR0000040487"""^^xsd:string ; skos:altLabel """dysgerminoma, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3375"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346185"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Morinda citrifolia"""@eng ; skos:notation """CDR0000304320"""^^xsd:string ; skos:altLabel """Awl Tree"""@eng , """Indian mulberg"""@eng , """noni"""@eng , """Indian Mulberry"""@eng , """Great Morinda"""@eng , """noni fruit extract"""@eng , """Noni"""@eng ; skos:definition """A plant that yields various herbal preparations, including fruit juice (noni) and extracts from the root and leaf. Noni juice has antioxidant properties, and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304320&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304320&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26662\" NCI Thesaurus)"""@eng ; """2003-04-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """C26662"""^^xsd:string ; umls:cui """C1328724"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pomegranate juice"""@eng ; skos:notation """CDR0000304321"""^^xsd:string ; skos:definition """A natural juice isolated from the fruit of the plant Punica granatum with antioxidant, potential antineoplastic, and chemopreventive activities. Pomegranate juice contains flavonoids which promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thereby inhibiting angiogenesis. The flavanoids in pomegranate juice also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304321&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304321&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26665\" NCI Thesaurus)"""@eng ; """2003-04-23"""^^xsd:string ; """C26665"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327962"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alefacept"""@eng ; skos:notation """CDR0000531798"""^^xsd:string ; skos:altLabel """Amevive"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1170049"""^^xsd:string ; umls:cui """C0962603"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/oblimersen/rituximab"""@eng ; skos:notation """CDR0000373941"""^^xsd:string ; skos:altLabel """CBDCA/G3139/IFF/MOAB IDEC-C2B8/VP-16"""@eng ; ; ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541302"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/dexamethasone/gemcitabine"""@eng ; skos:notation """CDR0000341119"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/DM"""@eng ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328086"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """OTI-010"""@eng ; skos:notation """CDR0000361537"""^^xsd:string ; skos:altLabel """Stromagen"""@eng , """Autologous Expanded Mesenchymal Stem Cells"""@eng ; skos:definition """Multipotent self-renewing adherent non-hematopoietic stromal cells harvested from a patient's bone marrow and grown in vitro. When injected back into the patient, autologous expanded mesenchymal stem cells may differentiate into various mesenchyme-derived cell types and, in some instances, may augment bone marrow engraftment after whole-body irradiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361537&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361537&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2534\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """C2534"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; umls:cui """C1541584"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levonorgestrel-releasing intrauterine system"""@eng ; skos:notation """CDR0000459975"""^^xsd:string ; skos:altLabel """LNG-IUS"""@eng , """Mirena"""@eng ; skos:definition """A long-acting, hormone-releasing, intrauterine device consisting of a small, T-shaped, polyethylene frame and a reservoired synthetic progesterone with progestational and potential antineoplastic activities. After insertion of this system into the uterus, the device slowly and gradually releases the hormone. Levonorgestrel acts by binding to the progesterone receptor in the nuclei of target cells, resulting in transcription activation and an alteration in protein synthesis. Subsequently, luteinizing hormone (LH) activity and ovulation are suppressed. Levonorgestrel may also exhibit antiproliferative activity in endometrial tissue. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459975&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459975&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52193\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-23"""^^xsd:string ; """C52193"""^^xsd:string ; umls:cui """C0591811"""^^xsd:string ; umls:cui """C1708694"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T203"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/PEG-interferon alfa-2b"""@eng ; skos:notation """CDR0000285641"""^^xsd:string ; skos:altLabel """MOAB VEGF/PEG-IFNA2b"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327908"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ARRY-334543"""@eng ; skos:notation """CDR0000487532"""^^xsd:string ; """C62530"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """2006-09-18"""^^xsd:string ; umls:cui """C1831861"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zileuton"""@eng ; skos:notation """CDR0000285649"""^^xsd:string ; skos:altLabel """ZLT"""@eng , """Zyflo"""@eng , """N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea"""@eng , """(+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea"""@eng ; skos:definition """A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26667\" NCI Thesaurus)"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """111406-87-2"""^^xsd:string ; """C26667"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0081408"""^^xsd:string ; umls:cui """C0724508"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000038014"""^^xsd:string ; skos:altLabel """CTX/MTX/PEG/VCR"""@eng ; ; ; ; ; """10530"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879562"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/dexamethasone/methotrexate/vincristine"""@eng ; skos:notation """CDR0000038015"""^^xsd:string ; skos:altLabel """DM/DNR/MTX/VCR"""@eng ; ; ; ; ; """10531"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879563"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/SU5416"""@eng ; skos:notation """CDR0000038016"""^^xsd:string ; skos:altLabel """dFdC/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10532"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879564"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000038017"""^^xsd:string ; skos:altLabel """ARA-C/CF/DM/MTX"""@eng ; ; ; ; ; """10533"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879565"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/suramin"""@eng ; skos:notation """CDR0000322263"""^^xsd:string ; skos:altLabel """dFdC/SUR"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328023"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus RSV-TK"""@eng ; skos:notation """CDR0000037907"""^^xsd:string ; """10316"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879467"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000040919"""^^xsd:string ; skos:altLabel """CDDP/MTX/VBL"""@eng , """MCV"""@eng , """CMV"""@eng ; ; ; ; """3958"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0285131"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/pemetrexed disodium"""@eng ; skos:notation """CDR0000038011"""^^xsd:string ; skos:altLabel """dFdC/LY231514"""@eng ; ; ; """10526"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879558"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/ascorbic acid"""@eng ; skos:notation """CDR0000038012"""^^xsd:string ; skos:altLabel """AS2O3/VIT-C"""@eng ; ; ; """10527"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879559"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000037904"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/L-OHP"""@eng ; ; ; ; ; """10313"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879464"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SCH-58500"""@eng ; skos:notation """CDR0000042631"""^^xsd:string ; skos:altLabel """Recombinant Adenovirus-p53"""@eng , """Sch 58500"""@eng , """rAd/p53"""@eng , """SCH 58500"""@eng ; skos:definition """A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53. This viral vector delivers p53 into tumor cells in order to initiate p53-dependent apoptosis and p53-induced cell cycle arrest. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42631&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42631&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2423\" NCI Thesaurus)"""@eng ; ; ; """6353"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C2423"""^^xsd:string ; umls:cui """C0393035"""^^xsd:string ; umls:cui """C1514767"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """5-fluoropyrimidinone"""@eng ; skos:notation """CDR0000042630"""^^xsd:string ; skos:altLabel """5-fluoro-pyrimidinone"""@eng , """5-FP"""@eng ; """6352"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393034"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/hydrocortisone"""@eng ; skos:notation """CDR0000042633"""^^xsd:string ; skos:altLabel """EM/HC/TXT"""@eng ; ; ; ; """6362"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393037"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/VX-710"""@eng ; skos:notation """CDR0000042632"""^^xsd:string ; skos:altLabel """TAX/VX 710"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """6355"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393036"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cladribine/cytarabine"""@eng ; skos:notation """CDR0000042635"""^^xsd:string ; skos:altLabel """ARA-C/2-CdA"""@eng ; ; ; """6364"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393039"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/decitabine"""@eng ; skos:notation """CDR0000042634"""^^xsd:string ; skos:altLabel """BU/CTX/DAC"""@eng ; ; ; ; """6363"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393038"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """umbilical cord blood transplantation"""@eng ; skos:notation """CDR0000042637"""^^xsd:string ; skos:altLabel """UCB transplantation"""@eng , """cord blood transplantation"""@eng , """transplantation, umbilical cord blood"""@eng ; ; rdfs:subClassOf ; """6366"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0935850"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/mesna/mitomycin"""@eng ; skos:notation """CDR0000042636"""^^xsd:string ; skos:altLabel """MIMIC"""@eng , """CDDP/IFF/MSA/MITO"""@eng ; ; ; ; ; """6365"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393040"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isosulfan blue"""@eng ; skos:notation """CDR0000042639"""^^xsd:string ; skos:altLabel """Lymphazurin"""@eng , """N-[4-[4-(Diethylamino)phenyl] (2,5-disulfophenyl) Methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium Hydroxide"""@eng ; skos:definition """A synthetic visual lymphatic imaging agent. Injected into the periphery of the tumor site, isosulfan blue localizes to the lymphatic system and aids in the surgical identification of tumor sentinel nodes which stain blue. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42639&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42639&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1386\" NCI Thesaurus)"""@eng ; """6369"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """68238-36-8"""^^xsd:string ; """C1386"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0126378"""^^xsd:string ; umls:cui """C0063908"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/melphalan"""@eng ; skos:notation """CDR0000042638"""^^xsd:string ; skos:altLabel """ATG/L-PAM"""@eng ; ; ; """6367"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393042"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate/PEG-interferon alfa-2b"""@eng ; skos:notation """CDR0000445423"""^^xsd:string ; skos:altLabel """CDDP/DOX/MTX/PEG-IFNA2b"""@eng ; ; ; ; ; """2005-08-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; umls:cui """C1831714"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/ifosfamide/methotrexate"""@eng ; skos:notation """CDR0000445422"""^^xsd:string ; skos:altLabel """CDDP/DOX/IFF/MTX/VP-16"""@eng ; ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """2005-08-18"""^^xsd:string ; umls:cui """C1831713"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alendronate sodium/anastrozole"""@eng ; skos:notation """CDR0000445425"""^^xsd:string ; skos:altLabel """ANAS/MK-217"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-18"""^^xsd:string ; """2005-08-19"""^^xsd:string ; umls:cui """C1831715"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cetuximab/fluorouracil"""@eng ; skos:notation """CDR0000445426"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/MOAB C225"""@eng ; ; ; ; """2005-08-18"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831716"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MGMTP140K-encoding retroviral vector"""@eng ; skos:notation """CDR0000487503"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831857"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uterine leiomyosarcoma"""@eng ; skos:notation """CDR0000041018"""^^xsd:string ; skos:altLabel """leiomyosarcoma, uterine"""@eng ; rdfs:subClassOf ; """4058"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280631"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiandrogen therapy"""@eng ; skos:notation """CDR0000039742"""^^xsd:string ; skos:altLabel """therapy, antiandrogen"""@eng ; ; rdfs:subClassOf ; """2403"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/etoposide"""@eng ; skos:notation """CDR0000041367"""^^xsd:string ; skos:altLabel """CDDP/VP-16/WR-2721"""@eng ; ; ; ; """4438"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280936"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000042734"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6528"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677704"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal complications"""@eng ; skos:notation """CDR0000269149"""^^xsd:string ; rdfs:subClassOf ; """2002-11-24"""^^xsd:string ; """2002-11-20"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0161819"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/erlotinib"""@eng ; skos:notation """CDR0000407439"""^^xsd:string ; skos:altLabel """MOAB C225/OSI774"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541413"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/mitoxantrone"""@eng ; skos:notation """CDR0000042240"""^^xsd:string ; skos:altLabel """DHAD/FAMP"""@eng ; ; ; """5489"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281747"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/vinorelbine"""@eng ; skos:notation """CDR0000042241"""^^xsd:string ; skos:altLabel """IFF/VNB"""@eng ; ; ; """5490"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281748"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/L-leucovorin/methotrexate"""@eng ; skos:notation """CDR0000042242"""^^xsd:string ; skos:altLabel """5-FU/L-CF/MTX"""@eng ; ; ; ; """5492"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281749"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nicotine"""@eng ; skos:notation """CDR0000042243"""^^xsd:string ; skos:altLabel """NIC"""@eng , """beta-Pyridyl-alpha-N-methylpyrrolidine"""@eng , """1-Methyl-2-(3-pyridyl)pyrrolidine"""@eng , """(S)-3-(1-Methyl-2-pyrrolidinyl)pyridine"""@eng ; skos:definition """A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain. Nicotine's CNS-stimulating activities may be mediated through the release of several neurotransmitters, including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and ACTH. As a result, peripheral vasoconstriction, tachycardia, and elevated blood pressure may be observed with nicotine intake. This agent may also stimulate the chemoreceptor trigger zone, thereby inducing nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42243&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42243&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C691\" NCI Thesaurus)"""@eng ; ; """5493"""^^xsd:string ; """54-11-5"""^^xsd:string ; """5065"""^^xsd:string ; """C691"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0028040"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000042244"""^^xsd:string ; skos:altLabel """ARA-C/DNR/G-CSF/VP-16"""@eng ; ; ; ; ; """5494"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281750"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """samarium Sm 153 lexidronam pentasodium"""@eng ; skos:notation """CDR0000042245"""^^xsd:string ; skos:altLabel """Samarium-153 EDTMP"""@eng , """Samarium-153 Ethylenediaminetetramethylenephosphonic Acid"""@eng , """Samarium-153 Ethylenediaminetetramethylenephosphonate"""@eng , """Sm-153 EDTMP"""@eng , """Quadramet"""@eng , """153Sm-EDTMP"""@eng ; skos:definition """The pentasodium salt of samarium Sm 135 lexidronam, a therapeutic agent consisting of a medium energy beta- and gamma-emitting radioisotope, samarium Sm 135, and a teraphosphonate chelator, ethylenediaminetetramethylene phosphonic acid (EDTMP). The chelator moiety of samarium Sm 153 lexidronam associates with hydroxyapatite crystals concentrated in areas of bone turnover, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to osteoblastic bone metastases. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42245&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42245&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1220\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """5495"""^^xsd:string ; """C1220"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0701498"""^^xsd:string ; umls:cui """C0993551"""^^xsd:string ; umls:cui """C0772051"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/isotretinoin"""@eng ; skos:notation """CDR0000042246"""^^xsd:string ; skos:altLabel """13-CRA/IFN-A/IL-2"""@eng ; ; ; ; """5496"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338194"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/interleukin-2/isotretinoin"""@eng ; skos:notation """CDR0000042247"""^^xsd:string ; skos:altLabel """13-CRA/5-FU/IFN-A/IL-2"""@eng ; ; ; ; ; """5497"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338195"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cytarabine/melphalan"""@eng ; skos:notation """CDR0000042248"""^^xsd:string ; skos:altLabel """ARA-C/BU/L-PAM"""@eng ; ; ; ; """5498"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281754"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III uterine sarcoma"""@eng ; skos:notation """CDR0000041013"""^^xsd:string ; skos:altLabel """uterine sarcoma, stage III"""@eng ; rdfs:subClassOf ; """uterine sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4053"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280626"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pixantrone/rituximab"""@eng ; skos:notation """CDR0000306460"""^^xsd:string ; skos:altLabel """BBR 2778/MOAB IDEC-C2B8"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327982"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040227"""^^xsd:string ; skos:altLabel """Hodgkin's disease, stage II, childhood"""@eng , """stage II childhood Hodgkin's disease"""@eng , """stage II childhood HD"""@eng , """Hodgkin's lymphoma, stage II, childhood"""@eng , """HD, stage II, childhood"""@eng , """pediatric HD, stage II"""@eng , """HD, childhood, stage II"""@eng , """pediatric Hodgkin's disease, stage II"""@eng , """childhood Hodgkin's lymphoma, stage II"""@eng , """lymphoma, stage II childhood Hodgkin's"""@eng , """stage II pediatric Hodgkin's disease"""@eng , """childhood HD, stage II"""@eng , """stage II HD, childhood"""@eng , """stage II Hodgkin's disease, childhood"""@eng ; rdfs:subClassOf ; """2003-01-10"""^^xsd:string ; """childhood Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3042"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279914"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/dexamethasone/thalidomide"""@eng ; skos:notation """CDR0000437217"""^^xsd:string ; skos:altLabel """DM/PS-341/THAL"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-17"""^^xsd:string ; """2005-06-15"""^^xsd:string ; umls:cui """C1831652"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adrenalectomy"""@eng ; skos:notation """CDR0000038849"""^^xsd:string ; ; rdfs:subClassOf ; """134"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0001632"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium thiosulfate"""@eng ; skos:notation """CDR0000039602"""^^xsd:string ; skos:altLabel """Thiosulfuric Acid Disodium Salt"""@eng , """Cyanide Antidote Package"""@eng , """Sodium Thiosulphate"""@eng , """Sodothiol"""@eng , """STS"""@eng , """S-Hydril"""@eng , """Disodium Thiosulfate"""@eng , """Sodium Thiosulfate Pentahydrate"""@eng , """Sodium Hyposulfate"""@eng ; skos:definition """A water soluble salt and reducing agent that reacts with oxidizing agents. Although its exact mechanism of action is unknown, thiosulfate likely provides an exogenous source of sulfur, thereby hastening the detoxification of cyanide through the enzyme rhodanese (thiosulfate cyanide sulfurtransferase) which converts cyanide to the relatively nontoxic, excretable thiocyanate ion. In addition, this agent neutralizes the reactive alkylating species of nitrogen mustard, thereby decreasing skin toxicity related to nitrogen mustard extravasation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39602&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39602&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1230\" NCI Thesaurus)"""@eng ; ; ; ; ; """2257"""^^xsd:string ; """10102-17-7 (pentahydrate)"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """45624"""^^xsd:string ; """26045"""^^xsd:string ; """7772-98-7"""^^xsd:string ; """C1230"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1519405"""^^xsd:string ; umls:cui """C1519404"""^^xsd:string ; umls:cui """C0074774"""^^xsd:string ; umls:cui """C2350033"""^^xsd:string ; umls:cui """C1519403"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T203"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil"""@eng ; skos:notation """CDR0000043113"""^^xsd:string ; skos:altLabel """WR-139013"""@eng , """4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid"""@eng , """chlorbutinum"""@eng , """4-[bis(2-chloroethyl)amino]benzenebutanoic acid"""@eng , """Chlorbutin"""@eng , """p-(N, N-di-2-chloroethyl)aminophenyl butyric acid"""@eng , """Chlorobutine"""@eng , """N,N-di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid"""@eng , """Chlorobutin"""@eng , """gamma-(p-bis(2-chloroethyl)aminophenyl)butyric acid"""@eng , """Alti-chlorambucil"""@eng , """Amboclorin"""@eng , """benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (9CI)"""@eng , """butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)"""@eng , """Chloraminophen"""@eng , """Lympholysin"""@eng , """Linfolysin"""@eng , """para-N,N-di(b-chloroethyl)aminophenylbutyric acid"""@eng , """Linfolizin"""@eng , """Leukersan"""@eng , """p-N, N-di-(beta-chloroethyl)aminophenyl butyric acid"""@eng , """N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid"""@eng , """CHL"""@eng , """Leukeran"""@eng , """CLB"""@eng , """CB-1348"""@eng , """Ambochlorin"""@eng , """CB 1348"""@eng , """Chloraminophene"""@eng , """phenylbutyric acid nitrogen mustard"""@eng , """gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid"""@eng , """chloroambucil"""@eng , """Leukoran"""@eng , """CBL"""@eng , """Chlorambucilum"""@eng , """Elcoril"""@eng , """Chlorbutine"""@eng ; skos:definition """An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43113&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43113&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C362\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """751"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """3088"""^^xsd:string ; """C362"""^^xsd:string ; """3074"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """305-03-3"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0729025"""^^xsd:string ; umls:cui """C1522697"""^^xsd:string ; umls:cui """C1522700"""^^xsd:string ; umls:cui """C1516481"""^^xsd:string ; umls:cui """C1516482"""^^xsd:string ; umls:cui """C1516483"""^^xsd:string ; umls:cui """C0740092"""^^xsd:string ; umls:cui """C0699996"""^^xsd:string ; umls:cui """C0008163"""^^xsd:string ; umls:cui """C0729022"""^^xsd:string ; umls:cui """C1522699"""^^xsd:string ; umls:cui """C1522698"""^^xsd:string ; umls:cui """C0729024"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/melphalan"""@eng ; skos:notation """CDR0000043112"""^^xsd:string ; skos:altLabel """BCNU/L-PAM"""@eng ; ; ; """7509"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796301"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BRCA1"""@eng ; skos:notation """CDR0000043111"""^^xsd:string ; rdfs:subClassOf ; """7506"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0376571"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin HCl liposome/prednisone/vincristine"""@eng ; skos:notation """CDR0000043110"""^^xsd:string ; skos:altLabel """CTX/LipoDox/PRED/VCR"""@eng ; ; ; ; ; """7503"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678105"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/paclitaxel"""@eng ; skos:notation """CDR0000043117"""^^xsd:string ; skos:altLabel """dFdC/TAX"""@eng ; ; ; """7513"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796302"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rutin"""@eng ; skos:notation """CDR0000043116"""^^xsd:string ; """7512"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0035976"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """curcumin"""@eng ; skos:notation """CDR0000043115"""^^xsd:string ; skos:altLabel """C.I. Natural Yellow 3"""@eng , """Turmeric Yellow"""@eng , """C.I. 75300"""@eng , """(E,E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione"""@eng , """Diferuloylmethane"""@eng , """CU"""@eng ; skos:definition """A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as tumeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43115&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43115&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C401\" NCI Thesaurus)"""@eng ; ; """7511"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C401"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """32982"""^^xsd:string ; """458-37-7"""^^xsd:string ; umls:cui """C0010467"""^^xsd:string ; umls:cui """C2830077"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quercetin"""@eng ; skos:notation """CDR0000043114"""^^xsd:string ; """7510"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0034392"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HRAS1"""@eng ; skos:notation """CDR0000043119"""^^xsd:string ; rdfs:subClassOf ; """7515"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0079471"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """genetic mapping"""@eng ; skos:notation """CDR0000043118"""^^xsd:string ; rdfs:subClassOf ; """7514"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0008630"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZD2171/capecitabine"""@eng ; skos:notation """CDR0000425597"""^^xsd:string ; skos:altLabel """AZD-2171/CAPE"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541531"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZD2171"""@eng ; skos:notation """CDR0000425596"""^^xsd:string ; skos:altLabel """AZD-2171"""@eng ; skos:definition """An indole ether quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, AZD2171 binds to and inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425596&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425596&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48379\" NCI Thesaurus)"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2006-05-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48379"""^^xsd:string ; umls:cui """C1541530"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZD2171/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000425598"""^^xsd:string ; skos:altLabel """AZD-2171/CBDCA/TAX"""@eng ; ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541532"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/mitoxantrone/tamoxifen"""@eng ; skos:notation """CDR0000040150"""^^xsd:string ; skos:altLabel """CDDP/DHAD/TMX/VP-16"""@eng , """TEMP"""@eng ; ; ; ; ; """2917"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279848"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """letrozole/zoledronate"""@eng ; skos:notation """CDR0000415928"""^^xsd:string ; skos:altLabel """LTZ/ZOLE"""@eng ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541490"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """optical coherence tomography"""@eng ; skos:notation """CDR0000504136"""^^xsd:string ; rdfs:subClassOf ; """2006-08-18"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-08-16"""^^xsd:string ; umls:cui """C0920367"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium butyrate"""@eng ; skos:notation """CDR0000039601"""^^xsd:string ; """2256"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0142812"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/GTI-2040"""@eng ; skos:notation """CDR0000301639"""^^xsd:string ; skos:altLabel """CAPE/GTI2040"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-03-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327950"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mercaptopurine/methotrexate/prednisone/vinblastine"""@eng ; skos:notation """CDR0000301638"""^^xsd:string ; skos:altLabel """DOX/MP/MTX/PRED/VBL"""@eng ; ; ; ; ; ; """2003-04-23"""^^xsd:string ; """2003-03-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327949"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GTI-2040"""@eng ; skos:notation """CDR0000301635"""^^xsd:string ; skos:altLabel """GTI2040"""@eng ; skos:definition """A 20-mer antisense oligonucleotide complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase. GTI-2040 decreases mRNA and protein levels of R2 in vitro and may inhibit tumor cell proliferation in human tumors in vivo. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301635&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301635&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26652\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """2003-04-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26652"""^^xsd:string ; """2006-08-25"""^^xsd:string ; """67368"""^^xsd:string ; """236391-66-5"""^^xsd:string ; umls:cui """C1142995"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ofatumumab"""@eng ; skos:notation """CDR0000530015"""^^xsd:string ; skos:altLabel """HuMax-CD20"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-08"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C1832027"""^^xsd:string ; umls:cui """C1541395"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine"""@eng ; skos:notation """CDR0000440127"""^^xsd:string ; skos:definition """An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=440127&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=440127&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48418\" NCI Thesaurus)"""@eng ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48418"""^^xsd:string ; """2005-07-15"""^^xsd:string ; umls:cui """C1711127"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/interleukin-2"""@eng ; skos:notation """CDR0000440126"""^^xsd:string ; skos:altLabel """IL-2/rhuMAb VEGF"""@eng ; ; ; """2005-07-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-11"""^^xsd:string ; umls:cui """C1831676"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/suberoylanilide hydroxamic acid"""@eng ; skos:notation """CDR0000440125"""^^xsd:string ; skos:altLabel """CAPE/SAHA"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-15"""^^xsd:string ; """2005-07-11"""^^xsd:string ; umls:cui """C1831675"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/gemcitabine/sorafenib"""@eng ; skos:notation """CDR0000440124"""^^xsd:string ; skos:altLabel """CAPE/dFdC/SFN"""@eng ; ; ; ; """2005-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-11"""^^xsd:string ; umls:cui """C1831674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/pamidronate"""@eng ; skos:notation """CDR0000440123"""^^xsd:string ; skos:altLabel """APD/AS2O3"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-11"""^^xsd:string ; """2005-07-23"""^^xsd:string ; umls:cui """C1831673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """healing touch"""@eng ; skos:notation """CDR0000470290"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-02-23"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0152054"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """simvastatin"""@eng ; skos:notation """CDR0000455226"""^^xsd:string ; skos:altLabel """Zocor"""@eng ; skos:definition """A lipid-lowering agent derived synthetically from a fermentation product of the fungus Aspergillus terreus. Hydrolyzed in vivo to an active metabolite, simvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=455226&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=455226&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29454\" NCI Thesaurus)"""@eng ; """2005-11-10"""^^xsd:string ; """C29454"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-18"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0678181"""^^xsd:string ; umls:cui """C0074554"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cefpodoxime proxetil"""@eng ; skos:notation """CDR0000455227"""^^xsd:string ; skos:altLabel """Vantin"""@eng , """cefpodoxime"""@eng ; skos:definition """A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=455227&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=455227&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28916\" NCI Thesaurus)"""@eng ; """C28916"""^^xsd:string ; """2005-11-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0055011"""^^xsd:string ; umls:cui """C0108938"""^^xsd:string ; umls:cui """C0724204"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-TRICOM vaccine/sargramostim/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000038687"""^^xsd:string ; skos:altLabel """fCEA-TRI/GM-CSF/vCEA-TRI"""@eng ; ; ; ; """11342"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134693"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-TRICOM vaccine/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000038686"""^^xsd:string ; skos:altLabel """fCEA-TRI/vCEA-TRI"""@eng ; ; ; """11341"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134692"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-TRICOM vaccine/sargramostim"""@eng ; skos:notation """CDR0000038681"""^^xsd:string ; skos:altLabel """fCEA-TRI/GM-CSF"""@eng ; ; ; """11335"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134687"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant fowlpox GM-CSF vaccine"""@eng ; skos:notation """CDR0000038680"""^^xsd:string ; skos:altLabel """Fowlpox-Sargramostim"""@eng , """Fowlpox-Sargramostim Vaccine"""@eng , """rF-GM-CSF"""@eng , """GM-CSF - Fowlpox"""@eng , """fowlpox-GM-CSF"""@eng ; skos:definition """A cancer vaccine consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of fowlpox-sargramostim may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38680&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38680&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2686\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """11334"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """707299"""^^xsd:string ; """C2686"""^^xsd:string ; umls:cui """C1134686"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ad5CMV-p53 gene/cisplatin/fluorouracil"""@eng ; skos:notation """CDR0000038683"""^^xsd:string ; skos:altLabel """Ad5CMV-p53/CDDP/5-FU"""@eng ; ; ; ; """11337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134689"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-TRICOM vaccine/recombinant fowlpox GM-CSF vaccine"""@eng ; skos:notation """CDR0000038682"""^^xsd:string ; skos:altLabel """fCEA-TRI/rF-GM-CSF"""@eng ; ; ; """2003-10-07"""^^xsd:string ; """11336"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134688"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III and IV childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000038689"""^^xsd:string ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """11344"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1134695"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III and IV childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000038688"""^^xsd:string ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """11343"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1134694"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone/methotrexate"""@eng ; skos:notation """CDR0000042408"""^^xsd:string ; skos:altLabel """HC/MTX"""@eng ; ; ; """5664"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338315"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/epirubicin/vincristine"""@eng ; skos:notation """CDR0000042409"""^^xsd:string ; skos:altLabel """ASP/DM/EPI/VCR"""@eng ; ; ; ; ; """5665"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338316"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """motexafin lutetium"""@eng ; skos:notation """CDR0000042402"""^^xsd:string ; skos:altLabel """Antrin"""@eng , """PCI-0123"""@eng , """Lutetium Texaphrin"""@eng , """Lu-Tex"""@eng , """lutetium texaphyrin"""@eng , """Lutrin"""@eng , """Lutex"""@eng ; skos:definition """A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42402&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42402&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1651\" NCI Thesaurus)"""@eng ; """5658"""^^xsd:string ; """58536"""^^xsd:string ; """695239"""^^xsd:string ; """246252-04-0"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """C1651"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C3536944"""^^xsd:string ; umls:cui """C1527060"""^^xsd:string ; umls:cui """C0338310"""^^xsd:string ; umls:cui """C1174770"""^^xsd:string ; umls:cui """C0950969"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nolatrexed dihydrochloride/cisplatin"""@eng ; skos:notation """CDR0000042403"""^^xsd:string ; skos:altLabel """AG337/CDDP"""@eng ; ; ; """5659"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338311"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000042400"""^^xsd:string ; skos:altLabel """MP/VCR"""@eng ; ; ; """5655"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338308"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/strontium chloride Sr 89/vinblastine"""@eng ; skos:notation """CDR0000042401"""^^xsd:string ; skos:altLabel """EM/strontium chloride Sr 89/VBL"""@eng ; ; ; ; """5656"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338309"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/daunorubicin/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000042406"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/DNR/VCR"""@eng ; ; ; ; ; ; """5662"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338313"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/methylprednisolone"""@eng ; skos:notation """CDR0000042407"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MePRDL"""@eng ; ; ; ; """5663"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338314"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """boronophenylalanine-fructose complex"""@eng ; skos:notation """CDR0000042404"""^^xsd:string ; skos:altLabel """p-Boronophenylalanine-Fructose Complex"""@eng , """BPA-F"""@eng ; skos:definition """A boronated phenylalanine complexed with fructose to increase its solubility. When exposed to neutron irradiation, boronophenylalanine absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42404&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42404&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2405\" NCI Thesaurus)"""@eng ; ; """5660"""^^xsd:string ; """C2405"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0289335"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenobarbital"""@eng ; skos:notation """CDR0000042405"""^^xsd:string ; skos:altLabel """PHENO"""@eng , """5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione"""@eng ; skos:definition """A long-acting barbituric acid derivative with antipsychotic property. Phenobarbital binds to and activates the gamma-aminobutyric acid (GABA)-A receptor, thereby mimicking the inhibitory actions of GABA in the brain. The activation effects of the phenobarbital-receptor-ionophore complex include increased frequency of chloride channel openings, membrane hyperpolarization and ultimately synaptic inhibition and decreased neuronal excitability. In addition, this agent inhibits glutamate induced depolarization. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42405&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42405&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C739\" NCI Thesaurus)"""@eng ; ; """5661"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """128143"""^^xsd:string ; """9848"""^^xsd:string ; """50-06-6"""^^xsd:string ; """C739"""^^xsd:string ; umls:cui """C0031412"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/tipifarnib"""@eng ; skos:notation """CDR0000258362"""^^xsd:string ; skos:altLabel """CTX/DOX/R115777"""@eng ; ; ; ; """2002-10-10"""^^xsd:string ; """11507"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327808"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estradiol/zoledronate"""@eng ; skos:notation """CDR0000258367"""^^xsd:string ; skos:altLabel """ESDL/ZOLE"""@eng ; ; ; """2002-10-11"""^^xsd:string ; """11508"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327809"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody GD2 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000257174"""^^xsd:string ; skos:definition """A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity. Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC). GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257174&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257174&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26450\" NCI Thesaurus)"""@eng ; ; ; """11411"""^^xsd:string ; """C26450"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-20"""^^xsd:string ; umls:cui """C1328690"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/monoclonal antibody 11D10 anti-idiotype vaccine/monoclonal antibody GD2 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000257173"""^^xsd:string ; skos:altLabel """CDDP/MOAB 11D10 VAC/MOAB GD2 VAC/VP-16"""@eng ; ; ; ; ; """2002-08-10"""^^xsd:string ; """11412"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327759"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/imatinib mesylate/irinotecan"""@eng ; skos:notation """CDR0000257171"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/STI571"""@eng ; ; ; ; """2002-08-10"""^^xsd:string ; """11410"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327758"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antifungal agent"""@eng ; skos:notation """CDR0000039794"""^^xsd:string ; rdfs:subClassOf ; """2454"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003308"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiviral agent"""@eng ; skos:notation """CDR0000039795"""^^xsd:string ; rdfs:subClassOf ; """2455"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003451"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiparasitic"""@eng ; skos:notation """CDR0000039796"""^^xsd:string ; rdfs:subClassOf ; """2456"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003404"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, laryngeal cancer"""@eng ; skos:notation """CDR0000039797"""^^xsd:string ; skos:altLabel """laryngeal cancer stage"""@eng , """larynx cancer stage"""@eng ; rdfs:subClassOf ; """2457"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279520"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biostim/melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000039790"""^^xsd:string ; skos:altLabel """Biostim/L-PAM/PRED/VCR"""@eng ; ; ; ; ; """2450"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279518"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """conjugated estrogens/cyclophosphamide/doxorubicin/fluorouracil/methotrexate/tamoxifen"""@eng ; skos:notation """CDR0000039791"""^^xsd:string ; skos:altLabel """CAMFTP"""@eng , """CTX/DOX/EST/5-FU/MTX/TMX"""@eng ; ; ; ; ; ; ; """2451"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279519"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nitrogen mustard"""@eng ; skos:notation """CDR0000039792"""^^xsd:string ; rdfs:subClassOf ; """2452"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0025033"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone marrow transplantation"""@eng ; skos:notation """CDR0000039793"""^^xsd:string ; skos:altLabel """BMT"""@eng , """transplantation, bone marrow"""@eng ; ; ; ; ; ; rdfs:subClassOf ; """2453"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0005961"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """kidney/urinary cancer"""@eng ; skos:notation """CDR0000039798"""^^xsd:string ; rdfs:subClassOf ; """2464"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279521"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unclassified/other cancer"""@eng ; skos:notation """CDR0000039799"""^^xsd:string ; rdfs:subClassOf ; """2465"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279522"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extraosseous Ewing's sarcoma/primitive neuroectodermal tumor"""@eng ; skos:notation """CDR0000040299"""^^xsd:string ; skos:altLabel """primitive peripheral neuroectodermal tumor"""@eng , """primitive neuroectodermal tumor"""@eng , """sarcoma, extraosseous Ewing's"""@eng , """peripheral neuroectodermal tumor"""@eng , """pPNET"""@eng , """PNET"""@eng , """peripheral primitive neuroectodermal tumor"""@eng ; rdfs:subClassOf ; """3138"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0684337"""^^xsd:string ; umls:cui """C0206663"""^^xsd:string ; umls:cui """C0279980"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, childhood soft tissue sarcoma"""@eng ; skos:notation """CDR0000040298"""^^xsd:string ; skos:altLabel """childhood soft tissue sarcoma, cellular diagnosis"""@eng ; rdfs:subClassOf ; """3137"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279979"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyanocobalamin"""@eng ; skos:notation """CDR0000040295"""^^xsd:string ; skos:altLabel """vitamin B12"""@eng ; """3134"""^^xsd:string ; """2007-01-15"""^^xsd:string ; """C64333"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0042845"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """porfimer sodium"""@eng ; skos:notation """CDR0000040294"""^^xsd:string ; skos:altLabel """DHE"""@eng , """Dihematoporphyrin Ester"""@eng , """Photofrin"""@eng , """dihematoporphyrin ether"""@eng , """CL-184116"""@eng , """Photofrin II"""@eng , """photofrin"""@eng , """Porfimer"""@eng ; skos:definition """A synthetic derivative of hematoporphyrin with photodynamic properties. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by laser light, resulting in cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40294&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40294&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1071\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """3133"""^^xsd:string ; """87806-31-3"""^^xsd:string ; """27637"""^^xsd:string ; """C1071"""^^xsd:string ; """603062"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0729236"""^^xsd:string ; umls:cui """C0729237"""^^xsd:string ; umls:cui """C1130428"""^^xsd:string ; umls:cui """C1521988"""^^xsd:string ; umls:cui """C0058031"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/vinblastine"""@eng ; skos:notation """CDR0000040297"""^^xsd:string ; skos:altLabel """CDDP/5-FU/VBL"""@eng , """FVP"""@eng ; ; ; ; """3136"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279978"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/carboplatin/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000040296"""^^xsd:string ; skos:altLabel """CHAC-1"""@eng , """CBDCA/CTX/DOX/HMM"""@eng ; ; ; ; ; """3135"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279977"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040291"""^^xsd:string ; skos:altLabel """ovarian germ cell tumor, stage IV"""@eng , """metastatic ovarian germ cell tumor"""@eng , """germ cell tumor, ovarian, metastatic"""@eng , """ovarian germ cell tumor, metastatic"""@eng , """germ cell tumor, ovarian, stage IV"""@eng ; rdfs:subClassOf ; """ovarian germ cell tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3129"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279974"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040290"""^^xsd:string ; skos:altLabel """germ cell tumor, ovarian, stage III"""@eng , """ovarian germ cell tumor, stage III"""@eng ; rdfs:subClassOf ; """ovarian germ cell tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3128"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279973"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylene dimethane sulfonate"""@eng ; skos:notation """CDR0000040293"""^^xsd:string ; skos:altLabel """MDMS"""@eng ; skos:definition """A member of the homologous series of dimethane sulphonic acid esters with alkylating properties. Methylene dimethane sulfonate alkylates DNA, resulting in interstrand DNA crosslinking, inhibition of DNA replication, disruption of the cell cycle, and cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40293&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40293&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1162\" NCI Thesaurus)"""@eng ; """3132"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1162"""^^xsd:string ; """2006-08-29"""^^xsd:string ; umls:cui """C0066350"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040292"""^^xsd:string ; skos:altLabel """ovarian germ cell tumor, recurrent"""@eng , """germ cell tumor, ovarian, recurrent"""@eng ; rdfs:subClassOf ; """ovarian germ cell tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3130"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279975"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """proton pump inhibitor therapy"""@eng ; skos:notation """CDR0000367244"""^^xsd:string ; """2004-04-23"""^^xsd:string ; """2004-04-16"""^^xsd:string ; """Intervention/procedure"""^^xsd:string ; umls:cui """C1541225"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """esomeprazole magnesium"""@eng ; skos:notation """CDR0000367246"""^^xsd:string ; skos:altLabel """Nexium"""@eng ; """2006-11-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2004-04-23"""^^xsd:string ; """C29032"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0937622"""^^xsd:string ; umls:cui """C0939400"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine"""@eng ; skos:notation """CDR0000039242"""^^xsd:string ; skos:altLabel """floxuridin"""@eng , """FdUrD"""@eng , """FUdR"""@eng , """5-fluorodeoxyuridine"""@eng , """5-Fluorouridine Deoxyribose"""@eng , """5FUDR"""@eng , """5-fluoro-2'-deoxyuridine"""@eng , """5-FUDR"""@eng , """Fluorouridine Deoxyribose"""@eng , """fluorodeoxyuridine"""@eng , """2-Deoxy-5-fluorouridine"""@eng , """5-Fluoro-2'-deoxy-beta-uridine"""@eng , """FUDF"""@eng , """FDUR"""@eng , """5-fluorouracil deoxyriboside"""@eng , """WR-138720"""@eng , """2'-deoxy-5-fluorouridine"""@eng , """1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil"""@eng , """fluoruridine deoxyribose"""@eng ; skos:definition """A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthetase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39242&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39242&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C504\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1864"""^^xsd:string ; """C504"""^^xsd:string ; """50-91-9"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """27640"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """947"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522361"""^^xsd:string ; umls:cui """C3495433"""^^xsd:string ; umls:cui """C0016343"""^^xsd:string ; umls:cui """C1517215"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludrocortisone acetate"""@eng ; skos:notation """CDR0000039243"""^^xsd:string ; skos:altLabel """fludrocortisone"""@eng , """Florinef Acetate"""@eng , """Florinef"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-29"""^^xsd:string ; """C1103"""^^xsd:string ; """1865"""^^xsd:string ; umls:cui """C0016280"""^^xsd:string ; umls:cui """C0616274"""^^xsd:string ; umls:cui """C0060486"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood brain tumor"""@eng ; skos:notation """CDR0000041539"""^^xsd:string ; skos:altLabel """brain tumor, childhood"""@eng , """pediatric brain tumor"""@eng , """childhood CNS tumor"""@eng , """central nervous system tumor, pediatric"""@eng , """CNS tumor, childhood"""@eng , """Brain tumor, child: General & other"""@eng , """CNS tumor, pediatric"""@eng , """central nervous system tumor, childhood"""@eng , """brain tumor, pediatric"""@eng , """pediatric CNS tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """47"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1377665"""^^xsd:string ; umls:cui """C0220603"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fentanyl citrate"""@eng ; skos:notation """CDR0000039241"""^^xsd:string ; skos:altLabel """Actiq"""@eng , """Sublimaze"""@eng , """Oralet"""@eng ; skos:definition """The citrate salt form of fentanyl, a synthetic opioid related to the phenylpiperidines with analgesic and anesthetic properties. Fentanyl exerts its analgesic effect by selectively binding to the mu-opioid receptor in the central nervous system (CNS), thereby mimicking the effects of endogenous opiates. Additional pharmacological effects of fentanyl include anxiolysis, euphoria, feelings of relaxation, respiratory depression, constipation, miosis, and cough suppression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39241&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39241&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47994\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """1863"""^^xsd:string ; """C47994"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-04-11"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517157"""^^xsd:string ; umls:cui """C0546864"""^^xsd:string ; umls:cui """C0718245"""^^xsd:string ; umls:cui """C0015845"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Freund's complete adjuvant"""@eng ; skos:notation """CDR0000039246"""^^xsd:string ; skos:altLabel """FCA"""@eng , """adjuvant, Freund's complete"""@eng , """Freunds complete adjuvant"""@eng , """complete Freund's adjuvant"""@eng ; """1868"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0016712"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """furosemide"""@eng ; skos:notation """CDR0000039247"""^^xsd:string ; skos:altLabel """FRS"""@eng , """Lasix"""@eng , """SK-Furosemide"""@eng , """LB-502"""@eng ; skos:definition """An anthranilic derivative and loop diuretic with antihypertensive effect. Furosemide blocks the Na-K-Cl cotransporter (NKCC) in the luminal membrane of the thick ascending limb of the loop of Henle in the kidney, by binding to the Cl-binding site located in the cotransporter's transmembrane domain, thereby inhibiting reabsorption of sodium, chloride, potassium ions and water. This agent reduces plasma and extracellular fluid volume resulting in decreased blood pressure and cardiac output. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39247&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39247&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C515\" NCI Thesaurus)"""@eng ; """1869"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """54-31-9"""^^xsd:string ; """C515"""^^xsd:string ; """269420"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0016860"""^^xsd:string ; umls:cui """C0699992"""^^xsd:string ; umls:cui """C0700686"""^^xsd:string ; umls:cui """C1328667"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine phosphate"""@eng ; skos:notation """CDR0000039244"""^^xsd:string ; skos:altLabel """FAMP"""@eng , """9-Beta-D-arabinofuranosyl-2-fluoroadenine"""@eng , """2-Fluoro-Ara-AMP"""@eng , """9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine"""@eng , """Fludara"""@eng , """2-Fluoro-9-beta-arabinofuranosyladenine"""@eng , """2Fluoro-Ara-AMP"""@eng , """2-Fluorovidarabine"""@eng ; skos:definition """The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39244&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39244&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1094\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """C1094"""^^xsd:string ; """1866"""^^xsd:string ; """2006-05-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """21679-14-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0060483"""^^xsd:string ; umls:cui """C0700805"""^^xsd:string ; umls:cui """C0059985"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flurbiprofen"""@eng ; skos:notation """CDR0000039245"""^^xsd:string ; skos:altLabel """BTS 18,322"""@eng , """U-27,182"""@eng , """2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid"""@eng , """Ansaid"""@eng , """E-7869"""@eng , """MPC-7869"""@eng ; skos:definition """A derivative of propionic acid, and a phenylalkanoic acid derivative of non-steroidal antiinflammatory drugs (NSAIDs) with analgesic, antiinflammatory and antipyretic effects. Flurbiprofen non-selectively binds to and inhibits cyclooxygenase (COX). This results in a reduction of arachidonic acid conversion into prostaglandins that are involved in the regulation of pain, inflammation and fever. This NSAID also inhibits carbonic anhydrase, thereby reducing the production of hydrogen and bicarbonate ions. Upon ocular administration, flurbiprofen may reduce bicarbonate ion concentrations leading to a decrease in the production of aqueous humor, thereby lowering intraocular pressure. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39245&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39245&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C508\" NCI Thesaurus)"""@eng ; """1867"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5104-49-4"""^^xsd:string ; """C508"""^^xsd:string ; """685701"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700848"""^^xsd:string ; umls:cui """C0700849"""^^xsd:string ; umls:cui """C1527220"""^^xsd:string ; umls:cui """C1527219"""^^xsd:string ; umls:cui """C0700847"""^^xsd:string ; umls:cui """C0016377"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-1-beta/interleukin-2"""@eng ; skos:notation """CDR0000041533"""^^xsd:string ; skos:altLabel """IL-1B/IL-2"""@eng ; ; ; """4694"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281166"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/interleukin-3"""@eng ; skos:notation """CDR0000041532"""^^xsd:string ; skos:altLabel """CBDCA/IL-3/VP-16"""@eng ; ; ; ; """4693"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281165"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tegafur"""@eng ; skos:notation """CDR0000039248"""^^xsd:string ; skos:altLabel """Ftoral"""@eng , """Florafur"""@eng , """FT"""@eng , """Tefsiel"""@eng , """Utefos"""@eng , """Futraful"""@eng , """Fulfeel"""@eng , """Citofur"""@eng , """N1-(2'-Furanidyl)-5-fluorouracil"""@eng , """Ftoralon"""@eng , """Neberk"""@eng , """Sunfural"""@eng , """Furafluor"""@eng , """Lifril"""@eng , """5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione"""@eng , """Lamar"""@eng , """Fluorofur"""@eng , """Furofutran"""@eng , """FT-207"""@eng , """Fulaid"""@eng , """MJF-12264"""@eng , """ftorafur"""@eng , """Sinoflurol"""@eng , """5-Fluoro-1-(tetrahydro-2-furyl)-uracil"""@eng , """Fental"""@eng , """Coparogin"""@eng , """5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-(1H,3H)-pyrimidinedione"""@eng , """WR-220066"""@eng , """Exonal"""@eng , """Riol"""@eng , """Nitobanil"""@eng ; skos:definition """A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39248&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39248&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C513\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """1870"""^^xsd:string ; """10207"""^^xsd:string ; """C513"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """17902-23-7"""^^xsd:string ; """148958"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0919261"""^^xsd:string ; umls:cui """C1515238"""^^xsd:string ; umls:cui """C1515239"""^^xsd:string ; umls:cui """C0919259"""^^xsd:string ; umls:cui """C0919258"""^^xsd:string ; umls:cui """C1515250"""^^xsd:string ; umls:cui """C1515251"""^^xsd:string ; umls:cui """C1515252"""^^xsd:string ; umls:cui """C1515253"""^^xsd:string ; umls:cui """C1515254"""^^xsd:string ; umls:cui """C1515255"""^^xsd:string ; umls:cui """C1515256"""^^xsd:string ; umls:cui """C0919257"""^^xsd:string ; umls:cui """C0016778"""^^xsd:string ; umls:cui """C1527297"""^^xsd:string ; umls:cui """C1527296"""^^xsd:string ; umls:cui """C1515249"""^^xsd:string ; umls:cui """C1515248"""^^xsd:string ; umls:cui """C1515243"""^^xsd:string ; umls:cui """C1515242"""^^xsd:string ; umls:cui """C1515241"""^^xsd:string ; umls:cui """C1515240"""^^xsd:string ; umls:cui """C1515247"""^^xsd:string ; umls:cui """C1515246"""^^xsd:string ; umls:cui """C1515245"""^^xsd:string ; umls:cui """C1515244"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gallium nitrate"""@eng ; skos:notation """CDR0000039249"""^^xsd:string ; skos:altLabel """Ganite"""@eng , """GaN"""@eng , """WR-135675"""@eng ; skos:definition """A hydrated nitrate salt of the group IIIa element gallium with potential use in the treatment of malignancy-associated hypercalcemia. Gallium nitrate localizes preferentially to areas of bone resorption and remodeling and inhibits osteoclast-mediated resorption by enhancing hydroxyapatite crystallization and reduction of bone mineral solubility. This agent also increases calcium and phosphorous deposition into bone and may increase collagen synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39249&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39249&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1109\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1871"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1109"""^^xsd:string ; """13494-90-1"""^^xsd:string ; """10123"""^^xsd:string ; """2006-12-13"""^^xsd:string ; """15200"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0720570"""^^xsd:string ; umls:cui """C0061008"""^^xsd:string ; umls:cui """C1524019"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pulmonary complications"""@eng ; skos:notation """CDR0000041537"""^^xsd:string ; rdfs:subClassOf ; """4698"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0281169"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal stromal tumor"""@eng ; skos:notation """CDR0000038161"""^^xsd:string ; skos:altLabel """stromal tumor, gastrointestinal"""@eng , """GIST"""@eng , """Gastrointestinal stromal tumor (GIST)"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10740"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238198"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nortriptyline hydrochloride"""@eng ; skos:notation """CDR0000041535"""^^xsd:string ; skos:altLabel """NTPL"""@eng ; """4696"""^^xsd:string ; """2006-11-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C704"""^^xsd:string ; umls:cui """C0028420"""^^xsd:string ; umls:cui """C0700459"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/paclitaxel"""@eng ; skos:notation """CDR0000041534"""^^xsd:string ; skos:altLabel """CDDP/CTX/TAX"""@eng ; ; ; ; """4695"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281167"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040129"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus cancer, stage II"""@eng , """paranasal sinus and nasal cavity cancer, stage II"""@eng ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2894"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279829"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040128"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus cancer, stage I"""@eng , """paranasal sinus and nasal cavity cancer, stage I"""@eng ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2893"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279828"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unspecified investigational agent/drug"""@eng ; skos:notation """CDR0000350138"""^^xsd:string ; """2003-12-23"""^^xsd:string ; """2003-12-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328127"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040123"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PRED/VCR"""@eng , """DOAP"""@eng ; ; ; ; ; """2887"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0073540"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diltiazem hydrochloride"""@eng ; skos:notation """CDR0000040122"""^^xsd:string ; skos:altLabel """diltiazem HCl"""@eng , """Cardizem"""@eng ; skos:definition """A benzothiazepine calcium channel blocking agent. Diltiazem hydrochloride inhibits the transmembrane influx of extracellular calcium ions into select myocardial and vascular smooth muscle cells, causing dilatation of coronary and systemic arteries and decreasing myocardial contractility. Because of its vasodilatory activity, this agent has been shown to improve the microcirculation in some tumors, thereby potentially improving the delivery of antineoplastic agents to tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40122&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40122&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C398\" NCI Thesaurus)"""@eng ; """2886"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33286-22-5"""^^xsd:string ; """C398"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700940"""^^xsd:string ; umls:cui """C0700579"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zidovudine"""@eng ; skos:notation """CDR0000040121"""^^xsd:string ; skos:altLabel """3'-azido-3'-deoxythymidine"""@eng , """Retrovir"""@eng , """AZT"""@eng , """BW-A509U"""@eng , """ZDV"""@eng , """azidothymidine"""@eng , """Aztec"""@eng ; skos:definition """A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40121&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40121&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C947\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2885"""^^xsd:string ; """26635"""^^xsd:string ; """C947"""^^xsd:string ; """30858"""^^xsd:string ; """35782"""^^xsd:string ; """30516-87-1"""^^xsd:string ; """34545"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33134"""^^xsd:string ; """602670"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0043474"""^^xsd:string ; umls:cui """C0701305"""^^xsd:string ; umls:cui """C1524114"""^^xsd:string ; umls:cui """C0699576"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peripheral blood lymphocyte therapy"""@eng ; skos:notation """CDR0000040120"""^^xsd:string ; skos:altLabel """lymphocyte therapy, peripheral blood"""@eng , """therapy, peripheral blood lymphocyte"""@eng , """blood lymphocyte therapy, peripheral"""@eng ; ; rdfs:subClassOf ; """2882"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279823"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040127"""^^xsd:string ; skos:altLabel """Paranasal sinus and nasal cavity cancer"""@eng , """nasal cavity and paranasal sinus cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2892"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1710095"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/dexamethasone/doxorubicin/melphalan/vincristine"""@eng ; skos:notation """CDR0000040126"""^^xsd:string ; skos:altLabel """BCNU/DM/DOX/L-PAM/VCR"""@eng , """VBAMDex"""@eng ; ; ; ; ; ; """2890"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078138"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood cerebellar astrocytoma"""@eng ; skos:notation """CDR0000040125"""^^xsd:string ; skos:altLabel """CNS tumor, pediatric cerebellar astrocytoma"""@eng , """cerebellar astrocytoma, childhood"""@eng , """CNS tumor, childhood cerebellar astrocytoma"""@eng , """brain tumor, childhood cerebellar astrocytoma"""@eng , """grade I childhood cerebellar astrocytoma"""@eng , """central nervous system tumor, cerebellar astrocytoma, childhood"""@eng , """childhood CNS tumor, cerebellar astrocytoma"""@eng , """pediatric brain tumor, cerebellar astrocytoma"""@eng , """grade II childhood cerebellar astrocytoma"""@eng , """brain tumor, pediatric cerebellar astrocytoma"""@eng , """low grade childhood cerebellar astrocytoma"""@eng , """Brain tumor, child: Astrocytoma, cerebellar"""@eng , """pediatric CNS tumor, cerebellar astrocytoma"""@eng , """childhood brain tumor, cerebellar astrocytoma"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """289"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278594"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000040124"""^^xsd:string ; skos:altLabel """5-FU/MTX/VBL"""@eng , """MFV"""@eng ; ; ; ; """2888"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279825"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl inhalation solution"""@eng ; skos:notation """CDR0000377520"""^^xsd:string ; skos:altLabel """Resmycin™"""@eng , """DOX-HCl"""@eng , """Resmycin![TRADE MARK SIGN]!"""@eng ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541322"""^^xsd:string ; umls:cui """C1541154"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/doxorubicin HCl inhalation solution"""@eng ; skos:notation """CDR0000377521"""^^xsd:string ; skos:altLabel """CDDP/DOX-HCl/TXT"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541323"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pamidronate/thalidomide"""@eng ; skos:notation """CDR0000377522"""^^xsd:string ; skos:altLabel """APD/THAL"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541324"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thalidomide/zoledronate"""@eng ; skos:notation """CDR0000377523"""^^xsd:string ; skos:altLabel """THAL/ZOLE"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541325"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """5-fluoro-2-deoxycytidine"""@eng ; skos:notation """CDR0000509184"""^^xsd:string ; skos:altLabel """FdCyd"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-15"""^^xsd:string ; umls:cui """C0049174"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/vatalanib"""@eng ; skos:notation """CDR0000387811"""^^xsd:string ; skos:altLabel """PTK-787/STI571"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541466"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cessation of tobacco use"""@eng ; skos:notation """CDR0000038162"""^^xsd:string ; skos:altLabel """cigarette smoking cessation"""@eng , """prevention of tobacco use"""@eng , """cessation of cigarette smoking"""@eng , """prevention of cigarette smoking"""@eng , """cigarette smoking prevention"""@eng ; """2003-06-19"""^^xsd:string ; """10742"""^^xsd:string ; umls:cui """C0600549"""^^xsd:string ; umls:tui """T055"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RNA-loaded dendritic cell vaccine"""@eng ; skos:notation """CDR0000387814"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """2004-08-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541467"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enclomiphene citrate"""@eng ; skos:notation """CDR0000039307"""^^xsd:string ; skos:altLabel """enclomifene"""@eng , """trans Clomiphene"""@eng , """trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine"""@eng ; skos:definition """The trans-isomer of clomiphene citrate (CC). Enclomiphene has a higher rate of clearance and is less active than the cis-isomer, cis-clomiphene. Clomiphene citrate has been evaluated for antineoplastic activity against breast cancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39307&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39307&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61745\" NCI Thesaurus)"""@eng ; """1943"""^^xsd:string ; """2007-01-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61745"""^^xsd:string ; umls:cui """C0086213"""^^xsd:string ; umls:cui """C0086214"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute monoblastic and acute monocytic leukemia (M5)"""@eng ; skos:notation """CDR0000039306"""^^xsd:string ; skos:altLabel """M5 adult AMOL"""@eng , """acute monocytic leukemia, adult"""@eng , """AMOL, adult"""@eng , """M5 adult acute monocytic leukemia"""@eng , """adult AMOL"""@eng , """leukemia, adult acute monocytic"""@eng , """monocytic leukemia, adult acute"""@eng ; rdfs:subClassOf ; ; ; ; """2004-06-21"""^^xsd:string ; """1942"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279180"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III papillary thyroid cancer"""@eng ; skos:notation """CDR0000039305"""^^xsd:string ; skos:altLabel """papillary thyroid cancer, stage III"""@eng , """papillary adenocarcinoma of the thyroid, stage III"""@eng , """mixed adenocarcinoma of the thyroid, stage III"""@eng , """thyroid cancer, stage III papillary"""@eng , """adenocarcinoma, papillary, thyroid, stage III"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1939"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279179"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III follicular thyroid cancer"""@eng ; skos:notation """CDR0000039304"""^^xsd:string ; skos:altLabel """follicular thyroid cancer, stage III"""@eng , """carcinoma, follicular, thyroid, stage III"""@eng , """follicular carcinoma of the thyroid, stage III"""@eng , """thyroid cancer, stage III follicular"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1938"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279178"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/etoposide/ketoconazole/metronidazole/tamoxifen"""@eng ; skos:notation """CDR0000041458"""^^xsd:string ; skos:altLabel """DP/KCZ/METRO/TMX/VP-16"""@eng ; ; ; ; ; ; """4528"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281006"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/etoposide/ketoconazole/metronidazole/quinidine/tamoxifen"""@eng ; skos:notation """CDR0000041459"""^^xsd:string ; skos:altLabel """DP/KCZ/METRO/QND/TMX/VP-16"""@eng ; ; ; ; ; ; ; """4529"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281007"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thyroid extract"""@eng ; skos:notation """CDR0000039301"""^^xsd:string ; """1934"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C3163618"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thyroglobulin"""@eng ; skos:notation """CDR0000039300"""^^xsd:string ; """1933"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0040123"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovector encoding MDA7"""@eng ; skos:notation """CDR0000441241"""^^xsd:string ; skos:altLabel """INGN 241"""@eng , """adenovector encoding IL24"""@eng ; skos:definition """A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=441241&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=441241&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48368\" NCI Thesaurus)"""@eng ; """2005-08-05"""^^xsd:string ; """C48368"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-02"""^^xsd:string ; umls:cui """C1831693"""^^xsd:string ; umls:cui """C1706719"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/metronidazole"""@eng ; skos:notation """CDR0000041455"""^^xsd:string ; skos:altLabel """METRO/VP-16"""@eng ; ; ; """4525"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281003"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """picoplatin"""@eng ; skos:notation """CDR0000441243"""^^xsd:string ; skos:altLabel """AMD473"""@eng , """Cis-Amminedichloro (2-Methylpyridine) Platinum"""@eng , """NX 473"""@eng , """ZD0473"""@eng , """Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)"""@eng ; skos:definition """A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=441243&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=441243&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48416\" NCI Thesaurus)"""@eng ; """2006-09-08"""^^xsd:string ; """2005-08-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48416"""^^xsd:string ; umls:cui """C0671137"""^^xsd:string ; umls:cui """C0671132"""^^xsd:string ; umls:cui """C1527086"""^^xsd:string ; umls:cui """C1709537"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """homoharringtonine/imatinib mesylate"""@eng ; skos:notation """CDR0000441242"""^^xsd:string ; skos:altLabel """HH/STI571"""@eng ; ; ; """2005-08-05"""^^xsd:string ; """2005-07-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831694"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000041450"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/IFN-A"""@eng ; ; ; ; ; """4520"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338152"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa/filgrastim"""@eng ; skos:notation """CDR0000041451"""^^xsd:string ; skos:altLabel """EPO/G-CSF"""@eng ; ; ; """4521"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280999"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nafoxidine hydrochloride"""@eng ; skos:notation """CDR0000039309"""^^xsd:string ; skos:altLabel """U 11100A"""@eng ; skos:definition """The hydrochloride salt of the partial estrogen antagonist nafoxidine. Nafoxidine competes with endogenous estrogen for binding to specific estrogen receptors. This agent also inhibits angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF); paradoxically, it may enhance angiogenesis in uterine tissue. Nafoxidine also induces oxidative stress, protein kinase C and calcium signaling. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39309&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39309&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1448\" NCI Thesaurus)"""@eng ; """2007-01-22"""^^xsd:string ; """1945"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1847-63-8"""^^xsd:string ; """C1448"""^^xsd:string ; umls:cui """C1764832"""^^xsd:string ; umls:cui """C0205850"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diethylstilbestrol diphosphate"""@eng ; skos:notation """CDR0000039308"""^^xsd:string ; skos:altLabel """Stilphostrol"""@eng , """DESP"""@eng ; """1944"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0060692"""^^xsd:string ; umls:cui """C0728967"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NY-ESO-B"""@eng ; skos:notation """CDR0000257347"""^^xsd:string ; skos:definition """A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257347&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257347&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26680\" NCI Thesaurus)"""@eng ; ; ; ; ; """11446"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """C26680"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327762"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/LY293111"""@eng ; skos:notation """CDR0000355414"""^^xsd:string ; skos:altLabel """dFdC/LY-293111"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328184"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxaliplatin/tezacitabine"""@eng ; skos:notation """CDR0000355415"""^^xsd:string ; skos:altLabel """FMdC/L-OHP"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328185"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """escitalopram oxalate"""@eng ; skos:notation """CDR0000497135"""^^xsd:string ; skos:altLabel """5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-,(1S)-, ethanedioate(1:1)"""@eng , """Lexapro"""@eng , """Lu 26-054-0"""@eng ; skos:definition """The oxalate salt of escitalopram, a pure S-enantiomer of the racemic bicyclic phthalane derivative citalopram, with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), escitalopram blocks the reuptake of serotonin by neurons in the central nervous system (CNS), thereby potentiating CNS serotonergic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=497135&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=497135&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47518\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """219861-08-2"""^^xsd:string ; """C47518"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-25"""^^xsd:string ; umls:cui """C1170746"""^^xsd:string ; umls:cui """C1765323"""^^xsd:string ; umls:cui """C1170371"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/dexamethasone/vinblastine"""@eng ; skos:notation """CDR0000041988"""^^xsd:string ; skos:altLabel """CYSP/DM/VBL"""@eng ; ; ; ; """5213"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281532"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/cyclophosphamide/etoposide/paclitaxel"""@eng ; skos:notation """CDR0000041989"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/CTX/TAX/VP-16"""@eng ; ; ; ; ; ; """5214"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281533"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/filgrastim/topotecan"""@eng ; skos:notation """CDR0000041982"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/TOPO"""@eng ; ; ; ; """5207"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281528"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/ifosfamide/vinblastine"""@eng ; skos:notation """CDR0000041983"""^^xsd:string ; skos:altLabel """BLEO/CDDP/IFF/VBL/VP-16"""@eng ; ; ; ; ; ; """5208"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281529"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide/methotrexate/muramyl tripeptide phosphatidylethanolamine liposome"""@eng ; skos:notation """CDR0000041980"""^^xsd:string ; skos:altLabel """DOX/IFF/MTP-PE Liposome/MTX"""@eng ; ; ; ; ; """5205"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281526"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/interleukin-6/sargramostim"""@eng ; skos:notation """CDR0000041981"""^^xsd:string ; skos:altLabel """CBDCA/GM-CSF/IL-6"""@eng ; ; ; ; """5206"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281527"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/floxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000041986"""^^xsd:string ; skos:altLabel """CDDP/CF/DOX/FUDR"""@eng ; ; ; ; ; """5211"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281530"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dexamethasone/doxorubicin/floxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000041987"""^^xsd:string ; skos:altLabel """CDDP/CF/DM/DOX/FUDR"""@eng ; ; ; ; ; ; """5212"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281531"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplaston A10"""@eng ; skos:notation """CDR0000041984"""^^xsd:string ; skos:altLabel """3-phenylacetylamino-2, 6-piperidinedione"""@eng , """A10"""@eng ; skos:definition """A piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41984&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41984&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1004\" NCI Thesaurus)"""@eng ; ; ; """5209"""^^xsd:string ; """619130"""^^xsd:string ; """C1004"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """43013"""^^xsd:string ; """91531-30-5"""^^xsd:string ; umls:cui """C0052080"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplaston AS2-1"""@eng ; skos:notation """CDR0000041985"""^^xsd:string ; skos:altLabel """AS2-1"""@eng ; skos:definition """A 4:1 mixture of phenylacetate and phenylacetylgluatmine, degradation products of the antineoplaston agent A10. Antineoplaston AS2-1 inhibits the incorporation of L-glutamine into tumor-cell proteins, leading to cell cycle arrest in the G1 phase and inhibition of mitosis. This agent may also inhibit RAS oncogene expression and activate tumor suppressor gene p53, resulting in cell differentiation and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41985&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41985&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1613\" NCI Thesaurus)"""@eng ; ; """5210"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """104624-98-8"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """43013"""^^xsd:string ; """620261"""^^xsd:string ; """C1613"""^^xsd:string ; umls:cui """C0294295"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """herbal medicine / botanical therapy"""@eng ; skos:notation """CDR0000372899"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0242388"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biologically based therapies"""@eng ; skos:notation """CDR0000372898"""^^xsd:string ; ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1511149"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """manipulative and body-based interventions"""@eng ; skos:notation """CDR0000372893"""^^xsd:string ; skos:altLabel """muscuoloskeletal manipulations"""@eng , """manual healing medicine"""@eng ; ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1541278"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """distance healing"""@eng ; skos:notation """CDR0000372892"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C1541277"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spirituality"""@eng ; skos:notation """CDR0000372891"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1541646"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mind-body interventions"""@eng ; skos:notation """CDR0000372890"""^^xsd:string ; ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1513305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant fowlpox GM-CSF vaccine/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000385679"""^^xsd:string ; skos:altLabel """rF-GM-CSF/vCEA-TRI"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541353"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """motexafin gadolinium/temozolomide"""@eng ; skos:notation """CDR0000372896"""^^xsd:string ; skos:altLabel """PCI-0120/TMZ"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541280"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """massage therapy"""@eng ; skos:notation """CDR0000372895"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C3536731"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acupressure therapy"""@eng ; skos:notation """CDR0000372894"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0282614"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mycophenolate mofetil/sirolimus/tacrolimus"""@eng ; skos:notation """CDR0000415241"""^^xsd:string ; skos:altLabel """FK506/MMF/SLM"""@eng ; ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541480"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ZD 0473"""@eng ; skos:notation """CDR0000038300"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """10910"""^^xsd:string ; umls:cui """C0671137"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/ZD0473"""@eng ; skos:notation """CDR0000038301"""^^xsd:string ; skos:altLabel """LipoDox/ZD 0473"""@eng ; ; """10911"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-21"""^^xsd:string ; umls:cui """C0935849"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/flavopiridol"""@eng ; skos:notation """CDR0000038302"""^^xsd:string ; skos:altLabel """FLAVO/TXT"""@eng ; ; ; """10915"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935851"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/docetaxel/estramustine"""@eng ; skos:notation """CDR0000038303"""^^xsd:string ; skos:altLabel """EM/MOAB VEGF/TXT"""@eng ; ; ; ; """10916"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935852"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/trastuzumab"""@eng ; skos:notation """CDR0000038304"""^^xsd:string ; skos:altLabel """CDDP/dFdC/MOAB HER2"""@eng ; ; ; ; """10917"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935853"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/ondansetron"""@eng ; skos:notation """CDR0000038305"""^^xsd:string ; skos:altLabel """DM/GR38032F"""@eng ; ; ; """10918"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935854"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000038306"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DM/VCR"""@eng ; ; ; ; ; """10920"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935855"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ImmTher/indomethacin"""@eng ; skos:notation """CDR0000042188"""^^xsd:string ; skos:altLabel """INDO/MDPMOD"""@eng ; ; ; """5427"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281699"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CT-1501R/interleukin-2"""@eng ; skos:notation """CDR0000042187"""^^xsd:string ; skos:altLabel """CT-1501R/IL-2"""@eng ; ; """5426"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281698"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Detox-B adjuvant/keyhole limpet hemocyanin/Sialyl Tn antigen"""@eng ; skos:notation """CDR0000042186"""^^xsd:string ; skos:altLabel """DETOXB/KLH/STn antigen"""@eng ; ; ; ; """5425"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935656"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/leucovorin calcium/raltitrexed"""@eng ; skos:notation """CDR0000042185"""^^xsd:string ; skos:altLabel """CF/5-FU/ICI D1694/IFN-A"""@eng ; ; ; ; ; """5424"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338191"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/epoetin alfa/iron"""@eng ; skos:notation """CDR0000042184"""^^xsd:string ; skos:altLabel """CDDP/EPO/iron"""@eng ; ; ; ; """5423"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281695"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iron"""@eng ; skos:notation """CDR0000042183"""^^xsd:string ; skos:altLabel """Fe"""@eng , """Niferex"""@eng ; skos:definition """An element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42183&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42183&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C598\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """5422"""^^xsd:string ; """C598"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7439-89-6"""^^xsd:string ; umls:cui """C0302583"""^^xsd:string ; umls:cui """C0212019"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042182"""^^xsd:string ; skos:altLabel """CBDCA/CTX/G-CSF/TAX"""@eng ; ; ; ; ; """5421"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281694"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/paclitaxel"""@eng ; skos:notation """CDR0000042181"""^^xsd:string ; skos:altLabel """CBDCA/CTX/TAX"""@eng ; ; ; ; """5420"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281693"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2/monoclonal antibody OKT3"""@eng ; skos:notation """CDR0000042180"""^^xsd:string ; skos:altLabel """CTX/IL-2/MOAB OKT3"""@eng ; ; ; ; """5419"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338202"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin HCl liposome/paclitaxel"""@eng ; skos:notation """CDR0000269351"""^^xsd:string ; skos:altLabel """CDDP/LipoDox/TAX"""@eng ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327851"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L1 adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039871"""^^xsd:string ; skos:altLabel """L1 adult ALL"""@eng , """L1 acute lymphoblastic leukemia, adult"""@eng , """L1 adult acute lymphocytic leukemia"""@eng , """adult acute lymphoblastic leukemia, L1"""@eng , """adult acute lymphocytic leukemia, L1"""@eng , """L1 lymphocytic leukemia, acute adult"""@eng , """L1 acute lymphocytic leukemia, adult"""@eng , """ALL, L1 adult"""@eng , """adult ALL, L1"""@eng , """leukemia, adult acute lymphocytic , L1"""@eng , """acute lymphocytic leukemia, adult L1"""@eng , """acute lymphoblastic leukemia, adult L1"""@eng , """ALL, adult L1"""@eng , """L1 lymphoblastic leukemia, acute adult"""@eng ; rdfs:subClassOf ; """2552"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279589"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039870"""^^xsd:string ; skos:altLabel """leukemia, pediatric ALL non-T, non-B, cALLa positive, pre-B"""@eng , """non-T, non-B, cALLa positive, pre-B childhood ALL"""@eng , """childhood ALL, pre-B, non-T, non-B, cALLa positive"""@eng , """ALL, pediatric pre-B, non-T, non-B, cALLa positive"""@eng , """ALL, pre-B, non-T, non-B, cALLa positive childhood"""@eng , """ALL, pediatric pre-B, cALLa positive, non-T, non-B"""@eng , """cALLa positive, pre-B childhood acute lymphocytic leukemia, non-T, non-B"""@eng , """leukemia, childhood acute lymphocytic non-T, non-B, cALLa positive, pre-B"""@eng , """non-T, non-B, cALLa positive, pre-B childhood acute lymphocytic leukemia"""@eng , """acute lymphocytic leukemia, childhood non-T, non-B, cALLa positive, pre-B"""@eng , """acute lymphoblastic leukemia, childhood non-T, non-B, cALLa positive, pre-B"""@eng , """ALL, cALLA positive, pre-B, non-T, non-B, childhood"""@eng , """pre-B, cALLA positive, non-T, non-B, childhood ALL"""@eng , """pediatric ALL, pre-B, non-T, non-B, cALLa positive"""@eng , """non-B, non-T, cALLa positive, pre-B childhood acute lymphocytic leukemia"""@eng , """ALL, childhood pre-B, non-T, non-B, cALLa positive"""@eng , """leukemia, childhood ALL non-T, non-B, cALLa positive, pre-B"""@eng , """leukemia, pediatric acute lymphocytic non-T, non-B, cALLa positive, pre-B"""@eng , """non T, non B, cALLa positive, pre-B childhood acute lymphocytic leukemia"""@eng , """ALL, pre-B, cALLa positive, non-T, non-B childhood"""@eng , """ALL, childhood pre-B, cALLa positive, non-T, non-B"""@eng , """non B, non T, cALLa positive, pre-B childhood acute lymphocytic leukemia"""@eng ; rdfs:subClassOf ; """2551"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279588"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L3 adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039873"""^^xsd:string ; skos:altLabel """L3 adult acute lymphocytic leukemia"""@eng , """adult acute lymphoblastic leukemia, L3"""@eng , """L3 acute lymphoblastic leukemia, adult"""@eng , """L3 lymphoblastic leukemia, acute adult"""@eng , """L3 adult ALL"""@eng , """adult acute lymphocytic leukemia, L3"""@eng , """acute lymphocytic leukemia, adult L3"""@eng , """L3 acute lymphocytic leukemia, adult"""@eng , """leukemia, adult acute lymphocytic , L3"""@eng , """ALL, L3 adult"""@eng , """adult ALL, L3"""@eng , """L3 lymphocytic leukemia, acute adult"""@eng , """acute lymphoblastic leukemia, adult L3"""@eng , """ALL, adult L3"""@eng ; rdfs:subClassOf ; """2554"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279591"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L2 adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039872"""^^xsd:string ; skos:altLabel """L2 acute lymphocytic leukemia, adult"""@eng , """L2 acute lymphoblastic leukemia, adult"""@eng , """L2 adult acute lymphocytic leukemia"""@eng , """L2 lymphoblastic leukemia, acute adult"""@eng , """adult acute lymphoblastic leukemia, L2"""@eng , """adult acute lymphocytic leukemia, L2"""@eng , """L2 adult ALL"""@eng , """leukemia, adult acute lymphocytic , L2"""@eng , """adult ALL, L2"""@eng , """acute lymphocytic leukemia, adult L2"""@eng , """ALL, L2 adult"""@eng , """L2 lymphocytic leukemia, acute adult"""@eng , """acute lymphoblastic leukemia, adult L2"""@eng , """ALL, adult L2"""@eng ; rdfs:subClassOf ; """2553"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279590"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """B-cell adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039875"""^^xsd:string ; skos:altLabel """B-cell adult acute lymphocytic leukemia"""@eng , """leukemia, adult acute lymphocytic B-cell"""@eng , """acute lymphocytic leukemia, adult B-cell"""@eng , """B-cell acute lymphocytic leukemia, adult"""@eng , """adult ALL, B cell"""@eng , """adult acute lymphoblastic leukemia, B-cell"""@eng , """B-cell lymphocytic leukemia, acute adult"""@eng , """acute lymphoblastic leukemia, adult B-cell"""@eng , """B cell acute lymphocytic leukemia, adult"""@eng , """B cell lymphocytic leukemia, acute adult"""@eng , """B-cell adult ALL"""@eng , """ALL, adult B-cell"""@eng , """B-cell acute lymphoblastic leukemia, adult"""@eng , """B-cell lymphoblastic leukemia, acute adult"""@eng , """adult acute lymphocytic leukemia, B-cell"""@eng , """B cell adult acute lymphocytic leukemia, adult"""@eng , """adult ALL, B-cell"""@eng , """ALL, adult B cell"""@eng , """B cell adult ALL"""@eng ; rdfs:subClassOf ; """2556"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279593"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T-cell adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039874"""^^xsd:string ; skos:altLabel """T-cell adult acute lymphocytic leukemia"""@eng , """T-cell lymphoblastic leukemia, acute adult"""@eng , """T cell lymphocytic leukemia, acute adult"""@eng , """adult ALL, T-cell"""@eng , """acute lymphoblastic leukemia, adult T-cell"""@eng , """T-cell acute lymphoblastic leukemia, adult"""@eng , """adult acute lymphocytic leukemia, T-cell"""@eng , """T-cell lymphocytic leukemia, acute adult"""@eng , """acute lymphocytic leukemia, adult T-cell"""@eng , """adult ALL, T cell"""@eng , """adult acute lymphoblastic leukemia, T-cell"""@eng , """T-cell acute lymphocytic leukemia, adult"""@eng , """T cell acute lymphocytic leukemia, adult"""@eng , """ALL, adult T-cell"""@eng , """ALL, adult T cell"""@eng , """T cell adult acute lymphocytic leukemia"""@eng , """T cell adult ALL"""@eng , """T-cell adult ALL"""@eng , """leukemia, adult acute lymphocytic T-cell"""@eng ; rdfs:subClassOf ; """2555"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279592"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B, cALLa positive adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039877"""^^xsd:string ; skos:altLabel """adult ALL, non-T, non-B, cALLa positive"""@eng , """ALL, cALLa positive, non T, non B, adult"""@eng , """non-T, non-B, cALLa positive adult ALL"""@eng , """cALLa positive, non T, non B, adult ALL"""@eng , """ALL, adult non-T, non-B, cALLa positive"""@eng , """ALL, adult non T, non B, cALLa positive"""@eng , """leukemia, ALL non T, non B, cALLa positive, adult"""@eng , """non B, non T, cALLa positive adult acute lymphocytic leukemia"""@eng , """leukemia, cALLa positive, non-T, non-B, adult"""@eng , """non-B, non-T, cALLa positive adult ALL"""@eng , """ALL, non T, non B, cALLa positive, adult"""@eng , """acute lymphoblastic leukemia, adult non-T, non-B, cALLa positive"""@eng , """cALLa positive, non-T, non-B adult acute lymphocytic leukemia"""@eng , """non T, non B, cALLa positive adult acute lymphocytic leukemia"""@eng , """adult ALL, non T, non B, cALLa positive"""@eng , """cALLa positive, non-T, non-B, adult ALL"""@eng , """ALL, non-T, non-B, cALLa positive, adult"""@eng , """acute lymphocytic leukemia, adult non-T, non-B, cALLa positive"""@eng , """non T, non B, adult ALL, cALLa positive"""@eng , """non-T, non-B, cALLa positive adult acute lymphocytic leukemia"""@eng , """leukemia, adult acute lymphocytic non-T, non-B, cALLa positive"""@eng ; rdfs:subClassOf ; """2558"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279595"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039876"""^^xsd:string ; skos:altLabel """non-T, non-B lymphocytic leukemia, acute adult"""@eng , """non-T, non-B acute lymphocytic leukemia, adult"""@eng , """leukemia, adult ALL non-T, non-B"""@eng , """non-T, non-B lymphoblastic leukemia, acute adult"""@eng , """adult acute lymphoblastic leukemia, non-T, non-B"""@eng , """non T, non B acute lymphocytic leukemia, adult"""@eng , """non T, non B ALL, adult"""@eng , """adult ALL, non T, non B"""@eng , """non-T, non-B adult ALL"""@eng , """non T, non B adult acute lymphocytic leukemia"""@eng , """non-T, non-B adult acute lymphocytic leukemia"""@eng , """ALL, adult non T, non B"""@eng , """ALL, non T, non B, adult"""@eng , """adult ALL, non-T, non-B"""@eng , """non T, non B adult ALL"""@eng , """acute lymphoblastic leukemia, adult non-T, non-B"""@eng , """non-T, non-B ALL, adult"""@eng , """leukemia, adult acute lymphocytic non-T, non-B"""@eng , """acute lymphocytic leukemia, adult non-T, non-B"""@eng , """non T, non B lymphocytic leukemia, acute adult"""@eng , """ALL, adult non-T, non-B"""@eng , """non B, non T adult acute lymphocytic leukemia"""@eng , """ALL, non-T, non-B, adult"""@eng , """adult acute lymphocytic leukemia, non-T, non-B"""@eng , """non-B, non-T adult acute lymphocytic leukemia"""@eng ; rdfs:subClassOf ; """2557"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279594"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B, cALLa negative adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039879"""^^xsd:string ; skos:altLabel """cALLa negative, non-T, non-B, adult ALL"""@eng , """adult ALL, non-T, non-B, cALLa negative"""@eng , """leukemia, adult acute lymphocytic non-T, non-B, cALLa negative"""@eng , """non T, non B, adult ALL, cALLa negative"""@eng , """non-T, non-B, cALLa negative adult ALL"""@eng , """leukemia, cALLa negative, non-T, non-B, adult"""@eng , """acute lymphocytic leukemia, adult non-T, non-B, cALLa negative"""@eng , """non-B, non-T, cALLa negative adult ALL"""@eng , """non-T, non-B, cALLa negative adult acute lymphocytic leukemia"""@eng , """non B, non T, cALLa negative adult acute lymphocytic leukemia"""@eng , """non T, non B, cALLa negative adult acute lymphocytic leukemia"""@eng , """cALLa negative, non T, non B, adult ALL"""@eng , """ALL, adult non T, non B, cALLa negative"""@eng , """ALL, non T, non B, cALLa negative, adult"""@eng , """leukemia, ALL non-T, non-B, cALLa negative, adult"""@eng , """ALL, adult non-T, non-B, cALLa negative"""@eng , """ALL, non-T, non-B, cALLa negative, adult"""@eng , """acute lymphoblastic leukemia, adult non-T, non-B, cALLa negative"""@eng , """ALL, cALLa negative, non-T, non-B, adult"""@eng , """adult ALL, non T, non B, cALLa negative"""@eng ; rdfs:subClassOf ; """2560"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279597"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B, cALLa positive, pre-B adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039878"""^^xsd:string ; skos:altLabel """pre-B, cALLa positive, non-T, non-B, adult ALL"""@eng , """ALL, non-T, non-B, cALLa positive, pre-B adult"""@eng , """cALLa positive, pre-B adult ALL, non-T, non-B"""@eng , """ALL, adult pre-B, non T, non B, cALLa positive, adult"""@eng , """ALL, cALLa positive, pre-B, non T, non B, adult"""@eng , """leukemia, adult ALL, non-T, non-B, cALLa positive, pre-B"""@eng , """acute lymphocytic leukemia, adult non-T, non-B, cALLa positive, pre-B"""@eng , """non T, non B, cALLa positive, pre-B adult acute lymphocytic leukemia"""@eng , """non-T, non-B, cALLa positive, pre-B adult acute lymphocytic leukemia"""@eng , """non B, non T, cALLa positive, pre-B adult acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, adult non-T, non-B, cALLa positive, pre-B"""@eng , """leukemia, adult acute lymphocytic non-T, non-B, cALLa positive, pre-B"""@eng , """ALL, non T, non B, cALLa positive, pre-B adult"""@eng , """adult ALL, pre-B, non T, non B, cALLa positive"""@eng , """non-B, non-T, cALLa positive, pre-B adult acute lymphocytic leukemia"""@eng , """non-T, non-B, cALLa positive, pre-B adult ALL"""@eng , """ALL, pre-B, non T, non B, cALLa positive, adult"""@eng , """adult ALL, pre-B, non-T, non-B, cALLa positive"""@eng ; rdfs:subClassOf ; """2559"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279596"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mannan-binding lectin"""@eng ; skos:notation """CDR0000486303"""^^xsd:string ; skos:altLabel """MBL"""@eng ; """Drug/agent"""^^xsd:string ; """2006-05-19"""^^xsd:string ; umls:cui """C0065661"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """S-dimethylarsino-glutathione"""@eng ; skos:notation """CDR0000486305"""^^xsd:string ; skos:altLabel """ZIO-101"""@eng ; skos:definition """An organic arsenic compound composed of the antioxidant glutathione combined with dimethylarsenic with potential antitumor activity. S-dimethylarsino-glutathione targets the mitochondria where it exerts its cytotoxic effect by disrupting electron transport and inducing intracellular reactive oxygen species (ROS) leading to changes in mitochondrial membrane potential. This induces G2/M arrest and leads to caspase-dependent apoptosis. Compared to inorganic arsenic compounds, S-dimethylarsino-glutathione has a more favorable therapeutic index. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486305&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486305&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61490\" NCI Thesaurus)"""@eng ; """2006-10-11"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61490"""^^xsd:string ; umls:cui """C2713972"""^^xsd:string ; umls:cui """C1872686"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody m170"""@eng ; skos:notation """CDR0000038169"""^^xsd:string ; skos:definition """A panadenocarcinoma murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody m170 may be conjugated with a radioactive element and used in radioimmunotherapy (RIT), a procedure that uses a tumor-specific monoclonal antibody to target radiation to cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38169&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38169&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2610\" NCI Thesaurus)"""@eng ; """10749"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """C2610"""^^xsd:string ; umls:cui """C0935746"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody 3622W94"""@eng ; skos:notation """CDR0000042987"""^^xsd:string ; skos:altLabel """IL-2/MOAB 3622W94"""@eng ; ; ; """7239"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677998"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody 3622W94/sargramostim"""@eng ; skos:notation """CDR0000042986"""^^xsd:string ; skos:altLabel """GM-CSF/IL-2/MOAB 3622W94"""@eng ; ; ; ; """7238"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677997"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 3622W94"""@eng ; skos:notation """CDR0000042985"""^^xsd:string ; skos:altLabel """MOAB 3622W94"""@eng , """3622W94"""@eng ; ; ; """7237"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677996"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peptide 946-tetanus peptide conjugate melanoma vaccine/QS21"""@eng ; skos:notation """CDR0000042984"""^^xsd:string ; skos:altLabel """p946-Tet p/QS 21"""@eng ; ; ; """7236"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677995"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/peptide 946-tetanus peptide conjugate melanoma vaccine"""@eng ; skos:notation """CDR0000042983"""^^xsd:string ; skos:altLabel """IFA/p946-Tet p"""@eng ; ; ; """7235"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796299"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/peptide 946 melanoma vaccine/tetanus peptide melanoma vaccine"""@eng ; skos:notation """CDR0000042982"""^^xsd:string ; skos:altLabel """IFA/p946/Tet p"""@eng ; ; ; ; """7234"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796299"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peptide 946 melanoma vaccine/QS21/tetanus peptide melanoma vaccine"""@eng ; skos:notation """CDR0000042981"""^^xsd:string ; skos:altLabel """p946/QS 21/Tet p"""@eng ; ; ; ; """7233"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677992"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/peptide 946 melanoma vaccine"""@eng ; skos:notation """CDR0000042980"""^^xsd:string ; skos:altLabel """IFA/p946"""@eng ; ; ; """7232"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796297"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/irinotecan"""@eng ; skos:notation """CDR0000042989"""^^xsd:string ; skos:altLabel """CPT-11/WR-2721"""@eng ; ; ; """7241"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678000"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-CEA vaccine/sargramostim"""@eng ; skos:notation """CDR0000042988"""^^xsd:string ; skos:altLabel """ALVAC-CEA/GM-CSF"""@eng ; ; ; """7240"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677999"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """histone deacetylase inhbitor LBH589"""@eng ; skos:notation """CDR0000530790"""^^xsd:string ; skos:altLabel """LBH589"""@eng , """HDAC inhibitor LBH589"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C1566164"""^^xsd:string ; umls:cui """C1832038"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """depsipeptide PM02734"""@eng ; skos:notation """CDR0000530791"""^^xsd:string ; skos:altLabel """PM02734"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C1832040"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tibolone"""@eng ; skos:notation """CDR0000530794"""^^xsd:string ; skos:altLabel """Livial"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0076660"""^^xsd:string ; umls:cui """C0730772"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV lymphoepithelioma of the oropharynx"""@eng ; skos:notation """CDR0000040728"""^^xsd:string ; skos:altLabel """metastatic lymphoepithelioma of the oropharynx"""@eng , """oropharynx lymphoepithelioma, stage IV"""@eng , """lymphoepithelioma of the oropharynx, stage IV"""@eng , """oropharyngeal lymphoepithelioma, stage IV"""@eng , """lymphoepithelioma of the oropharynx, metastatic"""@eng , """oropharyngeal lymphoepithelioma, metastatic"""@eng , """oropharynx lymphoepithelioma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3669"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280375"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III squamous cell carcinoma of the oropharynx"""@eng ; skos:notation """CDR0000040725"""^^xsd:string ; skos:altLabel """oropharyngeal squamous cell carcinoma, stage III"""@eng , """squamous cell carcinoma of the oropharynx, stage III"""@eng , """epidermoid carcinoma of the oropharynx, stage III"""@eng , """oropharynx squamous cell carcinoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3665"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280372"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II lymphoepithelioma of the oropharynx"""@eng ; skos:notation """CDR0000040724"""^^xsd:string ; skos:altLabel """oropharynx lymphoepithelioma, stage II"""@eng , """oropharyngeal lymphoepithelioma, stage II"""@eng , """lymphoepithelioma of the oropharynx, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3663"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280371"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV squamous cell carcinoma of the oropharynx"""@eng ; skos:notation """CDR0000040727"""^^xsd:string ; skos:altLabel """oropharyngeal squamous cell carcinoma, metastatic"""@eng , """epidermoid carcinoma of the oropharynx, stage IV"""@eng , """metastatic squamous cell carcinoma of the oropharynx"""@eng , """squamous cell carcinoma of the oropharynx, stage IV"""@eng , """oropharynx squamous cell carcinoma, stage IV"""@eng , """oropharyngeal squamous cell carcinoma, stage IV"""@eng , """epidermoid carcinoma of the oropharynx, metastatic"""@eng , """oropharynx squamous cell carcinoma, metastatic"""@eng , """squamous cell carcinoma of the oropharynx, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3668"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280374"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III lymphoepithelioma of the oropharynx"""@eng ; skos:notation """CDR0000040726"""^^xsd:string ; skos:altLabel """lymphoepithelioma of the oropharynx, stage III"""@eng , """oropharynx lymphoepithelioma, stage III"""@eng , """oropharyngeal lymphoepithelioma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3666"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280373"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypophysectomy"""@eng ; skos:notation """CDR0000040721"""^^xsd:string ; ; rdfs:subClassOf ; """366"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0020632"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I squamous cell carcinoma of the oropharynx"""@eng ; skos:notation """CDR0000040720"""^^xsd:string ; skos:altLabel """oropharynx squamous cell carcinoma, stage I"""@eng , """squamous cell carcinoma of the oropharynx, stage I"""@eng , """epidermoid carcinoma of the oropharynx, stage I"""@eng , """oropharyngeal squamous cell carcinoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3659"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280368"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II squamous cell carcinoma of the oropharynx"""@eng ; skos:notation """CDR0000040723"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the oropharynx, stage II"""@eng , """oropharynx squamous cell carcinoma, stage II"""@eng , """oropharyngeal squamous cell carcinoma, stage II"""@eng , """epidermoid carcinoma of the oropharynx, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3662"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280370"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I lymphoepithelioma of the oropharynx"""@eng ; skos:notation """CDR0000040722"""^^xsd:string ; skos:altLabel """oropharyngeal lymphoepithelioma, stage I"""@eng , """oropharynx lymphoepithelioma, stage I"""@eng , """lymphoepithelioma of the oropharynx, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3660"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280369"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody BC8"""@eng ; skos:notation """CDR0000043463"""^^xsd:string ; skos:altLabel """I 131 MOAB BC8"""@eng , """I 131 Monoclonal Antibody BC8"""@eng , """I131 MOAB BC8"""@eng , """iodine I 131 MOAB BC8"""@eng ; skos:definition """A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. CD45 is tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes; it is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43463&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43463&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2527\" NCI Thesaurus)"""@eng ; ; """8664"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2527"""^^xsd:string ; umls:cui """C0796627"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039386"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/DOX/TG/VCR"""@eng ; ; ; ; ; ; ; """2021"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279249"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000039385"""^^xsd:string ; skos:altLabel """BLEO/CDDP/CTX/DOX"""@eng , """BCAP"""@eng ; ; ; ; ; """2020"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1510468"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anhydrovinblastine"""@eng ; skos:notation """CDR0000043460"""^^xsd:string ; """8639"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796616"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000037769"""^^xsd:string ; skos:altLabel """lymphoma, adult lymphoblastic"""@eng , """lymphoblastic lymphoma, adult"""@eng , """diffuse lymphoblastic lymphoma, with or without convoluted cells"""@eng , """NHL, lymphoblastic"""@eng , """non-Hodgkin's lymphoma, adult lymphoblastic"""@eng ; rdfs:subClassOf ; """1007"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278721"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/prednisone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000039383"""^^xsd:string ; skos:altLabel """BCNU/CTX/PCB/PRED/VBL"""@eng , """BVCPP"""@eng ; ; ; ; ; ; """2018"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent retinoblastoma"""@eng ; skos:notation """CDR0000037768"""^^xsd:string ; skos:altLabel """retinoblastoma, recurrent"""@eng ; rdfs:subClassOf ; """retinoblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1006"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278720"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039382"""^^xsd:string ; skos:altLabel """DHAD/PCB/PRED/VCR"""@eng ; ; ; ; ; """2017"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0255600"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extraocular retinoblastoma"""@eng ; skos:notation """CDR0000037767"""^^xsd:string ; skos:altLabel """retinoblastoma, extraocular"""@eng , """childhood extraocular retinoblastoma"""@eng , """pediatric extraocular retinoblastoma"""@eng ; rdfs:subClassOf ; """retinoblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1005"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1321870"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dexamethasone/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000039381"""^^xsd:string ; skos:altLabel """BLEO/CTX/DM/DOX/VCR"""@eng ; ; ; ; ; ; """2016"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0171337"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000037766"""^^xsd:string ; skos:altLabel """leukemia, stage 0 chronic lymphocytic"""@eng , """CLL, stage 0"""@eng , """chronic lymphocytic Leukemia, stage 0"""@eng , """lymphocytic leukemia, stage 0 chronic"""@eng ; rdfs:subClassOf ; """chronic lymphocytic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1004"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278718"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """UGT1"""@eng ; skos:notation """CDR0000043464"""^^xsd:string ; rdfs:subClassOf ; """8673"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0537026"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/melphalan/methylprednisolone"""@eng ; skos:notation """CDR0000039525"""^^xsd:string ; skos:altLabel """CTX/L-PAM/MePRDL"""@eng ; ; ; ; """2163"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279343"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CL 286558"""@eng ; skos:notation """CDR0000040466"""^^xsd:string ; skos:altLabel """zeniplatin"""@eng ; """3346"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0055849"""^^xsd:string ; umls:cui """C0286234"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa"""@eng ; skos:notation """CDR0000040467"""^^xsd:string ; skos:altLabel """Intron A"""@eng , """alpha interferon"""@eng , """Ginterferon"""@eng , """interferon alpha"""@eng , """Leukocyte Interferon"""@eng , """Lymphoblastoid Interferon"""@eng , """alpha-interferon"""@eng , """Roferon-A"""@eng , """G-Interferon"""@eng , """IFN-A"""@eng , """interferon A"""@eng , """Recombinant Interferon Alfa"""@eng , """Alferon N"""@eng , """Lymphoblast Interferon"""@eng ; skos:definition """A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents. Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40467&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40467&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C225\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3347"""^^xsd:string ; """1559"""^^xsd:string ; """1577"""^^xsd:string ; """1544"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C225"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0751600"""^^xsd:string ; umls:cui """C0751598"""^^xsd:string ; umls:cui """C0699179"""^^xsd:string ; umls:cui """C0002199"""^^xsd:string ; umls:cui """C0718345"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ifosfamide"""@eng ; skos:notation """CDR0000040464"""^^xsd:string ; skos:altLabel """CBDCA/IFF"""@eng , """IMP"""@eng ; ; ; """3344"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280103"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040465"""^^xsd:string ; skos:altLabel """CTX/MTX/PRED/VCR/VP-16"""@eng , """MOPLEC"""@eng ; ; ; ; ; ; """3345"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280104"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polyethylene glycol"""@eng ; skos:notation """CDR0000040462"""^^xsd:string ; skos:altLabel """glycol, polyethylene"""@eng ; """3341"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0032483"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/vincristine"""@eng ; skos:notation """CDR0000040463"""^^xsd:string ; skos:altLabel """CBDCA/VCR"""@eng ; ; ; """3343"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280102"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult solid tumor"""@eng ; skos:notation """CDR0000040460"""^^xsd:string ; skos:altLabel """solid tumor, adult"""@eng ; rdfs:subClassOf ; """3335"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280099"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """solid tumor"""@eng ; skos:notation """CDR0000040461"""^^xsd:string ; rdfs:subClassOf ; """3336"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280100"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent Wilms' tumor and other childhood kidney tumors"""@eng ; skos:notation """CDR0000037763"""^^xsd:string ; skos:altLabel """recurrent nephroblastoma"""@eng , """Wilm's tumor, recurrent"""@eng , """nephroblastoma, recurrent"""@eng , """recurrent Wilm's tumor"""@eng , """Wilms tumor, recurrent"""@eng , """recurrent Wilms tumor"""@eng , """Wilms' tumor, recurrent"""@eng ; rdfs:subClassOf ; """Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1001"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278716"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etanercept"""@eng ; skos:notation """CDR0000257809"""^^xsd:string ; skos:altLabel """Enbrel"""@eng , """Tumor Necrosis Factor Receptor IgG Chimera"""@eng , """TNFR:Fc"""@eng , """ETN"""@eng ; skos:definition """A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257809&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257809&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2381\" NCI Thesaurus)"""@eng ; ; ; ; """11464"""^^xsd:string ; """C2381"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0717758"""^^xsd:string ; umls:cui """C0720193"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interferon beta"""@eng ; skos:notation """CDR0000040468"""^^xsd:string ; skos:altLabel """Betaseron"""@eng , """Rebif"""@eng , """IFN-B"""@eng ; skos:definition """A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40468&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40468&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C495\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """TRD"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C495"""^^xsd:string ; """3348"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0751599"""^^xsd:string ; umls:cui """C0752980"""^^xsd:string ; umls:cui """C0284968"""^^xsd:string ; umls:cui """C0015980"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma"""@eng ; skos:notation """CDR0000040469"""^^xsd:string ; skos:altLabel """gamma interferon"""@eng , """Actimmune"""@eng , """Interferon Gamma (BIO)"""@eng , """Recombinant Interferon Gamma"""@eng , """IFN-G"""@eng , """Gamma Interferon (GEN)"""@eng , """Gamma Interferon-SCH"""@eng , """gamma-interferon"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to the endogenous lymphokine interferon gamma (IFN-gamma) with antineoplastic, immunoregulatory, and antiviral activities. Therapeutic IFN-gamma binds to and activates the cell-surface IFN-gamma receptor, stimulating antibody-dependent cytotoxicity and enhances natural killer cell attachment to tumor cells. This agent also activates caspases, thereby inducing apoptosis in malignant cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40469&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40469&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C583\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3349"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2192"""^^xsd:string ; """1706"""^^xsd:string ; """2591"""^^xsd:string ; """82115-62-6"""^^xsd:string ; """635256"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """600662"""^^xsd:string ; """C583"""^^xsd:string ; """1951"""^^xsd:string ; """373360"""^^xsd:string ; """4521"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0021740"""^^xsd:string ; umls:cui """C0813623"""^^xsd:string ; umls:cui """C0021745"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II colon cancer"""@eng ; skos:notation """CDR0000037761"""^^xsd:string ; skos:altLabel """Dukes B colon cancer"""@eng , """colon cancer, Astler-Coller B2"""@eng , """colon cancer, stage II"""@eng , """colon cancer, Dukes B"""@eng , """Astler-Coller B2 colon cancer"""@eng ; rdfs:subClassOf ; """colon cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0740475"""^^xsd:string ; umls:cui """C0278479"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dextroamphetamine-amphetamine"""@eng ; skos:notation """CDR0000304345"""^^xsd:string ; skos:altLabel """Adderall"""@eng , """Adderall XR"""@eng , """amphetamine-dextroamphetamine"""@eng , """SLI381"""@eng , """D,L-amphetamine"""@eng ; skos:definition """A combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304345&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304345&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26643\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2003-04-23"""^^xsd:string ; """C26643"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0795571"""^^xsd:string ; umls:cui """C1170024"""^^xsd:string ; umls:cui """C0290795"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/oblimersen"""@eng ; skos:notation """CDR0000257804"""^^xsd:string ; skos:altLabel """DOX/G3139"""@eng ; ; ; """2002-09-10"""^^xsd:string ; """11463"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327786"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-glucan/rituximab"""@eng ; skos:notation """CDR0000373964"""^^xsd:string ; skos:altLabel """b-GLUC/MOAB IDEC-C2B8"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thioinosine"""@eng ; skos:notation """CDR0000039496"""^^xsd:string ; skos:altLabel """6-MP riboside"""@eng , """6-MP-R"""@eng , """6-mercaptopurine ribonucleoside"""@eng , """6-MPR"""@eng , """6-mercaptopurine riboside"""@eng ; """2129"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0039904"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methanol extraction residue of BCG"""@eng ; skos:notation """CDR0000039495"""^^xsd:string ; skos:altLabel """MER-BCG"""@eng , """MER"""@eng , """methanol extraction residue of bacillus Calmette-Guerin"""@eng ; skos:definition """A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39495&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39495&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1159\" NCI Thesaurus)"""@eng ; """2128"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1159"""^^xsd:string ; """642"""^^xsd:string ; """143769"""^^xsd:string ; umls:cui """C0065973"""^^xsd:string ; umls:tui """T007"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monobenzone"""@eng ; skos:notation """CDR0000039494"""^^xsd:string ; skos:altLabel """MBEH"""@eng , """Benoquin"""@eng , """monobenzyl ether of hydroquinone"""@eng ; skos:definition """A monobenzyl ether of hydroquinone with topical depigmentation activity. Although the exact mechanism of action of depigmentation is unknown, the metabolites of monobenzone appear to have a cytotoxic effect on melanocytes. Furthermore, the depigmentation effect might be mediated through the inhibition of tyrosinase, which is essential in the synthesis of melanin pigments, thereby causing permanent depigmentation of the skin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39494&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39494&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C992\" NCI Thesaurus)"""@eng ; """2127"""^^xsd:string ; """103-16-2"""^^xsd:string ; """C992"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33918"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0050962"""^^xsd:string ; umls:cui """C0718893"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mannitol"""@eng ; skos:notation """CDR0000039493"""^^xsd:string ; skos:altLabel """Resectisol"""@eng , """Osmitrol"""@eng , """D-Mannitol"""@eng ; skos:definition """A naturally occurring alcohol found in fruits and vegetables and used as an osmotic diuretic. Mannitol is freely filtered by the glomerulus and poorly reabsorbed from the renal tubule, thereby causing an increase in osmolarity of the glomerular filtrate. An increase in osmolarity limits tubular reabsorption of water and inhibits the renal tubular reabsorption of sodium, chloride, and other solutes, thereby promoting diuresis. In addition, mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from tissues into interstitial fluid and plasma. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39493&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39493&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C625\" NCI Thesaurus)"""@eng ; """2126"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C625"""^^xsd:string ; """407017"""^^xsd:string ; """69-65-8"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0024730"""^^xsd:string ; umls:cui """C0699452"""^^xsd:string ; umls:cui """C0699451"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """maytansine"""@eng ; skos:notation """CDR0000039492"""^^xsd:string ; skos:altLabel """alanine, N-acetyl-N-methyl-, 6-ester with 11-chloro-6, 21-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1(10,24).0(3,5)]hexacosa-10,12,14[26], 16,18-pentaene-8,23-dione"""@eng , """maitansine"""@eng , """Maytansin"""@eng , """L-alanine, N-acetyl-N-methyl-, 11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03, 5]hexacosa-10,12,14(26),16,18-pentaen-6-yl ester, [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]"""@eng , """Maysanine"""@eng ; skos:definition """An ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine binds to tubulin at the rhizoxin binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis. Maytansine exhibits cytotoxicity against many tumor cell lines and may inhibit tumor growth in vivo. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39492&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39492&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C626\" NCI Thesaurus)"""@eng ; """2125"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C626"""^^xsd:string ; """11857"""^^xsd:string ; """35846-53-8"""^^xsd:string ; """153858"""^^xsd:string ; umls:cui """C0024975"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lithium carbonate"""@eng ; skos:notation """CDR0000039491"""^^xsd:string ; skos:altLabel """Eskalith"""@eng , """Lithonate"""@eng , """Lithotabs"""@eng , """Lithane"""@eng , """Lithium"""@eng , """Lithobid"""@eng ; skos:definition """The carbonate salt of lithium, a monovalent cation with antimanic activity. Lithium carbonate interferes with transmembrane sodium exchange in nerve cells by affecting sodium, potassium-stimulated adenosine triphosphatase (Na+, K+-ATPase); alters the release of neurotransmitters; affects cyclic adenosine monophosphate (cAMP) concentrations; and blocks inositol metabolism resulting in depletion of cellular inositol and inhibition of phospholipase C-mediated signal transduction. The exact mechanism through which lithium carbonate exerts its mood-stabilizing effect has not been established. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39491&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39491&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1318\" NCI Thesaurus)"""@eng ; """2124"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1318"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0023870"""^^xsd:string ; umls:cui """C0700750"""^^xsd:string ; umls:cui """C0700751"""^^xsd:string ; umls:cui """C0700752"""^^xsd:string ; umls:cui """C0700753"""^^xsd:string ; umls:cui """C0085217"""^^xsd:string ; umls:cui """C0700189"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levonantradol"""@eng ; skos:notation """CDR0000039490"""^^xsd:string ; skos:altLabel """Levonantradol HCl"""@eng ; skos:definition """A synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) with antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39490&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39490&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1385\" NCI Thesaurus)"""@eng ; """2123"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """18087"""^^xsd:string ; """C1385"""^^xsd:string ; umls:cui """C0125660"""^^xsd:string ; umls:cui """C1524118"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine"""@eng ; skos:notation """CDR0000038731"""^^xsd:string ; skos:altLabel """ARA-C/ASP"""@eng ; ; ; """1165"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278793"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ropivacaine hydrochloride"""@eng ; skos:notation """CDR0000459953"""^^xsd:string ; skos:altLabel """Naropin"""@eng ; skos:definition """The hydrochloride salt of ropivacaine, a local anesthetic of the amide type with analgesic activity. Ropivacaine binds to voltage-gated sodium ion channels in the neuronal membrane, thereby preventing the permeability of sodium ions and resulting in. a stabilization of the neuronal membrane and inhibition of depolarization; nerve impulse generation and propagation are blocked, resulting in a reversible loss of sensation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459953&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459953&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52198\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """2006-06-26"""^^xsd:string ; """C52198"""^^xsd:string ; umls:cui """C0771826"""^^xsd:string ; umls:cui """C0525803"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """basiliximab"""@eng ; skos:notation """CDR0000459956"""^^xsd:string ; skos:altLabel """Simulect"""@eng , """SDZ-CHI-621"""@eng ; skos:definition """A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459956&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459956&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52186\" NCI Thesaurus)"""@eng ; """2006-07-27"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C52186"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0757163"""^^xsd:string ; umls:cui """C0723325"""^^xsd:string ; umls:cui """C0676831"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methadone hydrochloride"""@eng ; skos:notation """CDR0000039498"""^^xsd:string ; skos:altLabel """Althose"""@eng , """Dolophine"""@eng , """Methadose"""@eng , """Adanon"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2131"""^^xsd:string ; """2006-11-21"""^^xsd:string ; """C638"""^^xsd:string ; umls:cui """C0699058"""^^xsd:string ; umls:cui """C0699059"""^^xsd:string ; umls:cui """C0699057"""^^xsd:string ; umls:cui """C0592779"""^^xsd:string ; umls:cui """C0721688"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lutetium Lu 177 monoclonal antibody J591"""@eng ; skos:notation """CDR0000361550"""^^xsd:string ; skos:altLabel """Lu 177 MOAB J591"""@eng ; skos:definition """A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against the extracellular domain of prostate-specific membrane antigen linked to a beta-emitting radioisotope (lutetium-177). This radioimmunoconjugate binds to tumor cells that express the extracellular domain of prostate-specific membrane antigen, delivering beta particle radiation selectively to tumor cells expressing this antigen and so limiting the exposure of normal tissues to ionizing radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361550&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361550&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38701\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C38701"""^^xsd:string ; umls:cui """C1518042"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MTHFR"""@eng ; skos:notation """CDR0000257800"""^^xsd:string ; skos:altLabel """methylenetetrahydrofolate reductase gene"""@eng ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11461"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919427"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GPI-1485"""@eng ; skos:notation """CDR0000391251"""^^xsd:string ; skos:altLabel """GPI 1485"""@eng ; """2004-09-25"""^^xsd:string ; """2004-09-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1451920"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """type A thymoma"""@eng ; skos:notation """CDR0000040002"""^^xsd:string ; skos:altLabel """spindle cell thymoma"""@eng , """medullary thymoma"""@eng ; rdfs:subClassOf ; """2003-08-20"""^^xsd:string ; """2728"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1266091"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endoscopic surgery"""@eng ; skos:notation """CDR0000486891"""^^xsd:string ; skos:altLabel """surgery, endoscopic"""@eng ; rdfs:subClassOf ; """2006-05-23"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0282493"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Valeriana officinalis"""@eng ; skos:notation """CDR0000350071"""^^xsd:string ; skos:altLabel """Valeriana Officinalis Extract"""@eng , """Valerian"""@eng ; skos:definition """An extract isolated from the root of the plant Valeriana officinalis. Valeriana officinalis extract inhibits the metabolic enzyme gamma-aminobutyric acid (GABA) transaminase and stimulates the synaptic release of GABA, an inhibitory neurotransmitter, resulting in sedation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350071&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350071&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38725\" NCI Thesaurus)"""@eng ; """2003-12-23"""^^xsd:string ; """2003-12-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38725"""^^xsd:string ; umls:cui """C0795674"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/prednisone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000042619"""^^xsd:string ; skos:altLabel """CVPP"""@eng , """CCNU/PCB/PRED/VBL"""@eng ; ; ; ; ; """634"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056635"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethynyluracil/fluorouracil"""@eng ; skos:notation """CDR0000042618"""^^xsd:string ; skos:altLabel """776C85/5-FU"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """6339"""^^xsd:string ; umls:cui """C0393027"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/etoposide/mesna"""@eng ; skos:notation """CDR0000042616"""^^xsd:string ; skos:altLabel """BCNU/CTX/MSA/VP-16"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """6337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393025"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E1A lipid complex"""@eng ; skos:notation """CDR0000042615"""^^xsd:string ; skos:altLabel """lipid complex, E1A"""@eng , """tgDCC-E1A"""@eng ; ; """6336"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393024"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000042614"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB IDEC-C2B8/PRED/VCR"""@eng ; ; ; ; ; ; """6335"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393023"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rituximab"""@eng ; skos:notation """CDR0000042613"""^^xsd:string ; skos:altLabel """Rituxan"""@eng , """IDEC-102"""@eng , """IDEC-C2B8 monoclonal antibody"""@eng , """C2B8 Monoclonal Antibody"""@eng , """monoclonal antibody IDEC-C2B8"""@eng , """Mabthera"""@eng , """monoclonal antibody anti-CD20"""@eng , """IDEC-C2B8"""@eng , """anti-CD20 monoclonal antibody"""@eng , """MOAB IDEC-C2B8"""@eng ; skos:definition """A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1702\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """6334"""^^xsd:string ; """10624"""^^xsd:string ; """C1702"""^^xsd:string ; """687451"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """9968"""^^xsd:string ; """7028"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0732355"""^^xsd:string ; umls:cui """C0393022"""^^xsd:string ; umls:cui """C1314901"""^^xsd:string ; umls:cui """C1522477"""^^xsd:string ; umls:cui """C0295415"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arcitumomab"""@eng ; skos:notation """CDR0000042612"""^^xsd:string ; skos:altLabel """CEA-Scan"""@eng , """IMMU-4"""@eng , """anti-Carcinoembryonic Antigen Monoclonal Antibody Fab' Fragment"""@eng ; skos:definition """A murine IgG monoclonal Fab fragment antibody labeled with technetium-99m directed against carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cell types. For tumors that overexpress CEA, arcitumomab may be used as an adjunct diagnostic imaging tool to obtain prognostic information following resection and to monitor for recurrent disease. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42612&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42612&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1494\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """6333"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3371"""^^xsd:string ; """C1494"""^^xsd:string ; umls:cui """C0758540"""^^xsd:string ; umls:cui """C0758542"""^^xsd:string ; umls:cui """C0217156"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/procarbazine/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042611"""^^xsd:string ; skos:altLabel """CCNU/PCB/TG/VCR"""@eng ; ; ; ; ; """6332"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393021"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitomycin/vincristine"""@eng ; skos:notation """CDR0000042610"""^^xsd:string ; skos:altLabel """CDDP/MITO/VCR"""@eng ; ; ; ; """6331"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393020"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CHP-HER2 peptide vaccine"""@eng ; skos:notation """CDR0000489124"""^^xsd:string ; skos:altLabel """cholesterol-bearing hydrophobized pullulan HER2 protein 146"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831880"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PM00104"""@eng ; skos:notation """CDR0000502184"""^^xsd:string ; skos:altLabel """PM100104/50"""@eng ; """2006-08-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831946"""^^xsd:string ; umls:cui """C1568937"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MK-6592"""@eng ; skos:notation """CDR0000502185"""^^xsd:string ; """2006-08-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831947"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/leucovorin calcium/mitomycin"""@eng ; skos:notation """CDR0000041110"""^^xsd:string ; skos:altLabel """CDDP/CF/5-FU/MITO"""@eng ; ; ; ; ; """4150"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280709"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/oblimersen/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000331852"""^^xsd:string ; skos:altLabel """CTX/DOX/G3139/MOAB IDEC-C2B8/PRED/VCR"""@eng ; ; ; ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-08-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328045"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/capecitabine/oxaliplatin"""@eng ; skos:notation """CDR0000331850"""^^xsd:string ; skos:altLabel """CAPE/L-OHP/MOAB VEGF"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-08-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328044"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SGN-00101"""@eng ; skos:notation """CDR0000269165"""^^xsd:string ; skos:altLabel """HspE7"""@eng , """HPV 16 E7/HSP65 Vaccine"""@eng , """HPV E7 Peptide Epitope Vaccine"""@eng ; skos:definition """A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269165&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269165&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811\" NCI Thesaurus)"""@eng ; """2002-11-24"""^^xsd:string ; """2002-11-21"""^^xsd:string ; """295371-00-5"""^^xsd:string ; """C2811"""^^xsd:string ; """10007"""^^xsd:string ; """713219"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327844"""^^xsd:string ; umls:cui """C1328696"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody CC49"""@eng ; skos:notation """CDR0000269166"""^^xsd:string ; skos:altLabel """I131 MOAB CC49"""@eng , """I 131 Monoclonal Antibody CC49"""@eng , """131I-MOAB CC49"""@eng ; """2002-11-24"""^^xsd:string ; """2006-08-17"""^^xsd:string ; """C26442"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327845"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/exisulind"""@eng ; skos:notation """CDR0000269167"""^^xsd:string ; skos:altLabel """EM/FGN-1/TXT"""@eng ; ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327846"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """reduced glutathione-L-cysteine-anthocyanins gel"""@eng ; skos:notation """CDR0000484826"""^^xsd:string ; skos:altLabel """RayGel"""@eng ; skos:definition """A gel formulation containing reduced glutathione, L-cysteine, and anthocyanins with potential antioxifdant, immunostimulating, and chemoprotective properties. Reduced glutathione is the primary cellular antioxidant and plays important roles in the antioxidation of reactive oxygen species and free radicals and, as a thiol-containing co-enzyme, in the detoxification of xenobiotic compounds. In addition, glutathione affects DNA synthesis and repair and exerts immunostimulating activity by increasing the production of interleukin-2 (IL-2), promoting antigen presentation, and stimulating T-suppressor/cytotoxic (CD8 cells) cells. The flavonoid anthocyanins, derived from various blue and purple flowering plants, are potent scavengers of reactive oxygen species. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484826&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484826&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61323\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """C61323"""^^xsd:string ; umls:cui """C1831813"""^^xsd:string ; umls:cui """C1569841"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluoxymesterone"""@eng ; skos:notation """CDR0000494707"""^^xsd:string ; skos:altLabel """Halodrin"""@eng , """(11Beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one"""@eng , """11Beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one"""@eng , """Android-F"""@eng , """Halotestin"""@eng , """9Alpha-fluoro-11beta-hydroxy-17alpha-methyltestosterone"""@eng , """Oratestin"""@eng , """Ora-Testryl"""@eng , """Ultandren"""@eng , """FXM"""@eng , """Stenox"""@eng , """Testoral"""@eng , """Androsterolo"""@eng , """Androfluorene"""@eng ; skos:definition """A halogenated derivative of 17-alpha-methyltestosterone. Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus. This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=494707&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=494707&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C507\" NCI Thesaurus)"""@eng ; """76-43-7"""^^xsd:string ; """C507"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4573"""^^xsd:string ; """12165"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733925"""^^xsd:string ; umls:cui """C0733927"""^^xsd:string ; umls:cui """C0733926"""^^xsd:string ; umls:cui """C1517241"""^^xsd:string ; umls:cui """C0016366"""^^xsd:string ; umls:cui """C1517243"""^^xsd:string ; umls:cui """C1517242"""^^xsd:string ; umls:cui """C1517244"""^^xsd:string ; umls:cui """C0720810"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dermatologic complications"""@eng ; skos:notation """CDR0000494704"""^^xsd:string ; rdfs:subClassOf ; """2006-07-07"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C1831917"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/lomustine/methotrexate/procarbazine"""@eng ; skos:notation """CDR0000344418"""^^xsd:string ; skos:altLabel """ARA-C/CCNU/DM/MTX/PCB"""@eng ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328102"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """S-CKD602"""@eng ; skos:notation """CDR0000471934"""^^xsd:string ; skos:definition """A sterically stabilized, pegylated liposomal formulation containing CKD602, a semi-synthetic analogue of campthotecin with potential antitumor activity. CKD602 inhibits the action of topoisomerase I, an enzyme that produces reversible single-strand breaks in DNA during DNA replication. CDK602 stabilizes the topoisomerase I and DNA complex, thereby prevents religation of DNA breaks. This leads to an inhibition of DNA replication and triggers apoptotic cell death. The polyethylene glycol coating of S-CKD602 allows for greater plasma circulation time, thereby enhancing the concentration of CKD602 at the tumor site. Encapsulation of CKD602 preserves the active lactone form leading to an increased cytotoxic effect of CKD602. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471934&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471934&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61437\" NCI Thesaurus)"""@eng ; """2006-03-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-24"""^^xsd:string ; """C61437"""^^xsd:string ; umls:cui """C1831764"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/leuvocorin calcium/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000393427"""^^xsd:string ; skos:altLabel """CF/CTX/MP/MTX/VP-16"""@eng ; ; ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541371"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral leukoplakia"""@eng ; skos:notation """CDR0000422412"""^^xsd:string ; skos:altLabel """leukoplakia, oral"""@eng ; rdfs:subClassOf ; """2005-02-18"""^^xsd:string ; """2005-02-17"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0023532"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """boron neutron capture therapy"""@eng ; skos:notation """CDR0000042233"""^^xsd:string ; ; rdfs:subClassOf ; """5482"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0162505"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BIBX 1382"""@eng ; skos:notation """CDR0000043568"""^^xsd:string ; skos:altLabel """BIBX1382"""@eng , """BIBX-1382"""@eng ; skos:definition """A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43568&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43568&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2539\" NCI Thesaurus)"""@eng ; """8848"""^^xsd:string ; """C2539"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-14"""^^xsd:string ; umls:cui """C0879286"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/interleukin-2"""@eng ; skos:notation """CDR0000043569"""^^xsd:string ; skos:altLabel """BRYO/IL-2"""@eng ; ; ; """8849"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879287"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-3/SB AS-2"""@eng ; skos:notation """CDR0000043566"""^^xsd:string ; skos:altLabel """MAGE3/SBAS-2"""@eng ; ; ; """8846"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879284"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CHS 828"""@eng ; skos:notation """CDR0000043567"""^^xsd:string ; skos:altLabel """CHS828"""@eng , """CHS-828"""@eng ; """2003-10-29"""^^xsd:string ; """8847"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879285"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/trastuzumab"""@eng ; skos:notation """CDR0000043564"""^^xsd:string ; skos:altLabel """CPT-11/MOAB HER2"""@eng ; ; ; """8822"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KRN7000"""@eng ; skos:notation """CDR0000043562"""^^xsd:string ; skos:altLabel """KRN 7000"""@eng , """KRN-7000"""@eng ; """2003-10-28"""^^xsd:string ; """8820"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0534775"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/UCN-01"""@eng ; skos:notation """CDR0000043563"""^^xsd:string ; skos:altLabel """FAMP/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """8821"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib"""@eng ; skos:notation """CDR0000043560"""^^xsd:string ; skos:altLabel """LDP341"""@eng , """LDP 341"""@eng , """PS-341"""@eng , """VELCADE"""@eng , """PS 341"""@eng , """[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid"""@eng , """PS341"""@eng , """MLN341"""@eng , """LDP-341"""@eng ; skos:definition """A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43560&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43560&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1851\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """8818"""^^xsd:string ; """179324-69-7"""^^xsd:string ; """C1851"""^^xsd:string ; """58443"""^^xsd:string ; """681239"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879272"""^^xsd:string ; umls:cui """C1135131"""^^xsd:string ; umls:cui """C1174739"""^^xsd:string ; umls:cui """C1176309"""^^xsd:string ; umls:cui """C1328654"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody TNT-1/B"""@eng ; skos:notation """CDR0000043561"""^^xsd:string ; skos:altLabel """iodine I 131 MOAB TNT-1/B"""@eng , """I131 monoclonal antibody TNT-1/B"""@eng , """Cotara"""@eng , """I131 MOAB TNT-1/B"""@eng ; """8819"""^^xsd:string ; """2005-07-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0879273"""^^xsd:string ; umls:cui """C1831636"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/celecoxib/paclitaxel"""@eng ; skos:notation """CDR0000306448"""^^xsd:string ; skos:altLabel """CBDCA/SC-58635/TAX"""@eng ; ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327978"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/leuprolide/methotrexate/tamoxifen"""@eng ; skos:notation """CDR0000042090"""^^xsd:string ; skos:altLabel """CTX/5-FU/LEUP/MTX/TMX"""@eng ; ; ; ; ; ; """5325"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281621"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extracorporeal photophoresis"""@eng ; skos:notation """CDR0000474255"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-17"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; umls:cui """C0206373"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide"""@eng ; skos:notation """CDR0000040916"""^^xsd:string ; skos:altLabel """CDDP/VP-16"""@eng , """PVp"""@eng , """VPP"""@eng , """VP-Plat"""@eng , """PE"""@eng , """EP"""@eng ; ; ; """3955"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078414"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/methotrexate"""@eng ; skos:notation """CDR0000040917"""^^xsd:string ; skos:altLabel """MVP"""@eng , """CDDP/MTX/VP-16"""@eng , """MEP"""@eng ; ; ; ; """3956"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0084989"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoma of the appendix"""@eng ; skos:notation """CDR0000040914"""^^xsd:string ; skos:altLabel """Appendix carcinoma"""@eng , """appendix carcinoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3953"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0728951"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peritoneal cavity pseudomyxoma peritonei"""@eng ; skos:notation """CDR0000040915"""^^xsd:string ; skos:altLabel """malignant peritoneal pseudomyxoma peritonei"""@eng , """malignant pseudomyxoma peritonei"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3954"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280535"""^^xsd:string ; umls:cui """C0033822"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cholangiocarcinoma of the gallbladder"""@eng ; skos:notation """CDR0000040912"""^^xsd:string ; skos:altLabel """gallbladder cholangiocarcinoma"""@eng ; rdfs:subClassOf ; """3951"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280532"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cholangiocarcinoma of the extrahepatic bile duct"""@eng ; skos:notation """CDR0000040913"""^^xsd:string ; skos:altLabel """extrahepatic bile duct cholangiocarcinoma"""@eng ; rdfs:subClassOf ; """3952"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280533"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/diethylstilbestrol/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000040910"""^^xsd:string ; skos:altLabel """CTX/DES/5-FU/MTX"""@eng ; ; ; ; ; """3949"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280530"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiprogestational therapy"""@eng ; skos:notation """CDR0000040911"""^^xsd:string ; skos:altLabel """therapy, antiprogestational"""@eng ; ; rdfs:subClassOf ; """3950"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280531"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/mitoguazone"""@eng ; skos:notation """CDR0000040918"""^^xsd:string ; skos:altLabel """CDDP/MGBG/VP-16"""@eng , """CVM"""@eng , """CVpMG"""@eng , """PVpM"""@eng ; ; ; ; """3957"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280538"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/suramin"""@eng ; skos:notation """CDR0000322262"""^^xsd:string ; skos:altLabel """SUR/TXT"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328022"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/oblimersen/paclitaxel"""@eng ; skos:notation """CDR0000271182"""^^xsd:string ; skos:altLabel """CBDCA/G3139/TAX"""@eng ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327875"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MLL"""@eng ; skos:notation """CDR0000043179"""^^xsd:string ; rdfs:subClassOf ; """7622"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919528"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """p16"""@eng ; skos:notation """CDR0000043178"""^^xsd:string ; rdfs:subClassOf ; """7621"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0525037"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 14"""@eng ; skos:notation """CDR0000043171"""^^xsd:string ; rdfs:subClassOf ; """7614"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008656"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 8p"""@eng ; skos:notation """CDR0000043170"""^^xsd:string ; rdfs:subClassOf ; """7613"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796348"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 17p"""@eng ; skos:notation """CDR0000043173"""^^xsd:string ; rdfs:subClassOf ; """7616"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796349"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 15"""@eng ; skos:notation """CDR0000043172"""^^xsd:string ; rdfs:subClassOf ; """7615"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008657"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 22"""@eng ; skos:notation """CDR0000043175"""^^xsd:string ; rdfs:subClassOf ; """7618"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008665"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 18q"""@eng ; skos:notation """CDR0000043174"""^^xsd:string ; rdfs:subClassOf ; """7617"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796350"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DNA stability"""@eng ; skos:notation """CDR0000043177"""^^xsd:string ; rdfs:subClassOf ; """7620"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796351"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """loss of heterozygosity"""@eng ; skos:notation """CDR0000043176"""^^xsd:string ; rdfs:subClassOf ; """7619"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0524869"""^^xsd:string ; umls:tui """T045"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bioluminescence"""@eng ; skos:notation """CDR0000258345"""^^xsd:string ; rdfs:subClassOf ; """2002-10-10"""^^xsd:string ; """11490"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1367880"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult pure erythroid leukemia (M6b)"""@eng ; skos:notation """CDR0000377685"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541340"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SCIO-469"""@eng ; skos:notation """CDR0000387795"""^^xsd:string ; skos:altLabel """SCIO 469"""@eng ; ; """2004-08-24"""^^xsd:string ; """2004-11-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541463"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """talotrexin"""@eng ; skos:notation """CDR0000387796"""^^xsd:string ; skos:altLabel """PT523"""@eng ; skos:definition """An antimetabolite analog of aminopterin with antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=387796&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=387796&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29341\" NCI Thesaurus)"""@eng ; """2006-09-26"""^^xsd:string ; """C29341"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2004-08-24"""^^xsd:string ; umls:cui """C1765332"""^^xsd:string ; umls:cui """C0288639"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000037770"""^^xsd:string ; skos:altLabel """cutaneous T-cell lymphoma, stage III"""@eng , """stage III mycosis fungoides/Sezary syndrome"""@eng , """mycosis fungoides/Sezary syndrome, stage III"""@eng ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """101"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862221"""^^xsd:string ; umls:cui """C0278570"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SOM230"""@eng ; skos:notation """CDR0000387798"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """2004-08-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1136845"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chimeric anti-phosphotidylserine monoclonal antibody"""@eng ; skos:notation """CDR0000450954"""^^xsd:string ; skos:altLabel """Tarvacin"""@eng ; skos:definition """An IgG3 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Chimeric anti-phosphotidylserine monoclonal antibody binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=450954&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=450954&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49088\" NCI Thesaurus)"""@eng ; """2006-07-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-10-14"""^^xsd:string ; """C49088"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1707383"""^^xsd:string ; umls:cui """C1707382"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/paclitaxel"""@eng ; skos:notation """CDR0000038515"""^^xsd:string ; skos:altLabel """MOAB VEGF/TAX"""@eng ; ; ; """11138"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ixabepilone"""@eng ; skos:notation """CDR0000038514"""^^xsd:string ; skos:altLabel """BMS 247550/CBDCA"""@eng ; ; ; """2004-01-08"""^^xsd:string ; """11137"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134546"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """R(+)XK469"""@eng ; skos:notation """CDR0000038517"""^^xsd:string ; skos:definition """The R-isomer of a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38517&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38517&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2662\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """11140"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C2662"""^^xsd:string ; umls:cui """C0765292"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/cyclophosphamide/cytarabine"""@eng ; skos:notation """CDR0000038511"""^^xsd:string ; skos:altLabel """ARA-C/ATG/CTX"""@eng ; ; ; ; """11133"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134543"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-CEA-B7.1 vaccine/fluorouracil/irinotecan/leucovorin calcium/tetanus toxoid"""@eng ; skos:notation """CDR0000038510"""^^xsd:string ; skos:altLabel """ALVAC-CEA-B7.1/CF/CPT-11/5-FU/TETTOX"""@eng ; ; ; ; ; ; """11132"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134542"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/erlotinib/paclitaxel"""@eng ; skos:notation """CDR0000038513"""^^xsd:string ; skos:altLabel """CBDCA/OSI774/TAX"""@eng ; ; ; ; """11136"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134545"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """medullary thyroid cancer, genetics of"""@eng ; skos:notation """CDR0000038512"""^^xsd:string ; skos:altLabel """medullary thyroid cancer genetics"""@eng ; """2002-10-15"""^^xsd:string ; """11134"""^^xsd:string ; umls:cui """C1134544"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/imatinib mesylate"""@eng ; skos:notation """CDR0000038519"""^^xsd:string ; skos:altLabel """ARA-C/STI571"""@eng ; ; ; """11142"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134549"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000038518"""^^xsd:string ; skos:altLabel """IL-12/MOAB HER2/TAX"""@eng ; ; ; ; """11141"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134712"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/oblimersen/rituximab"""@eng ; skos:notation """CDR0000361787"""^^xsd:string ; skos:altLabel """FAMP/G3139/MOAB IDEC-C2B8"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541184"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan/leucovorin calcium/PHY906"""@eng ; skos:notation """CDR0000361786"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/PHY-906"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541183"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/ifosfamide/pegfilgrastim/vincristine"""@eng ; skos:notation """CDR0000361785"""^^xsd:string ; skos:altLabel """CTX/DOX/GCSF-SD01/IFF/VCR/VP-16"""@eng ; ; ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541182"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil-uracil/leucovorin calcium/paclitaxel"""@eng ; skos:notation """CDR0000361784"""^^xsd:string ; skos:altLabel """CF/TAX/UFT"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541181"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/rituximab"""@eng ; skos:notation """CDR0000361789"""^^xsd:string ; skos:altLabel """MOAB CD52/MOAB IDEC-C2B8"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541186"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/TLK286"""@eng ; skos:notation """CDR0000361788"""^^xsd:string ; skos:altLabel """CDDP/TLK-286"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541185"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 colon cancer"""@eng ; skos:notation """CDR0000042420"""^^xsd:string ; skos:altLabel """colon cancer, stage 0"""@eng ; rdfs:subClassOf ; """colon cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """57"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0154061"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GM2-KLH vaccine/interferon alfa"""@eng ; skos:notation """CDR0000042421"""^^xsd:string ; skos:altLabel """GM2-KLH/IFN-A"""@eng ; ; ; """5729"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338325"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/tirapazamine"""@eng ; skos:notation """CDR0000042422"""^^xsd:string ; skos:altLabel """CDDP/5-FU/SR-4233"""@eng ; ; ; ; """5730"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood brain stem glioma"""@eng ; skos:notation """CDR0000042423"""^^xsd:string ; skos:altLabel """brain tumor, pediatric brainstem glioma, untreated"""@eng , """brain tumor, childhood brainstem glioma, untreated"""@eng , """untreated brain stem glioma, pediatric"""@eng , """untreated gliosarcoma, pediatric brainstem"""@eng , """untreated CNS tumor, brainstem glioma, childhood"""@eng , """untreated brain tumor, brain stem glioma, childhood"""@eng , """brain stem glioma, pediatric, untreated"""@eng , """untreated glioma, childhood brain stem"""@eng , """untreated gliosarcoma, childhood brain stem"""@eng , """glioma, untreated childhood brain stem"""@eng , """childhood brain stem mixed glioma, untreated"""@eng , """pediatric brain stem glioma, untreated"""@eng , """gliosarcoma, untreated childhood brainstem"""@eng , """untreated pediatric brain stem glioma"""@eng , """brainstem glioma, pediatric, untreated"""@eng , """untreated brain tumor, brain stem glioma, pediatric"""@eng , """CNS tumor, untreated brain stem glioma, childhood"""@eng , """brain tumor, pediatric brain stem glioma, untreated"""@eng , """childhood brainstem glioma, untreated"""@eng , """CNS tumor, untreated childhood brain stem glioma"""@eng , """untreated pediatric brainstem glioma"""@eng , """untreated pediatric brainstem gliosarcoma"""@eng , """untreated CNS tumor, childhood brain stem glioma"""@eng , """childhood CNS tumor, brain stem glioma, untreated"""@eng , """untreated childhood brain tumor, brainstem glioma"""@eng , """untreated childhood brain stem gliosarcoma"""@eng , """untreated central nervous system tumor, brainstem glioma, pediatric"""@eng , """untreated mixed glioma, childhood brain stem"""@eng , """untreated childhood brain tumor, brain stem glioma"""@eng , """brain tumor, brainstem glioma, childhood, untreated"""@eng , """childhood CNS tumor, untreated brainstem glioma"""@eng , """untreated central nervous system tumor, brain stem glioma, pediatric"""@eng , """childhood brain stem gliosarcoma, untreated"""@eng , """untreated central nervous system tumor, brain stem glioma, childhood"""@eng , """CNS tumor, untreated childhood brainstem glioma"""@eng , """untreated glioma, childhood brainstem"""@eng , """untreated CNS tumor, childhood brainstem glioma"""@eng , """untreated childhood brainstem mixed glioma"""@eng , """untreated childhood brainstem gliosarcoma"""@eng , """untreated glioma, pediatric brainstem"""@eng , """pediatric CNS tumor, untreated brain stem glioma"""@eng , """childhood brainstem gliosarcoma, untreated"""@eng , """pediatric brain tumor, untreated brainstem glioma"""@eng , """untreated CNS tumor, brain stem glioma, childhood"""@eng , """untreated pediatric CNS tumor, brain stem glioma"""@eng , """untreated childhood brain stem mixed glioma"""@eng , """untreated brain tumor, brainstem glioma, pediatric"""@eng , """untreated brain tumor, childhood, brain stem glioma"""@eng , """untreated pediatric brain stem gliosarcoma"""@eng , """childhood brain stem glioma, untreated"""@eng , """untreated CNS tumor, pediatric brainstem glioma"""@eng , """pediatric brainstem glioma, untreated"""@eng , """untreated childhood brainstem glioma"""@eng , """untreated pediatric CNS tumor, brainstem glioma"""@eng , """untreated brain tumor, pediatric brainstem glioma"""@eng , """untreated pediatric brainstem mixed glioma"""@eng , """childhood CNS tumor, untreated brain stem glioma"""@eng , """CNS tumor, untreated pediatric brainstem glioma"""@eng , """untreated brainstem glioma, pediatric"""@eng , """pediatric brain stem mixed glioma, untreated"""@eng , """untreated brain tumor, brainstem glioma, childhood"""@eng , """untreated brain tumor, pediatric brain stem glioma"""@eng , """brain tumor, brain stem glioma, childhood, untreated"""@eng , """untreated brain stem glioma, childhood"""@eng , """CNS tumor, untreated pediatric brain stem glioma"""@eng , """untreated childhood CNS tumor, brainstem glioma"""@eng , """childhood CNS tumor, brainstem glioma, untreated"""@eng , """untreated pediatric brain tumor, brainstem glioma"""@eng , """pediatric brainstem mixed glioma, untreated"""@eng , """childhood brainstem mixed glioma, untreated"""@eng , """untreated mixed glioma, pediatric brain stem"""@eng , """mixed glioma, untreated childhood brainstem"""@eng , """brain tumor, childhood brain stem glioma, untreated"""@eng , """pediatric brain tumor, untreated brain stem glioma"""@eng , """untreated mixed glioma, pediatric brainstem"""@eng , """pediatric CNS tumor, untreated brainstem glioma"""@eng , """untreated childhood CNS tumor, brain stem glioma"""@eng , """untreated mixed glioma, childhood brainstem"""@eng , """untreated brainstem glioma, childhood"""@eng , """untreated central nervous system tumor, brainstem glioma, childhood"""@eng , """untreated gliosarcoma, childhood brainstem"""@eng , """untreated CNS tumor, pediatric brain stem glioma"""@eng , """childhood brain tumor, untreated brainstem glioma"""@eng , """glioma, untreated childhood brainstem"""@eng , """brain stem glioma, childhood, untreated"""@eng , """mixed glioma, untreated childhood brain stem"""@eng , """brainstem glioma, childhood, untreated"""@eng , """gliosarcoma, untreated childhood brain stem"""@eng , """untreated brain tumor, childhood, brainstem glioma"""@eng , """untreated glioma, pediatric brain stem"""@eng , """CNS tumor, untreated brainstem glioma, childhood"""@eng , """untreated gliosarcoma, pediatric brain stem"""@eng , """untreated pediatric brain tumor, brain stem glioma"""@eng , """childhood brain tumor, untreated brain stem glioma"""@eng , """umtreated pediatric brain stem mixed glioma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood brain stem glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5739"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338327"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/methotrexate/pegaspargase/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042424"""^^xsd:string ; skos:altLabel """ARA-C/MTX/PEG-ASP/PRED/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """5740"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338328"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood cerebral astrocytoma/malignant glioma"""@eng ; skos:notation """CDR0000042425"""^^xsd:string ; skos:altLabel """Brain tumor, child: Astrocytoma, cerebral"""@eng , """astrocytoma, childhood cerebral"""@eng , """cerebral astrocytoma/malignant glioma, childhood"""@eng , """cerebral astrocytoma/malignant glioma, pediatric"""@eng , """pediatric cerebral astrocytoma/malignant glioma"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5741"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0338070"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood brain stem glioma"""@eng ; skos:notation """CDR0000042426"""^^xsd:string ; skos:altLabel """CNS tumor, recurrent pediatric brainstem glioma"""@eng , """brain tumor, recurrent brain stem glioma, pediatric"""@eng , """CNS tumor, pediatric brainstem glioma, recurrent"""@eng , """glioma, recurrent childhood brainstem"""@eng , """pediatric brain stem mixed glioma, recurrent"""@eng , """childhood brain stem mixed glioma, recurrent"""@eng , """brain tumor, recurrent brainstem glioma, pediatric"""@eng , """pediatric brain stem glioma, recurrent"""@eng , """brain tumor, recurrent brain stem glioma, childhood"""@eng , """glioma, recurrent childhood brain stem"""@eng , """mixed glioma, recurrent childhood brain stem"""@eng , """recurrent pediatric brain stem glioma"""@eng , """childhood brainstem mixed glioma, recurrent"""@eng , """CNS tumor, childhood brain stem glioma, recurrent"""@eng , """gliosarcoma, recurrent childhood brain stem"""@eng , """pediatric brain stem gliosarcoma, recurrent"""@eng , """CNS tumor, recurrent pediatric brain stem glioma"""@eng , """brainstem glioma, pediatric, recurrent"""@eng , """pediatric CNS tumor, recurrent brain stem glioma"""@eng , """CNS tumor, childhood brainstem glioma, recurrent"""@eng , """pediatric brainstem gliosarcoma, recurrent"""@eng , """gliosarcoma, recurrent childhood brainstem"""@eng , """brainstem glioma, childhood, recurrent"""@eng , """CNS tumor, recurrent childhood brain stem glioma"""@eng , """childhood CNS tumor, recurrent brain stem glioma"""@eng , """childhood CNS tumor, recurrent brainstem glioma"""@eng , """CNS tumor, recurrent brainstem glioma, childhood"""@eng , """childhood brain stem gliosarcoma, recurrent"""@eng , """mixed glioma, recurrent pediatric brainstem"""@eng , """brain stem glioma, pediatric, recurrent"""@eng , """mixed glioma, recurrent pediatric brain stem"""@eng , """gliosarcoma, recurrent pediatric brain stem"""@eng , """CNS tumor, recurrent childhood brainstem glioma"""@eng , """pediatric brainstem mixed glioma, recurrent"""@eng , """mixed glioma, recurrent childhood brainstem"""@eng , """brain tumor, recurrent brainstem glioma, childhood"""@eng , """brain stem glioma, childhood, recurrent"""@eng , """glioma, recurrent pediatric brainstem"""@eng , """CNS tumor, recurrent brain stem glioma, childhood"""@eng , """CNS tumor, pediatric brain stem glioma, recurrent"""@eng , """glioma, recurrent pediatric brain stem"""@eng , """childhood brainstem gliosarcoma, recurrent"""@eng , """pediatric CNS tumor, recurrent brainstem glioma"""@eng , """childhood brain stem glioma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood brain stem glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5742"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338329"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/prednisolone/vincristine"""@eng ; skos:notation """CDR0000042427"""^^xsd:string ; skos:altLabel """ASP/PRDL/VCR"""@eng ; ; ; ; """5744"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338330"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/prednisolone/vincristine"""@eng ; skos:notation """CDR0000042428"""^^xsd:string ; skos:altLabel """MP/PRDL/VCR"""@eng ; ; ; ; """5745"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338331"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KW 2189"""@eng ; skos:notation """CDR0000042429"""^^xsd:string ; skos:altLabel """KW-2189"""@eng , """Duocamycin B2 Analog"""@eng , """Benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic Acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methy-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7,-trimethoxy-1H-indol-2-yl)carbonyl)-, Methyl Ester (S)"""@eng ; skos:definition """A semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2. Activated by carboxyl esterase, KW 2189 alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42429&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42429&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1542\" NCI Thesaurus)"""@eng ; """5746"""^^xsd:string ; """154889-68-6"""^^xsd:string ; """C1542"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C0254093"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """surface-enhanced laser desorption/ionization-time of flight mass spectrometry"""@eng ; skos:notation """CDR0000258344"""^^xsd:string ; skos:altLabel """SELDI-TOF"""@eng , """SELDI-TOF-MS"""@eng ; rdfs:subClassOf ; """11491"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-05-23"""^^xsd:string ; umls:cui """C1327806"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/doxorubicin HCl liposome"""@eng ; skos:notation """CDR0000371732"""^^xsd:string ; skos:altLabel """LipoDox/PS-341"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541259"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/interleukin-2"""@eng ; skos:notation """CDR0000371731"""^^xsd:string ; skos:altLabel """CTX/FAMP/IL-2"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541258"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/recombinant fowlpox GM-CSF vaccine/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000371730"""^^xsd:string ; skos:altLabel """rF-GM-CSF/SC-58635/vCEA-TRI"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541257"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """R-flurbiprofen"""@eng ; skos:notation """CDR0000257154"""^^xsd:string ; skos:altLabel """(R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid"""@eng , """E-7869"""@eng , """MPC-7869"""@eng , """Flurizan"""@eng ; skos:definition """An orally active synthetic enantiomer of flurbiprofen. R-flurbiprofen activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257154&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257154&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26666\" NCI Thesaurus)"""@eng ; """11406"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """51543-40-9"""^^xsd:string ; """C26666"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527220"""^^xsd:string ; umls:cui """C1327754"""^^xsd:string ; umls:cui """C1327755"""^^xsd:string ; umls:cui """C1527219"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Virulizin"""@eng ; skos:notation """CDR0000257159"""^^xsd:string ; skos:altLabel """VIRU"""@eng ; skos:definition """A natural biological response modifier (BRM) isolated from bovine reticuloendothelial tissue. Viruzlin may enhance cell-mediated immune response to tumor cells by direct macrophage activation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257159&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257159&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26677\" NCI Thesaurus)"""@eng ; ; ; """11407"""^^xsd:string ; """216586-46-8"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26677"""^^xsd:string ; umls:cui """C0254455"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methylprednisolone"""@eng ; skos:notation """CDR0000043055"""^^xsd:string ; skos:altLabel """CTX/MePRDL"""@eng ; ; ; """7403"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678057"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nimotuzumab"""@eng ; skos:notation """CDR0000507582"""^^xsd:string ; skos:altLabel """Theraloc"""@eng , """TheraCim hR3"""@eng , """Thera-CIM-hr3"""@eng ; skos:definition """A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. In addition, this agent may act synergistically with radiation therapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=507582&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=507582&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2733\" NCI Thesaurus)"""@eng ; """2006-09-10"""^^xsd:string ; """C2733"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1570308"""^^xsd:string ; umls:cui """C1570482"""^^xsd:string ; umls:cui """C1710379"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/PALA"""@eng ; skos:notation """CDR0000041089"""^^xsd:string ; skos:altLabel """CF/5-FU/PALA"""@eng ; ; ; ; """4128"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280692"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ceftriaxone sodium"""@eng ; skos:notation """CDR0000041088"""^^xsd:string ; skos:altLabel """Rocephin"""@eng ; ; """TRD"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4127"""^^xsd:string ; """C817"""^^xsd:string ; umls:cui """C0700527"""^^xsd:string ; umls:cui """C0035750"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/methotrexate"""@eng ; skos:notation """CDR0000041083"""^^xsd:string ; skos:altLabel """BCNU/MTX"""@eng ; ; ; """4122"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280687"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/hydroxyurea"""@eng ; skos:notation """CDR0000041082"""^^xsd:string ; skos:altLabel """DNR/HU"""@eng ; ; ; """4121"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280686"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/thioguanine"""@eng ; skos:notation """CDR0000041081"""^^xsd:string ; skos:altLabel """CTX/TG"""@eng ; ; ; """4120"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280685"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041080"""^^xsd:string ; skos:altLabel """CTX/DNR/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """4119"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280684"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/thiotepa/vincristine"""@eng ; skos:notation """CDR0000041087"""^^xsd:string ; skos:altLabel """CDDP/CTX/TSPA/VCR/VP-16"""@eng ; ; ; ; ; ; """4126"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280691"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thiotepa/vincristine"""@eng ; skos:notation """CDR0000041086"""^^xsd:string ; skos:altLabel """TSPA/VCR"""@eng ; ; ; """4125"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280690"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/mitoxantrone"""@eng ; skos:notation """CDR0000041085"""^^xsd:string ; skos:altLabel """DHAD/IFF/VP-16"""@eng ; ; ; ; """4124"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280689"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/vincristine"""@eng ; skos:notation """CDR0000041084"""^^xsd:string ; skos:altLabel """ARA-C/VCR"""@eng ; ; ; """4123"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280688"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """everolimus/imatinib mesylate"""@eng ; skos:notation """CDR0000391021"""^^xsd:string ; skos:altLabel """RAD/STI571"""@eng ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """caseinate protein isolate"""@eng ; skos:notation """CDR0000466062"""^^xsd:string ; skos:definition """An isolate comprised of the sodium or calcium salt of the glycoprotein casein, the primary protein found in milk and other dairy products, with anti-catabolic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=466062&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=466062&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53440\" NCI Thesaurus)"""@eng ; """2006-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """C53440"""^^xsd:string ; umls:cui """C1707311"""^^xsd:string ; umls:tui """T168"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methyltestosterone"""@eng ; skos:notation """CDR0000039268"""^^xsd:string ; skos:altLabel """Metandren"""@eng , """Oreton"""@eng ; """1899"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0740109"""^^xsd:string ; umls:cui """C0740108"""^^xsd:string ; umls:cui """C0025826"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/azacitidine/etoposide"""@eng ; skos:notation """CDR0000039269"""^^xsd:string ; skos:altLabel """AMSA/AZA/VP-16"""@eng , """MAZE"""@eng , """AVA"""@eng ; ; ; ; """19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083355"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostaglandin agent"""@eng ; skos:notation """CDR0000039260"""^^xsd:string ; rdfs:subClassOf ; """1891"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0033554"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplastic hormone and synthetic substitute"""@eng ; skos:notation """CDR0000039261"""^^xsd:string ; skos:altLabel """hormone and synthetic substitute, antineoplastic"""@eng ; rdfs:subClassOf ; """1892"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279177"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplastic"""@eng ; skos:notation """CDR0000039262"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """1893"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003392"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """natural product"""@eng ; skos:notation """CDR0000039263"""^^xsd:string ; rdfs:subClassOf ; """1894"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C1566558"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioactive agent"""@eng ; skos:notation """CDR0000039264"""^^xsd:string ; rdfs:subClassOf ; """1895"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279165"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """miscellaneous antineoplastic"""@eng ; skos:notation """CDR0000039265"""^^xsd:string ; rdfs:subClassOf ; """1896"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003392"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxymetholone"""@eng ; skos:notation """CDR0000039266"""^^xsd:string ; skos:altLabel """HMD"""@eng , """CL-406"""@eng , """Anadrol-50 Anapolon"""@eng , """Anadrol"""@eng , """Adroyd"""@eng ; """2003-10-23"""^^xsd:string ; """1897"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0030072"""^^xsd:string ; umls:cui """C0878417"""^^xsd:string ; umls:cui """C0878416"""^^xsd:string ; umls:cui """C0733714"""^^xsd:string ; umls:cui """C0733713"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/vinorelbine"""@eng ; skos:notation """CDR0000349698"""^^xsd:string ; skos:altLabel """SC-58635/VNB"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328119"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin therapy"""@eng ; skos:notation """CDR0000041551"""^^xsd:string ; skos:altLabel """therapy, interleukin"""@eng ; ; rdfs:subClassOf ; """4711"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281177"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytokine therapy"""@eng ; skos:notation """CDR0000041550"""^^xsd:string ; skos:altLabel """therapy, cytokine"""@eng ; ; rdfs:subClassOf ; ; ; ; ; ; ; """4710"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0199974"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytokine therapy"""@eng ; skos:notation """CDR0000041553"""^^xsd:string ; skos:altLabel """therapy, anti-cytokine"""@eng ; ; rdfs:subClassOf ; ; ; """4715"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281178"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transfer factor therapy"""@eng ; skos:notation """CDR0000041552"""^^xsd:string ; skos:altLabel """therapy, transfer factor"""@eng ; ; rdfs:subClassOf ; """4712"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0259788"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphokine-activated killer cell therapy"""@eng ; skos:notation """CDR0000041555"""^^xsd:string ; skos:altLabel """LAK cell therapy"""@eng , """cell therapy, lymphokine-activated killer"""@eng , """therapy, lymphokine-activated killer cell"""@eng ; ; rdfs:subClassOf ; """4717"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0199976"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leukocyte therapy"""@eng ; skos:notation """CDR0000041554"""^^xsd:string ; ; rdfs:subClassOf ; ; ; ; ; ; """4716"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281179"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccine therapy"""@eng ; skos:notation """CDR0000041557"""^^xsd:string ; skos:altLabel """therapy, vaccine"""@eng ; ; rdfs:subClassOf ; ; ; ; """4719"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0042209"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-tumor cell derivative vaccine"""@eng ; skos:notation """CDR0000041556"""^^xsd:string ; skos:altLabel """vaccine, non-tumor cell derivative"""@eng ; ; rdfs:subClassOf ; """4718"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281180"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/leucovorin calcium/mitoxantrone/vinblastine"""@eng ; skos:notation """CDR0000041559"""^^xsd:string ; skos:altLabel """CF/DHAD/5-FU/IFN-A/VBL"""@eng ; ; ; ; ; ; """4720"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338157"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/paclitaxel"""@eng ; skos:notation """CDR0000375039"""^^xsd:string ; skos:altLabel """17-AAG/TAX"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541311"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/irinotecan"""@eng ; skos:notation """CDR0000370024"""^^xsd:string ; skos:altLabel """CPT-11/SC-58635"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541239"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/trastuzumab"""@eng ; skos:notation """CDR0000370025"""^^xsd:string ; skos:altLabel """MOAB HER2/STI571"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541240"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/verapamil/vincristine"""@eng ; skos:notation """CDR0000040143"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/VCR/VPAM"""@eng , """CVAD"""@eng ; ; ; ; ; ; """2908"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279842"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/hydrazine sulfate/vinblastine"""@eng ; skos:notation """CDR0000040142"""^^xsd:string ; skos:altLabel """CDDP/HDZ/VBL"""@eng ; ; ; ; """2907"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279841"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """narcotic antagonist"""@eng ; skos:notation """CDR0000040145"""^^xsd:string ; rdfs:subClassOf ; """2910"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0027410"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/fluorouracil/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040144"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/5-FU/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """2909"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279843"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/methotrexate/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040147"""^^xsd:string ; skos:altLabel """MTX/NM/PCB/PRED/VCR"""@eng ; ; ; ; ; ; """2912"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279845"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol/gefitinib"""@eng ; skos:notation """CDR0000370023"""^^xsd:string ; skos:altLabel """CALTROL/ZD 1839"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541238"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/filgrastim"""@eng ; skos:notation """CDR0000040149"""^^xsd:string ; skos:altLabel """ARA-C/G-CSF"""@eng ; ; ; """2916"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279847"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian stromal cancer"""@eng ; skos:notation """CDR0000040148"""^^xsd:string ; skos:altLabel """Ovarian stromal cancer"""@eng , """stromal cancer, ovarian"""@eng , """cancer, ovarian stromal"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2913"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1518236"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABT-510"""@eng ; skos:notation """CDR0000350157"""^^xsd:string ; skos:altLabel """ABT 510"""@eng ; skos:definition """A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350157&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350157&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37447\" NCI Thesaurus)"""@eng ; ; """2003-12-23"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """C37447"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1704426"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox virus vaccine vector/interleukin-2/vaccinia-tyrosinase vaccine"""@eng ; skos:notation """CDR0000043489"""^^xsd:string ; skos:altLabel """FOWLVAC/IL-2/VACTYROS"""@eng ; ; ; ; """8718"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796658"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-tyrosinase vaccine"""@eng ; skos:notation """CDR0000043488"""^^xsd:string ; skos:altLabel """VACTYROS"""@eng , """rV-TYR Vaccine"""@eng ; skos:definition """A vaccine consisting of recombinant vaccinia virus encoding the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43488&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43488&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531\" NCI Thesaurus)"""@eng ; ; ; ; """8717"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2531"""^^xsd:string ; """8375"""^^xsd:string ; """702140"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0796657"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/flavopiridol/paclitaxel"""@eng ; skos:notation """CDR0000043481"""^^xsd:string ; skos:altLabel """CDDP/FLAVO/TAX"""@eng ; ; ; ; """8693"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796644"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trichothiodystrophy"""@eng ; skos:notation """CDR0000043480"""^^xsd:string ; """2002-09-10"""^^xsd:string ; """8692"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1955934"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/vinorelbine"""@eng ; skos:notation """CDR0000043483"""^^xsd:string ; skos:altLabel """CAPE/VNB"""@eng ; ; ; """8700"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796645"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent anal cancer"""@eng ; skos:notation """CDR0000043482"""^^xsd:string ; skos:altLabel """recurrent anus cancer"""@eng , """anus cancer, recurrent"""@eng , """anal cancer, recurrent"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """87"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278556"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000043485"""^^xsd:string ; skos:altLabel """CTX/EPI/5-FU/MTX"""@eng ; ; ; ; ; """8702"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796647"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/melphalan"""@eng ; skos:notation """CDR0000043484"""^^xsd:string ; skos:altLabel """FAMP/L-PAM"""@eng ; ; ; """8701"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796646"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dehydrodemnin B"""@eng ; skos:notation """CDR0000043487"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """8704"""^^xsd:string ; umls:cui """C0388638"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/irinotecan"""@eng ; skos:notation """CDR0000043486"""^^xsd:string ; skos:altLabel """CPT-11/TXT"""@eng ; ; ; """8703"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796648"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/filgrastim/thiotepa"""@eng ; skos:notation """CDR0000041438"""^^xsd:string ; skos:altLabel """DOX/G-CSF/TSPA"""@eng ; ; ; ; """4508"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280986"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/thiotepa"""@eng ; skos:notation """CDR0000041439"""^^xsd:string ; skos:altLabel """DOX/TSPA"""@eng ; ; ; """4509"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280987"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MK0752"""@eng ; skos:notation """CDR0000446541"""^^xsd:string ; skos:definition """A synthetic small molecule with potential antineoplastic activity. MK0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated. The Notch signaling pathway plays an important role in cell-fate determination, cell survival, and cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446541&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446541&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49175\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """2005-09-09"""^^xsd:string ; """C49175"""^^xsd:string ; umls:cui """C1708824"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentoxifylline"""@eng ; skos:notation """CDR0000041432"""^^xsd:string ; skos:altLabel """3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione"""@eng , """Trental"""@eng , """Pentoxyphylline"""@eng , """oxpentifylline"""@eng , """PTX"""@eng ; skos:definition """A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41432&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41432&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C733\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; """4502"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """637086"""^^xsd:string ; """6493-05-6"""^^xsd:string ; """C733"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699487"""^^xsd:string ; umls:cui """C0030899"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclopentenyl cytosine"""@eng ; skos:notation """CDR0000041433"""^^xsd:string ; skos:altLabel """cyclopentenylcytosine"""@eng , """CPE-C"""@eng ; """Drug/agent"""^^xsd:string ; """C1359"""^^xsd:string ; """2006-12-05"""^^xsd:string ; """4503"""^^xsd:string ; umls:cui """C0111606"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/interleukin-3/leucovorin calcium/sargramostim"""@eng ; skos:notation """CDR0000041430"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/5-FU/GM-CSF/IL-3"""@eng ; ; ; ; ; ; ; """4500"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280980"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """previously untreated childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000041431"""^^xsd:string ; skos:altLabel """rhabdomyosarcoma, childhood, previously untreated"""@eng , """rhabdomyosarcoma, previously untreated, childhood"""@eng , """pediatric rhabdomyosarcoma, previously untreated"""@eng , """childhood rhabdomyosarcoma, previously untreated"""@eng ; rdfs:subClassOf ; """childhood rhabdomyosarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4501"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280981"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentoxifylline/suramin/thiotepa"""@eng ; skos:notation """CDR0000041436"""^^xsd:string ; skos:altLabel """PTX/SUR/TSPA"""@eng ; ; ; ; """4506"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280984"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000041437"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/MTX/VBL"""@eng ; ; ; ; ; """4507"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280985"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041434"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/PRDL/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4504"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0286248"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/suramin"""@eng ; skos:notation """CDR0000041435"""^^xsd:string ; skos:altLabel """DOX/SUR"""@eng ; ; ; """4505"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280983"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/interleukin-2/temozolomide"""@eng ; skos:notation """CDR0000257909"""^^xsd:string ; skos:altLabel """DTIC/IL-2/TMZ"""@eng ; ; ; ; """2002-10-01"""^^xsd:string ; """11473"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327795"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-p53 T-cell receptor-transduced peripheral blood lymphocytes"""@eng ; skos:notation """CDR0000523273"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831990"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EGFR antisense DNA/keyhole limpet hemocyanin"""@eng ; skos:notation """CDR0000038387"""^^xsd:string ; skos:altLabel """EGFR antiDNA/KLH"""@eng ; ; ; """11007"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134451"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 123"""@eng ; skos:notation """CDR0000518286"""^^xsd:string ; """2006-11-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0303023"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 124"""@eng ; skos:notation """CDR0000518287"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-03"""^^xsd:string ; umls:cui """C0303024"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pregabalin"""@eng ; skos:notation """CDR0000518288"""^^xsd:string ; skos:altLabel """Lyrica"""@eng ; """2006-11-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1570232"""^^xsd:string ; umls:cui """C0657912"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zalutumumab"""@eng ; skos:notation """CDR0000518289"""^^xsd:string ; skos:altLabel """HuMax-EGFr"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-03"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831978"""^^xsd:string ; umls:cui """C1831979"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/erlotinib/gemcitabine"""@eng ; skos:notation """CDR0000385655"""^^xsd:string ; skos:altLabel """dFdC/MOAB VEGF/OSI774"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541348"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CMC-544"""@eng ; skos:notation """CDR0000352004"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """2004-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328139"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HuMax-CD4"""@eng ; skos:notation """CDR0000352000"""^^xsd:string ; skos:altLabel """HuMax-CD4 monoclonal antibody"""@eng , """MOAB HuMax-CD4"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328138"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/goserelin"""@eng ; skos:notation """CDR0000420970"""^^xsd:string ; skos:altLabel """TXT/ZDX"""@eng ; ; ; """2005-02-18"""^^xsd:string ; """2005-02-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541513"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MB07133"""@eng ; skos:notation """CDR0000352009"""^^xsd:string ; skos:altLabel """cytarabine monophosphate prodrug"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328712"""^^xsd:string ; umls:cui """C1328140"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa/interleukin-6/sargramostim"""@eng ; skos:notation """CDR0000042165"""^^xsd:string ; skos:altLabel """EPO/GM-CSF/IL-6"""@eng ; ; ; ; """5405"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338189"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/mitoxantrone/thiotepa"""@eng ; skos:notation """CDR0000042167"""^^xsd:string ; skos:altLabel """CBDCA/DHAD/TSPA/VP-16"""@eng ; ; ; ; ; """5407"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281682"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/tamoxifen"""@eng ; skos:notation """CDR0000042166"""^^xsd:string ; skos:altLabel """IFN-A/IL-2/TMX"""@eng ; ; ; ; """5406"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338190"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/prednisone/procarbazine/vinblastine/vincristine"""@eng ; skos:notation """CDR0000042161"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/PCB/PRED/VBL/VCR"""@eng ; ; ; ; ; ; ; ; """5400"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281677"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000042160"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/FXM/IFN-A/TMX"""@eng ; ; ; ; ; ; """54"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278515"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042163"""^^xsd:string ; skos:altLabel """PRED/TG/VCR"""@eng ; ; ; ; """5402"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281679"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/epirubicin/fluorouracil"""@eng ; skos:notation """CDR0000042162"""^^xsd:string ; skos:altLabel """CDDP/EPI/5-FU"""@eng , """FEP"""@eng ; ; ; ; """5401"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281678"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/monoclonal antibody anti-alpha V beta 3 integrin/prednisone/zoledronate"""@eng ; skos:notation """CDR0000393518"""^^xsd:string ; skos:altLabel """MOAB anti-avb3 integrin/PRED/TXT/ZOLE"""@eng ; ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541373"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CI-980/filgrastim"""@eng ; skos:notation """CDR0000042169"""^^xsd:string ; skos:altLabel """CI-980/G-CSF"""@eng ; ; ; """5409"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """talc"""@eng ; skos:notation """CDR0000042168"""^^xsd:string ; skos:altLabel """Sterile Talc Powder"""@eng , """Sclerosol Intrapleural Aerosol"""@eng , """Steritalc"""@eng ; skos:definition """Finely-powdered native hydrous magnesium silicate. When administered into the pleural space, talc initiates an inflammatory reaction, resulting in adhesion of the visceral pleura to the parietal pleura and fibrosis, thereby effectively closing the pleural space and preventing further accumulation of fluid. This agent exhibits no intrinsic antineoplastic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42168&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42168&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C854\" NCI Thesaurus)"""@eng ; """5408"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """14807-96-6"""^^xsd:string ; """C854"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1330541"""^^xsd:string ; umls:cui """C1586910"""^^xsd:string ; umls:cui """C1710346"""^^xsd:string ; umls:cui """C0039267"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/GTI-2040"""@eng ; skos:notation """CDR0000355387"""^^xsd:string ; skos:altLabel """dFdC/GTI2040"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328183"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/strontium chloride Sr 89/zoledronate"""@eng ; skos:notation """CDR0000362075"""^^xsd:string ; skos:altLabel """DOX/Sr89/ZOLE"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541194"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/zoledronate"""@eng ; skos:notation """CDR0000362076"""^^xsd:string ; skos:altLabel """DOX/ZOLE"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541195"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/goserelin/strontium chloride Sr 89/zoledronate"""@eng ; skos:notation """CDR0000362077"""^^xsd:string ; skos:altLabel """DOX/Sr89/ZDX/ZOLE"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541196"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbon-11 acetate"""@eng ; skos:notation """CDR0000362071"""^^xsd:string ; skos:definition """The acetate salt of the radioisotope carbon-11. Although the mechanism is unclear, carbon-11 acetate preferentially accumulates in tumor tissue, serving as a tracer for imaging tumors with positron emission tomography (PET). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=362071&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=362071&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38712\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """2006-07-30"""^^xsd:string ; """C38712"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1098488"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/celecoxib"""@eng ; skos:notation """CDR0000362072"""^^xsd:string ; skos:altLabel """CAPE/SC-58635"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541192"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """OSI-7904L/oxaliplatin"""@eng ; skos:notation """CDR0000362073"""^^xsd:string ; skos:altLabel """L-OHP/OSI 7904L"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541193"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/leuprolide/strontium chloride Sr 89/zoledronate"""@eng ; skos:notation """CDR0000362078"""^^xsd:string ; skos:altLabel """DOX/LEUP/Sr89/ZOLE"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541197"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/goserelin/zoledronate"""@eng ; skos:notation """CDR0000362079"""^^xsd:string ; skos:altLabel """DOX/ZDX/ZOLE"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541198"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody B3"""@eng ; skos:notation """CDR0000038188"""^^xsd:string ; skos:altLabel """Y90-B3"""@eng , """MOAB B3, yttrium Y 90"""@eng , """90 Y-B3"""@eng , """Y 90 monoclonal antibody B3"""@eng ; skos:definition """A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38188&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38188&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2614\" NCI Thesaurus)"""@eng ; """10772"""^^xsd:string ; """C2614"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935761"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody B3"""@eng ; skos:notation """CDR0000038189"""^^xsd:string ; skos:altLabel """B3, indium In 111 monoclonal antibody"""@eng , """MOAB B3, indium In 111"""@eng , """In 111 monoclonal antibody B3"""@eng , """In111 MOAB B3"""@eng ; """10773"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935762"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """caspofungin acetate"""@eng ; skos:notation """CDR0000038182"""^^xsd:string ; skos:altLabel """L-743,873"""@eng , """MK-0991"""@eng , """Cancidas"""@eng ; skos:definition """The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38182&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38182&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1724\" NCI Thesaurus)"""@eng ; """10762"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """C1724"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0935943"""^^xsd:string ; umls:cui """C0935942"""^^xsd:string ; umls:cui """C0537895"""^^xsd:string ; umls:cui """C0935984"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol/carboplatin"""@eng ; skos:notation """CDR0000038180"""^^xsd:string ; skos:altLabel """CALTROL/CBDCA"""@eng ; ; ; """10759"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935755"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/rituximab/vincristine"""@eng ; skos:notation """CDR0000038181"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB IDEC-C2B8/VCR/VP-16"""@eng ; ; ; ; ; ; """10760"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935756"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/methylprednisolone/mycophenolate mofetil"""@eng ; skos:notation """CDR0000038186"""^^xsd:string ; skos:altLabel """CYSP/MePRDL/MMF"""@eng ; ; ; ; """10770"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935759"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/fludarabine/melphalan"""@eng ; skos:notation """CDR0000038187"""^^xsd:string ; skos:altLabel """ATG/FAMP/L-PAM"""@eng ; ; ; ; """10771"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935760"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus encoding recombinant human endostatin"""@eng ; skos:notation """CDR0000486329"""^^xsd:string ; skos:altLabel """Ad-rhENDO"""@eng , """E10A"""@eng ; skos:definition """A replication-defective, recombinant oncolytic adenovirus encoding human endostatin with potential antineoplastic activity. Endostatin, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, is an important angiogenesis inhibitor. Upon intratumoral administration, the adenovirus infects and replicates in tumor cells. The expressed endostatin may inhibit endothelial cell proliferation and angiogenesis which may result in a reduction of tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486329&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486329&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61492\" NCI Thesaurus)"""@eng ; """2006-05-19"""^^xsd:string ; """2006-10-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61492"""^^xsd:string ; umls:cui """C1831833"""^^xsd:string ; umls:cui """C1831834"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """INS316"""@eng ; skos:notation """CDR0000038185"""^^xsd:string ; skos:altLabel """uridine 5-triphosphate solution"""@eng , """UTP solution"""@eng ; """10769"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935963"""^^xsd:string ; umls:cui """C0935758"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """esophageal cancer screening"""@eng ; skos:notation """CDR0000038145"""^^xsd:string ; skos:altLabel """early detection of esophageal cancer"""@eng , """esophageal cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """10726"""^^xsd:string ; umls:cui """C0935730"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody RAV12"""@eng ; skos:notation """CDR0000415732"""^^xsd:string ; skos:altLabel """anti-RAAG12 MOAB"""@eng , """anti-RAAG12 monoclonal antibody"""@eng , """RAV12"""@eng ; skos:definition """A chimeric monoclonal antibody directed against a primate-restricted N-linked carbohydrate epitope (glycotope) expressed on various human carcinomas with potential antineoplastic activity. Following binding, monoclonal antibody RAV12 disrupts sodium channels of tumor cells expressing this glycotope, resulting in cell and organelle swelling, loss of membrane integrity, and cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415732&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415732&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48409\" NCI Thesaurus)"""@eng ; """2005-01-13"""^^xsd:string ; """C48409"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541489"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stromal predominant Wilms' tumor"""@eng ; skos:notation """CDR0000039895"""^^xsd:string ; skos:altLabel """stromal predominant Wilm's tumor"""@eng , """Wilm's tumor, stromal predominant"""@eng , """Wilms tumor, stromal predominant"""@eng , """Wilms' tumor, stromal predominant"""@eng , """stromal predominant Wilms tumor"""@eng ; rdfs:subClassOf ; """2576"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279610"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sevoflurane"""@eng ; skos:notation """CDR0000524061"""^^xsd:string ; skos:altLabel """1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane"""@eng , """Ether, Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl-"""@eng , """Ultane"""@eng ; skos:definition """A fluorinated isopropyl ether with general anesthetic property. Although the mechanism of action has not been fully elucidated, sevoflurane may act by interfering with the release and re-uptake of neurotransmitters at post-synaptic terminals, and/or alter ionic conductance following receptor activation by a neurotransmitter. Sevoflurane may also interact directly with lipid matrix of neuronal membranes, thereby affecting gating properties of ion channels. In addition, this agent may activate gamma-aminobutyric acid (GABA) receptors hyperpolarizing cell membranes. This results in a general anesthetic effect, a decrease in myocardial contractility and mean arterial pressure as well as an increased respiratory rate. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=524061&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=524061&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47717\" NCI Thesaurus)"""@eng ; """28523-86-6"""^^xsd:string ; """2006-12-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C47717"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0724047"""^^xsd:string ; umls:cui """C0074414"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sufentanil citrate"""@eng ; skos:notation """CDR0000524060"""^^xsd:string ; skos:altLabel """N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide Citrate"""@eng , """Fentatienil"""@eng , """Sufenta"""@eng , """Propanamide, N-(4-(methoxymethyl)-1-(2-(thienyl)ethyl)-4-piperidinyl)-N-phenyl-, 2-hydroxy-1,2,3-propanetricarboxylate(1:1)"""@eng , """N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-N-phenylpropionamide Citrate"""@eng ; skos:definition """The citrate salt form of sufentanil, a synthetic congener of fentanyl and related to the phenylpieridines, with analgesic property. Sufentanil citrate binds to and activates the mu-opioid receptor, thereby producing analgesia, respiratory depression, miosis, reduced gastrointestinal motility, and euphoria. In addition, this agent has a more rapid onset of action and shorter duration of action compared to fentanyl. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=524060&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=524060&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47731\" NCI Thesaurus)"""@eng ; """60561-17-3"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-01"""^^xsd:string ; """C47731"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733851"""^^xsd:string ; umls:cui """C0162792"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adenoid cystic carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040709"""^^xsd:string ; skos:altLabel """adenoid cystic carcinoma of the oral cavity, stage III"""@eng , """oral cavity adenoid cystic carcinoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3648"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280357"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III mucoepidermoid carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040708"""^^xsd:string ; skos:altLabel """mucoepidermoid carcinoma of the oral cavity, stage III"""@eng , """oral cavity mucoepidermoid carcinoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3647"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280356"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """blastema predominant Wilms' tumor"""@eng ; skos:notation """CDR0000039894"""^^xsd:string ; skos:altLabel """blastema predominant Wilm's tumor"""@eng , """Wilm's tumor, blastema predominant"""@eng , """Wilms tumor, blastema predominant"""@eng , """Wilms' tumor, blastema predominant"""@eng , """blastema predominant Wilms tumor"""@eng ; rdfs:subClassOf ; """2575"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279609"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II mucoepidermoid carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040703"""^^xsd:string ; skos:altLabel """mucoepidermoid carcinoma of the oral cavity, stage II"""@eng , """oral cavity mucoepidermoid carcinoma, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3642"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280351"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II verrucous carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040702"""^^xsd:string ; skos:altLabel """oral cavity verrucous carcinoma, stage II"""@eng , """verrucous carcinoma of the oral cavity, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3641"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280350"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II basal cell carcinoma of the lip"""@eng ; skos:notation """CDR0000040701"""^^xsd:string ; skos:altLabel """lip basal cell carcinoma, stage II"""@eng , """basal cell carcinoma of the lip, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3640"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280349"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lonafarnib/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000329986"""^^xsd:string ; skos:altLabel """MOAB HER2/SCH 66336/TAX"""@eng ; ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328038"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III verrucous carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040707"""^^xsd:string ; skos:altLabel """oral cavity verrucous carcinoma, stage III"""@eng , """verrucous carcinoma of the oral cavity, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3646"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280355"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III basal cell carcinoma of the lip"""@eng ; skos:notation """CDR0000040706"""^^xsd:string ; skos:altLabel """basal cell carcinoma of the lip, stage III"""@eng , """lip basal cell carcinoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3645"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280354"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III squamous cell carcinoma of the lip and oral cavity"""@eng ; skos:notation """CDR0000040705"""^^xsd:string ; skos:altLabel """lip and oral cavity squamous cell carcinoma, stage III"""@eng , """oral cavity and lip squamous cell carcinoma, stage III"""@eng , """epidermoid carcinoma of the lip and oral cavity, stage III"""@eng , """squamous cell carcinoma of the lip and oral cavity, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3644"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280353"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adenoid cystic carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040704"""^^xsd:string ; skos:altLabel """oral cavity adenoid cystic carcinoma, stage II"""@eng , """adenoid cystic carcinoma of the oral cavity, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3643"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280352"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """differentiated adrenocortical carcinoma"""@eng ; skos:notation """CDR0000039859"""^^xsd:string ; skos:altLabel """adrenal cortex cancer, differentiated"""@eng , """differentiated adrenocortical cancer"""@eng , """carcinoma, differentiated adrenocortical"""@eng , """adrenal cortex carcinoma, differentiated"""@eng , """carcinoma, adrenocortical, differentiated"""@eng , """adrenocortical carcinoma, differentiated"""@eng ; rdfs:subClassOf ; """2540"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279578"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """combined type small cell lung cancer"""@eng ; skos:notation """CDR0000039858"""^^xsd:string ; skos:altLabel """combined type SCLC"""@eng , """SCLC, combined type"""@eng , """lung cancer, combined type, small cell"""@eng , """small cell lung cancer, combined type"""@eng ; rdfs:subClassOf ; """2539"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279572"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fusiform type small cell lung cancer"""@eng ; skos:notation """CDR0000039857"""^^xsd:string ; skos:altLabel """lung cancer, fusiform type, small cell"""@eng , """small cell lung cancer, fusiform type"""@eng , """fusiform type SCLC"""@eng , """SCLC, fusiform type"""@eng ; rdfs:subClassOf ; """2538"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279571"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized malignant mesothelioma"""@eng ; skos:notation """CDR0000038143"""^^xsd:string ; skos:altLabel """malignant mesothelioma, localized"""@eng , """localized mesothelial sarcoma"""@eng , """mesothelial sarcoma, localized"""@eng , """mesothelioma, malignant, localized"""@eng ; rdfs:subClassOf ; """malignant mesothelioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1072"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278751"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intermediate type small cell lung cancer"""@eng ; skos:notation """CDR0000039855"""^^xsd:string ; skos:altLabel """intermediate type SCLC"""@eng , """lung cancer, intermediate type, small cell"""@eng , """small cell lung cancer, intermediate type"""@eng , """SCLC, intermediate type"""@eng ; rdfs:subClassOf ; """2536"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279569"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphocyte-like type small cell lung cancer"""@eng ; skos:notation """CDR0000039854"""^^xsd:string ; skos:altLabel """lymphocyte-like type SCLC"""@eng , """small cell lung cancer, lymphocyte-like type"""@eng , """oat cell type lung cancer"""@eng , """lung cancer, lymphocyte-like type, small cell"""@eng , """SCLC, lymphocyte-like type"""@eng ; rdfs:subClassOf ; """2535"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279568"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Paget's disease of the breast with invasive ductal carcinoma"""@eng ; skos:notation """CDR0000039853"""^^xsd:string ; rdfs:subClassOf ; """2534"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279567"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Paget's disease of the breast with intraductal carcinoma"""@eng ; skos:notation """CDR0000039852"""^^xsd:string ; rdfs:subClassOf ; """2533"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279566"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Paget's disease of the breast"""@eng ; skos:notation """CDR0000039851"""^^xsd:string ; rdfs:subClassOf ; """2532"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0030185"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """invasive lobular breast carcinoma"""@eng ; skos:notation """CDR0000039850"""^^xsd:string ; skos:altLabel """lobular invasive breast carcinoma"""@eng ; rdfs:subClassOf ; """2531"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279565"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Hypericum perforatum"""@eng ; skos:notation """CDR0000037989"""^^xsd:string ; skos:altLabel """HyP"""@eng , """St John's Wort"""@eng , """Klamath weed"""@eng ; skos:definition """An herbal preparation isolated from the plant St. John's Wort with photodynamic, antineoplastic, and antidepressant properties. Hypericin, one of the active compounds found in hypericum perforatum, is a photosensitizer that, when exposed to a particular wavelength and intensity of light, may induce tumor cell apoptosis. Another compound, hyperforin, induces caspase-dependent apoptosis in certain tumor cell lines. Hypericum perforatum preparations may also stimulate the activity of cytochrome P450 enzymes and P-glycoprotein drug transporters, resulting in increased metabolism and decreased efficacy of various chemotherapeutic agents and other drugs. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37989&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37989&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2589\" NCI Thesaurus)"""@eng ; ; """10418"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2589"""^^xsd:string ; umls:cui """C0813171"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000037988"""^^xsd:string ; skos:altLabel """CF/FUDR/L-OHP"""@eng ; ; ; ; """10417"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000038728"""^^xsd:string ; skos:altLabel """lymphocytic leukemia, relapsed chronic"""@eng , """leukemia, relapsed chronic lymphocytic"""@eng , """chronic lymphocytic leukemia, refractory"""@eng , """relapsed chronic lymphocytic leukemia"""@eng , """lymphocytic leukemia, refractory chronic"""@eng , """chronic lymphocytic leukemia, relapsed"""@eng , """refractory CLL"""@eng , """leukemia, refractory chronic lymphocytic"""@eng , """CLL, relapsed"""@eng , """relapsed CLL"""@eng , """CLL, refractory"""@eng ; rdfs:subClassOf ; """chronic lymphocytic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1158"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278791"""^^xsd:string ; umls:cui """C0854802"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000038729"""^^xsd:string ; skos:altLabel """GTT"""@eng , """trophoblastic tumor, gestational"""@eng , """Gestational trophoblastic tumor"""@eng , """trophoblastic tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1163"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1135868"""^^xsd:string ; umls:cui """C0041182"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/selenium"""@eng ; skos:notation """CDR0000037983"""^^xsd:string ; skos:altLabel """SC-58635/SEL"""@eng ; ; ; """10407"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879517"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine/sulindac"""@eng ; skos:notation """CDR0000037982"""^^xsd:string ; skos:altLabel """DFMO/SULIN"""@eng ; ; ; """10400"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879516"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """molybdenum"""@eng ; skos:notation """CDR0000038724"""^^xsd:string ; skos:altLabel """Mo"""@eng ; skos:definition """An element with atomic symbol Mo, atomic number 42, and atomic weight 95.94. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38724&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38724&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C666\" NCI Thesaurus)"""@eng ; """1152"""^^xsd:string ; """7439-98-7"""^^xsd:string ; """C666"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C0026402"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/vincristine"""@eng ; skos:notation """CDR0000037980"""^^xsd:string ; skos:altLabel """BLEO/CTX/DHAD/PRDL/VCR/VP-16"""@eng ; ; ; ; ; ; ; """10399"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879515"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gadopentetate dimeglumine"""@eng ; skos:notation """CDR0000037987"""^^xsd:string ; skos:altLabel """Gd-DTPA"""@eng , """Magnevist"""@eng , """gadolinium DTPA"""@eng ; skos:definition """A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37987&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37987&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2588\" NCI Thesaurus)"""@eng ; """10412"""^^xsd:string ; """86050-77-3"""^^xsd:string ; """C2588"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0060933"""^^xsd:string ; umls:cui """C0721529"""^^xsd:string ; umls:cui """C0060934"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/filgrastim/methylprednisolone/monoclonal antibody OKT3"""@eng ; skos:notation """CDR0000037986"""^^xsd:string ; skos:altLabel """CYSP/G-CSF/MePRDL/MOAB OKT3"""@eng ; ; ; ; ; """10411"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879520"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/SU5416"""@eng ; skos:notation """CDR0000037985"""^^xsd:string ; skos:altLabel """CPT-11/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10409"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879519"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """O6-benzylguanine/temozolomide"""@eng ; skos:notation """CDR0000037984"""^^xsd:string ; skos:altLabel """BG/TMZ"""@eng ; ; ; """10408"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879518"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/danazol/medroxyprogesterone/tamoxifen"""@eng ; skos:notation """CDR0000040448"""^^xsd:string ; skos:altLabel """AGT/DAN/MPA/TMX"""@eng , """POND"""@eng ; ; ; ; ; """3320"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280091"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinorelbine ditartrate"""@eng ; skos:notation """CDR0000040449"""^^xsd:string ; skos:altLabel """Navelbine Ditartrate"""@eng , """Navelbine"""@eng , """NVB"""@eng , """Eunades"""@eng , """VNB"""@eng , """Vinorelbine Tartrate"""@eng , """Biovelbin"""@eng ; skos:definition """The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40449&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40449&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1395\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """608210"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3322"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C1395"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0131965"""^^xsd:string ; umls:cui """C1520001"""^^xsd:string ; umls:cui """C0377401"""^^xsd:string ; umls:cui """C0078257"""^^xsd:string ; umls:cui """C1520000"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pulmonary carcinoid tumor"""@eng ; skos:notation """CDR0000040444"""^^xsd:string ; skos:altLabel """carcinoid tumor, pulmonary"""@eng , """Pulmonary carcinoid tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3313"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280089"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oblimersen/rituximab"""@eng ; skos:notation """CDR0000271371"""^^xsd:string ; skos:altLabel """G3139/MOAB IDEC-C2B8"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327883"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trifluoperazine hydrochloride"""@eng ; skos:notation """CDR0000040446"""^^xsd:string ; ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-12-05"""^^xsd:string ; """C904"""^^xsd:string ; """3318"""^^xsd:string ; umls:cui """C0304381"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-tyrosinase vaccine"""@eng ; skos:notation """CDR0000271373"""^^xsd:string ; skos:altLabel """rF-TYR"""@eng , """FOWLTYROS"""@eng , """rFowlpox-Tyrosinase"""@eng , """rF-TYR vaccine (Tyrosinase-Fowl Pox)"""@eng , """Fowlpox-Tyrosinase"""@eng , """Recombinant Fowlpox-Tyrosinase"""@eng , """rF-TYR Vaccine"""@eng , """Recombinant Fowlpox-Tyrosinase Vaccine"""@eng ; skos:definition """A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, the fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271373&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271373&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2807\" NCI Thesaurus)"""@eng ; ; """2003-01-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """702141"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C2807"""^^xsd:string ; umls:cui """C1327884"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-tyrosinase vaccine/interleukin-2/vaccinia-tyrosinase vaccine"""@eng ; skos:notation """CDR0000271374"""^^xsd:string ; skos:altLabel """FOWLTYROS/IL-2/VACTYROS"""@eng ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327885"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """blood formation and coagulation agent"""@eng ; skos:notation """CDR0000040441"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3310"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280087"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T-gamma lymphoproliferative disorder"""@eng ; skos:notation """CDR0000040442"""^^xsd:string ; skos:altLabel """Leukemia, T-gamma lymphoproliferative disorder"""@eng , """T gamma lymphoproliferative disorder"""@eng , """lymphoproliferative disorder, T-gamma"""@eng , """T-gamma-lymphoproliferative disorder"""@eng ; rdfs:subClassOf ; """2003-05-22"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3311"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C1955861"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CL 246738"""@eng ; skos:notation """CDR0000040443"""^^xsd:string ; """3312"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0285036"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PR1 leukemia peptide vaccine"""@eng ; skos:notation """CDR0000037873"""^^xsd:string ; skos:altLabel """PR1 vac"""@eng ; skos:definition """A cancer vaccine consisting of PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3. Vaccination with PR1 leukemia peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Proteinase 3 is often overexpressed in leukemic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37873&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37873&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2235\" NCI Thesaurus)"""@eng ; ; """10276"""^^xsd:string ; """C2235"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; umls:cui """C0879440"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """surgical wound healing"""@eng ; skos:notation """CDR0000037872"""^^xsd:string ; ; rdfs:subClassOf ; """10275"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0879439"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes"""@eng ; skos:notation """CDR0000037871"""^^xsd:string ; skos:altLabel """Therapeutic Allogeneic Lymphocyte"""@eng , """ALLOLYMPH"""@eng ; skos:definition """A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37871&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37871&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28676\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """10274"""^^xsd:string ; """C28676"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; umls:cui """C0879438"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent malignant mesothelioma"""@eng ; skos:notation """CDR0000038160"""^^xsd:string ; skos:altLabel """malignant mesothelioma, recurrent"""@eng , """mesothelial sarcoma, recurrent"""@eng , """recurrent mesothelial sarcoma"""@eng , """mesothelioma, recurrent malignant"""@eng ; rdfs:subClassOf ; """malignant mesothelioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1074"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278753"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-grade squamous intraepithelial lesion"""@eng ; skos:notation """CDR0000321379"""^^xsd:string ; skos:altLabel """CIN 3"""@eng , """CIN 2"""@eng , """CIN II"""@eng , """HSIL"""@eng , """high-grade squamous intraepithelial neoplasia"""@eng , """CIN III"""@eng , """cervical intraepithelial neoplasia 2"""@eng , """cervical intraepithelial neoplasia 3"""@eng ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2004-03-14"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C0333875"""^^xsd:string ; umls:cui """C0349459"""^^xsd:string ; umls:cui """C0851140"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pleomorphic childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000039899"""^^xsd:string ; skos:altLabel """rhabdomyosarcoma, pediatric pleomorphic"""@eng , """rhabdomyosarcoma, pleomorphic childhood"""@eng , """pleomorphic pediatric rhabdomyosarcoma"""@eng , """pediatric rhabdomyosarcoma, pleomorphic"""@eng , """childhood rhabdomyosarcoma, pleomorphic"""@eng , """rhabdomyosarcoma, childhood pleomorphic"""@eng ; rdfs:subClassOf ; """2580"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279614"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/erlotinib"""@eng ; skos:notation """CDR0000357522"""^^xsd:string ; skos:altLabel """CDDP/OSI774/TXT"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328228"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan/leucovorin calcium/triacetyluridine"""@eng ; skos:notation """CDR0000357523"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/TAU"""@eng ; ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328229"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/lonafarnib/paclitaxel"""@eng ; skos:notation """CDR0000357521"""^^xsd:string ; skos:altLabel """CBDCA/SCH 66336/TAX"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328227"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """O6-benzylguanine/polifeprosan 20 with carmustine implant"""@eng ; skos:notation """CDR0000037874"""^^xsd:string ; skos:altLabel """BG/Gliadel"""@eng ; ; ; """10277"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879441"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Fluvastatin Sodium"""@eng ; skos:notation """CDR0000487588"""^^xsd:string ; skos:altLabel """Lescol"""@eng , """(3R,5S,6E)-(+/-)-7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic Acid"""@eng ; skos:definition """The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Due to anti-inflammatory effects mediated by their alterations of lipid metabolism, statins may possess chemopreventive and therapeutic antineoplastic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487588&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487588&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29062\" NCI Thesaurus)"""@eng ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """93957-55-2"""^^xsd:string ; """C29062"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0246203"""^^xsd:string ; umls:cui """C0591720"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palifermin"""@eng ; skos:notation """CDR0000042905"""^^xsd:string ; skos:altLabel """growth factor, recombinant human keratinocyte"""@eng , """rhu keratinocyte growth factor"""@eng , """recombinant human keratinocyte growth factor"""@eng , """keratinocyte growth factor, recombinant human"""@eng , """rHuKGF"""@eng , """Kepivance"""@eng , """rhKGF"""@eng ; skos:definition """A recombinant form of the endogenous human keratinocyte growth factor. Palifermin binds to epithelial cell surface receptors in the lining of the mouth and gastrointestinal tract, resulting in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42905&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42905&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C43599\" NCI Thesaurus)"""@eng ; """6736"""^^xsd:string ; """C43599"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0677829"""^^xsd:string ; umls:cui """C1589890"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alveolar childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000039898"""^^xsd:string ; skos:altLabel """rhabdomyosarcoma, pediatric alveolar"""@eng , """rhabdomyosarcoma, childhood alveolar"""@eng , """rhabdomyosarcoma, alveolar childhood"""@eng , """pediatric rhabdomyosarcoma, alveolar"""@eng , """childhood rhabdomyosarcoma, alveolar"""@eng , """alveolar pediatric rhabdomyosarcoma"""@eng ; rdfs:subClassOf ; """2579"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279613"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium 99m sestamibi"""@eng ; skos:notation """CDR0000037878"""^^xsd:string ; """10281"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0162680"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NRAS"""@eng ; skos:notation """CDR0000043188"""^^xsd:string ; rdfs:subClassOf ; """7631"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0809246"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buspirone hydrochloride"""@eng ; skos:notation """CDR0000270391"""^^xsd:string ; skos:altLabel """Buspar"""@eng ; skos:definition """The hydrochloride salt of an anxiolytic agent chemically and pharmacologically unrelated to benzodiazepines, barbiturates, or other sedative/hypnotic drugs. Although its exact mechanism of action is unknown, buspirone may exert its anti-anxiety effects via serotonin (5-HT1A) and dopamine receptors (D2) and may indirectly affect other neurotransmitter systems. Unlike typical benzodiazepine anxiolytics, this agent does not exert anticonvulsant or muscle relaxant effects and lacks prominent sedative effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=270391&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=270391&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26641\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2003-01-26"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26641"""^^xsd:string ; umls:cui """C0700444"""^^xsd:string ; umls:cui """C0600122"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/imatinib mesylate/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000270390"""^^xsd:string ; skos:altLabel """CF/CTX/MTX/STI571/VP-16"""@eng ; ; ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327868"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical adenocarcinoma"""@eng ; skos:notation """CDR0000039962"""^^xsd:string ; skos:altLabel """cervix cancer, adenocarcinoma"""@eng , """adenocarcinoma of the cervix"""@eng , """cervical cancer, adenocarcinoma"""@eng , """uterine cervix cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2667"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279672"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IVB cervical cancer"""@eng ; skos:notation """CDR0000038654"""^^xsd:string ; skos:altLabel """stage IVB cervix cancer"""@eng , """metastatic carcinoma of the cervix"""@eng , """uterine cervix cancer, stage IVB"""@eng , """stage IVB carcinoma of the cervix"""@eng , """stage IVB cancer of the cervix"""@eng , """cervix cancer, stage IVB"""@eng , """carcinoma of the cervix, metastatic"""@eng , """carcinoma of the cervix, stage IVB"""@eng , """cancer of the cervix, stage IVB"""@eng , """cervical cancer, stage IVB"""@eng , """uterine cervical cancer, metastatic"""@eng , """metastatic uterine cervix cancer"""@eng , """cervix cancer, metastatic"""@eng , """cancer of the cervix, metastatic"""@eng , """uterine cervical cancer, stage IVB"""@eng , """cervical cancer, metastatic"""@eng , """uterine cervix cancer, metastatic"""@eng , """stage IVB uterine cervix cancer"""@eng , """metastatic cancer of the cervix"""@eng , """metastatic cervical cancer"""@eng , """metastatic cervix cancer"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """113"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278584"""^^xsd:string ; umls:cui """C1527418"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical squamous cell carcinoma"""@eng ; skos:notation """CDR0000039961"""^^xsd:string ; skos:altLabel """cancer of the cervix, squamous cell"""@eng , """cervical epidermoid carcinoma"""@eng , """carcinoma of the cervix, squamous cell"""@eng , """uterine cervical cancer, squamous cell carcinoma"""@eng , """cervical cancer, squamous cell carcinoma"""@eng , """uterine cervix cancer, squamous cell carcinoma"""@eng , """squamous cell carcinoma of the cervix"""@eng , """epidermoid carcinoma of the cervix"""@eng , """squamous cell cancer of the cervix"""@eng , """cervix cancer, squamous cell carcinoma"""@eng ; rdfs:subClassOf ; """2666"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279671"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tadalafil"""@eng ; skos:notation """CDR0000462366"""^^xsd:string ; skos:altLabel """Ic351"""@eng , """Cialis"""@eng , """(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione"""@eng ; skos:definition """A carboline-based compound with vasodilatory properties. Tadalfil selectively inhibits the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase- (PDE-5)-mediated degradation of cGMP, which is found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis. Inhibition of cGMP degradation by tadalfil results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462366&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462366&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47743\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """171596-29-5"""^^xsd:string ; """C47743"""^^xsd:string ; """2006-06-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C0967376"""^^xsd:string ; umls:cui """C0967375"""^^xsd:string ; umls:cui """C1176316"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bemiparin sodium"""@eng ; skos:notation """CDR0000463367"""^^xsd:string ; skos:altLabel """Zibor"""@eng , """Hibor"""@eng , """Badyket"""@eng , """Ivor"""@eng ; skos:definition """The sodium salt of bemiparin, a second generation, synthetic, low-molecular-weight heparin (LMWH) with anticoagulant activity. Derived, after depolymerisation and fractionation, from medical-grade porcine unfractionated heparin (UFH), bemiparin has an average molecular weight of 3,600 daltons and has a higher anti-factor Xa/anti-factor IIa ratio (8:1) than first-generation LMWHs. This anticoagulant binds to antithrombin III, thereby enhancing the inactivation of activated Factor X (Factor Xa) and, to a lesser extent, activated factor II (Factor IIa). Compared to unfractionated heparins, the use of bemiparin is associated with lower incidences of major bleeding, osteoporosis, and heparin-induced thrombocytopenia. Bemiparin also promotes a greater release of tissue factor pathway inhibitor than UFH or dalteparin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463367&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463367&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53400\" NCI Thesaurus)"""@eng ; """C53400"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1711159"""^^xsd:string ; umls:cui """C1529923"""^^xsd:string ; umls:cui """C1365493"""^^xsd:string ; umls:cui """C1706919"""^^xsd:string ; umls:cui """C1706918"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CGP 48664"""@eng ; skos:notation """CDR0000042601"""^^xsd:string ; skos:altLabel """CGP 48 664"""@eng , """CGP48664"""@eng ; """6321"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0379972"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/vindesine"""@eng ; skos:notation """CDR0000039633"""^^xsd:string ; skos:altLabel """VAP"""@eng , """CDDP/DAVA/DOX"""@eng ; ; ; ; """2288"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0052148"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/prednisone"""@eng ; skos:notation """CDR0000039632"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/PRED"""@eng , """CAFP"""@eng ; ; ; ; ; """2287"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279419"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bovine cartilage"""@eng ; skos:notation """CDR0000042603"""^^xsd:string ; """6323"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0106940"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """comparison of screening methods"""@eng ; skos:notation """CDR0000038618"""^^xsd:string ; ; rdfs:subClassOf ; """11246"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134629"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ravuconazole"""@eng ; skos:notation """CDR0000315643"""^^xsd:string ; skos:altLabel """BMS-207147"""@eng , """ER-30346"""@eng ; skos:definition """A triazole with antifungal activity. Ravuconazole inhibits 14a demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315643&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315643&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38688\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C38688"""^^xsd:string ; umls:cui """C0535185"""^^xsd:string ; umls:cui """C0754490"""^^xsd:string ; umls:cui """C0535186"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """long-term screening"""@eng ; skos:notation """CDR0000038619"""^^xsd:string ; ; rdfs:subClassOf ; """11247"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134630"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HPV 16 E7:12-20 peptide vaccine"""@eng ; skos:notation """CDR0000042605"""^^xsd:string ; ; ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """6325"""^^xsd:string ; umls:cui """C1522082"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """study of socioeconomic and demographic variables"""@eng ; skos:notation """CDR0000038616"""^^xsd:string ; ; rdfs:subClassOf ; """11244"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134714"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mutation carrier screening"""@eng ; skos:notation """CDR0000038617"""^^xsd:string ; ; rdfs:subClassOf ; """11245"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134628"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000038024"""^^xsd:string ; skos:altLabel """pediatric lymphoblastic non-Hodgkin's lymphoma, recurrent"""@eng , """recurrent lymphoblastic childhood lymphoma"""@eng , """lymphoblastic recurrent non-Hodgkin's lymphoma, childhood"""@eng , """non-Hodgkin's lymphoma, lymphoblastic recurrent, childhood"""@eng , """relapsed lymphoblastic childhood lymphoma"""@eng , """lymphoma, non-Hodgkin's, lymphoblastic recurrent, childhood"""@eng , """childhood non-Hodgkin's lymphoma, lymphoblastic recurrent"""@eng , """relapsed childhood lymphoblastic lymphoma"""@eng , """NHL, lymphoblastic recurrent childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1054"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278739"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/filgrastim/fluorouracil"""@eng ; skos:notation """CDR0000042607"""^^xsd:string ; skos:altLabel """CTX/EPI/5-FU/G-CSF"""@eng ; ; ; ; ; """6328"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393018"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """study of high risk factors"""@eng ; skos:notation """CDR0000038614"""^^xsd:string ; ; rdfs:subClassOf ; """11242"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134626"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """study of physiologic variables"""@eng ; skos:notation """CDR0000038615"""^^xsd:string ; ; rdfs:subClassOf ; """11243"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134627"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000038483"""^^xsd:string ; skos:altLabel """Ibritumomab (In2B8/Y2B8 Radiolabeling Kit)"""@eng , """Ibritumomab Tiuxetan"""@eng , """Y90 Zevalin"""@eng , """IDEC-Y2B8 monoclonal antibody"""@eng , """Zevalin"""@eng , """Y90-labeled ibritumomab tiuxetan"""@eng , """IDEC-Y2B8 Monoclonal Antibody"""@eng , """IDEC-Y2B8"""@eng , """90Y ibritumomab tiuxetan"""@eng , """IDEC Y2B8"""@eng , """Yttrium-90 Ibritumomab Tiuxetan"""@eng ; skos:definition """A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38483&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38483&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1812\" NCI Thesaurus)"""@eng ; ; ; ; ; """TRD"""^^xsd:string ; """11103"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """710085"""^^xsd:string ; """9462"""^^xsd:string ; """C1812"""^^xsd:string ; """10624"""^^xsd:string ; umls:cui """C0919274"""^^xsd:string ; umls:cui """C0877880"""^^xsd:string ; umls:cui """C1134535"""^^xsd:string ; umls:cui """C1135144"""^^xsd:string ; umls:cui """C0879283"""^^xsd:string ; umls:cui """C1611197"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T203"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/sargramostim/vinblastine"""@eng ; skos:notation """CDR0000041160"""^^xsd:string ; skos:altLabel """CDDP/GM-CSF/IFF/VBL"""@eng ; ; ; ; ; """4233"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280758"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """screening intervention"""@eng ; skos:notation """CDR0000038613"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """11241"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134625"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039639"""^^xsd:string ; skos:altLabel """BCNU/DOX/PRED/VCR"""@eng , """VBAP"""@eng ; ; ; ; ; """2294"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078139"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethacrynic acid"""@eng ; skos:notation """CDR0000041163"""^^xsd:string ; skos:altLabel """EA"""@eng , """[2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic Acid"""@eng ; skos:definition """An aryloxy-acetic acid derivative belonging to the class of loop diuretics. Ethacrynic acid interferes with the chloride binding site of the Na+, K+, Cl- cotransporter system in the thick ascending loop of Henle, thereby inhibiting the reabsorption of sodium, potassium, and chloride ions. This leads to an increase in the excretion of sodium, potassium, chloride, calcium, and water. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41163&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41163&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C485\" NCI Thesaurus)"""@eng ; ; ; """4236"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """C485"""^^xsd:string ; """58-54-8"""^^xsd:string ; """85791"""^^xsd:string ; umls:cui """C0014963"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """corticosteroid"""@eng ; skos:notation """CDR0000039257"""^^xsd:string ; """1889"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0001617"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isolated plasmacytoma of bone"""@eng ; skos:notation """CDR0000041558"""^^xsd:string ; skos:altLabel """osseous plasmacytoma, solitary"""@eng , """solitary plasmacytoma"""@eng , """solitary osseous plasmacytoma"""@eng , """plasmacytoma of bone, isolated"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """472"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0272256"""^^xsd:string ; umls:cui """C0032131"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/GVAX lung cancer vaccine"""@eng ; skos:notation """CDR0000361736"""^^xsd:string ; skos:altLabel """CG8123V/CTX"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541180"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EL625"""@eng ; skos:notation """CDR0000354249"""^^xsd:string ; skos:altLabel """OL(1)p53"""@eng ; skos:definition """A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. EL625 hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=354249&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=354249&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37454\" NCI Thesaurus)"""@eng ; ; """2004-01-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C37454"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C1328177"""^^xsd:string ; umls:cui """C0700610"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/tamoxifen"""@eng ; skos:notation """CDR0000350217"""^^xsd:string ; skos:altLabel """TMX/ZD 1839"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328132"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/LY293111"""@eng ; skos:notation """CDR0000350211"""^^xsd:string ; skos:altLabel """CDDP/dFdC/LY-293111"""@eng ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328131"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamoxifen/tipifarnib"""@eng ; skos:notation """CDR0000269106"""^^xsd:string ; skos:altLabel """R115777/TMX"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327833"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyproterone/leuprolide"""@eng ; skos:notation """CDR0000269105"""^^xsd:string ; skos:altLabel """CPTR/LEUP"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327832"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrazine sulfate"""@eng ; skos:notation """CDR0000040141"""^^xsd:string ; skos:altLabel """Sehydrin"""@eng ; skos:definition """The synthetic sulfate salt of hydrazine, a derivative of ammonia. Hydrazine inhibits the enzyme phosphoenol pyruvate carboxykinase, thereby blocking gluconeogenesis. This agent has been reported to decrease the excessive energy needs and cachexia of cancer patients. Classified as a likely human carcinogen, hydrazine sulfate is also a weak inhibitor of mono-amine oxidase (MAO). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40141&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40141&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1129\" NCI Thesaurus)"""@eng ; ; ; """2906"""^^xsd:string ; """33233"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """10034-93-2"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C1129"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1512522"""^^xsd:string ; umls:cui """C0063067"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP1B1"""@eng ; skos:notation """CDR0000322864"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0298987"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP1A1"""@eng ; skos:notation """CDR0000322863"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919425"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anticachectic therapy"""@eng ; skos:notation """CDR0000040140"""^^xsd:string ; skos:altLabel """therapy, anticachectic"""@eng ; ; rdfs:subClassOf ; """2905"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0279840"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/triacetyluridine"""@eng ; skos:notation """CDR0000041771"""^^xsd:string ; skos:altLabel """5-FU/TAU"""@eng ; ; ; """4952"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281354"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Richter's syndrome"""@eng ; skos:notation """CDR0000475631"""^^xsd:string ; skos:altLabel """Richter's transformation"""@eng ; rdfs:subClassOf ; """2006-04-20"""^^xsd:string ; """neoplastic syndrome"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """2006-03-24"""^^xsd:string ; umls:cui """C0349631"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TroVax"""@eng ; skos:notation """CDR0000486953"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C1541801"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol/dexamethasone/gefitinib"""@eng ; skos:notation """CDR0000370022"""^^xsd:string ; skos:altLabel """CALTROL/DM/ZD 1839"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541237"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/sorafenib"""@eng ; skos:notation """CDR0000391854"""^^xsd:string ; skos:altLabel """CBDCA/SFN/TAX"""@eng ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541611"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/melphalan"""@eng ; skos:notation """CDR0000040146"""^^xsd:string ; skos:altLabel """MeliBU"""@eng , """BU/L-PAM"""@eng ; ; ; """2911"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279844"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/trastuzumab/vinorelbine"""@eng ; skos:notation """CDR0000391853"""^^xsd:string ; skos:altLabel """CAPE/MOAB HER2/VNB"""@eng ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541610"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/ifosfamide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000038482"""^^xsd:string ; skos:altLabel """ARA-C/IFF/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; """11102"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134520"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Birt Hogg Dube syndrome"""@eng ; skos:notation """CDR0000043544"""^^xsd:string ; """2002-09-10"""^^xsd:string ; """8803"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0346010"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """matuzumab/pemetrexed disodium"""@eng ; skos:notation """CDR0000437780"""^^xsd:string ; skos:altLabel """EMD 72000/LY231514"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-15"""^^xsd:string ; """2005-06-17"""^^xsd:string ; umls:cui """C1831656"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/vincristine"""@eng ; skos:notation """CDR0000043546"""^^xsd:string ; skos:altLabel """5-FU/VCR"""@eng ; ; ; """8805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879260"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/thalidomide"""@eng ; skos:notation """CDR0000043547"""^^xsd:string ; skos:altLabel """CBDCA/TAX/THAL"""@eng ; ; ; ; """8806"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879261"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 anal cancer"""@eng ; skos:notation """CDR0000043540"""^^xsd:string ; skos:altLabel """anal cancer, stage 0"""@eng , """stage 0 anus cancer"""@eng , """anus cancer, stage 0"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """88"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C2242854"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary papillary renal cancer (HPRC)"""@eng ; skos:notation """CDR0000043541"""^^xsd:string ; skos:altLabel """papillary renal cancer, hereditary"""@eng ; """2002-09-10"""^^xsd:string ; """8800"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0879257"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary type II papillary renal cancer"""@eng ; skos:notation """CDR0000043542"""^^xsd:string ; skos:altLabel """type II papillary renal cancer, hereditary"""@eng , """papillary renal cancer, hereditary, type II"""@eng ; """2002-09-10"""^^xsd:string ; """8801"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0879258"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """familial renal oncocytoma"""@eng ; skos:notation """CDR0000043543"""^^xsd:string ; """2002-09-10"""^^xsd:string ; """8802"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0879606"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """S-1"""@eng ; skos:notation """CDR0000043548"""^^xsd:string ; skos:altLabel """S1"""@eng , """TS-1"""@eng ; skos:definition """An oral fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, thereby inhibiting DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. CDHP is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyltransferase (the major enzyme responsible for 5-FU activation), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43548&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43548&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1833\" NCI Thesaurus)"""@eng ; ; ; """8807"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C1833"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C2828372"""^^xsd:string ; umls:cui """C0879262"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dendritic cell-gp100-MART-1 antigen vaccine"""@eng ; skos:notation """CDR0000043549"""^^xsd:string ; skos:altLabel """DC-gp100-MART-1"""@eng ; """8808"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879263"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """medullary ductal breast carcinoma with lymphocytic infiltrate"""@eng ; skos:notation """CDR0000039256"""^^xsd:string ; skos:altLabel """ductal medullary breast carcinoma with lymphocytic infiltrate"""@eng ; rdfs:subClassOf ; """1888"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279160"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/gemtuzumab ozogamicin"""@eng ; skos:notation """CDR0000331877"""^^xsd:string ; skos:altLabel """ARA-C/CMA-676/DNR/VP-16"""@eng ; ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-08-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328048"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/NY-ESO-1 peptide vaccine"""@eng ; skos:notation """CDR0000331870"""^^xsd:string ; skos:altLabel """BC-G/NY-ESO-1 peptide"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-10-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328047"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000040938"""^^xsd:string ; skos:altLabel """PVC"""@eng , """CDDP/CTX/VP-16"""@eng , """CEP"""@eng , """VCP-1"""@eng , """CVP"""@eng , """PCE"""@eng ; ; ; ; """3977"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280556"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/lomustine/vincristine"""@eng ; skos:notation """CDR0000040939"""^^xsd:string ; skos:altLabel """CCNU/CDDP/CTX/VCR/VP-16"""@eng , """VPC-LE"""@eng , """CCVVP"""@eng ; ; ; ; ; ; """3978"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280557"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/lomustine/prednisone/vincristine"""@eng ; skos:notation """CDR0000040934"""^^xsd:string ; skos:altLabel """COPAC"""@eng , """VPACC"""@eng , """CCNU/CTX/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """3973"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280552"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040935"""^^xsd:string ; skos:altLabel """AMCO"""@eng , """CTX/DOX/MTX/VCR"""@eng , """MOCA"""@eng , """MACO"""@eng , """LOMAC"""@eng , """CODOX-M"""@eng ; ; ; ; ; """3974"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0051817"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/doxorubicin/mechlorethamine/prednisone/procarbazine/vinblastine/vincristine"""@eng ; skos:notation """CDR0000040936"""^^xsd:string ; skos:altLabel """MOPP/ABVD"""@eng , """MA/MA"""@eng , """ABVD/MOPP"""@eng , """BLEO/DOX/DTIC/NM/PCB/PRED/VBL/VCR"""@eng , """MOPP alternating with ABVD"""@eng ; ; ; ; ; ; ; ; ; """3975"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280554"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/teniposide"""@eng ; skos:notation """CDR0000040937"""^^xsd:string ; skos:altLabel """CECA"""@eng , """CDDP/CTX/DOX/VM-26"""@eng , """VACP"""@eng , """AVEC"""@eng ; ; ; ; ; """3976"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280555"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/teniposide"""@eng ; skos:notation """CDR0000040930"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED/VM-26"""@eng , """CHVP"""@eng , """CICS"""@eng ; ; ; ; ; """3969"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055670"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040931"""^^xsd:string ; skos:altLabel """CHOP"""@eng , """VCAP"""@eng , """COPA"""@eng , """ACOP"""@eng , """VACP"""@eng , """CTX/DOX/PRED/VCR"""@eng , """CAVP"""@eng ; ; ; ; ; """3970"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055598"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040932"""^^xsd:string ; skos:altLabel """OCA"""@eng , """VAC"""@eng , """VA-C"""@eng , """ACO"""@eng , """CAV"""@eng , """CHO"""@eng , """CDV"""@eng , """CTX/DOX/VCR"""@eng , """VADRC"""@eng , """CVA"""@eng ; ; ; ; """3971"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054889"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000040933"""^^xsd:string ; skos:altLabel """VC"""@eng , """CTX/VP-16"""@eng , """CV"""@eng ; ; ; """3972"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280551"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamoxifen/triptorelin"""@eng ; skos:notation """CDR0000322249"""^^xsd:string ; skos:altLabel """TMX/TRIP"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328020"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exemestane/triptorelin"""@eng ; skos:notation """CDR0000322248"""^^xsd:string ; skos:altLabel """PNU 155971/TRIP"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328019"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimethylxanthenone acetic acid/docetaxel"""@eng ; skos:notation """CDR0000437254"""^^xsd:string ; skos:altLabel """DMXAA/TXT"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-30"""^^xsd:string ; """2005-06-17"""^^xsd:string ; umls:cui """C1831655"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000437253"""^^xsd:string ; skos:altLabel """CTX/DOX/rhuMAb VEGF"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-30"""^^xsd:string ; """2005-06-17"""^^xsd:string ; umls:cui """C1831654"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clotrimazole"""@eng ; skos:notation """CDR0000039116"""^^xsd:string ; skos:altLabel """CLOT"""@eng , """Lotrimin"""@eng , """Gyne-Lotrimin"""@eng , """Mycelex"""@eng , """Mycelex Troche"""@eng , """1-[(2-Chlorophenyl)diphenylmethyl]-1H-imidazole"""@eng ; skos:definition """A synthetic, imidazole derivate with broad-spectrum, antifungal activity. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39116&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39116&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C381\" NCI Thesaurus)"""@eng ; ; """1706"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """C381"""^^xsd:string ; """257473"""^^xsd:string ; """23593-75-1"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699671"""^^xsd:string ; umls:cui """C0720789"""^^xsd:string ; umls:cui """C0009074"""^^xsd:string ; umls:cui """C0699670"""^^xsd:string ; umls:cui """C0306874"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levothyroxine sodium"""@eng ; skos:notation """CDR0000039117"""^^xsd:string ; skos:altLabel """Therapeutic Levothyroxine"""@eng ; skos:definition """The sodium salt form of levothyroxine, a synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also posses cardiac stimulatory effect. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39117&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39117&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C888\" NCI Thesaurus)"""@eng ; """1707"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C888"""^^xsd:string ; """55-03-8"""^^xsd:string ; """36397"""^^xsd:string ; umls:cui """C0079691"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/eflornithine/interferon alfa"""@eng ; skos:notation """CDR0000039114"""^^xsd:string ; skos:altLabel """DFMO/DOX/IFN-A"""@eng ; ; ; ; """1704"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338087"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/diethyldithiocarbamate"""@eng ; skos:notation """CDR0000039115"""^^xsd:string ; skos:altLabel """CDDP/CTX/DTC"""@eng ; ; ; ; """1705"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279122"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/sargramostim/zidovudine"""@eng ; skos:notation """CDR0000039112"""^^xsd:string ; skos:altLabel """GM-CSF/IFN-A/ZDV"""@eng ; ; ; ; """1702"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338086"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/vincristine/zidovudine"""@eng ; skos:notation """CDR0000039113"""^^xsd:string ; skos:altLabel """BLEO/DOX/VCR/ZDV"""@eng ; ; ; ; ; """1703"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279120"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000039110"""^^xsd:string ; skos:altLabel """ARA-C/IFF/VP-16"""@eng ; ; ; ; """1700"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279117"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000039111"""^^xsd:string ; skos:altLabel """ARA-C/GM-CSF/IFF/VP-16"""@eng ; ; ; ; ; """1701"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279118"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000039118"""^^xsd:string ; skos:altLabel """CDDP/5-FU/VCR"""@eng ; ; ; ; """1708"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279123"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/dacarbazine/interleukin-2/tamoxifen"""@eng ; skos:notation """CDR0000039119"""^^xsd:string ; skos:altLabel """BCNU/CDDP/DTIC/IL-2/TMX"""@eng ; ; ; ; ; ; """1709"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279124"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GPI-0100"""@eng ; skos:notation """CDR0000038278"""^^xsd:string ; skos:definition """A semi-synthetic triterpene glycoside, derived from the naturally occurring saponins. GPI-0100 functions as an adjuvant when given as part of a vaccine preparation to improve the immunogenicity of antigens such as proteins, carbohydrates. GPI-0100 containing vaccines have been used with both viral and tumor antigens to elicit a Type 1 helper T cell response for those diseases in which a cytotoxic T lymphocyte (CTL) response is desired. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38278&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38278&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2627\" NCI Thesaurus)"""@eng ; ; """10888"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """C2627"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935831"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-hB7.1"""@eng ; skos:notation """CDR0000042860"""^^xsd:string ; skos:definition """A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42860&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42860&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2485\" NCI Thesaurus)"""@eng ; ; ; """6670"""^^xsd:string ; """7290"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """8370"""^^xsd:string ; """674306"""^^xsd:string ; """2006-12-28"""^^xsd:string ; """C2485"""^^xsd:string ; umls:cui """C0796294"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-hB7.1/interferon gamma"""@eng ; skos:notation """CDR0000042861"""^^xsd:string ; skos:altLabel """ALVAC hB7.1/IFN-G"""@eng ; ; ; """6671"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677795"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antibiotic therapy"""@eng ; skos:notation """CDR0000042314"""^^xsd:string ; skos:altLabel """therapy, antibiotic"""@eng ; ; rdfs:subClassOf ; """5562"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0338237"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rectal cancer"""@eng ; skos:notation """CDR0000043157"""^^xsd:string ; skos:altLabel """rectum cancer"""@eng , """Rectal cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """76"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007113"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/interleukin-2/von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043156"""^^xsd:string ; skos:altLabel """IFA/IL-2/VHL peptide"""@eng ; ; ; ; """7599"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796338"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043155"""^^xsd:string ; skos:altLabel """IFA/VHL peptide"""@eng ; ; ; """7598"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796337"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043154"""^^xsd:string ; skos:altLabel """VHL Peptides"""@eng , """VHL peptide"""@eng , """VHL peptide vaccine"""@eng ; skos:definition """A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43154&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43154&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2492\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """7597"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C2492"""^^xsd:string ; """900100"""^^xsd:string ; umls:cui """C0796336"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/epoetin alfa"""@eng ; skos:notation """CDR0000043153"""^^xsd:string ; skos:altLabel """EPO/WR-2721"""@eng ; ; ; """7596"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796335"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/sargramostim"""@eng ; skos:notation """CDR0000043152"""^^xsd:string ; skos:altLabel """GM-CSF/IFN-A/IL-2"""@eng ; ; ; ; """7595"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796334"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegylated interferon alfa"""@eng ; skos:notation """CDR0000043151"""^^xsd:string ; skos:altLabel """PEG-IFN-a"""@eng , """PEG-interferon alfa"""@eng , """PEG-IFNA"""@eng ; skos:definition """A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43151&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43151&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2491\" NCI Thesaurus)"""@eng ; ; ; """7593"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C2491"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0907160"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel/ifosfamide"""@eng ; skos:notation """CDR0000043150"""^^xsd:string ; skos:altLabel """CBDCA/IFF/TXT"""@eng ; ; ; ; """7590"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796332"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thermal ablation therapy"""@eng ; skos:notation """CDR0000042864"""^^xsd:string ; ; rdfs:subClassOf ; """6674"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0677798"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/fluorouracil/streptozocin/vincristine"""@eng ; skos:notation """CDR0000043159"""^^xsd:string ; skos:altLabel """BCNU/5-FU/SZC/VCR"""@eng ; ; ; ; ; """7601"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796340"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/sargramostim/von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043158"""^^xsd:string ; skos:altLabel """GM-CSF/IFA/VHL peptide"""@eng ; ; ; ; """7600"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796339"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ziconotide"""@eng ; skos:notation """CDR0000042866"""^^xsd:string ; skos:altLabel """SNX 111"""@eng , """SNX-111"""@eng ; """6676"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; umls:cui """C0211013"""^^xsd:string ; umls:cui """C0211011"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial cancer screening"""@eng ; skos:notation """CDR0000042867"""^^xsd:string ; skos:altLabel """early detection of endometrial cancer"""@eng , """endometrial cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """6677"""^^xsd:string ; umls:cui """C0677799"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostate cancer prevention"""@eng ; skos:notation """CDR0000041845"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """5029"""^^xsd:string ; umls:cui """C0281413"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000041842"""^^xsd:string ; skos:altLabel """BCNU/5-FU/IFN-A"""@eng ; ; ; ; """5026"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338172"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SJG-136"""@eng ; skos:notation """CDR0000415963"""^^xsd:string ; skos:definition """A pyrrolobenzodiazepine dimer with potential antineoplastic activity. SJG-136 binds to the minor groove of DNA and induces interstrand cross-links between two N-2 guanine positions, thereby inhibiting DNA replication and transcription. With a preference for binding to purine-GATC-pyrimidine sequences, SJG-136 adducts do not appear to be subject to p53-mediated DNA excision repair mechanisms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415963&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415963&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29435\" NCI Thesaurus)"""@eng ; """2005-01-24"""^^xsd:string ; """C29435"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C1519143"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """blood-brain barrier disruption"""@eng ; skos:notation """CDR0000467876"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C1831732"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-interferon alfa-2b/thalidomide"""@eng ; skos:notation """CDR0000269112"""^^xsd:string ; skos:altLabel """PEG-IFNA2b/THAL"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327835"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000038533"""^^xsd:string ; """11156"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134561"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000038532"""^^xsd:string ; skos:altLabel """CBDCA/PS-341/TAX"""@eng ; ; ; ; """2002-11-19"""^^xsd:string ; """11155"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134560"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fibrin sealant"""@eng ; skos:notation """CDR0000038531"""^^xsd:string ; skos:altLabel """Beriplast P"""@eng , """TISSEEL VH"""@eng ; skos:definition """A plasma-derived fibrin biomatrix preparation consisting of two separate solutions that are combined on application. The sealer protein solution contains clottable human fibrinogen and bovine aprotinin, a fibrinolysis inhibitor; the thrombin solution contains human thrombin and calcium chloride. When the solutions are combined, a clot is formed, reproducing the final stages of the coagulation cascade. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38531&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38531&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2664\" NCI Thesaurus)"""@eng ; """11154"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2664"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0879437"""^^xsd:string ; umls:cui """C1832057"""^^xsd:string ; umls:cui """C0016004"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Chinese herbs/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000038530"""^^xsd:string ; skos:altLabel """CHIHERB/CTX/DOX"""@eng ; ; ; ; """11153"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134559"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edotecarin"""@eng ; skos:notation """CDR0000038537"""^^xsd:string ; skos:altLabel """6-N-(1-hydroxymethyla-2-hydroxy)ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolol[3,4-c]-carbazole-5,7(6H)-dione"""@eng , """J 107088"""@eng , """J-107088"""@eng , """PHA-782615"""@eng ; skos:definition """A synthetic indolocarbazole with antineoplastic activity. Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme complex and enhanced single-strand DNA cleavage, resulting in inhibition of DNA replication and decreased tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38537&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38537&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2665\" NCI Thesaurus)"""@eng ; ; """11164"""^^xsd:string ; """C2665"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328673"""^^xsd:string ; umls:cui """C0909002"""^^xsd:string ; umls:cui """C1328674"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hepatic arterial infusion"""@eng ; skos:notation """CDR0000038536"""^^xsd:string ; """11163"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1134564"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin"""@eng ; skos:notation """CDR0000038535"""^^xsd:string ; skos:altLabel """CTX/DM/DOX"""@eng ; ; ; ; """11158"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134563"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin"""@eng ; skos:notation """CDR0000038534"""^^xsd:string ; skos:altLabel """DM/DOX"""@eng ; ; ; """11157"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134562"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000042396"""^^xsd:string ; skos:altLabel """ASP/DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """5651"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000042397"""^^xsd:string ; skos:altLabel """ADR-529/DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """5652"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexrazoxane/doxorubicin/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000042394"""^^xsd:string ; skos:altLabel """ADR-529/ASP/DOX/MP/PRED/VCR"""@eng ; ; ; ; ; ; ; """5649"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338302"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bexarotene/cisplatin/vinorelbine"""@eng ; skos:notation """CDR0000038538"""^^xsd:string ; skos:altLabel """CDDP/LGD1069/VNB"""@eng ; ; ; ; """11165"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134565"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/cytarabine/daunorubicin/etoposide"""@eng ; skos:notation """CDR0000042392"""^^xsd:string ; skos:altLabel """ARA-C/CYSP/DNR/VP-16"""@eng ; ; ; ; ; """5647"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338300"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/cytarabine/etoposide/idarubicin"""@eng ; skos:notation """CDR0000042393"""^^xsd:string ; skos:altLabel """ARA-C/CYSP/IDA/VP-16"""@eng ; ; ; ; ; """5648"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338301"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/monoclonal antibody CC49"""@eng ; skos:notation """CDR0000042390"""^^xsd:string ; skos:altLabel """IFN-G/MOAB CC49"""@eng ; ; ; """5645"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338298"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """motexafin gadolinium"""@eng ; skos:notation """CDR0000042391"""^^xsd:string ; skos:altLabel """Xcytrin"""@eng , """gadolinium texaphyrin"""@eng , """PCI-0120"""@eng , """Gd-Tex"""@eng , """Gd (III) Texaphryin"""@eng ; skos:definition """A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42391&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42391&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1881\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """5646"""^^xsd:string ; """55583"""^^xsd:string ; """695238"""^^xsd:string ; """C1881"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0964264"""^^xsd:string ; umls:cui """C0662850"""^^xsd:string ; umls:cui """C1098215"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cystemustine"""@eng ; skos:notation """CDR0000041294"""^^xsd:string ; """4367"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0067099"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TTI-237"""@eng ; skos:notation """CDR0000432958"""^^xsd:string ; skos:altLabel """TTI 237"""@eng ; skos:definition """A small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity. With a novel mechanism of action distinct from the action of other vinca alkaloid compounds, TTI-237 specifically binds to tubulin at the vinca site, and promotes the polymerization of tubulin into microtubules. TTI-237 stabilizes tubulin and inhibits microtubule disassembly. This results in cell cycle arrest at the G2/M phase, and leading to cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=432958&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=432958&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61566\" NCI Thesaurus)"""@eng ; """2005-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """C61566"""^^xsd:string ; umls:cui """C1831611"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GW679769"""@eng ; skos:notation """CDR0000491023"""^^xsd:string ; """2006-06-16"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C1831798"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BI 2536"""@eng ; skos:notation """CDR0000452943"""^^xsd:string ; skos:definition """A novel antiproliferative compound with anti-mitotic and potential antineoplastic activities. Described as an atypical cytostatic compound, BI 2536 inhibits mitosis, reulting in decreased cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452943&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=452943&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49091\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """2005-10-14"""^^xsd:string ; """C49091"""^^xsd:string ; umls:cui """C1706888"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/nitrocamptothecin"""@eng ; skos:notation """CDR0000438805"""^^xsd:string ; skos:altLabel """9-NC/dFdC"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-28"""^^xsd:string ; """2005-07-08"""^^xsd:string ; umls:cui """C1831668"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TPI 287"""@eng ; skos:notation """CDR0000438803"""^^xsd:string ; skos:definition """A synthetic, third generation taxane with potential antineoplastic activity. TPI 287 binds to tubulin and stabilizes microtubules, resulting in inhibition of microtubule assembly/disassembly dynamics, cell cycle arrest at the G2/M phase, and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=438803&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=438803&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48424\" NCI Thesaurus)"""@eng ; """C48424"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-07-08"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C1710314"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/ecteinascidin 743"""@eng ; skos:notation """CDR0000438802"""^^xsd:string ; skos:altLabel """ET 743/LipoDox"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-28"""^^xsd:string ; """2005-07-08"""^^xsd:string ; umls:cui """C1831667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ad5CMV-p53 gene/docetaxel/doxorubicin"""@eng ; skos:notation """CDR0000257137"""^^xsd:string ; skos:altLabel """Ad5CMV-p53/DOX/TXT"""@eng ; ; ; ; """2002-08-09"""^^xsd:string ; """11405"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327753"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/fowlpox-CEA-TRICOM vaccine/sargramostim/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000380852"""^^xsd:string ; skos:altLabel """fCEA-TRI/GM-CSF/TXT/vCEA-TRI"""@eng ; ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541342"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-1 peptide vaccine"""@eng ; skos:notation """CDR0000458103"""^^xsd:string ; skos:definition """A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon administration, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC-1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC-1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=458103&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=458103&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2407\" NCI Thesaurus)"""@eng ; """2006-08-30"""^^xsd:string ; """C2407"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C1711297"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood liver cancer"""@eng ; skos:notation """CDR0000043719"""^^xsd:string ; skos:altLabel """recurrent pediatric liver cancer"""@eng , """pediatric hepatoma, recurrent"""@eng , """recurrent childhood hepatoma"""@eng , """hepatoma, pediatric, recurrent"""@eng , """childhood liver cancer, recurrent"""@eng , """childhood hepatoma, recurrent"""@eng , """hepatoma, childhood, recurrent"""@eng , """pediatric liver cancer, recurrent"""@eng , """liver cancer, childhood, recurrent"""@eng , """liver cancer, pediatric, recurrent"""@eng , """recurrent pediatric hepatoma"""@eng ; rdfs:subClassOf ; """childhood liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """968"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1370832"""^^xsd:string ; umls:cui """C0278700"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV childhood liver cancer"""@eng ; skos:notation """CDR0000043718"""^^xsd:string ; skos:altLabel """group IV pediatric liver cancer"""@eng , """stage IV pediatric hepatoma"""@eng , """hepatoma, pediatric, stage IV"""@eng , """childhood liver cancer, group IV"""@eng , """childhood hepatoma, group IV"""@eng , """liver cancer, pediatric, group IV"""@eng , """stage IV childhood hepatoma"""@eng , """group IV pediatric hepatoma"""@eng , """stage IV pediatric liver cancer"""@eng , """liver cancer, childhood, group IV"""@eng , """liver cancer, pediatric, stage IV"""@eng , """liver cancer, childhood, stage IV"""@eng , """hepatoma, pediatric, group IV"""@eng , """pediatric liver cancer, stage IV"""@eng , """pediatric liver cancer, group IV"""@eng , """group IV childhood hepatoma"""@eng , """group IV childhood liver cancer"""@eng , """childhood hepatoma, stage IV"""@eng , """childhood liver cancer, stage IV"""@eng , """hepatoma, childhood, group IV"""@eng , """pediatric hepatoma, group IV"""@eng , """hepatoma, childhood, stage IV"""@eng , """pediatric hepatoma, stage IV"""@eng ; rdfs:subClassOf ; """childhood liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """967"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278699"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """disseminated neuroblastoma"""@eng ; skos:notation """CDR0000043711"""^^xsd:string ; skos:altLabel """neuroblastoma, disseminated"""@eng , """neuroblastoma, metastatic"""@eng , """metastatic neuroblastoma"""@eng ; rdfs:subClassOf ; """neuroblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """960"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1135161"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIB anal cancer"""@eng ; skos:notation """CDR0000043710"""^^xsd:string ; skos:altLabel """anal cancer, stage IIIB"""@eng , """stage IIIB anus cancer"""@eng , """anus cancer, stage IIIB"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """96"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278564"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent neuroblastoma"""@eng ; skos:notation """CDR0000043713"""^^xsd:string ; skos:altLabel """neuroblastoma, recurrent"""@eng ; rdfs:subClassOf ; """neuroblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """962"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278695"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 4S neuroblastoma"""@eng ; skos:notation """CDR0000043712"""^^xsd:string ; skos:altLabel """special neuroblastoma"""@eng , """neuroblastoma, stage 4S"""@eng , """stage IVS neuroblastoma"""@eng , """neuroblastoma, stage IVS"""@eng , """neuroblastoma, metastatic"""@eng , """metastatic neuroblastoma"""@eng ; rdfs:subClassOf ; """neuroblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """961"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1135161"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I childhood liver cancer"""@eng ; skos:notation """CDR0000043715"""^^xsd:string ; skos:altLabel """pediatric liver cancer, group I"""@eng , """hepatoma, pediatric, group I"""@eng , """pediatric liver cancer, stage I"""@eng , """childhood liver cancer, stage I"""@eng , """stage I childhood hepatoma"""@eng , """pediatric hepatoma, group I"""@eng , """hepatoma, childhood, stage I"""@eng , """liver cancer, pediatric, stage I"""@eng , """childhood hepatoma, stage I"""@eng , """childhood liver cancer, group I"""@eng , """hepatoma, childhood, group I"""@eng , """group I childhood hepatoma"""@eng , """stage I pediatric liver cancer"""@eng , """hepatoma, pediatric, stage I"""@eng , """group I childhood liver cancer"""@eng , """group I pediatric liver cancer"""@eng , """liver cancer, childhood, group I"""@eng , """liver cancer, childhood, stage I"""@eng , """childhood hepatoma, group I"""@eng , """liver cancer, pediatric, group I"""@eng , """stage I pediatric hepatoma"""@eng , """group I pediatric hepatoma"""@eng , """pediatric hepatoma, stage I"""@eng ; rdfs:subClassOf ; """childhood liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """964"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278696"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood liver cancer"""@eng ; skos:notation """CDR0000043714"""^^xsd:string ; skos:altLabel """hepatoma, pediatric"""@eng , """pediatric liver cancer"""@eng , """liver cancer, pediatric"""@eng , """hepatoma, childhood"""@eng , """Liver cancer, child primary"""@eng , """liver cancer, childhood"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """963"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1328722"""^^xsd:string ; umls:cui """C2945767"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III childhood liver cancer"""@eng ; skos:notation """CDR0000043717"""^^xsd:string ; skos:altLabel """hepatoma, pediatric, group III"""@eng , """pediatric hepatoma, group III"""@eng , """childhood liver cancer, group III"""@eng , """group III childhood liver cancer"""@eng , """liver cancer, childhood, stage III"""@eng , """hepatoma, childhood, group III"""@eng , """liver cancer, pediatric, group III"""@eng , """hepatoma, pediatric, stage III"""@eng , """stage III pediatric liver cancer"""@eng , """childhood hepatoma, group III"""@eng , """childhood hepatoma, stage III"""@eng , """pediatric liver cancer, group III"""@eng , """childhood liver cancer, stage III"""@eng , """group III childhood hepatoma"""@eng , """pediatric hepatoma, stage III"""@eng , """stage III childhood hepatoma"""@eng , """liver cancer, pediatric, stage III"""@eng , """liver cancer, childhood, group III"""@eng , """group III pediatric hepatoma"""@eng , """group III pediatric liver cancer"""@eng , """stage III pediatric hepatoma"""@eng , """hepatoma, childhood, stage III"""@eng , """pediatric liver cancer, stage III"""@eng ; rdfs:subClassOf ; """childhood liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """966"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278698"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II childhood liver cancer"""@eng ; skos:notation """CDR0000043716"""^^xsd:string ; skos:altLabel """hepatoma, pediatric, group II"""@eng , """liver cancer, childhood, stage II"""@eng , """liver cancer, pediatric, stage II"""@eng , """hepatoma, childhood, group II"""@eng , """liver cancer, childhood, group II"""@eng , """childhood hepatoma, group II"""@eng , """liver cancer, pediatric, group II"""@eng , """group II childhood liver cancer"""@eng , """childhood liver cancer, group II"""@eng , """stage II childhood hepatoma"""@eng , """pediatric hepatoma, stage II"""@eng , """group II pediatric hepatoma"""@eng , """hepatoma, childhood, stage II"""@eng , """group II childhood hepatoma"""@eng , """childhood hepatoma, stage II"""@eng , """pediatric hepatoma, group II"""@eng , """stage II pediatric liver cancer"""@eng , """childhood liver cancer, stage II"""@eng , """group II pediatric liver cancer"""@eng , """pediatric liver cancer, group II"""@eng , """hepatoma, pediatric, stage II"""@eng , """stage II pediatric hepatoma"""@eng , """pediatric liver cancer, stage II"""@eng ; rdfs:subClassOf ; """childhood liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """965"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278697"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thorax/respiratory cancer"""@eng ; skos:notation """CDR0000039286"""^^xsd:string ; skos:altLabel """respiratory/thorax cancer"""@eng ; rdfs:subClassOf ; """1919"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279170"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methimazole"""@eng ; skos:notation """CDR0000039287"""^^xsd:string ; """1920"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0025644"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hyperglycemic hormone"""@eng ; skos:notation """CDR0000039284"""^^xsd:string ; rdfs:subClassOf ; """1916"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279169"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral contraceptive"""@eng ; skos:notation """CDR0000039285"""^^xsd:string ; """1917"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0009905"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antithyroid agent"""@eng ; skos:notation """CDR0000039282"""^^xsd:string ; rdfs:subClassOf ; """1914"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0040125"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal drug"""@eng ; skos:notation """CDR0000039283"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """1915"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0017173"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progesterone agent"""@eng ; skos:notation """CDR0000039280"""^^xsd:string ; skos:altLabel """progestin"""@eng ; rdfs:subClassOf ; """1912"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0033306"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antidiabetic agent"""@eng ; skos:notation """CDR0000039281"""^^xsd:string ; rdfs:subClassOf ; """1913"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0935929"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide"""@eng ; skos:notation """CDR0000041577"""^^xsd:string ; skos:altLabel """BU/CTX"""@eng ; ; ; """474"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278611"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin reactions secondary to radiation therapy"""@eng ; skos:notation """CDR0000041576"""^^xsd:string ; skos:altLabel """radiation therapy, secondary skin reactions"""@eng ; rdfs:subClassOf ; """4739"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0281197"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """graft versus host disease"""@eng ; skos:notation """CDR0000041575"""^^xsd:string ; skos:altLabel """graft-versus-host disease"""@eng , """host versus graft disease"""@eng , """GVHD"""@eng ; rdfs:subClassOf ; """4738"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0018133"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-3/thiotepa"""@eng ; skos:notation """CDR0000041574"""^^xsd:string ; skos:altLabel """IL-3/TSPA"""@eng ; ; ; """4737"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281196"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """esophageal cancer prevention"""@eng ; skos:notation """CDR0000041573"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4736"""^^xsd:string ; umls:cui """C0281195"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lung cancer prevention"""@eng ; skos:notation """CDR0000041572"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4735"""^^xsd:string ; umls:cui """C0281194"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """propylthiouracil"""@eng ; skos:notation """CDR0000039288"""^^xsd:string ; skos:altLabel """6-Propyl-2-Thiouracil"""@eng ; skos:definition """A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39288&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39288&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C781\" NCI Thesaurus)"""@eng ; """1921"""^^xsd:string ; """70461"""^^xsd:string ; """C781"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """51-52-5"""^^xsd:string ; umls:cui """C0033511"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sulfonylurea"""@eng ; skos:notation """CDR0000039289"""^^xsd:string ; rdfs:subClassOf ; """1922"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0038766"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, endometrial cancer"""@eng ; skos:notation """CDR0000040169"""^^xsd:string ; skos:altLabel """uterine cancer cellular diagnosis"""@eng , """cancer of the endometrium cellular diagnosis"""@eng , """endometrial carcinoma cellular diagnosis"""@eng , """uterus cancer cellular diagnosis"""@eng , """endometrial cancer cellular diagnosis"""@eng , """carcinoma of the endometrium cellular diagnosis"""@eng , """uterine corpus cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2958"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279867"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adult acute myeloid leukemia"""@eng ; skos:notation """CDR0000040168"""^^xsd:string ; skos:altLabel """adult acute nonlymphocytic leukemia cellular diagnosis"""@eng , """cellular diagnosis, adult acute nonlymphocytic leukemia"""@eng , """adult acute myeloid leukemia cellular diagnosis"""@eng , """adult ANLL cellular diagnosis"""@eng ; rdfs:subClassOf ; """2957"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279866"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, esophageal cancer"""@eng ; skos:notation """CDR0000040167"""^^xsd:string ; skos:altLabel """esophageal cancer, cellular diagnosis"""@eng , """esophagus cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2956"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279865"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, thymoma and thymic carcinoma"""@eng ; skos:notation """CDR0000040166"""^^xsd:string ; rdfs:subClassOf ; """2003-08-20"""^^xsd:string ; """2955"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279864"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, Wilms' tumor"""@eng ; skos:notation """CDR0000040165"""^^xsd:string ; skos:altLabel """tumor, Wilms', cellular diagnosis"""@eng , """nephroblastoma cellular diagnosis"""@eng , """Wilms' tumor cellular diagnosis"""@eng ; rdfs:subClassOf ; """2954"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279863"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000040164"""^^xsd:string ; skos:altLabel """adult acute lymphocytic leukemia cellular diagnosis"""@eng , """adult ALL cellular diagnosis"""@eng , """cellular diagnosis, adult acute lymphocytic leukemia"""@eng ; rdfs:subClassOf ; """2953"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279862"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, malignant mesothelioma"""@eng ; skos:notation """CDR0000040163"""^^xsd:string ; skos:altLabel """malignant mesothelioma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2952"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279861"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, Ewing's sarcoma/primitive neuroepithelial tumor"""@eng ; skos:notation """CDR0000040162"""^^xsd:string ; skos:altLabel """sarcoma, Ewing's, cellular diagnosis"""@eng , """Ewing's sarcoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2951"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279860"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040161"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MP/MTX/VCR"""@eng ; ; ; ; ; ; ; """2950"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279859"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, gallbladder cancer"""@eng ; skos:notation """CDR0000040160"""^^xsd:string ; skos:altLabel """gallbladder cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2949"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279858"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """roquinimex"""@eng ; skos:notation """CDR0000041410"""^^xsd:string ; skos:altLabel """1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-3-quinolinecarboxanilide"""@eng , """LS 2616"""@eng , """LS2616"""@eng , """LS-2616"""@eng , """1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide"""@eng , """FCF 89"""@eng , """Linomide"""@eng , """N-Phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide"""@eng ; skos:definition """A quinoline-3-carboxamide with potential antineoplastic activity. Roquinimex inhibits endothelial cell proliferation, migration, and basement membrane invasion; reduces the secretion of the angiogenic factor tumor necrosis factor alpha by tumor-associated macrophages (TAMs); and inhibits angiogenesis. This agent is also an immune modulator that appears to alter cytokine profiles and enhance the activity of T cells, natural killer cells, and macrophages. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41410&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41410&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1519\" NCI Thesaurus)"""@eng ; """4481"""^^xsd:string ; """84088-42-6"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C1519"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0244748"""^^xsd:string ; umls:cui """C1527014"""^^xsd:string ; umls:cui """C0950650"""^^xsd:string ; umls:cui """C0950651"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethylchlorformate"""@eng ; skos:notation """CDR0000041411"""^^xsd:string ; """4482"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0280963"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/hydroxyurea"""@eng ; skos:notation """CDR0000041412"""^^xsd:string ; skos:altLabel """CDDP/5-FU/HU"""@eng ; ; ; ; """4483"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280964"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/fluorouracil/hydroxyurea"""@eng ; skos:notation """CDR0000041413"""^^xsd:string ; skos:altLabel """CDDP/5-FU/G-CSF/HU"""@eng ; ; ; ; ; """4484"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280965"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000041414"""^^xsd:string ; skos:altLabel """CF/5-FU/VP-16"""@eng ; ; ; ; """4485"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280966"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """brequinar/fluorouracil"""@eng ; skos:notation """CDR0000041415"""^^xsd:string ; skos:altLabel """BREQ/5-FU"""@eng ; ; ; """4486"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280967"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-3/sargramostim"""@eng ; skos:notation """CDR0000041416"""^^xsd:string ; skos:altLabel """CTX/GM-CSF/IL-3"""@eng ; ; ; ; """4487"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280968"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/carboplatin"""@eng ; skos:notation """CDR0000041417"""^^xsd:string ; skos:altLabel """AZA/CBDCA"""@eng ; ; ; """4488"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280969"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyrazoloacridine"""@eng ; skos:notation """CDR0000041418"""^^xsd:string ; skos:altLabel """PZA"""@eng ; skos:definition """A 9-methoxy acridine compound containing a reducible 5-nitro substituent. Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41418&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41418&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1564\" NCI Thesaurus)"""@eng ; ; ; ; ; """4489"""^^xsd:string ; """366140"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C1564"""^^xsd:string ; """36325"""^^xsd:string ; umls:cui """C0280970"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/monoclonal antibody R24"""@eng ; skos:notation """CDR0000041419"""^^xsd:string ; skos:altLabel """IFN-A/IL-2/MOAB R24"""@eng ; ; ; ; """4491"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338150"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/pirarubicin"""@eng ; skos:notation """CDR0000038889"""^^xsd:string ; skos:altLabel """CTX/5-FU/THP-DOX"""@eng ; ; ; ; """1383"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338080"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin"""@eng ; skos:notation """CDR0000038888"""^^xsd:string ; skos:altLabel """ARA-C/IDA"""@eng ; ; ; """1377"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278928"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038883"""^^xsd:string ; skos:altLabel """CTX/DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """1372"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278923"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/etoposide"""@eng ; skos:notation """CDR0000038882"""^^xsd:string ; skos:altLabel """AMSA/VP-16"""@eng ; ; ; """1371"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278922"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mitolactol"""@eng ; skos:notation """CDR0000038881"""^^xsd:string ; skos:altLabel """DBD/DOX"""@eng ; ; ; """1370"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278921"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/streptozocin"""@eng ; skos:notation """CDR0000038880"""^^xsd:string ; skos:altLabel """5-FU/SZC"""@eng ; ; ; """1369"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278920"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000038887"""^^xsd:string ; skos:altLabel """ASP/CTX/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """1376"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278927"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buserelin/tamoxifen"""@eng ; skos:notation """CDR0000038886"""^^xsd:string ; skos:altLabel """BSRL/TMX"""@eng ; ; ; """1375"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278926"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chemoprevention of cancer"""@eng ; skos:notation """CDR0000038885"""^^xsd:string ; skos:altLabel """cancer chemoprevention"""@eng ; ; rdfs:subClassOf ; """1374"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0278925"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038884"""^^xsd:string ; skos:altLabel """DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """1373"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278924"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cetuximab/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000410879"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/MOAB C225/MOAB VEGF"""@eng ; ; ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541444"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, gallbladder cancer"""@eng ; skos:notation """CDR0000040640"""^^xsd:string ; rdfs:subClassOf ; """3549"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280265"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DT(388)IL3 fusion protein"""@eng ; skos:notation """CDR0000516002"""^^xsd:string ; """2006-10-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831974"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aerodigestive tract cancer prevention"""@eng ; skos:notation """CDR0000042008"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """5233"""^^xsd:string ; umls:cui """C0281551"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tacrolimus"""@eng ; skos:notation """CDR0000042009"""^^xsd:string ; skos:altLabel """FK 506"""@eng , """FK506"""@eng , """Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone"""@eng , """FK-506"""@eng ; skos:definition """A macrolide isolated from the fungus Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42009&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42009&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1311\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5234"""^^xsd:string ; """717865"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """104987-11-3"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C1311"""^^xsd:string ; """109581-93-3 (monohydrate)"""^^xsd:string ; umls:cui """C0729218"""^^xsd:string ; umls:cui """C0085149"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daclizumab"""@eng ; skos:notation """CDR0000042006"""^^xsd:string ; skos:altLabel """Zenapax"""@eng , """humanized anti-Tac monoclonal antibody"""@eng , """Anti-Tac Humanized Monoclonal Antibody"""@eng , """anti-Tac monoclonal antibody"""@eng , """anti-Tac"""@eng , """MOAB anti-Tac"""@eng , """monoclonal antibody anti-Tac"""@eng , """Dacliximab"""@eng , """monoclonal antibody humanized anti-Tac"""@eng ; skos:definition """A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42006&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42006&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1569\" NCI Thesaurus)"""@eng ; ; ; """TRD"""^^xsd:string ; """5231"""^^xsd:string ; """2091"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1569"""^^xsd:string ; """152923-56-3"""^^xsd:string ; umls:cui """C0281549"""^^xsd:string ; umls:cui """C0663182"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody BEC2"""@eng ; skos:notation """CDR0000042007"""^^xsd:string ; skos:altLabel """BEC2"""@eng , """MOAB BEC2"""@eng , """monoclonal antibody BEC2, anti-idiotypic murine"""@eng , """anti-idiotypic murine monoclonal antibody BEC2"""@eng ; ; """5232"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281550"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/filgrastim"""@eng ; skos:notation """CDR0000042004"""^^xsd:string ; skos:altLabel """ARA-C/ASP/G-CSF"""@eng ; ; ; ; """5229"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intraperitoneal therapy"""@eng ; skos:notation """CDR0000042005"""^^xsd:string ; skos:altLabel """IP"""@eng ; """5230"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281548"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/idarubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000042002"""^^xsd:string ; skos:altLabel """CTX/IDA/PRED/VCR"""@eng ; ; ; ; ; """5227"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281545"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042003"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/TAX"""@eng ; ; ; ; """5228"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281546"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alum adjuvant"""@eng ; skos:notation """CDR0000042000"""^^xsd:string ; skos:altLabel """Aluminum Sulfate"""@eng , """ALUM"""@eng , """aluminum hydroxide"""@eng ; skos:definition """An inorganic compound containing aluminum. Used in various immunologic preparations to improve immunogenicity, alum adjuvant consists of aluminium sulfate. In vaccines, this agent binds to the protein conjugate, resulting in improved antigen processing by the immune system. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42000&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42000&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C228\" NCI Thesaurus)"""@eng ; ; ; ; """5225"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """664400"""^^xsd:string ; """C228"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """21645-51-2"""^^xsd:string ; umls:cui """C0002371"""^^xsd:string ; umls:cui """C0051522"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/procarbazine/vincristine"""@eng ; skos:notation """CDR0000042001"""^^xsd:string ; skos:altLabel """MTX/PCB/VCR"""@eng ; ; ; ; """5226"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281544"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV laryngeal cancer"""@eng ; skos:notation """CDR0000040114"""^^xsd:string ; skos:altLabel """larynx cancer, stage IV"""@eng , """metastatic laryngeal cancer"""@eng , """laryngeal cancer, stage IV"""@eng , """laryngeal cancer, metastatic"""@eng , """larynx cancer, metastatic"""@eng ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2876"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0851139"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast cancer and pregnancy"""@eng ; skos:notation """CDR0000042143"""^^xsd:string ; skos:altLabel """pregnancy and breast cancer"""@eng ; rdfs:subClassOf ; """5380"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281663"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/satraplatin"""@eng ; skos:notation """CDR0000042142"""^^xsd:string ; skos:altLabel """BMS-182751/VP-16"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """5379"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281662"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """satraplatin"""@eng ; skos:notation """CDR0000042141"""^^xsd:string ; skos:altLabel """(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum"""@eng , """JM216"""@eng , """(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum"""@eng , """BMY-45594"""@eng , """platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)"""@eng , """JM-126"""@eng ; skos:definition """An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42141&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42141&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1493\" NCI Thesaurus)"""@eng ; ; ; """5378"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1493"""^^xsd:string ; """2006-09-18"""^^xsd:string ; umls:cui """C1142934"""^^xsd:string ; umls:cui """C0216381"""^^xsd:string ; umls:cui """C1328263"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acarbose"""@eng ; skos:notation """CDR0000042140"""^^xsd:string ; skos:altLabel """Precose"""@eng , """Bay g 5421"""@eng , """O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose"""@eng ; skos:definition """A complex oligosaccharide used as a hypoglycemic agent in diabetes management. Acarbose inhibits enzymes required in catabolism of carbohydrates, specifically pancreatic alpha-amylase, which hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, and the membrane-bound intestinal alpha-glucosidases, which hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. When acarbose is orally administered, less digestion of complex carbohydrates occur and less glucose is absorbed in the small intestine, thereby producing a smaller rise in postprandial blood glucose levels after a carbohydrate load. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42140&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42140&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C983\" NCI Thesaurus)"""@eng ; """5377"""^^xsd:string ; """56180-94-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C983"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591572"""^^xsd:string ; umls:cui """C0752276"""^^xsd:string ; umls:cui """C0050393"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alitretinoin"""@eng ; skos:notation """CDR0000042147"""^^xsd:string ; skos:altLabel """9-cis Retinoic Acid"""@eng , """ALRT1057"""@eng , """Panretin"""@eng , """9-CRA"""@eng , """3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid"""@eng , """Retinoicacid-9-cis"""@eng , """Panretyn"""@eng , """Panrexin"""@eng , """LGD1057"""@eng , """9-cis-retinoic acid"""@eng , """3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic Acid"""@eng , """9-cis-RA"""@eng ; skos:definition """An orally- and topically-active naturally- occurring retinoic acid agent with antineoplastic and potential chemopreventive, teratogenic, and embryotoxic properties. 9-Cis-retinoic acid binds to nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR), resulting in inhibition of cell proliferation, induction of cell differentiation, and apoptosis of some tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42147&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42147&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1574\" NCI Thesaurus)"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """659772"""^^xsd:string ; """5384"""^^xsd:string ; """2007-01-12"""^^xsd:string ; """48234"""^^xsd:string ; """5300-03-8"""^^xsd:string ; """C1574"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0022265"""^^xsd:string ; umls:cui """C0281666"""^^xsd:string ; umls:cui """C1510846"""^^xsd:string ; umls:cui """C0722482"""^^xsd:string ; umls:cui """C1510845"""^^xsd:string ; umls:cui """C0918021"""^^xsd:string ; umls:cui """C0918022"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """theramide"""@eng ; skos:notation """CDR0000042146"""^^xsd:string ; """5383"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281665"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tallimustine"""@eng ; skos:notation """CDR0000042145"""^^xsd:string ; """5382"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0286890"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000042144"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/VP-16"""@eng ; ; ; ; ; """5381"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281664"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tecogalan sodium"""@eng ; skos:notation """CDR0000042149"""^^xsd:string ; skos:altLabel """Sulfated Polysaccharide Tecogalan DS-4152"""@eng , """DS-4152"""@eng , """SP-PG"""@eng ; skos:definition """A sulfated polysaccharide isolated from various Arthrobacter bacterial species. Possessing potential antiangiogenic and antineoplastic properties, tecogalan binds to basic fibroblast growth factor (bFGF), thereby preventing bFGF from binding to its receptors. Disruption of this receptor binding results in the inhibition of bFGF-stimulated endothelial cell growth, proliferation, and migration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42149&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42149&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1605\" NCI Thesaurus)"""@eng ; """5386"""^^xsd:string ; """C1605"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0287957"""^^xsd:string ; umls:cui """C0212199"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/vitamin E"""@eng ; skos:notation """CDR0000042148"""^^xsd:string ; skos:altLabel """13-CRA/VIT-E"""@eng ; ; ; """5385"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/poly ICLC"""@eng ; skos:notation """CDR0000043551"""^^xsd:string ; skos:altLabel """IL-2/poly ICLC"""@eng ; ; ; """881"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278658"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/gefitinib"""@eng ; skos:notation """CDR0000306450"""^^xsd:string ; skos:altLabel """TXT/ZD 1839"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327979"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/gemcitabine"""@eng ; skos:notation """CDR0000043556"""^^xsd:string ; skos:altLabel """CDDP/dFdC/5-FU"""@eng ; ; ; ; """8814"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879268"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/sargramostim"""@eng ; skos:notation """CDR0000043555"""^^xsd:string ; skos:altLabel """ATCV/GM-CSF"""@eng ; ; ; """8813"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879267"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine"""@eng ; skos:notation """CDR0000043554"""^^xsd:string ; skos:altLabel """ATCV"""@eng , """AC vaccine"""@eng , """Autologous Cell Vaccine"""@eng ; skos:definition """A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43554&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43554&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1980\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """8812"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1980"""^^xsd:string ; umls:cui """C0879266"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitomycin/triazinate"""@eng ; skos:notation """CDR0000040899"""^^xsd:string ; skos:altLabel """CDDP/MITO/TZT"""@eng ; ; ; ; """3938"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280519"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/ifosfamide/methotrexate"""@eng ; skos:notation """CDR0000040898"""^^xsd:string ; skos:altLabel """CDDP/DOX/IFF/MTX"""@eng ; ; ; ; ; """3937"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0246281"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dicumarol"""@eng ; skos:notation """CDR0000040893"""^^xsd:string ; skos:altLabel """DICUM"""@eng , """bishydroxycoumarin"""@eng , """Dicoumarol"""@eng ; """3932"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0005640"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040892"""^^xsd:string ; skos:altLabel """ASP/DNR/PRED/VCR"""@eng , """DVLP"""@eng , """VPLD"""@eng , """PVDA"""@eng ; ; ; ; ; """3931"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0072635"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000040891"""^^xsd:string ; skos:altLabel """AOPA"""@eng , """CALASP"""@eng , """ARA-C/ASP/PRED/VCR"""@eng ; ; ; ; ; """3930"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280512"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/prednisone/vincristine"""@eng ; skos:notation """CDR0000040890"""^^xsd:string ; skos:altLabel """BCNU/CTX/PRED/VCR"""@eng , """BCOP"""@eng , """BCVP"""@eng ; ; ; ; ; """3928"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053054"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/vinblastine"""@eng ; skos:notation """CDR0000040897"""^^xsd:string ; skos:altLabel """CBDCA/VBL"""@eng ; ; ; """3936"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280517"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/PALA"""@eng ; skos:notation """CDR0000040896"""^^xsd:string ; skos:altLabel """5-FU/MTX/PALA"""@eng ; ; ; ; """3935"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280516"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/carboplatin/etoposide"""@eng ; skos:notation """CDR0000040895"""^^xsd:string ; skos:altLabel """BLEO/CBDCA/VP-16"""@eng ; ; ; ; """3934"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083096"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine"""@eng ; skos:notation """CDR0000040894"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX"""@eng ; ; ; ; """3933"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/PSC 833"""@eng ; skos:notation """CDR0000037826"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PSC-833"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """10216"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879402"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benign prostatic hyperplasia"""@eng ; skos:notation """CDR0000524083"""^^xsd:string ; skos:altLabel """BPH"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-12-01"""^^xsd:string ; """2006-11-30"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C1704272"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glycine"""@eng ; skos:notation """CDR0000041347"""^^xsd:string ; skos:definition """A non-essential, non-polar, non-optical, glucogenic amino acid. Glycine, an inhibitory neurotransmitter in the CNS, triggers chloride ion influx via ionotropic receptors, thereby creating an inhibitory post-synaptic potential. In contrast, this agent also acts as a co-agonist, along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is an important component and precursor for many macromolecules in the cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41347&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41347&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C524\" NCI Thesaurus)"""@eng ; """4419"""^^xsd:string ; """25936"""^^xsd:string ; """56-40-6"""^^xsd:string ; """C524"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0017890"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II squamous cell carcinoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040761"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity squamous cell carcinoma, stage II"""@eng , """epidermoid carcinoma of the paranasal sinus and nasal cavity, stage II"""@eng , """nasal cavity and paranasal sinus squamous cell carcinoma, stage II"""@eng , """squamous cell carcinoma of the paranasal sinus and nasal cavity, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3711"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280407"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040760"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus esthesioneuroblastoma, stage I"""@eng , """esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage I"""@eng , """paranasal sinus and nasal cavity esthesioneuroblastoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3710"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280406"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II midline lethal granuloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040763"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus midline lethal granuloma, stage II"""@eng , """paranasal sinus and nasal cavity midline lethal granuloma, stage II"""@eng , """midline lethal granuloma of the paranasal sinus and nasal cavity, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3715"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280409"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamoxifen/tretinoin"""@eng ; skos:notation """CDR0000037827"""^^xsd:string ; skos:altLabel """ATRA/TMX"""@eng ; ; ; """10217"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879403"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III squamous cell carcinoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040765"""^^xsd:string ; skos:altLabel """epidermoid carcinoma of the paranasal sinus and nasal cavity, stage III"""@eng , """squamous cell carcinoma of the paranasal sinus and nasal cavity, stage III"""@eng , """paranasal sinus and nasal cavity squamous cell carcinoma, stage III"""@eng , """nasal cavity and paranasal sinus squamous cell carcinoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3718"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280411"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/filgrastim/prednisone/vincristine"""@eng ; skos:notation """CDR0000041342"""^^xsd:string ; skos:altLabel """CTX/DOX/G-CSF/PRED/VCR"""@eng ; ; ; ; ; ; """4414"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280918"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III midline lethal granuloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040767"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity midline lethal granuloma, stage III"""@eng , """midline lethal granuloma of the paranasal sinus and nasal cavity, stage III"""@eng , """nasal cavity and paranasal sinus midline lethal granuloma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3722"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280413"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III inverted papilloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040766"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity inverted papilloma, stage III"""@eng , """inverted papilloma of the paranasal sinus and nasal cavity, stage III"""@eng , """nasal cavity and paranasal sinus inverted papilloma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """3719"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280412"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040769"""^^xsd:string ; skos:altLabel """epidermoid carcinoma of the paranasal sinus and nasal cavity, stage IV"""@eng , """squamous cell carcinoma of the paranasal sinus and nasal cavity, stage IV"""@eng , """epidermoid carcinoma of the paranasal sinus and nasal cavity, metastatic"""@eng , """squamous cell carcinoma of the paranasal sinus and nasal cavity, metastatic"""@eng , """metastatic squamous cell carcinoma of the paranasal sinus and nasal cavity"""@eng , """paranasal sinus and nasal cavity squamous cell carcinoma, stage IV"""@eng , """nasal cavity and paranasal sinus squamous cell carcinoma, stage IV"""@eng , """nasal cavity and paranasal sinus squamous cell carcinoma, metastatic"""@eng , """paranasal sinus and nasal cavity squamous cell carcinoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3725"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280415"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040768"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity esthesioneuroblastoma, stage III"""@eng , """esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage III"""@eng , """nasal cavity and paranasal sinus esthesioneuroblastoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3724"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280414"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """brostallicin"""@eng ; skos:notation """CDR0000038704"""^^xsd:string ; skos:altLabel """PNU-166196"""@eng ; """11361"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1122890"""^^xsd:string ; umls:cui """C1135141"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BAY 56-3722"""@eng ; skos:notation """CDR0000038705"""^^xsd:string ; skos:altLabel """BAY 38-3441"""@eng ; skos:definition """A water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. BAY 56-3722 stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38705&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38705&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1886\" NCI Thesaurus)"""@eng ; """11363"""^^xsd:string ; """C1886"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1101785"""^^xsd:string ; umls:cui """C1134706"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IH636 grape seed proanthocyanidin extract"""@eng ; skos:notation """CDR0000038706"""^^xsd:string ; skos:altLabel """ActiVin"""@eng ; skos:definition """An oligomeric proanthocyanidin extracted from grape seeds. IH636 grape seed proanthocyanidin extract exhibits dose-dependent free-radical scavenging and antioxidant properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38706&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38706&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2689\" NCI Thesaurus)"""@eng ; """11364"""^^xsd:string ; """C2689"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135154"""^^xsd:string ; umls:cui """C0967936"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lycopene/multivitamins"""@eng ; skos:notation """CDR0000038707"""^^xsd:string ; skos:altLabel """LYCO/MULTIVIT"""@eng ; ; ; """11365"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134707"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/doxorubicin/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038700"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DM/DOX/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; """11357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134704"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038701"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DOX/TG/VCR"""@eng ; ; ; ; ; ; ; ; """11358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280922"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epothilone B"""@eng ; skos:notation """CDR0000038702"""^^xsd:string ; skos:altLabel """EPO906"""@eng , """(-)-Epothilone B"""@eng , """(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"""@eng , """patupilone"""@eng ; skos:definition """A compound isolated from the myxobacterium Sorangium cellulosum. Similar to paclitaxel, epothilone B induces microtubule polymerization and stabilizes microtubules against depolymerization conditions. In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes. Epothilone B may cause complete cell-cycle arrest. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38702&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38702&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1623\" NCI Thesaurus)"""@eng ; """11359"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """152044-54-7"""^^xsd:string ; """2006-06-07"""^^xsd:string ; """C1623"""^^xsd:string ; umls:cui """C0297960"""^^xsd:string ; umls:cui """C1328655"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG 7909/rituximab"""@eng ; skos:notation """CDR0000038703"""^^xsd:string ; skos:altLabel """CpG-7909/MOAB IDEC-C2B8"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """11360"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134705"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody SGN-40"""@eng ; skos:notation """CDR0000365545"""^^xsd:string ; skos:altLabel """anti-CD40 monoclonal antibody"""@eng , """anti-human CD40 monoclonal antibody"""@eng , """SGN-40"""@eng , """SGN-14"""@eng ; """2004-04-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-11"""^^xsd:string ; umls:cui """C1519138"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Sho-saiko-to"""@eng ; skos:notation """CDR0000038708"""^^xsd:string ; """11366"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1138004"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/lamivudine/zidovudine"""@eng ; skos:notation """CDR0000038709"""^^xsd:string ; skos:altLabel """IFN-A/3TC/ZDV"""@eng ; ; ; ; """11367"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134708"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/cyclophosphamide/fludarabine/rituximab"""@eng ; skos:notation """CDR0000365542"""^^xsd:string ; skos:altLabel """CTX/FAMP/MOAB CD52/MOAB IDEC-C2B8"""@eng ; ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541218"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pigmenting agent"""@eng ; skos:notation """CDR0000040428"""^^xsd:string ; rdfs:subClassOf ; """3298"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280079"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/mycophenolate mofetil/tacrolimus"""@eng ; skos:notation """CDR0000271395"""^^xsd:string ; skos:altLabel """FK506/MMF/MTX"""@eng ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327887"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cardiac drug"""@eng ; skos:notation """CDR0000040422"""^^xsd:string ; rdfs:subClassOf ; """3292"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280076"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vasodilating agent"""@eng ; skos:notation """CDR0000040423"""^^xsd:string ; rdfs:subClassOf ; """3293"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0042402"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/lomustine/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040420"""^^xsd:string ; skos:altLabel """CCNU/CTX/PCB/PRED/VCR"""@eng , """COPP-CCNU"""@eng ; ; ; ; ; ; """3288"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280074"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000040421"""^^xsd:string ; skos:altLabel """MePRDL/MP/MTX/VCR"""@eng , """POMP"""@eng ; ; ; ; ; """3290"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280075"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benzodiazepine"""@eng ; skos:notation """CDR0000040426"""^^xsd:string ; rdfs:subClassOf ; """3296"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0005064"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anxiolytic, sedative, and hypnotic agent"""@eng ; skos:notation """CDR0000040427"""^^xsd:string ; rdfs:subClassOf ; """3297"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280078"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """digestant"""@eng ; skos:notation """CDR0000040424"""^^xsd:string ; rdfs:subClassOf ; """3294"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0012237"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adrenal agent"""@eng ; skos:notation """CDR0000040425"""^^xsd:string ; rdfs:subClassOf ; """3295"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280077"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """regional anesthesia"""@eng ; skos:notation """CDR0000531733"""^^xsd:string ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """2007-01-17"""^^xsd:string ; umls:cui """C0002911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """general anesthesia"""@eng ; skos:notation """CDR0000531732"""^^xsd:string ; rdfs:subClassOf ; """2007-01-17"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0002915"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult desmoplastic small round cell tumor"""@eng ; skos:notation """CDR0000531736"""^^xsd:string ; skos:altLabel """small round cell tumor, desmoplastic, adult"""@eng , """tumor, desmoplastic small round cell, adult"""@eng ; rdfs:subClassOf ; """Cancer diagnosis"""^^xsd:string ; """2007-01-17"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C1332199"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IRX-2"""@eng ; skos:notation """CDR0000462160"""^^xsd:string ; skos:definition """A cell-free mixture comprised of a variety of naturally-derived cytokines obtained from normal, unrelated donor lymphocytes with potential immunostimulatory activity. The cytokines in IRX-2, including interleukin (IL)-1, -2, -6, -8, -10, -12, tumor necrosis factor alpha (TNF-a), interferon-gamma (IFN-g) and colony stimulating factors (CSFs), play vital roles in regulating cellular immunity and may synergistically stimulate a cellular immune response against tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462160&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462160&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53396\" NCI Thesaurus)"""@eng ; """C53396"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0758290"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/interleukin-1-beta"""@eng ; skos:notation """CDR0000041380"""^^xsd:string ; skos:altLabel """G-CSF/IL-1B"""@eng ; ; ; """4451"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280949"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer-related problem/condition"""@eng ; skos:notation """CDR0000041381"""^^xsd:string ; skos:altLabel """cancer related problem/condition"""@eng , """problem/condition, cancer related"""@eng , """problem/condition, cancer-related"""@eng ; rdfs:subClassOf ; """4452"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280950"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anemia"""@eng ; skos:notation """CDR0000041382"""^^xsd:string ; rdfs:subClassOf ; """4453"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0002871"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cerebral edema"""@eng ; skos:notation """CDR0000041383"""^^xsd:string ; skos:altLabel """edema, cerebral"""@eng ; rdfs:subClassOf ; """4454"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0006114"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drug toxicity"""@eng ; skos:notation """CDR0000041384"""^^xsd:string ; skos:altLabel """toxicity, drug"""@eng ; rdfs:subClassOf ; """4455"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0013221"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cardiac toxicity"""@eng ; skos:notation """CDR0000041385"""^^xsd:string ; skos:altLabel """toxicity, cardiac"""@eng ; rdfs:subClassOf ; """4456"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0876994"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drug extravasation"""@eng ; skos:notation """CDR0000041386"""^^xsd:string ; skos:altLabel """extravasation, drug"""@eng ; rdfs:subClassOf ; """4457"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280952"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neutropenia"""@eng ; skos:notation """CDR0000041387"""^^xsd:string ; rdfs:subClassOf ; """4458"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0027947"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neurotoxicity"""@eng ; skos:notation """CDR0000041388"""^^xsd:string ; rdfs:subClassOf ; """4459"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0235032"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urinary tract toxicity"""@eng ; skos:notation """CDR0000041389"""^^xsd:string ; skos:altLabel """toxicity, urinary tract"""@eng ; rdfs:subClassOf ; """4460"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280953"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """other anti-infective agent"""@eng ; skos:notation """CDR0000040390"""^^xsd:string ; rdfs:subClassOf ; """3251"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280051"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trichomonacide agent"""@eng ; skos:notation """CDR0000040391"""^^xsd:string ; rdfs:subClassOf ; """3252"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003447"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sulfonamide agent"""@eng ; skos:notation """CDR0000040392"""^^xsd:string ; rdfs:subClassOf ; """3253"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0599503"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plasmodicide agent"""@eng ; skos:notation """CDR0000040393"""^^xsd:string ; rdfs:subClassOf ; """3254"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280053"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antitubercular agent"""@eng ; skos:notation """CDR0000040394"""^^xsd:string ; rdfs:subClassOf ; """3255"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003448"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040395"""^^xsd:string ; skos:altLabel """BLEO/CTX/MTX/VCR"""@eng , """COMB"""@eng ; ; ; ; ; """3256"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280054"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil"""@eng ; skos:notation """CDR0000040396"""^^xsd:string ; skos:altLabel """CDDP/5-FU"""@eng , """P-FU"""@eng , """CF"""@eng ; ; ; """3257"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280055"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminosyn"""@eng ; skos:notation """CDR0000040397"""^^xsd:string ; skos:altLabel """Aminosyn RF"""@eng ; ; """3259"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0718492"""^^xsd:string ; umls:cui """C0103040"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000040398"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/CTX/PRED/VCR"""@eng , """COAP-BLEO"""@eng ; ; ; ; ; ; """3261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280057"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cyclophosphamide/hydroxyurea"""@eng ; skos:notation """CDR0000040399"""^^xsd:string ; skos:altLabel """AMSA/CTX/HU"""@eng , """CMH"""@eng ; ; ; ; """3262"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280058"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """midostaurin"""@eng ; skos:notation """CDR0000462346"""^^xsd:string ; skos:altLabel """PKC412"""@eng , """N-benzoyl-staurosporine"""@eng ; skos:definition """A synthetic indolocarbazole protein kinase C (PKC) inhibitor. As a nonspecific inhibitor of protein kinase C enzymes, midostaurin inhibits oncogenic PKC signal transduction pathways involved in the regulation of the cell cycle in tumor cells, thereby initiating tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462346&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462346&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1872\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """C1872"""^^xsd:string ; """2006-08-16"""^^xsd:string ; umls:cui """C0915830"""^^xsd:string ; umls:cui """C0526371"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory anemia with excess blasts"""@eng ; skos:notation """CDR0000040359"""^^xsd:string ; rdfs:subClassOf ; """3215"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0002894"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """miscellaneous islet cell cancer"""@eng ; skos:notation """CDR0000038793"""^^xsd:string ; skos:altLabel """endocrine pancreatic cancer, miscellaneous"""@eng , """islet cell cancer, miscellaneous"""@eng , """pancreatic endocrine cancer, miscellaneous"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1244"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278842"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EBV-specific cytotoxic T-lymphocytes/LMP2A-specific cytotoxic T-lymphocytes/Montanide ISA-51"""@eng ; skos:notation """CDR0000365539"""^^xsd:string ; skos:altLabel """EBV CTL/ISA-51/LMP2A CTL"""@eng ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541217"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II cervical cancer"""@eng ; skos:notation """CDR0000038063"""^^xsd:string ; skos:altLabel """cervical cancer, stage II"""@eng , """carcinoma of the cervix, stage II"""@eng , """stage II carcinoma of the cervix"""@eng , """cervix cancer, stage II"""@eng , """stage II uterine cervix cancer"""@eng , """stage II cancer of the cervix"""@eng , """uterine cervical cancer, stage II"""@eng , """uterine cervix cancer, stage II"""@eng , """stage II cervix cancer"""@eng , """cancer of the cervix, stage II"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """106"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278576"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000038790"""^^xsd:string ; skos:altLabel """childhood DL lymphoma"""@eng , """large cell lymphoma, diffuse, childhood"""@eng , """pediatric diffuse large cell lymphoma"""@eng , """DHL, childhood"""@eng , """diffuse histiocytic lymphoma, childhood"""@eng , """histiocytic lymphoma, diffuse, childhood"""@eng , """lymphoma, diffuse histiocytic, childhood"""@eng , """pediatric DL lymphoma"""@eng , """lymphoma, diffuse large cell, childhood"""@eng , """diffuse large cell lymphoma, childhood"""@eng ; rdfs:subClassOf ; """1239"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278840"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thymoma and thymic carcinoma"""@eng ; skos:notation """CDR0000038797"""^^xsd:string ; skos:altLabel """Thymoma and thymic carcinoma"""@eng ; rdfs:subClassOf ; """2003-08-21"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1248"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0205969"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimesna/paclitaxel"""@eng ; skos:notation """CDR0000357507"""^^xsd:string ; skos:altLabel """DIM/TAX"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328226"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/fludarabine"""@eng ; skos:notation """CDR0000357500"""^^xsd:string ; skos:altLabel """CTX/FAMP/VP-16"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328225"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """graft versus host disease prophylaxis/therapy"""@eng ; skos:notation """CDR0000038796"""^^xsd:string ; skos:altLabel """prophylaxis/therapy, GVHD"""@eng , """GVHD"""@eng , """prophylaxis/therapy, graft versus host disease"""@eng ; ; rdfs:subClassOf ; ; rdfs:subClassOf ; """1247"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0278845"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stanozolol"""@eng ; skos:notation """CDR0000039267"""^^xsd:string ; skos:altLabel """WIN 14833"""@eng , """Winstrol"""@eng ; """1898"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0592142"""^^xsd:string ; umls:cui """C0038149"""^^xsd:string ; umls:cui """C0733717"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000038795"""^^xsd:string ; skos:altLabel """immunoblastic large cell lymphoma, childhood"""@eng , """childhood IBL lymphoma"""@eng , """pediatric immunoblastic large cell lymphoma"""@eng , """pediatric IBL lymphoma"""@eng , """lymphoma, immunoblastic large cell childhood"""@eng , """IBL lymphoma, childhood"""@eng , """large cell lymphoma, childhood immunoblastic"""@eng ; rdfs:subClassOf ; """1246"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278844"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent islet cell carcinoma"""@eng ; skos:notation """CDR0000038794"""^^xsd:string ; skos:altLabel """pancreatic endocrine cancer, recurrent"""@eng , """recurrent cancer of the endocrine pancreas"""@eng , """carcinoma of the endocrine pancreas, recurrent"""@eng , """cancer of the endocrine pancreas, recurrent"""@eng , """recurrent carcinoma of the endocrine pancreas"""@eng , """islet cell carcinoma, recurrent"""@eng , """recurrent pancreatic endocrine cancer"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1245"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278843"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SL-11047"""@eng ; skos:notation """CDR0000467739"""^^xsd:string ; skos:altLabel """(N(1),N(12))bis(ethyl)-6,7-dehydrospermine"""@eng , """SL11047"""@eng , """((1)N,(12)N)bis(ethyl)-6,7-dehydrospermine"""@eng ; skos:definition """A second generation polyamine analog synthesized through the restriction of molecular conformations of parent polyamine compounds with potential antineoplastic activity. SL-11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467739&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467739&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60816\" NCI Thesaurus)"""@eng ; """2006-07-14"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """C60816"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1963112"""^^xsd:string ; umls:cui """C0962042"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tinzaparin sodium"""@eng ; skos:notation """CDR0000467737"""^^xsd:string ; skos:altLabel """Innohep"""@eng ; skos:definition """The sodium salt of a low molecular weight heparin (LMWH) obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467737&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467737&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60810\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-07"""^^xsd:string ; """C60810"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591649"""^^xsd:string ; umls:cui """C0354599"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uterine leiomyoma"""@eng ; skos:notation """CDR0000279773"""^^xsd:string ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """2003-02-20"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0042133"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alizapride"""@eng ; skos:notation """CDR0000039750"""^^xsd:string ; """2411"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0051162"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """caracemide"""@eng ; skos:notation """CDR0000039751"""^^xsd:string ; skos:altLabel """Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)"""@eng , """N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea"""@eng ; skos:definition """An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase. In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39751&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39751&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1037\" NCI Thesaurus)"""@eng ; """2412"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """253272"""^^xsd:string ; """C1037"""^^xsd:string ; """81424-67-1"""^^xsd:string ; """22624"""^^xsd:string ; umls:cui """C0054633"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/ifosfamide"""@eng ; skos:notation """CDR0000038539"""^^xsd:string ; skos:altLabel """IFF/LipoDox"""@eng ; ; ; """11166"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134566"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """APF530"""@eng ; skos:notation """CDR0000494748"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-07"""^^xsd:string ; umls:cui """C1831918"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/fluorouracil"""@eng ; skos:notation """CDR0000269123"""^^xsd:string ; skos:altLabel """5-FU/MOAB VEGF"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327837"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/monoclonal antibody Hu1D10"""@eng ; skos:notation """CDR0000269125"""^^xsd:string ; skos:altLabel """G-CSF/MOAB Hu1D10"""@eng ; ; """2002-11-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-16"""^^xsd:string ; umls:cui """C1327838"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/carboplatin/gemcitabine"""@eng ; skos:notation """CDR0000269128"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/PS-341"""@eng ; ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327839"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/gemcitabine"""@eng ; skos:notation """CDR0000269129"""^^xsd:string ; skos:altLabel """dFdC/PS-341"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327840"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PCNU"""@eng ; skos:notation """CDR0000039549"""^^xsd:string ; """2199"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0070165"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/razoxane/semustine"""@eng ; skos:notation """CDR0000039548"""^^xsd:string ; skos:altLabel """5-FU/ICRF-159/MeCCNU"""@eng , """FIME"""@eng ; ; ; ; """2198"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279362"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """papaverine"""@eng ; skos:notation """CDR0000039545"""^^xsd:string ; skos:altLabel """PAP"""@eng , """Pavatym"""@eng , """Vasal"""@eng , """Cerebid"""@eng , """Pavabid"""@eng , """Cerespan"""@eng , """Unicelles"""@eng , """Pavacap"""@eng , """papaverine HCl"""@eng ; skos:definition """An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. As a direct-acting smooth muscle relaxant, papaverine is not closely related to the other opium alkaloids in structure or pharmacological actions; its mechanism of action may involve the non-selective inhibition of phosphodiesterases and direct inhibition of calcium channels. This agent also exhibits antiviral activity against respiratory syncytial virus, cytomegalovirus, and HIV. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39545&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39545&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C726\" NCI Thesaurus)"""@eng ; ; """2194"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """35443"""^^xsd:string ; """C726"""^^xsd:string ; """58-74-2"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0702238"""^^xsd:string ; umls:cui """C0030350"""^^xsd:string ; umls:cui """C0030713"""^^xsd:string ; umls:cui """C0702233"""^^xsd:string ; umls:cui """C0700461"""^^xsd:string ; umls:cui """C0702235"""^^xsd:string ; umls:cui """C0702234"""^^xsd:string ; umls:cui """C0702237"""^^xsd:string ; umls:cui """C0702236"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/fowlpox-PSA-TRICOM vaccine/sargramostim/vaccinia-PSA-TRICOM vaccine"""@eng ; skos:notation """CDR0000441036"""^^xsd:string ; skos:altLabel """fPSA-TRI/GM-CSF/MOAB CTLA-4/vPSA-TRI"""@eng ; ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-23"""^^xsd:string ; """2005-07-19"""^^xsd:string ; umls:cui """C1831688"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """N-phosphonacetyl-L-aspartate"""@eng ; skos:notation """CDR0000039547"""^^xsd:string ; skos:altLabel """PALA"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """2197"""^^xsd:string ; """C1398"""^^xsd:string ; umls:cui """C0135096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/fluorouracil"""@eng ; skos:notation """CDR0000039546"""^^xsd:string ; skos:altLabel """CDDP/DOX/5-FU"""@eng , """FAP"""@eng ; ; ; ; """2195"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0060063"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peptichemio"""@eng ; skos:notation """CDR0000039541"""^^xsd:string ; """2189"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0030927"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/tegafur"""@eng ; skos:notation """CDR0000039540"""^^xsd:string ; skos:altLabel """FACP"""@eng , """CDDP/CTX/DOX/FT"""@eng ; ; ; ; ; """2187"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0059997"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/cyclophosphamide/doxorubicin/tegafur"""@eng ; skos:notation """CDR0000039543"""^^xsd:string ; skos:altLabel """BC-G/CTX/DOX/FT"""@eng , """FAC-BCG"""@eng ; ; ; ; ; """2003-10-29"""^^xsd:string ; """2190"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279358"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clomiphene citrate"""@eng ; skos:notation """CDR0000039542"""^^xsd:string ; skos:altLabel """Clomid"""@eng , """Serophene"""@eng , """2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine Citrate (1:1)"""@eng ; skos:definition """The citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues. This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39542&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39542&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C379\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """219"""^^xsd:string ; """50-41-9"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """35770"""^^xsd:string ; """C379"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591268"""^^xsd:string ; umls:cui """C0546859"""^^xsd:string ; umls:cui """C0036748"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """marcellomycin"""@eng ; skos:notation """CDR0000039758"""^^xsd:string ; skos:altLabel """1-Naphthacenecarboxylic acid, 4-[[O-2,6-dideoxy-.alpha.-L-lyxo-hexopyranosyl-(1.fwdarw.4)-O-2, 6-dideoxy-.alpha.-L-lyxo-hexopyranosyl-(1.fwdarw.4)-2,3, 6-trideoxy-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]oxy]-2-e thyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-dioxo-, methyl ester, (1R-(1.alpha.,2.beta.,4.beta.))- (9CI)"""@eng , """Rhodirubin E"""@eng ; skos:definition """An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum. Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39758&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39758&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1152\" NCI Thesaurus)"""@eng ; """2419"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """265211"""^^xsd:string ; """63710-10-1"""^^xsd:string ; """C1152"""^^xsd:string ; umls:cui """C0065718"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer"""@eng ; skos:notation """CDR0000041060"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """41"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0006826"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """defibrotide"""@eng ; skos:notation """CDR0000043522"""^^xsd:string ; skos:definition """A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties. Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43522&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43522&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1064\" NCI Thesaurus)"""@eng ; """8766"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """83712-60-1"""^^xsd:string ; """C1064"""^^xsd:string ; umls:cui """C0057257"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/SU5416"""@eng ; skos:notation """CDR0000043523"""^^xsd:string ; skos:altLabel """CF/5-FU/SU-5416"""@eng ; ; ; ; """2003-10-29"""^^xsd:string ; """8767"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796685"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/procarbazine"""@eng ; skos:notation """CDR0000043520"""^^xsd:string ; skos:altLabel """CCNU/PCB"""@eng ; ; ; """8764"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796683"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leflunomide/mitoxantrone"""@eng ; skos:notation """CDR0000043521"""^^xsd:string ; skos:altLabel """DHAD/SU101"""@eng ; ; ; """8765"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796684"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DetoxPC/lung tumor associated antigen"""@eng ; skos:notation """CDR0000043526"""^^xsd:string ; skos:altLabel """Detox PC/lung TAA"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """8770"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796688"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/methylprednisolone"""@eng ; skos:notation """CDR0000043527"""^^xsd:string ; skos:altLabel """ATG/MePRDL"""@eng ; ; ; """8771"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796689"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/irinotecan"""@eng ; skos:notation """CDR0000043524"""^^xsd:string ; skos:altLabel """CPT-11/CYSP"""@eng ; ; ; """8768"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796686"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lung tumor associated antigen"""@eng ; skos:notation """CDR0000043525"""^^xsd:string ; skos:altLabel """tumor associated antigen, lung"""@eng , """Lung TAA"""@eng ; ; """8769"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796687"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/cyclophosphamide/methylprednisolone"""@eng ; skos:notation """CDR0000043528"""^^xsd:string ; skos:altLabel """ATG/CTX/MePRDL"""@eng ; ; ; ; """8772"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796690"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/melphalan/methylprednisolone"""@eng ; skos:notation """CDR0000043529"""^^xsd:string ; skos:altLabel """ATG/L-PAM/MePRDL"""@eng ; ; ; ; """8773"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796691"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine"""@eng ; skos:notation """CDR0000427285"""^^xsd:string ; skos:altLabel """Uvidem"""@eng , """IDD-3"""@eng , """Allogeneic Melanoma Cell-Loaded Dendritic Cell Vaccine"""@eng ; skos:definition """A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=427285&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=427285&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48376\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2005-03-24"""^^xsd:string ; """C48376"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; umls:cui """C1541165"""^^xsd:string ; umls:cui """C1541538"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/cyclophosphamide"""@eng ; skos:notation """CDR0000427284"""^^xsd:string ; skos:altLabel """CAPE/CTX"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541537"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin/etoposide/thioguanine"""@eng ; skos:notation """CDR0000040958"""^^xsd:string ; skos:altLabel """VATA"""@eng , """ARA-C/DOX/TG/VP-16"""@eng , """VATA-II"""@eng ; ; ; ; ; """3997"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280575"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040959"""^^xsd:string ; skos:altLabel """ADOAP"""@eng , """HOAP"""@eng , """ARA-C/DOX/PRED/VCR"""@eng , """POCA"""@eng ; ; ; ; ; """3998"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050858"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040952"""^^xsd:string ; skos:altLabel """COMP"""@eng , """M-COP"""@eng , """CTX/MTX/PRED/VCR"""@eng ; ; ; ; ; """3991"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056167"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisolone/vincristine"""@eng ; skos:notation """CDR0000040953"""^^xsd:string ; skos:altLabel """CTX/PRDL/VCR"""@eng , """COP"""@eng , """PentaCOP"""@eng ; ; ; ; """3992"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078143"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000040950"""^^xsd:string ; skos:altLabel """AC"""@eng , """CTX/DOX"""@eng , """CA"""@eng , """ACe"""@eng ; ; ; """3989"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050385"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000040951"""^^xsd:string ; skos:altLabel """CTX/L-PAM/PRED/VCR"""@eng , """VMCP"""@eng , """VCMP"""@eng ; ; ; ; ; """3990"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078398"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin"""@eng ; skos:notation """CDR0000040956"""^^xsd:string ; skos:altLabel """ARA-C/DNR"""@eng , """CAD"""@eng , """AD"""@eng , """DA"""@eng ; ; ; """3995"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280573"""^^xsd:string ; umls:cui """C0170509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/thioguanine"""@eng ; skos:notation """CDR0000040957"""^^xsd:string ; skos:altLabel """DAT"""@eng , """ARA-C/DNR/TG"""@eng , """TAD"""@eng ; ; ; ; """3996"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057150"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040954"""^^xsd:string ; skos:altLabel """C-MOPP"""@eng , """COPP"""@eng , """CTX/PCB/PRED/VCR"""@eng ; ; ; ; ; """3993"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056286"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/vincristine"""@eng ; skos:notation """CDR0000040955"""^^xsd:string ; skos:altLabel """VCP"""@eng , """COP"""@eng , """CTX/PRED/VCR"""@eng , """CVP"""@eng ; ; ; ; """3994"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056633"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alanosine"""@eng ; skos:notation """CDR0000039138"""^^xsd:string ; skos:altLabel """L-Alanosine Sodium"""@eng , """3-(Hydroxynitrosoamino)-L-alanine"""@eng , """L-2-Amino-3-(hydroxynitrosoamino)propionic Acid"""@eng , """L-Alanosine"""@eng , """SDX-102"""@eng , """L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic Acid"""@eng ; skos:definition """An amino acid analog derived from Streptomyces alanosinicus, a purine antagonist, and an adenylosuccinate synthetase inhibitor with antineoplastic properties. L-alanosine deprives MTAP-deficient (salvage pathway) tumor cells of de novo synthesized adenosine and is probably responsible for diminished DNA synthesis. The clinical use of L-alanosine may be narrow due to its toxicity profile. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39138&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39138&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C994\" NCI Thesaurus)"""@eng ; """1759"""^^xsd:string ; """C994"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """529469"""^^xsd:string ; """5854-93-3"""^^xsd:string ; """14247"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """153353"""^^xsd:string ; umls:cui """C1328657"""^^xsd:string ; umls:cui """C0051066"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin"""@eng ; skos:notation """CDR0000039139"""^^xsd:string ; skos:altLabel """BLM"""@eng , """Blenoxane"""@eng , """BLEO"""@eng , """bleomycin sulfate"""@eng ; skos:definition """A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39139&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39139&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C313\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """176"""^^xsd:string ; """125066"""^^xsd:string ; """11056-06-7"""^^xsd:string ; """6649"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C313"""^^xsd:string ; """2006-07-27"""^^xsd:string ; umls:cui """C0005740"""^^xsd:string ; umls:cui """C0005739"""^^xsd:string ; umls:cui """C0701921"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acyclovir"""@eng ; skos:notation """CDR0000039134"""^^xsd:string ; skos:altLabel """BW-248U"""@eng , """Zovirax"""@eng , """Virorax"""@eng , """2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one"""@eng , """Aclovir"""@eng , """Wellcome-248U"""@eng , """ACV"""@eng , """9-[(2-Hydroxyethoxy)methyl]guanine"""@eng , """Cargosil"""@eng , """Acicloftal"""@eng , """acycloguanosine"""@eng ; skos:definition """A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39134&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39134&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C205\" NCI Thesaurus)"""@eng ; ; """1755"""^^xsd:string ; """59277-89-3"""^^xsd:string ; """2006-12-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """645011"""^^xsd:string ; """C205"""^^xsd:string ; """335752"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0920749"""^^xsd:string ; umls:cui """C0592290"""^^xsd:string ; umls:cui """C1510770"""^^xsd:string ; umls:cui """C1510771"""^^xsd:string ; umls:cui """C1510772"""^^xsd:string ; umls:cui """C0001367"""^^xsd:string ; umls:cui """C0700911"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valrubicin"""@eng ; skos:notation """CDR0000039135"""^^xsd:string ; skos:altLabel """AD 32"""@eng , """N-trifluoroacetyladriamycin-14-valerate"""@eng , """AD-32"""@eng ; """Drug/agent"""^^xsd:string ; """1756"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C1340"""^^xsd:string ; umls:cui """C0068314"""^^xsd:string ; umls:cui """C0101466"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bisantrene"""@eng ; skos:notation """CDR0000039136"""^^xsd:string ; skos:altLabel """Orange Crush"""@eng , """CL-216942"""@eng , """ADCA"""@eng , """Bisantrene Dihydrochloride"""@eng , """Zantrene"""@eng , """ADAH"""@eng , """9,10,Anthracenedicarboxaldehyde"""@eng , """9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl)hydrazone"""@eng , """Bisantrene Hydrochloride"""@eng , """Bisantrene HCL"""@eng , """9,10-Anthracenedicarboxakdehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]"""@eng ; skos:definition """An anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39136&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39136&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1019\" NCI Thesaurus)"""@eng ; """1757"""^^xsd:string ; """C1019"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """337766"""^^xsd:string ; """78186-34-2"""^^xsd:string ; """18412"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511180"""^^xsd:string ; umls:cui """C0109999"""^^xsd:string ; umls:cui """C0053776"""^^xsd:string ; umls:cui """C0955176"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HSP90 inhibitor CNF2024"""@eng ; skos:notation """CDR0000497050"""^^xsd:string ; skos:altLabel """CNF2024"""@eng , """HSP90 antagonist CNF2024"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """2006-10-04"""^^xsd:string ; umls:cui """C1831929"""^^xsd:string ; umls:cui """C1831928"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acetylcysteine"""@eng ; skos:notation """CDR0000039130"""^^xsd:string ; skos:altLabel """NAC"""@eng , """Neo-Fluimucil"""@eng , """Parvolex"""@eng , """Airbron"""@eng , """Muco Sanigen"""@eng , """N-acetyl-L-cysteine"""@eng , """Mucolyticum"""@eng , """Broncholysin"""@eng , """Mucret"""@eng , """N-acetylcysteine"""@eng , """Mucomyst"""@eng , """Fabrol"""@eng , """Fluprowit"""@eng , """Tixair"""@eng , """Mucocedyl"""@eng , """Fluatox"""@eng , """Mucosolvin"""@eng , """N-acetyl-3-mercaptoalanine"""@eng , """Mucolator"""@eng , """Respaire"""@eng , """Fluimucetin"""@eng , """L-Alpha-acetamido-beta-mercaptopropionic Acid"""@eng , """N-Acetyl Cysteine"""@eng , """Fluimucil"""@eng , """Brunac"""@eng ; skos:definition """A synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, a precursor of the antioxidant enzyme glutathione. Acetylcysteine regenerates liver stores of glutathione. This agent also reduces disulfide bonds in mucoproteins, resulting in liquification of mucus. Some evidence suggests that acetylcysteine may exert an anti-apoptotic effect due to its antioxidant activity, possibly preventing cancer cell development or growth. In addition, acetylcysteine has inhibited viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39130&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39130&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C200\" NCI Thesaurus)"""@eng ; ; ; """1751"""^^xsd:string ; """C200"""^^xsd:string ; """616-91-1"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """111180"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1510759"""^^xsd:string ; umls:cui """C0699250"""^^xsd:string ; umls:cui """C0699251"""^^xsd:string ; umls:cui """C0699252"""^^xsd:string ; umls:cui """C0699253"""^^xsd:string ; umls:cui """C1510760"""^^xsd:string ; umls:cui """C0001047"""^^xsd:string ; umls:cui """C1510761"""^^xsd:string ; umls:cui """C1510767"""^^xsd:string ; umls:cui """C1510766"""^^xsd:string ; umls:cui """C1510765"""^^xsd:string ; umls:cui """C1510764"""^^xsd:string ; umls:cui """C1510763"""^^xsd:string ; umls:cui """C1449419"""^^xsd:string ; umls:cui """C0591477"""^^xsd:string ; umls:cui """C1449415"""^^xsd:string ; umls:cui """C0135546"""^^xsd:string ; umls:cui """C1510768"""^^xsd:string ; umls:cui """C1510762"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aclarubicin"""@eng ; skos:notation """CDR0000039131"""^^xsd:string ; skos:altLabel """1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -.alpha.-L-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1.alpha.,2.beta.,4.beta.))-(9CI)"""@eng , """Aclacinomycin A hydrochloride"""@eng , """ACM"""@eng , """aclacinomycin"""@eng , """ACM-A"""@eng , """Aclacinon"""@eng , """Jaclacin"""@eng , """Aclarubicin Hydrochloride"""@eng , """[1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydeo-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-"""@eng , """Antibiotic MA144-A1"""@eng , """Aclaplastin"""@eng , """Aclacin"""@eng , """[1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-1-naphthacenecarboxylic acid methyl ester"""@eng , """Aclacinomycine"""@eng , """Aclacinomycin A"""@eng , """aclacinomycin-A"""@eng , """MA144-A1"""@eng ; skos:definition """An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39131&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39131&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C202\" NCI Thesaurus)"""@eng ; """1752"""^^xsd:string ; """2007-01-05"""^^xsd:string ; """16864"""^^xsd:string ; """57576-44-0"""^^xsd:string ; """240619"""^^xsd:string ; """C202"""^^xsd:string ; """208734"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0917820"""^^xsd:string ; umls:cui """C0050561"""^^xsd:string ; umls:cui """C1515871"""^^xsd:string ; umls:cui """C0591033"""^^xsd:string ; umls:cui """C1515873"""^^xsd:string ; umls:cui """C0771002"""^^xsd:string ; umls:cui """C1257665"""^^xsd:string ; umls:cui """C0001143"""^^xsd:string ; umls:cui """C1515872"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acivicin"""@eng ; skos:notation """CDR0000039132"""^^xsd:string ; skos:altLabel """AT-125"""@eng , """U-42126"""@eng ; skos:definition """A modified amino acid and structural analog of glutamine. Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39132&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39132&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C986\" NCI Thesaurus)"""@eng ; ; """1753"""^^xsd:string ; """16796"""^^xsd:string ; """52583-41-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """163501"""^^xsd:string ; """C986"""^^xsd:string ; umls:cui """C0104485"""^^xsd:string ; umls:cui """C0919370"""^^xsd:string ; umls:cui """C0050560"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """corticotropin"""@eng ; skos:notation """CDR0000039133"""^^xsd:string ; skos:altLabel """ACTH"""@eng , """acthar"""@eng , """adrenocorticotropic hormone"""@eng , """CCTROP"""@eng ; ; """1754"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0001655"""^^xsd:string ; umls:cui """C0718234"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/edatrexate/vinblastine"""@eng ; skos:notation """CDR0000041605"""^^xsd:string ; skos:altLabel """CDDP/DOX/EDAM/VBL"""@eng ; ; ; ; ; """4768"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281223"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000041604"""^^xsd:string ; skos:altLabel """CDDP/5-FU/IFN-A/VP-16"""@eng ; ; ; ; ; """4767"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338162"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """procarbazine hydrochloride"""@eng ; skos:notation """CDR0000041607"""^^xsd:string ; skos:altLabel """PCZ"""@eng , """MIH"""@eng , """PCB Hydrochloride"""@eng , """benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI)"""@eng , """Ibenzmethyzin Hydrochloride"""@eng , """N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide"""@eng , """MIH hydrochloride"""@eng , """N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine"""@eng , """Ibenzmethyzin"""@eng , """N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide"""@eng , """Natulan"""@eng , """Ibenzmethyzine Hydrochloride"""@eng , """PCB"""@eng , """NCI-C01810"""@eng , """p-toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-, monohydrochloride (8CI)"""@eng , """p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride"""@eng , """Ro 4-6467/1"""@eng , """Procarbazin"""@eng , """N-Methylhydrazine"""@eng , """Natunalar"""@eng , """Natulanar"""@eng , """Matulane"""@eng , """p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide"""@eng ; skos:definition """The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41607&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41607&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C773\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2006-09-11"""^^xsd:string ; """7180"""^^xsd:string ; """671-16-9"""^^xsd:string ; """477"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """77213"""^^xsd:string ; """366-70-1 (hydrochloride)"""^^xsd:string ; """C773"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0033223"""^^xsd:string ; umls:cui """C1522607"""^^xsd:string ; umls:cui """C1522606"""^^xsd:string ; umls:cui """C0701390"""^^xsd:string ; umls:cui """C0701389"""^^xsd:string ; umls:cui """C1514466"""^^xsd:string ; umls:cui """C1514467"""^^xsd:string ; umls:cui """C0205909"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radiation toxicity"""@eng ; skos:notation """CDR0000041606"""^^xsd:string ; skos:altLabel """toxicity, radiation"""@eng ; rdfs:subClassOf ; """4769"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C1510432"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000041601"""^^xsd:string ; skos:altLabel """DOX/PEG-ASP/PRED/VCR"""@eng ; ; ; ; ; """4764"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281219"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/pegaspargase"""@eng ; skos:notation """CDR0000041600"""^^xsd:string ; skos:altLabel """ARA-C/CTX/PEG-ASP"""@eng ; ; ; ; """4763"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281218"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/interferon alfa"""@eng ; skos:notation """CDR0000041603"""^^xsd:string ; skos:altLabel """FUDR/IFN-A"""@eng ; ; ; """4766"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338161"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/procarbazine/prednisone/vincristine"""@eng ; skos:notation """CDR0000041602"""^^xsd:string ; skos:altLabel """DOX/PCB/PRED/VCR"""@eng ; ; ; ; ; """4765"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0058827"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/ifosfamide/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041609"""^^xsd:string ; skos:altLabel """ARA-C/IFF/MP/MTX/VP-16"""@eng ; ; ; ; ; ; """4771"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281226"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allopurinol/fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000041608"""^^xsd:string ; skos:altLabel """ALLO/5-FU/IFN-A"""@eng ; ; ; ; """4770"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338163"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/valganciclovir/zidovudine"""@eng ; skos:notation """CDR0000400149"""^^xsd:string ; skos:altLabel """PS-341/VGCV/ZDV"""@eng ; ; ; ; """2004-10-25"""^^xsd:string ; """2004-10-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541388"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valganciclovir/zidovudine"""@eng ; skos:notation """CDR0000400148"""^^xsd:string ; skos:altLabel """VGCV/ZDV"""@eng ; ; ; """2004-10-25"""^^xsd:string ; """2004-10-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541387"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111-DOTA-chimeric monoclonal antibody cG250"""@eng ; skos:notation """CDR0000465806"""^^xsd:string ; skos:altLabel """111In-DOTA-cG250"""@eng ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C1831727"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XL184"""@eng ; skos:notation """CDR0000461103"""^^xsd:string ; skos:definition """An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL184 strongly binds to and inhibits several tyrosine receptor kinases. Specifically, XL184 appears to have a strong affinity for the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in inhibition of tumor growth and angiogenesis, and tumor regression. This agent has also been shown to inhibit mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (Flt3) and tyrosine-protein kinase receptor (Tie-2). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461103&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461103&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52200\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C52200"""^^xsd:string ; umls:cui """C1710686"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunoglobulin therapy"""@eng ; skos:notation """CDR0000474294"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-16"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C0021022"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """meloxicam"""@eng ; skos:notation """CDR0000472195"""^^xsd:string ; skos:altLabel """Mobic"""@eng , """4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide"""@eng , """Mobec"""@eng , """Mobicox"""@eng , """Movatec"""@eng , """Movalis"""@eng ; skos:definition """An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=472195&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=472195&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61439\" NCI Thesaurus)"""@eng ; """C61439"""^^xsd:string ; """71125-38-7"""^^xsd:string ; """2006-03-10"""^^xsd:string ; """2006-10-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0642799"""^^xsd:string ; umls:cui """C0083381"""^^xsd:string ; umls:cui """C1831767"""^^xsd:string ; umls:cui """C0592680"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/gp100 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000038559"""^^xsd:string ; skos:altLabel """gp100/ISA-51/MOAB CTLA-4"""@eng ; ; ; """2003-09-03"""^^xsd:string ; """11190"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134583"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imiquimod"""@eng ; skos:notation """CDR0000038558"""^^xsd:string ; skos:altLabel """IMQ"""@eng , """Aldara"""@eng , """R 837"""@eng , """4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline"""@eng , """S 26308"""@eng , """1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-"""@eng ; skos:definition """A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38558&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38558&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1431\" NCI Thesaurus)"""@eng ; ; ; """11189"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1431"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """99011-02-6"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0165032"""^^xsd:string ; umls:cui """C0073766"""^^xsd:string ; umls:cui """C0139801"""^^xsd:string ; umls:cui """C0718327"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/PSA prostate cancer vaccine"""@eng ; skos:notation """CDR0000038551"""^^xsd:string ; skos:altLabel """ISA-51/PSA VAC"""@eng ; ; """11178"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134577"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/paclitaxel"""@eng ; skos:notation """CDR0000038550"""^^xsd:string ; skos:altLabel """PS-341/TAX"""@eng ; ; ; """2002-11-19"""^^xsd:string ; """11177"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134576"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dacarbazine/doxorubicin"""@eng ; skos:notation """CDR0000038553"""^^xsd:string ; skos:altLabel """CIA"""@eng , """CTX/DOX/DTIC"""@eng , """CAD"""@eng ; ; ; ; """1118"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0170509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000038552"""^^xsd:string ; skos:altLabel """GLO-GM2-LE-MUC1-sTN-TF-TN-KLH"""@eng ; skos:definition """A heptavalent vaccine consisting of the tumor-associated carbohydrate antigens globohexaosylceramide (globo-H), GM2, Lewis-y, MUC1-32(aa), sTn(c), TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin (KLH), an immunomodulator. This vaccine may induce the production of IgG and IgM antibodies and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38552&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38552&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28551\" NCI Thesaurus)"""@eng ; ; """11179"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C28551"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134578"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Synchrovax SEM plasmid DNA vaccine"""@eng ; skos:notation """CDR0000038555"""^^xsd:string ; skos:altLabel """MA2M plasmid DNA vaccine, Synchrotope"""@eng , """plasmid DNA vaccine, Synchrovax SEM"""@eng , """Synchrotope MA2M plasmid DNA vaccine"""@eng ; """11186"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134580"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine/QS21"""@eng ; skos:notation """CDR0000038554"""^^xsd:string ; skos:altLabel """GLO-GM2-LE-MUC1-sTN-TF-TN-KLH/QS 21"""@eng ; ; ; """11180"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134579"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/UCN-01"""@eng ; skos:notation """CDR0000038557"""^^xsd:string ; skos:altLabel """CPT-11/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """11188"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134582"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/methotrexate/nelarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000038556"""^^xsd:string ; skos:altLabel """506U78/ASP/DNR/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """11187"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134581"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 tositumomab"""@eng ; skos:notation """CDR0000042806"""^^xsd:string ; skos:altLabel """I131-MOAB-B1"""@eng , """131-I-Anti-B1 Antibody"""@eng , """Iodine-131 Anti-B1 Antibody"""@eng , """131-I-Anti-B1 Monoclonal Antibody"""@eng , """iodine I 131 monoclonal antibody anti-B1"""@eng , """Bexxar"""@eng , """Iodine-131 Anti-CD20 Monoclonal Antibody"""@eng , """iodine I 131 MOAB anti-B1"""@eng ; skos:definition """A monoclonal antibody directed against a protein (CD20) expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope I 131 with potential antineoplastic activity. Iodine I 131 tositumomab delivers radiation selectively to neoplastic CD20-expressing B-lymphocytes cells, thereby decreasing the risk of systemic radiotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42806&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42806&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2444\" NCI Thesaurus)"""@eng ; ; ; ; ; """6605"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C2444"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0768182"""^^xsd:string ; umls:cui """C0919272"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/cyclophosphamide"""@eng ; skos:notation """CDR0000042807"""^^xsd:string ; skos:altLabel """ATG/CTX"""@eng ; ; ; """6606"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677755"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioimmunodetection"""@eng ; skos:notation """CDR0000042804"""^^xsd:string ; rdfs:subClassOf ; """6603"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0085264"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/raltitrexed"""@eng ; skos:notation """CDR0000042805"""^^xsd:string ; skos:altLabel """DOX/ICI D1694"""@eng ; ; ; """6604"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677753"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/leuprolide/testosterone"""@eng ; skos:notation """CDR0000334947"""^^xsd:string ; skos:altLabel """LEUP/TESTO/TXT"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328057"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/imatinib mesylate/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000334946"""^^xsd:string ; skos:altLabel """DOX/PEG-ASP/PRED/STI571/VCR"""@eng ; ; ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042800"""^^xsd:string ; skos:altLabel """NHL, adult"""@eng , """adult NHL"""@eng , """Non-Hodgkin's lymphoma, adult"""@eng , """non-Hodgkin's lymphoma, adult"""@eng , """lymphoma, non-Hodgkin's, adult"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """66"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220605"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide phosphate"""@eng ; skos:notation """CDR0000042801"""^^xsd:string ; skos:altLabel """ETOP"""@eng , """Etopophos"""@eng ; skos:definition """A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42801&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42801&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1093\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """6600"""^^xsd:string ; """C1093"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """117091-64-2"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0904036"""^^xsd:string ; umls:cui """C0059874"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AG-858"""@eng ; skos:notation """CDR0000334949"""^^xsd:string ; skos:altLabel """Autologous Heat-Shock Protein 70 Peptide Vaccine"""@eng , """AG858"""@eng ; skos:definition """A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=334949&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=334949&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37448\" NCI Thesaurus)"""@eng ; ; """2003-09-24"""^^xsd:string ; """C37448"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328058"""^^xsd:string ; umls:cui """C1527257"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/etoposide/paclitaxel"""@eng ; skos:notation """CDR0000042808"""^^xsd:string ; skos:altLabel """EM/TAX/VP-16"""@eng ; ; ; ; """6607"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677756"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/estramustine/ketoconazole/vinblastine"""@eng ; skos:notation """CDR0000042809"""^^xsd:string ; skos:altLabel """DOX/EM/KCZ/VBL"""@eng ; ; ; ; ; """6608"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677757"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CHIR-12.12"""@eng ; skos:notation """CDR0000432936"""^^xsd:string ; skos:altLabel """MOAB CHIR-12.12"""@eng ; skos:definition """A monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. Monoclonal antibody CHIR-12.12 binds to and inhibits CD40, thereby inhibiting CD40 ligand-induced cell proliferation and triggering cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells overexpressing CD40. CD40, an integral membrane protein found on the surface of B lymphocytes, is a member of the tumor necrosis factor receptor superfamily and is highly expressed in a number of B-cell malignancies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=432936&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=432936&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48405\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C48405"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """2005-05-06"""^^xsd:string ; umls:cui """C1709066"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isavuconazole"""@eng ; skos:notation """CDR0000529357"""^^xsd:string ; skos:altLabel """BAL8557"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1699921"""^^xsd:string ; umls:cui """C1832021"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mycobacterial cell wall-DNA complex"""@eng ; skos:notation """CDR0000529352"""^^xsd:string ; skos:altLabel """MCC"""@eng ; """2007-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832020"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Essiac"""@eng ; skos:notation """CDR0000304440"""^^xsd:string ; skos:altLabel """Esiak"""@eng ; skos:definition """An herbal formula containing burdock root (Arctium lappa), Turkey rhubarb root (Rheum palmatum), sheep sorrel (Rumex acetosella), and slippery elm bark (Ulmus fulva) with potential immunostimulating, anti-inflammatory and anti-tumor activities. The exact chemical profile, their respective concentrations and the mechanism of action of Essiac are largely unknown due to the proprietary nature of the formula and product inconsistency. Several chemical classes in Essiac are consistently represented and may attribute to its therapeutic effect, including anthraquinone derivatives such as rhein and emodin, high molecular polysaccharides, and lignans such as arctigenin. However, all these chemicals are unlikely to occur in high concentrations in Essiac, and its potential therapeutic effect may be attributed to a potential synergistic effect of these various compounds. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304440&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=304440&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26649\" NCI Thesaurus)"""@eng ; """2003-04-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26649"""^^xsd:string ; """2006-12-21"""^^xsd:string ; umls:cui """C0673827"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000416131"""^^xsd:string ; skos:altLabel """MP/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000416130"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/DOX/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/decitabine"""@eng ; skos:notation """CDR0000039736"""^^xsd:string ; skos:altLabel """AMSA/5-AZA-dCyd"""@eng , """AMSA/DAC"""@eng ; ; ; """2398"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279490"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ascorbic acid"""@eng ; skos:notation """CDR0000039737"""^^xsd:string ; skos:altLabel """L-Ascorbic Acid"""@eng , """Cecon"""@eng , """C-Long"""@eng , """Cenolate"""@eng , """vitamin C"""@eng , """Ce-Vi-Sol"""@eng , """Cetane"""@eng , """VIT C"""@eng , """Asorbicap"""@eng , """Cevalin"""@eng ; skos:definition """A natural water-soluble vitamin (Vitamin C). Ascorbic acid is a potent reducing and antioxidant agent that functions in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen in fibrous tissue, teeth, bones, connective tissue, skin, and capillaries. Found in citrus and other fruits, and in vegetables, vitamin C cannot be produced or stored by humans and must be obtained in the diet. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39737&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39737&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C285\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """2399"""^^xsd:string ; """C285"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """50-81-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33832"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1510950"""^^xsd:string ; umls:cui """C0699149"""^^xsd:string ; umls:cui """C0003968"""^^xsd:string ; umls:cui """C0699147"""^^xsd:string ; umls:cui """C0699153"""^^xsd:string ; umls:cui """C0699152"""^^xsd:string ; umls:cui """C0699151"""^^xsd:string ; umls:cui """C0699150"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cholecalciferol"""@eng ; skos:notation """CDR0000039734"""^^xsd:string ; skos:altLabel """(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol"""@eng , """Calciol"""@eng , """Vitamin D3"""@eng ; skos:definition """A steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39734&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39734&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48194\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """2396"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """C48194"""^^xsd:string ; """67-97-0"""^^xsd:string ; """62792"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0008318"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vitamin A"""@eng ; skos:notation """CDR0000039735"""^^xsd:string ; skos:altLabel """Idrurto A"""@eng , """Mulsal A Megadosis"""@eng , """A 313"""@eng , """Axerophtholum"""@eng , """Rinocusi Vitaminico"""@eng , """Ido A 50"""@eng , """Biosterol"""@eng , """3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol"""@eng , """Vitamin A USP"""@eng , """Vitamin A Alcohol"""@eng , """Lard-Factor"""@eng , """Avitol"""@eng , """Axerol"""@eng , """Biovit-A"""@eng , """Axerophthol"""@eng , """Oleovitamin A"""@eng , """Del-Vi-A"""@eng , """Vitaminum A"""@eng , """Ledovit A"""@eng , """Micelle A"""@eng , """Vitaminoftalmina"""@eng , """Anti-Infective Vitamin"""@eng , """Pedi-Vit-A"""@eng , """Antixerophthalmic Vitamin"""@eng , """Ophthalamin"""@eng , """retinol"""@eng , """Avibon"""@eng , """Vogan"""@eng , """All Trans Retinol"""@eng , """Vitamin A1"""@eng , """Aquasol A"""@eng , """Arovit"""@eng ; skos:definition """The fat soluble vitamin retinol. Vitamin A binds to and activates retinoid receptors (RARs), thereby inducing cell differentiation and apoptosis of some cancer cell types and inhibiting carcinogenesis. Vitamin A plays an essential role in many physiologic processes, including proper functioning of the retina, growth and differentiation of target tissues, proper functioning of the reproductive organs, and modulation of immune function. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39735&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39735&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C938\" NCI Thesaurus)"""@eng ; ; ; ; """2397"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C938"""^^xsd:string ; """122759"""^^xsd:string ; """68-26-8 (all-trans)"""^^xsd:string ; """2006-12-19"""^^xsd:string ; """11103-57-4"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1520034"""^^xsd:string ; umls:cui """C1520035"""^^xsd:string ; umls:cui """C0087161"""^^xsd:string ; umls:cui """C1520037"""^^xsd:string ; umls:cui """C1520045"""^^xsd:string ; umls:cui """C1520044"""^^xsd:string ; umls:cui """C1520047"""^^xsd:string ; umls:cui """C1520033"""^^xsd:string ; umls:cui """C0042839"""^^xsd:string ; umls:cui """C0699567"""^^xsd:string ; umls:cui """C1520046"""^^xsd:string ; umls:cui """C1520038"""^^xsd:string ; umls:cui """C1520036"""^^xsd:string ; umls:cui """C1520039"""^^xsd:string ; umls:cui """C1520042"""^^xsd:string ; umls:cui """C0947716"""^^xsd:string ; umls:cui """C1520043"""^^xsd:string ; umls:cui """C1520040"""^^xsd:string ; umls:cui """C1520041"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vindesine"""@eng ; skos:notation """CDR0000039732"""^^xsd:string ; skos:altLabel """3-(Aminocarbonyl)-O4-deacetyl-3-de-(methoxycarbonyl)vincaleukoblastine"""@eng , """VDS"""@eng , """Compound 112531"""@eng , """deacetylvinblastine carboxamide"""@eng , """DVA"""@eng , """Deacetyl Vinblastine Carboxamide"""@eng , """Eldisine"""@eng , """DAVA"""@eng , """Desacetylvinblastine Amide"""@eng ; skos:definition """A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39732&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39732&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C934\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2394"""^^xsd:string ; """21887"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """53643-48-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C934"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0042682"""^^xsd:string ; umls:cui """C0591439"""^^xsd:string ; umls:cui """C0877923"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinzolidine"""@eng ; skos:notation """CDR0000039733"""^^xsd:string ; """2395"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0078282"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """verapamil"""@eng ; skos:notation """CDR0000039730"""^^xsd:string ; skos:altLabel """Verapamil SR"""@eng , """alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile"""@eng ; skos:definition """A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39730&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39730&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C928\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """2392"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C928"""^^xsd:string ; """52-53-9"""^^xsd:string ; """2006-12-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527129"""^^xsd:string ; umls:cui """C0042523"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vancomycin"""@eng ; skos:notation """CDR0000039731"""^^xsd:string ; skos:altLabel """VANCO"""@eng , """Vancocin Hydrochloride"""@eng ; ; ; """2393"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0699052"""^^xsd:string ; umls:cui """C0042313"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent breast cancer"""@eng ; skos:notation """CDR0000039738"""^^xsd:string ; skos:altLabel """breast cancer, recurrent"""@eng ; rdfs:subClassOf ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """24"""^^xsd:string ; """prior adjuvant endocrine/hormonal therapy"""^^xsd:string ; """metastatic disease"""^^xsd:string ; """prior estrogen therapy"""^^xsd:string ; """progesterone receptor status unknown"""^^xsd:string ; """premenopausal"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """estrogen receptor status unknown"""^^xsd:string ; """estrogen receptor positive"""^^xsd:string ; """bilateral breast cancer"""^^xsd:string ; """prior progestin therapy"""^^xsd:string ; """prior radiation therapy"""^^xsd:string ; """estrogen receptor negative"""^^xsd:string ; """performance status 3"""^^xsd:string ; """prior LHRH agonist therapy"""^^xsd:string ; """performance status 4"""^^xsd:string ; """prior interferon therapy"""^^xsd:string ; """prior chemotherapy for advanced disease"""^^xsd:string ; """known bone marrow involvement"""^^xsd:string ; """prior endocrine therapy for advanced disease"""^^xsd:string ; """performance status 2"""^^xsd:string ; """prior antiestrogen therapy"""^^xsd:string ; """central nervous system involvement/metastases"""^^xsd:string ; """prior androgen therapy"""^^xsd:string ; """prior anthracycline therapy"""^^xsd:string ; """no measurable or evaluable disease"""^^xsd:string ; """progesterone receptor negative"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """prior biologic therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """prior oophorectomy"""^^xsd:string ; """HIV positive"""^^xsd:string ; """prior adjuvant chemotherapy"""^^xsd:string ; """postmenopausal"""^^xsd:string ; """progesterone receptor positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278493"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yoshi-864"""@eng ; skos:notation """CDR0000039739"""^^xsd:string ; skos:altLabel """1-Propanol, 3,3'-iminodi-, Dimethanesulfonate (Ester), Hydrochloride (8CI)"""@eng , """1-Propanol, 3,3'-, Dimethanesulfonate (Ester), Hydrochloride"""@eng , """Compound 864"""@eng , """3, 3'-Dimesyloxydipropylamine HCl"""@eng , """Bis(3-mesyloxypropyl)amine Hydrochloride"""@eng , """3, 3'-Dimesyloxydipropylamine Hydrochloride"""@eng , """1-Propanol-3,3'-iminodidimethanesulfonatehydrochloride"""@eng , """IPD Hydrochloride"""@eng , """3,3'-Imidodi-1-propanol, Dimethanesulfonate (Ester) HCl"""@eng , """Yoshi 864"""@eng , """3, 3'-Iminodi-1-propanol Di(methanesulfonate) Hydrochloride"""@eng , """Bis(3-mesyloxypropyl)amine HCl"""@eng , """3, 3'-Iminodi-1-propanol Di(methanesulfonate) HCl"""@eng , """3, 3'-Iminodi-1-propanol Dimethanesulfonate Ester HCl"""@eng , """3, 3'-Iminodi-1-propanol Dimethanesulfonate Ester Hydrochloride"""@eng , """1-Propanol, 3,3'-Iminobis-, Dimethanesulfonate (Ester), Hydrochloride (9CI"""@eng , """3,3'-Imidodi-1-propanol, Dimethanesulfonate (Ester), Hydrochloride"""@eng , """NCI-C01547"""@eng ; skos:definition """An alkylsulfonate. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39739&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39739&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1416\" NCI Thesaurus)"""@eng ; """2400"""^^xsd:string ; """7575"""^^xsd:string ; """3458-22-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1416"""^^xsd:string ; """102627"""^^xsd:string ; umls:cui """C0149214"""^^xsd:string ; umls:cui """C1527000"""^^xsd:string ; umls:cui """C0971903"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """digoxin"""@eng ; skos:notation """CDR0000485249"""^^xsd:string ; skos:altLabel """Lanoxin"""@eng ; skos:definition """A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility. This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity. Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485249&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485249&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28990\" NCI Thesaurus)"""@eng ; """2006-05-11"""^^xsd:string ; """C28990"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699988"""^^xsd:string ; umls:cui """C0012265"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II Wilms' tumor"""@eng ; skos:notation """CDR0000043736"""^^xsd:string ; skos:altLabel """Wilms' tumor, stage II"""@eng , """stage II Wilms tumor"""@eng , """Wilm's tumor, stage II"""@eng , """stage II nephroblastoma"""@eng , """Wilms tumor, stage II"""@eng , """nephroblastoma, stage II"""@eng , """stage II Wilm's tumor"""@eng ; rdfs:subClassOf ; """Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """996"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278712"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I Wilms' tumor"""@eng ; skos:notation """CDR0000043735"""^^xsd:string ; skos:altLabel """Wilms' tumor, stage I"""@eng , """nephroblastoma, stage I"""@eng , """Wilms tumor, stage I"""@eng , """stage I Wilms tumor"""@eng , """Wilm's tumor, stage I"""@eng , """stage I Wilm's tumor"""@eng , """stage I nephroblastoma"""@eng ; rdfs:subClassOf ; """Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """995"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278711"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/etoposide"""@eng ; skos:notation """CDR0000043734"""^^xsd:string ; skos:altLabel """BCNU/CDDP/VP-16"""@eng ; ; ; ; """994"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278710"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """retinoblastoma"""@eng ; skos:notation """CDR0000043733"""^^xsd:string ; skos:altLabel """Retinoblastoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """993"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0035335"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin"""@eng ; skos:notation """CDR0000043732"""^^xsd:string ; skos:altLabel """CBDCA/CDDP"""@eng ; ; ; """992"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278709"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000043731"""^^xsd:string ; skos:altLabel """CF/5-FU/MTX"""@eng , """MLF"""@eng ; ; ; ; """991"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000043730"""^^xsd:string ; skos:altLabel """CF/5-FU"""@eng ; ; ; """990"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278707"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TLK199"""@eng ; skos:notation """CDR0000485244"""^^xsd:string ; skos:altLabel """TELINTRA"""@eng ; skos:definition """A liposomal small-molecule glutathione analog inhibitor of glutathione S-transferase (GST) P1-1 with hematopoiesis-stimulating activity. After intracellular de-esterification, the active form of TLK199 (TLK117) binds to and inhibits GST P1-1, thereby restoring Jun kinase and MAPK pathway activities and promoting MAPK-mediated cellular proliferation and differentiation pathways. This agent promotes the proliferation and maturation of hematopoietic precursor cells, granulocytes, monocytes, erythrocytes and platelets. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485244&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485244&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61326\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-07-10"""^^xsd:string ; """C61326"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1613942"""^^xsd:string ; umls:cui """C1612297"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage V Wilms' tumor"""@eng ; skos:notation """CDR0000043739"""^^xsd:string ; skos:altLabel """stage V nephroblastoma"""@eng , """stage V Wilms tumor"""@eng , """Wilm's tumor, stage V"""@eng , """stage V Wilm's tumor"""@eng , """Wilms tumor, stage V"""@eng , """nephroblastoma, stage V"""@eng , """Wilms' tumor, stage V"""@eng ; rdfs:subClassOf ; """Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """999"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278715"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV Wilms' tumor"""@eng ; skos:notation """CDR0000043738"""^^xsd:string ; skos:altLabel """nephroblastoma, stage IV"""@eng , """stage IV nephroblastoma"""@eng , """stage IV Wilm's tumor"""@eng , """Wilms' tumor, metastatic"""@eng , """Wilms' tumor, stage IV"""@eng , """metastatic Wilms tumor"""@eng , """stage IV Wilms tumor"""@eng , """Wilms tumor, stage IV"""@eng , """metastatic nephroblastoma"""@eng , """nephroblastoma, metastatic"""@eng , """metastatic Wilms' tumor"""@eng , """Wilm's tumor, stage IV"""@eng , """metastatic Wilm's tumor"""@eng , """Wilms tumor, metastatic"""@eng , """Wilm's tumor, metastatic"""@eng ; rdfs:subClassOf ; """Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """998"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278714"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000041595"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/VCR"""@eng ; ; ; ; ; """4758"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281213"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041594"""^^xsd:string ; skos:altLabel """ASP/DNR/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """4757"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281212"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041597"""^^xsd:string ; skos:altLabel """IFF/MTX/VCR/VP-16"""@eng ; ; ; ; ; """4760"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281215"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000041596"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DOX/VCR"""@eng ; ; ; ; ; """4759"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281214"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capsaicin"""@eng ; skos:notation """CDR0000041591"""^^xsd:string ; """4754"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0006931"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Abelcet"""@eng ; skos:notation """CDR0000041590"""^^xsd:string ; skos:altLabel """ABLC"""@eng , """lipid complex, amphotericin B"""@eng ; """4753"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C0281209"""^^xsd:string ; umls:cui """C1145701"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/muramyl tripeptide phosphatidylethanolamine liposome"""@eng ; skos:notation """CDR0000041593"""^^xsd:string ; skos:altLabel """IFF/MTP-PE Liposome"""@eng ; ; ; """4756"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281211"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/muramyl tripeptide phosphatidylethanolamine liposome"""@eng ; skos:notation """CDR0000041592"""^^xsd:string ; skos:altLabel """CDDP/MTP-PE Liposome"""@eng ; ; ; """4755"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281210"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000041599"""^^xsd:string ; skos:altLabel """DM/MP/VCR"""@eng ; ; ; ; """4762"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281217"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/dexamethasone/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000041598"""^^xsd:string ; skos:altLabel """CTX/DM/DNR/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; ; """4761"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281216"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, prostate cancer"""@eng ; skos:notation """CDR0000040185"""^^xsd:string ; skos:altLabel """prostate cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2975"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279882"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, extrahepatic bile duct cancer"""@eng ; skos:notation """CDR0000040184"""^^xsd:string ; skos:altLabel """extrahepatic bile duct cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2974"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279881"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, pancreatic cancer"""@eng ; skos:notation """CDR0000040187"""^^xsd:string ; skos:altLabel """pancreas cancer cellular diagnosis"""@eng , """pancreatic cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2977"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279884"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, osteosarcoma"""@eng ; skos:notation """CDR0000040186"""^^xsd:string ; skos:altLabel """osteosarcoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2976"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279883"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, vaginal cancer"""@eng ; skos:notation """CDR0000040181"""^^xsd:string ; skos:altLabel """vaginal cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2971"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279878"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, non-small cell lung cancer"""@eng ; skos:notation """CDR0000040180"""^^xsd:string ; skos:altLabel """cellular diagnosis, nonsmall cell lung cancer"""@eng , """nonsmall cell lung cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2970"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279877"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, colon cancer"""@eng ; skos:notation """CDR0000040183"""^^xsd:string ; skos:altLabel """colon cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2973"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279880"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, bladder cancer"""@eng ; skos:notation """CDR0000040182"""^^xsd:string ; skos:altLabel """bladder cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2972"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279879"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, penile cancer"""@eng ; skos:notation """CDR0000040189"""^^xsd:string ; skos:altLabel """penis cancer cellular diagnosis"""@eng , """penile cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2980"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279886"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, parathyroid cancer"""@eng ; skos:notation """CDR0000040188"""^^xsd:string ; skos:altLabel """parathyroid cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2979"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279885"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/gp100 antigen/keyhole limpet hemocyanin/MAGE-3/MART-1 antigen/Melan-A/NY-ESO-B/tyrosinase peptide"""@eng ; skos:notation """CDR0000257352"""^^xsd:string ; skos:altLabel """flu/gp100/KLH/MAGE3/MART-1/MEL-A/NY ESO-B/TYRP"""@eng ; ; ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """11448"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327764"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706/carboplatin/paclitaxel/panitumumab"""@eng ; skos:notation """CDR0000407531"""^^xsd:string ; skos:altLabel """AMG-706/CBDCA/MOAB ABX-EGF/TAX"""@eng ; ; ; ; ; """2004-11-19"""^^xsd:string ; """2004-11-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541417"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706/panitumumab"""@eng ; skos:notation """CDR0000407530"""^^xsd:string ; skos:altLabel """AMG-706/MOAB ABX-EGF"""@eng ; ; ; """2004-11-19"""^^xsd:string ; """2004-11-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541416"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/gp100 antigen/MAGE-3/MART-1 antigen/Melan-A/NY-ESO-B/tyrosinase peptide"""@eng ; skos:notation """CDR0000257353"""^^xsd:string ; skos:altLabel """flu/gp100/MAGE3/MART-1/MEL-A/NY ESO-B/TYRP"""@eng ; ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """11449"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327765"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/gp100 antigen/keyhole limpet hemocyanin/MAGE-3 /MART-1 antigen/Melan-A/NY-ESO-B/QS21/tyrosinase peptide"""@eng ; skos:notation """CDR0000257350"""^^xsd:string ; skos:altLabel """flu/gp100/KLH/MAGE3/MART-1/MEL-A/NY ESO-B/QS 21/TYRP"""@eng ; ; ; ; ; ; ; ; ; """11447"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-18"""^^xsd:string ; umls:cui """C1327763"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/etoposide/procarbazine"""@eng ; skos:notation """CDR0000039684"""^^xsd:string ; skos:altLabel """VPH"""@eng , """HMM/PCB/VP-16"""@eng ; ; ; ; """2338"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279464"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anastrozole/gefitinib"""@eng ; skos:notation """CDR0000258295"""^^xsd:string ; skos:altLabel """ANAS/ZD 1839"""@eng ; ; ; """2002-10-10"""^^xsd:string ; """11484"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327800"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cell-adenovirus p53 vaccine"""@eng ; skos:notation """CDR0000258292"""^^xsd:string ; skos:definition """An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258292&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258292&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26445\" NCI Thesaurus)"""@eng ; """11483"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C26445"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327799"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant transforming growth factor-beta-2"""@eng ; skos:notation """CDR0000042024"""^^xsd:string ; skos:altLabel """Recombinant Transforming Growth Factor-Beta 2"""@eng , """TGF-beta-2"""@eng ; """C1286"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5251"""^^xsd:string ; """2006-11-21"""^^xsd:string ; umls:cui """C0079441"""^^xsd:string ; umls:cui """C1522073"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/paclitaxel"""@eng ; skos:notation """CDR0000042025"""^^xsd:string ; skos:altLabel """CDDP/IFF/TAX"""@eng ; ; ; ; """5252"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281566"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/prednisone"""@eng ; skos:notation """CDR0000042026"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED/VP-16"""@eng ; ; ; ; ; """5253"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281567"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/homoharringtonine"""@eng ; skos:notation """CDR0000042027"""^^xsd:string ; skos:altLabel """ARA-C/HH"""@eng ; ; ; """5255"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281568"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/interleukin-1-alpha"""@eng ; skos:notation """CDR0000042020"""^^xsd:string ; skos:altLabel """IL-1A/VP-16"""@eng ; ; ; """5246"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281562"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """synthetic peptide-based erythropoiesis stimulating agent"""@eng ; skos:notation """CDR0000434424"""^^xsd:string ; skos:altLabel """Hematide"""@eng ; skos:definition """A synthetic, non-recombinant, pegylated, peptidic erythropoiesis stimulating agent. Synthetic peptide-based erythropoiesis stimulating agent binds to and activates the erythropoietin (EPO) receptor on erythroid progenitor cells, thereby inducing their proliferation and differentiation into mature erythrocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434424&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434424&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48422\" NCI Thesaurus)"""@eng ; """C48422"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """2005-05-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1710272"""^^xsd:string ; umls:cui """C1710271"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel-loaded polymeric micelle"""@eng ; skos:notation """CDR0000434427"""^^xsd:string ; skos:altLabel """paclitaxel loaded polymeric micelle"""@eng , """Genexol-PM"""@eng ; skos:definition """A biodegradable poly(ethylene glycol)-poly(D,L-lactide) copolymer miceller nanoparticle-entrapped formulation of paclitaxel with antineoplastic properties. Paclitaxel promotes microtubule assembly and prevents depolymerization, thus interfering with normal mitosis. The copolymer residue increases the water-solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434427&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434427&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48415\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C48415"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831629"""^^xsd:string ; umls:cui """C1709446"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/tamoxifen"""@eng ; skos:notation """CDR0000042023"""^^xsd:string ; skos:altLabel """CBDCA/TMX/VP-16"""@eng ; ; ; ; """5250"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281564"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/SU011248"""@eng ; skos:notation """CDR0000438775"""^^xsd:string ; skos:altLabel """SU11248/ZD 1839"""@eng ; ; ; """2005-06-27"""^^xsd:string ; """2005-07-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831663"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim/tumor necrosis factor"""@eng ; skos:notation """CDR0000042028"""^^xsd:string ; skos:altLabel """GM-CSF/TNF"""@eng ; ; ; """5256"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281569"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/interferon alfa"""@eng ; skos:notation """CDR0000042029"""^^xsd:string ; skos:altLabel """DM/IFN-A"""@eng ; ; ; """5257"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338184"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/procarbazine/vincristine"""@eng ; skos:notation """CDR0000042129"""^^xsd:string ; skos:altLabel """DM/MTX/PCB/VCR"""@eng ; ; ; ; ; """5365"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281652"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/filgrastim/mitoxantrone"""@eng ; skos:notation """CDR0000042128"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/G-CSF/VP-16"""@eng ; ; ; ; ; """5364"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281651"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplaston A10/antineoplaston AS2-1"""@eng ; skos:notation """CDR0000042121"""^^xsd:string ; skos:altLabel """A10/AS2-1"""@eng ; ; ; """5357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281644"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant"""@eng ; skos:notation """CDR0000042120"""^^xsd:string ; skos:altLabel """ISA-51"""@eng , """Freund's incomplete adjuvant"""@eng , """IFA"""@eng , """Montanide ISA 51"""@eng ; skos:definition """A water-in-oil emulsion that stimulates the T-cell immune response to antigens and may be used in various types of cancer vaccines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42120&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42120&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1573\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5356"""^^xsd:string ; """7103"""^^xsd:string ; """6123"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5924"""^^xsd:string ; """7474"""^^xsd:string ; """8652"""^^xsd:string ; """C1573"""^^xsd:string ; """675756"""^^xsd:string ; """11024"""^^xsd:string ; """11152"""^^xsd:string ; """8709"""^^xsd:string ; """2006-08-27"""^^xsd:string ; umls:cui """C0281643"""^^xsd:string ; umls:cui """C1311732"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone/idarubicin/methotrexate"""@eng ; skos:notation """CDR0000042123"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/IDA/MTX"""@eng ; ; ; ; ; ; """5359"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281646"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone/idarubicin"""@eng ; skos:notation """CDR0000042122"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/IDA"""@eng ; ; ; ; ; """5358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281645"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/milodistim/paclitaxel"""@eng ; skos:notation """CDR0000042125"""^^xsd:string ; skos:altLabel """CBDCA/PIXY321/TAX"""@eng ; ; ; ; """5361"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281648"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/fluorouracil"""@eng ; skos:notation """CDR0000042124"""^^xsd:string ; skos:altLabel """5-FU/VP-16"""@eng ; ; ; """5360"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281647"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/filgrastim/idarubicin"""@eng ; skos:notation """CDR0000042127"""^^xsd:string ; skos:altLabel """ARA-C/G-CSF/IDA"""@eng ; ; ; ; """5363"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281650"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/tipifarnib"""@eng ; skos:notation """CDR0000393558"""^^xsd:string ; skos:altLabel """ARA-C/IDA/R115777"""@eng ; ; ; ; """2004-10-25"""^^xsd:string ; """2004-09-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541374"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/flutamide/goserelin"""@eng ; skos:notation """CDR0000358199"""^^xsd:string ; skos:altLabel """EM/FLUT/TXT/ZDX"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541574"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous immunoglobulin idiotype-KLH conjugate vaccine/sargramostim"""@eng ; skos:notation """CDR0000276473"""^^xsd:string ; skos:altLabel """GM-CSF/Id-KLH"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-04-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327898"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous immunoglobulin idiotype-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000276471"""^^xsd:string ; skos:altLabel """GTOP-99"""@eng , """recombinant Id-KLH"""@eng , """Id-KLH"""@eng , """Id-KLH conjugate vaccine"""@eng , """Autologous-Immunoglobulin-Idiotype-KLH-Conjugate-Vaccine"""@eng , """autologous immunoglobulin idiotype-keyhole limpet hemocyanin conjugate vaccine"""@eng ; skos:definition """A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immunostimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=276471&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=276471&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38715\" NCI Thesaurus)"""@eng ; ; """2003-02-21"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38715"""^^xsd:string ; umls:cui """C1327897"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mucositis"""@eng ; skos:notation """CDR0000491691"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2006-06-21"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-06-22"""^^xsd:string ; umls:cui """C0333355"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000037762"""^^xsd:string ; skos:altLabel """cutaneous T-cell lymphoma, stage II"""@eng , """mycosis fungoides/Sezary syndrome, stage II"""@eng , """stage II mycosis fungoides/Sezary syndrome"""@eng ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """100"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0862216"""^^xsd:string ; umls:cui """C0278568"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palmar-plantar erythrodysesthesia"""@eng ; skos:notation """CDR0000474333"""^^xsd:string ; skos:altLabel """hand-foot syndrome"""@eng ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """2006-03-16"""^^xsd:string ; umls:cui """C0549410"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypofractionated radiation therapy"""@eng ; skos:notation """CDR0000474332"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-16"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831786"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade I meningioma"""@eng ; skos:notation """CDR0000377494"""^^xsd:string ; skos:altLabel """meningioma, grade I"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult meningeal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1512260"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade II meningioma"""@eng ; skos:notation """CDR0000377495"""^^xsd:string ; skos:altLabel """meningioma, grade II"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult meningeal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1512259"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade III meningioma"""@eng ; skos:notation """CDR0000377496"""^^xsd:string ; skos:altLabel """adult papillary meningioma"""@eng , """adult anaplastic (malignant) meningioma"""@eng , """meningioma, grade III"""@eng , """adult rhabdoid meningioma"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult meningeal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280801"""^^xsd:string ; umls:cui """C0281334"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult melanocytic lesion"""@eng ; skos:notation """CDR0000377490"""^^xsd:string ; skos:altLabel """melanocytic lesion, adult"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult meningeal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541319"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone/prednimustine"""@eng ; skos:notation """CDR0000039099"""^^xsd:string ; skos:altLabel """DHAD/PM/VP-16"""@eng ; ; ; ; """1690"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279110"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/methotrexate/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000039098"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/MePRDL/MTX/VCR"""@eng ; ; ; ; ; ; ; """1689"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279109"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane/doxorubicin/sargramostim"""@eng ; skos:notation """CDR0000039093"""^^xsd:string ; skos:altLabel """ADR-529/DOX/GM-CSF"""@eng ; ; ; ; """1684"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279104"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/mesna/mitoxantrone"""@eng ; skos:notation """CDR0000042389"""^^xsd:string ; skos:altLabel """DHAD/IFF/MSA/VP-16"""@eng , """MINE"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """5644"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338297"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2/tumor necrosis factor"""@eng ; skos:notation """CDR0000039091"""^^xsd:string ; skos:altLabel """CTX/IL-2/TNF"""@eng ; ; ; ; """1682"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279102"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/mitoxantrone"""@eng ; skos:notation """CDR0000039090"""^^xsd:string ; skos:altLabel """CF/DHAD/5-FU"""@eng , """MFL"""@eng ; ; ; ; """1681"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0251760"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitotane"""@eng ; skos:notation """CDR0000039097"""^^xsd:string ; skos:altLabel """CDDP/DDD"""@eng ; ; ; """1688"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279108"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/pentostatin/prednisone"""@eng ; skos:notation """CDR0000039096"""^^xsd:string ; skos:altLabel """CLB/DCF/PRED"""@eng ; ; ; ; """1687"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279107"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000039095"""^^xsd:string ; skos:altLabel """ARA-C/DNR/GM-CSF/VP-16"""@eng ; ; ; ; ; """1686"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279106"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/diaziquone"""@eng ; skos:notation """CDR0000039094"""^^xsd:string ; skos:altLabel """AZQ/CTX"""@eng ; ; ; """1685"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279105"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immune globulin/zidovudine"""@eng ; skos:notation """CDR0000039398"""^^xsd:string ; skos:altLabel """immune globulin/ZDV"""@eng ; ; ; """2033"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279261"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/mechlorethamine/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039399"""^^xsd:string ; skos:altLabel """BLEO/NM/PCB/PRED/VCR"""@eng , """BLEO-MOPP"""@eng ; ; ; ; ; ; """2034"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279262"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II verrucous carcinoma of the larynx"""@eng ; skos:notation """CDR0000040749"""^^xsd:string ; skos:altLabel """verrucous carcinoma of the larynx, stage II"""@eng , """laryngeal verrucous carcinoma, stage II"""@eng , """larynx verrucous carcinoma, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3697"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280396"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II squamous cell carcinoma of the larynx"""@eng ; skos:notation """CDR0000040748"""^^xsd:string ; skos:altLabel """epidermoid carcinoma of the larynx, stage II"""@eng , """larynx squamous cell carcinoma, stage II"""@eng , """squamous cell carcinoma of the larynx, stage II"""@eng , """laryngeal squamous cell carcinoma, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3696"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280395"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I verrucous carcinoma of the larynx"""@eng ; skos:notation """CDR0000040747"""^^xsd:string ; skos:altLabel """verrucous carcinoma of the larynx, stage I"""@eng , """laryngeal verrucous carcinoma, stage I"""@eng , """larynx verrucous carcinoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3695"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280394"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I squamous cell carcinoma of the larynx"""@eng ; skos:notation """CDR0000040746"""^^xsd:string ; skos:altLabel """larynx squamous cell carcinoma, stage I"""@eng , """laryngeal squamous cell carcinoma, stage I"""@eng , """squamous cell carcinoma of the larynx, stage I"""@eng , """epidermoid carcinoma of the larynx, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3694"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280393"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent squamous cell carcinoma of the hypopharynx"""@eng ; skos:notation """CDR0000040745"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the hypopharynx, recurrent"""@eng , """hypopharyngeal squamous cell carcinoma, recurrent"""@eng , """epidermoid carcinoma of the hypopharynx, recurrent"""@eng , """hypopharynx squamous cell carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3692"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280392"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV squamous cell carcinoma of the hypopharynx"""@eng ; skos:notation """CDR0000040744"""^^xsd:string ; skos:altLabel """hypopharyngeal squamous cell carcinoma, stage IV"""@eng , """squamous cell carcinoma of the hypopharynx, stage IV"""@eng , """hypopharyngeal squamous cell carcinoma, metastatic"""@eng , """hypopharynx squamous cell carcinoma, stage IV"""@eng , """hypopharynx squamous cell carcinoma, metastatic"""@eng , """squamous cell carcinoma of the hypopharynx, metastatic"""@eng , """epidermoid carcinoma of the hypopharynx, stage IV"""@eng , """metastatic squamous cell carcinoma of the hypopharynx"""@eng , """epidermoid carcinoma of the hypopharynx, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3690"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280391"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/fludarabine"""@eng ; skos:notation """CDR0000353319"""^^xsd:string ; skos:altLabel """3AP/FAMP"""@eng ; skos:definition """A combination of the thiosemicarbazone 3-aminopyridine-2-carboxaldehyde (3-AP) and the nucleoside analogue fludarabine with antineoplastic activity. The agents in 3-AP/fludarabine, act synergistically to inhibit the enzyme ribonucleotide reductase.. Composed of two subunits, this enzyme catalyzes the rate-limiting step in the conversion of ribonucleotides to deoxyribonucleotides. The 3-AP binds to and inactivates one subunit while fludarabine binds to and inactivates the other. Fludarabine also inhibits DNA polymerase alpha and DNA primase. At low concentrations, this agent arrests tumor cells in the S-phase of the cell cycle; at higher concentrations, in the G0/G1 phase of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=353319&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=353319&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38719\" NCI Thesaurus)"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """C38719"""^^xsd:string ; umls:cui """C1328164"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II squamous cell carcinoma of the hypopharynx"""@eng ; skos:notation """CDR0000040742"""^^xsd:string ; skos:altLabel """hypopharynx squamous cell carcinoma, stage II"""@eng , """epidermoid carcinoma of the hypopharynx, stage II"""@eng , """squamous cell carcinoma of the hypopharynx, stage II"""@eng , """hypopharyngeal squamous cell carcinoma, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3686"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280389"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I squamous cell carcinoma of the hypopharynx"""@eng ; skos:notation """CDR0000040741"""^^xsd:string ; skos:altLabel """hypopharynx squamous cell carcinoma, stage I"""@eng , """hypopharyngeal squamous cell carcinoma, stage I"""@eng , """squamous cell carcinoma of the hypopharynx, stage I"""@eng , """epidermoid carcinoma of the hypopharynx, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3684"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280388"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent lymphoepithelioma of the nasopharynx"""@eng ; skos:notation """CDR0000040740"""^^xsd:string ; skos:altLabel """lymphoepithelioma of the nasopharynx, recurrent"""@eng , """nasopharyngeal lymphoepithelioma, recurrent"""@eng , """nasopharynx lymphoepithelioma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3683"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280387"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/mercaptopurine/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000043298"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DNR/MP/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; ; """7811"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796450"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polymorphism analysis"""@eng ; skos:notation """CDR0000043299"""^^xsd:string ; rdfs:subClassOf ; """7817"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796451"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dalteparin"""@eng ; skos:notation """CDR0000043290"""^^xsd:string ; skos:altLabel """DAL"""@eng , """Fragmin"""@eng ; skos:definition """A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, dalteparin binds to antithrombin and enhances the inhibition of Factor Xa. Compared to unfractionated heparins, the use of dalteparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43290&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43290&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1453\" NCI Thesaurus)"""@eng ; ; """7804"""^^xsd:string ; """714371"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C1453"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0917726"""^^xsd:string ; umls:cui """C0206461"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/pentostatin"""@eng ; skos:notation """CDR0000043291"""^^xsd:string ; skos:altLabel """CTX/DCF"""@eng ; ; ; """7805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796444"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin liposomal"""@eng ; skos:notation """CDR0000043292"""^^xsd:string ; skos:altLabel """SPI-77"""@eng , """STEALTH Liposomal Encapsulated Cisplatin"""@eng , """SPI-077"""@eng , """Cisplatin, Liposomal"""@eng , """STEALTH Liposome Cisplatin"""@eng , """Liposomal Cisplatin"""@eng , """STEALTH Cisplatin"""@eng , """STEALTH Liposomal Cisplatin"""@eng ; skos:definition """A synthetic formulation in which the antineoplastic agent cisplatin is encapsulated in lipids. Cisplatin liposomal consists of small aggregates of cisplatin covered by a single lipid bilayer. Encasement in liposomes improves cisplatin's tumor bioavailability and toxicity profile. Liposomal encapsulation does not affect the pharmacological properties of cisplatin directly. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43292&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43292&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2502\" NCI Thesaurus)"""@eng ; """7806"""^^xsd:string ; """72274"""^^xsd:string ; """C2502"""^^xsd:string ; """1508-45-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1176313"""^^xsd:string ; umls:cui """C0964924"""^^xsd:string ; umls:cui """C0796445"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenylbutyrate/tretinoin"""@eng ; skos:notation """CDR0000043293"""^^xsd:string ; skos:altLabel """ATRA/PBA"""@eng ; ; ; """7807"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796446"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000043294"""^^xsd:string ; skos:altLabel """ASP/DM/MP/VCR"""@eng ; ; ; ; ; """7808"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796447"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000043295"""^^xsd:string ; skos:altLabel """ASP/DM/DNR/VCR"""@eng ; ; ; ; ; """7809"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796448"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisolone"""@eng ; skos:notation """CDR0000043296"""^^xsd:string ; skos:altLabel """Dacortin H"""@eng , """Capsoid"""@eng , """Deltidrosol"""@eng , """Klismacort"""@eng , """1,2-Dehydrohydrocortisone"""@eng , """Cortalone"""@eng , """Panafcortelone"""@eng , """Gupisone"""@eng , """Frisolona"""@eng , """Delta- Cortef"""@eng , """Delta-Cortef"""@eng , """Deltasolone"""@eng , """Aprednislon"""@eng , """Lenisolone"""@eng , """Deltahydrocortisone"""@eng , """Cortisolone"""@eng , """PRDL"""@eng , """Delta-Phoricol"""@eng , """Prednicortelone"""@eng , """Prelone"""@eng , """Estilsona"""@eng , """Decaprednil"""@eng , """Dhasolone"""@eng , """Kuhlprednon"""@eng , """Fisopred"""@eng , """Meticortelone"""@eng , """Opredsone"""@eng , """Predeltilone"""@eng , """Hydeltrasol"""@eng , """Delta-F"""@eng , """Lepi-Cortinolo"""@eng , """Prednisolonum"""@eng , """Linola-H-Fett N"""@eng , """Meti-derm"""@eng , """(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione"""@eng , """Decortin H"""@eng , """Di-Adreson-F"""@eng , """Adnisolone"""@eng , """Deltacortril"""@eng , """Precortisyl"""@eng , """Delta(1)Hydrocortisone"""@eng , """Linola-H N"""@eng , """Dontisolon D"""@eng , """Predni-Coelin"""@eng , """Pred-Clysma"""@eng , """Delta-Diona"""@eng , """Longiprednil"""@eng , """Metacortandralone"""@eng , """Predni-Helvacort"""@eng , """Delta1-dehydro-hydrocortisone"""@eng , """Hydeltra"""@eng , """Prenilone"""@eng , """Hostacortin H"""@eng ; skos:definition """A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43296&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43296&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C769\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """781"""^^xsd:string ; """50-24-8"""^^xsd:string ; """2537"""^^xsd:string ; """C769"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """9900"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1514334"""^^xsd:string ; umls:cui """C1514329"""^^xsd:string ; umls:cui """C1514328"""^^xsd:string ; umls:cui """C1514309"""^^xsd:string ; umls:cui """C1514322"""^^xsd:string ; umls:cui """C1514321"""^^xsd:string ; umls:cui """C1514320"""^^xsd:string ; umls:cui """C1514327"""^^xsd:string ; umls:cui """C1514326"""^^xsd:string ; umls:cui """C1514325"""^^xsd:string ; umls:cui """C1514324"""^^xsd:string ; umls:cui """C0702183"""^^xsd:string ; umls:cui """C1514335"""^^xsd:string ; umls:cui """C0701477"""^^xsd:string ; umls:cui """C1514331"""^^xsd:string ; umls:cui """C0591991"""^^xsd:string ; umls:cui """C1514323"""^^xsd:string ; umls:cui """C1514317"""^^xsd:string ; umls:cui """C0591333"""^^xsd:string ; umls:cui """C1514338"""^^xsd:string ; umls:cui """C1514339"""^^xsd:string ; umls:cui """C1514333"""^^xsd:string ; umls:cui """C1514332"""^^xsd:string ; umls:cui """C1514318"""^^xsd:string ; umls:cui """C1514319"""^^xsd:string ; umls:cui """C1514316"""^^xsd:string ; umls:cui """C0722747"""^^xsd:string ; umls:cui """C1514314"""^^xsd:string ; umls:cui """C1514315"""^^xsd:string ; umls:cui """C1514312"""^^xsd:string ; umls:cui """C1514313"""^^xsd:string ; umls:cui """C1514310"""^^xsd:string ; umls:cui """C1514311"""^^xsd:string ; umls:cui """C1514330"""^^xsd:string ; umls:cui """C0699539"""^^xsd:string ; umls:cui """C1514336"""^^xsd:string ; umls:cui """C0032950"""^^xsd:string ; umls:cui """C0699535"""^^xsd:string ; umls:cui """C0699537"""^^xsd:string ; umls:cui """C0699536"""^^xsd:string ; umls:cui """C1514337"""^^xsd:string ; umls:cui """C1514341"""^^xsd:string ; umls:cui """C1514340"""^^xsd:string ; umls:cui """C1514342"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043297"""^^xsd:string ; skos:altLabel """CF/DM/MP/MTX/VCR"""@eng ; ; ; ; ; ; """7810"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796449"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epithelial predominant Wilms' tumor"""@eng ; skos:notation """CDR0000039893"""^^xsd:string ; skos:altLabel """epithelial predominant Wilms tumor"""@eng , """Wilm's tumor, epithelial predominant"""@eng , """Wilms' tumor, epithelial predominant"""@eng , """Wilms tumor, epithelial predominant"""@eng , """epithelial predominant Wilm's tumor"""@eng ; rdfs:subClassOf ; """2574"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279608"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult primary hepatocellular carcinoma"""@eng ; skos:notation """CDR0000039892"""^^xsd:string ; skos:altLabel """hepatocellular carcinoma, adult primary"""@eng ; rdfs:subClassOf ; """2573"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279607"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood hepatocellular carcinoma"""@eng ; skos:notation """CDR0000039891"""^^xsd:string ; skos:altLabel """carcinoma, hepatocellular, childhood"""@eng , """hepatocellular carcinoma, childhood"""@eng , """pediatric hepatocellular carcinoma"""@eng ; rdfs:subClassOf ; """2572"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279606"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anaplastic osteosarcoma"""@eng ; skos:notation """CDR0000039890"""^^xsd:string ; skos:altLabel """osteosarcoma, anaplastic"""@eng , """sarcoma, osteogenic anaplastic"""@eng , """undifferentiated osteogenic sarcoma"""@eng , """sarcoma, osteogenic undifferentiated"""@eng , """osteogenic sarcoma, anaplastic"""@eng , """osteogenic sarcoma, undifferentiated"""@eng , """anaplastic osteogenic sarcoma"""@eng , """undifferentiated osteosarcoma"""@eng , """osteosarcoma, undifferentiated"""@eng ; rdfs:subClassOf ; """2571"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279605"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """embryonal childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000039897"""^^xsd:string ; skos:altLabel """rhabdomyosarcoma, pediatric embryonal"""@eng , """rhabdomyosarcoma, childhood embryonal"""@eng , """pediatric rhabdomyosarcoma, embryonal"""@eng , """childhood rhabdomyosarcoma, embryonal"""@eng , """rhabdomyosarcoma, embryonal childhood"""@eng , """embryonal pediatric rhabdomyosarcoma"""@eng ; rdfs:subClassOf ; """2578"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279612"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/prednisone"""@eng ; skos:notation """CDR0000042383"""^^xsd:string ; skos:altLabel """CYSP/PRED"""@eng ; ; ; """5637"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338291"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/vincristine"""@eng ; skos:notation """CDR0000041838"""^^xsd:string ; skos:altLabel """CDDP/VCR/VP-16"""@eng ; ; ; ; """5022"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281406"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/edatrexate"""@eng ; skos:notation """CDR0000041839"""^^xsd:string ; skos:altLabel """DOX/EDAM"""@eng ; ; ; """5023"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281407"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin"""@eng ; skos:notation """CDR0000041836"""^^xsd:string ; skos:altLabel """KLH"""@eng ; skos:definition """A natural protein isolated from the marine mollusc keyhole limpet. Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41836&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41836&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1139\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5020"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-31"""^^xsd:string ; """713762"""^^xsd:string ; """5427"""^^xsd:string ; """C1139"""^^xsd:string ; umls:cui """C0064332"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/thiotepa"""@eng ; skos:notation """CDR0000041837"""^^xsd:string ; skos:altLabel """CBDCA/TSPA"""@eng ; ; ; """5021"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281405"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone/prednisone/vincristine"""@eng ; skos:notation """CDR0000041834"""^^xsd:string ; skos:altLabel """DHAD/PRED/VCR/VP-16"""@eng ; ; ; ; ; """5018"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281404"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydralazine hydrochloride"""@eng ; skos:notation """CDR0000041835"""^^xsd:string ; skos:altLabel """Apresoline"""@eng , """apressin"""@eng ; ; """5019"""^^xsd:string ; """C551"""^^xsd:string ; """2006-11-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0020223"""^^xsd:string ; umls:cui """C0282198"""^^xsd:string ; umls:cui """C0699178"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041832"""^^xsd:string ; skos:altLabel """ASP/CTX/MP/MTX"""@eng ; ; ; ; ; """5016"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281402"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mercaptopurine/methotrexate/teniposide/thioguanine"""@eng ; skos:notation """CDR0000041833"""^^xsd:string ; skos:altLabel """ARA-C/MP/MTX/TG/VM-26"""@eng ; ; ; ; ; ; """5017"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281403"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000041830"""^^xsd:string ; skos:altLabel """DNR/MePRDL/VCR"""@eng ; ; ; ; """5014"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281400"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methotrexate/teniposide/thioguanine"""@eng ; skos:notation """CDR0000041831"""^^xsd:string ; skos:altLabel """ARA-C/MTX/TG/VM-26"""@eng ; ; ; ; ; """5015"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281401"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adrenocortical carcinoma"""@eng ; skos:notation """CDR0000038762"""^^xsd:string ; skos:altLabel """stage II adrenocortical cancer"""@eng , """adrenocortical carcinoma, stage II"""@eng , """carcinoma, adrenocortical stage II"""@eng ; rdfs:subClassOf ; """adrenocortical carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1200"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0678051"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adrenocortical carcinoma"""@eng ; skos:notation """CDR0000038763"""^^xsd:string ; skos:altLabel """adrenocortical carcinoma, stage III"""@eng , """stage III adrenocortical cancer"""@eng , """carcinoma, adrenocortical stage III"""@eng ; rdfs:subClassOf ; """adrenocortical carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1201"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0678052"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV colon cancer"""@eng ; skos:notation """CDR0000038760"""^^xsd:string ; skos:altLabel """colon cancer, stage IV"""@eng , """Astler-Coller D colon cancer"""@eng , """metastatic colon cancer"""@eng , """colon cancer, Dukes D"""@eng , """colon cancer, Astler-Coller D"""@eng , """colon cancer, metastatic"""@eng , """Dukes D colon cancer"""@eng ; rdfs:subClassOf ; """colon cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """12"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278484"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIA cervical cancer"""@eng ; skos:notation """CDR0000038761"""^^xsd:string ; skos:altLabel """cervical cancer, stage IIA"""@eng , """carcinoma of the cervix, stage IIA"""@eng , """uterine cervical cancer, stage IIA"""@eng , """stage IIA cervix cancer"""@eng , """uterine cervix cancer, stage IIA"""@eng , """stage IIA cancer of the cervix"""@eng , """stage IIA carcinoma of the cervix"""@eng , """cervix cancer, stage IIA"""@eng , """stage IIA uterine cervix cancer"""@eng , """cancer of the cervix, stage IIA"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """120"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278588"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/methotrexate"""@eng ; skos:notation """CDR0000038766"""^^xsd:string ; skos:altLabel """CMV"""@eng , """CTX/MTX/VP-16"""@eng ; ; ; ; """1205"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278819"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bladder cancer"""@eng ; skos:notation """CDR0000038767"""^^xsd:string ; skos:altLabel """Bladder cancer"""@eng , """cancer of the bladder"""@eng , """urinary bladder cancer"""@eng , """carcinoma of the bladder"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1206"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0005684"""^^xsd:string ; umls:cui """C0699885"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adrenocortical carcinoma"""@eng ; skos:notation """CDR0000038764"""^^xsd:string ; skos:altLabel """carcinoma, adrenocortical stage IV"""@eng , """stage IV adrenocortical cancer"""@eng , """metastatic adrenocortical carcinoma"""@eng , """adrenocortical carcinoma, metastatic"""@eng , """adrenocortical carcinoma, stage IV"""@eng , """carcinoma, adrenocortical metastatic"""@eng ; rdfs:subClassOf ; """adrenocortical carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1202"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0678053"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adrenocortical carcinoma"""@eng ; skos:notation """CDR0000038765"""^^xsd:string ; skos:altLabel """carcinoma, adrenocortical recurrent"""@eng , """recurrent adrenocortical cancer"""@eng , """adrenocortical carcinoma, recurrent"""@eng ; rdfs:subClassOf ; """adrenocortical carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1203"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278818"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interferon beta/zidovudine"""@eng ; skos:notation """CDR0000039394"""^^xsd:string ; skos:altLabel """IFN-B/ZDV"""@eng ; ; ; """2029"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279257"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 bladder cancer"""@eng ; skos:notation """CDR0000038768"""^^xsd:string ; skos:altLabel """stage 0 carcinoma of the bladder"""@eng , """carcinoma of the bladder, stage 0"""@eng , """stage 0 cancer of the bladder"""@eng , """cancer of the bladder, stage 0"""@eng , """bladder cancer, stage 0"""@eng ; rdfs:subClassOf ; """bladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1207"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278820"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyproterone/goserelin"""@eng ; skos:notation """CDR0000038769"""^^xsd:string ; skos:altLabel """CPTR/ZDX"""@eng ; ; ; """1208"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278821"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus/interleukin-12 gene"""@eng ; skos:notation """CDR0000341626"""^^xsd:string ; skos:altLabel """ADV/IL-12 gene"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328091"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039395"""^^xsd:string ; skos:altLabel """BCNU/PCB/VCR"""@eng , """BVP"""@eng ; ; ; ; """2030"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279258"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/dexamethasone"""@eng ; skos:notation """CDR0000040400"""^^xsd:string ; skos:altLabel """CCD"""@eng , """BCNU/CTX/DM"""@eng ; ; ; ; """3263"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280059"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/fluorouracil/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040401"""^^xsd:string ; skos:altLabel """BLEO/5-FU/MTX/VCR"""@eng , """VBMF"""@eng ; ; ; ; ; """3264"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chordoma"""@eng ; skos:notation """CDR0000040402"""^^xsd:string ; skos:altLabel """Chordoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3265"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0008487"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplastic antibiotic"""@eng ; skos:notation """CDR0000040403"""^^xsd:string ; rdfs:subClassOf ; """3266"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003236"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fat-soluble vitamin"""@eng ; skos:notation """CDR0000040404"""^^xsd:string ; rdfs:subClassOf ; """3267"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0259753"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """water-soluble vitamin"""@eng ; skos:notation """CDR0000040405"""^^xsd:string ; rdfs:subClassOf ; """3268"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0259754"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vitamin"""@eng ; skos:notation """CDR0000040406"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3269"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0042890"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/polyvalent melanoma vaccine"""@eng ; skos:notation """CDR0000037771"""^^xsd:string ; skos:altLabel """BC-G/POLYMELVAC"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10127"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879365"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/vinblastine"""@eng ; skos:notation """CDR0000040408"""^^xsd:string ; skos:altLabel """VAC"""@eng , """CTX/DOX/VBL"""@eng ; ; ; ; """3271"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280062"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/vinblastine"""@eng ; skos:notation """CDR0000040409"""^^xsd:string ; skos:altLabel """VAC"""@eng , """CTX/DACT/VBL"""@eng ; ; ; ; """3272"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280063"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult medulloblastoma"""@eng ; skos:notation """CDR0000038828"""^^xsd:string ; skos:altLabel """brain tumor, adult medulloblastoma"""@eng , """CNS tumor, adult medulloblastoma"""@eng , """central nervous system tumor, medulloblastoma, adult"""@eng , """adult brain tumor, medulloblastoma"""@eng , """adult CNS tumor, medulloblastoma"""@eng , """medulloblastoma, adult"""@eng , """CNS tumor, medulloblastoma, adult"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1293"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278876"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/etoposide/ifosfamide/yttrium Y 90 humanized epratuzumab"""@eng ; skos:notation """CDR0000037772"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/IFF/VP-16/Y90 MOAB LL2"""@eng ; ; ; ; ; ; """10128"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879366"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/interleukin-11"""@eng ; skos:notation """CDR0000037773"""^^xsd:string ; skos:altLabel """G-CSF/IL-11"""@eng ; ; ; """10129"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879367"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin/MUC-1 antigen/QS21"""@eng ; skos:notation """CDR0000037774"""^^xsd:string ; skos:altLabel """KLH/MUC-1/QS 21"""@eng ; ; ; ; """10130"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879368"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/interferon alfa"""@eng ; skos:notation """CDR0000037775"""^^xsd:string ; skos:altLabel """BC-G/IFN-A"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10131"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879369"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dietary intervention"""@eng ; skos:notation """CDR0000038726"""^^xsd:string ; skos:altLabel """intervention, dietary"""@eng ; ; rdfs:subClassOf ; """1154"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0086153"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acridine carboxamide"""@eng ; skos:notation """CDR0000037776"""^^xsd:string ; skos:altLabel """DACA"""@eng , """XR5000"""@eng ; skos:definition """An agent that inhibits Topoisomerase II and intercalates with a DNA hexanucleotide, causing DNA damage and inhibition of DNA replication, RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37776&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37776&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2203\" NCI Thesaurus)"""@eng ; """10132"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2203"""^^xsd:string ; umls:cui """C0879370"""^^xsd:string ; umls:cui """C0919282"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic bone marrow transplantation"""@eng ; skos:notation """CDR0000038727"""^^xsd:string ; skos:altLabel """transplantation, allogenic bone marrow"""@eng , """bone marrow therapy, allogenic"""@eng , """transplantation, allogeneic bone marrow"""@eng , """allogenic bone marrow transplantation"""@eng , """bone marrow therapy, allogeneic"""@eng ; ; rdfs:subClassOf ; """1156"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0149615"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/gemcitabine"""@eng ; skos:notation """CDR0000037777"""^^xsd:string ; skos:altLabel """BRYO/dFdC"""@eng ; ; ; """10133"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879371"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 cervical cancer"""@eng ; skos:notation """CDR0000037981"""^^xsd:string ; skos:altLabel """uterine cervix cancer, stage 0"""@eng , """stage 0 cervix cancer"""@eng , """uterine cervical cancer, stage 0"""@eng , """cervix cancer, stage 0"""@eng , """cervical cancer, stage 0"""@eng , """stage 0 uterine cervix cancer"""@eng , """stage 0 carcinoma of the cervix"""@eng , """carcinoma of the cervix, stage 0"""@eng , """cancer of the cervix, stage 0"""@eng , """stage 0 cancer of the cervix"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """104"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0851140"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIC breast cancer"""@eng ; skos:notation """CDR0000340180"""^^xsd:string ; rdfs:subClassOf ; """2003-10-25"""^^xsd:string ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C2216700"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """selenium"""@eng ; skos:notation """CDR0000038725"""^^xsd:string ; skos:altLabel """Se"""@eng ; skos:definition """A nonmetallic chemical element found in trace amounts in human body. Selenium primarily occurs in vivo as selenocompounds, mostly selenoproteins such as glutathione peroxidase and thioredoxin reductase (enzymes responsible for detoxification). Alone or in combination with Vitamin E, selenocompounds act as antioxidants. These agents scavenge free radicals; prevent blood clots by inhibiting platelet aggregation; strengthen the immune system; and have been shown, in some instances, to inhibit chromosomal damage and mutations. Exhibiting chemopreventive activity, selenocompounds also inhibit the induction of protein kinase C. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38725&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38725&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C825\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """1153"""^^xsd:string ; """7782-49-2"""^^xsd:string ; """2006-10-02"""^^xsd:string ; """C825"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0036581"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Combid"""@eng ; skos:notation """CDR0000038722"""^^xsd:string ; skos:altLabel """prochlorperazine maleate and isopropamide iodide"""@eng , """COMB"""@eng , """Prochlor-Iso"""@eng ; """1150"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0278789"""^^xsd:string ; umls:cui """C1321920"""^^xsd:string ; umls:cui """C1328259"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """magnesium sulfate"""@eng ; skos:notation """CDR0000038723"""^^xsd:string ; """1151"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0024480"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PXD101"""@eng ; skos:notation """CDR0000454583"""^^xsd:string ; skos:definition """A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. PXD101 targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. PDX101 may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454583&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454583&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48812\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C48812"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """2005-11-04"""^^xsd:string ; umls:cui """C1452684"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """relapsing chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000038720"""^^xsd:string ; skos:altLabel """chronic myelogenous leukemia, relapsing"""@eng , """CML, refractory"""@eng , """chronic myelocytic leukemia, relapsed"""@eng , """chronic myelocytic leukemia, refractory"""@eng , """myelogenous leukemia, refractory chronic"""@eng , """CGL, relapsed"""@eng , """granulocytic leukemia, refractory chronic"""@eng , """refractory chronic myelocytic leukemia"""@eng , """relapsed chronic granulocytic leukemia"""@eng , """leukemia, refractory chronic myelogenous"""@eng , """chronic myelogenous leukemia, refractory"""@eng , """granulocytic leukemia, relapsed chronic"""@eng , """leukemia, relapsed chronic myelogenous"""@eng , """myelocytic leukemia, refractory chronic"""@eng , """refractory CML"""@eng , """CML, relapsing"""@eng , """relapsed CML"""@eng , """relapsed chronic myelocytic leukemia"""@eng , """chronic myelogenous leukemia, relapsed"""@eng , """CGL, refractory"""@eng , """refractory chronic granulocytic leukemia"""@eng , """relapsing CML"""@eng , """relapsed CGL"""@eng , """refractory CGL"""@eng , """myelogenous leukemia, relapsed chronic"""@eng , """chronic granulocytic leukemia, relapsed"""@eng , """relapsed chronic myelogenous leukemia"""@eng , """chronic granulocytic leukemia, refractory"""@eng , """CML, relapsed"""@eng , """myelocytic leukemia, relapsed chronic"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """chronic myelogenous leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1146"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1370868"""^^xsd:string ; umls:cui """C0278787"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PD-0332991"""@eng ; skos:notation """CDR0000454586"""^^xsd:string ; skos:definition """An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454586&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454586&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49176\" NCI Thesaurus)"""@eng ; """2006-07-25"""^^xsd:string ; """C49176"""^^xsd:string ; """2005-11-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1568660"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant dHER2 vaccine"""@eng ; skos:notation """CDR0000454589"""^^xsd:string ; skos:definition """A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454589&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454589&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49177\" NCI Thesaurus)"""@eng ; """C49177"""^^xsd:string ; """2006-01-30"""^^xsd:string ; """2005-11-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1709861"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zinc sulfate"""@eng ; skos:notation """CDR0000038721"""^^xsd:string ; skos:definition """A salt of the essential trace metal zinc. Zinc is involved in tissue repair and is an important constituent of some proteins, including those involved in taste and smell. Zinc sulfate supplementation may prevent radiation-induced aguesia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38721&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38721&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1280\" NCI Thesaurus)"""@eng ; ; """1148"""^^xsd:string ; """32677"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7733-02-0"""^^xsd:string ; """C1280"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0078794"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-mesothelin monoclonal antibody MORAb-009"""@eng ; skos:notation """CDR0000489384"""^^xsd:string ; skos:altLabel """MORAb-009"""@eng ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; umls:cui """C3179481"""^^xsd:string ; umls:cui """C2987611"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-641988"""@eng ; skos:notation """CDR0000489385"""^^xsd:string ; """C62522"""^^xsd:string ; """2006-09-19"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831892"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-690514"""@eng ; skos:notation """CDR0000489386"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; umls:cui """C1831893"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gonadorelin"""@eng ; skos:notation """CDR0000040445"""^^xsd:string ; """3317"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0023610"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/danazol/hydrocortisone/tamoxifen"""@eng ; skos:notation """CDR0000040447"""^^xsd:string ; skos:altLabel """TAD"""@eng , """AGT/DAN/HC/TMX"""@eng ; ; ; ; ; """3319"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280090"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anticoagulant agent"""@eng ; skos:notation """CDR0000040440"""^^xsd:string ; rdfs:subClassOf ; """3309"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003280"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gelonin"""@eng ; skos:notation """CDR0000357568"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0061184"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-GP-3 monoclonal antibody"""@eng ; skos:notation """CDR0000486728"""^^xsd:string ; skos:altLabel """MORAb-003"""@eng ; skos:definition """A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. MORab-003 specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, MORab-003 triggers a host immune response against GP-3 expressing cells resulting in cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486728&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486728&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61503\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """C61503"""^^xsd:string ; umls:cui """C1831844"""^^xsd:string ; umls:cui """C1831845"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I multiple myeloma"""@eng ; skos:notation """CDR0000037801"""^^xsd:string ; skos:altLabel """multiple myeloma, stage I"""@eng , """plasma cell neoplasm, stage I"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """1016"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278722"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/yttrium Y 90 ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000357562"""^^xsd:string ; skos:altLabel """CTX/FAMP/IDEC-Y2B8"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328231"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/gemcitabine/pegfilgrastim"""@eng ; skos:notation """CDR0000357560"""^^xsd:string ; skos:altLabel """dFdC/GCSF-SD01/TXT"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328230"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bendamustine/rituximab"""@eng ; skos:notation """CDR0000357564"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/SDX-105"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328232"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-lapachone"""@eng ; skos:notation """CDR0000357565"""^^xsd:string ; skos:altLabel """ARQ 501"""@eng , """3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione"""@eng , """ARQ501"""@eng , """b-Lapachone"""@eng ; skos:definition """A naphthoquinone compound derived from bark of Tabebuia sp., with antitumor, antibacterial, antifungal and antitrypanosomal activities. Beta-lapachone exerts its anti-tumor effect by indirect actions of inducing p53-independent apoptosis and cell cycle arrest mediated through altered activities of cell cycle control regulatory proteins; including down-regulating retinoblastoma protein (pRB), a transcriptional repressor target at transcription factor E2F-1, as well as induces expression of cyclin dependent kinase inhibitor 1A (CDKN1A or p21). Both E2F-1 and p21 are required for G1/S-phase transition during cell cycle. This agent also inhibits DNA topoisomerase I by a mechanism distinct from that of camptothecin, and thereby blocks the formation of a cleavable complex leading to enzyme inhibition and prevent DNA repair. Furthermore, beta-lapachone could induce reactive oxygen species in vivo, and result in cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357565&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357565&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28694\" NCI Thesaurus)"""@eng ; ; ; """4707-32-8"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C28694"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """26326"""^^xsd:string ; """629749"""^^xsd:string ; """2004-02-20"""^^xsd:string ; umls:cui """C1328233"""^^xsd:string ; umls:cui """C0053471"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progressive hairy cell leukemia, initial treatment"""@eng ; skos:notation """CDR0000040079"""^^xsd:string ; skos:altLabel """leukemia, progressive hairy cell, post-splenectomy"""@eng , """hairy cell leukemia, progressive post-splenectomy"""@eng ; rdfs:subClassOf ; """hairy cell leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2821"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279779"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated hairy cell leukemia"""@eng ; skos:notation """CDR0000040078"""^^xsd:string ; skos:altLabel """hairy cell leukemia, untreated"""@eng , """leukemia, untreated hairy cell"""@eng , """leukemia, hairy cell, untreated"""@eng ; rdfs:subClassOf ; """hairy cell leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2820"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279778"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polygonal type small cell lung cancer"""@eng ; skos:notation """CDR0000039856"""^^xsd:string ; skos:altLabel """small cell lung cancer, polygonal type"""@eng , """lung cancer, polygonal type, small cell"""@eng , """SCLC, polygonal type"""@eng , """polygonal type SCLC"""@eng ; rdfs:subClassOf ; """2537"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279570"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clofarabine"""@eng ; skos:notation """CDR0000257309"""^^xsd:string ; skos:altLabel """2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine"""@eng , """Clofarex"""@eng , """Clolar"""@eng , """2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine"""@eng , """CAFdA"""@eng ; skos:definition """A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factor, which activate apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257309&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257309&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26638\" NCI Thesaurus)"""@eng ; ; ; ; """11445"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26638"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0092777"""^^xsd:string ; umls:cui """C1174746"""^^xsd:string ; umls:cui """C1530623"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """STA-5312"""@eng ; skos:notation """CDR0000387720"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """2004-08-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541461"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bendamustine hydrochloride"""@eng ; skos:notation """CDR0000350251"""^^xsd:string ; skos:altLabel """bendamustine"""@eng , """Ribomustin"""@eng , """SDX-105"""@eng ; ; """2003-12-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-30"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0772139"""^^xsd:string ; umls:cui """C0525079"""^^xsd:string ; umls:cui """C1529660"""^^xsd:string ; umls:cui """C1328710"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAC-321"""@eng ; skos:notation """CDR0000354205"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """2004-01-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1313756"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/etoposide/vincristine"""@eng ; skos:notation """CDR0000043258"""^^xsd:string ; skos:altLabel """CYSP/VCR/VP-16"""@eng ; ; ; ; """7745"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796412"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3,4-methylenedioxymethamphetamine"""@eng ; skos:notation """CDR0000475676"""^^xsd:string ; skos:altLabel """MDMA"""@eng ; skos:definition """A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic (openess- and empathy-generating), neurotoxic, and motor-stimulatory activities. Although the mechanism by which it causes its unusual entactogenic effects is largely unknown, 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment, perhaps via indirect stimulation of 5-HT 1A receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475676&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475676&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61081\" NCI Thesaurus)"""@eng ; """C61081"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-24"""^^xsd:string ; umls:cui """C0115471"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/methotrexate/mitoguazone"""@eng ; skos:notation """CDR0000039569"""^^xsd:string ; skos:altLabel """IFF/MGBG/MTX/VP-16"""@eng , """MIME"""@eng ; ; ; ; ; """2223"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066554"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/lomustine/methotrexate"""@eng ; skos:notation """CDR0000039568"""^^xsd:string ; skos:altLabel """CCNU/CTX/DOX/MTX"""@eng , """MACC"""@eng ; ; ; ; ; """2222"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065473"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/methotrexate"""@eng ; skos:notation """CDR0000039563"""^^xsd:string ; skos:altLabel """ASP/MTX"""@eng , """L-AM"""@eng ; ; ; """2217"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279369"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cytarabine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039562"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/DOX/PRED/VCR"""@eng , """HOAP-BLEO"""@eng ; ; ; ; ; ; """2216"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0062900"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mitomycin/tegafur"""@eng ; skos:notation """CDR0000039561"""^^xsd:string ; skos:altLabel """DOX/FT/MITO"""@eng , """FURAM"""@eng ; ; ; ; """2212"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279365"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednimustine"""@eng ; skos:notation """CDR0000039560"""^^xsd:string ; skos:altLabel """Stereocyt"""@eng , """LEO-1031"""@eng , """PM"""@eng ; ; """2209"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0032949"""^^xsd:string ; umls:cui """C0878090"""^^xsd:string ; umls:cui """C0878088"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """promethazine hydrochloride"""@eng ; skos:notation """CDR0000039567"""^^xsd:string ; skos:altLabel """Anergan"""@eng , """Phenergan"""@eng ; skos:definition """The hydrochloride salt form of promethazine, a phenothiazine derivative with antihistaminic, sedative and antiemetic properties. Promethazine hydrochloride selectively blocks peripheral H1 receptors thereby diminishing the effects of histamine on effector cells. Promethazine hydrochloride also blocks the central histaminergic receptors, thereby depressing the reticular system causing sedative and hypnotic effects. In addition, promethazine hydrochloride also has centrally acting anticholinergic properties and probably mediates nausea and vomiting by acting on the medullary chemoreceptive trigger zone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39567&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39567&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C45907\" NCI Thesaurus)"""@eng ; """C45907"""^^xsd:string ; """2221"""^^xsd:string ; """231688"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58-33-3"""^^xsd:string ; """2007-01-22"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699110"""^^xsd:string ; umls:cui """C0591971"""^^xsd:string ; umls:cui """C0546876"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/prednisone/vinblastine/vincristine"""@eng ; skos:notation """CDR0000039566"""^^xsd:string ; skos:altLabel """CLB/PRED/VBL/VCR"""@eng , """LVVP"""@eng ; ; ; ; ; """2220"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279371"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039565"""^^xsd:string ; skos:altLabel """LAPOCA"""@eng , """ARA-C/ASP/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """2219"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279370"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prochlorperazine"""@eng ; skos:notation """CDR0000039564"""^^xsd:string ; skos:altLabel """SKF-4657"""@eng , """RP 6140"""@eng , """Compazine"""@eng , """2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine"""@eng , """PCPZ"""@eng ; skos:definition """A synthetic propylpiperazine derivative of phenothiazine with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities. Prochlorperazine antagonizes the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39564&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39564&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C774\" NCI Thesaurus)"""@eng ; ; ; """2218"""^^xsd:string ; """58-38-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C774"""^^xsd:string ; umls:cui """C2718116"""^^xsd:string ; umls:cui """C0033229"""^^xsd:string ; umls:cui """C0701017"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/oxaliplatin"""@eng ; skos:notation """CDR0000410680"""^^xsd:string ; skos:altLabel """L-OHP/VP-16"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541430"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/temsirolimus"""@eng ; skos:notation """CDR0000410685"""^^xsd:string ; skos:altLabel """CCI-779/STI571"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-05"""^^xsd:string ; umls:cui """C1541431"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil-uracil/gemcitabine/leucovorin calcium"""@eng ; skos:notation """CDR0000043508"""^^xsd:string ; skos:altLabel """CF/dFdC/UFT"""@eng ; ; ; ; """8745"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000043509"""^^xsd:string ; skos:altLabel """Y90 MOAB Lym-1"""@eng , """yttrium Y 90 MOAB Lym-1"""@eng , """monoclonal antibody Lym-1, yttrium Y 90"""@eng , """MOAB Lym-1, yttrium Y 90"""@eng , """Y90 monoclonal antibody Lym-1"""@eng ; ; ; """8746"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796675"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GEM 231/paclitaxel"""@eng ; skos:notation """CDR0000043500"""^^xsd:string ; skos:altLabel """GEM-231/TAX"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """8730"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796668"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody m170"""@eng ; skos:notation """CDR0000043501"""^^xsd:string ; skos:altLabel """monoclonal antibody m170, yttrium Y 90"""@eng , """Y 90 monoclonal antibody m170"""@eng , """Y90 MOAB m170"""@eng , """yttrium Y 90 MOAB m170"""@eng , """MOAB m170, yttrium Y 90"""@eng ; ; ; """8731"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796669"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody m170"""@eng ; skos:notation """CDR0000043502"""^^xsd:string ; skos:altLabel """In 111 MOAB m170"""@eng , """MOAB m170, indium In 111"""@eng , """monoclonal antibody m170, indium In 111"""@eng , """In 111 monoclonal antibody m170"""@eng , """indium In 111 MOAB m170"""@eng ; """8732"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796670"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lonafarnib"""@eng ; skos:notation """CDR0000043503"""^^xsd:string ; skos:altLabel """Sarasar"""@eng , """SCH66336"""@eng , """SCH 66336"""@eng , """SCH-66336"""@eng , """4-[2-[4-(3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide"""@eng ; skos:definition """A synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins. Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated ras proteins have been found in a wide range of human cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43503&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43503&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1829\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """8733"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C1829"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """719467"""^^xsd:string ; """193275-84-2"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1257385"""^^xsd:string ; umls:cui """C0759338"""^^xsd:string ; umls:cui """C1517935"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/lonafarnib"""@eng ; skos:notation """CDR0000043504"""^^xsd:string ; skos:altLabel """CF/5-FU/SCH 66336"""@eng ; ; ; ; """2003-02-07"""^^xsd:string ; """8734"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/tretinoin"""@eng ; skos:notation """CDR0000043505"""^^xsd:string ; skos:altLabel """ARA-C/ATRA/DNR"""@eng ; ; ; ; """8739"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/tretinoin"""@eng ; skos:notation """CDR0000043506"""^^xsd:string ; skos:altLabel """ATRA/DNR"""@eng ; ; ; """8740"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tropisetron"""@eng ; skos:notation """CDR0000043507"""^^xsd:string ; skos:altLabel """ICS 205-930"""@eng , """Navoban"""@eng ; skos:definition """An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43507&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43507&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1131\" NCI Thesaurus)"""@eng ; """8744"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """89565-68-4"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C1131"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0244753"""^^xsd:string ; umls:cui """C0063322"""^^xsd:string ; umls:cui """C0701391"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/lomustine/vincristine"""@eng ; skos:notation """CDR0000040970"""^^xsd:string ; skos:altLabel """CCAVV"""@eng , """VAC-LE"""@eng , """CCNU/CTX/DOX/VCR/VP-16"""@eng ; ; ; ; ; ; """4008"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280585"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methotrexate"""@eng ; skos:notation """CDR0000040971"""^^xsd:string ; skos:altLabel """CCM"""@eng , """MAIT"""@eng , """ARA-C/MTX"""@eng ; ; ; """4009"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280586"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000040972"""^^xsd:string ; skos:altLabel """CAPO"""@eng , """VCAV"""@eng , """CTX/DOX/VCR/VP-16"""@eng , """EVAC"""@eng , """VOCA"""@eng , """CAVE"""@eng , """ECHO"""@eng ; ; ; ; ; """4010"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0058928"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil"""@eng ; skos:notation """CDR0000040973"""^^xsd:string ; skos:altLabel """CAFFI"""@eng , """FAC"""@eng , """CDF"""@eng , """CTX/DOX/5-FU"""@eng , """CAF"""@eng ; ; ; ; """4011"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054427"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/thioguanine"""@eng ; skos:notation """CDR0000040974"""^^xsd:string ; skos:altLabel """ARA-C/TG"""@eng , """CAT"""@eng , """TA"""@eng ; ; ; """4012"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280589"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040975"""^^xsd:string ; skos:altLabel """VDP"""@eng , """DVP"""@eng , """DNR/PRED/VCR"""@eng ; ; ; ; """4013"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078144"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/methotrexate"""@eng ; skos:notation """CDR0000040976"""^^xsd:string ; skos:altLabel """VAM"""@eng , """DOX/MTX/VP-16"""@eng , """AMV"""@eng ; ; ; ; """4014"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280591"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/mitomycin/vincristine"""@eng ; skos:notation """CDR0000040977"""^^xsd:string ; skos:altLabel """FOAM"""@eng , """DOX/5-FU/MITO/VCR"""@eng , """VFAM"""@eng ; ; ; ; ; """4015"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280592"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/semustine"""@eng ; skos:notation """CDR0000040978"""^^xsd:string ; skos:altLabel """DOX/5-FU/MeCCNU"""@eng , """FAME"""@eng , """MEFA"""@eng ; ; ; ; """4016"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280593"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/oblimersen/oxaliplatin"""@eng ; skos:notation """CDR0000277247"""^^xsd:string ; skos:altLabel """CF/5-FU/G3139/L-OHP"""@eng ; ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327901"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/tipifarnib"""@eng ; skos:notation """CDR0000277242"""^^xsd:string ; skos:altLabel """CDDP/dFdC/R115777"""@eng ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327900"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """6-azauridine"""@eng ; skos:notation """CDR0000039158"""^^xsd:string ; skos:altLabel """azauridine"""@eng , """6-AZUR"""@eng , """ribo-azauracil"""@eng , """6-azauracil riboside"""@eng , """riboazauracil"""@eng ; """C291"""^^xsd:string ; """1778"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C0004483"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azimexon"""@eng ; skos:notation """CDR0000039159"""^^xsd:string ; """1779"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0104835"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human gp100 plasmid DNA vaccine"""@eng ; skos:notation """CDR0000419685"""^^xsd:string ; skos:altLabel """gp100 Plasmid DNA"""@eng ; skos:definition """A vaccine consisting of a plasmid DNA encoding the human melanoma-associated antigen gp100. Upon adminsistration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express this antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=419685&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=419685&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2759\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-02-18"""^^xsd:string ; """2005-07-28"""^^xsd:string ; """C2759"""^^xsd:string ; umls:cui """C1515637"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mouse gp100 plasmid DNA vaccine"""@eng ; skos:notation """CDR0000419686"""^^xsd:string ; skos:altLabel """Mouse gp100 DNA Plasmid Vaccine"""@eng ; skos:definition """A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=419686&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=419686&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48410\" NCI Thesaurus)"""@eng ; """2006-08-30"""^^xsd:string ; """2005-02-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48410"""^^xsd:string ; umls:cui """C1709081"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acetylsalicyclic acid"""@eng ; skos:notation """CDR0000039152"""^^xsd:string ; skos:altLabel """Ecotrin"""@eng , """Aspergum"""@eng , """Measurin"""@eng , """ASA"""@eng , """Acetylsalicylic Acid"""@eng , """Empirin"""@eng , """Extren"""@eng , """aspirin"""@eng , """2-(Acetyloxy)benzoic Acid"""@eng , """Entericin"""@eng , """Aspirin"""@eng ; skos:definition """An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39152&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39152&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C287\" NCI Thesaurus)"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """C287"""^^xsd:string ; """406186"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """1772"""^^xsd:string ; """50-78-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0004057"""^^xsd:string ; umls:cui """C0699269"""^^xsd:string ; umls:cui """C0699268"""^^xsd:string ; umls:cui """C0699270"""^^xsd:string ; umls:cui """C0699266"""^^xsd:string ; umls:cui """C0699267"""^^xsd:string ; umls:cui """C0699274"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine"""@eng ; skos:notation """CDR0000039153"""^^xsd:string ; skos:altLabel """Mylosar"""@eng , """ladakamycin"""@eng , """4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one"""@eng , """5-AC"""@eng , """U-18496"""@eng , """azacytidine"""@eng , """5-Aza-cytidine"""@eng , """Vidaza"""@eng , """5-AZC"""@eng , """5-azacytidine"""@eng ; skos:definition """A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation. Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39153&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39153&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C288\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """1773"""^^xsd:string ; """7574"""^^xsd:string ; """102816"""^^xsd:string ; """320-67-2"""^^xsd:string ; """C288"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527246"""^^xsd:string ; umls:cui """C0004475"""^^xsd:string ; umls:cui """C1563756"""^^xsd:string ; umls:cui """C1511000"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vidarabine"""@eng ; skos:notation """CDR0000039150"""^^xsd:string ; skos:altLabel """araadenosine"""@eng , """adenine arabinoside"""@eng , """Vira-A"""@eng , """Spongoadenosine"""@eng , """Arasena-A"""@eng , """CI-673"""@eng , """ARA-A"""@eng , """9-Beta-D-arabinofuranosyladenine Monohydrate"""@eng , """Beta Ara-A"""@eng , """Arabinosyladenine"""@eng , """9-Beta-D-arabinofuranosyl-9H-purine-6-amine Monohydrate"""@eng ; skos:definition """A nucleoside antibiotic isolated from the bacterium Streptomyces antibioticus with antineoplastic activity. Vidarabine inhibits DNA polymerase, resulting in the inhibition of DNA replication in tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39150&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39150&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C929\" NCI Thesaurus)"""@eng ; """1770"""^^xsd:string ; """5536-17-4"""^^xsd:string ; """18288"""^^xsd:string ; """404241"""^^xsd:string ; """8593"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """C929"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527321"""^^xsd:string ; umls:cui """C0042646"""^^xsd:string ; umls:cui """C0699565"""^^xsd:string ; umls:cui """C1519983"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asaley"""@eng ; skos:notation """CDR0000039151"""^^xsd:string ; skos:altLabel """leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI)"""@eng , """L-leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester"""@eng , """ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine"""@eng , """L-leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI)"""@eng , """Asalex"""@eng ; skos:definition """An L-leucine derivative of melphalan with antineoplastic activity. Asaley alkylates and crosslinks DNA, resulting in disruption of DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39151&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39151&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1346\" NCI Thesaurus)"""@eng ; """1771"""^^xsd:string ; """167780"""^^xsd:string ; """C1346"""^^xsd:string ; """10008"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0104300"""^^xsd:string ; umls:cui """C0064791"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azaserine"""@eng ; skos:notation """CDR0000039156"""^^xsd:string ; skos:altLabel """Diazoacetic Acid Ester with Serine"""@eng , """L-Azaserine"""@eng , """L-serine diazoacetate (ester)"""@eng , """AZAS"""@eng , """O-diazoacetyl-L-serine"""@eng , """Diazoacetate (Ester) L-Serine"""@eng , """L-diazoacetate (ester) serine"""@eng , """CL-337"""@eng , """CN-15757"""@eng , """Serine Diazoacetate"""@eng , """AZS"""@eng , """P-165"""@eng , """diazoacetylserine"""@eng ; skos:definition """A naturally occurring serine derivative diazo compound with antineoplastic properties, Azaserine functions as a purine antagonist and glutamine analogue (glutamine amidotransferase inhibitor) that competitively inhibits pathways in which glutamine is metabolized. An antibiotic and antitumor agent, Azaserine is used in clinical studies as a potential antineoplastic agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39156&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39156&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C289\" NCI Thesaurus)"""@eng ; """1776"""^^xsd:string ; """742"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """115-02-6"""^^xsd:string ; """C289"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C1527372"""^^xsd:string ; umls:cui """C0004480"""^^xsd:string ; umls:cui """C1527370"""^^xsd:string ; umls:cui """C1527371"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azathioprine sodium"""@eng ; skos:notation """CDR0000039157"""^^xsd:string ; skos:altLabel """AZA"""@eng , """Imurel"""@eng , """Imuran"""@eng , """AZTP"""@eng ; skos:definition """The sodium salt form of azathioprine, a pro-drug of purine analogue with immunosuppressive activity. Azathioprine is converted in vivo to its active metabolite 6-mercaptopurine (6-MP), which substitutes for the normal nucleoside and mistakenly gets incorporated into DNA sequences. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39157&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39157&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47961\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """1777"""^^xsd:string ; """446-86-6"""^^xsd:string ; """39084"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C47961"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C0887732"""^^xsd:string ; umls:cui """C0004482"""^^xsd:string ; umls:cui """C0699280"""^^xsd:string ; umls:cui """C0699279"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azapicyl"""@eng ; skos:notation """CDR0000039154"""^^xsd:string ; skos:altLabel """P-2292"""@eng , """1-acetyl-2-picolinoylhydrazine"""@eng , """2-acetylhydrazide-2-pyridinecarboxylic acid"""@eng ; skos:definition """A hydrazine compound that has been investigated for antineoplastic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39154&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39154&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1007\" NCI Thesaurus)"""@eng ; """1774"""^^xsd:string ; """C1007"""^^xsd:string ; """68626"""^^xsd:string ; """2941"""^^xsd:string ; """17433-31-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0052754"""^^xsd:string ; umls:cui """C1522017"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azaribine"""@eng ; skos:notation """CDR0000039155"""^^xsd:string ; skos:altLabel """AZR"""@eng , """Triazure"""@eng , """azauridine triacetate"""@eng ; """1775"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0052757"""^^xsd:string ; umls:cui """C0950954"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/interleukin-4/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000041623"""^^xsd:string ; skos:altLabel """IL-2/IL-4/TIL"""@eng ; ; ; ; """4785"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281236"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/tamoxifen/vinblastine"""@eng ; skos:notation """CDR0000041622"""^^xsd:string ; skos:altLabel """CYSP/TMX/VBL"""@eng ; ; ; ; """4784"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281235"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/cytarabine"""@eng ; skos:notation """CDR0000041621"""^^xsd:string ; skos:altLabel """ARA-C/BU/CTX"""@eng ; ; ; ; """4783"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281234"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/milodistim"""@eng ; skos:notation """CDR0000041620"""^^xsd:string ; skos:altLabel """CBDCA/PIXY321"""@eng ; ; ; """4782"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281233"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """site, AIDS-related lymphoma"""@eng ; skos:notation """CDR0000041627"""^^xsd:string ; skos:altLabel """AIDS-related lymphoma, site"""@eng , """AIDS-associated lymphoma, site"""@eng ; rdfs:subClassOf ; """4789"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281238"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flecainide acetate"""@eng ; skos:notation """CDR0000041626"""^^xsd:string ; """C499"""^^xsd:string ; """4788"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0086303"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/tretinoin"""@eng ; skos:notation """CDR0000041624"""^^xsd:string ; skos:altLabel """ARA-C/ATRA"""@eng ; ; ; """4786"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281237"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related peripheral/systemic lymphoma"""@eng ; skos:notation """CDR0000041629"""^^xsd:string ; skos:altLabel """peripheral/systemic lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """AIDS-related lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4791"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281240"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, AIDS-related lymphoma"""@eng ; skos:notation """CDR0000041628"""^^xsd:string ; skos:altLabel """AIDS-related lymphoma, cellular diagnosis"""@eng , """AIDS-associated lymphoma, cellular diagnosis"""@eng ; rdfs:subClassOf ; """4790"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281239"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """meclocycline sulfosalicylate"""@eng ; skos:notation """CDR0000526788"""^^xsd:string ; skos:altLabel """Meclan"""@eng , """Mecloderm"""@eng , """(4S,4aR,5S,5aR,12aS)-7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide Mono(5-sulfosalicylate)(Salt)"""@eng ; skos:definition """The sulfosalicylate salt form of meclocycline, a tetracycline antibiotic with broad-spectrum antibacterial and antiprotozoal activity. Meclocycline sulfosalicylate is bacteriostatic and inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby preventing the addition of amino acids to the growing peptide chain. This tetracycline is active against a wide range of gram-positive and gram-negative bacteria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526788&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526788&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47596\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """73816-42-9"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """C47596"""^^xsd:string ; umls:cui """C0700494"""^^xsd:string ; umls:cui """C0127392"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epothilone ZK-219477"""@eng ; skos:notation """CDR0000473738"""^^xsd:string ; skos:altLabel """ZK-Epothilone"""@eng , """ZK-219477"""@eng , """SHY03757"""@eng , """ZK 219477"""@eng ; skos:definition """A novel synthetic epothilone with potential antineoplastic activity. Epothilone ZK-219477 binds to microtubules, predominantly in tumor cells, thereby inducing microtubule bundling, formation of multipolar spindles, and mitotic arrest in a manner similar to taxanes. Epothilones are poor substrates for the multidrug resistance 1 (MDR1) P-glycoprotein drug efflux pump and, unlike the taxanes, appear to be able to evade some drug-resistance mechanisms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473738&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473738&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61072\" NCI Thesaurus)"""@eng ; """C61072"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-24"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831777"""^^xsd:string ; umls:cui """C1831775"""^^xsd:string ; umls:cui """C2930785"""^^xsd:string ; umls:cui """C2936903"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CS1 monoclonal antibody HuLuc63"""@eng ; skos:notation """CDR0000532249"""^^xsd:string ; skos:altLabel """HuLuc63"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-25"""^^xsd:string ; umls:cui """C1832048"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AFP464"""@eng ; skos:notation """CDR0000453584"""^^xsd:string ; skos:definition """A synthetic, lysyl prodrug of the amino-substituted flavone derivate aminoflavone with antiproliferative and anti-tumor activity. AFP464 is rapidly converted to the aminoflavone in plasma. Aminoflavone activates the aryl hydrocarbon receptor (AhR) signaling pathway leading to an increase in CYP1A1 enzyme activity and, to a lesser extent, an increase in CYP1B1 enzyme activity and gene expression. Subsequently, aminoflavone is metabolized by the CYP1A1 and CYP1B1 enzymes that it induces. Toxic metabolites of aminoflavone covalently bind to DNA, thereby inhibiting cell proliferation and inducing apoptosis. Pulmonary toxicity may be a dose-limiting toxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453584&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453584&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48370\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C48370"""^^xsd:string ; """2005-10-24"""^^xsd:string ; umls:cui """C1706653"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dermatologic complications management"""@eng ; skos:notation """CDR0000038610"""^^xsd:string ; skos:altLabel """management, dermatologic complications"""@eng , """complications management, dermatologic"""@eng ; ; rdfs:subClassOf ; """11238"""^^xsd:string ; """2004-08-10"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C1134623"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/STA-4783"""@eng ; skos:notation """CDR0000387738"""^^xsd:string ; skos:altLabel """CBDCA/STA 4783/TAX"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000038577"""^^xsd:string ; skos:altLabel """ASP/CF/MTX"""@eng ; ; ; ; """11208"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134597"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DetoxPC/interleukin-2/ras peptide cancer vaccine/sargramostim"""@eng ; skos:notation """CDR0000038576"""^^xsd:string ; skos:altLabel """Detox PC/GM-CSF/IL-2/ras pep vac"""@eng ; ; ; ; ; """2003-10-29"""^^xsd:string ; """11206"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134596"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/gp100 antigen/interleukin-2/Montanide ISA-51"""@eng ; skos:notation """CDR0000038575"""^^xsd:string ; skos:altLabel """AL/gp100/IL-2/ISA-51"""@eng ; ; ; ; """11205"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134595"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/prednisolone/rituximab/vincristine"""@eng ; skos:notation """CDR0000038574"""^^xsd:string ; skos:altLabel """BLEO/MOAB IDEC-C2B8/PRDL/VCR"""@eng ; ; ; ; ; """11204"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134594"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxychloroquine/prednisone/tacrolimus"""@eng ; skos:notation """CDR0000038573"""^^xsd:string ; skos:altLabel """FK506/HCQ/PRED"""@eng ; ; ; ; """11203"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134593"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/hydroxychloroquine/prednisone"""@eng ; skos:notation """CDR0000038572"""^^xsd:string ; skos:altLabel """CYSP/HCQ/PRED"""@eng ; ; ; ; """11202"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134592"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxychloroquine"""@eng ; skos:notation """CDR0000038571"""^^xsd:string ; skos:altLabel """HCQ"""@eng ; skos:definition """A 4-aminoquinoline with antimalarial and immunosuppressive properties. Although its precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. This agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38571&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38571&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C557\" NCI Thesaurus)"""@eng ; ; ; """11201"""^^xsd:string ; """C557"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """118-42-3"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0020336"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """megestrol/omega-3 fatty acids"""@eng ; skos:notation """CDR0000038570"""^^xsd:string ; skos:altLabel """MEG/O3FA"""@eng ; ; ; """11200"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134591"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/cytarabine"""@eng ; skos:notation """CDR0000042824"""^^xsd:string ; skos:altLabel """ARA-C/BRYO"""@eng ; ; ; """6623"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677767"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody di-dgA-RFB4"""@eng ; skos:notation """CDR0000042825"""^^xsd:string ; skos:altLabel """MOAB Di-dgA-RFB4"""@eng , """Di-dgA-RFB4"""@eng ; """6624"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677768"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liver cancer prevention"""@eng ; skos:notation """CDR0000042826"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """6625"""^^xsd:string ; umls:cui """C0677769"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cyclophosphamide/mitoxantrone/thiotepa"""@eng ; skos:notation """CDR0000042827"""^^xsd:string ; skos:altLabel """CTX/DHAD/TSPA/WR-2721"""@eng ; ; ; ; ; """6626"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677770"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oltipraz/vitamin A"""@eng ; skos:notation """CDR0000042820"""^^xsd:string ; skos:altLabel """OPZ/VIT-A"""@eng ; ; ; """6619"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677763"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenretinide/vitamin A"""@eng ; skos:notation """CDR0000042821"""^^xsd:string ; skos:altLabel """HPR/VIT-A"""@eng ; ; ; """6620"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677764"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 11D10"""@eng ; skos:notation """CDR0000042822"""^^xsd:string ; skos:altLabel """11D10"""@eng , """MOAB 11D10"""@eng ; """6621"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677765"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/rituximab"""@eng ; skos:notation """CDR0000038578"""^^xsd:string ; skos:altLabel """ARA-C/MOAB IDEC-C2B8/VP-16"""@eng ; ; ; ; """11209"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134598"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clopidogrel bisulfate"""@eng ; skos:notation """CDR0000038611"""^^xsd:string ; skos:altLabel """Plavix"""@eng , """CLOBI"""@eng ; skos:definition """A thienopyridine with antiplatelet activity. Clopidogrel bisulfate irreversibly alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38611&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38611&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2673\" NCI Thesaurus)"""@eng ; ; """11239"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2673"""^^xsd:string ; umls:cui """C0633084"""^^xsd:string ; umls:cui """C0772326"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/gemcitabine/paclitaxel"""@eng ; skos:notation """CDR0000043089"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/TAX"""@eng ; ; ; ; """7473"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678088"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin HCl liposome/paclitaxel"""@eng ; skos:notation """CDR0000043088"""^^xsd:string ; skos:altLabel """CBDCA/LipoDox/TAX"""@eng ; ; ; ; """7472"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678087"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phyllodes tumor"""@eng ; skos:notation """CDR0000043085"""^^xsd:string ; skos:altLabel """cystosarcoma phyllodes"""@eng ; rdfs:subClassOf ; """7469"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0010701"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/gemcitabine"""@eng ; skos:notation """CDR0000043084"""^^xsd:string ; skos:altLabel """dFdC/VP-16"""@eng ; ; ; """7467"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678084"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody muJ591"""@eng ; skos:notation """CDR0000043087"""^^xsd:string ; skos:altLabel """muJ591"""@eng , """MOAB muJ591"""@eng ; """7471"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678086"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium Tc 99m epratuzumab"""@eng ; skos:notation """CDR0000043086"""^^xsd:string ; skos:altLabel """epratuzumab, technetium Tc 99m"""@eng , """monoclonal antibody LL2, technetium Tc 99m"""@eng ; """2003-10-28"""^^xsd:string ; """7470"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678085"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diethylstilbestrol"""@eng ; skos:notation """CDR0000043081"""^^xsd:string ; skos:altLabel """Neo-Oestronol I"""@eng , """3,4-Bis(p-hydroxyphenyl)-3-hexene"""@eng , """Domestrol"""@eng , """Synestrin"""@eng , """DES"""@eng , """Palestrol"""@eng , """Synthoestrin"""@eng , """Apstil"""@eng , """Estrobene"""@eng , """Microest"""@eng , """Stilbetin"""@eng , """Sinestrol"""@eng , """Sibol"""@eng , """Diastyl"""@eng , """Stilboestrol"""@eng , """Stilkap"""@eng , """Makarol"""@eng , """Antigestil"""@eng , """Acnestrol"""@eng , """Boestrol"""@eng , """Oestrogenine"""@eng , """Estrosyn"""@eng , """Fonatol"""@eng , """Cyren A"""@eng , """Stilboefral"""@eng , """Estrogenine"""@eng , """Stilboestroform"""@eng , """4,4'-Dihydroxy-alpha,beta-diethylstilbene"""@eng , """Serral"""@eng , """Diethylstilbestrolum"""@eng , """Diethylstilboestrol"""@eng , """(E)-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol"""@eng , """Milestrol"""@eng , """Trans-bis-(hydroxy-4-phenyl)-3,4 hexene-3"""@eng , """Distilbene"""@eng , """Oestromon"""@eng , """Sexocretin"""@eng , """stilbestrol"""@eng , """Bufon"""@eng , """Grafestrol"""@eng , """Oestromensyl"""@eng , """Estromenin"""@eng , """Diethylstilbestrol Dipropionate"""@eng , """Vagestrol"""@eng , """Stilboestrol Dipropionate"""@eng , """Alpha,alpha'-diethylstilbenediol"""@eng , """Oestromenin"""@eng , """Deladumone"""@eng , """Diethylstilbenediol"""@eng ; skos:definition """DES; the acronym for diethylstilbestrol, a synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, DES inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43081&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43081&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C433\" NCI Thesaurus)"""@eng ; ; ; """745"""^^xsd:string ; """5019"""^^xsd:string ; """C433"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """56-53-1"""^^xsd:string ; """3070"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511906"""^^xsd:string ; umls:cui """C0057965"""^^xsd:string ; umls:cui """C0012203"""^^xsd:string ; umls:cui """C1511931"""^^xsd:string ; umls:cui """C1511930"""^^xsd:string ; umls:cui """C1511919"""^^xsd:string ; umls:cui """C1511918"""^^xsd:string ; umls:cui """C1511913"""^^xsd:string ; umls:cui """C1511912"""^^xsd:string ; umls:cui """C1511911"""^^xsd:string ; umls:cui """C1511910"""^^xsd:string ; umls:cui """C1511917"""^^xsd:string ; umls:cui """C1511916"""^^xsd:string ; umls:cui """C1511915"""^^xsd:string ; umls:cui """C1511914"""^^xsd:string ; umls:cui """C3537266"""^^xsd:string ; umls:cui """C0699333"""^^xsd:string ; umls:cui """C0591106"""^^xsd:string ; umls:cui """C0699331"""^^xsd:string ; umls:cui """C0057300"""^^xsd:string ; umls:cui """C1511921"""^^xsd:string ; umls:cui """C1831606"""^^xsd:string ; umls:cui """C0699332"""^^xsd:string ; umls:cui """C1511908"""^^xsd:string ; umls:cui """C1511909"""^^xsd:string ; umls:cui """C0699329"""^^xsd:string ; umls:cui """C1511928"""^^xsd:string ; umls:cui """C1511929"""^^xsd:string ; umls:cui """C1511926"""^^xsd:string ; umls:cui """C1511927"""^^xsd:string ; umls:cui """C1511924"""^^xsd:string ; umls:cui """C1511925"""^^xsd:string ; umls:cui """C1511922"""^^xsd:string ; umls:cui """C1511923"""^^xsd:string ; umls:cui """C1511920"""^^xsd:string ; umls:cui """C1511907"""^^xsd:string ; umls:cui """C1511932"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000043080"""^^xsd:string ; skos:altLabel """IDEC-2B8"""@eng , """Zevalin"""@eng ; ; """2004-02-05"""^^xsd:string ; """7448"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0919274"""^^xsd:string ; umls:cui """C0877880"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/pemetrexed disodium"""@eng ; skos:notation """CDR0000043083"""^^xsd:string ; skos:altLabel """CDDP/LY231514"""@eng ; ; ; """7466"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678083"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciprofloxacin/dexamethasone/pentoxifylline"""@eng ; skos:notation """CDR0000043082"""^^xsd:string ; skos:altLabel """CPFX/DM/PTX"""@eng ; ; ; ; """7464"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678082"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ticarcillin"""@eng ; skos:notation """CDR0000039718"""^^xsd:string ; skos:altLabel """Ticar"""@eng ; """2380"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0040193"""^^xsd:string ; umls:cui """C0699871"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trimethylcolchicinic acid"""@eng ; skos:notation """CDR0000039719"""^^xsd:string ; skos:altLabel """trimethylcolchicinic acid methyl ether d-tartrate"""@eng , """methyl ether"""@eng , """desacetyl colchicine D-tartrate"""@eng , """TMCA"""@eng ; skos:definition """A colchicine analog with potential antineoplastic activity. Trimethylcolchicinic acid binds to tubulin, inhibiting its polymerization into microtubules and preventing cell division. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39719&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39719&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1264\" NCI Thesaurus)"""@eng ; """2381"""^^xsd:string ; """36354"""^^xsd:string ; """3482-37-9"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """956"""^^xsd:string ; """36796"""^^xsd:string ; """C1264"""^^xsd:string ; umls:cui """C0338102"""^^xsd:string ; umls:cui """C0077183"""^^xsd:string ; umls:cui """C2584702"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thiazolidine carboxylic acid"""@eng ; skos:notation """CDR0000039714"""^^xsd:string ; skos:altLabel """thiazolidinecarboxylic acid"""@eng ; """2376"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0076425"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thymidine"""@eng ; skos:notation """CDR0000039715"""^^xsd:string ; skos:altLabel """thymidin"""@eng , """thymidine deoxyriboside"""@eng , """2'-deoxythymidine"""@eng , """TDR"""@eng , """DThyd"""@eng , """dT"""@eng ; skos:definition """A pyrimidine nucleoside that is composed of the pyrimidine base thymine attached to the sugar deoxyribose. As a constituent of DNA, thymidine pairs with adenine in the DNA double helix. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39715&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39715&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C880\" NCI Thesaurus)"""@eng ; ; ; ; """2377"""^^xsd:string ; """C880"""^^xsd:string ; """14794"""^^xsd:string ; """21548"""^^xsd:string ; """50-89-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0086126"""^^xsd:string ; umls:cui """C0040077"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thymosin"""@eng ; skos:notation """CDR0000039716"""^^xsd:string ; skos:altLabel """THYM"""@eng , """Zadaxin™"""@eng , """human thymosin -fraction 5"""@eng , """human thymosin -fraction alpha 1"""@eng , """thymalfasin"""@eng , """Zadaxin![TRADE MARK SIGN]!"""@eng ; """2378"""^^xsd:string ; """2004-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0040106"""^^xsd:string ; umls:cui """C0338101"""^^xsd:string ; umls:cui """C0076620"""^^xsd:string ; umls:cui """C1515426"""^^xsd:string ; umls:cui """C0076612"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tiazofurin"""@eng ; skos:notation """CDR0000039717"""^^xsd:string ; skos:altLabel """TCAR"""@eng , """2-Beta-D-ribofuranosylthiazole-4-carboxamide"""@eng , """Riboxamide"""@eng , """4-Thiazolecarboxamide, 2-Beta-D-ribofuranosyl- (9CI)"""@eng , """2-Beta-D-ribofuranosyl-4-thiazolecarboxamide"""@eng ; skos:definition """A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39717&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39717&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1254\" NCI Thesaurus)"""@eng ; ; ; """2379"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """286193"""^^xsd:string ; """21342"""^^xsd:string ; """60084-10-8"""^^xsd:string ; """C1254"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0092663"""^^xsd:string ; umls:cui """C0076656"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetrahydrouridine"""@eng ; skos:notation """CDR0000039710"""^^xsd:string ; skos:altLabel """THU"""@eng , """2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-"""@eng ; skos:definition """A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39710&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39710&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C868\" NCI Thesaurus)"""@eng ; ; """2372"""^^xsd:string ; """C868"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """112907"""^^xsd:string ; """68560"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """18771-50-1"""^^xsd:string ; umls:cui """C0039677"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta-thioguanine deoxyriboside"""@eng ; skos:notation """CDR0000039711"""^^xsd:string ; skos:altLabel """9H-purine-6-thiol, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) monohydrate"""@eng , """thioguanine 9-.beta-D-2'-deoxyriboside"""@eng , """6-Mercaptoguaninedeoxyriboside"""@eng , """1,9-dihydro-6H-purine-6-thione, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)"""@eng , """beta-2'-deoxythiol guanosine"""@eng , """B-TGDR"""@eng , """BTG"""@eng , """beta-2'-deoxy-6-thioguanosine"""@eng , """2'-desoxy-6-thioguanosine"""@eng , """beta thioguanine deoxyriboside"""@eng , """beta-2'-deoxythioguanosine"""@eng , """2'-deoxythioguanosine"""@eng ; skos:definition """A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication. This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo. Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39711&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39711&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1350\" NCI Thesaurus)"""@eng ; """2373"""^^xsd:string ; """64039-27-6 (monohydrate)"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """789-61-7"""^^xsd:string ; """C1350"""^^xsd:string ; """6874"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """71261"""^^xsd:string ; umls:cui """C0053376"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thalicarpine"""@eng ; skos:notation """CDR0000039712"""^^xsd:string ; skos:altLabel """4H-dibenzo[de,g]quinoline, 9-[4, 5-dimethoxy-2-[(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, [S-(R*,R*)]- (9CI)"""@eng , """taliblastine"""@eng , """thaliblastine"""@eng , """[S-(R*,R*)]-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)-methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinoline"""@eng , """6a.Alpha.-aporphine, 9-[[4, 5-dimethoxy-.alpha.-(1.beta.,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2, 10-trimethoxy- (8CI)"""@eng , """6a.Alpha.-aporphine, 9-[[4,5-dimethoxy-.alpha.-((S)-1,2,3, 4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1, 2,10-trimethoxy-"""@eng , """thalicarpin"""@eng , """4H-Dibenzo[de,g]quinoline, 5,6,6a, 7-tetrahydro-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-1,2,10-trimethoxy-6-methyl-"""@eng ; skos:definition """A natural aporphine benzylisoquinoline vinca alkaloid with antineoplastic activity. Thalicarpine binds to and inhibits p-glycoprotein, the multidrug resistance efflux pump. Thalicarpine also induces single-strand breaks in DNA and arrests cancer cells at the G2/M and G1 phase of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39712&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39712&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C869\" NCI Thesaurus)"""@eng ; """2374"""^^xsd:string ; """5373-42-2"""^^xsd:string ; """C869"""^^xsd:string ; """68075"""^^xsd:string ; """8334"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-18"""^^xsd:string ; umls:cui """C1112823"""^^xsd:string ; umls:cui """C0039735"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thiabendazole"""@eng ; skos:notation """CDR0000039713"""^^xsd:string ; skos:altLabel """Mintezol"""@eng , """Thibenzole"""@eng , """TBZ"""@eng , """MK-360"""@eng ; skos:definition """A benzimidazole derivative with anthelminthic property. Although the mechanism of action has not been fully elucidated, thiabendazole inhibits the helminth-specific mitochondrial enzyme fumarate reductase, thereby inhibiting the citric acid cycle, mitochondrial respiration and subsequent production of ATP, ultimately leading to helminth's death. In addition, it has been suggested that thiabendazole may lead to inhibition of microtubule polymerization by binding to beta-tubulin and has an overt ovicidal effect with regard to some trichostrongylids. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39713&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39713&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C873\" NCI Thesaurus)"""@eng ; """2375"""^^xsd:string ; """90507"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """148-79-8"""^^xsd:string ; """C873"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733598"""^^xsd:string ; umls:cui """C0700007"""^^xsd:string ; umls:cui """C0733600"""^^xsd:string ; umls:cui """C0039832"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CGS-16949A"""@eng ; skos:notation """CDR0000041025"""^^xsd:string ; """4065"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0055226"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Iodized Oil"""@eng ; skos:notation """CDR0000041024"""^^xsd:string ; skos:altLabel """Ethiodol"""@eng , """Lipiodol"""@eng ; """8008-53-5"""^^xsd:string ; """2006-10-24"""^^xsd:string ; """C487"""^^xsd:string ; """4064"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0720305"""^^xsd:string ; umls:cui """C0021972"""^^xsd:string ; umls:cui """C0947677"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ethiodized oil"""@eng ; skos:notation """CDR0000041027"""^^xsd:string ; skos:altLabel """DOX/ethiodized oil"""@eng ; ; """4067"""^^xsd:string ; """2006-08-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280636"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amphotericin B/flucytosine"""@eng ; skos:notation """CDR0000041026"""^^xsd:string ; skos:altLabel """amphotericin B/5-FC"""@eng ; ; ; """4066"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280635"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/thiotepa"""@eng ; skos:notation """CDR0000041021"""^^xsd:string ; skos:altLabel """TSPA/VP-16"""@eng ; ; ; """4061"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280633"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/isotretinoin"""@eng ; skos:notation """CDR0000041020"""^^xsd:string ; skos:altLabel """13-CRA/IFN-A"""@eng ; ; ; """4060"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338122"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flucytosine"""@eng ; skos:notation """CDR0000041023"""^^xsd:string ; skos:altLabel """Ancobon"""@eng , """Ro 2-9915"""@eng , """Alcobon"""@eng , """5FC"""@eng , """5-Fluorocytosine"""@eng , """Ancotil"""@eng , """4-Amino-5-fluoro-2(1H)-pyrimidinone"""@eng , """Ro-2-9915"""@eng , """5-FC"""@eng ; skos:definition """A pyrimidine compound and a fluorinated cytosine analog exhibiting antifungal activity. After penetration into the fungal cells, flucytosine is deaminated to its active metabolite 5-fluorouracil. 5-fluorouracil replaces uracil during fungal RNA synthesis, thereby inhibiting fungal protein synthesis. In addition, fluorouracil is further metabolized to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase, thereby interrupting nucleotide metabolism, DNA synthesis and ultimately protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41023&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41023&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C501\" NCI Thesaurus)"""@eng ; ; """4063"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """103805"""^^xsd:string ; """C501"""^^xsd:string ; """2022-85-7"""^^xsd:string ; """2006-12-06"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733923"""^^xsd:string ; umls:cui """C0016278"""^^xsd:string ; umls:cui """C0733924"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute monocytic leukemia (M5b)"""@eng ; skos:notation """CDR0000041022"""^^xsd:string ; skos:altLabel """adult acute differentiated M5b leukemia"""@eng , """leukemia, adult acute differentiated monoblastic"""@eng , """acute differentiated monoblastic leukemia, adult"""@eng , """adult acute differentiated monoblastic leukemia"""@eng , """monoblastic leukemia, adult acute differentiated"""@eng , """M5b leukemia, adult acute"""@eng , """M5b leukemia, adult acute differentiated"""@eng , """M5b adult acute differentiated monocytic leukemia"""@eng , """adult acute M5b leukemia"""@eng ; rdfs:subClassOf ; ; ; """2004-06-21"""^^xsd:string ; """4062"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280634"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DHA-paclitaxel"""@eng ; skos:notation """CDR0000038414"""^^xsd:string ; skos:altLabel """Taxoprexin"""@eng , """DHA-TAX"""@eng , """Docosahexaenoic Acid-Paclitaxel conjugate"""@eng , """TXP"""@eng ; skos:definition """A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel. Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38414&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38414&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2649\" NCI Thesaurus)"""@eng ; ; """11031"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2649"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135143"""^^xsd:string ; umls:cui """C1134470"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/interferon alfa"""@eng ; skos:notation """CDR0000041029"""^^xsd:string ; skos:altLabel """BCNU/IFN-A"""@eng ; ; ; """4069"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338123"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000041028"""^^xsd:string ; skos:altLabel """CDDP/DOX/5-FU/MITO/VP-16"""@eng ; ; ; ; ; ; """4068"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280637"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/cytarabine/etoposide"""@eng ; skos:notation """CDR0000040215"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/CTX/VP-16"""@eng , """BEAC"""@eng ; ; ; ; ; """3020"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0105125"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amonafide dihydrochloride"""@eng ; skos:notation """CDR0000040214"""^^xsd:string ; skos:altLabel """1H-benz(de)isoquinoline-1,3(2H)-dione, 5-amino-2-(2-(dimethylamino)ethyl)"""@eng , """Benzisoquinolinedione"""@eng , """AMON"""@eng , """Quinamed"""@eng , """nafidimide"""@eng , """M-FA-142"""@eng , """BIDA"""@eng , """Amonafide Hydrochloride"""@eng ; skos:definition """The dihydrochloride salt of amonafide, an imide derivative of naphthalic acid. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in protein-associated strand breaks and impaired DNA and RNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40214&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40214&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C999\" NCI Thesaurus)"""@eng ; """2006-07-26"""^^xsd:string ; """25852"""^^xsd:string ; """3015"""^^xsd:string ; """C999"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """308847"""^^xsd:string ; """69408-81-7"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0051733"""^^xsd:string ; umls:cui """C1527333"""^^xsd:string ; umls:cui """C0126606"""^^xsd:string ; umls:cui """C1706798"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """papillary thyroid cancer"""@eng ; skos:notation """CDR0000040217"""^^xsd:string ; skos:altLabel """thyroid cancer, papillary"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3025"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0238463"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine/vindesine"""@eng ; skos:notation """CDR0000040216"""^^xsd:string ; skos:altLabel """CDDP/CTX/DAVA/DOX/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """3021"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279909"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040211"""^^xsd:string ; skos:altLabel """Hodgkin's lymphoma cellular diagnosis, adult"""@eng , """adult Hodgkin's disease cellular diagnosis"""@eng , """cellular diagnosis, adult Hodgkin's disease"""@eng , """Hodgkin's disease cellular diagnosis, adult"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """3006"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279905"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, intraocular melanoma"""@eng ; skos:notation """CDR0000040210"""^^xsd:string ; skos:altLabel """melanoma, intraocular, cellular diagnosis"""@eng , """intraocular melanoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """3005"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279904"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040213"""^^xsd:string ; skos:altLabel """adult non-Hodgkin's lymphoma cellular diagnosis"""@eng , """adult NHL cellular diagnosis"""@eng ; rdfs:subClassOf ; """3012"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279907"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000040212"""^^xsd:string ; skos:altLabel """GTT cellular diagnosis"""@eng , """gestational trophoblastic tumor cellular diagnosis"""@eng , """cellular diagnosis, GTT"""@eng ; rdfs:subClassOf ; """3008"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279906"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000040219"""^^xsd:string ; skos:altLabel """LAK cells"""@eng , """LAK"""@eng , """Therapeutic Lymphokine-Activated Killer Cell"""@eng ; skos:definition """Killer cell lymphocytes activated in the presence of interleukin-2 (IL-2). Lymphokine-activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins. LAK cells exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40219&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40219&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C13008\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """3028"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C13008"""^^xsd:string ; umls:cui """C0022687"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """follicular thyroid cancer"""@eng ; skos:notation """CDR0000040218"""^^xsd:string ; skos:altLabel """thyroid cancer, follicular"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3026"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0206682"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Synchrotope TA2M plasmid DNA vaccine"""@eng ; skos:notation """CDR0000038415"""^^xsd:string ; skos:altLabel """TA2M plasmid DNA vaccine, Synchrotope"""@eng ; """11032"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134471"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/temozolomide/thalidomide"""@eng ; skos:notation """CDR0000340966"""^^xsd:string ; skos:altLabel """CCNU/THAL/TMZ"""@eng ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328083"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/busulfan/melphalan/methylprednisolone"""@eng ; skos:notation """CDR0000285704"""^^xsd:string ; skos:altLabel """ATG/BU/L-PAM/MePRDL"""@eng ; ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327913"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """delta-8-tetrahydrocannabinol"""@eng ; skos:notation """CDR0000485262"""^^xsd:string ; skos:altLabel """delta-8-THC"""@eng ; skos:definition """An analogue of tetrahydrocannabinol (THC) with antiemetic, anxiolytic, appetite-stimulating, analgesic, and neuroprotective properties. Delta-8-tetrahydrocannabinol (delta-8-THC) binds to the cannabinoid G-protein coupled receptor CB1, located in the central nervous system; CB1 receptor activation inhibits adenyl cyclase, increases mitogen-activated protein kinase activities, modulates several potassium channel conductances and inhibits N- and P/Q-type Ca2+ channels. This agent exhibits a lower psychotropic potency than delta-9-tetrahydrocannabinol (delta-9-THC), the primary form of THC found in cannabis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485262&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485262&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61312\" NCI Thesaurus)"""@eng ; """2006-08-07"""^^xsd:string ; """C61312"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-11"""^^xsd:string ; umls:cui """C0057341"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CHIR-258"""@eng ; skos:notation """CDR0000488976"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """C62435"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; umls:cui """C1568328"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II endometrial cancer"""@eng ; skos:notation """CDR0000038740"""^^xsd:string ; skos:altLabel """stage II cancer of the endometrium"""@eng , """uterine cancer, stage II"""@eng , """endometrial cancer, stage II"""@eng , """stage II carcinoma of the endometrium"""@eng , """endometrial carcinoma, stage II"""@eng , """carcinoma of the endometrium, stage II"""@eng , """stage II uterine cancer"""@eng , """cancer of the endometrium, stage II"""@eng ; rdfs:subClassOf ; """endometrial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1179"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278799"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EGb761"""@eng ; skos:notation """CDR0000257914"""^^xsd:string ; skos:altLabel """ginkgo biloba"""@eng , """EGb 761"""@eng ; skos:definition """A standardized ginkgo biloba extract with antioxidant and neuroprotective activities. EGb761 has been shown to inhibit the proliferation of certain tumor cells in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257914&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257914&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26646\" NCI Thesaurus)"""@eng ; """11475"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C26646"""^^xsd:string ; umls:cui """C0772125"""^^xsd:string ; umls:cui """C1095795"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/irinotecan"""@eng ; skos:notation """CDR0000370882"""^^xsd:string ; skos:altLabel """3AP/CPT-11"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541244"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indinavir sulfate"""@eng ; skos:notation """CDR0000042594"""^^xsd:string ; skos:altLabel """IDV"""@eng ; ; ; """6298"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1662"""^^xsd:string ; """2006-11-22"""^^xsd:string ; umls:cui """C0700483"""^^xsd:string ; umls:cui """C0376637"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 gastric cancer"""@eng ; skos:notation """CDR0000042595"""^^xsd:string ; skos:altLabel """gastric cancer, stage 0"""@eng , """stomach cancer, stage 0"""@eng ; rdfs:subClassOf ; """gastric cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """63"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0154060"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indinavir/lamivudine/stavudine"""@eng ; skos:notation """CDR0000042596"""^^xsd:string ; skos:altLabel """3TC/d4T/IDV"""@eng ; ; ; ; """6301"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393010"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/sargramostim/vincristine"""@eng ; skos:notation """CDR0000042597"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF/PRED/VCR"""@eng ; ; ; ; ; ; """6302"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393011"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/idarubicin/methylprednisolone/methotrexate/vincristine"""@eng ; skos:notation """CDR0000042590"""^^xsd:string ; skos:altLabel """BLEO/CTX/IDA/MEPRDL/MTX/VCR"""@eng ; ; ; ; ; ; ; """6294"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393007"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/tacrolimus"""@eng ; skos:notation """CDR0000042591"""^^xsd:string ; skos:altLabel """FK506/MTX"""@eng ; ; ; """6295"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393008"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Levels of Evidence"""@eng ; skos:notation """CDR0000042592"""^^xsd:string ; skos:altLabel """Evidence, Levels of"""@eng ; """2002-09-27"""^^xsd:string ; """6296"""^^xsd:string ; umls:cui """C0393009"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lamivudine"""@eng ; skos:notation """CDR0000042593"""^^xsd:string ; skos:altLabel """3TC"""@eng ; skos:definition """A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42593&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42593&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1471\" NCI Thesaurus)"""@eng ; ; ; """6297"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """134678-17-4"""^^xsd:string ; """C1471"""^^xsd:string ; umls:cui """C0209738"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bupivacaine hydrochloride"""@eng ; skos:notation """CDR0000481366"""^^xsd:string ; skos:altLabel """Sensorcaine-MPF"""@eng , """Bupivacaine"""@eng ; skos:definition """An amide-type, long-acting local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481366&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481366&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28876\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28876"""^^xsd:string ; """2006-04-20"""^^xsd:string ; umls:cui """C0723283"""^^xsd:string ; umls:cui """C0006400"""^^xsd:string ; umls:cui """C0887621"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABI-007/gemcitabine"""@eng ; skos:notation """CDR0000428317"""^^xsd:string ; skos:altLabel """ABI 007/dFdC"""@eng ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541545"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant vaccinia-NY-ESO-1 vaccine"""@eng ; skos:notation """CDR0000428314"""^^xsd:string ; skos:altLabel """rV-NY-ESO-1"""@eng , """vaccinia-NY-ESO-1 vaccine"""@eng ; skos:definition """A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia- NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428314&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428314&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48419\" NCI Thesaurus)"""@eng ; ; """2005-04-23"""^^xsd:string ; """C48419"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; umls:cui """C1541542"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-NY-ESO-1 vaccine"""@eng ; skos:notation """CDR0000428315"""^^xsd:string ; skos:altLabel """rF-NY-ESO-1"""@eng ; skos:definition """A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428315&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428315&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48465\" NCI Thesaurus)"""@eng ; ; """2005-04-23"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C48465"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541543"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody MX35 F(ab')2"""@eng ; skos:notation """CDR0000042598"""^^xsd:string ; skos:altLabel """MX35 F(ab')2"""@eng , """MX35 F(ab')2 monoclonal antibody"""@eng , """MOAB MX35 F(ab')2"""@eng ; """6316"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393012"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """post-traumatic stress disorder"""@eng ; skos:notation """CDR0000042599"""^^xsd:string ; skos:altLabel """PTSD"""@eng , """disorder, post-traumatic stress"""@eng ; rdfs:subClassOf ; """6317"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0038436"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """saponin-cholesterol-phospholipid adjuvant"""@eng ; skos:notation """CDR0000465382"""^^xsd:string ; skos:altLabel """Saponin Cholesterol Phospholipid Adjuvant"""@eng , """Iscomatrix"""@eng ; skos:definition """An adjuvant comprised of saponin, derived from the bark of Quillaia saponaria Molina, cholesterol and phospholipid with antigen-delivery and immunostimulatory activities. This saponin-based adjuvant in combination with various antigens, including those for human papilloma virus (HPV), hepatitis C virus (HCV), and the human cancer antigen NY-ESO-1, may result in potent antibody, CD4+ T-helper-cell, and CD8+ cytotoxic T-cell responses against the targeted antigen. In addition, this agent may reduce the amount of antigen necessary to induce an efficient immune response in the host. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465382&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465382&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53436\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """C53436"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1529741"""^^xsd:string ; umls:cui """C1710013"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody Ch14.18"""@eng ; skos:notation """CDR0000042042"""^^xsd:string ; skos:altLabel """Ch14.18 Monoclonal Antibody"""@eng , """MOAB Ch14.18"""@eng , """Ch14.18"""@eng ; skos:definition """A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42042&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42042&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1570\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """5271"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """623408"""^^xsd:string ; """4308"""^^xsd:string ; """5748"""^^xsd:string ; """C1570"""^^xsd:string ; umls:cui """C0281581"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbogen"""@eng ; skos:notation """CDR0000042043"""^^xsd:string ; skos:altLabel """UN1014"""@eng ; skos:definition """An inhalant consisting of hyperoxic gas (95%-98% oxygen and 2%-5% carbon dioxide) with radiosensitizing properties. Inhaled carbogen reduces diffusion-limited tumor hypoxia, increasing tumor radiosensitivity due to the increased availability of molecular oxygen for cytotoxic radiation-induced oxygen free radical production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42043&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42043&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1038\" NCI Thesaurus)"""@eng ; ; """5272"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-30"""^^xsd:string ; """8063-77-2"""^^xsd:string ; """C1038"""^^xsd:string ; umls:cui """C2945845"""^^xsd:string ; umls:cui """C0054692"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/idarubicin/methylprednisolone"""@eng ; skos:notation """CDR0000042040"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/IDA/MePRDL"""@eng ; ; ; ; ; """5269"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281579"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/idarubicin/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000042041"""^^xsd:string ; skos:altLabel """BLEO/CTX/IDA/MePRDL/VCR"""@eng ; ; ; ; ; """5270"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281580"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/filgrastim/ifosfamide/interleukin-6"""@eng ; skos:notation """CDR0000042046"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/IFF/IL-6/VP-16"""@eng ; ; ; ; ; ; """5276"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281584"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interferon alfa/interleukin-2/vinblastine"""@eng ; skos:notation """CDR0000042047"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IFN-A/IL-2/VBL"""@eng ; ; ; ; ; ; """5277"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338185"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """niacinamide"""@eng ; skos:notation """CDR0000042044"""^^xsd:string ; skos:altLabel """nicotinamide"""@eng , """Vitamin PP"""@eng , """Nicotinic Acid Amide"""@eng , """Nicamid"""@eng , """Nicosedine"""@eng , """Pellagra-Preventing Factor"""@eng , """Nicotylamide"""@eng , """Nicotinamidum"""@eng , """3-Pyridinecarboxamide"""@eng ; skos:definition """The active form of vitamin B3 and a component of the coenzyme nicotinamide adenine dinucleotide (NAD). Niacinamide acts as a chemo- and radio-sensitizing agent by enhancing tumor blood flow, thereby reducing tumor hypoxia. This agent also inhibits poly(ADP-ribose) polymerases, enzymes involved in the rejoining of DNA strand breaks induced by radiation or chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42044&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42044&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2327\" NCI Thesaurus)"""@eng ; ; """5273"""^^xsd:string ; """27452"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """98-92-0"""^^xsd:string ; """2006-08-31"""^^xsd:string ; """C2327"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1518323"""^^xsd:string ; umls:cui """C1518322"""^^xsd:string ; umls:cui """C0028027"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/interleukin-6"""@eng ; skos:notation """CDR0000042045"""^^xsd:string ; skos:altLabel """G-CSF/IL-6"""@eng ; ; ; """5274"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281582"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/topotecan/vincristine"""@eng ; skos:notation """CDR0000042048"""^^xsd:string ; skos:altLabel """CTX/TOPO/VCR"""@eng ; ; ; ; """5278"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281586"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lintuzumab"""@eng ; skos:notation """CDR0000042049"""^^xsd:string ; skos:altLabel """MOAB HuM195"""@eng , """monoclonal antibody HuM195"""@eng , """MOAB HuG1-M195"""@eng , """monoclonal antibody HuG1-M195"""@eng , """Hu-M195 monoclonal antibody"""@eng , """HuG1-M195 monoclonal antibody"""@eng , """HuG1-M195"""@eng ; skos:definition """A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42049&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42049&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1716\" NCI Thesaurus)"""@eng ; ; ; """Drug/agent"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """C1716"""^^xsd:string ; """5279"""^^xsd:string ; umls:cui """C0530093"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/rituximab"""@eng ; skos:notation """CDR0000355635"""^^xsd:string ; skos:altLabel """IFN-G/MOAB IDEC-C2B8"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328186"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ecteinascidin 743"""@eng ; skos:notation """CDR0000420917"""^^xsd:string ; skos:altLabel """DOX/ET-743"""@eng ; ; ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liarozole fumarate"""@eng ; skos:notation """CDR0000042107"""^^xsd:string ; skos:altLabel """R85246"""@eng ; skos:definition """An orally-active fumarate salt of liarozole, an agent with potential antineoplastic. As a retinoic acid metabolism blocking agent (RAMBA), liarozole fumarate inhibits cytochrome P450 dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42107&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42107&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1524\" NCI Thesaurus)"""@eng ; """5343"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1524"""^^xsd:string ; """145858-52-2"""^^xsd:string ; """2006-12-20"""^^xsd:string ; umls:cui """C1527019"""^^xsd:string ; umls:cui """C0245820"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tyrosinase-KLH"""@eng ; skos:notation """CDR0000042106"""^^xsd:string ; """5342"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281633"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TYR"""@eng ; skos:notation """CDR0000042105"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """5341"""^^xsd:string ; umls:cui """C0041484"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-LET neutron therapy"""@eng ; skos:notation """CDR0000042104"""^^xsd:string ; skos:altLabel """therapy, neutron"""@eng , """neutron therapy"""@eng , """therapy, high-LET neutron"""@eng ; ; rdfs:subClassOf ; """534"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0278623"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/dexniguldipine/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000042103"""^^xsd:string ; skos:altLabel """DM/DNIG/DOX/VCR"""@eng ; ; ; ; ; """5339"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281632"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/dexniguldipine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000042102"""^^xsd:string ; skos:altLabel """DM/DNIG/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """5338"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281631"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 3F8/sargramostim"""@eng ; skos:notation """CDR0000042101"""^^xsd:string ; skos:altLabel """GM-CSF/MOAB 3F8"""@eng ; ; ; """5337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281630"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/etoposide"""@eng ; skos:notation """CDR0000042100"""^^xsd:string ; skos:altLabel """HMM/VP-16"""@eng ; ; ; """5336"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281629"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """APC8015F"""@eng ; skos:notation """CDR0000385490"""^^xsd:string ; skos:definition """A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385490&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385490&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48640\" NCI Thesaurus)"""@eng ; """2004-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C48640"""^^xsd:string ; umls:cui """C1541593"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paroxysmal nocturnal hemoglobinuria"""@eng ; skos:notation """CDR0000471836"""^^xsd:string ; rdfs:subClassOf ; """precancerous/nonmalignant condition"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2007-01-11"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0024790"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amantadine hydrochloride"""@eng ; skos:notation """CDR0000471831"""^^xsd:string ; skos:altLabel """Symadine"""@eng , """Symmetrel"""@eng , """Amantadine HCl"""@eng ; skos:definition """The hydrochloride salt of amantadine, a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells; furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471831&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471831&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28818\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28818"""^^xsd:string ; umls:cui """C0936072"""^^xsd:string ; umls:cui """C0026055"""^^xsd:string ; umls:cui """C0723562"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/stem cell factor"""@eng ; skos:notation """CDR0000042109"""^^xsd:string ; skos:altLabel """G-CSF/SCF"""@eng ; ; ; """5345"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281634"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clofibrate"""@eng ; skos:notation """CDR0000042108"""^^xsd:string ; skos:altLabel """Ethyl 2-(4-Chlorophenoxy)-2-methylpropanoate"""@eng , """Atromid-S"""@eng , """Ethyl p-Chlorophenoxyisobyturate"""@eng , """CFB"""@eng , """2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester"""@eng ; skos:definition """An aryloxyisobutyric acid derivate with antihyperlipidemic activity. Although the exact mechanism of action has not been fully characterized, clofibrate may enhance the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL), decreasing the production of hepatic VLDL, inhibiting cholesterol production, and increasing fecal excretion of neutral sterols. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42108&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42108&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C378\" NCI Thesaurus)"""@eng ; """5344"""^^xsd:string ; """637-07-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """79389"""^^xsd:string ; """C378"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591129"""^^xsd:string ; umls:cui """C0009002"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/carcinoembryonic antigen peptide 1-6D/CMV pp65 peptide"""@eng ; skos:notation """CDR0000288839"""^^xsd:string ; skos:altLabel """ADC/CEA PEP 1-6D/CMV-PEP"""@eng ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327922"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unresectable extrahepatic bile duct cancer"""@eng ; skos:notation """CDR0000038754"""^^xsd:string ; skos:altLabel """extrahepatic bile duct cancer, unresectable"""@eng , """bile duct cancer, unresectable extrahepatic"""@eng ; rdfs:subClassOf ; """extrahepatic bile duct cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1193"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278811"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized extrahepatic bile duct cancer"""@eng ; skos:notation """CDR0000038753"""^^xsd:string ; skos:altLabel """bile duct cancer, localized extrahepatic"""@eng , """extrahepatic bile duct cancer, localized"""@eng ; rdfs:subClassOf ; """extrahepatic bile duct cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1192"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278810"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isoflavones"""@eng ; skos:notation """CDR0000466602"""^^xsd:string ; """C599"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C0022179"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbendazim"""@eng ; skos:notation """CDR0000043319"""^^xsd:string ; skos:altLabel """FB-642"""@eng ; """7846"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0065839"""^^xsd:string ; umls:cui """C0966571"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intoplicine"""@eng ; skos:notation """CDR0000043318"""^^xsd:string ; """7845"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0217476"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory cytopenia with multilineage dysplasia"""@eng ; skos:notation """CDR0000043315"""^^xsd:string ; rdfs:subClassOf ; """7842"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0796466"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/etoposide"""@eng ; skos:notation """CDR0000043314"""^^xsd:string ; skos:altLabel """VP-16/WR-2721"""@eng ; ; ; """7841"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796465"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/tipifarnib"""@eng ; skos:notation """CDR0000043317"""^^xsd:string ; skos:altLabel """dFdC/R115777"""@eng ; ; ; """2002-09-11"""^^xsd:string ; """7844"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796468"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """combretastatin A4 phosphate"""@eng ; skos:notation """CDR0000043316"""^^xsd:string ; skos:altLabel """CA4P"""@eng , """Combretastatin A4 Disodium Phosphate"""@eng , """Combretastatin A4 Prodrug"""@eng , """Combretastatin"""@eng , """CA4PD"""@eng ; skos:definition """A water-soluble prodrug derived from the African bush willow (Combretum caffrum) with tumor vascular-targeting activity. In vivo, combretastatin A4 phosphate is dephosphorylated to its active metabolite, combretastatin A4, which binds to tubulin and inhibits microtubule depolymerization, resulting in morphological changes in proliferating endothelial cells. As a result, the permeability of tumor vasculature is increased, leading to reduced tumor blood flow and ischemic necrosis of tumor tissue. In vitro, combretastatin A4 phosphate has been shown to be directly cytotoxic to proliferating endothelial cells and tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43316&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43316&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2503\" NCI Thesaurus)"""@eng ; ; """7843"""^^xsd:string ; """C2503"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """348103"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C0056152"""^^xsd:string ; umls:cui """C0962508"""^^xsd:string ; umls:cui """C0796467"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dyspnea management"""@eng ; skos:notation """CDR0000043311"""^^xsd:string ; skos:altLabel """management of dyspnea"""@eng ; ; rdfs:subClassOf ; """7838"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0796462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """semaxanib"""@eng ; skos:notation """CDR0000043310"""^^xsd:string ; skos:altLabel """SU-5416"""@eng , """Sumaxanib"""@eng , """SU5416"""@eng , """SU 5416"""@eng , """semoxind"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; """7837"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1831"""^^xsd:string ; """2006-11-29"""^^xsd:string ; umls:cui """C1135173"""^^xsd:string ; umls:cui """C1135174"""^^xsd:string ; umls:cui """C0762592"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/pemetrexed disodium"""@eng ; skos:notation """CDR0000043313"""^^xsd:string ; skos:altLabel """CPT-11/LY231514"""@eng ; ; ; """7840"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796464"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/flavopiridol"""@eng ; skos:notation """CDR0000043312"""^^xsd:string ; skos:altLabel """CDDP/FLAVO"""@eng ; ; ; """7839"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796463"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/ifosfamide/leucovorin calcium/methotrexate/prednisolone"""@eng ; skos:notation """CDR0000038292"""^^xsd:string ; skos:altLabel """ARA-C/CF/IFF/MTX/PRDL/VP-16"""@eng ; ; ; ; ; ; ; """10901"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935843"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Corynebacterium granulosum P40"""@eng ; skos:notation """CDR0000038293"""^^xsd:string ; skos:altLabel """Adjuvant P40"""@eng ; skos:definition """An insoluble fraction isolated from the bacterium Corynebacterium granulosum with potential cancer immunotherapeutic activity. As a non-specific immunostimulant, Corynebacterium granulosum P40 activates the reticulo-endothelial system; induces the production of certain cytokines; enhances macrophage activity; and potentiates a delayed-type hypersensitivity response when co-administered with an antigen. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38293&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38293&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C990\" NCI Thesaurus)"""@eng ; """10902"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C990"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C0050854"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent cervical cancer"""@eng ; skos:notation """CDR0000038290"""^^xsd:string ; skos:altLabel """carcinoma of the cervix, recurrent"""@eng , """uterine cervix cancer, recurrent"""@eng , """cervical cancer, recurrent"""@eng , """recurrent cervix cancer"""@eng , """cervix cancer recurrent"""@eng , """recurrent cancer of the cervix"""@eng , """cancer of the cervix, recurrent"""@eng , """uterine cervical cancer, recurrent"""@eng , """recurrent uterine cervix cancer"""@eng , """recurrent carcinoma of the cervix"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """109"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278579"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin/dexamethasone/methotrexate/prednisolone/vindesine"""@eng ; skos:notation """CDR0000038291"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DAVA/DM/DNR/MTX/PRDL"""@eng ; ; ; ; ; ; ; ; """10900"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935842"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexrazoxane/doxorubicin"""@eng ; skos:notation """CDR0000038296"""^^xsd:string ; skos:altLabel """ADR-529/CTX/DOX"""@eng ; ; ; ; """10905"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935845"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/nelarabine"""@eng ; skos:notation """CDR0000038297"""^^xsd:string ; skos:altLabel """506U78/MP/MTX"""@eng ; ; ; ; """10906"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935846"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MS-275"""@eng ; skos:notation """CDR0000038294"""^^xsd:string ; skos:altLabel """MS 275"""@eng ; skos:definition """A synthetic benzamide derivative. MS-275 binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. MS-275 appears to exert dose-dependent effects in human leukemia cells including p21(CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. p21(CIP1/WAF1) is an inhibitor of cyclin-dependent kinases; in normal cells, its expression has been associated with cell-cycle exit and differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38294&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38294&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2724\" NCI Thesaurus)"""@eng ; ; ; """10903"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """C2724"""^^xsd:string ; """706995"""^^xsd:string ; """61198"""^^xsd:string ; """209783-80-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1510480"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KSA-IL-2"""@eng ; skos:notation """CDR0000038295"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """10904"""^^xsd:string ; umls:cui """C1531415"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CD40-ligand/flt3 ligand"""@eng ; skos:notation """CDR0000038298"""^^xsd:string ; skos:altLabel """CD40-L/Flt3L"""@eng ; ; ; """10907"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935847"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000038299"""^^xsd:string ; skos:altLabel """IFN-A/LAK"""@eng ; ; ; """10908"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935848"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent gallbladder cancer"""@eng ; skos:notation """CDR0000038751"""^^xsd:string ; skos:altLabel """gallbladder cancer, recurrent"""@eng ; rdfs:subClassOf ; """gallbladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1190"""^^xsd:string ; """2004-12-14"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278809"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """decitabine/valproic acid"""@eng ; skos:notation """CDR0000353333"""^^xsd:string ; skos:altLabel """DAC/VA"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328165"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/CD40-ligand/interleukin-2 gene"""@eng ; skos:notation """CDR0000353336"""^^xsd:string ; skos:altLabel """ATCV/CD40-L/IL-2 gene"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328168"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/mitoxantrone"""@eng ; skos:notation """CDR0000353335"""^^xsd:string ; skos:altLabel """DHAD/PS-341"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328167"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/oxaliplatin/ZD6126"""@eng ; skos:notation """CDR0000353334"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/ZD 6126"""@eng ; ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328166"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/DN-101"""@eng ; skos:notation """CDR0000353339"""^^xsd:string ; skos:altLabel """DN101/TXT"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328170"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DN-101"""@eng ; skos:notation """CDR0000353338"""^^xsd:string ; skos:altLabel """DN101"""@eng ; ; """2004-01-23"""^^xsd:string ; """2004-01-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328169"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/estramustine/flutamide/ketoconazole/vinblastine"""@eng ; skos:notation """CDR0000363905"""^^xsd:string ; skos:altLabel """DOX/EM/FLUT/KCZ/VBL"""@eng ; ; ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-03-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541215"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/doxorubicin/estramustine/ketoconazole/vinblastine"""@eng ; skos:notation """CDR0000363904"""^^xsd:string ; skos:altLabel """CDX/DOX/EM/KCZ/VBL"""@eng ; ; ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-03-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541214"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soft tissue sarcoma, stage IA, adult"""@eng ; skos:notation """CDR0000043277"""^^xsd:string ; skos:altLabel """adult soft tissue sarcoma, stage IA"""@eng , """sarcoma, adult soft tissue, stage IA"""@eng ; """2004-06-10"""^^xsd:string ; """7791"""^^xsd:string ; umls:cui """C0796433"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult choroid plexus tumor"""@eng ; skos:notation """CDR0000043274"""^^xsd:string ; skos:altLabel """choroid plexus papilloma"""@eng , """choroid plexus tumor, adult"""@eng , """choroid plexus carcinoma"""@eng , """tumor, adult choroid plexus"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7788"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0431109"""^^xsd:string ; umls:cui """C0796430"""^^xsd:string ; umls:cui """C0205770"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """depression and suicide"""@eng ; skos:notation """CDR0000043272"""^^xsd:string ; skos:altLabel """cancer patients and suicide and depression"""@eng , """suicide"""@eng , """suicide and depression"""@eng , """cancer patients and depression and suicide"""@eng , """depression"""@eng ; rdfs:subClassOf ; """7786"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0812393"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antineoplaston A10/methotrexate"""@eng ; skos:notation """CDR0000043273"""^^xsd:string ; skos:altLabel """A10/MTX"""@eng ; ; ; """7787"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796429"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood visual pathway and hypothalamic glioma"""@eng ; skos:notation """CDR0000043270"""^^xsd:string ; skos:altLabel """childhood CNS tumor, optic nerve glioma"""@eng , """brain tumor, pediatric optic nerve glioma"""@eng , """brain tumor, pediatric optic tract glioma"""@eng , """central nervous system tumor, optic nerve glioma, childhood"""@eng , """glioma, pediatric optic tract"""@eng , """pediatric CNS tumor, optic tract glioma"""@eng , """brain tumor, childhood optic tract glioma"""@eng , """pediatric visual pathway glioma"""@eng , """glioma, pediatric optic nerve"""@eng , """CNS tumor, childhood optic nerve glioma"""@eng , """optic nerve glioma, pediatric"""@eng , """pediatric brain tumor, optic tract glioma"""@eng , """brain tumor, optic nerve glioma, childhood"""@eng , """central nervous system tumor, optic tract glioma, childhood"""@eng , """pediatric brain tumor, optic nerve glioma"""@eng , """visual pathway glioma, childhood"""@eng , """CNS tumor, childhood optic tract glioma"""@eng , """glioma, childhood optic tract"""@eng , """optic nerve glioma, childhood"""@eng , """childhood CNS tumor, optic tract glioma"""@eng , """childhood brain tumor, optic tract glioma"""@eng , """childhood visual pathway and hypothalamic glioma, untreated"""@eng , """pediatric optic nerve glioma"""@eng , """CNS tumor, pediatric optic tract glioma"""@eng , """childhood optic nerve glioma"""@eng , """brain tumor, optic tract glioma, childhood"""@eng , """optic tract glioma, pediatric"""@eng , """glioma, pediatric visual pathway"""@eng , """brain tumor, childhood optic nerve glioma"""@eng , """pediatric optic tract glioma"""@eng , """pediatric CNS tumor, optic nerve glioma"""@eng , """childhood optic tract glioma"""@eng , """glioma, childhood optic nerve"""@eng , """childhood brain tumor, optic nerve glioma"""@eng , """CNS tumor, pediatric optic nerve glioma"""@eng , """optic tract glioma, childhood"""@eng , """visual pathway glioma, pediatric"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood visual pathway and hypothalamic glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7783"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796427"""^^xsd:string ; umls:cui """C0278653"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood visual pathway and hypothalamic glioma"""@eng ; skos:notation """CDR0000043271"""^^xsd:string ; skos:altLabel """childhood CNS tumor, optic nerve glioma"""@eng , """brain tumor, pediatric optic nerve glioma"""@eng , """brain tumor, pediatric optic tract glioma"""@eng , """central nervous system tumor, optic nerve glioma, childhood"""@eng , """glioma, pediatric optic tract"""@eng , """pediatric CNS tumor, optic tract glioma"""@eng , """brain tumor, childhood optic tract glioma"""@eng , """pediatric visual pathway glioma"""@eng , """glioma, childhood optic tract"""@eng , """glioma, pediatric optic nerve"""@eng , """CNS tumor, childhood optic nerve glioma"""@eng , """optic nerve glioma, pediatric"""@eng , """pediatric brain tumor, optic tract glioma"""@eng , """brain tumor, optic nerve glioma, childhood"""@eng , """central nervous system tumor, optic tract glioma, childhood"""@eng , """glioma pediatric visual pathway"""@eng , """pediatric brain tumor, optic nerve glioma"""@eng , """visual pathway glioma, childhood"""@eng , """CNS tumor, childhood optic tract gloma"""@eng , """glioma, childhood visual pathway"""@eng , """optic nerve glioma, childhood"""@eng , """childhood CNS tumor, optic tract glioma"""@eng , """childhood brain tumor, optic tract glioma"""@eng , """pediatric optic nerve glioma"""@eng , """CNS tumor, pediatric optic tract glioma"""@eng , """childhood optic nerve glioma"""@eng , """brain tumor, optic tract glioma, childhood"""@eng , """optic tract glioma, pediatric"""@eng , """brain tumor, childhood optic nerve glioma"""@eng , """pediatric optic tract glioma"""@eng , """pediatric CNS tumor, optic nerve glioma"""@eng , """childhood optic tract glioma"""@eng , """glioma, childhood optic nerve"""@eng , """childhood brain tumor, optic nerve glioma"""@eng , """CNS tumor, pediatric optic nerve glioma"""@eng , """optic tract glioma, childhood"""@eng , """visual pathway glioma, pediatric"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood visual pathway and hypothalamic glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7784"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278653"""^^xsd:string ; umls:cui """C0796428"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IA cervical cancer"""@eng ; skos:notation """CDR0000038750"""^^xsd:string ; skos:altLabel """cervical cancer, stage IA"""@eng , """stage IA cancer of the cervix"""@eng , """stage IA carcinoma of the cervix"""@eng , """cervix cancer, IA"""@eng , """uterine cervical cancer, stage IA"""@eng , """uterine cervix cancer, stage IA"""@eng , """stage IA cervix cancer"""@eng , """cancer of the cervix, stage IA"""@eng , """stage IA uterine cervix cancer"""@eng , """carcinoma of the cervix, stage IA"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """119"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278587"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soft tissue sarcoma, adult, stage IB"""@eng ; skos:notation """CDR0000043278"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, stage IB"""@eng , """adult soft tissue sarcoma, stage IB"""@eng ; """2004-06-10"""^^xsd:string ; """7792"""^^xsd:string ; umls:cui """C0796434"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """THERATOPE STn-KLH vaccine"""@eng ; skos:notation """CDR0000043279"""^^xsd:string ; skos:altLabel """THERATOPE"""@eng ; ; """7793"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0906872"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edelfosine"""@eng ; skos:notation """CDR0000041814"""^^xsd:string ; skos:altLabel """edelfosin"""@eng , """edelfosinum"""@eng , """ET-18-OCH3"""@eng ; """4999"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-22"""^^xsd:string ; umls:cui """C0044549"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000041815"""^^xsd:string ; skos:altLabel """Hodgkin's disease, stage II, adult"""@eng , """lymphoma, stage II adult Hodgkin's"""@eng , """HD, stage II, adult"""@eng , """adult HD, stage II"""@eng , """adult Hodgkin's disease, stage II"""@eng , """stage II adult Hodgkin's disease"""@eng , """HD, adult, stage II"""@eng , """stage II adult HD"""@eng , """Hodgkin's lymphoma, stage II, adult"""@eng ; rdfs:subClassOf ; """2003-01-10"""^^xsd:string ; """adult Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278471"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized osteosarcoma"""@eng ; skos:notation """CDR0000041816"""^^xsd:string ; skos:altLabel """osteosarcoma, localized"""@eng , """osteogenic sarcoma, localized"""@eng , """sarcoma, localized osteogenic"""@eng , """localized osteogenic sarcoma"""@eng ; rdfs:subClassOf ; """osteosarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """50"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278511"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium citrate"""@eng ; skos:notation """CDR0000041817"""^^xsd:string ; skos:altLabel """Citracal"""@eng , """Tricalcium Citrate"""@eng , """Acicontral"""@eng , """CALCIT"""@eng , """2-Hydroxy-1,2,3-propanetricarboxylic Acid, Calcium Salt (2:3)"""@eng ; skos:definition """The citrate salt of calcium. An element necessary for normal nerve, muscle, and cardiac function, calcium as the citrate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41817&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41817&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1355\" NCI Thesaurus)"""@eng ; ; ; """5000"""^^xsd:string ; """813-94-5 (tribasic)"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C1355"""^^xsd:string ; """5785-44-4 (tetrahydrate)"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0719349"""^^xsd:string ; umls:cui """C1707243"""^^xsd:string ; umls:cui """C0108101"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """strontium chloride Sr 89"""@eng ; skos:notation """CDR0000041810"""^^xsd:string ; skos:altLabel """Metastron"""@eng , """Sr89"""@eng ; skos:definition """The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41810&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41810&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1238\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """4995"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """38270-90-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1238"""^^xsd:string ; umls:cui """C0919292"""^^xsd:string ; umls:cui """C0243930"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/vincristine"""@eng ; skos:notation """CDR0000041811"""^^xsd:string ; skos:altLabel """ARA-C/DM/VCR/VP-16"""@eng ; ; ; ; ; """4996"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281386"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/daunorubicin/thioguanine"""@eng ; skos:notation """CDR0000041812"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DNR/TG"""@eng ; ; ; ; ; """4997"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281387"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041813"""^^xsd:string ; skos:altLabel """IFN-A/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """4998"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338168"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/floxuridine/mitomycin"""@eng ; skos:notation """CDR0000041818"""^^xsd:string ; skos:altLabel """DM/FUDR/MITO"""@eng ; ; ; ; """5002"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281389"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/edatrexate/ifosfamide"""@eng ; skos:notation """CDR0000041819"""^^xsd:string ; skos:altLabel """CDDP/EDAM/IFF"""@eng ; ; ; ; """5003"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281390"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/tamoxifen"""@eng ; skos:notation """CDR0000433277"""^^xsd:string ; skos:altLabel """PS-341/TMX"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """2005-05-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831618"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Bowman-Birk inhibitor concentrate"""@eng ; skos:notation """CDR0000433272"""^^xsd:string ; skos:altLabel """BBIC"""@eng , """Bowman Birk inhibitor concentrate"""@eng ; skos:definition """An extract of soybeans enriched in Bowman-Birk inhibitor (BBI), a soybean-derived, 71-amino acid, polypeptide and serine protease inhibitor with potential chemopreventive activity. Bowman-Birk inhibitor contains distinct inhibitory sites for trypsin and chymotrypsin. Although the exact mechanism by which BBI suppresses carcinogenesis is unknown, its antiproliferative activity appears to be linked to the chymotrypsin inhibitory region. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=433272&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=433272&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48381\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """C48381"""^^xsd:string ; umls:cui """C1706991"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG 7909/gp100 antigen/MAGE-3/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000371821"""^^xsd:string ; skos:altLabel """CpG-7909/gp100/ISA-51/MAGE3/TYRP"""@eng ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541261"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LY293111"""@eng ; skos:notation """CDR0000038111"""^^xsd:string ; skos:altLabel """LY-293111"""@eng , """LY 293111"""@eng ; ; ; """2003-12-22"""^^xsd:string ; """10664"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0298619"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """donepezil/vitamin E"""@eng ; skos:notation """CDR0000038110"""^^xsd:string ; skos:altLabel """DONEP/VIT-E"""@eng ; ; ; """10663"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935698"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methylprednisolone/prednisone/vincristine"""@eng ; skos:notation """CDR0000039035"""^^xsd:string ; skos:altLabel """CTX/DOX/MePRDL/PRED/VCR"""@eng ; ; ; ; ; ; """1607"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279051"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000256418"""^^xsd:string ; skos:altLabel """CAPE/CF/5-FU/L-OHP"""@eng ; ; ; ; ; """2002-07-16"""^^xsd:string ; """11391"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327741"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000256419"""^^xsd:string ; skos:altLabel """MOAB HER2/OSI774/TAX"""@eng ; ; ; ; """2002-07-16"""^^xsd:string ; """11390"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327742"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant vaccinia DF3/MUC1 vaccine"""@eng ; skos:notation """CDR0000043350"""^^xsd:string ; skos:altLabel """rV-DF3/MUC1"""@eng ; """7898"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796497"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/erlotinib/etoposide"""@eng ; skos:notation """CDR0000256413"""^^xsd:string ; skos:altLabel """CDDP/OSI774/VP-16"""@eng ; ; ; ; """2002-07-16"""^^xsd:string ; """11387"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327738"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """V930 vaccine"""@eng ; skos:notation """CDR0000473030"""^^xsd:string ; skos:definition """A novel cancer vaccine designed to treat HER-2- and/or CEA-expressing cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473030&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473030&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61069\" NCI Thesaurus)"""@eng ; """2006-07-21"""^^xsd:string ; """C61069"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831771"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """islet cell carcinoma"""@eng ; skos:notation """CDR0000043353"""^^xsd:string ; skos:altLabel """carcinoma of the endocrine pancreas"""@eng , """pancreatic endocrine cancer"""@eng , """endocrine pancreatic cancer"""@eng , """Islet cell carcinoma"""@eng , """cancer of the endocrine pancreas"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """790"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1328479"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/erlotinib"""@eng ; skos:notation """CDR0000256414"""^^xsd:string ; skos:altLabel """OSI774/TXT"""@eng ; ; ; """2002-07-16"""^^xsd:string ; """11388"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327739"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/UCN-01"""@eng ; skos:notation """CDR0000256415"""^^xsd:string ; skos:altLabel """CF/5-FU/UCN 01"""@eng ; ; ; ; """2003-10-23"""^^xsd:string ; """11389"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327740"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone/ketoconazole"""@eng ; skos:notation """CDR0000038119"""^^xsd:string ; skos:altLabel """HC/KCZ"""@eng ; ; ; """10671"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C2928944"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II rectal cancer"""@eng ; skos:notation """CDR0000043352"""^^xsd:string ; skos:altLabel """stage II rectum cancer"""@eng , """rectum cancer, stage II"""@eng , """Dukes B rectal cancer"""@eng , """rectal cancer, Astler-Coller B2"""@eng , """rectal cancer, Dukes B"""@eng , """rectum cancer, Dukes B"""@eng , """rectum cancer, Astler-Coller B2"""@eng , """Astler-Coller B2 rectal cancer"""@eng , """rectal cancer, stage II"""@eng ; rdfs:subClassOf ; """rectal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """79"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278544"""^^xsd:string ; umls:cui """C0813237"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keratinocyte growth factor therapy"""@eng ; skos:notation """CDR0000042911"""^^xsd:string ; skos:altLabel """growth factor therapy, keratinocyte"""@eng , """therapy, keratinocyte growth factor"""@eng ; ; rdfs:subClassOf ; """6744"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0677833"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000039031"""^^xsd:string ; skos:altLabel """PEG-ASP/PRED/VCR"""@eng ; ; ; ; """1601"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279047"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diaziquone/mitoxantrone"""@eng ; skos:notation """CDR0000039030"""^^xsd:string ; skos:altLabel """AZQ/DHAD"""@eng ; ; ; """1600"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279046"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piperine extract (standardized)"""@eng ; skos:notation """CDR0000440023"""^^xsd:string ; skos:altLabel """PIPE"""@eng , """Bioperine"""@eng ; skos:definition """A standardized extract containing the active alkaloid piperine, derived from the fruit of the plant Piper nigrum (black pepper) and/or the plant Piper longum L. (long pepper), with thermogenic properties. Co-ingestion of piperidine enhances the bioavailability of various nutrients, including beta-carotene, curcumin, selenium, pyridoxine and coenzyme Q10. In addition, this agent may exert anti-inflammatory and anti-tumor activities and may enhance the production of serotonin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=440023&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=440023&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48417\" NCI Thesaurus)"""@eng ; ; """2006-09-11"""^^xsd:string ; """C48417"""^^xsd:string ; """2005-07-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1709546"""^^xsd:string ; umls:cui """C1709545"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """curcumin/piperine"""@eng ; skos:notation """CDR0000440026"""^^xsd:string ; skos:altLabel """CU/PIPE"""@eng ; ; ; """2005-07-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-08"""^^xsd:string ; umls:cui """C1831670"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/prednisone/vincristine"""@eng ; skos:notation """CDR0000043357"""^^xsd:string ; skos:altLabel """ASP/DM/PRED/VCR"""@eng ; ; ; ; ; """7903"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796501"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diaziquone/etoposide"""@eng ; skos:notation """CDR0000039032"""^^xsd:string ; skos:altLabel """AZQ/VP-16"""@eng ; ; ; """1602"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279048"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/thioguanine"""@eng ; skos:notation """CDR0000037925"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DNR/TG"""@eng ; ; ; ; ; ; """10339"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879474"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/rituximab"""@eng ; skos:notation """CDR0000037924"""^^xsd:string ; skos:altLabel """CBDCA/IFF/MOAB IDEC-C2B8/VP-16"""@eng ; ; ; ; ; """10338"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879473"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000037927"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CF/CTX/DM/DNR/MP/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; ; ; """10342"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879475"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II vulvar cancer"""@eng ; skos:notation """CDR0000037926"""^^xsd:string ; skos:altLabel """stage II carcinoma of the vulva"""@eng , """stage II cancer of the vulva"""@eng , """carcinoma of the vulva, stage II"""@eng , """vulva cancer, stage II"""@eng , """cancer of the vulva, stage II"""@eng , """vulvar cancer, stage II"""@eng , """stage II vulva cancer"""@eng ; rdfs:subClassOf ; """vulvar cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1034"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854961"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 21"""@eng ; skos:notation """CDR0000037921"""^^xsd:string ; rdfs:subClassOf ; """10335"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008664"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """genetic counseling"""@eng ; skos:notation """CDR0000037920"""^^xsd:string ; skos:altLabel """cancer genetics risk assessment"""@eng , """genetics counseling"""@eng , """counseling, cancer genetics"""@eng , """risk assessment, cancer genetics"""@eng ; """2002-10-15"""^^xsd:string ; """10334"""^^xsd:string ; umls:cui """C0886412"""^^xsd:string ; umls:cui """C0017382"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/topotecan"""@eng ; skos:notation """CDR0000037923"""^^xsd:string ; skos:altLabel """CBDCA/TOPO/VP-16"""@eng ; ; ; ; """10337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 vaginal cancer"""@eng ; skos:notation """CDR0000038039"""^^xsd:string ; skos:altLabel """vaginal cancer, stage 0"""@eng , """stage 0 carcinoma of the vagina"""@eng , """stage 0 cancer of the vagina"""@eng , """carcinoma of the vagina, stage 0"""@eng , """vagina cancer, stage 0"""@eng , """cancer of the vagina, stage 0"""@eng , """stage 0 vagina cancer"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1056"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0686277"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/mycophenolate mofetil/tacrolimus"""@eng ; skos:notation """CDR0000038036"""^^xsd:string ; skos:altLabel """FK506/G-CSF/MMF"""@eng ; ; ; ; """10550"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879582"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-214662/paclitaxel"""@eng ; skos:notation """CDR0000038037"""^^xsd:string ; skos:altLabel """BMS-214662/TAX"""@eng ; ; ; """10551"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879583"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV endometrial cancer"""@eng ; skos:notation """CDR0000038742"""^^xsd:string ; skos:altLabel """metastatic carcinoma of the endometrium"""@eng , """carcinoma of the endometrium, stage IV"""@eng , """metastatic endometrial cancer"""@eng , """uterine cancer, metastatic"""@eng , """endometrial cancer, metastatic"""@eng , """endometrial cancer, stage IV"""@eng , """metastatic uterine cancer"""@eng , """uterine cancer, stage IV"""@eng , """endometrial carcinoma, metastatic"""@eng , """carcinoma of the endometrium, metastatic"""@eng , """metastatic cancer of the endometrium"""@eng , """cancer of the endometrium, stage IV"""@eng , """stage IV carcinoma of the endometrium"""@eng , """cancer of the endometrium, metastatic"""@eng , """endometrial carcinoma, stage IV"""@eng , """stage IV uterine cancer"""@eng , """stage IV cancer of the endometrium"""@eng ; rdfs:subClassOf ; """endometrial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1181"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0678033"""^^xsd:string ; umls:cui """C0813148"""^^xsd:string ; umls:cui """C0278801"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaginal cancer"""@eng ; skos:notation """CDR0000038035"""^^xsd:string ; skos:altLabel """vagina cancer"""@eng , """cancer of the vagina"""@eng , """carcinoma of the vagina"""@eng , """Vaginal cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1055"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0042237"""^^xsd:string ; umls:cui """C0262659"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """staphylococcal enterotoxin B"""@eng ; skos:notation """CDR0000037929"""^^xsd:string ; skos:altLabel """SEB"""@eng ; ; """10344"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0059386"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/interleukin-12"""@eng ; skos:notation """CDR0000037928"""^^xsd:string ; skos:altLabel """IL-2/IL-12"""@eng ; ; ; """10343"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879476"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/mitoxantrone/monoclonal antibody HuG1-M195"""@eng ; skos:notation """CDR0000038030"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/MOAB HuM195/VP-16"""@eng ; ; ; ; ; """10545"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879577"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody Hu3S193"""@eng ; skos:notation """CDR0000038031"""^^xsd:string ; skos:altLabel """MOAB Hu3S193"""@eng , """Hu3S193"""@eng ; skos:definition """A humanized monoclonal antibody directed against the Lewis Y antigen, a tumor-associated epithelial antigen, with potential antineoplastic activity. Following binding, monoclonal antibody Hu3S193 triggers an antibody-dependent cell-mediated cytotoxicity in cells expressing Lewis Y antigen. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38031&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38031&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2547\" NCI Thesaurus)"""@eng ; """10546"""^^xsd:string ; """C2547"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879578"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/interferon alfa/melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000041119"""^^xsd:string ; skos:altLabel """BCNU/CTX/IFN-A/L-PAM/PRED/VCR"""@eng ; ; ; ; ; ; ; """4159"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338128"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/prednisolone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000041118"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PRDL/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4158"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280715"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA vaccine"""@eng ; skos:notation """CDR0000038629"""^^xsd:string ; skos:altLabel """F-PSA"""@eng , """Recombinant Fowlpox-Prostate Specific Antigen Vaccine"""@eng ; skos:definition """A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38629&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38629&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2675\" NCI Thesaurus)"""@eng ; ; ; ; """11258"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C2675"""^^xsd:string ; """694450"""^^xsd:string ; umls:cui """C1134640"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-GM-CSF vaccine"""@eng ; skos:notation """CDR0000038628"""^^xsd:string ; skos:altLabel """rV-GM-CSF"""@eng ; """11257"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134639"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/thioguanine/vincristine"""@eng ; skos:notation """CDR0000041111"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/TG/VCR"""@eng ; ; ; ; ; ; """4151"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280710"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """inulin"""@eng ; skos:notation """CDR0000486745"""^^xsd:string ; skos:definition """A naturally occurring, indigestible and non-absorbable oligosaccharide produced by certain plants with prebiotic and potential anticancer activity. Inulin stimulates the growth of beneficial bacteria in the colon, including Bifidobacteria and Lactobacilli, thereby modulating the composition of microflora. This creates an environment that protects against pathogens, toxins and carcinogens, which can cause inflammation and cancer. In addition, fermentation of inulin leads to an increase in short-chain fatty acids and lactic acid production, thereby reducing colonic pH, which may further control pathogenic bacteria growth and may contribute to inulin's cancer protective properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486745&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486745&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61506\" NCI Thesaurus)"""@eng ; """2006-10-12"""^^xsd:string ; """C61506"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9005-80-5"""^^xsd:string ; """2006-05-23"""^^xsd:string ; umls:cui """C0021936"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """live freeze-dried lactic acid bacteria probiotic"""@eng ; skos:notation """CDR0000486744"""^^xsd:string ; skos:altLabel """VSL#3"""@eng ; skos:definition """A probiotic containing live, cultivated, freeze-dried lactic acid bacteria with gastrointestinal (GI) protective, anti-inflammatory, immunomodulating and potential antitumor properties. Oral administration of probiotic bacteria help maintain adequate colonization of the GI tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier, interfere with the attachment of pathogenic bacteria and other harmful substances and may bind to and degrade carcinogens. This may prevent inflammation and possibly cancer. In addition, these bacteria produce lactic acid, thereby creating an acidic environment that is unfavorable for pathogens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486744&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486744&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61505\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C61505"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """2006-10-12"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831847"""^^xsd:string ; umls:cui """C1831848"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/idarubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039629"""^^xsd:string ; skos:altLabel """ASP/IDA/PRED/VCR"""@eng ; ; ; ; ; """2284"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279416"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast imaging studies"""@eng ; skos:notation """CDR0000038621"""^^xsd:string ; ; rdfs:subClassOf ; """11249"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134632"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin-e therpautic implant"""@eng ; skos:notation """CDR0000042697"""^^xsd:string ; skos:altLabel """MPI 5010"""@eng , """IntraDose"""@eng , """Cisplatin-E Therapeutic Implant"""@eng , """Intradose MPI-5010"""@eng ; ; """C17879"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """6489"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328684"""^^xsd:string ; umls:cui """C0677669"""^^xsd:string ; umls:cui """C1135125"""^^xsd:string ; umls:cui """C1522277"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa/fluorouracil/hydroxyurea/paclitaxel"""@eng ; skos:notation """CDR0000042696"""^^xsd:string ; skos:altLabel """EPO/5-FU/HU/TAX"""@eng ; ; ; ; ; """6486"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393083"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/hydroxyurea/paclitaxel"""@eng ; skos:notation """CDR0000042695"""^^xsd:string ; skos:altLabel """5-FU/HU/TAX"""@eng ; ; ; ; """6485"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393082"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nelfinavir mesylate"""@eng ; skos:notation """CDR0000042694"""^^xsd:string ; skos:altLabel """Viracept"""@eng ; skos:definition """The mesylate salt form of the antiviral agent nelfinavir. Nelfinavir selectively inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. In vivo, this agent exhibits broad tissue distribution compared to related agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42694&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42694&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1624\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """6484"""^^xsd:string ; """722664"""^^xsd:string ; """159989-65-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1624"""^^xsd:string ; umls:cui """C0525004"""^^xsd:string ; umls:cui """C0886530"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """saquinavir mesylate"""@eng ; skos:notation """CDR0000042693"""^^xsd:string ; skos:altLabel """Invirase"""@eng ; skos:definition """The mesylate salt form of saquinavir, a synthetic peptidomimetic substrate with antiviral property. Saquinavir selectively binds to and inhibits human immunodeficiency virus type 1 (HIV-1) protease, an aspartic protease that cleaves viral gag and gag-pol polyprotein (precursors for viral proteases, reverse transcriptase, and integrase). Inhibition of HIV-1 protease prevents functional viral proteins to be cleaved from the viral polyprotein precursor and results in the release of immature, noninfectious virions. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42693&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42693&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1602\" NCI Thesaurus)"""@eng ; """6483"""^^xsd:string ; """722663"""^^xsd:string ; """C1602"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """149845-06-7"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0286737"""^^xsd:string ; umls:cui """C0701215"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethynyluracil"""@eng ; skos:notation """CDR0000042692"""^^xsd:string ; skos:altLabel """GW776C85"""@eng , """ADH300004"""@eng , """eniluracil"""@eng , """5-ethynyluracil"""@eng , """5-Ethynyl-2,4(1H,3H)-pyrimidinedione"""@eng , """GW776"""@eng ; skos:definition """An orally-active fluoropyrimidine analogue. Ethynyluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42692&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42692&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1773\" NCI Thesaurus)"""@eng ; ; ; ; """C1773"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """6478"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393026"""^^xsd:string ; umls:cui """C0650422"""^^xsd:string ; umls:cui """C0098361"""^^xsd:string ; umls:cui """C1831604"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-PSA vaccine"""@eng ; skos:notation """CDR0000042691"""^^xsd:string ; skos:altLabel """rV-PSA vaccine"""@eng , """rV-PSA"""@eng , """VPSA"""@eng , """PROSTVAC"""@eng , """Vaccinia PSA Vaccine"""@eng , """RV-PSA (RECOMB VACCINIA/PSA-CV-1)"""@eng , """Vaccinia Prostate Specific Antigen Vaccine"""@eng , """Prostate Specific Antigen Expressing Vaccinia Virus Vaccine"""@eng , """vaccinia-prostate-specific antigen vaccine"""@eng ; skos:definition """A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with vaccinia-PSA stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42691&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42691&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433\" NCI Thesaurus)"""@eng ; ; ; """6477"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """678892"""^^xsd:string ; """6698"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """697729"""^^xsd:string ; """C2433"""^^xsd:string ; """8202"""^^xsd:string ; """7718"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0393081"""^^xsd:string ; umls:cui """C1519903"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """voriconazole"""@eng ; skos:notation """CDR0000042690"""^^xsd:string ; skos:altLabel """VCZ"""@eng ; skos:definition """A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42690&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42690&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1707\" NCI Thesaurus)"""@eng ; ; """6476"""^^xsd:string ; """C1707"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0393080"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """counseling and communications studies"""@eng ; skos:notation """CDR0000038627"""^^xsd:string ; ; rdfs:subClassOf ; """11255"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134638"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anastrozole/fulvestrant"""@eng ; skos:notation """CDR0000350019"""^^xsd:string ; skos:altLabel """ANAS/ICI 182780"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328120"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IL-2 plasmid DNA/lipid complex"""@eng ; skos:notation """CDR0000042699"""^^xsd:string ; skos:altLabel """Leuvectin"""@eng , """VCL-1102"""@eng , """Plasmid DNA IL-2 Lipid Complex"""@eng , """IL-2 Plasmid DNA/DMRIE/DOPE lipid complex"""@eng , """interleukin-2 DNA/lipid complex"""@eng ; skos:definition """An immunotherapeutic agent consisting of a plasmid DNA encoding human Interleukin-2 (IL-2) complexed with a cationic lipid, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE), in a 5:1 ratio. Due to the lipophilic nature of this cation liposome complex, this gene transfer system may improve the efficiency of introducing the IL-2 gene into the cells, thereby increasing the production of IL-2 and inducing an immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42699&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42699&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2437\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """6491"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2437"""^^xsd:string ; umls:cui """C0677671"""^^xsd:string ; umls:cui """C1527172"""^^xsd:string ; umls:cui """C1527173"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody A1G4 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000042698"""^^xsd:string ; skos:altLabel """A1G4 anti-idiotype monoclonal antibody vaccine"""@eng ; """6490"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677670"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bronchoscopic and lung imaging studies"""@eng ; skos:notation """CDR0000038625"""^^xsd:string ; ; rdfs:subClassOf ; """11253"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134636"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """screening questionnaire"""@eng ; skos:notation """CDR0000038624"""^^xsd:string ; ; rdfs:subClassOf ; """11252"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1134635"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radium-223-based radiopharmaceutical"""@eng ; skos:notation """CDR0000491866"""^^xsd:string ; skos:altLabel """Alpharadin"""@eng ; """2006-06-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831899"""^^xsd:string ; umls:cui """C1831898"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/GM.CD40L cell vaccine/interleukin-2"""@eng ; skos:notation """CDR0000409604"""^^xsd:string ; skos:altLabel """ATCV/GM.CD40L/IL-2"""@eng ; ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541423"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GM.CD40L cell vaccine"""@eng ; skos:notation """CDR0000409603"""^^xsd:string ; skos:altLabel """GM.CD40L"""@eng ; skos:definition """A cell-based vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. Upon administration, this vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=409603&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=409603&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48391\" NCI Thesaurus)"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """C48391"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; umls:cui """C1541422"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drug screening assays, antitumor"""@eng ; skos:notation """CDR0000043013"""^^xsd:string ; skos:altLabel """antitumor drug screening assays"""@eng ; """7286"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0013207"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metyrosine"""@eng ; skos:notation """CDR0000039501"""^^xsd:string ; skos:altLabel """MK-781"""@eng , """L-588357-0"""@eng , """DEMSER"""@eng , """Metirosine"""@eng , """Alpha-methyl-p-tyrosine"""@eng , """methyl-tyrosine"""@eng ; skos:definition """A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39501&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39501&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C998\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """2135"""^^xsd:string ; """672-87-7"""^^xsd:string ; """C998"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0591337"""^^xsd:string ; umls:cui """C0051427"""^^xsd:string ; umls:cui """C0886584"""^^xsd:string ; umls:cui """C1524090"""^^xsd:string ; umls:cui """C1524091"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoguazone"""@eng ; skos:notation """CDR0000039500"""^^xsd:string ; skos:altLabel """MeGAG"""@eng , """Methylglyoxal bis(amidinohydrazone)"""@eng , """methylglyoxal bis(guanylhydrazone)"""@eng , """NSC 32946"""@eng , """Zyrkamine"""@eng , """1,1'-[(methylethanediylidene)dinitrilo)diguanidine"""@eng , """Mitoguazone Dihydrochloride"""@eng , """DRG-0223"""@eng , """methyl GAG"""@eng , """MGBG"""@eng , """methyl-G"""@eng , """methyl-GAG"""@eng , """Methylglyoxal Bisguanylhydrazone"""@eng , """pyruvaldehyde bis(amidinohydrazone)"""@eng , """2,2\"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]"""@eng , """MGGH"""@eng ; skos:definition """A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39500&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39500&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C661\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """2133"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """927"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """32946"""^^xsd:string ; """459-86-9"""^^xsd:string ; """C661"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1711225"""^^xsd:string ; umls:cui """C0771772"""^^xsd:string ; umls:cui """C0878487"""^^xsd:string ; umls:cui """C1513345"""^^xsd:string ; umls:cui """C0026251"""^^xsd:string ; umls:cui """C0025716"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metronidazole"""@eng ; skos:notation """CDR0000039503"""^^xsd:string ; skos:altLabel """Flagyl"""@eng , """Satric"""@eng , """METRO"""@eng , """Metro I.V."""@eng ; skos:definition """A synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39503&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39503&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C651\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """2137"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """C651"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0025872"""^^xsd:string ; umls:cui """C0699684"""^^xsd:string ; umls:cui """C0699678"""^^xsd:string ; umls:cui """C0699675"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metoclopramide hydrochloride"""@eng ; skos:notation """CDR0000039502"""^^xsd:string ; skos:altLabel """Reglan"""@eng , """MCP"""@eng ; ; ; """2136"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """C649"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0025853"""^^xsd:string ; umls:cui """C0034977"""^^xsd:string ; umls:cui """C0887128"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mezlocillin"""@eng ; skos:notation """CDR0000039505"""^^xsd:string ; skos:altLabel """Mezlin"""@eng ; """2139"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0025893"""^^xsd:string ; umls:cui """C0701901"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """misonidazole"""@eng ; skos:notation """CDR0000039504"""^^xsd:string ; skos:altLabel """Ro-07-0582"""@eng , """Ro-7-0582"""@eng , """1-(alpha-methoxymethyl ethanol)-2-Nitroimidazole"""@eng ; skos:definition """A nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39504&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39504&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C657\" NCI Thesaurus)"""@eng ; ; ; ; ; """2138"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """13462"""^^xsd:string ; """13551-87-6"""^^xsd:string ; """261037"""^^xsd:string ; """C657"""^^xsd:string ; """16288"""^^xsd:string ; umls:cui """C0026218"""^^xsd:string ; umls:cui """C0878346"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tretinoin"""@eng ; skos:notation """CDR0000041258"""^^xsd:string ; skos:altLabel """ATRA"""@eng , """Airol"""@eng , """Vesanoid"""@eng , """All-trans Vitamin A Acid"""@eng , """Retin-A MICRO"""@eng , """Epi-Aberel"""@eng , """Trans Retinoic Acid"""@eng , """Aknoten"""@eng , """Aberel"""@eng , """Retinoic Acid"""@eng , """Retin-A"""@eng , """Avita"""@eng , """Tretinoinum"""@eng , """Vitamin A Acid"""@eng , """(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid"""@eng , """Retisol-A"""@eng , """Dermairol"""@eng , """Stieva-A Forte"""@eng , """TRA"""@eng , """Stieva-A"""@eng , """All-trans Retinoic Acid"""@eng , """Eudyna"""@eng , """Trans Vitamin A Acid"""@eng , """beta-Retinoic Acid"""@eng , """Renova"""@eng , """Cordes Vas"""@eng , """Vitinoin"""@eng , """Ro 5488"""@eng ; skos:definition """A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41258&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41258&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C900\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4331"""^^xsd:string ; """302-79-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """34987"""^^xsd:string ; """122758"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C900"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1520049"""^^xsd:string ; umls:cui """C0595126"""^^xsd:string ; umls:cui """C1520048"""^^xsd:string ; umls:cui """C1520055"""^^xsd:string ; umls:cui """C0040845"""^^xsd:string ; umls:cui """C0593762"""^^xsd:string ; umls:cui """C1520050"""^^xsd:string ; umls:cui """C1520051"""^^xsd:string ; umls:cui """C1520056"""^^xsd:string ; umls:cui """C1522491"""^^xsd:string ; umls:cui """C1520052"""^^xsd:string ; umls:cui """C0718748"""^^xsd:string ; umls:cui """C1171295"""^^xsd:string ; umls:cui """C0723021"""^^xsd:string ; umls:cui """C1520054"""^^xsd:string ; umls:cui """C1520057"""^^xsd:string ; umls:cui """C1520053"""^^xsd:string ; umls:cui """C1515230"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitotane"""@eng ; skos:notation """CDR0000039506"""^^xsd:string ; skos:altLabel """Lysodren"""@eng , """Chlodithane"""@eng , """Mytotan"""@eng , """Chloditan"""@eng , """WR-13045"""@eng , """DDD"""@eng , """Khloditan"""@eng , """2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane"""@eng , """2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane"""@eng , """o,p' - DDD"""@eng , """1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene"""@eng , """CB-313"""@eng , """2,4'-Dichlorodiphenyldichloroethane"""@eng , """Ortho,para-DDD"""@eng , """Lisodren"""@eng , """o,p'-DDD"""@eng , """1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane"""@eng ; skos:definition """A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties. Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39506&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39506&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C664\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """2140"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """38721"""^^xsd:string ; """C664"""^^xsd:string ; """53-19-0"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522708"""^^xsd:string ; umls:cui """C1522709"""^^xsd:string ; umls:cui """C0702004"""^^xsd:string ; umls:cui """C1513353"""^^xsd:string ; umls:cui """C0702007"""^^xsd:string ; umls:cui """C0026256"""^^xsd:string ; umls:cui """C0702006"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """naloxone hydrochloride"""@eng ; skos:notation """CDR0000039509"""^^xsd:string ; skos:altLabel """NLX"""@eng , """Narcan"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2143"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """C678"""^^xsd:string ; umls:cui """C0027358"""^^xsd:string ; umls:cui """C0700549"""^^xsd:string ; umls:cui """C0684237"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/fluorouracil/PALA"""@eng ; skos:notation """CDR0000041257"""^^xsd:string ; skos:altLabel """DP/5-FU/PALA"""@eng ; ; ; ; """4330"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280848"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mafosfamide"""@eng ; skos:notation """CDR0000041254"""^^xsd:string ; skos:definition """A synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41254&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41254&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1150\" NCI Thesaurus)"""@eng ; ; """4327"""^^xsd:string ; """88859-04-5"""^^xsd:string ; """C1150"""^^xsd:string ; """345842"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """34353"""^^xsd:string ; umls:cui """C0065506"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/cisplatin"""@eng ; skos:notation """CDR0000041255"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/WR-2721"""@eng ; ; ; ; """4328"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280846"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liarozole"""@eng ; skos:notation """CDR0000041252"""^^xsd:string ; skos:altLabel """R75251"""@eng , """R 75251"""@eng , """R-75251"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """4325"""^^xsd:string ; """C1433"""^^xsd:string ; umls:cui """C0165479"""^^xsd:string ; umls:cui """C0139797"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quinine"""@eng ; skos:notation """CDR0000041253"""^^xsd:string ; skos:altLabel """QUIN"""@eng ; skos:definition """A quinidine alkaloid isolated from the bark of the cinchona tree. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41253&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41253&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C794\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """4326"""^^xsd:string ; """C794"""^^xsd:string ; """130-95-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """192949"""^^xsd:string ; umls:cui """C0034417"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/fluorouracil/leucovorin calcium/levamisole"""@eng ; skos:notation """CDR0000041250"""^^xsd:string ; skos:altLabel """CF/5-FU/FUDR/LEV"""@eng ; ; ; ; ; """4323"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280844"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cimetidine/cyclophosphamide/indomethacin/interleukin-2"""@eng ; skos:notation """CDR0000041251"""^^xsd:string ; skos:altLabel """cimetidine/CTX/IL-2/Indomethacin"""@eng ; ; ; ; ; """4324"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280845"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ispinesib"""@eng ; skos:notation """CDR0000391236"""^^xsd:string ; skos:altLabel """SB-715992"""@eng , """CK0238273"""@eng , """SB 715992"""@eng ; skos:definition """A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=391236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=391236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38131\" NCI Thesaurus)"""@eng ; ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """2004-09-25"""^^xsd:string ; """C38131"""^^xsd:string ; umls:cui """C1527260"""^^xsd:string ; umls:cui """C1519127"""^^xsd:string ; umls:cui """C1701752"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IDN-6556"""@eng ; skos:notation """CDR0000391231"""^^xsd:string ; """2004-09-25"""^^xsd:string ; """2004-09-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1452745"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic D1 interacinar cell adenoma"""@eng ; skos:notation """CDR0000040028"""^^xsd:string ; skos:altLabel """adenoma, pancreatic D1 interacinar cell"""@eng , """adenoma, pancreatic polypeptide producing"""@eng , """PP secreting adenoma"""@eng , """pancreatic polypeptide producing adenoma"""@eng , """D1 interacinar cell, pancreatic, adenoma"""@eng , """PP producing adenoma"""@eng ; rdfs:subClassOf ; """2753"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279728"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic D1 interacinar cell carcinoma"""@eng ; skos:notation """CDR0000040029"""^^xsd:string ; skos:altLabel """PP producing carcinoma"""@eng , """pancreatic polypeptide producing carcinoma"""@eng , """D1 interacinar cell, pancreatic, carcinoma"""@eng , """carcinoma, pancreatic D1 interacinar cell"""@eng , """carcinoma, pancreatic polypeptide producing"""@eng , """PP secreting carcinoma"""@eng ; rdfs:subClassOf ; """2754"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279729"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic delta cell adenoma"""@eng ; skos:notation """CDR0000040026"""^^xsd:string ; skos:altLabel """somatostatin producing adenoma"""@eng , """adenoma, somatostatin producing"""@eng , """adenoma, delta cell, pancreatic"""@eng , """adenoma, pancreatic delta cell"""@eng , """somatostatin secreting adenoma"""@eng ; rdfs:subClassOf ; """2751"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279726"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic delta cell carcinoma"""@eng ; skos:notation """CDR0000040027"""^^xsd:string ; skos:altLabel """somatostatin producing carcinoma"""@eng , """carcinoma, pancreatic delta cell"""@eng , """carcinoma, somatostatin producing"""@eng , """carcinoma, delta cell, pancreatic"""@eng , """somatostatin secreting carcinoma"""@eng ; rdfs:subClassOf ; """2752"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279727"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide"""@eng ; skos:notation """CDR0000040024"""^^xsd:string ; skos:altLabel """Ifomide"""@eng , """isophosphamide"""@eng , """Ifomida"""@eng , """IFO-Cell"""@eng , """Ifex"""@eng , """IFX"""@eng , """Z-4942"""@eng , """Cyfos"""@eng , """IFF"""@eng , """Iso-Endoxan"""@eng , """Holoxan"""@eng , """Ifosfamidum"""@eng , """MJF-9325"""@eng , """IFO"""@eng , """Mitoxana"""@eng , """Tronoxal"""@eng , """3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide"""@eng , """Naxamide"""@eng , """Asta Z-4942"""@eng , """Iphosphamid"""@eng , """2-oxo-N,3-bis-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin- 2-amine"""@eng , """Isoendoxan"""@eng , """iphosphamide"""@eng , """Ifolem"""@eng , """N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide"""@eng , """IPP"""@eng , """Holoxane"""@eng , """Ifoxan"""@eng ; skos:definition """A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40024&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40024&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C564\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """275"""^^xsd:string ; """7887"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """109724"""^^xsd:string ; """C564"""^^xsd:string ; """3778-73-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522402"""^^xsd:string ; umls:cui """C1512617"""^^xsd:string ; umls:cui """C1512616"""^^xsd:string ; umls:cui """C0733929"""^^xsd:string ; umls:cui """C1512618"""^^xsd:string ; umls:cui """C1512622"""^^xsd:string ; umls:cui """C0733930"""^^xsd:string ; umls:cui """C1512620"""^^xsd:string ; umls:cui """C0721031"""^^xsd:string ; umls:cui """C1522401"""^^xsd:string ; umls:cui """C1512619"""^^xsd:string ; umls:cui """C1704313"""^^xsd:string ; umls:cui """C1512621"""^^xsd:string ; umls:cui """C0591812"""^^xsd:string ; umls:cui """C0020823"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic alpha-D islet cell carcinoma"""@eng ; skos:notation """CDR0000040025"""^^xsd:string ; skos:altLabel """vasoactive intestinal peptide producing carcinoma"""@eng , """vasoactive intestinal peptide secreting carcinoma"""@eng , """islet cell, alpha-D, pancreatic carcinoma"""@eng , """VIP secreting carcinoma"""@eng , """VIP producing carcinoma"""@eng , """carcinoma, pancreatic alpha-D islet cell"""@eng ; rdfs:subClassOf ; """2750"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279725"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic D islet cell carcinoma"""@eng ; skos:notation """CDR0000040022"""^^xsd:string ; skos:altLabel """carcinoma, pancreatic D islet cell"""@eng , """islet cell, D, pancreatic carcinoma"""@eng , """D islet cell carcinoma, pancreatic"""@eng , """gastrin secreting carcinoma"""@eng , """gastrin producing carcinoma"""@eng ; rdfs:subClassOf ; """2748"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279723"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic alpha-D islet cell adenoma"""@eng ; skos:notation """CDR0000040023"""^^xsd:string ; skos:altLabel """vasoactive intestinal peptide producing adenoma"""@eng , """adenoma, pancreatic alpha-D islet cell"""@eng , """islet cell, alpha-D, pancreatic adenoma"""@eng , """VIP producing adenoma"""@eng , """vasoactive intestinal peptide secreting adenoma"""@eng , """VIP secreting adenoma"""@eng , """VIPoma"""@eng ; rdfs:subClassOf ; """2749"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0011993"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic beta islet cell carcinoma"""@eng ; skos:notation """CDR0000040020"""^^xsd:string ; skos:altLabel """islet cell, beta, pancreatic carcinoma"""@eng , """insulin secreting carcinoma"""@eng , """carcinoma, pancreatic beta islet cell"""@eng , """insulin producing carcinoma"""@eng , """beta islet cell carcinoma, pancreatic"""@eng ; rdfs:subClassOf ; """2746"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334281"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic D islet cell adenoma"""@eng ; skos:notation """CDR0000040021"""^^xsd:string ; skos:altLabel """adenoma, pancreatic D islet cell"""@eng , """gastrin secreting adenoma"""@eng , """gastrin producing adenoma"""@eng , """islet cell, D, pancreatic adenoma"""@eng , """D islet cell adenoma, pancreatic"""@eng ; rdfs:subClassOf ; """2747"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279722"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gelatin sponge (absorbable)"""@eng ; skos:notation """CDR0000355797"""^^xsd:string ; skos:altLabel """Gelfoam"""@eng , """Gelatin Sponge, Absorbable"""@eng , """Absorbable Gelatin Sponge"""@eng , """gelatin sponge, absorbable"""@eng , """Gelfoam![REGISTERED SIGN]!"""@eng , """Gelfoam®"""@eng ; skos:definition """A sterile hemostatic agent composed of purified porcine-derived gelatin. In regional chemotherapy, absorbable gelatin sponge may be used to embolize arteries in the region of a tumor in order to block or retard blood flow; this blockage results in a locally increased concentration of chemotherapeutic agents delivered to the tumor when chemotherapeutic agents are infused into the embolized arterial circulation upstream of the blockage. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355797&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355797&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38705\" NCI Thesaurus)"""@eng ; """2004-02-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C38705"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0017238"""^^xsd:string ; umls:cui """C0918040"""^^xsd:string ; umls:tui """T074"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethiodized oil"""@eng ; skos:notation """CDR0000355795"""^^xsd:string ; skos:altLabel """Iodized Oil"""@eng , """Ethiodol"""@eng , """Lipiodol"""@eng ; skos:definition """A synthetic iodine addition product of the ethyl ester of the fatty acids of poppyseed oil. Ethiodized oil contains 37% organically bound iodine and is used as a diagnostic radiopaque medium or, labeled with I-131, as an antineoplastic agent. Selectively retained in tumor vessels for long periods, ethiodized oil is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodol can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355795&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355795&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C487\" NCI Thesaurus)"""@eng ; """2006-08-02"""^^xsd:string ; """C487"""^^xsd:string ; """8008-53-5"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0720305"""^^xsd:string ; umls:cui """C0015018"""^^xsd:string ; umls:cui """C0021972"""^^xsd:string ; umls:cui """C0947677"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/idarubicin"""@eng ; skos:notation """CDR0000043239"""^^xsd:string ; skos:altLabel """IDA/VP-16"""@eng ; ; ; """7705"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796394"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABT-510/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000354220"""^^xsd:string ; skos:altLabel """ABT 510/CBDCA/TAX"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328174"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E7070/irinotecan"""@eng ; skos:notation """CDR0000354221"""^^xsd:string ; skos:altLabel """CPT-11/E-7070"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328175"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AP23573"""@eng ; skos:notation """CDR0000354223"""^^xsd:string ; skos:definition """A small molecule and non-prodrug analog of rapamycin with potent antitumor activity. AP23573 binds to and inhibits the mammalian target of rapamycin (mTOR), a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream of the phosphatidylinositol (PI3K)/Akt (protein kinase B) signaling pathway. Inhibition of mTOR by AP23573 may lead to cell cycle arrest, and consequently blocks tumor cell growth and proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=354223&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=354223&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49061\" NCI Thesaurus)"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C49061"""^^xsd:string ; umls:cui """C1873068"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buserelin"""@eng ; skos:notation """CDR0000039170"""^^xsd:string ; skos:altLabel """Suprefact Depot"""@eng , """Buserelin Acetate"""@eng , """BSRL"""@eng , """Receptal"""@eng , """Suprefact"""@eng , """Busereline"""@eng , """Suprefact Flakon"""@eng , """6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)"""@eng , """D-Ser (Bu(t))(6) Pro(9) NEt LHRH Acetate"""@eng , """ICI 123215"""@eng , """Suprecur"""@eng , """HOE 766"""@eng , """S74-6766"""@eng , """Bigonist"""@eng , """Etilamide"""@eng , """Profact"""@eng , """Profact Depot"""@eng ; skos:definition """A synthetic analog of gonadotropin-releasing hormone (GnRH). Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39170&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39170&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C320\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1790"""^^xsd:string ; """C320"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """57982-77-1"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C3179386"""^^xsd:string ; umls:cui """C1521928"""^^xsd:string ; umls:cui """C0006456"""^^xsd:string ; umls:cui """C0085935"""^^xsd:string ; umls:cui """C3179387"""^^xsd:string ; umls:cui """C1511344"""^^xsd:string ; umls:cui """C3179388"""^^xsd:string ; umls:cui """C0701272"""^^xsd:string ; umls:cui """C1511345"""^^xsd:string ; umls:cui """C0701274"""^^xsd:string ; umls:cui """C1511343"""^^xsd:string ; umls:cui """C1707062"""^^xsd:string ; umls:cui """C0600174"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/vinorelbine"""@eng ; skos:notation """CDR0000041648"""^^xsd:string ; skos:altLabel """5-FU/VNB"""@eng ; ; ; """4809"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281257"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium gluconate"""@eng ; skos:notation """CDR0000039172"""^^xsd:string ; skos:altLabel """Calcium D-gluconate"""@eng , """CALGLUC"""@eng , """Calglucon"""@eng ; skos:definition """The gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39172&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39172&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C336\" NCI Thesaurus)"""@eng ; ; ; """1792"""^^xsd:string ; """2006-07-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """299-28-5"""^^xsd:string ; """C336"""^^xsd:string ; umls:cui """C0700874"""^^xsd:string ; umls:cui """C0006699"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """camptothecin"""@eng ; skos:notation """CDR0000039173"""^^xsd:string ; skos:altLabel """camptothecine"""@eng ; """2003-12-01"""^^xsd:string ; """1793"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0006812"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbenicillin"""@eng ; skos:notation """CDR0000039174"""^^xsd:string ; skos:altLabel """Pyopen"""@eng , """Geopen"""@eng , """Geocillin"""@eng ; """1794"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0034217"""^^xsd:string ; umls:cui """C0006976"""^^xsd:string ; umls:cui """C0733862"""^^xsd:string ; umls:cui """C0878118"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carubicin"""@eng ; skos:notation """CDR0000039175"""^^xsd:string ; skos:altLabel """(8S-cis)-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-5,12-naphthacenedione"""@eng , """5,12-naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetra-hydroxy-(8S-cis)-(8CI 9CI)"""@eng , """(2S,3S)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,10,12-tetrahydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"""@eng , """Karminomitsin"""@eng , """4-O-demethyldaunorubicin"""@eng , """carminomycin"""@eng , """CMM"""@eng , """Karminomycin"""@eng , """5,12-naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetra-hydroxy-,(8S-cis)-(8CI)-(9CI)"""@eng , """Carminomycin I"""@eng , """Demethyldaunomycin"""@eng ; skos:definition """An anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. Carubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39175&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39175&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C352\" NCI Thesaurus)"""@eng ; """1795"""^^xsd:string ; """180024"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """39472-31-6"""^^xsd:string ; """C352"""^^xsd:string ; umls:cui """C0007308"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin"""@eng ; skos:notation """CDR0000039176"""^^xsd:string ; skos:altLabel """Platinwas"""@eng , """CBDCA"""@eng , """cis-diammine(cyclobutanedicarboxylato)platinum II"""@eng , """Carboplatin Hexal"""@eng , """Paraplatin"""@eng , """Paraplatine"""@eng , """Carbosin"""@eng , """Carboplatino"""@eng , """Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum"""@eng , """cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)"""@eng , """Novoplatinum"""@eng , """Carboplat"""@eng , """Ercar"""@eng , """Nealorin"""@eng , """1,1-cyclobutanedicarboxylic acid platinum complex"""@eng , """Ribocarbo"""@eng , """Displata"""@eng , """Blastocarb"""@eng , """Carbotec"""@eng , """(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum"""@eng , """Paraplatin AQ"""@eng , """Paraplat"""@eng , """platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)"""@eng , """Carbosol"""@eng ; skos:definition """A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39176&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39176&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1282\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1796"""^^xsd:string ; """241240"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """41575-94-4"""^^xsd:string ; """19314"""^^xsd:string ; """C1282"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591953"""^^xsd:string ; umls:cui """C1516261"""^^xsd:string ; umls:cui """C1516255"""^^xsd:string ; umls:cui """C1516254"""^^xsd:string ; umls:cui """C1516257"""^^xsd:string ; umls:cui """C1516256"""^^xsd:string ; umls:cui """C1524092"""^^xsd:string ; umls:cui """C1516253"""^^xsd:string ; umls:cui """C1516252"""^^xsd:string ; umls:cui """C1516260"""^^xsd:string ; umls:cui """C0079083"""^^xsd:string ; umls:cui """C1516259"""^^xsd:string ; umls:cui """C1516258"""^^xsd:string ; umls:cui """C1516262"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cefotaxime"""@eng ; skos:notation """CDR0000039177"""^^xsd:string ; skos:altLabel """Claforan"""@eng ; skos:definition """A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39177&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39177&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C354\" NCI Thesaurus)"""@eng ; """1797"""^^xsd:string ; """63527-52-6"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """C354"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701052"""^^xsd:string ; umls:cui """C0007554"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide/melphalan"""@eng ; skos:notation """CDR0000041641"""^^xsd:string ; skos:altLabel """CBDCA/CTX/L-PAM/VP-16"""@eng ; ; ; ; ; """4802"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281251"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/filgrastim/tretinoin"""@eng ; skos:notation """CDR0000041640"""^^xsd:string ; skos:altLabel """ARA-C/ATRA/G-CSF"""@eng ; ; ; ; """4801"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281250"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/interleukin-3/prednisone/vincristine/zidovudine"""@eng ; skos:notation """CDR0000041643"""^^xsd:string ; skos:altLabel """CTX/DOX/IL-3/PRED/VCR/ZDV"""@eng ; ; ; ; ; ; ; """4804"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281253"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-3/zidovudine"""@eng ; skos:notation """CDR0000041642"""^^xsd:string ; skos:altLabel """IL-3/ZDV"""@eng ; ; ; """4803"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281252"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-leucyl-L-leucine methyl ester"""@eng ; skos:notation """CDR0000041645"""^^xsd:string ; skos:altLabel """LLME"""@eng ; """4806"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281255"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane/doxorubicin"""@eng ; skos:notation """CDR0000041644"""^^xsd:string ; skos:altLabel """ADR-529/DOX"""@eng ; ; ; """4805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281254"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/vinorelbine"""@eng ; skos:notation """CDR0000041647"""^^xsd:string ; skos:altLabel """DOX/VNB"""@eng ; ; ; """4808"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281256"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000041646"""^^xsd:string ; skos:altLabel """Hodgkins lymphoma"""@eng , """Hodgkin disease"""@eng , """Hodgkin lymphoma"""@eng , """Hodgkin's disease"""@eng , """Hodgkins disease"""@eng ; rdfs:subClassOf ; """2003-01-16"""^^xsd:string ; """4807"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0019829"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP-4055"""@eng ; skos:notation """CDR0000463939"""^^xsd:string ; skos:definition """The lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, CP-4055 is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, CP-4055 shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463939&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463939&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53401\" NCI Thesaurus)"""@eng ; """C53401"""^^xsd:string ; """2006-06-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C1707141"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cyclosporine/fludarabine/methylprednisolone/thiotepa"""@eng ; skos:notation """CDR0000322038"""^^xsd:string ; skos:altLabel """CTX/CYSP/FAMP/MePRDL/TSPA"""@eng ; ; ; ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328015"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/levamisole/L-leucovorin"""@eng ; skos:notation """CDR0000042231"""^^xsd:string ; skos:altLabel """5-FU/L-CF/LEV"""@eng ; ; ; ; """5480"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281741"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 rectal cancer"""@eng ; skos:notation """CDR0000043235"""^^xsd:string ; skos:altLabel """rectal cancer, stage 0"""@eng , """stage 0 rectum cancer"""@eng , """rectum cancer, stage 0"""@eng ; rdfs:subClassOf ; """rectal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """77"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0154062"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """axillary node biopsy"""@eng ; skos:notation """CDR0000467891"""^^xsd:string ; rdfs:subClassOf ; """Diagnostic test/procedure"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C0398434"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZD5438"""@eng ; skos:notation """CDR0000389264"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """2004-08-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541359"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/cyclophosphamide/docetaxel/doxorubicin"""@eng ; skos:notation """CDR0000389265"""^^xsd:string ; skos:altLabel """CAPE/CTX/DOX/TXT"""@eng ; ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541360"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MK0731"""@eng ; skos:notation """CDR0000446551"""^^xsd:string ; skos:definition """A synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446551&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446551&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49174\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C49174"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """2005-09-09"""^^xsd:string ; umls:cui """C1708823"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes/MOv-gamma chimeric receptor gene"""@eng ; skos:notation """CDR0000271908"""^^xsd:string ; skos:altLabel """ALLOLYMPH/MOv-gCR"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-01-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327891"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/pegylated doxorubicin HCl liposome"""@eng ; skos:notation """CDR0000378198"""^^xsd:string ; skos:altLabel """PEG-LD/PS-341"""@eng ; ; """2004-07-23"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541451"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """therapeutic epinephrine"""@eng ; skos:notation """CDR0000041857"""^^xsd:string ; skos:definition """The synthetic form of the naturally occurring sympathomimetic amine with bronchodilating, intraocular pressure reducing, and vasoconstricting activity. By stimulating alpha adrenergic receptors, this agent causes vasoconstriction, thereby increasing vascular resistance and blood pressure. When administered in the conjunctiva, epinephrine binds to alpha-adrenergic receptors in the iris sphincter muscle, thereby causing vasoconstriction and a decrease in the production of aqueous humor. Through its beta1-receptor stimulating actions, this agent increases the force and rate of myocardial contraction and relaxes bronchial smooth muscle, thereby causing bronchodilatation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41857&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41857&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C473\" NCI Thesaurus)"""@eng ; """2007-01-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C473"""^^xsd:string ; """5069"""^^xsd:string ; umls:cui """C0014563"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multiple endocrine neoplasia 1 and 2 (MEN1, MEN2)"""@eng ; skos:notation """CDR0000042848"""^^xsd:string ; ; """2002-09-10"""^^xsd:string ; """6658"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0677785"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/cisplatin"""@eng ; skos:notation """CDR0000042849"""^^xsd:string ; skos:altLabel """BRYO/CDDP"""@eng ; ; ; """6659"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677786"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/irinotecan/vincristine"""@eng ; skos:notation """CDR0000334902"""^^xsd:string ; skos:altLabel """CPT-11/CTX/DACT/VCR"""@eng ; ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328054"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary retinoblastoma (RB1)"""@eng ; skos:notation """CDR0000042842"""^^xsd:string ; ; """2002-09-10"""^^xsd:string ; """6647"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0751483"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary Wilms' tumor (WT1)"""@eng ; skos:notation """CDR0000042843"""^^xsd:string ; ; """2002-09-10"""^^xsd:string ; """6648"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0677779"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary breast/ovarian cancer (BRCA1, BRCA2)"""@eng ; skos:notation """CDR0000042840"""^^xsd:string ; """2002-09-10"""^^xsd:string ; """6641"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0677776"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2)"""@eng ; skos:notation """CDR0000042841"""^^xsd:string ; skos:altLabel """HNPCC"""@eng ; ; ; ; """2002-09-10"""^^xsd:string ; """6643"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1333990"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """von Hippel-Lindau syndrome"""@eng ; skos:notation """CDR0000042846"""^^xsd:string ; skos:altLabel """VHL"""@eng ; ; ; """6653"""^^xsd:string ; """2005-12-14"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0019562"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary melanoma 1 and 2 (CDKN2, CDK4)"""@eng ; skos:notation """CDR0000042847"""^^xsd:string ; ; """2002-09-10"""^^xsd:string ; """6654"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0677782"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Li Fraumeni syndrome (TP53)"""@eng ; skos:notation """CDR0000042844"""^^xsd:string ; skos:altLabel """LFS"""@eng ; ; ; ; """2002-09-10"""^^xsd:string ; """6649"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0085390"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neurofibromatosis type 1 (NF1)"""@eng ; skos:notation """CDR0000042845"""^^xsd:string ; ; """Genetic condition"""^^xsd:string ; """2006-06-21"""^^xsd:string ; """6652"""^^xsd:string ; umls:cui """C0027831"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lapatinib/tamoxifen"""@eng ; skos:notation """CDR0000437137"""^^xsd:string ; skos:altLabel """GW-572016/TAM"""@eng ; ; ; """2005-06-14"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831648"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostaglandin inhibition"""@eng ; skos:notation """CDR0000039749"""^^xsd:string ; ; rdfs:subClassOf ; """2410"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279497"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP2B6"""@eng ; skos:notation """CDR0000322866"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1382176"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """evaluation of evidence"""@eng ; skos:notation """CDR0000257669"""^^xsd:string ; skos:altLabel """evidence, evaluation of"""@eng ; """2002-10-19"""^^xsd:string ; """2002-09-27"""^^xsd:string ; """Research activity"""^^xsd:string ; umls:cui """C1327779"""^^xsd:string ; umls:tui """T062"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TGFa-PE38 immunotoxin"""@eng ; skos:notation """CDR0000346468"""^^xsd:string ; skos:altLabel """Cervene"""@eng , """TP-38"""@eng ; skos:definition """A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain. The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346468&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346468&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29483\" NCI Thesaurus)"""@eng ; """2003-11-20"""^^xsd:string ; """C29483"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328109"""^^xsd:string ; umls:cui """C1710312"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/gemcitabine/leucovorin calcium"""@eng ; skos:notation """CDR0000364827"""^^xsd:string ; skos:altLabel """CDDP/CF/dFdC/5-FU"""@eng ; ; ; ; ; """2004-04-01"""^^xsd:string ; """2004-03-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541216"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039778"""^^xsd:string ; skos:altLabel """MLMOPP"""@eng , """MTX/PCB/PRED/VCR"""@eng ; ; ; ; ; """2439"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279510"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin hydrochloride"""@eng ; skos:notation """CDR0000039779"""^^xsd:string ; skos:altLabel """Rubomycin C"""@eng , """5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-, hydrochloride"""@eng , """DNM"""@eng , """daunorubicin"""@eng , """Cerubidin"""@eng , """L-lyxo-Hexopyranoside, 3.beta.-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,.alpha.-,hydrochloride"""@eng , """daunomycin"""@eng , """DNR"""@eng , """DRB"""@eng , """Cerubidine"""@eng , """Rubilem"""@eng , """Daunoblastin"""@eng , """Rubidomycin"""@eng , """Dauno-Rubidomycine"""@eng , """(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione"""@eng , """Daunomycin-HCL"""@eng , """FI-6339"""@eng , """Cloridrato de Daunorubicina"""@eng , """Ondena"""@eng ; skos:definition """The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39779&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39779&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1583\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1583"""^^xsd:string ; """244"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """20830-81-3"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511736"""^^xsd:string ; umls:cui """C1511735"""^^xsd:string ; umls:cui """C1522599"""^^xsd:string ; umls:cui """C0594564"""^^xsd:string ; umls:cui """C0701063"""^^xsd:string ; umls:cui """C0701062"""^^xsd:string ; umls:cui """C0011015"""^^xsd:string ; umls:cui """C0969848"""^^xsd:string ; umls:cui """C0282123"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039772"""^^xsd:string ; skos:altLabel """ADCOMP"""@eng , """ASP/CTX/DNR/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """2433"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279504"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/mitoguazone/vindesine"""@eng ; skos:notation """CDR0000039773"""^^xsd:string ; skos:altLabel """BLEO/CDDP/DAVA/MGBG"""@eng , """DVMB"""@eng ; ; ; ; ; """2434"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279505"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/tamoxifen"""@eng ; skos:notation """CDR0000039770"""^^xsd:string ; skos:altLabel """CTX/5-FU/MTX/TMX"""@eng , """CMFT"""@eng ; ; ; ; ; """2431"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039771"""^^xsd:string ; skos:altLabel """CCNU/MTX/VCR"""@eng , """CcOM"""@eng ; ; ; ; """2432"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/prednisone/teniposide"""@eng ; skos:notation """CDR0000039776"""^^xsd:string ; skos:altLabel """ARA-C/PRED/VM-26/VP16"""@eng ; ; ; ; ; """2437"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279508"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039777"""^^xsd:string ; skos:altLabel """ASP/CTX/DOX/MTX/PRED/VCR"""@eng , """MACHO"""@eng ; ; ; ; ; ; ; """2438"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/vincristine"""@eng ; skos:notation """CDR0000039774"""^^xsd:string ; skos:altLabel """CDDP/CTX/VCR"""@eng ; ; ; ; """2435"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279506"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/etoposide"""@eng ; skos:notation """CDR0000039775"""^^xsd:string ; skos:altLabel """DVD"""@eng , """CDDP/DTIC/VP-16"""@eng ; ; ; ; """2436"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide"""@eng ; skos:notation """CDR0000041003"""^^xsd:string ; skos:altLabel """CBDCA/VP-16"""@eng ; ; ; """4041"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280617"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000041002"""^^xsd:string ; skos:altLabel """FEMEX"""@eng , """EPI/5-FU/MITO"""@eng ; ; ; ; """4040"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083097"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/methotrexate/prednisone/tamoxifen/vinblastine"""@eng ; skos:notation """CDR0000041001"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/FXM/HMM/MTX/PRED/TMX/VBL"""@eng ; ; ; ; ; ; ; ; ; """4039"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280615"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/doxorubicin/fluoxymesterone/methotrexate/mitolactol/prednisone/tamoxifen/vincristine"""@eng ; skos:notation """CDR0000041000"""^^xsd:string ; skos:altLabel """DBD/DOX/FXM/HMM/MTX/PRED/TMX/VCR"""@eng ; ; ; ; ; ; ; ; """4038"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280614"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin/prednisone/teniposide/vincristine"""@eng ; skos:notation """CDR0000041007"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DNR/PRED/VCR/VM-26"""@eng ; ; ; ; ; ; ; """4045"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280620"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000041006"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/MTX"""@eng ; ; ; ; """4044"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280619"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000041005"""^^xsd:string ; skos:altLabel """IL-2/TIL"""@eng ; ; ; """4043"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280618"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """therapeutic tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000041004"""^^xsd:string ; skos:altLabel """tumor infiltrating lymphocytes"""@eng ; skos:definition """A preparation of cells, consisting of autologous tumor infiltrating lymphocytes, that are manipulated in vitro and, upon administration in vivo, re-infiltrate the tumor to initiate tumor cell lysis. In vitro, therapeutic tumor-infiltrating lymphocytes (TILs) are isolated from tumor tissue and cultured with lymphokines such as interleukin-2; the therapeutic TILs are then infused into the patient, where, after re-infiltration of the tumor, they may induce lysis of tumor cells and tumor regression. The use of therapeutic TILs is considered a form of adoptive immunotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41004&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41004&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28699\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """C28699"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """4042"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1515408"""^^xsd:string ; umls:cui """C0079722"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/vinblastine"""@eng ; skos:notation """CDR0000041009"""^^xsd:string ; skos:altLabel """CDDP/IFF/VBL"""@eng ; ; ; ; """4047"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280622"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interleukin-2"""@eng ; skos:notation """CDR0000041008"""^^xsd:string ; skos:altLabel """CDDP/IL-2"""@eng ; ; ; """4046"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078150"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood lymphocyte predominant Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040233"""^^xsd:string ; skos:altLabel """pediatric lymphocyte predominant Hodgkin's disease"""@eng , """childhood lymphocyte predominant Hodgkin's disease"""@eng , """lymphocyte predominant Hodgkin's disease, childhood"""@eng , """lymphocyte predominant HD, childhood"""@eng , """HD lymphocyte predominant, childhood"""@eng , """HDLP, childhood"""@eng , """lymphoma, lymphocyte predominant childhood Hodgkin's"""@eng , """pediatric Hodgkin's disease, lymphocyte predominant"""@eng , """pediatric HD, lymphocyte predominant"""@eng , """Hodgkin's disease, lymphocyte predominant, childhood"""@eng , """HD LP, childhood"""@eng , """childhood Hodgkin's disease, lymphocyte predominant"""@eng , """LPHD, childhood"""@eng , """LP HD, childhood"""@eng , """childhood HD, lymphocyte predominant"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """3048"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279919"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent/refractory childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040232"""^^xsd:string ; skos:altLabel """relapsed childhood Hodgkin's disease"""@eng , """relapsed Hodgkin's disease, childhood"""@eng , """recurrent pediatric Hodgkin's disease"""@eng , """HD, childhood, relapsed"""@eng , """HD, childhood, refractory"""@eng , """recurrent childhood HD"""@eng , """recurrent Hodgkin's disease, childhood"""@eng , """recurrent HD, pediatric"""@eng , """childhood HD, relapsed"""@eng , """childhood HD, recurrent"""@eng , """HD, pediatric, recurrent"""@eng , """relapsed HD, childhood"""@eng , """pediatric HD, relapsed"""@eng , """recurrent pediatric HD"""@eng , """pediatric Hodgkin's disease, relapsed"""@eng , """Hodgkin's lymphoma, relapsed, childhood"""@eng , """HD, childhood, recurrent"""@eng , """relapsed pediatric Hodgkin's disease"""@eng , """HD, relapsed, childhood"""@eng , """lymphoma, relapsed childhood Hodgkin's"""@eng , """childhood Hodgkin's disease, relapsed"""@eng , """refractory childhood Hodgkin's disease"""@eng , """relapsed childhood HD"""@eng , """Hodgkin's disease, relapsed, childhood"""@eng , """Hodgkin's disease, recurrent, childhood"""@eng , """recurrent/refractory childhood Hodgkin's disease"""@eng , """refractory childhood HD"""@eng , """recurrent HD, childhood"""@eng ; rdfs:subClassOf ; """childhood Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3047"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279918"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040231"""^^xsd:string ; skos:altLabel """pediatric Hodgkin's disease, metastatic"""@eng , """HD, metastatic, childhood"""@eng , """stage IV childhood Hodgkin's disease"""@eng , """metastatic Hodgkin's disease, childhood"""@eng , """metastatic childhood Hodgkin's disease"""@eng , """childhood Hodgkin's lymphoma, stage IV"""@eng , """pediatric Hodgkin's disease, stage IV"""@eng , """HD, childhood, stage IV"""@eng , """Hodgkin's disease, stage IV, childhood"""@eng , """pediatric HD, stage IV"""@eng , """HD, stage IV, childhood"""@eng , """stage IV Hodgkin's disease, childhood"""@eng , """Hodgkin's lymphoma, metastatic, childhood"""@eng , """childhood HD, stage IV"""@eng , """HD, childhood, metastatic"""@eng , """lymphoma, metastatic childhood Hodgkin's"""@eng , """pediatric HD, metastatic"""@eng , """Hodgkin's disease, metastatic, childhood"""@eng , """metastatic childhood HD"""@eng , """childhood Hodgkin's lymphoma, metastatic"""@eng , """Hodgkin's lymphoma, stage IV, childhood"""@eng , """stage IV childhood HD"""@eng , """childhood HD, metastatic"""@eng , """lymphoma, stage IV childhood Hodgkin's"""@eng ; rdfs:subClassOf ; """2003-01-14"""^^xsd:string ; """childhood Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3046"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279917"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040230"""^^xsd:string ; skos:altLabel """Hodgkin's lymphoma, stage III, childhood"""@eng , """lymphoma, stage III childhood Hodgkin's"""@eng , """stage III childhood HD"""@eng , """HD, childhood, stage III"""@eng , """childhood Hodgkin's lymphoma, stage III"""@eng , """pediatric HD, stage III"""@eng , """Hodgkin's disease, stage III, childhood"""@eng , """pediatric Hodgkin's disease, stage III"""@eng , """HD, stage III, childhood"""@eng , """stage III pediatric Hodgkin's disease"""@eng , """childhood HD, stage III"""@eng , """stage III Hodgkin's disease, childhood"""@eng , """stage III childhood Hodgkin's disease"""@eng ; rdfs:subClassOf ; """2003-01-10"""^^xsd:string ; """childhood Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3045"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279916"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, childhood Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040237"""^^xsd:string ; skos:altLabel """Hodgkin's lymphoma cellular diagnosis, childhood"""@eng , """childhood Hodgkin's disease cellular diagnosis"""@eng , """cellular diagnosis, childhood Hodgkin's disease"""@eng , """Hodgkin's disease cellular diagnosis, childhood"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """3052"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279923"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood mixed cellularity Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040236"""^^xsd:string ; skos:altLabel """mixed cellularity childhood Hodgkin's disease"""@eng , """lymphoma, mixed cellularity childhood Hodgkin's"""@eng , """HD, mixed cellularity, childhood"""@eng , """pediatric Hodgkin's disease, mixed cellularity"""@eng , """childhood Hodgkin's disease, mixed cellularity"""@eng , """childhood mixed cellularity Hodgkin's disease"""@eng , """mixed cellularity Hodgkin's disease, childhood"""@eng , """Hodgkin's disease, mixed cellularity, childhood"""@eng , """pediatric HD, mixed cellularity"""@eng , """MC HD, childhood"""@eng , """childhood HD, mixed cellularity"""@eng , """mixed cellularity HD, childhood"""@eng , """pediatric mixed cellularity Hodgkin's disease"""@eng , """MCHD, childhood"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """3051"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279922"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood nodular sclerosis Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040235"""^^xsd:string ; skos:altLabel """nodular sclerosing HD, childhood"""@eng , """pediatric HD, nodular sclerosis"""@eng , """NS HD, childhood"""@eng , """childhood nodular sclerosis Hodgkin's disease"""@eng , """HD, nodular sclerosis, childhood"""@eng , """pediatric Hogkin's disease, nodular sclerosis"""@eng , """childhood HD, nodular sclerosis"""@eng , """childhood Hodgkin's disease, nodular sclerosis"""@eng , """nodular sclerosing Hodgkin's disease, childhood"""@eng , """pediatric nodular sclerosis Hodgkin's disease"""@eng , """nodular sclerosis Hodgkin's disease, childhood"""@eng , """NSHD, childhood"""@eng , """Hodgkin's disease, nodular sclerosis, childhood"""@eng , """lymphoma, nodular sclerosing childhood Hodgkin's"""@eng ; rdfs:subClassOf ; """2003-01-10"""^^xsd:string ; """3050"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279921"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood lymphocyte depletion Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040234"""^^xsd:string ; skos:altLabel """childhood Hodgkin's disease, lymphocyte depleted"""@eng , """HD lymphocyte depleted, childhood"""@eng , """lymphocyte depleted Hodgkin's disease, childhood"""@eng , """lymphocyte depletion HD, childhood"""@eng , """lymphocyte depleted HD, childhood"""@eng , """LDHD, childhood"""@eng , """Hodgkin's disease, lymphocyte depleted, childhood"""@eng , """lymphoma, lymphocyte depleted childhood Hodgkin's"""@eng , """childhood HD, lymphocyte depletion"""@eng , """lymphocyte depletion Hodgkin's disease, childhood"""@eng , """childhood lymphocyte depletion Hodgkin's disease"""@eng , """pediatric Hodgkin's disease, lymphocyte depletion"""@eng , """HDLD, childhood"""@eng , """pediatric HD, lymphocyte depletion"""@eng , """HD LD, childhood"""@eng , """pediatric lymphocyte depletion Hodgkin's disease"""@eng , """LD HD, childhood"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """3049"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279920"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dexamethasone/doxorubicin/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040239"""^^xsd:string ; skos:altLabel """COD-BLAM IV"""@eng , """BLEO/CTX/DM/DOX/PCB/VCR"""@eng ; ; ; ; ; ; ; """3055"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279924"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Fluosol-DA"""@eng ; skos:notation """CDR0000040238"""^^xsd:string ; skos:altLabel """FSOL"""@eng ; """3053"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0060574"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate/pamidronate"""@eng ; skos:notation """CDR0000340940"""^^xsd:string ; skos:altLabel """APD/CDDP/DOX/MTX"""@eng ; ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328080"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/edotecarin"""@eng ; skos:notation """CDR0000340945"""^^xsd:string ; skos:altLabel """CDDP/J 107088"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328081"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """selected vegetables/Sun's soup"""@eng ; skos:notation """CDR0000285729"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327914"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """duborimycin"""@eng ; skos:notation """CDR0000039228"""^^xsd:string ; skos:altLabel """Daunomycinol"""@eng , """Duborimycine"""@eng , """5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-, hydrochloride"""@eng , """Daunorubicineal"""@eng , """Daunomycinol HCl"""@eng , """Duborimycin Hydrochloride"""@eng , """13-Hydroxydaunomycin"""@eng , """Duborimycine, Hydrochloride"""@eng ; skos:definition """An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Duborimycin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39228&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39228&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1062\" NCI Thesaurus)"""@eng ; """1850"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """28008-55-1"""^^xsd:string ; """C1062"""^^xsd:string ; """180510"""^^xsd:string ; umls:cui """C0057159"""^^xsd:string ; umls:cui """C0969848"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult brain stem glioma"""@eng ; skos:notation """CDR0000038825"""^^xsd:string ; skos:altLabel """CNS tumor, adult brainstem glioma"""@eng , """brain stem glioma, adult"""@eng , """glioma, brain stem, adult"""@eng , """brain tumor, brain stem glioma, adult"""@eng , """adult brain tumor, brain stem glioma"""@eng , """CNS tumor, adult brain stem glioma"""@eng , """glioma, adult brain stem"""@eng , """adult brainstem mixed glioma"""@eng , """glioma, brainstem, adult"""@eng , """adult brain stem mixed glioma"""@eng , """gliosarcoma, adult brain stem"""@eng , """adult brainstem glioma"""@eng , """glioma, adult brainstem"""@eng , """CNS tumor, brain stem glioma, adult"""@eng , """gliosarcoma, adult brainstem"""@eng , """mixed glioma, adult brain stem"""@eng , """mixed glioma, adult brainstem"""@eng , """brainstem glioma, adult"""@eng , """adult brain tumor, brainstem glioma"""@eng , """adult CNS tumor, brainstem glioma"""@eng , """brain tumor, brainstem glioma, adult"""@eng , """CNS tumor, brainstem glioma, adult"""@eng , """central nervous system tumor, brainstem glioma, adult"""@eng , """adult brain stem gliosarcoma"""@eng , """brain tumor, adult brainstem glioma"""@eng , """adult brainstem gliosarcoma"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1290"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278873"""^^xsd:string ; umls:cui """C1377915"""^^xsd:string ; umls:cui """C1377914"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nonfunctioning pituitary tumor"""@eng ; skos:notation """CDR0000038824"""^^xsd:string ; skos:altLabel """pituitary tumor, nonfunctioning"""@eng , """non-functioning pituitary tumor"""@eng ; rdfs:subClassOf ; """pituitary tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1286"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338078"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult craniopharyngioma"""@eng ; skos:notation """CDR0000038827"""^^xsd:string ; skos:altLabel """CNS tumor, craniopharyngioma, adult"""@eng , """central nervous system tumor, craniopharyngioma, adult"""@eng , """CNS tumor, adult craniopharyngioma"""@eng , """craniopharyngioma, adult"""@eng , """brain tumor, craniopharyngioma, adult"""@eng , """adult CNS tumor, craniopharyngioma"""@eng , """adult brain tumor, craniopharyngioma"""@eng , """brain tumor, adult craniopharyngioma"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1292"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278875"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult ependymoma"""@eng ; skos:notation """CDR0000038826"""^^xsd:string ; skos:altLabel """brain tumor, adult ependymoma"""@eng , """brain tumor, ependymoma, adult"""@eng , """CNS tumor, ependymoma, adult"""@eng , """central nervous system tumor, ependymoma, adult"""@eng , """CNS tumor, adult ependymoma"""@eng , """ependymoma, adult"""@eng , """adult CNS tumor, ependymoma"""@eng , """adult brain tumor, ependymoma"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """1291"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult ependymal tumors"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278874"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extraocular extension melanoma"""@eng ; skos:notation """CDR0000038821"""^^xsd:string ; skos:altLabel """intraocular melanoma extrauveal extension"""@eng , """extension, extrauveal melanoma"""@eng , """melanoma, intraocular extrauveal extension"""@eng ; rdfs:subClassOf ; """intraocular melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1283"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278869"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciliary body and choroid melanoma, medium/large size"""@eng ; skos:notation """CDR0000038820"""^^xsd:string ; skos:altLabel """melanoma, intraocular ciliary body and choroid, medium/large size"""@eng , """posterior uvea melanoma, medium/large size"""@eng , """intraocular melanoma ciliary body and choroid, medium/large size"""@eng , """uveal melanoma, posterior, medium/large size"""@eng , """melanoma, posterior uveal, medium/large size"""@eng , """medium/large size ciliary body and choroid melanoma"""@eng ; rdfs:subClassOf ; """intraocular melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1282"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278868"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TSH producing pituitary tumor"""@eng ; skos:notation """CDR0000038823"""^^xsd:string ; skos:altLabel """pituitary tumor, TSH producing"""@eng ; rdfs:subClassOf ; """pituitary tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1285"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0346303"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent intraocular melanoma"""@eng ; skos:notation """CDR0000038822"""^^xsd:string ; skos:altLabel """intraocular melanoma, recurrent"""@eng , """uveal melanoma, recurrent"""@eng , """melanoma, uveal recurrent"""@eng , """recurrent uveal melanoma"""@eng ; rdfs:subClassOf ; """intraocular melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1284"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278870"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult meningioma"""@eng ; skos:notation """CDR0000038829"""^^xsd:string ; skos:altLabel """brain tumor, meningioma, adult"""@eng , """adult CNS tumor, meningioma"""@eng , """brain tumor, adult meningioma"""@eng , """meningioma, adult"""@eng , """adult brain tumor, meningioma"""@eng , """central nervous system tumor, meningioma, adult"""@eng , """CNS tumor, meningioma, adult"""@eng , """CNS tumor, adult meningioma"""@eng ; rdfs:subClassOf ; """1294"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278877"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """black cohosh"""@eng ; skos:notation """CDR0000302635"""^^xsd:string ; skos:altLabel """Remifemin"""@eng ; skos:definition """A triterpene-containing herb isolated from the roots and rhizomes of the plant Cimicifuga racemosa (also known as Actaea racemosa). While the mechanism of action of black cohosh is not completely understood, it appears to act as a selective estrogen receptor modulator. In vitro, this preparation has been shown to induce cell cycle arrest and caspase-dependent apoptosis of estrogen-sensitive breast cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=302635&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=302635&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26647\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2003-04-23"""^^xsd:string ; """C26647"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0771967"""^^xsd:string ; umls:cui """C0650355"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """talampanel"""@eng ; skos:notation """CDR0000315898"""^^xsd:string ; skos:altLabel """GYKI-53773"""@eng , """LY 300164"""@eng , """GYKI 53405"""@eng ; skos:definition """A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity. Talampanel noncompetitively binds to the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315898&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315898&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38139\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C38139"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """729898"""^^xsd:string ; umls:cui """C0250723"""^^xsd:string ; umls:cui """C1527261"""^^xsd:string ; umls:cui """C0994515"""^^xsd:string ; umls:cui """C0380105"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/pemetrexed disodium/suberoylanilide hydroxamic acid"""@eng ; skos:notation """CDR0000428333"""^^xsd:string ; skos:altLabel """CDDP/LY231514/SAHA"""@eng ; ; ; ; """2005-04-07"""^^xsd:string ; """2005-04-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """denosumab"""@eng ; skos:notation """CDR0000481348"""^^xsd:string ; skos:altLabel """AMG 162"""@eng , """Densosumab"""@eng ; skos:definition """A humanized monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481348&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481348&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61313\" NCI Thesaurus)"""@eng ; """2006-07-05"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61313"""^^xsd:string ; umls:cui """C1690432"""^^xsd:string ; umls:cui """C1530450"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, laryngeal cancer"""@eng ; skos:notation """CDR0000040671"""^^xsd:string ; skos:altLabel """laryngeal cancer cellular diagnosis"""@eng , """larynx cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """3586"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280293"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia with t(8;21)(q22;q22)"""@eng ; skos:notation """CDR0000377655"""^^xsd:string ; skos:altLabel """adult acute myeloid leukemia with AML1/ETO translocation"""@eng ; ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-18"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541331"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol"""@eng ; skos:notation """CDR0000042068"""^^xsd:string ; skos:altLabel """Flavopirodol/HMR-1275"""@eng , """(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one Hydrochloride"""@eng , """Alvocidib"""@eng , """FLAVO"""@eng ; skos:definition """A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, flavopiridol induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (cdk) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42068&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42068&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1571\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5300"""^^xsd:string ; """46211"""^^xsd:string ; """649890"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C1571"""^^xsd:string ; """146426-40-6"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """131740-09-5 (hydrochloride)"""^^xsd:string ; umls:cui """C0281603"""^^xsd:string ; umls:cui """C2709281"""^^xsd:string ; umls:cui """C2709282"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isolated perfusion"""@eng ; skos:notation """CDR0000042069"""^^xsd:string ; skos:altLabel """perfusion, isolated"""@eng ; """5301"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0031006"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/thiotepa"""@eng ; skos:notation """CDR0000042060"""^^xsd:string ; skos:altLabel """BU/CTX/TSPA"""@eng ; ; ; ; """5294"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281597"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/filgrastim/idarubicin/interleukin-6"""@eng ; skos:notation """CDR0000042061"""^^xsd:string ; skos:altLabel """ARA-C/G-CSF/IDA/IL-6"""@eng ; ; ; ; ; """5295"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281598"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/filgrastim/interleukin-6/mitoxantrone"""@eng ; skos:notation """CDR0000042062"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/G-CSF/IL-6/VP-16"""@eng ; ; ; ; ; ; """5296"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281599"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim/interleukin-6"""@eng ; skos:notation """CDR0000042063"""^^xsd:string ; skos:altLabel """CTX/G-CSF/IL-6"""@eng ; ; ; ; """5297"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281600"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/filgrastim/ifosfamide/paclitaxel"""@eng ; skos:notation """CDR0000042064"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/IFF/TAX/VP-16"""@eng ; ; ; ; ; ; """5298"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281601"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide/paclitaxel"""@eng ; skos:notation """CDR0000042065"""^^xsd:string ; skos:altLabel """CBDCA/IFF/TAX/VP-16"""@eng , """ICE-T"""@eng ; ; ; ; ; """5299"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281602"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/thiotepa"""@eng ; skos:notation """CDR0000042066"""^^xsd:string ; skos:altLabel """CHUT"""@eng , """CTX/TSPA"""@eng ; ; ; """53"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neuroblastoma"""@eng ; skos:notation """CDR0000042067"""^^xsd:string ; skos:altLabel """Neuroblastoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """530"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0027819"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP2C19"""@eng ; skos:notation """CDR0000322908"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1332828"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen receptor alpha"""@eng ; skos:notation """CDR0000322904"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0665341"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T192"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen receptor beta"""@eng ; skos:notation """CDR0000322905"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1414462"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17betaHSD"""@eng ; skos:notation """CDR0000322906"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1328030"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP2C9"""@eng ; skos:notation """CDR0000322907"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1332829"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SULT"""@eng ; skos:notation """CDR0000322900"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1328027"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SULT1A1"""@eng ; skos:notation """CDR0000322901"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1420514"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SULT1A2"""@eng ; skos:notation """CDR0000322902"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1420515"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen receptor"""@eng ; skos:notation """CDR0000322903"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0034804"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T192"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """letrozole/temsirolimus"""@eng ; skos:notation """CDR0000305872"""^^xsd:string ; skos:altLabel """CCI-779/LTZ"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-05-05"""^^xsd:string ; """2003-05-23"""^^xsd:string ; umls:cui """C1327970"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/oxaliplatin"""@eng ; skos:notation """CDR0000043545"""^^xsd:string ; skos:altLabel """CAPE/L-OHP"""@eng ; ; ; """8804"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879259"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sulindac/thalidomide"""@eng ; skos:notation """CDR0000038251"""^^xsd:string ; skos:altLabel """SULIN/THAL"""@eng ; ; ; """10859"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935813"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/pemetrexed disodium"""@eng ; skos:notation """CDR0000410765"""^^xsd:string ; skos:altLabel """EPI/LY231514"""@eng ; ; ; """2004-12-10"""^^xsd:string ; """2004-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541438"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/pertuzumab"""@eng ; skos:notation """CDR0000410763"""^^xsd:string ; skos:altLabel """dFdC/MOAB 2C4"""@eng ; ; ; """2004-12-10"""^^xsd:string ; """2004-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541437"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IPI-504"""@eng ; skos:notation """CDR0000437784"""^^xsd:string ; skos:definition """A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activity. IPI-504 binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. IPI-504-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=437784&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=437784&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48401\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C48401"""^^xsd:string ; """2005-06-17"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C1708447"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia"""@eng ; skos:notation """CDR0000037885"""^^xsd:string ; skos:altLabel """AML, adult"""@eng , """non-lymphoblastic leukemia, adult acute"""@eng , """adult ANLL"""@eng , """adult acute nonlymphoblastic leukemia"""@eng , """acute nonlymphocytic leukemia, adult"""@eng , """adult AML"""@eng , """ANLL, adult"""@eng , """Leukemia, acute myeloid (AML), adult"""@eng , """adult acute nonlymphocytic leukemia"""@eng , """leukemia, adult acute myelogenous"""@eng , """acute myeloid leukemia, adult"""@eng , """adult leukemia, acute nonlymphoblastic"""@eng , """myelogenous leukemia, adult acute"""@eng , """non-lymphocytic leukemia, adult acute"""@eng , """acute non-lymphocytic leukemia, adult"""@eng , """adult acute non-lymphoblastic leukemia"""@eng , """acute nonlymphoblastic leukemia, adult"""@eng , """adult leukemia, acute myelogenous"""@eng , """adult leukemia, acute non-lymphoblastic"""@eng , """nonlymphoblastic leukemia, adult acute"""@eng , """adult acute non-lymphocytic leukemia"""@eng , """adult leukemia, acute non-lymphocytic"""@eng , """adult acute myelogenous leukemia"""@eng , """acute myelogenous leukemia, adult"""@eng , """adult leukemia, acute myeloid"""@eng , """leukemia, adult acute non-lymphocytic"""@eng , """nonlymphocytic leukemia, adult acute"""@eng , """leukemia, adult acute nonlymphocytic"""@eng , """leukemia, adult acute nonlymphoblastic"""@eng , """leukemia, adult acute non-lymphoblastic"""@eng , """myeloid leukemia, adult acute"""@eng , """adult leukemia, acute nonlymphocytic"""@eng , """acute non-lymphoblastic leukemia, adult"""@eng , """leukemia, adult acute myeloid"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1029"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220615"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KLH-FITC"""@eng ; skos:notation """CDR0000489285"""^^xsd:string ; skos:altLabel """EC90"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62478"""^^xsd:string ; """2006-09-18"""^^xsd:string ; umls:cui """C1831884"""^^xsd:string ; umls:cui """C0257324"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unspecified adult solid tumor, protocol specific"""@eng ; skos:notation """CDR0000038974"""^^xsd:string ; skos:altLabel """protocol specific, unspecified adult solid tumor"""@eng , """adult solid tumor, unspecified, protocol specific"""@eng , """Solid tumor, unspecified, adult"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1532"""^^xsd:string ; """stage II squamous cell carcinoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """small intestine lymphoma"""^^xsd:string ; """stage 0 melanoma"""^^xsd:string ; """recurrent transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """recurrent anal cancer"""^^xsd:string ; """recurrent squamous cell carcinoma of the oropharynx"""^^xsd:string ; """stage II vulvar cancer"""^^xsd:string ; """stage I mucoepidermoid carcinoma of the oral cavity"""^^xsd:string ; """stage I vulvar cancer"""^^xsd:string ; """stage IVB cervical cancer"""^^xsd:string ; """stage IV rectal cancer"""^^xsd:string ; """hydatidiform mole"""^^xsd:string ; """intraocular melanoma"""^^xsd:string ; """breast cancer in situ"""^^xsd:string ; """stage III renal cell cancer"""^^xsd:string ; """stage II ovarian germ cell tumor"""^^xsd:string ; """localized unresectable adult primary liver cancer"""^^xsd:string ; """male breast cancer"""^^xsd:string ; """recurrent metastatic squamous neck cancer with occult primary"""^^xsd:string ; """stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """recurrent midline lethal granuloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """adult choroid plexus tumor"""^^xsd:string ; """stage IV cutaneous T-cell lymphoma"""^^xsd:string ; """stage II non-small cell lung cancer"""^^xsd:string ; """stage I squamous cell carcinoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """malignant pleural effusion"""^^xsd:string ; """recurrent malignant mesothelioma"""^^xsd:string ; """stage 4S neuroblastoma"""^^xsd:string ; """stage III prostate cancer"""^^xsd:string ; """stage II midline lethal granuloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """noninvasive thymoma and thymic carcinoma"""^^xsd:string ; """recurrent tumors of the Ewing's family"""^^xsd:string ; """stage II basal cell carcinoma of the lip"""^^xsd:string ; """stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """bone metastases"""^^xsd:string ; """mixed gliomas"""^^xsd:string ; """primary central nervous system lymphoma"""^^xsd:string ; """stage III ovarian epithelial cancer"""^^xsd:string ; """peritoneal cavity pseudomyxoma peritonei"""^^xsd:string ; """desmoid tumor"""^^xsd:string ; """localized malignant mesothelioma"""^^xsd:string ; """TSH producing pituitary tumor"""^^xsd:string ; """recurrent non-small cell lung cancer"""^^xsd:string ; """stage I non-small cell lung cancer"""^^xsd:string ; """insulinoma"""^^xsd:string ; """stage IVB vaginal cancer"""^^xsd:string ; """stage 0 vulvar cancer"""^^xsd:string ; """stage II verrucous carcinoma of the oral cavity"""^^xsd:string ; """localized osteosarcoma"""^^xsd:string ; """stage I colon cancer"""^^xsd:string ; """regional neuroblastoma"""^^xsd:string ; """recurrent pancreatic cancer"""^^xsd:string ; """stage II endometrial cancer"""^^xsd:string ; """somatostatinoma"""^^xsd:string ; """recurrent ovarian epithelial cancer"""^^xsd:string ; """peritoneal cavity cancer"""^^xsd:string ; """small intestine leiomyosarcoma"""^^xsd:string ; """actinic keratosis"""^^xsd:string ; """stage 0 laryngeal cancer"""^^xsd:string ; """stage IV mucoepidermoid carcinoma of the oral cavity"""^^xsd:string ; """stage 0 colon cancer"""^^xsd:string ; """stage I salivary gland cancer"""^^xsd:string ; """immunosuppressive treatment related Kaposi's sarcoma"""^^xsd:string ; """recurrent cutaneous T-cell lymphoma"""^^xsd:string ; """extraocular retinoblastoma"""^^xsd:string ; """disseminated neuroblastoma"""^^xsd:string ; """stage 0 cervical cancer"""^^xsd:string ; """stage IIIA non-small cell lung cancer"""^^xsd:string ; """stage II lymphoepithelioma of the nasopharynx"""^^xsd:string ; """adult ependymoblastoma"""^^xsd:string ; """recurrent pheochromocytoma"""^^xsd:string ; """lung metastases"""^^xsd:string ; """stage I papillary thyroid cancer"""^^xsd:string ; """stage II penile cancer"""^^xsd:string ; """recurrent adult primary liver cancer"""^^xsd:string ; """stage III mucoepidermoid carcinoma of the oral cavity"""^^xsd:string ; """recurrent gastric cancer"""^^xsd:string ; """recurrent adenoid cystic carcinoma of the oral cavity"""^^xsd:string ; """stage II adrenocortical carcinoma"""^^xsd:string ; """stage III melanoma"""^^xsd:string ; """stage I bladder cancer"""^^xsd:string ; """untreated metastatic squamous neck cancer with occult primary"""^^xsd:string ; """recurrent penile cancer"""^^xsd:string ; """recurrent gastrointestinal carcinoid tumor"""^^xsd:string ; """stage III penile cancer"""^^xsd:string ; """stage IV adrenocortical carcinoma"""^^xsd:string ; """stage III squamous cell carcinoma of the lip and oral cavity"""^^xsd:string ; """basal cell carcinoma of the skin"""^^xsd:string ; """extragonadal germ cell tumor"""^^xsd:string ; """recurrent breast cancer"""^^xsd:string ; """stage III lymphoepithelioma of the oropharynx"""^^xsd:string ; """stage IIIA breast cancer"""^^xsd:string ; """ovarian stromal cancer"""^^xsd:string ; """ovarian low malignant potential tumor"""^^xsd:string ; """stage IV squamous cell carcinoma of the oropharynx"""^^xsd:string ; """stage II squamous cell carcinoma of the oropharynx"""^^xsd:string ; """growth hormone-producing pituitary tumor"""^^xsd:string ; """stage IVB pancreatic cancer"""^^xsd:string ; """recurrent carcinoma of unknown primary"""^^xsd:string ; """stage IV salivary gland cancer"""^^xsd:string ; """recurrent gallbladder cancer"""^^xsd:string ; """stage II anal cancer"""^^xsd:string ; """adult medulloblastoma"""^^xsd:string ; """recurrent esophageal cancer"""^^xsd:string ; """adult central nervous system germ cell tumor"""^^xsd:string ; """localized resectable neuroblastoma"""^^xsd:string ; """small intestine adenocarcinoma"""^^xsd:string ; """adult brain stem glioma"""^^xsd:string ; """stage I follicular thyroid cancer"""^^xsd:string ; """stage III Wilms' tumor"""^^xsd:string ; """stage IIIB anal cancer"""^^xsd:string ; """gastrinoma"""^^xsd:string ; """stage I prostate cancer"""^^xsd:string ; """stage IV penile cancer"""^^xsd:string ; """recurrent rectal cancer"""^^xsd:string ; """stage 0 bladder cancer"""^^xsd:string ; """stage III adenoid cystic carcinoma of the oral cavity"""^^xsd:string ; """stage IV breast cancer"""^^xsd:string ; """stage IIB cervical cancer"""^^xsd:string ; """stage I adrenocortical carcinoma"""^^xsd:string ; """recurrent renal cell cancer"""^^xsd:string ; """stage IV prostate cancer"""^^xsd:string ; """stage I penile cancer"""^^xsd:string ; """stage IV papillary thyroid cancer"""^^xsd:string ; """stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """localized unresectable neuroblastoma"""^^xsd:string ; """recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage III squamous cell carcinoma of the larynx"""^^xsd:string ; """stage I lymphoepithelioma of the oropharynx"""^^xsd:string ; """invasive thymoma and thymic carcinoma"""^^xsd:string ; """stage I Wilms' tumor"""^^xsd:string ; """stage IV adenoid cystic carcinoma of the oral cavity"""^^xsd:string ; """stage II lymphoepithelioma of the oropharynx"""^^xsd:string ; """epidemic Kaposi's sarcoma"""^^xsd:string ; """classic Kaposi's sarcoma"""^^xsd:string ; """stage IA cervical cancer"""^^xsd:string ; """recurrent uterine sarcoma"""^^xsd:string ; """recurrent adult brain tumor"""^^xsd:string ; """stage IIA cervical cancer"""^^xsd:string ; """adult pineoblastoma"""^^xsd:string ; """stage II vaginal cancer"""^^xsd:string ; """stage III cervical cancer"""^^xsd:string ; """recurrent mucoepidermoid carcinoma of the oral cavity"""^^xsd:string ; """stage 0 paranasal sinus and nasal cavity cancer"""^^xsd:string ; """recurrent verrucous carcinoma of the oral cavity"""^^xsd:string ; """stage II testicular cancer"""^^xsd:string ; """recurrent vaginal cancer"""^^xsd:string ; """recurrent Kaposi's sarcoma"""^^xsd:string ; """stage II melanoma"""^^xsd:string ; """stage IIIA anal cancer"""^^xsd:string ; """neuroendocrine carcinoma of the skin"""^^xsd:string ; """localized transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """stage III cutaneous T-cell lymphoma"""^^xsd:string ; """stage III squamous cell carcinoma of the nasopharynx"""^^xsd:string ; """prolactin-producing pituitary tumor"""^^xsd:string ; """stage I squamous cell carcinoma of the larynx"""^^xsd:string ; """glucagonoma"""^^xsd:string ; """localized resectable adult primary liver cancer"""^^xsd:string ; """stage IV lymphoepithelioma of the oropharynx"""^^xsd:string ; """stage I squamous cell carcinoma of the oropharynx"""^^xsd:string ; """recurrent bladder cancer"""^^xsd:string ; """stage I midline lethal granuloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage III squamous cell carcinoma of the hypopharynx"""^^xsd:string ; """recurrent lymphoepithelioma of the nasopharynx"""^^xsd:string ; """recurrent parathyroid cancer"""^^xsd:string ; """adult anaplastic astrocytoma"""^^xsd:string ; """stage II papillary thyroid cancer"""^^xsd:string ; """ciliary body and choroid melanoma, small size"""^^xsd:string ; """recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage I adenoid cystic carcinoma of the oral cavity"""^^xsd:string ; """stage I breast cancer"""^^xsd:string ; """stage 0 endometrial cancer"""^^xsd:string ; """stage II pancreatic cancer"""^^xsd:string ; """localized extrahepatic bile duct cancer"""^^xsd:string ; """stage I lymphoepithelioma of the nasopharynx"""^^xsd:string ; """stage I ovarian germ cell tumor"""^^xsd:string ; """stage III papillary thyroid cancer"""^^xsd:string ; """recurrent neuroblastoma"""^^xsd:string ; """leptomeningeal metastases"""^^xsd:string ; """stage 0 hypopharyngeal cancer"""^^xsd:string ; """recurrent squamous cell carcinoma of the lip and oral cavity"""^^xsd:string ; """stage IV endometrial cancer"""^^xsd:string ; """recurrent vulvar cancer"""^^xsd:string ; """stage IV vulvar cancer"""^^xsd:string ; """stage II gastric cancer"""^^xsd:string ; """poor prognosis metastatic gestational trophoblastic tumor"""^^xsd:string ; """stage 0 esophageal cancer"""^^xsd:string ; """stage I anal cancer"""^^xsd:string ; """extensive stage small cell lung cancer"""^^xsd:string ; """stage IV follicular thyroid cancer"""^^xsd:string ; """occult non-small cell lung cancer"""^^xsd:string ; """stage II squamous cell carcinoma of the lip and oral cavity"""^^xsd:string ; """stage IV verrucous carcinoma of the larynx"""^^xsd:string ; """stage I vaginal cancer"""^^xsd:string ; """posterior urethral cancer"""^^xsd:string ; """stage I uterine sarcoma"""^^xsd:string ; """recurrent salivary gland cancer"""^^xsd:string ; """stage II prostate cancer"""^^xsd:string ; """adult pineocytoma"""^^xsd:string ; """stage IV Wilms' tumor"""^^xsd:string ; """stage II squamous cell carcinoma of the hypopharynx"""^^xsd:string ; """stage I ovarian epithelial cancer"""^^xsd:string ; """stage II esophageal cancer"""^^xsd:string ; """stage I gastric cancer"""^^xsd:string ; """stage I pancreatic cancer"""^^xsd:string ; """stage IV esophageal cancer"""^^xsd:string ; """recurrent pituitary tumor"""^^xsd:string ; """intraocular retinoblastoma"""^^xsd:string ; """stage III adult soft tissue sarcoma"""^^xsd:string ; """regional pheochromocytoma"""^^xsd:string ; """recurrent urethral cancer"""^^xsd:string ; """localized benign pheochromocytoma"""^^xsd:string ; """stage 0 lip and oral cavity cancer"""^^xsd:string ; """fallopian tube cancer"""^^xsd:string ; """stage III vulvar cancer"""^^xsd:string ; """regional gastrointestinal carcinoid tumor"""^^xsd:string ; """recurrent colon cancer"""^^xsd:string ; """recurrent testicular cancer"""^^xsd:string ; """stage III uterine sarcoma"""^^xsd:string ; """stage III bladder cancer"""^^xsd:string ; """stage II adenoid cystic carcinoma of the oral cavity"""^^xsd:string ; """stage I endometrial cancer"""^^xsd:string ; """stage I melanoma"""^^xsd:string ; """stage III vaginal cancer"""^^xsd:string ; """stage II cutaneous T-cell lymphoma"""^^xsd:string ; """stage IV renal cell cancer"""^^xsd:string ; """stage IV squamous cell carcinoma of the hypopharynx"""^^xsd:string ; """recurrent extrahepatic bile duct cancer"""^^xsd:string ; """recurrent endometrial cancer"""^^xsd:string ; """metastatic tumors of the Ewing's family"""^^xsd:string ; """unresectable extrahepatic bile duct cancer"""^^xsd:string ; """stage IVA pancreatic cancer"""^^xsd:string ; """recurrent basal cell carcinoma of the lip"""^^xsd:string ; """stage II Wilms' tumor"""^^xsd:string ; """anaplastic thyroid cancer"""^^xsd:string ; """stage II bladder cancer"""^^xsd:string ; """stage II uterine sarcoma"""^^xsd:string ; """stage IV uterine sarcoma"""^^xsd:string ; """stage I rectal cancer"""^^xsd:string ; """stage IV bladder cancer"""^^xsd:string ; """localized tumors of the Ewing's family"""^^xsd:string ; """regional transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """stage 0 nasopharyngeal cancer"""^^xsd:string ; """recurrent islet cell carcinoma"""^^xsd:string ; """stage III endometrial cancer"""^^xsd:string ; """WDHA syndrome"""^^xsd:string ; """localized parathyroid cancer"""^^xsd:string ; """recurrent adult soft tissue sarcoma"""^^xsd:string ; """stage IIIB breast cancer"""^^xsd:string ; """stage I cutaneous T-cell lymphoma"""^^xsd:string ; """metastatic transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """stage II verrucous carcinoma of the larynx"""^^xsd:string ; """recurrent retinoblastoma"""^^xsd:string ; """ACTH-producing pituitary tumor"""^^xsd:string ; """intraocular lymphoma"""^^xsd:string ; """recurrent osteosarcoma"""^^xsd:string ; """stage III pancreatic cancer"""^^xsd:string ; """stage I verrucous carcinoma of the oral cavity"""^^xsd:string ; """recurrent verrucous carcinoma of the larynx"""^^xsd:string ; """stage 0 non-small cell lung cancer"""^^xsd:string ; """stage II ovarian epithelial cancer"""^^xsd:string ; """stage II squamous cell carcinoma of the nasopharynx"""^^xsd:string ; """metastatic pheochromocytoma"""^^xsd:string ; """ciliary body and choroid melanoma, medium/large size"""^^xsd:string ; """stage I verrucous carcinoma of the larynx"""^^xsd:string ; """stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """recurrent small intestine cancer"""^^xsd:string ; """stage IV verrucous carcinoma of the oral cavity"""^^xsd:string ; """malignant pericardial effusion"""^^xsd:string ; """stage IV gastric cancer"""^^xsd:string ; """stage IV squamous cell carcinoma of the larynx"""^^xsd:string ; """stage IV melanoma"""^^xsd:string ; """recurrent melanoma"""^^xsd:string ; """medullary thyroid cancer"""^^xsd:string ; """stage 0 anal cancer"""^^xsd:string ; """stage IIIB non-small cell lung cancer"""^^xsd:string ; """liver metastases"""^^xsd:string ; """stage IB cervical cancer"""^^xsd:string ; """adult anaplastic oligodendroglioma"""^^xsd:string ; """extraocular extension melanoma"""^^xsd:string ; """recurrent intraocular melanoma"""^^xsd:string ; """stage IVA vaginal cancer"""^^xsd:string ; """recurrent skin cancer"""^^xsd:string ; """recurrent adrenocortical carcinoma"""^^xsd:string ; """pulmonary carcinoid tumor"""^^xsd:string ; """stage IV squamous cell carcinoma of the nasopharynx"""^^xsd:string ; """stage III ovarian germ cell tumor"""^^xsd:string ; """carcinoma of the appendix"""^^xsd:string ; """stage II breast cancer"""^^xsd:string ; """recurrent ovarian germ cell tumor"""^^xsd:string ; """nonmetastatic gestational trophoblastic tumor"""^^xsd:string ; """metastatic parathyroid cancer"""^^xsd:string ; """metastatic osteosarcoma"""^^xsd:string ; """stage IV non-small cell lung cancer"""^^xsd:string ; """stage IV anal cancer"""^^xsd:string ; """nonfunctioning pituitary tumor"""^^xsd:string ; """placental-site gestational trophoblastic tumor"""^^xsd:string ; """stage I squamous cell carcinoma of the hypopharynx"""^^xsd:string ; """stage III squamous cell carcinoma of the oropharynx"""^^xsd:string ; """stage I squamous cell carcinoma of the nasopharynx"""^^xsd:string ; """stage IV colon cancer"""^^xsd:string ; """stage I basal cell carcinoma of the lip"""^^xsd:string ; """ovarian sarcoma"""^^xsd:string ; """advanced malignant mesothelioma"""^^xsd:string ; """stage III salivary gland cancer"""^^xsd:string ; """squamous cell carcinoma of the skin"""^^xsd:string ; """stage II mucoepidermoid carcinoma of the oral cavity"""^^xsd:string ; """stage III basal cell carcinoma of the lip"""^^xsd:string ; """recurrent lymphoepithelioma of the oropharynx"""^^xsd:string ; """stage III squamous cell carcinoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage V Wilms' tumor"""^^xsd:string ; """stage I testicular cancer"""^^xsd:string ; """stage IV midline lethal granuloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage 0 oropharyngeal cancer"""^^xsd:string ; """stage II salivary gland cancer"""^^xsd:string ; """localized gallbladder cancer"""^^xsd:string ; """recurrent squamous cell carcinoma of the hypopharynx"""^^xsd:string ; """stage III gastric cancer"""^^xsd:string ; """stage IV ovarian germ cell tumor"""^^xsd:string ; """stage II colon cancer"""^^xsd:string ; """recurrent squamous cell carcinoma of the nasopharynx"""^^xsd:string ; """stage I renal cell cancer"""^^xsd:string ; """stage II rectal cancer"""^^xsd:string ; """recurrent small cell lung cancer"""^^xsd:string ; """stage III lymphoepithelioma of the nasopharynx"""^^xsd:string ; """urethral cancer associated with invasive bladder cancer"""^^xsd:string ; """stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity"""^^xsd:string ; """good prognosis metastatic gestational trophoblastic tumor"""^^xsd:string ; """stage III verrucous carcinoma of the oral cavity"""^^xsd:string ; """recurrent gestational trophoblastic tumor"""^^xsd:string ; """stage I squamous cell carcinoma of the lip and oral cavity"""^^xsd:string ; """newly diagnosed carcinoma of unknown primary"""^^xsd:string ; """stage IV lymphoepithelioma of the nasopharynx"""^^xsd:string ; """respiratory papillomas"""^^xsd:string ; """stage III verrucous carcinoma of the larynx"""^^xsd:string ; """recurrent thymoma and thymic carcinoma"""^^xsd:string ; """limited stage small cell lung cancer"""^^xsd:string ; """stage I esophageal cancer"""^^xsd:string ; """stage II follicular thyroid cancer"""^^xsd:string ; """stage IVA cervical cancer"""^^xsd:string ; """stage IV basal cell carcinoma of the lip"""^^xsd:string ; """stage II squamous cell carcinoma of the larynx"""^^xsd:string ; """stage III adrenocortical carcinoma"""^^xsd:string ; """chordoma"""^^xsd:string ; """recurrent thyroid cancer"""^^xsd:string ; """stage III esophageal cancer"""^^xsd:string ; """iris melanoma"""^^xsd:string ; """stage III follicular thyroid cancer"""^^xsd:string ; """recurrent squamous cell carcinoma of the larynx"""^^xsd:string ; """stage IV ovarian epithelial cancer"""^^xsd:string ; """stage 0 gastric cancer"""^^xsd:string ; """stage III midline lethal granuloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage III testicular cancer"""^^xsd:string ; """stage III colon cancer"""^^xsd:string ; """recurrent Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """chondrosarcoma"""^^xsd:string ; """recurrent prostate cancer"""^^xsd:string ; """localized gastrointestinal carcinoid tumor"""^^xsd:string ; """anterior urethral cancer"""^^xsd:string ; """adult meningioma"""^^xsd:string ; """stage 0 rectal cancer"""^^xsd:string ; """stage II renal cell cancer"""^^xsd:string ; """unresectable gallbladder cancer"""^^xsd:string ; """stage IV squamous cell carcinoma of the lip and oral cavity"""^^xsd:string ; """stage III rectal cancer"""^^xsd:string ; """recurrent cervical cancer"""^^xsd:string ; """inflammatory breast cancer"""^^xsd:string ; """advanced adult primary liver cancer"""^^xsd:string ; """metastatic gastrointestinal carcinoid tumor"""^^xsd:string ; """skin metastases"""^^xsd:string ; """stage 0 vaginal cancer"""^^xsd:string ; """adult craniopharyngioma"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """pancreatic polypeptide tumor"""^^xsd:string ; """adult subependymoma"""^^xsd:string ; """stage I adult soft tissue sarcoma"""^^xsd:string ; """stage IV adult soft tissue sarcoma"""^^xsd:string ; """grade I lymphomatoid granulomatosis"""^^xsd:string ; """adult grade III lymphomatoid granulomatosis"""^^xsd:string ; """stage II adult soft tissue sarcoma"""^^xsd:string ; """adult glioblastoma"""^^xsd:string ; """adult meningeal hemangiopericytoma"""^^xsd:string ; """adult oligodendroglioma"""^^xsd:string ; """recurrent adult grade III lymphomatoid granulomatosis"""^^xsd:string ; """adult tumors metastatic to brain"""^^xsd:string ; """adult pilocytic astrocytoma"""^^xsd:string ; """grade III meningioma"""^^xsd:string ; """adult anaplastic ependymoma"""^^xsd:string ; """grade II lymphomatoid granulomatosis"""^^xsd:string ; """adult myxopapillary ependymoma"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """recurrent inverted papilloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage III inverted papilloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage IV inverted papilloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage I inverted papilloma of the paranasal sinus and nasal cavity"""^^xsd:string ; """stage II inverted papilloma of the paranasal sinus and nasal cavity"""^^xsd:string ; umls:cui """C0279004"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """newly diagnosed carcinoma of unknown primary"""@eng ; skos:notation """CDR0000040835"""^^xsd:string ; skos:altLabel """carcinoma of unknown primary, newly diagnosed"""@eng , """newly diagnosed CUP"""@eng , """CUP, newly diagnosed"""@eng ; rdfs:subClassOf ; """carcinoma of unknown primary"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3864"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280460"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, carcinoma of unknown primary"""@eng ; skos:notation """CDR0000040834"""^^xsd:string ; skos:altLabel """carcinoma of unknown primary stage"""@eng , """CUP stage"""@eng ; rdfs:subClassOf ; """3863"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280459"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/tamoxifen"""@eng ; skos:notation """CDR0000040837"""^^xsd:string ; skos:altLabel """CTX/5-FU/TMX"""@eng , """CFT"""@eng ; ; ; ; """3866"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, carcinoma of unknown primary"""@eng ; skos:notation """CDR0000040836"""^^xsd:string ; skos:altLabel """CUP cellular diagnosis"""@eng , """carcinoma of unknown primary cellular diagnosis"""@eng ; rdfs:subClassOf ; """3865"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280461"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malignant pericardial effusion"""@eng ; skos:notation """CDR0000040831"""^^xsd:string ; skos:altLabel """pericardial effusion, malignant"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3860"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0220655"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leptomeningeal metastases"""@eng ; skos:notation """CDR0000040830"""^^xsd:string ; skos:altLabel """meningitis, leukemic"""@eng , """carcinomatous meningitis"""@eng , """metastatic cancer to leptomeninges"""@eng , """cancer, metastatic to leptomeninges"""@eng , """lymphomatous meningitis"""@eng , """leptomeningitis, leukemic"""@eng , """leptomeninges, metastatic cancer to"""@eng , """leukemic meningitis"""@eng , """meningitis, lymphomatous"""@eng , """lymphomatous leptomeningitis"""@eng , """leukemic leptomeningitis"""@eng , """leptomeningitis, lymphomatous"""@eng , """meningitis, carcinomatous"""@eng , """leptomeningitis, carcinomatous"""@eng , """carcinomatous leptomeningitis"""@eng , """cancer with leptomeningeal spread"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3859"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0220654"""^^xsd:string ; umls:cui """C1704231"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malignant ascites"""@eng ; skos:notation """CDR0000040833"""^^xsd:string ; skos:altLabel """ascites, malignant"""@eng ; rdfs:subClassOf ; """2003-04-03"""^^xsd:string ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3862"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0220656"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malignant pleural effusion"""@eng ; skos:notation """CDR0000040832"""^^xsd:string ; skos:altLabel """pleural effusion, malignant"""@eng ; rdfs:subClassOf ; """metastatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3861"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0080032"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imexon"""@eng ; skos:notation """CDR0000468469"""^^xsd:string ; skos:altLabel """Amplimexon"""@eng , """4-imino-1,3-diazabicyclo[3,1,0]-hexan-2-one"""@eng ; skos:definition """A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma. Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8. Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468469&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468469&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29115\" NCI Thesaurus)"""@eng ; """2006-03-03"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """C29115"""^^xsd:string ; """714597"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0097147"""^^xsd:string ; umls:cui """C0123374"""^^xsd:string ; umls:cui """C1708468"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/etoposide/methylprednisolone"""@eng ; skos:notation """CDR0000040839"""^^xsd:string ; skos:altLabel """ESHAP"""@eng , """ARA-C/CDDP/MePRDL/VP-16"""@eng , """E-SHAP"""@eng ; ; ; ; ; """3868"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0285858"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/methylprednisolone"""@eng ; skos:notation """CDR0000040838"""^^xsd:string ; skos:altLabel """ESHA"""@eng , """ARA-C/MePRDL/VP-16"""@eng ; ; ; ; """3867"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280463"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """R440"""@eng ; skos:notation """CDR0000043339"""^^xsd:string ; skos:altLabel """Ro-31-7453"""@eng ; """7876"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-10"""^^xsd:string ; umls:cui """C0796487"""^^xsd:string ; umls:cui """C1508754"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/floxuridine/irinotecan"""@eng ; skos:notation """CDR0000043338"""^^xsd:string ; skos:altLabel """CPT-11/DM/FUDR"""@eng ; ; ; ; """7875"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 folic acid"""@eng ; skos:notation """CDR0000043333"""^^xsd:string ; """7870"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796481"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HeFi-1"""@eng ; skos:notation """CDR0000043332"""^^xsd:string ; skos:altLabel """MOAB HeFi-1"""@eng , """HeFi-1"""@eng ; skos:definition """A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells. Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43332&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43332&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2505\" NCI Thesaurus)"""@eng ; """7869"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """2400"""^^xsd:string ; """603573"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9848"""^^xsd:string ; """C2505"""^^xsd:string ; umls:cui """C0796480"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-184476"""@eng ; skos:notation """CDR0000043331"""^^xsd:string ; skos:altLabel """BMS 184476"""@eng ; """2003-10-07"""^^xsd:string ; """7868"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796479"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/hydrocortisone/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000043330"""^^xsd:string ; skos:altLabel """ARA-C/CF/HC/MTX"""@eng ; ; ; ; ; """7867"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796478"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/thalidomide"""@eng ; skos:notation """CDR0000043337"""^^xsd:string ; skos:altLabel """CTX/THAL"""@eng ; ; ; """7874"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796485"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/irinotecan/paclitaxel"""@eng ; skos:notation """CDR0000043336"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/TAX"""@eng ; ; ; ; """7873"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796484"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/docetaxel"""@eng ; skos:notation """CDR0000043335"""^^xsd:string ; skos:altLabel """CAPE/TXT"""@eng ; ; ; """7872"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796483"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/mitomycin"""@eng ; skos:notation """CDR0000043334"""^^xsd:string ; skos:altLabel """CPT-11/MITO"""@eng ; ; ; """7871"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041784"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/MP/MTX/VCR"""@eng ; ; ; ; ; ; ; ; """4965"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281365"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypotension"""@eng ; skos:notation """CDR0000041785"""^^xsd:string ; rdfs:subClassOf ; """4968"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0020649"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/interleukin-2/methylprednisolone"""@eng ; skos:notation """CDR0000041786"""^^xsd:string ; skos:altLabel """CYSP/IL-2/MePRDL"""@eng ; ; ; ; """4969"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281366"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine/zidovudine"""@eng ; skos:notation """CDR0000041787"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED/VCR/VP-16/ZDV"""@eng ; ; ; ; ; ; ; """4970"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281367"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylene blue"""@eng ; skos:notation """CDR0000041780"""^^xsd:string ; skos:altLabel """Methylenum Caeruleum"""@eng , """CI Basic Blue 9"""@eng , """Blu di Metilene"""@eng , """Methylthioninium Chloride"""@eng , """Azul de Metileno"""@eng , """Urolene Blue"""@eng , """Azul Metile"""@eng , """Vitableu"""@eng , """MB"""@eng , """Methylthioninii Chloridum"""@eng , """CI-52015"""@eng , """Desmoidpillen"""@eng , """Colour Index No. 52015"""@eng , """Collubleu"""@eng , """Schultz No. 1038"""@eng , """Tetramethylthionine Chloride Trihydrate"""@eng ; skos:definition """A synthetic basic dye. Methylene blue stains to negatively charged cell components like nucleic acids; when administered in the lymphatic bed of a tumor during oncologic surgery, methylene blue may stain lymph nodes draining from the tumor, thereby aiding in the visual localization of tumor sentinel lymph nodes. When administered intravenously in low doses, this agent may convert methemoglobin to hemoglobin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41780&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41780&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C644\" NCI Thesaurus)"""@eng ; ; """4961"""^^xsd:string ; """617593"""^^xsd:string ; """61-73-4"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C644"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0025746"""^^xsd:string ; umls:cui """C0813444"""^^xsd:string ; umls:cui """C2366665"""^^xsd:string ; umls:cui """C1513227"""^^xsd:string ; umls:cui """C1513226"""^^xsd:string ; umls:cui """C1513225"""^^xsd:string ; umls:cui """C1513224"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/interleukin-1-alpha/methylene blue"""@eng ; skos:notation """CDR0000041781"""^^xsd:string ; skos:altLabel """CBDCA/IL-1A/MB"""@eng ; ; ; ; """4962"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281362"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/doxorubicin/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000041782"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DM/DOX/MP/VCR"""@eng ; ; ; ; ; ; ; """4963"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281363"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000041783"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DOX/MP/VCR"""@eng ; ; ; ; ; ; ; ; """4964"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281364"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody 14G2A/sargramostim"""@eng ; skos:notation """CDR0000041788"""^^xsd:string ; skos:altLabel """GM-CSF/IL-2/MOAB 14G2A"""@eng ; ; ; ; """4971"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281368"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/etoposide/prednisone"""@eng ; skos:notation """CDR0000041789"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/PRED/VP-16"""@eng ; ; ; ; ; """4972"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281369"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amoxicillin-clavulanate potassium"""@eng ; skos:notation """CDR0000040783"""^^xsd:string ; skos:altLabel """Augmentin"""@eng ; skos:definition """A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40783&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40783&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1023\" NCI Thesaurus)"""@eng ; ; """3747"""^^xsd:string ; """C1023"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591132"""^^xsd:string ; umls:cui """C0054066"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fertility assessment/management"""@eng ; skos:notation """CDR0000040782"""^^xsd:string ; skos:altLabel """assessment/management, fertility"""@eng , """infertility"""@eng , """fertility management/assessment"""@eng ; ; rdfs:subClassOf ; """3745"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280429"""^^xsd:string ; umls:cui """C0021359"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult T-cell leukemia/lymphoma"""@eng ; skos:notation """CDR0000040781"""^^xsd:string ; skos:altLabel """adult T-cell leukemia/lymphoma, relapsed"""@eng , """recurrent HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """relapsed HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """relapsed adult T-Cell leukemia/lymphoma"""@eng , """adult T-cell leukemia/lymphoma, recurrent"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, relapsed"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, recurrent"""@eng ; rdfs:subClassOf ; """adult T-cell leukemia/lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3743"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280427"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adult T-cell leukemia/lymphoma"""@eng ; skos:notation """CDR0000040780"""^^xsd:string ; skos:altLabel """stage IV HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """metastatic adult T-cell leukemia/lymphoma"""@eng , """metastatic HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, stage IV"""@eng , """adult T-cell leukemia/lymphoma, stage IV"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, metastatic"""@eng , """adult T-cell leukemia/lymphoma, metastatic"""@eng ; rdfs:subClassOf ; """adult T-cell leukemia/lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3742"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280426"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/carmustine/etoposide/methotrexate/prednisone"""@eng ; skos:notation """CDR0000040787"""^^xsd:string ; skos:altLabel """BCNU/BLEO/MTX/PRED/VP-16"""@eng , """BBVP-M"""@eng ; ; ; ; ; ; """3751"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280434"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/paclitaxel"""@eng ; skos:notation """CDR0000043259"""^^xsd:string ; skos:altLabel """BLEO/CDDP/TAX/VP-16"""@eng ; ; ; ; ; """7746"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796413"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ganglioside GM2"""@eng ; skos:notation """CDR0000040785"""^^xsd:string ; skos:altLabel """GM2 ganglioside"""@eng ; """3749"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0016896"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciprofloxacin"""@eng ; skos:notation """CDR0000040784"""^^xsd:string ; skos:altLabel """1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid"""@eng , """CPFX"""@eng , """Cipro"""@eng ; skos:definition """A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40784&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40784&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C375\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """3748"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C375"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """85721-33-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0008809"""^^xsd:string ; umls:cui """C0701042"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bladder cancer prevention"""@eng ; skos:notation """CDR0000043254"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """7741"""^^xsd:string ; umls:cui """C0796409"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multivitamin"""@eng ; skos:notation """CDR0000043255"""^^xsd:string ; skos:altLabel """MULTIVIT"""@eng , """Geritol"""@eng ; skos:definition """A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43255&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43255&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1654\" NCI Thesaurus)"""@eng ; ; ; """7742"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-02"""^^xsd:string ; """C1654"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0301532"""^^xsd:string ; umls:cui """C0644258"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gentamicin/piperacillin/vancomycin"""@eng ; skos:notation """CDR0000040789"""^^xsd:string ; skos:altLabel """GM/PIPER/VANCO"""@eng , """VGP"""@eng ; ; ; ; """3753"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280436"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/thiotepa"""@eng ; skos:notation """CDR0000040788"""^^xsd:string ; skos:altLabel """BCNU/CTX/TSPA"""@eng , """TACT II"""@eng ; ; ; ; """3752"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280435"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PSA prostate cancer vaccine"""@eng ; skos:notation """CDR0000043250"""^^xsd:string ; skos:altLabel """OncoVax-Pr"""@eng , """PSA VAC"""@eng , """CaPVax"""@eng ; ; ; """7735"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796406"""^^xsd:string ; umls:cui """C0919275"""^^xsd:string ; umls:cui """C1527176"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oregovomab"""@eng ; skos:notation """CDR0000043251"""^^xsd:string ; skos:altLabel """OvaRex"""@eng , """B43.13"""@eng , """MOAB B43.13"""@eng , """monoclonal antibody B43.13"""@eng ; skos:definition """A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43251&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43251&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1784\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2004-07-26"""^^xsd:string ; """7737"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1784"""^^xsd:string ; umls:cui """C0664207"""^^xsd:string ; umls:cui """C0664206"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Allovectin-7/dacarbazine"""@eng ; skos:notation """CDR0000043252"""^^xsd:string ; skos:altLabel """ALLO-7/DTIC"""@eng ; ; ; """7738"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796407"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000043253"""^^xsd:string ; skos:altLabel """CBDCA/MOAB HER2/TAX"""@eng ; ; ; ; """7739"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796408"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tobacco use disorder"""@eng ; skos:notation """CDR0000482224"""^^xsd:string ; rdfs:subClassOf ; """2006-04-20"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C0040336"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acyclovir sodium"""@eng ; skos:notation """CDR0000531923"""^^xsd:string ; skos:altLabel """Zovirax"""@eng ; skos:definition """The sodium salt form of acyclovir, a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=531923&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=531923&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47956\" NCI Thesaurus)"""@eng ; """2007-01-25"""^^xsd:string ; """C47956"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0592290"""^^xsd:string ; umls:cui """C0282040"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AEG35156"""@eng ; skos:notation """CDR0000492218"""^^xsd:string ; skos:altLabel """GEM640"""@eng ; skos:definition """A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492218&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492218&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49180\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C49180"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """2006-06-23"""^^xsd:string ; umls:cui """C1567121"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hereditary neoplastic syndrome"""@eng ; skos:notation """CDR0000482229"""^^xsd:string ; rdfs:subClassOf ; """Cancer diagnosis"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """2007-01-28"""^^xsd:string ; """neoplastic syndrome"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; umls:cui """C0027672"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/hydroxyurea/interferon alfa"""@eng ; skos:notation """CDR0000041872"""^^xsd:string ; skos:altLabel """5-FU/HU/IFN-A"""@eng ; ; ; ; """5086"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338175"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/interferon alfa/tretinoin"""@eng ; skos:notation """CDR0000041873"""^^xsd:string ; skos:altLabel """ATRA/DOX/IFN-A"""@eng ; ; ; ; """5087"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338176"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciprofloxacin/cisplatin/cyclophosphamide/etoposide/pentoxifylline"""@eng ; skos:notation """CDR0000041870"""^^xsd:string ; skos:altLabel """CDDP/CPFX/CTX/PTX/VP-16"""@eng ; ; ; ; ; ; """5084"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281434"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antisense-RNA"""@eng ; skos:notation """CDR0000041871"""^^xsd:string ; skos:altLabel """antisense oligodeoxyribonucleotide LR-3001"""@eng , """LR-3001"""@eng , """antisense oligodeoxyribonucleotide OL(1)p53"""@eng , """OL(1)p53"""@eng ; """5085"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0080124"""^^xsd:string ; umls:cui """C0253788"""^^xsd:string ; umls:cui """C0700610"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """proteasome inhibitor NPI-0052"""@eng ; skos:notation """CDR0000518316"""^^xsd:string ; skos:altLabel """NPI-0052"""@eng ; """2006-11-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1570638"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/etoposide/melphalan"""@eng ; skos:notation """CDR0000041877"""^^xsd:string ; skos:altLabel """BCNU/CTX/L-PAM/VP-16"""@eng ; ; ; ; ; """5090"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281439"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Spherex"""@eng ; skos:notation """CDR0000041874"""^^xsd:string ; skos:altLabel """starch microspheres"""@eng ; """5088"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0074981"""^^xsd:string ; umls:cui """C1524076"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T122"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/doxorubicin/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041875"""^^xsd:string ; skos:altLabel """ASP/CTX/DOX/PRDL/VCR"""@eng ; ; ; ; ; ; """5089"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0119180"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/hydroxyurea"""@eng ; skos:notation """CDR0000041878"""^^xsd:string ; skos:altLabel """DOX/HU"""@eng ; ; ; """5091"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281440"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/methotrexate"""@eng ; skos:notation """CDR0000041879"""^^xsd:string ; skos:altLabel """CCNU/MTX"""@eng ; ; ; """5092"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281441"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spiromustine"""@eng ; skos:notation """CDR0000039441"""^^xsd:string ; skos:altLabel """1,3-diazaspiro(4,5)decane-2,4-dione,3-(2-(bis-chloroethyl)amino)ethyl"""@eng , """spirohydantoin mustard"""@eng , """SHM"""@eng ; skos:definition """A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39441&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39441&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1233\" NCI Thesaurus)"""@eng ; """2076"""^^xsd:string ; """C1233"""^^xsd:string ; """21354"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """172112"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """56605-16-4"""^^xsd:string ; umls:cui """C0075019"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XL844"""@eng ; skos:notation """CDR0000469731"""^^xsd:string ; skos:definition """A synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of DNA damage or incomplete DNA replication, eukaryotic cells activate cell cycle checkpoints that temporarily halt the cell cycle to permit DNA repair or completion of DNA replication to take place. In the presence of extensive damage or absence of timely repair, these checkpoint-signaling pathways may also trigger a pathway that effects apoptosis. Normal functions of Chks involve the initiation of cell-cycle arrest and the up-regulation of transcription genes involved with DNA excision repair and dNTP synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469731&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469731&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61102\" NCI Thesaurus)"""@eng ; """2006-07-18"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """C61102"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831757"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SAOB-0401"""@eng ; skos:notation """CDR0000418694"""^^xsd:string ; skos:altLabel """Xenavex![TRADE MARK SIGN]!"""@eng , """Xenavex™"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2005-02-04"""^^xsd:string ; """2005-01-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541497"""^^xsd:string ; umls:cui """C1541162"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """M40403"""@eng ; skos:notation """CDR0000418695"""^^xsd:string ; """2005-02-04"""^^xsd:string ; """2005-01-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0909605"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/thalidomide"""@eng ; skos:notation """CDR0000305852"""^^xsd:string ; skos:altLabel """CBDCA/THAL/VP-16"""@eng ; ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327968"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/mafosfamide/vincristine"""@eng ; skos:notation """CDR0000037903"""^^xsd:string ; skos:altLabel """CDDP/CTX/MAF/VCR/VP-16"""@eng ; ; ; ; ; ; """10312"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879463"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/irinotecan"""@eng ; skos:notation """CDR0000037902"""^^xsd:string ; skos:altLabel """CPT-11/MOAB C225"""@eng ; ; ; """10311"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/tirapazamine/vinorelbine"""@eng ; skos:notation """CDR0000037901"""^^xsd:string ; skos:altLabel """CDDP/SR-4233/VNB"""@eng ; ; ; ; """10310"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879461"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000037900"""^^xsd:string ; skos:altLabel """CML"""@eng , """granulocytic leukemia, chronic"""@eng , """myelocytic leukemia, chronic"""@eng , """chronic myelocytic leukemia"""@eng , """leukemia, chronic myelogenous"""@eng , """Chronic myelogenous leukemia (CML)"""@eng , """myelogenous leukemia, chronic"""@eng , """chronic granulocytic leukemia"""@eng , """CGL"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """chronic myeloproliferative disorders"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1031"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023473"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/SU5416"""@eng ; skos:notation """CDR0000038010"""^^xsd:string ; skos:altLabel """DM/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10525"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879617"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/methotrexate"""@eng ; skos:notation """CDR0000037906"""^^xsd:string ; skos:altLabel """MTX/TXT"""@eng ; ; ; """10315"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879466"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/tirapazamine"""@eng ; skos:notation """CDR0000037905"""^^xsd:string ; skos:altLabel """CBDCA/SR-4233/TAX"""@eng ; ; ; ; """10314"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879465"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000038013"""^^xsd:string ; skos:altLabel """DOX/MTX/PEG/VCR"""@eng ; ; ; ; ; """10528"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879560"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 22q"""@eng ; skos:notation """CDR0000037909"""^^xsd:string ; rdfs:subClassOf ; """10318"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0935661"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 22q11"""@eng ; skos:notation """CDR0000037908"""^^xsd:string ; rdfs:subClassOf ; """10317"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0935660"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000038018"""^^xsd:string ; skos:altLabel """DM/IFF/VP-16"""@eng ; ; ; ; """10534"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879566"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin liposomal/SU5416"""@eng ; skos:notation """CDR0000038019"""^^xsd:string ; skos:altLabel """Daunoxome/SU-5416"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10535"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879567"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent prostate cancer"""@eng ; skos:notation """CDR0000038787"""^^xsd:string ; skos:altLabel """prostate cancer, recurrent"""@eng ; rdfs:subClassOf ; """prostate cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1234"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278838"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III testicular cancer"""@eng ; skos:notation """CDR0000038780"""^^xsd:string ; skos:altLabel """carcinoma of the testis, stage III"""@eng , """stage III carcinoma of the testis"""@eng , """testicle cancer, stage III"""@eng , """testis cancer, stage III"""@eng , """stage III cancer of the testis"""@eng , """cancer of the testis, stage III"""@eng , """stage III testis cancer"""@eng , """testicular cancer, stage III"""@eng ; rdfs:subClassOf ; """testicular cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1227"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278833"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin cancer"""@eng ; skos:notation """CDR0000038781"""^^xsd:string ; skos:altLabel """carcinoma of the skin"""@eng , """Skin cancer, nonmelanomatous (squamous and basal cell)"""@eng , """cancer of the skin"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; ; """2002-10-15"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1228"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0699893"""^^xsd:string ; umls:cui """C0007114"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AE-941/cisplatin/vinorelbine"""@eng ; skos:notation """CDR0000037967"""^^xsd:string ; skos:altLabel """AE941/CDDP/VNB"""@eng ; ; ; ; """2003-04-21"""^^xsd:string ; """10385"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879505"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/keyhole limpet hemocyanin/MAGE-3/Melan-A/survivin"""@eng ; skos:notation """CDR0000346074"""^^xsd:string ; skos:altLabel """ADC/KLH/MAGE3/MEL-A/SRV"""@eng ; ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328105"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I prostate cancer"""@eng ; skos:notation """CDR0000038783"""^^xsd:string ; skos:altLabel """stage A carcinoma of the prostate"""@eng , """prostate cancer, stage I"""@eng , """cancer of the prostate, stage I"""@eng , """stage A prostate cancer"""@eng , """stage I carcinoma of the prostate"""@eng , """prostate cancer, stage A"""@eng , """cancer of the prostate, stage A"""@eng , """stage I cancer of the prostate"""@eng , """carcinoma of the prostate, stage A"""@eng , """stage A cancer of the prostate"""@eng , """carcinoma of the prostate, stage I"""@eng ; rdfs:subClassOf ; """prostate cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1230"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278834"""^^xsd:string ; umls:cui """C1370970"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """survivin antigen"""@eng ; skos:notation """CDR0000346072"""^^xsd:string ; skos:altLabel """survivin"""@eng , """SRV"""@eng ; skos:definition """A tumor-associated antigen. Vaccination with survivin antigen may result in a cytotoxic T-cell response against survivin antigen-expressing tumor cells, resulting in decreased tumor cell proliferation and tumor cell death. Overexpressed in many tumors, endogenous survivin inhibits tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346072&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346072&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37449\" NCI Thesaurus)"""@eng ; ; ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """2003-11-20"""^^xsd:string ; """C37449"""^^xsd:string ; umls:cui """C0664336"""^^xsd:string ; umls:cui """C1515097"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/MAGE-3/Melan-A/survivin"""@eng ; skos:notation """CDR0000346073"""^^xsd:string ; skos:altLabel """ADC/MAGE3/MEL-A/SRV"""@eng ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328104"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HuHMFG1"""@eng ; skos:notation """CDR0000322247"""^^xsd:string ; skos:altLabel """humanized IgG1 monoclonal antibody HMFG-1"""@eng , """Therex"""@eng , """humanized human milk fat globule-1 monoclonal antibody"""@eng , """HuHMFG1"""@eng , """R1550"""@eng , """MOAB HuHMFG1"""@eng ; skos:definition """A humanized monoclonal antibody directed against MUC1, a mucin glycoprotein overexpressed in breast and other carcinomas. Monoclonal antibody HuHMFG1 stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing MUC1, resulting in a decrease in tumor burden. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322247&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322247&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38697\" NCI Thesaurus)"""@eng ; """2003-07-26"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """C38697"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328704"""^^xsd:string ; umls:cui """C1328018"""^^xsd:string ; umls:cui """C1328017"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vitamin D"""@eng ; skos:notation """CDR0000467750"""^^xsd:string ; skos:altLabel """VIT D"""@eng , """Vitamin-D"""@eng , """D vitamin"""@eng ; skos:definition """A family of lipo-soluble steroids important to the absorption, metabolism, and function of calcium and phosphorus and the growth and development of bone and tooth enamel. Found naturally in animal tissues, cholecalciferol (vitamin D3) is formed in the skin when ultraviolet light activates cholesterol conversion into vitamin D3. Ultraviolet irradiation of ergosterol (plant vitamin D) forms ergocalciferol (vitamin D2). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467750&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467750&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C941\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C941"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C3537249"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ZYC300"""@eng ; skos:notation """CDR0000513166"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-14"""^^xsd:string ; umls:cui """C1831967"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/doxorubicin"""@eng ; skos:notation """CDR0000039691"""^^xsd:string ; skos:altLabel """HAD"""@eng , """CDDP/DOX/HMM"""@eng ; ; ; ; """2345"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0062074"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000039690"""^^xsd:string ; skos:altLabel """HAC"""@eng , """CTX/DOX/HMM"""@eng ; ; ; ; """2344"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279470"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/dactinomycin/vincristine"""@eng ; skos:notation """CDR0000039693"""^^xsd:string ; skos:altLabel """AVD"""@eng , """DACT/DTIC/VCR"""@eng ; ; ; ; """2347"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279473"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039692"""^^xsd:string ; skos:altLabel """ARA-C/PRED/TG/VCR"""@eng , """ATOP"""@eng ; ; ; ; ; """2346"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/cytarabine/hydroxyurea/lomustine/methylprednisolone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039695"""^^xsd:string ; skos:altLabel """ARA-C/CCNU/CDDP/CTX/HU/MePRDL/PCB/VCR"""@eng ; ; ; ; ; ; ; ; ; """2349"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279475"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/zorubicin"""@eng ; skos:notation """CDR0000039694"""^^xsd:string ; skos:altLabel """ARA-C/RBZ"""@eng ; ; ; """2348"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279474"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/doxorubicin/melphalan"""@eng ; skos:notation """CDR0000039697"""^^xsd:string ; skos:altLabel """HAM"""@eng , """DOX/HMM/L-PAM"""@eng ; ; ; ; """2353"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279477"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000039696"""^^xsd:string ; skos:altLabel """AVM"""@eng , """DOX/MTX/VBL"""@eng ; ; ; ; """2352"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279476"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/doxorubicin/methotrexate"""@eng ; skos:notation """CDR0000039699"""^^xsd:string ; skos:altLabel """HAM-II"""@eng , """DOX/HMM/MTX"""@eng ; ; ; ; """2355"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279479"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide"""@eng ; skos:notation """CDR0000039698"""^^xsd:string ; skos:altLabel """DOX/VP-16"""@eng , """AVP-16"""@eng ; ; ; """2354"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077972"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000039448"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF/VP-16"""@eng ; ; ; ; ; """2083"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/lomustine/vincristine"""@eng ; skos:notation """CDR0000039449"""^^xsd:string ; skos:altLabel """CCV"""@eng , """CCNU/CTX/VCR"""@eng ; ; ; ; """2084"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054931"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/mercaptopurine/prednisolone"""@eng ; skos:notation """CDR0000039529"""^^xsd:string ; skos:altLabel """ARA-C/DNR/MP/PRDL"""@eng , """DCMP"""@eng ; ; ; ; ; """2172"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057181"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/vindesine"""@eng ; skos:notation """CDR0000039528"""^^xsd:string ; skos:altLabel """BLEO/CDDP/DAVA"""@eng , """DVB"""@eng ; ; ; ; """2171"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056631"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluoxymesterone/mitolactol/tamoxifen"""@eng ; skos:notation """CDR0000039527"""^^xsd:string ; skos:altLabel """DATH"""@eng , """DBD/DOX/FXM/TMX"""@eng ; ; ; ; """2170"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279345"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/vincristine/zorubicin"""@eng ; skos:notation """CDR0000039526"""^^xsd:string ; skos:altLabel """CTX/PRED/VCR/RBZ"""@eng , """CROP"""@eng ; ; ; ; ; """2164"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279344"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000037765"""^^xsd:string ; skos:altLabel """CLL"""@eng , """lymphocytic leukemia, chronic"""@eng , """Leukemia, chronic lymphocytic (CLL)"""@eng , """leukemia, chronic lymphocytic"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1003"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023434"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/methotrexate/prednisone/vincristine/zorubicin"""@eng ; skos:notation """CDR0000039524"""^^xsd:string ; skos:altLabel """ASP/CTX/MTX/PRED/RBZ/VCR"""@eng , """CROPAM"""@eng ; ; ; ; ; ; ; """2162"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279342"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisolone/tamoxifen"""@eng ; skos:notation """CDR0000039523"""^^xsd:string ; skos:altLabel """PRDL/TMX"""@eng ; ; ; """2161"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279341"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/lomustine/vincristine"""@eng ; skos:notation """CDR0000039522"""^^xsd:string ; skos:altLabel """CVAC"""@eng , """CCNU/CTX/DOX/VCR"""@eng ; ; ; ; ; """2160"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054932"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039521"""^^xsd:string ; skos:altLabel """ASP/MTX/VCR"""@eng ; ; ; ; """2159"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279339"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cytarabine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039520"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/MTX/VCR"""@eng , """CytaBOM"""@eng ; ; ; ; ; """2158"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279338"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000041274"""^^xsd:string ; skos:altLabel """G-CSF/TAX"""@eng ; ; ; """4347"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280863"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000041275"""^^xsd:string ; skos:altLabel """CBDCA/DOX/VP-16"""@eng ; ; ; ; """4348"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0295717"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/mitomycin"""@eng ; skos:notation """CDR0000041276"""^^xsd:string ; skos:altLabel """MITO/WR-2721"""@eng ; ; ; """4349"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280865"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/dacarbazine/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000041277"""^^xsd:string ; skos:altLabel """BCNU/CDDP/DTIC/IFN-A/TMX"""@eng ; ; ; ; ; ; """4350"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338137"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041270"""^^xsd:string ; skos:altLabel """CTX/DOX/PRDL/VCR/VP-16"""@eng ; ; ; ; ; ; """4343"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280859"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000041271"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED/R-VPAM/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4344"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280860"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041272"""^^xsd:string ; skos:altLabel """CTX/DOX/PRDL/R-VPAM/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4345"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280861"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/idoxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000041273"""^^xsd:string ; skos:altLabel """CF/5-FU/IUDR"""@eng ; ; ; ; """4346"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280862"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/interleukin-3"""@eng ; skos:notation """CDR0000041278"""^^xsd:string ; skos:altLabel """ARA-C/IL-3"""@eng ; ; ; """4351"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280867"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/fluorouracil/interferon alfa/leucovorin calcium"""@eng ; skos:notation """CDR0000041279"""^^xsd:string ; skos:altLabel """CF/5-FU/FUDR/IFN-A"""@eng ; ; ; ; ; """4352"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338138"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular embryonal carcinoma"""@eng ; skos:notation """CDR0000040004"""^^xsd:string ; skos:altLabel """embryonal carcinoma of the testis"""@eng , """testis cancer, embryonal"""@eng , """embryonal carcinoma, testicular"""@eng , """testicle cancer, embryonal"""@eng , """testicular cancer, embryonal"""@eng ; rdfs:subClassOf ; """2730"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238448"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular choriocarcinoma"""@eng ; skos:notation """CDR0000040005"""^^xsd:string ; skos:altLabel """testicle cancer, choriocarcinoma"""@eng , """testicular cancer, choriocarcinoma"""@eng , """choriocarcinoma of the testis"""@eng , """testis cancer, choriocarcinoma"""@eng , """choriocarcinoma, testicular"""@eng ; rdfs:subClassOf ; """2731"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238449"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular teratoma"""@eng ; skos:notation """CDR0000040006"""^^xsd:string ; skos:altLabel """teratoma, testicular"""@eng , """testicular cancer, teratoma"""@eng , """testis cancer, teratoma"""@eng , """testicle cancer, teratoma"""@eng , """teratoma of the testis"""@eng ; rdfs:subClassOf ; """2732"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238451"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular yolk sac tumor"""@eng ; skos:notation """CDR0000040007"""^^xsd:string ; skos:altLabel """testis cancer, yolk sac tumor"""@eng , """yolk sac tumor, testicular"""@eng , """testicular cancer, yolk sac tumor"""@eng , """testicle cancer, yolk sac tumor"""@eng , """yolk sac tumor of the testis"""@eng ; rdfs:subClassOf ; """2733"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279708"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """type B3 thymoma"""@eng ; skos:notation """CDR0000040000"""^^xsd:string ; skos:altLabel """atypical thymoma"""@eng , """squamoid thymoma"""@eng , """well-differentiated thymic carcinoma"""@eng , """epithelial thymoma"""@eng ; rdfs:subClassOf ; """2003-08-21"""^^xsd:string ; """2726"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279705"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEP-3-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000391254"""^^xsd:string ; skos:altLabel """PEP-3-KLH"""@eng ; """2004-09-25"""^^xsd:string ; """2004-09-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541477"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular seminoma"""@eng ; skos:notation """CDR0000040003"""^^xsd:string ; skos:altLabel """testicular cancer, seminoma"""@eng , """seminoma of the testis"""@eng , """seminoma, testicular"""@eng , """testicle cancer, seminoma"""@eng , """testis cancer, seminoma"""@eng ; rdfs:subClassOf ; """2729"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0036631"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CD137 monoclonal antibody"""@eng ; skos:notation """CDR0000489120"""^^xsd:string ; skos:altLabel """BMS-663513"""@eng ; """2006-09-18"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """C62449"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831875"""^^xsd:string ; umls:cui """C1831876"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NY-ESO-1 plasmid DNA cancer vaccine"""@eng ; skos:notation """CDR0000489121"""^^xsd:string ; skos:altLabel """NY-ESO-1 Plasmid DNA Vaccine"""@eng ; """2006-09-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """C62452"""^^xsd:string ; umls:cui """C1831877"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """topotecan hydrochloride (oral)"""@eng ; skos:notation """CDR0000489122"""^^xsd:string ; skos:altLabel """oral Hycamtin"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831879"""^^xsd:string ; umls:cui """C0886549"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular embryonal carcinoma and teratoma"""@eng ; skos:notation """CDR0000040008"""^^xsd:string ; skos:altLabel """testis cancer, teratocarcinoma"""@eng , """testis cancer, teratoma and embryonal carcinoma"""@eng , """embryonal carcinoma and teratoma, testicular"""@eng , """teratocarcinoma, testicular"""@eng , """testicle cancer, teratoma and embryonal carcinoma"""@eng , """testicle cancer, teratocarcinoma"""@eng , """testicular cancer, teratocarcinoma"""@eng , """testicular teratoma and embryonal carcinoma"""@eng , """teratoma and embryonal carcinoma of the testis"""@eng , """testicular cancer, teratoma and embryonal carcinoma"""@eng , """testicular cancer, embryonal carcinoma and teratoma"""@eng , """testis cancer, embryonal carcinoma and teratoma"""@eng ; rdfs:subClassOf ; """2734"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279709"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular embryonal carcinoma and teratoma with seminoma"""@eng ; skos:notation """CDR0000040009"""^^xsd:string ; skos:altLabel """testicular cancer, teratoma with seminoma and embryonal carcinoma"""@eng , """testicle cancer, embryonal carcinoma and teratoma with seminoma"""@eng , """testicular teratoma with seminoma and embryonal carcinoma"""@eng , """teratoma with seminoma and embryonal carcinoma of the testis"""@eng , """testis cancer, teratoma with seminoma and embryonal carcinoma"""@eng , """testis cancer, embryonal carcinoma and teratoma with seminoma"""@eng , """embryonal carcinoma and teratoma with seminoma, testicular"""@eng , """testicular cancer, embryonal carcinoma and teratoma with seminoma"""@eng ; rdfs:subClassOf ; """2735"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279710"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XL880"""@eng ; skos:notation """CDR0000428188"""^^xsd:string ; """2005-04-01"""^^xsd:string ; """2005-03-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C2973988"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lonidamine"""@eng ; skos:notation """CDR0000040249"""^^xsd:string ; skos:altLabel """AF 1890"""@eng , """LND"""@eng , """diclondazolic acid"""@eng , """DICA"""@eng ; """3077"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0065175"""^^xsd:string ; umls:cui """C0950353"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-IL-6 chimeric monoclonal antibody"""@eng ; skos:notation """CDR0000475765"""^^xsd:string ; skos:altLabel """cCLB8"""@eng , """CNTO 328"""@eng ; skos:definition """A human-mouse chimeric antibody, constructed from a murine antiinterleukin 6 (IL-6) monoclonal antibody, with antitumor and antiinflammatory activities. Containing the antigen-binding variable region of the murine antibody, CLB-IL-6-8, and the constant region of a human IgG1kappa immunoglobulin, anti-IL-6 chimeric monoclonal antibody has high affinity for recombinant as well as native IL-6 and inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), resulting in the blockade of the IL-6/IL-6R/gp130 signal transduction pathway, and, subsequently, antitumor and antiinflammatory activities. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475765&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475765&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61084\" NCI Thesaurus)"""@eng ; """C61084"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-24"""^^xsd:string ; """2006-07-26"""^^xsd:string ; umls:cui """C1831794"""^^xsd:string ; umls:cui """C1609931"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium stibogluconate"""@eng ; skos:notation """CDR0000475763"""^^xsd:string ; skos:altLabel """SSG"""@eng , """Pentostam"""@eng ; skos:definition """Pentavalent antimony (Sb) in differential complex formation with gluconic acid with established leishmanicidal use and potential antitumor activity. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phophorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475763&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475763&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61083\" NCI Thesaurus)"""@eng ; """2006-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-04"""^^xsd:string ; """C61083"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0030895"""^^xsd:string ; umls:cui """C0591962"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/interferon gamma/leucovorin calcium"""@eng ; skos:notation """CDR0000041667"""^^xsd:string ; skos:altLabel """CF/5-FU/IFN-A/IFN-G"""@eng ; ; ; ; ; """4830"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338165"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/tretinoin"""@eng ; skos:notation """CDR0000041666"""^^xsd:string ; skos:altLabel """ATRA/IFN-A"""@eng ; ; ; """4829"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338164"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboxypeptidase-G2"""@eng ; skos:notation """CDR0000041665"""^^xsd:string ; skos:altLabel """Voraxaze"""@eng , """CPDG2"""@eng , """CPG2"""@eng , """carboxypeptidase G2"""@eng , """Glucarpidase"""@eng ; skos:definition """A zinc-dependent enzyme isolated from a strain of the bacterium Pseudomonas. Because carboxypeptidase-G2 rapidly hydrolyzes methotrexate into inactive metabolites, it may be useful as a rescue agent for methotrexate-induced nephrotoxicity. In antibody-directed enzyme prodrug therapy (ADEPT), this agent is conjugated with an antibody that binds to a specific tumor cell type, allowing for carboxypeptidase-G2-catalyzed activation of a co-administered prodrug at the site of the tumor. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41665&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41665&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C346\" NCI Thesaurus)"""@eng ; ; """4828"""^^xsd:string ; """641273"""^^xsd:string ; """C346"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4663"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1707272"""^^xsd:string ; umls:cui """C0007072"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenylacetate"""@eng ; skos:notation """CDR0000041664"""^^xsd:string ; """4827"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0220893"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sorivudine"""@eng ; skos:notation """CDR0000041663"""^^xsd:string ; skos:altLabel """BV-araU"""@eng , """SQ 32756"""@eng , """BV-ara-U"""@eng , """Bravavir"""@eng ; """4826"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0701502"""^^xsd:string ; umls:cui """C0701503"""^^xsd:string ; umls:cui """C0207628"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """known bone marrow involvement"""@eng ; skos:notation """CDR0000041662"""^^xsd:string ; """4824"""^^xsd:string ; umls:cui """C0281268"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bilateral breast cancer"""@eng ; skos:notation """CDR0000041661"""^^xsd:string ; skos:altLabel """bilateral"""@eng ; """4823"""^^xsd:string ; umls:cui """C0238767"""^^xsd:string ; umls:cui """C0281267"""^^xsd:string ; umls:tui """T082"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior adjuvant endocrine/hormonal therapy"""@eng ; skos:notation """CDR0000041660"""^^xsd:string ; """4822"""^^xsd:string ; umls:cui """C0281266"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lobaplatin"""@eng ; skos:notation """CDR0000041669"""^^xsd:string ; """4832"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0165747"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/streptozocin"""@eng ; skos:notation """CDR0000041668"""^^xsd:string ; skos:altLabel """DOX/SZC"""@eng ; ; ; """4831"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281271"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tranexamic acid"""@eng ; skos:notation """CDR0000453549"""^^xsd:string ; skos:altLabel """Cyklokapron"""@eng ; skos:definition """A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, transexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453549&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453549&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47765\" NCI Thesaurus)"""@eng ; """2005-10-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C47765"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591311"""^^xsd:string ; umls:cui """C0040613"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HKI-272"""@eng ; skos:notation """CDR0000453548"""^^xsd:string ; skos:definition """An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile, irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. HKI-272 binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. HKI-272 also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453548&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453548&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49094\" NCI Thesaurus)"""@eng ; """2006-08-25"""^^xsd:string ; """2005-10-24"""^^xsd:string ; """C49094"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1454298"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dolastatin 10"""@eng ; skos:notation """CDR0000042316"""^^xsd:string ; skos:altLabel """Dolastatin-10"""@eng , """L-Valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1- methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(R*)]]]"""@eng , """B720389K560"""@eng ; skos:definition """A pentapeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity. Binding to tubulin, Dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis. This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42316&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42316&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1300\" NCI Thesaurus)"""@eng ; """5564"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """376128"""^^xsd:string ; """110417-88-4"""^^xsd:string ; """48119"""^^xsd:string ; """C1300"""^^xsd:string ; umls:cui """C1524096"""^^xsd:string ; umls:cui """C0082338"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant platelet factor 4"""@eng ; skos:notation """CDR0000042317"""^^xsd:string ; skos:altLabel """rhPF4"""@eng , """rPF4"""@eng , """platelet factor 4"""@eng ; """2006-11-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5565"""^^xsd:string ; """C2251"""^^xsd:string ; umls:cui """C3887655"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/irinotecan"""@eng ; skos:notation """CDR0000042862"""^^xsd:string ; skos:altLabel """CPT-11/dFdC"""@eng ; ; ; """6672"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677796"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """H2 receptor antagonist therapy"""@eng ; skos:notation """CDR0000042315"""^^xsd:string ; skos:altLabel """therapy, H2 receptor antagonist"""@eng ; """5563"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0338238"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042312"""^^xsd:string ; skos:altLabel """CTX/G-CSF/TAX"""@eng ; ; ; ; """5560"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338235"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/paclitaxel/sargramostim"""@eng ; skos:notation """CDR0000042313"""^^xsd:string ; skos:altLabel """CTX/GM-CSF/TAX"""@eng ; ; ; ; """5561"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338236"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amoxicillin"""@eng ; skos:notation """CDR0000042310"""^^xsd:string ; skos:altLabel """Wymox"""@eng , """AMOX"""@eng , """Amoxil"""@eng , """Trimox"""@eng , """Polymox"""@eng , """Utimox"""@eng ; skos:definition """A broad-spectrum, semisynthetic aminopenicillin antibiotic with bactericidal activity. Amoxicillin binds to and inactivates penicillin-binding protein (PBP) 1A located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42310&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42310&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C237\" NCI Thesaurus)"""@eng ; ; ; ; """5558"""^^xsd:string ; """26787-78-0"""^^xsd:string ; """277174"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C237"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0723903"""^^xsd:string ; umls:cui """C0002645"""^^xsd:string ; umls:cui """C0700524"""^^xsd:string ; umls:cui """C0041058"""^^xsd:string ; umls:cui """C0740069"""^^xsd:string ; umls:cui """C0740076"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bismuth subsalicylate"""@eng ; skos:notation """CDR0000042311"""^^xsd:string ; skos:altLabel """Pepto-Bismol"""@eng ; skos:definition """A bismuth salt of salicylic acid. Little absorbed from the gastrointestinal tract, bismuth subsalicylate exerts a local effect on the gastric mucosa, coating it and protecting it from the corrosive effects of acid and pepsin. This agent also has local antimicrobial properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42311&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42311&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1020\" NCI Thesaurus)"""@eng ; """5559"""^^xsd:string ; """14882-18-9"""^^xsd:string ; """C1020"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0136074"""^^xsd:string ; umls:cui """C0053792"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemtuzumab ozogamicin"""@eng ; skos:notation """CDR0000042868"""^^xsd:string ; skos:altLabel """hP67.6-Calicheamicin"""@eng , """Mylotarg"""@eng , """CDP-771"""@eng , """WAY-CMA-676"""@eng , """CMA 676"""@eng , """CMA-676"""@eng , """Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody"""@eng ; skos:definition """A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42868&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42868&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1806\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """6678"""^^xsd:string ; """720568"""^^xsd:string ; """C1806"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-09"""^^xsd:string ; umls:cui """C1533699"""^^xsd:string ; umls:cui """C1527091"""^^xsd:string ; umls:cui """C1527090"""^^xsd:string ; umls:cui """C0677800"""^^xsd:string ; umls:cui """C0876099"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """surgery"""@eng ; skos:notation """CDR0000042869"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; ; ; ; ; """668"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0543467"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """conventional surgery"""@eng ; skos:notation """CDR0000042318"""^^xsd:string ; skos:altLabel """laparotomy"""@eng , """surgery, conventional"""@eng ; ; rdfs:subClassOf ; """5566"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0023038"""^^xsd:string ; umls:cui """C1521745"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioimmunoguided surgery"""@eng ; skos:notation """CDR0000042319"""^^xsd:string ; skos:altLabel """surgery, radioimmunoguided"""@eng ; ; rdfs:subClassOf ; """5567"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0338239"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3'-deoxy-3'-[18F]fluorothymidine"""@eng ; skos:notation """CDR0000453547"""^^xsd:string ; skos:altLabel """18F-FLT"""@eng ; skos:definition """A radioconjugate consisting of a thymidine analogue radiolabeled with fluorine F 18, a positron emitting isotope. Phosphorylated by S-phase-specific thymidine kinase 1, 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) is trapped intracellularly by entering the salvage pathway of DNA synthesis without incorporation into DNA. 18F-FLT serves a marker of tumor cell proliferation for imaging with positron emission tomography (PET); as a marker of proliferation rather than metabolism, it is more specific to tumor tissue than 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG). This agent is metabolically stable, accumulates in the normal bone marrow and the liver, and does not cross the blood-brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453547&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453547&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49093\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C49093"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """2005-10-24"""^^xsd:string ; umls:cui """C1432709"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AVR118"""@eng ; skos:notation """CDR0000453546"""^^xsd:string ; skos:altLabel """Reticulose"""@eng , """Product R"""@eng ; skos:definition """A peptide-nucleic acid immunomodulator with proinflammatory, broad-spectrum antiviral, and potential antineoplastic activities. AVR118 stimulates the peripheral blood mononuclear cell (PBMC) production of the proinflammatory cytokines IFN-y, IL-1b, IL-6 and TNF-a. This agent may reduce HIV-1 p24 antigen; viral reverse transcriptase activity; syncitial cell formation; and viral mRNA in infected PBMCs and human CD4+ lymphocyte H9 cells, and may decrease viral loads and increase CD4+ and CD8+ T-cell counts in HIV patients. In vitro, AVR118 has been shown to induce the maturation of HL60 leukemic cells and to inhibit the invasive and metastatic properties of a highly malignant breast cancer cell line. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453546&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453546&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49092\" NCI Thesaurus)"""@eng ; """2006-07-27"""^^xsd:string ; """2005-10-24"""^^xsd:string ; """C49092"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1172837"""^^xsd:string ; umls:cui """C0140261"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040648"""^^xsd:string ; skos:altLabel """adult Hodgkin's disease stage"""@eng , """stage, adult Hodgkin's disease"""@eng , """Hodgkin's lymphoma stage, adult"""@eng , """Hodgkin's disease stage, adult"""@eng ; rdfs:subClassOf ; """2003-01-14"""^^xsd:string ; """3557"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280273"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiviral therapy"""@eng ; skos:notation """CDR0000040649"""^^xsd:string ; skos:altLabel """anti-HIV therapy"""@eng , """therapy, antiviral"""@eng , """therapy, anti-HIV"""@eng , """therapy, AIDS anti-HIV"""@eng , """AIDS anti-HIV therapy"""@eng ; """3559"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280274"""^^xsd:string ; umls:cui """C1510425"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, hairy cell leukemia"""@eng ; skos:notation """CDR0000040646"""^^xsd:string ; skos:altLabel """hairy cell leukemia, stage"""@eng ; rdfs:subClassOf ; """3555"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280271"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/interleukin-2"""@eng ; skos:notation """CDR0000040647"""^^xsd:string ; skos:altLabel """CDDP/IL-2/WR-2721"""@eng ; ; ; ; """3556"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280272"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone"""@eng ; skos:notation """CDR0000040644"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM"""@eng , """DHAP"""@eng ; ; ; ; """3553"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057634"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/piroxicam"""@eng ; skos:notation """CDR0000040645"""^^xsd:string ; skos:altLabel """IFN-A/PXM"""@eng ; ; ; """3554"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338116"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, gastrointestinal carcinoid tumor"""@eng ; skos:notation """CDR0000040642"""^^xsd:string ; skos:altLabel """carcinoid tumor, gastrointestinal, stage"""@eng , """gastrointestinal carcinoid tumor, stage"""@eng ; rdfs:subClassOf ; """3551"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280267"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, Wilms' tumor and other childhood kidney tumors"""@eng ; skos:notation """CDR0000040643"""^^xsd:string ; skos:altLabel """Wilm's tumor stage"""@eng , """Wilms' tumor stage"""@eng ; rdfs:subClassOf ; """3552"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280268"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """captopril/recombinant tissue plasminogen activator"""@eng ; skos:notation """CDR0000347392"""^^xsd:string ; skos:altLabel """CPT/t-PA"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2003-12-02"""^^xsd:string ; umls:cui """C1328116"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, vulvar cancer"""@eng ; skos:notation """CDR0000040641"""^^xsd:string ; skos:altLabel """vulvar cancer stage"""@eng ; rdfs:subClassOf ; """3550"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280266"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult diffuse astrocytoma"""@eng ; skos:notation """CDR0000041743"""^^xsd:string ; skos:altLabel """diffuse astrocytoma, adult"""@eng , """infiltrating astrocytoma, adult"""@eng , """astrocytoma, adult infiltrating"""@eng , """adult protoplasmic astrocytoma"""@eng , """adult fibrillary astrocytoma"""@eng , """adult gemistocytic astrocytoma"""@eng , """adult infiltrating astrocytoma"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4914"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281329"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """J5 antiserum"""@eng ; skos:notation """CDR0000038469"""^^xsd:string ; skos:altLabel """Antiserum to endotoxin core"""@eng ; """11091"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134511"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """albumin"""@eng ; skos:notation """CDR0000038468"""^^xsd:string ; """11090"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0001924"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/gemcitabine"""@eng ; skos:notation """CDR0000038465"""^^xsd:string ; skos:altLabel """dFdC/OSI774"""@eng ; ; ; """11082"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide/vinorelbine"""@eng ; skos:notation """CDR0000038464"""^^xsd:string ; skos:altLabel """TMZ/VNB"""@eng ; ; ; """11081"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134508"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000038467"""^^xsd:string ; skos:altLabel """leukemia, stage I chronic lymphocytic"""@eng , """chronic lymphocytic leukemia, stage I"""@eng , """CLL, stage I"""@eng , """stage I CLL"""@eng , """lymphocytic leukemia, stage I chronic"""@eng ; rdfs:subClassOf ; """chronic lymphocytic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1109"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278767"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """conjugated estrogens/medroxyprogesterone"""@eng ; skos:notation """CDR0000038466"""^^xsd:string ; skos:altLabel """EST/MPA"""@eng ; ; ; """11083"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1524068"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vinblastine/vincristine"""@eng ; skos:notation """CDR0000038461"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/PRED/VBL/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """11078"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134505"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/interferon alfa"""@eng ; skos:notation """CDR0000038460"""^^xsd:string ; skos:altLabel """IFN-A/MOAB VEGF"""@eng ; ; ; """11077"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134504"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/oxaliplatin"""@eng ; skos:notation """CDR0000038463"""^^xsd:string ; skos:altLabel """L-OHP/ZD 1839"""@eng ; ; ; """2002-10-10"""^^xsd:string ; """11080"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """insular thyroid cancer"""@eng ; skos:notation """CDR0000038462"""^^xsd:string ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """11079"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1134506"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/sirolimus"""@eng ; skos:notation """CDR0000353163"""^^xsd:string ; skos:altLabel """CYSP/SLM"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328157"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000360858"""^^xsd:string ; skos:altLabel """CF/FLAVO/5-FU/L-OHP"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541583"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes/cyclosporine"""@eng ; skos:notation """CDR0000353164"""^^xsd:string ; skos:altLabel """ALLOLYMPH/CYSP"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328158"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes/cyclosporine/sirolimus"""@eng ; skos:notation """CDR0000353165"""^^xsd:string ; skos:altLabel """ALLOLYMPH/CYSP/SLM"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328159"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tucotuzumab celmoleukin"""@eng ; skos:notation """CDR0000456358"""^^xsd:string ; skos:altLabel """KSA-Interleukin-2 Fusion Protein"""@eng , """EMD 273066"""@eng , """huKS-IL2 fusion protein"""@eng ; skos:definition """A recombinant fusion protein comprised of a human monoclonal antibody directed against the epithelial cell adhesion molecule (EpCAM or KS) linked to an active interleukin-2 (IL2) molecule with potential antineoplastic activity. The humanized monoclonal antibody moiety of tucotuzumab celmoleukin recognizes and binds to EpCAM, a cell surface epithelial protein that is expressed on a wide variety of cancer cells, thereby concentrating IL2 in EpCAM-expressing tumor tissue. Subsequently, the localized IL2 moiety of this fusion protein may stimulate a cytotoxic T-cell antitumor immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456358&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456358&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2630\" NCI Thesaurus)"""@eng ; """2006-08-17"""^^xsd:string ; """2005-11-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2630"""^^xsd:string ; umls:cui """C1721369"""^^xsd:string ; umls:cui """C1531415"""^^xsd:string ; umls:cui """C1530077"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/vincristine"""@eng ; skos:notation """CDR0000041069"""^^xsd:string ; skos:altLabel """CDDP/VCR"""@eng ; ; ; """4108"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/vincristine"""@eng ; skos:notation """CDR0000041068"""^^xsd:string ; skos:altLabel """MTX/VCR"""@eng ; ; ; """4107"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorpromazine"""@eng ; skos:notation """CDR0000039752"""^^xsd:string ; skos:altLabel """Chlor-PZ"""@eng , """Thorazine"""@eng , """2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine"""@eng ; skos:definition """A phenothiazine and traditional antipsychotic agent with anti-emetic activity. Chlorpromazine exerts its antipsychotic effect by blocking postsynaptic dopamine receptors in cortical and limbic areas of the brain, thereby preventing the excess of dopamine in the brain. This leads to a reduction in psychotic symptoms, such as hallucinations and delusions. Chlorpromazine appears to exert its anti-emetic activity by blocking the dopamine receptors in the chemical trigger zone (CTZ) in the brain, thereby relieving nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39752&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39752&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C367\" NCI Thesaurus)"""@eng ; """2413"""^^xsd:string ; """50-53-3"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """167745"""^^xsd:string ; """C367"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699065"""^^xsd:string ; umls:cui """C1443002"""^^xsd:string ; umls:cui """C0008286"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idarubicin"""@eng ; skos:notation """CDR0000039753"""^^xsd:string ; skos:altLabel """4-DMDR"""@eng , """4-demethoxydaunorubicin"""@eng , """DMDR"""@eng , """Idamycin"""@eng , """4DMDR"""@eng , """(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione"""@eng , """(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside"""@eng , """4-Demethoxydaunomycin"""@eng , """IDA"""@eng ; skos:definition """A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin. Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics. Idarubicin hydrochloride is the therapeutic form of this drug. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39753&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39753&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C562\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2414"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C562"""^^xsd:string ; """58957-92-9"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0728795"""^^xsd:string ; umls:cui """C0020789"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine"""@eng ; skos:notation """CDR0000039754"""^^xsd:string ; skos:altLabel """Ornidyl"""@eng , """2-(Difluoromethyl)-DL-ornithine"""@eng , """MDL 71782"""@eng , """difluoromethylornithine"""@eng , """Alpha-Difluoromethylornithine"""@eng , """DFMO"""@eng , """2-Difluoromethylornithine"""@eng , """D,L-alpha-Difluoromethylornithine"""@eng , """2-(Difluoromethyl)-dl-ornithine Hydrochloride, Monohydrate"""@eng , """RMI-71782"""@eng ; skos:definition """A difluoromethylated ornithine compound with antineoplastic activity. Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39754&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39754&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C226\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """2415"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """70052-12-9"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C226"""^^xsd:string ; """25344"""^^xsd:string ; umls:cui """C0002260"""^^xsd:string ; umls:cui """C0949215"""^^xsd:string ; umls:cui """C0029275"""^^xsd:string ; umls:cui """C0282042"""^^xsd:string ; umls:cui """C1521916"""^^xsd:string ; umls:cui """C0086156"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glutamic acid"""@eng ; skos:notation """CDR0000039755"""^^xsd:string ; skos:altLabel """Acidulin"""@eng , """Acidoride"""@eng , """glutamic acid hydrochloride"""@eng , """Muriamic"""@eng ; """2416"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0304564"""^^xsd:string ; umls:cui """C1263024"""^^xsd:string ; umls:cui """C1263026"""^^xsd:string ; umls:cui """C1263025"""^^xsd:string ; umls:cui """C0061472"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aldesleukin"""@eng ; skos:notation """CDR0000039756"""^^xsd:string ; skos:altLabel """Ro-236019"""@eng , """TCGF, Interleukin"""@eng , """Thymocyte Stimulating Factor"""@eng , """TSF"""@eng , """Interleukin II"""@eng , """TCGF"""@eng , """Interleukin-2"""@eng , """IL-2"""@eng , """Lymphocyte Mitogenic Factor"""@eng , """interleukin-2"""@eng , """recombinant interleukin-2"""@eng , """Proleukin"""@eng , """Interleukin 2"""@eng , """Mitogenic Factor"""@eng , """T-Cell Growth Factor"""@eng ; skos:definition """A recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. Aldesleukin binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39756&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39756&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1498\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4182"""^^xsd:string ; """4184"""^^xsd:string ; """8709"""^^xsd:string ; """10080"""^^xsd:string ; """3654"""^^xsd:string ; """3713"""^^xsd:string ; """3437"""^^xsd:string ; """6651"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2946"""^^xsd:string ; """7458"""^^xsd:string ; """4781"""^^xsd:string ; """C1498"""^^xsd:string ; """2417"""^^xsd:string ; """4129"""^^xsd:string ; """4176"""^^xsd:string ; """6897"""^^xsd:string ; """11024"""^^xsd:string ; """8267"""^^xsd:string ; """102524-44-7"""^^xsd:string ; """4204"""^^xsd:string ; """7103"""^^xsd:string ; """4201"""^^xsd:string ; """3358"""^^xsd:string ; """5854"""^^xsd:string ; """2006-02-17"""^^xsd:string ; """6883"""^^xsd:string ; """2982"""^^xsd:string ; """2474"""^^xsd:string ; """1969"""^^xsd:string ; """9593"""^^xsd:string ; """11152"""^^xsd:string ; """6123"""^^xsd:string ; """3860"""^^xsd:string ; """3062"""^^xsd:string ; """10662"""^^xsd:string ; """7752"""^^xsd:string ; """4903"""^^xsd:string ; """6796"""^^xsd:string ; """8748"""^^xsd:string ; """3044"""^^xsd:string ; """373364"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0919268"""^^xsd:string ; umls:cui """C0701339"""^^xsd:string ; umls:cui """C0218986"""^^xsd:string ; umls:cui """C0021756"""^^xsd:string ; umls:cui """C1522405"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lorazepam"""@eng ; skos:notation """CDR0000039757"""^^xsd:string ; skos:altLabel """7-Chloro-5-(2-chlorophenyl)-1, 3-Dihydro-3-Hydroxy-1,4- Benzodiazepin-2-one"""@eng , """Ativan"""@eng ; skos:definition """A benzodiazepine with anxiolytic, anti-anxiety, anticonvulsant, anti-emetic and sedative properties. Lorazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid on the GABA receptors by binding to a site that is distinct from the GABA binding site in the central nervous system. This leads to an increase in chloride channel opening events, a facilitation of chloride ion conductance, membrane hyperpolarization, and eventually inhibition of the transmission of nerve signals, thereby decreasing nervous excitation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39757&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39757&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C619\" NCI Thesaurus)"""@eng ; """2418"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """289758"""^^xsd:string ; """846-49-1"""^^xsd:string ; """C619"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0024002"""^^xsd:string ; umls:cui """C0699194"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/edatrexate"""@eng ; skos:notation """CDR0000041061"""^^xsd:string ; skos:altLabel """CDDP/CTX/EDAM"""@eng ; ; ; ; """4100"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280665"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mesna"""@eng ; skos:notation """CDR0000039759"""^^xsd:string ; skos:altLabel """Mesnil"""@eng , """Mistabronco"""@eng , """Mexan"""@eng , """Sodium 2-Mercaptoethanesulphonate"""@eng , """Mucofluid"""@eng , """2-Mercaptoethanesulfonic Acid Sodium Salt"""@eng , """Ziken"""@eng , """Mesnum"""@eng , """Mucolene"""@eng , """Sodium 2-Mercaptoethane Sulfonate"""@eng , """mercaptoethanesulfonate"""@eng , """MSA"""@eng , """Filesna"""@eng , """D-7093"""@eng , """Mitexan"""@eng , """UCB 3983"""@eng , """Mesnex"""@eng , """mercaptoethane sulfonate"""@eng , """Ausobronc"""@eng , """Uromitexan"""@eng , """Mistabron"""@eng ; skos:definition """A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents. Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39759&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39759&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C192\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """2420"""^^xsd:string ; """113891"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """25232"""^^xsd:string ; """19767-45-4"""^^xsd:string ; """C192"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1521833"""^^xsd:string ; umls:cui """C0733876"""^^xsd:string ; umls:cui """C0733875"""^^xsd:string ; umls:cui """C0733874"""^^xsd:string ; umls:cui """C1513150"""^^xsd:string ; umls:cui """C1513153"""^^xsd:string ; umls:cui """C0678115"""^^xsd:string ; umls:cui """C0000294"""^^xsd:string ; umls:cui """C1513154"""^^xsd:string ; umls:cui """C0721681"""^^xsd:string ; umls:cui """C1513149"""^^xsd:string ; umls:cui """C1513147"""^^xsd:string ; umls:cui """C1513148"""^^xsd:string ; umls:cui """C0917779"""^^xsd:string ; umls:cui """C0085721"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/sargramostim"""@eng ; skos:notation """CDR0000041063"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF"""@eng ; ; ; ; """4102"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/sargramostim/vincristine"""@eng ; skos:notation """CDR0000041062"""^^xsd:string ; skos:altLabel """BLEO/CTX/DM/DOX/GM-CSF/MTX/VCR"""@eng ; ; ; ; ; ; ; ; """4101"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280666"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041065"""^^xsd:string ; skos:altLabel """IFN-A/MP/MTX"""@eng ; ; ; ; """4104"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338125"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stavudine"""@eng ; skos:notation """CDR0000041064"""^^xsd:string ; skos:altLabel """dideoxydidehydrothymidine"""@eng , """Zerit"""@eng , """BMY-27857"""@eng , """1-(2,3-Dideoxy-beta-glycero-pent-2-enofuranosyl)thymine"""@eng , """didehydrodeoxythymidine"""@eng , """3'-Deoxy-2'-thymidinene"""@eng , """2',3'-Didehydro-3'-deoxythymidine"""@eng , """d4T"""@eng ; skos:definition """A synthetic nucleoside, analog of didehydro-3-deoxythymidine with potent antiretroviral activity. In vivo, stavudine is phosphorylated by cellular kinases to the active metabolite stavudine triphosphate; this metabolite inhibits the activity of HIV reverse transcriptase both by competing with the natural substrate deoxythymidine triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack the essential 3'-OH group). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41064&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41064&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1428\" NCI Thesaurus)"""@eng ; ; ; """4103"""^^xsd:string ; """C1428"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """163661"""^^xsd:string ; """3056-17-5"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0164662"""^^xsd:string ; umls:cui """C0701313"""^^xsd:string ; umls:cui """C0701312"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000041067"""^^xsd:string ; skos:altLabel """CTX/DOX/G-CSF/VP-16"""@eng ; ; ; ; ; """4106"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/etoposide/filgrastim"""@eng ; skos:notation """CDR0000041066"""^^xsd:string ; skos:altLabel """BCNU/CTX/G-CSF/VP-16"""@eng ; ; ; ; ; """4105"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280670"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood soft tissue sarcoma"""@eng ; skos:notation """CDR0000040259"""^^xsd:string ; skos:altLabel """childhood soft tissue sarcoma, recurrent"""@eng , """STS, recurrent, childhood"""@eng , """pediatric soft tissue sarcoma, recurrent"""@eng , """STS, childhood, recurrent"""@eng , """childhood STS, recurrent"""@eng , """pediatric STS, recurrent"""@eng ; rdfs:subClassOf ; """childhood soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3088"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279943"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic childhood soft tissue sarcoma"""@eng ; skos:notation """CDR0000040258"""^^xsd:string ; skos:altLabel """soft tissue sarcoma, childhood, metastatic"""@eng , """pediatric STS, metastatic"""@eng , """pediatric metastatic STS"""@eng , """childhood metastatic STS"""@eng , """childhood STS, metastatic"""@eng , """STS, metastatic, childhood"""@eng , """childhood soft tissue sarcoma, metastatic"""@eng ; rdfs:subClassOf ; """childhood soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3087"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279942"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/ganciclovir"""@eng ; skos:notation """CDR0000391081"""^^xsd:string ; skos:altLabel """BW-B759U/PS-341"""@eng ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541474"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic transitional cell cancer of the renal pelvis and ureter"""@eng ; skos:notation """CDR0000040251"""^^xsd:string ; skos:altLabel """transitional cell cancer of the renal pelvis and ureter, metastatic"""@eng , """carcinoma of the renal pelvis and ureter, metastatic"""@eng , """cancer of the renal pelvis and ureter, metastatic"""@eng ; rdfs:subClassOf ; """transitional cell cancer of the renal pelvis and ureter"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3079"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279937"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant tumor necrosis factor"""@eng ; skos:notation """CDR0000040250"""^^xsd:string ; skos:altLabel """Tumor Necrosis Factor Family Protein"""@eng , """Tumor Necrosis Factors"""@eng , """tumor necrosis factor"""@eng , """TNF"""@eng , """Recombinant Tumor Necrosis Factor Family Protein"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to one of a number of endogenous tumor necrosis factor (TNF) proteins. TNF family cytokines bind to and activate specific cell-surface receptors, thereby mediating inflammatory processes, cell proliferation, immunity, angiogenesis, and tumor cell cytotoxicity. One primary antitumor effect of TNFs involves stimulation of T cell-mediated antitumor cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40250&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40250&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1941\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """3078"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C1941"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1522668"""^^xsd:string ; umls:cui """C0041368"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040253"""^^xsd:string ; skos:altLabel """APO"""@eng , """CDDP/DOX/VCR"""@eng ; ; ; ; """3080"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0285452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult fibrosarcoma"""@eng ; skos:notation """CDR0000040252"""^^xsd:string ; skos:altLabel """sarcoma, fibro-, adult"""@eng , """fibrosarcoma, adult"""@eng ; rdfs:subClassOf ; """308"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278595"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/vindesine"""@eng ; skos:notation """CDR0000040255"""^^xsd:string ; skos:altLabel """VPIV"""@eng , """DAVA/IFF/VP-16"""@eng ; ; ; ; """3084"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279940"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/melphalan/teniposide"""@eng ; skos:notation """CDR0000040254"""^^xsd:string ; skos:altLabel """DOX/L-PAM/VM-26"""@eng , """MAV"""@eng ; ; ; ; """3083"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279939"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nonmetastatic childhood soft tissue sarcoma"""@eng ; skos:notation """CDR0000040257"""^^xsd:string ; skos:altLabel """pediatric nonmetastatic STS"""@eng , """STS, childhood, nonmetastatic"""@eng , """childhood STS, nonmetastatic"""@eng , """childhood soft tissue sarcoma, nonmetastatic"""@eng , """pediatric STS, nonmetastatic"""@eng , """STS, nonmetastatic, childhood"""@eng , """childhood nonmetastatic STS"""@eng , """soft tissue sarcoma, nonmetastatic, childhood,"""@eng ; rdfs:subClassOf ; """childhood soft tissue sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3086"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279941"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood soft tissue sarcoma"""@eng ; skos:notation """CDR0000040256"""^^xsd:string ; skos:altLabel """pediatric soft tissue sarcoma"""@eng , """pediatric STS"""@eng , """childhood STS"""@eng , """STS, childhood"""@eng , """Soft tissue sarcoma, child"""@eng , """soft tissue sarcoma, childhood"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3085"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220645"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quinacrine dihydrochloride"""@eng ; skos:notation """CDR0000531122"""^^xsd:string ; skos:altLabel """mepacrine dihydrochoride"""@eng , """atabrine dihydrochloride"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C0949411"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/DJ-927"""@eng ; skos:notation """CDR0000346919"""^^xsd:string ; skos:altLabel """CAPE/DJ927"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """2003-11-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328114"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DJ-927"""@eng ; skos:notation """CDR0000346914"""^^xsd:string ; skos:altLabel """DJ927"""@eng , """DJ 927"""@eng ; skos:definition """A semi-synthetic orally-available taxane derivative with potent antineoplastic properties. DJ-927 binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. DJ-927I is more potent than paclitaxel and docetaxel and is the first oral taxane derivative. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346914&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346914&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37451\" NCI Thesaurus)"""@eng ; ; """2003-12-23"""^^xsd:string ; """C37451"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1313820"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ISS 1018 CpG oligodeoxynucleotide"""@eng ; skos:notation """CDR0000474964"""^^xsd:string ; skos:definition """A short, synthetic, unmethylated CpG motif-based oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. As an immunostimulatory sequence (ISS) that signals through Toll-like receptor 9 (TLR9), ISS 1018 CpG ODN induces the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin (IL) -12, and tumor necrosis factor (TNF) -alpha by plasmacytoid dendritic cells (pDC). pDC, through cell-cell contact, and IFN-alpha and -beta, in turn, induce natural killer (NK) cell proliferation, NK cell production of IFN-gamma, and NK cell-mediated cytotoxicity; secreted IFNs also stimulate bystander T cell activation and differentiation of naive CD4+ T cells into T-helper 1 cells on specific antigen challenge. In addition, ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression. Unmethylated CpG motifs are regions of genomic DNA containing the cytosine-guanine dinucleotide, in which cytosine remains unmethylated, especially in prokaryotic DNA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474964&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=474964&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61080\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C61080"""^^xsd:string ; """2006-03-24"""^^xsd:string ; umls:cui """C1831789"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II papillary thyroid cancer"""@eng ; skos:notation """CDR0000038803"""^^xsd:string ; skos:altLabel """papillary thyroid cancer, stage II"""@eng , """mixed adenocarcinoma of the thyroid, stage II"""@eng , """papillary adenocarcinoma of the thyroid, stage II"""@eng , """thyroid cancer, stage II papillary"""@eng , """adenocarcinoma, papillary, thyroid, stage II"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1254"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278850"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I papillary thyroid cancer"""@eng ; skos:notation """CDR0000038802"""^^xsd:string ; skos:altLabel """mixed adenocarcinoma of the thyroid, stage I"""@eng , """papillary thyroid cancer, stage I"""@eng , """papillary adenocarcinoma of the thyroid, stage I"""@eng , """adenocarcinoma, papillary, thyroid, stage I"""@eng , """thyroid cancer, stage I papillary"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1253"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278849"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thyroid cancer"""@eng ; skos:notation """CDR0000038801"""^^xsd:string ; skos:altLabel """Thyroid cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1252"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0549473"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent thymoma and thymic carcinoma"""@eng ; skos:notation """CDR0000038800"""^^xsd:string ; skos:altLabel """recurrent thymoma"""@eng ; rdfs:subClassOf ; """thymoma and thymic carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1251"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278848"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV follicular thyroid cancer"""@eng ; skos:notation """CDR0000038807"""^^xsd:string ; skos:altLabel """follicular thyroid cancer, metastatic"""@eng , """thyroid cancer, metastatic follicular"""@eng , """metastatic follicular thyroid cancer"""@eng , """follicular thyroid cancer, stage IV"""@eng , """thyroid cancer, stage IV follicular"""@eng , """carcinoma, follicular, thyroid, stage IV"""@eng , """follicular carcinoma of the thyroid, stage IV"""@eng , """follicular carcinoma of the thyroid, metastatic"""@eng , """carcinoma, follicular, thyroid, metastatic"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1258"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278854"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II follicular thyroid cancer"""@eng ; skos:notation """CDR0000038806"""^^xsd:string ; skos:altLabel """carcinoma, follicular, thyroid, stage II"""@eng , """thyroid cancer, stage II follicular"""@eng , """follicular carcinoma of the thyroid, stage II"""@eng , """follicular thyroid cancer, stage II"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1257"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278853"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I follicular thyroid cancer"""@eng ; skos:notation """CDR0000038805"""^^xsd:string ; skos:altLabel """thyroid cancer, stage I follicular"""@eng , """follicular carcinoma of the thyroid, stage I"""@eng , """follicular thyroid cancer, stage I"""@eng , """carcinoma, follicular, thyroid, stage I"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1256"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278852"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV papillary thyroid cancer"""@eng ; skos:notation """CDR0000038804"""^^xsd:string ; skos:altLabel """thyroid cancer, stage IV papillary"""@eng , """papillary thyroid cancer, stage IV"""@eng , """papillary thyroid cancer, metastatic"""@eng , """papillary adenocarcinoma of the thyroid, metastatic"""@eng , """mixed adenocarcinoma of the thyroid, stage IV"""@eng , """papillary adenocarcinoma of the thyroid, stage IV"""@eng , """metastatic papillary thyroid cancer"""@eng , """adenocarcinoma, papillary, thyroid, stage IV"""@eng , """thyroid cancer, metastatic papillary"""@eng , """mixed adenocarcinoma of the thyroid, metastatic"""@eng , """adenocarcinoma, papillary, thyroid, metastatic"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1255"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278851"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anaplastic thyroid cancer"""@eng ; skos:notation """CDR0000038809"""^^xsd:string ; skos:altLabel """undifferentiated carcinoma of the thyroid"""@eng , """anaplastic carcinoma of the thyroid"""@eng , """undifferentiated thyroid cancer"""@eng , """thyroid cancer, anaplastic carcinoma"""@eng , """thyroid cancer, undifferentiated carcinoma"""@eng ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1260"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0238461"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """medullary thyroid cancer"""@eng ; skos:notation """CDR0000038808"""^^xsd:string ; skos:altLabel """thyroid cancer, medullary"""@eng , """medullary carcinoma of the thyroid"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """thyroid cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1259"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0238462"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/iodine I 131 tositumomab"""@eng ; skos:notation """CDR0000428357"""^^xsd:string ; skos:altLabel """FAMP/I131-MOAB-B1"""@eng ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541548"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/iodine I 131 metaiodobenzylguanidine"""@eng ; skos:notation """CDR0000426494"""^^xsd:string ; skos:altLabel """AS2O3/I131-MIBG"""@eng ; ; ; """2005-03-24"""^^xsd:string ; """2005-03-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541536"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/GTI-2040/oxaliplatin"""@eng ; skos:notation """CDR0000369989"""^^xsd:string ; skos:altLabel """CAPE/GTI2040/L-OHP"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541236"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """letrozole"""@eng ; skos:notation """CDR0000042086"""^^xsd:string ; skos:altLabel """LTZ"""@eng , """Femara"""@eng , """CGS 20267"""@eng ; skos:definition """A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, anastrozole may inhibit tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42086&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42086&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1527\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """5321"""^^xsd:string ; """2006-05-30"""^^xsd:string ; """C1527"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """719345"""^^xsd:string ; """112809-51-5"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701348"""^^xsd:string ; umls:cui """C0246421"""^^xsd:string ; umls:cui """C0701347"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/filgrastim/ifosfamide"""@eng ; skos:notation """CDR0000042087"""^^xsd:string ; skos:altLabel """DOX/G-CSF/IFF"""@eng ; ; ; ; """5322"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281618"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/goserelin/suramin"""@eng ; skos:notation """CDR0000042084"""^^xsd:string ; skos:altLabel """FLUT/SUR/ZDX"""@eng ; ; ; ; """5319"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281616"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/vincristine"""@eng ; skos:notation """CDR0000042085"""^^xsd:string ; skos:altLabel """CBDCA/VCR/VP-16"""@eng ; ; ; ; """5320"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281617"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/filgrastim/interleukin-6/paclitaxel"""@eng ; skos:notation """CDR0000042082"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/IL-6/TAX"""@eng ; ; ; ; ; """5316"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281614"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benznidazole/lomustine"""@eng ; skos:notation """CDR0000042083"""^^xsd:string ; skos:altLabel """benznidazole/CCNU"""@eng ; ; ; """5318"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281615"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/epoetin alfa/etoposide/filgrastim/ifosfamide/vinblastine"""@eng ; skos:notation """CDR0000042080"""^^xsd:string ; skos:altLabel """BLEO/CDDP/EPO/G-CSF/IFF/VBL/VP-16"""@eng ; ; ; ; ; ; ; ; """5314"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281612"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/epoetin alfa/etoposide/filgrastim/ifosfamide"""@eng ; skos:notation """CDR0000042081"""^^xsd:string ; skos:altLabel """CDDP/EPO/G-CSF/IFF/VP-16"""@eng ; ; ; ; ; ; """5315"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281613"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """everolimus/octreotide"""@eng ; skos:notation """CDR0000438715"""^^xsd:string ; skos:altLabel """RAD/SSTN"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-23"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831661"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """goserelin/tamoxifen"""@eng ; skos:notation """CDR0000042088"""^^xsd:string ; skos:altLabel """TMX/ZDX"""@eng ; ; ; """5323"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281619"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leuprolide/tamoxifen"""@eng ; skos:notation """CDR0000042089"""^^xsd:string ; skos:altLabel """LEUP/TMX"""@eng ; ; ; """5324"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281620"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000349491"""^^xsd:string ; skos:altLabel """CDDP/CF/CPT-11/5-FU"""@eng ; ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328117"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/decitabine/doxorubicin"""@eng ; skos:notation """CDR0000349494"""^^xsd:string ; skos:altLabel """CTX/DAC/DOX"""@eng ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328118"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """platelet transfusion"""@eng ; skos:notation """CDR0000470308"""^^xsd:string ; ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-02-23"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0086818"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/tretinoin"""@eng ; skos:notation """CDR0000410707"""^^xsd:string ; skos:altLabel """ATRA/IL-2"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541436"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I renal cell cancer"""@eng ; skos:notation """CDR0000043689"""^^xsd:string ; skos:altLabel """renal cell cancer, stage I"""@eng , """stage I kidney cancer"""@eng , """stage I hypernephroma"""@eng , """renal cell carcinoma, stage I"""@eng , """stage I renal cell carcinoma"""@eng , """kidney cancer, stage I"""@eng , """hypernephroma, stage I"""@eng ; rdfs:subClassOf ; """renal cell cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """937"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278675"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000043688"""^^xsd:string ; skos:altLabel """ASP/PRED/VCR/VP-16"""@eng ; ; ; ; ; """935"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RC-1291 ghrelin mimetic"""@eng ; skos:notation """CDR0000460131"""^^xsd:string ; skos:definition """A synthetic, orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. RC-1291 ghrelin mimetic binds to and stimulates the growth hormone secretagogue receptor (GHSR) centrally, thereby mimicking the appetite-stimulating and growth hormone-releasing effects of grhelin. Stimulation of GHSR may also reduce the production of the pro-inflammatory cytokines TNF-alpha and interleukin-6, which may play a direct role in cancer-related loss of appetite. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460131&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460131&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52197\" NCI Thesaurus)"""@eng ; """2006-09-11"""^^xsd:string ; """C52197"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C2001495"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/carboplatin"""@eng ; skos:notation """CDR0000043683"""^^xsd:string ; skos:altLabel """BLEO/CBDCA"""@eng ; ; ; """930"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278669"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III esophageal cancer"""@eng ; skos:notation """CDR0000043682"""^^xsd:string ; skos:altLabel """esophagus cancer, stage III"""@eng , """esophageal cancer, stage III"""@eng ; rdfs:subClassOf ; """esophageal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """93"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278561"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000043681"""^^xsd:string ; skos:altLabel """ARA-C/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """929"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278668"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000043680"""^^xsd:string ; skos:altLabel """ASP/MP/PRED/VCR"""@eng ; ; ; ; ; """928"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/zidovudine"""@eng ; skos:notation """CDR0000043687"""^^xsd:string ; skos:altLabel """IL-2/ZDV"""@eng ; ; ; """934"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/idoxuridine"""@eng ; skos:notation """CDR0000043686"""^^xsd:string ; skos:altLabel """5-FU/IUDR"""@eng ; ; ; """933"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000043685"""^^xsd:string ; skos:altLabel """STAMP I"""@eng , """BCNU/CDDP/CTX"""@eng ; ; ; ; """932"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000043684"""^^xsd:string ; skos:altLabel """CBDCA/CTX"""@eng ; ; ; """931"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054403"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/gp100 antigen/interleukin-2/interleukin-12/MAGE-3/Melan-A/NA17-A"""@eng ; skos:notation """CDR0000316036"""^^xsd:string ; skos:altLabel """AL/gp100/IL-2/IL-12/MAGE3/MEL-A/NA17A"""@eng ; ; ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-11-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328007"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/gp100 antigen/interleukin-12/MAGE-3/Melan-A/NA17-A"""@eng ; skos:notation """CDR0000316034"""^^xsd:string ; skos:altLabel """AL/gp100/IL-12/MAGE3/MEL-A/NA17A"""@eng ; ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-11-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328006"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gene therapy"""@eng ; skos:notation """CDR0000041293"""^^xsd:string ; skos:altLabel """therapy, gene"""@eng ; """4366"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0017296"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus B7-1"""@eng ; skos:notation """CDR0000037922"""^^xsd:string ; skos:definition """A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen. Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37922&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37922&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2204\" NCI Thesaurus)"""@eng ; """10336"""^^xsd:string ; """C2204"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879611"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related lymphoma"""@eng ; skos:notation """CDR0000040813"""^^xsd:string ; skos:altLabel """Lymphoma, AIDS-related"""@eng , """AIDS-associated lymphoma"""@eng , """lymphoma, AIDS-related"""@eng , """AIDS related lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3779"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0085090"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """de novo myelodysplastic syndromes"""@eng ; skos:notation """CDR0000040812"""^^xsd:string ; skos:altLabel """myelodysplastic syndromes, untreated"""@eng , """untreated myelodysplastic syndromes"""@eng , """myelodysplastic syndromes, de novo"""@eng ; rdfs:subClassOf ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """myelodysplastic syndromes"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3776"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280451"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, myelodysplastic syndromes"""@eng ; skos:notation """CDR0000040811"""^^xsd:string ; skos:altLabel """myelodysplastic syndromes stage"""@eng ; rdfs:subClassOf ; """3775"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280450"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """foscarnet sodium"""@eng ; skos:notation """CDR0000040810"""^^xsd:string ; """C1193"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-29"""^^xsd:string ; """3774"""^^xsd:string ; umls:cui """C0146934"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """caffeine"""@eng ; skos:notation """CDR0000040817"""^^xsd:string ; skos:altLabel """1,3,7-trimethylxanthine"""@eng , """3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione"""@eng , """CAF"""@eng ; skos:definition """A naturally occurring xanthine derivative with central nervous system (CNS) stimulating activity. Due to the structural similarity to adenosine, caffeine binds to and blocks adenosine receptors, thereby preventing the inhibitory effects of adenosine on nerve cells. This leads to stimulation of medullary, vagal, vasomotor, and respiratory centers in the brain; and the release of epinephrine. Physiologic responses can include bradycardia, tachycardia, vasoconstriction, CNS excitablility, increased respiratory rate, increased blood pressure, increased blood flow to muscles, decreased blood flow to skin and inner organs, and release of glucose by the liver. Due to the interaction between adenosine A2A and dopamine D2 receptors, caffeine can also indirectly increase the levels of dopamine in the brain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40817&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40817&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C328\" NCI Thesaurus)"""@eng ; ; """3846"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5036"""^^xsd:string ; """58-08-2"""^^xsd:string ; """C328"""^^xsd:string ; """2006-12-28"""^^xsd:string ; umls:cui """C0006644"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """inflammatory breast cancer"""@eng ; skos:notation """CDR0000040816"""^^xsd:string ; skos:altLabel """breast cancer, inflammatory"""@eng , """carcinoma of the breast, inflammatory"""@eng ; rdfs:subClassOf ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """384"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278601"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biological therapy"""@eng ; skos:notation """CDR0000040815"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """381"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0005527"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent gastric cancer"""@eng ; skos:notation """CDR0000040814"""^^xsd:string ; skos:altLabel """gastric cancer, recurrent"""@eng , """stomach cancer, recurrent"""@eng ; rdfs:subClassOf ; """gastric cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """38"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278502"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040819"""^^xsd:string ; skos:altLabel """VAA"""@eng , """ASP/DOX/VCR"""@eng ; ; ; ; """3848"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """naltrexone hydrochloride"""@eng ; skos:notation """CDR0000040818"""^^xsd:string ; """2006-11-30"""^^xsd:string ; """3847"""^^xsd:string ; """C679"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0355800"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/ascorbic acid/melphalan"""@eng ; skos:notation """CDR0000371824"""^^xsd:string ; skos:altLabel """AS203/L-PAM/VIT-C"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541262"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penicillamine/pyridoxine"""@eng ; skos:notation """CDR0000043351"""^^xsd:string ; skos:altLabel """peni-cillamine/VIT-B6"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """7899"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796498"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/melphalan"""@eng ; skos:notation """CDR0000039034"""^^xsd:string ; skos:altLabel """CDDP/CTX/L-PAM"""@eng ; ; ; ; """1605"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279050"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/teniposide"""@eng ; skos:notation """CDR0000039037"""^^xsd:string ; skos:altLabel """ARA-C/CTX/VM-26"""@eng ; ; ; ; """1609"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279053"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/doxorubicin/teniposide"""@eng ; skos:notation """CDR0000039036"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DOX/VM-26"""@eng ; ; ; ; ; """1608"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279052"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/toremifene"""@eng ; skos:notation """CDR0000043355"""^^xsd:string ; skos:altLabel """IFN-A/TOR"""@eng ; ; ; """7901"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796500"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daclizumab/interleukin-2"""@eng ; skos:notation """CDR0000043354"""^^xsd:string ; skos:altLabel """IL-2/MOAB anti-Tac"""@eng , """monoclonal antibody anti-Tac"""@eng ; ; ; """7900"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796499"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000039033"""^^xsd:string ; skos:altLabel """DHAD/VP-16"""@eng ; ; ; """1603"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279049"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lepirudin"""@eng ; skos:notation """CDR0000043356"""^^xsd:string ; skos:altLabel """Recombinant Hirudin"""@eng , """Refludan"""@eng ; skos:definition """A recombinant hirudin, a polypeptide naturally produced by the leech Hirudo medicinalis, derived from yeast cells and a highly specific inhibitor of thrombin. Lepirudin directly binds to thrombin, thereby inactivating the thrombogenic activity of thrombin. This anticoagulant produces dose-dependent increases in activated partial thromboplastin time (aPTT). Its action is independent of antithrombin III and it is not inhibited by platelet factor 4. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43356&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43356&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1839\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """7902"""^^xsd:string ; """C1839"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-13"""^^xsd:string ; umls:cui """C0661608"""^^xsd:string ; umls:cui """C0772394"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carmustine/cyclophosphamide/cytarabine/etoposide"""@eng ; skos:notation """CDR0000043359"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/CTX/VP-16/WR-2721"""@eng ; ; ; ; ; ; """7905"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/PSC 833"""@eng ; skos:notation """CDR0000043358"""^^xsd:string ; skos:altLabel """CBDCA/PSC-833/TAX"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """7904"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/docetaxel/gemcitabine"""@eng ; skos:notation """CDR0000437138"""^^xsd:string ; skos:altLabel """CAPE/dFdC/TXT"""@eng ; ; ; ; """2005-06-14"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831649"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000039039"""^^xsd:string ; skos:altLabel """ASP/DM/DOX/VCR"""@eng ; ; ; ; ; """1611"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279055"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/hydrocortisone"""@eng ; skos:notation """CDR0000039038"""^^xsd:string ; skos:altLabel """ARA-C/HC"""@eng ; ; ; """1610"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1527326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/dexamethasone/leucovorin calcium/methotrexate/thioguanine/vindesine"""@eng ; skos:notation """CDR0000043401"""^^xsd:string ; skos:altLabel """ASP/CF/CTX/DAVA/DM/DNR/MTX/TG"""@eng ; ; ; ; ; ; ; ; ; """7958"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796539"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/doxorubicin/pegaspargase/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042398"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/DOX/PEG-ASP/TG/VCR"""@eng ; ; ; ; ; ; ; ; """5653"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338306"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/leucovorin calcium/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000043400"""^^xsd:string ; skos:altLabel """ASP/CF/MP/MTX"""@eng ; ; ; ; ; """7957"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796538"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042399"""^^xsd:string ; skos:altLabel """capi33i I"""@eng , """MTX/PEG-ASP/VCR"""@eng ; ; ; ; """5654"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338307"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000043403"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DHAD/DM/VP-16"""@eng ; ; ; ; ; ; """7960"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796541"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methylprednisolone/rituximab"""@eng ; skos:notation """CDR0000322034"""^^xsd:string ; skos:altLabel """CTX/MePRDL/MOAB IDEC-C2B8"""@eng ; ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328013"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/rituximab"""@eng ; skos:notation """CDR0000322035"""^^xsd:string ; skos:altLabel """CTX/MOAB IDEC-C2B8/PRED"""@eng ; ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328014"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """venlafaxine"""@eng ; skos:notation """CDR0000043238"""^^xsd:string ; skos:altLabel """VNF"""@eng , """Effexor"""@eng ; skos:definition """A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors. This agent may reduce hormone-related vasomotor symptoms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43238&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43238&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1278\" NCI Thesaurus)"""@eng ; ; """7704"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """C1278"""^^xsd:string ; """93413-69-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591437"""^^xsd:string ; umls:cui """C0078569"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043402"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CF/DM/MP/MTX/VCR"""@eng ; ; ; ; ; ; ; ; """7959"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796540"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In111-DOTA-biotin"""@eng ; skos:notation """CDR0000043232"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """7697"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541568"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/sargramostim"""@eng ; skos:notation """CDR0000043233"""^^xsd:string ; skos:altLabel """GM-CSF/IFN-A"""@eng ; ; ; """7698"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796391"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dexamethasone/paclitaxel"""@eng ; skos:notation """CDR0000043230"""^^xsd:string ; skos:altLabel """CDDP/DM/TAX"""@eng ; ; ; ; """7695"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796388"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/epirubicin/etoposide"""@eng ; skos:notation """CDR0000043231"""^^xsd:string ; skos:altLabel """CDDP/CTX/EPI/VP-16"""@eng ; ; ; ; ; """7696"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796389"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dimesna"""@eng ; skos:notation """CDR0000043236"""^^xsd:string ; skos:altLabel """2,2'-Dithiobisethanesulfonic Acid, Disodium Salt"""@eng , """DIM"""@eng , """BNP7787"""@eng , """2,2'-Dithio-bis-ethanesulfonate, Disodium Salt"""@eng , """Tavocept"""@eng , """Mesna Disulfide"""@eng ; skos:definition """A synthetic derivative of dithio-ethane sulfonate with uroprotective properties. In the kidney, dimesna undergoes reduction to the free thiol compound, mesna, which reacts chemically with the urotoxic ifosfamide metabolites acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. This agent also inhibits cyclophosphamide-induced hemorrhagic cystitis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1365\" NCI Thesaurus)"""@eng ; ; ; ; """7700"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """716976"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C1365"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0752700"""^^xsd:string ; umls:cui """C0114346"""^^xsd:string ; umls:cui """C1707754"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dimesna/paclitaxel"""@eng ; skos:notation """CDR0000043237"""^^xsd:string ; skos:altLabel """CDDP/DIM/TAX"""@eng ; ; ; ; """7701"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796393"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab"""@eng ; skos:notation """CDR0000043234"""^^xsd:string ; skos:altLabel """rhuMAb VEGF"""@eng , """anti-VEGF monoclonal antibody"""@eng , """Anti-VEGF Humanized Monoclonal Antibody"""@eng , """Avastin"""@eng , """Anti-VEGF RhuMAb"""@eng , """Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor"""@eng , """Anti-VEGF"""@eng , """Recombinant Humanized Anti-VEGF Monoclonal Antibody"""@eng ; skos:definition """A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43234&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43234&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2039\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """7699"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """11460"""^^xsd:string ; """704865"""^^xsd:string ; """C2039"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9877"""^^xsd:string ; """7921"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0796392"""^^xsd:string ; umls:cui """C1135130"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/mercaptopurine/methotrexate/thioguanine/vincristine/vindesine"""@eng ; skos:notation """CDR0000043404"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DAVA/DM/DNR/MP/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; ; ; """7961"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796542"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate-e therapeutic implant"""@eng ; skos:notation """CDR0000041858"""^^xsd:string ; skos:altLabel """MTX-e TI"""@eng , """MTX/epi gel"""@eng , """Methotrexate-epinephrine therapeutic implant"""@eng , """Methotrexate/epi"""@eng ; skos:definition """An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41858&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41858&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C17876\" NCI Thesaurus)"""@eng ; """5070"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C17876"""^^xsd:string ; umls:cui """C0281425"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil-e therapeutic implant"""@eng ; skos:notation """CDR0000041859"""^^xsd:string ; skos:altLabel """Fluorouracil/epi"""@eng , """5-Fluorouracil/epi"""@eng , """5-FU/epi gel"""@eng , """5-FU-e TI"""@eng , """Fluorouracil-epinephrine therapeutic implant"""@eng ; skos:definition """An injectable collagen matrix gel containing the antimetabolite fluorouracil and the symhathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis whereas another active metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate inhibits thymidylate synthase, thereby interfering with DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of fluorouracil and increasing its anti-tumor activity. Intratumoral injection of fluorouracil combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41859&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41859&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C17877\" NCI Thesaurus)"""@eng ; """5071"""^^xsd:string ; """C17877"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281426"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/gemcitabine"""@eng ; skos:notation """CDR0000310396"""^^xsd:string ; skos:altLabel """3AP/dFdC"""@eng ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327986"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexrazoxane/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000042395"""^^xsd:string ; skos:altLabel """ADR-529/ASP/DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """5650"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338303"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-interferon alfa-2b"""@eng ; skos:notation """CDR0000043407"""^^xsd:string ; skos:altLabel """polyethylene glycol interferon alfa-2b"""@eng , """PEG interferon alfa-2b"""@eng , """PEG-IFN-a 2b"""@eng , """SCH 54031"""@eng , """PEG-IFNA2b"""@eng , """polyethylene glycol IFN-A2b"""@eng , """PEG-Intron"""@eng , """pegylated interferon alfa-2b"""@eng , """PEG-IFN alfa-2b"""@eng ; skos:definition """A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43407&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43407&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1845\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """7966"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C1845"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527096"""^^xsd:string ; umls:cui """C1527737"""^^xsd:string ; umls:cui """C0796545"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/doxorubicin/interferon alfa/prednisone/vincristine"""@eng ; skos:notation """CDR0000041850"""^^xsd:string ; skos:altLabel """BCNU/DOX/IFN-A/PRED/VCR"""@eng ; ; ; ; ; ; """5061"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338173"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/recombinant interferon beta"""@eng ; skos:notation """CDR0000041851"""^^xsd:string ; skos:altLabel """13-CRA/IFN-B"""@eng ; ; ; """5062"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281419"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta carotene/vitamin A"""@eng ; skos:notation """CDR0000041852"""^^xsd:string ; skos:altLabel """Beta CT/VIT-A"""@eng ; ; ; """5063"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281420"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/fluorouracil/leucovorin calcium/mitomycin"""@eng ; skos:notation """CDR0000041853"""^^xsd:string ; skos:altLabel """CF/DP/5-FU/MITO"""@eng ; ; ; ; ; """5064"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281421"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/paclitaxel"""@eng ; skos:notation """CDR0000041854"""^^xsd:string ; skos:altLabel """MTX/TAX"""@eng ; ; ; """5065"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281422"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/methotrexate/paclitaxel"""@eng ; skos:notation """CDR0000041855"""^^xsd:string ; skos:altLabel """G-CSF/MTX/TAX"""@eng ; ; ; ; """5066"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281423"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/paclitaxel"""@eng ; skos:notation """CDR0000041856"""^^xsd:string ; skos:altLabel """CTX/DOX/TAX"""@eng ; ; ; ; """5067"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281424"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cyclophosphamide/docetaxel/doxorubicin"""@eng ; skos:notation """CDR0000442106"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB VEGF/TXT"""@eng ; ; ; ; ; """2005-08-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-28"""^^xsd:string ; umls:cui """C1831695"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000037994"""^^xsd:string ; skos:altLabel """lymphoma, non-Hodgkin's, lymphoblastic stage IV childhood"""@eng , """lymphoblastic metastatic non-Hodgkin's lymphoma, childhood"""@eng , """stage IV lymphoblastic childhood lymphoma"""@eng , """lymphoblastic stage IV non-Hodgkin's lymphoma, childhood"""@eng , """metastatic childhood lymphoblastic lymphoma"""@eng , """childhood non-Hodgkin's lymphoma, lymphoblastic metastatic"""@eng , """childhood non-Hodgkin's lymphoma, lymphoblastic stage IV"""@eng , """NHL, lymphoblastic stage IV childhood"""@eng , """Non-Hodgkin's lymphoma, lymphoblastic metastatic childhood"""@eng , """Non-Hodgkin's lymphoma, lymphoblastic stage IV childhood"""@eng , """lymphoma, non-Hodgkin's, lymphoblastic metastatic childhood"""@eng , """pediatric lymphoblastic non-Hodgkin's lymphoma, stage IV"""@eng , """pediatric lymphoblastic non-Hodgkin's lymphoma, metastatic"""@eng , """metastatic lymphoblastic childhood non-Hodgkin's lymphoma"""@eng , """metastatic lymphoblastic childhood lymphoma"""@eng , """NHL, lymphoblastic metastatic childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1048"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278738"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult brain tumor"""@eng ; skos:notation """CDR0000038719"""^^xsd:string ; skos:altLabel """CNS tumor, adult brain, recurrent"""@eng , """recurrent brain tumor, adult"""@eng , """adult brain tumor, recurrent"""@eng , """central nervous system tumor, recurrent, adult"""@eng , """adult CNS tumor, recurrent"""@eng , """brain tumor, recurrent, adult"""@eng , """recurrent CNS tumor, adult"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1145"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278786"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """WT1 126-134 peptide vaccine"""@eng ; skos:notation """CDR0000472216"""^^xsd:string ; skos:definition """A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=472216&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=472216&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61442\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C61442"""^^xsd:string ; """2006-10-10"""^^xsd:string ; """2006-03-10"""^^xsd:string ; umls:cui """C1831770"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic hematopoietic stem cell transplantation"""@eng ; skos:notation """CDR0000467919"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1705576"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous hematopoietic stem cell transplantation"""@eng ; skos:notation """CDR0000467918"""^^xsd:string ; ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C1831743"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrinoma"""@eng ; skos:notation """CDR0000038718"""^^xsd:string ; skos:altLabel """pancreatic gastrinoma"""@eng , """islet cell gastrinoma"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1144"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0017150"""^^xsd:string ; umls:cui """C1368066"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """obesity"""@eng ; skos:notation """CDR0000467910"""^^xsd:string ; rdfs:subClassOf ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0028754"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """poor performance status"""@eng ; skos:notation """CDR0000467914"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C1831741"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nonmyeloablative allogeneic hematopoietic stem cell transplantation"""@eng ; skos:notation """CDR0000467917"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831742"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AN-9/docetaxel"""@eng ; skos:notation """CDR0000352178"""^^xsd:string ; skos:altLabel """AN9/TXT"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328148"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pivaloyloxymethylbutyrate"""@eng ; skos:notation """CDR0000352177"""^^xsd:string ; skos:altLabel """AN-9"""@eng , """Pivanex"""@eng , """AN9"""@eng ; ; """2004-01-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """C1344"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0137152"""^^xsd:string ; umls:cui """C1328147"""^^xsd:string ; umls:cui """C0103186"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/irinotecan/vincristine"""@eng ; skos:notation """CDR0000352174"""^^xsd:string ; skos:altLabel """CBDCA/CPT-11/VCR"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328146"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CC-4047"""@eng ; skos:notation """CDR0000352172"""^^xsd:string ; skos:altLabel """ACTIMID"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C2347625"""^^xsd:string ; umls:cui """C1176324"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VEGFR-2 inhibitor CT-322"""@eng ; skos:notation """CDR0000512990"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-24"""^^xsd:string ; umls:cui """C1831965"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/cisplatin"""@eng ; skos:notation """CDR0000038256"""^^xsd:string ; skos:altLabel """17-AAG/CDDP"""@eng ; ; ; """2004-04-20"""^^xsd:string ; """10863"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541457"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/tariquidar"""@eng ; skos:notation """CDR0000038257"""^^xsd:string ; skos:altLabel """DOX/XR9576"""@eng ; ; ; """2004-04-12"""^^xsd:string ; """10864"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541458"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody 4G7xH22"""@eng ; skos:notation """CDR0000038254"""^^xsd:string ; skos:definition """A bispecific antibody containing a 4G7 hybridoma secreting IgG1 antibody specific for B-lymphocytes and a monoclonal antibody targeting Fc gamma RI-expressing cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38254&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38254&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2624\" NCI Thesaurus)"""@eng ; """10861"""^^xsd:string ; """C2624"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935815"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000038255"""^^xsd:string ; skos:altLabel """CBDCA/MTX/VBL"""@eng ; ; ; ; """10862"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935816"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV penile cancer"""@eng ; skos:notation """CDR0000038252"""^^xsd:string ; skos:altLabel """penile cancer, metastatic"""@eng , """metastatic penile cancer"""@eng , """penis cancer, stage IV"""@eng , """penis cancer, metastatic"""@eng , """penile cancer, stage IV"""@eng ; rdfs:subClassOf ; """penile cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1086"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854963"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dexamethasone/gemcitabine"""@eng ; skos:notation """CDR0000038253"""^^xsd:string ; skos:altLabel """CDDP/dFdC/DM"""@eng ; ; ; ; """10860"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935814"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-interferon alfa-2b/temozolomide"""@eng ; skos:notation """CDR0000038250"""^^xsd:string ; skos:altLabel """PEG-IFNA2b/TMZ"""@eng ; """2003-08-27"""^^xsd:string ; """10858"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935812"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/irinotecan"""@eng ; skos:notation """CDR0000305870"""^^xsd:string ; skos:altLabel """CPT-11/PS-341"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327969"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vapreotide"""@eng ; skos:notation """CDR0000038258"""^^xsd:string ; skos:altLabel """Octastatin"""@eng ; """10865"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0164678"""^^xsd:string ; umls:cui """C0285417"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neuroendocrine carcinoma"""@eng ; skos:notation """CDR0000038259"""^^xsd:string ; skos:altLabel """carcinoma, neuroendocrine"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """10866"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206695"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-A3 peptide vaccine"""@eng ; skos:notation """CDR0000391278"""^^xsd:string ; skos:altLabel """MAGE-A3"""@eng ; ; """2004-09-25"""^^xsd:string ; """2004-09-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541478"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine hydrochloride"""@eng ; skos:notation """CDR0000041213"""^^xsd:string ; skos:altLabel """Gemzar"""@eng , """gemcitabine"""@eng , """dFdC"""@eng , """LY-188011"""@eng , """2'Deoxy-2',2'-Difluorocytidine"""@eng , """1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose"""@eng , """2'-Deoxy-2',2'-difluorocytidine"""@eng , """dFdCyd"""@eng , """difluorodeoxycytidine"""@eng ; skos:definition """The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41213&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41213&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C961\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """47762"""^^xsd:string ; """C961"""^^xsd:string ; """103882-84-4"""^^xsd:string ; """4286"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """613327"""^^xsd:string ; umls:cui """C0771488"""^^xsd:string ; umls:cui """C0701235"""^^xsd:string ; umls:cui """C0045093"""^^xsd:string ; umls:cui """C0338133"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult brain tumor"""@eng ; skos:notation """CDR0000038717"""^^xsd:string ; skos:altLabel """central nervous system tumor, adult"""@eng , """Brain tumor, adult: General and other"""@eng , """adult CNS tumor"""@eng , """brain tumor, adult"""@eng , """CNS tumor, adult"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1143"""^^xsd:string ; """2005-04-25"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220624"""^^xsd:string ; umls:cui """C1377678"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000038716"""^^xsd:string ; skos:altLabel """adult acute lymphocytic leukemia, relapsed"""@eng , """acute lymphocytic leukemia, relapsed, adult"""@eng , """lymphocytic leukemia, relapsed adult acute"""@eng , """recurrent ALL, adult"""@eng , """leukemia, relapsed adult acute lymphocytic"""@eng , """relapsed ALL, adult"""@eng , """recurrent adult acute lymphocytic leukemia"""@eng , """recurrent adult ALL"""@eng , """acute lymphocytic leukemia, recurrent, adult"""@eng , """relapsed adult acute lymphocytic leukemia"""@eng , """relapsed adult ALL"""@eng , """ALL, recurrent, adult"""@eng , """ALL, relapsed, adult"""@eng ; rdfs:subClassOf ; """adult acute lymphoblastic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1142"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278785"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/trastuzumab"""@eng ; skos:notation """CDR0000037969"""^^xsd:string ; skos:altLabel """MOAB HER2/TXT"""@eng ; ; ; """10387"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progenipoietin"""@eng ; skos:notation """CDR0000037968"""^^xsd:string ; skos:altLabel """ProGP"""@eng , """filgrastim-fetal liver tyrosine kinase-3 fusion protein"""@eng ; ; """10386"""^^xsd:string ; """C2587"""^^xsd:string ; """2006-11-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879506"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """actinic keratosis"""@eng ; skos:notation """CDR0000038788"""^^xsd:string ; skos:altLabel """keratosis, actinic"""@eng ; rdfs:subClassOf ; """2004-11-17"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1237"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0022602"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent skin cancer"""@eng ; skos:notation """CDR0000038789"""^^xsd:string ; skos:altLabel """recurrent carcinoma of the skin"""@eng , """carcinoma of the skin, recurrent"""@eng , """skin cancer, recurrent"""@eng , """cancer of the skin, recurrent"""@eng , """recurrent cancer of the skin"""@eng ; rdfs:subClassOf ; """skin cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1238"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278839"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vulvar cancer"""@eng ; skos:notation """CDR0000037961"""^^xsd:string ; skos:altLabel """carcinoma of the vulva"""@eng , """Vulvar cancer"""@eng , """vulva cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1038"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0677055"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/topotecan"""@eng ; skos:notation """CDR0000037960"""^^xsd:string ; skos:altLabel """ARA-C/DNR/TOPO/VP-16"""@eng ; ; ; ; ; """10379"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879500"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/tretinoin/vinorelbine"""@eng ; skos:notation """CDR0000037963"""^^xsd:string ; skos:altLabel """ATRA/CDDP/VNB"""@eng ; ; ; ; """10381"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitomycin/tretinoin/vinorelbine"""@eng ; skos:notation """CDR0000037962"""^^xsd:string ; skos:altLabel """ATRA/CDDP/MITO/VNB"""@eng ; ; ; ; ; """10380"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879501"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/dexamethasone/etoposide/thalidomide"""@eng ; skos:notation """CDR0000037965"""^^xsd:string ; skos:altLabel """CDDP/CTX/DM/THAL/VP-16"""@eng ; ; ; ; ; ; """10383"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879504"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fenretinide/paclitaxel"""@eng ; skos:notation """CDR0000037964"""^^xsd:string ; skos:altLabel """CDDP/HPR/TAX"""@eng ; ; ; ; """10382"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-CEA-B7.1 vaccine/tetanus toxoid"""@eng ; skos:notation """CDR0000298885"""^^xsd:string ; skos:altLabel """ALVAC-CEA-B7.1/TETTOX"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327928"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AE-941/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000037966"""^^xsd:string ; skos:altLabel """AE941/CBDCA/TAX"""@eng ; ; ; ; """2003-04-21"""^^xsd:string ; """10384"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879613"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/octreotide"""@eng ; skos:notation """CDR0000038072"""^^xsd:string ; skos:altLabel """CPT-11/SSTN"""@eng ; ; ; """10611"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935666"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unusual cancers of childhood"""@eng ; skos:notation """CDR0000038073"""^^xsd:string ; rdfs:subClassOf ; """10612"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1134441"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/dexamethasone/mitoxantrone"""@eng ; skos:notation """CDR0000038070"""^^xsd:string ; skos:altLabel """CLB/DHAD/DM"""@eng ; ; ; ; """10609"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935665"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IVB vaginal cancer"""@eng ; skos:notation """CDR0000038071"""^^xsd:string ; skos:altLabel """vaginal cancer, stage IVB"""@eng , """metastatic vaginal cancer"""@eng , """vagina cancer, metastatic"""@eng , """carcinoma of the vagina, metastatic"""@eng , """cancer of the vagina, stage IVB"""@eng , """cancer of the vagina, metastatic"""@eng , """metastatic cancer of the vagina"""@eng , """vagina cancer, stage IVB"""@eng , """stage IVB vagina cancer"""@eng , """metastatic vagina cancer"""@eng , """carcinoma of the vagina, stage IVB"""@eng , """stage IVB cancer of the vagina"""@eng , """metastatic carcinoma of the vagina"""@eng , """stage IVB carcinoma of the vagina"""@eng , """vaginal cancer, metastatic"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1061"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1377787"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent vaginal cancer"""@eng ; skos:notation """CDR0000038076"""^^xsd:string ; skos:altLabel """vagina cancer, recurrent"""@eng , """cancer of the vagina, recurrent"""@eng , """recurrent carcinoma of the vagina"""@eng , """recurrent vagina cancer"""@eng , """vaginal cancer, recurrent"""@eng , """recurrent cancer of the vagina"""@eng , """carcinoma of the vagina, recurrent"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1062"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278746"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/trastuzumab"""@eng ; skos:notation """CDR0000038077"""^^xsd:string ; skos:altLabel """IL-2/MOAB HER2"""@eng ; ; ; """10620"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935669"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DX-8951f/gemcitabine"""@eng ; skos:notation """CDR0000038074"""^^xsd:string ; skos:altLabel """dFdC/DX-8951f"""@eng ; ; ; """10613"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/docetaxel"""@eng ; skos:notation """CDR0000038075"""^^xsd:string ; skos:altLabel """CTX/TXT"""@eng ; ; ; """10614"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935668"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-12 peptide vaccine"""@eng ; skos:notation """CDR0000038078"""^^xsd:string ; skos:altLabel """MAGE-12"""@eng ; ; ; """10621"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935670"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-12 peptide vaccine/Montanide ISA-51"""@eng ; skos:notation """CDR0000038079"""^^xsd:string ; skos:altLabel """ISA-51/MAGE-12"""@eng ; ; """10622"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935671"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CHIR-265"""@eng ; skos:notation """CDR0000484456"""^^xsd:string ; skos:definition """A novel, orally active, small molecule with potential antineoplastic activity.CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484456&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484456&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61311\" NCI Thesaurus)"""@eng ; """2006-08-31"""^^xsd:string ; """C61311"""^^xsd:string ; """2006-05-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C3537162"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hematopoietic stem cell mobilizer"""@eng ; skos:notation """CDR0000484458"""^^xsd:string ; """2006-05-05"""^^xsd:string ; """2006-05-04"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831811"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant TNF-related apoptosis-inducing ligand"""@eng ; skos:notation """CDR0000529297"""^^xsd:string ; skos:altLabel """TNF-Related Apoptosis-Inducing Ligand"""@eng , """TRAIL"""@eng , """APO2L/TRAIL"""@eng , """Apo2L"""@eng ; skos:definition """TNF-related apoptosis-inducing ligand (TRAIL) is a homotrimeric type II membrane protein that rapidly induces oligomerization of receptor intracellular death domains and apoptosis in a variety of tumor cells. TRAIL mRNA is up regulated in response to IFNA and IFNB. TRAIL demonstrated antineoplastic activity in vivo without significant toxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=529297&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=529297&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1685\" NCI Thesaurus)"""@eng ; """C1685"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1522480"""^^xsd:string ; umls:cui """C0385242"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """silymarin"""@eng ; skos:notation """CDR0000284684"""^^xsd:string ; skos:altLabel """milk thistle"""@eng ; skos:definition """A mixture of flavonolignans isolated from the milk thistle plant Silybum marianum. Silymarin may act as an antioxidant, protecting hepatic cells from chemotherapy-related free radical damage. This agent may also promote the growth of new hepatic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=284684&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=284684&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26671\" NCI Thesaurus)"""@eng ; """2003-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C26671"""^^xsd:string ; """65666-07-1"""^^xsd:string ; umls:cui """C0937640"""^^xsd:string ; umls:cui """C0037135"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tin Sn 117m DTPA"""@eng ; skos:notation """CDR0000042863"""^^xsd:string ; """6673"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677797"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MK0429"""@eng ; skos:notation """CDR0000489322"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831889"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CS-1008"""@eng ; skos:notation """CDR0000489323"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62482"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """2006-09-19"""^^xsd:string ; umls:cui """C1831890"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone"""@eng ; skos:notation """CDR0000037785"""^^xsd:string ; skos:altLabel """ASP/DM"""@eng ; ; ; """10145"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879377"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/fludarabine"""@eng ; skos:notation """CDR0000037784"""^^xsd:string ; skos:altLabel """ARA-C/CTX/FAMP"""@eng ; ; ; ; """10143"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879376"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/vincristine"""@eng ; skos:notation """CDR0000037787"""^^xsd:string ; skos:altLabel """DNR/VCR"""@eng ; ; ; """10147"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879379"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/vincristine"""@eng ; skos:notation """CDR0000037786"""^^xsd:string ; skos:altLabel """DM/MTX/VCR"""@eng ; ; ; ; """10146"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879378"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ifosfamide/thiotepa"""@eng ; skos:notation """CDR0000037781"""^^xsd:string ; skos:altLabel """CBDCA/IFF/TSPA"""@eng ; ; ; ; """10137"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879374"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodinated contrast dye"""@eng ; skos:notation """CDR0000037780"""^^xsd:string ; skos:altLabel """contrast dye, iodinated"""@eng ; """10136"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879373"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab"""@eng ; skos:notation """CDR0000037783"""^^xsd:string ; skos:altLabel """MabCampath"""@eng , """anti-CD52 monoclonal antibody"""@eng , """Campath-1H"""@eng , """Monoclonal Antibody Campath-1H"""@eng , """Monoclonal Antibody CD52"""@eng , """MoAb CD52"""@eng , """Campath"""@eng ; skos:definition """A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37783&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37783&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1681\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """10139"""^^xsd:string ; """10864"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C1681"""^^xsd:string ; """715969"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1271482"""^^xsd:string ; umls:cui """C0939276"""^^xsd:string ; umls:cui """C1178562"""^^xsd:string ; umls:cui """C0383429"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000037782"""^^xsd:string ; skos:altLabel """LipoDox/MTX/PRED/VCR"""@eng ; ; ; ; ; """10138"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879375"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ruthenium Ru 106"""@eng ; skos:notation """CDR0000357497"""^^xsd:string ; skos:altLabel """Ruthenium 106"""@eng , """Ru-106"""@eng ; skos:definition """A radioactive isotope of the rare element ruthenium, a member of the light platinum group. A radioactive plaque containing ruthenium 106 may be inserted into the eye to irradiate ophthalmic tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357497&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357497&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38686\" NCI Thesaurus)"""@eng ; """2004-02-20"""^^xsd:string ; """C38686"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; umls:cui """C0303733"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/prinomastat"""@eng ; skos:notation """CDR0000037789"""^^xsd:string ; skos:altLabel """AG3340/CDDP/dFdC"""@eng ; ; ; ; """10149"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879381"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prinomastat/temozolomide"""@eng ; skos:notation """CDR0000037788"""^^xsd:string ; skos:altLabel """AG3340/TMZ"""@eng ; ; ; """10148"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879380"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """garlic"""@eng ; skos:notation """CDR0000357490"""^^xsd:string ; skos:altLabel """Allium sativum"""@eng , """GarliPure Maximum Allicin"""@eng , """ajo"""@eng ; skos:definition """A bulbous herb isolated from the plant Allium sativum with potential antineoplastic activity. Garlic contains a number of different organosulfur compounds, some of which have displayed antineoplastic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357490&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357490&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38706\" NCI Thesaurus)"""@eng ; ; """2004-02-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C38706"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328222"""^^xsd:string ; umls:cui """C0885057"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/gemcitabine/irinotecan"""@eng ; skos:notation """CDR0000357491"""^^xsd:string ; skos:altLabel """CPT-11/dFdC/FLAVO"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328223"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """miltefosine"""@eng ; skos:notation """CDR0000041212"""^^xsd:string ; skos:altLabel """HDPC"""@eng , """Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt"""@eng , """hexadecylphosphocholine"""@eng , """Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate"""@eng , """Miltefosinum"""@eng , """2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt"""@eng , """n-Hexadecylphosphorylcholine"""@eng , """D-18506"""@eng , """Miltefosin"""@eng , """Miltex"""@eng , """Miltefosina"""@eng ; skos:definition """An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity. Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41212&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41212&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1170\" NCI Thesaurus)"""@eng ; """4285"""^^xsd:string ; """C1170"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58066-85-6"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0111934"""^^xsd:string ; umls:cui """C0068006"""^^xsd:string ; umls:cui """C1513304"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-A3 peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000391279"""^^xsd:string ; skos:altLabel """GM-CSF/MAGE-A3"""@eng ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541479"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nimodipine"""@eng ; skos:notation """CDR0000041210"""^^xsd:string ; skos:altLabel """NIMO"""@eng , """Nimotop"""@eng ; skos:definition """A dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity. Nimodipine inhibits the transmembrane influx of calcium ions in response to depolarization in smooth muscle cells, thereby inhibiting vascular smooth muscle contraction and inducing vasodilatation. Nimodipine has a greater effect on cerebral arteries than on peripheral smooth muscle cells and myocardial cells, probably because this agent can cross the blood brain barrier due to its lipophilic nature. Furthermore, this agent also inhibits the drug efflux pump P-glycoprotein, which is overexpressed in some multi-drug resistant tumors, and may improve the efficacy of some antineoplastic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41210&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41210&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C692\" NCI Thesaurus)"""@eng ; ; ; """4283"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """66085-59-4"""^^xsd:string ; """C692"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0028094"""^^xsd:string ; umls:cui """C0678207"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ormaplatin"""@eng ; skos:notation """CDR0000041211"""^^xsd:string ; skos:altLabel """tetraplatin"""@eng ; """Drug/agent"""^^xsd:string ; """C1250"""^^xsd:string ; """4284"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C0076329"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/fluorouracil"""@eng ; skos:notation """CDR0000041216"""^^xsd:string ; skos:altLabel """5-FU/FUDR"""@eng ; ; ; """4289"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280815"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/interferon alfa"""@eng ; skos:notation """CDR0000041217"""^^xsd:string ; skos:altLabel """CDDP/IFN-A/VP-16"""@eng ; ; ; ; """4290"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338134"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/vincristine"""@eng ; skos:notation """CDR0000041214"""^^xsd:string ; skos:altLabel """BCNU/VCR"""@eng ; ; ; """4287"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280813"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/nimodipine/vincristine"""@eng ; skos:notation """CDR0000041215"""^^xsd:string ; skos:altLabel """BCNU/NIMO/VCR"""@eng ; ; ; ; """4288"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280814"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/interleukin-2"""@eng ; skos:notation """CDR0000041218"""^^xsd:string ; skos:altLabel """CDDP/CTX/IL-2"""@eng ; ; ; ; """4291"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280817"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/fluorouracil"""@eng ; skos:notation """CDR0000041219"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/5-FU"""@eng ; ; ; ; """4293"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280818"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial clear cell carcinoma"""@eng ; skos:notation """CDR0000040062"""^^xsd:string ; skos:altLabel """carcinoma, clearcell, endometrial"""@eng , """uterus cancer, clearcell carcinoma"""@eng , """clearcell carcinoma of the uterus"""@eng , """uterine corpus cancer, clearcell carcinoma"""@eng , """carcinoma of the uterus, clearcell"""@eng , """uterine cancer, clearcell carcinoma"""@eng ; rdfs:subClassOf ; """2803"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279765"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progesterone receptor negative"""@eng ; skos:notation """CDR0000040063"""^^xsd:string ; skos:altLabel """PR-"""@eng , """negative progesterone receptor"""@eng ; """2804"""^^xsd:string ; umls:cui """C0279766"""^^xsd:string ; umls:tui """T034"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial adenoacanthoma"""@eng ; skos:notation """CDR0000040060"""^^xsd:string ; skos:altLabel """uterine corpus cancer, adenoacanthoma"""@eng , """adenoacanthoma of the uterus"""@eng , """uterus cancer, adenoacanthoma"""@eng , """uterine cancer, adenoacanthoma"""@eng ; rdfs:subClassOf ; """2801"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279763"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial papillary carcinoma"""@eng ; skos:notation """CDR0000040061"""^^xsd:string ; skos:altLabel """uterine cancer, papillary carcinoma"""@eng , """carcinoma, papillary, endometrial"""@eng , """uterine corpus cancer, papillary carcinoma"""@eng , """papillary carcinoma of the uterus"""@eng , """uterus cancer, papillary carcinoma"""@eng , """carcinoma of the uterus, papillary"""@eng ; rdfs:subClassOf ; """2802"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279764"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/mitolactol/procarbazine/thioguanine/vincristine"""@eng ; skos:notation """CDR0000040066"""^^xsd:string ; skos:altLabel """TPDCV"""@eng , """CCNU/DBD/PCB/TG/VCR"""@eng ; ; ; ; ; ; """2807"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279769"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sarcoma, adult soft tissue, metastatic"""@eng ; skos:notation """CDR0000040067"""^^xsd:string ; skos:altLabel """soft tissue sarcoma, adult stage IVB"""@eng , """metastatic adult soft tissue sarcoma"""@eng , """sarcoma, adult soft tissue, stage IVB"""@eng , """adult soft tissue sarcoma, stage IVB"""@eng , """adult soft tissue sarcoma, metastatic"""@eng ; """2004-06-10"""^^xsd:string ; """2809"""^^xsd:string ; umls:cui """C0278664"""^^xsd:string ; umls:cui """C0279770"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/etoposide/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040064"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MTX/PRED/VCR/VP-16"""@eng , """MOPLACE"""@eng ; ; ; ; ; ; ; """2805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279767"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progesterone receptor status unknown"""@eng ; skos:notation """CDR0000040065"""^^xsd:string ; skos:altLabel """unknown status, progesterone receptor"""@eng ; """2806"""^^xsd:string ; umls:cui """C0279768"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plasma cell neoplasm"""@eng ; skos:notation """CDR0000040068"""^^xsd:string ; skos:altLabel """neoplasm, plasma cell"""@eng , """myeloma, plasma cell"""@eng , """multiple myeloma"""@eng , """plasma cell myeloma"""@eng ; rdfs:subClassOf ; """281"""^^xsd:string ; """2006-03-28"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0026764"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soft tissue sarcoma, adult, stage IVA"""@eng ; skos:notation """CDR0000040069"""^^xsd:string ; skos:altLabel """adult soft tissue sarcoma, stage IVA"""@eng , """sarcoma, adult soft tissue, stage IVA"""@eng ; """2004-06-10"""^^xsd:string ; """2810"""^^xsd:string ; umls:cui """C0279771"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eltrombopag"""@eng ; skos:notation """CDR0000491973"""^^xsd:string ; skos:altLabel """SB-497115-GR"""@eng ; """Drug/agent"""^^xsd:string ; """2006-06-22"""^^xsd:string ; umls:cui """C1831905"""^^xsd:string ; umls:cui """C1831906"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """deferasirox"""@eng ; skos:notation """CDR0000435986"""^^xsd:string ; skos:altLabel """Exjade"""@eng , """ICL670"""@eng ; skos:definition """A synthetic, orally available, achiral, tridentate triazole derived from salicylic acid with iron chelator properties. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availablity,and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435986&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435986&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48384\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C48384"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-06-08"""^^xsd:string ; umls:cui """C1619629"""^^xsd:string ; umls:cui """C1609706"""^^xsd:string ; umls:cui """C0971122"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/sorafenib"""@eng ; skos:notation """CDR0000435983"""^^xsd:string ; skos:altLabel """DTIC/SFN"""@eng ; ; ; """2005-06-08"""^^xsd:string ; """2005-06-01"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831637"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nilotinib"""@eng ; skos:notation """CDR0000435988"""^^xsd:string ; skos:altLabel """4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide"""@eng , """AMN 107"""@eng ; skos:definition """An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435988&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435988&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48375\" NCI Thesaurus)"""@eng ; """2006-07-26"""^^xsd:string ; """2005-06-08"""^^xsd:string ; """C48375"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1721377"""^^xsd:string ; umls:cui """C1567379"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dextropropoxyphene hydrochloride"""@eng ; skos:notation """CDR0000508976"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-15"""^^xsd:string ; umls:cui """C0242451"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ultrasonic surgical aspiration"""@eng ; skos:notation """CDR0000526234"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C1832004"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yoga"""@eng ; skos:notation """CDR0000526236"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C1883583"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """music therapy"""@eng ; skos:notation """CDR0000526238"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C0026868"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ofloxacin"""@eng ; skos:notation """CDR0000042865"""^^xsd:string ; skos:definition """A fluoroquinolone antibacterial antibiotic. Ofloxacin binds to and inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes involved in DNA replication and repair, resulting in cell death in sensitive bacterial species. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42865&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42865&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C712\" NCI Thesaurus)"""@eng ; """6675"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C712"""^^xsd:string ; """82419-36-1"""^^xsd:string ; umls:cui """C0028902"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, stage IV adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042749"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6546"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677719"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, stage III adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042748"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6545"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677718"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III mantle cell lymphoma"""@eng ; skos:notation """CDR0000042744"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6541"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677714"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000042741"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6535"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677711"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000042740"""^^xsd:string ; skos:altLabel """noncontiguous stage II adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6534"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677710"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indolent, stage III adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042742"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6536"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677712"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """velafermin"""@eng ; skos:notation """CDR0000436982"""^^xsd:string ; skos:altLabel """CG53135-05"""@eng , """rhFGF-20"""@eng , """recombinant human fibroblast growth factor-20"""@eng ; skos:definition """A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity. Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=436982&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=436982&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48425\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """C48425"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C1831647"""^^xsd:string ; umls:cui """C1710622"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """propofol"""@eng ; skos:notation """CDR0000461189"""^^xsd:string ; skos:altLabel """Diprivan"""@eng ; skos:definition """A hypnotic alkylphenol derivative. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). This agent is associated with minimal respiratory depression and has a short half-life with a duration of action of 2 to 10 minutes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461189&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461189&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29384\" NCI Thesaurus)"""@eng ; """2006-09-11"""^^xsd:string ; """C29384"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0678120"""^^xsd:string ; umls:cui """C0033487"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/thiotepa"""@eng ; skos:notation """CDR0000434637"""^^xsd:string ; skos:altLabel """FAMP/TSPA"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-23"""^^xsd:string ; umls:cui """C1831635"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/irinotecan"""@eng ; skos:notation """CDR0000269700"""^^xsd:string ; skos:altLabel """ARA-C/CPT-11"""@eng ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327859"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglycoside agent"""@eng ; skos:notation """CDR0000040385"""^^xsd:string ; rdfs:subClassOf ; """3246"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002556"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium carbonate/cholecalciferol/risedronate"""@eng ; skos:notation """CDR0000256446"""^^xsd:string ; skos:altLabel """CACO3/RISE/VIT-D"""@eng ; ; ; ; """2002-07-16"""^^xsd:string ; """11396"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327746"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/flutamide/leuprolide"""@eng ; skos:notation """CDR0000358058"""^^xsd:string ; skos:altLabel """EM/FLUT/LEUP/TXT"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541573"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tyrosinase peptide"""@eng ; skos:notation """CDR0000042338"""^^xsd:string ; skos:altLabel """Tyrosinase Peptides"""@eng , """TYRP"""@eng ; skos:definition """One of a number of recombinant peptides consisting of amino acid residues of the enzyme tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with tyrosinase peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42338&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42338&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2401\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5590"""^^xsd:string ; """C2401"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338254"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """QS21/tyrosinase peptide"""@eng ; skos:notation """CDR0000042339"""^^xsd:string ; skos:altLabel """QS 21/TYRP"""@eng ; ; ; """5591"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338255"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """perillyl alcohol"""@eng ; skos:notation """CDR0000042334"""^^xsd:string ; skos:altLabel """Dihydrocuminyl Alcohol"""@eng , """Perillol"""@eng , """1-Cyclohexene-1-methanol"""@eng , """4-Isopropenylcyclohex-1-ene-1-methanol"""@eng , """4-(1-Methylethenyl)-1-cyclohexene-1-methanol"""@eng , """POH"""@eng , """Perillic Alcohol"""@eng , """p-Mentha-1,8-dien-7-ol"""@eng , """4-(1-Methylethenyl)"""@eng , """(S)-(-)-Perillyl Alcohol"""@eng , """perilla alcohol"""@eng ; skos:definition """A naturally occurring monoterpene related to limonene with antineoplastic activity. Perillyl alcohol inhibits farnesyl transferase and geranylgeranyl transferase, thereby preventing post-translational protein farnesylation and isoprenylation and activation of oncoproteins such as p21-ras, and arresting tumor cells in the G1 phase of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42334&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42334&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1461\" NCI Thesaurus)"""@eng ; """5586"""^^xsd:string ; """47472"""^^xsd:string ; """536-59-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1461"""^^xsd:string ; """641066"""^^xsd:string ; umls:cui """C0207661"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/vinorelbine"""@eng ; skos:notation """CDR0000042335"""^^xsd:string ; skos:altLabel """TXT/VNB"""@eng ; ; ; """5587"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338251"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/filgrastim/vinorelbine"""@eng ; skos:notation """CDR0000042336"""^^xsd:string ; skos:altLabel """G-CSF/TXT/VNB"""@eng ; ; ; ; """5588"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338252"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/gemcitabine/leucovorin calcium"""@eng ; skos:notation """CDR0000042337"""^^xsd:string ; skos:altLabel """CF/dFdC/FUDR"""@eng ; ; ; ; """5589"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338253"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cytarabine/etoposide/melphalan"""@eng ; skos:notation """CDR0000042330"""^^xsd:string ; skos:altLabel """BEAM"""@eng , """ARA-C/BCNU/L-PAM/VP-16"""@eng ; ; ; ; ; """5580"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338248"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lurtotecan"""@eng ; skos:notation """CDR0000042331"""^^xsd:string ; skos:altLabel """GG 211"""@eng , """GI147211C"""@eng , """GI-147211"""@eng ; skos:definition """A semisynthetic analogue of camptothecin with antineoplastic activity. Lurtotecan selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. Independent from DNA replication inhibition, lurtotecan also inhibits RNA synthesis, multi-ubiquitination and degradation of topoisomerase I and chromatin reorganization. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42331&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42331&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1610\" NCI Thesaurus)"""@eng ; """5581"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1610"""^^xsd:string ; umls:cui """C0754092"""^^xsd:string ; umls:cui """C0293658"""^^xsd:string ; umls:cui """C1527052"""^^xsd:string ; umls:cui """C0293660"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thalidomide"""@eng ; skos:notation """CDR0000042332"""^^xsd:string ; skos:altLabel """2,6-Dioxo-3-phthalimidopiperidine"""@eng , """Thalomid"""@eng , """Sedoval K-17"""@eng , """Synovir"""@eng , """Contergan"""@eng , """2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione"""@eng , """Softenon"""@eng , """N-(2,6-Dioxo-3-piperidyl)phthalimide"""@eng , """Distaval"""@eng , """THAL"""@eng , """Alpha-Phthalimidoglutarimide"""@eng , """Talimol"""@eng , """Pantosediv"""@eng , """3-Phthalimidoglutarimide"""@eng , """N-Phthaloylglutamimide"""@eng , """Kevadon"""@eng , """Neurosedyn"""@eng , """N-Phthalylglutamic Acid Imide"""@eng ; skos:definition """A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42332&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42332&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C870\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5584"""^^xsd:string ; """66847"""^^xsd:string ; """C870"""^^xsd:string ; """91729"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """48832"""^^xsd:string ; """50-35-1"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1515348"""^^xsd:string ; umls:cui """C0729008"""^^xsd:string ; umls:cui """C1515342"""^^xsd:string ; umls:cui """C1515343"""^^xsd:string ; umls:cui """C0723668"""^^xsd:string ; umls:cui """C1515346"""^^xsd:string ; umls:cui """C1515347"""^^xsd:string ; umls:cui """C1515344"""^^xsd:string ; umls:cui """C1515345"""^^xsd:string ; umls:cui """C0729006"""^^xsd:string ; umls:cui """C0039736"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idarubicin/tretinoin liposome"""@eng ; skos:notation """CDR0000042333"""^^xsd:string ; skos:altLabel """IDA/L-ATRA"""@eng ; ; ; """5585"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338250"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adjustment disorder"""@eng ; skos:notation """CDR0000257623"""^^xsd:string ; rdfs:subClassOf ; """2002-10-19"""^^xsd:string ; """2002-08-29"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0001546"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000040664"""^^xsd:string ; skos:altLabel """DOX/PRED/VCR/VP-16"""@eng , """AOPE"""@eng ; ; ; ; ; """3579"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280286"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040665"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer stage"""@eng , """oral cavity and lip cancer stage"""@eng ; rdfs:subClassOf ; """3580"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280287"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, lip and oral cavity cancer"""@eng ; skos:notation """CDR0000040666"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer cellular diagnosis"""@eng , """oral cavity and lip cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """3581"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280288"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, oropharyngeal cancer"""@eng ; skos:notation """CDR0000040667"""^^xsd:string ; skos:altLabel """oropharyngeal cancer stage"""@eng , """oropharynx cancer stage"""@eng ; rdfs:subClassOf ; """3582"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280289"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """drug extravasation therapy"""@eng ; skos:notation """CDR0000040660"""^^xsd:string ; skos:altLabel """therapy, drug extravasation"""@eng , """extravasation management, drug"""@eng , """drug extravasation management"""@eng ; ; rdfs:subClassOf ; """3575"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280283"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """psychosocial assessment/care"""@eng ; skos:notation """CDR0000040661"""^^xsd:string ; skos:altLabel """psychosocial assessment"""@eng , """psychosocial support"""@eng , """psychosocial care/assessment"""@eng , """psychosocial studies"""@eng , """psychosocial care"""@eng ; ; rdfs:subClassOf ; """3576"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C3665378"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxacillin sodium"""@eng ; skos:notation """CDR0000040662"""^^xsd:string ; """3577"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C720"""^^xsd:string ; umls:cui """C0037536"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/teniposide/vincristine"""@eng ; skos:notation """CDR0000040663"""^^xsd:string ; skos:altLabel """CTX/DOX/PRED/VCR/VM-26"""@eng , """CAVPE"""@eng ; ; ; ; ; ; """3578"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280285"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia with 11q23 (MLL) abnormalities"""@eng ; skos:notation """CDR0000377661"""^^xsd:string ; ; ; ; ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-18"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541334"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia with inv(16)(p13;q22)"""@eng ; skos:notation """CDR0000377660"""^^xsd:string ; ; ; ; ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-08-10"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541333"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, oropharyngeal cancer"""@eng ; skos:notation """CDR0000040668"""^^xsd:string ; skos:altLabel """oropharyngeal cancer cellular diagnosis"""@eng , """oropharynx cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """3583"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280290"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, hypopharyngeal cancer"""@eng ; skos:notation """CDR0000040669"""^^xsd:string ; skos:altLabel """hypopharynx cancer stage"""@eng , """hypopharyngeal cancer stage"""@eng ; rdfs:subClassOf ; """3584"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280291"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia with t(15;17)(q22;q12)"""@eng ; skos:notation """CDR0000377664"""^^xsd:string ; skos:altLabel """adult acute myeloid leukemia with PML/RARalpha translocation"""@eng ; ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-08-09"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541335"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/ifosfamide"""@eng ; skos:notation """CDR0000038449"""^^xsd:string ; skos:altLabel """IFF/TXT"""@eng ; ; ; """11065"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/gp100 antigen/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000038448"""^^xsd:string ; skos:altLabel """gp100/ISA-51/MART-1/MOAB CTLA-4/TYRP"""@eng ; ; ; ; ; """2003-09-03"""^^xsd:string ; """11064"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134494"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dexamethasone/methotrexate/mitoxantrone/vincristine"""@eng ; skos:notation """CDR0000038443"""^^xsd:string ; skos:altLabel """M-BNCOD"""@eng , """BLEO/CTX/DHAD/DM/MTX/VCR"""@eng ; ; ; ; ; ; ; """1106"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083303"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/ifosfamide/prednisolone"""@eng ; skos:notation """CDR0000038442"""^^xsd:string ; skos:altLabel """CDDP/IFF/PRDL/VP-16"""@eng ; ; ; ; ; """11059"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134490"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fecal occult blood test"""@eng ; skos:notation """CDR0000038441"""^^xsd:string ; ; rdfs:subClassOf ; """11058"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0201811"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VNP40101M"""@eng ; skos:notation """CDR0000038440"""^^xsd:string ; skos:altLabel """Cloretazine"""@eng , """VNP-40101M"""@eng , """1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine"""@eng , """VNP 40101M"""@eng ; skos:definition """A sulfonyl hydrazine prodrug with antineoplastic activity. VNP40101M alkylates the 06 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits 06-alkyl-guanine transferase, an enzyme involved with DNA repair. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38440&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38440&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2653\" NCI Thesaurus)"""@eng ; ; ; ; """11057"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2653"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1541592"""^^xsd:string ; umls:cui """C1134489"""^^xsd:string ; umls:cui """C1450161"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ipilimumab"""@eng ; skos:notation """CDR0000038447"""^^xsd:string ; skos:altLabel """monoclonal antibody CTLA-4"""@eng , """MDX-010"""@eng , """MDX-CTLA4"""@eng , """MDX-CTLA-4"""@eng , """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody"""@eng , """MOAB CTLA-4"""@eng ; skos:definition """A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38447&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38447&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2654\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """10200"""^^xsd:string ; """2006-10-11"""^^xsd:string ; """11063"""^^xsd:string ; """C2654"""^^xsd:string ; """720801"""^^xsd:string ; umls:cui """C1691227"""^^xsd:string ; umls:cui """C1367202"""^^xsd:string ; umls:cui """C1692339"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/ixabepilone"""@eng ; skos:notation """CDR0000038446"""^^xsd:string ; skos:altLabel """BMS 247550/EM"""@eng ; ; ; """2004-01-08"""^^xsd:string ; """11062"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gefitinib/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000038445"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/ZD 1839"""@eng ; ; ; ; ; """2002-10-10"""^^xsd:string ; """11061"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/irinotecan/thalidomide"""@eng ; skos:notation """CDR0000038444"""^^xsd:string ; skos:altLabel """CBDCA/CPT-11/THAL"""@eng ; ; ; ; """11060"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134491"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tandutinib"""@eng ; skos:notation """CDR0000353146"""^^xsd:string ; skos:altLabel """CT53518"""@eng , """MLN518"""@eng , """CT 53518"""@eng ; skos:definition """A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=353146&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=353146&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48404\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-05-16"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """C48404"""^^xsd:string ; umls:cui """C1143028"""^^xsd:string ; umls:cui """C1384662"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ILX-651"""@eng ; skos:notation """CDR0000353147"""^^xsd:string ; skos:altLabel """ILX651"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328153"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood meningioma"""@eng ; skos:notation """CDR0000041047"""^^xsd:string ; skos:altLabel """brain tumor, childhood meningioma"""@eng , """brain tumor, meningioma, childhood"""@eng , """meningioma, childhood"""@eng , """pediatric brain tumor, meningioma"""@eng , """childhood brain tumor, meningioma"""@eng , """pediatric meningioma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4087"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280656"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bropirimine/tamoxifen"""@eng ; skos:notation """CDR0000041046"""^^xsd:string ; skos:altLabel """ABPP/TAX"""@eng ; ; ; """4086"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280655"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/fluorouracil"""@eng ; skos:notation """CDR0000041045"""^^xsd:string ; skos:altLabel """BC-G/5-FU"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """4085"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280654"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quinidine/vinblastine"""@eng ; skos:notation """CDR0000041044"""^^xsd:string ; skos:altLabel """QND/VBL"""@eng ; ; ; """4084"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280653"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/quinidine"""@eng ; skos:notation """CDR0000041043"""^^xsd:string ; skos:altLabel """DOX/QND"""@eng ; ; ; """4083"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280652"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amiodarone/vinblastine"""@eng ; skos:notation """CDR0000041042"""^^xsd:string ; skos:altLabel """amiodarone/VBL"""@eng ; ; ; """4082"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280651"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interferon alfa"""@eng ; skos:notation """CDR0000041041"""^^xsd:string ; skos:altLabel """CTX/IFN-A"""@eng ; ; ; """4081"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338124"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/mercaptopurine/methotrexate/prednisone/teniposide"""@eng ; skos:notation """CDR0000041040"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MP/MTX/PRED/VM-26"""@eng ; ; ; ; ; ; ; """4080"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280649"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/vincristine"""@eng ; skos:notation """CDR0000041049"""^^xsd:string ; skos:altLabel """CTX/VCR"""@eng ; ; ; """4089"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280658"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acyclovir/zidovudine"""@eng ; skos:notation """CDR0000041048"""^^xsd:string ; skos:altLabel """ACV/ZDV"""@eng ; ; ; """4088"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280657"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, high grade, stage I adult"""@eng ; skos:notation """CDR0000040277"""^^xsd:string ; skos:altLabel """NHL, high grade, stage I adult"""@eng , """high-grade, stage I adult NHL"""@eng , """lymphoma, high grade, stage I adult non-Hodgkin's"""@eng , """adult non-Hodgkin's lymphoma, high grade, stage I"""@eng , """adult NHL, stage I, high grade"""@eng ; """2005-01-21"""^^xsd:string ; """3115"""^^xsd:string ; umls:cui """C0279964"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000040276"""^^xsd:string ; skos:altLabel """stage I adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng , """adult small noncleaved cell lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3114"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279963"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000040275"""^^xsd:string ; skos:altLabel """adult lymphoblastic lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3113"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279962"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000040274"""^^xsd:string ; skos:altLabel """adult immunoblastic large cell lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3112"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279961"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000040273"""^^xsd:string ; skos:altLabel """adult diffuse large cell lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3111"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279960"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000040272"""^^xsd:string ; skos:altLabel """adult diffuse mixed cell lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3110"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279959"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000040271"""^^xsd:string ; skos:altLabel """adult diffuse small cleaved cell lymphoma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3109"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279958"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, intermediate grade, stage I adult"""@eng ; skos:notation """CDR0000040270"""^^xsd:string ; skos:altLabel """adult non-Hodgkin's lymphoma, intermediate grade, stage I"""@eng , """lymphoma, intermediate grade, stage I adult non-Hodgkin's"""@eng , """NHL, intermediate grade, stage I adult"""@eng , """adult NHL, stage I, intermediate grade"""@eng ; """2005-01-21"""^^xsd:string ; """3108"""^^xsd:string ; umls:cui """C0279957"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urinary complications"""@eng ; skos:notation """CDR0000472005"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-03-03"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0161820"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fecal incontinence"""@eng ; skos:notation """CDR0000472004"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """2006-03-03"""^^xsd:string ; umls:cui """C0015732"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urinary incontinence"""@eng ; skos:notation """CDR0000472006"""^^xsd:string ; rdfs:subClassOf ; """2006-03-03"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0042024"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """whole blood transfusion"""@eng ; skos:notation """CDR0000472001"""^^xsd:string ; ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-03-03"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0199961"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tauromustine"""@eng ; skos:notation """CDR0000040279"""^^xsd:string ; skos:altLabel """TCNU"""@eng ; """3117"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0044133"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biliary stenting"""@eng ; skos:notation """CDR0000472002"""^^xsd:string ; ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """2006-03-03"""^^xsd:string ; umls:cui """C0851194"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """abagovomab"""@eng ; skos:notation """CDR0000531148"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832044"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706/fluorouracil/irinotecan/leucovorin calcium/panitumumab"""@eng ; skos:notation """CDR0000417733"""^^xsd:string ; skos:altLabel """AMG-706/CF/CPT-11/5-FU/MOAB ABX-EGF"""@eng ; ; ; ; ; ; """2005-02-04"""^^xsd:string ; """2005-01-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706/fluorouracil/leucovorin calcium/oxaliplatin/panitumumab"""@eng ; skos:notation """CDR0000417736"""^^xsd:string ; skos:altLabel """AMG-706/CF/5-FU/L-OHP/MOAB ABX-EGF"""@eng ; ; ; ; ; ; """2005-02-04"""^^xsd:string ; """2005-01-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541496"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 satumomab pendetide"""@eng ; skos:notation """CDR0000042795"""^^xsd:string ; skos:altLabel """OncoScint CR/OV"""@eng ; """6595"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0209389"""^^xsd:string ; umls:cui """C0740254"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/etoposide/vinblastine"""@eng ; skos:notation """CDR0000038869"""^^xsd:string ; skos:altLabel """EVAP"""@eng , """ARA-C/CDDP/VBL/VP-16"""@eng ; ; ; ; ; """1359"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278910"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/teniposide"""@eng ; skos:notation """CDR0000038868"""^^xsd:string ; skos:altLabel """CDDP/VM-26"""@eng ; ; ; """1358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278909"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/mitomycin"""@eng ; skos:notation """CDR0000038861"""^^xsd:string ; skos:altLabel """5-FU/MITO/MTX"""@eng ; ; ; ; """1350"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278904"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin hydrochloride"""@eng ; skos:notation """CDR0000038860"""^^xsd:string ; skos:altLabel """Adriblastina"""@eng , """Rubex"""@eng , """3-Hydroxyacetyldaunorubicin Hydrochloride"""@eng , """Adriamycin"""@eng , """FI-106"""@eng , """Adria"""@eng , """Adriacin"""@eng , """DOX"""@eng , """5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)"""@eng , """ADR"""@eng , """ADM"""@eng , """14-Hydroxydaunorubicin Hydrochloride"""@eng ; skos:definition """The hydrochloride salt of doxorubicin, an anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38860&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38860&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1326\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """135"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """25316-40-9"""^^xsd:string ; """C1326"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0740176"""^^xsd:string ; umls:cui """C1522679"""^^xsd:string ; umls:cui """C0546861"""^^xsd:string ; umls:cui """C1512053"""^^xsd:string ; umls:cui """C0013089"""^^xsd:string ; umls:cui """C0699076"""^^xsd:string ; umls:cui """C0085752"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide"""@eng ; skos:notation """CDR0000038863"""^^xsd:string ; skos:altLabel """DOX/IFF"""@eng ; ; ; """1352"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278906"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/prednisone/vindesine"""@eng ; skos:notation """CDR0000038862"""^^xsd:string ; skos:altLabel """DAVA/MP/MTX/PRED"""@eng ; ; ; ; ; """1351"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278905"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fotemustine"""@eng ; skos:notation """CDR0000038865"""^^xsd:string ; skos:altLabel """Muphoran"""@eng , """[1-[[[(2-chloroethyl)nitrosamino]-carbonyl]amino]ethyl]phosphonic acid diethyl ester"""@eng , """S 10036"""@eng , """diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate"""@eng , """1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester"""@eng ; skos:definition """A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38865&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38865&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1106\" NCI Thesaurus)"""@eng ; """1355"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C1106"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0060696"""^^xsd:string ; umls:cui """C1517301"""^^xsd:string ; umls:cui """C0950718"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """somatostatin analogue therapy"""@eng ; skos:notation """CDR0000038864"""^^xsd:string ; skos:altLabel """therapy, somatostatin analogue"""@eng ; ; rdfs:subClassOf ; """1354"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0278907"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/interferon alfa/interleukin-2/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000038867"""^^xsd:string ; skos:altLabel """CTX/DOX/IFN-A/IL-2/LAK"""@eng ; ; ; ; ; ; """1357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278908"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """octreotide acetate"""@eng ; skos:notation """CDR0000038866"""^^xsd:string ; skos:altLabel """Sandostatin Lar Depot"""@eng , """Sandostatin"""@eng , """Sandostatine"""@eng , """Samilstin"""@eng , """D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide Acetate"""@eng , """SMS 201-995"""@eng , """Longastatin"""@eng , """Longastatina"""@eng , """Sandostatina"""@eng , """Sandostatin-LAR"""@eng ; skos:definition """The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38866&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38866&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53447\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2006-07-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """79517-01-4"""^^xsd:string ; """671663"""^^xsd:string ; """1356"""^^xsd:string ; """C53447"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1170602"""^^xsd:string ; umls:cui """C1521974"""^^xsd:string ; umls:cui """C1518539"""^^xsd:string ; umls:cui """C1518540"""^^xsd:string ; umls:cui """C0678117"""^^xsd:string ; umls:cui """C0728977"""^^xsd:string ; umls:cui """C0723209"""^^xsd:string ; umls:cui """C0724649"""^^xsd:string ; umls:cui """C1709307"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/melphalan/mitoxantrone"""@eng ; skos:notation """CDR0000042536"""^^xsd:string ; skos:altLabel """CTX/DHAD/L-PAM"""@eng ; ; ; ; """6181"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392967"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/bicalutamide/hydrocortisone"""@eng ; skos:notation """CDR0000042537"""^^xsd:string ; skos:altLabel """AGT/CDX/HC"""@eng ; ; ; ; """6182"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392968"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mantle cell lymphoma"""@eng ; skos:notation """CDR0000042534"""^^xsd:string ; skos:altLabel """lymphoma, mantle cell"""@eng ; rdfs:subClassOf ; """6178"""^^xsd:string ; """2004-08-03"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334634"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/PSC 833"""@eng ; skos:notation """CDR0000042535"""^^xsd:string ; skos:altLabel """DOX/PSC-833"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """6180"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392966"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dronabinol/megestrol"""@eng ; skos:notation """CDR0000042532"""^^xsd:string ; skos:altLabel """MEG/THC"""@eng ; ; ; """6171"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392964"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/edatrexate/filgrastim/vinblastine"""@eng ; skos:notation """CDR0000042533"""^^xsd:string ; skos:altLabel """CDDP/DOX/EDAM/G-CSF/VBL"""@eng ; ; ; ; ; ; """6172"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392965"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/epirubicin"""@eng ; skos:notation """CDR0000042530"""^^xsd:string ; skos:altLabel """EPI/TXT"""@eng ; ; ; """6169"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392962"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/epirubicin/filgrastim"""@eng ; skos:notation """CDR0000042531"""^^xsd:string ; skos:altLabel """EPI/G-CSF/TXT"""@eng ; ; ; ; """6170"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392963"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liposome-encapsulated doxorubicin citrate complex"""@eng ; skos:notation """CDR0000481301"""^^xsd:string ; skos:altLabel """Myocet"""@eng , """liposome encapsulated doxorubicin citrate complex"""@eng , """Liposome-Encapsulated Doxorubicin Citrate"""@eng ; skos:definition """A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481301&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481301&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61317\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """C61317"""^^xsd:string ; umls:cui """C1512062"""^^xsd:string ; umls:cui """C1831805"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide/hydrocortisone"""@eng ; skos:notation """CDR0000042538"""^^xsd:string ; skos:altLabel """AGT/HC"""@eng ; ; ; """6183"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392969"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/doxorubicin"""@eng ; skos:notation """CDR0000042539"""^^xsd:string ; skos:altLabel """DOX/TXT"""@eng ; ; ; """6184"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392970"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/lenalidomide"""@eng ; skos:notation """CDR0000315586"""^^xsd:string ; skos:altLabel """CC 5013/DM"""@eng ; ; ; """2003-06-23"""^^xsd:string ; """2004-09-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327993"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/sargramostim"""@eng ; skos:notation """CDR0000315587"""^^xsd:string ; skos:altLabel """GM-CSF/MOAB CTLA-4"""@eng ; ; ; """2003-06-23"""^^xsd:string ; """2003-09-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327994"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/imatinib mesylate"""@eng ; skos:notation """CDR0000315584"""^^xsd:string ; skos:altLabel """FLAVO/STI571"""@eng ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327991"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """selenium/soy protein isolate/vitamin E"""@eng ; skos:notation """CDR0000315585"""^^xsd:string ; skos:altLabel """SEL/SOY/VIT-E"""@eng ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327992"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000315582"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/SC-58635"""@eng ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327990"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flaxseed"""@eng ; skos:notation """CDR0000258213"""^^xsd:string ; skos:altLabel """linum"""@eng , """Linum usitatissimum"""@eng , """linseed"""@eng , """lint bells"""@eng ; skos:definition """Seed isolated from one of several species of the plant genus Linum. Flaxseed-derived foods, lignans, and essential fatty acids such as alpha-linolenic acid, possess anti-inflammatory, lipid-lowering, antioxidant, and antineoplastic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258213&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258213&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26650\" NCI Thesaurus)"""@eng ; """11480"""^^xsd:string ; """C26650"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1095866"""^^xsd:string ; umls:tui """T002"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/oblimersen"""@eng ; skos:notation """CDR0000315580"""^^xsd:string ; skos:altLabel """CDDP/5-FU/G3139"""@eng ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327988"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/celecoxib/irinotecan"""@eng ; skos:notation """CDR0000315581"""^^xsd:string ; skos:altLabel """CAPE/CPT-11/SC-58635"""@eng ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327989"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/mistletoe"""@eng ; skos:notation """CDR0000258218"""^^xsd:string ; skos:altLabel """dFdC/Viscum"""@eng ; ; ; """2002-10-07"""^^xsd:string ; """11481"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327797"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spiritual concerns"""@eng ; skos:notation """CDR0000330082"""^^xsd:string ; skos:altLabel """spiritual needs"""@eng ; rdfs:subClassOf ; """2003-08-24"""^^xsd:string ; """2003-08-15"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C1328039"""^^xsd:string ; umls:tui """T169"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """letrozole/tipifarnib"""@eng ; skos:notation """CDR0000301892"""^^xsd:string ; skos:altLabel """LTZ/R115777"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327953"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levocarnitine"""@eng ; skos:notation """CDR0000301896"""^^xsd:string ; skos:altLabel """L-carnitine"""@eng , """Carnitor"""@eng ; skos:definition """An amino acid derivative. Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301896&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301896&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26657\" NCI Thesaurus)"""@eng ; """2003-04-23"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C26657"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0087163"""^^xsd:string ; umls:cui """C0591236"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transfusion"""@eng ; skos:notation """CDR0000470291"""^^xsd:string ; ; ; ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-03-03"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C1879316"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """silatecan DB-67"""@eng ; skos:notation """CDR0000522726"""^^xsd:string ; skos:altLabel """7-tert-butyldimethylsilyl-10-hydroxycamptothecin"""@eng , """DB-67"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-17"""^^xsd:string ; umls:cui """C0961890"""^^xsd:string ; umls:cui """C1955483"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxyurea/VNP40101M"""@eng ; skos:notation """CDR0000367083"""^^xsd:string ; skos:altLabel """HU/VNP-40101M"""@eng ; ; ; """2004-04-16"""^^xsd:string ; """2004-04-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541224"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABI-007/paclitaxel"""@eng ; skos:notation """CDR0000398822"""^^xsd:string ; skos:altLabel """ABI 007/TAX"""@eng ; ; ; """2004-10-25"""^^xsd:string ; """2004-10-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541386"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PPAR gamma agonist CS-7017"""@eng ; skos:notation """CDR0000529846"""^^xsd:string ; skos:altLabel """CS-7017"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1832026"""^^xsd:string ; umls:cui """C1832025"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """apoptosis-inducing small molecule MPC-2130"""@eng ; skos:notation """CDR0000526178"""^^xsd:string ; skos:altLabel """MPC-2130"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-18"""^^xsd:string ; umls:cui """C1832002"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levetiracetam"""@eng ; skos:notation """CDR0000526173"""^^xsd:string ; skos:altLabel """Keppra"""@eng , """1-pyrrolidineacetamide, alpha-ethyl-2-oxo-,(S)-"""@eng , """(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide"""@eng ; skos:definition """A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526173&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526173&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47581\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """C47581"""^^xsd:string ; """102767-28-2"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0377265"""^^xsd:string ; umls:cui """C0876060"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen-expressing measles virus"""@eng ; skos:notation """CDR0000523412"""^^xsd:string ; skos:altLabel """MV-CEA"""@eng ; """2006-12-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831970"""^^xsd:string ; umls:cui """C1831991"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """microtubule inhibitor MPC-6827"""@eng ; skos:notation """CDR0000526176"""^^xsd:string ; skos:altLabel """MPC-6827"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-18"""^^xsd:string ; umls:cui """C1832001"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DACH polymer platinate AP5346"""@eng ; skos:notation """CDR0000526175"""^^xsd:string ; skos:altLabel """AP5346"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-18"""^^xsd:string ; umls:cui """C2745883"""^^xsd:string ; umls:cui """C1723251"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 resin microspheres"""@eng ; skos:notation """CDR0000523414"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-01"""^^xsd:string ; umls:cui """C1831993"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iron overload"""@eng ; skos:notation """CDR0000436017"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2005-06-02"""^^xsd:string ; """2005-06-08"""^^xsd:string ; umls:cui """C0282193"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim/fludarabine"""@eng ; skos:notation """CDR0000367332"""^^xsd:string ; skos:altLabel """CTX/FAMP/G-CSF"""@eng ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541227"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """type B2 thymoma"""@eng ; skos:notation """CDR0000331683"""^^xsd:string ; skos:altLabel """cortical thymoma"""@eng , """polygonal cell thymoma"""@eng ; rdfs:subClassOf ; """2003-08-24"""^^xsd:string ; """2003-08-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1266095"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitomycin"""@eng ; skos:notation """CDR0000040879"""^^xsd:string ; skos:altLabel """MITO/VP-16"""@eng ; ; ; """3917"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mitoxantrone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000040878"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/TG/VCR"""@eng ; ; ; ; ; """3916"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280501"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitoxantrone"""@eng ; skos:notation """CDR0000040871"""^^xsd:string ; skos:altLabel """CDDP/DHAD"""@eng ; ; ; """3909"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280494"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interferon alfa"""@eng ; skos:notation """CDR0000040870"""^^xsd:string ; skos:altLabel """CDDP/IFN-A"""@eng ; ; ; """3908"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338118"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/dexamethasone/etoposide/thioguanine"""@eng ; skos:notation """CDR0000040873"""^^xsd:string ; skos:altLabel """DCTER"""@eng , """ARA-C/DM/DNR/TG/VP-16"""@eng ; ; ; ; ; ; """3911"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280496"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2"""@eng ; skos:notation """CDR0000040872"""^^xsd:string ; skos:altLabel """CTX/IL-2"""@eng ; ; ; """3910"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280495"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000040875"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/VP-16"""@eng , """MCE"""@eng , """MAE"""@eng ; ; ; ; """3913"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0286540"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide"""@eng ; skos:notation """CDR0000040874"""^^xsd:string ; skos:altLabel """ARA-C/VP-16"""@eng ; ; ; """3912"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280497"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mitoxantrone/thioguanine"""@eng ; skos:notation """CDR0000040877"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/TG"""@eng ; ; ; ; """3915"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280500"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mitoxantrone"""@eng ; skos:notation """CDR0000040876"""^^xsd:string ; skos:altLabel """MidAC"""@eng , """ARA-C/DHAD"""@eng , """S-HAM"""@eng ; ; ; """3914"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0068899"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TEL"""@eng ; skos:notation """CDR0000043379"""^^xsd:string ; rdfs:subClassOf ; """7931"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796520"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RAS"""@eng ; skos:notation """CDR0000043378"""^^xsd:string ; rdfs:subClassOf ; """7930"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0034678"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMB-2 immunotoxin"""@eng ; skos:notation """CDR0000043377"""^^xsd:string ; skos:altLabel """LMB-2 (Anti-TAC(FV)-PE-38)"""@eng , """Anti-Tac(Fv)-PE38"""@eng , """immunotoxin LMB-2"""@eng , """Humanized AntiTac Toxin"""@eng , """LMB-2"""@eng ; skos:definition """A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted). LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies. The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43377&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43377&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2513\" NCI Thesaurus)"""@eng ; """7928"""^^xsd:string ; """6662"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2513"""^^xsd:string ; """676422"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C0655013"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GPA"""@eng ; skos:notation """CDR0000043376"""^^xsd:string ; rdfs:subClassOf ; """7924"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0017955"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NAT-2"""@eng ; skos:notation """CDR0000043375"""^^xsd:string ; rdfs:subClassOf ; """7923"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796518"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP"""@eng ; skos:notation """CDR0000043374"""^^xsd:string ; rdfs:subClassOf ; """7922"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796517"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GST"""@eng ; skos:notation """CDR0000043373"""^^xsd:string ; rdfs:subClassOf ; """7921"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796516"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/gp100 antigen/MAGE-3/MART-1 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000043372"""^^xsd:string ; skos:altLabel """flu/gp100/MAGE3/MART-1/TYRP"""@eng ; ; ; ; ; ; """7920"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796515"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix antigen"""@eng ; skos:notation """CDR0000043371"""^^xsd:string ; ; ; ; ; ; ; ; """2006-11-22"""^^xsd:string ; """C39677"""^^xsd:string ; """7919"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796514"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MAGE-3/MART-1 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000043370"""^^xsd:string ; skos:altLabel """gp100/MAGE3/MART-1/TYRP"""@eng ; ; ; ; ; """7918"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796513"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pain therapy"""@eng ; skos:notation """CDR0000039013"""^^xsd:string ; skos:altLabel """management of cancer pain"""@eng , """analgesia"""@eng , """therapy, pain"""@eng , """pain management"""@eng , """cancer pain management"""@eng ; ; rdfs:subClassOf ; """1577"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0002766"""^^xsd:string ; umls:cui """C0392921"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phototherapy"""@eng ; skos:notation """CDR0000039012"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; ; ; """1575"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; umls:cui """C0031765"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anticoagulation"""@eng ; skos:notation """CDR0000039011"""^^xsd:string ; ; rdfs:subClassOf ; """1574"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0003281"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adrenal blockade"""@eng ; skos:notation """CDR0000039010"""^^xsd:string ; skos:altLabel """blockade, adrenal"""@eng ; ; rdfs:subClassOf ; """1573"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279034"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nutritional support"""@eng ; skos:notation """CDR0000039017"""^^xsd:string ; skos:altLabel """support, nutritional"""@eng , """nutritional assessment"""@eng , """nutritional care"""@eng ; ; ; rdfs:subClassOf ; """1581"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0028708"""^^xsd:string ; umls:cui """C0242739"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hematologic toxicity attenuation"""@eng ; skos:notation """CDR0000039016"""^^xsd:string ; skos:altLabel """attenuation, hematologic toxicity"""@eng , """neutropenia attenuation"""@eng ; ; rdfs:subClassOf ; """1580"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0279037"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine"""@eng ; skos:notation """CDR0000039015"""^^xsd:string ; skos:altLabel """Cytosine Arabinosine Hydrochloride"""@eng , """Erpalfa"""@eng , """1-Beta-D-arabinofuranosylcytosine"""@eng , """Cytarabine Hydrochloride"""@eng , """Alexan"""@eng , """Cytosar-U"""@eng , """cytosine arabinoside"""@eng , """WR-28453"""@eng , """Tarabine PFS"""@eng , """U-29920A HCl"""@eng , """Beta-Cytosine Arabinoside"""@eng , """arabinosylcytosine"""@eng , """Aracytin"""@eng , """Cytosar"""@eng , """ARA-cell"""@eng , """CHX-3311"""@eng , """Arabine"""@eng , """Aracytidine"""@eng , """arabinofuranosylcytosine"""@eng , """Udicil"""@eng , """4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"""@eng , """Cytarabinum"""@eng , """Aracytine"""@eng , """Cytarbel"""@eng , """ARA-C"""@eng , """U-19920"""@eng ; skos:definition """An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytosine arabinoside is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39015&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39015&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C408\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """158"""^^xsd:string ; """147-94-4"""^^xsd:string ; """287459"""^^xsd:string ; """C408"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1714"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511631"""^^xsd:string ; umls:cui """C1511630"""^^xsd:string ; umls:cui """C0591057"""^^xsd:string ; umls:cui """C0733524"""^^xsd:string ; umls:cui """C0733521"""^^xsd:string ; umls:cui """C1511627"""^^xsd:string ; umls:cui """C0591320"""^^xsd:string ; umls:cui """C1521934"""^^xsd:string ; umls:cui """C1521935"""^^xsd:string ; umls:cui """C1511626"""^^xsd:string ; umls:cui """C1521933"""^^xsd:string ; umls:cui """C0723603"""^^xsd:string ; umls:cui """C1521931"""^^xsd:string ; umls:cui """C1511629"""^^xsd:string ; umls:cui """C1511628"""^^xsd:string ; umls:cui """C0282120"""^^xsd:string ; umls:cui """C0010711"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nausea and vomiting therapy"""@eng ; skos:notation """CDR0000039014"""^^xsd:string ; skos:altLabel """therapy, nausea and vomiting"""@eng , """vomiting and nausea management"""@eng , """management of nausea and vomiting"""@eng , """antiemetic support"""@eng , """nausea and vomiting management"""@eng ; ; rdfs:subClassOf ; """1578"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0279035"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """complications of therapy assessment/management"""@eng ; skos:notation """CDR0000039019"""^^xsd:string ; skos:altLabel """complications of therapy, management of"""@eng , """assessment/management of complications of therapy"""@eng , """complications of therapy, assessment of"""@eng , """management/assessment of complications of therapy"""@eng ; ; rdfs:subClassOf ; """1584"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C2355588"""^^xsd:string ; umls:cui """C0279039"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radioprotection"""@eng ; skos:notation """CDR0000039018"""^^xsd:string ; ; rdfs:subClassOf ; """1582"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0034533"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/azacitidine"""@eng ; skos:notation """CDR0000436860"""^^xsd:string ; skos:altLabel """5-AC/AS2O3"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """2005-06-09"""^^xsd:string ; umls:cui """C1831646"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HUMARA"""@eng ; skos:notation """CDR0000043210"""^^xsd:string ; rdfs:subClassOf ; """7653"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796370"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BAT loci"""@eng ; skos:notation """CDR0000043211"""^^xsd:string ; rdfs:subClassOf ; """7654"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796371"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/sargramostim/vincristine"""@eng ; skos:notation """CDR0000043212"""^^xsd:string ; skos:altLabel """CTX/GM-CSF/PRED/VCR"""@eng ; ; ; ; ; """7655"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796372"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """videothoracoscopy"""@eng ; skos:notation """CDR0000043213"""^^xsd:string ; rdfs:subClassOf ; """7656"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796373"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """genistein"""@eng ; skos:notation """CDR0000043214"""^^xsd:string ; skos:altLabel """genisterin"""@eng , """4',5,7-Trihydroxyisoflavone"""@eng , """5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one"""@eng , """CI 75610"""@eng , """sophoricol"""@eng , """Genestein"""@eng , """prunetol"""@eng , """genisteol"""@eng ; skos:definition """A soy-derived isoflavone and phytoestrogen with antineoplastic activity. Genistein binds to and inhibits protein-tyrosine kinase, thereby disrupting signal transduction and inducing cell differentiation. This agent also inhibits topoisomerase-II, leading to DNA fragmentation and apoptosis, and induces G2/M cell cycle arrest. Genistein exhibits antioxidant, antiangiogenic, and immunosuppressive activities. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43214&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43214&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1113\" NCI Thesaurus)"""@eng ; """7673"""^^xsd:string ; """36586"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1113"""^^xsd:string ; """446-72-0"""^^xsd:string ; umls:cui """C2830174"""^^xsd:string ; umls:cui """C0061202"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/procarbazine"""@eng ; skos:notation """CDR0000043215"""^^xsd:string ; skos:altLabel """13-CRA/PCB"""@eng ; ; ; """7680"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796376"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/cyclophosphamide/fludarabine"""@eng ; skos:notation """CDR0000043216"""^^xsd:string ; skos:altLabel """ATG/CTX/FAMP"""@eng ; ; ; ; """7681"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796377"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000043217"""^^xsd:string ; skos:altLabel """DM/MTX/TG/VCR"""@eng ; ; ; ; ; """7682"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796378"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/prednisolone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000043218"""^^xsd:string ; skos:altLabel """MTX/PRDL/TG/VCR"""@eng ; ; ; ; ; """7683"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796379"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flt3 ligand/gp100 antigen/MART-1 antigen/tyrosinase"""@eng ; skos:notation """CDR0000043219"""^^xsd:string ; skos:altLabel """Flt3L/gp100/MART-1/TYR"""@eng ; ; ; ; """7684"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-16"""^^xsd:string ; umls:cui """C0796380"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iron sucrose injection"""@eng ; skos:notation """CDR0000467930"""^^xsd:string ; skos:altLabel """Venofer"""@eng ; skos:definition """A sterile aqueous complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use. Following intravenous administration, iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose; the sucrose component is eliminated mainly by urinary excretion. Iron sucrose can be administered with or without erythropoietin to raise hemoglobin levels and may be used in cases of oral iron therapy intolerance or ineffectiveness. Hypersensitivity reactions are less common with iron sucrose compared to other parenteral iron products, such as iron dextran. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467930&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467930&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60883\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-10"""^^xsd:string ; """C60883"""^^xsd:string ; umls:cui """C0529374"""^^xsd:string ; umls:cui """C1831745"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noscapine hydrochloride"""@eng ; skos:notation """CDR0000469778"""^^xsd:string ; skos:altLabel """narcotine hydrochloride"""@eng , """6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3- dioxolo[4,5-g]isoquinolin-5-yl)-1(3H)-isobenzofuranone, [S-(R*,S*)] hydrochloride monohydrate"""@eng , """narcosine hydrochloride"""@eng ; skos:definition """The orally available hydrochloride salt of the opioid agonist noscapine, a phthalideisoquinoline alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine binds to tubulin and alters its conformation, resulting in a disruption of the dynamics of microtubule assembly (by increasing the time that microtubules spend idle in a paused state) and, subsequently, the inhibition of mitosis and tumor cell death. Unlike other tubulin inhibitors such as the taxanes and vinca alkaloids, noscapine does not affect microtubule polymerization. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469778&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469778&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61103\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-18"""^^xsd:string ; """C61103"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C1450474"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dimesna/docetaxel"""@eng ; skos:notation """CDR0000352150"""^^xsd:string ; skos:altLabel """CDDP/DIM/TXT"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328145"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-2-Globo H-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000038279"""^^xsd:string ; skos:altLabel """MUC2-GLO H-KLH"""@eng ; ; ; """2003-12-01"""^^xsd:string ; """10889"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935832"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, mycosis fungoides/Sezary syndrome"""@eng ; skos:notation """CDR0000038274"""^^xsd:string ; rdfs:subClassOf ; """10884"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0935827"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/BCG"""@eng ; skos:notation """CDR0000038275"""^^xsd:string ; skos:altLabel """ATCV/BC-G"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """10885"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935828"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/oblimersen"""@eng ; skos:notation """CDR0000038276"""^^xsd:string ; skos:altLabel """DTIC/G3139"""@eng ; ; ; """10886"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935829"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/cisplatin/paclitaxel"""@eng ; skos:notation """CDR0000038277"""^^xsd:string ; skos:altLabel """3AP/CDDP/TAX"""@eng ; ; ; ; """10887"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935830"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/filgrastim/gemcitabine"""@eng ; skos:notation """CDR0000038270"""^^xsd:string ; skos:altLabel """dFdC/G-CSF/TXT"""@eng ; ; ; ; """10878"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935823"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bismuth Bi213 monoclonal antibody M195"""@eng ; skos:notation """CDR0000038271"""^^xsd:string ; skos:altLabel """Bi213 MOAB M195"""@eng ; skos:definition """A radioimmunoconjugate consisting of murine monoclonal antibody (M195) and bismuth 213 (Bi213). Monoclonal antibody M195 binds to CD33, a surface antigen expressed by myelogenous leukemia cells. Bi213 is an isotope that emits short-ranged high-energy alpha particles. This radioimmunoconjugate selectively delivers alpha particle-mediated cytotoxicity to leukemic cells, thereby limiting the exposure of normal tissues to ionizing radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38271&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38271&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28502\" NCI Thesaurus)"""@eng ; ; """10879"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C28502"""^^xsd:string ; umls:cui """C0935824"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bismuth Bi213 monoclonal antibody M195/cytarabine/filgrastim"""@eng ; skos:notation """CDR0000038272"""^^xsd:string ; skos:altLabel """ARA-C/Bi213 MOAB M195/G-CSF"""@eng ; ; ; ; """10880"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935825"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, Merkel cell carcinoma"""@eng ; skos:notation """CDR0000038273"""^^xsd:string ; rdfs:subClassOf ; """10883"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0935826"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer and suicide"""@eng ; skos:notation """CDR0000042299"""^^xsd:string ; skos:altLabel """suicide and cancer"""@eng ; rdfs:subClassOf ; """5546"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0338230"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glutamine"""@eng ; skos:notation """CDR0000042298"""^^xsd:string ; skos:altLabel """2-aminoglutaramic acid"""@eng , """Glutaven"""@eng , """Gln"""@eng , """Memoril"""@eng , """Q. Levoglutamide"""@eng , """L-glutamine"""@eng , """glutamic acid 5-amide"""@eng , """levoglutamide"""@eng , """Glutacerebro"""@eng ; skos:definition """A nonessential amino acid. Glutamine can donate the ammonia on its side chain to the formation of urea (for eventual excretion by the kidneys) and to purines (necessary for the synthesis of nucleic acids). Glutamic acid-to-glutamine conversion, in which an ammonia group is added to glutamic acid (catalyzed by glutamine synthase), is of central importance in the regulation of toxic levels of ammonia in the body. This agent is a substrate for the production of both excitatory and inhibitory neurotransmitters (glutamate and GABA) and is also an important source of energy for the nervous system. Glutamine may become a conditionally essential amino acid during certain catabolic states. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42298&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42298&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C522\" NCI Thesaurus)"""@eng ; """5545"""^^xsd:string ; """56-85-9"""^^xsd:string ; """C522"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """27421"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1512215"""^^xsd:string ; umls:cui """C1512214"""^^xsd:string ; umls:cui """C0017797"""^^xsd:string ; umls:cui """C1512216"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """disulfiram/tretinoin"""@eng ; skos:notation """CDR0000042293"""^^xsd:string ; skos:altLabel """ATRA/DS"""@eng ; ; ; """5540"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338227"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ketoconazole/tretinoin"""@eng ; skos:notation """CDR0000042292"""^^xsd:string ; skos:altLabel """ATRA/KCZ"""@eng ; ; ; """5539"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338226"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """disulfiram"""@eng ; skos:notation """CDR0000042291"""^^xsd:string ; skos:altLabel """Tetraethylthiuram Disulfide"""@eng , """Tetraethylthioperoxydicarbonic Diamide"""@eng , """Bis(diethylthiocarbamoyl) Disulfide"""@eng , """Antabuse"""@eng , """Teturamin"""@eng , """DS"""@eng , """TTD"""@eng ; skos:definition """A carbamoyl derivate used in the treatment of alcoholism. Disulfiram irreversibly inhibits acetaldehyde dehydrogenase that oxidizes the ethanol metabolite acetaldehyde into acetic acid. This leads to an accumulation of acetaldehyde that produces a variety of very unpleasant symptoms referred to as the disulfiram-alcohol reaction. This reaction includes , but is not limited to, flushing, headache, respiratory difficulty, nausea,vomiting, sweating, thirst, chest pain, tachycardia, blurred vision and hypotension. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42291&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42291&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C447\" NCI Thesaurus)"""@eng ; ; """5538"""^^xsd:string ; """97-77-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C447"""^^xsd:string ; """25953"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591096"""^^xsd:string ; umls:cui """C0012772"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tributyrin"""@eng ; skos:notation """CDR0000042290"""^^xsd:string ; skos:altLabel """Glyceryl Tributyrate"""@eng , """1,2,3-Propanetriyl Butanoate"""@eng , """Butyryl Triglyceride"""@eng , """1,2,3-Tributyrylglycerol"""@eng , """TB"""@eng , """Butanoic Acid 1,2,3-Propanetriyl Ester"""@eng ; skos:definition """A triglyceride prodrug of butyric acid with potential antineoplastic activity. Butyrate, the active metabolite of tributyrin, inhibits histone deacetylase, resulting in increased differentiation, decreased proliferation, cell cycle arrest, and apoptosis in some tumor cell lines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42290&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42290&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1260\" NCI Thesaurus)"""@eng ; """5536"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """47776"""^^xsd:string ; """661583"""^^xsd:string ; """60-01-5"""^^xsd:string ; """C1260"""^^xsd:string ; umls:cui """C0077025"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exemestane"""@eng ; skos:notation """CDR0000042297"""^^xsd:string ; skos:altLabel """Aromasin"""@eng , """6-Methyleneandrosta-1,4-diene-3,17-dione"""@eng , """FCE-24304"""@eng , """FCE 24304"""@eng , """PNU 155971"""@eng ; skos:definition """A synthetic androgen analogue. Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42297&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42297&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1097\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """5544"""^^xsd:string ; """107868-30-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """713563"""^^xsd:string ; """C1097"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328679"""^^xsd:string ; umls:cui """C0876723"""^^xsd:string ; umls:cui """C0851344"""^^xsd:string ; umls:cui """C0060116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ganglioside GD2-KLH"""@eng ; skos:notation """CDR0000042296"""^^xsd:string ; skos:altLabel """GD2-KLH ganglioside"""@eng , """GD2-KLH"""@eng ; """5543"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338229"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ganglioside GD2"""@eng ; skos:notation """CDR0000042295"""^^xsd:string ; skos:altLabel """GD2 ganglioside"""@eng ; """5542"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0061104"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cytarabine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000042294"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/MTX/VCR"""@eng ; ; ; ; ; """5541"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338228"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Brenner tumor"""@eng ; skos:notation """CDR0000043342"""^^xsd:string ; rdfs:subClassOf ; """7887"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0006160"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloblastic leukemia with maturation (M2)"""@eng ; skos:notation """CDR0000039909"""^^xsd:string ; skos:altLabel """M2 adult acute myeloblastic leukemia with maturation"""@eng , """adult acute M2 leukemia"""@eng , """M2 leukemia, adult acute"""@eng ; rdfs:subClassOf ; ; ; """2590"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279624"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloblastic leukemia without maturation (M1)"""@eng ; skos:notation """CDR0000039908"""^^xsd:string ; skos:altLabel """adult acute M1 leukemia"""@eng , """M1 leukemia, adult acute"""@eng , """M1 adult acute myeloblastic leukemia without maturation"""@eng ; rdfs:subClassOf ; ; """2589"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279623"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/pentostatin"""@eng ; skos:notation """CDR0000039027"""^^xsd:string ; skos:altLabel """DCF/FAMP"""@eng ; ; ; """1597"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279044"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acral lentiginous malignant melanoma"""@eng ; skos:notation """CDR0000039905"""^^xsd:string ; skos:altLabel """malignant melanoma, acral lentiginous"""@eng , """melanoma, acral lentiginous malignant"""@eng ; rdfs:subClassOf ; """2586"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346037"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute erythroid leukemia (M6)"""@eng ; skos:notation """CDR0000039904"""^^xsd:string ; skos:altLabel """leukemia, adult acute erythro-"""@eng , """adult acute M6 leukemia"""@eng , """M6 leukemia, adult acute"""@eng ; rdfs:subClassOf ; """2004-06-21"""^^xsd:string ; """2585"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279619"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small cell bone sarcoma"""@eng ; skos:notation """CDR0000039907"""^^xsd:string ; skos:altLabel """sarcoma of bone, small cell"""@eng , """sarcoma, bone, small cell"""@eng , """osteogenic sarcoma, small cell"""@eng , """small cell sarcoma of bone"""@eng , """bone sarcoma, small cell"""@eng , """small cell osteogenic sarcoma"""@eng , """osteosarcoma, small cell"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2588"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279622"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nodular malignant melanoma"""@eng ; skos:notation """CDR0000039906"""^^xsd:string ; skos:altLabel """malignant melanoma, nodular"""@eng , """melanoma, nodular malignant"""@eng ; rdfs:subClassOf ; """2587"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334424"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """embryonal-botryoid childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000039901"""^^xsd:string ; skos:altLabel """embryonal-botryoid pediatric rhabdomyosarcoma"""@eng , """rhabdomyosarcoma, pediatric embryonal-botryoid"""@eng , """pediatric rhabdomyosarcoma, embryonal-botryoid"""@eng , """rhabdomyosarcoma, embryonal-botryoid childhood"""@eng , """rhabdomyosarcoma, childhood embryonal-botryoid"""@eng , """childhood rhabdomyosarcoma, embryonal-botryoid"""@eng ; rdfs:subClassOf ; """2582"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279616"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/tamoxifen"""@eng ; skos:notation """CDR0000039024"""^^xsd:string ; skos:altLabel """5-FU/MTX/TMX"""@eng ; ; ; ; """1593"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279041"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """superficial spreading malignant melanoma"""@eng ; skos:notation """CDR0000039903"""^^xsd:string ; skos:altLabel """malignant melanoma, superficial spreading"""@eng , """melanoma, superficial spreading malignant"""@eng ; rdfs:subClassOf ; """2584"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334438"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lentigo maligna malignant melanoma"""@eng ; skos:notation """CDR0000039902"""^^xsd:string ; skos:altLabel """melanoma, lentigo maligna malignant"""@eng , """malignant melanoma, lentigo maligna malignant"""@eng ; rdfs:subClassOf ; """2583"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279617"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/temozolomide"""@eng ; skos:notation """CDR0000043341"""^^xsd:string ; skos:altLabel """CBDCA/TMZ"""@eng ; ; ; """7886"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796490"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quinidine"""@eng ; skos:notation """CDR0000039022"""^^xsd:string ; skos:definition """An alkaloid extracted from the bark of the Cinchona tree with class 1A antiarrhythmic and antimalarial effects. Quinidine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the sodium influx required for the initiation and conduction of impulses resulting in an increase of the threshold for excitation and decreased depolarization during phase 0 of the action potential. In addition, the effective refractory period (ERP), action potential duration (APD), and ERP/APD ratios are increased, resulting in decreased conduction velocity of nerve impulses. Quinidine exerts its antimalarial activity by acting primarily as an intra-erythrocytic schizonticide through association with the heme polymer (hemazoin) in the acidic food vacuole of the parasite thereby preventing further polymerization by heme polymerase enzyme. This results in accumulation of toxic heme and death of the parasite. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39022&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39022&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C793\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1588"""^^xsd:string ; """56-54-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C793"""^^xsd:string ; umls:cui """C0034414"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/gemcitabine"""@eng ; skos:notation """CDR0000043347"""^^xsd:string ; skos:altLabel """dFdC/TXT"""@eng ; ; ; """7893"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp209-2M antigen/heat shock protein 70/OVA BiP peptide/tyrosinase peptide"""@eng ; skos:notation """CDR0000037947"""^^xsd:string ; skos:altLabel """gp-209-2M/HSP70/OVA BiP/TYRP"""@eng ; ; ; ; ; """10367"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879488"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-188797/carboplatin"""@eng ; skos:notation """CDR0000038059"""^^xsd:string ; skos:altLabel """BMS-188797/CBDCA"""@eng ; ; ; """10595"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879600"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant 70-kD heat-shock protein"""@eng ; skos:notation """CDR0000037945"""^^xsd:string ; skos:altLabel """HSP70"""@eng , """70-kD Heat-Shock Protein"""@eng , """Heat Shock Protein 70"""@eng ; skos:definition """A recombinant peptide that is chemically identical to or similar to the endogenous 70-kD heat shock protein (HSP70). HSP70 is a molecular chaperone that prevents physiologic stress-induced cell death by inhibiting both caspase-dependent and caspase-independent apoptosis. Because this peptide is often overexpressed in tumor cells, autologous vaccination with HSP70 derived from tumor cells may stimulate the host immune system to mount a tumoricidal cytotoxic T lymphocyte (CTL) response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37945&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37945&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28696\" NCI Thesaurus)"""@eng ; ; """10365"""^^xsd:string ; """C28696"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0243043"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vorinostat"""@eng ; skos:notation """CDR0000037944"""^^xsd:string ; skos:altLabel """Zolinza"""@eng , """L-001079038"""@eng , """suberoylanilide hydroxamic acid"""@eng , """Suberoylanilide Hydroxamic Acid"""@eng , """SAHA"""@eng ; skos:definition """A synthetic agent with antineoplastic properties. Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), inhibits the enzyme histone deacetylase (HDAC), induces differentiation in some cell types, and has been shown to induce p53-independent apoptosis in a number of tumor cell lines. This agent crosses the blood-brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37944&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37944&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1796\" NCI Thesaurus)"""@eng ; ; ; ; ; """C1796"""^^xsd:string ; """2006-10-10"""^^xsd:string ; """10363"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0672708"""^^xsd:string ; umls:cui """C1832065"""^^xsd:string ; umls:cui """C1738860"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/phenylbutyrate"""@eng ; skos:notation """CDR0000037943"""^^xsd:string ; skos:altLabel """AZA/PBA"""@eng ; ; ; """10362"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clindamycin"""@eng ; skos:notation """CDR0000039020"""^^xsd:string ; """1585"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0008947"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RFT5-dgA immunotoxin"""@eng ; skos:notation """CDR0000486413"""^^xsd:string ; skos:altLabel """IgG-RFT5-dgA"""@eng ; skos:definition """A recombinant immunotoxin consisting of the monoclonal antibody RFT5 fused to deglycosylated ricin A-chain with potential antitumor activity. The RFT5-dgA immunotoxin selectively targets the interleukin 2 receptor (IL-2R), a cell surface antigen expressed on activated normal T and B cells and macrophages and frequently upregulated on the cell surface of many hematologic malignancies. The antibody attaches to the IL-2R on the cell membrane, thereby facilitating the entry of the immunotoxin and killing tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486413&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486413&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61498\" NCI Thesaurus)"""@eng ; """C61498"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-11"""^^xsd:string ; umls:cui """C1831838"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """palladium-bacteriopheophorbide"""@eng ; skos:notation """CDR0000483132"""^^xsd:string ; skos:altLabel """WST09"""@eng , """Tookad"""@eng ; skos:definition """A novel palladium-substituted bacteriochlorophyll derivative and photosensitizer with potential antitumor activity. Upon administration, inactive palladium-bacteriophephorbide is activated locally when the tumor bed is exposed to photoirradiation; the activated form induces local cytotoxic processes, resulting in local tissue damage, disruption of tumor vasculature, and tumor hypoxia and necrosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=483132&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=483132&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61321\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-05-05"""^^xsd:string ; """C61321"""^^xsd:string ; """2006-07-06"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1136634"""^^xsd:string ; umls:cui """C1453598"""^^xsd:string ; umls:cui """C1568323"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral complications of chemotherapy and head/neck radiation"""@eng ; skos:notation """CDR0000038050"""^^xsd:string ; rdfs:subClassOf ; """10577"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0879594"""^^xsd:string ; umls:tui """T037"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CC-1088"""@eng ; skos:notation """CDR0000038051"""^^xsd:string ; skos:definition """An analog of thalidomide with potential antineoplastic activity that belongs to the functional class of agents called selective cytokine inhibitory drugs (SelCIDs). SelCIDs inhibit phosphodiesterase-4 (PDE 4), an enzyme involved in tumor necrosis factor alpha (TNF alpha) production. CC-1088 inhibits production of the cytokines vascular endothelial growth factor (VEGF) (a pro-angiogenic factor) and interleukin-6 (IL-6). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38051&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38051&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2210\" NCI Thesaurus)"""@eng ; """10578"""^^xsd:string ; """C2210"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879595"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp209-2M antigen/interleukin-2/Montanide ISA-51"""@eng ; skos:notation """CDR0000038052"""^^xsd:string ; skos:altLabel """gp209-2M/IL-2/ISA-51"""@eng ; ; ; """10579"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879596"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II vaginal cancer"""@eng ; skos:notation """CDR0000038053"""^^xsd:string ; skos:altLabel """carcinoma of the vagina, stage II"""@eng , """stage II cancer of the vagina"""@eng , """vaginal cancer, stage II"""@eng , """stage II vagina cancer"""@eng , """stage II carcinoma of the vagina"""@eng , """cancer of the vagina, stage II"""@eng , """vagina cancer, stage II"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1058"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278742"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/paclitaxel"""@eng ; skos:notation """CDR0000038054"""^^xsd:string ; skos:altLabel """CDDP/dFdC/TAX"""@eng ; ; ; ; """10581"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879597"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/gefitinib/paclitaxel"""@eng ; skos:notation """CDR0000037949"""^^xsd:string ; skos:altLabel """CBDCA/TAX/ZD 1839"""@eng ; ; ; ; """2002-10-10"""^^xsd:string ; """10369"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879490"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enzyme inhibitor therapy"""@eng ; skos:notation """CDR0000037948"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; """10368"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0879489"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """l-gossypol"""@eng ; skos:notation """CDR0000485226"""^^xsd:string ; skos:altLabel """AT-101"""@eng ; """Drug/agent"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """2006-07-10"""^^xsd:string ; umls:cui """C1831824"""^^xsd:string ; umls:cui """C1831823"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """QS21"""@eng ; skos:notation """CDR0000041579"""^^xsd:string ; skos:altLabel """NIAID VEU 016"""@eng , """QS-21 Adjuvant"""@eng , """QS 21"""@eng , """QS-21"""@eng , """Stimulon QS-21 Adjuvant"""@eng ; skos:definition """A purified, natural saponin isolated from the soapbark tree Quillaja saponaria Molina with potential immunoadjuvant properties. When co-administered with vaccine peptides, QS21 may increase total antitumoral vaccine-specific antibody responses and cytotoxic T-cell responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41579&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41579&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1478\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4741"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """6335"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C1478"""^^xsd:string ; """141256-04-4"""^^xsd:string ; """679689"""^^xsd:string ; umls:cui """C1527010"""^^xsd:string ; umls:cui """C0211668"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluoxetine"""@eng ; skos:notation """CDR0000041578"""^^xsd:string ; skos:altLabel """N-methyl-gamma-(4-(trifluoromethyl) -phenoxy)-benzenepropanamine"""@eng , """FLUOX"""@eng , """Prozac"""@eng ; ; """4740"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0016365"""^^xsd:string ; umls:cui """C0162373"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/motexafin gadolinium"""@eng ; skos:notation """CDR0000038636"""^^xsd:string ; skos:altLabel """DOX/PCI-0120"""@eng ; ; ; """11269"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134645"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """large cell lung cancer"""@eng ; skos:notation """CDR0000041109"""^^xsd:string ; skos:altLabel """lung cancer, undifferentiated large cell"""@eng , """lung cancer, large cell"""@eng , """non-oat cell lung cancer, large cell"""@eng , """lung cancer, anaplastic large cell"""@eng , """undifferentiated large cell lung cancer"""@eng , """anaplastic large cell lung cancer"""@eng ; rdfs:subClassOf ; """415"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0345958"""^^xsd:string ; umls:cui """C2239115"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """R7160"""@eng ; skos:notation """CDR0000529277"""^^xsd:string ; """2007-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0615028"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical cancer prevention"""@eng ; skos:notation """CDR0000041571"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4734"""^^xsd:string ; umls:cui """C0281193"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin cancer prevention"""@eng ; skos:notation """CDR0000041570"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4733"""^^xsd:string ; umls:cui """C0281192"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/UCN-01"""@eng ; skos:notation """CDR0000038638"""^^xsd:string ; skos:altLabel """CBDCA/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """11270"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134646"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/sargramostim"""@eng ; skos:notation """CDR0000038639"""^^xsd:string ; skos:altLabel """13-CRA/GM-CSF"""@eng ; ; ; """11271"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134647"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """octreotide/tamoxifen"""@eng ; skos:notation """CDR0000039655"""^^xsd:string ; skos:altLabel """SSTN/TMX"""@eng ; ; ; """2310"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279440"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/streptozocin"""@eng ; skos:notation """CDR0000039654"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/SZC"""@eng , """FAC-S"""@eng ; ; ; ; ; """2309"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279439"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/fluorouracil"""@eng ; skos:notation """CDR0000039657"""^^xsd:string ; skos:altLabel """FACVP"""@eng , """CTX/DOX/5-FU/VP-16"""@eng ; ; ; ; ; """2312"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000039656"""^^xsd:string ; skos:altLabel """L-PAM/MePRDL/VCR"""@eng ; ; ; ; """2311"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279441"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/UCN-01"""@eng ; skos:notation """CDR0000257381"""^^xsd:string ; skos:altLabel """PRED/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """11421"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327774"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000039650"""^^xsd:string ; skos:altLabel """IFN-A/IL-2/TIL"""@eng ; ; ; ; """2305"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338097"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-PSA vaccine/sargramostim"""@eng ; skos:notation """CDR0000257383"""^^xsd:string ; skos:altLabel """F-PSA/GM-CSF"""@eng ; ; ; """2002-08-16"""^^xsd:string ; """11424"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327775"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide/topotecan"""@eng ; skos:notation """CDR0000429561"""^^xsd:string ; skos:altLabel """TMZ/TOPO"""@eng ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541556"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alprazolam"""@eng ; skos:notation """CDR0000039659"""^^xsd:string ; skos:altLabel """Nu-Alpraz"""@eng , """Apo-Alpzar"""@eng , """Xanax"""@eng ; skos:definition """A triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities. Alprazolam binds to a specific site distinct from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and leads to a decrease in neuronal excitability. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39659&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39659&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C227\" NCI Thesaurus)"""@eng ; """2314"""^^xsd:string ; """28981-97-7"""^^xsd:string ; """C227"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1257671"""^^xsd:string ; umls:cui """C0002333"""^^xsd:string ; umls:cui """C0699034"""^^xsd:string ; umls:cui """C1515925"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rV-B7.1 vaccine/sargramostim/vaccinia-PSA vaccine"""@eng ; skos:notation """CDR0000257388"""^^xsd:string ; skos:altLabel """GM-CSF/rV-B7.1/VPSA"""@eng ; ; ; ; """2004-11-03"""^^xsd:string ; """11425"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327776"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041182"""^^xsd:string ; skos:altLabel """CTX/MP/MTX/VCR"""@eng ; ; ; ; ; """4255"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280777"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/leuprolide"""@eng ; skos:notation """CDR0000041183"""^^xsd:string ; skos:altLabel """FLUT/LEUP"""@eng ; ; ; """4256"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280778"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000041180"""^^xsd:string ; skos:altLabel """CTX/MP/MTX/VP-16"""@eng ; ; ; ; ; """4253"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280775"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000041181"""^^xsd:string ; skos:altLabel """ASP/DM/VCR"""@eng ; ; ; ; """4254"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280776"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leukemia"""@eng ; skos:notation """CDR0000041186"""^^xsd:string ; rdfs:subClassOf ; """426"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023418"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/hydrazine sulfate"""@eng ; skos:notation """CDR0000041187"""^^xsd:string ; skos:altLabel """CDDP/HDZ/VP-16"""@eng ; ; ; ; """4260"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280779"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cladribine"""@eng ; skos:notation """CDR0000041184"""^^xsd:string ; skos:altLabel """2-chlorodeoxyadenosine"""@eng , """RWJ-26251"""@eng , """Leustat"""@eng , """2-CdA"""@eng , """Leustatin"""@eng , """Leustatine"""@eng , """2CDA"""@eng , """2-Chloro-2-Deoxyadenosine"""@eng , """Cladribina"""@eng ; skos:definition """A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis. Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41184&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41184&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1336\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """4257"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """37433"""^^xsd:string ; """105014-F"""^^xsd:string ; """C1336"""^^xsd:string ; """4291-63-8"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1516589"""^^xsd:string ; umls:cui """C1524107"""^^xsd:string ; umls:cui """C0730684"""^^xsd:string ; umls:cui """C0701346"""^^xsd:string ; umls:cui """C0092801"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """topotecan hydrochloride"""@eng ; skos:notation """CDR0000041185"""^^xsd:string ; skos:altLabel """TOPO"""@eng , """Hycamtin"""@eng , """hycamptamine"""@eng , """(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4'; 6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione monohydrochloride"""@eng ; skos:definition """The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata, with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41185&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41185&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2828\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """4259"""^^xsd:string ; """C2828"""^^xsd:string ; """123948-87-8"""^^xsd:string ; umls:cui """C0146224"""^^xsd:string ; umls:cui """C0886549"""^^xsd:string ; umls:cui """C0700915"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/L-leucovorin"""@eng ; skos:notation """CDR0000041188"""^^xsd:string ; skos:altLabel """5-FU/L-CF"""@eng ; ; ; """4261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280780"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noninfiltrating astrocytoma, adult"""@eng ; skos:notation """CDR0000041189"""^^xsd:string ; skos:altLabel """astrocytoma, adult noninfiltrating"""@eng ; """2004-06-17"""^^xsd:string ; """4262"""^^xsd:string ; umls:cui """C0280781"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, anal cancer"""@eng ; skos:notation """CDR0000040592"""^^xsd:string ; skos:altLabel """anus cancer stage"""@eng , """anal cancer stage"""@eng ; rdfs:subClassOf ; """3492"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280215"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, neuroblastoma"""@eng ; skos:notation """CDR0000040593"""^^xsd:string ; skos:altLabel """neuroblastoma stage"""@eng ; rdfs:subClassOf ; """3493"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280216"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/epirubicin/prednisone/vinblastine"""@eng ; skos:notation """CDR0000040590"""^^xsd:string ; skos:altLabel """BLEO/EPI/PRED/VBL"""@eng ; ; ; ; ; """3490"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0058907"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, nasopharyngeal cancer"""@eng ; skos:notation """CDR0000040591"""^^xsd:string ; skos:altLabel """nasopharynx cancer stage"""@eng , """nasopharyngeal cancer stage"""@eng ; rdfs:subClassOf ; """3491"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280214"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, osteosarcoma"""@eng ; skos:notation """CDR0000040596"""^^xsd:string ; skos:altLabel """osteosarcoma stage"""@eng ; rdfs:subClassOf ; """3496"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280219"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, ovarian epithelial cancer"""@eng ; skos:notation """CDR0000040597"""^^xsd:string ; skos:altLabel """stage, ovarian cancer"""@eng , """ovarian carcinoma stage"""@eng , """ovarian cancer stage"""@eng , """ovarian epithelial cancer stage"""@eng , """stage, ovarian carcinoma"""@eng ; rdfs:subClassOf ; """3497"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280220"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, non-small cell lung cancer"""@eng ; skos:notation """CDR0000040594"""^^xsd:string ; skos:altLabel """stage, nonsmall cell lung cancer"""@eng , """nonsmall cell lung cancer stage"""@eng ; rdfs:subClassOf ; """3494"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280217"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, bladder cancer"""@eng ; skos:notation """CDR0000040595"""^^xsd:string ; skos:altLabel """bladder cancer stage"""@eng ; rdfs:subClassOf ; """3495"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280218"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040598"""^^xsd:string ; skos:altLabel """ovarian germ cell tumor stage"""@eng ; rdfs:subClassOf ; """3498"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280221"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, pancreatic cancer"""@eng ; skos:notation """CDR0000040599"""^^xsd:string ; skos:altLabel """pancreatic cancer stage"""@eng ; rdfs:subClassOf ; """3499"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280222"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Aurora kinase inhibitor MK-0457"""@eng ; skos:notation """CDR0000485305"""^^xsd:string ; skos:altLabel """VX-680"""@eng , """MK-0457"""@eng , """MK0457"""@eng ; skos:definition """A synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Aurora kinase inhibitor MK-0457 binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed.AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485305&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485305&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61319\" NCI Thesaurus)"""@eng ; """2006-07-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61319"""^^xsd:string ; """2006-05-23"""^^xsd:string ; umls:cui """C1451033"""^^xsd:string ; umls:cui """C1831830"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/idarubicin/methotrexate"""@eng ; skos:notation """CDR0000041238"""^^xsd:string ; skos:altLabel """IDA/MTX/VP-16"""@eng ; ; ; ; """4311"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280832"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/thiotepa"""@eng ; skos:notation """CDR0000041239"""^^xsd:string ; skos:altLabel """CDDP/TSPA/VP-16"""@eng ; ; ; ; """4312"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280833"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/etoposide"""@eng ; skos:notation """CDR0000041230"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/VP-16"""@eng ; ; ; ; """4303"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280825"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/hydroxyurea/idoxuridine"""@eng ; skos:notation """CDR0000041231"""^^xsd:string ; skos:altLabel """5-FU/HU/IUDR"""@eng ; ; ; ; """4304"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280826"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/doxorubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000041232"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/DOX/MTX/VBL"""@eng ; ; ; ; ; ; """4305"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280827"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclosporine"""@eng ; skos:notation """CDR0000041233"""^^xsd:string ; skos:altLabel """CDDP/CYSP"""@eng ; ; ; """4306"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280828"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acivicin/aminosyn"""@eng ; skos:notation """CDR0000041234"""^^xsd:string ; skos:altLabel """Aminosyn/AT-125"""@eng ; ; ; """4307"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280829"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000041235"""^^xsd:string ; skos:altLabel """CBDCA/DOX/MTX/VBL"""@eng ; ; ; ; ; """4309"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280830"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult liposarcoma"""@eng ; skos:notation """CDR0000041236"""^^xsd:string ; skos:altLabel """liposarcoma, adult"""@eng , """sarcoma, lipo-, adult"""@eng ; rdfs:subClassOf ; """431"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278608"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/etoposide/thiotepa"""@eng ; skos:notation """CDR0000041237"""^^xsd:string ; skos:altLabel """BCNU/TSPA/VP-16"""@eng ; ; ; ; """4310"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280831"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland adenoid cystic carcinoma"""@eng ; skos:notation """CDR0000040048"""^^xsd:string ; skos:altLabel """cancer of the salivary gland, adenoid cystic carcinoma"""@eng , """carcinoma of the salivary gland, adenoid cystic carcinoma"""@eng , """adenoid cystic carcinoma, salivary gland"""@eng ; rdfs:subClassOf ; """2786"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279751"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """premenopausal"""@eng ; skos:notation """CDR0000040049"""^^xsd:string ; """2788"""^^xsd:string ; umls:cui """C0279752"""^^xsd:string ; umls:tui """T079"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-grade salivary gland mucoepidermoid carcinoma"""@eng ; skos:notation """CDR0000040040"""^^xsd:string ; skos:altLabel """low grade mucoepidermoid carcinoma, salivary gland"""@eng , """salivary gland mucoepidermoid carcinoma low grade"""@eng , """mucoepidermoid carcinoma low grade, salivary gland"""@eng ; rdfs:subClassOf ; """2775"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279740"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-grade salivary gland carcinoma"""@eng ; skos:notation """CDR0000040041"""^^xsd:string ; skos:altLabel """cancer of the salivary gland, high grade"""@eng , """salivary gland cancer, high grade"""@eng , """carcinoma of the salivary gland, high grade"""@eng , """salivary gland carcinoma, high grade"""@eng , """high-grade salivary gland cancer"""@eng ; rdfs:subClassOf ; """2776"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279743"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-grade salivary gland mucoepidermoid carcinoma"""@eng ; skos:notation """CDR0000040042"""^^xsd:string ; skos:altLabel """salivary gland mucoepidermoid carcinoma high grade"""@eng , """high grade mucoepidermoid carcinoma, salivary gland"""@eng , """mucoepidermoid carcinoma high grade, salivary gland"""@eng ; rdfs:subClassOf ; """2777"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279744"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland adenocarcinoma"""@eng ; skos:notation """CDR0000040043"""^^xsd:string ; skos:altLabel """adenocarcinoma, salivary gland"""@eng ; rdfs:subClassOf ; """2779"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279746"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland poorly differentiated carcinoma"""@eng ; skos:notation """CDR0000040044"""^^xsd:string ; skos:altLabel """carcinoma of the salivary gland, poorly differentiated"""@eng , """poorly differentiated carcinoma, salivary gland"""@eng , """cancer of the salivary gland, poorly differentiated"""@eng ; rdfs:subClassOf ; """2780"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279747"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nasopharyngeal lymphoepithelioma"""@eng ; skos:notation """CDR0000040045"""^^xsd:string ; skos:altLabel """nasopharynx lymphoepithelioma"""@eng , """lymphoepithelioma, nasopharyngeal"""@eng ; rdfs:subClassOf ; """2781"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279748"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland anaplastic carcinoma"""@eng ; skos:notation """CDR0000040046"""^^xsd:string ; skos:altLabel """cancer of the salivary gland, undifferentiated"""@eng , """carcinoma of the salivary gland, anaplastic"""@eng , """anaplastic carcinoma, salivary gland"""@eng , """undifferentiated carcinoma, salivary gland"""@eng ; rdfs:subClassOf ; """2782"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279749"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland malignant mixed cell type tumor"""@eng ; skos:notation """CDR0000040047"""^^xsd:string ; skos:altLabel """malignant mixed cell type tumor, salivary gland"""@eng , """cancer of the salivary gland, malignant mixed cell type tumor"""@eng , """mixed cell type tumor, salivary gland, malignant"""@eng , """carcinoma of the salivary gland, malignant mixed cell type tumor"""@eng , """salivary gland mixed cell type tumor, malignant"""@eng ; rdfs:subClassOf ; """2784"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0344459"""^^xsd:string ; umls:cui """C0279750"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """androgen receptor"""@eng ; skos:notation """CDR0000043580"""^^xsd:string ; rdfs:subClassOf ; """8861"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1367578"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leflunomide/mitoxantrone/prednisone"""@eng ; skos:notation """CDR0000043581"""^^xsd:string ; skos:altLabel """DHAD/PRED/SU101"""@eng ; ; ; ; """8862"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879291"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood extracranial germ cell tumor"""@eng ; skos:notation """CDR0000043582"""^^xsd:string ; rdfs:subClassOf ; """8863"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0879292"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-778,123/paclitaxel"""@eng ; skos:notation """CDR0000043583"""^^xsd:string ; skos:altLabel """L 778,123/TAX"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """8864"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879293"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PNU 166148"""@eng ; skos:notation """CDR0000043584"""^^xsd:string ; skos:altLabel """PNU-166148"""@eng , """PNU166148"""@eng ; """2003-10-28"""^^xsd:string ; """8865"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879294"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/UCN-01"""@eng ; skos:notation """CDR0000043585"""^^xsd:string ; skos:altLabel """5-FU/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """8866"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879295"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mutant p53 peptide pulsed dendritic cell vaccine"""@eng ; skos:notation """CDR0000043586"""^^xsd:string ; skos:altLabel """p53 DEN"""@eng , """mutant p53 peptide pulsed DC vaccine"""@eng ; skos:definition """A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43586&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43586&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2540\" NCI Thesaurus)"""@eng ; ; """8867"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-31"""^^xsd:string ; """C2540"""^^xsd:string ; umls:cui """C0879296"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043587"""^^xsd:string ; skos:altLabel """gp100/ISA-51/TYRP"""@eng ; ; ; """8868"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879297"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MART-1 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000043588"""^^xsd:string ; skos:altLabel """gp100/ISA-51/MART-1"""@eng ; ; ; """8869"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879298"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-2/MART-1 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000043589"""^^xsd:string ; skos:altLabel """gp100/IL-2/ISA-51/MART-1"""@eng ; ; ; ; """8870"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879299"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-EpCAM-Pseudomonas-exotoxin fusion protein"""@eng ; skos:notation """CDR0000485164"""^^xsd:string ; skos:altLabel """Proxinium"""@eng , """Vicinium"""@eng , """VB4-845"""@eng ; skos:definition """A fusion protein consisting of a human monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Anti-EpCAM-Pseudomonas-exotoxin fusion protein binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485164&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485164&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61307\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """C61307"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831819"""^^xsd:string ; umls:cui """C1831818"""^^xsd:string ; umls:cui """C1831820"""^^xsd:string ; umls:cui """C1831821"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """INO-1001"""@eng ; skos:notation """CDR0000485165"""^^xsd:string ; skos:definition """A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485165&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485165&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61315\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-10"""^^xsd:string ; """C61315"""^^xsd:string ; """2006-05-11"""^^xsd:string ; umls:cui """C1504945"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes"""@eng ; skos:notation """CDR0000504600"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831954"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunohistochemistry"""@eng ; skos:notation """CDR0000042769"""^^xsd:string ; rdfs:subClassOf ; """6567"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0021044"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diagnostic test"""@eng ; skos:notation """CDR0000042768"""^^xsd:string ; """6566"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0086143"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042760"""^^xsd:string ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6557"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677730"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000042767"""^^xsd:string ; skos:altLabel """CBDCA/TAX/WR-2721"""@eng ; ; ; ; """6565"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677736"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """canarypox-hIL-12 melanoma vaccine"""@eng ; skos:notation """CDR0000042766"""^^xsd:string ; skos:altLabel """ALVAC-hIL-12"""@eng , """ALVAC-hIL-12 melanoma vaccine"""@eng ; skos:definition """A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42766&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42766&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2442\" NCI Thesaurus)"""@eng ; ; """6564"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2442"""^^xsd:string ; """689514"""^^xsd:string ; """7125"""^^xsd:string ; umls:cui """C0677735"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """angioimmunoblastic T-cell lymphoma"""@eng ; skos:notation """CDR0000042765"""^^xsd:string ; skos:altLabel """angioimmunoblastic lymphadenopathy with dysproteinemia"""@eng , """AILD"""@eng ; rdfs:subClassOf ; """6563"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0020981"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABR-217620"""@eng ; skos:notation """CDR0000355730"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328194"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/fludarabine/monoclonal antibody BC8"""@eng ; skos:notation """CDR0000355733"""^^xsd:string ; skos:altLabel """FAMP/MOAB BC8/MOAB CD52"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328196"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody BC8"""@eng ; skos:notation """CDR0000355732"""^^xsd:string ; skos:altLabel """anti-CD45"""@eng , """MOAB BC8"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328195"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/monoclonal antibody BC8"""@eng ; skos:notation """CDR0000355734"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MOAB BC8"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328197"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/phenoxodiol"""@eng ; skos:notation """CDR0000389202"""^^xsd:string ; skos:altLabel """CDDP/NV-06"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541357"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dapsone gel, 5%"""@eng ; skos:notation """CDR0000494632"""^^xsd:string ; skos:altLabel """Aczone Gel"""@eng ; """2006-07-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831916"""^^xsd:string ; umls:cui """C1639494"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """octreotide pamoate"""@eng ; skos:notation """CDR0000042358"""^^xsd:string ; skos:altLabel """OncoLAR"""@eng , """SMS 201-995 pa LAR"""@eng , """SMS 201-995 pa"""@eng , """OP LAR"""@eng , """Sandostatin pamoate LAR"""@eng , """Octreotide Pamoate LAR(SMS 201-995)"""@eng , """Sandostatin pamoate"""@eng ; skos:definition """A synthetic long-acting octapeptide analogue of endogenous somatostatin. Octreotide pamoate binds to somatostatin receptors expressed by some neuroendocrine and non-neuroendocrine tumor cells, thereby initiating somatostatin receptor-mediated apoptosis. Other possible antineoplastic activities of this agent include suppression of tumor angiogenesis and tumor growth-promoting insulin-like growth factor 1 (IGF-1). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42358&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42358&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2402\" NCI Thesaurus)"""@eng ; ; ; ; """5611"""^^xsd:string ; """52010"""^^xsd:string ; """135467-16-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2402"""^^xsd:string ; """685403"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328682"""^^xsd:string ; umls:cui """C1328681"""^^xsd:string ; umls:cui """C0338271"""^^xsd:string ; umls:cui """C1518541"""^^xsd:string ; umls:cui """C1328680"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/losoxantrone"""@eng ; skos:notation """CDR0000042359"""^^xsd:string ; skos:altLabel """CTX/DuP-941"""@eng , """CL"""@eng ; ; ; """5612"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338272"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XL647"""@eng ; skos:notation """CDR0000386183"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """C62496"""^^xsd:string ; """2006-09-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541356"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lobradimil"""@eng ; skos:notation """CDR0000042352"""^^xsd:string ; skos:altLabel """L-Prolinamide,L-Arginyl-L-protyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-02-004-0(aminoiminomethyl)amino)-1-0(4-methoxyphenyl)methyl)ethyl)-,0S-(R*,R*))"""@eng , """DRG-0182"""@eng , """Cereport"""@eng , """RMP-7"""@eng , """L-Prolinamide, L-Arginyl-L-prolyl-trans-4- hydroxy-L-prolyl-3-(2- thienyl)-L-alanylglycl -L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1- -carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (S-(R*,R*))"""@eng ; skos:definition """A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB). Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42352&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42352&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1606\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """5605"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """159768-75-9"""^^xsd:string ; """C1606"""^^xsd:string ; """950021"""^^xsd:string ; umls:cui """C0289630"""^^xsd:string ; umls:cui """C3853657"""^^xsd:string ; umls:cui """C3853656"""^^xsd:string ; umls:cui """C1522598"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/lobradimil"""@eng ; skos:notation """CDR0000042353"""^^xsd:string ; skos:altLabel """CBDCA/RMP-7"""@eng ; ; ; """5606"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338266"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000042350"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MP/MTX/VP-16"""@eng ; ; ; ; ; ; ; """5603"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338264"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine"""@eng ; skos:notation """CDR0000042351"""^^xsd:string ; skos:altLabel """CDDP/dFdC"""@eng ; ; ; """5604"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338265"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Allovectin-7"""@eng ; skos:notation """CDR0000042356"""^^xsd:string ; skos:altLabel """ALLO-7"""@eng ; ; ; """5609"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338269"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Allovectin-7/interleukin-2"""@eng ; skos:notation """CDR0000042357"""^^xsd:string ; skos:altLabel """allovectin-7/IL-2"""@eng ; ; ; """5610"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338270"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/vinorelbine"""@eng ; skos:notation """CDR0000042354"""^^xsd:string ; skos:altLabel """EPI/VNB"""@eng ; ; ; """5607"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338267"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neuroendocrine therapy"""@eng ; skos:notation """CDR0000042355"""^^xsd:string ; skos:altLabel """therapy, neuroendocrine"""@eng ; ; rdfs:subClassOf ; """5608"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0338268"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """714-X"""@eng ; skos:notation """CDR0000257609"""^^xsd:string ; """2002-10-19"""^^xsd:string ; """2002-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0539517"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP2C"""@eng ; skos:notation """CDR0000322875"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1378702"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, breast cancer"""@eng ; skos:notation """CDR0000040602"""^^xsd:string ; skos:altLabel """breast cancer stage"""@eng ; rdfs:subClassOf ; """3501"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C2216702"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, parathyroid cancer"""@eng ; skos:notation """CDR0000040603"""^^xsd:string ; skos:altLabel """parathyroid cancer stage"""@eng ; rdfs:subClassOf ; """3502"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280225"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I anal cancer"""@eng ; skos:notation """CDR0000040600"""^^xsd:string ; skos:altLabel """anal cancer, stage I"""@eng , """anus cancer, stage I"""@eng , """stage I anus cancer"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """35"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278499"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040601"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MTX/VCR"""@eng ; ; ; ; ; """3500"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280223"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior endocrine therapy for advanced disease"""@eng ; skos:notation """CDR0000040606"""^^xsd:string ; """3506"""^^xsd:string ; umls:cui """C0280229"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/type, pituitary tumor"""@eng ; skos:notation """CDR0000040607"""^^xsd:string ; skos:altLabel """pituitary tumor stage"""@eng ; rdfs:subClassOf ; """3507"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280230"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, penile cancer"""@eng ; skos:notation """CDR0000040604"""^^xsd:string ; skos:altLabel """penile cancer stage"""@eng , """penis cancer stage"""@eng ; rdfs:subClassOf ; """3503"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280226"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, pheochromocytoma"""@eng ; skos:notation """CDR0000040605"""^^xsd:string ; skos:altLabel """pheochromocytoma stage"""@eng ; rdfs:subClassOf ; """3505"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280228"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, plasma cell neoplasm"""@eng ; skos:notation """CDR0000040608"""^^xsd:string ; skos:altLabel """plasma cell neoplasm stage"""@eng ; rdfs:subClassOf ; """3508"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280231"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, cervical cancer"""@eng ; skos:notation """CDR0000040609"""^^xsd:string ; skos:altLabel """cervical cancer stage"""@eng ; rdfs:subClassOf ; """3509"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280232"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide/VNP40101M"""@eng ; skos:notation """CDR0000405999"""^^xsd:string ; skos:altLabel """TMZ/VNP-40101M"""@eng ; ; ; """2004-11-19"""^^xsd:string ; """2004-11-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541406"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1"""@eng ; skos:notation """CDR0000041959"""^^xsd:string ; skos:altLabel """BRYO"""@eng , """Bryostatin-1"""@eng , """B705008K112"""@eng , """Bryostatin"""@eng ; skos:definition """A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity. Bryostatin-1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41959&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41959&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1026\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5183"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """42780"""^^xsd:string ; """339555"""^^xsd:string ; """83314-01-6"""^^xsd:string ; """C1026"""^^xsd:string ; umls:cui """C1524002"""^^xsd:string ; umls:cui """C0054173"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood desmoplastic small round cell tumor"""@eng ; skos:notation """CDR0000041958"""^^xsd:string ; skos:altLabel """small round cell tumor, desmoplastic, childhood"""@eng , """tumor, desmoplastic small round cell, childhood"""@eng ; rdfs:subClassOf ; """5182"""^^xsd:string ; """2007-01-17"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1332966"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/ifosfamide/methotrexate"""@eng ; skos:notation """CDR0000041955"""^^xsd:string ; skos:altLabel """ARA-C/DM/IFF/MTX/VP-16"""@eng ; ; ; ; ; ; """5178"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281505"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/toremifene"""@eng ; skos:notation """CDR0000041954"""^^xsd:string ; skos:altLabel """CTX/EPI/TOR"""@eng ; ; ; ; """5177"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281504"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone"""@eng ; skos:notation """CDR0000041957"""^^xsd:string ; skos:altLabel """CTX/DM"""@eng ; ; ; """5181"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/methotrexate"""@eng ; skos:notation """CDR0000041956"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/MTX"""@eng ; ; ; ; ; """5180"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281506"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/tumor necrosis factor receptor IgG chimera"""@eng ; skos:notation """CDR0000041951"""^^xsd:string ; skos:altLabel """IL-2/TNFR:Fc"""@eng ; ; """5174"""^^xsd:string ; """2006-08-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281501"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TNFR:Fc"""@eng ; skos:notation """CDR0000041950"""^^xsd:string ; """5173"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C0717758"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/toremifene"""@eng ; skos:notation """CDR0000041953"""^^xsd:string ; skos:altLabel """CTX/DOX/TOR"""@eng ; ; ; ; """5176"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/tamoxifen"""@eng ; skos:notation """CDR0000041952"""^^xsd:string ; skos:altLabel """CTX/EPI/TMX"""@eng ; ; ; ; """5175"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SU6668"""@eng ; skos:notation """CDR0000038421"""^^xsd:string ; skos:altLabel """Sugen SU6668"""@eng ; skos:definition """An orally bioavailable receptor tyrosine kinase inhibitor. SU6668 binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. SU6668 also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38421&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38421&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1884\" NCI Thesaurus)"""@eng ; """11039"""^^xsd:string ; """C1884"""^^xsd:string ; """62531"""^^xsd:string ; """210644-62-5"""^^xsd:string ; """702827"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C0970963"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Biomed 101/interleukin-2"""@eng ; skos:notation """CDR0000037883"""^^xsd:string ; skos:altLabel """Biomed-101/IL-2"""@eng ; ; ; """2003-10-07"""^^xsd:string ; """10286"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879448"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enoxaparin"""@eng ; skos:notation """CDR0000037880"""^^xsd:string ; skos:altLabel """Lovenox"""@eng , """Enoxaparin Sodium"""@eng ; skos:definition """A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells. Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37880&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37880&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1452\" NCI Thesaurus)"""@eng ; """10283"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1452"""^^xsd:string ; """728167"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0728963"""^^xsd:string ; umls:cui """C0724579"""^^xsd:string ; umls:cui """C0206460"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/PR1 leukemia peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000037881"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/PR1 vac"""@eng ; ; ; """10284"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879446"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody huJ591"""@eng ; skos:notation """CDR0000038425"""^^xsd:string ; skos:altLabel """MOAB huJ591"""@eng , """huJ591"""@eng ; ; """11042"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134478"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I and II childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000037887"""^^xsd:string ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10295"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0879450"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/methylprednisolone/tacrolimus"""@eng ; skos:notation """CDR0000037884"""^^xsd:string ; skos:altLabel """ATG/FK506/MePRDL"""@eng ; ; ; ; """10287"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879449"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peptide 946 melanoma vaccine/QS21"""@eng ; skos:notation """CDR0000042979"""^^xsd:string ; skos:altLabel """p946/QS 21"""@eng ; ; ; """7231"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677990"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Freund's Incomplete Adjuvant"""@eng ; skos:notation """CDR0000042976"""^^xsd:string ; skos:altLabel """ISA-51"""@eng , """Incomplete Freund's Adjuvant"""@eng , """Montanide ISA 51"""@eng ; """7103"""^^xsd:string ; """675756"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """C1573"""^^xsd:string ; """7229"""^^xsd:string ; """11152"""^^xsd:string ; """11024"""^^xsd:string ; """5924"""^^xsd:string ; """8709"""^^xsd:string ; """7474"""^^xsd:string ; """6123"""^^xsd:string ; """8652"""^^xsd:string ; umls:cui """C0281643"""^^xsd:string ; umls:cui """C1311732"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alkylating agent"""@eng ; skos:notation """CDR0000042977"""^^xsd:string ; rdfs:subClassOf ; """723"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002073"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peptide 946 melanoma vaccine"""@eng ; skos:notation """CDR0000042974"""^^xsd:string ; skos:altLabel """p946"""@eng ; ; ; ; ; ; ; """7227"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677986"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peptide 946-tetanus peptide conjugate melanoma vaccine"""@eng ; skos:notation """CDR0000042975"""^^xsd:string ; skos:altLabel """p946-Tet p"""@eng ; ; ; ; """7228"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677987"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/sargramostim/vinblastine"""@eng ; skos:notation """CDR0000042972"""^^xsd:string ; skos:altLabel """GM-CSF/IL-2/VBL"""@eng ; ; ; ; """7207"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677982"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan"""@eng ; skos:notation """CDR0000042973"""^^xsd:string ; skos:altLabel """L-Sarcolysin"""@eng , """L-Sarcolysin Phenylalanine mustard"""@eng , """Phenylalanine Mustard"""@eng , """Melfalan"""@eng , """L-Sarcolysine"""@eng , """Alkerana"""@eng , """Sarcoclorin"""@eng , """Phenylalanine Nitrogen Mustard"""@eng , """L-phenylalanine mustard"""@eng , """Alkeran"""@eng , """L-PAM"""@eng , """Melphalanum"""@eng , """Sarkolysin"""@eng , """alanine nitrogen mustard"""@eng , """4-[bis(2-chloroethyl)amino]-L-phenylalanine"""@eng , """CB-3025"""@eng , """p-di(chloroethyl)amino-L-phenylalanine"""@eng , """WR-19813"""@eng ; skos:definition """An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42973&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42973&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C633\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """722"""^^xsd:string ; """1335"""^^xsd:string ; """C633"""^^xsd:string ; """4631"""^^xsd:string ; """948"""^^xsd:string ; """8806"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """148-82-3"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0025444"""^^xsd:string ; umls:cui """C0591063"""^^xsd:string ; umls:cui """C0025241"""^^xsd:string ; umls:cui """C0733456"""^^xsd:string ; umls:cui """C1513104"""^^xsd:string ; umls:cui """C1522637"""^^xsd:string ; umls:cui """C1522636"""^^xsd:string ; umls:cui """C1513105"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/cytarabine/dexamethasone"""@eng ; skos:notation """CDR0000042970"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/WR-2721"""@eng ; ; ; ; ; """7201"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677980"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GEM 231"""@eng ; skos:notation """CDR0000042971"""^^xsd:string ; skos:altLabel """GEM-231"""@eng , """GEM231"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """7206"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677981"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """decitabine/imatinib mesylate"""@eng ; skos:notation """CDR0000271297"""^^xsd:string ; skos:altLabel """DAC/STI571"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327879"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000043005"""^^xsd:string ; skos:altLabel """CTX/MP/MTX"""@eng ; ; ; ; """7260"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678015"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/rituximab"""@eng ; skos:notation """CDR0000043004"""^^xsd:string ; skos:altLabel """FAMP/MOAB IDEC-C2B8"""@eng ; ; ; """7259"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678014"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anakinra"""@eng ; skos:notation """CDR0000043007"""^^xsd:string ; skos:altLabel """Kineret"""@eng , """IL-1ra"""@eng , """interleukin-1 receptor antagonist"""@eng ; skos:definition """A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43007&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43007&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38717\" NCI Thesaurus)"""@eng ; """7263"""^^xsd:string ; """C38717"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0245109"""^^xsd:string ; umls:cui """C1704264"""^^xsd:string ; umls:cui """C1170364"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboxyamidotriazole/ketoconazole"""@eng ; skos:notation """CDR0000043006"""^^xsd:string ; skos:altLabel """CAI/KCZ"""@eng ; ; ; """7261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678016"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cladribine/cyclophosphamide/prednisone"""@eng ; skos:notation """CDR0000043001"""^^xsd:string ; skos:altLabel """2-CdA/CTX/PRED"""@eng ; ; ; ; """7255"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678010"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/prednisone"""@eng ; skos:notation """CDR0000043000"""^^xsd:string ; skos:altLabel """DHAD/PRED"""@eng ; ; ; """7252"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678009"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/ritonavir"""@eng ; skos:notation """CDR0000043003"""^^xsd:string ; skos:altLabel """IFN-A/RIT"""@eng ; ; ; """7257"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678012"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043002"""^^xsd:string ; skos:altLabel """CTX/ARA-C/DM/DOX/MTX/VCR"""@eng ; ; ; ; ; ; ; """7256"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678011"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CRL 1005"""@eng ; skos:notation """CDR0000043009"""^^xsd:string ; ; ; """7275"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0676826"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antibiotic"""@eng ; skos:notation """CDR0000043008"""^^xsd:string ; skos:altLabel """drug, antibiotic"""@eng ; rdfs:subClassOf owl:Thing ; """727"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003232"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CD19/anti-CD3 recombinant monoclonal antibody"""@eng ; skos:notation """CDR0000487684"""^^xsd:string ; skos:altLabel """MT-103"""@eng ; """2006-06-02"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62528"""^^xsd:string ; umls:cui """C1831863"""^^xsd:string ; umls:cui """C1722284"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HuC242-DM4"""@eng ; skos:notation """CDR0000492706"""^^xsd:string ; skos:altLabel """maytansinoid DM4-conjugated humanized monoclonal antibody huC242"""@eng ; skos:definition """An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated with a derivative of cytotoxic agent maytansine, DM4, with potential antitumor activity. huC242-DM4 is generated based on MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492706&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492706&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61576\" NCI Thesaurus)"""@eng ; """2006-07-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61576"""^^xsd:string ; """2006-09-20"""^^xsd:string ; umls:cui """C1831909"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-dimethylaminoethylamino-17-demethoxygeldanamycin"""@eng ; skos:notation """CDR0000378203"""^^xsd:string ; skos:altLabel """17-Dimethylaminoethylamino_17-Demethoxygeldanamycin"""@eng , """17-DMAG"""@eng ; skos:definition """An analogue of the benzoquinone antineoplastic antibiotic geldanamycin. 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=378203&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=378203&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38142\" NCI Thesaurus)"""@eng ; """2004-07-23"""^^xsd:string ; """C38142"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-25"""^^xsd:string ; umls:cui """C1527262"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/imatinib mesylate"""@eng ; skos:notation """CDR0000346482"""^^xsd:string ; skos:altLabel """MOAB VEGF/STI571"""@eng ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328110"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paricalcitol"""@eng ; skos:notation """CDR0000315740"""^^xsd:string ; skos:altLabel """Zemplar"""@eng ; skos:definition """A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315740&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=315740&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38693\" NCI Thesaurus)"""@eng ; """2003-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """C38693"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0724464"""^^xsd:string ; umls:cui """C0249582"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/irinotecan"""@eng ; skos:notation """CDR0000315748"""^^xsd:string ; skos:altLabel """CPT-11/FUDR"""@eng ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327997"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/fluorouracil/paclitaxel"""@eng ; skos:notation """CDR0000315749"""^^xsd:string ; skos:altLabel """CDDP/5-FU/G-CSF/TAX"""@eng ; ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327998"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """deslorelin/estradiol/testosterone"""@eng ; skos:notation """CDR0000357621"""^^xsd:string ; skos:altLabel """DSLN/ESDL/TESTO"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541569"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """deslorelin"""@eng ; skos:notation """CDR0000357620"""^^xsd:string ; skos:altLabel """GnRH Agonist"""@eng , """DSLN"""@eng , """6-D-Tryptophan-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Swine)"""@eng , """Deslorelin Acetate"""@eng ; skos:definition """A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357620&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357620&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38709\" NCI Thesaurus)"""@eng ; ; """2004-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """70235-53-9"""^^xsd:string ; """C38709"""^^xsd:string ; """2006-08-01"""^^xsd:string ; umls:cui """C0083220"""^^xsd:string ; umls:cui """C0378714"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BSI-201"""@eng ; skos:notation """CDR0000488465"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """C62526"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831868"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil"""@eng ; skos:notation """CDR0000038847"""^^xsd:string ; skos:altLabel """CBDCA/5-FU"""@eng ; ; ; """1338"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278893"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/etoposide/hydroxyurea"""@eng ; skos:notation """CDR0000038846"""^^xsd:string ; skos:altLabel """HED"""@eng , """DTIC/HU/VP-16"""@eng ; ; ; ; """1337"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278892"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/goserelin"""@eng ; skos:notation """CDR0000038845"""^^xsd:string ; skos:altLabel """FLUT/ZDX"""@eng ; ; ; """1336"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278891"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """goserelin/nilutamide"""@eng ; skos:notation """CDR0000038844"""^^xsd:string ; skos:altLabel """ANAN/ZDX"""@eng ; ; ; """1335"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278890"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/etoposide/ifosfamide/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042518"""^^xsd:string ; skos:altLabel """DM/IFF/PEG-ASP/VCR/VP-16"""@eng ; ; ; ; ; ; """6138"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392949"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/recombinant interferon beta"""@eng ; skos:notation """CDR0000038842"""^^xsd:string ; skos:altLabel """IFN-B/IL-2"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """1333"""^^xsd:string ; umls:cui """C0278888"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine"""@eng ; skos:notation """CDR0000038841"""^^xsd:string ; skos:altLabel """CDDP/DTIC"""@eng ; ; ; """1332"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278887"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/doxorubicin/hydroxyurea/lomustine/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038840"""^^xsd:string ; skos:altLabel """ARA-C/CCNU/CTX/DOX/HU/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; """1331"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278886"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclosporine/dipyridamole/etoposide/prochlorperazine"""@eng ; skos:notation """CDR0000042514"""^^xsd:string ; skos:altLabel """CBDCA/CYSP/DP/PCPZ/VP-16"""@eng ; ; ; ; ; ; """6128"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392945"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegylated recombinant human megakaryocyte growth and development factor"""@eng ; skos:notation """CDR0000042515"""^^xsd:string ; skos:altLabel """polyethylene glycosylated recombinant human MGDF"""@eng , """polyethylene glycollated recombinant human MGDF"""@eng , """PEG-MGDF"""@eng , """PEG-rMGDF"""@eng , """PEG-rHuMGDF"""@eng ; ; """6130"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0533199"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclosporine/interferon alfa"""@eng ; skos:notation """CDR0000042516"""^^xsd:string ; skos:altLabel """CBDCA/CYSP/IFN-A"""@eng ; ; ; ; """6132"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392947"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/toremifene"""@eng ; skos:notation """CDR0000042517"""^^xsd:string ; skos:altLabel """CDDP/TOR"""@eng ; ; ; """6135"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392948"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/9-cis-retinoic acid"""@eng ; skos:notation """CDR0000042510"""^^xsd:string ; skos:altLabel """CBDCA/9-CRA"""@eng ; ; ; """6122"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392941"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dexrazoxane/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000042511"""^^xsd:string ; skos:altLabel """ADR-529/BLEO/DOX/VCR/VP-16"""@eng ; ; ; ; ; ; """6124"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392942"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zolpidem tartrate"""@eng ; skos:notation """CDR0000370808"""^^xsd:string ; skos:altLabel """Ambien"""@eng , """ZPD"""@eng ; skos:definition """The tartrate salt of a non-benzodiazepine of the imidazopyridine class with sedative-hypnotic activity. Zolpidem binds to the omega-1 subclass of the gamma-aminobutyric acid type A (GABA-A ) receptor-chloride ionophore complex, thereby opening the chloride channel and resulting in hyperpolarization and inhibition of neuronal firing. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=370808&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=370808&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29553\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """2004-05-28"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C29553"""^^xsd:string ; umls:cui """C0078839"""^^xsd:string ; umls:cui """C0487782"""^^xsd:string ; umls:cui """C0724725"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """venlafaxine/zolpidem tartrate"""@eng ; skos:notation """CDR0000370809"""^^xsd:string ; skos:altLabel """VNF/ZPD"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2004-05-06"""^^xsd:string ; """2004-05-28"""^^xsd:string ; umls:cui """C1541243"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclosporine/etoposide/vincristine"""@eng ; skos:notation """CDR0000428394"""^^xsd:string ; skos:altLabel """CBDCA/CYSP/VCR/VP-16"""@eng ; ; ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541549"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ARQ 197"""@eng ; skos:notation """CDR0000488957"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """C62437"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; umls:cui """C1831873"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/cisplatin/irinotecan"""@eng ; skos:notation """CDR0000430106"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/MOAB C225"""@eng ; ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541561"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/docetaxel/prednisone"""@eng ; skos:notation """CDR0000430107"""^^xsd:string ; skos:altLabel """MOAB VEGF/PRED/TXT"""@eng ; ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541562"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/gemcitabine/methylprednisolone"""@eng ; skos:notation """CDR0000430105"""^^xsd:string ; skos:altLabel """CDDP/dFdC/MePRDL/VP-16"""@eng ; ; ; ; ; """2005-04-23"""^^xsd:string ; """2005-04-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541560"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate/prednisone/tamoxifen"""@eng ; skos:notation """CDR0000039468"""^^xsd:string ; skos:altLabel """CTX/5-FU/FXM/MTX/PRED/TMX"""@eng , """CMF(P)TH"""@eng ; ; ; ; ; ; """2101"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279322"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluoxymesterone/mitolactol/prednisone/tamoxifen"""@eng ; skos:notation """CDR0000039469"""^^xsd:string ; skos:altLabel """CTX/DBD/FXM/PRED/TMX"""@eng , """CD(P)TH"""@eng ; ; ; ; ; """2102"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279323"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Ewing's sarcoma/primitive neuroectodermal tumor (PNET)"""@eng ; skos:notation """CDR0000039466"""^^xsd:string ; skos:altLabel """sarcoma, Ewing's"""@eng , """Askin tumor"""@eng , """neuroepithelioma, peripheral"""@eng , """PNET"""@eng , """peripheral primitive neuroectodermal tumor"""@eng , """peripheral neuroectodermal tumor"""@eng , """primitive neuroectodermal tumor"""@eng , """pPNET"""@eng , """primitive peripheral neuroectodermal tumor"""@eng , """primitive neuroectodermal tumor, peripheral"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C3489398"""^^xsd:string ; umls:cui """C0877849"""^^xsd:string ; umls:cui """C0206663"""^^xsd:string ; umls:cui """C0684337"""^^xsd:string ; umls:cui """C0553580"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/semustine/vincristine"""@eng ; skos:notation """CDR0000039467"""^^xsd:string ; skos:altLabel """CTX/MeCCNU/VCR"""@eng , """COM"""@eng ; ; ; ; """2100"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279321"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/etoposide/prednisone/teniposide/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039464"""^^xsd:string ; skos:altLabel """CTX/DNR/PRED/TG/VCR/VM-26/VP-16"""@eng ; ; ; ; ; ; ; ; """2098"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279319"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/vincristine"""@eng ; skos:notation """CDR0000039465"""^^xsd:string ; skos:altLabel """COB"""@eng , """BLEO/CDDP/VCR"""@eng ; ; ; ; """2099"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056020"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/etoposide/prednisone/teniposide/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039462"""^^xsd:string ; skos:altLabel """DNR/PRED/TG/VCR/VM-26/VP-16"""@eng ; ; ; ; ; ; ; """2096"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000039463"""^^xsd:string ; skos:altLabel """CMF-BLEO"""@eng , """BLEO/CTX/5-FU/MTX"""@eng ; ; ; ; ; """2097"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055983"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/cyclophosphamide/cytarabine/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039460"""^^xsd:string ; skos:altLabel """ARA-C/AZA/CTX/TG/VCR"""@eng ; ; ; ; ; ; """2094"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279315"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/teniposide"""@eng ; skos:notation """CDR0000039461"""^^xsd:string ; skos:altLabel """CTX/VM-26/VP-16"""@eng ; ; ; ; """2095"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279316"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal cancer"""@eng ; skos:notation """CDR0000038967"""^^xsd:string ; skos:altLabel """digestive cancer"""@eng ; rdfs:subClassOf ; """1523"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0685938"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """severe congenital neutropenia"""@eng ; skos:notation """CDR0000285983"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1853118"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hybridization, DNA Southern blotting"""@eng ; skos:notation """CDR0000043533"""^^xsd:string ; rdfs:subClassOf ; """8788"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796696"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypothyroidism"""@eng ; skos:notation """CDR0000489292"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """2006-06-05"""^^xsd:string ; umls:cui """C0020676"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EP-2101/Montanide ISA-51"""@eng ; skos:notation """CDR0000303804"""^^xsd:string ; skos:altLabel """EP2101/ISA-51"""@eng ; ; """2003-04-23"""^^xsd:string ; """2003-04-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327959"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hyperthyroidism"""@eng ; skos:notation """CDR0000489293"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """2006-06-05"""^^xsd:string ; umls:cui """C0020550"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/vincristine"""@eng ; skos:notation """CDR0000042410"""^^xsd:string ; skos:altLabel """ARA-C/VCR/VP-16"""@eng ; ; ; ; """5666"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian cancer, genetics of"""@eng ; skos:notation """CDR0000043538"""^^xsd:string ; skos:altLabel """breast cancer, genetics of"""@eng , """genetics of breast cancer"""@eng , """genetics of ovarian cancer"""@eng , """genetics of ovarian and breast cancer"""@eng , """breast and ovarian cancer, genetics of"""@eng ; """2002-10-15"""^^xsd:string ; """8793"""^^xsd:string ; umls:cui """C0879255"""^^xsd:string ; umls:tui """T091"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MK0646"""@eng ; skos:notation """CDR0000489297"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; umls:cui """C1831888"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbidopa/iodine I 131 metaiodobenzylguanidine/isotretinoin/methylprednisolone/metyrosine"""@eng ; skos:notation """CDR0000363635"""^^xsd:string ; skos:altLabel """CBD/13-CRA/DEMSER/I131-MIBG/MePRDL"""@eng ; ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541207"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbidopa"""@eng ; skos:notation """CDR0000363634"""^^xsd:string ; skos:altLabel """Lodosyn"""@eng , """CBD"""@eng , """methyldopahydrazine"""@eng , """Lodosin"""@eng ; ; """2004-03-24"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0700879"""^^xsd:string ; umls:cui """C0006982"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interleukin-1-beta"""@eng ; skos:notation """CDR0000040855"""^^xsd:string ; skos:altLabel """5-FU/IL-1B"""@eng ; ; ; """3890"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280480"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """good prognosis metastatic gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000040854"""^^xsd:string ; skos:altLabel """GTT, metastatic, good prognosis"""@eng , """metastatic GTT, good prognosis"""@eng , """GTT, good prognosis, metastatic"""@eng , """gestational trophoblastic tumor, good prognosis, metastatic"""@eng , """trophoblastic tumor, metastatic, good prognosis"""@eng , """gestational trophoblastic tumor, metastatic, good prognosis"""@eng , """good prognosis metastatic GTT"""@eng ; rdfs:subClassOf ; """gestational trophoblastic tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3889"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280479"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nonmetastatic gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000040853"""^^xsd:string ; skos:altLabel """nonmetastatic GTT"""@eng , """GTT, non-metastatic"""@eng , """gestational trophoblastic tumor, non-metastatic"""@eng , """non-metastatic gestational trophoblastic tumor"""@eng , """non-metastatic GTT"""@eng , """trophoblastic tumor, non-metastatic"""@eng ; rdfs:subClassOf ; """gestational trophoblastic tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3888"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280478"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000040852"""^^xsd:string ; skos:altLabel """GTT stage"""@eng , """gestational trophoblastic tumor stage"""@eng , """trophoblastic tumor stage, gestational"""@eng , """stage, GTT"""@eng ; rdfs:subClassOf ; """3887"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280477"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/fluorouracil"""@eng ; skos:notation """CDR0000040851"""^^xsd:string ; skos:altLabel """DFV"""@eng , """CDDP/5-FU/VP-16"""@eng ; ; ; ; """3886"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0115560"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/octreotide"""@eng ; skos:notation """CDR0000363632"""^^xsd:string ; skos:altLabel """IFN-A/SSTN"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541206"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult meningeal tumors"""@eng ; skos:notation """CDR0000377472"""^^xsd:string ; skos:altLabel """Brain tumor, adult: Meningeal tumors"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541318"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CMD-193"""@eng ; skos:notation """CDR0000489295"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """C52176"""^^xsd:string ; umls:cui """C1709067"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ret/PTC"""@eng ; skos:notation """CDR0000363639"""^^xsd:string ; rdfs:subClassOf ; """2004-03-24"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1541208"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TSHR"""@eng ; skos:notation """CDR0000363638"""^^xsd:string ; skos:altLabel """thyroid stimulating hormone receptor"""@eng ; rdfs:subClassOf ; """2004-03-24"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1336679"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hematoporphyrin derivative"""@eng ; skos:notation """CDR0000040859"""^^xsd:string ; skos:altLabel """Photofrin"""@eng , """HPD"""@eng ; """3897"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0729236"""^^xsd:string ; umls:cui """C0121300"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult anaplastic astrocytoma"""@eng ; skos:notation """CDR0000040858"""^^xsd:string ; skos:altLabel """anaplastic astrocytoma, adult"""@eng , """astrocytoma, adult anaplastic"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """3893"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280483"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/dexamethasone/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043395"""^^xsd:string ; skos:altLabel """ASP/CTX/DM/DNR/MTX/VCR"""@eng ; ; ; ; ; ; ; """7950"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796533"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/dexamethasone/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043394"""^^xsd:string ; skos:altLabel """ASP/DM/DNR/MTX/VCR"""@eng ; ; ; ; ; ; """7948"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796532"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000043397"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MP/MTX"""@eng ; ; ; ; ; """7953"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796535"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000043396"""^^xsd:string ; skos:altLabel """ASP/CTX/DNR/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; ; """7952"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796534"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/trastuzumab"""@eng ; skos:notation """CDR0000043391"""^^xsd:string ; skos:altLabel """dFdC/MOAB HER2"""@eng ; ; ; """7943"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796529"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flow cytometry"""@eng ; skos:notation """CDR0000043390"""^^xsd:string ; rdfs:subClassOf ; """7942"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0016263"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate"""@eng ; skos:notation """CDR0000043393"""^^xsd:string ; skos:altLabel """DM/MTX"""@eng ; ; ; """7947"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796531"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/prednisolone"""@eng ; skos:notation """CDR0000043392"""^^xsd:string ; skos:altLabel """MTX/PRDL"""@eng ; ; ; """7946"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796530"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/busulfan/fludarabine"""@eng ; skos:notation """CDR0000392734"""^^xsd:string ; skos:altLabel """ATG/BU/FAMP"""@eng ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541368"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """accelerated phase chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000039070"""^^xsd:string ; skos:altLabel """granulocytic leukemia, accelerated phase chronic"""@eng , """leukemia, accelerated phase chronic myelogenous"""@eng , """myelocytic leukemia, accelerated phase chronic"""@eng , """accelerated phase CGL"""@eng , """chronic myelocytic leukemia, accelerated phase"""@eng , """CGL, accelerated phase"""@eng , """chronic granulocytic leukemia, accelerated phase"""@eng , """CML, accelerated phase"""@eng , """accelerated phase CML"""@eng , """myelogenous leukemia, accelerated phase chronic"""@eng , """chronic myelogenous leukemia, accelerated phase"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """chronic myelogenous leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1656"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0023472"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """classic Kaposi's sarcoma"""@eng ; skos:notation """CDR0000039073"""^^xsd:string ; skos:altLabel """sarcoma, classical Kaposi's"""@eng , """classical multiple hemorrhagic sarcoma"""@eng , """sarcoma, classical multiple hemorrhagic"""@eng , """multiple hemorrhagic sarcoma, classical"""@eng , """Kaposi's sarcoma, classical"""@eng ; rdfs:subClassOf ; """Kaposi's sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1659"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279084"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """meningeal chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000039072"""^^xsd:string ; skos:altLabel """CML, meningeal"""@eng , """chronic granulocytic leukemia, meningeal"""@eng , """meningeal CML"""@eng , """myelocytic leukemia, meningeal chronic"""@eng , """CGL, meningeal"""@eng , """chronic myelogenous leukemia, meningeal"""@eng , """myelogenous leukemia, meningeal chronic"""@eng , """meningeal CGL"""@eng , """chronic myelocytic leukemia, meningeal"""@eng , """leukemia, meningeal chronic myelogenous"""@eng , """granulocytic leukemia, meningeal chronic"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """chronic myelogenous leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1658"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279083"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methotrexate/thioguanine"""@eng ; skos:notation """CDR0000043399"""^^xsd:string ; skos:altLabel """ARA-C/MTX/TG"""@eng ; ; ; ; """7955"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796537"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/mercaptopurine"""@eng ; skos:notation """CDR0000043398"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MP"""@eng ; ; ; ; ; """7954"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796536"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039077"""^^xsd:string ; skos:altLabel """acute lymphocytic leukemia, adult untreated"""@eng , """adult acute lymphocytic leukemia, untreated"""@eng , """untreated adult ALL"""@eng , """ALL, untreated adult"""@eng , """lymphocytic leukemia, untreated adult acute"""@eng , """untreated adult acute lymphocytic leukemia"""@eng , """leukemia, untreated adult acute lymphocytic"""@eng ; rdfs:subClassOf ; """adult acute lymphoblastic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1663"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279088"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinflunine"""@eng ; skos:notation """CDR0000419548"""^^xsd:string ; skos:altLabel """4'-Deoxy-20',20'-difluoro-C'-norvincaleukoblastine"""@eng ; skos:definition """A novel fluorinated Vinca alkaloid with superior antiangiogenesis and antitumor activities to that of two clinically useful Vinca alkaloids, vinorelbine and vinblastine. Although the detail mechanism of the mitotic block is not clear, vinflunine could induce G2 + M arrest, and cause a concentration-dependent reduction of the microtubular network of interphase cells, leading to apoptosis. This agent appears to function as a definite inhibitor of tubulin assembly, while exhibiting quantitatively different tubulin binding properties (with least binding capacity) to the classic Vinca alkaloids. Furthermore, vinflunine exhibits improved pharmacokinetic properties, including increased lipophilicity, and more resistant to metabolic degradation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=419548&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=419548&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61564\" NCI Thesaurus)"""@eng ; """2005-02-04"""^^xsd:string ; """2005-01-31"""^^xsd:string ; """162652-95-1"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61564"""^^xsd:string ; umls:cui """C0672663"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mercaptopurine"""@eng ; skos:notation """CDR0000041726"""^^xsd:string ; skos:altLabel """ARA-C/MP"""@eng ; ; ; """4896"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281315"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/vinblastine"""@eng ; skos:notation """CDR0000041727"""^^xsd:string ; skos:altLabel """CYSP/VBL"""@eng ; ; ; """4897"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281316"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mistletoe extract"""@eng ; skos:notation """CDR0000041724"""^^xsd:string ; skos:altLabel """Cefalektin"""@eng , """Plenosol N"""@eng , """Isugran"""@eng , """Apotheker Bauer's Misteltinktur"""@eng , """Mistel Curarina"""@eng , """Vysorel"""@eng , """Viscum"""@eng , """Mistelol-Kapseln"""@eng , """Viscysat"""@eng , """Viscum album Loranthacea"""@eng , """Iscar"""@eng , """Helixor"""@eng , """Isorel"""@eng , """Iscador"""@eng , """Eurixor"""@eng , """Lektinol"""@eng , """Mistel- Krautertabletten"""@eng ; skos:definition """An extract of the whole plant Viscum album (mistletoe) with potential biological response modifier (BRM) activity. Mistletoe extract may both stimulate the antitumoral functions of the immune system and have a direct toxic effect on tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41724&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41724&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2703\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """4894"""^^xsd:string ; """75882-01-8 (Helixor)"""^^xsd:string ; """53986-31-5 (Iscador)"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """C2703"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1513338"""^^xsd:string ; umls:cui """C0525160"""^^xsd:string ; umls:cui """C0063891"""^^xsd:string ; umls:cui """C0062189"""^^xsd:string ; umls:cui """C0949847"""^^xsd:string ; umls:cui """C0083075"""^^xsd:string ; umls:cui """C1513339"""^^xsd:string ; umls:cui """C1513333"""^^xsd:string ; umls:cui """C1513332"""^^xsd:string ; umls:cui """C1513335"""^^xsd:string ; umls:cui """C1513334"""^^xsd:string ; umls:cui """C1513337"""^^xsd:string ; umls:cui """C1513336"""^^xsd:string ; umls:cui """C1328245"""^^xsd:string ; umls:cui """C1328244"""^^xsd:string ; umls:cui """C0331018"""^^xsd:string ; umls:cui """C1166209"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T002"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TNP-470"""@eng ; skos:notation """CDR0000041725"""^^xsd:string ; skos:altLabel """(3R,4S,5S,6R)-5-Methoxy-4- [(2R,3R)-2-methyl-3-(3-methyl-2-butenyl) -oxiranyl]-1-oxaspiro [2,5] oct-6-yl(chloroacetyl) Carbamate"""@eng , """5-Methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl)carbamate"""@eng , """O-(Chloroacetylcarbamoyl)fumagillol"""@eng ; skos:definition """A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity. TNP-470 binds to and irreversibly inactivates methionine animopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis. This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41725&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41725&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1298\" NCI Thesaurus)"""@eng ; """4895"""^^xsd:string ; """129298-91-5"""^^xsd:string ; """C1298"""^^xsd:string ; """642492"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """40065"""^^xsd:string ; """2006-09-27"""^^xsd:string ; umls:cui """C0950779"""^^xsd:string ; umls:cui """C0081489"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/melphalan/methylprednisolone"""@eng ; skos:notation """CDR0000041722"""^^xsd:string ; skos:altLabel """DOX/L-PAM/MePRDL"""@eng ; ; ; ; """4892"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281313"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/methylprednisolone"""@eng ; skos:notation """CDR0000041723"""^^xsd:string ; skos:altLabel """L-PAM/MePRDL"""@eng ; ; ; """4893"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281314"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/idarubicin"""@eng ; skos:notation """CDR0000041720"""^^xsd:string ; skos:altLabel """ARA-C/IDA/VP-16"""@eng , """ICE"""@eng ; ; ; ; """4890"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0249492"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexverapamil/etoposide/idarubicin"""@eng ; skos:notation """CDR0000041721"""^^xsd:string ; skos:altLabel """ARA-C/IDA/R-VPAM/VP-16"""@eng ; ; ; ; ; """4891"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281312"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamoxifen/vinblastine"""@eng ; skos:notation """CDR0000041728"""^^xsd:string ; skos:altLabel """TMX/VBL"""@eng ; ; ; """4899"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """osteosarcoma"""@eng ; skos:notation """CDR0000041729"""^^xsd:string ; skos:altLabel """Osteosarcoma"""@eng , """osteogenic sarcoma"""@eng , """sarcoma, osteogenic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """49"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0029463"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000041898"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/VCR"""@eng ; ; ; ; """5116"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281456"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """meropenem"""@eng ; skos:notation """CDR0000041899"""^^xsd:string ; skos:altLabel """Meropenem Trihydrate"""@eng , """SM-7338"""@eng , """Merrem I.V."""@eng ; skos:definition """A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41899&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41899&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1160\" NCI Thesaurus)"""@eng ; """5117"""^^xsd:string ; """C1160"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-19"""^^xsd:string ; """119478-56-7"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0740029"""^^xsd:string ; umls:cui """C0066005"""^^xsd:string ; umls:cui """C1513141"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/methylprednisolone/prednisone/vincristine"""@eng ; skos:notation """CDR0000041894"""^^xsd:string ; skos:altLabel """CTX/DOX/MePRDL/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """5112"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/tamoxifen"""@eng ; skos:notation """CDR0000041895"""^^xsd:string ; skos:altLabel """CDDP/TMX/VP-16"""@eng ; ; ; ; """5113"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281453"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/bropirimine"""@eng ; skos:notation """CDR0000041896"""^^xsd:string ; skos:altLabel """ABPP/BC-G"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """5114"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281454"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium/milodistim"""@eng ; skos:notation """CDR0000041897"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/5-FU/PIXY321"""@eng ; ; ; ; ; ; """5115"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281455"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/paclitaxel"""@eng ; skos:notation """CDR0000041890"""^^xsd:string ; skos:altLabel """CF/5-FU/TAX"""@eng ; ; ; ; """5106"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281448"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/fluorouracil/leucovorin calcium/paclitaxel"""@eng ; skos:notation """CDR0000041891"""^^xsd:string ; skos:altLabel """CF/5-FU/G-CSF/TAX"""@eng ; ; ; ; ; """5107"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281449"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edatrexate/leucovorin calcium"""@eng ; skos:notation """CDR0000041892"""^^xsd:string ; skos:altLabel """CF/EDAM"""@eng ; ; ; """5109"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281450"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/cytarabine/etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000041893"""^^xsd:string ; skos:altLabel """ARA-C/CYSP/DHAD/VP-16"""@eng ; ; ; ; ; """5110"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281451"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gene expression"""@eng ; skos:notation """CDR0000474394"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2006-03-17"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0017262"""^^xsd:string ; umls:tui """T045"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamsulosin hydrochloride"""@eng ; skos:notation """CDR0000479148"""^^xsd:string ; skos:altLabel """Flomax"""@eng ; skos:definition """The hydrochloride salt of tamsulosin, a sulfonamide derivative with adrenergic antagonist activity. Tamsulosin selectivity binds to and blocks the activity of alpha1 adrenoreceptors in the human prostate and bladder neck; blockade of these adrenoceptors can cause smooth muscle in the prostate and bladder neck to relax, resulting in an improvement in urine flow rate. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=479148&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=479148&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29486\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """C29486"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0662903"""^^xsd:string ; umls:cui """C0771774"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin HCl liposome/thalidomide"""@eng ; skos:notation """CDR0000415354"""^^xsd:string ; skos:altLabel """DM/LipoDox/THAL"""@eng ; ; ; ; """2005-01-07"""^^xsd:string ; """2005-01-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin HCl liposome/mitomycin"""@eng ; skos:notation """CDR0000258432"""^^xsd:string ; skos:altLabel """CDDP/LipoDox/MITO"""@eng ; ; ; ; """2002-10-15"""^^xsd:string ; """11515"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327821"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus 5-tumor necrosis factor alpha"""@eng ; skos:notation """CDR0000258431"""^^xsd:string ; skos:altLabel """Ad5-TNFa"""@eng , """tumor necrosis factor adenovirus 5 vector"""@eng , """Ad 5-TNF Alpha"""@eng , """AdGV11-TNFalpha"""@eng , """TNFerade"""@eng ; skos:definition """A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258431&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258431&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26444\" NCI Thesaurus)"""@eng ; ; ; """11514"""^^xsd:string ; """C26444"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-02-17"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1327820"""^^xsd:string ; umls:cui """C1327819"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000038218"""^^xsd:string ; skos:altLabel """CF/5-FU/MOAB VEGF"""@eng ; ; ; ; """10826"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935792"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/irinotecan"""@eng ; skos:notation """CDR0000038219"""^^xsd:string ; skos:altLabel """CPT-11/MOAB VEGF"""@eng ; ; ; """10827"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935793"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/thalidomide"""@eng ; skos:notation """CDR0000038212"""^^xsd:string ; skos:altLabel """FAMP/THAL"""@eng ; ; ; """10813"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935787"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benzoylphenylurea"""@eng ; skos:notation """CDR0000038213"""^^xsd:string ; skos:altLabel """BPU"""@eng ; skos:definition """A low molecular weight agent with antineoplastic activity. Benzoylphenylurea binds to the colchicine binding site on tubulin, thereby blocking tubulin polymerization and disrupting mitotic function. This agent also inhibits DNA polymerase, and has been shown to arrest leukemia cells in the G1-S transition phase of the cell cycle. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38213&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38213&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2618\" NCI Thesaurus)"""@eng ; """10818"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """61039"""^^xsd:string ; """639829"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C2618"""^^xsd:string ; umls:cui """C0935907"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol/dexamethasone"""@eng ; skos:notation """CDR0000038210"""^^xsd:string ; skos:altLabel """CALTROL/DM"""@eng ; ; ; """10811"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935786"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """karenitecin"""@eng ; skos:notation """CDR0000038211"""^^xsd:string ; skos:altLabel """BNP1350"""@eng , """BNP 1350"""@eng ; skos:definition """A synthetic silicon-containing agent related to camptothecin with antineoplastic properties. Karenitecin stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis. Because it is lipophilic, karenitecin exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38211&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38211&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1877\" NCI Thesaurus)"""@eng ; """10812"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1877"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """710270"""^^xsd:string ; umls:cui """C0913202"""^^xsd:string ; umls:cui """C0935985"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000038216"""^^xsd:string ; skos:altLabel """fowlpox-CEA-B7-1/ICAM-1/LFA-3"""@eng , """rF-CEA(6D)TRICOM"""@eng , """fCEA-TRI"""@eng ; skos:definition """A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA) and TRICOM. TRICOM is comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38216&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38216&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2620\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """10821"""^^xsd:string ; """710068"""^^xsd:string ; """9306"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C2620"""^^xsd:string ; umls:cui """C0935790"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide phosphate/ifosfamide"""@eng ; skos:notation """CDR0000038217"""^^xsd:string ; skos:altLabel """CBDCA/ETOP/IFF"""@eng ; ; ; ; """10825"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935791"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penile cancer"""@eng ; skos:notation """CDR0000038214"""^^xsd:string ; skos:altLabel """penis cancer"""@eng , """Penile cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1082"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153601"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000038215"""^^xsd:string ; skos:altLabel """rV-CEA(6D)/TRICOM"""@eng , """vaccinia-CEA-B7.1/ICAM1/LFA-3"""@eng , """vCEA-TRI"""@eng ; skos:definition """A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a triad of costimulatory molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with vaccinia-CEA-TRICOM stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38215&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38215&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2619\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """10820"""^^xsd:string ; """9306"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2619"""^^xsd:string ; """710067"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0935789"""^^xsd:string ; umls:cui """C1328668"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cyclophosphamide/methotrexate"""@eng ; skos:notation """CDR0000365677"""^^xsd:string ; skos:altLabel """CTX/MOAB VEGF/MTX"""@eng ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541219"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iloprost"""@eng ; skos:notation """CDR0000365679"""^^xsd:string ; skos:altLabel """iloprost clathrate"""@eng , """Pentanoic Acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)"""@eng , """(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric Acid"""@eng , """Ciloprost"""@eng , """ZK 36374"""@eng , """Ventavis"""@eng ; skos:definition """A prostacyclin analogue with potential chemopreventive activity. Iloprost binds to the prostacyclin receptor in various target cells, thereby causing vasodilation, inhibition of platelet aggregation, and decreased tumor cell adhesion to endothelium among other effects. Prostacyclin is a naturally occurring eicosanoid with anti-inflammatory, antineoplastic, and anti-metastatic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=365679&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=365679&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48397\" NCI Thesaurus)"""@eng ; """2004-04-23"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """C48397"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733549"""^^xsd:string ; umls:cui """C0079594"""^^xsd:string ; umls:cui """C1704333"""^^xsd:string ; umls:cui """C1541936"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/paclitaxel"""@eng ; skos:notation """CDR0000365678"""^^xsd:string ; skos:altLabel """TAX/ZD 1839"""@eng ; ; ; """2004-04-23"""^^xsd:string ; """2004-04-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541220"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/pegylated doxorubicin HCl liposome"""@eng ; skos:notation """CDR0000269243"""^^xsd:string ; skos:altLabel """CBDCA/PEG-LD"""@eng ; ; """2002-12-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-09"""^^xsd:string ; umls:cui """C1327849"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Liposomal-Encapsulated Doxorubicin"""@eng ; skos:notation """CDR0000269242"""^^xsd:string ; skos:altLabel """Pegylated Liposomal Doxorubicin Hydrochloride"""@eng , """Liposomal Doxorubicin Hydrochloride"""@eng , """(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride"""@eng , """Doxorubicin Hydrochloride Liposomal"""@eng , """DOX-SL"""@eng , """Pegylated Liposomal Doxorubicin"""@eng , """Liposomal Adriamycin"""@eng , """TLC D-99"""@eng , """Doxorubicin HCl Liposome"""@eng , """Liposomal Doxorubicin"""@eng , """Doxilen"""@eng , """Sterically Stabilized Liposome"""@eng , """Caelyx"""@eng , """Doxil"""@eng , """PEG-LD"""@eng , """Doxorubicin Hydrochloride Liposome Injection"""@eng , """Doxorubicin Hydrochloride Liposome"""@eng , """S-Liposomal Doxorubicin"""@eng , """Stealth Liposomal Doxorubicin"""@eng , """LipoDox"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2002-12-04"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """31919"""^^xsd:string ; """712227"""^^xsd:string ; """C1555"""^^xsd:string ; umls:cui """C1522689"""^^xsd:string ; umls:cui """C1704361"""^^xsd:string ; umls:cui """C0701184"""^^xsd:string ; umls:cui """C0701182"""^^xsd:string ; umls:cui """C0701183"""^^xsd:string ; umls:cui """C0279284"""^^xsd:string ; umls:cui """C1522683"""^^xsd:string ; umls:cui """C1512061"""^^xsd:string ; umls:cui """C0717726"""^^xsd:string ; umls:cui """C1522690"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """scirrhous carcinoma of the colon"""@eng ; skos:notation """CDR0000039929"""^^xsd:string ; skos:altLabel """carcinoma of the colon, scirrhous"""@eng , """colon, scirrhous carcinoma of the"""@eng ; rdfs:subClassOf ; """2609"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279642"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute promyelocytic leukemia (M3)"""@eng ; skos:notation """CDR0000039928"""^^xsd:string ; skos:altLabel """childhood acute progranulocytic leukemia"""@eng , """progranulocytic leukemia, childhood acute"""@eng , """leukemia, childhood acute promyelocytic"""@eng , """promyelocytic leukemia, childhood acute"""@eng , """APL, pediatric"""@eng , """acute promyelocytic leukemia, childhood"""@eng , """pediatric acute M3 leukemia"""@eng , """M3 leukemia, childhood acute"""@eng , """M3 childhood APL"""@eng , """acute progranulocytic leukemia, childhood"""@eng , """pediatric acute promyelocytic leukemia"""@eng , """M3 childhood acute promyelocytic leukemia"""@eng , """childhood APL"""@eng , """M3 pediatric acute promyelocytic leukemia"""@eng , """childhood acute M3 leukemia"""@eng , """APL, childhood"""@eng , """pediatric APL"""@eng , """pediatric acute progranulocytic leukemia"""@eng ; rdfs:subClassOf ; """2608"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279641"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PD0325901"""@eng ; skos:notation """CDR0000456780"""^^xsd:string ; skos:definition """A synthetic, organic, mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor with potential antineoplastic activity. PD325901 selectively binds to and inhibits MEK, thereby preventing phosphorylation and activation of MAPKs 1 and 2, which may result in inhibition of tumor cell proliferation. MEK is phosphorylated and activated by Raf. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456780&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456780&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52195\" NCI Thesaurus)"""@eng ; """2006-09-08"""^^xsd:string ; """C52195"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-11-25"""^^xsd:string ; umls:cui """C1675748"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute myeloblastic leukemia with maturation (M2)"""@eng ; skos:notation """CDR0000039923"""^^xsd:string ; skos:altLabel """childhood acute M2 leukemia"""@eng , """pediatric acute M2 leukemia"""@eng , """pediatric acute granulocytic leukemia"""@eng , """acute granulocytic leukemia, childhood"""@eng , """AGL, childhood"""@eng , """granulocytic leukemia, childhood acute"""@eng , """childhood AML with maturation"""@eng , """AGL, pediatric"""@eng , """pediatric AGL"""@eng , """M2 childhood acute myeloblastic leukemia with maturation"""@eng , """M2 childhood AML with maturation"""@eng , """pediatric acute myeloblastic leukemia with maturation"""@eng , """childhood acute granulocytic leukemia"""@eng , """M2 leukemia, childhood acute"""@eng ; rdfs:subClassOf ; """2603"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220621"""^^xsd:string ; umls:cui """C0279636"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diffuse adenocarcinoma of the stomach"""@eng ; skos:notation """CDR0000039922"""^^xsd:string ; skos:altLabel """gastric cancer, diffuse adenocarcinoma"""@eng , """stomach, diffuse adenocarcinoma of the"""@eng , """stomach cancer, diffuse adenocarcinoma"""@eng ; rdfs:subClassOf ; """2602"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279635"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the colon"""@eng ; skos:notation """CDR0000039921"""^^xsd:string ; skos:altLabel """colon cancer, adenocarcinoma"""@eng , """colon, adenocarcinoma of the"""@eng ; rdfs:subClassOf ; """2601"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0338106"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute myeloblastic leukemia without maturation (M1)"""@eng ; skos:notation """CDR0000039920"""^^xsd:string ; skos:altLabel """childhood acute M1 leukemia"""@eng , """pediatric acute myeloblastic leukemia"""@eng , """pediatric acute myeloblastic leukemia without maturation"""@eng , """acute myeloblastic leukemia, childhood"""@eng , """leukemia, childhood acute myeloblastic"""@eng , """childhood acute myeloblastic leukemia"""@eng , """M1 leukemia, childhood acute"""@eng , """pediatric acute M1 leukemia"""@eng , """myeloblastic leukemia, childhood acute"""@eng , """M1 childhood AML without maturation"""@eng , """childhood AML without maturation"""@eng , """M1 childhood acute myeloblastic leukemia without maturation"""@eng , """M1 pediatric acute myeloblastic leukemia without maturation"""@eng ; rdfs:subClassOf ; """2600"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220621"""^^xsd:string ; umls:cui """C0279634"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """signet ring adenocarcinoma of the colon"""@eng ; skos:notation """CDR0000039927"""^^xsd:string ; skos:altLabel """adenocarcinoma of the colon, signet ring"""@eng , """colon, signet ring adenocarcinoma of the"""@eng ; rdfs:subClassOf ; """2607"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279640"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mucinous adenocarcinoma of the colon"""@eng ; skos:notation """CDR0000039926"""^^xsd:string ; skos:altLabel """colloid adenocarcinoma of the colon"""@eng , """adenocarcinoma of the colon, colloid"""@eng , """colon, mucinous adenocarcinoma of the"""@eng ; rdfs:subClassOf ; """2606"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279639"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed adenocarcinoma of the stomach"""@eng ; skos:notation """CDR0000039925"""^^xsd:string ; skos:altLabel """stomach cancer, mixed adenocarcinoma"""@eng , """gastric cancer, mixed adenocarcinoma"""@eng , """stomach, mixed adenocarcinoma of the"""@eng ; rdfs:subClassOf ; """2605"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279638"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of the anus"""@eng ; skos:notation """CDR0000039924"""^^xsd:string ; skos:altLabel """anal cancer, squamous cell carcinoma"""@eng , """anal cancer, epidermoid carcinoma"""@eng , """epidermoid carcinoma of the anus"""@eng , """anus cancer, squamous cell carcinoma"""@eng , """anus cancer, epidermoid carcinoma"""@eng ; rdfs:subClassOf ; """2604"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1412036"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """siRNA-expressing SV40 vector"""@eng ; skos:notation """CDR0000492229"""^^xsd:string ; """2006-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62536"""^^xsd:string ; """2006-09-20"""^^xsd:string ; umls:cui """C1831908"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HER-2/neu intracellular domain protein"""@eng ; skos:notation """CDR0000038047"""^^xsd:string ; skos:altLabel """HER-2/neu ICD Protein"""@eng , """HER-2 ICD Peptide"""@eng ; skos:definition """A peptide fragment of the carboxyl terminal and the intracellular domain (ICD) of HER2/neu protein. HER-2/neu protein, a glycoprotein of cell surface receptor, is overexpressed by many adenocarcinomas including breast adenocarcinoma. Based on sensitization theory, co-administration of trastuzumab (anti HER-2/neu monoclonal antibody) and HER2 ICD peptide may result in the potentiation of a HER-2 specific CTL response in breast cancer patients via MHC class I antigen presentation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38047&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38047&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2593\" NCI Thesaurus)"""@eng ; """10567"""^^xsd:string ; """C2593"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C3146228"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T192"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenretinide lipid matrix"""@eng ; skos:notation """CDR0000468556"""^^xsd:string ; skos:altLabel """Fenretinide Lym-X-Sorb"""@eng , """fenretinide LXS"""@eng ; """Drug/agent"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """2006-11-01"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831748"""^^xsd:string ; umls:cui """C1831747"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """congenital amegakaryocytic thrombocytopenia"""@eng ; skos:notation """CDR0000285975"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C1327915"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/gemcitabine/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000037973"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/MOAB HER2/TAX"""@eng ; ; ; ; ; """10391"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thrombocytopenia-absent radius syndrome"""@eng ; skos:notation """CDR0000285979"""^^xsd:string ; skos:altLabel """TAR syndrome"""@eng , """thrombocytopenia-absent radii syndrome"""@eng ; """2003-02-21"""^^xsd:string ; """2003-02-19"""^^xsd:string ; """Genetic condition"""^^xsd:string ; umls:cui """C0175703"""^^xsd:string ; umls:tui """T019"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2 gene"""@eng ; skos:notation """CDR0000038045"""^^xsd:string ; skos:altLabel """IL-2 gene"""@eng ; skos:definition """The DNA sequence that encodes the protein cytokine interleukin-2 (IL-2). When introduced as the complementary DNA (cDNA) form into tumor cells by, for example, a genetically engineered adenovirus vector, the transfected IL-2 cDNA expresses IL-2 which may activate antitumoral natural killer cells and elicit an antitumoral cytotoxic T-cell response, resulting in an inhibition of tumor progression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38045&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38045&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2549\" NCI Thesaurus)"""@eng ; ; """10565"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C2549"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879590"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/filgrastim/fludarabine"""@eng ; skos:notation """CDR0000037971"""^^xsd:string ; skos:altLabel """ARA-C/FAMP/G-CSF"""@eng ; ; ; ; """10389"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879509"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/cisplatin/docetaxel"""@eng ; skos:notation """CDR0000368788"""^^xsd:string ; skos:altLabel """CAPE/CDDP/TXT"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-04-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541232"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lycopene"""@eng ; skos:notation """CDR0000037976"""^^xsd:string ; skos:altLabel """Lyc-O-Mato"""@eng , """psi,psi-Carotene"""@eng , """all-trans-Lycopene"""@eng , """LYCO"""@eng ; skos:definition """A linear, unsaturated hydrocarbon carotenoid, the major red pigment in fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava. As a class, carotenoids are pigment compounds found in photosynthetic organisms (plants, algae, and some types of fungus), and are chemically characterized by a large polyene chain containing 35-40 carbon atoms; some carotenoid polyene chains are terminated by two 6-carbon rings. In animals, carotenoids such as lycopene may possess antioxidant properties which may retard ageing and many degenerative diseases. As an essential nutrient, lycopene is required in the animal diet. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37976&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37976&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2226\" NCI Thesaurus)"""@eng ; ; """10394"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """407322"""^^xsd:string ; """502-65-8"""^^xsd:string ; """C2226"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0965256"""^^xsd:string ; umls:cui """C1700635"""^^xsd:string ; umls:cui """C0065331"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenethyl isothiocyanate"""@eng ; skos:notation """CDR0000037977"""^^xsd:string ; skos:altLabel """PEITC"""@eng ; """10396"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0070558"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multiple myeloma and other plasma cell neoplasms"""@eng ; skos:notation """CDR0000037974"""^^xsd:string ; skos:altLabel """Multiple myeloma / Plasma cell neoplasm"""@eng , """neoplasm, plasma cell"""@eng , """myeloma, plasma cell"""@eng , """plasma cell neoplasms"""@eng , """multiple myeloma"""@eng , """plasma cell myeloma"""@eng ; rdfs:subClassOf ; """10392"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """2006-03-28"""^^xsd:string ; umls:cui """C0026764"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide/thalidomide"""@eng ; skos:notation """CDR0000037975"""^^xsd:string ; skos:altLabel """THAL/TMZ"""@eng ; ; ; """10393"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879513"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daclizumab/methylprednisolone"""@eng ; skos:notation """CDR0000271170"""^^xsd:string ; skos:altLabel """MePRDL/MOAB anti-Tac"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327874"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nesiritide"""@eng ; skos:notation """CDR0000434520"""^^xsd:string ; skos:altLabel """L-Histidine, L-seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-arginyl-L-lysyl-L-methionyl-L-alpha-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-, Cyclic (10-26)-disulfide"""@eng , """Natriuretic Peptide Type-B"""@eng , """Natriuretic factor-32"""@eng , """Natrecor"""@eng , """Human Brain Natriuretic Factor-32"""@eng , """1,2-Dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane, Cyclic Peptide Derivative"""@eng ; skos:definition """A recombinant version of the cardiac neurohormone, human B-type natriuretic peptide (hBNP) produced by the ventricular myocardium. Nesiritide binds to natriuretic peptide receptors on vascular smooth muscle and endothelial cells, through which it triggers guanylate cyclase dependent signal transduction resulting in increase of intracellular concentrations of cGMP. This leads to smooth muscle cell relaxation causing arterial and venous dilatation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434520&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=434520&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47636\" NCI Thesaurus)"""@eng ; """2005-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-05-20"""^^xsd:string ; """124584-08-3"""^^xsd:string ; """C47636"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0054015"""^^xsd:string ; umls:cui """C1170421"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/doxorubicin/fluorouracil"""@eng ; skos:notation """CDR0000039673"""^^xsd:string ; skos:altLabel """FAB"""@eng , """BCNU/DOX/5-FU"""@eng ; ; ; ; """2328"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0059994"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fever, sweats, and hot flashes"""@eng ; skos:notation """CDR0000039672"""^^xsd:string ; skos:altLabel """management of fever, sweats, and hot flashes"""@eng ; rdfs:subClassOf ; """2327"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0279456"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039671"""^^xsd:string ; skos:altLabel """VMV"""@eng , """MTX/VCR/VP-16"""@eng ; ; ; ; """2326"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078404"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/levamisole"""@eng ; skos:notation """CDR0000039670"""^^xsd:string ; skos:altLabel """IFN-G/LEV"""@eng ; ; ; """2325"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279454"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laser surgery"""@eng ; skos:notation """CDR0000039677"""^^xsd:string ; skos:altLabel """conventional laser therapy"""@eng , """surgery, laser"""@eng , """laser therapy, conventional"""@eng ; ; rdfs:subClassOf ; ; rdfs:subClassOf ; """2331"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0023087"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """photodynamic therapy"""@eng ; skos:notation """CDR0000039676"""^^xsd:string ; skos:altLabel """Light Infusion Therapy™"""@eng , """PDT"""@eng , """Light Infusion Therapy![TRADE MARK SIGN]!"""@eng , """therapy, photodynamic"""@eng ; ; rdfs:subClassOf ; """2002-10-08"""^^xsd:string ; """2330"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0031740"""^^xsd:string ; umls:cui """C1328242"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin"""@eng ; skos:notation """CDR0000039675"""^^xsd:string ; skos:altLabel """actinomycin D"""@eng , """Dactinomycine"""@eng , """Actinomycin X 1"""@eng , """Cosmegen"""@eng , """actinomycin-C1"""@eng , """Actinomycin I1"""@eng , """actinomycin C1"""@eng , """Actinomycin A IV"""@eng , """2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3"""@eng , """Lyovac Cosmegen"""@eng , """AD"""@eng , """Actinomycin-[thr-val-pro-sar-meval]"""@eng , """actinomycin-D"""@eng , """ACT-D"""@eng , """Actinomycin IV"""@eng , """DACT"""@eng , """Meractinomycin"""@eng ; skos:definition """A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39675&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39675&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C412\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """233"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """928"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3053"""^^xsd:string ; """C412"""^^xsd:string ; """50-76-0"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701095"""^^xsd:string ; umls:cui """C0010934"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000039674"""^^xsd:string ; skos:altLabel """VOCAP"""@eng , """CDDP/CTX/DOX/VCR/VP-16"""@eng ; ; ; ; ; ; """2329"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0111342"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """creatine"""@eng ; skos:notation """CDR0000361777"""^^xsd:string ; skos:altLabel """Glycine, N-(aminoiminomethyl)-N-methyl-"""@eng ; skos:definition """An endogenous amino acid derivative produced by vertebrate animals and occurring primarily in muscle cells. Creatine is important for energy storage; it is phosphorylated to creatine phosphate, which serves as a phosphate donor in the conversion of ADP to ATP and supplies energy necessary for muscle contraction. Dietary supplementation with creatine may improve muscle wasting associated with cancer and other chronic diseases. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361777&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361777&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37937\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """C37937"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C0010286"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium carbonate"""@eng ; skos:notation """CDR0000039679"""^^xsd:string ; skos:altLabel """CaCO3"""@eng ; skos:definition """The carbonic salt of calcium (CaCO3). Calcium carbonate is used therapeutically as a phosphate buffer in hemodialysis, as an antacid in gastric hyperacidity for temporary relief of indigestion and heartburn, and as a calcium supplement for preventing and treating osteoporosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39679&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39679&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C332\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """2333"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """471-34-1"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C332"""^^xsd:string ; umls:cui """C0006681"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """UV light therapy"""@eng ; skos:notation """CDR0000039678"""^^xsd:string ; skos:altLabel """light therapy, UV"""@eng , """therapy, UV light"""@eng ; ; rdfs:subClassOf ; """2332"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0041626"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000380935"""^^xsd:string ; skos:altLabel """MOAB CD52/MP/MTX"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541347"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisolone/teniposide"""@eng ; skos:notation """CDR0000039589"""^^xsd:string ; skos:altLabel """CTX/PRDL/VM-26"""@eng , """PEP"""@eng ; ; ; ; """2244"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279386"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian undifferentiated adenocarcinoma"""@eng ; skos:notation """CDR0000039588"""^^xsd:string ; skos:altLabel """undifferentiated adenocarcinoma, ovarian"""@eng , """adenocarcinoma, ovarian undifferentiated"""@eng ; rdfs:subClassOf ; """2242"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279385"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039581"""^^xsd:string ; skos:altLabel """ARA-C/PRED/VCR"""@eng , """OAP"""@eng ; ; ; ; """2236"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0069290"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody OKT3"""@eng ; skos:notation """CDR0000039580"""^^xsd:string ; skos:altLabel """Muromonab-CD3 Monoclonal Antibody"""@eng , """OKT3"""@eng , """MOAB OKT 3"""@eng , """monoclonal antibody OKT 3"""@eng , """MOAB OKT3"""@eng , """Anti-CD3 monoclonal antibody OKT3"""@eng , """Orthoclone"""@eng , """Anti-CD3 monoclonal antibody OKT 3"""@eng ; skos:definition """An anti-CD3 monoclonal antibody with immunosuppressive activity. Monoclonal Antibody OKT3 binds to and blocks the function of the CD3 receptor molecule in the membrane of human T cells. In in vitro cytolytic assays, this agent blocks both the generation and function of effector T cells. Binding of monoclonal antibody OKT3 to CD3-positive T cells, results in early activation of this T cell subset, followed by cytokine release and inhibition of CD3-positive T cell functions. CD3 has been associated in vitro with the antigen recognition structure of T cells and is essential for signal transduction. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39580&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39580&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1321\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """2235"""^^xsd:string ; """C1321"""^^xsd:string ; """3860"""^^xsd:string ; """6883"""^^xsd:string ; """618843"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3546"""^^xsd:string ; """2851"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1513458"""^^xsd:string ; umls:cui """C0085379"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/semustine/vincristine"""@eng ; skos:notation """CDR0000039583"""^^xsd:string ; skos:altLabel """5-FU/MeCCNU/VCR"""@eng , """MOF"""@eng ; ; ; ; """2238"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066686"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenretinide"""@eng ; skos:notation """CDR0000039582"""^^xsd:string ; skos:altLabel """all-trans-N-(4-Hydroxyphenyl)retinamide"""@eng , """4-(all-trans-retino-yl)aminophenol"""@eng , """All-trans-4'-Hydroxyretinanilide"""@eng , """N-(4-hydroxyphenyl)retinamide"""@eng , """4-hydroxyphenylretinamide"""@eng , """Fenretinimide"""@eng , """4-HPR"""@eng , """McN-R-1967"""@eng , """all-trans-N-4'-hydroxyretinanilide"""@eng ; skos:definition """An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types. This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39582&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39582&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1098\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """2237"""^^xsd:string ; """40294"""^^xsd:string ; """65646-68-6"""^^xsd:string ; """374551"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C1098"""^^xsd:string ; umls:cui """C0750611"""^^xsd:string ; umls:cui """C0060197"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colorectal cancer"""@eng ; skos:notation """CDR0000039585"""^^xsd:string ; rdfs:subClassOf ; """224"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1527249"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039584"""^^xsd:string ; skos:altLabel """OMAD"""@eng , """DACT/DOX/MTX/VCR"""@eng ; ; ; ; ; """2239"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279383"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """echinomycin"""@eng ; skos:notation """CDR0000039587"""^^xsd:string ; skos:altLabel """Quinomycin A"""@eng , """Bis-Quinoline Analogue"""@eng , """BRN 0078671"""@eng , """Levomycin"""@eng , """SK 302B"""@eng , """Echinomycin A"""@eng , """N,N'-(2,4,12,15,17,25-hexamethyl-11,24-bis(1-methylethyl)-27-(methylthio)-3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo(12.12.3)nonacosane-7,20-diyl)bis(2-quinoxalinecarboxamide)"""@eng , """quinomycin A"""@eng ; skos:definition """A polypeptide quinoxaline antineoplastic antibiotic isolated from the bacterium Streptomyces echinatus. Echinomycin intercalates into DNA at two locations simultaneously in a sequence-specific fashion, thereby inhibiting DNA replication and RNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39587&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39587&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C462\" NCI Thesaurus)"""@eng ; """2241"""^^xsd:string ; """512-64-1"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """526417"""^^xsd:string ; """19671"""^^xsd:string ; """C462"""^^xsd:string ; umls:cui """C1527289"""^^xsd:string ; umls:cui """C0013508"""^^xsd:string ; umls:cui """C1527290"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000039586"""^^xsd:string ; skos:altLabel """CLB/5-FU/MTX"""@eng , """LMF"""@eng ; ; ; ; """2240"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065134"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-citrulline"""@eng ; skos:notation """CDR0000464795"""^^xsd:string ; skos:altLabel """citrulline"""@eng , """2-amino-5-(carbamoylamino)pentanoic acid"""@eng ; skos:definition """A non-essential amino acid. In hepatocytes, L-citrulline is synthesized in the urea cycle by the addition of carbon dioxide and ammonia to ornithine. L-citrulline is converted into L-arginine by the enzymes argininosuccinate synthetase and argininosuccinate lyase in the presence of L-aspartate and ATP. Subsequently, L-arginine is converted to nitric oxide by nitric oxide synthase and L-citrulline is regenerated as a by-product . Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464795&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464795&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53406\" NCI Thesaurus)"""@eng ; """C53406"""^^xsd:string ; """2006-06-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C0008864"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CNGRC peptide-TNF alpha conjugate"""@eng ; skos:notation """CDR0000403156"""^^xsd:string ; skos:altLabel """NGR-TNF"""@eng , """NGR-hTNF"""@eng , """CNGRC peptide-tumor necrosis factor alpha conjugate"""@eng , """tumor vasculature-targeted tumor necrosis factor alpha"""@eng ; skos:definition """A cytokine-peptide conjugate composed of the cytokine tumor necrosis factor alpha (TNF-alpha) chemically linked to the peptide CNGRC. The peptide moiety CNGRC, a ligand for the membrane-bound metalloprotease CD13, binds to endothelial cells of the angiogenic vasculature that express CD13 (also known as aminopeptidase N); subsequently, the TNF-alpha moiety induces apoptosis in endothelial cells expressing CD13, thereby inhibiting tumor-associated angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=403156&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=403156&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48383\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """C48383"""^^xsd:string ; """2004-11-22"""^^xsd:string ; umls:cui """C1143119"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PR-104"""@eng ; skos:notation """CDR0000492222"""^^xsd:string ; skos:altLabel """PR104"""@eng ; skos:definition """A non-toxic small molecule prodrug with potential antitumor activity. PR-104 is activated via reduction reaction under hypoxic conditions, such as seen in hypoxic tumors. Activated PR-104 causes DNA damage, and inhibits DNA replication, thereby leading to hypoxic tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492222&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=492222&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61590\" NCI Thesaurus)"""@eng ; """2006-09-20"""^^xsd:string ; """2006-06-23"""^^xsd:string ; """C61590"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831907"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ADH-1"""@eng ; skos:notation """CDR0000462569"""^^xsd:string ; skos:altLabel """Exherin"""@eng ; skos:definition """A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and anti-angiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, a transmembrane glycoprotein of the cadherin superfamily of proteins. Inhibition of N-cadherin-mediated cell-cell binding may lead to disruption of tumor vasculature, inhibition of tumor cell growth, and induction of apoptosis. Involved in calcium- mediated cell-cell adhesion and signaling mechanisms, N-cadherin is found on the surfaces of liver and colorectal tumor cells, and the endothelial cells and pericytes of tumor blood vessels. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462569&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462569&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53399\" NCI Thesaurus)"""@eng ; """2006-06-28"""^^xsd:string ; """C53399"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1706643"""^^xsd:string ; umls:cui """C1706644"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PF-00299804"""@eng ; skos:notation """CDR0000462567"""^^xsd:string ; skos:definition """A highly selective, small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with potential antineoplastic activity. PF-00299804 specifically binds to and inhibits human EGFRs Her-1, Her-2, and Her-4, resulting in decreased tumor cell proliferation and survival of cells that overexpress these receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462567&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462567&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53398\" NCI Thesaurus)"""@eng ; """2006-01-25"""^^xsd:string ; """C53398"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-28"""^^xsd:string ; umls:cui """C1709400"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polyvinylpyrrolidone-sodium hyaluronate gel"""@eng ; skos:notation """CDR0000491931"""^^xsd:string ; skos:altLabel """Gelclair"""@eng ; skos:definition """An oral bioadherent gel containing polyvinylpyrrolidone (PVP) and sodium hyaluronate with muco-protective property. Upon oral application, this gel adheres to and forms a thin layer over the mucosal surface of the mouth and throat. This creates a barrier that protects the exposed and sensitized nerve endings from painful stimuli during eating, drinking and talking. Polyvinylpyrrolidone-sodium hyaluronate gel provides instant comfort and reduces pain caused by inflamed and irritated oral mucosa. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491931&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491931&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61593\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-06-22"""^^xsd:string ; """2006-10-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61593"""^^xsd:string ; umls:cui """C1098961"""^^xsd:string ; umls:cui """C1831902"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lyso-thermosensitive liposome doxorubicin"""@eng ; skos:notation """CDR0000491935"""^^xsd:string ; skos:altLabel """ThermoDox"""@eng ; skos:definition """A formulation containing the anthracycline antibiotic doxorubicin encapsulated in temperature-sensitive liposomes with potential antitumor activity. Upon intravenous administration, circulating thermo-sensitive liposomes are activated locally by heating the tumor to a specific temperature (40-41 degrees C) using an outside heat source. In turn, the heat causes composition changes in liposome, thereby creating openings that trigger the release of the encapsulated doxorubicin. Compared to non-thermosensitive liposomes, lyso-thermosensitive liposomes deliver even higher concentrations of the cytotoxic agent at the tumor site while diminishing drug concentrations at other non heat-activated sites. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491935&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=491935&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61571\" NCI Thesaurus)"""@eng ; """2006-09-19"""^^xsd:string ; """2006-06-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61571"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831903"""^^xsd:string ; umls:cui """C1831904"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000038982"""^^xsd:string ; skos:altLabel """DOX/GM-CSF/IFF"""@eng ; ; ; ; """1540"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279011"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/interleukin-2/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000038983"""^^xsd:string ; skos:altLabel """CDDP/IL-2/LAK/VP-16"""@eng ; ; ; ; ; """1541"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279012"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buserelin/cyproterone"""@eng ; skos:notation """CDR0000038980"""^^xsd:string ; skos:altLabel """BSRL/CPTR"""@eng ; ; ; """1538"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279009"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/zidovudine"""@eng ; skos:notation """CDR0000038981"""^^xsd:string ; skos:altLabel """DM/MTX/ZDV"""@eng ; ; ; ; """1539"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279010"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """WDHA syndrome"""@eng ; skos:notation """CDR0000038986"""^^xsd:string ; skos:altLabel """watery diarrhea, hypokalemia, and achlorhydria syndrome"""@eng , """islet cell WDHA syndrome"""@eng , """pancreatic WDHA syndrome"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1544"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0086768"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """somatostatinoma"""@eng ; skos:notation """CDR0000038987"""^^xsd:string ; skos:altLabel """islet cell somatostatinoma"""@eng , """pancreatic somatostatinoma"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1546"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1368041"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/prednisone"""@eng ; skos:notation """CDR0000038984"""^^xsd:string ; skos:altLabel """DOX/PRED"""@eng ; ; ; """1542"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279013"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pediatric germ cell tumor"""@eng ; skos:notation """CDR0000038985"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """1543"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279014"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methazolamide"""@eng ; skos:notation """CDR0000484587"""^^xsd:string ; skos:altLabel """Neptazane"""@eng ; skos:definition """A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484587&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484587&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61318\" NCI Thesaurus)"""@eng ; """2006-07-06"""^^xsd:string ; """2006-05-07"""^^xsd:string ; """C61318"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0722061"""^^xsd:string ; umls:cui """C0025631"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glucagonoma"""@eng ; skos:notation """CDR0000038989"""^^xsd:string ; skos:altLabel """islet cell glucagonoma"""@eng , """pancreatic glucagonoma"""@eng ; rdfs:subClassOf ; """islet cell carcinoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1548"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0017689"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/dexamethasone"""@eng ; skos:notation """CDR0000258393"""^^xsd:string ; skos:altLabel """DM/PS-341"""@eng ; ; ; """2002-11-19"""^^xsd:string ; """11510"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327816"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """licorice root"""@eng ; skos:notation """CDR0000471833"""^^xsd:string ; skos:altLabel """Glycyrrhiza glabra root"""@eng ; skos:definition """The root of the plant Glycyrrhiza glabra with potential anti-inflammatory, antioxidant and antineoplastic activities. Licorice root contains the calcium and potassium salts of the glycoside glycerrhizinic acid (also known as glycyrrhizin) and numerous flavonoids. After hydrolysis from glycerrhizinic acid in vivo, glycyrrhetinic acid (GA) inhibits 11 beta-hydroxysteroid dehydrogenase, resulting in inhibition of the conversion of cortisol to the inactive steroid cortisone, elevated cortisol levels, and increased binding of cortisol to mineralocorticoid receptors. In addition, GA inhibits 17,20-lyase and 17 beta-hydroxysteroid dehydrogenase, resulting in decreased conversions of 17-hydroxyprogesterone to androstenedione and androstenedione to testosterone. The primary antioxidant found in licorice root, the flavonoid glabridin, has been shown to inactivate or inhibit the activities of some human P450 enzymes in vitro. In some tumor cells, beta-hydroxy-DHP, another flavonoid found in licorice root, may induce Bcl-2 phosphorylation, apoptosis, and G2/M cell cycle arrest; this mechanism of action is similar to that of the antimicrotubule agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471833&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471833&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61436\" NCI Thesaurus)"""@eng ; """C61436"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C2756786"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/gemcitabine"""@eng ; skos:notation """CDR0000042701"""^^xsd:string ; skos:altLabel """CDDP/dFdC/TXT"""@eng ; ; ; ; """6493"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radiofrequency ablation"""@eng ; skos:notation """CDR0000042700"""^^xsd:string ; ; rdfs:subClassOf ; """2003-02-20"""^^xsd:string ; """6492"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0850292"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/mitoxantrone/PSC 833"""@eng ; skos:notation """CDR0000042703"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/PSC-833/VP-16"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """6495"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677675"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ras peptide cancer vaccine"""@eng ; skos:notation """CDR0000042702"""^^xsd:string ; skos:altLabel """ras pep vac"""@eng ; skos:definition """A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42702&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42702&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2438\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """6494"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C2438"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677674"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/estramustine/paclitaxel"""@eng ; skos:notation """CDR0000042705"""^^xsd:string ; skos:altLabel """CBDCA/EM/TAX"""@eng ; ; ; ; """6497"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677677"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen RNA-pulsed DC cancer vaccine"""@eng ; skos:notation """CDR0000042704"""^^xsd:string ; skos:altLabel """CEA RNA-pulsed DC cancer vaccine"""@eng , """CEARNAVAC"""@eng ; """6496"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677676"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 124 monoclonal antibody A33"""@eng ; skos:notation """CDR0000042707"""^^xsd:string ; skos:altLabel """iodine I 124 MOAB A33"""@eng ; """2003-10-07"""^^xsd:string ; """6499"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677678"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """troglitazone"""@eng ; skos:notation """CDR0000042706"""^^xsd:string ; skos:altLabel """5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\\-2,4-thiazolidinedione"""@eng , """Romozin"""@eng , """Prelay"""@eng , """CI-991"""@eng , """Rezulin"""@eng , """5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione"""@eng , """CS-045"""@eng ; skos:definition """An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity. Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42706&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42706&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1522\" NCI Thesaurus)"""@eng ; """6498"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """97322-87-7"""^^xsd:string ; """C1522"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0595409"""^^xsd:string ; umls:cui """C0701265"""^^xsd:string ; umls:cui """C0056565"""^^xsd:string ; umls:cui """C1527015"""^^xsd:string ; umls:cui """C1097080"""^^xsd:string ; umls:cui """C0245514"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-4 PE38KDEL cytotoxin"""@eng ; skos:notation """CDR0000042709"""^^xsd:string ; skos:altLabel """IL-4 PE38KDEL cytotoxin"""@eng , """interleukin-4-PE38KDEL cytotoxin"""@eng , """interleukin-4 toxin"""@eng , """NBI-3001"""@eng , """IL-4 toxin"""@eng , """IL-4(38-37)-PE38KDEL cytotoxin"""@eng ; """6501"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1313726"""^^xsd:string ; umls:cui """C1313727"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/paclitaxel"""@eng ; skos:notation """CDR0000042708"""^^xsd:string ; skos:altLabel """CDDP/TAX/WR-2721"""@eng ; ; ; ; """6500"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677679"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus 5-tumor necrosis factor alpha/cisplatin/fluorouracil"""@eng ; skos:notation """CDR0000355717"""^^xsd:string ; skos:altLabel """Ad5-TNFa/CDDP/5-FU"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328188"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ibritumomab tiuxetan/rituximab"""@eng ; skos:notation """CDR0000355713"""^^xsd:string ; skos:altLabel """IDEC-2B8/MOAB IDEC-C2B8"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328187"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plexiform neurofibroma"""@eng ; skos:notation """CDR0000472003"""^^xsd:string ; rdfs:subClassOf ; """precancerous/nonmalignant condition"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-04-17"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; umls:cui """C0206728"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liposomal vinorelbine"""@eng ; skos:notation """CDR0000507579"""^^xsd:string ; """2006-09-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831959"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, low grade, stage II adult"""@eng ; skos:notation """CDR0000040278"""^^xsd:string ; skos:altLabel """low-grade, stage II adult NHL"""@eng , """NHL, low grade, stage II adult"""@eng , """lymphoma, low grade, stage II adult non-Hodgkin's"""@eng , """adult non-Hodgkin's lymphoma, low grade, stage II"""@eng , """adult NHL, stage II, low grade"""@eng ; """2005-01-21"""^^xsd:string ; """3116"""^^xsd:string ; umls:cui """C0279965"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/tezacitabine"""@eng ; skos:notation """CDR0000355719"""^^xsd:string ; skos:altLabel """FMdC/5-FU"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328189"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/paclitaxel"""@eng ; skos:notation """CDR0000269743"""^^xsd:string ; skos:altLabel """IL-12/TAX"""@eng ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327862"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bacteriolytic therapy"""@eng ; skos:notation """CDR0000504143"""^^xsd:string ; rdfs:subClassOf ; """2006-08-16"""^^xsd:string ; """2006-08-18"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831950"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/flavopiridol/mitoxantrone"""@eng ; skos:notation """CDR0000269749"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/FLAVO"""@eng ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327863"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/methotrexate/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000437891"""^^xsd:string ; skos:altLabel """CF/MTX/TMTX"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-20"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831657"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DTA-H19 plasmid"""@eng ; skos:notation """CDR0000525721"""^^xsd:string ; skos:altLabel """DTA-H19"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-08"""^^xsd:string ; umls:cui """C1831996"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/etanercept"""@eng ; skos:notation """CDR0000437892"""^^xsd:string ; skos:altLabel """5-AZC/ETN"""@eng ; ; ; """2005-06-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831658"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane/doxorubicin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042370"""^^xsd:string ; skos:altLabel """ADR-529/DOX/G-CSF/TAX"""@eng ; ; ; ; ; """5624"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338281"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/carmustine/cytarabine/etoposide"""@eng ; skos:notation """CDR0000042371"""^^xsd:string ; skos:altLabel """AMSA/ARA-C/BCNU/VP-16"""@eng ; ; ; ; ; """5625"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338282"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/mitoxantrone"""@eng ; skos:notation """CDR0000042372"""^^xsd:string ; skos:altLabel """CTX/DHAD/VP-16"""@eng , """CEN"""@eng ; ; ; ; """5626"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338283"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TA-HPV"""@eng ; skos:notation """CDR0000042373"""^^xsd:string ; skos:altLabel """TA-human papillomavirus"""@eng , """human papillomavirus TA"""@eng ; """5627"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0390856"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxaliplatin"""@eng ; skos:notation """CDR0000042374"""^^xsd:string ; skos:altLabel """oxalato (1R,2R-cyclohexanediamine)platinum(II)"""@eng , """trans-l DACH oxalatoplatinum"""@eng , """L-OHP"""@eng , """SR-96669"""@eng , """Oxalatoplatinum"""@eng , """Eloxatin"""@eng , """Diaminocyclohexane Oxalatoplatinum"""@eng , """[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"""@eng , """Oxalatoplatin"""@eng , """1-OHP"""@eng , """Eloxatine"""@eng , """[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"""@eng , """oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)"""@eng , """Dacplat"""@eng , """Dacotin"""@eng , """JM-83"""@eng , """RP-54780"""@eng , """trans-l diaminocyclohexane oxalatoplatinum"""@eng ; skos:definition """An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42374&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42374&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1181\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5628"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """63121-00-6"""^^xsd:string ; """57004"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """266046"""^^xsd:string ; """C1181"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0069717"""^^xsd:string ; umls:cui """C1522140"""^^xsd:string ; umls:cui """C1522141"""^^xsd:string ; umls:cui """C0954916"""^^xsd:string ; umls:cui """C1522139"""^^xsd:string ; umls:cui """C1518756"""^^xsd:string ; umls:cui """C1518757"""^^xsd:string ; umls:cui """C1135117"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/topotecan"""@eng ; skos:notation """CDR0000042375"""^^xsd:string ; skos:altLabel """CF/5-FU/TOPO"""@eng ; ; ; ; """5629"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338285"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thoracoscopic surgery"""@eng ; skos:notation """CDR0000042376"""^^xsd:string ; skos:altLabel """surgery, thoracoscopic"""@eng ; ; rdfs:subClassOf ; """5630"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0751551"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/etoposide"""@eng ; skos:notation """CDR0000042377"""^^xsd:string ; skos:altLabel """BCNU/VP-16"""@eng ; ; ; """5631"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338287"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/monoclonal antibody CC49/paclitaxel"""@eng ; skos:notation """CDR0000042378"""^^xsd:string ; skos:altLabel """IFN-A/MOAB CC49/TAX"""@eng ; ; ; ; """5632"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338288"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """letrozole/tamoxifen"""@eng ; skos:notation """CDR0000042379"""^^xsd:string ; skos:altLabel """LTZ/TMX"""@eng ; ; ; """2003-04-07"""^^xsd:string ; """5633"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338289"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, gastric cancer"""@eng ; skos:notation """CDR0000040628"""^^xsd:string ; skos:altLabel """gastric cancer stage"""@eng , """stomach cancer stage"""@eng ; rdfs:subClassOf ; """3534"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280253"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000040629"""^^xsd:string ; skos:altLabel """cutaneous T cell lymphoma, stage"""@eng , """cutaneous T-cell lymphoma, stage"""@eng ; rdfs:subClassOf ; """3536"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280254"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood soft tissue sarcoma"""@eng ; skos:notation """CDR0000040620"""^^xsd:string ; skos:altLabel """childhood soft tissue sarcoma, stage"""@eng ; rdfs:subClassOf ; """3524"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280245"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, salivary gland cancer"""@eng ; skos:notation """CDR0000040621"""^^xsd:string ; skos:altLabel """salivary gland cancer stage"""@eng ; rdfs:subClassOf ; """3526"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280246"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/cell type, skin cancer"""@eng ; skos:notation """CDR0000040622"""^^xsd:string ; skos:altLabel """skin cancer stage"""@eng ; rdfs:subClassOf ; """3527"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280247"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000040623"""^^xsd:string ; skos:altLabel """chronic lymphocytic leukemia stage"""@eng ; rdfs:subClassOf ; """3528"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280248"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, small cell lung cancer"""@eng ; skos:notation """CDR0000040624"""^^xsd:string ; skos:altLabel """small cell lung cancer stage"""@eng ; rdfs:subClassOf ; """3529"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280249"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/cell type, small intestine cancer"""@eng ; skos:notation """CDR0000040625"""^^xsd:string ; skos:altLabel """small intestine cancer stage"""@eng ; rdfs:subClassOf ; """3530"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280250"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000040626"""^^xsd:string ; skos:altLabel """chronic myelogenous leukemia stage"""@eng ; rdfs:subClassOf ; """3531"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280251"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, colon cancer"""@eng ; skos:notation """CDR0000040627"""^^xsd:string ; skos:altLabel """colon cancer stage"""@eng ; rdfs:subClassOf ; """3533"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280252"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/muramyl tripeptide phosphatidylethanolamine liposome"""@eng ; skos:notation """CDR0000041979"""^^xsd:string ; skos:altLabel """CDDP/IFF/MTP-PE Liposome"""@eng ; ; ; ; """5204"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281525"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate/muramyl tripeptide phosphatidylethanolamine liposome"""@eng ; skos:notation """CDR0000041978"""^^xsd:string ; skos:altLabel """CDDP/DOX/MTP-PE Liposome/MTX"""@eng ; ; ; ; ; """5203"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281524"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penclomedine"""@eng ; skos:notation """CDR0000041973"""^^xsd:string ; skos:altLabel """PEN"""@eng , """3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine"""@eng , """CRC 88-04"""@eng ; skos:definition """A synthetic derivative of pyrimidine with antineoplastic activity. Penclomedine alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis. This agent is more active against tumor cells that are defective in p53 function. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41973&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41973&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1188\" NCI Thesaurus)"""@eng ; ; """5199"""^^xsd:string ; """43409"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """338720"""^^xsd:string ; """108030-77-9"""^^xsd:string ; """C1188"""^^xsd:string ; umls:cui """C0070220"""^^xsd:string ; umls:cui """C1527076"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000041972"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/TAX/VP-16"""@eng ; ; ; ; ; """5198"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281520"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/paclitaxel"""@eng ; skos:notation """CDR0000041971"""^^xsd:string ; skos:altLabel """TPE"""@eng , """CDDP/TAX/VP-16"""@eng ; ; ; ; """5197"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281519"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intra-operative blood salvage"""@eng ; skos:notation """CDR0000041970"""^^xsd:string ; skos:altLabel """IOBS"""@eng , """intraoperative blood salvage"""@eng , """blood salvage, intraoperative"""@eng , """blood salvage, intra-operative"""@eng ; ; rdfs:subClassOf ; """5196"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0200591"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/methotrexate"""@eng ; skos:notation """CDR0000041977"""^^xsd:string ; skos:altLabel """DOX/MTX"""@eng ; ; ; """5202"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281523"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/leucovorin calcium/sargramostim"""@eng ; skos:notation """CDR0000041976"""^^xsd:string ; skos:altLabel """CF/5-FU/IFN-A/GM-CSF"""@eng ; ; ; ; ; """5201"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338181"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/penclomedine"""@eng ; skos:notation """CDR0000041975"""^^xsd:string ; skos:altLabel """G-CSF/PEN"""@eng ; ; ; """5200"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIB breast cancer"""@eng ; skos:notation """CDR0000041974"""^^xsd:string ; skos:altLabel """breast cancer, stage IIIB"""@eng ; rdfs:subClassOf ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """52"""^^xsd:string ; """progesterone receptor status unknown"""^^xsd:string ; """premenopausal"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """estrogen receptor status unknown"""^^xsd:string ; """estrogen receptor positive"""^^xsd:string ; """bilateral breast cancer"""^^xsd:string ; """estrogen receptor negative"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """performance status 2"""^^xsd:string ; """no measurable or evaluable disease"""^^xsd:string ; """progesterone receptor negative"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """postmenopausal"""^^xsd:string ; """progesterone receptor positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278513"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/PSC 833"""@eng ; skos:notation """CDR0000042954"""^^xsd:string ; skos:altLabel """Lipodox/PSC-833"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """7187"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677968"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CD80 breast cancer vaccine"""@eng ; skos:notation """CDR0000042955"""^^xsd:string ; skos:altLabel """breast cancer vaccine, CD80"""@eng ; """7188"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677969"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/busulfan/melphalan/thiotepa"""@eng ; skos:notation """CDR0000042956"""^^xsd:string ; skos:altLabel """BU/L-PAM/TSPA/WR-2721"""@eng ; ; ; ; ; """7189"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677970"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Wilms' tumor and other childhood kidney tumors"""@eng ; skos:notation """CDR0000042957"""^^xsd:string ; skos:altLabel """Wilms tumor"""@eng , """nephroblastoma"""@eng , """Wilms' tumor"""@eng , """Wilm's tumor"""@eng , """tumor, Wilms'"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """719"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0027708"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/thiotepa"""@eng ; skos:notation """CDR0000042950"""^^xsd:string ; skos:altLabel """CBDCA/CTX/TSPA"""@eng , """STAMP V"""@eng ; ; ; ; """711"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0111197"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus L523S vaccine/L523S DNA vaccine"""@eng ; skos:notation """CDR0000353189"""^^xsd:string ; skos:altLabel """Ad-L523S/L523S-DNA"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328163"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """streptavidin"""@eng ; skos:notation """CDR0000042952"""^^xsd:string ; skos:definition """An extracellular protein that has four high affinity binding sites for biotin. Streptavidin is widely utilized in fluorescence microscopy applications due to the ease with which a conjugate fluorescent moiety can be coupled to the protein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42952&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42952&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C17334\" NCI Thesaurus)"""@eng ; """7147"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C17334"""^^xsd:string ; umls:cui """C0075278"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ISIS 3521"""@eng ; skos:notation """CDR0000042953"""^^xsd:string ; skos:altLabel """LY900003"""@eng , """DNA, d(P-thio)(GTTCTCGCTGGTGAGTTTCA)"""@eng , """Affinitac"""@eng , """CGP 64128A"""@eng , """ISIS3521"""@eng , """Protein Kinase C-Alpha Antisense"""@eng , """Affinitak"""@eng ; skos:definition """A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, ISIS 3521 hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42953&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42953&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1788\" NCI Thesaurus)"""@eng ; ; ; """7186"""^^xsd:string ; """151879-73-1"""^^xsd:string ; """2006-12-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1788"""^^xsd:string ; """719337"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1512603"""^^xsd:string ; umls:cui """C1708453"""^^xsd:string ; umls:cui """C1708454"""^^xsd:string ; umls:cui """C0666551"""^^xsd:string ; umls:cui """C0666550"""^^xsd:string ; umls:cui """C1135123"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant adenovirus-L523S vaccine"""@eng ; skos:notation """CDR0000353187"""^^xsd:string ; skos:altLabel """Ad-L523S"""@eng ; ; """C49289"""^^xsd:string ; """2004-01-23"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328161"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """green tea extract"""@eng ; skos:notation """CDR0000042958"""^^xsd:string ; skos:altLabel """Polyphenon E"""@eng , """Polyphenon E topical ointment"""@eng , """epigallocatechin gallate"""@eng , """Green Tea Polyphenols"""@eng ; skos:definition """A defined, decaffeinated green tea polyphenol mixture isolated from Camellia sinensis, a plant native to Asia, with antiviral and antioxidant activities and potential chemopreventive activity. Green tea extract contains antioxidant compounds, including flavonoids, vitamins and polyphenols such as epigallocatechin-3-gallate (EGCG), which may have antineoplastic properties. Consumption of green tea extract may confer chemopreventive protection against various cancers including those of the prostate, stomach, and esophagus. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42958&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42958&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38689\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """7190"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38689"""^^xsd:string ; umls:cui """C0917976"""^^xsd:string ; umls:cui """C0917977"""^^xsd:string ; umls:cui """C0059438"""^^xsd:string ; umls:cui """C1704263"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/topotecan"""@eng ; skos:notation """CDR0000042959"""^^xsd:string ; skos:altLabel """IFF/TOPO"""@eng ; ; ; """7191"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677972"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/monoclonal antibody anti-alpha V beta 3 integrin"""@eng ; skos:notation """CDR0000353183"""^^xsd:string ; skos:altLabel """DTIC/MOAB anti-avb3 integrin"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328160"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib"""@eng ; skos:notation """CDR0000043023"""^^xsd:string ; skos:altLabel """SC-58635"""@eng , """4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide"""@eng , """SC 58635"""@eng , """Celebrex"""@eng , """YM 177"""@eng , """SC58635"""@eng ; skos:definition """A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43023&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43023&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1728\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """7301"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """169590-42-5"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """719627"""^^xsd:string ; """C1728"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0719198"""^^xsd:string ; umls:cui """C0538926"""^^xsd:string ; umls:cui """C1527143"""^^xsd:string ; umls:cui """C0538927"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antifungal therapy"""@eng ; skos:notation """CDR0000043022"""^^xsd:string ; skos:altLabel """therapy, antifungal"""@eng ; ; rdfs:subClassOf ; """7300"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0678026"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisone"""@eng ; skos:notation """CDR0000043021"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/PRED/VP-16"""@eng , """ProMACE"""@eng ; ; ; ; ; ; """73"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278531"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/estramustine/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000043020"""^^xsd:string ; skos:altLabel """CBDCA/EM/G-CSF/TAX"""@eng ; ; ; ; ; """7299"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678025"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine"""@eng ; skos:notation """CDR0000043027"""^^xsd:string ; skos:altLabel """Carmubris"""@eng , """N,N'-bis(2-chloroethyl)-N-nitrosourea"""@eng , """Nitrourean"""@eng , """Becenum"""@eng , """Nitrumon"""@eng , """bis-chloronitrosourea"""@eng , """Carmustinum"""@eng , """FDA 0345"""@eng , """Becenun"""@eng , """Carmustin"""@eng , """SRI 1720"""@eng , """BCNU"""@eng , """1,3-Bis(2-chloroethyl)-1-nitrosourea"""@eng , """1,3-Bis(beta-chloroethyl)-1-nitrosourea"""@eng , """SK 27702"""@eng , """WR-139021"""@eng , """Bis(chloroethyl) Nitrosourea"""@eng , """BiCNU"""@eng ; skos:definition """An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43027&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43027&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C349\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """731"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """969"""^^xsd:string ; """154-93-8"""^^xsd:string ; """C349"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """409962"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1765324"""^^xsd:string ; umls:cui """C0007257"""^^xsd:string ; umls:cui """C0729059"""^^xsd:string ; umls:cui """C1516303"""^^xsd:string ; umls:cui """C1527255"""^^xsd:string ; umls:cui """C1145713"""^^xsd:string ; umls:cui """C1516299"""^^xsd:string ; umls:cui """C1764853"""^^xsd:string ; umls:cui """C1764854"""^^xsd:string ; umls:cui """C1516302"""^^xsd:string ; umls:cui """C1516301"""^^xsd:string ; umls:cui """C1516300"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorescent antibody technique"""@eng ; skos:notation """CDR0000043026"""^^xsd:string ; rdfs:subClassOf ; """7304"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0016318"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EF5"""@eng ; skos:notation """CDR0000043025"""^^xsd:string ; skos:altLabel """EF-5"""@eng , """2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) Acetamide"""@eng ; skos:definition """A fluorinated derivative of the 2-nitroimidazole etanidazole. EF5 is effective in accessing oxygen levels in tumor tissue through its adduct formation to intracellular macromolecules in the absence of oxygen. Reduction of this agent is carried out by a diverse group of enzymes in the cytoplasm, microsomes and mitochondria. Tissue hypoxia detection via EF5 has been reported in several cancers, including squamous cell carcinoma of the cervix and the head and neck, and in sarcoma. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43025&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43025&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C45873\" NCI Thesaurus)"""@eng ; """7303"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C45873"""^^xsd:string ; """684681"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0382334"""^^xsd:string ; umls:cui """C1521807"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/monoclonal antibody BEC2"""@eng ; skos:notation """CDR0000043024"""^^xsd:string ; skos:altLabel """BC-G/MOAB BEC2"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """7302"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678027"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus"""@eng ; skos:notation """CDR0000043029"""^^xsd:string ; skos:altLabel """ADV"""@eng , """Adenoviral Vector"""@eng , """Adenovirus Vector"""@eng ; skos:definition """One of a number of genetically-engineered adenoviruses designed to insert a gene of interest into a eukaryotic cell where the gene of interest is subsequently expressed. Unlike most other vectors, adenovirus vectors have the ability to infect post-mitotic cells. Thus, these agents are especially useful for gene transfer into neuronal cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43029&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43029&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1890\" NCI Thesaurus)"""@eng ; ; ; """2003-10-22"""^^xsd:string ; """7329"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1890"""^^xsd:string ; umls:cui """C0001483"""^^xsd:string ; umls:cui """C1510800"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T005"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG"""@eng ; skos:notation """CDR0000043028"""^^xsd:string ; skos:altLabel """bacillus Calmette-Guerin"""@eng , """BCG (Pasteur)"""@eng , """BC-G"""@eng , """Mycobacterium bovis (Strain BCG)"""@eng , """bacille Calmette-Guerin"""@eng ; skos:definition """An attenuated strain of Mycobacterium bovis with non-specific immunoadjuvant and immunotherapeutic properties. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG (bacillus Calmette-Guerin) likely activates a Th1 cytokine response that includes induction of interferon. Vaccination with BCG may be immunoprotective against infection with Mycobacterium tuberculosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43028&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43028&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1328\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """732"""^^xsd:string ; """C1328"""^^xsd:string ; """729"""^^xsd:string ; """7817"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-16"""^^xsd:string ; umls:cui """C0085957"""^^xsd:string ; umls:tui """T007"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """D2S123"""@eng ; skos:notation """CDR0000257378"""^^xsd:string ; rdfs:subClassOf ; """2002-08-16"""^^xsd:string ; """11419"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327772"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GM-CSF-encoding oncolytic herpes simplex virus"""@eng ; skos:notation """CDR0000485296"""^^xsd:string ; skos:altLabel """OncoVEX GM-CSF"""@eng ; skos:definition """An oncolytic, recombinant herpes simplex type-1 virus (HSV) encoding thuman cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antitumor and immunostimulating properties. Upon administration, GM-CSF-encoding oncolytic HSV selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, expressed GM-CSF may stimulate a cytotoxic T cell response against tumor cells, resulting in immune-mediated tumor cell death in addition to HSV-mediated oncolytic tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485296&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485296&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61314\" NCI Thesaurus)"""@eng ; """2006-05-23"""^^xsd:string ; """C61314"""^^xsd:string ; """2006-07-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831828"""^^xsd:string ; umls:cui """C1831829"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, kidney tumor"""@eng ; skos:notation """CDR0000038159"""^^xsd:string ; rdfs:subClassOf ; """10739"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0935741"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/suramin"""@eng ; skos:notation """CDR0000038158"""^^xsd:string ; skos:altLabel """CBDCA/SUR/TAX"""@eng ; ; ; ; """10738"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935740"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/Montanide ISA-51/tyrosinase-related protein-2"""@eng ; skos:notation """CDR0000038409"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/TRP-2"""@eng ; ; ; """11027"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134466"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/tyrosinase-related protein-2"""@eng ; skos:notation """CDR0000038408"""^^xsd:string ; skos:altLabel """ISA-51/TRP-2"""@eng ; ; """11026"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134465"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000038155"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/MOAB VEGF"""@eng ; ; ; ; ; """10735"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935737"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxercalciferol"""@eng ; skos:notation """CDR0000038406"""^^xsd:string ; skos:altLabel """Hectorol"""@eng , """(1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol"""@eng , """1-alpha-hydroxyvitamin D2"""@eng ; skos:definition """A synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion. This agent has also been shown to inhibit the growth of retinoblastomas, and may exhibit some antiproliferative activity against prostate cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38406&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38406&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2645\" NCI Thesaurus)"""@eng ; """11024"""^^xsd:string ; """54573-75-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """C2645"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0043668"""^^xsd:string ; umls:cui """C0876052"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin/fluorouracil/paclitaxel"""@eng ; skos:notation """CDR0000038405"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/TAX/WR-2721"""@eng ; ; ; ; ; """11023"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134464"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-214662/trastuzumab"""@eng ; skos:notation """CDR0000038404"""^^xsd:string ; skos:altLabel """BMS-214662/MOAB HER2"""@eng ; ; ; """11022"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134463"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CI-1033"""@eng ; skos:notation """CDR0000038403"""^^xsd:string ; skos:altLabel """CI-1033/PD183805"""@eng , """N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide"""@eng , """N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide Dihydrochloride"""@eng , """PD183805"""@eng ; skos:definition """An orally bioavailable quinazoline with potential antineoplastic and radiosensitizing activities. CI-1033 binds to the intracellular domains of pan-erbB tyrosine kinases, irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents. erbB is a member of the epidermal growth factor receptor (EGFR) family and is implicated in the malignant transformation of many solid tumors, including breast, ovarian, prostate, lung, and brain cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38403&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38403&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1880\" NCI Thesaurus)"""@eng ; """11021"""^^xsd:string ; """289499-45-2"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1880"""^^xsd:string ; umls:cui """C1450570"""^^xsd:string ; umls:cui """C1138033"""^^xsd:string ; umls:cui """C1707132"""^^xsd:string ; umls:cui """C0964184"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gabapentin"""@eng ; skos:notation """CDR0000038402"""^^xsd:string ; skos:altLabel """1-(aminomethyl)cyclohexaneacetic Acid"""@eng , """Neurontin"""@eng ; skos:definition """A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38402&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38402&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1108\" NCI Thesaurus)"""@eng ; """11020"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """60142-96-3"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C1108"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0678176"""^^xsd:string ; umls:cui """C0060926"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/thalidomide"""@eng ; skos:notation """CDR0000038153"""^^xsd:string ; skos:altLabel """PRED/THAL"""@eng ; ; ; """10733"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935735"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/imatinib mesylate/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000038400"""^^xsd:string ; skos:altLabel """DM/MP/MTX/STI571/VCR"""@eng ; ; ; ; ; ; """11019"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134462"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Z-360"""@eng ; skos:notation """CDR0000485295"""^^xsd:string ; skos:definition """A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485295&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485295&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61329\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-11"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """C61329"""^^xsd:string ; umls:cui """C1831827"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """everolimus/letrozole"""@eng ; skos:notation """CDR0000429572"""^^xsd:string ; skos:altLabel """LTZ/RAD"""@eng ; ; ; """2005-04-15"""^^xsd:string ; """2005-04-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541558"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dysphagia"""@eng ; skos:notation """CDR0000524080"""^^xsd:string ; rdfs:subClassOf ; """2006-11-30"""^^xsd:string ; """2006-12-01"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0011168"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """magnesium citrate"""@eng ; skos:notation """CDR0000480467"""^^xsd:string ; skos:altLabel """Citroma"""@eng , """Citramag"""@eng , """citrate of magnesia"""@eng ; skos:definition """The citrate salt of the element magnesium with laxative properties. The cathartic action of magnesium cations appears to result, in part, from osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may also stimulate the activity of nitric oxide (NO) synthase and increase the biosynthesis of the phospholipid proinflammatory mediator platelet activating factor (PAF) in the gut. NO may stimulate intestinal secretion via prostglandin- and cyclic GMP-dependent mechansisms while PAFproduces significant stimulation of colonic secretion and gastrointestinal motility. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480467&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480467&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29241\" NCI Thesaurus)"""@eng ; """2006-04-14"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """C29241"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0126774"""^^xsd:string ; umls:cui """C0591262"""^^xsd:string ; umls:cui """C0719355"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CDK4"""@eng ; skos:notation """CDR0000257373"""^^xsd:string ; rdfs:subClassOf ; """2002-08-16"""^^xsd:string ; """11415"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0246957"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000357354"""^^xsd:string ; skos:altLabel """BLEO/CTX/DHAD/PCB/PRDL/VBL/VP-16"""@eng ; ; ; ; ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328217"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody ING-1"""@eng ; skos:notation """CDR0000357603"""^^xsd:string ; skos:altLabel """ING-1"""@eng ; """2004-02-20"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328238"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetra-O-methyl-nordihydroguaiaretic acid"""@eng ; skos:notation """CDR0000357601"""^^xsd:string ; skos:altLabel """BCM2114"""@eng ; """2004-02-20"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C1328720"""^^xsd:string ; umls:cui """C0654036"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody SGN-30"""@eng ; skos:notation """CDR0000357600"""^^xsd:string ; skos:altLabel """anti-CD30 monoclonal antibody"""@eng , """SGN-30"""@eng ; skos:definition """A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Monoclonal antibody SGN-30 specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkins lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357600&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357600&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2007\" NCI Thesaurus)"""@eng ; """2004-02-20"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2007"""^^xsd:string ; umls:cui """C1328236"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ondansetron hydrochloride"""@eng ; skos:notation """CDR0000489533"""^^xsd:string ; skos:altLabel """GR-C507/75"""@eng , """Zofran"""@eng , """GR 38032F"""@eng , """SN-307"""@eng ; skos:definition """The hydrochloride salt of the racemic form of ondansetron, a carbazole derivative and a selective, competitive serotonin 5-HT3 receptor antagonist with antiemetic properties. Although its mechanism of action has not been fully characterized, ondansetron appears to competitively block the action of serotonin at 5HT3 receptors peripherally in the gastrointestinal tract as well as centrally in the area postrema of the CNS (the chemoreceptor trigger zone for vomiting), resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489533&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489533&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48007\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """99614-01-4"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """665799"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """C48007"""^^xsd:string ; umls:cui """C0733434"""^^xsd:string ; umls:cui """C0733437"""^^xsd:string ; umls:cui """C0700478"""^^xsd:string ; umls:cui """C0733435"""^^xsd:string ; umls:cui """C0206046"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LU 79553"""@eng ; skos:notation """CDR0000042578"""^^xsd:string ; """6263"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0294830"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian carcinosarcoma"""@eng ; skos:notation """CDR0000042579"""^^xsd:string ; skos:altLabel """carcinosarcoma, ovarian"""@eng , """malignant mixed mesodermal Mullerian tumor, ovarian"""@eng , """ovarian malignant mixed mesodermal Mullerian tumor"""@eng , """Mullerian sarcoma, ovarian malignant mixed mesodermal"""@eng , """Mullerian tumor, ovarian malignant mixed mesodermal"""@eng ; rdfs:subClassOf ; """6265"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0392998"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KW-2149"""@eng ; skos:notation """CDR0000042572"""^^xsd:string ; skos:altLabel """KT6149"""@eng , """7-N-(2-((2-(gamma-L-Glutamylamino)ethyl)dithio)ethyl)mitomycin C"""@eng , """KW 2149"""@eng ; skos:definition """A semisynthetic water-soluble disulfide derivative of the antineoplastic antibiotic mitomycin C. Activated by serum and glutathione, KW-2149 causes interstrand DNA cross-links and DNA-protein cross-links, resulting in single-strand DNA breaks and inhibition of DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42572&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42572&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1140\" NCI Thesaurus)"""@eng ; """6256"""^^xsd:string ; """118359-59-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1140"""^^xsd:string ; umls:cui """C0064443"""^^xsd:string ; umls:cui """C0124754"""^^xsd:string ; umls:cui """C0099921"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/vincristine"""@eng ; skos:notation """CDR0000042573"""^^xsd:string ; skos:altLabel """BRYO/VCR"""@eng ; ; ; """6257"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392994"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/MART-1 antigen"""@eng ; skos:notation """CDR0000042570"""^^xsd:string ; skos:altLabel """gp100/MART-1"""@eng ; ; ; """6254"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392993"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carzelesin"""@eng ; skos:notation """CDR0000042571"""^^xsd:string ; """6255"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0172048"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/raltitrexed"""@eng ; skos:notation """CDR0000042576"""^^xsd:string ; skos:altLabel """CPT-11/ICI D1694"""@eng ; ; ; """6261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392997"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trabectedin"""@eng ; skos:notation """CDR0000042577"""^^xsd:string ; skos:altLabel """ecteinascidin-743"""@eng , """Ecteinascidin"""@eng , """Yondelis"""@eng , """Ecteinascidin 743"""@eng , """ecteinascidin 743"""@eng , """ET 743"""@eng ; skos:definition """A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinate. Trabectedin, also known as ecteinascidin 743 (ET743), exhibits potent tumor cytotoxicity by prolonging the G2-M phase of the cell cycle. This agent interacts with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42577&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42577&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1691\" NCI Thesaurus)"""@eng ; ; ; """6262"""^^xsd:string ; """114899-77-3"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1691"""^^xsd:string ; """648766"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1311070"""^^xsd:string ; umls:cui """C0388976"""^^xsd:string ; umls:cui """C1312408"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/progesterone"""@eng ; skos:notation """CDR0000042574"""^^xsd:string ; skos:altLabel """DOX/progesterone"""@eng ; ; ; """6258"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392995"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042575"""^^xsd:string ; skos:altLabel """CTX/DOX/G-CSF/TAX"""@eng ; ; ; ; ; """6259"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392996"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """meningioma, adult malignant"""@eng ; skos:notation """CDR0000041198"""^^xsd:string ; skos:altLabel """malignant meningioma, adult"""@eng ; """2004-06-17"""^^xsd:string ; """4271"""^^xsd:string ; umls:cui """C3468050"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spironolactone"""@eng ; skos:notation """CDR0000039444"""^^xsd:string ; skos:altLabel """SC 9420"""@eng , """Aldactone"""@eng , """SPL"""@eng , """17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic Acid, gamma Lactone, Acetate"""@eng ; skos:definition """A synthetic 17-spironolactone corticosteroid with potassium-sparing diuretic, antihypertensive, and antiandrogen activities. Spironolactone competitively inhibits adrenocortical hormone aldosterone activity in the distal renal tubules, myocardium, and vasculature. This agent may inhibit the pathophysiologic effects of aldosterone produced in excess by various types of malignant and benign tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39444&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39444&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C840\" NCI Thesaurus)"""@eng ; """2079"""^^xsd:string ; """11222"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """150399"""^^xsd:string ; """52-01-7"""^^xsd:string ; """C840"""^^xsd:string ; umls:cui """C0037982"""^^xsd:string ; umls:cui """C0591054"""^^xsd:string ; umls:cui """C0701468"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039445"""^^xsd:string ; skos:altLabel """CABO"""@eng , """BLEO/CDDP/MTX/VCR"""@eng ; ; ; ; ; """2080"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078397"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etanidazole"""@eng ; skos:notation """CDR0000039446"""^^xsd:string ; skos:altLabel """SR-2508"""@eng , """2-nitro-imidazole derivative"""@eng ; skos:definition """A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39446&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39446&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1092\" NCI Thesaurus)"""@eng ; ; ; ; ; """2081"""^^xsd:string ; """301467"""^^xsd:string ; """2006-02-17"""^^xsd:string ; """C1092"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338094"""^^xsd:string ; umls:cui """C0059682"""^^xsd:string ; umls:cui """C0740264"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000039447"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/GM-CSF/VP-16"""@eng ; ; ; ; ; ; """2082"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim"""@eng ; skos:notation """CDR0000041379"""^^xsd:string ; skos:altLabel """CTX/G-CSF"""@eng ; ; ; """4450"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280948"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041378"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/MTX/VCR"""@eng ; ; ; ; ; ; """4449"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280947"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000039442"""^^xsd:string ; skos:altLabel """CBDCA/GM-CSF/VP-16"""@eng ; ; ; ; """2077"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279301"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/mitoxantrone"""@eng ; skos:notation """CDR0000039443"""^^xsd:string ; skos:altLabel """CNF"""@eng , """CTX/DHAD/5-FU"""@eng ; ; ; ; """2078"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0118004"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Detox-B adjuvant"""@eng ; skos:notation """CDR0000041375"""^^xsd:string ; skos:altLabel """Detox-B Stable Emulsion"""@eng , """Enhanzyn"""@eng , """DETOXB"""@eng , """Detox-B SE Adjuvant"""@eng ; skos:definition """A cancer vaccine adjuvant that consists of an oil droplet emulsion of monophosphoryl lipid A and mycobacterial cell wall skeleton. Detox-B adjuvant is a non-specific immunostimulant that may enhance the host immune response to certain cancer vaccines. Detox-B differs from Detox adjuvant in that Detox-B contains lecithin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41375&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41375&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2566\" NCI Thesaurus)"""@eng ; ; ; ; """4446"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C2566"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0935654"""^^xsd:string ; umls:cui """C1511792"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/dexamethasone/sargramostim"""@eng ; skos:notation """CDR0000041374"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/DM/GM-CSF"""@eng ; ; ; ; ; """4445"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280943"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/dacarbazine/tamoxifen"""@eng ; skos:notation """CDR0000041377"""^^xsd:string ; skos:altLabel """CBDCA/DTIC/TMX"""@eng ; ; ; ; """4448"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280946"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/dacarbazine"""@eng ; skos:notation """CDR0000041376"""^^xsd:string ; skos:altLabel """CBDCA/DTIC"""@eng ; ; ; """4447"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280945"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/epoetin alfa/etoposide"""@eng ; skos:notation """CDR0000041371"""^^xsd:string ; skos:altLabel """CBDCA/EPO/VP-16"""@eng ; ; ; ; """4442"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280940"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piroxantrone/sargramostim"""@eng ; skos:notation """CDR0000041370"""^^xsd:string ; skos:altLabel """GM-CSF/PXT"""@eng ; ; ; """4441"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280939"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/dexamethasone"""@eng ; skos:notation """CDR0000041373"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/DM"""@eng ; ; ; ; """4444"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280942"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000041372"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/IFN-A/TMX"""@eng ; ; ; ; ; """4443"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338149"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gusperimus"""@eng ; skos:notation """CDR0000040369"""^^xsd:string ; skos:altLabel """Deoxyspergualin Hydrochloride"""@eng , """15-Deoxyspergualin Hydrochloride"""@eng , """BMY-42215-1"""@eng , """NKT-01"""@eng , """N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-7-guanidinoheptanamide"""@eng , """BMS-181173"""@eng , """deoxyspergualin"""@eng , """15-Deoxyspergualin"""@eng , """1-Amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione"""@eng , """DSG"""@eng , """Spanidin"""@eng , """Gusperimus Trihydrochloride"""@eng , """7-{(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amnio]-1-hydroxy-2-oxoethyl]heptanamide"""@eng ; skos:definition """A derivative of the antitumor antibiotic spergualin with immunosuppressant activity. Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40369&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40369&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1598\" NCI Thesaurus)"""@eng ; ; """3229"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1598"""^^xsd:string ; """28053"""^^xsd:string ; """356894"""^^xsd:string ; """84937-45-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0132640"""^^xsd:string ; umls:cui """C1522143"""^^xsd:string ; umls:cui """C1522144"""^^xsd:string ; umls:cui """C1512285"""^^xsd:string ; umls:cui """C0284559"""^^xsd:string ; umls:cui """C0284558"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triazene"""@eng ; skos:notation """CDR0000040368"""^^xsd:string ; rdfs:subClassOf ; """3228"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280036"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mitomycin/vinblastine"""@eng ; skos:notation """CDR0000040365"""^^xsd:string ; skos:altLabel """MVA"""@eng , """DOX/MITO/VBL"""@eng ; ; ; ; """3225"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0052712"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ricin immunoconjugate"""@eng ; skos:notation """CDR0000040364"""^^xsd:string ; skos:altLabel """immunoconjugate, ricin"""@eng ; """3222"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0280032"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alkylsulfonate"""@eng ; skos:notation """CDR0000040367"""^^xsd:string ; rdfs:subClassOf ; """3227"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002072"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethylenimine"""@eng ; skos:notation """CDR0000040366"""^^xsd:string ; rdfs:subClassOf ; """3226"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0052794"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic myelomonocytic leukemia"""@eng ; skos:notation """CDR0000040361"""^^xsd:string ; skos:altLabel """CMML"""@eng , """myelomonocytic leukemia, chronic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2003-10-06"""^^xsd:string ; """myelodysplastic/myeloproliferative diseases"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3217"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023480"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory anemia with excess blasts in transformation"""@eng ; skos:notation """CDR0000040360"""^^xsd:string ; rdfs:subClassOf ; """3216"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280028"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody T101"""@eng ; skos:notation """CDR0000040363"""^^xsd:string ; skos:altLabel """T101"""@eng , """T-101 monoclonal antibody"""@eng , """MOAB T-101"""@eng , """MOAB T101"""@eng , """antibody T-101, monoclonal"""@eng , """monoclonal antibody T-101"""@eng , """T101 monoclonal antibody"""@eng ; """3221"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0280031"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, thymoma and thymic carcinoma"""@eng ; skos:notation """CDR0000040584"""^^xsd:string ; rdfs:subClassOf ; """2003-08-21"""^^xsd:string ; """3484"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280207"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HPV 16 E7:86-93 peptide vaccine"""@eng ; skos:notation """CDR0000043625"""^^xsd:string ; skos:altLabel """HPV 16 E7:86-93 Peptide"""@eng , """E7(86-93) lipopeptide"""@eng , """E7(86-93)"""@eng ; ; """2006-11-27"""^^xsd:string ; """8909"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38761"""^^xsd:string ; umls:cui """C0879333"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HER-2/neu peptide vaccine/Montanide ISA-51"""@eng ; skos:notation """CDR0000043624"""^^xsd:string ; skos:altLabel """HER-2/ISA-51"""@eng ; ; """Drug/agent combination"""^^xsd:string ; """8908"""^^xsd:string ; umls:cui """C0879332"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E7(86-93) lipopeptide/HPV-16 E7(12-20) peptide vaccine/Montanide ISA-51"""@eng ; skos:notation """CDR0000043627"""^^xsd:string ; skos:altLabel """E7(86-93)/HPV16E7(12-20)/ISA-51"""@eng ; ; ; """8912"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879335"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bcr-abl peptide vaccine/QS21"""@eng ; skos:notation """CDR0000043626"""^^xsd:string ; skos:altLabel """bcr-abl/QS 21"""@eng ; ; ; """8910"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879334"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/Montanide ISA-51/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000043621"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/ISA-51/TYRP"""@eng ; ; ; ; """8905"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879329"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CRL 1005/gp100 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043620"""^^xsd:string ; skos:altLabel """CRL 1005/gp100/ISA-51/TYRP"""@eng ; ; ; ; """8904"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879328"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bcr-abl peptide vaccine"""@eng ; skos:notation """CDR0000043623"""^^xsd:string ; skos:altLabel """bcr-abl vaccine"""@eng ; skos:definition """A multivalent antineoplastic vaccine comprised of the bcr-abl oncogene breakpoint fusion peptide that elicits a bcr-abl specific T-cell immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43623&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43623&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2205\" NCI Thesaurus)"""@eng ; ; """8907"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C2205"""^^xsd:string ; umls:cui """C0879331"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/MART-1 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000043622"""^^xsd:string ; skos:altLabel """IL-12/ISA-51/MART-1"""@eng ; ; ; """8906"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879330"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liothyronine sodium"""@eng ; skos:notation """CDR0000043629"""^^xsd:string ; skos:altLabel """Cytomel"""@eng , """Triostat"""@eng ; skos:definition """The sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43629&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43629&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2581\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """8914"""^^xsd:string ; """C2581"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0010826"""^^xsd:string ; umls:cui """C0723907"""^^xsd:string ; umls:cui """C0546882"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mutant p53 peptide pulsed dendritic cell vaccine/sargramostim"""@eng ; skos:notation """CDR0000043628"""^^xsd:string ; skos:altLabel """GM-CSF/p53 DEN"""@eng ; ; ; """8913"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879336"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040764"""^^xsd:string ; skos:altLabel """esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage II"""@eng , """paranasal sinus and nasal cavity esthesioneuroblastoma, stage II"""@eng , """nasal cavity and paranasal sinus esthesioneuroblastoma, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3717"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280410"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lamotrigine"""@eng ; skos:notation """CDR0000328241"""^^xsd:string ; skos:altLabel """Lamictal"""@eng ; skos:definition """A synthetic phenyltriazine with antiepileptic and analgesic properties. Lamotrigine enhances the action of gamma-aminobutyric acid, an inhibitory neurotransmitter, which may result in a reduction of pain-related transmission of signals along nerve fibers. This agent may also inhibit voltage-gated sodium channels, suppress glutamate release, and inhibit serotonin reuptake. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=328241&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=328241&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38703\" NCI Thesaurus)"""@eng ; """2003-08-24"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38703"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0678180"""^^xsd:string ; umls:cui """C0064636"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/topotecan"""@eng ; skos:notation """CDR0000328243"""^^xsd:string ; skos:altLabel """PS-341/TOPO"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328035"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anidulafungin"""@eng ; skos:notation """CDR0000328242"""^^xsd:string ; skos:altLabel """LY303366"""@eng , """VER-002"""@eng , """V-echinocandin"""@eng ; skos:definition """A cyclic lipopeptide echinocandin derivative with antifungal activity. Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=328242&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=328242&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38716\" NCI Thesaurus)"""@eng ; """2003-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C38716"""^^xsd:string ; umls:cui """C1527264"""^^xsd:string ; umls:cui """C0532508"""^^xsd:string ; umls:cui """C1142738"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/epoetin alfa/paclitaxel"""@eng ; skos:notation """CDR0000038524"""^^xsd:string ; skos:altLabel """CBDCA/EPO/TAX"""@eng ; ; ; ; """11147"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134554"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """type B thymoma"""@eng ; skos:notation """CDR0000331645"""^^xsd:string ; skos:altLabel """epithelioid thymoma"""@eng , """dendritic cell thymoma"""@eng , """plump cell thymoma"""@eng ; rdfs:subClassOf ; """2003-08-24"""^^xsd:string ; """2003-08-20"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1328042"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan liposome"""@eng ; skos:notation """CDR0000506099"""^^xsd:string ; skos:altLabel """IHL-305"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-24"""^^xsd:string ; umls:cui """C1831956"""^^xsd:string ; umls:cui """C1831957"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetanus toxoid helper peptide"""@eng ; skos:notation """CDR0000436110"""^^xsd:string ; skos:altLabel """TET TOX PEP VAC"""@eng ; skos:definition """Obtained by genetic engineering from the bacterial Clostridium tetani toxoid, tetanus toxoid helper peptide QYIKANSKFIGITEL (amino acids 830-844) binds to class II MHC molecules as a nonspecific vaccine helper epitope (adjuvant) and induces an increased (and long term) immune response by increasing the helper T-cell response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=436110&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=436110&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38134\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """2006-09-26"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """C38134"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1515333"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/S-3304"""@eng ; skos:notation """CDR0000363617"""^^xsd:string ; skos:altLabel """CBDCA/S3304/TAX"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541204"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/autologous tumor cell vaccine"""@eng ; skos:notation """CDR0000363615"""^^xsd:string ; skos:altLabel """ADC/ATCV"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541203"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP2E1"""@eng ; skos:notation """CDR0000322899"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-24"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919426"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E7820"""@eng ; skos:notation """CDR0000363619"""^^xsd:string ; skos:definition """A small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=363619&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=363619&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61501\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """C61501"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-11"""^^xsd:string ; umls:cui """C1533733"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """staphylococcus aureus protein A"""@eng ; skos:notation """CDR0000039057"""^^xsd:string ; skos:altLabel """Staph. Protein A"""@eng , """S. aureus protein A"""@eng ; skos:definition """A protein that resides in the microbial wall of staphylococcus aureus and interferes with opsonization by binding to the Fc portion of immunoglobulin. The protein has a deleterious effect on the epithelial cells that line the respiratory tract, and plays a role in the induction of pneumonia. Protein A also initiates polymorphonuclear cell migration into airway passages via TNFR1 activation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39057&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39057&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C17166\" NCI Thesaurus)"""@eng ; """1641"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C17166"""^^xsd:string ; umls:cui """C0038164"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult oligodendroglioma"""@eng ; skos:notation """CDR0000039056"""^^xsd:string ; skos:altLabel """CNS tumor, adult oligodendroglioma"""@eng , """oligodendroglioma, adult"""@eng , """adult well-differentiated oligodendroglioma"""@eng , """central nervous system tumor, oligodendroglioma, adult"""@eng , """adult brain tumor, oligodendroglioma"""@eng , """CNS tumor, oligodendroglioma, adult"""@eng , """adult CNS tumor, oligodendroglioma"""@eng , """brain tumor, oligodendroglioma"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """1635"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult oligodendroglial tumors"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280789"""^^xsd:string ; umls:cui """C0279070"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult grade III lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000039055"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1634"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541469"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Langerhans cell histiocytosis"""@eng ; skos:notation """CDR0000039054"""^^xsd:string ; skos:altLabel """histiocytosis X"""@eng ; rdfs:subClassOf ; """1633"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0019621"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/paclitaxel"""@eng ; skos:notation """CDR0000041708"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/TAX"""@eng ; ; ; ; """4877"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281303"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult grade III lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000039052"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1627"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541468"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urethral cancer"""@eng ; skos:notation """CDR0000039051"""^^xsd:string ; skos:altLabel """Urethral cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1623"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0700101"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade II lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000039050"""^^xsd:string ; rdfs:subClassOf ; """2004-06-22"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1622"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0862090"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """desmoid tumor"""@eng ; skos:notation """CDR0000041704"""^^xsd:string ; skos:altLabel """musculoaponeurotic fibromatosis"""@eng , """aggressive fibromatosis"""@eng , """fibromatosis"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """4872"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0079218"""^^xsd:string ; umls:cui """C0016048"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/leucovorin calcium/vinorelbine"""@eng ; skos:notation """CDR0000041705"""^^xsd:string ; skos:altLabel """CF/DOX/5-FU/VNB"""@eng ; ; ; ; ; """4873"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281300"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/melphalan/tumor necrosis factor"""@eng ; skos:notation """CDR0000041706"""^^xsd:string ; skos:altLabel """IFN-G/L-PAM/TNF"""@eng ; ; ; ; """4874"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281301"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/paclitaxel"""@eng ; skos:notation """CDR0000041707"""^^xsd:string ; skos:altLabel """HMM/TAX"""@eng ; ; ; """4875"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281302"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/vinorelbine"""@eng ; skos:notation """CDR0000041700"""^^xsd:string ; skos:altLabel """DOX/5-FU/VNB"""@eng ; ; ; ; """4867"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281298"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/paclitaxel"""@eng ; skos:notation """CDR0000041701"""^^xsd:string ; skos:altLabel """TAX/VP-16"""@eng ; ; ; """4868"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281299"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """progesterone"""@eng ; skos:notation """CDR0000039059"""^^xsd:string ; skos:altLabel """Lipo-Lutin"""@eng , """Gestiron"""@eng , """Luteohormone"""@eng , """Lutocylin"""@eng , """Delta4-pregnene-3,20-dione"""@eng , """Prolidon"""@eng , """Utrogestan"""@eng , """Lutogyl"""@eng , """Lutocyclin"""@eng , """Lutromone"""@eng , """Progestasert"""@eng , """Colprosterone"""@eng , """Progestin"""@eng , """Syngesterone"""@eng , """Progestol"""@eng , """Progestogel"""@eng , """Corluvite"""@eng , """Lutocylin M"""@eng , """PRG"""@eng , """Cyclogest"""@eng , """Corlutina"""@eng , """Gesterol 100"""@eng , """Progesterol"""@eng , """Proluton"""@eng , """Gestone"""@eng , """Syngestrets"""@eng , """Progeston"""@eng , """Therapeutic Progesterone"""@eng , """Lucorteum"""@eng , """Nalutron"""@eng ; skos:definition """A synthetic form of the endogenous hormone progesterone. Progesterone binds to the progesterone receptor, resulting in dissociation of heat shock proteins, receptor phosphorylation, and transcription activation through direct or indirect interaction with transcription factors. This agent exerts inhibitory effects on estrogens by decreasing the number of estrogen receptors and increasing its metabolism to inactive metabolites. Progesterone induces secretory changes in the endometrium, decreases uterine contractility during pregnancy, and maintains pregnancy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39059&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39059&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C777\" NCI Thesaurus)"""@eng ; ; ; """1643"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9704"""^^xsd:string ; """57-83-0"""^^xsd:string ; """C777"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1515399"""^^xsd:string ; umls:cui """C1515398"""^^xsd:string ; umls:cui """C1515391"""^^xsd:string ; umls:cui """C1515390"""^^xsd:string ; umls:cui """C1515393"""^^xsd:string ; umls:cui """C1515392"""^^xsd:string ; umls:cui """C1515395"""^^xsd:string ; umls:cui """C1515394"""^^xsd:string ; umls:cui """C1515397"""^^xsd:string ; umls:cui """C1515396"""^^xsd:string ; umls:cui """C0591309"""^^xsd:string ; umls:cui """C0701120"""^^xsd:string ; umls:cui """C1515400"""^^xsd:string ; umls:cui """C0033306"""^^xsd:string ; umls:cui """C0033308"""^^xsd:string ; umls:cui """C1515388"""^^xsd:string ; umls:cui """C1515389"""^^xsd:string ; umls:cui """C0701111"""^^xsd:string ; umls:cui """C0701110"""^^xsd:string ; umls:cui """C0701113"""^^xsd:string ; umls:cui """C0701112"""^^xsd:string ; umls:cui """C0701115"""^^xsd:string ; umls:cui """C0701114"""^^xsd:string ; umls:cui """C0701117"""^^xsd:string ; umls:cui """C0701116"""^^xsd:string ; umls:cui """C0701119"""^^xsd:string ; umls:cui """C0701118"""^^xsd:string ; umls:cui """C0591564"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fostriecin"""@eng ; skos:notation """CDR0000041703"""^^xsd:string ; skos:altLabel """FST"""@eng , """2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans"""@eng , """phosphotrienin"""@eng ; skos:definition """An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in protein-associated strand breaks and impaired DNA and RNA synthesis in various malignant cell types. This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41703&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41703&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1372\" NCI Thesaurus)"""@eng ; """4870"""^^xsd:string ; """87810-56-8"""^^xsd:string ; """C1372"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """39667"""^^xsd:string ; """339638"""^^xsd:string ; umls:cui """C0118175"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/ciprofloxacin/pentoxifylline"""@eng ; skos:notation """CDR0000042811"""^^xsd:string ; skos:altLabel """CPFX/PTX/WR-2721"""@eng ; ; ; ; """6610"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677759"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interleukin-1-alpha"""@eng ; skos:notation """CDR0000523327"""^^xsd:string ; skos:altLabel """interleukin-1-alpha"""@eng ; skos:definition """A recombinant agent which is chemically identical to or similar to the endogenous protein cytokine interleukin-1 (IL-1). The IL-1 precursor is produced by monocytes, activated macrophages, and other cell types; mature IL-1 is generated by proteolytic cleavage by proteases such as IL-1-beta converting enzyme (ICE). This agent enhances T cell proliferation and B cell growth and differentiation and induces the expression of proinflammatory cytokines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=523327&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=523327&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1754\" NCI Thesaurus)"""@eng ; """2006-12-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4160"""^^xsd:string ; """3132"""^^xsd:string ; """C1754"""^^xsd:string ; umls:cui """C1523980"""^^xsd:string ; umls:cui """C0600251"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic tumors of the Ewing's family"""@eng ; skos:notation """CDR0000043412"""^^xsd:string ; skos:altLabel """PNET, metastatic"""@eng , """metastatic peripheral neuroectodermal tumor"""@eng , """metastatic Ewing's sarcoma"""@eng , """pPNET, metastatic"""@eng , """metastatic primitive neuroectodermal tumor (PNET)"""@eng , """primitive neuroectodermal tumor (PNET), metastatic"""@eng , """metastatic PNET"""@eng , """Askin's tumor, metastatic"""@eng , """Ewing's sarcoma, metastatic"""@eng , """metastatic pPNET"""@eng , """metastatic peripheral neuroepithelioma"""@eng , """metastatic Askin's tumor"""@eng , """peripheral neuroectodermal tumor, metastatic"""@eng , """neuroepithelioma, metastatic, peripheral"""@eng ; rdfs:subClassOf ; """Ewing's family of tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7971"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796548"""^^xsd:string ; umls:cui """C0278586"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent tumors of the Ewing's family"""@eng ; skos:notation """CDR0000043413"""^^xsd:string ; skos:altLabel """recurrent neuroepithelioma, peripheral"""@eng , """peripheral neuroectodermal tumor, recurrent"""@eng , """pPNET, recurrent"""@eng , """Ewing's sarcoma, recurrent"""@eng , """PNET, recurrent"""@eng , """recurrent PNET"""@eng , """recurrent Askin's tumor"""@eng , """recurrent primitive neuroectodermal tumor (PNET)"""@eng , """primitive neuroectodermal tumor (PNET), recurrent"""@eng , """recurrent Ewing's sarcoma"""@eng , """recurrent pPNET"""@eng , """recurrent peripheral neuroectodermal tumor"""@eng , """neuroepithelioma, recurrent, peripheral"""@eng , """Askin's tumor, recurrent"""@eng ; rdfs:subClassOf ; """Ewing's family of tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7972"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796549"""^^xsd:string ; umls:cui """C0278590"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, Ewing's family of tumors"""@eng ; skos:notation """CDR0000043410"""^^xsd:string ; rdfs:subClassOf ; """7969"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0796546"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized tumors of the Ewing's family"""@eng ; skos:notation """CDR0000043411"""^^xsd:string ; skos:altLabel """localized primitive neuroectodermal tumor (PNET)"""@eng , """localized pPNET"""@eng , """localized peripheral neuroepithelioma"""@eng , """Askin's tumor, localized"""@eng , """primitive neuroectodermal tumor (PNET), localized"""@eng , """localized PNET"""@eng , """Ewing's sarcoma, localized"""@eng , """localized peripheral neuroectodermal tumor"""@eng , """neuroepithelioma, localized, peripheral"""@eng , """PNET, localized"""@eng , """localized Ewing's sarcoma"""@eng , """pPNET, localized"""@eng , """localized Askin's tumor"""@eng , """peripheral neuroectodermal tumor, localized"""@eng ; rdfs:subClassOf ; """Ewing's family of tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """7970"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796547"""^^xsd:string ; umls:cui """C1321778"""^^xsd:string ; umls:cui """C0863029"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039372"""^^xsd:string ; skos:altLabel """BAVIP"""@eng , """BLEO/DOX/DTIC/PRED/VCR"""@eng ; ; ; ; ; ; """2007"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0052853"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cephalexin"""@eng ; skos:notation """CDR0000043417"""^^xsd:string ; skos:altLabel """Keflex"""@eng ; skos:definition """A beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cephalexin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to second and third generation cephalosporins, cephalexin is more active against gram-positive and less active against gram-negative organisms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43417&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43417&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C356\" NCI Thesaurus)"""@eng ; """7976"""^^xsd:string ; """C356"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """15686-71-2"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700517"""^^xsd:string ; umls:cui """C0007716"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, Ewing's family of tumors"""@eng ; skos:notation """CDR0000043414"""^^xsd:string ; skos:altLabel """Ewing's family of tumors, cellular diagnosis"""@eng ; rdfs:subClassOf ; """7973"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0796550"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alendronate sodium/ketoconazole"""@eng ; skos:notation """CDR0000043415"""^^xsd:string ; skos:altLabel """KCZ/MK-217"""@eng ; ; ; """7974"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796551"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dermatofibrosarcoma protuberans"""@eng ; skos:notation """CDR0000474442"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2006-03-17"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0392784"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/fowlpox-PSA vaccine/sargramostim"""@eng ; skos:notation """CDR0000269485"""^^xsd:string ; skos:altLabel """F-PSA/GM-CSF/TXT"""@eng ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327852"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/bleomycin/cisplatin/etoposide"""@eng ; skos:notation """CDR0000043418"""^^xsd:string ; skos:altLabel """BLEO/CDDP/VP-16/WR-2721"""@eng ; ; ; ; ; """7979"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796553"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colon cancer"""@eng ; skos:notation """CDR0000043419"""^^xsd:string ; skos:altLabel """Colon cancer"""@eng ; ; rdfs:subClassOf ; ; rdfs:subClassOf ; """2002-10-15"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """8"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007102"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Waldenstrom's macroglobulinemia"""@eng ; skos:notation """CDR0000037790"""^^xsd:string ; skos:altLabel """macroglobulinemia, Waldenstrom's"""@eng , """macroglobulinemia"""@eng , """plasmacytoma, macroglobulinemia"""@eng , """lymphoplasmacytic lymphoma"""@eng , """lymphoplasmacytoid lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1015"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0024419"""^^xsd:string ; umls:cui """C0334633"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clonidine"""@eng ; skos:notation """CDR0000041228"""^^xsd:string ; skos:altLabel """Catapres"""@eng , """Catapres-TTS"""@eng ; """4301"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0699881"""^^xsd:string ; umls:cui """C0917969"""^^xsd:string ; umls:cui """C0009014"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/idarubicin/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000258412"""^^xsd:string ; skos:altLabel """DM/IDA/PEG-ASP/VCR"""@eng ; ; ; ; ; """2002-10-13"""^^xsd:string ; """11512"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327817"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/imatinib mesylate"""@eng ; skos:notation """CDR0000258413"""^^xsd:string ; skos:altLabel """CTX/STI571/VP-16"""@eng ; ; ; ; """2002-10-13"""^^xsd:string ; """11513"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327818"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gusperimus/monoclonal antibody L6"""@eng ; skos:notation """CDR0000041481"""^^xsd:string ; skos:altLabel """DSG/MOAB L6"""@eng ; ; ; """4552"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281026"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/PALA/zidovudine"""@eng ; skos:notation """CDR0000041480"""^^xsd:string ; skos:altLabel """CF/5-FU/PALA/ZDV"""@eng ; ; ; ; ; """4551"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281025"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """annamycin liposomal"""@eng ; skos:notation """CDR0000038230"""^^xsd:string ; skos:altLabel """liposomal annamycin"""@eng ; skos:definition """A liposome-encapsulated form of the antineoplastic antibiotic annamycin. Annamycin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also circumvents multidrug-resistance (MDR) transporters, including p-glycoprotein. Less toxic than annamycin, liposomal annamycin also shows improved antitumor properties compared to its parent compound. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38230&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38230&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C25838\" NCI Thesaurus)"""@eng ; """10837"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C25838"""^^xsd:string ; """700363"""^^xsd:string ; umls:cui """C0935796"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/capecitabine"""@eng ; skos:notation """CDR0000038231"""^^xsd:string ; skos:altLabel """CAPE/MOAB VEGF"""@eng ; ; ; """10838"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935797"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/interleukin-12"""@eng ; skos:notation """CDR0000038232"""^^xsd:string ; skos:altLabel """IL-12/LipoDox"""@eng ; ; ; """10839"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935798"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II penile cancer"""@eng ; skos:notation """CDR0000038233"""^^xsd:string ; skos:altLabel """penis cancer, stage II"""@eng , """penile cancer, stage II"""@eng ; rdfs:subClassOf ; """penile cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1084"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854966"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/UCN-01"""@eng ; skos:notation """CDR0000038234"""^^xsd:string ; skos:altLabel """CDDP/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """10840"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935799"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous tumor cell vaccine/interleukin-2"""@eng ; skos:notation """CDR0000038235"""^^xsd:string ; skos:altLabel """ATCV/IL-2"""@eng ; ; ; """10841"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935800"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen peptide 1-6D"""@eng ; skos:notation """CDR0000038236"""^^xsd:string ; skos:altLabel """CEA:571-579 (576D)"""@eng , """CEA PEP 1-6D"""@eng , """Modified CEA Peptide"""@eng , """CAP-1-6D Peptide"""@eng , """mCEA Peptide"""@eng ; skos:definition """A 9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). CEA:571-579 peptide, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2622\" NCI Thesaurus)"""@eng ; ; ; ; """2002-12-09"""^^xsd:string ; """10842"""^^xsd:string ; """C2622"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """701524"""^^xsd:string ; """6843"""^^xsd:string ; umls:cui """C0935801"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NV1020"""@eng ; skos:notation """CDR0000038237"""^^xsd:string ; """10843"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935802"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/sargramostim"""@eng ; skos:notation """CDR0000038238"""^^xsd:string ; skos:altLabel """BRYO/GM-CSF"""@eng ; ; ; """10844"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935803"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000038239"""^^xsd:string ; skos:altLabel """IDEC-In2B8/IDEC-Y2B8/MOAB IDEC-C2B8"""@eng ; ; ; ; """10845"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935804"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/iodine I 131 tositumomab/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000422434"""^^xsd:string ; skos:altLabel """CTX/DOX/I131-MOAB-B1/MOAB IDEC-C2B8/PRED/VCR"""@eng ; ; ; ; ; ; ; """2005-02-18"""^^xsd:string ; """2005-02-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541516"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/methotrexate"""@eng ; skos:notation """CDR0000041221"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/MTX"""@eng ; ; ; ; ; """4295"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280820"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/fluorouracil/sargramostim"""@eng ; skos:notation """CDR0000041220"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/5-FU/GM-CSF"""@eng ; ; ; ; ; """4294"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280819"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anaplastic carcinoma of the gallbladder"""@eng ; skos:notation """CDR0000039941"""^^xsd:string ; skos:altLabel """undifferentiated carcinoma of the gallbladder"""@eng , """gallbladder cancer, anaplastic"""@eng , """gallbladder, undifferentiated carcinoma of the"""@eng , """gallbladder cancer, undifferentiated"""@eng ; rdfs:subClassOf ; """2621"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279653"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mucinous adenocarcinoma of the rectum"""@eng ; skos:notation """CDR0000039940"""^^xsd:string ; skos:altLabel """adenocarcinoma of the rectum, mucinous"""@eng , """adenocarcinoma of the rectum, colloid"""@eng , """rectal, mucinous adenocarcinoma of the"""@eng , """rectum, mucinous adenocarcinoma of the"""@eng , """colloid adenocarcinoma of the rectum"""@eng ; rdfs:subClassOf ; """2620"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279652"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma with squamous metaplasia of the gallbladder"""@eng ; skos:notation """CDR0000039943"""^^xsd:string ; skos:altLabel """gallbladder cancer, adenocarcinoma with squamous metaplasia"""@eng , """gallbladder cancer, adenoacanthoma"""@eng , """gallbladder adenocarcinoma with squamous metaplasia"""@eng , """gallbladder adenoacanthoma"""@eng , """gallbladder cancer with squamous metaplasia and adenocarcinoma"""@eng , """adenoacanthoma of the gallbladder"""@eng ; rdfs:subClassOf ; """2623"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279655"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """signet ring adenocarcinoma of the rectum"""@eng ; skos:notation """CDR0000039942"""^^xsd:string ; skos:altLabel """rectum, signet ring adenocarcinoma of the"""@eng , """rectal, signet ring adenocarcinoma of the"""@eng , """adenocarcinoma of the rectum, signet ring"""@eng ; rdfs:subClassOf ; """2622"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279654"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoma simplex of the rectum"""@eng ; skos:notation """CDR0000039945"""^^xsd:string ; skos:altLabel """undifferentiated adenocarcinoma of the rectum"""@eng , """rectum, carcinoma simplex of the"""@eng , """rectal, undifferentiated adenocarcinoma"""@eng , """rectal, carcinoma simplex of the"""@eng , """rectum, anaplastic adenocarcinoma"""@eng , """anaplastic adenocarcinoma of the rectum"""@eng , """rectal, anaplastic adenocarcinoma"""@eng , """rectum, undifferentiated adenocarcinoma"""@eng ; rdfs:subClassOf ; """2625"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279657"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """scirrhous carcinoma of the rectum"""@eng ; skos:notation """CDR0000039944"""^^xsd:string ; skos:altLabel """carcinoma of the rectum, scirrhous"""@eng , """rectal, scirrhous carcinoma of the"""@eng , """rectum, scirrhous carcinoma of the"""@eng ; rdfs:subClassOf ; """2624"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279656"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the extrahepatic bile duct"""@eng ; skos:notation """CDR0000039947"""^^xsd:string ; skos:altLabel """bile duct cancer, extrahepatic, adenocarcinoma"""@eng , """extrahepatic bile duct, adenocarcinoma of the"""@eng , """extrahepatic bile duct cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """2632"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279659"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of the gallbladder"""@eng ; skos:notation """CDR0000039946"""^^xsd:string ; skos:altLabel """epidermoid carcinoma of the gallbladder"""@eng , """gallbladder, squamous cell carcinoma of the"""@eng , """gallbladder cancer, squamous cell carcinoma"""@eng , """gallbladder cancer, epidermoid carcinoma"""@eng ; rdfs:subClassOf ; """2628"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279658"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian serous cystadenoma with proliferating activity"""@eng ; skos:notation """CDR0000039949"""^^xsd:string ; skos:altLabel """cystadenoma with proliferating activity, serous, ovarian"""@eng , """cystadenoma with proliferating activity, ovarian serous"""@eng , """serous cystadenoma with proliferating activity, of the ovary"""@eng , """ovarian cancer, serous cystadenoma with proliferating activity"""@eng , """ovary cancer, serous cystadenoma with proliferating activity"""@eng ; rdfs:subClassOf ; """2640"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279662"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acinar cell adenocarcinoma of the pancreas"""@eng ; skos:notation """CDR0000039948"""^^xsd:string ; skos:altLabel """pancreas cancer, acinar cell adenocarcinoma"""@eng , """adenocarcinoma, acinar cell, pancreatic"""@eng , """pancreatic cancer, acinar cell adenocarcinoma"""@eng ; rdfs:subClassOf ; """2634"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279661"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """denileukin diftitox/dexamethasone"""@eng ; skos:notation """CDR0000038098"""^^xsd:string ; skos:altLabel """DAB389-IL2/DM"""@eng ; ; ; """10646"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935689"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized gastrointestinal carcinoid tumor"""@eng ; skos:notation """CDR0000038099"""^^xsd:string ; skos:altLabel """gastrointestinal carcinoid tumor, localized"""@eng ; rdfs:subClassOf ; """gastrointestinal carcinoid tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1065"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278747"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin HCl liposome"""@eng ; skos:notation """CDR0000038094"""^^xsd:string ; skos:altLabel """CBDCA/LipoDox"""@eng ; ; ; """10642"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935685"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cintredekin besudotox"""@eng ; skos:notation """CDR0000038095"""^^xsd:string ; skos:altLabel """IL13-PE38QQR"""@eng , """Interleukin-13 PE38QQR Immunotoxin"""@eng ; skos:definition """A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R).The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38095&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38095&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2599\" NCI Thesaurus)"""@eng ; """950012"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """C2599"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """10643"""^^xsd:string ; umls:cui """C1434448"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ganciclovir/interleukin-2/zidovudine"""@eng ; skos:notation """CDR0000038096"""^^xsd:string ; skos:altLabel """BW-B759U/IL-2/ZDV"""@eng ; ; ; ; """10644"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935687"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 daclizumab"""@eng ; skos:notation """CDR0000038097"""^^xsd:string ; skos:altLabel """Y90 daclizumab"""@eng , """Y90 MOAB anti-Tac"""@eng ; skos:definition """A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity. Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes. As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38097&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38097&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2600\" NCI Thesaurus)"""@eng ; """10645"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C2600"""^^xsd:string ; umls:cui """C0935688"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/tretinoin"""@eng ; skos:notation """CDR0000038090"""^^xsd:string ; skos:altLabel """AS203/ATRA"""@eng ; ; ; """10634"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935680"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """virtual colonoscopy"""@eng ; skos:notation """CDR0000038091"""^^xsd:string ; rdfs:subClassOf ; """10635"""^^xsd:string ; """2004-04-23"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0935912"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal carcinoid tumor"""@eng ; skos:notation """CDR0000038092"""^^xsd:string ; skos:altLabel """carcinoid tumor, gastrointestinal"""@eng , """GCT"""@eng , """Gastrointestinal carcinoid tumor"""@eng , """GI carcinoid tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1064"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220620"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000038093"""^^xsd:string ; skos:altLabel """CDDP/CTX/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; """10641"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935684"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malignant giant cell tumor of bone"""@eng ; skos:notation """CDR0000530113"""^^xsd:string ; rdfs:subClassOf ; """Cancer diagnosis"""^^xsd:string ; """2007-01-09"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C0334552"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """benign giant cell tumor of bone"""@eng ; skos:notation """CDR0000530111"""^^xsd:string ; rdfs:subClassOf ; """2007-01-16"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """2007-01-09"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0855006"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylprednisolone/mycophenolate mofetil/tacrolimus"""@eng ; skos:notation """CDR0000271394"""^^xsd:string ; skos:altLabel """FK506/MePRDL/MMF"""@eng ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327886"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin and mucous membrane agent"""@eng ; skos:notation """CDR0000040429"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3299"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0304573"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gemcitabine"""@eng ; skos:notation """CDR0000042513"""^^xsd:string ; skos:altLabel """dFdC/5-FU"""@eng ; ; ; """6127"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392944"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interleukin-7"""@eng ; skos:notation """CDR0000305941"""^^xsd:string ; skos:altLabel """IL-7"""@eng , """CYT 99 007"""@eng ; skos:definition """A recombinant protein which is chemically identical to or similar to endogenous interleukin-7 (IL-7) with hematopoietic and immunopotentiating properties. Produced by bone marrow, thymic stromal, and spleen cells, the cytokine interleukin-7 is a hematopoietic growth factor for progenitor B cells and T cells and stimulates proliferation and differentiation of mature T-cells and natural killer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305941&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=305941&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C592\" NCI Thesaurus)"""@eng ; ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C592"""^^xsd:string ; """2003-05-23"""^^xsd:string ; umls:cui """C1527134"""^^xsd:string ; umls:cui """C1328727"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laryngeal squamous cell carcinoma"""@eng ; skos:notation """CDR0000040683"""^^xsd:string ; skos:altLabel """squamous cell carcinoma, laryngeal"""@eng , """larynx squamous cell carcinoma"""@eng , """epidermoid carcinoma, laryngeal"""@eng ; rdfs:subClassOf ; """3599"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280324"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/sargramostim/vincristine"""@eng ; skos:notation """CDR0000039619"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/CTX/DOX/GM-CSF/MTX/PRED/VCR/VP-16"""@eng , """ProMACE/CytaBOM/GM-CSF"""@eng ; ; ; ; ; ; ; ; ; ; """2274"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279406"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/cyclophosphamide/doxorubicin/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000039618"""^^xsd:string ; skos:altLabel """BLEO/CDDP/CTX/DOX/5-FU/VCR"""@eng , """COAd/COB-5P"""@eng ; ; ; ; ; ; ; """2273"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279405"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dactinomycin/vinblastine"""@eng ; skos:notation """CDR0000039611"""^^xsd:string ; skos:altLabel """VAB"""@eng , """BLEO/DACT/VBL"""@eng ; ; ; ; """2266"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077960"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """porfiromycin"""@eng ; skos:notation """CDR0000039610"""^^xsd:string ; skos:altLabel """Methyl Mitomycin"""@eng , """Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-,[1aR-(1a.alpha.,8.beta., 8a.alpha.,8b.alpha.)]- (9CI)"""@eng , """Porfiromycine"""@eng , """[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"""@eng , """Methylmitomycin"""@eng , """U-14743"""@eng , """Azirino[2',3':3,4]pyrrolo[1, 2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a, 8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-1,5-dimethyl-, carbamate (ester)(8CI)"""@eng , """ENT-50825"""@eng , """Methyl Mitomycin C"""@eng , """N-methylmitomycin C"""@eng , """Promycin"""@eng , """Porphyromycin"""@eng ; skos:definition """An N-methyl derivative of the antineoplastic antibiotic mitomycin C isolated from the bacterium Streptomyces ardus and other Streptomyces bacterial species. Bioreduced porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks, thereby inhibiting DNA synthesis. Porfiromycin is preferentially toxic to hypoxic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39610&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39610&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C763\" NCI Thesaurus)"""@eng ; """2265"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """56410"""^^xsd:string ; """1230"""^^xsd:string ; """33509"""^^xsd:string ; """801-52-5"""^^xsd:string ; """C763"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0032697"""^^xsd:string ; umls:cui """C0309911"""^^xsd:string ; umls:cui """C1527315"""^^xsd:string ; umls:cui """C1527316"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/chlorambucil/cisplatin/cyclophosphamide/dactinomycin/vinblastine"""@eng ; skos:notation """CDR0000039613"""^^xsd:string ; skos:altLabel """VAB-III"""@eng , """BLEO/CDDP/CLB/CTX/DACT/VBL"""@eng ; ; ; ; ; ; ; """2268"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077962"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/dactinomycin/vinblastine"""@eng ; skos:notation """CDR0000039612"""^^xsd:string ; skos:altLabel """VAB-II"""@eng , """BLEO/CDDP/DACT/VBL"""@eng ; ; ; ; ; """2267"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077959"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/vincristine"""@eng ; skos:notation """CDR0000039615"""^^xsd:string ; skos:altLabel """VAC"""@eng , """VAC (CTX/DACT/VCR)"""@eng , """CTX/DACT/VCR"""@eng ; ; ; ; """2270"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077964"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/monoclonal antibody R24"""@eng ; skos:notation """CDR0000039614"""^^xsd:string ; skos:altLabel """CDDP/MOAB R24/WR-2721"""@eng ; ; ; ; """2269"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279401"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine/interferon alfa"""@eng ; skos:notation """CDR0000039617"""^^xsd:string ; skos:altLabel """DFMO/IFN-A"""@eng ; ; ; """2272"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338096"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/sargramostim"""@eng ; skos:notation """CDR0000039616"""^^xsd:string ; skos:altLabel """CF/5-FU/GM-CSF"""@eng ; ; ; ; """2271"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279403"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase"""@eng ; skos:notation """CDR0000041146"""^^xsd:string ; skos:altLabel """Leunase"""@eng , """Leucogen"""@eng , """Erwinia Asparaginase"""@eng , """ASNase"""@eng , """L-Asnase"""@eng , """Colaspase"""@eng , """L-ASP"""@eng , """ASP-1"""@eng , """Erwinase"""@eng , """Re-82-TAD-15"""@eng , """Lcf-ASP"""@eng , """Cristanaspase"""@eng , """Kidrolase"""@eng , """MK-965"""@eng , """Elspar"""@eng , """Asparaginase Erwinia"""@eng , """L-asparagine amidohydrolase"""@eng , """EC 3.5.1.1"""@eng , """Crasnitine"""@eng , """Laspar"""@eng , """Paronal"""@eng , """Asparaginase II"""@eng , """Crasnitin"""@eng , """L-asparaginase"""@eng ; skos:definition """An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting leukemic cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. This agent also induces apoptosis in tumor cells. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41146&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41146&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C286\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """422"""^^xsd:string ; """109229"""^^xsd:string ; """290"""^^xsd:string ; """C286"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """106977"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1510951"""^^xsd:string ; umls:cui """C1510952"""^^xsd:string ; umls:cui """C1510953"""^^xsd:string ; umls:cui """C1510954"""^^xsd:string ; umls:cui """C0771210"""^^xsd:string ; umls:cui """C1522681"""^^xsd:string ; umls:cui """C0699261"""^^xsd:string ; umls:cui """C1522682"""^^xsd:string ; umls:cui """C1257721"""^^xsd:string ; umls:cui """C1257720"""^^xsd:string ; umls:cui """C1527242"""^^xsd:string ; umls:cui """C0591457"""^^xsd:string ; umls:cui """C0003993"""^^xsd:string ; umls:cui """C0699262"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian sarcoma"""@eng ; skos:notation """CDR0000041147"""^^xsd:string ; skos:altLabel """sarcoma, ovarian"""@eng , """Ovarian sarcoma"""@eng , """sarcoma of the ovary"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4220"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280746"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """previously treated myelodysplastic syndromes"""@eng ; skos:notation """CDR0000041144"""^^xsd:string ; skos:altLabel """myelodysplastic syndromes, previously treated"""@eng ; rdfs:subClassOf ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """myelodysplastic syndromes"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4218"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280744"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """secondary myelodysplastic syndromes"""@eng ; skos:notation """CDR0000041145"""^^xsd:string ; skos:altLabel """myelodysplastic syndromes, secondary"""@eng ; rdfs:subClassOf ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """myelodysplastic syndromes"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4219"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280745"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/mitoxantrone"""@eng ; skos:notation """CDR0000041142"""^^xsd:string ; skos:altLabel """BU/DHAD"""@eng ; ; ; """4216"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280742"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2/monoclonal antibody R24"""@eng ; skos:notation """CDR0000041143"""^^xsd:string ; skos:altLabel """CTX/IL-2/MOAB R24"""@eng ; ; ; ; """4217"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280743"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/interleukin-2"""@eng ; skos:notation """CDR0000041140"""^^xsd:string ; skos:altLabel """DTIC/IL-2"""@eng ; ; ; """4214"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280740"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/tamoxifen"""@eng ; skos:notation """CDR0000041141"""^^xsd:string ; skos:altLabel """CDDP/DTIC/TMX"""@eng ; ; ; ; """4215"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280741"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000041148"""^^xsd:string ; skos:altLabel """CLB/PRED/VCR/VP-16"""@eng ; ; ; ; ; """4221"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280747"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/prednisone"""@eng ; skos:notation """CDR0000041149"""^^xsd:string ; skos:altLabel """ARA-C/PRED/VP-16"""@eng ; ; ; ; """4222"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280748"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/gefitinib/oxaliplatin"""@eng ; skos:notation """CDR0000377335"""^^xsd:string ; skos:altLabel """CAPE/L-OHP/ZD 1839"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541313"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000040557"""^^xsd:string ; skos:altLabel """adult diffuse large cell lymphoma, recurrent"""@eng , """diffuse large cell lymphoma, recurrent, adult"""@eng , """relapsed adult diffuse large cell lymphoma"""@eng , """adult diffuse large cell lymphoma, relapsed"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3453"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280188"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult supratentorial primitive neuroectodermal tumor (PNET)"""@eng ; skos:notation """CDR0000377337"""^^xsd:string ; skos:altLabel """supratentorial primitive neuroectodermal tumor (PNET), adult"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541315"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult embryonal tumors"""@eng ; skos:notation """CDR0000377336"""^^xsd:string ; skos:altLabel """embryonal tumors, adult"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541314"""^^xsd:string ; umls:tui """T077"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000040552"""^^xsd:string ; skos:altLabel """follicular mixed cell lymphoma, recurrent"""@eng , """recurrent grade II follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma, relapsed"""@eng , """relapsed follicular mixed cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3448"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280183"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """relapsed adult non-Hodgkin's lymphoma, intermediate grade"""@eng ; skos:notation """CDR0000040553"""^^xsd:string ; skos:altLabel """recurrent adult non-Hodgkin's lymphoma, intermediate grade"""@eng , """NHL, intermediate grade, recurrent adult"""@eng , """adult non-Hodgkin's lymphoma, intermediate grade, recurrent"""@eng , """non-Hodgin's lymphoma intermediate grade, recurrent adult"""@eng , """adult non-Hodgkin's lymphoma, intermediate grade, relapsed"""@eng , """relapsed adult NHL, intermediate grade"""@eng , """recurrent adult NHL, intermediate grade"""@eng , """intermediate-grade, relapsed adult NHL"""@eng , """intermediate-grade, relapsed adult non-Hodgkin's lymphoma"""@eng , """intermediate-grade, recurrent adult NHL"""@eng , """adult NHL, recurrent, intermediate grade"""@eng , """non-Hodgkin's lymphoma, intermediate grade, relapsed adult"""@eng , """adult NHL, relapsed, intermediate grade"""@eng , """NHL, intermediate grade, relapsed adult"""@eng ; """2005-01-21"""^^xsd:string ; """3449"""^^xsd:string ; umls:cui """C0280184"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000040550"""^^xsd:string ; skos:altLabel """small lymphocytic lymphoma, recurrent"""@eng , """relapsed small lymphocytic lymphoma"""@eng , """small lymphocytic lymphoma, relapsed"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3446"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """small lymphocytic lymphoma"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0855096"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000040551"""^^xsd:string ; skos:altLabel """follicular small cleaved cell lymphoma, recurrent"""@eng , """relapsed follicular small cleaved cell lymphoma"""@eng , """follicular small cleaved cell lymphoma, relapsed"""@eng , """recurrent grade I follicular small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3447"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280182"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """relapsed adult non-Hodgkin's lymphoma, high grade"""@eng ; skos:notation """CDR0000040558"""^^xsd:string ; skos:altLabel """non-Hodgkin's lymphoma, high grade, relapsed adult"""@eng , """high-grade, relapsed adult NHL"""@eng , """adult non-Hodgkin's lymphoma, high grade, recurrent"""@eng , """recurrent adult NHL, high grade"""@eng , """lymphoma, high grade, relapsed adult non-Hodgkin's"""@eng , """recurrent adult non-Hodgkin's lymphoma, high grade"""@eng , """lymphoma, high grade, recurrent adult non-Hodgkin's"""@eng , """high-grade, recurrent adult NHL"""@eng , """non-hodgkin's lymphoma, high grade, recurrent adult"""@eng , """adult NHL, recurrent, high grade"""@eng , """adult non-Hodgkin's lymphoma, high grade, relapsed"""@eng , """relapsed adult NHL, high grade"""@eng , """high-grade, relapsed adult non-Hodgkin's lymphoma"""@eng , """NHL, high grade, recurrent adult"""@eng , """adult NHL, relapsed, high grade"""@eng , """NHL, high grade, relapsed adult"""@eng ; """2005-01-21"""^^xsd:string ; """3454"""^^xsd:string ; umls:cui """C0280189"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000040559"""^^xsd:string ; skos:altLabel """adult immunoblastic large cell lymphoma, recurrent"""@eng , """adult immunoblastic large cell lymphoma, relapsed"""@eng , """immunoblastic large cell lymphoma, adult, recurrent"""@eng , """immunoblastic large cell lymphoma, recurrent, adult"""@eng , """relapsed adult immunoblastic large cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3455"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280190"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/tipifarnib"""@eng ; skos:notation """CDR0000373810"""^^xsd:string ; skos:altLabel """OSI774/R115777"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541291"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior oophorectomy"""@eng ; skos:notation """CDR0000040088"""^^xsd:string ; skos:altLabel """oophorectomy, prior"""@eng ; """2836"""^^xsd:string ; umls:cui """C0279787"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbetimer"""@eng ; skos:notation """CDR0000040089"""^^xsd:string ; skos:altLabel """carbethimer"""@eng , """carboxyaminidate"""@eng , """NED-137"""@eng , """POLIMA"""@eng , """N-137"""@eng ; """2837"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0068482"""^^xsd:string ; umls:cui """C0108454"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """1 or more positive axillary node"""@eng ; skos:notation """CDR0000040084"""^^xsd:string ; skos:altLabel """axillary node, 1 or more positive"""@eng , """one or more positive axillary node"""@eng , """positive axillary node, 1 or more"""@eng ; """2831"""^^xsd:string ; umls:cui """C0279784"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CGP-6809"""@eng ; skos:notation """CDR0000040085"""^^xsd:string ; skos:altLabel """CGP 6'809"""@eng ; """2833"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0055205"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dezaguanine"""@eng ; skos:notation """CDR0000040086"""^^xsd:string ; skos:altLabel """CI-908"""@eng , """deazaguanine"""@eng , """3-deazaguanine"""@eng ; """2834"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1527328"""^^xsd:string ; umls:cui """C0047332"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/prednisone/vincristine"""@eng ; skos:notation """CDR0000040087"""^^xsd:string ; skos:altLabel """VPF"""@eng , """5-FU/PRED/VCR"""@eng ; ; ; ; """2835"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279786"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory hairy cell leukemia"""@eng ; skos:notation """CDR0000040080"""^^xsd:string ; skos:altLabel """hairy cell leukemia, refractory"""@eng , """leukemia, hairy cell, recurrent"""@eng , """hairy cell leukemia, recurrent"""@eng , """leukemia, hairy cell, refractory"""@eng , """recurrent hairy cell leukemia"""@eng ; rdfs:subClassOf ; """hairy cell leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2822"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279780"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """no positive axillary nodes"""@eng ; skos:notation """CDR0000040081"""^^xsd:string ; skos:altLabel """axillary nodes, no positive"""@eng ; """2827"""^^xsd:string ; umls:cui """C0279781"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040082"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/CTX/DOX/MTX/PRED/VCR/VP-16"""@eng , """ProMACE-CytaBOM"""@eng ; ; ; ; ; ; ; ; ; """2828"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0072146"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040083"""^^xsd:string ; skos:altLabel """DM/DOX/VCR"""@eng , """VAD"""@eng ; ; ; ; """2829"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077973"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diindolylmethane"""@eng ; skos:notation """CDR0000462587"""^^xsd:string ; skos:altLabel """3,3'-diindoylmethane"""@eng , """DIM"""@eng , """BioResponse DIM"""@eng ; skos:definition """A phytonutrient and plant indole found in cruciferous vegetables including broccoli, brussels sprouts, cabbage, cauliflower and kale, with potential antiandrogenic and antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) promotes beneficial estrogen metabolism in both sexes by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of 2-hydroxy estrogen metabolites, resulting in increased antioxidant activity. Although this agent induces apoptosis in tumor cells in vitro, the exact mechanism by which DIM exhibits its antineoplastic activity in vivo is unknown. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462587&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=462587&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53434\" NCI Thesaurus)"""@eng ; """2006-06-28"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C53434"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1707751"""^^xsd:string ; umls:cui """C1100708"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glutathione disulfide NOV-002"""@eng ; skos:notation """CDR0000494994"""^^xsd:string ; """C62537"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """2006-09-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831919"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amonafide L-malate"""@eng ; skos:notation """CDR0000485171"""^^xsd:string ; skos:definition """The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485171&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=485171&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61306\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-10"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """C61306"""^^xsd:string ; umls:cui """C1831822"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMP-2:340-349 peptide vaccine"""@eng ; skos:notation """CDR0000504594"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-24"""^^xsd:string ; umls:cui """C1831952"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """coumarin"""@eng ; skos:notation """CDR0000042491"""^^xsd:string ; skos:altLabel """tonka bean camphor"""@eng ; """6029"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0010206"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dextromethorphan hydrobromide"""@eng ; skos:notation """CDR0000042490"""^^xsd:string ; skos:altLabel """DXM"""@eng ; ; """C423"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-05"""^^xsd:string ; """6022"""^^xsd:string ; umls:cui """C0350422"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soy protein isolate"""@eng ; skos:notation """CDR0000042493"""^^xsd:string ; skos:altLabel """Revival"""@eng , """Soybean Protein Isolate"""@eng , """soy isoflavones"""@eng , """Isolated Soy Protein"""@eng , """SOY"""@eng , """Prevastein HC"""@eng , """Soybean Isoflavones Extract"""@eng , """Soybean Protein"""@eng , """Soy Isoflavone"""@eng ; skos:definition """A dietary protein isolated from soybeans that contains isoflavone phytoestrogens. Soy protein isolate has been shown to reduce tumor incidence and growth in some animal studies, possibly by modulating estrogen metabolism, reducing tumor cell proliferation, and inducing tumor cell apoptosis. Soy protein isolate may also inhibit endothelial cell proliferation. Isoflavone phytoestrogens display mild estrogen-like activities which may regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42493&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42493&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1803\" NCI Thesaurus)"""@eng ; ; ; """6052"""^^xsd:string ; """C1803"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9010-10-0"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0677666"""^^xsd:string ; umls:cui """C1123022"""^^xsd:string ; umls:cui """C1831600"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arginine butyrate"""@eng ; skos:notation """CDR0000042492"""^^xsd:string ; skos:altLabel """L-arginine"""@eng , """Arginine HCL"""@eng ; skos:definition """The butyric acid salt of the amino acid arginine. In EBV-related lymphomas, arginine butyrate induces EBV thymidine kinase transcription and may act synergistically with the antiviral agent ganciclovir to inhibit cell proliferation and decrease cell viability. In addition, the butyrate moiety inhibits histone deacetylase, which results in hyperacetylation of histones H3 and H4. Acetylated histones have a reduced affinity for chromatin; this reduced histone-chromatin affinity may allow chromosomal unfolding, potentially enhancing the expression of genes related to tumor cell growth arrest and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42492&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42492&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2570\" NCI Thesaurus)"""@eng ; ; """6032"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2570"""^^xsd:string ; """80407-72-3"""^^xsd:string ; """2006-07-27"""^^xsd:string ; umls:cui """C0052329"""^^xsd:string ; umls:cui """C0301556"""^^xsd:string ; umls:cui """C0003765"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/phenylbutyrate"""@eng ; skos:notation """CDR0000042495"""^^xsd:string ; skos:altLabel """5-FU/PBA"""@eng ; ; ; """6059"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392930"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxycycline"""@eng ; skos:notation """CDR0000042494"""^^xsd:string ; skos:altLabel """Vibramycin"""@eng , """Doxycycline Monohydrate"""@eng ; skos:definition """A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42494&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42494&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C457\" NCI Thesaurus)"""@eng ; """6054"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """564-25-0"""^^xsd:string ; """C457"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699957"""^^xsd:string ; umls:cui """C0700451"""^^xsd:string ; umls:cui """C0013090"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/mitoxantrone"""@eng ; skos:notation """CDR0000042497"""^^xsd:string ; skos:altLabel """DHAD/L-PAM"""@eng ; ; ; """6061"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392932"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/methylprednisolone"""@eng ; skos:notation """CDR0000042496"""^^xsd:string ; skos:altLabel """MePRDL/VP-16"""@eng ; ; ; """6060"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392931"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclosporine/doxorubicin"""@eng ; skos:notation """CDR0000042499"""^^xsd:string ; skos:altLabel """CBDCA/CYSP/DOX"""@eng ; ; ; ; """6063"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392934"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/paclitaxel"""@eng ; skos:notation """CDR0000042498"""^^xsd:string ; skos:altLabel """CBDCA/TAX/VP-16"""@eng ; ; ; ; """6062"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392933"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """real-time contrast-enhanced ultrasonography"""@eng ; skos:notation """CDR0000532283"""^^xsd:string ; rdfs:subClassOf ; """2007-01-25"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2007-01-22"""^^xsd:string ; umls:cui """C1832052"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """noncontiguous stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042729"""^^xsd:string ; rdfs:subClassOf ; """6523"""^^xsd:string ; """2004-05-27"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677699"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000042727"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6521"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677697"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000042726"""^^xsd:string ; skos:altLabel """contiguous stage II adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """6520"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677696"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000042725"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6519"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677695"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000042724"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6518"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796292"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000042723"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6517"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677693"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II mantle cell lymphoma"""@eng ; skos:notation """CDR0000042722"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6516"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677692"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aggressive, contiguous stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042721"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6515"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677691"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000042720"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """6514"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677690"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """compliance monitoring"""@eng ; skos:notation """CDR0000480143"""^^xsd:string ; rdfs:subClassOf ; """2006-04-07"""^^xsd:string ; """2006-04-06"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C1831803"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CMV pp65 peptide"""@eng ; skos:notation """CDR0000273709"""^^xsd:string ; skos:altLabel """CMV-PEP"""@eng ; skos:definition """A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an HLA-A-restricted epitope to produce vaccines and specific CD8+ and CD4+ cell responses against CMV infection, a serious complication of allogeneic bone marrow transplantation (BMT). In BMT, CMV infection may be prevented by passive immunization with donor-derived CMV-pp65-specific T-cell clones if provided early post-BMT. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=273709&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=273709&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26640\" NCI Thesaurus)"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """C26640"""^^xsd:string ; umls:cui """C1327895"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/tetanus toxoid"""@eng ; skos:notation """CDR0000273708"""^^xsd:string ; skos:altLabel """ADC/TETTOX"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327894"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vascular endothelial growth factor antisense oligonucleotide"""@eng ; skos:notation """CDR0000465178"""^^xsd:string ; skos:altLabel """Veglin"""@eng , """VEGF-AS"""@eng ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1710620"""^^xsd:string ; umls:cui """C1710619"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dendritic cell-autologous lung tumor vaccine"""@eng ; skos:notation """CDR0000256453"""^^xsd:string ; skos:altLabel """DCVax-Lung"""@eng ; skos:definition """A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient. In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen. Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256453&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256453&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26446\" NCI Thesaurus)"""@eng ; """11401"""^^xsd:string ; """C26446"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327750"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dendritic cell-recombinant prostate-specific membrane antigen vaccine"""@eng ; skos:notation """CDR0000256450"""^^xsd:string ; skos:altLabel """DC-RPSMA vaccine"""@eng , """DCVAX-PSMA"""@eng , """DCVAX-Prostate"""@eng ; """2002-07-16"""^^xsd:string ; """11400"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327749"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant thyroid-stimulating hormone"""@eng ; skos:notation """CDR0000526653"""^^xsd:string ; skos:altLabel """Thyrotropin"""@eng , """Recombinant TSH"""@eng , """Thytropar"""@eng , """Thyroid Stimulating Hormone"""@eng ; skos:definition """A peptide hormone secreted by the anterior pituitary. It promotes the growth of the thyroid gland and stimulates the synthesis of thyroid hormones and the release of thyroxine by the thyroid gland. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526653&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526653&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C887\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """9002-71-5"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """C887"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1535531"""^^xsd:string ; umls:cui """C0040160"""^^xsd:string ; umls:cui """C1832006"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CD20"""@eng ; skos:notation """CDR0000043458"""^^xsd:string ; skos:altLabel """monoclonal antibody, CD20"""@eng , """MOAB CD20"""@eng ; """8637"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796614"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GVAX prostate cancer vaccine"""@eng ; skos:notation """CDR0000043459"""^^xsd:string ; skos:altLabel """GM-CSF prostate cancer vaccine"""@eng , """allogeneic prostate cancer vaccine, GM-CSF gene transduced"""@eng , """GVAX prostate vac"""@eng , """prostate cancer vaccine, GVAX"""@eng , """prostate cancer vaccine, GM-CSF gene transduced"""@eng , """GM-CSF gene transduced allogeneic prostate cancer vaccine"""@eng , """human GM-CSF gene transduced allogeneic prostate cancer vaccine"""@eng ; """2004-03-23"""^^xsd:string ; """8638"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796615"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood ependymoma"""@eng ; skos:notation """CDR0000043456"""^^xsd:string ; skos:altLabel """childhood ependymoma, recurrent"""@eng , """ependymoma, recurrent childhood"""@eng , """ependymoma, childhood, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood ependymoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """8635"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796612"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CD19"""@eng ; skos:notation """CDR0000043457"""^^xsd:string ; skos:altLabel """CD19, monoclonal antibody"""@eng , """MOAB CD19"""@eng ; """8636"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796613"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """newly diagnosed childhood ependymoma"""@eng ; skos:notation """CDR0000043455"""^^xsd:string ; skos:altLabel """childhood ependymoma, newly diagnosed"""@eng , """ependymoma, childhood, newly diagnosed"""@eng , """ependymoma, newly diagnosed childhood"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood ependymoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """8634"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796611"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/SCH-58500"""@eng ; skos:notation """CDR0000043452"""^^xsd:string ; skos:altLabel """CBDCA/SCH 58500/TAX"""@eng ; ; ; ; """2003-10-22"""^^xsd:string ; """8631"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796609"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cytarabine/topotecan"""@eng ; skos:notation """CDR0000043453"""^^xsd:string ; skos:altLabel """ARA-C/TOPO/WR-2721"""@eng ; ; ; ; """8632"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796610"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/temozolomide"""@eng ; skos:notation """CDR0000043450"""^^xsd:string ; skos:altLabel """13-CRA/TMZ"""@eng ; ; ; """8629"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796607"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/interferon alfa/sargramostim"""@eng ; skos:notation """CDR0000043451"""^^xsd:string ; skos:altLabel """CYSP/GM-CSF/IFN-A"""@eng ; ; ; ; """8630"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796608"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111-CMD-193"""@eng ; skos:notation """CDR0000489294"""^^xsd:string ; skos:altLabel """Indium In 111 CMD-193"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-19"""^^xsd:string ; """C62481"""^^xsd:string ; umls:cui """C1831887"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytochlor"""@eng ; skos:notation """CDR0000353478"""^^xsd:string ; skos:altLabel """CldC"""@eng ; skos:definition """A radio-sensitizing pyrimidine nucleoside with potential antineoplastic activity. Cytochlor is metabolized first to a phosphate derivative, CldCMP, by the enzyme deoxycytidine kinase and then to the active uracyl derivative, CldUMP, by the enzyme dCMP deaminase; deoxycytidine kinase and dCMP deaminase have been found in abnormally high concentrations in most cancers. CldUMP, the active metabolite, incorporates into DNA and, upon exposure to radiation, induces the formation of uracil radicals and double-strand DNA breaks. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=353478&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=353478&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28950\" NCI Thesaurus)"""@eng ; ; """2004-01-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """68560"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C28950"""^^xsd:string ; umls:cui """C1328172"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytochlor/tetrahydrouridine"""@eng ; skos:notation """CDR0000353479"""^^xsd:string ; skos:altLabel """CldC/THU"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328173"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/epirubicin/pegfilgrastim"""@eng ; skos:notation """CDR0000322130"""^^xsd:string ; skos:altLabel """EPI/GCSF-SD01/TXT"""@eng ; ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328016"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """loperamide hydrochloride"""@eng ; skos:notation """CDR0000041911"""^^xsd:string ; skos:altLabel """Imodium A-D"""@eng ; skos:definition """The hydrochloride salt form of loperamide, a synthetic, piperidine derivative and opioid agonist with antidiarrheal activity. Loperamide acts on the mu-receptors in the intestinal mucosa. This leads to a decrease in gastrointestinal motility by decreasing the circular and longitudinal smooth muscle activity of the intestinal wall. This slows intestinal transit and allows for more water and electrolyte absorption from the intestines. Loperamide is not significantly absorbed from the gut and does not cross the blood-brain barrier. Therefore it has no central nervous system effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41911&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41911&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1584\" NCI Thesaurus)"""@eng ; """2007-01-24"""^^xsd:string ; """34552-83-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5129"""^^xsd:string ; """C1584"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0282221"""^^xsd:string ; umls:cui """C0721047"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-threo-dihydrosphingosine"""@eng ; skos:notation """CDR0000041910"""^^xsd:string ; skos:altLabel """Safingol"""@eng , """Sphinganine"""@eng , """Kynacyte"""@eng , """2-Amino-1,3-Dihydroxyoctadecane"""@eng ; skos:definition """A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), L-threo-dihydrosphingosine competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41910&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41910&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1568\" NCI Thesaurus)"""@eng ; ; """Drug/agent"""^^xsd:string ; """C1568"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0281466"""^^xsd:string ; umls:cui """C0919368"""^^xsd:string ; umls:cui """C0074987"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/topotecan"""@eng ; skos:notation """CDR0000041913"""^^xsd:string ; skos:altLabel """CTX/TOPO"""@eng ; ; ; """5132"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281468"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fazarabine/filgrastim"""@eng ; skos:notation """CDR0000041912"""^^xsd:string ; skos:altLabel """ARA-AC/G-CSF"""@eng ; ; ; """5130"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281467"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adozelesin"""@eng ; skos:notation """CDR0000041915"""^^xsd:string ; skos:altLabel """U-73,975"""@eng ; skos:definition """An alkylating agent that bind to the DNA minor groove in a sequence-specific manner and form covalent adducts with adenines, resulting in the inhibition of DNA replication and induction of apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41915&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41915&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1270\" NCI Thesaurus)"""@eng ; """5134"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """615284"""^^xsd:string ; """123219-86-3"""^^xsd:string ; """C1270"""^^xsd:string ; umls:cui """C0077640"""^^xsd:string ; umls:cui """C0165376"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/thiotepa"""@eng ; skos:notation """CDR0000041914"""^^xsd:string ; skos:altLabel """CDDP/CTX/TSPA"""@eng ; ; ; ; """5133"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281469"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gallium nitrate/ifosfamide/vinblastine"""@eng ; skos:notation """CDR0000041917"""^^xsd:string ; skos:altLabel """GAN/IFF/VBL"""@eng , """VIG"""@eng ; ; ; ; """5137"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281471"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000041916"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IFN-A/TMX"""@eng ; ; ; ; ; """5136"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338177"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol"""@eng ; skos:notation """CDR0000041919"""^^xsd:string ; skos:altLabel """CALTROL"""@eng , """Rocaltrol"""@eng , """(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol"""@eng , """1,25(OH)2-D3"""@eng , """1,25-Dihydroxycholecalciferol"""@eng ; skos:definition """A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form. Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth. A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types. This agent may be chemopreventive for colon and prostate cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41919&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41919&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C330\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """5139"""^^xsd:string ; """32222-06-3"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C330"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0006674"""^^xsd:string ; umls:cui """C0592076"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/thiotepa"""@eng ; skos:notation """CDR0000041918"""^^xsd:string ; skos:altLabel """BU/TSPA"""@eng ; ; ; """5138"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281472"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """azacitidine/etoposide"""@eng ; skos:notation """CDR0000042932"""^^xsd:string ; skos:altLabel """AZA/VP-16"""@eng ; ; ; """68"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278526"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thiotepa"""@eng ; skos:notation """CDR0000042933"""^^xsd:string ; skos:altLabel """STEPA"""@eng , """Tifosyl"""@eng , """1,1',1''-Phosphinothioyldynetrisaziridine"""@eng , """TSPA"""@eng , """Thiophosphamide"""@eng , """Thiotef"""@eng , """N,N',N''-triethylenethiophosphoramide"""@eng , """Thiophosphoramide"""@eng , """Ledertepa"""@eng , """Oncotiotepa"""@eng , """Tespamine"""@eng , """1,1',1\"-phosphinothioylidynetrisaziridine"""@eng , """triethylenethiophosphoramide"""@eng , """Tio-TEF"""@eng , """Tespamin"""@eng , """Onco Tiotepa"""@eng , """TESPA"""@eng , """tris(1-aziridinyl)phosphine sulfide"""@eng , """Thioplex"""@eng , """triethylene thiophosphoramide"""@eng , """Girostan"""@eng , """WR 45312"""@eng , """Thiofozil"""@eng ; skos:definition """A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42933&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42933&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C875\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """680"""^^xsd:string ; """6396"""^^xsd:string ; """9547"""^^xsd:string ; """52-24-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """C875"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522499"""^^xsd:string ; umls:cui """C1305297"""^^xsd:string ; umls:cui """C0729090"""^^xsd:string ; umls:cui """C0729088"""^^xsd:string ; umls:cui """C1515416"""^^xsd:string ; umls:cui """C1515414"""^^xsd:string ; umls:cui """C1515415"""^^xsd:string ; umls:cui """C0729089"""^^xsd:string ; umls:cui """C0039871"""^^xsd:string ; umls:cui """C0728766"""^^xsd:string ; umls:cui """C0729083"""^^xsd:string ; umls:cui """C0729085"""^^xsd:string ; umls:cui """C0729087"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000042930"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; """6764"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0246511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dexrazoxane/doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000042931"""^^xsd:string ; skos:altLabel """ADR-529/BLEO/CTX/DOX/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """6765"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677847"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bronchoscopy"""@eng ; skos:notation """CDR0000042936"""^^xsd:string ; """6825"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0006290"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colonoscopy"""@eng ; skos:notation """CDR0000042937"""^^xsd:string ; rdfs:subClassOf ; """6852"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0009378"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """therapeutic autologous lymphocytes"""@eng ; skos:notation """CDR0000042934"""^^xsd:string ; skos:altLabel """Autologous Lymphocytes"""@eng , """AL"""@eng ; skos:definition """A population of lymphocytes isolated from an individual, altered in vitro, and returned to the same individual for therapeutic purposes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42934&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42934&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28681\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """6801"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C28681"""^^xsd:string ; umls:cui """C1711172"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oblimersen"""@eng ; skos:notation """CDR0000042935"""^^xsd:string ; skos:altLabel """BCL2 Gene Anticode Oligodeoxynucleotide"""@eng , """G3139 BCL-2 Antisense"""@eng , """BCL-2 Antisense/G3139"""@eng , """G3139 BCL-2 Antisense Oligonucleotide"""@eng , """bcl-2 antisense oligonucleotide (G3139)"""@eng , """G3139 Antisense Oligonucleotide"""@eng , """G3139"""@eng , """bcl-2 AO G3139"""@eng , """G3139 bcl-2 antisense oligodeoxynucleotide"""@eng , """Genasense"""@eng , """bcl-2 antisense oligodeoxynucleotide (G3139)"""@eng , """BCL-2 Antisense Oligodeoxynucleotide G3139"""@eng , """augmerosen"""@eng ; skos:definition """A phosphorothioate antisense oligonucleotide. Targeted to the initiation codon region of the bcl-2 mRNA, oblimersen inhibits bcl-2 mRNA translation, resulting in decreased expression of the bcl-2 protein, an apoptotic inhibitor expressed in some types of cancer and linked to tumor drug resistance. This agent may enhance the efficacy of standard cytotoxic chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42935&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42935&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1870\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """6809"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """58842"""^^xsd:string ; """683428"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1870"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1258613"""^^xsd:string ; umls:cui """C1144384"""^^xsd:string ; umls:cui """C0935954"""^^xsd:string ; umls:cui """C0914297"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """crisnatol mesylate"""@eng ; skos:notation """CDR0000042938"""^^xsd:string ; """6864"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677880"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epidermal growth factor receptor"""@eng ; skos:notation """CDR0000042939"""^^xsd:string ; skos:altLabel """EGFR"""@eng ; rdfs:subClassOf ; """6887"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0034802"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T192"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """finasteride/flutamide"""@eng ; skos:notation """CDR0000043049"""^^xsd:string ; skos:altLabel """FLUT/MK-906"""@eng ; ; ; """7373"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678049"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liposomal amphotericin B"""@eng ; skos:notation """CDR0000043048"""^^xsd:string ; skos:altLabel """Abelcet"""@eng , """amphotericin B-lipid complex"""@eng , """AmBisome"""@eng , """amphotericin B liposomal"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """7372"""^^xsd:string ; """2006-08-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1566"""^^xsd:string ; umls:cui """C0281209"""^^xsd:string ; umls:cui """C1145701"""^^xsd:string ; umls:cui """C0591076"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squalamine lactate"""@eng ; skos:notation """CDR0000043041"""^^xsd:string ; skos:altLabel """MSI-1256F"""@eng ; ; """7360"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935915"""^^xsd:string ; umls:cui """C0678046"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-11/sargramostim"""@eng ; skos:notation """CDR0000043040"""^^xsd:string ; skos:altLabel """GM-CSF/IL-11"""@eng ; ; ; """7359"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678045"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diagnostic radiology"""@eng ; skos:notation """CDR0000043043"""^^xsd:string ; rdfs:subClassOf ; """7362"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0043299"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mammography"""@eng ; skos:notation """CDR0000043042"""^^xsd:string ; rdfs:subClassOf ; """7361"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0024671"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """magnetic resonance imaging"""@eng ; skos:notation """CDR0000043045"""^^xsd:string ; rdfs:subClassOf ; """7364"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0024485"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/tyrosinase peptide"""@eng ; skos:notation """CDR0000043044"""^^xsd:string ; skos:altLabel """gp100/TYRP"""@eng ; ; ; """7363"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678047"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/interleukin-2/ionomycin"""@eng ; skos:notation """CDR0000043047"""^^xsd:string ; skos:altLabel """BRYO/IL-2/IONO"""@eng ; ; ; ; """7366"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678048"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ionomycin"""@eng ; skos:notation """CDR0000043046"""^^xsd:string ; skos:altLabel """IONO"""@eng ; ; """7365"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0022020"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/interferon gamma/paclitaxel"""@eng ; skos:notation """CDR0000356027"""^^xsd:string ; skos:altLabel """CBDCA/IFN-G/TAX"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328213"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/lonafarnib"""@eng ; skos:notation """CDR0000356029"""^^xsd:string ; skos:altLabel """SCH 66336/STI571"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328214"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABT-263"""@eng ; skos:notation """CDR0000523413"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-01"""^^xsd:string ; umls:cui """C1831992"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/etoposide/imatinib mesylate/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000038399"""^^xsd:string ; skos:altLabel """CTX/DM/MP/MTX/STI571/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """11018"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134461"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/imatinib mesylate"""@eng ; skos:notation """CDR0000038398"""^^xsd:string ; skos:altLabel """ARA-C/ASP/STI571"""@eng ; ; ; ; """11017"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134460"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/daunorubicin/dexamethasone/imatinib mesylate/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000038397"""^^xsd:string ; skos:altLabel """CTX/DM/DNR/MTX/PEG-ASP/STI571/VCR"""@eng ; ; ; ; ; ; ; ; """11016"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134459"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/imatinib mesylate/methotrexate"""@eng ; skos:notation """CDR0000038396"""^^xsd:string ; skos:altLabel """IFF/MTX/STI571/VP-16"""@eng ; ; ; ; ; """11015"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134458"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium carbonate/cholecalciferol/zoledronate"""@eng ; skos:notation """CDR0000038395"""^^xsd:string ; skos:altLabel """CACO3/VIT-D/ZOLE"""@eng ; ; ; ; """11014"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134457"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium citrate/cholecalciferol/zoledronate"""@eng ; skos:notation """CDR0000038394"""^^xsd:string ; skos:altLabel """CALCIT/VIT-D/ZOLE"""@eng ; ; ; ; """11013"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134456"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium gluconate/cholecalciferol/zoledronate"""@eng ; skos:notation """CDR0000038393"""^^xsd:string ; skos:altLabel """CALGLUC/VIT-D/ZOLE"""@eng ; ; ; ; """11012"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134455"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium gluconate/cholecalciferol"""@eng ; skos:notation """CDR0000038392"""^^xsd:string ; skos:altLabel """CALGLUC/VIT-D"""@eng ; ; ; """11011"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134454"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium citrate/cholecalciferol"""@eng ; skos:notation """CDR0000038391"""^^xsd:string ; skos:altLabel """CALCIT/VIT-D"""@eng ; ; ; """11010"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134453"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000038390"""^^xsd:string ; skos:altLabel """adult DM lymphoma"""@eng , """DML, adult"""@eng , """DM lymphoma, adult"""@eng , """diffuse mixed lymphoma, adult"""@eng , """mixed cell lymphoma, diffuse, adult"""@eng , """lymphoma, diffuse mixed cell, adult"""@eng , """diffuse mixed cell lymphoma, adult"""@eng ; rdfs:subClassOf ; """1101"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278761"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/temozolomide"""@eng ; skos:notation """CDR0000352306"""^^xsd:string ; skos:altLabel """OSI774/TMZ"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328151"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gemcitabine/oxaliplatin"""@eng ; skos:notation """CDR0000037846"""^^xsd:string ; skos:altLabel """dFdC/5-FU/L-OHP"""@eng ; ; ; ; """10248"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879418"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isolated limb infusion"""@eng ; skos:notation """CDR0000037847"""^^xsd:string ; """10249"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0396670"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/melphalan"""@eng ; skos:notation """CDR0000038179"""^^xsd:string ; skos:altLabel """G-CSF/L-PAM"""@eng ; ; ; """10758"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935754"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/rituximab"""@eng ; skos:notation """CDR0000037845"""^^xsd:string ; skos:altLabel """IL-12/MOAB IDEC-C2B8"""@eng ; ; ; """10247"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879417"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exemestane/raloxifene"""@eng ; skos:notation """CDR0000037842"""^^xsd:string ; skos:altLabel """PNU 155971/RALOX"""@eng ; ; ; """10244"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879415"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/UCN-01"""@eng ; skos:notation """CDR0000037843"""^^xsd:string ; skos:altLabel """ARA-C/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """10245"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879416"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin/polysialic acid"""@eng ; skos:notation """CDR0000037840"""^^xsd:string ; skos:altLabel """KLH/POLYSIALIC"""@eng ; ; ; """10242"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879413"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin/polysialic acid/QS21"""@eng ; skos:notation """CDR0000037841"""^^xsd:string ; skos:altLabel """KLH/POLYSIALIC/QS 21"""@eng ; ; ; ; """10243"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879414"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/paclitaxel/yttrium Y 90 monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000038173"""^^xsd:string ; skos:altLabel """CYSP/TAX/Y90 MOAB Lym-1"""@eng ; ; ; ; """10752"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935749"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/paclitaxel/yttrium Y 90 monoclonal antibody m170"""@eng ; skos:notation """CDR0000038172"""^^xsd:string ; skos:altLabel """CYSP/TAX/Y90 MOAB m170"""@eng ; ; ; ; """10751"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935748"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/yttrium Y 90 monoclonal antibody m170"""@eng ; skos:notation """CDR0000038171"""^^xsd:string ; skos:altLabel """CYSP/Y90 MOAB m170"""@eng ; ; ; """10750"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935747"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000038170"""^^xsd:string ; skos:altLabel """WDL, diffuse lymphocytic"""@eng , """diffuse well-differentiated lymphocytic lymphoma"""@eng , """well-differentiated lymphoma, diffuse lymphocytic"""@eng , """SL lymphoma"""@eng , """lymphoma, small lymphocytic"""@eng , """lymphocytic lymphoma, small"""@eng , """Small lymphocytic lymphoma"""@eng , """diffuse lymphocytic, well-differentiated lymphoma"""@eng , """lymphoma, diffuse lymphocytic, well-differentiated"""@eng , """diffuse WDL lymphoma"""@eng , """DLWD lymphoma"""@eng , """DWDL lymphoma"""@eng ; rdfs:subClassOf ; """1075"""^^xsd:string ; """2004-05-28"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0855095"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/thalidomide"""@eng ; skos:notation """CDR0000038177"""^^xsd:string ; skos:altLabel """DM/DOX/THAL"""@eng ; ; ; ; """10756"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935753"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/floxuridine"""@eng ; skos:notation """CDR0000038176"""^^xsd:string ; skos:altLabel """DM/FUDR"""@eng ; ; ; """10755"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935752"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/gemcitabine"""@eng ; skos:notation """CDR0000038175"""^^xsd:string ; skos:altLabel """dFdC/FLAVO"""@eng ; ; ; """10754"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935751"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/yttrium Y 90 monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000038174"""^^xsd:string ; skos:altLabel """CYSP/Y90 MOAB Lym-1"""@eng ; ; ; """10753"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935750"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """milk thistle"""@eng ; skos:notation """CDR0000459958"""^^xsd:string ; skos:definition """A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum. Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin. These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin. The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04) Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459958&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459958&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29261\" NCI Thesaurus)"""@eng ; """C29261"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C0937640"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immune globulin/methotrexate/tacrolimus"""@eng ; skos:notation """CDR0000368428"""^^xsd:string ; skos:altLabel """FK506/IG/MTX"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-04-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541229"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cefepime hydrochloride"""@eng ; skos:notation """CDR0000038350"""^^xsd:string ; skos:altLabel """Maxipime"""@eng , """cefepime"""@eng ; skos:definition """The hydrochoride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefipime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38350&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38350&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1041\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """10969"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-06"""^^xsd:string ; """C1041"""^^xsd:string ; umls:cui """C0055003"""^^xsd:string ; umls:cui """C0284915"""^^xsd:string ; umls:cui """C0771284"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edrecolomab/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000042550"""^^xsd:string ; skos:altLabel """CF/5-FU/MOAB 17-1A"""@eng ; ; ; ; """6208"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392974"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/tesmilifene"""@eng ; skos:notation """CDR0000042551"""^^xsd:string ; skos:altLabel """DOX/DPPE"""@eng ; ; ; """2005-01-10"""^^xsd:string ; """6209"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392975"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000042552"""^^xsd:string ; skos:altLabel """DOX/DTIC/IFF/VCR"""@eng ; ; ; ; ; """6210"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392976"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/PSC 833/vincristine"""@eng ; skos:notation """CDR0000042553"""^^xsd:string ; skos:altLabel """DM/DOX/PSC-833/VCR"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """6216"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392978"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """larotaxel"""@eng ; skos:notation """CDR0000042554"""^^xsd:string ; skos:altLabel """RPR 109881A"""@eng , """RPR 109881"""@eng , """XRP9881"""@eng ; skos:definition """A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic properties. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42554&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42554&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48427\" NCI Thesaurus)"""@eng ; """2006-09-28"""^^xsd:string ; """C48427"""^^xsd:string ; """6218"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C2603884"""^^xsd:string ; umls:cui """C0392979"""^^xsd:string ; umls:cui """C2603883"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sirolimus"""@eng ; skos:notation """CDR0000042555"""^^xsd:string ; skos:altLabel """rapamycin"""@eng , """AY 22989"""@eng , """9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2"""@eng , """SLM"""@eng , """WY-090217"""@eng , """Rapamune"""@eng , """RAPA"""@eng , """SILA 9268A"""@eng ; skos:definition """A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42555&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42555&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1212\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """6222"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """226080"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1212"""^^xsd:string ; """53123-88-9"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0072980"""^^xsd:string ; umls:cui """C0813828"""^^xsd:string ; umls:cui """C1710099"""^^xsd:string ; umls:cui """C1710098"""^^xsd:string ; umls:cui """C0878382"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/methotrexate/sirolimus"""@eng ; skos:notation """CDR0000042556"""^^xsd:string ; skos:altLabel """CYSP/MTX/SLM"""@eng ; ; ; ; """2004-01-13"""^^xsd:string ; """6223"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392980"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/interleukin-1-beta/interleukin-2/sargramostim/tumor necrosis factor"""@eng ; skos:notation """CDR0000042557"""^^xsd:string ; skos:altLabel """GM-CSF/IFN-G/IL-1B/IL-2/TNF"""@eng ; ; ; ; ; ; """6225"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392981"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/indomethacin/zinc sulfate"""@eng ; skos:notation """CDR0000042558"""^^xsd:string ; skos:altLabel """CTX/indomethacin/zinc sulfate"""@eng ; ; ; ; """6226"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392982"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboxyphenyl retinamide"""@eng ; skos:notation """CDR0000042559"""^^xsd:string ; skos:altLabel """N-(4-carboxyphenyl)retinamide"""@eng , """4-carboxyphenyl retinamide"""@eng , """RII"""@eng ; skos:definition """A synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Carboxyphenyl retinamide induces cell differentiation and inhibits tumor cell growth and carcinogenesis. This agent may also induce cell cycle arrest in the G1 phase in some cancer cell types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42559&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42559&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1169\" NCI Thesaurus)"""@eng ; """6234"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """74193-17-2"""^^xsd:string ; """C1169"""^^xsd:string ; umls:cui """C0067533"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lapatinib/trastuzumab"""@eng ; skos:notation """CDR0000371642"""^^xsd:string ; skos:altLabel """GW-572016/MOAB HER2"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-08-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541246"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """betulinic acid"""@eng ; skos:notation """CDR0000496932"""^^xsd:string ; skos:altLabel """Mairin"""@eng , """BA"""@eng , """(3beta)-3-Hydroxy-lup-20(29)-en-28-oic Acid"""@eng ; skos:definition """A pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosisthrough induction of changes in mitochondrial membrane potential, production of reactive oxygenspecies, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrialapogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal.and brain tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=496932&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=496932&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38126\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C38126"""^^xsd:string ; """113090"""^^xsd:string ; """472-15-1"""^^xsd:string ; """2006-07-21"""^^xsd:string ; """2006-07-25"""^^xsd:string ; umls:cui """C0053530"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KW-2449"""@eng ; skos:notation """CDR0000496931"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-23"""^^xsd:string ; umls:cui """C1831922"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Aurora kinase inhibitor AZD1152"""@eng ; skos:notation """CDR0000496937"""^^xsd:string ; skos:altLabel """AZD1152"""@eng ; """Drug/agent"""^^xsd:string ; """2006-07-21"""^^xsd:string ; """2006-07-25"""^^xsd:string ; umls:cui """C1831923"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IMP321"""@eng ; skos:notation """CDR0000496939"""^^xsd:string ; skos:altLabel """ImmuFact"""@eng ; skos:definition """A T-cell immunostimulatory factor derived from the soluble form of lymphocyte-activation gene 3 (LAG-3) protein with potential antineoplastic activity. Upon administration, alone or in combination with tumor antigens, IMP321 binds, with high affinity, to MHC class II molecules expressed by dendritic cells (DC), which may result in DC maturation, DC migration to lymph nodes, enhanced DC cross-presentation of antigens to T cells, and antitumor cytotoxic T cell responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=496939&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=496939&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62509\" NCI Thesaurus)"""@eng ; """2006-09-21"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62509"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1739076"""^^xsd:string ; umls:cui """C1831926"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ECO-4601"""@eng ; skos:notation """CDR0000496938"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62508"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """2006-09-21"""^^xsd:string ; umls:cui """C1831925"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine"""@eng ; skos:notation """CDR0000409722"""^^xsd:string ; skos:definition """A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=409722&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=409722&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48377\" NCI Thesaurus)"""@eng ; """2004-12-22"""^^xsd:string ; """C48377"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-27"""^^xsd:string ; umls:cui """C1541428"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/combretastatin A4 phosphate/paclitaxel"""@eng ; skos:notation """CDR0000438793"""^^xsd:string ; skos:altLabel """CA4P/CBDCA/TAX"""@eng ; ; ; ; """2005-06-28"""^^xsd:string ; """2005-07-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831665"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/cisplatin/epirubicin/matuzumab"""@eng ; skos:notation """CDR0000438791"""^^xsd:string ; skos:altLabel """CAPE/CDDP/EMD 72000/EPI"""@eng ; ; ; ; ; """2005-06-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-08"""^^xsd:string ; umls:cui """C1831664"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fludarabine/siplizumab"""@eng ; skos:notation """CDR0000438798"""^^xsd:string ; skos:altLabel """CTX/FAMP/MEDI-507"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-08"""^^xsd:string ; """2005-06-28"""^^xsd:string ; umls:cui """C1831666"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/prednisone/vincristine"""@eng ; skos:notation """CDR0000039422"""^^xsd:string ; skos:altLabel """CAFVP"""@eng , """CTX/DOX/5-FU/PRED/VCR"""@eng ; ; ; ; ; ; """2057"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054438"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """batanopride"""@eng ; skos:notation """CDR0000039423"""^^xsd:string ; skos:altLabel """BMY-25801"""@eng ; """2058"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0950748"""^^xsd:string ; umls:cui """C0053879"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/doxorubicin/ifosfamide"""@eng ; skos:notation """CDR0000041359"""^^xsd:string ; skos:altLabel """CBDCA/DOX/IFF"""@eng ; ; ; ; """4430"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280928"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitomycin/vinblastine"""@eng ; skos:notation """CDR0000039421"""^^xsd:string ; skos:altLabel """MITO/VBL"""@eng , """VeMi"""@eng ; ; ; """2056"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279282"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate"""@eng ; skos:notation """CDR0000039426"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX"""@eng , """CAM"""@eng ; ; ; ; """2061"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054551"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/fludarabine"""@eng ; skos:notation """CDR0000039427"""^^xsd:string ; skos:altLabel """CLB/FAMP"""@eng ; ; ; """2062"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279287"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin hydrochloride liposome"""@eng ; skos:notation """CDR0000039424"""^^xsd:string ; skos:altLabel """Pegylated Liposomal Doxorubicin Hydrochloride"""@eng , """Liposomal Doxorubicin Hydrochloride"""@eng , """(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride"""@eng , """Evacet"""@eng , """CAELYX"""@eng , """Pegylated Liposomal Doxorubicin"""@eng , """Doxorubicin Hydrochloride Liposomal"""@eng , """Dox-SL"""@eng , """Stealth Liposomal Doxorubicin"""@eng , """Liposomal Adriamycin"""@eng , """TLC D-99"""@eng , """Liposomal Doxorubicin"""@eng , """Doxilen"""@eng , """DOXIL"""@eng , """liposome-encapsulated doxorubicin"""@eng , """Doxorubicin HCl Liposome"""@eng , """Doxorubicin Hydrochloride Liposome Injection"""@eng , """S-Liposomal Doxorubicin"""@eng , """Pegylated Doxorubicin HCl Liposome"""@eng , """LipoDox"""@eng ; skos:definition """A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39424&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39424&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1555\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """712227"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2059"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """C1555"""^^xsd:string ; """31919"""^^xsd:string ; umls:cui """C1522689"""^^xsd:string ; umls:cui """C1704361"""^^xsd:string ; umls:cui """C0701184"""^^xsd:string ; umls:cui """C0701182"""^^xsd:string ; umls:cui """C0701183"""^^xsd:string ; umls:cui """C0279284"""^^xsd:string ; umls:cui """C1512060"""^^xsd:string ; umls:cui """C1512061"""^^xsd:string ; umls:cui """C0717726"""^^xsd:string ; umls:cui """C1522690"""^^xsd:string ; umls:cui """C1522683"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/vinblastine"""@eng ; skos:notation """CDR0000039425"""^^xsd:string ; skos:altLabel """CDDP/VBL/VP-16"""@eng , """VPV"""@eng ; ; ; ; """2060"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0148304"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/thioguanine"""@eng ; skos:notation """CDR0000041353"""^^xsd:string ; skos:altLabel """MTX/TG"""@eng ; ; ; """4424"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280924"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/interleukin-3"""@eng ; skos:notation """CDR0000041352"""^^xsd:string ; skos:altLabel """CBDCA/IL-3"""@eng ; ; ; """4423"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280923"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/procarbazine"""@eng ; skos:notation """CDR0000039428"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/PCB"""@eng , """CAMP"""@eng ; ; ; ; ; """2063"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054557"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/tamoxifen"""@eng ; skos:notation """CDR0000039429"""^^xsd:string ; skos:altLabel """IFN-A/TMX"""@eng ; ; ; """2064"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338092"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """placental-site gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000041357"""^^xsd:string ; skos:altLabel """gestational trophoblastic tumor, placental site"""@eng , """placental site GTT"""@eng , """GTT, placental site"""@eng , """placental site gestational trophoblastic tumor"""@eng , """GTT, placental-site"""@eng , """placental-site GTT"""@eng , """gestational trophoblastic tumor, placental-site"""@eng ; rdfs:subClassOf ; """gestational trophoblastic tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4428"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0206666"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/hydroxyurea/leucovorin calcium"""@eng ; skos:notation """CDR0000041356"""^^xsd:string ; skos:altLabel """CDDP/CF/5-FU/HU"""@eng ; ; ; ; ; """4427"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280926"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil/hydroxyurea/leucovorin calcium"""@eng ; skos:notation """CDR0000041355"""^^xsd:string ; skos:altLabel """CBDCA/CF/5-FU/HU"""@eng ; ; ; ; ; """4426"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280925"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dolasetron mesylate"""@eng ; skos:notation """CDR0000041354"""^^xsd:string ; skos:altLabel """MDL-73,147 EF"""@eng , """MDL73,147EF"""@eng , """MDL 73,147EF"""@eng , """Anzemet"""@eng ; skos:definition """An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, dolasetron mesylate competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41354&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41354&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1153\" NCI Thesaurus)"""@eng ; """4425"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1153"""^^xsd:string ; """115956-13-3"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0740030"""^^xsd:string ; umls:cui """C0065818"""^^xsd:string ; umls:cui """C0718607"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zalcitabine"""@eng ; skos:notation """CDR0000040349"""^^xsd:string ; skos:altLabel """ddC"""@eng , """Hivid"""@eng , """2',3'-Dideoxycytidine"""@eng , """dideoxycytidine"""@eng ; skos:definition """A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40349&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40349&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C430\" NCI Thesaurus)"""@eng ; ; ; """3201"""^^xsd:string ; """606170"""^^xsd:string ; """28975"""^^xsd:string ; """7481-89-2"""^^xsd:string ; """C430"""^^xsd:string ; """33134"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """30858"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0012132"""^^xsd:string ; umls:cui """C0678123"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/mitomycin/vindesine"""@eng ; skos:notation """CDR0000040348"""^^xsd:string ; skos:altLabel """DAVA/DOX/MITO"""@eng , """VAM"""@eng ; ; ; ; """3200"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280021"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """medroxyprogesterone/mitomycin/vinblastine"""@eng ; skos:notation """CDR0000040343"""^^xsd:string ; skos:altLabel """MVP"""@eng , """MITO/MPA/VBL"""@eng ; ; ; ; """3195"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280017"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal agent"""@eng ; skos:notation """CDR0000040342"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3188"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0017173"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastrointestinal anti-emetic"""@eng ; skos:notation """CDR0000040341"""^^xsd:string ; rdfs:subClassOf ; """3187"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280011"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """histamine receptor antagonist"""@eng ; skos:notation """CDR0000040340"""^^xsd:string ; rdfs:subClassOf ; """3186"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0019590"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II gastric cancer"""@eng ; skos:notation """CDR0000040347"""^^xsd:string ; skos:altLabel """stomach cancer, stage II"""@eng , """gastric cancer, stage II"""@eng ; rdfs:subClassOf ; """gastric cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """32"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278496"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZP"""@eng ; skos:notation """CDR0000040346"""^^xsd:string ; skos:altLabel """N(3)P(3)Az(2)(NHMe)4"""@eng , """1,3-Diaziridino-2,4,6-Triaza-1,3,5,5-Tetraaminomethyl-1,3,5-Triphosphorin"""@eng ; skos:definition """An aziridinyl-substituted cyclophosphazene and a putrescence derivative that may cause DNA cross-linkage. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40346&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40346&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C953\" NCI Thesaurus)"""@eng ; """3199"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """101395-77-1"""^^xsd:string ; """C953"""^^xsd:string ; umls:cui """C0043914"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/interferon alfa"""@eng ; skos:notation """CDR0000040345"""^^xsd:string ; skos:altLabel """CCNU/IFN-A"""@eng ; ; ; """3198"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338112"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """procarbazine/semustine/vincristine"""@eng ; skos:notation """CDR0000040344"""^^xsd:string ; skos:altLabel """MVP"""@eng , """MeCCNU/PCB/VCR"""@eng ; ; ; ; """3197"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280018"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/irinotecan/phenobarbital"""@eng ; skos:notation """CDR0000043603"""^^xsd:string ; skos:altLabel """CPT-11/CYSP/PHENO"""@eng ; ; ; ; """8885"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879312"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-2/Montanide ISA-51"""@eng ; skos:notation """CDR0000043602"""^^xsd:string ; skos:altLabel """gp100/IL-2/ISA-51"""@eng ; ; ; """8884"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879311"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/sargramostim/von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043601"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/VHL peptide"""@eng ; ; ; """8883"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879310"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/Montanide ISA-51/von Hippel-Lindau peptide vaccine"""@eng ; skos:notation """CDR0000043600"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/VHL peptide"""@eng ; ; ; """8882"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879309"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043607"""^^xsd:string ; skos:altLabel """IL-12/ISA-51/TYRP"""@eng ; ; ; """8892"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879316"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043606"""^^xsd:string ; skos:altLabel """IL-2/ISA-51/TYRP"""@eng ; ; ; """8891"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879315"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000043605"""^^xsd:string ; skos:altLabel """ISA-51/TYRP"""@eng ; ; """8889"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879314"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/Montanide ISA-51"""@eng ; skos:notation """CDR0000043604"""^^xsd:string ; skos:altLabel """gp100/ISA-51"""@eng ; ; """8886"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879313"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-12/Montanide ISA-51"""@eng ; skos:notation """CDR0000043609"""^^xsd:string ; skos:altLabel """gp100/IL-12/ISA-51"""@eng ; ; ; """8894"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879318"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000043608"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/TYRP"""@eng ; ; ; """8893"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879317"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """targeted protein toxin therapy"""@eng ; skos:notation """CDR0000526337"""^^xsd:string ; rdfs:subClassOf ; """2006-12-18"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C1832005"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hetastarch"""@eng ; skos:notation """CDR0000041768"""^^xsd:string ; """4949"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0020352"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/leuprolide"""@eng ; skos:notation """CDR0000041769"""^^xsd:string ; skos:altLabel """CDX/LEUP"""@eng ; ; ; """4950"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281352"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """packed red blood cell transfusion"""@eng ; skos:notation """CDR0000470295"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-23"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0199962"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/estramustine/etoposide"""@eng ; skos:notation """CDR0000041762"""^^xsd:string ; skos:altLabel """CBDCA/EM/VP-16"""@eng ; ; ; ; """4941"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281347"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin"""@eng ; skos:notation """CDR0000041763"""^^xsd:string ; skos:altLabel """CTX/EPI"""@eng ; ; ; """4942"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281348"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CC49"""@eng ; skos:notation """CDR0000041760"""^^xsd:string ; skos:altLabel """CC49"""@eng , """CC49 monoclonal antibody"""@eng , """MOAB CC-49/TAG72 (DW)"""@eng , """MOAB CC49"""@eng , """CC-49 Monoclonal Antibody"""@eng , """antibody CC49, monoclonal"""@eng , """monoclonal antibody CC-49"""@eng , """MAb CC49"""@eng ; skos:definition """A second-generation murine monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72). TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41760&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41760&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2567\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """4937"""^^xsd:string ; """4427"""^^xsd:string ; """3088"""^^xsd:string ; """3496"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2567"""^^xsd:string ; """3006"""^^xsd:string ; """6218"""^^xsd:string ; """620537"""^^xsd:string ; """2006-12-15"""^^xsd:string ; umls:cui """C0281345"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000041761"""^^xsd:string ; skos:altLabel """CDDP/DOX/VCR/VP-16"""@eng ; ; ; ; ; """4939"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281346"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """formestane"""@eng ; skos:notation """CDR0000041766"""^^xsd:string ; skos:altLabel """4-OHA"""@eng , """CGP-32349"""@eng , """Lentaron"""@eng , """4-Hydroxyandrost-4-ene-3,17-dione"""@eng , """4-OHAD"""@eng , """4-hydroxyandrostenedione"""@eng ; skos:definition """A synthetic steroidal substance with antineoplastic activity. Formestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41766&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41766&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C974\" NCI Thesaurus)"""@eng ; """4945"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C974"""^^xsd:string ; """566-48-3"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0048306"""^^xsd:string ; umls:cui """C0525213"""^^xsd:string ; umls:cui """C0283111"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triacetyluridine"""@eng ; skos:notation """CDR0000041767"""^^xsd:string ; skos:altLabel """TAU"""@eng , """PN401"""@eng , """RG2133"""@eng , """PN 401"""@eng ; skos:definition """A synthetic uridine pro-drug that is converted to uridine in vivo. Uridine, a pyrimidine nucleotide, has been used in a variety of diseases including depressive disorders and inherited myopathies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41767&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41767&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2379\" NCI Thesaurus)"""@eng ; ; ; ; ; """4948"""^^xsd:string ; """79269"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C2379"""^^xsd:string ; umls:cui """C0540124"""^^xsd:string ; umls:cui """C1831598"""^^xsd:string ; umls:cui """C0281351"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa/interleukin-3"""@eng ; skos:notation """CDR0000041764"""^^xsd:string ; skos:altLabel """EPO/IL-3"""@eng ; ; ; """4943"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281349"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/macrophage colony-stimulating factor"""@eng ; skos:notation """CDR0000041765"""^^xsd:string ; skos:altLabel """IL-2/M-CSF"""@eng ; ; ; """4944"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281350"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/pegylated doxorubicin HCl liposome/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000410781"""^^xsd:string ; skos:altLabel """CTX/MOAB IDCE-C2B8/PEG-LD/PRED/VCR"""@eng ; ; ; ; ; """2004-12-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-09"""^^xsd:string ; umls:cui """C1541442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMD3100"""@eng ; skos:notation """CDR0000410786"""^^xsd:string ; skos:altLabel """AMD-3100"""@eng , """1,1'-[1,4-Phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane"""@eng , """LM-3100"""@eng , """AMD 3100"""@eng , """Bis(Tetraazacyclotetradecane) Derivative"""@eng ; skos:definition """A bicyclam with hematopoietic stem cell-mobilizing properties. AMD3100 blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=410786&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=410786&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1777\" NCI Thesaurus)"""@eng ; ; """2004-12-22"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C1777"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1955474"""^^xsd:string ; umls:cui """C1527081"""^^xsd:string ; umls:cui """C0662900"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMD3100/filgrastim"""@eng ; skos:notation """CDR0000410787"""^^xsd:string ; skos:altLabel """AMD 3100/G-CSF"""@eng ; ; ; """2004-12-22"""^^xsd:string ; """2004-12-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541443"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PPI-2458"""@eng ; skos:notation """CDR0000415572"""^^xsd:string ; skos:altLabel """PPI 2458"""@eng ; skos:definition """A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415572&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415572&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38129\" NCI Thesaurus)"""@eng ; """2005-01-13"""^^xsd:string ; """C38129"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1505437"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """abarelix"""@eng ; skos:notation """CDR0000415570"""^^xsd:string ; skos:altLabel """PPI-149"""@eng , """Plenaxis"""@eng , """R-3827"""@eng ; skos:definition """A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415570&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415570&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2015\" NCI Thesaurus)"""@eng ; """2005-01-13"""^^xsd:string ; """2005-01-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2015"""^^xsd:string ; """183552-38-7"""^^xsd:string ; umls:cui """C1174732"""^^xsd:string ; umls:cui """C0965390"""^^xsd:string ; umls:cui """C0965389"""^^xsd:string ; umls:cui """C1527184"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rhenium Re 188 P2045"""@eng ; skos:notation """CDR0000415571"""^^xsd:string ; skos:altLabel """Re-188 P2045"""@eng ; """2005-01-13"""^^xsd:string ; """2005-01-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541488"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dutasteride"""@eng ; skos:notation """CDR0000479183"""^^xsd:string ; skos:altLabel """GG 745"""@eng , """Avodart"""@eng , """alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide"""@eng , """Avolve,(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide"""@eng ; skos:definition """A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5-alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5-alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5-alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=479183&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=479183&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47503\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """164656-23-9"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """C47503"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1170079"""^^xsd:string ; umls:cui """C0666267"""^^xsd:string ; umls:cui """C0754659"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MLH1"""@eng ; skos:notation """CDR0000037802"""^^xsd:string ; rdfs:subClassOf ; """10160"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879389"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PMS1"""@eng ; skos:notation """CDR0000037803"""^^xsd:string ; rdfs:subClassOf ; """10161"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879390"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/irinotecan/sorafenib"""@eng ; skos:notation """CDR0000445256"""^^xsd:string ; skos:altLabel """CPT-11/MOAB C225/SFN"""@eng ; ; ; ; """2005-08-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; umls:cui """C1831708"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000445257"""^^xsd:string ; skos:altLabel """CTX/MOAB IDEC-C2B8/PRED/VCR"""@eng ; ; ; ; ; """2005-08-16"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831709"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salmonella VNP20009"""@eng ; skos:notation """CDR0000037800"""^^xsd:string ; skos:altLabel """VNP-20009"""@eng , """VNP 20009"""@eng ; """C2556"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """10159"""^^xsd:string ; umls:cui """C0879622"""^^xsd:string ; umls:tui """T007"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """venous sampling"""@eng ; skos:notation """CDR0000374969"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-03"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1541308"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """volociximab"""@eng ; skos:notation """CDR0000415313"""^^xsd:string ; skos:altLabel """anti-α5β1 integrin"""@eng , """anti-α5β1 integrin MOAB"""@eng , """anti-![GREEK SMALL LETTER ALPHA]!5![GREEK SMALL LETTER BETA]!1 integrin"""@eng , """anti-alpha 5 beta 1 integrin monoclonal antibody"""@eng , """M200"""@eng , """anti-![GREEK SMALL LETTER ALPHA]!5![GREEK SMALL LETTER BETA]!1 integrin MOAB"""@eng ; skos:definition """A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415313&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415313&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48426\" NCI Thesaurus)"""@eng ; ; """2005-01-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C48426"""^^xsd:string ; umls:cui """C2987578"""^^xsd:string ; umls:cui """C1541160"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ARQ 501/docetaxel"""@eng ; skos:notation """CDR0000415310"""^^xsd:string ; skos:altLabel """ARQ-501/TXT"""@eng ; ; ; """2005-01-07"""^^xsd:string ; """2005-01-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541481"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-275183"""@eng ; skos:notation """CDR0000415311"""^^xsd:string ; skos:altLabel """BMS 275183"""@eng ; ; """2005-01-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-07"""^^xsd:string ; umls:cui """C1098058"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/volociximab"""@eng ; skos:notation """CDR0000415314"""^^xsd:string ; skos:altLabel """anti-α5β1 integrin MOAB/DTIC"""@eng , """anti-![GREEK SMALL LETTER ALPHA]!5![GREEK SMALL LETTER BETA]!1 integrin MOAB/DTIC"""@eng ; ; ; """2005-01-07"""^^xsd:string ; """2005-01-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541161"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MSH6"""@eng ; skos:notation """CDR0000037806"""^^xsd:string ; rdfs:subClassOf ; """10164"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879393"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """angiography"""@eng ; skos:notation """CDR0000374967"""^^xsd:string ; skos:altLabel """arteriography"""@eng ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-03"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0003844"""^^xsd:string ; umls:cui """C0002978"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000038132"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/MTX/VBL"""@eng ; ; ; ; ; ; """10691"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935717"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PMS2"""@eng ; skos:notation """CDR0000037804"""^^xsd:string ; rdfs:subClassOf ; """10162"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879391"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MSH3"""@eng ; skos:notation """CDR0000037805"""^^xsd:string ; rdfs:subClassOf ; """10163"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879392"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin/QS21/Sialyl Tn antigen"""@eng ; skos:notation """CDR0000042235"""^^xsd:string ; skos:altLabel """KLH/QS 21/STn antigen"""@eng ; ; ; ; """5484"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281744"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epratuzumab"""@eng ; skos:notation """CDR0000042234"""^^xsd:string ; skos:altLabel """LL2 monoclonal antibody"""@eng , """AMG 412"""@eng , """hLL2"""@eng , """LL2"""@eng , """LymphoCide"""@eng , """MOAB LL2"""@eng , """monoclonal antibody LL2"""@eng , """Humanized Anti-CD22 Monoclonal Antibody IgG1"""@eng ; skos:definition """A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42234&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42234&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1887\" NCI Thesaurus)"""@eng ; ; ; ; """5483"""^^xsd:string ; """C1887"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1174750"""^^xsd:string ; umls:cui """C1120776"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uracil"""@eng ; skos:notation """CDR0000042237"""^^xsd:string ; ; ; """5486"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C917"""^^xsd:string ; umls:cui """C0041917"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """granisetron hydrochloride"""@eng ; skos:notation """CDR0000042236"""^^xsd:string ; skos:altLabel """Kytril"""@eng , """GRAN"""@eng ; skos:definition """The hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1353\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """5485"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """109889-09-0"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """C1353"""^^xsd:string ; """672814"""^^xsd:string ; umls:cui """C0543476"""^^xsd:string ; umls:cui """C0061863"""^^xsd:string ; umls:cui """C0107189"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/ifosfamide/oxaliplatin/paclitaxel"""@eng ; skos:notation """CDR0000422413"""^^xsd:string ; skos:altLabel """BLEO/CDDP/IFF/L-OHP/TAX/VP-16"""@eng ; ; ; ; ; ; ; """2005-02-18"""^^xsd:string ; """2005-02-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541515"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphoid tissue, mucosa-associated"""@eng ; skos:notation """CDR0000042230"""^^xsd:string ; skos:altLabel """MALT"""@eng ; """2005-01-21"""^^xsd:string ; """5479"""^^xsd:string ; umls:cui """C0242647"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/mercaptopurine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000393425"""^^xsd:string ; skos:altLabel """CTX/DM/MP/MTX/VCR"""@eng ; ; ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541370"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carbogen/niacinamide"""@eng ; skos:notation """CDR0000042232"""^^xsd:string ; skos:altLabel """NICOGEN/UN1014"""@eng ; ; ; """5481"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281742"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate/pegaspargase"""@eng ; skos:notation """CDR0000393428"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/MTX/PEG-ASP/VP-16"""@eng ; ; ; ; ; ; ; """2004-09-25"""^^xsd:string ; """2004-09-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541372"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/tegafur/uracil"""@eng ; skos:notation """CDR0000042239"""^^xsd:string ; skos:altLabel """CF/FT/uracil"""@eng ; ; ; ; """5488"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281746"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tegafur/uracil"""@eng ; skos:notation """CDR0000042238"""^^xsd:string ; skos:altLabel """FT/uracil"""@eng , """UFT"""@eng ; ; ; """5487"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0936116"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide phosphate/sodium thiosulfate"""@eng ; skos:notation """CDR0000346889"""^^xsd:string ; skos:altLabel """CBDCA/CTX/ETOP/STS"""@eng ; ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-11-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328112"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/fludarabine"""@eng ; skos:notation """CDR0000327799"""^^xsd:string ; skos:altLabel """FAMP/PS-341"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328034"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nasopharyngeal squamous cell carcinoma"""@eng ; skos:notation """CDR0000039991"""^^xsd:string ; skos:altLabel """squamous cell carcinoma, nasopharyngeal"""@eng , """nasopharynx squamous cell carcinoma"""@eng , """epidermoid carcinoma, nasopharyngeal"""@eng ; rdfs:subClassOf ; """2714"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279698"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/gemcitabine"""@eng ; skos:notation """CDR0000327790"""^^xsd:string ; skos:altLabel """dFdC/SC-58635"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328033"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III ovarian epithelial cancer"""@eng ; skos:notation """CDR0000043704"""^^xsd:string ; skos:altLabel """stage III ovary cancer"""@eng , """ovary cancer, stage III"""@eng , """ovarian epithelial cancer, stage III"""@eng , """stage III ovarian carcinoma"""@eng , """ovarian carcinoma, stage III"""@eng , """stage III ovarian cancer"""@eng , """ovarian cancer, stage III"""@eng ; rdfs:subClassOf ; """ovarian epithelial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """953"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278687"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000040989"""^^xsd:string ; skos:altLabel """CDDP/CTX/HMM"""@eng , """HCC"""@eng , """CHD"""@eng ; ; ; ; """4027"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280604"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000040988"""^^xsd:string ; skos:altLabel """5-FU/MTX"""@eng , """FUM"""@eng , """MeF"""@eng , """MF"""@eng ; ; ; """4026"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280603"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/prednisone/procarbazine/vinblastine/vincristine"""@eng ; skos:notation """CDR0000040985"""^^xsd:string ; skos:altLabel """MVVPP"""@eng , """MVOPP"""@eng , """NM/PCB/PRED/VBL/VCR"""@eng ; ; ; ; ; ; """4023"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066988"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/etoposide/methotrexate"""@eng ; skos:notation """CDR0000040984"""^^xsd:string ; skos:altLabel """HMM/MTX/VP-16"""@eng , """HEM"""@eng , """VHM"""@eng , """MVH"""@eng ; ; ; ; """4022"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280599"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/mitomycin/vincristine"""@eng ; skos:notation """CDR0000040987"""^^xsd:string ; skos:altLabel """FOM"""@eng , """FOMI"""@eng , """5-FU/MITO/VCR"""@eng ; ; ; ; """4025"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0060627"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040986"""^^xsd:string ; skos:altLabel """MP/MTX/PRED/VCR"""@eng , """POMP"""@eng , """POMP-24"""@eng , """MMVP"""@eng ; ; ; ; ; """4024"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0071715"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040981"""^^xsd:string ; skos:altLabel """DOX/PRED/VCR"""@eng , """VAP"""@eng , """APO"""@eng , """HOP"""@eng ; ; ; ; """4019"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078040"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000040980"""^^xsd:string ; skos:altLabel """COAd/CO-5"""@eng , """CTX/DOX/5-FU/VCR"""@eng , """FACV"""@eng , """ADCONFU"""@eng ; ; ; ; ; """4018"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0104713"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040983"""^^xsd:string ; skos:altLabel """DOX/VCR"""@eng , """AO"""@eng , """AV"""@eng ; ; ; """4021"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280598"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040982"""^^xsd:string ; skos:altLabel """DOX/PCB/VCR"""@eng , """VAP"""@eng , """AVP"""@eng ; ; ; ; """4020"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078039"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluoxetine/gemcitabine"""@eng ; skos:notation """CDR0000038641"""^^xsd:string ; skos:altLabel """CDDP/dFdC/FLUOX"""@eng ; ; ; ; """11273"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134649"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/trastuzumab"""@eng ; skos:notation """CDR0000038640"""^^xsd:string ; skos:altLabel """CTX/5-FU/MOAB HER2/MTX"""@eng ; ; ; ; ; """11272"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134648"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood acute myeloid leukemia"""@eng ; skos:notation """CDR0000038643"""^^xsd:string ; skos:altLabel """relapsed childhood acute nonlymphocytic leukemia"""@eng , """AML, recurrent, pediatric"""@eng , """childhood AML, recurrent"""@eng , """childhood acute nonlymphocytic leukemia, relapsed"""@eng , """AML, recurrent, childhood"""@eng , """relapsed pediatric acute myeloid leukemia"""@eng , """leukemia, recurrent childhood acute myeloid"""@eng , """recurrent pediatric acute nonlymphocytic leukemia"""@eng , """recurent childhood AML"""@eng , """childhood AML, relapsed"""@eng , """myeloid leukemia, relapsed childhood acute"""@eng , """pediatric leukemia, acute myeloid relapsed"""@eng , """recurrent pediatric acute myeloid leukemia"""@eng , """childhood leukemia, acute myeloid relapsed"""@eng , """nonlymphocytic leukemia, relapsed childhood acute"""@eng , """relapsed childhood AML"""@eng , """relapsed pediatric acute nonlymphocytic leukemia"""@eng , """ANLL, relapsed, pediatric"""@eng , """childhood acute myeloid leukemia, relapsed"""@eng , """recurrent childhood ANLL"""@eng , """ANLL, recurrent, childhood"""@eng , """ANLL, recurrent, pediatric"""@eng , """relapsed pediatric AML"""@eng , """acute myeloid leukemia, recurrent, childhood"""@eng , """pediatric acute nonlymphocytic leukemia, relapsed"""@eng , """nonlymphocytic leukemia, relapsed pediatric acute"""@eng , """relapsed pediatric ANLL"""@eng , """myeloid leukemia, relapsed pediatric acute"""@eng , """leukemia, relapsed childhood acute nonlymphocytic"""@eng , """leukemia, relapsed childhood acute myeloid"""@eng , """acute nonlymphocytic leukemia, relapsed, childhood"""@eng , """childhood leukemia, acute nonlymphocytic relapsed"""@eng , """childhood acute myeloid leukemia, recurrent"""@eng , """AML, relapsed, pediatric"""@eng , """ANLL, relapsed, childhood"""@eng , """recurrent childhood acute nonlymphocytic leukemia"""@eng , """AML, relapsed, childhood"""@eng , """leukemia, reucrrent childhood acute nonlymphocytic"""@eng , """relapsed childhood acute myeloid leukemia"""@eng , """pediatric leukemia, acute nonlymphocytic relapsed"""@eng , """relapsed childhood ANLL"""@eng , """pediatric acute myeloid leukemia, relapsed"""@eng , """acute myeloid leukemia, relapsed, childhood"""@eng ; rdfs:subClassOf ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1129"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278776"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/erlotinib"""@eng ; skos:notation """CDR0000305923"""^^xsd:string ; skos:altLabel """OSI774/SC-58635"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327971"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related malignancies"""@eng ; skos:notation """CDR0000041134"""^^xsd:string ; skos:altLabel """AIDS related malignancies"""@eng , """malignancies, AIDS-related"""@eng , """AIDS-associated cancer"""@eng , """cancer, AIDS related"""@eng , """AIDS-related cancer"""@eng , """AIDS related cancer"""@eng ; rdfs:subClassOf ; """4208"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280734"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin cancer screening"""@eng ; skos:notation """CDR0000041561"""^^xsd:string ; skos:altLabel """early detection of skin cancer"""@eng , """skin cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4724"""^^xsd:string ; umls:cui """C2919584"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent carcinoma of unknown primary"""@eng ; skos:notation """CDR0000041133"""^^xsd:string ; skos:altLabel """carcinoma of unknown primary, recurrent"""@eng , """CUP, recurrent"""@eng , """recurrent CUP"""@eng ; rdfs:subClassOf ; """carcinoma of unknown primary"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4207"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280733"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000041132"""^^xsd:string ; skos:altLabel """IL-2/MOAB Lym-1"""@eng ; ; ; """4206"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280732"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """early detection of colorectal cancer"""@eng ; skos:notation """CDR0000041563"""^^xsd:string ; skos:altLabel """colorectal cancer early detection"""@eng , """colorectal cancer screening"""@eng ; """2002-10-17"""^^xsd:string ; """4726"""^^xsd:string ; umls:cui """C0281185"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NA17-A"""@eng ; skos:notation """CDR0000038647"""^^xsd:string ; skos:altLabel """NA17 A"""@eng , """NA17A"""@eng , """NA17-A Antigen"""@eng ; skos:definition """A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. The NA-17-A antigen is part of the enzyme N-acetyl glucosaminyl-transferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38647&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38647&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37450\" NCI Thesaurus)"""@eng ; ; ; ; """11293"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-31"""^^xsd:string ; """C37450"""^^xsd:string ; umls:cui """C1134655"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABT-751"""@eng ; skos:notation """CDR0000038646"""^^xsd:string ; skos:altLabel """N-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide"""@eng , """E7010"""@eng ; skos:definition """An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38646&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38646&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2679\" NCI Thesaurus)"""@eng ; """11292"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """141430-65-1"""^^xsd:string ; """C2679"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134654"""^^xsd:string ; umls:cui """C0656781"""^^xsd:string ; umls:cui """C0656780"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosomal translocation"""@eng ; skos:notation """CDR0000043184"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2002-10-14"""^^xsd:string ; """7627"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0040715"""^^xsd:string ; umls:tui """T049"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mutation analysis"""@eng ; skos:notation """CDR0000043185"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """7628"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796357"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HRAS"""@eng ; skos:notation """CDR0000043186"""^^xsd:string ; rdfs:subClassOf ; """7629"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0079471"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KRAS"""@eng ; skos:notation """CDR0000043187"""^^xsd:string ; rdfs:subClassOf ; """7630"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0022457"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TEL-AML1"""@eng ; skos:notation """CDR0000043180"""^^xsd:string ; rdfs:subClassOf ; """7623"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0531832"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HOX11"""@eng ; skos:notation """CDR0000043181"""^^xsd:string ; rdfs:subClassOf ; """7624"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0122269"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TAL1"""@eng ; skos:notation """CDR0000043182"""^^xsd:string ; """7625"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796355"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uterine choriocarcinoma"""@eng ; skos:notation """CDR0000039968"""^^xsd:string ; skos:altLabel """chorioepithelioma, uterine"""@eng , """choriocarcinoma, GTT"""@eng , """choriocarcinoma, gestational trophoblastic tumor"""@eng , """gestational trophoblastic tumor, choriocarcinoma"""@eng , """GTT, choriocarcinoma"""@eng , """uterine chorioepithelioma"""@eng , """choriocarcinoma of the uterus"""@eng , """choriocarcinoma, uterine"""@eng ; rdfs:subClassOf ; """2673"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279677"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chorioadenoma destruens"""@eng ; skos:notation """CDR0000039967"""^^xsd:string ; skos:altLabel """chorioadenoma"""@eng , """gestational trophoblastic tumor, invasive mole"""@eng , """GTT, invasive mole"""@eng , """invasive mole"""@eng ; rdfs:subClassOf ; """2672"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0008493"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian clear cell tumor with proliferating activity"""@eng ; skos:notation """CDR0000039966"""^^xsd:string ; skos:altLabel """mesonephroid tumor with proliferating activity, ovarian"""@eng , """clear cell tumor with proliferating activity, ovarian"""@eng ; rdfs:subClassOf ; """2671"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279676"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian endometrioid tumor with proliferating activity"""@eng ; skos:notation """CDR0000039965"""^^xsd:string ; skos:altLabel """endometrioid tumor with proliferating activity, ovarian"""@eng ; rdfs:subClassOf ; """2670"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334338"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical small cell carcinoma"""@eng ; skos:notation """CDR0000039964"""^^xsd:string ; skos:altLabel """uterine cervix cancer, small cell carcinoma"""@eng , """small cell carcinoma of the cervix"""@eng , """cervix cancer, small cell carcinoma"""@eng , """cancer of the cervix, small cell"""@eng , """uterine cervical cancer, small cell carcinoma"""@eng , """carcinoma of the cervix, small cell"""@eng , """cervical cancer, small cell carcinoma"""@eng , """small cell cancer of the cervix"""@eng ; rdfs:subClassOf ; """2669"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279674"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical adenosquamous cell carcinoma"""@eng ; skos:notation """CDR0000039963"""^^xsd:string ; skos:altLabel """uterine cervical cancer, adenosquamous cell carcinoma"""@eng , """cervix cancer, adenosquamous cell carcinoma"""@eng , """cancer of the cervix, adenosquamous cell"""@eng , """carcinoma of the cervix, adenosquamous cell"""@eng , """adenosquamous cell carcinoma of the cervix"""@eng , """cervical cancer, adenosquamous cell carcinoma"""@eng , """uterine cervix cancer, adenosquamous cell carcinoma"""@eng , """adenosquamous cell cancer of the cervix"""@eng ; rdfs:subClassOf ; """2668"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346202"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 6"""@eng ; skos:notation """CDR0000043189"""^^xsd:string ; rdfs:subClassOf ; """7632"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008669"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody CC49-deltaCH2"""@eng ; skos:notation """CDR0000453590"""^^xsd:string ; skos:altLabel """131I-HuCC49-deltaCH2"""@eng , """131I-MOAB CC49-deltaCH2"""@eng ; skos:definition """A radioimmunoconjugate consisting of the humanized CH2 domain-deleted monoclonal antibody CC49 and iodine I 131 with antineoplastic activity. Monoclonal antibody CC49-deltaCH2 targets the tumor-associated glycoprotein 72 (TAG-72) that is expressed by a wide range of human neoplasms including colorectal, gastric, pancreatic, ovarian, endometrial, breast, non-small cell lung, and prostate cancers. Iodine I 131 monoclonal antibody CC49-deltaCH2 binds to tumor cells expressing TAG-72, selectively delivering a cytotoxic dose of beta and gamma radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453590&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453590&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2697\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C2697"""^^xsd:string ; """2005-10-24"""^^xsd:string ; umls:cui """C1134477"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial adenosquamous cell carcinoma"""@eng ; skos:notation """CDR0000039960"""^^xsd:string ; skos:altLabel """carcinoma, adenosquamous cell, endometrial"""@eng , """uterine cancer, adenosquamous cell carcinoma"""@eng , """uterine corpus cancer, adenosquamous cell carcinoma"""@eng , """adenosquamous cell carcinoma of the uterus"""@eng , """carcinoma of the uterus, adenosquamous cell"""@eng , """uterus cancer, adenosquamous cell carcinoma"""@eng ; rdfs:subClassOf ; """2661"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279670"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/daunorubicin/dexamethasone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039637"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/DNR/TG/VCR"""@eng ; ; ; ; ; ; ; """2292"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279424"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/folic acid/methotrexate"""@eng ; skos:notation """CDR0000039636"""^^xsd:string ; skos:altLabel """CAMF"""@eng , """CTX/DOX/FA/MTX"""@eng ; ; ; ; ; """2291"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279423"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039635"""^^xsd:string ; skos:altLabel """VAFAC"""@eng , """CTX/DOX/5-FU/MTX/VCR"""@eng ; ; ; ; ; ; """2290"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055984"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/daunorubicin"""@eng ; skos:notation """CDR0000039634"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DNR"""@eng ; ; ; ; """2289"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279421"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/diethylstilbestrol/fluorouracil"""@eng ; skos:notation """CDR0000041168"""^^xsd:string ; skos:altLabel """CTX/DES/5-FU"""@eng ; ; ; ; """4240"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280763"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BCG/mitomycin"""@eng ; skos:notation """CDR0000041169"""^^xsd:string ; skos:altLabel """BC-G/MITO"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """4241"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280764"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/idarubicin"""@eng ; skos:notation """CDR0000039631"""^^xsd:string ; skos:altLabel """ARA-C/ASP/IDA"""@eng ; ; ; ; """2286"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279418"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/triazinate"""@eng ; skos:notation """CDR0000039630"""^^xsd:string ; skos:altLabel """BT"""@eng , """BCNU/TZT"""@eng ; ; ; """2285"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279417"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/sargramostim"""@eng ; skos:notation """CDR0000041164"""^^xsd:string ; skos:altLabel """ARA-C/DNR/GM-CSF"""@eng ; ; ; ; """4237"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280760"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethacrynic acid/melphalan"""@eng ; skos:notation """CDR0000041165"""^^xsd:string ; skos:altLabel """EA/L-PAM"""@eng ; ; ; """4238"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280761"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/poly ICLC"""@eng ; skos:notation """CDR0000041166"""^^xsd:string ; skos:altLabel """IFN-A/Poly ICLC"""@eng ; ; ; """4239"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338131"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult leiomyosarcoma"""@eng ; skos:notation """CDR0000041167"""^^xsd:string ; skos:altLabel """leiomyosarcoma, adult"""@eng , """sarcoma, leiomyo-, adult"""@eng ; rdfs:subClassOf ; """424"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278607"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aspirin/clopidogrel bisulfate"""@eng ; skos:notation """CDR0000038612"""^^xsd:string ; skos:altLabel """ASA/CLOBI"""@eng ; ; ; """11240"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134624"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000041161"""^^xsd:string ; skos:altLabel """CDDP/GM-CSF/IFF/VP-16"""@eng ; ; ; ; ; """4234"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280759"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """4'-iodo-4'-deoxydoxorubicin"""@eng ; skos:notation """CDR0000041162"""^^xsd:string ; skos:altLabel """IDOX"""@eng , """iododoxorubicin"""@eng ; """4235"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C971"""^^xsd:string ; umls:cui """C0047758"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenretinide/tamoxifen"""@eng ; skos:notation """CDR0000039638"""^^xsd:string ; skos:altLabel """HPR/TMX"""@eng ; ; ; """2293"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279425"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, Kaposi's sarcoma"""@eng ; skos:notation """CDR0000040578"""^^xsd:string ; skos:altLabel """Kaposi's sarcoma stage"""@eng ; rdfs:subClassOf ; """3478"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280201"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, renal cell cancer"""@eng ; skos:notation """CDR0000040579"""^^xsd:string ; skos:altLabel """renal cell cancer stage"""@eng , """stage, renal cell carcinoma"""@eng , """kidney cancer stage"""@eng , """stage, kidney cancer"""@eng , """renal cell carcinoma stage"""@eng ; rdfs:subClassOf ; """3479"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280202"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage/type, islet cell carcinoma"""@eng ; skos:notation """CDR0000040574"""^^xsd:string ; skos:altLabel """islet cell carcinoma stage"""@eng ; rdfs:subClassOf ; """3474"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280197"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adrenocortical carcinoma"""@eng ; skos:notation """CDR0000040575"""^^xsd:string ; skos:altLabel """adrenocortical carcinoma stage"""@eng ; rdfs:subClassOf ; """3475"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280198"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000040576"""^^xsd:string ; skos:altLabel """adult acute lymphocytic leukemia stage"""@eng , """stage, adult acute lymphocytic leukemia"""@eng ; rdfs:subClassOf ; """3476"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280199"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, adult acute myeloid leukemia"""@eng ; skos:notation """CDR0000040577"""^^xsd:string ; skos:altLabel """leukemia, adult acute myeloid stage"""@eng , """stage, adult acute myelogenous leukemia"""@eng , """stage, adult acute nonlymphocytic leukemia"""@eng , """AML stage, adult"""@eng , """adult acute nonlymphocytic stage"""@eng , """adult acute myeloid stage"""@eng , """adult acute myelogenous stage"""@eng , """leukemia, adult acute nonlymphocytic stage"""@eng , """ANLL stage, adult"""@eng , """leukemia, adult acute myelogenous stage"""@eng ; rdfs:subClassOf ; """3477"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280200"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/leucovorin calcium/mitomycin"""@eng ; skos:notation """CDR0000040570"""^^xsd:string ; skos:altLabel """FAM-CF"""@eng , """CF/DOX/5-FU/MITO"""@eng ; ; ; ; ; """3469"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280194"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood infratentorial ependymoma"""@eng ; skos:notation """CDR0000040571"""^^xsd:string ; skos:altLabel """brain tumor, pediatric infratentorial ependymoma"""@eng , """infratentorial ependyoblastoma, childhood"""@eng , """brain tumor, childhood infratentorial ependymoma"""@eng , """childhood CNS tumor, infratentorial ependymoma"""@eng , """childhood infratentorial ependyoblastoma"""@eng , """ependyoblastoma, childhood infratentorial"""@eng , """childhood brain tumor, infratentorial ependymoma"""@eng , """central nervous system tumor, infratentorial ependymoma, childhood"""@eng , """CNS tumor, pediatric infratentorial ependymoma"""@eng , """infratentorial ependymoma, childhood"""@eng , """CNS tumor, childhood infratentorial ependymoma"""@eng , """brain tumor, infratentorial ependymoma, childhood"""@eng , """pediatric brain tumor, infratentorial ependymoma"""@eng , """ependymoma, infratentorial, childhood"""@eng , """pediatric CNS tumor, infratentorial ependymoma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood ependymoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """347"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278599"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040572"""^^xsd:string ; skos:altLabel """ASP/DOX/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """3471"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280195"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, intraocular melanoma"""@eng ; skos:notation """CDR0000040573"""^^xsd:string ; skos:altLabel """intraocular melanoma stage"""@eng ; rdfs:subClassOf ; """3472"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280196"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorine F 18 EF5"""@eng ; skos:notation """CDR0000427615"""^^xsd:string ; skos:altLabel """18F-EF5"""@eng ; skos:definition """A radioconjugate consisting of EF5, a fluorinated derivative of etanidazole, conjugated to fluorine F 18, a positron emitting isotope. EF5 binds to hypoxic tissue; conjugation to Fluorine F 18 allows imaging of hypoxic regions within tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=427615&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=427615&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48389\" NCI Thesaurus)"""@eng ; """2005-04-23"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48389"""^^xsd:string ; umls:cui """C1541539"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sclerotherapy"""@eng ; skos:notation """CDR0000467889"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0036435"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tomotherapy"""@eng ; skos:notation """CDR0000467888"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831735"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bosutinib"""@eng ; skos:notation """CDR0000467222"""^^xsd:string ; skos:altLabel """SKI-606"""@eng ; skos:definition """A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467222&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467222&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60809\" NCI Thesaurus)"""@eng ; """2006-02-21"""^^xsd:string ; """2006-08-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C60809"""^^xsd:string ; umls:cui """C1831731"""^^xsd:string ; umls:cui """C1174836"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intratumoral therapy"""@eng ; skos:notation """CDR0000467883"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831733"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intensity-modulated radiation therapy"""@eng ; skos:notation """CDR0000467887"""^^xsd:string ; skos:altLabel """IMRT"""@eng ; ; rdfs:subClassOf ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C1512814"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """conformal radiation therapy"""@eng ; skos:notation """CDR0000467886"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0600521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """total-body irradiation"""@eng ; skos:notation """CDR0000467885"""^^xsd:string ; ; rdfs:subClassOf ; """2006-02-10"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0043162"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intrathecal therapy"""@eng ; skos:notation """CDR0000467884"""^^xsd:string ; """2006-02-10"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831734"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide"""@eng ; skos:notation """CDR0000041298"""^^xsd:string ; skos:altLabel """Casodex"""@eng , """4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide"""@eng , """4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline"""@eng , """ICI 176334"""@eng , """ICI 176,334"""@eng , """ICI-176334"""@eng , """(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide"""@eng , """N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide"""@eng , """CDX"""@eng , """Cosudex"""@eng ; skos:definition """A synthetic, nonsteroidal antiandrogen. Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41298&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41298&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1599\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4371"""^^xsd:string ; """C1599"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """90357-06-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """950118"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591237"""^^xsd:string ; umls:cui """C0740019"""^^xsd:string ; umls:cui """C0285590"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alendronate sodium"""@eng ; skos:notation """CDR0000041299"""^^xsd:string ; skos:altLabel """G-704650"""@eng , """Fosamax"""@eng , """Alendronate"""@eng , """Alendronic Acid Monosodium Salt Trihydrate"""@eng , """MK-217"""@eng , """Adronat"""@eng , """Onclast"""@eng , """Alendros"""@eng , """MK 217"""@eng ; skos:definition """The sodium salt form of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, bone resorption and turnover are reduced. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41299&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41299&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C973\" NCI Thesaurus)"""@eng ; ; ; """TRD"""^^xsd:string ; """4372"""^^xsd:string ; """C973"""^^xsd:string ; """129318-43-0"""^^xsd:string ; """2006-12-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0047995"""^^xsd:string ; umls:cui """C1521992"""^^xsd:string ; umls:cui """C0102118"""^^xsd:string ; umls:cui """C0376569"""^^xsd:string ; umls:cui """C1510842"""^^xsd:string ; umls:cui """C1510843"""^^xsd:string ; umls:cui """C0700482"""^^xsd:string ; umls:cui """C1510841"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/leuprolide/suramin"""@eng ; skos:notation """CDR0000041292"""^^xsd:string ; skos:altLabel """FLUT/LEUP/SUR"""@eng ; ; ; ; """4365"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280880"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, renal cell cancer"""@eng ; skos:notation """CDR0000040174"""^^xsd:string ; skos:altLabel """cellular diagnosis, renal cell carcinoma"""@eng , """renal cell cancer cellular diagnosis"""@eng , """cellular diagnosis, kidney cancer"""@eng , """kidney cancer cellular diagnosis"""@eng , """renal cell carcinoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2963"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279871"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/interferon alfa/leucovorin calcium"""@eng ; skos:notation """CDR0000041290"""^^xsd:string ; skos:altLabel """CDDP/CF/5-FU/IFN-A"""@eng ; ; ; ; ; """4363"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338140"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000041291"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/TAX"""@eng ; ; ; ; """4364"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280879"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/mitoxantrone/vincristine"""@eng ; skos:notation """CDR0000041296"""^^xsd:string ; skos:altLabel """CF/DHAD/5-FU/VCR"""@eng ; ; ; ; ; """4369"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280881"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000041297"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PEG-ASP/PRED/VCR"""@eng ; ; ; ; ; ; """4370"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280882"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ixabepilone/trastuzumab"""@eng ; skos:notation """CDR0000357418"""^^xsd:string ; skos:altLabel """BMS 247550/MOAB HER2"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328219"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxidopamine"""@eng ; skos:notation """CDR0000041295"""^^xsd:string ; skos:altLabel """6-hydroxydopamine"""@eng ; """4368"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0085196"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000341570"""^^xsd:string ; skos:altLabel """CF/5-FU/SC-58635"""@eng ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328089"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PHA-739358"""@eng ; skos:notation """CDR0000489092"""^^xsd:string ; skos:definition """A small synthetic molecule with potential antitumor activity. PHA-739358 inhibits catalytic activity of Aurora kinases, a family of serine-threonine kinases that are important regulators of cellular proliferation and division, and are overexpressed in certain types of cancer. Through the inhibition of Aurora kinases, PHA-739358 may induce cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489092&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489092&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61587\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C61587"""^^xsd:string ; umls:cui """C1831874"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/rosiglitazone"""@eng ; skos:notation """CDR0000370782"""^^xsd:string ; skos:altLabel """ROS/SC-58635"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541242"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland cancer"""@eng ; skos:notation """CDR0000038946"""^^xsd:string ; skos:altLabel """Salivary gland cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1455"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220636"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I salivary gland cancer"""@eng ; skos:notation """CDR0000038947"""^^xsd:string ; skos:altLabel """salivary gland cancer, stage I"""@eng ; rdfs:subClassOf ; """salivary gland cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1456"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278989"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000038944"""^^xsd:string ; skos:altLabel """CTX/IFN-A/IL-2"""@eng ; ; ; ; """1453"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338083"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic squamous neck cancer with occult primary"""@eng ; skos:notation """CDR0000038945"""^^xsd:string ; skos:altLabel """neck cancer, metastatic squamous with occult primary"""@eng , """Metastatic squamous neck cancer with occult primary"""@eng , """occult primary cancer metastatic squamous to the neck"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1454"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220635"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV non-small cell lung cancer"""@eng ; skos:notation """CDR0000038942"""^^xsd:string ; skos:altLabel """non-oat cell lung cancer, metastatic"""@eng , """NSCLC, stage IV"""@eng , """lung cancer, nonsmall cell, stage IV"""@eng , """stage IV NSCLC"""@eng , """non-oat cell lung cancer, stage IV"""@eng , """nonsmall cell lung cancer, stage IV"""@eng , """lung cancer, non-oat cell, stage IV"""@eng , """stage IV nonsmall cell lung cancer"""@eng , """nonsmall cell lung cancer, metastatic"""@eng , """metastatic nonsmall cell lung cancer"""@eng , """non-small cell lung cancer, stage IV"""@eng , """NSCLC, metastatic"""@eng , """lung cancer, nonsmall cell, metastatic"""@eng , """lung cancer, non-oat cell, metastatic"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1451"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278987"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CI-921"""@eng ; skos:notation """CDR0000038943"""^^xsd:string ; skos:altLabel """Amsalog"""@eng , """4-Acridinecarboxamide,9-((2-methoxy-4-((methylsulfonyl)amino)phenyl)amino-N,5-dimethyl"""@eng ; skos:definition """A synthetic derivative of acridine carboxamide with antineoplastic properties. CI-921, a lipophilic and water-soluble analog of amsacrine, inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38943&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38943&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1050\" NCI Thesaurus)"""@eng ; """1452"""^^xsd:string ; """C1050"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """80841-47-0"""^^xsd:string ; """343499"""^^xsd:string ; umls:cui """C0055687"""^^xsd:string ; umls:cui """C0130561"""^^xsd:string ; umls:cui """C1765331"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult extraskeletal osteosarcoma"""@eng ; skos:notation """CDR0000038940"""^^xsd:string ; skos:altLabel """extraskeletal osteosarcoma, adult"""@eng , """osteosarcoma, adult extraskeletal"""@eng ; rdfs:subClassOf ; """1449"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278985"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 non-small cell lung cancer"""@eng ; skos:notation """CDR0000038941"""^^xsd:string ; skos:altLabel """non-small cell lung cancer stage 0"""@eng , """stage 0 NSCLC"""@eng , """NSCLC, stage 0"""@eng , """nonsmall cell lung cancer, stage 0"""@eng , """stage 0 nonsmall cell lung cancer"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1450"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278986"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AdRTVP-1-transduced prostate cancer cell-based vaccine"""@eng ; skos:notation """CDR0000526815"""^^xsd:string ; skos:altLabel """Adenoviral vector-mediated RTVP-1 gene-modified prostate cancer cell-based vaccine"""@eng ; """2006-12-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832007"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II salivary gland cancer"""@eng ; skos:notation """CDR0000038948"""^^xsd:string ; skos:altLabel """salivary gland cancer, stage II"""@eng ; rdfs:subClassOf ; """salivary gland cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1457"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278990"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III salivary gland cancer"""@eng ; skos:notation """CDR0000038949"""^^xsd:string ; skos:altLabel """salivary gland cancer, stage III"""@eng ; rdfs:subClassOf ; """salivary gland cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1458"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278991"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TS"""@eng ; skos:notation """CDR0000257799"""^^xsd:string ; skos:altLabel """thymidylate synthase gene"""@eng ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11460"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1366824"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epidermal growth factor"""@eng ; skos:notation """CDR0000354196"""^^xsd:string ; skos:altLabel """EGF"""@eng ; rdfs:subClassOf ; """2004-01-23"""^^xsd:string ; """2004-01-21"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0242275"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """galactomannan derivative"""@eng ; skos:notation """CDR0000355829"""^^xsd:string ; skos:altLabel """DAVANAT"""@eng , """1,4-beta-D-galactomannan"""@eng , """GD"""@eng ; ; """TRD"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328211"""^^xsd:string ; umls:cui """C1328725"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """temozolomide/tipifarnib"""@eng ; skos:notation """CDR0000355821"""^^xsd:string ; skos:altLabel """R115777/TMZ"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328209"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """procarbazine/thalidomide"""@eng ; skos:notation """CDR0000355820"""^^xsd:string ; skos:altLabel """PCB/THAL"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328208"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/PEG-interferon alfa-2b/sargramostim"""@eng ; skos:notation """CDR0000355823"""^^xsd:string ; skos:altLabel """GM-CSF/PEG-IFNA2b/STI571"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328210"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/glufosfamide"""@eng ; skos:notation """CDR0000420837"""^^xsd:string ; skos:altLabel """D-19575/dFdC"""@eng ; ; ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E1A lipid complex/paclitaxel"""@eng ; skos:notation """CDR0000420836"""^^xsd:string ; skos:altLabel """TAX/tgDCC-E1A"""@eng ; ; ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541502"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody IDEC-159"""@eng ; skos:notation """CDR0000420839"""^^xsd:string ; skos:altLabel """yttrium Y 90 MOAB IDEC-159"""@eng , """Y90 MOAB IDEC-159"""@eng ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541504"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/enzastaurin"""@eng ; skos:notation """CDR0000269071"""^^xsd:string ; skos:altLabel """CAPE/LY317615"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2004-08-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541169"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plitidepsin"""@eng ; skos:notation """CDR0000460052"""^^xsd:string ; skos:altLabel """Aplidin"""@eng , """aplidine"""@eng , """dehydrodemnin B"""@eng ; skos:definition """A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460052&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460052&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1689\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """2006-01-17"""^^xsd:string ; """C1689"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C3160737"""^^xsd:string ; umls:cui """C0388638"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/irinotecan"""@eng ; skos:notation """CDR0000043474"""^^xsd:string ; skos:altLabel """CAPE/CPT-11"""@eng ; ; ; """8685"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796639"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MG 98"""@eng ; skos:notation """CDR0000043475"""^^xsd:string ; skos:altLabel """MG-98"""@eng , """MG98"""@eng ; """2006-12-05"""^^xsd:string ; """C2530"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """8686"""^^xsd:string ; umls:cui """C0796640"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SR49059"""@eng ; skos:notation """CDR0000043476"""^^xsd:string ; skos:altLabel """SR 49059"""@eng , """SR-49059"""@eng ; """8687"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0218069"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leridistim"""@eng ; skos:notation """CDR0000043477"""^^xsd:string ; skos:altLabel """SC 70935"""@eng , """MPO"""@eng , """Myelopoietin"""@eng , """SC70935"""@eng , """SC-70935"""@eng ; skos:definition """A recombinant chimeric dual G-CSF and IL-3 receptor agonist. Leridistim binds with high affinity to both the interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF) receptors, thereby stimulating the production and maturation of neutrophils, platelets, and lymphocytes after chemotherapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43477&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43477&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1846\" NCI Thesaurus)"""@eng ; """8688"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1846"""^^xsd:string ; """193700-51-5"""^^xsd:string ; """2006-12-14"""^^xsd:string ; umls:cui """C0919350"""^^xsd:string ; umls:cui """C0796641"""^^xsd:string ; umls:cui """C0912079"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Thompson-Friedenreich antigen"""@eng ; skos:notation """CDR0000043470"""^^xsd:string ; skos:altLabel """antigen, Thompson-Friedenreich"""@eng , """TF(c)"""@eng ; """8680"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0053438"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TF(c)-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000043471"""^^xsd:string ; skos:altLabel """TF(c)-KLH"""@eng , """vaccine, TF(c)-KLH conjugate"""@eng ; ; """8681"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796636"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """QS21/TF(c)-KLH conjugate vaccine"""@eng ; skos:notation """CDR0000043472"""^^xsd:string ; skos:altLabel """QS 21/TF(c)-KLH"""@eng ; ; ; """8682"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796637"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lurtotecan liposome"""@eng ; skos:notation """CDR0000043473"""^^xsd:string ; skos:altLabel """NX211"""@eng , """NX 211"""@eng , """liposome, lurtotecan"""@eng , """OSI-211"""@eng ; ; """2004-02-07"""^^xsd:string ; """8683"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935959"""^^xsd:string ; umls:cui """C0796638"""^^xsd:string ; umls:cui """C1328719"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/dacarbazine/hydroxyurea/vincristine"""@eng ; skos:notation """CDR0000039390"""^^xsd:string ; skos:altLabel """BCNU/DTIC/HU/VCR"""@eng , """BHD-V"""@eng ; ; ; ; ; """2025"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279253"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/vinblastine"""@eng ; skos:notation """CDR0000039391"""^^xsd:string ; skos:altLabel """BLEO/CDDP/VBL/VP-16"""@eng , """PVBV"""@eng ; ; ; ; ; """2026"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0072636"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/tamoxifen"""@eng ; skos:notation """CDR0000039392"""^^xsd:string ; skos:altLabel """CAFTH"""@eng , """CTX/DOX/5-FU/FXM/TMX"""@eng ; ; ; ; ; """2027"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279255"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentamidine/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000039393"""^^xsd:string ; skos:altLabel """PAD/TMTX"""@eng ; ; ; """2028"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279256"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 125/polifeprosan 20 with carmustine implant"""@eng ; skos:notation """CDR0000043478"""^^xsd:string ; skos:altLabel """Gliadel/I-125"""@eng ; ; ; """8689"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796642"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cisplatin/fluorouracil/paclitaxel"""@eng ; skos:notation """CDR0000043479"""^^xsd:string ; skos:altLabel """CDDP/5-FU/TAX/WR-2721"""@eng ; ; ; ; ; """8691"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796643"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/melphalan"""@eng ; skos:notation """CDR0000039396"""^^xsd:string ; skos:altLabel """CDDP/L-PAM/VP-16"""@eng ; ; ; ; """2031"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279259"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000039397"""^^xsd:string ; skos:altLabel """BLEO/MTX/VBL"""@eng , """BVM"""@eng ; ; ; ; """2032"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279260"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039371"""^^xsd:string ; skos:altLabel """POACH"""@eng , """ARA-C/CTX/DOX/PRED/VCR"""@eng ; ; ; ; ; ; """2006"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078044"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/monoclonal antibody 3F8"""@eng ; skos:notation """CDR0000269697"""^^xsd:string ; skos:altLabel """MOAB 3F8/VP-16"""@eng ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327858"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/flavopiridol"""@eng ; skos:notation """CDR0000363804"""^^xsd:string ; skos:altLabel """FLAVO/PS-341"""@eng ; ; ; """2004-04-23"""^^xsd:string ; """2004-03-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541210"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/mitotane/vincristine"""@eng ; skos:notation """CDR0000041939"""^^xsd:string ; skos:altLabel """DDD/DOX/VCR/VP-16"""@eng ; ; ; ; ; """5161"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281490"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ammonium trichlorotellurate"""@eng ; skos:notation """CDR0000041938"""^^xsd:string ; skos:altLabel """Ossirene"""@eng , """IVX-Q-101"""@eng , """Tellurate(1-), trichloro[1,2-ethanediolato(2-)-.kappa.O,.kappa.O']-,ammonium, (SP-5-22)-"""@eng , """AS101"""@eng ; skos:definition """A synthetic non-toxic tellurium derivative, structurally similar to cisplatin, with immuno-modulating and anti hair loss properties. Ammonium trichlorotellurate induces production of colony stimulating factor (CSF), interleukin-2 (IL-2), and IL-2 receptors by increasing the calcium ion influx through the cell membrane and subsequently exerts its immunomodulating effects through the CSF-mediated increase in macrophage/granulocytes. This agent is also a potent inducer of interferon and a spectrum of cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF). In animal studies, ammonium trichlorotellurate exerts its anti hair loss effect by possessing dual ability to induce anagen and to retard spontaneous catagen development via promotion of follicular keratinocyte proliferation and to interfere with terminal differentiation, respectively. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41938&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41938&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1006\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """106566-58-9"""^^xsd:string ; """5160"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """C1006"""^^xsd:string ; """618654"""^^xsd:string ; umls:cui """C0950716"""^^xsd:string ; umls:cui """C0052457"""^^xsd:string ; umls:cui """C1706673"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """saperconazole"""@eng ; skos:notation """CDR0000041937"""^^xsd:string ; skos:altLabel """SPZ"""@eng ; """5159"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0074037"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """in vitro sensitivity-directed chemotherapy"""@eng ; skos:notation """CDR0000041936"""^^xsd:string ; """5158"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281488"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/vindesine"""@eng ; skos:notation """CDR0000041935"""^^xsd:string ; skos:altLabel """ARA-C/DAVA/DM/VP-16"""@eng ; ; ; ; ; """5157"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281487"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/ifosfamide/methotrexate/teniposide/vincristine"""@eng ; skos:notation """CDR0000041934"""^^xsd:string ; skos:altLabel """ARA-C/DM/IFF/MTX/VCR/VM-26"""@eng ; ; ; ; ; ; ; """5156"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/prednisolone"""@eng ; skos:notation """CDR0000041933"""^^xsd:string ; skos:altLabel """CTX/PRDL"""@eng ; ; ; """5155"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281485"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041932"""^^xsd:string ; skos:altLabel """DOX/PRDL/VCR"""@eng ; ; ; ; """5154"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281484"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/ifosfamide/methotrexate/prednisolone"""@eng ; skos:notation """CDR0000041931"""^^xsd:string ; skos:altLabel """ARA-C/IFF/MTX/PRDL/VP-16"""@eng ; ; ; ; ; ; """5153"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281483"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/daunorubicin/prednisolone/vindesine"""@eng ; skos:notation """CDR0000041930"""^^xsd:string ; skos:altLabel """ASP/DAVA/DNR/PRDL"""@eng ; ; ; ; ; """5152"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenestrin"""@eng ; skos:notation """CDR0000039544"""^^xsd:string ; """2192"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0070556"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/sorafenib"""@eng ; skos:notation """CDR0000433194"""^^xsd:string ; skos:altLabel """DOX/SFN"""@eng ; ; ; """2005-05-05"""^^xsd:string ; """2005-05-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831614"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine"""@eng ; skos:notation """CDR0000433196"""^^xsd:string ; skos:altLabel """SRV PEP VAC"""@eng , """survivin peptide vaccine"""@eng ; skos:definition """A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, -A2 and -B35 restricted survivin peptides/Montanide ISA-51 may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=433196&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=433196&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48393\" NCI Thesaurus)"""@eng ; ; """Drug/agent"""^^xsd:string ; """2006-08-25"""^^xsd:string ; """2005-05-06"""^^xsd:string ; """C48393"""^^xsd:string ; umls:cui """C1708275"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/survivin peptide vaccine"""@eng ; skos:notation """CDR0000433197"""^^xsd:string ; skos:altLabel """ISA-51/SRV PEP VAC"""@eng ; ; """2005-05-05"""^^xsd:string ; """2005-05-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831615"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide"""@eng ; skos:notation """CDR0000043067"""^^xsd:string ; skos:altLabel """Arsenous Acid Anhydride"""@eng , """White Arsenic"""@eng , """AS2O3"""@eng , """Arsenic (III) Oxide"""@eng , """Arsenous Acid"""@eng , """Trisenox"""@eng , """Arsenous Oxide"""@eng , """Arsenic Sesquioxide"""@eng ; skos:definition """A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43067&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43067&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1005\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """7430"""^^xsd:string ; """C1005"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """57974"""^^xsd:string ; """1327-53-3"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """706363"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0052422"""^^xsd:string ; umls:cui """C1096917"""^^xsd:string ; umls:cui """C0052416"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/paclitaxel"""@eng ; skos:notation """CDR0000043066"""^^xsd:string ; skos:altLabel """LipoDox/TAX"""@eng ; ; ; """7429"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678066"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine"""@eng ; skos:notation """CDR0000043065"""^^xsd:string ; skos:altLabel """WR-139017"""@eng , """Belustin"""@eng , """Lomeblastin"""@eng , """Lomustinum"""@eng , """Chloroethylcyclo-hexylnitrosourea"""@eng , """CeeNU"""@eng , """1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea"""@eng , """Lucostin"""@eng , """chloroethylcyclohexylnitrosourea"""@eng , """CCNU"""@eng , """RB-1509"""@eng , """Belustine"""@eng , """Cecenu"""@eng , """Prava"""@eng , """Lucostine"""@eng , """Citostal"""@eng , """N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea"""@eng ; skos:definition """A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis. This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing. Lomustine is lipophilic and crosses the blood-brain barrier. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43065&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43065&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C617\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """742"""^^xsd:string ; """79037"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4595"""^^xsd:string ; """C617"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """13010-47-4"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517929"""^^xsd:string ; umls:cui """C1517933"""^^xsd:string ; umls:cui """C0687700"""^^xsd:string ; umls:cui """C1517931"""^^xsd:string ; umls:cui """C1517930"""^^xsd:string ; umls:cui """C0023972"""^^xsd:string ; umls:cui """C1517934"""^^xsd:string ; umls:cui """C0699180"""^^xsd:string ; umls:cui """C1522648"""^^xsd:string ; umls:cui """C1450043"""^^xsd:string ; umls:cui """C1522645"""^^xsd:string ; umls:cui """C0699181"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/leucovorin calcium/methotrexate/vincristine"""@eng ; skos:notation """CDR0000043064"""^^xsd:string ; skos:altLabel """CDDP/CF/CTX/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; """7419"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678065"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/lomustine/procarbazine/vincristine"""@eng ; skos:notation """CDR0000043063"""^^xsd:string ; skos:altLabel """CBDCA/CCNU/PCB/VCR"""@eng ; ; ; ; ; """7418"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678064"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/doxorubicin HCl liposome"""@eng ; skos:notation """CDR0000043062"""^^xsd:string ; skos:altLabel """LipoDox/TXT"""@eng ; ; ; """7417"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678063"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MART-1 Antigen"""@eng ; skos:notation """CDR0000043061"""^^xsd:string ; skos:altLabel """MART-1"""@eng , """Antigen SK29-AA"""@eng , """MART1"""@eng , """Melan A"""@eng , """MLANA"""@eng , """MART-1 Tumor Antigen"""@eng , """Antigen LB39-AA"""@eng , """Melan-A Protein"""@eng , """Melanoma Antigen Recognized by T-Cells 1"""@eng , """MEL-A"""@eng , """MLANA Protein"""@eng ; """7416"""^^xsd:string ; """C28724"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C1522481"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/prednisone/prinomastat"""@eng ; skos:notation """CDR0000043060"""^^xsd:string ; skos:altLabel """AG3340/DHAD/PRED"""@eng ; ; ; ; """7414"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678061"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/pegylated recombinant human megakaryocyte growth and development factor"""@eng ; skos:notation """CDR0000043069"""^^xsd:string ; skos:altLabel """G-CSF/PEG-MGDF"""@eng ; ; ; """7433"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678068"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/thalidomide"""@eng ; skos:notation """CDR0000043068"""^^xsd:string ; skos:altLabel """CBDCA/THAL"""@eng ; ; ; """7431"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678067"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """COMT"""@eng ; skos:notation """CDR0000038375"""^^xsd:string ; rdfs:subClassOf ; """10996"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1135159"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/pegaspargase/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038374"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/DOX/MTX/PEG-ASP/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; """10993"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134445"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NAT"""@eng ; skos:notation """CDR0000038377"""^^xsd:string ; rdfs:subClassOf ; """10998"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1135166"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EPHX"""@eng ; skos:notation """CDR0000038376"""^^xsd:string ; rdfs:subClassOf ; """10997"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1134446"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenoxodiol"""@eng ; skos:notation """CDR0000038371"""^^xsd:string ; skos:altLabel """3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol"""@eng , """NV-06"""@eng ; skos:definition """A synthetic flavonoid derivative. Phenoxodiol activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38371&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38371&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2642\" NCI Thesaurus)"""@eng ; ; ; """10990"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C2642"""^^xsd:string ; """81267-65-4"""^^xsd:string ; umls:cui """C1134444"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000038370"""^^xsd:string ; skos:altLabel """PDL, diffuse lymphocytic, adult"""@eng , """DSC lymphoma, adult"""@eng , """lymphoma, diffuse small cleaved cell, adult"""@eng , """diffuse lymphocytic, poorly-differentiated lymphoma, adult"""@eng , """diffuse small cleaved cell lymphoma, adult"""@eng , """diffuse poorly-differentiated lymphocytic lymphoma"""@eng , """poorly-differentiated lymphoma, diffuse lymphocytic, adult"""@eng , """diffuse PDL lymphoma"""@eng , """small cleaved cell lymphoma, diffuse, adult"""@eng , """lymphoma, diffuse lymphocytic, poorly-differentiated, adult"""@eng , """DPDL lymphoma"""@eng , """adult DSC lymphoma"""@eng , """DLPD lymphoma, adult"""@eng ; rdfs:subClassOf ; """1099"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0334634"""^^xsd:string ; umls:cui """C1622814"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000038373"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; ; """10992"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879561"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentoxifylline/vitamin E"""@eng ; skos:notation """CDR0000038372"""^^xsd:string ; skos:altLabel """PTX/VIT-E"""@eng ; ; ; """10991"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134710"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III colon cancer"""@eng ; skos:notation """CDR0000038379"""^^xsd:string ; skos:altLabel """colon cancer, stage III"""@eng , """Dukes C colon cancer"""@eng , """colon cancer, Dukes C"""@eng ; rdfs:subClassOf ; """colon cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """11"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278480"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NAT-1"""@eng ; skos:notation """CDR0000038378"""^^xsd:string ; rdfs:subClassOf ; """10999"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1426489"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/MS-209"""@eng ; skos:notation """CDR0000037868"""^^xsd:string ; skos:altLabel """MS 209/TXT"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """10271"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879435"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-2-KLH vaccine/QS21"""@eng ; skos:notation """CDR0000037869"""^^xsd:string ; skos:altLabel """MUC-2-KLH/QS 21"""@eng ; ; ; """10272"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879436"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/epirubicin/paclitaxel"""@eng ; skos:notation """CDR0000037864"""^^xsd:string ; skos:altLabel """CBDCA/EPI/TAX"""@eng ; ; ; ; """10268"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879433"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/fludarabine/oblimersen"""@eng ; skos:notation """CDR0000037865"""^^xsd:string ; skos:altLabel """ARA-C/FAMP/G3139"""@eng ; ; ; ; """10269"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879434"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitolactol"""@eng ; skos:notation """CDR0000037866"""^^xsd:string ; skos:altLabel """CDDP/DBD"""@eng ; ; ; """1027"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278728"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MS-209"""@eng ; skos:notation """CDR0000037867"""^^xsd:string ; skos:altLabel """MS 209"""@eng , """MS209"""@eng ; ; """2003-10-23"""^^xsd:string ; """10270"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0255738"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ixabepilone"""@eng ; skos:notation """CDR0000037860"""^^xsd:string ; skos:altLabel """(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione"""@eng , """BMS 247550"""@eng , """BMS-247550"""@eng , """BMS247550"""@eng , """Epothilone-B BMS 247550"""@eng , """Azaepothilone B"""@eng , """epothilone B lactam"""@eng ; skos:definition """A semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone (BMS-247550) binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37860&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37860&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37452\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """10264"""^^xsd:string ; """2006-05-24"""^^xsd:string ; """710428"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """219989-84-1"""^^xsd:string ; """C37452"""^^xsd:string ; umls:cui """C1524100"""^^xsd:string ; umls:cui """C1135132"""^^xsd:string ; umls:cui """C0879430"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ILX23-7553"""@eng ; skos:notation """CDR0000037861"""^^xsd:string ; skos:altLabel """ILX23 7553"""@eng ; """2003-10-28"""^^xsd:string ; """10265"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879431"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate"""@eng ; skos:notation """CDR0000037862"""^^xsd:string ; skos:altLabel """CGP-57148"""@eng , """CGP57148B"""@eng , """CGP57148"""@eng , """STI571"""@eng , """4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"""@eng , """STI-571"""@eng , """Gleevec"""@eng , """Glivec"""@eng , """CGP 57148"""@eng ; skos:definition """The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that harbor the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37862&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37862&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1687\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """10266"""^^xsd:string ; """61135"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """716051"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """C1687"""^^xsd:string ; """152459-95-5"""^^xsd:string ; umls:cui """C0935987"""^^xsd:string ; umls:cui """C0935989"""^^xsd:string ; umls:cui """C0906802"""^^xsd:string ; umls:cui """C0385728"""^^xsd:string ; umls:cui """C0939537"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/raltitrexed"""@eng ; skos:notation """CDR0000037863"""^^xsd:string ; skos:altLabel """CDDP/ICI D1694"""@eng ; ; ; """10267"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879432"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """histamine dihydrochloride"""@eng ; skos:notation """CDR0000042918"""^^xsd:string ; skos:altLabel """HIST"""@eng , """Maxamine"""@eng ; ; """6751"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135572"""^^xsd:string ; umls:cui """C0543456"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """histamine dihydrochloride/interleukin-2"""@eng ; skos:notation """CDR0000042919"""^^xsd:string ; skos:altLabel """HIST/IL-2"""@eng ; ; ; """6752"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677840"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody muJ591"""@eng ; skos:notation """CDR0000038113"""^^xsd:string ; skos:altLabel """I131 MOAB muJ591"""@eng ; """10666"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935700"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ERA-923"""@eng ; skos:notation """CDR0000038112"""^^xsd:string ; """10665"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935699"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/lonafarnib"""@eng ; skos:notation """CDR0000038115"""^^xsd:string ; skos:altLabel """dFdC/SCH 66336"""@eng ; ; ; """2003-02-07"""^^xsd:string ; """10668"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935702"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxaliplatin/topotecan"""@eng ; skos:notation """CDR0000038114"""^^xsd:string ; skos:altLabel """L-OHP/TOPO"""@eng ; ; ; """10667"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935701"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic gastrointestinal carcinoid tumor"""@eng ; skos:notation """CDR0000038117"""^^xsd:string ; skos:altLabel """gastrointestinal carcinoid tumor, metastatic"""@eng ; rdfs:subClassOf ; """gastrointestinal carcinoid tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1067"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278749"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interferon alfa/MART-1 antigen/Montanide ISA-51/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000038116"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/IFN-A/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; ; """10669"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935703"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cladribine/idarubicin"""@eng ; skos:notation """CDR0000042910"""^^xsd:string ; skos:altLabel """2-CdA/IDA"""@eng ; ; ; """6743"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677832"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interferon alfa/MART-1 antigen/Montanide ISA-51/tyrosinase peptide"""@eng ; skos:notation """CDR0000038118"""^^xsd:string ; skos:altLabel """gp100/IFN-A/ISA-51/MART-1/TYRP"""@eng ; ; ; ; ; """10670"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935704"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buserelin/flutamide"""@eng ; skos:notation """CDR0000042912"""^^xsd:string ; skos:altLabel """BSRL/FLUT"""@eng ; ; ; """6745"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677834"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buserelin/nilutamide"""@eng ; skos:notation """CDR0000042913"""^^xsd:string ; skos:altLabel """ANAN/BSRL"""@eng ; ; ; """6746"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677835"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/buserelin"""@eng ; skos:notation """CDR0000042914"""^^xsd:string ; skos:altLabel """BSRL/CDX"""@eng ; ; ; """6747"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677836"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leuprolide/nilutamide"""@eng ; skos:notation """CDR0000042915"""^^xsd:string ; skos:altLabel """ANAN/LEUP"""@eng ; ; ; """6748"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677837"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testolactone"""@eng ; skos:notation """CDR0000042916"""^^xsd:string ; skos:altLabel """Therapeutic Testolactone"""@eng , """Teslac"""@eng , """D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione"""@eng , """1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic Acid Delta-Lactone"""@eng , """SQ-9538"""@eng , """13-Hydroxy-3-0x0-13,17-secoandrosta-1,4-dien-17-oic Acid Delta-Lactone"""@eng , """TL"""@eng , """Delta-1-Testololactone"""@eng , """Fludestrin"""@eng , """1-Dehydrotestololactone"""@eng , """17Alpha-oxo-D-homo-1,4-androstadiene-3,17-dione"""@eng ; skos:definition """A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42916&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42916&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2301\" NCI Thesaurus)"""@eng ; """675"""^^xsd:string ; """23759"""^^xsd:string ; """C2301"""^^xsd:string ; """968-93-4"""^^xsd:string ; """920"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0039600"""^^xsd:string ; umls:cui """C0740162"""^^xsd:string ; umls:cui """C1527154"""^^xsd:string ; umls:cui """C1527155"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """loss, grief, and bereavement"""@eng ; skos:notation """CDR0000042917"""^^xsd:string ; skos:altLabel """bereavement, loss and grief"""@eng , """grief, loss and bereavement"""@eng , """bereavement, grief and loss"""@eng , """loss and grief"""@eng ; """6750"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0677838"""^^xsd:string ; umls:tui """T041"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adjuvant therapy"""@eng ; skos:notation """CDR0000334859"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """2003-09-08"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0677850"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human MHC non-restricted cytotoxic T-cell line TALL-104"""@eng ; skos:notation """CDR0000531055"""^^xsd:string ; skos:altLabel """TALL-104"""@eng ; """2007-01-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832043"""^^xsd:string ; umls:cui """C1832042"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lutetium Lu 177-labelled chimeric monoclonal antibody cG250"""@eng ; skos:notation """CDR0000531051"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-19"""^^xsd:string ; umls:cui """C1832041"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """constipation, impaction, and bowel obstruction"""@eng ; skos:notation """CDR0000040610"""^^xsd:string ; skos:altLabel """bowel obstruction"""@eng , """impaction"""@eng ; rdfs:subClassOf ; """2002-11-20"""^^xsd:string ; """3510"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0333124"""^^xsd:string ; umls:cui """C0280233"""^^xsd:string ; umls:cui """C0021843"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """WX-UK1"""@eng ; skos:notation """CDR0000377676"""^^xsd:string ; skos:altLabel """WX UK1"""@eng ; ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1453900"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, childhood acute myeloid leukemia"""@eng ; skos:notation """CDR0000040612"""^^xsd:string ; skos:altLabel """pediatric acute myeloid leukemia stage"""@eng , """childhood acute nonlymphocytic leukemia stage"""@eng , """childhood acute myeloid leukemia stage"""@eng , """stage, childhood acute nonlymphocytic leukemia"""@eng , """pediatric acute nonlymphocytic leukemia stage"""@eng ; rdfs:subClassOf ; """3514"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280237"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """xaliproden hydrochloride"""@eng ; skos:notation """CDR0000480399"""^^xsd:string ; skos:altLabel """SR 57746A"""@eng ; skos:definition """The hydrochloride salt of xaliproden, an orally-active, synthetic, non-peptidic 5-HT1A receptor agonist with neurotrophic and neuroprotective properties. Although the mechanism of action of xaliproden is not fully understood, it appears to either mimic the effects of neurotrophins or stimulate their synthesis, thereby stimulating neuronal cell differentiation and proliferation and inhibiting neuronal cell death. Xaliprodens neuroprotective effect involves the activation of MAP kinase pathways via stimulation of the 5-HT1A receptor. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480399&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480399&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61328\" NCI Thesaurus)"""@eng ; """2006-04-14"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61328"""^^xsd:string ; umls:cui """C1138236"""^^xsd:string ; umls:cui """C0247952"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """2-deoxy-D-glucose"""@eng ; skos:notation """CDR0000409701"""^^xsd:string ; skos:altLabel """2DG"""@eng , """deoxyglucose"""@eng , """2-deoxyglucose"""@eng ; ; """2004-12-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-03-14"""^^xsd:string ; umls:cui """C0011501"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """deoxyglucose/docetaxel"""@eng ; skos:notation """CDR0000409702"""^^xsd:string ; skos:altLabel """2DG/TXT"""@eng ; ; ; """2004-12-03"""^^xsd:string ; """2004-12-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541427"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/triazinate"""@eng ; skos:notation """CDR0000039408"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/TZT"""@eng , """T-CAP"""@eng ; ; ; ; ; """2043"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279271"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluoxymesterone/tamoxifen/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000039409"""^^xsd:string ; skos:altLabel """TsAVbTH"""@eng , """DOX/FXM/TMX/TSPA/VBL"""@eng ; ; ; ; ; """2044"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279272"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dacarbazine/hydroxyurea/lomustine/methylprednisolone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039400"""^^xsd:string ; skos:altLabel """ARA-C/CCNU/CDDP/DTIC/HU/MePRDL/PCB/VCR"""@eng ; ; ; ; ; ; ; ; ; """2035"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279263"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/lomustine/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039401"""^^xsd:string ; skos:altLabel """BLEO/CCNU/CTX/PCB/PRED/VCR"""@eng , """BLEO-CCVPP"""@eng ; ; ; ; ; ; ; """2036"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279264"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/prednisolone/vincristine"""@eng ; skos:notation """CDR0000039402"""^^xsd:string ; skos:altLabel """CCNU/PRDL/VCR"""@eng ; ; ; ; """2037"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279265"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/methotrexate/procarbazine"""@eng ; skos:notation """CDR0000039403"""^^xsd:string ; skos:altLabel """BMP"""@eng , """BCNU/MTX/PCB"""@eng ; ; ; ; """2038"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279266"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aspirin/interferon alfa"""@eng ; skos:notation """CDR0000039404"""^^xsd:string ; skos:altLabel """ASA/IFN-A"""@eng ; ; ; """2039"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338091"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/semustine/streptozocin"""@eng ; skos:notation """CDR0000039405"""^^xsd:string ; skos:altLabel """DOX/MeCCNU/SZC"""@eng , """SAM"""@eng ; ; ; ; """2040"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279268"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/lomustine/streptozocin"""@eng ; skos:notation """CDR0000039406"""^^xsd:string ; skos:altLabel """CABS"""@eng , """BLEO/CCNU/DOX/SZC"""@eng ; ; ; ; ; """2041"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0074125"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 lip and oral cavity cancer"""@eng ; skos:notation """CDR0000039407"""^^xsd:string ; skos:altLabel """lip and oral cavity cancer, stage 0"""@eng , """oral cavity and lip cancer, stage 0"""@eng ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2042"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279270"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/PEG-interleukin-2"""@eng ; skos:notation """CDR0000041331"""^^xsd:string ; skos:altLabel """IL-2/PEG-IL-2"""@eng ; ; ; """4403"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/etoposide"""@eng ; skos:notation """CDR0000041330"""^^xsd:string ; skos:altLabel """ARA-C/ASP/VP-16"""@eng ; ; ; ; """4402"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280910"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idoxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000041333"""^^xsd:string ; skos:altLabel """CF/IUDR"""@eng ; ; ; """4405"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280913"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interleukin-2/tamoxifen"""@eng ; skos:notation """CDR0000041332"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IL-2/TMX"""@eng ; ; ; ; ; """4404"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280912"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000041335"""^^xsd:string ; skos:altLabel """CTX/DM/VCR"""@eng ; ; ; ; """4407"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280915"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """in vitro-treated peripheral blood stem cell transplantation"""@eng ; skos:notation """CDR0000041334"""^^xsd:string ; skos:altLabel """in vitro-treated PBSC"""@eng , """peripheral blood progenitor cell transplantation, in vitro-treated"""@eng , """in vitro-treated PBPC transplantation"""@eng , """in vitro-treated peripheral blood progenitor cell transplantation"""@eng , """peripheral blood stem cell transplantation, in vitro-treated"""@eng , """PBPC transplantation, in vitro-treated"""@eng , """PBSC transplantation, in vitro-treated"""@eng ; ; rdfs:subClassOf ; """4406"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280914"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/cyclophosphamide/filgrastim"""@eng ; skos:notation """CDR0000041337"""^^xsd:string ; skos:altLabel """BCNU/CDDP/CTX/G-CSF"""@eng ; ; ; ; ; """4409"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280917"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/filgrastim/vincristine"""@eng ; skos:notation """CDR0000041336"""^^xsd:string ; skos:altLabel """CTX/DM/G-CSF/VCR"""@eng ; ; ; ; ; """4408"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280916"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """albuterol sulfate"""@eng ; skos:notation """CDR0000041339"""^^xsd:string ; skos:altLabel """Ventolin"""@eng , """Proventil"""@eng , """salbutamol sulfate"""@eng ; skos:definition """The sulfate salt form of albuterol, a racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta2-adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of ATP to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta1-adrenergic receptors, thereby increasing the force and rate of myocardial contraction. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41339&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41339&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47957\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """51022-70-9"""^^xsd:string ; """C47957"""^^xsd:string ; """4411"""^^xsd:string ; """2007-01-23"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0033744"""^^xsd:string ; umls:cui """C0543495"""^^xsd:string ; umls:cui """C0699770"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """male breast cancer"""@eng ; skos:notation """CDR0000041338"""^^xsd:string ; skos:altLabel """Breast cancer, male"""@eng , """breast cancer, male"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4410"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238033"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """butyrophenone"""@eng ; skos:notation """CDR0000040321"""^^xsd:string ; rdfs:subClassOf ; """3162"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0006525"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenothiazine"""@eng ; skos:notation """CDR0000040320"""^^xsd:string ; rdfs:subClassOf ; """3161"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0031434"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dapsone"""@eng ; skos:notation """CDR0000040323"""^^xsd:string ; ; """3165"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0010980"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-inflammatory analgesic"""@eng ; skos:notation """CDR0000040322"""^^xsd:string ; rdfs:subClassOf ; """3163"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002773"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ribavirin"""@eng ; skos:notation """CDR0000040325"""^^xsd:string ; skos:altLabel """ICN-1229"""@eng , """RTCA"""@eng , """Rebetol"""@eng , """Viramide"""@eng , """RIBA"""@eng , """1-Beta-D-ribofuranosyl-1,2,4-triazolo-3-carboxamide"""@eng , """Virazole"""@eng , """1-Beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide"""@eng , """Virazid"""@eng ; skos:definition """A synthetic nucleoside analogue of ribofuranosyl with antiviral activity. Ribavirin incorporates into viral nucleic acid, inhibits viral ribonucleic acid (RNA) synthesis, induces viral genome mutations, and inhibits normal viral replication. Ribavirin shows activity against a variety of RNA viruses, especially hepatitis C virus. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40325&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40325&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C807\" NCI Thesaurus)"""@eng ; ; """3167"""^^xsd:string ; """163039"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """36791-04-5"""^^xsd:string ; """C807"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1170576"""^^xsd:string ; umls:cui """C1622085"""^^xsd:string ; umls:cui """C0731013"""^^xsd:string ; umls:cui """C0702029"""^^xsd:string ; umls:cui """C0702025"""^^xsd:string ; umls:cui """C0035525"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentamidine"""@eng ; skos:notation """CDR0000040324"""^^xsd:string ; skos:altLabel """Aerosolized Pentamadine"""@eng ; skos:definition """A synthetic derivative of amidine with antiprotozoal and antifungal activities. Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40324&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40324&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C731\" NCI Thesaurus)"""@eng ; ; ; """3166"""^^xsd:string ; """9921"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """100-33-4"""^^xsd:string ; """C731"""^^xsd:string ; umls:cui """C0030863"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040327"""^^xsd:string ; skos:altLabel """non-Hodgkin's lymphoma, relapsed, adult"""@eng , """recurrent adult NHL"""@eng , """relapsed adult non-Hodgkin's lymphoma"""@eng , """non-Hodgkin's lymphoma, recurrent, adult"""@eng , """NHL, recurrent, adult"""@eng , """NHL, relapsed, adult"""@eng , """adult non-Hodgkin's lymphoma, recurrent"""@eng , """adult non-Hodgkin's lymphoma, relapsed"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3169"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279999"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/vinblastine"""@eng ; skos:notation """CDR0000040326"""^^xsd:string ; skos:altLabel """FUVA"""@eng , """DOX/5-FU/VBL"""@eng ; ; ; ; """3168"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279998"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dexamethasone/etoposide"""@eng ; skos:notation """CDR0000040329"""^^xsd:string ; skos:altLabel """CED"""@eng , """CDDP/DM/VP-16"""@eng ; ; ; ; """3171"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280001"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/prednisolone/vincristine"""@eng ; skos:notation """CDR0000040328"""^^xsd:string ; skos:altLabel """COAP"""@eng , """ARA-C/CTX/PRDL/VCR"""@eng ; ; ; ; ; """3170"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280000"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thioguanine"""@eng ; skos:notation """CDR0000043669"""^^xsd:string ; skos:altLabel """2-Aminopurine-6-thiol"""@eng , """Tabloid"""@eng , """6 Mercaptoguanine"""@eng , """2-Amino-6-mercaptopurine"""@eng , """Wellcome U3B"""@eng , """6 Thioguanine"""@eng , """Tabloid brand thioguanine"""@eng , """2-Aminopurin-6-thiol"""@eng , """6-mercaptoguanine"""@eng , """2-Amino 6MP"""@eng , """BW 5071"""@eng , """2-Amino-6-purinethiol"""@eng , """Tioguanin"""@eng , """6-TG"""@eng , """2-Amino-1,7-dihydro-6H-purine-6-thione"""@eng , """X 27"""@eng , """6-thioguanine"""@eng , """WR-1141"""@eng , """Tioguanine"""@eng , """6-Mercapto-2-aminopurine"""@eng , """Lanvis"""@eng , """TG"""@eng , """6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)"""@eng , """2-Aminopurine-6(1H)-thione"""@eng ; skos:definition """A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43669&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43669&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C876\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """914"""^^xsd:string ; """936"""^^xsd:string ; """752"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """C876"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7258"""^^xsd:string ; """154-42-7"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C2350041"""^^xsd:string ; umls:cui """C1521983"""^^xsd:string ; umls:cui """C1521987"""^^xsd:string ; umls:cui """C1521986"""^^xsd:string ; umls:cui """C0039902"""^^xsd:string ; umls:cui """C1521984"""^^xsd:string ; umls:cui """C0591704"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult synovial sarcoma"""@eng ; skos:notation """CDR0000043668"""^^xsd:string ; skos:altLabel """sarcoma, synovial, adult"""@eng , """synovial sarcoma, adult"""@eng ; rdfs:subClassOf ; """912"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278660"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """12-O-tetradecanoylphorbol-13-acetate"""@eng ; skos:notation """CDR0000043661"""^^xsd:string ; skos:altLabel """Phorbol Myristate Acetate"""@eng , """TPA"""@eng , """PMA"""@eng , """Tetradecanoylphorbol Acetate"""@eng , """Lonomycin"""@eng ; skos:definition """A phorbol ester with potential antineoplastic effects. Tetradecanoylphorbol acetate (TPA) induces maturation and differentiation of hematopoietic cell lines, including leukemic cells. This agent may induce gene expression and protein kinase C (PKC) activity. In addition to potential antineoplastic effects, TPA may exhibit tumor promoting activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43661&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43661&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C866\" NCI Thesaurus)"""@eng ; """8960"""^^xsd:string ; """61321"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C866"""^^xsd:string ; """16561-29-8"""^^xsd:string ; umls:cui """C0039654"""^^xsd:string ; umls:cui """C0065176"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vinorelbine/zosuquidar trihydrochloride"""@eng ; skos:notation """CDR0000043660"""^^xsd:string ; skos:altLabel """LY335979/VNB"""@eng ; ; ; """2002-09-12"""^^xsd:string ; """8959"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879361"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccine-draining lymph node lymphocyte therapy"""@eng ; skos:notation """CDR0000043663"""^^xsd:string ; """8962"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0879364"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-2/Montanide ISA-51/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000043662"""^^xsd:string ; skos:altLabel """gp100/IL-2/ISA-51/TIL"""@eng ; ; ; ; """8961"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879363"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 esophageal cancer"""@eng ; skos:notation """CDR0000043665"""^^xsd:string ; skos:altLabel """esophagus cancer, stage 0"""@eng , """esophageal cancer, stage 0"""@eng ; rdfs:subClassOf ; """esophageal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """90"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0154059"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I colon cancer"""@eng ; skos:notation """CDR0000043664"""^^xsd:string ; skos:altLabel """Dukes A colon cancer"""@eng , """colon cancer, stage I"""@eng , """colon cancer, Dukes A"""@eng ; rdfs:subClassOf ; """colon cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """9"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278474"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I esophageal cancer"""@eng ; skos:notation """CDR0000043667"""^^xsd:string ; skos:altLabel """esophagus cancer, stage I"""@eng , """esophageal cancer, stage I"""@eng ; rdfs:subClassOf ; """esophageal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """91"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278559"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """body system/site cancer"""@eng ; skos:notation """CDR0000043666"""^^xsd:string ; skos:altLabel """cancer, body system/site"""@eng , """body site cancer"""@eng ; rdfs:subClassOf ; """903"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278659"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/sorafenib"""@eng ; skos:notation """CDR0000441005"""^^xsd:string ; skos:altLabel """OSI774/SFN"""@eng ; ; ; """2005-07-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-23"""^^xsd:string ; umls:cui """C1831679"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/tipifarnib"""@eng ; skos:notation """CDR0000441004"""^^xsd:string ; skos:altLabel """ARA-C/DNR/R115777/VP-16"""@eng ; ; ; ; ; """2005-07-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-07-14"""^^xsd:string ; umls:cui """C1831678"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/MAGE-10.A2/Melan-A/SB AS-2"""@eng ; skos:notation """CDR0000441009"""^^xsd:string ; skos:altLabel """flu/MAGE10.A2/MEL-A/SBAS-2"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-07-14"""^^xsd:string ; """2005-07-15"""^^xsd:string ; umls:cui """C1831681"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flu matrix/MAGE-10.A2/Melan-A/Montanide ISA-51"""@eng ; skos:notation """CDR0000441008"""^^xsd:string ; skos:altLabel """flu/ISA-51/MAGE10.A2/MEL-A"""@eng ; ; ; """2005-07-15"""^^xsd:string ; """2005-07-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831680"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/goserelin/nilutamide"""@eng ; skos:notation """CDR0000358333"""^^xsd:string ; skos:altLabel """ANAN/EM/TXT/ZDX"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541576"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I and II childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000037890"""^^xsd:string ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10298"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0879453"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-TRICOM vaccine/recombinant fowlpox GM-CSF vaccine"""@eng ; skos:notation """CDR0000339969"""^^xsd:string ; skos:altLabel """rF-GM-CSF/rF-TRICOM"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2004-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328078"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colorectal cancer, genetics of"""@eng ; skos:notation """CDR0000037893"""^^xsd:string ; skos:altLabel """colorectal cancer genetics"""@eng ; """2002-10-15"""^^xsd:string ; """10301"""^^xsd:string ; umls:cui """C0879455"""^^xsd:string ; umls:tui """T049"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexverapamil/paclitaxel"""@eng ; skos:notation """CDR0000041740"""^^xsd:string ; skos:altLabel """R-VPAM/TAX"""@eng ; ; ; """4911"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult pilocytic astrocytoma"""@eng ; skos:notation """CDR0000041741"""^^xsd:string ; skos:altLabel """pilocytic astrocytoma, adult"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult astrocytic tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4912"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280781"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult subependymoma"""@eng ; skos:notation """CDR0000041742"""^^xsd:string ; skos:altLabel """subependymoma, adult"""@eng , """adult subependymal astrocytoma"""@eng ; rdfs:subClassOf ; """2005-04-22"""^^xsd:string ; """adult ependymal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4913"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281328"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cervical cancer"""@eng ; skos:notation """CDR0000037892"""^^xsd:string ; skos:altLabel """cervix cancer"""@eng , """uterine cervix cancer"""@eng , """Cervical cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """103"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0302592"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult ependymoblastoma"""@eng ; skos:notation """CDR0000041744"""^^xsd:string ; skos:altLabel """ependymoblastoma, adult"""@eng ; rdfs:subClassOf ; """adult brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4915"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281330"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult pineocytoma"""@eng ; skos:notation """CDR0000041745"""^^xsd:string ; skos:altLabel """pineocytoma, adult"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """4916"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult pineal parenchymal tumor"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281331"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult pineoblastoma"""@eng ; skos:notation """CDR0000041746"""^^xsd:string ; skos:altLabel """pineoblastoma, adult"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """4917"""^^xsd:string ; """2005-04-22"""^^xsd:string ; """adult pineal parenchymal tumor"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281332"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult anaplastic meningioma"""@eng ; skos:notation """CDR0000041747"""^^xsd:string ; rdfs:subClassOf ; """4918"""^^xsd:string ; """2005-05-03"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C3468050"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult papillary meningioma"""@eng ; skos:notation """CDR0000041748"""^^xsd:string ; rdfs:subClassOf ; """4919"""^^xsd:string ; """2005-05-03"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281334"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/paclitaxel"""@eng ; skos:notation """CDR0000041749"""^^xsd:string ; skos:altLabel """IFF/TAX"""@eng ; ; ; """4922"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281335"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042968"""^^xsd:string ; skos:altLabel """recurrent adult HD"""@eng , """recurrent Hodgkin's disease, adult"""@eng , """relapsed Hodgkin's disease, adult"""@eng , """recurrent HD, adult"""@eng , """Hodgkin's disease, relapsed, adult"""@eng , """adult Hodgkin's disease, recurrent"""@eng , """recurrent adult Hodgkin's disease"""@eng , """lymphoma, relapsed adult Hodgkin's"""@eng , """adult Hodgkin's disease, relapsed"""@eng , """relapsed adult HD"""@eng , """adult HD, recurrent"""@eng , """HD, adult, recurrent"""@eng , """HD, recurrent, adult"""@eng , """Hodgkin's lymphoma, relapsed, adult"""@eng , """adult HD, relapsed"""@eng , """HD, relapsed, adult"""@eng , """relapsed adult Hodgkin's disease"""@eng , """HD, adult, relapsed"""@eng ; rdfs:subClassOf ; """adult Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """72"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278530"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human 6Ckine"""@eng ; skos:notation """CDR0000459900"""^^xsd:string ; skos:altLabel """recombinant human secondary lymphoid chemokine"""@eng , """rhSLC"""@eng , """recombinant human Exodus-2"""@eng ; skos:definition """A therapeutic recombinant analogue of a member of the endogenous CC chemokines with potential antineoplastic activity. Expressed by various lymphoid tissues, endogenous 6Ckine is chemotactic for B and T lymphocytes and dendritic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459900&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459900&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1792\" NCI Thesaurus)"""@eng ; """C1792"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C1523979"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian Pap test"""@eng ; skos:notation """CDR0000037897"""^^xsd:string ; skos:altLabel """Pap test, ovarian"""@eng ; rdfs:subClassOf ; """10307"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-02-06"""^^xsd:string ; umls:cui """C0879459"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Aurora kinase inhibitor MLN8054"""@eng ; skos:notation """CDR0000473901"""^^xsd:string ; skos:altLabel """MLN8054"""@eng ; skos:definition """An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Auora kinase inhibitor MLN8054 binds to and inhibits Aurora kinase A, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregration, and inhibition of cell proliferation. Aurora A localizes in mitosis to the spindle poles and to spindle microtubules and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473901&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473901&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61075\" NCI Thesaurus)"""@eng ; """2006-08-04"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61075"""^^xsd:string ; umls:cui """C1831779"""^^xsd:string ; umls:cui """C1831780"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """apolizumab/rituximab"""@eng ; skos:notation """CDR0000038453"""^^xsd:string ; skos:altLabel """MOAB 1D10/MOAB IDEC-C2B8"""@eng ; ; ; """11070"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134497"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic dendritic cell-myeloma idiotype vaccine"""@eng ; skos:notation """CDR0000471236"""^^xsd:string ; skos:definition """A cell-based vaccine composed of allogeneic dendritic cells pulsed ex -vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61434\" NCI Thesaurus)"""@eng ; """2006-03-07"""^^xsd:string ; """C61434"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; umls:cui """C1831762"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """perflutren protein-type A microspheres"""@eng ; skos:notation """CDR0000471234"""^^xsd:string ; skos:altLabel """Optison"""@eng ; skos:definition """A sterile non-pyrogenic suspension of microspheres of human serum albumin with the stable, high-molecular-weight fluorocarbon gas perflutren, used as a contrast enhancement agent for ultrasound procedures. Because the acoustic impedance of perflutren protein-type A microspheres is much lower than that of blood, impinging ultrasound waves are scattered and reflected at the microsphere-blood interface andmay be visualized with ultrasound imaging. At the frequencies used in adult echocardiography (2-5 MHZ), the microspheres resonate which further increases the extent of ultrasound scattering and reflection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471234&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471234&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61105\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-18"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """C61105"""^^xsd:string ; umls:cui """C1509955"""^^xsd:string ; umls:cui """C0754326"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/vinorelbine"""@eng ; skos:notation """CDR0000042961"""^^xsd:string ; skos:altLabel """DHAD/VNB"""@eng ; ; ; """7193"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677974"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/PSC 833"""@eng ; skos:notation """CDR0000042960"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PSC-833/VP-16"""@eng ; ; ; ; ; """2003-10-28"""^^xsd:string ; """7192"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677973"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bcr-abl (b2a2)-derived peptide vaccine"""@eng ; skos:notation """CDR0000484895"""^^xsd:string ; skos:altLabel """Bcr-Abl (b2a2) Derived Peptide Vaccine"""@eng , """CML-VAX B2"""@eng ; skos:definition """A peptide vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a 'b3a2' or a 'b2a2' fusion. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484895&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484895&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61309\" NCI Thesaurus)"""@eng ; """2006-07-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61309"""^^xsd:string ; """2006-05-11"""^^xsd:string ; umls:cui """C1831817"""^^xsd:string ; umls:cui """C1831816"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bcr-abl (b3a2)-derived peptide vaccine"""@eng ; skos:notation """CDR0000484893"""^^xsd:string ; skos:altLabel """CML-VAX B3"""@eng , """Bcr-Abl (b3a2) Derived Peptide Vaccine"""@eng ; skos:definition """A peptide vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a 'b3a2' or a 'b2a2' fusion. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484893&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=484893&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61310\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C61310"""^^xsd:string ; """2006-07-07"""^^xsd:string ; """2006-05-11"""^^xsd:string ; umls:cui """C1831815"""^^xsd:string ; umls:cui """C1831814"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine"""@eng ; skos:notation """CDR0000387966"""^^xsd:string ; skos:altLabel """HLA-A2A3-FGF5-ISA51"""@eng ; skos:definition """A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=387966&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=387966&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48394\" NCI Thesaurus)"""@eng ; ; """Drug/agent"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """C48394"""^^xsd:string ; """2006-08-25"""^^xsd:string ; umls:cui """C1541599"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen peptide vaccine"""@eng ; skos:notation """CDR0000387963"""^^xsd:string ; skos:altLabel """CEA peptide vaccine"""@eng , """CEA-PEP-VAC"""@eng ; """2004-08-24"""^^xsd:string ; """2004-08-16"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541597"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vatalanib/warfarin"""@eng ; skos:notation """CDR0000387962"""^^xsd:string ; skos:altLabel """PTK-787/WARF"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541596"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/irinotecan"""@eng ; skos:notation """CDR0000042213"""^^xsd:string ; skos:altLabel """CDDP/CPT-11"""@eng ; ; ; """5453"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281724"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/interleukin-2"""@eng ; skos:notation """CDR0000042212"""^^xsd:string ; skos:altLabel """gp100/IL-2"""@eng ; ; ; """5452"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281723"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen"""@eng ; skos:notation """CDR0000042211"""^^xsd:string ; skos:altLabel """gp 100"""@eng , """gp100"""@eng ; skos:definition """A melanoma-associated antigen. When administered in a vaccine formulation, gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumors that express this antigen, which may result in a reduction in tumor size. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42211&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42211&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2386\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5451"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """C2386"""^^xsd:string ; umls:cui """C0281722"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/MART-1 antigen"""@eng ; skos:notation """CDR0000042210"""^^xsd:string ; skos:altLabel """IL-2/MART-1"""@eng ; ; ; """5450"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281721"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sedoxantrone trihydrochloride"""@eng ; skos:notation """CDR0000042217"""^^xsd:string ; skos:altLabel """CI-958"""@eng , """CI 958"""@eng ; """5462"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C1576"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281727"""^^xsd:string ; umls:cui """C1519223"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone/PSC 833"""@eng ; skos:notation """CDR0000042216"""^^xsd:string ; skos:altLabel """DHAD/PSC-833/VP-16"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """5461"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281726"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/tamoxifen"""@eng ; skos:notation """CDR0000042214"""^^xsd:string ; skos:altLabel """CDDP/DOX/TMX"""@eng ; ; ; ; """5456"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281725"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/vinorelbine"""@eng ; skos:notation """CDR0000042219"""^^xsd:string ; skos:altLabel """EM/VNB"""@eng ; ; ; """5464"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281729"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody HuG1-M195"""@eng ; skos:notation """CDR0000042218"""^^xsd:string ; skos:altLabel """IL-2/MOAB HuM195"""@eng ; ; ; """5463"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281728"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """5,10-methylenetetrahydrofolate/fluorouracil"""@eng ; skos:notation """CDR0000405876"""^^xsd:string ; skos:altLabel """5,10-MTHF/5-FU"""@eng ; ; ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541398"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/mitotane"""@eng ; skos:notation """CDR0000405877"""^^xsd:string ; skos:altLabel """CDDP/DDD/DOX/VP-16"""@eng ; ; ; ; ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541399"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NS-9"""@eng ; skos:notation """CDR0000405874"""^^xsd:string ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541397"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """5,10-methylenetetrahydrofolate"""@eng ; skos:notation """CDR0000405875"""^^xsd:string ; skos:altLabel """MTHF"""@eng , """CoFactor"""@eng , """5,10 methylenetetrahydrofolate"""@eng , """5,10-MTHF"""@eng , """ANX-510"""@eng ; skos:definition """A folate-based biomodulator with potential antineoplastic activity. 5,10-methylenetetrahydrofolate (MTHF) stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, MTHF, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=405875&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=405875&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61304\" NCI Thesaurus)"""@eng ; ; """2004-11-05"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C61304"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831592"""^^xsd:string ; umls:cui """C1541159"""^^xsd:string ; umls:cui """C0048858"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes/autologous lymphocytes"""@eng ; skos:notation """CDR0000415555"""^^xsd:string ; skos:altLabel """AL/ALLOLYMPH"""@eng ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541485"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic tumor cell vaccine/autologous dendritic cells"""@eng ; skos:notation """CDR0000415550"""^^xsd:string ; skos:altLabel """ADC/ALLOTCV"""@eng ; ; ; """2005-01-24"""^^xsd:string ; """2005-01-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541484"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitotane/streptozocin"""@eng ; skos:notation """CDR0000405878"""^^xsd:string ; skos:altLabel """DDD/SZC"""@eng ; ; ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541400"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nitric oxide-releasing acetylsalicylic acid derivative"""@eng ; skos:notation """CDR0000486415"""^^xsd:string ; skos:altLabel """NCX 4016"""@eng , """nitric oxide-releasing aspirin derivative"""@eng , """nitroaspirin"""@eng ; """Drug/agent"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """C61499"""^^xsd:string ; """2007-01-12"""^^xsd:string ; umls:cui """C0531264"""^^xsd:string ; umls:cui """C0950966"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """OVA BiP peptide"""@eng ; skos:notation """CDR0000037946"""^^xsd:string ; skos:altLabel """OVABiP"""@eng ; ; """10366"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879487"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """seocalcitol"""@eng ; skos:notation """CDR0000298863"""^^xsd:string ; skos:altLabel """EB 1089"""@eng ; """2003-03-24"""^^xsd:string ; """2003-03-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0287937"""^^xsd:string ; umls:cui """C0905598"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fulvestrant/gefitinib"""@eng ; skos:notation """CDR0000298864"""^^xsd:string ; skos:altLabel """ICI 182780/ZD 1839"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327927"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """FEZ1/LZTS1"""@eng ; skos:notation """CDR0000360451"""^^xsd:string ; rdfs:subClassOf ; """2004-03-24"""^^xsd:string ; """2004-02-25"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1541580"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BMS-188797"""@eng ; skos:notation """CDR0000037942"""^^xsd:string ; ; """10361"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879485"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levofloxacin"""@eng ; skos:notation """CDR0000037941"""^^xsd:string ; skos:altLabel """Levaquin"""@eng , """Quixin"""@eng ; skos:definition """A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37941&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37941&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1586\" NCI Thesaurus)"""@eng ; """10360"""^^xsd:string ; """100986-85-4"""^^xsd:string ; """C1586"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0721336"""^^xsd:string ; umls:cui """C0282386"""^^xsd:string ; umls:cui """C0939461"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV vulvar cancer"""@eng ; skos:notation """CDR0000037940"""^^xsd:string ; skos:altLabel """vulva cancer, stage IV"""@eng , """carcinoma of the vulva, stage IV"""@eng , """metastatic carcinoma of the vulva"""@eng , """vulvar cancer, metastatic"""@eng , """vulva cancer, metastatic"""@eng , """stage IV carcinoma of the vulva"""@eng , """cancer of the vulva, metastatic"""@eng , """vulvar cancer, stage IV"""@eng , """metastatic vulvar cancer"""@eng , """cancer of the vulva, stage IV"""@eng , """stage IV vulva cancer"""@eng , """stage IV cancer of the vulva"""@eng , """carcinoma of the vulva, metastatic"""@eng , """metastatic vulva cancer"""@eng , """metastatic cancer of the vulva"""@eng ; rdfs:subClassOf ; """vulvar cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1036"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0852667"""^^xsd:string ; umls:cui """C0278733"""^^xsd:string ; umls:cui """C0878546"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II prostate cancer"""@eng ; skos:notation """CDR0000038784"""^^xsd:string ; skos:altLabel """stage II cancer of the prostate"""@eng , """cancer of the prostate, stage II"""@eng , """stage B prostate cancer"""@eng , """prostate cancer, stage II"""@eng , """prostate cancer, stage B"""@eng , """stage II carcinoma of the prostate"""@eng , """cancer of the prostate, stage B"""@eng , """stage B carcinoma of the prostate"""@eng , """carcinoma of the prostate, stage II"""@eng , """stage B cancer of the prostate"""@eng , """carcinoma of the prostate, stage B"""@eng ; rdfs:subClassOf ; """prostate cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1231"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278835"""^^xsd:string ; umls:cui """C1370963"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/melphalan"""@eng ; skos:notation """CDR0000039189"""^^xsd:string ; skos:altLabel """L-PAM/VP-16"""@eng ; ; ; """1808"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279141"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colchicine"""@eng ; skos:notation """CDR0000039188"""^^xsd:string ; skos:altLabel """(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide"""@eng ; skos:definition """An alkaloid isolated from Colchicum autumnale with anti-gout and anti-inflammatory activity. The exact mechanism of action by which colchicines exerts its effect has not been completely established. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis. This leads to an inhibition of migration of leukocytes and other inflammatory cells, thereby reducing the inflammatory response to deposited urate crystals. Colchicine may also interrupt the cycle of monosodium urate crystal deposition in joint tissues, thereby also preventing the resultant inflammatory response. Overall, colchicine decreases leukocyte chemotaxis/migration and phagocytosis to inflamed areas, and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39188&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39188&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C385\" NCI Thesaurus)"""@eng ; """1807"""^^xsd:string ; """64-86-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C385"""^^xsd:string ; """757"""^^xsd:string ; umls:cui """C0009262"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cimetidine"""@eng ; skos:notation """CDR0000039185"""^^xsd:string ; skos:altLabel """N-Cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine"""@eng , """Tagamet"""@eng ; skos:definition """A histamine H(2)-receptor antagonist. Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production. Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39185&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39185&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C374\" NCI Thesaurus)"""@eng ; ; ; """1804"""^^xsd:string ; """335308"""^^xsd:string ; """51481-61-9"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C374"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0592157"""^^xsd:string ; umls:cui """C0008783"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromomycin A3"""@eng ; skos:notation """CDR0000039184"""^^xsd:string ; skos:altLabel """toyomycin"""@eng , """Olivomycin D, 3B-O-(4-O-Acetyl-2, 6-dideoxy-3-C-methyl-.alpha.-L-arabino-hexopyranosyl)-7-methyl- (9CI)"""@eng , """chromomycin A-3"""@eng , """3B-O-(4-O-Acetyl-2,6-dideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-7-methylolivomycin D"""@eng , """Antibiotic from Streptomyces griseus"""@eng , """Aburamycin B"""@eng , """Antibiotic B 599"""@eng ; skos:definition """A glycosidic antineoplastic antibiotic isolated from the bacterium Streptomyces griseus. Chromomycin A3 reversibly binds to guanine-cytosine (G-C) base pairs in the minor groove of DNA, thereby inhibiting RNA synthesis. This agent is used as a fluorescent chromosome dye. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39184&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39184&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C895\" NCI Thesaurus)"""@eng ; """1803"""^^xsd:string ; """9019"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58514"""^^xsd:string ; """C895"""^^xsd:string ; """7059-24-7"""^^xsd:string ; umls:cui """C0040563"""^^xsd:string ; umls:cui """C3536902"""^^xsd:string ; umls:cui """C0917882"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """coenzyme Q10"""@eng ; skos:notation """CDR0000039187"""^^xsd:string ; skos:altLabel """Ubiquinone"""@eng , """Co-Q10"""@eng , """Ubiquinone 10"""@eng , """2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecanyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione"""@eng , """coenzyme-Q"""@eng , """coenzyme-Q10"""@eng , """CoQ10"""@eng , """Ubidecarenone"""@eng ; skos:definition """A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme-Q functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme-Q may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39187&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39187&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C916\" NCI Thesaurus)"""@eng ; ; """1806"""^^xsd:string ; """140865"""^^xsd:string ; """C916"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """303-98-0"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C0056077"""^^xsd:string ; umls:cui """C0077666"""^^xsd:string ; umls:cui """C0041536"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine"""@eng ; skos:notation """CDR0000039186"""^^xsd:string ; skos:altLabel """ARA-C/ASP/DM/DOX/TG/VCR"""@eng ; ; ; ; ; ; ; """1805"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279140"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cephalothin sodium"""@eng ; skos:notation """CDR0000039181"""^^xsd:string ; skos:altLabel """Keflin"""@eng ; """1800"""^^xsd:string ; """C358"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0037490"""^^xsd:string ; umls:cui """C0733789"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIA breast cancer"""@eng ; skos:notation """CDR0000039180"""^^xsd:string ; skos:altLabel """breast cancer, stage IIIA"""@eng ; rdfs:subClassOf ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """18"""^^xsd:string ; """gross residual disease after surgery"""^^xsd:string ; """progesterone receptor status unknown"""^^xsd:string ; """premenopausal"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """estrogen receptor status unknown"""^^xsd:string ; """estrogen receptor positive"""^^xsd:string ; """bilateral breast cancer"""^^xsd:string ; """estrogen receptor negative"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """microscopic residual disease after surgery"""^^xsd:string ; """performance status 2"""^^xsd:string ; """no evidence of disease after surgery"""^^xsd:string ; """progesterone receptor negative"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """postmenopausal"""^^xsd:string ; """progesterone receptor positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278489"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iproplatin"""@eng ; skos:notation """CDR0000039183"""^^xsd:string ; skos:altLabel """JM-9"""@eng , """CHIP"""@eng , """(OC-6-33)-dichlorodihydroxybis(2-propanamine)platinum"""@eng ; skos:definition """A synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death. Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39183&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39183&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1070\" NCI Thesaurus)"""@eng ; """1802"""^^xsd:string ; """22794"""^^xsd:string ; """256927"""^^xsd:string ; """83291-20-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1070"""^^xsd:string ; umls:cui """C0057856"""^^xsd:string ; umls:cui """C0950437"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorozotocin"""@eng ; skos:notation """CDR0000039182"""^^xsd:string ; skos:altLabel """2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose"""@eng , """D-glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI)"""@eng , """D-glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy"""@eng , """2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2-deoxy-D-glucose"""@eng , """Chlorozotocyna"""@eng , """CZT"""@eng , """CLZ"""@eng , """DCNU"""@eng , """1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea"""@eng , """D-Glucopyranose"""@eng ; skos:definition """A glucose-linked chloroethylnitrosourea with potential antineoplastic activity. Chlorozotocin alkylates DNA and proteins, induces the formation of interstrand DNA and DNA-protein crosslinks, and causes DNA strand breakage, thereby damaging DNA and resulting in cell death. This agent has been shown to exhibit antitumor and immunomodulatory effects in cell lines and animal models. Chlorozotocin is a mutagen and is less myelotoxic than other nitrosoureas. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39182&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39182&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1049\" NCI Thesaurus)"""@eng ; """1801"""^^xsd:string ; """C1049"""^^xsd:string ; """54749-90-5"""^^xsd:string ; """12491"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """178248"""^^xsd:string ; umls:cui """C0055465"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/oblimersen"""@eng ; skos:notation """CDR0000038588"""^^xsd:string ; skos:altLabel """DM/G3139"""@eng ; ; ; """11218"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134606"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody Mik-beta-1"""@eng ; skos:notation """CDR0000038589"""^^xsd:string ; skos:altLabel """MOAB Mik-beta-1"""@eng ; skos:definition """A murine monoclonal antibody directed against the beta subunit of the interleukin-2 receptor (IL-2R), expressed on resting T-lymphocytes, natural killer (NK) cells, and some leukemic cell types. Monoclonal antibody Mik-beta-1 prevents the binding of IL-2 to IL-2R beta, thereby inhibiting the IL-2-mediated proliferation and activation of T-cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38589&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38589&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2669\" NCI Thesaurus)"""@eng ; """11219"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2669"""^^xsd:string ; """2006-08-30"""^^xsd:string ; umls:cui """C1134607"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/carboplatin/epirubicin"""@eng ; skos:notation """CDR0000038586"""^^xsd:string ; skos:altLabel """CAPE/CBDCA/EPI"""@eng ; ; ; ; """11216"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134604"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemtuzumab ozogamicin/oblimersen"""@eng ; skos:notation """CDR0000038587"""^^xsd:string ; skos:altLabel """CMA-676/G3139"""@eng ; ; ; """11217"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134605"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox virus vaccine vector/gp100 antigen/interleukin-2"""@eng ; skos:notation """CDR0000038584"""^^xsd:string ; skos:altLabel """FOWLVAC/gp100/IL-2"""@eng ; ; ; ; """11214"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134602"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/cyclophosphamide/fludarabine"""@eng ; skos:notation """CDR0000038585"""^^xsd:string ; skos:altLabel """CTX/FAMP/MOAB CD52"""@eng ; ; ; ; """11215"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134603"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/idarubicin/leucovorin calcium/methotrexate/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000038582"""^^xsd:string ; skos:altLabel """BLEO/CF/CTX/IDA/MePRDL/MTX/VCR"""@eng ; ; ; ; ; ; ; ; """11212"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134600"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic lymphocytes/interleukin-2"""@eng ; skos:notation """CDR0000038583"""^^xsd:string ; skos:altLabel """ALLOLYMPH/IL-2"""@eng ; ; ; """11213"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134601"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa/filgrastim/flt3 ligand/interleukin-3/sargramostim"""@eng ; skos:notation """CDR0000038580"""^^xsd:string ; skos:altLabel """EPO/Flt3L/G-CSF/GM-CSF/IL-3"""@eng ; ; ; ; ; ; """11210"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134599"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """combination therapy"""@eng ; skos:notation """CDR0000038581"""^^xsd:string ; """11211"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0556895"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III vaginal cancer"""@eng ; skos:notation """CDR0000038056"""^^xsd:string ; skos:altLabel """cancer of the vagina, stage III"""@eng , """carcinoma of the vagina, stage III"""@eng , """stage III cancer of the vagina"""@eng , """vaginal cancer, stage III"""@eng , """stage III vagina cancer"""@eng , """vagina cancer, stage III"""@eng , """stage III carcinoma of the vagina"""@eng ; rdfs:subClassOf ; """vaginal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1059"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278743"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP-609,754"""@eng ; skos:notation """CDR0000038057"""^^xsd:string ; """10593"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879599"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin-DNA complex"""@eng ; skos:notation """CDR0000039137"""^^xsd:string ; skos:altLabel """ADR-DNA"""@eng , """Adriamycin-DNA Complex"""@eng , """DOX-DNA"""@eng ; """1758"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0058725"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed cell type intraocular melanoma"""@eng ; skos:notation """CDR0000039985"""^^xsd:string ; skos:altLabel """intraocular melanoma, mixed cell type"""@eng , """melanoma, intraocular, mixed cell type"""@eng , """melanoma, mixed cell type intraocular"""@eng ; rdfs:subClassOf ; """2692"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279693"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epithelioid cell intraocular melanoma"""@eng ; skos:notation """CDR0000039984"""^^xsd:string ; skos:altLabel """melanoma, intraocular, epithelioid cell"""@eng , """intraocular melanoma, epithelioid cell"""@eng , """melanoma, epithelioid cell intraocular"""@eng ; rdfs:subClassOf ; """2691"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279692"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """necrotic intraocular melanoma"""@eng ; skos:notation """CDR0000039987"""^^xsd:string ; skos:altLabel """melanoma, intraocular, necrotic"""@eng , """intraocular melanoma, necrotic"""@eng , """melanoma, necrotic intraocular"""@eng ; rdfs:subClassOf ; """2694"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279695"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody therapy"""@eng ; skos:notation """CDR0000039986"""^^xsd:string ; skos:altLabel """monoclonal antibodies"""@eng , """antibody therapy, monoclonal"""@eng , """MoAb"""@eng , """therapy, monoclonal antibody"""@eng ; ; rdfs:subClassOf ; """2693"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0003250"""^^xsd:string ; umls:cui """C0279694"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spindle cell B type intraocular melanoma"""@eng ; skos:notation """CDR0000039981"""^^xsd:string ; skos:altLabel """intraocular melanoma, spindle cell B type"""@eng , """B type spindle cell intraocular melanoma"""@eng , """melanoma, intraocular, spindle cell B type"""@eng , """melanoma, spindle cell B type intraocular"""@eng , """type B spindle cell intraocular melanoma"""@eng ; rdfs:subClassOf ; """2688"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279689"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spindle cell A type intraocular melanoma"""@eng ; skos:notation """CDR0000039980"""^^xsd:string ; skos:altLabel """melanoma, intraocular, spindle cell A type"""@eng , """A type intraocular melanoma, spindle cell"""@eng , """type A spindle cell intraocular melanoma"""@eng , """melanoma, spindle cell A type intraocular"""@eng , """intraocular melanoma, spindle cell A type"""@eng ; rdfs:subClassOf ; """2687"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279688"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nonspindle cell intraocular melanoma"""@eng ; skos:notation """CDR0000039983"""^^xsd:string ; skos:altLabel """melanoma, intraocular, nonspindle cell"""@eng , """non-spindle cell intraocular melanoma"""@eng , """melanoma, nonspindle cell intraocular"""@eng , """intraocular melanoma, nonspindle cell"""@eng ; rdfs:subClassOf ; """2690"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279691"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """releasing hormone agonist therapy"""@eng ; skos:notation """CDR0000039982"""^^xsd:string ; skos:altLabel """therapy, releasing hormone agonist"""@eng , """agonist, releasing hormone therapy"""@eng ; ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-04-17"""^^xsd:string ; """2689"""^^xsd:string ; umls:cui """C0279690"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """salivary gland squamous cell carcinoma"""@eng ; skos:notation """CDR0000039989"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the salivary gland"""@eng , """salivary gland cancer, squamous cell carcinoma"""@eng , """epidermoid carcinoma, salivary gland"""@eng ; rdfs:subClassOf ; """2708"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279697"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic squamous neck cancer with occult primary squamous cell carcinoma"""@eng ; skos:notation """CDR0000039988"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the neck, metastatic squamous with occult primary"""@eng , """epidermoid carcinoma, metastatic squamous neck cancer with occult primary"""@eng ; rdfs:subClassOf ; """2701"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279696"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """G207"""@eng ; skos:notation """CDR0000038634"""^^xsd:string ; skos:definition """A genetic engineered herpes simplex virus (HSV-1) mutant strain, with antineoplastic property. G207 is an attenuated, replication-competent, engineered to selectively replicate within cancer cells. This oncolytic HSV mutant virus has defects in genes encoding for both ribonucleotide reductase and the neurovirulence factor, ICP34.5 (gamma34.5), and is thus neuroattenuated. G207 has potent anticancer vaccination effects due to its cytotoxicity to cancer cells. Furthermore, it can be used as a gene transfer vector without compromising safety. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38634&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38634&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2676\" NCI Thesaurus)"""@eng ; """11262"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """C2676"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134718"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BAY 59-8862"""@eng ; skos:notation """CDR0000038635"""^^xsd:string ; """11268"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135138"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/tiazofurin"""@eng ; skos:notation """CDR0000041108"""^^xsd:string ; skos:altLabel """BCNU/TCAR"""@eng ; ; ; """4149"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280708"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult primary liver cancer"""@eng ; skos:notation """CDR0000038637"""^^xsd:string ; skos:altLabel """adult primary liver cancer, recurrent"""@eng , """hepatoma, recurrent adult primary"""@eng , """liver cancer, recurrent adult primary"""@eng , """adult primary hepatoma, recurrent"""@eng ; rdfs:subClassOf ; """adult primary liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1127"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1370860"""^^xsd:string ; umls:cui """C0278775"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/ifosfamide/leucovorin calcium/methotrexate/teniposide/vincristine"""@eng ; skos:notation """CDR0000038630"""^^xsd:string ; skos:altLabel """ARA-C/CF/DM/IFF/MTX/VCR/VM-26"""@eng ; ; ; ; ; ; ; ; """11259"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134641"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """advanced adult primary liver cancer"""@eng ; skos:notation """CDR0000038631"""^^xsd:string ; skos:altLabel """adult primary liver cancer, advanced"""@eng , """liver cancer, advanced adult primary"""@eng , """hepatoma, advanced adult primary"""@eng , """adult primary hepatoma, advanced"""@eng ; rdfs:subClassOf ; """adult primary liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1126"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278774"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/leucovorin calcium/methotrexate/vincristine"""@eng ; skos:notation """CDR0000038632"""^^xsd:string ; skos:altLabel """CF/CTX/DM/DOX/MTX/VCR"""@eng ; ; ; ; ; ; ; """11260"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134642"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bexarotene/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000038633"""^^xsd:string ; skos:altLabel """CBDCA/LGD1069/TAX"""@eng ; ; ; ; """11261"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134643"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa"""@eng ; skos:notation """CDR0000041102"""^^xsd:string ; skos:altLabel """EPO"""@eng , """Epogen"""@eng , """erythropoietin"""@eng , """Procrit"""@eng , """r-HuEPO"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41102&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41102&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2695\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """4143"""^^xsd:string ; """C2695"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """113427-24-0"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0014822"""^^xsd:string ; umls:cui """C0376541"""^^xsd:string ; umls:cui """C0733467"""^^xsd:string ; umls:cui """C0357126"""^^xsd:string ; umls:cui """C0700704"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """toremifene"""@eng ; skos:notation """CDR0000041103"""^^xsd:string ; skos:altLabel """TOR"""@eng , """Fareston"""@eng , """(Z)-4-Chloro-1,2-diphenyl-1[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene"""@eng , """(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine"""@eng ; skos:definition """A nonsteroidal triphenylethylene antiestrogen. Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM). This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity. Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41103&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41103&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1256\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """4144"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """89778-26-7"""^^xsd:string ; """C1256"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0076836"""^^xsd:string ; umls:cui """C0600382"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000041100"""^^xsd:string ; skos:altLabel """CDDP/DOX/IFF/VP-16"""@eng ; ; ; ; ; """4140"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280702"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """5a-reductase inhibition"""@eng ; skos:notation """CDR0000041101"""^^xsd:string ; skos:altLabel """inhibition, 5a-reductase"""@eng ; ; rdfs:subClassOf ; """4141"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280703"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/goserelin/tamoxifen"""@eng ; skos:notation """CDR0000041106"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/TMX/ZDX"""@eng ; ; ; ; ; ; """4147"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280706"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/goserelin"""@eng ; skos:notation """CDR0000041107"""^^xsd:string ; skos:altLabel """CTX/DOX/5-FU/ZDX"""@eng ; ; ; ; ; """4148"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280707"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-2/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000041104"""^^xsd:string ; skos:altLabel """CTX/IL-2/LAK"""@eng ; ; ; ; """4145"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280704"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edatrexate/mitomycin/vinblastine"""@eng ; skos:notation """CDR0000041105"""^^xsd:string ; skos:altLabel """EDAM/MITO/VBL"""@eng ; ; ; ; """4146"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280705"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000040518"""^^xsd:string ; skos:altLabel """adult diffuse large cell lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3414"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280149"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, high grade, stage II adult"""@eng ; skos:notation """CDR0000040519"""^^xsd:string ; skos:altLabel """adult NHL, stage II, high grade"""@eng , """lymphoma, high grade, stage II adult non-Hodgkin's"""@eng , """high-grade, stage II adult NHL"""@eng , """NHL, high grade, stage II adult"""@eng , """adult non-Hodgkin's lymphoma, high grade, stage II"""@eng ; """2005-01-21"""^^xsd:string ; """3415"""^^xsd:string ; umls:cui """C0280150"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000040512"""^^xsd:string ; skos:altLabel """stage II follicular small cleaved cell lymphoma"""@eng , """follicular small cleaved cell lymphoma, stage II"""@eng , """stage II grade I follicular small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3408"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280143"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000040513"""^^xsd:string ; skos:altLabel """stage II follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma, stage II"""@eng , """stage II grade II follicular mixed cell lymphoma"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3409"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280144"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acute undifferentiated leukemia"""@eng ; skos:notation """CDR0000040510"""^^xsd:string ; skos:altLabel """leukemia, acute undifferentiated"""@eng , """AUL"""@eng , """undifferentiated leukemia, acute"""@eng ; rdfs:subClassOf ; """3406"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280141"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000040511"""^^xsd:string ; skos:altLabel """small lymphocytic lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3407"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """small lymphocytic lymphoma"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0855099"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000040516"""^^xsd:string ; skos:altLabel """adult diffuse small cleaved cell lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3412"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280147"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000040517"""^^xsd:string ; skos:altLabel """adult diffuse mixed cell lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3413"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280148"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, intermediate grade, stage II adult"""@eng ; skos:notation """CDR0000040514"""^^xsd:string ; skos:altLabel """adult non-Hodgkin's lymphoma, intermediate grade, stage II"""@eng , """NHL, intermediate grade, stage II adult"""@eng , """adult NHL, stage II, intermediate grade"""@eng , """lymphoma, intermediate grade, stage II adult non-Hodgkin's"""@eng , """intermediate-grade, stage II adult NHL"""@eng ; """2005-01-21"""^^xsd:string ; """3410"""^^xsd:string ; umls:cui """C0280145"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II grade 3 follicular lymphoma"""@eng ; skos:notation """CDR0000040515"""^^xsd:string ; skos:altLabel """follicular large cell lymphoma, stage II"""@eng , """stage II grade III follicular large cell lymphoma"""@eng , """stage II follicular large cell lymphoma"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3411"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280146"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cladribine/rituximab"""@eng ; skos:notation """CDR0000269656"""^^xsd:string ; skos:altLabel """2-CdA/MOAB IDEC-C2B8"""@eng ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327855"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XL999"""@eng ; skos:notation """CDR0000425377"""^^xsd:string ; """2005-03-11"""^^xsd:string ; """2005-03-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541529"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sorafenib tosylate"""@eng ; skos:notation """CDR0000299013"""^^xsd:string ; skos:altLabel """SFN"""@eng , """Nexavar"""@eng , """BAY 54-9085"""@eng , """BAY 43-9006"""@eng , """BAY 43-9006 Tosylate Salt"""@eng ; skos:definition """The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299013&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299013&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2194\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """724772"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """C2194"""^^xsd:string ; """2003-03-24"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1516119"""^^xsd:string ; umls:cui """C1676709"""^^xsd:string ; umls:cui """C3537122"""^^xsd:string ; umls:cui """C3537123"""^^xsd:string ; umls:cui """C1174389"""^^xsd:string ; umls:cui """C1677799"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/thalidomide"""@eng ; skos:notation """CDR0000299016"""^^xsd:string ; skos:altLabel """EPI/THAL"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327937"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/sirolimus"""@eng ; skos:notation """CDR0000406030"""^^xsd:string ; skos:altLabel """SLM/ZD 1839"""@eng ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541408"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """liver and intrahepatic biliary tract cancer"""@eng ; skos:notation """CDR0000038968"""^^xsd:string ; rdfs:subClassOf ; """1524"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279000"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin tumor"""@eng ; skos:notation """CDR0000038969"""^^xsd:string ; rdfs:subClassOf ; """1526"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0037286"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000038964"""^^xsd:string ; skos:altLabel """IFF/VCR/VP-16"""@eng ; ; ; ; """1520"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278997"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oropharyngeal cancer"""@eng ; skos:notation """CDR0000038965"""^^xsd:string ; skos:altLabel """Oropharyngeal cancer"""@eng , """oropharynx cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1521"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C2349952"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """central nervous system cancer"""@eng ; skos:notation """CDR0000038966"""^^xsd:string ; skos:altLabel """neurological cancer"""@eng ; rdfs:subClassOf ; """1522"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0348374"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/cladribine"""@eng ; skos:notation """CDR0000042909"""^^xsd:string ; skos:altLabel """BRYO/2-CdA"""@eng ; ; ; """6742"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677831"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """female reproductive cancer"""@eng ; skos:notation """CDR0000038960"""^^xsd:string ; skos:altLabel """gynecologic cancer"""@eng ; rdfs:subClassOf ; """1517"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0699889"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """head and neck cancer"""@eng ; skos:notation """CDR0000038961"""^^xsd:string ; rdfs:subClassOf ; """1518"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278996"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laryngeal cancer"""@eng ; skos:notation """CDR0000038962"""^^xsd:string ; skos:altLabel """Laryngeal cancer"""@eng , """larynx cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1519"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007107"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiestrogen"""@eng ; skos:notation """CDR0000038963"""^^xsd:string ; rdfs:subClassOf ; """152"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0014930"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biricodar dicitrate"""@eng ; skos:notation """CDR0000042455"""^^xsd:string ; skos:altLabel """VX-710"""@eng ; ; ; ; """Drug/agent"""^^xsd:string ; """2006-12-05"""^^xsd:string ; """5796"""^^xsd:string ; """C1653"""^^xsd:string ; umls:cui """C0338354"""^^xsd:string ; umls:cui """C1522523"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MUC-1 antigen"""@eng ; skos:notation """CDR0000042454"""^^xsd:string ; skos:altLabel """MUC-1"""@eng , """Cancer Antigen 15-3"""@eng , """Muc1 Mucin"""@eng , """ImMucin"""@eng , """Mucin Peptide MUC-1"""@eng , """DF3 Antigen"""@eng , """Polymorphic Epithelial Mucin"""@eng , """Glycosylated MUC-1"""@eng , """CA15-3 Antigen"""@eng , """Episialin"""@eng ; skos:definition """MUC-1 antigen is a mammary-type apomucin, a high molecular weight transmembrane glycoprotein, of which the extracellular domain is formed by a repeating 20 amino acid sequence (in tandem) with a high content of serine and threonine on which are O-linked carbohydrate chains. MUC-1 synthesis and secretion are features of glandular epithelial tissues, and is overexpressed in lactating breast and in breast, ovary, lung, and prostate malignancies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42454&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42454&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2407\" NCI Thesaurus)"""@eng ; ; ; ; ; """5775"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2407"""^^xsd:string ; umls:cui """C0006611"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/interferon gamma/interleukin-2"""@eng ; skos:notation """CDR0000042457"""^^xsd:string ; skos:altLabel """CYSP/IFN-G/IL-2"""@eng ; ; ; ; """5798"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338356"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/VX-710"""@eng ; skos:notation """CDR0000042456"""^^xsd:string ; skos:altLabel """DOX/VX 710"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """5797"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338355"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentetic acid"""@eng ; skos:notation """CDR0000042451"""^^xsd:string ; skos:altLabel """Detarex"""@eng , """Detapac"""@eng , """DTPA"""@eng ; ; """5772"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0013254"""^^xsd:string ; umls:cui """C1527288"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """suramin/topotecan"""@eng ; skos:notation """CDR0000042450"""^^xsd:string ; skos:altLabel """SUR/TOPO"""@eng ; ; ; """5771"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338350"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp209-2M antigen"""@eng ; skos:notation """CDR0000042453"""^^xsd:string ; skos:altLabel """antigen, gp209-2m"""@eng , """gp209-2M"""@eng ; ; ; ; """5774"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338352"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/monoclonal antibody CC49/pentetic acid"""@eng ; skos:notation """CDR0000042452"""^^xsd:string ; skos:altLabel """DTPA/IFN-A/MOAB CC49"""@eng ; ; ; ; """5773"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338351"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin/MUC-1 antigen"""@eng ; skos:notation """CDR0000042459"""^^xsd:string ; skos:altLabel """KLH/MUC-1"""@eng ; ; ; """5800"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338357"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000042458"""^^xsd:string ; skos:altLabel """childhood ALL, recurrent"""@eng , """pediatric acute lymphocytic leukemia, relapsed"""@eng , """ALL, recurrent, childhood"""@eng , """recurrent childhood acute lymphocytic leukemia"""@eng , """ALL, childhood, relapsed"""@eng , """relapsed pediatric ALL"""@eng , """recurrent childhood ALL"""@eng , """recurrent pediatric acute lymphocytic leukemia"""@eng , """pediatric ALL, relapsed"""@eng , """leukemia, acute lymphocytic, childhood, relapsed"""@eng , """childhood ALL, relapsed"""@eng , """pediatric ALL, recurrent"""@eng , """recurrent pediatric ALL"""@eng , """acute lymphocytic leukemia, childhood, relapsed"""@eng , """lymphocytic leukemia, acute, childhood, relapsed"""@eng , """relapsed childhood acute lymphocytic leukemia"""@eng , """ALL, relapsed, pediatric"""@eng , """relapsed childhood ALL"""@eng , """relapsed pediatric acute lymphocytic leukemia"""@eng , """childhood acute lymphocytic leukemia, relapsed"""@eng , """ALL, recurrent, pediatric"""@eng , """ALL, pediatric, relapsed"""@eng , """ALL, relapsed, childhood"""@eng ; rdfs:subClassOf ; """childhood acute lymphoblastic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """58"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278519"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/ixabepilone"""@eng ; skos:notation """CDR0000258334"""^^xsd:string ; skos:altLabel """BMS 247550/CAPE"""@eng ; ; ; """2004-01-08"""^^xsd:string ; """11488"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327804"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """emitefur"""@eng ; skos:notation """CDR0000042908"""^^xsd:string ; skos:altLabel """BOF A2"""@eng , """BOF-A2"""@eng ; """6741"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0950708"""^^xsd:string ; umls:cui """C0053902"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/docetaxel"""@eng ; skos:notation """CDR0000258338"""^^xsd:string ; skos:altLabel """PS-341/TXT"""@eng ; ; ; """2002-11-19"""^^xsd:string ; """11489"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327805"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """18F-fluoroazomycin arabinoside"""@eng ; skos:notation """CDR0000486925"""^^xsd:string ; skos:altLabel """18F-FAZA"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62520"""^^xsd:string ; umls:cui """C1566975"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Glutathione Disulfide"""@eng ; skos:notation """CDR0000486929"""^^xsd:string ; skos:altLabel """GSH"""@eng , """Glutathione"""@eng , """N-(N-L-gamma-glutamyl-L-cysteinyl)glycine"""@eng ; skos:definition """A tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) present in most mammalian tissue. Glutathione acts as an antioxidant, a free radical scavenger and as a detoxifying agent. Glutathione is also important as a cofactor for the enzyme glutathione peroxidase, in the uptake of amino acids and participates in leukotriene synthesis. Under the influence of glutathione S-transferase, glutathione can react with a number of harmful products, such as halides, epoxides and free radicals, to form harmless inactive products. In erythrocytes, these reactions prevent oxidative damage by reduction of methemoglobin and peroxides. Glutathione is also involved in the formation and maintenance of disulfide bonds in proteins and in transport of amino acids across cell membranes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486929&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486929&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C523\" NCI Thesaurus)"""@eng ; """400639"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """70-18-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C523"""^^xsd:string ; umls:cui """C0061516"""^^xsd:string ; umls:cui """C0017817"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/cyclophosphamide/doxorubicin/etoposide/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000445060"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB IDEC-C2B8/PRED/PS-341/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """2005-08-24"""^^xsd:string ; """2005-08-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831701"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anastrozole/celecoxib"""@eng ; skos:notation """CDR0000321914"""^^xsd:string ; skos:altLabel """ANAS/SC-58635"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328012"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/exemestane"""@eng ; skos:notation """CDR0000321913"""^^xsd:string ; skos:altLabel """PNU 155971/SC-58635"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328011"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gallium maltolate"""@eng ; skos:notation """CDR0000355806"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """2004-02-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328202"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SN-38 liposome"""@eng ; skos:notation """CDR0000355805"""^^xsd:string ; skos:altLabel """LE-SN38"""@eng , """liposomal SN-38"""@eng , """liposomal SN38"""@eng ; """2004-02-20"""^^xsd:string ; """2004-02-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328201"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NM-3"""@eng ; skos:notation """CDR0000355804"""^^xsd:string ; skos:definition """An orally bioavailable antiangiogenic isocoumarin with potential antineoplastic activity. NM-3 inhibits vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, thereby inhibiting endothelial cell proliferation. This agent also induces apoptosis by a mechanism involving reactive oxygen species. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355804&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=355804&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1888\" NCI Thesaurus)"""@eng ; """2004-02-20"""^^xsd:string ; """2004-02-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1888"""^^xsd:string ; umls:cui """C1328200"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/docetaxel"""@eng ; skos:notation """CDR0000355803"""^^xsd:string ; skos:altLabel """MOAB CTLA-4/TXT"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328199"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/TLK286"""@eng ; skos:notation """CDR0000330214"""^^xsd:string ; skos:altLabel """TLK-286/TXT"""@eng ; ; ; """2003-08-24"""^^xsd:string ; """2003-08-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328041"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-CD20 monoclonal antibody AME-133v"""@eng ; skos:notation """CDR0000500055"""^^xsd:string ; skos:altLabel """LY 2469298"""@eng , """AME-133v"""@eng ; """2006-08-06"""^^xsd:string ; """C2524"""^^xsd:string ; """2006-12-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831934"""^^xsd:string ; umls:cui """C1831935"""^^xsd:string ; umls:cui """C1831936"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epoetin alfa/thalidomide"""@eng ; skos:notation """CDR0000269052"""^^xsd:string ; skos:altLabel """EPO/THAL"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327824"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone hydrochloride"""@eng ; skos:notation """CDR0000039219"""^^xsd:string ; skos:altLabel """Mitoxantroni Hydrochloridum"""@eng , """Pralifan"""@eng , """dihydroxyanthracenedione"""@eng , """Mitozantrone"""@eng , """Dihydroxyanthracenedione Dihydrochloride"""@eng , """mitoxantrone dihydrochloride"""@eng , """1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione"""@eng , """Mitroxone"""@eng , """Neotalem"""@eng , """Onkotrone"""@eng , """DHAD"""@eng , """CL 232315"""@eng , """mitoxantrone HCl"""@eng , """1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone"""@eng , """DHAQ"""@eng , """CL 232,315"""@eng , """Novantrone"""@eng ; skos:definition """The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39219&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39219&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C665\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """301739"""^^xsd:string ; """65271-80-9"""^^xsd:string ; """16802"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """1841"""^^xsd:string ; """C665"""^^xsd:string ; """279836"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700458"""^^xsd:string ; umls:cui """C1513357"""^^xsd:string ; umls:cui """C1513356"""^^xsd:string ; umls:cui """C0282248"""^^xsd:string ; umls:cui """C0026259"""^^xsd:string ; umls:cui """C0701409"""^^xsd:string ; umls:cui """C1513359"""^^xsd:string ; umls:cui """C1513358"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """inosine dialdehyde"""@eng ; skos:notation """CDR0000039218"""^^xsd:string ; skos:altLabel """diglycoaldehyde"""@eng , """9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R,R)- (8CI)"""@eng , """diglycolaldehyde, alpha-(hydroxymethyl)-.alpha.'-(6-hydroxy-9H-purin-9-yl)"""@eng , """9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R-(R*, R*))- (9CI)"""@eng , """INOX"""@eng , """Wy-5321"""@eng , """IdA"""@eng ; skos:definition """A toxic purine analogue. Inosine dialdehyde inhibits ribonucleotide reductase, resulting in decreased synthesis of DNA, RNA, and proteins, and G2/M-phase cell cycle arrest. This agent also forms stable covalent crosslinks in proteins, thereby inhibiting the activity of enzymes involved in nucleic acid synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39218&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39218&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1136\" NCI Thesaurus)"""@eng ; """1840"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """10027"""^^xsd:string ; """118994"""^^xsd:string ; """23590-99-0"""^^xsd:string ; """C1136"""^^xsd:string ; umls:cui """C0063555"""^^xsd:string ; umls:cui """C1328665"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dianhydrogalactitol"""@eng ; skos:notation """CDR0000039215"""^^xsd:string ; skos:altLabel """1,2:5,6 dianhydrogalactitol"""@eng , """DAG"""@eng , """1,2:5, 6-diepoxydulcitol"""@eng , """galactitol, 1,2:5,6-dianhydro- (8CI 9CI)"""@eng , """1,2:5,6-dianhydrodulcitol"""@eng , """dianhydrodulcitol"""@eng , """diepoxygalactitol"""@eng , """diepoxydulcitol"""@eng , """dulcitol diepoxide"""@eng , """Galactitol"""@eng , """1,2,5,6 dianhydrogalactitol"""@eng ; skos:definition """A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39215&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39215&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C425\" NCI Thesaurus)"""@eng ; ; ; ; """1837"""^^xsd:string ; """C425"""^^xsd:string ; """10899"""^^xsd:string ; """132313"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """23261-20-3"""^^xsd:string ; umls:cui """C0013283"""^^xsd:string ; umls:cui """C0011967"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DHEA mustard"""@eng ; skos:notation """CDR0000039214"""^^xsd:string ; skos:altLabel """dehydroepiandrosterone mustard"""@eng ; skos:definition """A steroidal alkylating agent with potential antineoplastic activity. Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39214&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39214&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2707\" NCI Thesaurus)"""@eng ; """1836"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2707"""^^xsd:string ; """121210"""^^xsd:string ; umls:cui """C0279151"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dichloromethotrexate"""@eng ; skos:notation """CDR0000039217"""^^xsd:string ; skos:altLabel """DCM"""@eng , """3'-5'-dichloromethotrexate"""@eng , """Amethopterin, 3',5'-dichloro"""@eng , """Methotrexate, Dichloro"""@eng , """dichloroamethopterin"""@eng , """3',5'-Dichloroamethopterin"""@eng , """Glutamic Acid, N-{3,5-dichloro-4-{[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl}-"""@eng , """Glutamic Acid, N-{3,5-dichloro-4-{[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl}-L- (8CI)"""@eng , """N-[3,5-Dichloro-4-[(2,4-diamino-6-pteridinylmethyl)methylamino]benzoyl] Glutamic Acid"""@eng , """L-Glutamic Acid, N-{3,5-dichloro-4-{[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl}-(9CI)"""@eng ; skos:definition """A chlorinated methotrexate derivative. Dichloromethotrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylates and inhibiting DNA and RNA synthesis. This agent is metabolized and excreted by the liver. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39217&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39217&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C966\" NCI Thesaurus)"""@eng ; """1839"""^^xsd:string ; """29630"""^^xsd:string ; """3168"""^^xsd:string ; """528-74-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C966"""^^xsd:string ; umls:cui """C0046764"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitolactol"""@eng ; skos:notation """CDR0000039216"""^^xsd:string ; skos:altLabel """6-dibromodideoxydulcitol"""@eng , """Elobromol"""@eng , """Dibromdicil"""@eng , """6-dibromodulcitol"""@eng , """dibromodulcitol"""@eng , """Mitolac"""@eng , """DBD"""@eng ; skos:definition """A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties. Mitolactol alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA and RNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39216&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39216&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C662\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1838"""^^xsd:string ; """10318-26-0"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5217"""^^xsd:string ; """104800"""^^xsd:string ; """C662"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0878349"""^^xsd:string ; umls:cui """C0026252"""^^xsd:string ; umls:cui """C1513346"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """esorubicin"""@eng ; skos:notation """CDR0000039211"""^^xsd:string ; skos:altLabel """4'deoxydoxorubicin"""@eng , """DXDX"""@eng , """deoxydoxorubicin"""@eng , """4'-deoxyadriamycin hydrochloride"""@eng , """deoxyadriamycin"""@eng , """4'-DxDx"""@eng , """IMI 58"""@eng ; """1833"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C972"""^^xsd:string ; """2007-01-12"""^^xsd:string ; umls:cui """C0047760"""^^xsd:string ; umls:cui """C1328664"""^^xsd:string ; umls:cui """C0955070"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentostatin"""@eng ; skos:notation """CDR0000039210"""^^xsd:string ; skos:altLabel """Covidarabine"""@eng , """DCF"""@eng , """co-vidarabine"""@eng , """Pentostatine"""@eng , """deoxycoformycin"""@eng , """2'-deoxycoformycin"""@eng , """CI-825"""@eng , """PD-81565"""@eng , """Nipent"""@eng , """(R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol"""@eng ; skos:definition """A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39210&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39210&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C732\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """1832"""^^xsd:string ; """247520"""^^xsd:string ; """16505"""^^xsd:string ; """52325"""^^xsd:string ; """218321"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C732"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """53910-25-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733530"""^^xsd:string ; umls:cui """C0030896"""^^xsd:string ; umls:cui """C0733529"""^^xsd:string ; umls:cui """C1522539"""^^xsd:string ; umls:cui """C0591865"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """detorubicin"""@eng ; skos:notation """CDR0000039213"""^^xsd:string ; skos:altLabel """Diethoxy-,2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester,(2S-cis) Acetic Acid"""@eng , """14-Diethoxyacetoxydaunorubicin"""@eng ; skos:definition """A semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39213&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39213&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1066\" NCI Thesaurus)"""@eng ; """1835"""^^xsd:string ; """292652"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """66211-92-5"""^^xsd:string ; """C1066"""^^xsd:string ; umls:cui """C0057578"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """desmethylmisonidazole"""@eng ; skos:notation """CDR0000039212"""^^xsd:string ; skos:altLabel """SR-1530"""@eng , """demethylmisonidazole"""@eng , """Ro 05-9963"""@eng , """DMM"""@eng ; """1834"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1135157"""^^xsd:string ; umls:cui """C0057545"""^^xsd:string ; umls:cui """C0950279"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Biafine cream"""@eng ; skos:notation """CDR0000042903"""^^xsd:string ; skos:altLabel """Biafine"""@eng ; """6734"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1876840"""^^xsd:string ; umls:cui """C0677828"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/rituximab"""@eng ; skos:notation """CDR0000371906"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/MOAB VEGF"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541271"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anastrozole/lonafarnib"""@eng ; skos:notation """CDR0000371901"""^^xsd:string ; skos:altLabel """ANAS/SCH 66336"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541268"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III marginal zone lymphoma"""@eng ; skos:notation """CDR0000371902"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541269"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV marginal zone lymphoma"""@eng ; skos:notation """CDR0000371903"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541270"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/prednisone"""@eng ; skos:notation """CDR0000039376"""^^xsd:string ; skos:altLabel """IFN-A/PRED"""@eng ; ; ; """2011"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338090"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/etoposide/prednisone/procarbazine"""@eng ; skos:notation """CDR0000039377"""^^xsd:string ; skos:altLabel """BLEO/CTX/PCB/PRED/VP-16"""@eng , """B-CEPP"""@eng ; ; ; ; ; ; """2012"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279240"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/streptozocin/vincristine"""@eng ; skos:notation """CDR0000039374"""^^xsd:string ; skos:altLabel """BLEO/DOX/SZC/VCR"""@eng , """BAVS"""@eng ; ; ; ; ; """2009"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279237"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovine sialomucin"""@eng ; skos:notation """CDR0000039375"""^^xsd:string ; skos:altLabel """OSM"""@eng ; """2010"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0279238"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AAG"""@eng ; skos:notation """CDR0000043416"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """C2516"""^^xsd:string ; """7975"""^^xsd:string ; umls:cui """C0796552"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dipyridamole/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000039373"""^^xsd:string ; skos:altLabel """CF/DP/5-FU"""@eng ; ; ; ; """2008"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279236"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/mechlorethamine/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039370"""^^xsd:string ; skos:altLabel """BLEO/DOX/MTX/NM/VCR"""@eng , """BAMON"""@eng ; ; ; ; ; ; """2005"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279233"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cytarabine/etoposide"""@eng ; skos:notation """CDR0000041488"""^^xsd:string ; skos:altLabel """MACE"""@eng , """AMSA/ARA-C/VP-16"""@eng ; ; ; ; """4644"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0286421"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic cancer"""@eng ; skos:notation """CDR0000041487"""^^xsd:string ; skos:altLabel """Pancreatic cancer"""@eng , """pancreas cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """46"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346647"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2 liposome"""@eng ; skos:notation """CDR0000041486"""^^xsd:string ; skos:altLabel """Liposome encapsulated interleukin-2"""@eng , """IL-2 LIPO"""@eng ; skos:definition """A formulation in which liposomes are loaded with the cytokine interleukin-2 (IL-2). By activating cytotoxic T-lymphocytes, such as lymphokine-activated killer cells, and increasing levels of the cytotoxic cytokines interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta), IL-2 may exhibit antitumoral activity. Liposomal formulations of IL-2 may promote entry of the cytokine into target tumor cells and may be used as an immunoadjuvant in cancer vaccine therapy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41486&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41486&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2373\" NCI Thesaurus)"""@eng ; ; """4557"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C2373"""^^xsd:string ; umls:cui """C0281031"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000041485"""^^xsd:string ; skos:altLabel """CF/5-FU/TMTX"""@eng ; ; ; ; """4556"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281030"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/interleukin-6"""@eng ; skos:notation """CDR0000041484"""^^xsd:string ; skos:altLabel """IL-2/IL-6"""@eng ; ; ; """4555"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281029"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/leuprolide/somatuline/suramin"""@eng ; skos:notation """CDR0000041483"""^^xsd:string ; skos:altLabel """FLUT/LEUP/somatuline/SUR"""@eng ; ; ; ; """4554"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281028"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """somatuline/suramin"""@eng ; skos:notation """CDR0000041482"""^^xsd:string ; skos:altLabel """somatuline/SUR"""@eng ; ; """4553"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281027"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/mitomycin/vincristine"""@eng ; skos:notation """CDR0000039378"""^^xsd:string ; skos:altLabel """BLEO/CDDP/MITO/VCR"""@eng , """POMB"""@eng , """BOMP"""@eng ; ; ; ; ; """2013"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053926"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/prednisone"""@eng ; skos:notation """CDR0000039379"""^^xsd:string ; skos:altLabel """BCP"""@eng , """BCNU/CTX/PRED"""@eng ; ; ; ; """2014"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053051"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sustained-release lipid inhaled cisplatin"""@eng ; skos:notation """CDR0000420851"""^^xsd:string ; skos:altLabel """SLIT![TRADE MARK SIGN]! cisplatin"""@eng , """SLIT™ cisplatin"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2005-02-11"""^^xsd:string ; """2005-02-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541510"""^^xsd:string ; umls:cui """C1541163"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paranasal sinus and nasal cavity inverted papilloma"""@eng ; skos:notation """CDR0000040688"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus inverted papilloma"""@eng , """inverted papilloma, paranasal sinus and nasal cavity"""@eng ; rdfs:subClassOf ; """2006-11-28"""^^xsd:string ; """3602"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280335"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paranasal sinus and nasal cavity midline lethal granuloma"""@eng ; skos:notation """CDR0000040689"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus midline lethal granuloma"""@eng , """midline lethal granuloma, paranasal sinus and nasal cavity"""@eng ; rdfs:subClassOf ; """3605"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0018197"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypopharyngeal squamous cell carcinoma"""@eng ; skos:notation """CDR0000040682"""^^xsd:string ; skos:altLabel """squamous cell carcinoma, hypopharyngeal"""@eng , """hypopharynx squamous cell carcinoma"""@eng , """epidermoid carcinoma, hypopharyngeal"""@eng ; rdfs:subClassOf ; """3597"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280321"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/autologous tumor cell vaccine/keyhole limpet hemocyanin"""@eng ; skos:notation """CDR0000377680"""^^xsd:string ; skos:altLabel """ADC/ATCV/KLH"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541338"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oropharyngeal squamous cell carcinoma"""@eng ; skos:notation """CDR0000040680"""^^xsd:string ; skos:altLabel """squamous cell carcinoma, oropharyngeal"""@eng , """epidermoid carcinoma, oropharyngeal"""@eng , """oropharynx squamous cell carcinoma"""@eng ; rdfs:subClassOf ; """3594"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280313"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oropharyngeal lymphoepithelioma"""@eng ; skos:notation """CDR0000040681"""^^xsd:string ; skos:altLabel """oropharynx lymphoepithelioma"""@eng , """lymphoepithelioma, oropharyngeal"""@eng ; rdfs:subClassOf ; """3595"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280318"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laryngeal verrucous carcinoma"""@eng ; skos:notation """CDR0000040686"""^^xsd:string ; skos:altLabel """verrucous carcinoma, laryngeal"""@eng , """larynx verrucous carcinoma"""@eng ; rdfs:subClassOf ; """3600"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280328"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paranasal sinus and nasal cavity squamous cell carcinoma"""@eng ; skos:notation """CDR0000040687"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity cancer squamous cell carcinoma"""@eng , """squamous cell carcinoma, paranasal sinus and nasal cavity"""@eng , """epidermoid carcinoma, paranasal sinus and nasal cavity"""@eng , """nasal cavity and paranasal sinus cancer squamous cell carcinoma"""@eng ; rdfs:subClassOf ; """3601"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280332"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II anal cancer"""@eng ; skos:notation """CDR0000040684"""^^xsd:string ; skos:altLabel """anus cancer, stage II"""@eng , """stage II anus cancer"""@eng , """anal cancer, stage II"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """36"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278500"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxyurea"""@eng ; skos:notation """CDR0000040685"""^^xsd:string ; skos:altLabel """Oncocarbide"""@eng , """WR 83799"""@eng , """HYD"""@eng , """Hydroxycarbamide"""@eng , """HU"""@eng , """Droxia"""@eng , """Onco-Carbide"""@eng , """Hydrea"""@eng , """Oxeron"""@eng , """Litalir"""@eng , """SQ-1089"""@eng , """Syrea"""@eng , """Hydurea"""@eng ; skos:definition """A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C560\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """360"""^^xsd:string ; """937"""^^xsd:string ; """7179"""^^xsd:string ; """C560"""^^xsd:string ; """38558"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """32065"""^^xsd:string ; """127-07-1"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """9235"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527301"""^^xsd:string ; umls:cui """C1512544"""^^xsd:string ; umls:cui """C0729130"""^^xsd:string ; umls:cui """C1527299"""^^xsd:string ; umls:cui """C0729128"""^^xsd:string ; umls:cui """C0729129"""^^xsd:string ; umls:cui """C0720055"""^^xsd:string ; umls:cui """C1512543"""^^xsd:string ; umls:cui """C1527300"""^^xsd:string ; umls:cui """C0020402"""^^xsd:string ; umls:cui """C0591617"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytogenetic analysis"""@eng ; skos:notation """CDR0000043194"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """7637"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0752095"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multidrug resistance-associated protein"""@eng ; skos:notation """CDR0000276592"""^^xsd:string ; skos:altLabel """MDR"""@eng , """MRP"""@eng ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """2003-02-06"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0290741"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neurofibromatosis type 2 (NF2)"""@eng ; skos:notation """CDR0000474016"""^^xsd:string ; """Genetic condition"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """2006-06-21"""^^xsd:string ; umls:cui """C0027832"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idoxifene"""@eng ; skos:notation """CDR0000042969"""^^xsd:string ; """7200"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0139560"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GM-K562 cell vaccine"""@eng ; skos:notation """CDR0000460926"""^^xsd:string ; skos:definition """A cell-based vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. Vaccination with GM-K562 cells may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. K562 cells are derived from the human erythroleukemia cell line K562. GM-CSF (also known as sagramostim) expressed by vaccine cells binds to specific cell surface receptors, modulating the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production. GM-CSF also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460926&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=460926&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52190\" NCI Thesaurus)"""@eng ; """C52190"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C1708127"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daptomycin"""@eng ; skos:notation """CDR0000469015"""^^xsd:string ; skos:altLabel """Cubicin"""@eng , """N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone"""@eng , """LY146032"""@eng ; skos:definition """A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum anitbiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469015&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469015&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47470\" NCI Thesaurus)"""@eng ; """103060-53-3"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """C47470"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0057144"""^^xsd:string ; umls:cui """C1330170"""^^xsd:string ; umls:cui """C0918009"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/G17DT"""@eng ; skos:notation """CDR0000038353"""^^xsd:string ; skos:altLabel """CDDP/5-FU/G17-DT"""@eng ; ; ; ; """2003-10-29"""^^xsd:string ; """10971"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935890"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """G17DT"""@eng ; skos:notation """CDR0000038352"""^^xsd:string ; skos:altLabel """anti-gastrin 17 immunogen"""@eng , """G17-DT"""@eng , """anti-gastrin 17"""@eng , """Gastrimmune"""@eng ; ; """2003-10-29"""^^xsd:string ; """10970"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1619625"""^^xsd:string ; umls:cui """C0935889"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """niacin"""@eng ; skos:notation """CDR0000038351"""^^xsd:string ; skos:altLabel """Vitamin B3"""@eng , """nicotinic acid"""@eng , """3-Pyridinecarboxylic Acid"""@eng ; skos:definition """A water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38351&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38351&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C689\" NCI Thesaurus)"""@eng ; """1097"""^^xsd:string ; """59-67-6"""^^xsd:string ; """C689"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """169454"""^^xsd:string ; umls:cui """C0028027"""^^xsd:string ; umls:cui """C0027996"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """telomerase inhibitor GRN163L"""@eng ; skos:notation """CDR0000447136"""^^xsd:string ; skos:altLabel """GRN163L"""@eng ; skos:definition """A synthetic lipid-conjugated, 13-mer oligonucleotide N3' P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase RNA (hTR), telomerase inhibitor GRN163L as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a \"telomerase template antagonist\"), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by telomerase inhibitor GRN163L results in telomere shortening, which leads to cell cycle arrest or apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=447136&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=447136&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49084\" NCI Thesaurus)"""@eng ; """C49084"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """2005-09-23"""^^xsd:string ; umls:cui """C1708156"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan/leucovorin calcium/SU5416"""@eng ; skos:notation """CDR0000038357"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/SU-5416"""@eng ; ; ; ; ; """2003-10-29"""^^xsd:string ; """10975"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935893"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/interleukin-2/sargramostim"""@eng ; skos:notation """CDR0000038356"""^^xsd:string ; skos:altLabel """AL/GM-CSF/IL-2"""@eng ; ; ; ; """10974"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935892"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """eflornithine/triamcinolone"""@eng ; skos:notation """CDR0000038355"""^^xsd:string ; skos:altLabel """ARIST/DFMO"""@eng ; ; ; """10973"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935891"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """taurolidine"""@eng ; skos:notation """CDR0000038354"""^^xsd:string ; skos:altLabel """Taurolin"""@eng ; """10972"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0144567"""^^xsd:string ; umls:cui """C0144568"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000038359"""^^xsd:string ; skos:altLabel """grade II follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma"""@eng , """nodular MC lymphoma"""@eng , """lymphoma, follicular mixed cell"""@eng , """FM lymphoma"""@eng , """NM lymphoma"""@eng , """lymphoma, nodular mixed"""@eng , """nodular mixed lymphoma"""@eng , """mixed cell lymphoma, follicular"""@eng , """NML"""@eng ; rdfs:subClassOf ; """2003-11-19"""^^xsd:string ; """1098"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0079758"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-FLT-1 ribozyme"""@eng ; skos:notation """CDR0000038358"""^^xsd:string ; skos:altLabel """Angiozyme"""@eng , """RPI-4610"""@eng , """RPI.4610"""@eng , """RPI4610"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """C1865"""^^xsd:string ; """10979"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0908892"""^^xsd:string ; umls:cui """C1832064"""^^xsd:string ; umls:cui """C2980021"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """18F-fluoroazomycin arabinoside"""@eng ; skos:notation """CDR0000520337"""^^xsd:string ; skos:altLabel """18F-FAZA"""@eng ; """2006-11-06"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1566975"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """contiguous stage II adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000042715"""^^xsd:string ; rdfs:subClassOf ; """6509"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677685"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PSA RNA-pulsed dendritic cell vaccine"""@eng ; skos:notation """CDR0000037808"""^^xsd:string ; """10166"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879395"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cefixime"""@eng ; skos:notation """CDR0000037809"""^^xsd:string ; skos:altLabel """FK 027"""@eng , """FK-027"""@eng ; skos:definition """A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37809&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37809&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1100\" NCI Thesaurus)"""@eng ; ; """10167"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """C1100"""^^xsd:string ; umls:cui """C0752064"""^^xsd:string ; umls:cui """C0060400"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III cervical cancer"""@eng ; skos:notation """CDR0000038139"""^^xsd:string ; skos:altLabel """uterine cervical cancer, stage III"""@eng , """stage III cervix cancer"""@eng , """uterine cervix cancer, stage III"""@eng , """stage III cancer of the cervix"""@eng , """carcinoma of the cervix, stage III"""@eng , """stage III carcinoma of the cervix"""@eng , """stage III uterine cervix cancer"""@eng , """cancer of the cervix, stage III"""@eng , """cervical cancer, stage III"""@eng , """cervix cancer, stage III"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """107"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278577"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ascorbic acid/selenium"""@eng ; skos:notation """CDR0000038138"""^^xsd:string ; skos:altLabel """SEL/VIT-C"""@eng ; ; ; """10699"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935723"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/thalidomide"""@eng ; skos:notation """CDR0000038137"""^^xsd:string ; skos:altLabel """MOAB VEGF/THAL"""@eng ; ; ; """10696"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935722"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 11D10 anti-idiotype vaccine/monoclonal antibody 3H1 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000038136"""^^xsd:string ; skos:altLabel """MOAB 11D10 VAC/MOAB 3H1"""@eng ; ; ; """10695"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935721"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody 11D10 anti-idiotype vaccine"""@eng ; skos:notation """CDR0000038135"""^^xsd:string ; skos:altLabel """MOAB 11D10 VAC"""@eng , """11D10 anti-idiotype vaccine"""@eng , """vaccine, MOAB 11D10 anti-idiotype"""@eng , """TriAb anti-idiotype antibody"""@eng , """11D10 anti-idiotype vaccine, monoclonal antibody"""@eng , """TriAb"""@eng ; skos:definition """A vaccine consisting of a monoclonal antibody (MoAB) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope. Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38135&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38135&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2606\" NCI Thesaurus)"""@eng ; ; ; ; """10694"""^^xsd:string ; """C2606"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0935720"""^^xsd:string ; umls:cui """C0935983"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/irinotecan/oxaliplatin"""@eng ; skos:notation """CDR0000038134"""^^xsd:string ; skos:altLabel """CAPE/CPT-11/L-OHP"""@eng ; ; ; ; """10693"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935719"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/interleukin-2"""@eng ; skos:notation """CDR0000038133"""^^xsd:string ; skos:altLabel """AL/IL-2"""@eng ; ; ; """10692"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935718"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pegfilgrastim"""@eng ; skos:notation """CDR0000037807"""^^xsd:string ; skos:altLabel """Neulasta"""@eng , """filgrastim-SD/01"""@eng , """SD-01 sustained duration G-CSF"""@eng , """Filgrastim SD-01"""@eng , """GCSF-SD01"""@eng , """SD-01"""@eng ; skos:definition """A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37807&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37807&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1854\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """10165"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """C1854"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1171279"""^^xsd:string ; umls:cui """C1136535"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/ifosfamide/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000038131"""^^xsd:string ; skos:altLabel """ARA-C/DM/IFF/MTX/VBL/VP-16"""@eng ; ; ; ; ; ; ; """10690"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935716"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent gastrointestinal carcinoid tumor"""@eng ; skos:notation """CDR0000038130"""^^xsd:string ; skos:altLabel """gastrointestinal carcinoid tumor, recurrent"""@eng ; rdfs:subClassOf ; """gastrointestinal carcinoid tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1069"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278750"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/leucovorin calcium/mitoxantrone"""@eng ; skos:notation """CDR0000039651"""^^xsd:string ; skos:altLabel """CF/CTX/DHAD/5-FU"""@eng ; ; ; ; ; """2306"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279436"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """maribavir"""@eng ; skos:notation """CDR0000429563"""^^xsd:string ; """2005-04-23"""^^xsd:string ; """2005-04-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1508759"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000040560"""^^xsd:string ; skos:altLabel """lymphoblastic lymphoma, recurrent, adult"""@eng , """relapsed adult lymphoblastic lymphoma"""@eng , """adult lymphoblastic lymphoma, relapsed"""@eng , """adult lymphoblastic lymphoma, recurrent"""@eng , """lymphoblastic lymphoma, adult, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3456"""^^xsd:string ; """2005-01-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280191"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/recombinant interferon beta"""@eng ; skos:notation """CDR0000039653"""^^xsd:string ; skos:altLabel """5-FU/IFN-B"""@eng ; ; ; """2308"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279438"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/leucovorin calcium"""@eng ; skos:notation """CDR0000039652"""^^xsd:string ; skos:altLabel """CF/FUDR"""@eng ; ; ; """2307"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279437"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """senna fruit"""@eng ; skos:notation """CDR0000480407"""^^xsd:string ; """2006-04-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """C29447"""^^xsd:string ; umls:cui """C1519240"""^^xsd:string ; umls:tui """T168"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """senna extract"""@eng ; skos:notation """CDR0000480408"""^^xsd:string ; skos:altLabel """senna"""@eng ; skos:definition """An extract made from the dried leaflets on the pods of Cassia angustifolia or Cassia acutifolia with laxative properties. Dimeric glycosides in dried senna extract are converted to the active monoanthrones by bacterial action in the colon. Through direct effects on enterocytes, enteric neurons, and muscle, monoanthrones produce giant migrating colonic contractions in addition to water and electrolyte secretion. As do other stimulant laxatives, monoanthrones may induce a limited low-grade inflammation in the colon through activation of prostaglandin/cyclic AMP and nitric oxide/cyclic GMP pathways and perhaps inhibition of Na+, K+-ATPase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480408&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=480408&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61324\" NCI Thesaurus)"""@eng ; """2006-04-14"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C61324"""^^xsd:string ; umls:cui """C0074332"""^^xsd:string ; umls:cui """C0036656"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EWS-ETS"""@eng ; skos:notation """CDR0000257792"""^^xsd:string ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11456"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327784"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IGF1R"""@eng ; skos:notation """CDR0000257793"""^^xsd:string ; skos:altLabel """insulin-like growth factor I receptor"""@eng ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """10321"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0140080"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T192"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """UGT1A1"""@eng ; skos:notation """CDR0000257796"""^^xsd:string ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11457"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0537026"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP3A4"""@eng ; skos:notation """CDR0000257797"""^^xsd:string ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11458"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1176140"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """IGFBP3"""@eng ; skos:notation """CDR0000257794"""^^xsd:string ; skos:altLabel """insulin-like growth factor binding protein 3"""@eng ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11455"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0123707"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/fowlpox-PSA vaccine"""@eng ; skos:notation """CDR0000257389"""^^xsd:string ; skos:altLabel """F-PSA/TXT"""@eng ; ; ; """2002-08-16"""^^xsd:string ; """11426"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327777"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP3A5"""@eng ; skos:notation """CDR0000257798"""^^xsd:string ; rdfs:subClassOf ; """2002-09-09"""^^xsd:string ; """11459"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C3714750"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/docetaxel/tipifarnib"""@eng ; skos:notation """CDR0000334874"""^^xsd:string ; skos:altLabel """CAPE/R115777/TXT"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328052"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/interferon alfa/vincristine"""@eng ; skos:notation """CDR0000039658"""^^xsd:string ; skos:altLabel """DM/DOX/IFN-A/VCR"""@eng ; ; ; ; ; """2313"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338098"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """refractory anemia with ringed sideroblasts"""@eng ; skos:notation """CDR0000040358"""^^xsd:string ; rdfs:subClassOf ; """3214"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1264195"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG oligodeoxynucleotide"""@eng ; skos:notation """CDR0000467169"""^^xsd:string ; skos:altLabel """CpG ODN"""@eng ; """C62280"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-14"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C0914671"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant modified vaccinia Ankara-5T4 vaccine"""@eng ; skos:notation """CDR0000449683"""^^xsd:string ; skos:altLabel """TroVax"""@eng , """vaccinia-5T4 antigen vaccine"""@eng , """rV-5T4 VAC"""@eng , """recombinant MVA-5T4 vaccine"""@eng , """recombinant pox virus encoding 5T4 vaccine"""@eng ; skos:definition """A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=449683&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=449683&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49087\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-21"""^^xsd:string ; """C49087"""^^xsd:string ; """2005-09-23"""^^xsd:string ; umls:cui """C1709858"""^^xsd:string ; umls:cui """C1541801"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """proteomic profiling"""@eng ; skos:notation """CDR0000257243"""^^xsd:string ; rdfs:subClassOf ; """2002-08-13"""^^xsd:string ; """11422"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1327760"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/voriconazole"""@eng ; skos:notation """CDR0000304319"""^^xsd:string ; skos:altLabel """IFN-G/VCZ"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327961"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/procarbazine/rituximab/vincristine"""@eng ; skos:notation """CDR0000304318"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/MTX/PCB/VCR"""@eng ; ; ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327960"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluoxymesterone/tamoxifen"""@eng ; skos:notation """CDR0000041319"""^^xsd:string ; skos:altLabel """FXM/TMX"""@eng ; ; """4392"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280900"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interferon alfa/interleukin-2/vinblastine"""@eng ; skos:notation """CDR0000041318"""^^xsd:string ; skos:altLabel """CDDP/IFN-A/IL-2/VBL"""@eng ; ; ; ; ; """4390"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338145"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/lomustine/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000041317"""^^xsd:string ; skos:altLabel """BLEO/CCNU/MTX/VBL"""@eng ; ; ; ; ; """439"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278609"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/estradiol/goserelin/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000041316"""^^xsd:string ; skos:altLabel """DOX/ESDL/TSPA/VBL/ZDX"""@eng ; ; ; ; ; ; """4389"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280898"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000041315"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DNR/MTX/PRED/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; """4388"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280897"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000041314"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DNR/MTX/PRED/TG/VCR"""@eng ; ; ; ; ; ; ; ; """4387"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280896"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/prednisone"""@eng ; skos:notation """CDR0000041313"""^^xsd:string ; skos:altLabel """ASP/PRED"""@eng ; ; ; """4386"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280895"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041312"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; """4385"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280894"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/methotrexate/prednisone/thioguanine"""@eng ; skos:notation """CDR0000041311"""^^xsd:string ; skos:altLabel """ARA-C/ASP/MTX/PRED/TG"""@eng ; ; ; ; ; ; """4384"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280893"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000041310"""^^xsd:string ; skos:altLabel """CF/5-FU/IFN-A/MTX"""@eng ; ; ; ; ; """4383"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338144"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/dexamethasone/gemcitabine/rituximab"""@eng ; skos:notation """CDR0000341120"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/DM/MOAB IDEC-C2B8"""@eng ; ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328087"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood malignant fibrous histiocytoma"""@eng ; skos:notation """CDR0000040309"""^^xsd:string ; skos:altLabel """histiocytoma, malignant fibrous, childhood"""@eng , """malignant fibrous histiocytoma, childhood"""@eng , """fibrous histiocytoma, malignant, childhood"""@eng , """pediatric malignant fibrous histiocytoma"""@eng ; rdfs:subClassOf ; """3149"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279990"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood epithelioid sarcoma"""@eng ; skos:notation """CDR0000040308"""^^xsd:string ; skos:altLabel """epithelioid sarcoma, childhood"""@eng , """pediatric epithelioid sarcoma"""@eng , """sarcoma, epithelioid, childhood"""@eng ; rdfs:subClassOf ; """3148"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279989"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood angiosarcoma"""@eng ; skos:notation """CDR0000040307"""^^xsd:string ; skos:altLabel """sarcoma, angio-, pediatric"""@eng , """hemangiosarcoma, childhood"""@eng , """angiosarcoma, childhood"""@eng , """sarcoma, angio-, childhood"""@eng , """hemangiosarcoma, pediatric"""@eng , """pediatric hemangiosarcoma"""@eng , """pediatric angiosarcoma"""@eng , """childhood hemangiosarcoma"""@eng , """angiosarcoma, pediatric"""@eng ; rdfs:subClassOf ; """3147"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279988"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood neurofibrosarcoma"""@eng ; skos:notation """CDR0000040306"""^^xsd:string ; skos:altLabel """schwannoma, malignant, childhood"""@eng , """neurofibrosarcoma, childhood"""@eng , """neurolemma, malignant, childhood"""@eng , """sarcoma, neurofibro-, childhood"""@eng , """neurogenic sarcoma, childhood"""@eng , """pediatric neurofibrosarcoma"""@eng , """neurofibrosarcoma, pediatric"""@eng , """malignant neurolemma, childhood"""@eng , """malignant schwannoma, childhood"""@eng , """sarcoma, neurogenic, childhood"""@eng ; rdfs:subClassOf ; """3145"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279987"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood leiomyosarcoma"""@eng ; skos:notation """CDR0000040305"""^^xsd:string ; skos:altLabel """leiomyosarcoma, childhood"""@eng , """leiomyosarcoma, pediatric"""@eng , """sarcoma, leiomyo-, childhood"""@eng , """sarcoma, leiomyo-, pediatric"""@eng , """pediatric leiomyosarcoma"""@eng ; rdfs:subClassOf ; """3144"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279986"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood alveolar soft-part sarcoma"""@eng ; skos:notation """CDR0000040304"""^^xsd:string ; skos:altLabel """sarcoma, alveolar soft-part, pediatric"""@eng , """alveolar soft-part sarcoma, pediatric"""@eng , """soft-part sarcoma, alveolar, childhood"""@eng , """alveolar soft-part sarcoma, childhood"""@eng , """sarcoma, alveolar soft-part, childhood"""@eng , """pediatric alveolar soft-part sarcoma"""@eng , """soft-part sarcoma, alveolar, pediatric"""@eng ; rdfs:subClassOf ; """3143"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279985"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood liposarcoma"""@eng ; skos:notation """CDR0000040303"""^^xsd:string ; skos:altLabel """liposarcoma, pediatric"""@eng , """liposarcoma, childhood"""@eng , """sarcoma, lipo-, childhood"""@eng , """pediatric liposarcoma"""@eng ; rdfs:subClassOf ; """3142"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279984"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood malignant hemangiopericytoma"""@eng ; skos:notation """CDR0000040302"""^^xsd:string ; skos:altLabel """malignant hemangiopericytoma, pediatric"""@eng , """pediatric malignant hemangiopericytoma"""@eng , """hemangiopericytoma, malignant, childhood"""@eng , """malignant hemangiopericytoma, childhood"""@eng ; rdfs:subClassOf ; """3141"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279983"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood synovial sarcoma"""@eng ; skos:notation """CDR0000040301"""^^xsd:string ; skos:altLabel """synovial sarcoma, pediatric"""@eng , """pediatric synovial sarcoma"""@eng , """sarcoma, synovial, childhood"""@eng , """synovial sarcoma, childhood"""@eng ; rdfs:subClassOf ; """3140"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279982"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood fibrosarcoma"""@eng ; skos:notation """CDR0000040300"""^^xsd:string ; skos:altLabel """pediatric fibrosarcoma"""@eng , """fibrosarcoma, pediatric"""@eng , """sarcoma, fibro-, childhood"""@eng , """fibrosarcoma, childhood"""@eng ; rdfs:subClassOf ; """3139"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279981"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alprostadil"""@eng ; skos:notation """CDR0000360459"""^^xsd:string ; skos:altLabel """prostaglandin E1"""@eng , """Prostaglandin E1"""@eng , """PGE1"""@eng , """Caverject"""@eng , """MUSE"""@eng , """(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic Acid"""@eng ; skos:definition """The naturally occuring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions. Alprostadil is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=360459&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=360459&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28816\" NCI Thesaurus)"""@eng ; ; """745-65-3"""^^xsd:string ; """2004-03-24"""^^xsd:string ; """C28816"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C2366566"""^^xsd:string ; umls:cui """C0002335"""^^xsd:string ; umls:cui """C0591238"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/ISIS 3521"""@eng ; skos:notation """CDR0000285618"""^^xsd:string ; skos:altLabel """CDDP/dFdC/ISIS-3521"""@eng ; ; ; ; """2003-02-21"""^^xsd:string ; """2003-10-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327905"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP-724,714"""@eng ; skos:notation """CDR0000285619"""^^xsd:string ; skos:definition """An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth. HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285619&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285619&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26648\" NCI Thesaurus)"""@eng ; """2003-02-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26648"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C1327906"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/triptorelin"""@eng ; skos:notation """CDR0000285615"""^^xsd:string ; skos:altLabel """CDX/TRIP"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327902"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyproterone/triptorelin"""@eng ; skos:notation """CDR0000285616"""^^xsd:string ; skos:altLabel """CPTR/TRIP"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327903"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nilutamide/triptorelin"""@eng ; skos:notation """CDR0000285617"""^^xsd:string ; skos:altLabel """ANAN/TRIP"""@eng ; ; ; """2003-02-21"""^^xsd:string ; """2003-02-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327904"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MOAB Hu1D10"""@eng ; skos:notation """CDR0000043647"""^^xsd:string ; """8946"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C1122758"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """troxacitabine"""@eng ; skos:notation """CDR0000043646"""^^xsd:string ; skos:altLabel """L-Oddc"""@eng , """2(1H)-Pyrimidinone, 4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-"""@eng , """BCH-4556"""@eng , """Troxatyl"""@eng ; skos:definition """A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, Troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts proliferation of cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43646&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43646&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1438\" NCI Thesaurus)"""@eng ; """8945"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1438"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """145918-75-8"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0935960"""^^xsd:string ; umls:cui """C0877874"""^^xsd:string ; umls:cui """C1831645"""^^xsd:string ; umls:cui """C0168829"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/paclitaxel/vinorelbine"""@eng ; skos:notation """CDR0000043645"""^^xsd:string ; skos:altLabel """EM/TAX/VNB"""@eng ; ; ; ; """8944"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879350"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody HMFG1"""@eng ; skos:notation """CDR0000043644"""^^xsd:string ; skos:altLabel """MOAB HMFG1, yttrium Y 90"""@eng , """Y90 monoclonal antibody HMFG1"""@eng , """yttrium Y 90 MOAB HMFG1"""@eng , """Y90 MOAB HMFG1"""@eng , """monoclonal antibody HMFG1, yttrium Y 90"""@eng ; """8943"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879349"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/docetaxel/gemcitabine"""@eng ; skos:notation """CDR0000043643"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/TXT"""@eng ; ; ; ; """8942"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879348"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I and II childhood liver cancer"""@eng ; skos:notation """CDR0000043642"""^^xsd:string ; rdfs:subClassOf ; """childhood liver cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """8941"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0879620"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/tetanus peptide melanoma vaccine/tyrosinase peptide"""@eng ; skos:notation """CDR0000043641"""^^xsd:string ; skos:altLabel """gp100/Tet p/TYRP"""@eng ; ; ; ; """8940"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879347"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus/CD40-ligand"""@eng ; skos:notation """CDR0000043640"""^^xsd:string ; skos:altLabel """ADENO/CD40-L"""@eng ; ; ; """8939"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879346"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib"""@eng ; skos:notation """CDR0000043649"""^^xsd:string ; skos:altLabel """4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy]"""@eng , """ZD1839"""@eng , """4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline"""@eng , """ZD 1839"""@eng , """Iressa"""@eng ; skos:definition """An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43649&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43649&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1855\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """8948"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """184475-35-2"""^^xsd:string ; """715055"""^^xsd:string ; """C1855"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """61187"""^^xsd:string ; umls:cui """C1122962"""^^xsd:string ; umls:cui """C0879396"""^^xsd:string ; umls:cui """C0919281"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 humanized epratuzumab"""@eng ; skos:notation """CDR0000043648"""^^xsd:string ; skos:altLabel """Yttrium Y 90 Humanized Monoclonal Antibody LL2"""@eng , """Y 90 MoAb LL2"""@eng , """MOAB LL2, yttrium Y 90"""@eng , """Y 90 monoclonal antibody LL2"""@eng , """Y 90 Humanized Monoclonal Antibody LL2"""@eng , """Y 90 epratuzumab"""@eng , """Y-90 MOAB LL2"""@eng , """Y90 MOAB LL2"""@eng , """epratuzumab, yttrium Y 90"""@eng , """Y90 Humanized Epratuzumab"""@eng , """yttrium Y 90 MOAB LL2"""@eng , """monoclonal antibody LL2, yttrium Y 90"""@eng , """yttrium Y-90 epratuzumab"""@eng ; skos:definition """A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD222, delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43648&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43648&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2582\" NCI Thesaurus)"""@eng ; ; """8947"""^^xsd:string ; """C2582"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879352"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent inverted papilloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040774"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus inverted papilloma, recurrent"""@eng , """inverted papilloma of the paranasal sinus and nasal cavity, recurrent"""@eng , """paranasal sinus and nasal cavity inverted papilloma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Cancer stage"""^^xsd:string ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """3733"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C0280420"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent midline lethal granuloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040775"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus midline lethal granuloma, recurrent"""@eng , """midline lethal granuloma of the paranasal sinus and nasal cavity, recurrent"""@eng , """paranasal sinus and nasal cavity midline lethal granuloma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3736"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280421"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atypical squamous cells of undetermined significance"""@eng ; skos:notation """CDR0000398210"""^^xsd:string ; skos:altLabel """ASCUS"""@eng ; rdfs:subClassOf ; """2004-10-25"""^^xsd:string ; """2004-10-15"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0521184"""^^xsd:string ; umls:tui """T025"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II adult T-cell leukemia/lymphoma"""@eng ; skos:notation """CDR0000040778"""^^xsd:string ; skos:altLabel """stage II HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """adult T-cell leukemia/lymphoma, stage II"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, stage II"""@eng ; rdfs:subClassOf ; """adult T-cell leukemia/lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3740"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280424"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult T-cell leukemia/lymphoma"""@eng ; skos:notation """CDR0000040779"""^^xsd:string ; skos:altLabel """stage III HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """adult T-cell leukemia/lymphoma, stage III"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, stage III"""@eng ; rdfs:subClassOf ; """adult T-cell leukemia/lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3741"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280425"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cordycepin/pentostatin"""@eng ; skos:notation """CDR0000042668"""^^xsd:string ; skos:altLabel """COR/DCF"""@eng ; ; ; """6430"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393065"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/paclitaxel"""@eng ; skos:notation """CDR0000042669"""^^xsd:string ; skos:altLabel """FLAVO/TAX"""@eng ; ; ; """6431"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393066"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/ritonavir/stavudine"""@eng ; skos:notation """CDR0000042666"""^^xsd:string ; skos:altLabel """d4T/IFN-A/RIT"""@eng ; ; ; ; """6428"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393064"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cordycepin"""@eng ; skos:notation """CDR0000042667"""^^xsd:string ; skos:altLabel """COR"""@eng , """Cordycepine"""@eng , """3'-Deoxyadenosine-5'-triphosphate"""@eng , """3-dAdenosine"""@eng , """9-Cordyceposidoadenine"""@eng , """3'-dA-CE Phosphoramidite"""@eng , """3'-Deoxyadenosine"""@eng , """Kordicepin"""@eng ; skos:definition """A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic activity. Cordycepin is an adenosine analogue, which is readily phosphorylated to its mono-, di-, and triphosphate intracellularly. Triphosphate cordycepin can be incorporated into RNA, and inhibits transcription elongation and RNA synthesis due to the absence of a hydroxyl moiety at the 3' position. Because it can be converted to an inactive metabolite by adenosine deaminase, this agent must be administered with an adenosine deaminase inhibitor in order to be effective. Cordycepin has displayed cytotoxicity against some leukemic cell lines in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42667&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42667&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1057\" NCI Thesaurus)"""@eng ; ; """6429"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """63984"""^^xsd:string ; """C1057"""^^xsd:string ; """52325"""^^xsd:string ; """401022"""^^xsd:string ; """627047"""^^xsd:string ; """73-03-0"""^^xsd:string ; umls:cui """C0046803"""^^xsd:string ; umls:cui """C0056331"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dendritic cell-G9-209-2M peptide vaccine"""@eng ; skos:notation """CDR0000042664"""^^xsd:string ; skos:altLabel """dendritic cell G9-209-2M peptide vaccine"""@eng ; """6426"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393063"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ritonavir"""@eng ; skos:notation """CDR0000042665"""^^xsd:string ; skos:altLabel """RIT"""@eng , """Norvir"""@eng ; skos:definition """A synthetic aromatic derivative with antiviral properties. Ritonavir is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases, thereby preventing the cleavage of Gag-Pol polyproteins and resulting in the production of noninfectious viral particles. This agent is more active against HIV-1. Because ritonavir targets the HIV replication cycle after translation and before assembly, it is active in chronically infected cells that generally are not affected by nucleoside reverse transcriptase inhibitors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42665&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42665&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1609\" NCI Thesaurus)"""@eng ; ; ; """6427"""^^xsd:string ; """693184"""^^xsd:string ; """C1609"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0678152"""^^xsd:string ; umls:cui """C0292818"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HER-2/neu peptide vaccine"""@eng ; skos:notation """CDR0000042662"""^^xsd:string ; skos:altLabel """HER-2"""@eng ; skos:definition """A cancer vaccine comprised of peptides derived from the extracellular domain of the tumor-associated antigen Her-2/neu with potential antineoplastic activity. HER-2/neu peptide vaccine may induce antibodies with anti-tumor activity and may also elicit a specific CD8 T-cell response against specific tumor cell types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42662&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42662&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2537\" NCI Thesaurus)"""@eng ; ; ; ; """C2537"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """6416"""^^xsd:string ; """2006-08-25"""^^xsd:string ; umls:cui """C0879250"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dendritic cell-MART-1 peptide vaccine"""@eng ; skos:notation """CDR0000042663"""^^xsd:string ; skos:altLabel """dendritic cell MART-1 peptide vaccine"""@eng , """MART-1 peptide-pulsed dendritic cell vaccine"""@eng , """Vaccine, dendritic cell-MART-1 peptide"""@eng , """MART-1 peptide-pulsed DC vaccine"""@eng ; skos:definition """A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of MART-1 (melanoma antigen recognized by T-cells), an antigen expressed by melanoma cells. When the altered dendritic cells are returned to the patient, they stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42663&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42663&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2426\" NCI Thesaurus)"""@eng ; """6425"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2426"""^^xsd:string ; """2006-08-01"""^^xsd:string ; umls:cui """C0393062"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/irinotecan"""@eng ; skos:notation """CDR0000042660"""^^xsd:string ; skos:altLabel """BCNU/CPT-11"""@eng ; ; ; """6412"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393059"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisolone/vincristine"""@eng ; skos:notation """CDR0000042661"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/PRDL/VCR/VP-16"""@eng ; ; ; ; ; ; ; """6414"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393060"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stromal cell-derived factor 1"""@eng ; skos:notation """CDR0000471252"""^^xsd:string ; skos:altLabel """CXCL12"""@eng , """Chemokine (C-X-C Motif) Ligand 12"""@eng , """Pre-B Cell Growth Stimulating Factor"""@eng , """PBSF"""@eng , """SDF-1"""@eng , """hIRH"""@eng ; """C28774"""^^xsd:string ; """2006-03-24"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0218504"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SR31747A"""@eng ; skos:notation """CDR0000471256"""^^xsd:string ; skos:definition """A synthetic peripheral sigma receptor ligand with immunomodulatory and potential antitumor activities. Although the exact mechanism by which SR31747A exerts its antitumor effects has not been fully established, SR31747A binds to and inhibits the sigma1 receptor (SR31747A-binding protein-1 or SR-BP1), human sterol isomerase (emopamil-binding protein) and the sigma2 receptor, which may result in a reduction in tumor cell proliferation and tumor cell apoptosis. In addition, this agent inhibits the production of pro-inflammatory cytokines while increasing anti-inflammatory cytokines. Upregulated in various cancers, the sigma1 and sigma2 receptors and human sterol isomerase are proteins that are involved in the regulation of cell proliferation and survival. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471256&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=471256&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61435\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-03-07"""^^xsd:string ; """C61435"""^^xsd:string ; """2006-08-01"""^^xsd:string ; umls:cui """C1831763"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide phosphate/topotecan"""@eng ; skos:notation """CDR0000042802"""^^xsd:string ; skos:altLabel """ETOP/TOPO"""@eng ; ; ; """6601"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677751"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000042803"""^^xsd:string ; skos:altLabel """DOX/IFF/VP-16"""@eng ; ; ; ; """6602"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677752"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/procarbazine/teniposide"""@eng ; skos:notation """CDR0000039343"""^^xsd:string ; skos:altLabel """MVPD-26"""@eng , """DM/MTX/PCB/VM-26"""@eng ; ; ; ; ; """1979"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279211"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/lomustine/vinblastine"""@eng ; skos:notation """CDR0000038871"""^^xsd:string ; skos:altLabel """VIC"""@eng , """CCNU/IFF/VBL"""@eng ; ; ; ; """1360"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000039342"""^^xsd:string ; skos:altLabel """DOX/IFF/VCR"""@eng ; ; ; ; """1978"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279210"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic myeloproliferative disorders"""@eng ; skos:notation """CDR0000039347"""^^xsd:string ; skos:altLabel """Myeloproliferative disorders (incl. CML)"""@eng ; rdfs:subClassOf ; """2003-02-05"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1983"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1292778"""^^xsd:string ; umls:cui """C0027022"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000286994"""^^xsd:string ; skos:altLabel """chronic myelogenous leukemia, childhood"""@eng ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """chronic myeloproliferative disorders"""^^xsd:string ; """chronic myelogenous leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1327920"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neoplasm of uncertain malignant potential"""@eng ; skos:notation """CDR0000286993"""^^xsd:string ; rdfs:subClassOf ; """2003-02-21"""^^xsd:string ; """2003-02-21"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0154129"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """everolimus"""@eng ; skos:notation """CDR0000372905"""^^xsd:string ; skos:altLabel """42-O-(2-Hydroxy)ethyl Rapamycin"""@eng , """Certican"""@eng , """RAD001"""@eng ; skos:definition """A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=372905&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=372905&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48387\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """2004-05-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48387"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0962969"""^^xsd:string ; umls:cui """C1174751"""^^xsd:string ; umls:cui """C0541315"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phytoestrogen therapy"""@eng ; skos:notation """CDR0000372904"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1541283"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/talabostat"""@eng ; skos:notation """CDR0000372907"""^^xsd:string ; skos:altLabel """PT-100/TXT"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541285"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """talabostat mesylate"""@eng ; skos:notation """CDR0000372906"""^^xsd:string ; skos:altLabel """PT-100"""@eng ; skos:definition """The mesylate salt of an orally active small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell- dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=372906&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=372906&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48264\" NCI Thesaurus)"""@eng ; ; ; ; ; """Drug/agent"""^^xsd:string ; """C48264"""^^xsd:string ; """2006-07-20"""^^xsd:string ; """2004-05-28"""^^xsd:string ; umls:cui """C1311786"""^^xsd:string ; umls:cui """C1765344"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dietary modification"""@eng ; skos:notation """CDR0000372901"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0086153"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nutritional supplementation"""@eng ; skos:notation """CDR0000372900"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0242297"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alternative product therapy"""@eng ; skos:notation """CDR0000372903"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C1541282"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diflomotecan"""@eng ; skos:notation """CDR0000372902"""^^xsd:string ; skos:altLabel """BN-80915"""@eng , """BN80915"""@eng ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541796"""^^xsd:string ; umls:cui """C0965785"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HuPAM4"""@eng ; skos:notation """CDR0000425351"""^^xsd:string ; skos:altLabel """MOAB HuPAM4"""@eng ; skos:definition """A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1 with potential antineoplastic activity. Monoclonal antibody HuPAM4 (mAb HuPAM4) binds to cells expressing MUC1 antigen; mAb HuPAM4 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425351&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425351&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48408\" NCI Thesaurus)"""@eng ; """2005-03-24"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48408"""^^xsd:string ; umls:cui """C1541527"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """myelodysplastic/myeloproliferative diseases"""@eng ; skos:notation """CDR0000335173"""^^xsd:string ; skos:altLabel """Myelodysplastic/myeloproliferative diseases"""@eng , """MDS/MPD"""@eng ; rdfs:subClassOf ; """2003-09-24"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1301355"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 DOTA monoclonal antibody HuPAM4"""@eng ; skos:notation """CDR0000425350"""^^xsd:string ; skos:altLabel """Y90 DOTA MOAB HuPAM4"""@eng ; skos:definition """A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425350&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425350&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48429\" NCI Thesaurus)"""@eng ; """2005-03-24"""^^xsd:string ; """C48429"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C1541526"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zoledronate"""@eng ; skos:notation """CDR0000042507"""^^xsd:string ; skos:altLabel """[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid"""@eng , """ZOL 446"""@eng , """NDC-Zoledronate"""@eng , """Zometa"""@eng , """ZOLE"""@eng , """CGP 42446"""@eng , """CGP42446A"""@eng , """zoledronic acid"""@eng ; skos:definition """The brand name for zoledronic acid, a bisphosphonic imidazol compound which inhibits osteoclastic bone resorption. Although its mechanisms of action is yet to be fully characterized, zoledronic acid appears to directly inhibit osteoclast function and trigger osteoclast apoptotic cell death, thereby decreasing the osteoclast stimulation and bone calcium loss induced by various tumor-associated cytokines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42507&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42507&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1699\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """6117"""^^xsd:string ; """118072-93-8"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """C1699"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """721517"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0528130"""^^xsd:string ; umls:cui """C1521936"""^^xsd:string ; umls:cui """C0257685"""^^xsd:string ; umls:cui """C0939788"""^^xsd:string ; umls:cui """C0392938"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039349"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/PRED/VCR"""@eng , """OAP-BLEO"""@eng ; ; ; ; ; """1985"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279216"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, chronic myeloproliferative disorders"""@eng ; skos:notation """CDR0000039348"""^^xsd:string ; skos:altLabel """chronic myeloproliferative disorders stage"""@eng ; rdfs:subClassOf ; """2003-02-05"""^^xsd:string ; """1984"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279215"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III pancreatic cancer"""@eng ; skos:notation """CDR0000042505"""^^xsd:string ; skos:altLabel """pancreatic cancer, stage III"""@eng , """pancreas cancer, stage III"""@eng , """stage III pancreas cancer"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """61"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1167722"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DOTAP:chol-Fus1 liposome complex"""@eng ; skos:notation """CDR0000372908"""^^xsd:string ; skos:altLabel """DOTAP:chol-Fus1"""@eng , """DOTAP:cholesterol-Fus1"""@eng , """DOTAP:cholesterol-Fus1 liposome complex"""@eng ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541286"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000042279"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IFN-A/IL-2"""@eng ; ; ; ; ; """5525"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338216"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/zinc oxide"""@eng ; skos:notation """CDR0000042278"""^^xsd:string ; skos:altLabel """IL-2/ZnO"""@eng ; ; ; """5524"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338215"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AQ4N"""@eng ; skos:notation """CDR0000393464"""^^xsd:string ; """2004-09-25"""^^xsd:string ; """2004-09-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0299316"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant MAGE-3.1 antigen"""@eng ; skos:notation """CDR0000042271"""^^xsd:string ; skos:altLabel """MAGEA3"""@eng , """MAGE-3.1"""@eng , """MAGE-3"""@eng ; skos:definition """A recombinant tumor-specific melanoma antigen. Vaccination with recombinant MAGE-3.1 antigen may induce a host immune response against MAGE-expressing cells, resulting in antitumoral T cell-mediated cytotoxicity. MAGE-expressing cells are found in melanoma, non-small-cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, transitional cell carcinoma of the bladder, and esophageal carcinoma. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42271&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42271&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38724\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """C38724"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """5518"""^^xsd:string ; umls:cui """C1510427"""^^xsd:string ; umls:cui """C0677907"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PADRE 965.10"""@eng ; skos:notation """CDR0000042270"""^^xsd:string ; skos:altLabel """15 Amino Acid Helper Peptide"""@eng , """PADRE 96510"""@eng ; skos:definition """Pan-DR epitope (PADRE) 965.10 is a helper peptide. PADRE peptides have been shown the capacity to deliver help for antibody responses in vivo. They were also found to be able to provide significant helper T-cell activity in vivo. Acts as an adjuvant. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42270&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42270&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2397\" NCI Thesaurus)"""@eng ; ; ; """5517"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """C2397"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0338209"""^^xsd:string ; umls:cui """C1527166"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """orchiectomy"""@eng ; skos:notation """CDR0000042273"""^^xsd:string ; ; rdfs:subClassOf ; """552"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0029189"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-3/PADRE 965.10"""@eng ; skos:notation """CDR0000042272"""^^xsd:string ; skos:altLabel """MAGE3/PADRE96510"""@eng ; ; ; """5519"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879247"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human papillomavirus 16 E7 peptide"""@eng ; skos:notation """CDR0000042275"""^^xsd:string ; skos:altLabel """HPV16 E7"""@eng , """HPV-16 E7"""@eng ; ; """5521"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-27"""^^xsd:string ; umls:cui """C3241978"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """synthetic human papillomavirus 16 E6 peptide"""@eng ; skos:notation """CDR0000042274"""^^xsd:string ; skos:altLabel """HPV16 E6"""@eng , """HPV-16 E6"""@eng , """human papillomavirus 16 E6 peptide"""@eng ; skos:definition """A synthetic peptide sequence of human papillomavirus (HPV) type 16 oncoprotein E6. The E6 oncoprotein is implicated in the tumorigenesis of cervical carcinoma. Vaccination with HPV 16 E6 peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42274&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42274&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38726\" NCI Thesaurus)"""@eng ; """5520"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """C38726"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C3146227"""^^xsd:string ; umls:cui """C0133938"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zinc oxide"""@eng ; skos:notation """CDR0000042277"""^^xsd:string ; skos:altLabel """ZnO"""@eng ; ; """5523"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0043491"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human papillomavirus 16 E7 peptide/PADRE 965.10"""@eng ; skos:notation """CDR0000042276"""^^xsd:string ; skos:altLabel """HPV16 E7/PADRE96510"""@eng ; ; ; """5522"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338214"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/lenalidomide"""@eng ; skos:notation """CDR0000405858"""^^xsd:string ; skos:altLabel """CC 5013/PS-341"""@eng ; ; ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541396"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TRAIL-R1 monoclonal antibody"""@eng ; skos:notation """CDR0000405851"""^^xsd:string ; skos:altLabel """MOAB TRAIL-R1"""@eng , """TRM-1"""@eng , """monoclonal antibody TRAIL-R1"""@eng ; """2006-10-09"""^^xsd:string ; """2004-11-05"""^^xsd:string ; umls:cui """C1541394"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HuMax-CD20"""@eng ; skos:notation """CDR0000405853"""^^xsd:string ; skos:altLabel """HuMax-CD20 monoclonal antibody"""@eng , """MOAB HuMax-CD20"""@eng , """HuMax-CD20"""@eng ; """2004-11-05"""^^xsd:string ; """2004-11-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541395"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/floxuridine"""@eng ; skos:notation """CDR0000042899"""^^xsd:string ; skos:altLabel """CBDCA/FUDR"""@eng ; ; ; """6711"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677825"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/floxuridine"""@eng ; skos:notation """CDR0000042898"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/FUDR"""@eng ; ; ; ; """6710"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677824"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/sargramostim/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000042895"""^^xsd:string ; skos:altLabel """GM-CSF/IFA/TRP-1"""@eng ; ; ; ; """2003-10-23"""^^xsd:string ; """6707"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677822"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/interleukin-2/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000042894"""^^xsd:string ; skos:altLabel """IFA/IL-2/TRP-1"""@eng ; ; ; ; """2003-10-23"""^^xsd:string ; """6706"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677821"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vorozole"""@eng ; skos:notation """CDR0000042897"""^^xsd:string ; skos:altLabel """R 83 842"""@eng , """Rivizor"""@eng ; """6709"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-15"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0286224"""^^xsd:string ; umls:cui """C0281232"""^^xsd:string ; umls:cui """C1710640"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/interleukin-12/tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000042896"""^^xsd:string ; skos:altLabel """IFA/IL-12/TRP-1"""@eng ; ; ; ; """2003-10-23"""^^xsd:string ; """6708"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677823"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000042891"""^^xsd:string ; skos:altLabel """GM-CSF/IFA/TYRP"""@eng ; ; ; ; """6703"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677819"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/sargramostim"""@eng ; skos:notation """CDR0000042890"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/IFA"""@eng ; ; ; ; """6702"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677818"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tyrosinase-related protein-1"""@eng ; skos:notation """CDR0000042893"""^^xsd:string ; skos:altLabel """tyrosinase related protein-1"""@eng , """gp75 antigen"""@eng , """TRP-1"""@eng , """tyrosinase-related protein 1"""@eng ; ; ; ; ; ; ; ; """6705"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0700256"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """incomplete Freund's adjuvant/interleukin-12/tyrosinase peptide"""@eng ; skos:notation """CDR0000042892"""^^xsd:string ; skos:altLabel """IFA/IL-12/TYRP"""@eng ; ; ; ; """6704"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677820"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP-547,632"""@eng ; skos:notation """CDR0000391298"""^^xsd:string ; """2004-09-25"""^^xsd:string ; """2004-09-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1433879"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mycophenolate mofetil/prednisone/tacrolimus"""@eng ; skos:notation """CDR0000380740"""^^xsd:string ; skos:altLabel """FK506/MMF/PRED"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541588"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amrubicin/irinotecan"""@eng ; skos:notation """CDR0000443684"""^^xsd:string ; skos:altLabel """AMR/CPT-11"""@eng ; ; ; """2005-08-09"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-12"""^^xsd:string ; umls:cui """C1831700"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amrubicin hydrochloride"""@eng ; skos:notation """CDR0000443682"""^^xsd:string ; skos:altLabel """Calsed"""@eng , """AMR"""@eng , """Amirubicin Hydrochloride"""@eng ; skos:definition """The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=443682&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=443682&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47948\" NCI Thesaurus)"""@eng ; ; """2005-08-12"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-04-28"""^^xsd:string ; """C47948"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1706800"""^^xsd:string ; umls:cui """C1706799"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/multi-epitope melanoma peptide vaccine"""@eng ; skos:notation """CDR0000380745"""^^xsd:string ; skos:altLabel """ISA-51/MULTI-EP MP VAC"""@eng ; ; """2004-07-23"""^^xsd:string ; """2004-07-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541589"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MLN2704"""@eng ; skos:notation """CDR0000299464"""^^xsd:string ; skos:altLabel """MLN591DM1"""@eng , """DM1-conjugated monoclonal antibody MLN591"""@eng , """maytansinoid -1 conjugated with MLN591 monoclonal antibody"""@eng ; skos:definition """An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299464&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=299464&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26660\" NCI Thesaurus)"""@eng ; """2003-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26660"""^^xsd:string ; """2006-08-29"""^^xsd:string ; umls:cui """C1327945"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/sargramostim"""@eng ; skos:notation """CDR0000380749"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51"""@eng ; ; """2004-07-23"""^^xsd:string ; """2004-07-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541590"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lumiliximab"""@eng ; skos:notation """CDR0000299460"""^^xsd:string ; skos:altLabel """IDEC-152 monoclonal antibody"""@eng , """IDEC-152"""@eng , """MOAB IDEC-152"""@eng , """anti-CD23 monoclonal antibody"""@eng ; ; """2003-03-24"""^^xsd:string ; """2005-03-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327944"""^^xsd:string ; umls:cui """C3467790"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide phosphate"""@eng ; skos:notation """CDR0000346890"""^^xsd:string ; skos:altLabel """CBDCA/CTX/ETOP"""@eng ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-11-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328113"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VEGF Trap"""@eng ; skos:notation """CDR0000038652"""^^xsd:string ; skos:altLabel """VEGF Trap R1R2"""@eng , """vascular endothelial growth factor trap"""@eng ; skos:definition """A protein comprised of segments of the extracellular domains of human vascular endothelial growth factor receptors 1 (VEGFR1) and 2 (VEGFR2) fused to the constant region (Fc) of human IgG1. VEGF trap binds to vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, thereby preventing VEGF from binding to its cell receptors. Disruption of this cell receptor binding results in the inhibition of angiogenesis and metastasis, and tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38652&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38652&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2682\" NCI Thesaurus)"""@eng ; """11298"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2682"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C1134659"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/filgrastim/prednisone/vincristine"""@eng ; skos:notation """CDR0000041121"""^^xsd:string ; skos:altLabel """CTX/DOX/G-CSF/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4164"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280717"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-10.A2/Melan-A/NY-ESO-1 peptide vaccine/tyrosinase peptide"""@eng ; skos:notation """CDR0000038650"""^^xsd:string ; skos:altLabel """MAGE10.A2/MEL-A/NY-ESO-1 peptide/TYRP"""@eng ; ; ; ; """11296"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-18"""^^xsd:string ; umls:cui """C1134657"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAGE-10.A2/Melan-A/NY-ESO-1 peptide vaccine/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000038651"""^^xsd:string ; skos:altLabel """GM-CSF/MAGE10.A2/MEL-A/NY-ESO-1 peptide/TYRP"""@eng ; ; ; ; ; """11297"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-18"""^^xsd:string ; umls:cui """C1134658"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody D6.12"""@eng ; skos:notation """CDR0000038656"""^^xsd:string ; skos:altLabel """MOAB D6.12"""@eng ; """11300"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134661"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """occult non-small cell lung cancer"""@eng ; skos:notation """CDR0000041125"""^^xsd:string ; skos:altLabel """NSCLC, occult"""@eng , """occult NSCLC"""@eng , """occult non-oat cell lung cancer"""@eng , """nonsmall cell lung cancer, occult"""@eng , """occult nonsmall cell lung cancer"""@eng , """non-oat cell lung cancer, occult"""@eng , """non-small cell lung cancer, occult"""@eng , """lung cancer, non-oat cell, occult"""@eng , """lung cancer, nonsmall cell, occult"""@eng , """nonsmall-cell lung cancer, occult"""@eng , """occult nonsmall-cell lung cancer"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """42"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278503"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000041126"""^^xsd:string ; skos:altLabel """MOAB Lym-1"""@eng , """IgG2a murine monoclonal antibody Lym-1"""@eng , """monoclonal antibody Lym-1, IgG2a murine"""@eng , """Lym-1"""@eng ; skos:definition """A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells. When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues. This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41126&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41126&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1561\" NCI Thesaurus)"""@eng ; ; """4200"""^^xsd:string ; """620858"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """3097"""^^xsd:string ; """C1561"""^^xsd:string ; umls:cui """C0280726"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/etoposide"""@eng ; skos:notation """CDR0000041127"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/VP-16"""@eng ; ; ; ; """4201"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280727"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/idarubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041128"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/IDA/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; """4202"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280728"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dactinomycin/idarubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000041129"""^^xsd:string ; skos:altLabel """DACT/IDA/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """4203"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280729"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody C-58"""@eng ; skos:notation """CDR0000038658"""^^xsd:string ; """11303"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134662"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-TRICOM vaccine"""@eng ; skos:notation """CDR0000038659"""^^xsd:string ; skos:altLabel """Vaccinia-TRICOM"""@eng , """rV-TRICOM"""@eng ; skos:definition """A vaccine consisting of recombinant vaccinia virus encoding a triad of costimulatory molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with vaccinia-TRICOM stimulates the host immune system to mount a non-specific T-cell response. With the addition of a tumor-associated antigen peptide, this vaccine may enhance a tumor-specific immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38659&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38659&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2685\" NCI Thesaurus)"""@eng ; ; ; """11304"""^^xsd:string ; """C2685"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """9710"""^^xsd:string ; """708039"""^^xsd:string ; umls:cui """C1099097"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000040530"""^^xsd:string ; skos:altLabel """adult diffuse mixed cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3426"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280161"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult diffuse large cell lymphoma"""@eng ; skos:notation """CDR0000040531"""^^xsd:string ; skos:altLabel """adult diffuse large cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3427"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280162"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, high grade, stage III adult"""@eng ; skos:notation """CDR0000040532"""^^xsd:string ; skos:altLabel """NHL, high grade, stage III adult"""@eng , """adult non-Hodgkin's lymphoma, high grade, stage III"""@eng , """high-grade, stage III adult NHL"""@eng , """adult NHL, stage III, high grade"""@eng , """lymphoma, high grade, stage III adult non-Hodgkin's"""@eng ; """2005-01-21"""^^xsd:string ; """3428"""^^xsd:string ; umls:cui """C0280163"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult immunoblastic large cell lymphoma"""@eng ; skos:notation """CDR0000040533"""^^xsd:string ; skos:altLabel """adult immunoblastic large cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3429"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280164"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000040534"""^^xsd:string ; skos:altLabel """adult lymphoblastic lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3430"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280165"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000040535"""^^xsd:string ; skos:altLabel """stage III adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng , """adult small noncleaved cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3431"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280166"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-Hodgkin's lymphoma, low grade, stage IV adult"""@eng ; skos:notation """CDR0000040536"""^^xsd:string ; skos:altLabel """lymphoma, low grade, stage IV adult non-Hodgkin's"""@eng , """NHL, low grade, stage IV adult"""@eng , """non-Hodgkin's lymphoma, low grade, metastatic adult"""@eng , """adult non-Hodgkin's lymphoma, low grade, stage IV"""@eng , """NHL, low grade, metastatic adult"""@eng , """adult non-Hodgkin's lymphoma, low grade, metastatic"""@eng , """low-grade, metastatic adult non-Hodgkin's lymphoma"""@eng , """adult NHL, stage IV, low grade"""@eng , """lymphoma, low grade, metastatic adult non-Hodgkin's"""@eng , """adult NHL, metastatic, low grade"""@eng , """low-grade, stage IV adult NHL"""@eng , """low-grade, metastatic adult NHL"""@eng ; """2005-01-21"""^^xsd:string ; """3432"""^^xsd:string ; umls:cui """C0280167"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV small lymphocytic lymphoma"""@eng ; skos:notation """CDR0000040537"""^^xsd:string ; skos:altLabel """small lymphocytic lymphoma, stage IV"""@eng , """metastatic small lymphocytic lymphoma"""@eng , """small lymphocytic lymphoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3433"""^^xsd:string ; """2004-05-17"""^^xsd:string ; """small lymphocytic lymphoma"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0855101"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000040538"""^^xsd:string ; skos:altLabel """follicular small cleaved cell lymphoma, stage IV"""@eng , """metastatic follicular small cleaved cell lymphoma"""@eng , """follicular small cleaved cell lymphoma, metastatic"""@eng , """stage IV grade I follicular small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3434"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280169"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV grade 2 follicular lymphoma"""@eng ; skos:notation """CDR0000040539"""^^xsd:string ; skos:altLabel """stage IV grade II follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma, stage IV"""@eng , """metastatic follicular mixed cell lymphoma"""@eng , """follicular mixed cell lymphoma, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3435"""^^xsd:string ; """2005-01-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280170"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VTP195183"""@eng ; skos:notation """CDR0000462650"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C1831726"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/docetaxel"""@eng ; skos:notation """CDR0000299071"""^^xsd:string ; skos:altLabel """17-AAG/TXT"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327941"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sulindac"""@eng ; skos:notation """CDR0000041538"""^^xsd:string ; skos:altLabel """Sulindac Sulfoxide"""@eng , """Sudac"""@eng , """Reumyl"""@eng , """Aflodac"""@eng , """MK-231"""@eng , """Novo-Sundac"""@eng , """(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid"""@eng , """Apo-Sulin"""@eng , """Imbaral"""@eng , """Sulinol"""@eng , """Clinoril"""@eng , """Arthrocine"""@eng , """Clisundac"""@eng , """Sulreuma"""@eng , """Artribid"""@eng , """cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid"""@eng , """Reumofil"""@eng , """Citireuma"""@eng , """SULIN"""@eng , """Algocetil"""@eng ; skos:definition """A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41538&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41538&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C850\" NCI Thesaurus)"""@eng ; ; ; ; ; """C850"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-22"""^^xsd:string ; """38194-50-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0038792"""^^xsd:string ; umls:cui """C1515048"""^^xsd:string ; umls:cui """C1515042"""^^xsd:string ; umls:cui """C1515038"""^^xsd:string ; umls:cui """C1515039"""^^xsd:string ; umls:cui """C1515041"""^^xsd:string ; umls:cui """C0733670"""^^xsd:string ; umls:cui """C1515043"""^^xsd:string ; umls:cui """C0591267"""^^xsd:string ; umls:cui """C1515045"""^^xsd:string ; umls:cui """C1515044"""^^xsd:string ; umls:cui """C1515047"""^^xsd:string ; umls:cui """C1515046"""^^xsd:string ; umls:cui """C1515050"""^^xsd:string ; umls:cui """C1515040"""^^xsd:string ; umls:cui """C1515049"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """3-AP/cytarabine"""@eng ; skos:notation """CDR0000315408"""^^xsd:string ; skos:altLabel """3AP/ARA-C"""@eng ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327987"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038908"""^^xsd:string ; skos:altLabel """nasopharyngeal cancer, metastatic"""@eng , """nasopharynx cancer, stage IV"""@eng , """nasopharyngeal cancer, stage IV"""@eng , """nasopharynx cancer, metastatic"""@eng , """metastatic nasopharyngeal cancer"""@eng ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1406"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1377919"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038909"""^^xsd:string ; skos:altLabel """nasopharynx cancer, recurrent"""@eng , """nasopharyngeal cancer, recurrent"""@eng ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1408"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278952"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I breast cancer"""@eng ; skos:notation """CDR0000038902"""^^xsd:string ; skos:altLabel """breast cancer, stage I"""@eng ; rdfs:subClassOf ; """2003-06-16"""^^xsd:string ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """14"""^^xsd:string ; """progesterone receptor status unknown"""^^xsd:string ; """premenopausal"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """estrogen receptor status unknown"""^^xsd:string ; """estrogen receptor positive"""^^xsd:string ; """bilateral breast cancer"""^^xsd:string ; """estrogen receptor negative"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """performance status 2"""^^xsd:string ; """progesterone receptor negative"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """postmenopausal"""^^xsd:string ; """progesterone receptor positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278485"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior biologic therapy"""@eng ; skos:notation """CDR0000038903"""^^xsd:string ; """1401"""^^xsd:string ; umls:cui """C0278947"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior chemotherapy for advanced disease"""@eng ; skos:notation """CDR0000038900"""^^xsd:string ; """1394"""^^xsd:string ; umls:cui """C0278940"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior anthracycline therapy"""@eng ; skos:notation """CDR0000038901"""^^xsd:string ; skos:altLabel """anthracyclines"""@eng ; """1395"""^^xsd:string ; umls:cui """C0278941"""^^xsd:string ; umls:tui """T201"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038906"""^^xsd:string ; skos:altLabel """nasopharyngeal cancer, stage II"""@eng , """nasopharynx cancer, stage II"""@eng ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1404"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278949"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038907"""^^xsd:string ; skos:altLabel """nasopharyngeal cancer, stage III"""@eng , """nasopharynx cancer, stage III"""@eng ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1405"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278950"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038904"""^^xsd:string ; skos:altLabel """Nasopharyngeal cancer"""@eng , """nasopharynx cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1402"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238301"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I nasopharyngeal cancer"""@eng ; skos:notation """CDR0000038905"""^^xsd:string ; skos:altLabel """nasopharynx cancer, stage I"""@eng , """nasopharyngeal cancer, stage I"""@eng ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1403"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278948"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciclopirox olamine"""@eng ; skos:notation """CDR0000514473"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-10-21"""^^xsd:string ; umls:cui """C0126169"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """screening and diagnostic assessment"""@eng ; skos:notation """CDR0000042472"""^^xsd:string ; """5931"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0879249"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dialysis"""@eng ; skos:notation """CDR0000042471"""^^xsd:string ; """5925"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0011946"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/daunorubicin"""@eng ; skos:notation """CDR0000042470"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DNR"""@eng ; ; ; ; """5920"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338365"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/filgrastim/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000042477"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/TAX/TOPO"""@eng ; ; ; ; ; """5947"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338368"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000042476"""^^xsd:string ; skos:altLabel """CBDCA/TAX/TOPO"""@eng ; ; ; ; """5946"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338367"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/interleukin-2/paclitaxel/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000042475"""^^xsd:string ; skos:altLabel """CDDP/IL-2/TAX/TIL"""@eng ; ; ; ; ; """5945"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338366"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/fludarabine"""@eng ; skos:notation """CDR0000340992"""^^xsd:string ; skos:altLabel """AL/FAMP"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328085"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anxiety disorder"""@eng ; skos:notation """CDR0000042479"""^^xsd:string ; rdfs:subClassOf ; """5966"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0003469"""^^xsd:string ; umls:tui """T048"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ranpirnase/tamoxifen"""@eng ; skos:notation """CDR0000042478"""^^xsd:string ; skos:altLabel """P30/TMX"""@eng ; ; ; """2003-08-12"""^^xsd:string ; """5948"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338369"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """talaporfin sodium"""@eng ; skos:notation """CDR0000258313"""^^xsd:string ; skos:altLabel """LS11"""@eng , """Laserphyrin"""@eng , """NPe6"""@eng , """ME2906"""@eng , """mono-L-aspartyl chlorin e6"""@eng ; skos:definition """An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258313&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=258313&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26675\" NCI Thesaurus)"""@eng ; """11486"""^^xsd:string ; """C26675"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328648"""^^xsd:string ; umls:cui """C0245194"""^^xsd:string ; umls:cui """C2350202"""^^xsd:string ; umls:cui """C1312955"""^^xsd:string ; umls:cui """C1328647"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diagnostic imaging"""@eng ; skos:notation """CDR0000042789"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """6589"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0011923"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II mantle cell lymphoma"""@eng ; skos:notation """CDR0000042788"""^^xsd:string ; skos:altLabel """lymphoma, stage II mantle cell lymphoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6587"""^^xsd:string ; """2004-08-03"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0677745"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alpha-type-1 polarized dendritic cells"""@eng ; skos:notation """CDR0000513178"""^^xsd:string ; skos:altLabel """alphaDC1"""@eng ; """2006-10-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831973"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CDK inhibitor AT7519M"""@eng ; skos:notation """CDR0000513177"""^^xsd:string ; skos:altLabel """AT7519M"""@eng ; """Drug/agent"""^^xsd:string ; """2006-10-14"""^^xsd:string ; umls:cui """C1879520"""^^xsd:string ; umls:cui """C1831971"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin HCl liposome/VX-853"""@eng ; skos:notation """CDR0000042780"""^^xsd:string ; skos:altLabel """LipoDox/VX 853"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """6579"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677741"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alfentanil hydrochloride"""@eng ; skos:notation """CDR0000042783"""^^xsd:string ; skos:altLabel """Alfenta"""@eng , """Rapifen"""@eng ; skos:definition """The hydrochloride salt form of alfentanil, an ultra short-acting, synthetic, opioid agonist with analgesic and local anesthesia enhancing activity. Alfentanil hydrochloride primarily binds to and stimulates the opiate receptors in the central nervous system (CNS), thereby mimicking the actions of endogenous opioids. Stimulation of the mu-subtype opioid receptor stimulates the exchange of GTP for GDP on the G-protein complex and subsequently inhibits adenylate cyclase. This results in a decrease in intracellular cAMP and leads to a reduction in the release of various neurotransmitters. The analgesic effect of alfentanil is likely due to the actions of its metabolite morphine, which induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, thereby resulting in hyperpolarization and reduced neuronal excitability. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42783&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42783&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C220\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """6582"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """70879-28-6"""^^xsd:string ; """C220"""^^xsd:string ; umls:cui """C0002025"""^^xsd:string ; umls:cui """C0700562"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/leucovorin calcium/melphalan"""@eng ; skos:notation """CDR0000042782"""^^xsd:string ; skos:altLabel """CF/FUDR/L-PAM"""@eng ; ; ; ; """6581"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677743"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anaplastic large cell lymphoma"""@eng ; skos:notation """CDR0000042785"""^^xsd:string ; skos:altLabel """lymphoma, anaplastic large cell"""@eng ; rdfs:subClassOf ; """6584"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206180"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tomography, emission computed"""@eng ; skos:notation """CDR0000042784"""^^xsd:string ; skos:altLabel """PET scan"""@eng ; rdfs:subClassOf ; """6583"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0040398"""^^xsd:string ; umls:cui """C0032743"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphoma, stage II diffuse small lymphocytic/marginal zone"""@eng ; skos:notation """CDR0000042787"""^^xsd:string ; """2004-06-10"""^^xsd:string ; """6586"""^^xsd:string ; umls:cui """C0677744"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radionuclide imaging"""@eng ; skos:notation """CDR0000042786"""^^xsd:string ; rdfs:subClassOf ; """6585"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0034606"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/doxorubicin/strontium chloride Sr 89"""@eng ; skos:notation """CDR0000358812"""^^xsd:string ; skos:altLabel """DOX/SC-58635/Sr89"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541577"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody mono-dgA-RFB4"""@eng ; skos:notation """CDR0000038178"""^^xsd:string ; """10757"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935906"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """G250 peptide vaccine"""@eng ; skos:notation """CDR0000465193"""^^xsd:string ; skos:definition """A cancer vaccine consisting of a synthetic form of the antigen G250, a cell surface tumor-associated antigen found in the majority of renal cell carcinomas, with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465193&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465193&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53410\" NCI Thesaurus)"""@eng ; """2006-06-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """C53410"""^^xsd:string ; umls:cui """C1711251"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etidronate"""@eng ; skos:notation """CDR0000039239"""^^xsd:string ; skos:altLabel """EHDP"""@eng , """Didronel"""@eng ; """1861"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0591373"""^^xsd:string ; umls:cui """C0086268"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethinyl estradiol"""@eng ; skos:notation """CDR0000039238"""^^xsd:string ; skos:altLabel """EE"""@eng , """Ethinoral"""@eng , """(17alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol"""@eng , """Inestra"""@eng , """Eticylol"""@eng , """ethinylestradiol"""@eng , """Diogyn E"""@eng , """Estinyl"""@eng , """Lynoral"""@eng , """Orestralyn"""@eng , """Feminone"""@eng ; skos:definition """A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39238&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39238&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C486\" NCI Thesaurus)"""@eng ; ; ; """1860"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """7259"""^^xsd:string ; """57-63-6"""^^xsd:string ; """C486"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """10973"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699362"""^^xsd:string ; umls:cui """C0699363"""^^xsd:string ; umls:cui """C0699364"""^^xsd:string ; umls:cui """C0699365"""^^xsd:string ; umls:cui """C0699366"""^^xsd:string ; umls:cui """C0699367"""^^xsd:string ; umls:cui """C0699368"""^^xsd:string ; umls:cui """C0015011"""^^xsd:string ; umls:cui """C0700721"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoglucid"""@eng ; skos:notation """CDR0000039233"""^^xsd:string ; skos:altLabel """ETOG"""@eng , """Epodyl"""@eng ; """1855"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0015039"""^^xsd:string ; umls:cui """C0795735"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin hydrochloride"""@eng ; skos:notation """CDR0000039232"""^^xsd:string ; skos:altLabel """Epidoxorubicin"""@eng , """epi-ADR"""@eng , """4'-epi-doxorubicin HCl"""@eng , """EPI"""@eng , """3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside"""@eng , """Pharmorubicin PFS"""@eng , """4'-epiadriamycin"""@eng , """4'-epi-DX"""@eng , """(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione"""@eng , """4'-epi-doxorubicin"""@eng , """Ellence"""@eng , """4'-epidoxorubicin"""@eng , """Epi DX"""@eng , """(8S-cis)-10-[(-Amino-2,3,6-trideoxy-alpha-L-arabino-hexpyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxacetyl)-1-methoxy-5,12-naphthacenedione"""@eng , """Pidorubicin"""@eng , """IMI-28"""@eng , """4'-epi DX"""@eng , """4'-epi-Adriamycin"""@eng ; skos:definition """The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39232&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39232&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C474\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """Drug/agent"""^^xsd:string ; """1854"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """56420-45-2"""^^xsd:string ; """256942"""^^xsd:string ; """C474"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1516927"""^^xsd:string ; umls:cui """C0700582"""^^xsd:string ; umls:cui """C0014582"""^^xsd:string ; umls:cui """C0701345"""^^xsd:string ; umls:cui """C0282387"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """elliptinium"""@eng ; skos:notation """CDR0000039231"""^^xsd:string ; skos:altLabel """HME"""@eng , """9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium Acetate (Salt)"""@eng , """Celiptium"""@eng , """9-Hydroxy-2-methylellipticinium Acetate"""@eng , """9-HME"""@eng , """Elliptinium Acetate"""@eng , """ellipticinium acetate"""@eng ; skos:definition """A derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties. As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39231&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39231&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1367\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """1853"""^^xsd:string ; """58337-35-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1367"""^^xsd:string ; """264137"""^^xsd:string ; umls:cui """C0046355"""^^xsd:string ; umls:cui """C0115685"""^^xsd:string ; umls:cui """C0100593"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta endophorin"""@eng ; skos:notation """CDR0000039230"""^^xsd:string ; """1852"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0678106"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """conjugated estrogens"""@eng ; skos:notation """CDR0000039237"""^^xsd:string ; skos:altLabel """EST"""@eng , """Premarin"""@eng , """Conestron"""@eng , """Sodestrin"""@eng , """Tag-39"""@eng , """Femest"""@eng ; skos:definition """Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39237&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39237&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C482\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1859"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """18313"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """C482"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0014938"""^^xsd:string ; umls:cui """C0699710"""^^xsd:string ; umls:cui """C0701270"""^^xsd:string ; umls:cui """C0701271"""^^xsd:string ; umls:cui """C0701269"""^^xsd:string ; umls:cui """C0701268"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estradiol"""@eng ; skos:notation """CDR0000039236"""^^xsd:string ; skos:altLabel """Ovocylin"""@eng , """(17beta)-Estra-1,3,5(10)-triene-3,17-diol"""@eng , """Aquadiol"""@eng , """Diogyn"""@eng , """Dimenformon"""@eng , """Therapeutic Estradiol"""@eng , """Estrace"""@eng , """17 Beta-Estradiol"""@eng , """Diogynets"""@eng , """ESDL"""@eng , """Estraldine"""@eng , """Vivelle"""@eng , """Progynon"""@eng ; skos:definition """A steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Typically esterified, estradiol derivatives are formulated for oral or parenteral administration. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39236&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39236&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C478\" NCI Thesaurus)"""@eng ; ; ; ; ; """1858"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C478"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9895"""^^xsd:string ; """50-28-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0014912"""^^xsd:string ; umls:cui """C0724374"""^^xsd:string ; umls:cui """C0878472"""^^xsd:string ; umls:cui """C0878477"""^^xsd:string ; umls:cui """C0878476"""^^xsd:string ; umls:cui """C0878475"""^^xsd:string ; umls:cui """C0878474"""^^xsd:string ; umls:cui """C0699359"""^^xsd:string ; umls:cui """C0699352"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine phosphate sodium"""@eng ; skos:notation """CDR0000039235"""^^xsd:string ; skos:altLabel """EM"""@eng , """Estramustine 17-(Dihydrogenphosphate) Disodium Salt"""@eng , """Ro 22-2296/000"""@eng , """Emcyt"""@eng , """Leo-299"""@eng , """estra-1,3,5(10)-triene-3,17-diol(17(beta))-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate"""@eng , """Estramustine Phosphate"""@eng , """Estracyt"""@eng ; skos:definition """The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39235&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39235&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C479\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """89201"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2998-57-4"""^^xsd:string ; """1857"""^^xsd:string ; """C479"""^^xsd:string ; umls:cui """C0014911"""^^xsd:string ; umls:cui """C0013953"""^^xsd:string ; umls:cui """C1521873"""^^xsd:string ; umls:cui """C0014922"""^^xsd:string ; umls:cui """C0014921"""^^xsd:string ; umls:cui """C1831589"""^^xsd:string ; umls:cui """C0356799"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erythromycin"""@eng ; skos:notation """CDR0000039234"""^^xsd:string ; skos:altLabel """E-Mycin"""@eng , """Ery-Tab"""@eng , """RP-Mycin"""@eng , """Ilotycin"""@eng , """ERYC"""@eng , """Robimycin"""@eng ; skos:definition """A broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39234&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39234&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C476\" NCI Thesaurus)"""@eng ; """1856"""^^xsd:string ; """55929"""^^xsd:string ; """114-07-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C476"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699344"""^^xsd:string ; umls:cui """C0699345"""^^xsd:string ; umls:cui """C0699340"""^^xsd:string ; umls:cui """C0699341"""^^xsd:string ; umls:cui """C0014806"""^^xsd:string ; umls:cui """C0699348"""^^xsd:string ; umls:cui """C0699339"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EGEN-001"""@eng ; skos:notation """CDR0000454593"""^^xsd:string ; skos:altLabel """phIL-12-005/PPC"""@eng ; skos:definition """A novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity. EGEN-001 is designed to increase the local concentration of IL-12 in the tumor microenvironment. IL-12 stimulates T-cell-independent production of IFN-gamma by peripheral blood mononuclear cells (PBMCs); enhances natural killer (NK) cell lytic activity; acts as a growth factor for T- and NK-cells; and is important for T-cell differentiation. IL-12 may potentiate antitumoral functions of the host immune system, resulting in immune-mediated tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454593&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454593&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49178\" NCI Thesaurus)"""@eng ; """2006-08-01"""^^xsd:string ; """C49178"""^^xsd:string ; """2005-11-04"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1707844"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/talabostat"""@eng ; skos:notation """CDR0000377519"""^^xsd:string ; skos:altLabel """CDDP/PT-100"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541321"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/rituximab"""@eng ; skos:notation """CDR0000377518"""^^xsd:string ; skos:altLabel """BRYO/MOAB IDEC-C2B8"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541320"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV anal cancer"""@eng ; skos:notation """CDR0000043438"""^^xsd:string ; skos:altLabel """metastatic anal cancer"""@eng , """stage IV anus cancer"""@eng , """metastatic anus cancer"""@eng , """anal cancer, metastatic"""@eng , """anus cancer, metastatic"""@eng , """anal cancer, stage IV"""@eng , """anus cancer, stage IV"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """86"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0861424"""^^xsd:string ; umls:cui """C1369136"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piperacillin-tazobactam/vancomycin"""@eng ; skos:notation """CDR0000043439"""^^xsd:string ; skos:altLabel """PIPER-TAZO/VANCO"""@eng ; ; ; """2004-02-19"""^^xsd:string ; """8600"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796596"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent marginal zone lymphoma"""@eng ; skos:notation """CDR0000371961"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-18"""^^xsd:string ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """marginal zone lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541273"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/tamoxifen"""@eng ; skos:notation """CDR0000039358"""^^xsd:string ; skos:altLabel """PACT"""@eng , """CTX/DOX/PRED/TMX"""@eng ; ; ; ; ; """1994"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279223"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/lomustine/vincristine"""@eng ; skos:notation """CDR0000039359"""^^xsd:string ; skos:altLabel """BACO"""@eng , """BLEO/CCNU/DOX/VCR"""@eng ; ; ; ; ; """1995"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279224"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dianhydrogalactitol/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000039354"""^^xsd:string ; skos:altLabel """ODAP"""@eng , """CDDP/DAG/DOX/VCR"""@eng ; ; ; ; ; """1990"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279220"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/lomustine/mechlorethamine/vincristine"""@eng ; skos:notation """CDR0000039355"""^^xsd:string ; skos:altLabel """BACON"""@eng , """BLEO/CCNU/DOX/NM/VCR"""@eng ; ; ; ; ; ; """1991"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0052889"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """minor tranquilizer"""@eng ; skos:notation """CDR0000043432"""^^xsd:string ; rdfs:subClassOf ; """843"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0040616"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chronic idiopathic myelofibrosis"""@eng ; skos:notation """CDR0000039357"""^^xsd:string ; skos:altLabel """AMM"""@eng , """agnogenic myeloid metaplasia"""@eng , """myelofibrosis with myeloid metaplasia"""@eng , """primary myelofibrosis"""@eng , """myeloid metaplasia, agnogenic"""@eng , """idiopathic myelofibrosis"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1993"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0001815"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine hydrochloride"""@eng ; skos:notation """CDR0000043434"""^^xsd:string ; skos:altLabel """Chlorethamine HCl"""@eng , """Mustine"""@eng , """Bis(2-chloroethyl)methylamine"""@eng , """NH-2"""@eng , """Mechlorethamine"""@eng , """NM"""@eng , """Chlormethine"""@eng , """chloromethine"""@eng , """mechlorethamine HCl"""@eng , """Erasol"""@eng , """chlorethazine"""@eng , """Caryolysine"""@eng , """Mustargen"""@eng , """mechlorethamine-HCl"""@eng , """chlorethamine hydrochloride"""@eng , """WR-147650"""@eng , """Mustargen Hydrochloride"""@eng , """Chloramin"""@eng , """NH2"""@eng , """Mustine Hydrochloride"""@eng , """Chloromethine HCl"""@eng , """Mustard"""@eng , """HN 2"""@eng , """Methylbis(beta-chloroethyl)amine"""@eng , """Chlorethazine Hydrochloride"""@eng , """Chlormethine Hydrochloride"""@eng , """methylchlorethamine"""@eng , """ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl"""@eng , """N-Lost"""@eng , """nitrogen mustard"""@eng , """Cloramin"""@eng , """Mustargen HCl"""@eng , """Onco-Cloramin"""@eng ; skos:definition """The hydrochloride salt of a synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43434&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43434&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C627\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """853"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """51-75-2"""^^xsd:string ; """55-86-7 (hydrochloride)"""^^xsd:string ; """762"""^^xsd:string ; """C627"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522603"""^^xsd:string ; umls:cui """C1518337"""^^xsd:string ; umls:cui """C0025033"""^^xsd:string ; umls:cui """C1518338"""^^xsd:string ; umls:cui """C0919295"""^^xsd:string ; umls:cui """C0007310"""^^xsd:string ; umls:cui """C0701936"""^^xsd:string ; umls:cui """C0701935"""^^xsd:string ; umls:cui """C0917712"""^^xsd:string ; umls:cui """C0600266"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/dacarbazine/dactinomycin/doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000039351"""^^xsd:string ; skos:altLabel """ALOMAD"""@eng , """CLB/DACT/DOX/DTIC/MTX/VCR"""@eng ; ; ; ; ; ; ; """1987"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279217"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine"""@eng ; skos:notation """CDR0000043436"""^^xsd:string ; skos:altLabel """6H-Purine-6-thione, 1,7-dihydro- (9CI)"""@eng , """Mercaptina"""@eng , """6-Thiopurine"""@eng , """6 Thiopurine"""@eng , """6 Thiohypoxanthine"""@eng , """Alti-Mercaptopurine"""@eng , """Purine-6-thiol (8CI)"""@eng , """Mercaleukim"""@eng , """Purine-6-thiol Monohydrate"""@eng , """Leupurin"""@eng , """Mercapto-6-purine"""@eng , """6-MP"""@eng , """WR-2785"""@eng , """MP"""@eng , """Purinethiol"""@eng , """3H-Purine-6-thiol"""@eng , """6-Purinethiol"""@eng , """Mern"""@eng , """1,7-Dihydro-6H-purine-6-thione Monohydrate"""@eng , """6-Thioxopurine"""@eng , """BW 57-323H"""@eng , """Puri-Nethol"""@eng , """U-4748"""@eng , """Azathiopurine"""@eng , """6-Mercaptopurine Monohydrate"""@eng , """Mercaptopurinum"""@eng , """7-Mercapto-1,3,4,6-tetrazaindene"""@eng , """Ismipur"""@eng , """6MP"""@eng , """Flocofil"""@eng , """Mercapurin"""@eng , """1,7-Dihydro-6H-purine-6-thione"""@eng , """Leukerin"""@eng , """Purinethol"""@eng , """Purine-6-thiol, Monohydrate"""@eng , """6-mercaptopurine"""@eng , """Purimethol"""@eng ; skos:definition """A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43436&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43436&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C195\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """858"""^^xsd:string ; """24850"""^^xsd:string ; """C195"""^^xsd:string ; """50-44-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1226"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """755"""^^xsd:string ; """6112-76-1 (monohydrate)"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1455642"""^^xsd:string ; umls:cui """C1522534"""^^xsd:string ; umls:cui """C1522533"""^^xsd:string ; umls:cui """C1513135"""^^xsd:string ; umls:cui """C0729098"""^^xsd:string ; umls:cui """C0729099"""^^xsd:string ; umls:cui """C1513137"""^^xsd:string ; umls:cui """C1513136"""^^xsd:string ; umls:cui """C0886849"""^^xsd:string ; umls:cui """C1513134"""^^xsd:string ; umls:cui """C1513133"""^^xsd:string ; umls:cui """C0917847"""^^xsd:string ; umls:cui """C0722911"""^^xsd:string ; umls:cui """C0729100"""^^xsd:string ; umls:cui """C0000618"""^^xsd:string ; umls:cui """C1513139"""^^xsd:string ; umls:cui """C1513138"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039353"""^^xsd:string ; skos:altLabel """AMVP"""@eng , """ARA-C/MTX/PRED/VCR"""@eng ; ; ; ; ; """1989"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279219"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/filgrastim/mercaptopurine/vincristine"""@eng ; skos:notation """CDR0000041465"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/G-CSF/MP/VCR"""@eng ; ; ; ; ; ; ; """4536"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281012"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/filgrastim/prednisone/vincristine"""@eng ; skos:notation """CDR0000041464"""^^xsd:string ; skos:altLabel """ASP/CTX/DNR/G-CSF/PRED/VCR"""@eng ; ; ; ; ; ; ; """4535"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281011"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interleukin-2/tumor necrosis factor"""@eng ; skos:notation """CDR0000041467"""^^xsd:string ; skos:altLabel """IFN-A/IL-2/TNF"""@eng ; ; ; ; """4538"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338153"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/etoposide"""@eng ; skos:notation """CDR0000041466"""^^xsd:string ; skos:altLabel """CDDP/HMM/VP-16"""@eng ; ; ; ; """4537"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281013"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rogletimide"""@eng ; skos:notation """CDR0000041461"""^^xsd:string ; skos:altLabel """pyridoglutethimide"""@eng ; """4531"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0164550"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/dipyridamole/etoposide/ketoconazole/metronidazole/quinidine/tamoxifen"""@eng ; skos:notation """CDR0000041460"""^^xsd:string ; skos:altLabel """CYSP/DP/KCZ/METRO/QND/TMX/VP-16"""@eng ; ; ; ; ; ; ; ; """4530"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281008"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/filgrastim/melphalan"""@eng ; skos:notation """CDR0000041463"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/L-PAM/VP-16"""@eng ; ; ; ; ; """4534"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281010"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/verapamil"""@eng ; skos:notation """CDR0000041462"""^^xsd:string ; skos:altLabel """DOX/VPAM"""@eng ; ; ; """4533"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281009"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/pegaspargase"""@eng ; skos:notation """CDR0000041469"""^^xsd:string ; skos:altLabel """ARA-C/PEG-ASP"""@eng ; ; ; """4540"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281016"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/melphalan"""@eng ; skos:notation """CDR0000041468"""^^xsd:string ; skos:altLabel """L-PAM/WR-2721"""@eng ; ; ; """4539"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281015"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """angiomyolipoma"""@eng ; skos:notation """CDR0000441219"""^^xsd:string ; rdfs:subClassOf ; """precancerous/nonmalignant condition"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2005-07-23"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2005-07-21"""^^xsd:string ; umls:cui """C0206633"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bicalutamide/eflornithine"""@eng ; skos:notation """CDR0000354489"""^^xsd:string ; skos:altLabel """CDX/DFMO"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-01-26"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328180"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/pamidronate/thalidomide"""@eng ; skos:notation """CDR0000355356"""^^xsd:string ; skos:altLabel """APD/IFN-A/THAL"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328182"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/pamidronate"""@eng ; skos:notation """CDR0000355355"""^^xsd:string ; skos:altLabel """APD/IFN-A"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328181"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphangioleiomyomatosis"""@eng ; skos:notation """CDR0000532373"""^^xsd:string ; skos:altLabel """LAM"""@eng , """Lymphangiomyomatosis"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2007-01-25"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; """C3725"""^^xsd:string ; umls:cui """C0751674"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody Ch14.18/sargramostim"""@eng ; skos:notation """CDR0000038339"""^^xsd:string ; skos:altLabel """GM-CSF/MOAB Ch14.18"""@eng ; ; ; """10958"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935879"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000038338"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU/MOAB C225"""@eng ; ; ; ; ; """10957"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935878"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/epoetin alfa"""@eng ; skos:notation """CDR0000038331"""^^xsd:string ; skos:altLabel """CDDP/EPO"""@eng ; ; ; """10950"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935875"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """riboflavin"""@eng ; skos:notation """CDR0000038330"""^^xsd:string ; skos:altLabel """Vitamin B2"""@eng , """Lactoflavin"""@eng , """6,7-Dimethyl-9-D-ribitylisoalloxazine"""@eng , """riboflavine"""@eng ; skos:definition """An essential human nutrient that is a heat-stable and water-soluble flavin belonging to the vitamin B family. Riboflavin is a precursor of the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are of vital importance in normal tissue respiration, pyridoxine activation, tryptophan to niacin conversion, fat, carbohydrate, and protein metabolism, and glutathione reductase mediated detoxification. Riboflavin may also be involved in maintaining erythrocyte integrity. This vitamin is essential for healthy skin, nails, and hair. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38330&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38330&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C808\" NCI Thesaurus)"""@eng ; """1095"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C808"""^^xsd:string ; """83-88-5"""^^xsd:string ; """33298"""^^xsd:string ; umls:cui """C0035527"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atrasentan hydrochloride"""@eng ; skos:notation """CDR0000038333"""^^xsd:string ; skos:altLabel """ABT627"""@eng , """(2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid"""@eng , """ABT-627"""@eng , """ABT 627"""@eng , """(+)-A 127722"""@eng , """Xinlay"""@eng ; skos:definition """The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38333&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38333&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1779\" NCI Thesaurus)"""@eng ; ; """TRD"""^^xsd:string ; """720763"""^^xsd:string ; """10952"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """173937-91-2"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C1779"""^^xsd:string ; umls:cui """C0935914"""^^xsd:string ; umls:cui """C0663262"""^^xsd:string ; umls:cui """C1568545"""^^xsd:string ; umls:cui """C1765313"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP4071"""@eng ; skos:notation """CDR0000038332"""^^xsd:string ; skos:altLabel """CP 4071"""@eng , """CP-4071"""@eng ; """10951"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935876"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HPPH"""@eng ; skos:notation """CDR0000038335"""^^xsd:string ; skos:altLabel """Photochlor"""@eng , """2-(1-Hexyloxyethyl)-2-Devinyl Pyropheophorbide-a"""@eng ; skos:definition """A chlorin based second-generation photosensitizer used in adjuvant Photodynamic therapy to prevent recurrence of tumor after surgical removal. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. Photodynamic reaction between HPPH and oxygen occurs when laser light is applied. As a result, reactants from the photodynamic reaction trigger serial cytotoxic events, thereby killing tumor cells. HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity that declines rapidly over a few days in comparison with the first generation photosensitizer Photofrin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38335&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38335&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2636\" NCI Thesaurus)"""@eng ; """10954"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2636"""^^xsd:string ; """149402-51-7"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0248392"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polyglutamate camptothecin"""@eng ; skos:notation """CDR0000302921"""^^xsd:string ; skos:altLabel """PG-CPT"""@eng , """CT-2106"""@eng , """Camptothecin Polyglutamate"""@eng ; skos:definition """A therapeutic formulation consisting of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with polyglutamate. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Conjugation with polyglutamate renders this agent more water soluble and less toxic than the parent molecule. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=302921&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=302921&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26664\" NCI Thesaurus)"""@eng ; """2003-04-23"""^^xsd:string ; """C26664"""^^xsd:string ; """2006-05-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327958"""^^xsd:string ; umls:cui """C1328703"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000038337"""^^xsd:string ; skos:altLabel """DOX/IFF/VCR/VP-16"""@eng ; ; ; ; ; """10956"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935877"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MVF-HER-2(628-647)-CRL 1005 vaccine"""@eng ; skos:notation """CDR0000038336"""^^xsd:string ; """10955"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0935910"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult mixed cellularity Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000039828"""^^xsd:string ; skos:altLabel """HD MC, adult"""@eng , """lymphoma, mixed cellularity adult Hodgkin's"""@eng , """Hodgkin's disease, mixed cellularity, adult"""@eng , """HD, mixed cellularity, adult"""@eng , """Hodgkin's lymphoma, mixed cellularity, adult"""@eng , """adult Hodgkin's disease, mixed cellularity"""@eng , """MC HD, adult"""@eng , """adult mixed cellularity Hodgkin's disease"""@eng , """mixed cellularity, Hodgkin's disease, adult"""@eng , """mixed cellularity adult Hodgkin's disease"""@eng , """mixed cellularity, HD, adult"""@eng , """HDMC, adult"""@eng , """MCHD, adult"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """2507"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279542"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Philadelphia chromosome positive chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000039829"""^^xsd:string ; skos:altLabel """Ph' positive chronic myelogenous leukemia"""@eng , """chronic myelocytic leukemia, Philadelphia chromosome positive"""@eng , """chronic myelogenous leukemia, Philadelphia chromosome positive"""@eng , """Ph1 positive CML"""@eng , """CGL, Philadelphia chromosome positive"""@eng , """CML, Philadelphia chromosome positive"""@eng , """myelocytic leukemia, chronic, Philadelphia chromosome positive"""@eng , """chronic granulocytic leukemia, Philadelphia chromosome positive"""@eng , """myelogenous leukemia, chronic, Philadelphia chromosome positive"""@eng , """Ph1 positive chronic myelogenous leukemia"""@eng , """granulocytic leukemia, chronic, Philadelphia chromosome positive"""@eng ; rdfs:subClassOf ; """2508"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279543"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult lymphocyte depletion Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000039826"""^^xsd:string ; skos:altLabel """HDLD, adult"""@eng , """adult lymphocyte depletion Hodgkin's disease"""@eng , """Hodgkin's lymphoma, lymphocyte depleted, adult"""@eng , """lymphocyte depleted Hodgkin's disease, adult"""@eng , """HD LD, adult"""@eng , """HD, lymphocyte depleted, adult"""@eng , """lymphocyte depleted HD, adult"""@eng , """LDHD, adult"""@eng , """Hodgkin's disease, lymphocyte depleted, adult"""@eng , """lymphoma, lymphocyte depleted adult Hodgkin's"""@eng , """LD HD, adult"""@eng , """lymphocyte depletion HD, adult"""@eng , """adult Hodgkin's disease, lymphocyte depleted"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """2505"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279540"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult nodular sclerosis Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000039827"""^^xsd:string ; skos:altLabel """adult Hodgkin's disease, nodular sclerosis"""@eng , """Hodgkin's disease, nodular sclerosis, adult"""@eng , """Hodgkin's lymphoma, nodular sclerosis, adult"""@eng , """NS HD, adult"""@eng , """nodular sclerosis Hodgkin's disease, adult"""@eng , """NSHD, adult"""@eng , """HD, nodular sclerosis, adult"""@eng , """nodular sclerosing Hodgkin's disease, adult"""@eng , """nodular sclerosing HD, adult"""@eng , """lymphoma, nodular sclerosing adult Hodgkin's"""@eng , """adult nodular sclerosis Hodgkin's disease"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """2506"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279541"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """B-cell chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000039824"""^^xsd:string ; skos:altLabel """chronic lymphocytic leukemia, B-cell"""@eng , """lymphocytic leukemia, B-cell chronic"""@eng , """CLL, B-cell"""@eng , """B-cell CLL"""@eng , """leukemia, B-cell chronic lymphocytic"""@eng , """B cell chronic lymphocytic leukemia"""@eng ; rdfs:subClassOf ; """2503"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023434"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult lymphocyte predominant Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000039825"""^^xsd:string ; skos:altLabel """LP HD, adult"""@eng , """adult Hodgkin's disease, lymphocyte predominant"""@eng , """adult lymphocyte predominant Hodgkin's disease"""@eng , """Hodgkin's lymphoma, lymphocyte predominant, adult"""@eng , """Hodgkin's disease, lymphocyte predominant, adult"""@eng , """lymphocyte predominant Hodgkin's disease, adult"""@eng , """HDLP, adult"""@eng , """HD LP, adult"""@eng , """lymphoma, lymphocyte predominant adult Hodgkin's"""@eng , """HD, lymphocyte predominant, adult"""@eng , """LPHD, adult"""@eng , """lymphocyte predominant HD, adult"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """2504"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279539"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """copovithane"""@eng ; skos:notation """CDR0000039822"""^^xsd:string ; """2501"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0056285"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T-cell large granular lymphocyte leukemia"""@eng ; skos:notation """CDR0000039823"""^^xsd:string ; skos:altLabel """T-cell lymphocytic leukemia"""@eng , """T-cell chronic lymphocytic leukemia"""@eng , """LGL leukemia"""@eng , """T-gamma lymphoproliferative disorder"""@eng ; rdfs:subClassOf ; """2502"""^^xsd:string ; """2006-01-11"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023494"""^^xsd:string ; umls:cui """C1955861"""^^xsd:string ; umls:cui """C1522378"""^^xsd:string ; umls:cui """C0023492"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000039820"""^^xsd:string ; skos:altLabel """DNR/MP/MTX/PRED/VCR"""@eng , """MTX-DOMP"""@eng ; ; ; ; ; ; """2498"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279537"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gastric cancer"""@eng ; skos:notation """CDR0000039821"""^^xsd:string ; skos:altLabel """Stomach (gastric) cancer"""@eng , """stomach cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """25"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0699791"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/fludarabine/melphalan"""@eng ; skos:notation """CDR0000038487"""^^xsd:string ; skos:altLabel """FAMP/L-PAM/MOAB CD52"""@eng ; ; ; ; """11107"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134523"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/thalidomide"""@eng ; skos:notation """CDR0000038486"""^^xsd:string ; skos:altLabel """EM/THAL/TXT"""@eng ; ; ; ; """11106"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134522"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """halofuginone hydrobromide"""@eng ; skos:notation """CDR0000038485"""^^xsd:string ; skos:altLabel """RU 19110"""@eng , """halofuginone"""@eng , """Tempostatin"""@eng , """halofuginone HBr"""@eng ; skos:definition """A quinazolinone alkaloid anticoccidial with potential antineoplastic activity. Halofuginone hydrobromide inhibits type I collagen synthesis and matrix metalloproteinase 2 (MMP-2) gene expression, which results in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to due to an effect of halofuginone on the activity of the MMP-2 promoter. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38485&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38485&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2656\" NCI Thesaurus)"""@eng ; """11105"""^^xsd:string ; """C2656"""^^xsd:string ; """2006-08-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0062095"""^^xsd:string ; umls:cui """C0521922"""^^xsd:string ; umls:cui """C1527213"""^^xsd:string ; umls:cui """C1512331"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cisplatin/gemcitabine"""@eng ; skos:notation """CDR0000038484"""^^xsd:string ; skos:altLabel """CDDP/dFdC/MOAB VEGF"""@eng ; ; ; ; """11104"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/multi-epitope melanoma peptide vaccine/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000436056"""^^xsd:string ; skos:altLabel """ISA-51/MULTI-EP MP VAC/TET TOX PEP VAC"""@eng ; ; ; """2005-06-06"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831641"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/Montanide ISA-51/multi-epitope melanoma peptide vaccine/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000436057"""^^xsd:string ; skos:altLabel """CTX/ISA-51/MULTI-EP MP VAC/TET TOX PEP VAC"""@eng ; ; ; ; """2005-06-06"""^^xsd:string ; """2005-06-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831642"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/melanoma helper peptide vaccine/Montanide ISA-51/multi-epitope melanoma peptide vaccine"""@eng ; skos:notation """CDR0000436054"""^^xsd:string ; skos:altLabel """CTX/ISA-51/MHP VAC/MULTI-EP MP VAC"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-06"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831639"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MKC-1"""@eng ; skos:notation """CDR0000486351"""^^xsd:string ; skos:altLabel """R440"""@eng , """Ro 31-7453"""@eng ; """2007-01-10"""^^xsd:string ; """C2507"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796487"""^^xsd:string ; umls:cui """C1508754"""^^xsd:string ; umls:cui """C2987728"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """10-propargyl-10-deazaaminopterin"""@eng ; skos:notation """CDR0000037828"""^^xsd:string ; skos:altLabel """PDX"""@eng ; ; """10218"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879404"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extensive stage small cell lung cancer"""@eng ; skos:notation """CDR0000037829"""^^xsd:string ; skos:altLabel """oat cell lung cancer, extensive stage"""@eng , """extensive stage SCLC"""@eng , """lung cancer, extensive stage small cell"""@eng , """small cell lung cancer, extensive stage"""@eng , """SCLC, extensive stage"""@eng ; rdfs:subClassOf ; """small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1022"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278726"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/carboplatin/etoposide"""@eng ; skos:notation """CDR0000038489"""^^xsd:string ; skos:altLabel """CBDCA/PS-341/VP-16"""@eng ; ; ; ; """2002-11-19"""^^xsd:string ; """11109"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134525"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/fowlpox-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000038488"""^^xsd:string ; skos:altLabel """ADC/fCEA-TRI"""@eng ; ; ; """2003-11-04"""^^xsd:string ; """11108"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134524"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NOS3"""@eng ; skos:notation """CDR0000334897"""^^xsd:string ; rdfs:subClassOf ; """2003-09-24"""^^xsd:string ; """2003-09-09"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1328053"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PgR"""@eng ; skos:notation """CDR0000334896"""^^xsd:string ; rdfs:subClassOf ; """2003-09-24"""^^xsd:string ; """2003-09-09"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1366500"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/dactinomycin/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000038851"""^^xsd:string ; skos:altLabel """BCNU/CTX/DACT/DOX/MP/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; ; ; """1341"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278896"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell immature teratoma"""@eng ; skos:notation """CDR0000040499"""^^xsd:string ; skos:altLabel """immature teratoma, ovarian germ cell"""@eng , """teratoma, immature, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3388"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346182"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell teratoma"""@eng ; skos:notation """CDR0000040498"""^^xsd:string ; skos:altLabel """teratoma, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3387"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280131"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell choriocarcinoma"""@eng ; skos:notation """CDR0000040497"""^^xsd:string ; skos:altLabel """choriocarcinoma, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3386"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0346181"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell polyembryoma"""@eng ; skos:notation """CDR0000040496"""^^xsd:string ; skos:altLabel """polyembryoma, ovarian germ cell"""@eng ; rdfs:subClassOf ; """3385"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280129"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/doxorubicin/melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000040495"""^^xsd:string ; skos:altLabel """VMCPP/VBAPP"""@eng , """BCNU/CTX/DOX/L-PAM/PRED/VCR"""@eng , """VMCPP alternating with VBAPP"""@eng , """VBAPP/VMCPP"""@eng ; ; ; ; ; ; ; """3384"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280128"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000040494"""^^xsd:string ; skos:altLabel """L-PAM/PCB/VBL"""@eng , """PAVe"""@eng ; ; ; ; """3382"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0211067"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate/vinblastine"""@eng ; skos:notation """CDR0000040493"""^^xsd:string ; skos:altLabel """CDDP/DOX/MTX/VBL"""@eng , """MVAC"""@eng ; ; ; ; ; """3381"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/dexamethasone/etoposide"""@eng ; skos:notation """CDR0000040492"""^^xsd:string ; skos:altLabel """ARA-C/CDDP/DM/VP-16"""@eng , """E-DHAP"""@eng ; ; ; ; ; """3380"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0058942"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040491"""^^xsd:string ; skos:altLabel """EOP"""@eng , """EPI/PRED/VCR"""@eng ; ; ; ; """3379"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280124"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-leucovorin"""@eng ; skos:notation """CDR0000040490"""^^xsd:string ; skos:altLabel """Levofolinic acid"""@eng , """Elvorine, Isovorin, Levofolene, Levorin"""@eng , """L-CF"""@eng , """Isovorin"""@eng , """L-5-Formyltetrahydrofolate"""@eng , """Levofolinate calcium"""@eng , """Levoleucovorin"""@eng , """CL-307,782"""@eng , """Calcium levoleucovorin"""@eng , """Levofolinate"""@eng ; skos:definition """The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40490&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40490&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1559\" NCI Thesaurus)"""@eng ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """3378"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """58-05-9"""^^xsd:string ; """C1559"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C1517682"""^^xsd:string ; umls:cui """C1522590"""^^xsd:string ; umls:cui """C2721771"""^^xsd:string ; umls:cui """C0731033"""^^xsd:string ; umls:cui """C1881372"""^^xsd:string ; umls:cui """C0280123"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aromatherapy"""@eng ; skos:notation """CDR0000441095"""^^xsd:string ; rdfs:subClassOf ; """2005-07-23"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """2005-07-18"""^^xsd:string ; umls:cui """C0376547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus 5-tumor necrosis factor alpha/capecitabine"""@eng ; skos:notation """CDR0000339944"""^^xsd:string ; skos:altLabel """Ad5-TNFa/CAPE"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328076"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nordihydroguaiaretic acid"""@eng ; skos:notation """CDR0000479648"""^^xsd:string ; skos:altLabel """NDGA"""@eng , """4,4'-(2,3-Dimethyl-1,4-butanediyl)bis[1,2-benzenediol]"""@eng , """Actinex"""@eng , """Masoprocol"""@eng ; skos:definition """A naturally occurring antioxidant dicatechol originally derived from the creosote bush Larrea divaricatta with antipromoter, anti-inflammatory, and antineoplastic activities. Nordihydroguaiaretic acid (NDGA) directly inhibits activation of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu receptor, resulting in decreased proliferation of susceptible tumor cell populations. This agent may induce apoptosis in susceptible tumor cell populations as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases (SAPKs). In addition, NDGA inhibits arachidonic acid 5-lipoxygenase (5LOX), resulting in diminished synthesis of inflammatory mediators such as prostaglandins and leukotrines; it may prevent leukocyte infiltration into tissues and the release of reactive oxygen species and, at higher concentrations, may also inhibit cyclooxygenase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=479648&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=479648&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C701\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-28"""^^xsd:string ; """2006-04-07"""^^xsd:string ; """C701"""^^xsd:string ; """4291"""^^xsd:string ; """500-38-9"""^^xsd:string ; umls:cui """C0733396"""^^xsd:string ; umls:cui """C0733397"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aprepitant"""@eng ; skos:notation """CDR0000454517"""^^xsd:string ; skos:altLabel """MK-0869"""@eng , """L-754030"""@eng , """Emend"""@eng , """ONO-7436"""@eng ; skos:definition """A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454517&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454517&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49173\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """C49173"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-11-04"""^^xsd:string ; umls:cui """C1175300"""^^xsd:string ; umls:cui """C0759820"""^^xsd:string ; umls:cui """C0757679"""^^xsd:string ; umls:cui """C1706844"""^^xsd:string ; umls:cui """C1176306"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 chlorotoxin"""@eng ; skos:notation """CDR0000440314"""^^xsd:string ; skos:altLabel """131I-TM-601"""@eng ; """2005-07-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-07-12"""^^xsd:string ; umls:cui """C1569697"""^^xsd:string ; umls:cui """C2316450"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cytarabine/etoposide/melphalan/rituximab"""@eng ; skos:notation """CDR0000357718"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/L-PAM/MOAB IDEC-C2B8/VP-16"""@eng ; ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-02-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541570"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lanreotide acetate copolymer microparticles"""@eng ; skos:notation """CDR0000463333"""^^xsd:string ; skos:altLabel """Somatuline LA"""@eng ; skos:definition """A prolonged-release depot suspension of microparticles containing the acetate salt of lanreotide, a synthetic peptide analog of the naturally occurring somatostatin, and copolymers. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent has a much longer duration of action than natural somatostatin and is selective towards the inhibition of growth hormone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463333&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=463333&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53437\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """2006-06-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C53437"""^^xsd:string ; umls:cui """C1708642"""^^xsd:string ; umls:cui """C0732169"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """barium enema"""@eng ; skos:notation """CDR0000043430"""^^xsd:string ; """8411"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0203075"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arginine/omega-3 fatty acids/nucleotides oral supplement"""@eng ; skos:notation """CDR0000489464"""^^xsd:string ; skos:altLabel """Impact"""@eng , """Immun-Aid"""@eng ; """TRD"""^^xsd:string ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62534"""^^xsd:string ; """2006-09-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831895"""^^xsd:string ; umls:cui """C0726639"""^^xsd:string ; umls:cui """C1831894"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T168"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ferumoxsil"""@eng ; skos:notation """CDR0000489463"""^^xsd:string ; skos:altLabel """GastroMARK"""@eng ; """2006-06-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62485"""^^xsd:string ; """2006-09-19"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0257928"""^^xsd:string ; umls:cui """C0380253"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/lomustine/methotrexate/methylprednisolone/procarbazine"""@eng ; skos:notation """CDR0000042644"""^^xsd:string ; skos:altLabel """ARA-C/CCNU/MePRDL/MTX/PCB"""@eng ; ; ; ; ; ; """6378"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393046"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/mesna"""@eng ; skos:notation """CDR0000042645"""^^xsd:string ; skos:altLabel """IFF/MSA/VP-16"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """6381"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393047"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/mesna/mitoxantrone"""@eng ; skos:notation """CDR0000042646"""^^xsd:string ; skos:altLabel """DHAD/IFF/MSA"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """6382"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393048"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/octreotide pamoate/tamoxifen"""@eng ; skos:notation """CDR0000042647"""^^xsd:string ; skos:altLabel """CTX/DOX/SMS 201-995 pa/TMX"""@eng ; ; ; ; ; """6384"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393049"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/filgrastim/thiotepa"""@eng ; skos:notation """CDR0000042640"""^^xsd:string ; skos:altLabel """BCNU/CTX/G-CSF/TSPA"""@eng ; ; ; ; ; """6370"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393043"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/prednisone/samarium Sm 153 lexidronam pentasodium"""@eng ; skos:notation """CDR0000445459"""^^xsd:string ; skos:altLabel """PRED/153Sm-EDTMP/TXT"""@eng ; ; ; ; """2005-08-23"""^^xsd:string ; """2005-08-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831718"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/etoposide"""@eng ; skos:notation """CDR0000042642"""^^xsd:string ; skos:altLabel """CTX/DM/VP-16"""@eng ; ; ; ; """6374"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393044"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/marimastat"""@eng ; skos:notation """CDR0000042643"""^^xsd:string ; skos:altLabel """BB-2516/5-FU"""@eng ; ; ; """6377"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393045"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxifluridine"""@eng ; skos:notation """CDR0000481255"""^^xsd:string ; skos:altLabel """5'-deoxy-5-fluorouridine"""@eng , """5-DFUR"""@eng ; skos:definition """A fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481255&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=481255&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C978\" NCI Thesaurus)"""@eng ; """C978"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0048808"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminolevulinic acid"""@eng ; skos:notation """CDR0000042648"""^^xsd:string ; skos:altLabel """5-Aminolevulinic Acid"""@eng , """amino-levulinic acid"""@eng , """Delta Aminolevulinic Acid"""@eng , """Levulan"""@eng , """5-ALA"""@eng , """ALA"""@eng , """Delta-Aminolevulinic Acid"""@eng , """5-Amino-4-oxopentanoic Acid"""@eng , """5-Aminolaevulinic Acid"""@eng , """d-Amino-Levulinic Acid"""@eng , """Amino-Levulinic Acid"""@eng ; skos:definition """A topically administered metabolic precursor of protoporphyrin IX. After topical administration, aminolevulinic acid (ALA) is converted to protoporphyrin IX (PpIX) which is a photosensitizer. When the proper wavelength of light activates protoporphyrin IX, singlet oxygen is produced, resulting in a local cytotoxic effect. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42648&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42648&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C234\" NCI Thesaurus)"""@eng ; """6386"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """106-60-5"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C234"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1449662"""^^xsd:string ; umls:cui """C0002563"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim/vincristine"""@eng ; skos:notation """CDR0000042649"""^^xsd:string ; skos:altLabel """CTX/G-CSF/VCR"""@eng ; ; ; ; """6387"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393050"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000037837"""^^xsd:string ; skos:altLabel """adult leukemia, acute lymphocytic"""@eng , """leukemia, acute lymphoblastic, adult"""@eng , """ALL, adult"""@eng , """lymphoblastic leukemia, acute adult"""@eng , """leukemia, acute lymphocytic, adult"""@eng , """adult acute lymphocytic leukemia"""@eng , """adult leukemia, acute lymphoblastic"""@eng , """lymphocytic leukemia, acute adult"""@eng , """adult ALL"""@eng , """Leukemia, acute lymphocytic (ALL), adult"""@eng , """acute lymphoblastic leukemia, adult"""@eng , """acute lymphocytic leukemia, adult"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1024"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0751606"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/hydrocortisone/methotrexate"""@eng ; skos:notation """CDR0000038129"""^^xsd:string ; skos:altLabel """DOX/HC/MTX"""@eng ; ; ; ; """10689"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935715"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TAS-108"""@eng ; skos:notation """CDR0000486347"""^^xsd:string ; skos:altLabel """SR16234"""@eng , """(7)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate"""@eng ; skos:definition """A synthetic, antiestrogenic steroidal compound with potential antitumor activity. TAS-108 binds to and inhibits estrogenic receptor alpha (ERa), mainly expressed in the mammary gland and uterus and upregulated in estrogen-dependent tumors. Blockage of ERa by TAS-108 prevents the binding and effects of estrogen and may lead to an inhibition of estrogen-dependent cancer cell proliferation. TAS-108 also is a partial agonist of the estrogenic receptor beta (ERb), expressed in many tissues including the central nervous system, urogenital tract, bone and cardiovascular system, thereby exerting a positive effect on these tissues. In addition, TAS-108 activates the co-repressor Silencing Mediator for Retinoid and Thyroid hormone receptor (SMRT), a protein that inhibits the activities of the estrogen receptors, which may contribute to the antitumor activity of TAS-108. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486347&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486347&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61494\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C61494"""^^xsd:string ; """2006-10-11"""^^xsd:string ; """2006-05-19"""^^xsd:string ; umls:cui """C1831835"""^^xsd:string ; umls:cui """C1435233"""^^xsd:string ; umls:cui """C1435232"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rituximab/talabostat"""@eng ; skos:notation """CDR0000382133"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/PT-100"""@eng ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541455"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent small cell lung cancer"""@eng ; skos:notation """CDR0000037831"""^^xsd:string ; skos:altLabel """lung cancer, recurrent small cell"""@eng , """recurrent SCLC"""@eng , """small cell lung cancer, recurrent"""@eng , """oat cell lung cancer, recurrent"""@eng , """SCLC, recurrent"""@eng ; rdfs:subClassOf ; """small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1023"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278727"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ARRY-142886"""@eng ; skos:notation """CDR0000382135"""^^xsd:string ; """2004-07-23"""^^xsd:string ; """2004-07-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541456"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atiprimod"""@eng ; skos:notation """CDR0000382134"""^^xsd:string ; skos:altLabel """N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine"""@eng , """SK&F106615"""@eng ; skos:definition """An orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=382134&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=382134&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52184\" NCI Thesaurus)"""@eng ; """2004-07-23"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C52184"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0754307"""^^xsd:string ; umls:cui """C0388703"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cetuximab/pemetrexed disodium"""@eng ; skos:notation """CDR0000438667"""^^xsd:string ; skos:altLabel """CBDCA/LY231514/MOAB C225"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-22"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831660"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mycophenolate mofetil/tacrolimus"""@eng ; skos:notation """CDR0000445235"""^^xsd:string ; skos:altLabel """CTX/FK506/MMF"""@eng ; ; ; ; """2005-08-19"""^^xsd:string ; """2005-08-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831707"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/topotecan"""@eng ; skos:notation """CDR0000038120"""^^xsd:string ; skos:altLabel """IFF/TOPO/VP-16"""@eng ; ; ; ; """10677"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935707"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VEGF inhibitor BIBF 1120"""@eng ; skos:notation """CDR0000504524"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831951"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pharmacological studies"""@eng ; skos:notation """CDR0000470274"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-02-23"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C1831759"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DNA methylation"""@eng ; skos:notation """CDR0000470275"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """2006-02-23"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0376452"""^^xsd:string ; umls:tui """T044"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """coagulation studies"""@eng ; skos:notation """CDR0000470273"""^^xsd:string ; """2006-02-23"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; """2006-03-07"""^^xsd:string ; umls:cui """C0005790"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III Wilms' tumor"""@eng ; skos:notation """CDR0000043737"""^^xsd:string ; skos:altLabel """stage III Wilms tumor"""@eng , """Wilm's tumor, stage III"""@eng , """Wilms tumor, stage III"""@eng , """stage III nephroblastoma"""@eng , """stage III Wilm's tumor"""@eng , """Wilms' tumor, stage III"""@eng , """nephroblastoma, stage III"""@eng ; rdfs:subClassOf ; """Wilms' tumor and other childhood kidney tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """997"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278713"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """LMP-2:419-427 peptide vaccine"""@eng ; skos:notation """CDR0000504596"""^^xsd:string ; """2006-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831953"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Melan-A VLP vaccine"""@eng ; skos:notation """CDR0000486348"""^^xsd:string ; skos:altLabel """CYT004-MelQbG10"""@eng ; skos:definition """A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) and noninfectious virus-like particles (VLP) with potential antitumor and immunostimulating activities. Melan A, an antigen upregulated in most melanomas, activates the immune system to exert a specific cytotoxic T-cell (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. VLP stimulates the immune system and promotes the CTL response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486348&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486348&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61495\" NCI Thesaurus)"""@eng ; """C61495"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """2006-10-11"""^^xsd:string ; umls:cui """C1831836"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rebeccamycin analogue"""@eng ; skos:notation """CDR0000042257"""^^xsd:string ; skos:altLabel """BMY-27557-14"""@eng , """becatecarin"""@eng , """5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-"""@eng , """REBECCA"""@eng , """rebeccamycin analogue, tartrate salt"""@eng , """XL119"""@eng , """Rebeccamycin Analog"""@eng , """BMS-181176"""@eng , """DEAE-Rebeccamycin"""@eng ; skos:definition """A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin. The rebeccamycin analogue intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42257&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42257&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1620\" NCI Thesaurus)"""@eng ; ; ; """5505"""^^xsd:string ; """655649"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C1620"""^^xsd:string ; """46941"""^^xsd:string ; """119673-08-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0936065"""^^xsd:string ; umls:cui """C1522479"""^^xsd:string ; umls:cui """C1328676"""^^xsd:string ; umls:cui """C0296895"""^^xsd:string ; umls:cui """C0296894"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/milodistim/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000042256"""^^xsd:string ; skos:altLabel """DNR/PEG-ASP/PIXY321/PRED/VCR"""@eng ; ; ; ; ; ; """5504"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281759"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """daunorubicin/pegaspargase/prednisone/vincristine"""@eng ; skos:notation """CDR0000042255"""^^xsd:string ; skos:altLabel """DNR/PEG-ASP/PRED/VCR"""@eng ; ; ; ; ; """5503"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281758"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexverapamil/doxorubicin"""@eng ; skos:notation """CDR0000042254"""^^xsd:string ; skos:altLabel """DOX/R-VPAM"""@eng ; ; ; """5502"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281757"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leflunomide"""@eng ; skos:notation """CDR0000042253"""^^xsd:string ; skos:altLabel """SU101"""@eng , """4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-"""@eng , """Arava"""@eng ; skos:definition """A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties. As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes. This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42253&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42253&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1128\" NCI Thesaurus)"""@eng ; ; ; """5501"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """677411"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """75706-12-6"""^^xsd:string ; """C1128"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0718644"""^^xsd:string ; umls:cui """C0966994"""^^xsd:string ; umls:cui """C0063041"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beta alethine"""@eng ; skos:notation """CDR0000038126"""^^xsd:string ; skos:altLabel """BetaLT"""@eng , """Beta-LT"""@eng , """Beta LT"""@eng , """Betathine"""@eng ; """10685"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1522622"""^^xsd:string ; umls:cui """C1522621"""^^xsd:string ; umls:cui """C0290021"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vincristine"""@eng ; skos:notation """CDR0000042251"""^^xsd:string ; skos:altLabel """22-Oxovincaleukoblastine"""@eng , """Oncovin"""@eng , """LCR"""@eng , """leurocristine sulfate"""@eng , """VCR"""@eng , """Leurocristine"""@eng , """Vincrystine"""@eng , """Vincasar"""@eng ; skos:definition """A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42251&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42251&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C933\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """550"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """57-22-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C933"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0042680"""^^xsd:string ; umls:cui """C0733847"""^^xsd:string ; umls:cui """C0042679"""^^xsd:string ; umls:cui """C0591904"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitomycin"""@eng ; skos:notation """CDR0000042250"""^^xsd:string ; skos:altLabel """CDDP/MITO"""@eng ; ; ; """55"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278516"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil/paclitaxel"""@eng ; skos:notation """CDR0000038127"""^^xsd:string ; skos:altLabel """CBDCA/5-FU/TAX"""@eng ; ; ; ; """10686"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935713"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon therapy"""@eng ; skos:notation """CDR0000039006"""^^xsd:string ; skos:altLabel """therapy, interferon"""@eng ; ; rdfs:subClassOf ; """1568"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279030"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/NG-monomethyl-L-arginine"""@eng ; skos:notation """CDR0000042259"""^^xsd:string ; skos:altLabel """IL-2/NMA"""@eng ; ; ; """5507"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281762"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NG-monomethyl-L-arginine"""@eng ; skos:notation """CDR0000042258"""^^xsd:string ; skos:altLabel """NMA"""@eng , """N-Methylarginine"""@eng ; skos:definition """An amino acid derivative with potential antineoplastic activity. NG-monomethyl-L-arginine inhibits the enzyme nitric oxide synthase, resulting in a diminution of nitrous oxide production. This agent may inhibit tumor angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42258&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42258&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1178\" NCI Thesaurus)"""@eng ; ; """5506"""^^xsd:string ; """8138"""^^xsd:string ; """C1178"""^^xsd:string ; """17035-90-4"""^^xsd:string ; """683245"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0069477"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunotoxin therapy"""@eng ; skos:notation """CDR0000043363"""^^xsd:string ; rdfs:subClassOf ; ; """7909"""^^xsd:string ; """2006-12-12"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0796507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """radiosensitization"""@eng ; skos:notation """CDR0000039000"""^^xsd:string ; """1561"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279024"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/mitotane/tariquidar/vincristine"""@eng ; skos:notation """CDR0000343771"""^^xsd:string ; skos:altLabel """DDD/DOX/VCR/VP-16/XR9576"""@eng ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328098"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endocrine therapy"""@eng ; skos:notation """CDR0000039001"""^^xsd:string ; skos:altLabel """therapy, endocrine"""@eng ; rdfs:subClassOf owl:Thing ; ; ; ; """1562"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279025"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AFP gene hepatocellular carcinoma vaccine"""@eng ; skos:notation """CDR0000043366"""^^xsd:string ; skos:definition """A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43366&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43366&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2512\" NCI Thesaurus)"""@eng ; ; """7913"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C2512"""^^xsd:string ; umls:cui """C0796510"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laser therapy"""@eng ; skos:notation """CDR0000039003"""^^xsd:string ; skos:altLabel """therapy, laser"""@eng ; ; ; ; rdfs:subClassOf ; """1565"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1955835"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic GM-CSF-secreting breast cancer vaccine"""@eng ; skos:notation """CDR0000392723"""^^xsd:string ; skos:altLabel """GM-CSF BREAST VAC"""@eng ; skos:definition """An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=392723&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=392723&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48371\" NCI Thesaurus)"""@eng ; ; ; """2004-09-17"""^^xsd:string ; """C48371"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541366"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oncolytic virus therapy"""@eng ; skos:notation """CDR0000474226"""^^xsd:string ; ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1563738"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunopotentiation"""@eng ; skos:notation """CDR0000474225"""^^xsd:string ; ; rdfs:subClassOf ; """2006-03-16"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1512675"""^^xsd:string ; umls:tui """T039"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mouse renal adenocarcinoma cell-containing agarose-agarose macrobeads"""@eng ; skos:notation """CDR0000489176"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; umls:cui """C1831882"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/rituximab"""@eng ; skos:notation """CDR0000377720"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/PS-341"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541445"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/interleukin-1-beta"""@eng ; skos:notation """CDR0000041698"""^^xsd:string ; skos:altLabel """CBDCA/CTX/IL-1B"""@eng ; ; ; ; """4864"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281296"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000041699"""^^xsd:string ; skos:altLabel """CBDCA/TAX"""@eng ; ; ; """4866"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281297"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """deferoxamine mesylate"""@eng ; skos:notation """CDR0000041696"""^^xsd:string ; skos:altLabel """DFM"""@eng , """Desferal"""@eng ; skos:definition """The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41696&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41696&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C417\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """138-14-7"""^^xsd:string ; """C417"""^^xsd:string ; """644468"""^^xsd:string ; """2007-01-23"""^^xsd:string ; """4858"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591350"""^^xsd:string ; umls:cui """C0011148"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/diaziquone"""@eng ; skos:notation """CDR0000041697"""^^xsd:string ; skos:altLabel """AZQ/BU/CTX"""@eng ; ; ; ; """4862"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281295"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/dactinomycin/vincristine"""@eng ; skos:notation """CDR0000041694"""^^xsd:string ; skos:altLabel """CYSP/DACT/VCR"""@eng ; ; ; ; """4856"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281292"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HIV-associated Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000041695"""^^xsd:string ; skos:altLabel """AIDS-associated Hodgkin's lymphoma"""@eng , """HIV-associated Hodgkin's disease"""@eng , """AIDS-associated Hodgkin's disease"""@eng , """AIDS-related Hodgkin's disease"""@eng ; rdfs:subClassOf ; """2003-01-14"""^^xsd:string ; """4857"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281293"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/vincristine/zalcitabine"""@eng ; skos:notation """CDR0000041692"""^^xsd:string ; skos:altLabel """BLEO/ddC/DOX/VCR"""@eng ; ; ; ; ; """4854"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338166"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/didanosine/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000041693"""^^xsd:string ; skos:altLabel """BLEO/ddI/DOX/VCR"""@eng ; ; ; ; ; """4855"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281291"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """omega-3 fatty acids"""@eng ; skos:notation """CDR0000041690"""^^xsd:string ; skos:altLabel """O3FA"""@eng , """omega-3 polyunsaturated fatty acid"""@eng , """fish oils"""@eng , """fish oil"""@eng , """omega-3 PUFA"""@eng ; ; """4852"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0015689"""^^xsd:string ; umls:cui """C0016157"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/ifosfamide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000041691"""^^xsd:string ; skos:altLabel """ARA-C/DM/IFF/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4853"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281289"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/pentostatin/rituximab"""@eng ; skos:notation """CDR0000038653"""^^xsd:string ; skos:altLabel """CTX/DCF/MOAB IDEC-C2B8"""@eng ; ; ; ; """11299"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134660"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sulofenur"""@eng ; skos:notation """CDR0000041122"""^^xsd:string ; skos:altLabel """LY186641"""@eng ; skos:definition """A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41122&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41122&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1432\" NCI Thesaurus)"""@eng ; """4197"""^^xsd:string ; """110311-27-8"""^^xsd:string ; """C1432"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """41769"""^^xsd:string ; """656667"""^^xsd:string ; umls:cui """C0950735"""^^xsd:string ; umls:cui """C0165187"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult primary cholangiocellular carcinoma"""@eng ; skos:notation """CDR0000041123"""^^xsd:string ; skos:altLabel """cholangiocellular carcinoma, adult primary"""@eng ; rdfs:subClassOf ; """4198"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280725"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/indinavir"""@eng ; skos:notation """CDR0000271407"""^^xsd:string ; skos:altLabel """ADC/IDV"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327888"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """motexafin gadolinium/rituximab/yttrium Y 90 ibritumomab tiuxetan"""@eng ; skos:notation """CDR0000380761"""^^xsd:string ; skos:altLabel """IDEC-Y2B8/MOAB IDEC-C2B8/PCI-0120"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541341"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beclomethasone/prednisone"""@eng ; skos:notation """CDR0000271408"""^^xsd:string ; skos:altLabel """BECLOMETH/PRED"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327889"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beclomethasone/methylprednisolone"""@eng ; skos:notation """CDR0000271409"""^^xsd:string ; skos:altLabel """BECLOMETH/MePRDL"""@eng ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327890"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethylchlorformate vaccine"""@eng ; skos:notation """CDR0000038657"""^^xsd:string ; """11301"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134716"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lipids"""@eng ; skos:notation """CDR0000043126"""^^xsd:string ; skos:altLabel """Intralipid"""@eng ; """7544"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0023779"""^^xsd:string ; umls:cui """C0733854"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 pentetreotide"""@eng ; skos:notation """CDR0000043127"""^^xsd:string ; """7549"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0379955"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/vinorelbine"""@eng ; skos:notation """CDR0000043124"""^^xsd:string ; skos:altLabel """dFdC/VNB"""@eng ; ; ; """7520"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796306"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/methotrexate/prednisolone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000043125"""^^xsd:string ; skos:altLabel """ARA-C/DNR/MTX/PRDL/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """7521"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796307"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """XRCC group"""@eng ; skos:notation """CDR0000043122"""^^xsd:string ; rdfs:subClassOf ; """7518"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796304"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/doxorubicin/etoposide/prednisolone/procarbazine/vinblastine/vincristine"""@eng ; skos:notation """CDR0000043123"""^^xsd:string ; skos:altLabel """CLB/DOX/PCB/PRDL/VBL/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """7519"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ATM"""@eng ; skos:notation """CDR0000043121"""^^xsd:string ; rdfs:subClassOf ; """7517"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0919524"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-LET cobalt-60 gamma ray therapy"""@eng ; skos:notation """CDR0000038655"""^^xsd:string ; skos:altLabel """therapy, low-LET cobalt-60 gamma ray"""@eng ; ; rdfs:subClassOf ; """1130"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0278777"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """holmium Ho 166 DOTMP"""@eng ; skos:notation """CDR0000043128"""^^xsd:string ; skos:altLabel """166Ho-DOTMP"""@eng ; ; """7551"""^^xsd:string ; """2004-06-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1130449"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """enzyme"""@eng ; skos:notation """CDR0000043129"""^^xsd:string ; rdfs:subClassOf ; """756"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0014442"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adult acute myeloid leukemia"""@eng ; skos:notation """CDR0000038678"""^^xsd:string ; skos:altLabel """adult AML, recurrent"""@eng , """adult leukemia, relapsed acute nonlymphocytic"""@eng , """myelogenous leukemia, relapsed adult acute"""@eng , """recurrent adult AML"""@eng , """AML, adult recurrent"""@eng , """adult acute myeloid leukemia, relapsed"""@eng , """adult acute myelogenous leukemia, relapsed"""@eng , """recurrent adult ANLL"""@eng , """acute nonlymphocytic leukemia, relapsed, adult"""@eng , """ANLL, relapsed, adult"""@eng , """ANLL, adult recurrent"""@eng , """adult leukemia, relapsed acute myeloid"""@eng , """nonlymphocytic leukemia, relapsed adult acute"""@eng , """relapsed adult acute myelogenous leukemia"""@eng , """adult AML, relapsed"""@eng , """leukemia, relapsed adult acute nonlymphocytic"""@eng , """leukemia, relapsed adult acute myelogenous"""@eng , """relapsed adult acute myeloid leukemia"""@eng , """adult ANLL, recurrent"""@eng , """acute myelogenous leukemia, relapsed, adult"""@eng , """recurrent acute myeloid leukemia, adult"""@eng , """adult leukemia, relapsed acute myelogenous"""@eng , """relapsed adult ANLL"""@eng , """acute myeloid leukemia, relapsed, adult"""@eng , """leukemia, relapsed adult acute myeloid"""@eng , """myeloid leukemia, relapsed adult acute"""@eng , """adult acute nonlymphocytic leukemia, relapsed"""@eng , """AML, relapsed, adult"""@eng , """relapsed adult AML"""@eng ; rdfs:subClassOf ; """adult acute myeloid leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1133"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278780"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/paclitaxel"""@eng ; skos:notation """CDR0000038679"""^^xsd:string ; skos:altLabel """CTX/EPI/TAX"""@eng ; ; ; ; """11330"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134684"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human endostatin"""@eng ; skos:notation """CDR0000459758"""^^xsd:string ; skos:altLabel """rhEndostatin"""@eng ; skos:definition """A recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. Endostatin induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction in tumor burden. This agent also may decrease hepatic metastasis by inhibiting proinflammatory cytokines and vascular cell adhesion molecule (VCAM)-dependent cell attachment to the hepatic microvasculature. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459758&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459758&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C45515\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C45515"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1705207"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """P501-AS15 vaccine"""@eng ; skos:notation """CDR0000459759"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831724"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/doxorubicin/filgrastim/leucovorin calcium/methotrexate/rituximab/vincristine"""@eng ; skos:notation """CDR0000038670"""^^xsd:string ; skos:altLabel """ARA-C/CF/CTX/DM/DOX/G-CSF/MOAB IDEC-C2B8/MTX/VCR"""@eng ; ; ; ; ; ; ; ; ; ; """11315"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexrazoxane/doxorubicin/oblimersen"""@eng ; skos:notation """CDR0000038671"""^^xsd:string ; skos:altLabel """ADR-529/CTX/DOX/G3139"""@eng ; ; ; ; ; """11316"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fenofibrate"""@eng ; skos:notation """CDR0000459750"""^^xsd:string ; skos:altLabel """Tricor"""@eng ; skos:definition """A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates perioxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459750&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459750&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29047\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C29047"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0723893"""^^xsd:string ; umls:cui """C0033228"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavopiridol/trastuzumab"""@eng ; skos:notation """CDR0000038673"""^^xsd:string ; skos:altLabel """FLAVO/MOAB HER2"""@eng ; ; ; """11318"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134676"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/UCN-01"""@eng ; skos:notation """CDR0000038674"""^^xsd:string ; skos:altLabel """dFdC/UCN 01"""@eng ; ; ; """2003-10-23"""^^xsd:string ; """11319"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134677"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent osteosarcoma"""@eng ; skos:notation """CDR0000038675"""^^xsd:string ; skos:altLabel """sarcoma, recurrent osteogenic"""@eng , """recurrent osteogenic sarcoma"""@eng , """osteogenic sarcoma, recurrent"""@eng , """osteosarcoma, recurrent"""@eng ; rdfs:subClassOf ; """osteosarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1132"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278779"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """darbepoetin alfa"""@eng ; skos:notation """CDR0000038676"""^^xsd:string ; skos:altLabel """Nespo"""@eng , """Novel Erythropoiesis Stimulating Protein"""@eng , """Aranesp"""@eng , """NESP"""@eng , """KRN321"""@eng ; skos:definition """A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein. Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin. Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38676&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38676&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1878\" NCI Thesaurus)"""@eng ; """11328"""^^xsd:string ; """209810-58-2"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1878"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1744401"""^^xsd:string ; umls:cui """C1511724"""^^xsd:string ; umls:cui """C0937950"""^^xsd:string ; umls:cui """C1134440"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """menatetrenone"""@eng ; skos:notation """CDR0000459755"""^^xsd:string ; skos:altLabel """E0167"""@eng ; skos:definition """A menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signalling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459755&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459755&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52194\" NCI Thesaurus)"""@eng ; """2005-12-22"""^^xsd:string ; """C52194"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C2949740"""^^xsd:string ; umls:cui """C0065936"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dehydroepiandrosterone"""@eng ; skos:notation """CDR0000042419"""^^xsd:string ; skos:altLabel """GL701"""@eng , """Therapeutic Dehydroepiandrosterone"""@eng , """Fidelin"""@eng , """3beta-Hydroxyandrost-5-en-17-one"""@eng , """Dehydroisoandrosterone"""@eng , """DHEA"""@eng , """Prasterone"""@eng ; skos:definition """A synthetic form of dehydroepiandrosterone with potential chemopreventive activity. Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens. Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42419&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42419&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2265\" NCI Thesaurus)"""@eng ; """5694"""^^xsd:string ; """C2265"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9896"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """53-43-0"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0917987"""^^xsd:string ; umls:cui """C1710380"""^^xsd:string ; umls:cui """C0011185"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000038921"""^^xsd:string ; skos:altLabel """EPOCH"""@eng , """CHOPE"""@eng , """CTX/DOX/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; """1429"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C3887850"""^^xsd:string ; umls:cui """C0212922"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """androgen"""@eng ; skos:notation """CDR0000038922"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """143"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002844"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000038923"""^^xsd:string ; skos:altLabel """CDDP/TMTX"""@eng ; ; ; """1430"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278967"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/trimetrexate glucuronate"""@eng ; skos:notation """CDR0000038924"""^^xsd:string ; skos:altLabel """TMTX/VP-16"""@eng ; ; ; """1431"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278968"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000038925"""^^xsd:string ; skos:altLabel """CF/DOX/5-FU"""@eng ; ; ; ; """1432"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0295180"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin"""@eng ; skos:notation """CDR0000038926"""^^xsd:string ; skos:altLabel """BCNU/CDDP"""@eng ; ; ; """1433"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278970"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """zalcitabine/zidovudine"""@eng ; skos:notation """CDR0000038927"""^^xsd:string ; skos:altLabel """ddC/ZDV"""@eng ; ; ; """1434"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338082"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042411"""^^xsd:string ; skos:altLabel """ARA-C/CTX/TG/VP-16"""@eng ; ; ; ; ; """5667"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338318"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/vincristine"""@eng ; skos:notation """CDR0000038929"""^^xsd:string ; skos:altLabel """PRED/VCR"""@eng ; ; ; """1436"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278972"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate/prednisolone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042413"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/MTX/PRDL/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; ; """5669"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338320"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/epirubicin/etoposide/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042412"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/EPI/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; ; """5668"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338319"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cimetidine/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000042415"""^^xsd:string ; skos:altLabel """cimetidine/TIL"""@eng ; ; ; """5671"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338322"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/filgrastim"""@eng ; skos:notation """CDR0000042414"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF"""@eng ; ; ; """5670"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338321"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GM2-KLH vaccine/QS21"""@eng ; skos:notation """CDR0000042417"""^^xsd:string ; skos:altLabel """GM2-KLH/QS 21"""@eng ; ; ; """5678"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338324"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/daunorubicin/dexamethasone/vincristine"""@eng ; skos:notation """CDR0000042416"""^^xsd:string ; skos:altLabel """ASP/CTX/DM/DNR/VCR"""@eng ; ; ; ; ; ; """5672"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338323"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AKT1"""@eng ; skos:notation """CDR0000258379"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11501"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0812228"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 1p"""@eng ; skos:notation """CDR0000258370"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11492"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327810"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 11p"""@eng ; skos:notation """CDR0000258373"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11495"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327812"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 9p"""@eng ; skos:notation """CDR0000258372"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11494"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327811"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 14q"""@eng ; skos:notation """CDR0000258375"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11496"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327813"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MAPK"""@eng ; skos:notation """CDR0000258377"""^^xsd:string ; rdfs:subClassOf ; """2002-10-11"""^^xsd:string ; """11498"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1370600"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/idarubicin/imatinib mesylate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000258376"""^^xsd:string ; skos:altLabel """DM/IDA/PEG-ASP/STI571/VCR"""@eng ; ; ; ; ; ; """2002-10-11"""^^xsd:string ; """11497"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327814"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxaliplatin/rebeccamycin analogue"""@eng ; skos:notation """CDR0000373894"""^^xsd:string ; skos:altLabel """L-OHP/REBECCA"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-09-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541301"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/Virulizin"""@eng ; skos:notation """CDR0000257161"""^^xsd:string ; skos:altLabel """5-FU/VIRU"""@eng ; ; ; """2002-08-09"""^^xsd:string ; """11409"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327757"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/Virulizin"""@eng ; skos:notation """CDR0000257160"""^^xsd:string ; skos:altLabel """dFdC/VIRU"""@eng ; ; ; """2002-08-09"""^^xsd:string ; """11408"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327756"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cyclophosphamide"""@eng ; skos:notation """CDR0000341591"""^^xsd:string ; skos:altLabel """CTX/MOAB VEGF"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328090"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """matuzumab"""@eng ; skos:notation """CDR0000350433"""^^xsd:string ; skos:altLabel """EMD 72000"""@eng , """humanized anti-EGFR monoclonal antibody"""@eng ; skos:definition """A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with highaffinity, competitively blocking natural ligand binding andblocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350433&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350433&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2012\" NCI Thesaurus)"""@eng ; ; ; """C2012"""^^xsd:string ; """2006-06-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2004-01-23"""^^xsd:string ; umls:cui """C1328134"""^^xsd:string ; umls:cui """C1328711"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult oligodendroglial tumors"""@eng ; skos:notation """CDR0000430660"""^^xsd:string ; skos:altLabel """Brain tumor, adult: Oligodendroglial tumors"""@eng ; rdfs:subClassOf ; """2005-04-23"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """2005-04-25"""^^xsd:string ; umls:cui """C1541567"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lapatinib/letrozole"""@eng ; skos:notation """CDR0000350434"""^^xsd:string ; skos:altLabel """GW-572016/LTZ"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-08-31"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328135"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP-751871"""@eng ; skos:notation """CDR0000456793"""^^xsd:string ; skos:definition """A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. CP-751871 selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456793&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456793&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52187\" NCI Thesaurus)"""@eng ; """C52187"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-11-25"""^^xsd:string ; """2006-05-18"""^^xsd:string ; umls:cui """C1707143"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """axillary lymph node dissection"""@eng ; skos:notation """CDR0000526247"""^^xsd:string ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """2006-12-12"""^^xsd:string ; umls:cui """C0193867"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone"""@eng ; skos:notation """CDR0000039789"""^^xsd:string ; skos:altLabel """Azona"""@eng , """Deenar"""@eng , """Dexamethasonum"""@eng , """Fortecortin"""@eng , """Cortisumman"""@eng , """Decaspray"""@eng , """Dexapos"""@eng , """9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione"""@eng , """Orgadrone"""@eng , """Dexamonozon"""@eng , """Auxiloson"""@eng , """Dexalocal"""@eng , """Baycuten N"""@eng , """Baycuten"""@eng , """Dexafluorene"""@eng , """Dekacort"""@eng , """Dexace"""@eng , """Anemul mono"""@eng , """Dexacortal"""@eng , """Cortidexason"""@eng , """Alin Depot"""@eng , """Decasone R.p."""@eng , """Hexadecadrol"""@eng , """Methylfluorprednisolone"""@eng , """Dexa-Rhinosan"""@eng , """Corson"""@eng , """Auricularum"""@eng , """Lokalison-F"""@eng , """Ocasa"""@eng , """Dexa-Mamallet"""@eng , """Deronil"""@eng , """Deltafluorene"""@eng , """Aquapred"""@eng , """Decalix"""@eng , """(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione"""@eng , """Dexamecortin"""@eng , """9Alpha-fluoro-16alpha-methylprednisolone"""@eng , """Aeroseb-Dex"""@eng , """Aacidexam"""@eng , """Dexone"""@eng , """Dexa-Scheroson"""@eng , """Dectancyl"""@eng , """Aknichthol Dexa"""@eng , """DM"""@eng , """Dexameth"""@eng , """16Alpha-methyl-9alpha-fluoroprednisolone"""@eng , """Desamethasone"""@eng , """Dezone"""@eng , """Dinormon"""@eng , """Dexinoral"""@eng , """Decaderm"""@eng , """Gammacorten"""@eng , """Fluoro-9alpha Methyl-16alpha Prednisolone"""@eng , """Ambene"""@eng , """Sk-Dexamethasone"""@eng , """Antimicotico"""@eng , """Millicorten"""@eng , """16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone"""@eng , """Alba-Dex"""@eng , """Loverine"""@eng , """Visumetazone"""@eng , """Mymethasone"""@eng , """Alin Oftalmico"""@eng , """Predni-F"""@eng , """Decadron"""@eng , """Decadrol"""@eng , """Dexafarma"""@eng , """Alin"""@eng , """Spersadex"""@eng , """Hexadrol"""@eng , """Adexone"""@eng , """Fluorodelta"""@eng , """16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione"""@eng , """Dex-4"""@eng , """Decameth"""@eng , """Dexacortin"""@eng , """Decacort"""@eng , """Maxidex"""@eng , """DXM"""@eng , """Desameton"""@eng , """Dexa-sine"""@eng , """9alpha-Fluoro-16alpha- methylprednisolone"""@eng , """Amplidermis"""@eng , """1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone"""@eng ; skos:definition """A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39789&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39789&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C422\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """245"""^^xsd:string ; """34521"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C422"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """50-02-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511858"""^^xsd:string ; umls:cui """C1511859"""^^xsd:string ; umls:cui """C1511852"""^^xsd:string ; umls:cui """C1511853"""^^xsd:string ; umls:cui """C1511850"""^^xsd:string ; umls:cui """C1511851"""^^xsd:string ; umls:cui """C1511856"""^^xsd:string ; umls:cui """C1511857"""^^xsd:string ; umls:cui """C0011777"""^^xsd:string ; umls:cui """C1511855"""^^xsd:string ; umls:cui """C1511838"""^^xsd:string ; umls:cui """C1511830"""^^xsd:string ; umls:cui """C1511818"""^^xsd:string ; umls:cui """C1511819"""^^xsd:string ; umls:cui """C1511816"""^^xsd:string ; umls:cui """C1511817"""^^xsd:string ; umls:cui """C1511832"""^^xsd:string ; umls:cui """C1511815"""^^xsd:string ; umls:cui """C1511834"""^^xsd:string ; umls:cui """C1511835"""^^xsd:string ; umls:cui """C1511836"""^^xsd:string ; umls:cui """C1511837"""^^xsd:string ; umls:cui """C0740057"""^^xsd:string ; umls:cui """C1511833"""^^xsd:string ; umls:cui """C0052674"""^^xsd:string ; umls:cui """C1511831"""^^xsd:string ; umls:cui """C0525283"""^^xsd:string ; umls:cui """C0701257"""^^xsd:string ; umls:cui """C0701254"""^^xsd:string ; umls:cui """C0701255"""^^xsd:string ; umls:cui """C0701252"""^^xsd:string ; umls:cui """C0701251"""^^xsd:string ; umls:cui """C1511868"""^^xsd:string ; umls:cui """C0701258"""^^xsd:string ; umls:cui """C0701259"""^^xsd:string ; umls:cui """C1511846"""^^xsd:string ; umls:cui """C1511849"""^^xsd:string ; umls:cui """C1511848"""^^xsd:string ; umls:cui """C1511845"""^^xsd:string ; umls:cui """C1511844"""^^xsd:string ; umls:cui """C1511847"""^^xsd:string ; umls:cui """C0051545"""^^xsd:string ; umls:cui """C1511841"""^^xsd:string ; umls:cui """C1511840"""^^xsd:string ; umls:cui """C1511843"""^^xsd:string ; umls:cui """C1511842"""^^xsd:string ; umls:cui """C1511829"""^^xsd:string ; umls:cui """C1511828"""^^xsd:string ; umls:cui """C1511863"""^^xsd:string ; umls:cui """C1511854"""^^xsd:string ; umls:cui """C1511861"""^^xsd:string ; umls:cui """C1511860"""^^xsd:string ; umls:cui """C1511823"""^^xsd:string ; umls:cui """C1511822"""^^xsd:string ; umls:cui """C1511821"""^^xsd:string ; umls:cui """C1511820"""^^xsd:string ; umls:cui """C1511827"""^^xsd:string ; umls:cui """C1511826"""^^xsd:string ; umls:cui """C1511825"""^^xsd:string ; umls:cui """C1511824"""^^xsd:string ; umls:cui """C1511864"""^^xsd:string ; umls:cui """C0053032"""^^xsd:string ; umls:cui """C1511839"""^^xsd:string ; umls:cui """C0525106"""^^xsd:string ; umls:cui """C1511865"""^^xsd:string ; umls:cui """C0701263"""^^xsd:string ; umls:cui """C0701262"""^^xsd:string ; umls:cui """C0701261"""^^xsd:string ; umls:cui """C0701260"""^^xsd:string ; umls:cui """C1511862"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antianemic"""@eng ; skos:notation """CDR0000039788"""^^xsd:string ; """2448"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279517"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/prednisone/vincristine"""@eng ; skos:notation """CDR0000039783"""^^xsd:string ; skos:altLabel """L-PAM/PRED/VCR"""@eng ; ; ; ; """2443"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279514"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000039782"""^^xsd:string ; skos:altLabel """CDDP/IFF/VP-16"""@eng , """VIP"""@eng ; ; ; ; """2442"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078294"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/prednisone/thioguanine"""@eng ; skos:notation """CDR0000039781"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PRED/TG"""@eng , """TRAP"""@eng ; ; ; ; ; """2441"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279512"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/prednisone/teniposide"""@eng ; skos:notation """CDR0000039780"""^^xsd:string ; skos:altLabel """DOX/PRED/VM-26"""@eng , """PATen"""@eng ; ; ; ; """2440"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antipsychotic agent"""@eng ; skos:notation """CDR0000039787"""^^xsd:string ; rdfs:subClassOf ; """2447"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0040615"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acodazole"""@eng ; skos:notation """CDR0000039786"""^^xsd:string ; skos:altLabel """1H-imidazo[4,5-f]quinoline, acetamide deriv"""@eng , """acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI)"""@eng , """Acodazole Hydrochloride"""@eng ; skos:definition """A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication. Use of this agent has been associated with significant cardiotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39786&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39786&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C988\" NCI Thesaurus)"""@eng ; """2446"""^^xsd:string ; """21351"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """305884"""^^xsd:string ; """C988"""^^xsd:string ; """79152-85-5"""^^xsd:string ; umls:cui """C0050565"""^^xsd:string ; umls:cui """C0970589"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antibacterial agent"""@eng ; skos:notation """CDR0000039785"""^^xsd:string ; """2445"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279516"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiadrenal agent"""@eng ; skos:notation """CDR0000039784"""^^xsd:string ; """2444"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279515"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glutaminase-asparaginase"""@eng ; skos:notation """CDR0000039251"""^^xsd:string ; skos:altLabel """AGA"""@eng ; """1873"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0071561"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gentamicin"""@eng ; skos:notation """CDR0000039250"""^^xsd:string ; skos:altLabel """Garamycin"""@eng , """U-Gencin"""@eng , """Garamicin"""@eng , """GM"""@eng , """gentamycin"""@eng , """Genoptic"""@eng , """Genoptic S.O.P."""@eng ; ; ; """1872"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0546866"""^^xsd:string ; umls:cui """C0699089"""^^xsd:string ; umls:cui """C0699088"""^^xsd:string ; umls:cui """C0701041"""^^xsd:string ; umls:cui """C0699090"""^^xsd:string ; umls:cui """C0699091"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """musculoskeletal cancer"""@eng ; skos:notation """CDR0000039253"""^^xsd:string ; skos:altLabel """sarcoma"""@eng ; rdfs:subClassOf ; """1880"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0036210"""^^xsd:string ; umls:cui """C1261473"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """guanazole"""@eng ; skos:notation """CDR0000039252"""^^xsd:string ; skos:definition """A cytostatic triazole derivative antimetabolite. Guanazole scavenges tyrosine free radicals, thereby inhibiting mammalian ribonucleotide reductase activity and DNA synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39252&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39252&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C531\" NCI Thesaurus)"""@eng ; """1874"""^^xsd:string ; """C531"""^^xsd:string ; """1455-77-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1895"""^^xsd:string ; """7065"""^^xsd:string ; umls:cui """C0018316"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antiandrogen"""@eng ; skos:notation """CDR0000039255"""^^xsd:string ; rdfs:subClassOf ; """1887"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0002842"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """norethindrone acetate"""@eng ; skos:notation """CDR0000039254"""^^xsd:string ; skos:altLabel """Norlutate"""@eng , """Norlutin"""@eng , """norethindrone"""@eng , """Nor-Q.D."""@eng , """Micronor"""@eng , """norethisterone acetate"""@eng ; ; """1881"""^^xsd:string ; """C702"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-29"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0028356"""^^xsd:string ; umls:cui """C0699160"""^^xsd:string ; umls:cui """C0699161"""^^xsd:string ; umls:cui """C0699165"""^^xsd:string ; umls:cui """C0700709"""^^xsd:string ; umls:cui """C0068980"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/etoposide/mechlorethamine/vinblastine/vincristine"""@eng ; skos:notation """CDR0000041508"""^^xsd:string ; skos:altLabel """BLEO/DOX/NM/VBL/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4664"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281137"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000041509"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/G-CSF/VP-16"""@eng ; ; ; ; ; ; """4665"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338155"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody OKT3/pentoxifylline"""@eng ; skos:notation """CDR0000041506"""^^xsd:string ; skos:altLabel """IL-2/MOAB OKT3/PTX"""@eng ; ; ; ; """4662"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338201"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/etoposide/filgrastim/ifosfamide"""@eng ; skos:notation """CDR0000041507"""^^xsd:string ; skos:altLabel """CDDP/DOX/G-CSF/IFF/VP-16"""@eng ; ; ; ; ; ; """4663"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281136"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/doxorubicin/filgrastim/vincristine"""@eng ; skos:notation """CDR0000041504"""^^xsd:string ; skos:altLabel """CTX/DACT/DOX/G-CSF/VCR"""@eng ; ; ; ; ; ; """4660"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281133"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/filgrastim/melphalan"""@eng ; skos:notation """CDR0000041505"""^^xsd:string ; skos:altLabel """G-CSF/L-PAM/VP-16"""@eng ; ; ; ; """4661"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281134"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/filgrastim/mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000041502"""^^xsd:string ; skos:altLabel """DOX/G-CSF/MP/PRED/VCR"""@eng ; ; ; ; ; ; """4658"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281131"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/filgrastim/prednisone/vincristine"""@eng ; skos:notation """CDR0000041503"""^^xsd:string ; skos:altLabel """DOX/G-CSF/PRED/VCR"""@eng ; ; ; ; ; """4659"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281132"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/filgrastim"""@eng ; skos:notation """CDR0000041500"""^^xsd:string ; skos:altLabel """ARA-C/CTX/G-CSF"""@eng ; ; ; ; """4656"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281129"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/filgrastim/teniposide"""@eng ; skos:notation """CDR0000041501"""^^xsd:string ; skos:altLabel """ARA-C/G-CSF/VM-26"""@eng ; ; ; ; """4657"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281130"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic pheochromocytoma"""@eng ; skos:notation """CDR0000040118"""^^xsd:string ; skos:altLabel """pheochromocytoma, metastatic"""@eng ; rdfs:subClassOf ; """pheochromocytoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2880"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279821"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent pheochromocytoma"""@eng ; skos:notation """CDR0000040119"""^^xsd:string ; skos:altLabel """pheochromocytoma, recurrent"""@eng ; rdfs:subClassOf ; """pheochromocytoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2881"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279822"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized benign pheochromocytoma"""@eng ; skos:notation """CDR0000040116"""^^xsd:string ; skos:altLabel """pheochromocytoma, localized benign"""@eng , """benign pheochromocytoma, localized"""@eng , """pheochromocytoma, benign, localized"""@eng ; rdfs:subClassOf ; """pheochromocytoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2878"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279819"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """regional pheochromocytoma"""@eng ; skos:notation """CDR0000040117"""^^xsd:string ; skos:altLabel """pheochromocytoma, regional"""@eng ; rdfs:subClassOf ; """pheochromocytoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2879"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279820"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000257847"""^^xsd:string ; skos:altLabel """CBDCA/G-CSF/VP-16"""@eng ; ; ; ; """2002-09-11"""^^xsd:string ; """11466"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327788"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lanreotide (long-acting aqueous preparation)"""@eng ; skos:notation """CDR0000486962"""^^xsd:string ; skos:altLabel """Somatuline Autogel"""@eng ; """2006-06-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1831853"""^^xsd:string ; umls:cui """C1831852"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II laryngeal cancer"""@eng ; skos:notation """CDR0000040112"""^^xsd:string ; skos:altLabel """laryngeal cancer, stage II"""@eng , """larynx cancer, stage II"""@eng ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2874"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279815"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III laryngeal cancer"""@eng ; skos:notation """CDR0000040113"""^^xsd:string ; skos:altLabel """laryngeal cancer, stage III"""@eng , """larynx cancer, stage III"""@eng ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2875"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279816"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior androgen therapy"""@eng ; skos:notation """CDR0000040110"""^^xsd:string ; skos:altLabel """androgen therapy, prior"""@eng ; """2872"""^^xsd:string ; umls:cui """C0279813"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I laryngeal cancer"""@eng ; skos:notation """CDR0000040111"""^^xsd:string ; skos:altLabel """laryngeal cancer, stage I"""@eng , """larynx cancer, stage I"""@eng ; rdfs:subClassOf ; """laryngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2873"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279814"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/imatinib mesylate"""@eng ; skos:notation """CDR0000374717"""^^xsd:string ; skos:altLabel """CAPE/STI571"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541307"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/cyclophosphamide/epirubicin/fluorouracil"""@eng ; skos:notation """CDR0000374712"""^^xsd:string ; skos:altLabel """CTX/EPI/5-FU/SC-58635"""@eng ; ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541306"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """STA-4783"""@eng ; skos:notation """CDR0000377539"""^^xsd:string ; skos:altLabel """STA 4783"""@eng ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541326"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000374711"""^^xsd:string ; skos:altLabel """CTX/DOX/SC-58635"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541305"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039338"""^^xsd:string ; skos:altLabel """ACOPP"""@eng , """CTX/DOX/PCB/PRED/VCR"""@eng ; ; ; ; ; ; """1974"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0069578"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """4-nitroestrone 3-methyl ether"""@eng ; skos:notation """CDR0000039339"""^^xsd:string ; skos:altLabel """4-Nitroestrone"""@eng ; skos:definition """A synthetic derivative of estradiol. 4-nitroestrone 3-methyl ether inhibits estrogen sulfotransferase (EST), a progesterone-induced secretory endometrial enzyme which affects estrogen receptor levels. This agent has been shown to be an effective growth inhibitor of some chemically induced animal mammary tumors. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39339&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39339&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C977\" NCI Thesaurus)"""@eng ; """1975"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """C977"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """14846-62-9"""^^xsd:string ; """321803"""^^xsd:string ; umls:cui """C0048573"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/thymidine"""@eng ; skos:notation """CDR0000039332"""^^xsd:string ; skos:altLabel """BCNU/TDR"""@eng ; ; ; """1968"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279201"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000039333"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/PRED/VCR"""@eng ; ; ; ; ; ; """1969"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279202"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/prednisone"""@eng ; skos:notation """CDR0000039330"""^^xsd:string ; skos:altLabel """MP"""@eng , """L-PAM/PRED"""@eng ; ; ; """1966"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0284383"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/interleukin-4"""@eng ; skos:notation """CDR0000039331"""^^xsd:string ; skos:altLabel """IL-2/IL-4"""@eng ; ; ; """1967"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279200"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/dexamethasone/doxorubicin HCl liposome"""@eng ; skos:notation """CDR0000441230"""^^xsd:string ; skos:altLabel """DM/LipoDox/PS-341"""@eng ; ; ; ; """2005-07-25"""^^xsd:string ; """2005-08-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831690"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin"""@eng ; skos:notation """CDR0000039337"""^^xsd:string ; skos:altLabel """ATG"""@eng , """Thymoglobulin"""@eng , """ATGAM"""@eng , """antithymocyte globulin"""@eng , """lymphocyte immune globulin"""@eng ; skos:definition """A purified gamma immunoglobulin with immunosuppressive properties. Obtained from rabbits that have been immunized with human thymocytes, antithymocyte globulin specifically recognizes and destroys T lymphocytes. Although the exact mechanism of action is not completely understood, it appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering antithymocyte globulin with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39337&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39337&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C278\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1973"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C278"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0730920"""^^xsd:string ; umls:cui """C0004149"""^^xsd:string ; umls:cui """C0003442"""^^xsd:string ; umls:cui """C0305055"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/talabostat"""@eng ; skos:notation """CDR0000441232"""^^xsd:string ; skos:altLabel """dFdC/PT-100"""@eng ; ; ; """2005-07-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-05"""^^xsd:string ; umls:cui """C1831691"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/sargramostim"""@eng ; skos:notation """CDR0000039335"""^^xsd:string ; skos:altLabel """CBDCA/GM-CSF"""@eng ; ; ; """1971"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279204"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melphalan/vincristine"""@eng ; skos:notation """CDR0000041443"""^^xsd:string ; skos:altLabel """L-PAM/VCR"""@eng ; ; ; """4513"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280991"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/methotrexate/sargramostim/vinblastine"""@eng ; skos:notation """CDR0000041442"""^^xsd:string ; skos:altLabel """CDDP/DOX/GM-CSF/MTX/VBL"""@eng ; ; ; ; ; ; """4512"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280990"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/mitomycin/vindesine"""@eng ; skos:notation """CDR0000041441"""^^xsd:string ; skos:altLabel """CDDP/DAVA/5-FU/MITO"""@eng ; ; ; ; ; """4511"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280989"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """macrophage colony-stimulating factor/monoclonal antibody R24"""@eng ; skos:notation """CDR0000041440"""^^xsd:string ; skos:altLabel """M-CSF/MOAB R24"""@eng ; ; ; """4510"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280988"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/quinine/verapamil/vincristine"""@eng ; skos:notation """CDR0000041447"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/QUIN/VCR/VPAM"""@eng ; ; ; ; ; ; ; """4517"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280995"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/topotecan"""@eng ; skos:notation """CDR0000041446"""^^xsd:string ; skos:altLabel """G-CSF/TOPO"""@eng ; ; ; """4516"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280994"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cisplatin/cyclophosphamide/filgrastim"""@eng ; skos:notation """CDR0000041445"""^^xsd:string ; skos:altLabel """CBDCA/CDDP/CTX/G-CSF"""@eng ; ; ; ; ; """4515"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280993"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/prednisolone/vincristine"""@eng ; skos:notation """CDR0000041444"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/PRDL/VCR"""@eng ; ; ; ; ; ; """4514"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078165"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000041449"""^^xsd:string ; skos:altLabel """5-FU/G-CSF/IFN-A"""@eng ; ; ; ; """4519"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338151"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000041448"""^^xsd:string ; skos:altLabel """CBDCA/GM-CSF/IFF"""@eng ; ; ; ; """4518"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280996"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alfuzosin hydrochloride"""@eng ; skos:notation """CDR0000465648"""^^xsd:string ; skos:altLabel """Uroxatrol"""@eng ; skos:definition """The hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. Alfuzosin selectively binds to and antagonizes post-synaptic alpha1-adrenoreceptors in smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). This agent also blocks alpha1-adrenoreceptors in peripheral vascular smooth muscle, resulting in vasodilatation and a decrease in peripheral vascular resistance. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465648&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=465648&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53408\" NCI Thesaurus)"""@eng ; """C53408"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0102130"""^^xsd:string ; umls:cui """C1706764"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000038481"""^^xsd:string ; skos:altLabel """ARA-C/DM/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; ; """11101"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134519"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/filgrastim/topotecan"""@eng ; skos:notation """CDR0000041999"""^^xsd:string ; skos:altLabel """CTX/G-CSF/TOPO"""@eng ; ; ; ; """5224"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281543"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/interleukin-2/melphalan/tumor necrosis factor"""@eng ; skos:notation """CDR0000041998"""^^xsd:string ; skos:altLabel """IFN-G/IL-2/L-PAM/TNF"""@eng ; ; ; ; ; """5223"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281542"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gallium nitrate/hydroxyurea"""@eng ; skos:notation """CDR0000041991"""^^xsd:string ; skos:altLabel """GAN/HU"""@eng ; ; ; """5216"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281535"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000041990"""^^xsd:string ; skos:altLabel """CF/CPT-11/5-FU"""@eng ; ; ; ; """5215"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281534"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/milodistim/thiotepa"""@eng ; skos:notation """CDR0000041993"""^^xsd:string ; skos:altLabel """CBDCA/CTX/PIXY321/TSPA"""@eng ; ; ; ; ; """5218"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281537"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/milodistim"""@eng ; skos:notation """CDR0000041992"""^^xsd:string ; skos:altLabel """CTX/PIXY321"""@eng ; ; ; """5217"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281536"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000041995"""^^xsd:string ; skos:altLabel """ARA-C/DOX/PRED/TG/VCR"""@eng ; ; ; ; ; ; """5220"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281539"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cyclophosphamide/etoposide/interferon alfa"""@eng ; skos:notation """CDR0000041994"""^^xsd:string ; skos:altLabel """BCNU/CTX/IFN-A/VP-16"""@eng ; ; ; ; ; """5219"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338182"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/vincristine"""@eng ; skos:notation """CDR0000041997"""^^xsd:string ; skos:altLabel """CCNU/VCR"""@eng ; ; ; """5222"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281541"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-1-alpha/methotrexate"""@eng ; skos:notation """CDR0000041996"""^^xsd:string ; skos:altLabel """IL-1A/MTX"""@eng ; ; ; """5221"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281540"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cBR96-doxorubicin immunoconjugate/docetaxel"""@eng ; skos:notation """CDR0000038480"""^^xsd:string ; skos:altLabel """SGN-15/TXT"""@eng ; ; ; """11100"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134518"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hepatitis B vaccine"""@eng ; skos:notation """CDR0000532310"""^^xsd:string ; skos:definition """A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=532310&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=532310&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29091\" NCI Thesaurus)"""@eng ; """2007-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C29091"""^^xsd:string ; umls:cui """C0062527"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """synthetic human corticotropin-releasing factor"""@eng ; skos:notation """CDR0000385686"""^^xsd:string ; skos:altLabel """corticorelin"""@eng , """corticoliberin"""@eng , """hCRF"""@eng , """Xerecept"""@eng ; skos:definition """A synthetic therapeutic agent which is chemically identical to or similar to the endogenous human corticotropin-releasing factor (hCRF). Synthesized in the hypothalamus, hCRF stimulates the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH). In cerebral edema, hCRF acts by impeding the flow of fluid from blood vessels into brain tissue, thereby decreasing edema and stabilizing intracranial pressure. This agent possesses anti-edema properties independent of adrenal gland function. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385686&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385686&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C394\" NCI Thesaurus)"""@eng ; """C394"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1515366"""^^xsd:string ; umls:cui """C1515367"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/IM-862/paclitaxel"""@eng ; skos:notation """CDR0000038317"""^^xsd:string ; skos:altLabel """CBDCA/IM 862/TAX"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """10930"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935864"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """grade 1 follicular lymphoma"""@eng ; skos:notation """CDR0000038316"""^^xsd:string ; skos:altLabel """nodular lymphocytic, poorly-differentiated lymphoma"""@eng , """lymphoma, follicular small cleaved cell"""@eng , """nodular PDL lymphoma"""@eng , """nodular poorly-differentiated lymphocytic lymphoma"""@eng , """NPDL lymphoma"""@eng , """poorly-differentiated lymphoma, nodular lymphocytic"""@eng , """PDL, nodular lymphocytic"""@eng , """small cleaved cell lymphoma, follicular"""@eng , """follicular small cleaved cell lymphoma"""@eng , """lymphoma, nodular lymphocytic, poorly-differentiated"""@eng , """NLPD lymphoma"""@eng , """grade I follicular small cleaved cell lymphoma"""@eng , """FSC lymphoma"""@eng ; rdfs:subClassOf ; """2003-11-19"""^^xsd:string ; """1093"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1956130"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cevimeline hydrochloride"""@eng ; skos:notation """CDR0000038315"""^^xsd:string ; skos:altLabel """Evoxac"""@eng , """AF-102B"""@eng , """cevimeline"""@eng ; skos:definition """A cholinergic analogue with glandular secretion stimulatory activity. Cevimeline binds to and activates muscarinic receptors, thereby increasing the secretions in exocrine salivary and sweat glands. This cholinergic agonist also increases the tone of smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is being studied as a treatment for dry mouth caused by radiation therapy to the head and neck. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38315&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38315&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1337\" NCI Thesaurus)"""@eng ; """2006-05-10"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """107233-08-9"""^^xsd:string ; """C1337"""^^xsd:string ; """10929"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0050910"""^^xsd:string ; umls:cui """C0874063"""^^xsd:string ; umls:cui """C0093437"""^^xsd:string ; umls:cui """C0876027"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/ISIS 3521/paclitaxel"""@eng ; skos:notation """CDR0000038314"""^^xsd:string ; skos:altLabel """CBDCA/ISIS-3521/TAX"""@eng ; ; ; ; """2003-10-28"""^^xsd:string ; """10928"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935863"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """keyhole limpet hemocyanin/sargramostim"""@eng ; skos:notation """CDR0000038313"""^^xsd:string ; skos:altLabel """GM-CSF/KLH"""@eng ; ; ; """10927"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935862"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/pegaspargase"""@eng ; skos:notation """CDR0000038312"""^^xsd:string ; skos:altLabel """DM/PEG-ASP"""@eng ; ; ; """10926"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935861"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000038311"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/MP/MTX"""@eng ; ; ; ; ; ; """10925"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935860"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisolone"""@eng ; skos:notation """CDR0000038310"""^^xsd:string ; skos:altLabel """ARA-C/CTX/MP/MTX/PRDL"""@eng ; ; ; ; ; ; """10924"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935859"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/gemcitabine"""@eng ; skos:notation """CDR0000038319"""^^xsd:string ; skos:altLabel """dFdC/EPI"""@eng ; ; ; """10933"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935866"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/dexamethasone"""@eng ; skos:notation """CDR0000038318"""^^xsd:string ; skos:altLabel """AS203/DM"""@eng ; ; ; """10932"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935865"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """muscle cancer"""@eng ; skos:notation """CDR0000039804"""^^xsd:string ; rdfs:subClassOf ; """2471"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0684743"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mediastinal cancer"""@eng ; skos:notation """CDR0000039805"""^^xsd:string ; rdfs:subClassOf ; """2475"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153504"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pleura cancer"""@eng ; skos:notation """CDR0000039806"""^^xsd:string ; rdfs:subClassOf ; """2476"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153494"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """kidney tumor"""@eng ; skos:notation """CDR0000039807"""^^xsd:string ; ; rdfs:subClassOf ; ; """2477"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0022665"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hematopoietic/lymphoid cancer"""@eng ; skos:notation """CDR0000039800"""^^xsd:string ; skos:altLabel """hematologic cancer"""@eng ; ; ; rdfs:subClassOf ; """2002-10-16"""^^xsd:string ; """2467"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0376545"""^^xsd:string ; umls:cui """C0348393"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """male reproductive cancer"""@eng ; skos:notation """CDR0000039801"""^^xsd:string ; rdfs:subClassOf ; """2468"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0699888"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000039802"""^^xsd:string ; skos:altLabel """lymphoma, childhood lymphoblastic non-Hodgkin's"""@eng , """lymphoma, pediatric lymphoblastic"""@eng , """lymphoblastic lymphoma, pediatric"""@eng , """CLNHL"""@eng , """lymphoblastic non-Hodgkin's lymphoma, childhood"""@eng , """lymphoma, childhood lymphoblastic"""@eng , """NHL, childhood lymphoblastic"""@eng , """pediatric lymphoblastic non-Hodgkin's lymphoma"""@eng , """lymphoblastic lymphoma, childhood"""@eng , """non-Hodgkin's lymphoma, childhood lymphoblastic"""@eng , """pediatric lymphoblastic lymphoma"""@eng ; rdfs:subClassOf ; """2469"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279525"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxyprogesterone caproate"""@eng ; skos:notation """CDR0000039803"""^^xsd:string ; skos:altLabel """Delalutin"""@eng ; """247"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0044971"""^^xsd:string ; umls:cui """C0112800"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone cancer"""@eng ; skos:notation """CDR0000039808"""^^xsd:string ; rdfs:subClassOf ; """2478"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279530"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypercalcemia therapy"""@eng ; skos:notation """CDR0000039809"""^^xsd:string ; skos:altLabel """hypercalcemia control/bone resorption"""@eng , """therapy, hypercalcemia"""@eng , """bone resorption/hypercalcemia control"""@eng ; ; rdfs:subClassOf ; """2486"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0279531"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BB-10901"""@eng ; skos:notation """CDR0000346110"""^^xsd:string ; skos:altLabel """huN901-DM1"""@eng ; skos:definition """An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346110&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346110&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38714\" NCI Thesaurus)"""@eng ; """2003-11-20"""^^xsd:string ; """C38714"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C3537051"""^^xsd:string ; umls:cui """C1328107"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/oxaliplatin"""@eng ; skos:notation """CDR0000319029"""^^xsd:string ; skos:altLabel """L-OHP/PS-341"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328009"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AZD7762"""@eng ; skos:notation """CDR0000530784"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832037"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """donor lymphocytes"""@eng ; skos:notation """CDR0000468767"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-12"""^^xsd:string ; """2006-02-10"""^^xsd:string ; umls:cui """C1395724"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """light-scattering spectroscopy"""@eng ; skos:notation """CDR0000353384"""^^xsd:string ; rdfs:subClassOf ; """2004-01-23"""^^xsd:string ; """2004-01-20"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C1328171"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spectroscopy"""@eng ; skos:notation """CDR0000353385"""^^xsd:string ; rdfs:subClassOf ; """2004-01-23"""^^xsd:string ; """2004-01-20"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0037812"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interferon alpha-1b"""@eng ; skos:notation """CDR0000466520"""^^xsd:string ; skos:altLabel """Recombinant Interferon Alfa-1b"""@eng ; skos:definition """The non-glycosylated recombinant interferon alpha, subtype 1b, with immunostimulatory and antineoplastic activities. Alpha interferon-1b binds to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=466520&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=466520&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53411\" NCI Thesaurus)"""@eng ; """2006-07-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """C53411"""^^xsd:string ; umls:cui """C1831728"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mouse prostate-specific membrane antigen plasmid DNA vaccine"""@eng ; skos:notation """CDR0000394099"""^^xsd:string ; skos:altLabel """mouse PSMA DNA"""@eng ; skos:definition """A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=394099&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=394099&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48411\" NCI Thesaurus)"""@eng ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2004-10-25"""^^xsd:string ; """C48411"""^^xsd:string ; umls:cui """C1709080"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human prostate-specific membrane antigen plasmid DNA vaccine"""@eng ; skos:notation """CDR0000394098"""^^xsd:string ; skos:altLabel """human PSMA DNA"""@eng ; skos:definition """A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=394098&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=394098&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48396\" NCI Thesaurus)"""@eng ; """C48396"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """2004-10-25"""^^xsd:string ; umls:cui """C1711177"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/panitumumab"""@eng ; skos:notation """CDR0000329881"""^^xsd:string ; skos:altLabel """CBDCA/MOAB ABX-EGF/TAX"""@eng ; ; ; ; """2003-08-24"""^^xsd:string ; """2004-10-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328036"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ibuprofen"""@eng ; skos:notation """CDR0000040475"""^^xsd:string ; skos:altLabel """Motrin"""@eng , """Benzeneacetic Acid, Alpha-methyl-4-(2-methylpropyl)-"""@eng , """p-Isobutylhydratropic Acid"""@eng ; skos:definition """A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40475&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40475&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C561\" NCI Thesaurus)"""@eng ; """3359"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """256857"""^^xsd:string ; """C561"""^^xsd:string ; """15687-27-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699203"""^^xsd:string ; umls:cui """C0020740"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """perfosfamide"""@eng ; skos:notation """CDR0000040474"""^^xsd:string ; skos:altLabel """Pergamid"""@eng , """cis-2-[bis(2-chloroethyl)amino]tetrahydro-3H-1,3,2-oxazaphosphorin-4-yl hydroperoxide P-oxide"""@eng , """Hydroperoxycyclophosphamide"""@eng , """4-hydroperoxycyclophosphamide"""@eng , """4-HC"""@eng , """2-[bis(2-chloroethyl)amino]-4-hydroperoxytetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide"""@eng , """4-Pergamid"""@eng , """cis-4-hydroperoxycyclophosphamide"""@eng , """4'-hydroperoxycyclophosphamide"""@eng ; skos:definition """The active metabolite of the nitrogen mustard cyclophosphamide with potent antineoplastic and immunosuppressive properties. Perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40474&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40474&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1423\" NCI Thesaurus)"""@eng ; """3358"""^^xsd:string ; """C1423"""^^xsd:string ; """39800-16-3"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """181815"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1328687"""^^xsd:string ; umls:cui """C0163054"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """growth factor antagonist therapy"""@eng ; skos:notation """CDR0000040477"""^^xsd:string ; skos:altLabel """therapy, growth factor antagonist"""@eng ; ; rdfs:subClassOf ; ; """3362"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0280112"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000040476"""^^xsd:string ; skos:altLabel """CF/5-FU/FUDR"""@eng ; ; ; ; """3360"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280110"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin"""@eng ; skos:notation """CDR0000040471"""^^xsd:string ; skos:altLabel """DOX/DTIC"""@eng , """AD"""@eng ; ; ; """3355"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050841"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/mitomycin/vindesine"""@eng ; skos:notation """CDR0000040470"""^^xsd:string ; skos:altLabel """BLEO/DAVA/MITO"""@eng , """BEM"""@eng ; ; ; ; """3354"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280106"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/interleukin-2"""@eng ; skos:notation """CDR0000040473"""^^xsd:string ; skos:altLabel """CTX/DOX/IL-2/VP-16"""@eng , """LACE"""@eng ; ; ; ; ; """3357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280109"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin/ifosfamide"""@eng ; skos:notation """CDR0000040472"""^^xsd:string ; skos:altLabel """DOX/DTIC/IFF"""@eng , """AID"""@eng ; ; ; ; """3356"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280108"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult non-Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040479"""^^xsd:string ; skos:altLabel """stage I adult NHL"""@eng , """adult non-Hodgkin's lymphoma, stage I"""@eng , """lymphoma, stage I, adult non-Hodgkin's"""@eng , """non-Hodgkin's lymphoma, stage I adult"""@eng , """NHL, stage I adult"""@eng ; rdfs:subClassOf ; """adult non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3365"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280114"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """transitional cell cancer of the renal pelvis and ureter"""@eng ; skos:notation """CDR0000040478"""^^xsd:string ; skos:altLabel """carcinoma of the renal pelvis and ureter"""@eng , """cancer of the renal pelvis and ureter"""@eng , """TCC of the renal pelvis and ureter"""@eng , """transitional cell carcinoma of the renal pelvis and ureter"""@eng , """Renal pelvis and ureter cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3364"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1370932"""^^xsd:string ; umls:cui """C0220648"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim/telomerase: 540-548 peptide vaccine"""@eng ; skos:notation """CDR0000304353"""^^xsd:string ; skos:altLabel """GM-CSF/TEL540-548"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327964"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """balloon brachytherapy"""@eng ; skos:notation """CDR0000531782"""^^xsd:string ; rdfs:subClassOf ; """2007-01-18"""^^xsd:string ; """2007-01-19"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1832047"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lonafarnib/temozolomide"""@eng ; skos:notation """CDR0000361541"""^^xsd:string ; skos:altLabel """SCH 66336/TMZ"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541171"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/gemtuzumab ozogamicin"""@eng ; skos:notation """CDR0000361540"""^^xsd:string ; skos:altLabel """ARA-C/CMA-676/DNR"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541170"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody huJ591"""@eng ; skos:notation """CDR0000361543"""^^xsd:string ; skos:altLabel """IL-2/MOAB huJ591"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541173"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/lonafarnib"""@eng ; skos:notation """CDR0000361542"""^^xsd:string ; skos:altLabel """SCH 66336/TXT"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541172"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/gemtuzumab ozogamicin/melphalan"""@eng ; skos:notation """CDR0000361545"""^^xsd:string ; skos:altLabel """CMA-676/FAMP/L-PAM"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541175"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/tipifarnib"""@eng ; skos:notation """CDR0000361544"""^^xsd:string ; skos:altLabel """R115777/STI571"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541174"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/imatinib mesylate/methotrexate"""@eng ; skos:notation """CDR0000361547"""^^xsd:string ; skos:altLabel """ARA-C/MTX/STI571"""@eng ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541177"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/imatinib mesylate/vincristine"""@eng ; skos:notation """CDR0000361546"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/STI571/VCR"""@eng ; ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541176"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/doxorubicin/pegfilgrastim/vinblastine"""@eng ; skos:notation """CDR0000361549"""^^xsd:string ; skos:altLabel """BLEO/DOX/DTIC/GCSF-SD01/VBL"""@eng ; ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541179"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/paclitaxel/trastuzumab/vinorelbine"""@eng ; skos:notation """CDR0000361548"""^^xsd:string ; skos:altLabel """G-CSF/MOAB HER2/TAX/VNB"""@eng ; ; ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541178"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood grade III lymphomatoid granulomatosis"""@eng ; skos:notation """CDR0000377891"""^^xsd:string ; rdfs:subClassOf ; """2004-06-23"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1541446"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pNGVL3-hICD vaccine"""@eng ; skos:notation """CDR0000468837"""^^xsd:string ; skos:definition """A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468837&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468837&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61146\" NCI Thesaurus)"""@eng ; """2006-07-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """C61146"""^^xsd:string ; umls:cui """C1831753"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triptorelin pamoate"""@eng ; skos:notation """CDR0000468834"""^^xsd:string ; skos:altLabel """Trelstar Depot"""@eng , """Pamorelin"""@eng , """6-D-Tryptophan-, 4,4'Mmethylenebis(3-hydroxy-2-naphthalenecarboxylate) (Salt)"""@eng ; skos:definition """The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration. After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed. The serum testosterone concentration may fall to levels typically seen in surgically castrated men. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468834&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=468834&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29523\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """724666"""^^xsd:string ; """C29523"""^^xsd:string ; """124508-66-3"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C1137102"""^^xsd:string ; umls:cui """C0939509"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """precancerous/nonmalignant condition"""@eng ; skos:notation """CDR0000306533"""^^xsd:string ; skos:altLabel """precancerous state"""@eng , """premalignant condition"""@eng , """nonmalignant condition"""@eng , """premalignant state"""@eng , """Precancerous/nonmalignant condition"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """2003-05-23"""^^xsd:string ; umls:cui """C0032927"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dual-energy x-ray absorptiometry"""@eng ; skos:notation """CDR0000495448"""^^xsd:string ; skos:altLabel """DEXA scan"""@eng ; rdfs:subClassOf ; """Diagnostic test/procedure"""^^xsd:string ; """2006-07-14"""^^xsd:string ; """2006-07-13"""^^xsd:string ; umls:cui """C1510486"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """shark cartilage extract AE-941"""@eng ; skos:notation """CDR0000042021"""^^xsd:string ; skos:altLabel """Neovastat"""@eng , """AE-941"""@eng , """Neovastat/AE-941"""@eng ; skos:definition """A multifunctional antiangiogenic agent derived from shark cartilage with potential antineoplastic activity. Shark cartilage extract AE-941 competitively inhibits the binding of pro-angiogenic vascular endothelial growth factor (VEGF) to its cell receptor, thereby inhibiting endothelial cell proliferation. This agent also inhibits matrix metalloproteinases (MMPs), stimulates tissue plasminogen activator (tPA), and activates caspase-mediated apoptotic pathways in endothelial cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42021&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42021&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1798\" NCI Thesaurus)"""@eng ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """5247"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """59439"""^^xsd:string ; """305838-77-1"""^^xsd:string ; """2006-07-19"""^^xsd:string ; """706456"""^^xsd:string ; """C1798"""^^xsd:string ; umls:cui """C0935986"""^^xsd:string ; umls:cui """C1963096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cognitive assessment"""@eng ; skos:notation """CDR0000042473"""^^xsd:string ; ; rdfs:subClassOf ; """5932"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0870300"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """complementary and alternative therapy"""@eng ; skos:notation """CDR0000042022"""^^xsd:string ; ; rdfs:subClassOf ; ; ; ; ; ; """5248"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1456846"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Biomed 101"""@eng ; skos:notation """CDR0000037882"""^^xsd:string ; skos:definition """An agent binding to the leukotriene B4 receptor, leading to reduced interleukin-2 mediated hypoxia. Biomed 101 does not affect interleukin-2 antitumor activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37882&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37882&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2206\" NCI Thesaurus)"""@eng ; ; """10285"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C2206"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879447"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/doxorubicin"""@eng ; skos:notation """CDR0000038420"""^^xsd:string ; skos:altLabel """DOX/PS-341"""@eng ; ; ; """2002-11-19"""^^xsd:string ; """11037"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134476"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """silicon phthalocyanine 4"""@eng ; skos:notation """CDR0000038423"""^^xsd:string ; skos:altLabel """Pc-4 (Silicone phthalocyanine)"""@eng , """Pc 4"""@eng , """Pc4"""@eng ; skos:definition """A synthetic photosensitizer agent containing a large macrocyclic ring chelated with silicon. Silicon phthalocyanine 4 localizes primarily in mitochondrial cytosolic membranes and, after photoexcitation, forms reactive oxygen species that induce apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38423&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38423&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2651\" NCI Thesaurus)"""@eng ; """11040"""^^xsd:string ; """676418"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2651"""^^xsd:string ; umls:cui """C1328695"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult Burkitt's lymphoma"""@eng ; skos:notation """CDR0000038422"""^^xsd:string ; skos:altLabel """lymphoma, small noncleaved cell, adult"""@eng , """diffuse undifferentiated lymphoma, adult"""@eng , """adult diffuse small noncleaved cell/Burkitt's lymphoma"""@eng , """lymphoma, diffuse undifferentiated, adult"""@eng , """DUL, adult"""@eng , """SNC lymphoma, adult"""@eng , """adult SNC lymphoma"""@eng , """small noncleaved cell lymphoma, adult"""@eng ; rdfs:subClassOf ; """2003-11-19"""^^xsd:string ; """1104"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278764"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thromboembolism"""@eng ; skos:notation """CDR0000037886"""^^xsd:string ; rdfs:subClassOf ; """10294"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0040038"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levodopa"""@eng ; skos:notation """CDR0000042622"""^^xsd:string ; skos:altLabel """(--)-3-(3,4-Dihydroxyphenyl)-L-alanine"""@eng , """3-Hydroxy-L-tyrosine"""@eng , """Levopa"""@eng , """Dopar"""@eng , """Doparkine"""@eng , """Maipedopa"""@eng , """Doparl"""@eng , """Cidandopa"""@eng , """Parda"""@eng , """(--)-2Amino-3-)3,4-dihydroxyphenyl)propanoic Acid"""@eng , """Dopal"""@eng , """Veldopa"""@eng , """beta-(3,4-Dihydroxyphenyl)-L-alanine"""@eng , """Laradopa"""@eng , """Ledopa"""@eng , """Eldopal"""@eng , """Eldopatec"""@eng , """Dopaston"""@eng , """Dopastral"""@eng , """Eurodopa"""@eng , """Bendopa"""@eng , """Dopaflex"""@eng , """Doprin"""@eng , """Deadopa"""@eng , """Dopalina"""@eng , """Dopasol"""@eng , """L-dopa"""@eng , """Larodopa"""@eng , """Dopaidan"""@eng , """Eldopar"""@eng ; skos:definition """An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42622&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42622&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C611\" NCI Thesaurus)"""@eng ; """6342"""^^xsd:string ; """C611"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """118381"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517861"""^^xsd:string ; umls:cui """C1517860"""^^xsd:string ; umls:cui """C1517849"""^^xsd:string ; umls:cui """C1517848"""^^xsd:string ; umls:cui """C1517865"""^^xsd:string ; umls:cui """C1517864"""^^xsd:string ; umls:cui """C0700880"""^^xsd:string ; umls:cui """C1517846"""^^xsd:string ; umls:cui """C1517845"""^^xsd:string ; umls:cui """C1517863"""^^xsd:string ; umls:cui """C1517862"""^^xsd:string ; umls:cui """C1517851"""^^xsd:string ; umls:cui """C1517852"""^^xsd:string ; umls:cui """C1517858"""^^xsd:string ; umls:cui """C1517859"""^^xsd:string ; umls:cui """C1517850"""^^xsd:string ; umls:cui """C1517847"""^^xsd:string ; umls:cui """C0720022"""^^xsd:string ; umls:cui """C1517853"""^^xsd:string ; umls:cui """C1517854"""^^xsd:string ; umls:cui """C1517855"""^^xsd:string ; umls:cui """C1517856"""^^xsd:string ; umls:cui """C1517857"""^^xsd:string ; umls:cui """C0023570"""^^xsd:string ; umls:cui """C1449995"""^^xsd:string ; umls:cui """C0699991"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 melanoma"""@eng ; skos:notation """CDR0000042623"""^^xsd:string ; skos:altLabel """melanoma, stage 0"""@eng ; rdfs:subClassOf ; """melanoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """6344"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0346040"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ethynyluracil/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000042620"""^^xsd:string ; skos:altLabel """776C85/CF/5-FU"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """6340"""^^xsd:string ; umls:cui """C0393028"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/paclitaxel"""@eng ; skos:notation """CDR0000042621"""^^xsd:string ; skos:altLabel """EPI/TAX"""@eng ; ; ; """6341"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393029"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tipifarnib"""@eng ; skos:notation """CDR0000042626"""^^xsd:string ; skos:altLabel """R115777"""@eng , """Zarnestra"""@eng , """(+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone"""@eng ; skos:definition """A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42626&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42626&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1703\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """6348"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """702818"""^^xsd:string ; """2006-06-05"""^^xsd:string ; """58359"""^^xsd:string ; """192185-72-1"""^^xsd:string ; """C1703"""^^xsd:string ; umls:cui """C0393031"""^^xsd:string ; umls:cui """C1174783"""^^xsd:string ; umls:cui """C1176289"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/fludarabine/mitoxantrone"""@eng ; skos:notation """CDR0000042627"""^^xsd:string ; skos:altLabel """DHAD/DM/FAMP"""@eng ; ; ; ; """6349"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393032"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """efaproxiral"""@eng ; skos:notation """CDR0000042624"""^^xsd:string ; skos:altLabel """RSR-13"""@eng , """RSR 13"""@eng , """RSR13"""@eng ; skos:definition """A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42624&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42624&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37453\" NCI Thesaurus)"""@eng ; ; """6345"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C37453"""^^xsd:string ; """2006-08-01"""^^xsd:string ; umls:cui """C0080719"""^^xsd:string ; umls:cui """C0165792"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """raltitrexed"""@eng ; skos:notation """CDR0000042625"""^^xsd:string ; skos:altLabel """N-(5-[N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic Acid"""@eng , """ZD1694"""@eng , """N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic Acid"""@eng , """ICI D1694"""@eng , """TDX"""@eng , """Tomudex"""@eng , """ICI-D1694"""@eng , """D1694"""@eng ; skos:definition """A quinazoline folate analogue with antineoplastic activity. After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42625&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42625&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1804\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """6346"""^^xsd:string ; """639186"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """37230"""^^xsd:string ; """C1804"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1527088"""^^xsd:string ; umls:cui """C0677667"""^^xsd:string ; umls:cui """C0878095"""^^xsd:string ; umls:cui """C0123106"""^^xsd:string ; umls:cui """C0950790"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """luteinizing hormone-releasing factor"""@eng ; skos:notation """CDR0000042628"""^^xsd:string ; skos:altLabel """LHRH"""@eng , """D-His-6-Pro-8-NEt-LHRH"""@eng ; ; """635"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0023610"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium Tc 99m monoclonal antibody 170"""@eng ; skos:notation """CDR0000042629"""^^xsd:string ; skos:altLabel """Tc99m MOAB 170"""@eng ; """6351"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393033"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/fludarabine/isotretinoin"""@eng ; skos:notation """CDR0000038429"""^^xsd:string ; skos:altLabel """ARA-C/13-CRA/FAMP"""@eng ; ; ; ; """11046"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134481"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib hydrochloride"""@eng ; skos:notation """CDR0000038428"""^^xsd:string ; skos:altLabel """OSI-774"""@eng , """CP-358,774"""@eng , """OSI774"""@eng , """CP358774"""@eng , """Tarceva"""@eng , """N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride"""@eng , """erlotinib"""@eng ; skos:definition """The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38428&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38428&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2693\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """11045"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """718781"""^^xsd:string ; """183319-69-9"""^^xsd:string ; """63383"""^^xsd:string ; """C2693"""^^xsd:string ; umls:cui """C1533491"""^^xsd:string ; umls:cui """C1135137"""^^xsd:string ; umls:cui """C1135136"""^^xsd:string ; umls:cui """C1135135"""^^xsd:string ; umls:cui """C0910101"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I and II childhood large cell lymphoma"""@eng ; skos:notation """CDR0000037888"""^^xsd:string ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10296"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0879451"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III and IV childhood large cell lymphoma"""@eng ; skos:notation """CDR0000037889"""^^xsd:string ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """10297"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0879452"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ZD6474"""@eng ; skos:notation """CDR0000269177"""^^xsd:string ; skos:altLabel """Zactima"""@eng , """AZD6474"""@eng , """ZD 6474"""@eng , """ZD-6474"""@eng ; skos:definition """An orally bioavailable 4-anilinoquinazoline. ZD-6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269177&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269177&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2737\" NCI Thesaurus)"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """443913-73-3"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2737"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1701110"""^^xsd:string ; umls:cui """C1384659"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fecal occult blood test for screening"""@eng ; skos:notation """CDR0000038622"""^^xsd:string ; ; rdfs:subClassOf ; """11250"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134633"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sertraline"""@eng ; skos:notation """CDR0000322832"""^^xsd:string ; skos:altLabel """Zoloft"""@eng , """Sertraline Hydrochloride"""@eng ; skos:definition """The salt form of a synthetic derivative of naphthalenamine with anti-serotoninergic and anti-depressant properties. Sertraline appears to selectively inhibit the neuronal uptake of serotonin, raising serotonin levels in the CNS. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322832&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322832&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29451\" NCI Thesaurus)"""@eng ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C29451"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0600526"""^^xsd:string ; umls:cui """C0074393"""^^xsd:string ; umls:cui """C0284660"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """seizure"""@eng ; skos:notation """CDR0000525976"""^^xsd:string ; rdfs:subClassOf ; """Secondary related condition"""^^xsd:string ; """2006-12-07"""^^xsd:string ; """2006-12-08"""^^xsd:string ; umls:cui """C0036572"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cetuximab/erlotinib"""@eng ; skos:notation """CDR0000407440"""^^xsd:string ; skos:altLabel """MOAB C225/MOAB VEGF/OSI774"""@eng ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541414"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anticonvulsant therapy"""@eng ; skos:notation """CDR0000525978"""^^xsd:string ; rdfs:subClassOf ; """Supportive care modality"""^^xsd:string ; """2006-12-07"""^^xsd:string ; """2006-12-08"""^^xsd:string ; umls:cui """C0521306"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/cytarabine/etoposide/rituximab/sodium thiosulfate"""@eng ; skos:notation """CDR0000344407"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/CTX/MOAB IDEC-C2B8/STS/VP-16"""@eng ; ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328100"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/cytarabine/etoposide phosphate/rituximab/sodium thiosulfate"""@eng ; skos:notation """CDR0000344408"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/CTX/ETOP/MOAB IDEC-C2B8/STS"""@eng ; ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328101"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MSH2"""@eng ; skos:notation """CDR0000043579"""^^xsd:string ; rdfs:subClassOf ; """8860"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879290"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MSH1"""@eng ; skos:notation """CDR0000043578"""^^xsd:string ; rdfs:subClassOf ; """8858"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0879609"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """VHL"""@eng ; skos:notation """CDR0000043575"""^^xsd:string ; rdfs:subClassOf ; """8855"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0694897"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """resveratrol"""@eng ; skos:notation """CDR0000405819"""^^xsd:string ; skos:definition """A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=405819&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=405819&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1215\" NCI Thesaurus)"""@eng ; """2004-11-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C1215"""^^xsd:string ; umls:cui """C0073096"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/thiotepa"""@eng ; skos:notation """CDR0000043577"""^^xsd:string ; skos:altLabel """ATG/TSPA"""@eng ; ; ; """8857"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879289"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PTCH"""@eng ; skos:notation """CDR0000043576"""^^xsd:string ; rdfs:subClassOf ; """8856"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0694887"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RB1"""@eng ; skos:notation """CDR0000043571"""^^xsd:string ; rdfs:subClassOf ; """8851"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0694889"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/fludarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000043570"""^^xsd:string ; skos:altLabel """CTX/DOX/FAMP/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; """8850"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879288"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BRCA2"""@eng ; skos:notation """CDR0000043573"""^^xsd:string ; rdfs:subClassOf ; """8853"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0598034"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """APC"""@eng ; skos:notation """CDR0000043572"""^^xsd:string ; rdfs:subClassOf ; """8852"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0162832"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/cyclophosphamide/doxorubicin/etoposide/ifosfamide/vinblastine/vincristine"""@eng ; skos:notation """CDR0000306473"""^^xsd:string ; skos:altLabel """CTX/DOX/IFF/SC-58635/VBL/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327983"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate"""@eng ; skos:notation """CDR0000040905"""^^xsd:string ; skos:altLabel """MP/MTX"""@eng ; ; ; """3944"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280525"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/semustine"""@eng ; skos:notation """CDR0000040904"""^^xsd:string ; skos:altLabel """5-FU/MeCCNU"""@eng ; ; ; """3943"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280524"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/prednisone/vincristine"""@eng ; skos:notation """CDR0000040907"""^^xsd:string ; skos:altLabel """PVA"""@eng , """VLP"""@eng , """VAP"""@eng , """ASP/PRED/VCR"""@eng ; ; ; ; """3946"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280527"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/doxorubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000040906"""^^xsd:string ; skos:altLabel """OPAL"""@eng , """VAAP"""@eng , """ASP/DOX/PRED/VCR"""@eng ; ; ; ; ; """3945"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0084990"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/teniposide"""@eng ; skos:notation """CDR0000040901"""^^xsd:string ; skos:altLabel """ARA-C/VM-26"""@eng ; ; ; """3940"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280521"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine"""@eng ; skos:notation """CDR0000040900"""^^xsd:string ; skos:altLabel """ARA-C/CTX"""@eng ; ; ; """3939"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280520"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone/thiotepa"""@eng ; skos:notation """CDR0000040903"""^^xsd:string ; skos:altLabel """DHAD/TSPA/VP-16"""@eng , """MVT"""@eng ; ; ; ; """3942"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280523"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/interferon alfa"""@eng ; skos:notation """CDR0000040902"""^^xsd:string ; skos:altLabel """DOX/IFN-A"""@eng ; ; ; """3941"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338120"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/prednisone"""@eng ; skos:notation """CDR0000040909"""^^xsd:string ; skos:altLabel """FAMP/PRED"""@eng ; ; ; """3948"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280529"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/prednisone/vincristine"""@eng ; skos:notation """CDR0000040908"""^^xsd:string ; skos:altLabel """MP/PRED/VCR"""@eng ; ; ; ; """3947"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280528"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cetuximab"""@eng ; skos:notation """CDR0000351778"""^^xsd:string ; skos:altLabel """MOAB C225/MOAB VEGF"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328136"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/busulfan/cyclophosphamide/methylprednisolone"""@eng ; skos:notation """CDR0000269827"""^^xsd:string ; skos:altLabel """ATG/BU/CTX/MePRDL"""@eng ; ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327866"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/docetaxel/doxorubicin"""@eng ; skos:notation """CDR0000043108"""^^xsd:string ; skos:altLabel """CTX/DOX/TXT"""@eng ; ; ; ; """7501"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678104"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """raloxifene"""@eng ; skos:notation """CDR0000043109"""^^xsd:string ; skos:altLabel """LY 139481"""@eng , """RALOX"""@eng , """[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone"""@eng , """Evista"""@eng , """Keoxifene"""@eng ; skos:definition """A selective benzothiophene estrogen receptor modulator (SERM). Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect. This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43109&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43109&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1518\" NCI Thesaurus)"""@eng ; ; ; """7502"""^^xsd:string ; """C1518"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """84449-90-1"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0720318"""^^xsd:string ; umls:cui """C0244404"""^^xsd:string ; umls:cui """C0752233"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cytarabine/mitoxantrone"""@eng ; skos:notation """CDR0000043104"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/WR-2721"""@eng ; ; ; ; """7498"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678101"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gemcitabine/topotecan"""@eng ; skos:notation """CDR0000043105"""^^xsd:string ; skos:altLabel """dFdC/TOPO"""@eng ; ; ; """7499"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678102"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/lomustine/methotrexate"""@eng ; skos:notation """CDR0000043106"""^^xsd:string ; skos:altLabel """BLEO/CCNU/MTX"""@eng ; ; ; ; """75"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278533"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T138067 sodium"""@eng ; skos:notation """CDR0000043107"""^^xsd:string ; skos:altLabel """T138067"""@eng , """2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene"""@eng , """2-Fluoro-1-methoxy-4-(pentafluorophenyl-sulfonamido)benzene, Sodium Salt"""@eng ; skos:definition """A synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. T138067 covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43107&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43107&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1835\" NCI Thesaurus)"""@eng ; """7500"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1835"""^^xsd:string ; umls:cui """C1523985"""^^xsd:string ; umls:cui """C0678103"""^^xsd:string ; umls:cui """C0767920"""^^xsd:string ; umls:cui """C0767921"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/busulfan/melphalan"""@eng ; skos:notation """CDR0000043100"""^^xsd:string ; skos:altLabel """ATG/BU/L-PAM"""@eng ; ; ; ; """7494"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678097"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/melphalan/methylprednisolone"""@eng ; skos:notation """CDR0000043101"""^^xsd:string ; skos:altLabel """BU/L-PAM/MePRDL"""@eng ; ; ; ; """7495"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678098"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """obatoclax mesylate"""@eng ; skos:notation """CDR0000504100"""^^xsd:string ; skos:altLabel """GX15-070MS"""@eng ; """Drug/agent"""^^xsd:string ; """2006-08-18"""^^xsd:string ; umls:cui """C1831949"""^^xsd:string ; umls:cui """C1831948"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dinitrophenyl"""@eng ; skos:notation """CDR0000043103"""^^xsd:string ; skos:altLabel """DNP"""@eng ; skos:definition """A small molecule containing 2 phenol rings, characterized as a hapten for use in vaccine preparation. Dinitrophenyl by itself will not elicit any immune response nor bind to antigen. Dinitrophenyl compound is commonly used to couple with peptides in vaccine preparation to enhance the immunogenicity of otherwise weak immunogenic antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43103&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43103&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2478\" NCI Thesaurus)"""@eng ; """7497"""^^xsd:string ; """2006-03-29"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2478"""^^xsd:string ; umls:cui """C0678100"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/marimastat"""@eng ; skos:notation """CDR0000042781"""^^xsd:string ; skos:altLabel """BB-2516/CTX/DOX"""@eng ; ; ; ; """6580"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677742"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interleukin-2/vinblastine"""@eng ; skos:notation """CDR0000042126"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IL-2/VBL"""@eng ; ; ; ; ; """5362"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281649"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """telangiectatic osteosarcoma"""@eng ; skos:notation """CDR0000039888"""^^xsd:string ; skos:altLabel """telangiectatic osteogenic sarcoma"""@eng , """osteosarcoma, telangiectatic"""@eng , """sarcoma, osteogenic telangiectatic"""@eng , """osteogenic sarcoma, telangiectatic"""@eng ; rdfs:subClassOf ; """2569"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0259782"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed osteosarcoma"""@eng ; skos:notation """CDR0000039889"""^^xsd:string ; skos:altLabel """sarcoma, osteogenic mixed"""@eng , """mixed cell type osteosarcoma"""@eng , """mixed type osteogenic sarcoma"""@eng , """osteosarcoma, mixed"""@eng , """mixed cell type osteogenic sarcoma"""@eng , """mixed type osteosarcoma"""@eng , """mixed osteogenic sarcoma"""@eng , """osteogenic sarcoma, mixed"""@eng ; rdfs:subClassOf ; """2570"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279604"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000258744"""^^xsd:string ; skos:altLabel """ARA-C/CF/MTX"""@eng ; ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327822"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/p53 peptide vaccine"""@eng ; skos:notation """CDR0000258746"""^^xsd:string ; skos:altLabel """IL-2/p53 VAC"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327823"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/oblimersen"""@eng ; skos:notation """CDR0000301624"""^^xsd:string ; skos:altLabel """G3139/IFN-A"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-03-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327948"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/exisulind"""@eng ; skos:notation """CDR0000038696"""^^xsd:string ; skos:altLabel """CBDCA/FGN-1/VP-16"""@eng ; ; ; ; """11353"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134701"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """decitabine/FR901228"""@eng ; skos:notation """CDR0000038697"""^^xsd:string ; skos:altLabel """DAC/FR 901228"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """11354"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134702"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/exisulind/gemcitabine"""@eng ; skos:notation """CDR0000038694"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/FGN-1"""@eng ; ; ; ; """11351"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134699"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/filgrastim/trastuzumab/vinorelbine"""@eng ; skos:notation """CDR0000038695"""^^xsd:string ; skos:altLabel """G-CSF/MOAB HER2/TXT/VNB"""@eng ; ; ; ; ; """11352"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134700"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-1-alpha"""@eng ; skos:notation """CDR0000038692"""^^xsd:string ; skos:altLabel """IL-1A"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """1135"""^^xsd:string ; """Gene"""^^xsd:string ; """2006-11-27"""^^xsd:string ; umls:cui """C0600251"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/leucovorin calcium/methotrexate/rituximab"""@eng ; skos:notation """CDR0000038693"""^^xsd:string ; skos:altLabel """ARA-C/CF/MOAB IDEC-C2B8/MTX"""@eng ; ; ; ; ; """11350"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134698"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """5-hydroxytryptophan"""@eng ; skos:notation """CDR0000459776"""^^xsd:string ; skos:altLabel """2-Amino-3-(5-hydroxy-1-H-indol-3-yl)propionic Acid"""@eng , """Oxitriptan"""@eng , """5-HTP"""@eng ; skos:definition """An aromatic amino acid with antidepressant activity. In vivo, 5-hydroxytryptophan (5-HTP) is converted into 5-hydroxytryptamine (5-HT or serotonin) as well as other neurotransmitters. 5-HTP may exert its antidepressant activity via conversion to serotonin or directly by binding to serotonin (5-HT) receptors within the central nervous system (CNS). Endogenous 5-HTP is produced from the essential amino acid L-tryptophan. Exogenous therapeutic 5-HTP is isolated from the seeds of the African plant Griffonia simplicifolia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459776&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459776&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52181\" NCI Thesaurus)"""@eng ; """C52181"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; umls:cui """C0000578"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/doxorubicin/rituximab/vincristine"""@eng ; skos:notation """CDR0000038691"""^^xsd:string ; skos:altLabel """CTX/DM/DOX/MOAB IDEC-C2B8/VCR"""@eng ; ; ; ; ; ; """11349"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134697"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """infliximab"""@eng ; skos:notation """CDR0000038698"""^^xsd:string ; skos:altLabel """cA2"""@eng , """INF"""@eng , """Remicade"""@eng , """INFLIX"""@eng , """Avakine"""@eng ; skos:definition """A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38698&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38698&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1789\" NCI Thesaurus)"""@eng ; ; """11355"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C1789"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1522155"""^^xsd:string ; umls:cui """C0723012"""^^xsd:string ; umls:cui """C0666743"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/infliximab"""@eng ; skos:notation """CDR0000038699"""^^xsd:string ; skos:altLabel """INF/TXT"""@eng ; ; ; """11356"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134703"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood cerebral astrocytoma"""@eng ; skos:notation """CDR0000042437"""^^xsd:string ; skos:altLabel """cerebral astrocytoma, childhood, recurrent"""@eng , """cerebral astrocytoma, pediatric, recurrent"""@eng , """pediatric cerebral astrocytoma, recurrent"""@eng , """childhood cerebral astrocytoma, recurrent"""@eng , """recurrent pediatric cerebral astrocytoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood cerebral astrocytoma/malignant glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5754"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338339"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood cerebellar astrocytoma"""@eng ; skos:notation """CDR0000042436"""^^xsd:string ; skos:altLabel """pediatric cerebellar astrocytoma, recurrent"""@eng , """cerebellar astrocytoma, childhood, recurrent"""@eng , """recurrent pediatric cerebellar astrocytoma"""@eng , """childhood cerebellar astrocytoma, recurrent"""@eng , """cerebellar astrocytoma, pediatric, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood cerebellar astrocytoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5753"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338338"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood cerebellar astrocytoma"""@eng ; skos:notation """CDR0000042435"""^^xsd:string ; skos:altLabel """childhood cerebellar astrocytoma, untreated"""@eng , """cerebellar astrocytoma, pediatric, untreated"""@eng , """untreated pediatric cerebellar astrocytoma"""@eng , """cerebellar astrocytoma, childhood, untreated"""@eng , """pediatric cerebellar astrocytoma, untreated"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood cerebellar astrocytoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5752"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338337"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood visual pathway glioma"""@eng ; skos:notation """CDR0000042434"""^^xsd:string ; skos:altLabel """childhood recurrent visual pathway glioma"""@eng , """pediatric CNS tumor, optic tract glioma, recurrent"""@eng , """pediatric CNS tumor, visual pathway glioma, recurrent"""@eng , """visual pathway glioma, childhood, recurrent"""@eng , """recurrent glioma, childhood optic tract"""@eng , """recurrent childhood optic nerve glioma"""@eng , """recurrent childhood optic tract glioma"""@eng , """recurrent childhood brain tumor, visual pathway glioma"""@eng , """pediatric recurrent optic nerve glioma"""@eng , """optic tract glioma, pediatric, recurrent"""@eng , """childhood recurrent optic nerve glioma"""@eng , """pediatric brain tumor, visual pathway glioma, recurrent"""@eng , """pediatric recurrent optic tract glioma"""@eng , """pediatric brain tumor, optic nerve glioma, recurrent"""@eng , """glioma, pediatric optic tract, recurrent"""@eng , """recurrent glioma, pediatric optic nerve"""@eng , """childhood brain tumor, recurrent visual pathway glioma"""@eng , """recurrent pediatric visual pathway glioma"""@eng , """recurrent pediatric brain tumor, visual pathway glioma"""@eng , """recurrent visual pathway glioma, pediatric"""@eng , """optic nerve glioma, pediatric, recurrent"""@eng , """glioma, childhood optic tract, recurrent"""@eng , """recurrent pediatric CNS tumor, visual pathway glioma"""@eng , """optic nerve glioma, childhood, recurrent"""@eng , """recurrent optic nerve glioma, childhood"""@eng , """recurrent optic tract glioma, pediatric"""@eng , """pediatric brain tumor, optic tract glioma, recurrent"""@eng , """recurrent childhood brain tumor, optic nerve glioma"""@eng , """childhood CNS tumor, recurrent optic tract glioma"""@eng , """recurrent pediatric CNS tumor, optic tract glioma"""@eng , """recurrent pediatric CNS tumor, optic nerve glioma"""@eng , """childhood brain tumor, recurrent optic nerve glioma"""@eng , """visual pathway glioma, pediatric, recurrent"""@eng , """glioma, pediatric optic nerve, recurrent"""@eng , """glioma, childhood visual pathway, recurrent"""@eng , """childhood CNS tumor, recurrent optic nerve glioma"""@eng , """recurrent glioma, childhood visual pathway"""@eng , """childhood CNS tumor, recurrent visual pathway glioma"""@eng , """recurrent visual pathway glioma, childhood"""@eng , """pediatric recurrent visual pathway glioma"""@eng , """pediatric CNS tumor, optic nerve glioma, recurrent"""@eng , """glioma, childhood optic nerve, recurrent"""@eng , """recurrent optic tract glioma, childhood"""@eng , """childhood recurrent optic tract glioma"""@eng , """recurrent pediatric brain tumor, optic nerve glioma"""@eng , """recurrent childhood CNS tumor, optic tract glioma"""@eng , """optic tract glioma, childhood, recurrent"""@eng , """recurrent childhood CNS tumor, visual pathway glioma"""@eng , """recurrent optic nerve glioma, pediatric"""@eng , """recurrent childhood brain tumor, optic tract glioma"""@eng , """recurrent childhood CNS tumor, optic nerve glioma"""@eng , """recurrent glioma, pediatric visual pathway"""@eng , """recurrent glioma, pediatric optic tract"""@eng , """childhood brain tumor, recurrent optic tract glioma"""@eng , """glioma, pediatric visual pathway, recurrent"""@eng , """recurrent glioma, childhood optic nerve"""@eng , """recurrent pediatric brain tumor, optic tract glioma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood visual pathway and hypothalamic glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5751"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1370943"""^^xsd:string ; umls:cui """C0338336"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood visual pathway glioma"""@eng ; skos:notation """CDR0000042433"""^^xsd:string ; skos:altLabel """untreated childhood CNS tumor, optic nerve glioma"""@eng , """untreated glioma, pediatric optic tract"""@eng , """childhood optic nerve glioma, untreated"""@eng , """untreated pediatric CNS tumor, optic nerve glioma"""@eng , """untreated childhood brain tumor, visual pathway glioma"""@eng , """childhood optic tract glioma, untreated"""@eng , """untreated visual pathway glioma, childhood"""@eng , """pediatric brain tumor, optic nerve glioma, untreated"""@eng , """glioma, pediatric optic nerve, untreated"""@eng , """untreated childhood brain tumor, optic tract glioma"""@eng , """untreated pediatric optic tract glioma"""@eng , """untreated pediatric optic nerve glioma"""@eng , """visual pathway glioma, childhood, untreated"""@eng , """childhood untreated optic tract glioma"""@eng , """untreated childhood CNS tumor, optic tract glioma"""@eng , """untreated childhood CNS tumor, visual pathway glioma"""@eng , """glioma, childhood optic nerve, untreated"""@eng , """glioma, pediatric visual pathway, untreated"""@eng , """childhood brain tumor, untreated visual pathway glioma"""@eng , """optic tract glioma, childhood, untreated"""@eng , """untreated childhood brain tumor, optic nerve glioma"""@eng , """pediatric visual pathway glioma, untreated"""@eng , """optic tract glioma, pediatric, untreated"""@eng , """pediatric untreated visual pathway glioma"""@eng , """glioma, pediatric optic tract, untreated"""@eng , """untreated pediatric CNS tumor, visual pathway glioma"""@eng , """pediatric CNS tumor, visual pathway glioma, untreated"""@eng , """pediatric CNS tumor, optic tract glioma, untreated"""@eng , """pediatric untreated optic nerve glioma"""@eng , """pediatric CNS tumor, optic nerve glioma, untreated"""@eng , """untreated glioma, childhood optic nerve"""@eng , """childhood brain tumor, untreated optic tract glioma"""@eng , """optic nerve glioma, pediatric, untreated"""@eng , """untreated glioma, pediatric optic nerve"""@eng , """untreated optic tract glioma, childhood"""@eng , """untreated pediatric brain tumor, visual pathway glioma"""@eng , """childhood brain tumor, untreated optic nerve glioma"""@eng , """untreated pediatric brain tumor, optic tract glioma"""@eng , """glioma, childhood visual pathway, untreated"""@eng , """untreated pediatric visual pathway glioma"""@eng , """pediatric optic tract glioma, untreated"""@eng , """pediatric brain tumor, visual pathway glioma, untreated"""@eng , """childhood visual pathway glioma, untreated"""@eng , """childhood untreated visual pathway glioma"""@eng , """glioma, childhood optic tract, untreated"""@eng , """optic nerve glioma, childhood, untreated"""@eng , """untreated pediatric CNS tumor, optic tract glioma"""@eng , """untreated visual pathway glioma, pediatric"""@eng , """childhood untreated optic nerve glioma"""@eng , """childhood CNS tumor, untreated optic tract glioma"""@eng , """childhood CNS tumor, untreated visual pathway glioma"""@eng , """visual pathway glioma, pediatric, untreated"""@eng , """untreated optic nerve glioma, pediatric"""@eng , """untreated glioma, childhood visual pathway"""@eng , """untreated optic nerve glioma, childhood"""@eng , """untreated childhood optic tract glioma"""@eng , """untreated glioma, childhood optic tract"""@eng , """untreated optic tract glioma, pediatric"""@eng , """pediatric optic nerve glioma, untreated"""@eng , """untreated glioma, pediatric visual pathway"""@eng , """untreated childhood optic nerve glioma"""@eng , """pediatric untreated optic tract glioma"""@eng , """childhood CNS tumor, untreated optic nerve glioma"""@eng , """pediatric brain tumor, optic tract glioma, untreated"""@eng , """untreated pediatric brain tumor, optic nerve glioma"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood visual pathway and hypothalamic glioma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5750"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338335"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood supratentorial primitive neuroectodermal tumors"""@eng ; skos:notation """CDR0000042432"""^^xsd:string ; skos:altLabel """recurrent pediatric primitive neuroectodermal tumor, supratentorial"""@eng , """recurrent pineal parenchymal tumor, pediatric"""@eng , """pediatric recurrent PNET, pineoblastoma"""@eng , """cerebral neuroblastoma, recurrent, childhood"""@eng , """recurrent neuroectodermal tumor, childhood, primitive, supratentorial"""@eng , """childhood pineoblastoma, recurrent"""@eng , """recurrent childhood pineoblastoma"""@eng , """recurrent pediatric supratentorial PNET"""@eng , """recurrent cerebral neuroblastoma, childhood"""@eng , """recurrent childhood PNET, pineoblastoma"""@eng , """recurrent childhood cerebral neuroblastoma"""@eng , """cerebral neuroblastoma, recurrent, pediatric"""@eng , """recurrent supratentorial primitive neuroectodermal and pineal tumors, childhood"""@eng , """recurrent primitive neuroectodermal tumor, childhood supratentorial"""@eng , """PNET, recurrent childhood supratentorial"""@eng , """recurrent primitive neuroectodermal tumor, supratentorial, childhood"""@eng , """recurrent pineoblastoma, childhood"""@eng , """childhood pineal parenchymal tumor, recurrent"""@eng , """childhood pineocytoma, recurrent"""@eng , """recurrent pediatric pineoblastoma"""@eng , """recurrent PNET, pediatric supratentorial"""@eng , """childhood supratentorial PNET, recurrent"""@eng , """recurrent pediatric supratentorial primitive neuroectodermal tumor"""@eng , """recurrent supratentorial primitive neuroectodermal and pineal tumors, pediatric"""@eng , """PNET, recurrent pediatric supratentorial"""@eng , """recurrent childhood primitive neuroectodermal tumor, supratentorial"""@eng , """recurrent childhood pineocytoma"""@eng , """recurrent neuroblastoma, cerebral, pediatric"""@eng , """pediatric supratentorial primitive neuroectodermal tumor, recurrent"""@eng , """recurrent pineocytoma, pediatric"""@eng , """recurrent primitive neuroectodermal tumor, pediatric supratentorial"""@eng , """childhood supratentorial primitive neuroectodermal tumor, recurrent"""@eng , """childhood cerebral neuroblastoma, recurrent"""@eng , """recurrent supratentorial primitive neuroectodermal tumor, pediatric"""@eng , """recurrent neuroblastoma, pediatric cerebral"""@eng , """PNET, supratentorial, pediatric, recurrent"""@eng , """recurrent cerebral neuroblastoma, pediatric"""@eng , """childhood recurrent PNET, pineoblastoma"""@eng , """PNET, supratentorial, childhood, recurrent"""@eng , """recurrent supratentorial primitive neuroectodermal tumor, childhood"""@eng , """recurrent neuroblastoma, cerebral, childhood"""@eng , """pediatric cerebral neuroblastoma, recurrent"""@eng , """recurrent pediatric PNET, pineoblastoma"""@eng , """recurrent pediatric pineocytoma"""@eng , """recurrent pediatric supratentorial primitive neuroectodermal and pineal tumors"""@eng , """recurrent pediatric cerebral neuroblastoma"""@eng , """pediatric pineal parenchymal tumor, recurrent"""@eng , """recurrent neuroectodermal tumor, pediatric, primitive, supratentorial"""@eng , """recurrent pediatric pineal and supratentorial primitive neuroectodermal tumors"""@eng , """recurrent primitive neuroectodermal tumor, supratentorial, pediatric"""@eng , """pediatric pineoblastoma, recurrent"""@eng , """recurrent pineocytoma, childhood"""@eng , """recurrent pineoblastoma, pediatric"""@eng , """recurrent pineal parenchymal tumor, childhood"""@eng , """recurrent childhood pineal and supratentorial primitive neuroectodermal tumors"""@eng , """pediatric supratentorial PNET, recurrent"""@eng , """recurrent neuroblastoma, childhood cerebral"""@eng , """recurrent PNET, childhood supratentorial"""@eng , """recurrent childhood pineal parenchymal tumor"""@eng , """recurrent pediatric pineal parenchymal tumor"""@eng , """recurrent childhood supratentorial PNET"""@eng , """pediatric pineocytoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2002-08-09"""^^xsd:string ; """childhood brain tumor"""^^xsd:string ; """childhood supratentorial primitive neuroectodermal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5749"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C3887521"""^^xsd:string ; umls:cui """C0338334"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood supratentorial primitive neuroectodermal tumors"""@eng ; skos:notation """CDR0000042431"""^^xsd:string ; skos:altLabel """pediatric supratentorial PNET, untreated"""@eng , """untreated pediatric primitive neuroectodermal tumor, supratentorial"""@eng , """untreated primitive neuroectodermal tumor, pediatric supratentorial"""@eng , """untreated primitive neuroectodermal tumor, supratentorial, pediatric"""@eng , """pediatric pineocytoma, untreated"""@eng , """untreated pediatric PNET, pineoblastoma"""@eng , """untreated pediatric pineal parenchymal tumor"""@eng , """PNET, untreated pediatric supratentorial"""@eng , """untreated pineocytoma, childhood"""@eng , """childhood supratentorial primitive neuroectodermal tumor, untreated"""@eng , """untreated neuroblastoma, childhood cerebral"""@eng , """childhood supratentorial PNET, untreated"""@eng , """untreated childhood primitive neuroectodermal tumor, supratentorial"""@eng , """untreated supratentorial primitive neuroectodermal tumor, childhood"""@eng , """childhood supratentorial primitive neuroectodermal and pineal tumors, untreated"""@eng , """pediatric cerebral neuroblastoma, untreated"""@eng , """untreated childhood supratentorial PNET"""@eng , """untreated pineal parenchymal tumor, childhood"""@eng , """untreated primitive neuroectodermal tumor, supratentorial, childhood"""@eng , """untreated cerebral neuroblastoma, pediatric"""@eng , """untreated pineoblastoma, pediatric"""@eng , """untreated pediatric pineocytoma"""@eng , """PNET, supratentorial, pediatric, untreated"""@eng , """untreated PNET, pediatric supratentorial"""@eng , """childhood untreated PNET, pineoblastoma"""@eng , """childhood pineoblastoma, untreated"""@eng , """untreated pineocytoma, pediatric"""@eng , """untreated primitive neuroectodermal tumor, childhood supratentorial"""@eng , """untreated pineal parenchymal tumor, pediatric"""@eng , """childhood supratentorial primitive neuroectodermal tumors, untreated"""@eng , """untreated pediatric pineal and supratentorial primitive neuroectodermal tumors"""@eng , """untreated neuroectodermal tumor, pediatric, primitive, supratentorial"""@eng , """untreated childhood pineal and supratentorial primitive neuroectodermal tumors"""@eng , """untreated pediatric supratentorial PNET"""@eng , """childhood cerebral neuroblastoma, untreated"""@eng , """untreated pediatric cerebral neuroblastoma"""@eng , """untreated childhood pineal parenchymal tumor"""@eng , """untreated childhood pineocytoma"""@eng , """cerebral neuroblastoma, untreated, pediatric"""@eng , """untreated pineoblastoma, childhood"""@eng , """untreated childhood PNET, pineoblastoma"""@eng , """untreated neuroectodermal tumor, childhood, primitive, supratentorial"""@eng , """untreated neuroblastoma, cerebral, pediatric"""@eng , """pediatric pineoblastoma, untreated"""@eng , """untreated supratentorial primitive neuroectodermal tumor, pediatric"""@eng , """PNET, untreated childhood supratentorial"""@eng , """PNET, supratentorial, childhood, untreated"""@eng , """untreated cerebral neuroblastoma, childhood"""@eng , """untreated pediatric supratentorial primitive neuroectodermal tumor"""@eng , """childhood pineal parenchymal tumor, untreated"""@eng , """cerebral neuroblastoma, untreated, childhood"""@eng , """untreated childhood pineoblastoma"""@eng , """pediatric pineal parenchymal tumor, untreated"""@eng , """untreated childhood cerebral neuroblastoma"""@eng , """pediatric supratentorial primitive neuroectodermal and pineal tumors, untreated"""@eng , """untreated neuroblastoma, cerebral, childhood"""@eng , """childhood pineocytoma, untreated"""@eng , """untreated pediatric pineoblastoma"""@eng , """untreated neuroblastoma, pediatric cerebral"""@eng , """untreated PNET, childhood supratentorial"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood supratentorial primitive neuroectodermal tumors"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5748"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338333"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/octreotide"""@eng ; skos:notation """CDR0000042430"""^^xsd:string ; skos:altLabel """FAMP/SSTN"""@eng ; ; ; """5747"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338332"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood medulloblastoma"""@eng ; skos:notation """CDR0000042439"""^^xsd:string ; skos:altLabel """PNET, infratentorial, pediatric, untreated"""@eng , """childhood cerebellar primitive neuroectodermal tumor, untreated"""@eng , """untreated medulloblastoma, childhood"""@eng , """untreated cerebellar PNET, pediatric"""@eng , """untreated childhood infratentorial PNET"""@eng , """untreated pediatric infratentorial primitive neuroectodermal tumor"""@eng , """untreated pediatric medulloblastoma"""@eng , """untreated childhood cerebellar PNET"""@eng , """PNET, pediatric infratentorial, untreated"""@eng , """pediatric cerebellar PNET, untreated"""@eng , """childhood cerebellar PNET, untreated"""@eng , """untreated primitive neuroectodermal tumor, childhood cerebellar"""@eng , """untreated infratentorial PNET, pediatric"""@eng , """childhood infratentorial PNET, untreated"""@eng , """untreated primitive neuroectodermal tumor, pediatric cerebellar"""@eng , """untreated infratentorial, pediatric, PNET"""@eng , """untreated primitive neuroectodermal tumor, childhood infratentorial"""@eng , """PNET, cerebellar, pediatric, untreated"""@eng , """untreated PNET, childhood infratentorial"""@eng , """untreated infratentorial primitive neuroectodermal tumor, pediatric"""@eng , """untreated medulloblastoma, pediatric"""@eng , """untreated pediatric infratentorial PNET"""@eng , """untreated cerebellar PNET, childhood"""@eng , """untreated childhood cerebellar primitive neuroectodermal tumor"""@eng , """pediatric infratentorial PNET, untreated"""@eng , """untreated PNET, pediatric infratentorial"""@eng , """untreated infratentorial PNET, childhood"""@eng , """PNET, pediatric cerebellar, untreated"""@eng , """untreated pediatric cerebellar primitive neuroectodermal tumor"""@eng , """untreated cerebellar, pediatric, PNET"""@eng , """untreated PNET, childhood cerebellar"""@eng , """untreated cerebellar primitive neuroectodermal tumor, childhood"""@eng , """untreated pediatric cerebellar PNET"""@eng , """untreated primitive neuroectodermal tumor, pediatric infratentorial"""@eng , """untreated infratentorial primitive neuroectodermal tumor, childhood"""@eng , """PNET, cerebellar, childhood, untreated"""@eng , """pediatric cerebellar primitive neuroectodermal tumor, untreated"""@eng , """pediatric medulloblastoma, untreated"""@eng , """untreated childhood infratentorial primitive neuroectodermal tumor"""@eng , """untreated infratentorial, childhood, PNET"""@eng , """untreated cerebellar primitive neuroectodermal tumor, pediatric"""@eng , """untreated PNET, pediatric cerebellar"""@eng , """untreated cerebellar, childhood, PNET"""@eng , """medulloblastoma, childhood, untreated"""@eng , """medulloblastoma, pediatric, untreated"""@eng , """childhood medulloblastoma, untreated"""@eng , """PNET, childhood cerebellar, untreated"""@eng , """PNET, infratentorial, childhood, untreated"""@eng , """PNET, childhood infratentorial, untreated"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """childhood medulloblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5759"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0338341"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/hydroxyurea/interferon alfa"""@eng ; skos:notation """CDR0000042438"""^^xsd:string ; skos:altLabel """ARA-C/HU/IFN-A"""@eng ; ; ; ; """5758"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338340"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/oblimersen/thalidomide"""@eng ; skos:notation """CDR0000258357"""^^xsd:string ; skos:altLabel """DM/G3139/THAL"""@eng ; ; ; ; """2002-10-10"""^^xsd:string ; """11506"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327807"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """4-hydroxytamoxifen"""@eng ; skos:notation """CDR0000371709"""^^xsd:string ; skos:altLabel """4-Hydroxy-Tamoxifen"""@eng ; skos:definition """A tamoxifen metabolite with both estrogenic and anti-estrogenic effects. 4-hydroxytamoxifen has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=371709&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=371709&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C975\" NCI Thesaurus)"""@eng ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """68392-35-8"""^^xsd:string ; """C975"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """68047-06-3 (trans)"""^^xsd:string ; umls:cui """C0048403"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In111/yttrium Y90-DOTA-biotin"""@eng ; skos:notation """CDR0000371701"""^^xsd:string ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541248"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RASSF1A"""@eng ; skos:notation """CDR0000371706"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1419285"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/filgrastim"""@eng ; skos:notation """CDR0000371705"""^^xsd:string ; skos:altLabel """CDDP/CTX/G-CSF"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541249"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nevoid basal cell carcinoma syndrome"""@eng ; skos:notation """CDR0000529382"""^^xsd:string ; skos:altLabel """basal cell nevus syndrome"""@eng ; rdfs:subClassOf ; """2007-01-05"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Genetic condition"""^^xsd:string ; """2007-01-03"""^^xsd:string ; umls:cui """C0004779"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040288"""^^xsd:string ; skos:altLabel """germ cell tumor, ovarian, stage I"""@eng , """ovarian germ cell tumor, stage I"""@eng ; rdfs:subClassOf ; """ovarian germ cell tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3126"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279971"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040289"""^^xsd:string ; skos:altLabel """germ cell tumor, ovarian, stage II"""@eng , """ovarian germ cell tumor, stage II"""@eng ; rdfs:subClassOf ; """ovarian germ cell tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3127"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279972"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urea"""@eng ; skos:notation """CDR0000040286"""^^xsd:string ; skos:altLabel """Ureaphil"""@eng , """Elaqua XX"""@eng ; """3124"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0729127"""^^xsd:string ; umls:cui """C0728794"""^^xsd:string ; umls:cui """C0041942"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian germ cell tumor"""@eng ; skos:notation """CDR0000040287"""^^xsd:string ; skos:altLabel """germ cell tumor, ovarian"""@eng , """Ovarian germ cell tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3125"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238324"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/doxorubicin/hydroxyurea/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040284"""^^xsd:string ; skos:altLabel """CTX/DACT/DOX/HU/MTX/VCR"""@eng , """CHAMOCA"""@eng ; ; ; ; ; ; ; """3122"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279969"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040285"""^^xsd:string ; skos:altLabel """AMOPLACE"""@eng , """ARA-C/CTX/DOX/MTX/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """3123"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279970"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/mechlorethamine/methotrexate/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040282"""^^xsd:string ; skos:altLabel """CTX/DOX/MTX/NM/PCB/PRED/VCR/VP-16"""@eng , """ProMACE/MOPP"""@eng ; ; ; ; ; ; ; ; ; """3120"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0084185"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/prednisone/teniposide/vincristine"""@eng ; skos:notation """CDR0000040283"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/PRED/VCR/VM-26"""@eng , """CHVMP/VCR-BLEO"""@eng ; ; ; ; ; ; ; """3121"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0255601"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/mitoxantrone"""@eng ; skos:notation """CDR0000040280"""^^xsd:string ; skos:altLabel """NMF"""@eng , """DHAD/5-FU/MTX"""@eng , """MMF"""@eng ; ; ; ; """3119"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0083765"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the prostate"""@eng ; skos:notation """CDR0000040281"""^^xsd:string ; skos:altLabel """adenocarcinoma, prostatic"""@eng , """prostate cancer, adenocarcinoma"""@eng , """prostatic adenocarcinoma"""@eng ; rdfs:subClassOf ; """312"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0007112"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """TdT negative adult acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039881"""^^xsd:string ; skos:altLabel """TdT negative acute lymphocytic leukemia, adult"""@eng , """acute lymphocytic leukemia, adult TdT negative"""@eng , """leukemia, adult acute lymphocytic TdT negative"""@eng , """acute lymphoblastic leukemia, adult TdT negative"""@eng , """TdT negative adult acute lymphocytic leukemia"""@eng , """ALL, TdT negative, adult"""@eng , """TdT negative ALL, adult"""@eng , """ALL, adult TdT negative"""@eng , """TdT negative adult ALL"""@eng , """TdT negative lymphocytic leukemia, acute adult"""@eng , """adult ALL, TdT negative"""@eng ; rdfs:subClassOf ; """2562"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279599"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostoglandin agent"""@eng ; skos:notation """CDR0000039279"""^^xsd:string ; """1911"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0033554"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """meperidine hydrochloride"""@eng ; skos:notation """CDR0000039278"""^^xsd:string ; skos:altLabel """Demerol"""@eng ; """Drug/agent"""^^xsd:string ; """1910"""^^xsd:string ; """2006-11-30"""^^xsd:string ; """C635"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0353148"""^^xsd:string ; umls:cui """C0935966"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dinoprost tromethamine"""@eng ; skos:notation """CDR0000039277"""^^xsd:string ; skos:altLabel """Dinoprost"""@eng , """Prostin F2 alpha"""@eng ; skos:definition """A synthetic analogue of the naturally occurring prostaglandin F2 alpha. Prostaglandin F2 alpha stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39277&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39277&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1074\" NCI Thesaurus)"""@eng ; """1908"""^^xsd:string ; """196515"""^^xsd:string ; """38562-01-5"""^^xsd:string ; """C1074"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0012471"""^^xsd:string ; umls:cui """C0058310"""^^xsd:string ; umls:cui """C0701180"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human menopausal gonadotropin"""@eng ; skos:notation """CDR0000039276"""^^xsd:string ; skos:altLabel """Pergonal"""@eng ; """1907"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0025326"""^^xsd:string ; umls:cui """C0700188"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triamcinolone"""@eng ; skos:notation """CDR0000039275"""^^xsd:string ; skos:altLabel """(11beta,16alpha)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione"""@eng , """Aristocort"""@eng ; skos:definition """A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39275&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39275&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C901\" NCI Thesaurus)"""@eng ; ; """1906"""^^xsd:string ; """C901"""^^xsd:string ; """124-94-7"""^^xsd:string ; """13397"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699563"""^^xsd:string ; umls:cui """C0040864"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone"""@eng ; skos:notation """CDR0000039274"""^^xsd:string ; skos:altLabel """Cortril"""@eng , """Nutracort"""@eng , """cortisol"""@eng , """Rectoid"""@eng , """Barseb-HC"""@eng , """Cortef"""@eng , """Cetacort"""@eng , """Hytone"""@eng , """Cort-Dome"""@eng , """Therapeutic Hydrocortisone"""@eng , """HC"""@eng , """Komed-HC"""@eng , """Domolene"""@eng , """Aeroseb-HC"""@eng , """Cortenema"""@eng , """Eldecort"""@eng , """Domolene-HC"""@eng , """Barseb HC"""@eng , """Cortispray"""@eng , """(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione"""@eng , """Proctocort"""@eng , """Cortifan"""@eng , """Komed HC"""@eng , """Hydrocortone"""@eng , """Dermacort"""@eng ; skos:definition """A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39274&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39274&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C555\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """1904"""^^xsd:string ; """10483"""^^xsd:string ; """C555"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """50-23-7"""^^xsd:string ; """2006-08-27"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699388"""^^xsd:string ; umls:cui """C0699389"""^^xsd:string ; umls:cui """C0699399"""^^xsd:string ; umls:cui """C0699398"""^^xsd:string ; umls:cui """C0020268"""^^xsd:string ; umls:cui """C0699383"""^^xsd:string ; umls:cui """C0699397"""^^xsd:string ; umls:cui """C0699396"""^^xsd:string ; umls:cui """C0699386"""^^xsd:string ; umls:cui """C0699387"""^^xsd:string ; umls:cui """C0699384"""^^xsd:string ; umls:cui """C0699385"""^^xsd:string ; umls:cui """C0699393"""^^xsd:string ; umls:cui """C0699645"""^^xsd:string ; umls:cui """C0699390"""^^xsd:string ; umls:cui """C0699392"""^^xsd:string ; umls:cui """C0699402"""^^xsd:string ; umls:cui """C0699400"""^^xsd:string ; umls:cui """C0699391"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """betamethasone"""@eng ; skos:notation """CDR0000039273"""^^xsd:string ; skos:altLabel """Celestone"""@eng ; skos:definition """A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39273&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39273&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C303\" NCI Thesaurus)"""@eng ; """1903"""^^xsd:string ; """378-44-9"""^^xsd:string ; """C303"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """39470"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0005308"""^^xsd:string ; umls:cui """C0701247"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """beclomethasone dipropionate"""@eng ; skos:notation """CDR0000039272"""^^xsd:string ; skos:altLabel """Vanceril"""@eng , """Beclovent"""@eng , """BECLOMETH"""@eng , """Vancenase"""@eng , """(11beta,16beta)-9-Chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione"""@eng , """Beconase"""@eng , """BDP"""@eng ; skos:definition """The dipropionate salt of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39272&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39272&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C299\" NCI Thesaurus)"""@eng ; ; ; """5534-09-8 (dipropionate)"""^^xsd:string ; """1902"""^^xsd:string ; """C299"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """4419-39-0"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591154"""^^xsd:string ; umls:cui """C0004905"""^^xsd:string ; umls:cui """C0004906"""^^xsd:string ; umls:cui """C0699071"""^^xsd:string ; umls:cui """C0699072"""^^xsd:string ; umls:cui """C0699073"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrone"""@eng ; skos:notation """CDR0000039271"""^^xsd:string ; skos:altLabel """Theelin"""@eng ; """1901"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0014942"""^^xsd:string ; umls:cui """C1123064"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estradiol valerate"""@eng ; skos:notation """CDR0000039270"""^^xsd:string ; skos:definition """The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39270&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39270&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1090\" NCI Thesaurus)"""@eng ; """1900"""^^xsd:string ; """C1090"""^^xsd:string ; """979-32-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0059623"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000041524"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/5-FU/VCR/VP-16"""@eng ; ; ; ; ; ; ; """4686"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281159"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/etoposide"""@eng ; skos:notation """CDR0000041525"""^^xsd:string ; skos:altLabel """BU/VP-16"""@eng ; ; ; """4687"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281160"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/methotrexate/prednisone"""@eng ; skos:notation """CDR0000041526"""^^xsd:string ; skos:altLabel """ARA-C/MTX/PRED/VP-16"""@eng ; ; ; ; ; """4688"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281161"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/mitomycin"""@eng ; skos:notation """CDR0000041527"""^^xsd:string ; skos:altLabel """CDDP/IFF/MITO"""@eng , """MIC"""@eng ; ; ; ; """4689"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281162"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cefixime/irinotecan/temozolomide"""@eng ; skos:notation """CDR0000375023"""^^xsd:string ; skos:altLabel """CPT-11/FK-027/TMZ"""@eng ; ; ; ; """2004-06-23"""^^xsd:string ; """2004-06-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541310"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/ketoconazole/leuprolide"""@eng ; skos:notation """CDR0000041521"""^^xsd:string ; skos:altLabel """FLUT/KCZ/LEUP"""@eng ; ; ; ; """4677"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281150"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flutamide/ketoconazole"""@eng ; skos:notation """CDR0000041522"""^^xsd:string ; skos:altLabel """FLUT/KCZ"""@eng ; ; ; """4678"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281151"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trifluoperazine/verapamil/vinblastine"""@eng ; skos:notation """CDR0000041523"""^^xsd:string ; skos:altLabel """TFPZ/VBL/VPAM"""@eng ; ; ; ; """4685"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281158"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methylprednisolone"""@eng ; skos:notation """CDR0000041528"""^^xsd:string ; skos:altLabel """Duralone"""@eng , """Depo-Medrate"""@eng , """Depo Moderin"""@eng , """D-Med"""@eng , """Solu-Medrol"""@eng , """Solu Moderin"""@eng , """Depo-Nisolone"""@eng , """MePRDL"""@eng , """Depo-Medrol"""@eng , """Methylprednisolonum"""@eng , """Meprolone"""@eng , """Metysolon"""@eng , """Caberdelta M"""@eng , """Medrone"""@eng , """Metilbetasone Solubile"""@eng , """Medlone 21"""@eng , """Predni-M-Tablinen"""@eng , """Methylprednisolone Succinate"""@eng , """Radilem"""@eng , """Solu-Medrone"""@eng , """Metypresol"""@eng , """Cryosolona"""@eng , """Prednilem"""@eng , """Methylprednisolone Acetate"""@eng , """Medrate"""@eng , """Medrol Veriderm"""@eng , """Metypred"""@eng , """Medrol"""@eng , """Mega-Star"""@eng , """DepMedalone"""@eng , """Adlone"""@eng , """Esametone"""@eng , """Urbason"""@eng , """Summicort"""@eng , """Veriderm Medrol"""@eng , """6Alpha-Methylprednisolone"""@eng , """Firmacort"""@eng , """A-MethaPred"""@eng , """Asmacortone"""@eng , """(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione"""@eng , """Emmetipi"""@eng , """Wyacort"""@eng , """Solpredone"""@eng , """Metrocort"""@eng , """Depo-Medrone"""@eng ; skos:definition """A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41528&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41528&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C647\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """469"""^^xsd:string ; """2006-05-26"""^^xsd:string ; """83-43-2"""^^xsd:string ; """12619"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """19987"""^^xsd:string ; """C647"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699627"""^^xsd:string ; umls:cui """C1513252"""^^xsd:string ; umls:cui """C1513250"""^^xsd:string ; umls:cui """C1513251"""^^xsd:string ; umls:cui """C0600901"""^^xsd:string ; umls:cui """C1513238"""^^xsd:string ; umls:cui """C1513239"""^^xsd:string ; umls:cui """C1513230"""^^xsd:string ; umls:cui """C1513231"""^^xsd:string ; umls:cui """C1513232"""^^xsd:string ; umls:cui """C1513233"""^^xsd:string ; umls:cui """C1513234"""^^xsd:string ; umls:cui """C1513235"""^^xsd:string ; umls:cui """C1513236"""^^xsd:string ; umls:cui """C1513237"""^^xsd:string ; umls:cui """C0065862"""^^xsd:string ; umls:cui """C1527312"""^^xsd:string ; umls:cui """C0720088"""^^xsd:string ; umls:cui """C0719755"""^^xsd:string ; umls:cui """C1513249"""^^xsd:string ; umls:cui """C1513248"""^^xsd:string ; umls:cui """C1513245"""^^xsd:string ; umls:cui """C1513244"""^^xsd:string ; umls:cui """C1513247"""^^xsd:string ; umls:cui """C1513246"""^^xsd:string ; umls:cui """C1513241"""^^xsd:string ; umls:cui """C0701467"""^^xsd:string ; umls:cui """C1513243"""^^xsd:string ; umls:cui """C0592123"""^^xsd:string ; umls:cui """C1513229"""^^xsd:string ; umls:cui """C1513228"""^^xsd:string ; umls:cui """C1513242"""^^xsd:string ; umls:cui """C0591766"""^^xsd:string ; umls:cui """C0025815"""^^xsd:string ; umls:cui """C0701466"""^^xsd:string ; umls:cui """C0699458"""^^xsd:string ; umls:cui """C0699459"""^^xsd:string ; umls:cui """C0699457"""^^xsd:string ; umls:cui """C0025819"""^^xsd:string ; umls:cui """C0057476"""^^xsd:string ; umls:cui """C1513240"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """educational intervention"""@eng ; skos:notation """CDR0000041529"""^^xsd:string ; skos:altLabel """intervention, educational"""@eng ; ; rdfs:subClassOf ; ; """4690"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0281163"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal gammopathy of undetermined significance"""@eng ; skos:notation """CDR0000040134"""^^xsd:string ; skos:altLabel """MGUS"""@eng , """plasma cell neoplasm, monoclonal gammopathy of unknown significance"""@eng ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """29"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """multiple myeloma and other plasma cell neoplasms"""^^xsd:string ; umls:cui """C0026470"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II oropharyngeal cancer"""@eng ; skos:notation """CDR0000040135"""^^xsd:string ; skos:altLabel """oropharyngeal cancer, stage II"""@eng , """oropharynx cancer, stage II"""@eng ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2900"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279835"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III oropharyngeal cancer"""@eng ; skos:notation """CDR0000040136"""^^xsd:string ; skos:altLabel """oropharyngeal cancer, stage III"""@eng , """oropharynx cancer, stage III"""@eng ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2901"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279836"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV oropharyngeal cancer"""@eng ; skos:notation """CDR0000040137"""^^xsd:string ; skos:altLabel """oropharynx cancer, metastatic"""@eng , """metastatic oropharyngeal cancer"""@eng , """oropharynx cancer, stage IV"""@eng , """oropharyngeal cancer, metastatic"""@eng , """oropharyngeal cancer, stage IV"""@eng ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2902"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1378462"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040130"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus cancer, stage III"""@eng , """paranasal sinus and nasal cavity cancer, stage III"""@eng ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2895"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279830"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV paranasal sinus and nasal cavity cancer"""@eng ; skos:notation """CDR0000040131"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity cancer, stage IV"""@eng , """nasal cavity and paranasal sinus cancer, stage IV"""@eng , """nasal cavity and paranasal sinus cancer, metastatic"""@eng , """metastatic paranasal sinus and nasal cavity cancer"""@eng , """paranasal sinus and nasal cavity cancer, metastatic"""@eng ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2896"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279831"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MGCD0103"""@eng ; skos:notation """CDR0000486941"""^^xsd:string ; skos:altLabel """MG-0103"""@eng ; """2006-09-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62521"""^^xsd:string ; umls:cui """C1831851"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I oropharyngeal cancer"""@eng ; skos:notation """CDR0000040133"""^^xsd:string ; skos:altLabel """oropharyngeal cancer, stage I"""@eng , """oropharynx cancer, stage I"""@eng ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2899"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279834"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/S-1"""@eng ; skos:notation """CDR0000350142"""^^xsd:string ; skos:altLabel """CDDP/S1"""@eng ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-18"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328128"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent oropharyngeal cancer"""@eng ; skos:notation """CDR0000040138"""^^xsd:string ; skos:altLabel """oropharyngeal cancer, recurrent"""@eng , """oropharynx cancer, recurrent"""@eng ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2903"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279838"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral complications of cancer and cancer therapy"""@eng ; skos:notation """CDR0000040139"""^^xsd:string ; skos:altLabel """stomatitis management"""@eng , """management of xerostomia"""@eng , """mucositis management"""@eng , """oral complications of cancer therapy"""@eng , """cancer therapy, oral complications of"""@eng , """complications secondary to cancer therapy, oral"""@eng , """complications of cancer therapy, oral"""@eng , """xerostomia management"""@eng , """cancer therapy, oral complications secondary to"""@eng , """management of stomatitis"""@eng , """management of mucositis"""@eng ; rdfs:subClassOf ; """2904"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0279839"""^^xsd:string ; umls:cui """C1321873"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human anti-TGF-beta monoclonal antibody"""@eng ; skos:notation """CDR0000509194"""^^xsd:string ; skos:altLabel """recombinant human anti-transforming growth factor-beta monoclonal antibody"""@eng , """GC1008"""@eng ; """Drug/agent"""^^xsd:string ; """2006-10-05"""^^xsd:string ; """2006-09-15"""^^xsd:string ; umls:cui """C1832030"""^^xsd:string ; umls:cui """C2980070"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/TLK286"""@eng ; skos:notation """CDR0000387808"""^^xsd:string ; skos:altLabel """CBDCA/TAX/TLK-286"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-11"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541464"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MST-997"""@eng ; skos:notation """CDR0000387809"""^^xsd:string ; skos:altLabel """TL-909"""@eng ; """2004-08-24"""^^xsd:string ; """2004-08-11"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541803"""^^xsd:string ; umls:cui """C1541465"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """norgestrel"""@eng ; skos:notation """CDR0000039310"""^^xsd:string ; skos:altLabel """(17Alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one"""@eng , """D-(-)-Norgestrel"""@eng , """(+/-)-13-Ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yne-3-one"""@eng , """NORGES"""@eng , """Ovrette"""@eng , """Neogest"""@eng , """Microlut"""@eng , """Wy-3707"""@eng , """Levonorgestrel"""@eng ; skos:definition """A synthetic progestin commonly used alone or in combination with an estrogen for contraception. Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes. This agent also exhibits antiproliferative activity in endometrial tissue and may exhibit chemopreventive and antineoplastic activities in endometrial carcinoma. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39310&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39310&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C703\" NCI Thesaurus)"""@eng ; ; """1946"""^^xsd:string ; """797-63-7 (levo isomer)"""^^xsd:string ; """6533-00-2 (racemic)"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C703"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0023566"""^^xsd:string ; umls:cui """C0699698"""^^xsd:string ; umls:cui """C0028368"""^^xsd:string ; umls:cui """C0701266"""^^xsd:string ; umls:cui """C0699168"""^^xsd:string ; umls:cui """C0699169"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/mitomycin"""@eng ; skos:notation """CDR0000039311"""^^xsd:string ; skos:altLabel """ABCM"""@eng , """BLEO/CTX/DOX/MITO"""@eng ; ; ; ; ; """1947"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279181"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine/cytarabine/thioguanine"""@eng ; skos:notation """CDR0000039312"""^^xsd:string ; skos:altLabel """AAT"""@eng , """AMSA/ARA-C/TG"""@eng ; ; ; ; """1948"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0052586"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cyclophosphamide/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000039313"""^^xsd:string ; skos:altLabel """HEXA-VAC"""@eng , """CTX/DOX/HMM/VCR"""@eng ; ; ; ; ; """1949"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279183"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000039314"""^^xsd:string ; skos:altLabel """HEXMF"""@eng , """5-FU/HMM/MITO"""@eng ; ; ; ; """1950"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279184"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ifosfamide/prednisone/vincristine"""@eng ; skos:notation """CDR0000039315"""^^xsd:string ; skos:altLabel """DOX/IFF/PRED/VCR"""@eng , """IHOP"""@eng ; ; ; ; ; """1951"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279185"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epirubicin/rituximab"""@eng ; skos:notation """CDR0000306041"""^^xsd:string ; skos:altLabel """EPI/MOAB IDEC-C2B8"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327977"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/lomustine/methotrexate/prednisone"""@eng ; skos:notation """CDR0000039317"""^^xsd:string ; skos:altLabel """CCNU/MTX/PRED/VP-16"""@eng , """LEMP"""@eng ; ; ; ; ; """1953"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279187"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000041421"""^^xsd:string ; skos:altLabel """BLEO/CDDP/G-CSF/VP-16"""@eng ; ; ; ; ; """4493"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280973"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/Detox-B adjuvant/interleukin-2"""@eng ; skos:notation """CDR0000041420"""^^xsd:string ; skos:altLabel """CTX/DETOXB/IL-2"""@eng ; ; ; ; """4492"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935655"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/filgrastim/ifosfamide"""@eng ; skos:notation """CDR0000041423"""^^xsd:string ; skos:altLabel """BLEO/CDDP/G-CSF/IFF/VP-16"""@eng ; ; ; ; ; ; """4495"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280975"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/filgrastim/vincristine"""@eng ; skos:notation """CDR0000041422"""^^xsd:string ; skos:altLabel """BLEO/CDDP/G-CSF/VCR"""@eng ; ; ; ; ; """4494"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280974"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/dexamethasone/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000041425"""^^xsd:string ; skos:altLabel """CYSP/DM/DOX/VCR"""@eng ; ; ; ; ; """4497"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280977"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """retrovector encoding mutant anti-cyclin G1"""@eng ; skos:notation """CDR0000446577"""^^xsd:string ; skos:altLabel """retroviral expression vector bearing anti-cyclin G1 gene construct"""@eng , """Mx-dnG1 retroviral vector"""@eng , """REXIN-G"""@eng ; skos:definition """A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446577&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=446577&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49082\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-09-09"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C49082"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1709936"""^^xsd:string ; umls:cui """C1709935"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/fluorouracil/interleukin-3/leucovorin calcium"""@eng ; skos:notation """CDR0000041427"""^^xsd:string ; skos:altLabel """CF/CTX/DOX/5-FU/IL-3"""@eng ; ; ; ; ; ; """4499"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280979"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/macrophage colony-stimulating factor"""@eng ; skos:notation """CDR0000041426"""^^xsd:string ; skos:altLabel """IFN-G/M-CSF"""@eng ; ; ; """4498"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280978"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """valdecoxib"""@eng ; skos:notation """CDR0000038320"""^^xsd:string ; skos:altLabel """SC 65872"""@eng , """Bextra"""@eng , """4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide"""@eng ; skos:definition """A sulfonamide derivative and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. Valdecoxib selectively binds to and inhibits cyclooxygenase (COX)-2, thereby preventing the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever. This NSAID does not inhibit COX-1 at therapeutic concentrations and therefore does not interfere with blood coagulation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38320&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38320&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1869\" NCI Thesaurus)"""@eng ; """10937"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1869"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """181695-72-7"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1101725"""^^xsd:string ; umls:cui """C0913246"""^^xsd:string ; umls:cui """C1130481"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """inalimarev"""@eng ; skos:notation """CDR0000385666"""^^xsd:string ; skos:altLabel """PANVAC-V"""@eng , """vCEA-MUC-1-TRI"""@eng , """vaccinia-CEA-MUC-1-TRICOM vaccine"""@eng , """recombinant vaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine"""@eng , """rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine"""@eng ; skos:definition """A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and activate a cytotoxic T-cells response against CEA- and MUC-1-expressing tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385666&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=385666&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29317\" NCI Thesaurus)"""@eng ; ; ; """TRD"""^^xsd:string ; """2004-08-24"""^^xsd:string ; """2006-10-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C29317"""^^xsd:string ; umls:cui """C1515694"""^^xsd:string ; umls:cui """C1541349"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/motexafin gadolinium"""@eng ; skos:notation """CDR0000372885"""^^xsd:string ; skos:altLabel """CDDP/5-FU/PCI-0120"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541275"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/motexafin gadolinium"""@eng ; skos:notation """CDR0000372886"""^^xsd:string ; skos:altLabel """PCI-0120/TXT"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541276"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alternative medical systems"""@eng ; skos:notation """CDR0000372887"""^^xsd:string ; ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1515927"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/epirubicin/fluorouracil/paclitaxel/trastuzumab"""@eng ; skos:notation """CDR0000372882"""^^xsd:string ; skos:altLabel """CTX/EPI/5-FU/MOAB HER2/TAX"""@eng ; ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541274"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acupuncture"""@eng ; skos:notation """CDR0000372888"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0394664"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """electroacupuncture"""@eng ; skos:notation """CDR0000372889"""^^xsd:string ; rdfs:subClassOf ; """2004-05-28"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0013794"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-MUC-1-TRICOM vaccine/sargramostim/vaccinia-CEA-MUC-1-TRICOM vaccine"""@eng ; skos:notation """CDR0000385668"""^^xsd:string ; skos:altLabel """fCEA-MUC-1-TRI/GM-CSF/vCEA-MUC-1-TRI"""@eng ; ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541351"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-MUC-1-TRICOM vaccine/sargramostim"""@eng ; skos:notation """CDR0000385669"""^^xsd:string ; skos:altLabel """fCEA-MUC-1-TRI/GM-CSF"""@eng ; ; ; """2004-08-24"""^^xsd:string ; """2004-08-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541352"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine/monoclonal antibody anti-alpha V beta 3 integrin/zoledronate"""@eng ; skos:notation """CDR0000352014"""^^xsd:string ; skos:altLabel """EM/MOAB anti-avb3 integrin/TXT/ZOLE"""@eng ; ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328143"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """OSI-7904L"""@eng ; skos:notation """CDR0000352016"""^^xsd:string ; skos:altLabel """OSI-7904 liposomal"""@eng , """GS7904L"""@eng , """OSI 7904L"""@eng ; skos:definition """A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352016&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352016&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38694\" NCI Thesaurus)"""@eng ; ; """2004-01-23"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C38694"""^^xsd:string ; umls:cui """C1328144"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """arsenic trioxide/cholecalciferol"""@eng ; skos:notation """CDR0000420969"""^^xsd:string ; skos:altLabel """AS2O3/VIT-D"""@eng ; ; ; """2005-02-18"""^^xsd:string ; """2005-02-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541512"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/monoclonal antibody anti-alpha V beta 3 integrin"""@eng ; skos:notation """CDR0000352013"""^^xsd:string ; skos:altLabel """MOAB anti-avb3 integrin/TXT"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-02-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328142"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CpG 7909/dacarbazine"""@eng ; skos:notation """CDR0000352012"""^^xsd:string ; skos:altLabel """CpG-7909/DTIC"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328141"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood large cell lymphoma"""@eng ; skos:notation """CDR0000042198"""^^xsd:string ; skos:altLabel """pediatric large cell lymphoma, recurrent"""@eng , """pediatric large cell lymphoma, relapsed"""@eng , """childhood large cell lymphoma, relapsed"""@eng , """recurrent large cell lymphoma, childhood"""@eng , """lymphoma, recurrent childhood large cell"""@eng , """large cell lymphoma, childhood, relapsed"""@eng , """relapsed large cell lymphoma, childhood"""@eng , """recurrent pediatric large cell lymphoma"""@eng , """relapsed pediatric large cell lymphoma"""@eng , """lymphoma, relapsed childhood large cell"""@eng , """childhood large cell lymphoma, recurrent"""@eng , """relapsed childhood large cell lymphoma"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5438"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281709"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood large cell lymphoma"""@eng ; skos:notation """CDR0000042199"""^^xsd:string ; skos:altLabel """large cell lymphoma, childhood"""@eng , """pediatric large cell lymphoma"""@eng , """lymphoma, childhood large cell"""@eng ; rdfs:subClassOf ; """5439"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281710"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SNS-595"""@eng ; skos:notation """CDR0000393833"""^^xsd:string ; """2004-10-25"""^^xsd:string ; """2006-03-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541378"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I childhood large cell lymphoma"""@eng ; skos:notation """CDR0000042190"""^^xsd:string ; skos:altLabel """stage I large cell lymphoma, childhood"""@eng , """pediatric large cell lymphoma, stage I"""@eng , """childhood large cell lymphoma, stage I"""@eng , """lymphoma, stage I childhood large cell"""@eng , """large cell lymphoma, childhood, stage I"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5430"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281701"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000042191"""^^xsd:string ; skos:altLabel """pediatric small noncleaved cell lymphoma, stage II"""@eng , """lymphoma, stage II childhood small noncleaved cell"""@eng , """small noncleaved cell lymphoma, childhood, stage II"""@eng , """stage II small noncleaved cell lymphoma, childhood"""@eng , """childhood small noncleaved cell lymphoma, stage II"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5431"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281702"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II childhood large cell lymphoma"""@eng ; skos:notation """CDR0000042192"""^^xsd:string ; skos:altLabel """childhood large cell lymphoma, stage II"""@eng , """large cell lymphoma, childhood, stage II"""@eng , """lymphoma, stage II childhood large cell"""@eng , """pediatric large cell lymphoma, stage II"""@eng , """stage II large cell lymphoma, childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5432"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281703"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000042193"""^^xsd:string ; skos:altLabel """lymphoma, stage III childhood small noncleaved cell lymphoma"""@eng , """pediatric small noncleaved cell lymphoma, stage III"""@eng , """childhood small noncleaved cell lymphoma, stage III"""@eng , """small noncleaved cell lymphoma, childhood, stage III"""@eng , """stage III small noncleaved cell lymphoma, childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5433"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281704"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III childhood large cell lymphoma"""@eng ; skos:notation """CDR0000042194"""^^xsd:string ; skos:altLabel """large cell lymphoma, childhood, stage III"""@eng , """childhood large cell lymphoma, stage III"""@eng , """lymphoma, stage III childhood large cell"""@eng , """stage III large cell lymphoma, childhood"""@eng , """pediatric large cell lymphoma, stage III"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5434"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281705"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000042195"""^^xsd:string ; skos:altLabel """lymphoma, stage IV childhood small noncleaved cell"""@eng , """metastatic childhood small noncleaved cell lymphoma"""@eng , """small noncleaved cell lymphoma, childhood, stage IV"""@eng , """pediatric small noncleaved cell lymphoma, stage IV"""@eng , """childhood small noncleaved cell lymphoma, metastatic"""@eng , """pediatric small noncleaved cell lymphoma, metastatic"""@eng , """lymphoma, metastatic childhood small noncleaved cell"""@eng , """small noncleaved cell lymphoma, childhood, metastatic"""@eng , """childhood small noncleaved cell lymphoma, stage IV"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5435"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281706"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV childhood large cell lymphoma"""@eng ; skos:notation """CDR0000042196"""^^xsd:string ; skos:altLabel """lymphoma, metastatic childhood large cell"""@eng , """lymphoma, stage IV childhood large cell"""@eng , """metastatic large cell lymphoma, childhood"""@eng , """large cell lymphoma, childhood, stage IV"""@eng , """pediatric large cell lymphoma, metastatic"""@eng , """stage IV large cell lymphoma, childhood"""@eng , """childhood large cell lymphoma, stage IV"""@eng , """large cell lymphoma, childhood, metastatic"""@eng , """metastatic childhood large cell lymphoma"""@eng , """pediatric large cell lymphoma, stage IV"""@eng , """childhood large cell lymphoma, metastatic"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5436"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281707"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood small noncleaved cell lymphoma"""@eng ; skos:notation """CDR0000042197"""^^xsd:string ; skos:altLabel """relapsed childhood small noncleaved cell lymphoma"""@eng , """small noncleaved cell lymphoma, childhood, relapsed"""@eng , """childhood small noncleaved cell lymphoma, relapsed"""@eng , """recurrent small noncleaved cell lymphoma, childhood"""@eng , """lymphoma, relapsed childhood small noncleaved cell"""@eng , """lymphoma, recurrent childhood small noncleaved cell"""@eng , """relapsed small noncleaved cell lymphoma, childhood"""@eng , """pediatric small noncleaved cell lymphoma, relapsed"""@eng , """small noncleaved cell lymphoma, childhood, recurrent"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5437"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0281708"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gemcitabine/interferon alfa"""@eng ; skos:notation """CDR0000363888"""^^xsd:string ; skos:altLabel """CDDP/dFdC/IFN-A"""@eng ; ; ; ; """2004-04-23"""^^xsd:string ; """2004-03-30"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541212"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L1 childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039862"""^^xsd:string ; skos:altLabel """L1 childhood ALL"""@eng , """L1 pediatric acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, childhood L1"""@eng , """pediatric ALL, L1"""@eng , """acute lymphocytic leukemia, childhood L1"""@eng , """childhood acute lymphocytic leukemia, L1"""@eng , """ALL, childhood L1"""@eng , """ALL, pediatric L1"""@eng , """ALL, L1 childhood"""@eng , """L1 acute lymphocytic leukemia, childhood"""@eng , """pediatric acute lymphocytic leukemia, L1"""@eng , """childhood acute lymphoblastic leukemia, L1"""@eng , """leukemia, childhood acute lymphocytic , L1"""@eng , """pediatric acute lymphoblastic leukemia, L1"""@eng , """L1 acute lymphoblastic leukemia, childhood"""@eng , """L1 pediatric ALL"""@eng , """L1 childhood acute lymphocytic leukemia"""@eng , """L1 lymphoblastic leukemia, acute childhood"""@eng , """L1 lymphocytic leukemia, acute childhood"""@eng , """ALL, L1 pediatric"""@eng , """childhood ALL, L1"""@eng ; rdfs:subClassOf ; """2543"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279580"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L2 childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039863"""^^xsd:string ; skos:altLabel """L2 childhood acute lymphocytic leukemia"""@eng , """acute lymphocytic leukemia, childhood L2"""@eng , """L2 acute lymphocytic leukemia, childhood"""@eng , """childhood ALL, L2"""@eng , """acute lymphoblastic leukemia, childhood L2"""@eng , """L2 pediatric acute lymphocytic leukemia"""@eng , """L2 lymphoblastic leukemia, acute childhood"""@eng , """ALL, childhood L2"""@eng , """childhood acute lymphocytic leukemia, L2"""@eng , """L2 lymphocytic leukemia, acute childhood"""@eng , """ALL, pediatric L2"""@eng , """L2 childhood ALL"""@eng , """ALL, L2 pediatric"""@eng , """pediatric ALL, L2"""@eng , """leukemia, childhood acute lymphocytic , L2"""@eng , """childhood acute lymphoblastic leukemia, L2"""@eng , """pediatric acute lymphocytic leukemia, L2"""@eng , """L2 pediatric ALL"""@eng , """L2 acute lymphoblastic leukemia, childhood"""@eng , """pediatric acute lymphoblastic leukemia, L2"""@eng , """ALL, L2 childhood"""@eng ; rdfs:subClassOf ; """2544"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279581"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anaplastic adrenocortical carcinoma"""@eng ; skos:notation """CDR0000039860"""^^xsd:string ; skos:altLabel """carcinoma, undifferentiated adrenocortical"""@eng , """adrenal cortical, anaplastic carcinoma"""@eng , """carcinoma, adrenocortical, anaplastic"""@eng , """adrenal cortical carcinoma, anaplastic"""@eng , """undifferentiated adrenocortical carcinoma"""@eng , """adrenal cortex cancer, anaplastic"""@eng , """anaplastic adrenocortical cancer"""@eng , """carcinoma, anaplastic adrenocortical"""@eng , """adrenocortical carcinoma, anaplastic"""@eng ; rdfs:subClassOf ; """2541"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279579"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydrocortisone sodium succinate"""@eng ; skos:notation """CDR0000039861"""^^xsd:string ; skos:altLabel """Hycorace"""@eng , """A-hydroCort"""@eng , """HDC"""@eng , """Solu-Cortef"""@eng , """Hydrocortisone Na succinate"""@eng ; """2542"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0701090"""^^xsd:string ; umls:cui """C0770560"""^^xsd:string ; umls:cui """C0701089"""^^xsd:string ; umls:cui """C0701088"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """B-cell childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039866"""^^xsd:string ; skos:altLabel """B cell acute lymphocytic leukemia, childhood"""@eng , """childhood ALL, B-cell"""@eng , """ALL, pediatric B-cell"""@eng , """childhood acute lymphoblastic leukemia, B-cell"""@eng , """acute lymphoblastic leukemia, childhood B-cell"""@eng , """pediatric ALL, B cell"""@eng , """B cell ALL, childhood"""@eng , """B-cell childhood acute lymphocytic leukemia"""@eng , """B-cell ALL, childhood"""@eng , """B-cell acute lymphocytic leukemia, childhood"""@eng , """B cell childhood ALL"""@eng , """B cell childhood acute lymphocytic leukemia"""@eng , """childhood acute lymphocytic leukemia, B-cell"""@eng , """B-cell childhood ALL"""@eng , """childhood ALL, B cell"""@eng , """leukemia, childhood acute lymphocytic leukemia, B-cell"""@eng , """B-cell pediatric ALL"""@eng , """B-cell ALL, pediatric"""@eng , """leukemia, pediatric acute lymphocytic leukemia, B-cell"""@eng , """B cell pediatric ALL"""@eng , """B cell pediatric acute lymphocytic leukemia"""@eng , """B-cell pediatric acute lymphocytic leukemia"""@eng , """pediatric ALL, B-cell"""@eng , """B cell ALL, pediatric"""@eng , """acute lymphocytic leukemia, childhood B-cell"""@eng , """pediatric acute lymphocytic leukemia, B-cell"""@eng , """ALL, childhood B-cell"""@eng ; rdfs:subClassOf ; """2547"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279584"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039867"""^^xsd:string ; skos:altLabel """ALL, non-T, non-B, pediatric"""@eng , """acute lymphoblastic leukemia, childhood non-T, non-B"""@eng , """non-T, non-B ALL, pediatric"""@eng , """ALL, childhood, non-T, non-B"""@eng , """non-T, non-B ALL, childhood"""@eng , """pediatric ALL, non-T, non-B"""@eng , """leukemia, childhood acute lymphocytic non-T, non-B"""@eng , """non-T, non-B pediatric ALL"""@eng , """ALL, non-T, non-B, childhood"""@eng , """acute lymphocytic leukemia, childhood non-T, non-B"""@eng , """non B, non T childhood acute lymphocytic leukemia"""@eng , """childhood acute lymphoblastic leukemia, non-T, non-B"""@eng , """non T, non B childhood ALL"""@eng , """pediatric ALL, non T, non B"""@eng , """leukemia, pediatric acute lymphocytic, non-T, non-B"""@eng , """ALL, non T, non B, childhood"""@eng , """childhood ALL, non T, non B"""@eng , """childhood ALL, non-T, non-B"""@eng , """pediatric acute lymhoblastic leukemia, non-T, non-B"""@eng , """non-T, non-B pediatric acute lymphocytic leukemia"""@eng , """non T, non B ALL, pediatric"""@eng , """ALL, non T, non B, pediatric"""@eng , """ALL, childhood, non T, non B"""@eng , """leukemia, childhood ALL non-T, non-B"""@eng , """non T, non B ALL, childhood"""@eng , """non-B, non-T childhood acute lymphocytic leukemia"""@eng , """childhood acute lymphocytic leukemia, non-T, non-B"""@eng , """non-T, non-B childhood acute lymphocytic leukemia"""@eng , """non B, non T pediatric acute lymphocytic leukemia"""@eng , """leukemia, pediatric ALL non-T, non-B"""@eng , """non T, non B pediatric ALL"""@eng , """ALL, pediatric, non T, non B"""@eng , """non-T, non-B childhood ALL"""@eng , """ALL, pediatric, non-T, non-B"""@eng , """non T, non B childhood acute lymphocytic leukemia"""@eng , """non-T, non-B acute lymphocytic leukemia, childhood"""@eng ; rdfs:subClassOf ; """2548"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279585"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L3 childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039864"""^^xsd:string ; skos:altLabel """pediatric ALL, L3"""@eng , """L3 childhood acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, childhood L3"""@eng , """ALL, L3 pediatric"""@eng , """acute lymphocytic leukemia, childhood L3"""@eng , """ALL, childhood L3"""@eng , """ALL, pediatric L3"""@eng , """childhood ALL, L3"""@eng , """childhood acute lymphocytic leukemia, L3"""@eng , """L3 childhood ALL"""@eng , """leukemia, childhood acute lymphocytic , L3"""@eng , """pediatric acute lymphocytic leukemia, L3"""@eng , """childhood acute lymphoblastic leukemia, L3"""@eng , """L3 acute lymphocytic leukemia, childhood"""@eng , """L3 pediatric ALL"""@eng , """L3 pediatric acute lymphocytic leukemia"""@eng , """pediatric acute lymphoblastic leukemia, L3"""@eng , """L3 acute lymphoblastic leukemia, childhood"""@eng , """ALL, L3 childhood"""@eng , """L3 lymphocytic leukemia, acute childhood"""@eng , """L3 lymphoblastic leukemia, acute childhood"""@eng ; rdfs:subClassOf ; """2545"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279582"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """T-cell childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039865"""^^xsd:string ; skos:altLabel """T cell pediatric ALL"""@eng , """T-cell childhood ALL"""@eng , """ALL, childhood T-cell"""@eng , """T cell childhood ALL"""@eng , """T-cell pediatric acute lymphocytic leukemia"""@eng , """pediatric ALL, T-cell"""@eng , """ALL, pediatric T-cell"""@eng , """childhood acute lymphoblastic leukemia, T-cell"""@eng , """T cell childhood acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, childhood T-cell"""@eng , """T cell acute lymphocytic leukemia, childhood"""@eng , """T-cell ALL, childhood"""@eng , """leukemia, childhood acute lymphocytic T-cell"""@eng , """T-cell ALL, pediatric"""@eng , """T-cell pediatric ALL"""@eng , """childhood ALL, T cell"""@eng , """T cell ALL, pediatric"""@eng , """T cell ALL, childhood"""@eng , """pediatric acute lymphocytic leukemia, T-cell"""@eng , """acute lymphocytic leukemia, childhood T-cell"""@eng , """T-cell childhood acute lymphocytic leukemia"""@eng , """T-cell acute lymphocytic leukemia, childhood"""@eng , """childhood acute lymphocytic leukemia, T-cell"""@eng , """pediatric ALL, T cell"""@eng , """leukemia, pediatric acute lymphocytic T-cell"""@eng , """T cell pediatric acute lymphocytic leukemia"""@eng , """childhood ALL, T-cell"""@eng ; rdfs:subClassOf ; """2546"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279583"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039868"""^^xsd:string ; skos:altLabel """leukemia, ALL non T, non B, cALLa positive, childhood"""@eng , """leukemia, childhood ALL non-T, non-B, cALLa positive"""@eng , """pediatric ALL, non T, non B, cALLa positive"""@eng , """pediatric ALL, non-T, non-B, cALLa positive"""@eng , """ALL, pediatric, non T, non B, cALLa positive"""@eng , """non T, non B, cALLa positive childhood acute lymphocytic leukemia"""@eng , """childhood ALL, non T, non B, cALLa positive"""@eng , """ALL, cALLa positive, non-T, non-B, pediatric"""@eng , """acute lymphocytic leukemia, childhood non-T, non-B, cALLa positive"""@eng , """leukemia, pediatric ALL non-T, non-B, cALLa positive"""@eng , """childhood ALL, non-T, non-B, cALLa positive"""@eng , """ALL, non-T, non-B, cALLa positive, childhood"""@eng , """ALL, pediatric, non-T, non-B, cALLa positive"""@eng , """non-B, non-T, cALLa positive childhood acute lymphocytic leukemia"""@eng , """ALL, childhood, non T, non B, cALLa positive"""@eng , """leukemia, ALL non-T, non-B, cALLa positive, childhood"""@eng , """ALL, childhood, non-T, non-B, cALLa positive"""@eng , """non-T, non-B, cALLa positive childhood acute lymphocytic leukemia"""@eng , """non-T, non-B, cALLa positive childhood ALL"""@eng , """leukemia, childhood acute lymphocytic non-T, non-B, cALLa positive"""@eng , """leukemia, pediatric acute lymphocytic non-T, non-B, cALLa positive"""@eng , """ALL, non T, non B, cALLa positive, childhood"""@eng , """cALLa positive, non T, non B, childhood ALL"""@eng , """cALLa positive, non-T, non-B, childhood ALL"""@eng , """non B, non T, cALLa positive childhood acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, childhood non-T, non-B, cALLa positive"""@eng ; rdfs:subClassOf ; """2549"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279586"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039869"""^^xsd:string ; skos:altLabel """ALL, non-T, non-B, cALLa negative, childhood"""@eng , """cALLa negative, non T, non B, childhood ALL"""@eng , """leukemia, childhood acute lymphocytic non-T, non-B, cALLa negative"""@eng , """cALLa negative, non-T, non-B, childhood ALL"""@eng , """pediatric ALL, non T, non B, cALLA negative"""@eng , """non-B, non-T, cALLa negative childhood acute lymphocytic leukemia"""@eng , """acute lymphoblastic leukemia, childhood non-T, non-B, cALLa negative"""@eng , """non-T, non-B, cALLa negative childhood acute lymphocytic leukemia"""@eng , """non-T, non-B, cALLa negative childhood ALL"""@eng , """ALL, non T, non B, cALLa negative, childhood"""@eng , """leukemia, ALL non-T, non-B, cALLa negative, childhood"""@eng , """ALL, pediatric, non T, non B, cALLa negative"""@eng , """non T, non B, cALLa negative childhood acute lymphocytic leukemia"""@eng , """childhood ALL, non-T, non-B, cALLa negative"""@eng , """childhood ALL, non T, non B, cALLa negative"""@eng , """ALL, childhood, non-T, non-B, cALLa negative"""@eng , """pediatric ALL, non-T, non-B, cALLA negative"""@eng , """non B, non T, cALLa negative childhood acute lymphocytic leukemia"""@eng , """ALL, childhood, non T, non B, cALLa negative"""@eng , """leukemia, childhood ALL non-T, non-B, cALLa negative"""@eng , """ALL, pediatric, non-T, non-B, cALLa negative"""@eng , """ALL, cALLa negative, non-T, non-B childhood"""@eng , """acute lymphocytic leukemia, childhood non-T, non-B, cALLa negative"""@eng ; rdfs:subClassOf ; """2550"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279587"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood central nervous system germ cell tumor"""@eng ; skos:notation """CDR0000038199"""^^xsd:string ; skos:altLabel """pediatric germ cell CNS tumor"""@eng , """pediatric CNS tumor, intracranial germ cell"""@eng , """childhood malignant intracranial germ cell brain tumor"""@eng , """childhood malignant germ cell brain tumor"""@eng , """brain tumor, germ cell, childhood"""@eng , """pediatric brain tumor, intracranial germ cell"""@eng , """central nervous system tumor, germ cell, childhood"""@eng , """childhood intracranial germ cell tumor"""@eng , """brain tumor, childhood, intracranial germ cell"""@eng , """childhood CNS tumor, intracranial germ cell"""@eng , """pediatric CNS endodermal sinus tumor"""@eng , """pediatric CNS tumor, germ cell"""@eng , """brain tumor, intracranial germ cell, childhood"""@eng , """CNS tumor, pediatric germ cell"""@eng , """pediatric brain tumor, germ cell"""@eng , """childhood brain tumor, germ cell"""@eng , """CNS tumor, childhood germ cell"""@eng , """childhood germ cell brain tumor"""@eng , """brain tumor, childhood, germ cell"""@eng , """childhood CNS tumor, germ cell"""@eng , """childhood CNS endodermal sinus tumor"""@eng , """childhood germ cell CNS tumor"""@eng , """pediatric germ cell brain tumor"""@eng , """pediatric intracranial germ cell brain tumor"""@eng , """childhood intracranial mixed germ cell brain tumor"""@eng , """childhood CNS embryonal cell carcinoma"""@eng , """childhood germinoma brain tumor"""@eng , """germ cell brain tumor, childhood"""@eng , """intracranial germ cell brain tumor, childhood"""@eng , """childhood intracranial germ cell CNS tumor"""@eng , """brain tumor, pediatric, germ cell"""@eng , """brain tumor, pediatric, intracranial germ cell"""@eng , """intracranial germ cell CNS tumor, childhood"""@eng , """childhood mixed germ cell brain tumor"""@eng , """pediatric intracranial germ cell CNS tumor"""@eng , """childhood intracranial germinoma brain tumor"""@eng , """CNS tumor, childhood intracranial germ cell"""@eng , """childhood CNS teratoma"""@eng , """germ cell CNS tumor, childhood"""@eng , """pediatric CNS choriocarcinoma"""@eng , """childhood CNS choriocarcinoma"""@eng , """pediatric CNS teratoma"""@eng , """pediatric CNS embryonal cell carcinoma"""@eng , """childhood brain tumor, intracranial germ cell"""@eng , """central nervous system tumor, intracranial germ cell, childhood"""@eng , """CNS tumor, pediatric intracranial germ cell"""@eng , """pediatric intracrainal germ cell tumor"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1080"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1377605"""^^xsd:string ; umls:cui """C1377604"""^^xsd:string ; umls:cui """C1377599"""^^xsd:string ; umls:cui """C1377598"""^^xsd:string ; umls:cui """C0278754"""^^xsd:string ; umls:cui """C1377612"""^^xsd:string ; umls:cui """C1377613"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV cervical cancer"""@eng ; skos:notation """CDR0000038198"""^^xsd:string ; skos:altLabel """cancer of the cervix, stage IV"""@eng , """uterine cervix cancer, stage IV"""@eng , """stage IV cervix cancer"""@eng , """cervix cancer, stage IV"""@eng , """stage IV carcinoma of the cervix"""@eng , """stage IV cancer of the cervix"""@eng , """stage IV uterine cervix cancer"""@eng , """carcinoma of the cervix, stage IV"""@eng , """cervical cancer, stage IV"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """108"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278578"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/sargramostim"""@eng ; skos:notation """CDR0000039092"""^^xsd:string ; skos:altLabel """DHAD/GM-CSF"""@eng ; ; ; """1683"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279103"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """selenium/vitamin E"""@eng ; skos:notation """CDR0000038191"""^^xsd:string ; skos:altLabel """SEL/VIT-E"""@eng ; ; ; """10789"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935773"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MRI-guided focused ultrasound ablation"""@eng ; skos:notation """CDR0000038190"""^^xsd:string ; skos:altLabel """thermal ablation"""@eng , """focused ultrasound ablation, MRI-guided"""@eng , """ultrasound ablation, MRI-guided focused"""@eng ; """10777"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0935764"""^^xsd:string ; umls:cui """C0677798"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gene expression profiling"""@eng ; skos:notation """CDR0000038193"""^^xsd:string ; rdfs:subClassOf ; """10791"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0752248"""^^xsd:string ; umls:tui """T063"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """INI1"""@eng ; skos:notation """CDR0000038192"""^^xsd:string ; rdfs:subClassOf ; """10790"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0292369"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atamestane"""@eng ; skos:notation """CDR0000038195"""^^xsd:string ; skos:definition """A synthetic steroidal substance with antineoplastic activity. Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38195&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38195&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1224\" NCI Thesaurus)"""@eng ; ; """10796"""^^xsd:string ; """C1224"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """96301-34-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0074442"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/interferon alfa"""@eng ; skos:notation """CDR0000038194"""^^xsd:string ; skos:altLabel """IFN-A/STI571"""@eng ; ; ; """10792"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935774"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exemestane/goserelin"""@eng ; skos:notation """CDR0000038197"""^^xsd:string ; skos:altLabel """PNU 155971/ZDX"""@eng ; ; ; """10798"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935776"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atamestane/toremifene"""@eng ; skos:notation """CDR0000038196"""^^xsd:string ; skos:altLabel """ATAM/TOR"""@eng ; ; ; """10797"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0935775"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/metoclopramide"""@eng ; skos:notation """CDR0000042990"""^^xsd:string ; skos:altLabel """DM/MCP"""@eng ; ; ; """7242"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678001"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/granisetron"""@eng ; skos:notation """CDR0000042991"""^^xsd:string ; skos:altLabel """DM/GRAN"""@eng ; ; ; """7243"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678002"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bryostatin 1/paclitaxel"""@eng ; skos:notation """CDR0000042992"""^^xsd:string ; skos:altLabel """BRYO/TAX"""@eng ; ; ; """7244"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678003"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/isotretinoin/vitamin E"""@eng ; skos:notation """CDR0000042993"""^^xsd:string ; skos:altLabel """13-CRA/IFN-A/VIT-E"""@eng ; ; ; ; """7245"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678004"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ISIS 5132"""@eng ; skos:notation """CDR0000042994"""^^xsd:string ; skos:altLabel """CGP69846A"""@eng , """ISIS 5132/CGP69846A"""@eng , """ISIS-5132"""@eng , """c-RAF Antisense"""@eng , """CGP 69846A"""@eng , """RAF-IK Antisense ODN"""@eng ; skos:definition """A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA. ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo. Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42994&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42994&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2721\" NCI Thesaurus)"""@eng ; """2003-10-28"""^^xsd:string ; """7246"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """719336"""^^xsd:string ; """C2721"""^^xsd:string ; umls:cui """C0389883"""^^xsd:string ; umls:cui """C0663309"""^^xsd:string ; umls:cui """C1527235"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colposcopic biopsy"""@eng ; skos:notation """CDR0000042995"""^^xsd:string ; rdfs:subClassOf ; """7247"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0678005"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaginal smears"""@eng ; skos:notation """CDR0000042996"""^^xsd:string ; """7248"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0079104"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/homoharringtonine/interferon alfa"""@eng ; skos:notation """CDR0000042997"""^^xsd:string ; skos:altLabel """ARA-C/HH/IFN-A"""@eng ; ; ; ; """7249"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678006"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium/methotrexate/vincristine"""@eng ; skos:notation """CDR0000042998"""^^xsd:string ; skos:altLabel """CF/MTX/VCR"""@eng ; ; ; ; """7250"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678007"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clodronate/mitoxantrone/prednisone"""@eng ; skos:notation """CDR0000042999"""^^xsd:string ; skos:altLabel """CLOD/DHAD/PRED"""@eng ; ; ; ; """7251"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0678008"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """N-Benzoylstaurosporine"""@eng ; skos:notation """CDR0000257390"""^^xsd:string ; skos:altLabel """CGP41251"""@eng , """PKC 412"""@eng , """Midostaurin"""@eng , """PKC-412"""@eng ; """11427"""^^xsd:string ; """C1872"""^^xsd:string ; """2006-10-09"""^^xsd:string ; umls:cui """C0915830"""^^xsd:string ; umls:cui """C0526371"""^^xsd:string ; umls:cui """C1527106"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000257774"""^^xsd:string ; ; ; ; """2002-09-08"""^^xsd:string ; """11453"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327782"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RK-0202"""@eng ; skos:notation """CDR0000257775"""^^xsd:string ; skos:altLabel """RK0202"""@eng ; skos:definition """An oral polymer matrix-based rinse formulation that contains N-acetylcysteine, an antioxidant amino acid derivative with antiinflammatory properties. RK-0202 may alleviate symptoms of radiation-induced oral mucositis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257775&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257775&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26668\" NCI Thesaurus)"""@eng ; """11454"""^^xsd:string ; """C26668"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; umls:cui """C1327783"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """erlotinib/irinotecan"""@eng ; skos:notation """CDR0000257391"""^^xsd:string ; skos:altLabel """CPT-11/OSI774"""@eng ; ; ; """2002-08-16"""^^xsd:string ; """11428"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327778"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melastatin gene"""@eng ; skos:notation """CDR0000257772"""^^xsd:string ; rdfs:subClassOf ; """2002-09-08"""^^xsd:string ; """11451"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327780"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E7389"""@eng ; skos:notation """CDR0000257773"""^^xsd:string ; skos:altLabel """ER-086526"""@eng , """B1939"""@eng , """halichrondrin B analog"""@eng ; skos:definition """A synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. E7389 binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257773&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257773&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26644\" NCI Thesaurus)"""@eng ; """11452"""^^xsd:string ; """64395"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """C26644"""^^xsd:string ; umls:cui """C1328692"""^^xsd:string ; umls:cui """C2350866"""^^xsd:string ; umls:cui """C0964708"""^^xsd:string ; umls:cui """C1506837"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Seneca Valley virus"""@eng ; skos:notation """CDR0000488482"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """C62524"""^^xsd:string ; """2006-06-02"""^^xsd:string ; umls:cui """C1831871"""^^xsd:string ; umls:tui """T005"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """852A"""@eng ; skos:notation """CDR0000396824"""^^xsd:string ; skos:altLabel """852-A"""@eng ; skos:definition """A synthetic Toll-like receptor 7 (TLR7) agonist with immunostimulating and potential antitumor activities. 852A binds to and activates TLR7, thereby stimulating plasmacytoid dendritic cells (pDC) through the TLR7-MyD88-dependent signaling pathway. Activation of pDC results in secretion of interferon alpha, the production of proimflammatory cytokines, the upregulation of co-stimulatory molecules, and enhanced T and B-cell stimulatory responses. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=396824&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=396824&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61104\" NCI Thesaurus)"""@eng ; """2004-10-25"""^^xsd:string ; """2006-07-18"""^^xsd:string ; """C61104"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541384"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV lymphoepithelioma of the nasopharynx"""@eng ; skos:notation """CDR0000040738"""^^xsd:string ; skos:altLabel """lymphoepithelioma of the nasopharynx, stage IV"""@eng , """nasopharyngeal lymphoepithelioma, stage IV"""@eng , """nasopharyngeal lymphoepithelioma, metastatic"""@eng , """lymphoepithelioma of the nasopharynx, metastatic"""@eng , """metastatic lymphoepithelioma of the nasopharynx"""@eng , """nasopharynx lymphoepithelioma, metastatic"""@eng , """nasopharynx lymphoepithelioma, stage IV"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3681"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280385"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent squamous cell carcinoma of the nasopharynx"""@eng ; skos:notation """CDR0000040739"""^^xsd:string ; skos:altLabel """nasopharyngeal squamous cell carcinoma, recurrent"""@eng , """nasopharynx squamous cell carcinoma, recurrent"""@eng , """squamous cell carcinoma of the nasopharynx, recurrent"""@eng , """epidermoid carcinoma of the nasopharynx, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3682"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280386"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III lymphoepithelioma of the nasopharynx"""@eng ; skos:notation """CDR0000040736"""^^xsd:string ; skos:altLabel """nasopharyngeal lymphoepithelioma, stage III"""@eng , """nasopharynx lymphoepithelioma, stage III"""@eng , """lymphoepithelioma of the nasopharynx, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3679"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280383"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV squamous cell carcinoma of the nasopharynx"""@eng ; skos:notation """CDR0000040737"""^^xsd:string ; skos:altLabel """nasopharyngeal squamous cell carcinoma, stage IV"""@eng , """metastatic squamous cell carcinoma of the nasopharynx"""@eng , """epidermoid carcinoma of the nasopharynx, metastatic"""@eng , """nasopharyngeal squamous cell carcinoma, metastatic"""@eng , """epidermoid carcinoma of the nasopharynx, stage IV"""@eng , """nasopharynx squamous cell carcinoma, stage IV"""@eng , """nasopharynx squamous cell carcinoma, metastatic"""@eng , """squamous cell carcinoma of the nasopharynx, metastatic"""@eng , """squamous cell carcinoma of the nasopharynx, stage IV"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3680"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280384"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II lymphoepithelioma of the nasopharynx"""@eng ; skos:notation """CDR0000040734"""^^xsd:string ; skos:altLabel """nasopharyngeal lymphoepithelioma, stage II"""@eng , """nasopharynx lymphoepithelioma, stage II"""@eng , """lymphoepithelioma of the nasopharynx, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3677"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280381"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III squamous cell carcinoma of the nasopharynx"""@eng ; skos:notation """CDR0000040735"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the nasopharynx, stage III"""@eng , """nasopharynx squamous cell carcinoma, stage III"""@eng , """nasopharyngeal squamous cell carcinoma, stage III"""@eng , """epidermoid carcinoma of the nasopharynx, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3678"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280382"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I lymphoepithelioma of the nasopharynx"""@eng ; skos:notation """CDR0000040732"""^^xsd:string ; skos:altLabel """nasopharyngeal lymphoepithelioma, stage I"""@eng , """lymphoepithelioma of the nasopharynx, stage I"""@eng , """nasopharynx lymphoepithelioma, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3675"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280379"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II squamous cell carcinoma of the nasopharynx"""@eng ; skos:notation """CDR0000040733"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the nasopharynx, stage II"""@eng , """nasopharynx squamous cell carcinoma, stage II"""@eng , """nasopharyngeal squamous cell carcinoma, stage II"""@eng , """epidermoid carcinoma of the nasopharynx, stage II"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3676"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280380"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent lymphoepithelioma of the oropharynx"""@eng ; skos:notation """CDR0000040730"""^^xsd:string ; skos:altLabel """oropharyngeal lymphoepithelioma, recurrent"""@eng , """lymphoepithelioma of the oropharynx, recurrent"""@eng , """oropharynx lymphoepithelioma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """oropharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3672"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280377"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I squamous cell carcinoma of the nasopharynx"""@eng ; skos:notation """CDR0000040731"""^^xsd:string ; skos:altLabel """epidermoid carcinoma of the nasopharynx, stage I"""@eng , """nasopharyngeal squamous cell carcinoma, stage I"""@eng , """nasopharynx squamous cell carcinoma, stage I"""@eng , """squamous cell carcinoma of the nasopharynx, stage I"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """nasopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3674"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280378"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I endometrial cancer"""@eng ; skos:notation """CDR0000038739"""^^xsd:string ; skos:altLabel """cancer of the endometrium, stage I"""@eng , """uterine cancer, stage I"""@eng , """endometrial carcinoma, stage I"""@eng , """carcinoma of the endometrium, stage I"""@eng , """stage I uterine cancer"""@eng , """stage I cancer of the endometrium"""@eng , """stage I carcinoma of the endometrium"""@eng , """endometrial cancer, stage I"""@eng ; rdfs:subClassOf ; """endometrial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1178"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278798"""^^xsd:string ; umls:cui """C0678030"""^^xsd:string ; umls:cui """C0813147"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage 0 endometrial cancer"""@eng ; skos:notation """CDR0000038738"""^^xsd:string ; skos:altLabel """uterine cancer, stage 0"""@eng , """endometrial carcinoma, stage 0"""@eng , """carcinoma of the endometrium, stage 0"""@eng , """stage 0 cancer of the endometrium"""@eng , """stage 0 carcinoma of the endometrium"""@eng , """stage 0 uterine cancer"""@eng , """endometrial cancer, stage 0"""@eng , """cancer of the endometrium, stage 0"""@eng ; rdfs:subClassOf ; """endometrial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1177"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0346191"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """olanzapine"""@eng ; skos:notation """CDR0000449664"""^^xsd:string ; skos:altLabel """Zydis"""@eng , """2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine"""@eng , """Zyprexa"""@eng , """LY 170053"""@eng ; skos:definition """A synthetic derivative of thienobenzodiazepine with antipsychotic properties. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotonin, dopamine, muscarinic M1-5, histamine H1, and alpha1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through a combination of dopamine and serotonin type 2 antagonism. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=449664&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=449664&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47639\" NCI Thesaurus)"""@eng ; """2005-09-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """C47639"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0527258"""^^xsd:string ; umls:cui """C0171021"""^^xsd:string ; umls:cui """C0171023"""^^xsd:string ; umls:cui """C1709310"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """metastatic Ewing's sarcoma/primitive neuroectodermal tumor"""@eng ; skos:notation """CDR0000038735"""^^xsd:string ; skos:altLabel """Ewing's sarcoma, metastatic"""@eng , """metastatic Ewing's sarcoma/PNET"""@eng ; rdfs:subClassOf ; """117"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796548"""^^xsd:string ; umls:cui """C0278586"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000038734"""^^xsd:string ; skos:altLabel """gestational trophoblastic tumor, recurrent"""@eng , """recurrent GTT"""@eng , """GTT, recurrent"""@eng ; rdfs:subClassOf ; """gestational trophoblastic tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1168"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278796"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endometrial cancer"""@eng ; skos:notation """CDR0000038737"""^^xsd:string ; skos:altLabel """endometrial carcinoma"""@eng , """uterine corpus cancer"""@eng , """carcinoma of the endometrium"""@eng , """Endometrial cancer"""@eng , """cancer of the endometrium"""@eng , """uterine cancer"""@eng , """uterus cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1176"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0476089"""^^xsd:string ; umls:cui """C0153567"""^^xsd:string ; umls:cui """C0153574"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small intestine cancer"""@eng ; skos:notation """CDR0000038736"""^^xsd:string ; skos:altLabel """small bowel cancer"""@eng , """Small intestine cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1175"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153425"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/flavopiridol/irinotecan"""@eng ; skos:notation """CDR0000257802"""^^xsd:string ; skos:altLabel """CDDP/CPT-11/FLAVO"""@eng ; ; ; ; """2002-09-10"""^^xsd:string ; """11462"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327785"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ifosfamide/vincristine"""@eng ; skos:notation """CDR0000038730"""^^xsd:string ; skos:altLabel """CDDP/IFF/VCR"""@eng , """HOP"""@eng ; ; ; ; """1164"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0295183"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000038733"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CTX/DM/DOX/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; ; ; """1167"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278795"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/methotrexate/methylprednisolone"""@eng ; skos:notation """CDR0000038732"""^^xsd:string ; skos:altLabel """ARA-C/MePRDL/MTX"""@eng ; ; ; ; """1166"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278794"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 1q"""@eng ; skos:notation """CDR0000271361"""^^xsd:string ; rdfs:subClassOf ; """2003-01-26"""^^xsd:string ; """2003-01-21"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1327882"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fumarase hydratase"""@eng ; skos:notation """CDR0000271360"""^^xsd:string ; skos:altLabel """FH"""@eng ; rdfs:subClassOf ; """2003-01-26"""^^xsd:string ; """2003-01-21"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C1366530"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040453"""^^xsd:string ; skos:altLabel """BLEO/DOX/VCR"""@eng , """ABV"""@eng ; ; ; ; """3327"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280093"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """spiramycin"""@eng ; skos:notation """CDR0000040452"""^^xsd:string ; """3326"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0037962"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pyrimethamine-sulfadoxine"""@eng ; skos:notation """CDR0000040451"""^^xsd:string ; skos:altLabel """Fansidar"""@eng , """pyrimethamine sulfadoxine"""@eng ; """3325"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0060061"""^^xsd:string ; umls:cui """C0700599"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nilutamide"""@eng ; skos:notation """CDR0000040450"""^^xsd:string ; skos:altLabel """RU-23908"""@eng , """Nilandron"""@eng , """ANAN"""@eng , """Anandron"""@eng , """5,5-Dimethyl-3-[4-nitro-3-(trifluoro-methyl)phenyl]-2,4-imidazolidinedione"""@eng , """1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione"""@eng ; skos:definition """A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40450&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40450&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1173\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """3324"""^^xsd:string ; """2006-09-07"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """63612-50-0"""^^xsd:string ; """C1173"""^^xsd:string ; """684588"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0068771"""^^xsd:string ; umls:cui """C0740136"""^^xsd:string ; umls:cui """C0722107"""^^xsd:string ; umls:cui """C0740137"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of unknown primary"""@eng ; skos:notation """CDR0000040457"""^^xsd:string ; skos:altLabel """adenocarcinoma CUP"""@eng , """unknown primary, adenocarcinoma"""@eng , """adenocarcinoma, unknown primary"""@eng , """CUP, adenocarcinoma"""@eng ; rdfs:subClassOf ; """3332"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280096"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoma of unknown primary"""@eng ; skos:notation """CDR0000040456"""^^xsd:string ; skos:altLabel """Carcinoma of unknown primary"""@eng , """cancer, unknown primary"""@eng , """unknown primary carcinoma"""@eng , """unknown primary cancer"""@eng , """CUP"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3331"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0027667"""^^xsd:string ; umls:cui """C0220647"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/lomustine/melphalan/prednisolone/vincristine"""@eng ; skos:notation """CDR0000040455"""^^xsd:string ; skos:altLabel """CCVMP"""@eng , """CCNU/CTX/L-PAM/PRDL/VCR"""@eng ; ; ; ; ; ; """3330"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280095"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/vinblastine"""@eng ; skos:notation """CDR0000040454"""^^xsd:string ; skos:altLabel """MV"""@eng , """MTX/VBL"""@eng ; ; ; """3329"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280094"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """undifferentiated carcinoma of unknown primary"""@eng ; skos:notation """CDR0000040459"""^^xsd:string ; skos:altLabel """undifferentiated carcinoma CUP"""@eng , """unknown primary, undifferentiated carcinoma"""@eng , """undifferentiated carcinoma, unknown primary"""@eng , """CUP, undifferentiated carcinoma"""@eng ; rdfs:subClassOf ; """3334"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280098"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """squamous cell carcinoma of unknown primary"""@eng ; skos:notation """CDR0000040458"""^^xsd:string ; skos:altLabel """unknown primary, squamous cell carcinoma"""@eng , """CUP, squamous cell"""@eng , """squamous cell carcinoma, unknown primary"""@eng , """squamous cell CUP"""@eng ; rdfs:subClassOf ; """3333"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0280097"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SB-743921"""@eng ; skos:notation """CDR0000456262"""^^xsd:string ; skos:definition """A synthetic small molecule with potential antineoplastic properties. SB-743921 selectively inhibits kinesin spindle protein (KSP), an important protein involved in the early stages of mitosis that is expressed in proliferating cells. Inhibition of KSP results in inhibition of mitotic spindle assembly and interrupts cell division, thereby causing cell cycle arrest and induction of apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456262&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456262&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52199\" NCI Thesaurus)"""@eng ; """2006-09-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-11-18"""^^xsd:string ; """C52199"""^^xsd:string ; umls:cui """C1709979"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """infrared photocoagulation therapy"""@eng ; skos:notation """CDR0000321369"""^^xsd:string ; skos:altLabel """IRC"""@eng , """infrared coagulation"""@eng ; ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-14"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1328010"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human growth hormone"""@eng ; skos:notation """CDR0000456264"""^^xsd:string ; skos:altLabel """Genotropin"""@eng , """rhGH"""@eng , """somatotropin"""@eng ; skos:definition """A recombinant form of endogenous human growth hormone (GH), a polypeptide produced by the anterior lobe of the human pituitary gland. GH exhibits growth-promoting effects and metabolic effects on carbohydrate, fat, protein and bone metabolism. GH stimulates protein synthesis and the uptake of amino acids into cells, and induces lipolysis in adipose tissues. The secretion of GH increases with sexual maturation and then declines steadily. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456264&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=456264&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C837\" NCI Thesaurus)"""@eng ; """2005-11-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C837"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0037663"""^^xsd:string ; umls:cui """C0699616"""^^xsd:string ; umls:cui """C0384570"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """razoxane"""@eng ; skos:notation """CDR0000039480"""^^xsd:string ; skos:altLabel """ICI 59118"""@eng , """ICRF-159"""@eng , """ICRF 159"""@eng , """ICRF159"""@eng , """Razoxin"""@eng ; skos:definition """A bis-dioxopiperazine and a derivative of the chelating agent EDTA with antineoplastic activity. Razoxane inhibits the enzyme topoisomerase II without inducing DNA strand breaks, thereby inhibiting DNA synthesis and inducing cytotoxicity. Although its mechanism is unknown, this agent exhibits anti-angiogenic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39480&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39480&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C801\" NCI Thesaurus)"""@eng ; ; """2114"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """C801"""^^xsd:string ; """21416-87-5"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7651"""^^xsd:string ; """129943"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0034738"""^^xsd:string ; umls:cui """C0678114"""^^xsd:string ; umls:cui """C0877950"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """idoxuridine"""@eng ; skos:notation """CDR0000039481"""^^xsd:string ; skos:altLabel """SKF 14287"""@eng , """IDU"""@eng , """Idulea"""@eng , """5-Iodo-2'-deoxyuridine"""@eng , """Virudox"""@eng , """Kerecid"""@eng , """Idexur"""@eng , """IUDR"""@eng , """5-IUdR"""@eng , """Dendrid"""@eng , """1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil"""@eng , """5 IUdR"""@eng , """Idoxene"""@eng , """Stoxil"""@eng , """5IUdR"""@eng , """2'-deoxy-5-iodouridine"""@eng , """Iduridin"""@eng , """Iododeoxyuridine"""@eng , """Herplex"""@eng ; skos:definition """An iodinated analogue of deoxyuridine. Idoxuridine incorporates into DNA during the S-phase of the cell cycle, sensitizing cells to ionizing radiation by increasing DNA strand breaks. When this agent contains a radioactive isomer of iodine, the radioactive idoxuridine kills cancer cells directly after preferential incorporation into the DNA of rapidly dividing tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39481&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39481&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C563\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; """2115"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """22475"""^^xsd:string ; """54-42-2"""^^xsd:string ; """934"""^^xsd:string ; """39661"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C563"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0020811"""^^xsd:string ; umls:cui """C1512613"""^^xsd:string ; umls:cui """C1512615"""^^xsd:string ; umls:cui """C1512614"""^^xsd:string ; umls:cui """C0731235"""^^xsd:string ; umls:cui """C0701475"""^^xsd:string ; umls:cui """C0731020"""^^xsd:string ; umls:cui """C0699409"""^^xsd:string ; umls:cui """C1186909"""^^xsd:string ; umls:cui """C0699407"""^^xsd:string ; umls:cui """C0699410"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indicine-N-oxide"""@eng ; skos:notation """CDR0000039482"""^^xsd:string ; skos:altLabel """Butanoic Acid, 2,3-Dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) Methyl Ester, N-Oxide,(1R-(1.alpha.,7(2R*,3S*),7a.beta))-(9CI)"""@eng , """INDI"""@eng , """Indicine N-Oxide"""@eng , """2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl Ester N-Oxide"""@eng ; skos:definition """A natural pyrrolizidine alkaloid with antineoplastic properties. Indicine-N-oxide alkylates and crosslinks DNA. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39482&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39482&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1134\" NCI Thesaurus)"""@eng ; """2116"""^^xsd:string ; """13952"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1134"""^^xsd:string ; """41708-76-3"""^^xsd:string ; """132319"""^^xsd:string ; umls:cui """C0063465"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imidazole mustard"""@eng ; skos:notation """CDR0000039483"""^^xsd:string ; skos:altLabel """HN2"""@eng , """BIC"""@eng , """5-[3,3-Bis(2-Chloroethyl)-1-Triazeno]Imidazole-4-Carboxamide"""@eng , """TIC mustard"""@eng ; skos:definition """A synthetic derivative of imidazole with potent antineoplastic properties. Imidazole mustard alkylates DNA, preferentially at guanine residues, resulting in DNA interstrand crosslinks and inhibition of DNA replication and RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39483&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39483&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2216\" NCI Thesaurus)"""@eng ; """2117"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-21"""^^xsd:string ; """C2216"""^^xsd:string ; """82196"""^^xsd:string ; """5034-77-5"""^^xsd:string ; umls:cui """C0063382"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isoniazid"""@eng ; skos:notation """CDR0000039484"""^^xsd:string ; skos:altLabel """INH"""@eng , """isonicotinyl hydrazine"""@eng , """isonicotinic acid hydrazide"""@eng ; skos:definition """A synthetic derivative of nicotinic acid with anti-mycobacterial properties. Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6. Resistance occurs due to decreased bacterial wall penetration. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39484&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39484&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C600\" NCI Thesaurus)"""@eng ; ; """2118"""^^xsd:string ; """9659"""^^xsd:string ; """C600"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """54-85-3"""^^xsd:string ; umls:cui """C0022209"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane hydrochloride"""@eng ; skos:notation """CDR0000039485"""^^xsd:string ; skos:altLabel """(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione)"""@eng , """2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)"""@eng , """Razoxane (+)-form"""@eng , """ICRF-187"""@eng , """2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI)"""@eng , """ADR-529"""@eng , """DZR"""@eng , """Soluble ICRF (L-Isomer)"""@eng , """Zinecard"""@eng ; skos:definition """The hydrochloride salt of a bisdioxopiperazine with cardioprotective and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, thereby preventing the metal-catalyzed formation of reactive oxygen radicals produced by anthracycline antibiotics such as doxorubicin. This agent also inhibits the catalytic activity of topoisomerase II, resulting in cell growth inhibition. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39485&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39485&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1333\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """14490"""^^xsd:string ; """169780"""^^xsd:string ; """C1333"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2119"""^^xsd:string ; """24584-09-6"""^^xsd:string ; umls:cui """C0733406"""^^xsd:string ; umls:cui """C0728750"""^^xsd:string ; umls:cui """C0733405"""^^xsd:string ; umls:cui """C0086444"""^^xsd:string ; umls:cui """C0982118"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chondrosarcoma"""@eng ; skos:notation """CDR0000039486"""^^xsd:string ; skos:altLabel """Chondrosarcoma"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """212"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0008479"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """inosine pranobex"""@eng ; skos:notation """CDR0000039487"""^^xsd:string ; skos:altLabel """NPT 10381"""@eng , """IPR"""@eng , """inosiplex"""@eng , """NPT-10381"""@eng , """methisoprinol"""@eng , """Isoprinosine"""@eng ; """2120"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0795761"""^^xsd:string ; umls:cui """C0022230"""^^xsd:string ; umls:cui """C0795760"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ketoconazole"""@eng ; skos:notation """CDR0000039488"""^^xsd:string ; skos:altLabel """Panfungol"""@eng , """Ketoisdin"""@eng , """Orifungal M"""@eng , """Fungarest"""@eng , """Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine"""@eng , """Ketoderm"""@eng , """Nizoral"""@eng , """R-41400"""@eng , """Fungoral"""@eng , """KCZ"""@eng ; skos:definition """A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity. Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39488&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39488&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C605\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """2121"""^^xsd:string ; """317629"""^^xsd:string ; """65277-42-1"""^^xsd:string ; """C605"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517669"""^^xsd:string ; umls:cui """C1517668"""^^xsd:string ; umls:cui """C0022625"""^^xsd:string ; umls:cui """C1517667"""^^xsd:string ; umls:cui """C1517670"""^^xsd:string ; umls:cui """C0699439"""^^xsd:string ; umls:cui """C1517671"""^^xsd:string ; umls:cui """C0701304"""^^xsd:string ; umls:cui """C1517666"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indomethacin"""@eng ; skos:notation """CDR0000039489"""^^xsd:string ; skos:altLabel """INDO"""@eng , """Indometacin"""@eng , """1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid"""@eng , """Indocin"""@eng ; skos:definition """A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39489&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39489&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C576\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; """2122"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C576"""^^xsd:string ; """77541"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """53-86-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0021246"""^^xsd:string ; umls:cui """C0700798"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III squamous cell carcinoma of the hypopharynx"""@eng ; skos:notation """CDR0000040743"""^^xsd:string ; skos:altLabel """hypopharynx squamous cell carcinoma, stage III"""@eng , """hypopharyngeal squamous cell carcinoma, stage III"""@eng , """epidermoid carcinoma of the hypopharynx, stage III"""@eng , """squamous cell carcinoma of the hypopharynx, stage III"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """hypopharyngeal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3688"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280390"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/MDX-1379 melanoma vaccine"""@eng ; skos:notation """CDR0000409698"""^^xsd:string ; skos:altLabel """MDX-1379/MOAB CTLA-4"""@eng ; ; ; """2004-12-03"""^^xsd:string ; """2004-12-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541426"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant human interleukin-21"""@eng ; skos:notation """CDR0000409696"""^^xsd:string ; skos:altLabel """rhIL-21"""@eng ; """Drug/agent"""^^xsd:string ; """2006-09-19"""^^xsd:string ; """2004-12-03"""^^xsd:string ; """C62492"""^^xsd:string ; umls:cui """C1831593"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """MDX-1379 melanoma vaccine"""@eng ; skos:notation """CDR0000409697"""^^xsd:string ; skos:altLabel """MDX-1379"""@eng ; ; """2004-12-03"""^^xsd:string ; """2004-12-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541425"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/pemetrexed disodium"""@eng ; skos:notation """CDR0000409692"""^^xsd:string ; skos:altLabel """LY231514/MOAB C225"""@eng ; ; ; """2004-12-03"""^^xsd:string ; """2004-12-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541424"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mapatumumab"""@eng ; skos:notation """CDR0000486626"""^^xsd:string ; skos:altLabel """Anti-TRAIL R1-mAb"""@eng , """HGS-ETR1"""@eng , """TRM-1 mAb"""@eng ; skos:definition """A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486626&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486626&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61502\" NCI Thesaurus)"""@eng ; """2006-05-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C61502"""^^xsd:string ; umls:cui """C1665688"""^^xsd:string ; umls:cui """C1831843"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """human monoclonal antibody 216"""@eng ; skos:notation """CDR0000488467"""^^xsd:string ; """C62532"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """2006-09-18"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831869"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """retrovirus vector LN"""@eng ; skos:notation """CDR0000038034"""^^xsd:string ; """10549"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879581"""^^xsd:string ; umls:tui """T005"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/erlotinib"""@eng ; skos:notation """CDR0000038547"""^^xsd:string ; skos:altLabel """CBDCA/OSI774"""@eng ; ; ; """11174"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134574"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/paclitaxel"""@eng ; skos:notation """CDR0000042608"""^^xsd:string ; skos:altLabel """CPT-11/TAX"""@eng ; ; ; """6329"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393019"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludeoxyglucose F 18"""@eng ; skos:notation """CDR0000042609"""^^xsd:string ; skos:altLabel """18 FDG"""@eng , """FDG"""@eng , """Fluorodeoxyglucose F18"""@eng , """18FDG"""@eng , """fluorodeoxyglucose F 18"""@eng , """Fluorine-18 2-Fluoro-2-deoxy-D-Glucose"""@eng , """2-F18-fluoro-2-deoxyglucose"""@eng , """2-F18-fluoro-2-deoxy-D-glucose"""@eng ; skos:definition """A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42609&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42609&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C964\" NCI Thesaurus)"""@eng ; """6330"""^^xsd:string ; """C964"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """63503-12-8"""^^xsd:string ; umls:cui """C0046056"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """low-grade squamous intraepithelial lesion"""@eng ; skos:notation """CDR0000398204"""^^xsd:string ; skos:altLabel """LSIL"""@eng , """CIN 1"""@eng , """LGSIL"""@eng , """cervical intraepithelial neoplasia 1"""@eng , """mild dysplasia"""@eng ; rdfs:subClassOf ; """2004-10-25"""^^xsd:string ; """2004-10-15"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """precancerous/nonmalignant condition"""^^xsd:string ; umls:cui """C1302773"""^^xsd:string ; umls:cui """C0349458"""^^xsd:string ; umls:cui """C0334046"""^^xsd:string ; umls:tui """T049"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """allogeneic tumor cell vaccine"""@eng ; skos:notation """CDR0000350082"""^^xsd:string ; skos:altLabel """ALLOTCV"""@eng , """allogenic tumor cell vaccine"""@eng , """Allogenic Cell Vaccine"""@eng ; skos:definition """A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient in order to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350082&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=350082&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1983\" NCI Thesaurus)"""@eng ; ; """2003-12-23"""^^xsd:string ; """C1983"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood visual pathway and hypothalamic glioma"""@eng ; skos:notation """CDR0000043431"""^^xsd:string ; skos:altLabel """childhood CNS tumor, optic nerve glioma"""@eng , """brain tumor, pediatric optic nerve glioma"""@eng , """brain tumor, pediatric optic tract glioma"""@eng , """central nervous system tumor, optic nerve glioma, childhood"""@eng , """glioma, pediatric optic tract"""@eng , """pediatric CNS tumor, optic tract glioma"""@eng , """brain tumor, childhood optic tract glioma"""@eng , """pediatric visual pathway glioma"""@eng , """glioma, childhood optic tract"""@eng , """glioma, pediatric optic nerve"""@eng , """CNS tumor, childhood optic nerve glioma"""@eng , """optic nerve glioma, pediatric"""@eng , """pediatric brain tumor, optic tract glioma"""@eng , """brain tumor, optic nerve glioma, childhood"""@eng , """central nervous system tumor, optic tract glioma, childhood"""@eng , """glioma, childhood visual pathway"""@eng , """pediatric brain tumor, optic nerve glioma"""@eng , """visual pathway glioma, childhood"""@eng , """CNS tumor, childhood optic tract glioma"""@eng , """Brain tumor, child: Visual pathway glioma"""@eng , """optic nerve glioma, childhood"""@eng , """childhood CNS tumor, optic tract glioma"""@eng , """childhood brain tumor, optic tract glioma"""@eng , """pediatric optic nerve glioma"""@eng , """CNS tumor, pediatric optic tract glioma"""@eng , """childhood optic nerve glioma"""@eng , """brain tumor, optic tract glioma, childhood"""@eng , """optic tract glioma, pediatric"""@eng , """glioma, pediatric visual pathway"""@eng , """brain tumor, childhood optic nerve glioma"""@eng , """pediatric optic tract glioma"""@eng , """pediatric CNS tumor, optic nerve glioma"""@eng , """childhood optic tract glioma"""@eng , """glioma, childhood optic nerve"""@eng , """childhood brain tumor, optic nerve glioma"""@eng , """CNS tumor, pediatric optic nerve glioma"""@eng , """optic tract glioma, childhood"""@eng , """visual pathway glioma, pediatric"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """842"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278653"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """romidepsin"""@eng ; skos:notation """CDR0000042600"""^^xsd:string ; skos:altLabel """L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-"""@eng , """depsipeptide"""@eng , """NSC 630176"""@eng , """FK228"""@eng , """FR901228"""@eng , """FR-901228"""@eng , """FR 901228"""@eng , """N-[(3S,4E-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic"""@eng ; skos:definition """A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), thereby affecting the regulation of gene expression and inducing cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several HSP90-dependent oncoproteins. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42600&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42600&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1544\" NCI Thesaurus)"""@eng ; ; ; ; ; """128517-07-7"""^^xsd:string ; """2006-09-13"""^^xsd:string ; """6320"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """630176"""^^xsd:string ; """51810"""^^xsd:string ; """C1544"""^^xsd:string ; umls:cui """C1527027"""^^xsd:string ; umls:cui """C2607887"""^^xsd:string ; umls:cui """C1831603"""^^xsd:string ; umls:cui """C0963679"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/recombinant interferon beta"""@eng ; skos:notation """CDR0000038843"""^^xsd:string ; skos:altLabel """IFN-B/IFN-G"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """1334"""^^xsd:string ; umls:cui """C0278889"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042602"""^^xsd:string ; skos:altLabel """CBDCA/CTX/G-CSF/TAX/VP-16"""@eng ; ; ; ; ; ; """6322"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393014"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mass spectrometry"""@eng ; skos:notation """CDR0000486889"""^^xsd:string ; rdfs:subClassOf ; """Diagnostic test/procedure"""^^xsd:string ; """2006-05-23"""^^xsd:string ; """2006-05-23"""^^xsd:string ; umls:cui """C0037813"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vaccinia-CEA vaccine"""@eng ; skos:notation """CDR0000042604"""^^xsd:string ; skos:altLabel """recombinant vaccinia-CEA (180 kd) vaccine"""@eng , """vaccinia-carcinoembryonic antigen vaccine"""@eng , """rV-CEA (180 Kd)"""@eng , """rV-CEA (180 Kd) vaccine"""@eng ; """6324"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393016"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039356"""^^xsd:string ; skos:altLabel """OPP"""@eng , """PCB/PRED/VCR"""@eng ; ; ; ; """1992"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279222"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tin ethyl etiopurpurin"""@eng ; skos:notation """CDR0000042606"""^^xsd:string ; skos:altLabel """Tin, (Ethyl Tetramethyl-20-phorbinecarboxylato(2-)-N23,N24,N25,N26)-, (SP-4-2)"""@eng , """Purlytin"""@eng , """SnET2"""@eng , """Tin Etiopurpurin"""@eng ; skos:definition """A synthetic purpurin with photosensitizing activity. Tin ethyl etiopurpurin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42606&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42606&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1255\" NCI Thesaurus)"""@eng ; """6326"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1255"""^^xsd:string ; """113471-15-1"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1519514"""^^xsd:string ; umls:cui """C0076691"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042519"""^^xsd:string ; skos:altLabel """DM/MTX/PEG-ASP/VCR"""@eng ; ; ; ; ; """6140"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392950"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bropirimine"""@eng ; skos:notation """CDR0000043433"""^^xsd:string ; skos:altLabel """Remisar"""@eng , """ABPP"""@eng ; ; ; """844"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0054150"""^^xsd:string ; umls:cui """C1328714"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/S-1"""@eng ; skos:notation """CDR0000445417"""^^xsd:string ; skos:altLabel """CPT-11/S1"""@eng ; ; ; """2005-08-18"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831710"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """atrasentan/docetaxel/prednisone"""@eng ; skos:notation """CDR0000445418"""^^xsd:string ; skos:altLabel """ABT-627/PRED/TXT"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-19"""^^xsd:string ; """2005-08-18"""^^xsd:string ; umls:cui """C1831711"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polycythemia vera"""@eng ; skos:notation """CDR0000039350"""^^xsd:string ; skos:altLabel """PV"""@eng , """p.vera"""@eng , """polycythemia ruba vera"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1986"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0032463"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """megestrol acetate"""@eng ; skos:notation """CDR0000043435"""^^xsd:string ; skos:altLabel """Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-"""@eng , """MEG"""@eng , """Compound 5071"""@eng , """megestrol"""@eng , """Megace"""@eng , """Ovaban"""@eng , """Pallace"""@eng ; skos:definition """The acetate salt of a synthetic derivative of progesterone with antiestrogenic activity. Megestrol binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. In addition, megestrol stimulates appetite in cachectic subjects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43435&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43435&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C630\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """855"""^^xsd:string ; """C630"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; """3562-63-8"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700004"""^^xsd:string ; umls:cui """C0065879"""^^xsd:string ; umls:cui """C1328258"""^^xsd:string ; umls:cui """C0025175"""^^xsd:string ; umls:cui """C0733353"""^^xsd:string ; umls:cui """C1522433"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III prostate cancer"""@eng ; skos:notation """CDR0000038785"""^^xsd:string ; skos:altLabel """stage C prostate cancer"""@eng , """prostate cancer, stage C"""@eng , """stage C cancer of the prostate"""@eng , """cancer of the prostate, stage C"""@eng , """stage III carcinoma of the prostate"""@eng , """cancer of the prostate, stage III"""@eng , """stage C carcinoma of the prostate"""@eng , """carcinoma of the prostate, Stage III"""@eng , """stage III cancer of the prostate"""@eng , """carcinoma of the prostate, stage C"""@eng , """prostate cancer, stage III"""@eng ; rdfs:subClassOf ; """prostate cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1232"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """no measurable or evaluable disease"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278836"""^^xsd:string ; umls:cui """C1370962"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edrecolomab"""@eng ; skos:notation """CDR0000039352"""^^xsd:string ; skos:altLabel """MOAB 17-1A"""@eng , """Panorex"""@eng , """monoclonal antibody 17-1A"""@eng ; skos:definition """A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39352&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39352&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1554\" NCI Thesaurus)"""@eng ; ; ; ; """1988"""^^xsd:string ; """2176"""^^xsd:string ; """7053"""^^xsd:string ; """C1554"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """377963"""^^xsd:string ; """2006-12-14"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0279218"""^^xsd:string ; umls:cui """C0919250"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piperacillin-tazobactam"""@eng ; skos:notation """CDR0000043437"""^^xsd:string ; skos:altLabel """Zosyn"""@eng , """PIPER-TAZO"""@eng , """Tazocin"""@eng ; ; """2004-02-19"""^^xsd:string ; """8599"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0250482"""^^xsd:string ; umls:cui """C0250480"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed cell type Wilms' tumor"""@eng ; skos:notation """CDR0000039896"""^^xsd:string ; skos:altLabel """mixed cell type Wilms tumor"""@eng , """Wilm's tumor, mixed cell type"""@eng , """Wilms' tumor, mixed cell type"""@eng , """Wilms tumor, mixed cell type"""@eng , """mixed cell type Wilm's tumor"""@eng ; rdfs:subClassOf ; """2577"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279611"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxandrolone"""@eng ; skos:notation """CDR0000331866"""^^xsd:string ; skos:altLabel """Oxandrin"""@eng ; skos:definition """A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=331866&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=331866&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29306\" NCI Thesaurus)"""@eng ; """2003-09-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C29306"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0728775"""^^xsd:string ; umls:cui """C0029995"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cetuximab/paclitaxel"""@eng ; skos:notation """CDR0000331865"""^^xsd:string ; skos:altLabel """CBDCA/MOAB C225/TAX"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-08-27"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328046"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tezacitabine"""@eng ; skos:notation """CDR0000354256"""^^xsd:string ; skos:altLabel """(E)-2'-deoxy-2'-(fluoromethylene)cytidine"""@eng , """MDL 101,731"""@eng , """FMdC"""@eng , """MDL101731"""@eng ; ; ; """2004-01-23"""^^xsd:string ; """2006-08-09"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1539"""^^xsd:string ; umls:cui """C0969834"""^^xsd:string ; umls:cui """C0253087"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/EL625/idarubicin"""@eng ; skos:notation """CDR0000354250"""^^xsd:string ; skos:altLabel """ARA-C/EL-625/IDA"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328178"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV prostate cancer"""@eng ; skos:notation """CDR0000038786"""^^xsd:string ; skos:altLabel """stage D cancer of the prostate"""@eng , """stage D prostate cancer"""@eng , """cancer of the prostate, stage D"""@eng , """stage IV carcinoma of the prostate"""@eng , """carcinoma of the prostate, stage IV"""@eng , """stage D carcinoma of the prostate"""@eng , """carcinoma of the prostate, stage D"""@eng , """prostate cancer, stage D"""@eng , """stage IV cancer of the prostate"""@eng , """cancer of the prostate, stage IV"""@eng , """prostate cancer, stage IV"""@eng ; rdfs:subClassOf ; """prostate cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1233"""^^xsd:string ; """metastatic disease"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """central nervous system involvement/metastases"""^^xsd:string ; """no measurable or evaluable disease"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278837"""^^xsd:string ; umls:cui """C3146265"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000042512"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP"""@eng ; ; ; ; """6126"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0392943"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 DOTA monoclonal antibody HuAFP31"""@eng ; skos:notation """CDR0000425347"""^^xsd:string ; skos:altLabel """Y90 DOTA MOAB HuAFP31"""@eng ; skos:definition """A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425347&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425347&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48428\" NCI Thesaurus)"""@eng ; """2005-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """C48428"""^^xsd:string ; umls:cui """C1541525"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/CD40-ligand"""@eng ; skos:notation """CDR0000269111"""^^xsd:string ; skos:altLabel """ADC/CD40-L"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327834"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/thiotepa"""@eng ; skos:notation """CDR0000038848"""^^xsd:string ; skos:altLabel """CBDCA/TSPA/VP-16"""@eng ; ; ; ; """1339"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278894"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody HuAFP31"""@eng ; skos:notation """CDR0000425344"""^^xsd:string ; skos:altLabel """MOAB HuAFP31"""@eng , """Monoclonal Antibody HuAPF31"""@eng ; skos:definition """A fully humanized monoclonal antibody directed against alpha fetoprotein with potential antineoplastic activity. Upon administration, monoclonal antibody HuAFP31 (mAb HuAFP31) binds to and stimulates a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425344&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=425344&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48407\" NCI Thesaurus)"""@eng ; """2005-03-24"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """C48407"""^^xsd:string ; umls:cui """C1541524"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """patent blue V dye/technetium Tc 99m sulfur colloid"""@eng ; skos:notation """CDR0000269116"""^^xsd:string ; skos:altLabel """Patent Blue V/Tc-99m SC"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327836"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ataxia telangiectasia (ATM)"""@eng ; skos:notation """CDR0000042838"""^^xsd:string ; skos:altLabel """Louis-Bar syndrome"""@eng , """ATM"""@eng ; ; ; """6638"""^^xsd:string ; """Genetic condition"""^^xsd:string ; """2005-12-14"""^^xsd:string ; umls:cui """C0004135"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP17"""@eng ; skos:notation """CDR0000322851"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0038302"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CYP19"""@eng ; skos:notation """CDR0000322854"""^^xsd:string ; rdfs:subClassOf ; """2003-07-26"""^^xsd:string ; """2003-07-23"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0003805"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """therapeutic triiodothyronine"""@eng ; skos:notation """CDR0000470233"""^^xsd:string ; skos:altLabel """Triiodothyronine"""@eng , """Liothyronine"""@eng , """Therapeutic T3"""@eng , """L-Triiodothyronine"""@eng ; skos:definition """A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470233&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470233&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C907\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """1297"""^^xsd:string ; """6893-02-3"""^^xsd:string ; """C907"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C0041014"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ranimustine"""@eng ; skos:notation """CDR0000470235"""^^xsd:string ; skos:altLabel """Cymer"""@eng , """Ranomustine"""@eng , """methyl 6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-alpha-D-glucopyranoside"""@eng , """Cymerin"""@eng , """alpha-D-glucopyranoside, methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-"""@eng , """methyl 6-(3-(2-chloroethyl)-3-nitrosoiureido)-6-deoxy-alpha-D-glucopyranoside"""@eng , """MCNU"""@eng , """methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl) amino)-6-deoxy-alpha-D-glucopyranoside"""@eng ; skos:definition """A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470235&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470235&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1515\" NCI Thesaurus)"""@eng ; """58994-96-0"""^^xsd:string ; """C1515"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """270516"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0243666"""^^xsd:string ; umls:cui """C1514723"""^^xsd:string ; umls:cui """C1514722"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """WT1 peptide vaccine"""@eng ; skos:notation """CDR0000518351"""^^xsd:string ; skos:altLabel """WT-1 vax"""@eng ; """Drug/agent"""^^xsd:string ; """2006-11-03"""^^xsd:string ; umls:cui """C1831984"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/etoposide phosphate/methotrexate"""@eng ; skos:notation """CDR0000344423"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DM/ETOP/MTX"""@eng ; ; ; ; ; ; """2003-11-20"""^^xsd:string ; """2003-11-10"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328103"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indisulam"""@eng ; skos:notation """CDR0000043559"""^^xsd:string ; skos:altLabel """E7070"""@eng , """E 7070"""@eng , """E-7070"""@eng ; ; """8817"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-12-05"""^^xsd:string ; umls:cui """C0879271"""^^xsd:string ; umls:cui """C1099211"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tamoxifen/trastuzumab"""@eng ; skos:notation """CDR0000043558"""^^xsd:string ; skos:altLabel """MOAB HER2/TMX"""@eng ; ; ; """8816"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879270"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000043553"""^^xsd:string ; skos:altLabel """BLEO/CTX/DOX/PCB/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """8811"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879265"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """FK463"""@eng ; skos:notation """CDR0000043552"""^^xsd:string ; skos:altLabel """micafungin"""@eng ; """2003-10-29"""^^xsd:string ; """8810"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879264"""^^xsd:string ; umls:cui """C1120386"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """moxifloxacin hydrochloride"""@eng ; skos:notation """CDR0000306456"""^^xsd:string ; skos:altLabel """Viagmox"""@eng , """Avelox"""@eng , """MOXI"""@eng , """BAY 128039"""@eng ; skos:definition """The hydrochloride salt of a fluoroquinolone antibacterial antibiotic. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=306456&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=306456&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38696\" NCI Thesaurus)"""@eng ; """C38696"""^^xsd:string ; """2003-05-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1513705"""^^xsd:string ; umls:cui """C0754517"""^^xsd:string ; umls:cui """C0536495"""^^xsd:string ; umls:cui """C0875968"""^^xsd:string ; umls:cui """C0878537"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amoxicillin-clavulanate potassium/ciprofloxacin"""@eng ; skos:notation """CDR0000306457"""^^xsd:string ; skos:altLabel """AUGMENTIN/CPFX"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327981"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SB AS-2"""@eng ; skos:notation """CDR0000043557"""^^xsd:string ; skos:altLabel """SBAS-2"""@eng ; ; ; ; """8815"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879269"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium borocaptate"""@eng ; skos:notation """CDR0000306451"""^^xsd:string ; skos:altLabel """Borocarpin"""@eng , """borocaptate sodium"""@eng , """BSH"""@eng ; skos:definition """A boron-carrying compound. After parenteral administration, borocaptate sodium accumulates preferentially in tumor cells. When exposed to neutron irradiation, borocaptate absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=306451&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=306451&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2208\" NCI Thesaurus)"""@eng ; ; """2003-05-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """12448-24-7"""^^xsd:string ; """C2208"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1511273"""^^xsd:string ; umls:cui """C0127575"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """boronophenylalanine-fructose complex/sodium borocaptate"""@eng ; skos:notation """CDR0000306452"""^^xsd:string ; skos:altLabel """BPA-F/BSH"""@eng ; ; ; """2003-05-23"""^^xsd:string ; """2003-05-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327980"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ursodiol"""@eng ; skos:notation """CDR0000306453"""^^xsd:string ; skos:altLabel """UDCA"""@eng , """Actigall"""@eng , """Deursil"""@eng , """URSO"""@eng , """ursodeoxycholic acid"""@eng , """(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-oic acid"""@eng ; skos:definition """A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder. Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries. This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol. Ursodiol also reduces the absorption of cholesterol from the intestinal tract. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=306453&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=306453&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1818\" NCI Thesaurus)"""@eng ; """2003-05-23"""^^xsd:string ; """683769"""^^xsd:string ; """C1818"""^^xsd:string ; """128-13-2"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0042105"""^^xsd:string ; umls:cui """C1519841"""^^xsd:string ; umls:cui """C0724157"""^^xsd:string ; umls:cui """C0718244"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostate cancer"""@eng ; skos:notation """CDR0000038782"""^^xsd:string ; skos:altLabel """prostatic cancer"""@eng , """Prostate cancer"""@eng , """carcinoma, prostatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2002-10-15"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1229"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0376358"""^^xsd:string ; umls:cui """C0600139"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/doxorubicin/prednisone/vindesine"""@eng ; skos:notation """CDR0000040923"""^^xsd:string ; skos:altLabel """BCNU/DAVA/DOX/PRED"""@eng , """BEAP"""@eng , """EBAP"""@eng ; ; ; ; ; """3962"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0058894"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/vinblastine"""@eng ; skos:notation """CDR0000040922"""^^xsd:string ; skos:altLabel """VBD"""@eng , """PVB"""@eng , """VBP"""@eng , """CVB"""@eng , """BLEO/CDDP/VBL"""@eng ; ; ; ; """3961"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0072634"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitomycin/vindesine"""@eng ; skos:notation """CDR0000040921"""^^xsd:string ; skos:altLabel """MVP"""@eng , """MiViP"""@eng , """MiPE"""@eng , """CDDP/DAVA/MITO"""@eng , """MEP"""@eng ; ; ; ; """3960"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280541"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/mitomycin/vinblastine"""@eng ; skos:notation """CDR0000040920"""^^xsd:string ; skos:altLabel """MVP"""@eng , """MiPV"""@eng , """CVeMi"""@eng , """PVeMi"""@eng , """CDDP/MITO/VBL"""@eng ; ; ; ; """3959"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280540"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000040927"""^^xsd:string ; skos:altLabel """PAC"""@eng , """CDDP/CTX/DOX"""@eng , """CAP-I"""@eng , """CISCA-II"""@eng , """CAP"""@eng , """CAP-II"""@eng ; ; ; ; """3966"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280547"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide"""@eng ; skos:notation """CDR0000040926"""^^xsd:string ; skos:altLabel """PC"""@eng , """CP"""@eng , """CDDP/CTX"""@eng , """CD"""@eng ; ; ; """3965"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056447"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/vindesine"""@eng ; skos:notation """CDR0000040925"""^^xsd:string ; skos:altLabel """Vind-Plat"""@eng , """CDDP/DAVA"""@eng ; ; ; """3964"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280545"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/vinblastine"""@eng ; skos:notation """CDR0000040924"""^^xsd:string ; skos:altLabel """CDDP/VBL"""@eng , """V-DDP"""@eng , """PVe"""@eng , """VeP"""@eng ; ; ; """3963"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280544"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin/cyclophosphamide/doxorubicin"""@eng ; skos:notation """CDR0000040929"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/HMM"""@eng , """HEXA-CAP"""@eng , """HCAP"""@eng , """CHAD"""@eng , """CHAP-5"""@eng ; ; ; ; ; """3968"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056451"""^^xsd:string ; umls:cui """C1622511"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000040928"""^^xsd:string ; skos:altLabel """CECA"""@eng , """PACE"""@eng , """VCAP-I"""@eng , """CDDP/CTX/DOX/VP-16"""@eng ; ; ; ; ; """3967"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0520526"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SC-48334"""@eng ; skos:notation """CDR0000039105"""^^xsd:string ; skos:altLabel """N-butyl deoxynojirimycin"""@eng ; """1697"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0074118"""^^xsd:string ; umls:cui """C1321596"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/interleukin-3"""@eng ; skos:notation """CDR0000039104"""^^xsd:string ; skos:altLabel """IFF/IL-3/VP-16"""@eng ; ; ; ; """1696"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279115"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methotrexate/sargramostim/vincristine"""@eng ; skos:notation """CDR0000039107"""^^xsd:string ; skos:altLabel """CTX/DOX/GM-CSF/MTX/VCR"""@eng ; ; ; ; ; ; """1699"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279116"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """itraconazole"""@eng ; skos:notation """CDR0000039106"""^^xsd:string ; skos:altLabel """ICZ"""@eng , """Sporanox"""@eng ; skos:definition """A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis. Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39106&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39106&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1138\" NCI Thesaurus)"""@eng ; ; ; """1698"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """84625-61-6"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C1138"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699614"""^^xsd:string ; umls:cui """C0064113"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/doxorubicin/thioguanine"""@eng ; skos:notation """CDR0000039101"""^^xsd:string ; skos:altLabel """ARA-C/DOX/TG"""@eng ; ; ; ; """1692"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279112"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/melphalan"""@eng ; skos:notation """CDR0000039100"""^^xsd:string ; skos:altLabel """CDDP/L-PAM"""@eng ; ; ; """1691"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279111"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/filgrastim/ifosfamide"""@eng ; skos:notation """CDR0000039103"""^^xsd:string ; skos:altLabel """G-CSF/IFF/VP-16"""@eng ; ; ; ; """1694"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279114"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide/sargramostim"""@eng ; skos:notation """CDR0000039102"""^^xsd:string ; skos:altLabel """GM-CSF/IFF/VP-16"""@eng ; ; ; ; """1693"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279113"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """basal cell carcinoma of the skin"""@eng ; skos:notation """CDR0000039109"""^^xsd:string ; skos:altLabel """skin cancer, basal cell"""@eng , """cancer of the skin, basal cell"""@eng , """carcinoma of the skin, basal cell"""@eng , """carcinoma, basal cell, skin"""@eng ; rdfs:subClassOf ; """skin cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """170"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0751676"""^^xsd:string ; umls:cui """C0007117"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV breast cancer"""@eng ; skos:notation """CDR0000039108"""^^xsd:string ; skos:altLabel """metastatic breast cancer"""@eng , """breast cancer, stage IV"""@eng , """breast cancer, metastatic"""@eng ; rdfs:subClassOf ; """2003-06-16"""^^xsd:string ; """breast cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """17"""^^xsd:string ; """progesterone receptor status unknown"""^^xsd:string ; """premenopausal"""^^xsd:string ; """congestive heart failure"""^^xsd:string ; """New York Heart Association class III/IV"""^^xsd:string ; """estrogen receptor status unknown"""^^xsd:string ; """estrogen receptor positive"""^^xsd:string ; """bilateral breast cancer"""^^xsd:string ; """estrogen receptor negative"""^^xsd:string ; """performance status 3"""^^xsd:string ; """performance status 4"""^^xsd:string ; """known bone marrow involvement"""^^xsd:string ; """performance status 2"""^^xsd:string ; """central nervous system involvement/metastases"""^^xsd:string ; """no measurable or evaluable disease"""^^xsd:string ; """progesterone receptor negative"""^^xsd:string ; """arrhythmias requiring therapy"""^^xsd:string ; """history of myocardial infarction within 6 months"""^^xsd:string ; """HIV positive"""^^xsd:string ; """postmenopausal"""^^xsd:string ; """progesterone receptor positive"""^^xsd:string ; """active peptic ulcer disease/GI bleeding"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278488"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """psilocybin"""@eng ; skos:notation """CDR0000487535"""^^xsd:string ; """C62529"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """2006-09-18"""^^xsd:string ; umls:cui """C0033850"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABT-888"""@eng ; skos:notation """CDR0000496464"""^^xsd:string ; skos:definition """A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=496464&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=496464&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60768\" NCI Thesaurus)"""@eng ; """737664"""^^xsd:string ; """2006-07-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C60768"""^^xsd:string ; umls:cui """C1831920"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/thalidomide/vincristine"""@eng ; skos:notation """CDR0000271194"""^^xsd:string ; skos:altLabel """DM/DOX/THAL/VCR"""@eng ; ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327876"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """OGX-011"""@eng ; skos:notation """CDR0000271195"""^^xsd:string ; skos:altLabel """clusterin antisense oligonucleotide"""@eng , """ISIS 112989"""@eng , """TRPM-2 Antisense"""@eng , """Antisense Clusterin"""@eng , """Antisense TRPM-2"""@eng , """Antisense Testosterone-Repressed Prostate Message 2"""@eng ; skos:definition """A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of OGX-011 abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271195&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271195&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1055\" NCI Thesaurus)"""@eng ; """2003-01-26"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1055"""^^xsd:string ; """2006-09-07"""^^xsd:string ; umls:cui """C1328699"""^^xsd:string ; umls:cui """C1327877"""^^xsd:string ; umls:cui """C1524013"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040407"""^^xsd:string ; skos:altLabel """DOX/MTX/VCR"""@eng , """VAM"""@eng ; ; ; ; """3270"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280061"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ixabepilone/ketoconazole"""@eng ; skos:notation """CDR0000394171"""^^xsd:string ; skos:altLabel """BMS 247550/KCZ"""@eng ; ; ; """2004-10-25"""^^xsd:string ; """2004-10-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541383"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 1"""@eng ; skos:notation """CDR0000043168"""^^xsd:string ; rdfs:subClassOf ; """7611"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0008651"""^^xsd:string ; umls:tui """T026"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chromosome 5q"""@eng ; skos:notation """CDR0000043169"""^^xsd:string ; rdfs:subClassOf ; """7612"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0796347"""^^xsd:string ; umls:tui """T086"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus 5-CD40-L vector"""@eng ; skos:notation """CDR0000043162"""^^xsd:string ; skos:altLabel """AD-CD40-L"""@eng ; ; """7605"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796342"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenovirus 5-CD40-L vector/interleukin-2"""@eng ; skos:notation """CDR0000043163"""^^xsd:string ; skos:altLabel """AD-CD40-L/IL-2"""@eng ; ; ; """7606"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796343"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prosthesis"""@eng ; skos:notation """CDR0000043160"""^^xsd:string ; ; rdfs:subClassOf ; """7603"""^^xsd:string ; """2006-02-06"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0525024"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-hB7.1/canarypox-hIL-12 melanoma vaccine"""@eng ; skos:notation """CDR0000043161"""^^xsd:string ; skos:altLabel """ALVAC hB7.1/ALVAC-hIL-12"""@eng ; ; ; """7604"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796341"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gene rearrangement"""@eng ; skos:notation """CDR0000043166"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """7609"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0017287"""^^xsd:string ; umls:tui """T045"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polymorphic microsatellite markers"""@eng ; skos:notation """CDR0000043167"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """7610"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796346"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """genetic analysis"""@eng ; skos:notation """CDR0000043164"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """7607"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796344"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """linkage analysis"""@eng ; skos:notation """CDR0000043165"""^^xsd:string ; rdfs:subClassOf ; """7608"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796345"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tegafur-uracil"""@eng ; skos:notation """CDR0000461135"""^^xsd:string ; skos:altLabel """oral fluorouracil-uracil"""@eng , """Uracil and Ftorafur"""@eng , """Uracil/Tegafur (UFT)"""@eng , """UFT"""@eng , """Uracil and Tetrahydrofuranyl-5-Fluorouracil"""@eng , """Uftoral"""@eng , """Uracil and Tegafur"""@eng ; skos:definition """A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug, tetrahydrofuranyl-5-fluorouracil, and uracil (1:4). Because of its higher concentration in the combination, uracil saturates the uracil-reducing enzymatic activity of dihydropyrimidine dehydrogenase, thereby inhibiting first-pass dihydropyrimidine dehydrogenase-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tetrahydrofuranyl-5-fluorouracil. 5-FU inhibits the enzyme thymidylate synthase, resulting in decreased thymidine synthesis and so reduced DNA synthesis and tumor cell cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461135&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461135&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C9506\" NCI Thesaurus)"""@eng ; ; ; ; ; """2005-12-22"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-06"""^^xsd:string ; """719164"""^^xsd:string ; """C9506"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1446539"""^^xsd:string ; umls:cui """C1564291"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/fluorouracil/leucovorin calcium/oxaliplatin"""@eng ; skos:notation """CDR0000405348"""^^xsd:string ; skos:altLabel """CF/5-FU/L-OHP/PS-341"""@eng ; ; ; ; ; """2004-11-22"""^^xsd:string ; """2004-11-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541390"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """APC8015 vaccine/bevacizumab"""@eng ; skos:notation """CDR0000038506"""^^xsd:string ; skos:altLabel """APC 8015/MOAB VEGF"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """11128"""^^xsd:string ; umls:cui """C1134539"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-CEA-B7.1 vaccine"""@eng ; skos:notation """CDR0000038507"""^^xsd:string ; skos:altLabel """ALVAC-CEA-B7.1"""@eng ; ; ; ; """11129"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134540"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cetuximab/gemcitabine"""@eng ; skos:notation """CDR0000038504"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/MOAB C225"""@eng ; ; ; ; """11126"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134538"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody CAL"""@eng ; skos:notation """CDR0000038505"""^^xsd:string ; skos:altLabel """MOAB CAL"""@eng , """CAL"""@eng ; skos:definition """A humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). As a poly-hormone with diverse biological roles, PTH-rP is expressed by normal tissues, acting in local tissue environments in a variety of ways; it is commonly overexpressed by breast, prostate, and other cancers, acting systemically by promoting bone resorption, inhibiting calcium excretion from the kidney, inducing hypercalcemia, and possibly playing a role in the formation of bony metastases. By blocking the effects of PTH-rP on calcium metabolism, monoclonal antibody CAL may inhibit cancer-related hypercalcemia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38505&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38505&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2659\" NCI Thesaurus)"""@eng ; """11127"""^^xsd:string ; """2006-08-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2659"""^^xsd:string ; umls:cui """C1135160"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gefitinib/temozolomide"""@eng ; skos:notation """CDR0000038502"""^^xsd:string ; skos:altLabel """TMZ/ZD 1839"""@eng ; ; ; """2002-10-10"""^^xsd:string ; """11120"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134534"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/doxorubicin"""@eng ; skos:notation """CDR0000042388"""^^xsd:string ; skos:altLabel """DOX/MOAB C225"""@eng ; ; ; """5643"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338296"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/fludarabine"""@eng ; skos:notation """CDR0000038500"""^^xsd:string ; skos:altLabel """BU/FAMP"""@eng ; ; ; """11119"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134533"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV chronic lymphocytic leukemia"""@eng ; skos:notation """CDR0000038501"""^^xsd:string ; skos:altLabel """CLL, stage IV"""@eng , """chronic lymphocytic leukemia, stage IV"""@eng , """lymphocytic leukemia, stage IV chronic"""@eng , """leukemia, stage IV chronic lymphocytic"""@eng ; rdfs:subClassOf ; """chronic lymphocytic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1112"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854804"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edrecolomab/fluorouracil/levamisole"""@eng ; skos:notation """CDR0000042385"""^^xsd:string ; skos:altLabel """5-FU/LEV/MOAB 17-1A"""@eng ; ; ; ; """5640"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338293"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab"""@eng ; skos:notation """CDR0000042384"""^^xsd:string ; skos:altLabel """Chimeric Anti-EGFR Monoclonal Antibody"""@eng , """IMC-C225"""@eng , """MOAB C225"""@eng , """Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer"""@eng , """Anti-Epidermal Growth Factor Receptor Monoclonal Antibody"""@eng , """Chimeric Monoclonal Antibody C225"""@eng , """monoclonal antibody C225"""@eng , """Chimeric MoAb C225"""@eng , """C225"""@eng , """C225 monoclonal antibody"""@eng , """Erbitux"""@eng , """Anti-EGFR Monoclonal Antibody"""@eng ; skos:definition """A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division. Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors. This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42384&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42384&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1723\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5638"""^^xsd:string ; """714692"""^^xsd:string ; """11460"""^^xsd:string ; """C1723"""^^xsd:string ; """3610"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """205923-56-4"""^^xsd:string ; """2006-07-31"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0995188"""^^xsd:string ; umls:cui """C0879636"""^^xsd:string ; umls:cui """C1173436"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/estramustine"""@eng ; skos:notation """CDR0000042387"""^^xsd:string ; skos:altLabel """DOX/EM"""@eng ; ; ; """5642"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338295"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/paclitaxel"""@eng ; skos:notation """CDR0000042386"""^^xsd:string ; skos:altLabel """MOAB C225/TAX"""@eng ; ; ; """5641"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338294"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tumor lysis syndrome"""@eng ; skos:notation """CDR0000042381"""^^xsd:string ; rdfs:subClassOf ; """5635"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0041364"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hyperuricemia"""@eng ; skos:notation """CDR0000042380"""^^xsd:string ; rdfs:subClassOf ; """5634"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0740394"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tetanus toxoid"""@eng ; skos:notation """CDR0000038508"""^^xsd:string ; skos:altLabel """TETTOX"""@eng ; skos:definition """A solution of formaldehyde-deactivated toxin isolated from the bacterium Clostridium tetani. Tetanus toxoid stimulates the production of antitoxin antibodies. This agent may be used as an adjuvant in cancer vaccines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38508&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38508&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2660\" NCI Thesaurus)"""@eng ; ; ; ; """11130"""^^xsd:string ; """2006-05-31"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2660"""^^xsd:string ; umls:cui """C0305062"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ALVAC-CEA-B7.1 vaccine/fluorouracil/irinotecan/leucovorin calcium"""@eng ; skos:notation """CDR0000038509"""^^xsd:string ; skos:altLabel """ALVAC-CEA-B7.1/CF/CPT-11/5-FU"""@eng ; ; ; ; ; """11131"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134541"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """broccoli sprout extract"""@eng ; skos:notation """CDR0000455271"""^^xsd:string ; skos:definition """A cruciferous vegetable extract with potential chemopreventive properties. Broccoli sprout extract contains a high amount of sulforaphane, a naturally occurring isothiocyanate. Sulforaphane activates transcription factor Nrf2, a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs, cis-acting regulatory enhancer elements found in the 5 flanking region of many phase II detoxification enzymes, mediate the transcription of these enzymes (particularly glutathione-S-transferase and quinone oxidoreductase) resulting in the detoxification of highly reactive carcinogens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=455271&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=455271&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52174\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C52174"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """2005-11-10"""^^xsd:string ; umls:cui """C1707048"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/gp100 antigen"""@eng ; skos:notation """CDR0000373764"""^^xsd:string ; skos:altLabel """ADC/gp100"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541287"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/autologous tumor cell vaccine/interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000373765"""^^xsd:string ; skos:altLabel """ADC/ATCV/IFN-A/IL-2"""@eng ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541288"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gimatecan"""@eng ; skos:notation """CDR0000361790"""^^xsd:string ; skos:altLabel """ST1481"""@eng , """ST 1481"""@eng ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0969276"""^^xsd:string ; umls:cui """C1455513"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """kanglaite"""@eng ; skos:notation """CDR0000361791"""^^xsd:string ; skos:altLabel """Kanglaite Injection"""@eng , """KLT"""@eng , """coix seed extract"""@eng ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1568044"""^^xsd:string ; umls:cui """C1541792"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """S-8184 paclitaxel emulsion"""@eng ; skos:notation """CDR0000361792"""^^xsd:string ; skos:altLabel """TOCOSOL![TRADE MARK SIGN]! Paclitaxel"""@eng , """vitamin E paclitaxel emulsion"""@eng , """TOCOSOL™ Paclitaxel"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """2004-03-24"""^^xsd:string ; umls:cui """C1541153"""^^xsd:string ; umls:cui """C1541793"""^^xsd:string ; umls:cui """C1541188"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """posaconazole"""@eng ; skos:notation """CDR0000361793"""^^xsd:string ; skos:altLabel """SCH 56592"""@eng , """Noxafil"""@eng ; skos:definition """A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361793&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361793&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61500\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """2006-10-11"""^^xsd:string ; """C61500"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0936148"""^^xsd:string ; umls:cui """C0529792"""^^xsd:string ; umls:cui """C1174778"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluconazole/itraconazole"""@eng ; skos:notation """CDR0000361794"""^^xsd:string ; skos:altLabel """FCZ/ICZ"""@eng ; ; ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541189"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sodium citrate"""@eng ; skos:notation """CDR0000361795"""^^xsd:string ; skos:altLabel """Bicitra"""@eng , """Modified Shohl's Solution"""@eng , """Oracit"""@eng , """Albright's Solution"""@eng ; skos:definition """The sodium salt form of citrate with alkalinizing property. Upon absorption, sodium citrate dissociate and causes increased plasma bicarbonate concentration, thereby buffer excess H+, raise blood pH and reverse the clinical manifestations of acidosis. Furthermore, increased free sodium load could foster intravascular blood volume, and facilitate excretion of bicarbonate compounds and result in anti-urolithic effect. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361795&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=361795&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62075\" NCI Thesaurus)"""@eng ; """2004-03-24"""^^xsd:string ; """2004-03-13"""^^xsd:string ; """C62075"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0718938"""^^xsd:string ; umls:cui """C0722284"""^^xsd:string ; umls:cui """C0142825"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/filgrastim/vincristine"""@eng ; skos:notation """CDR0000371720"""^^xsd:string ; skos:altLabel """CDDP/CTX/G-CSF/VCR/VP-16"""@eng ; ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541251"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/dexrazoxane/doxorubicin/filgrastim/temozolomide/vincristine"""@eng ; skos:notation """CDR0000371721"""^^xsd:string ; skos:altLabel """ADR-529/CTX/DACT/DOX/G-CSF/TMZ/VCR"""@eng ; ; ; ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-06-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541252"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/filgrastim/vincristine"""@eng ; skos:notation """CDR0000371722"""^^xsd:string ; skos:altLabel """CTX/DACT/G-CSF/VCR"""@eng ; ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541253"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/filgrastim/methylprednisolone"""@eng ; skos:notation """CDR0000371726"""^^xsd:string ; skos:altLabel """CYSP/G-CSF/MePRDL"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541254"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AEE788"""@eng ; skos:notation """CDR0000371727"""^^xsd:string ; skos:altLabel """AEE-788"""@eng ; skos:definition """An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=371727&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=371727&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48369\" NCI Thesaurus)"""@eng ; ; """2004-05-28"""^^xsd:string ; """2006-07-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48369"""^^xsd:string ; umls:cui """C1506057"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-CEA-TRICOM vaccine/recombinant fowlpox GM-CSF vaccine/vaccinia-CEA-TRICOM vaccine"""@eng ; skos:notation """CDR0000371728"""^^xsd:string ; skos:altLabel """fCEA-TRI/rF-GM-CSF/vCEA-TRI"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541255"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/fowlpox-CEA-TRICOM vaccine/recombinant fowlpox GM-CSF vaccine"""@eng ; skos:notation """CDR0000371729"""^^xsd:string ; skos:altLabel """fCEA-TRI/rF-GM-CSF/SC-58635"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541256"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intraocular retinoblastoma"""@eng ; skos:notation """CDR0000037764"""^^xsd:string ; skos:altLabel """retinoblastoma, intraocular"""@eng , """childhood intraocular retinoblastoma"""@eng , """pediatric intraocular retinoblastoma"""@eng ; rdfs:subClassOf ; """retinoblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1002"""^^xsd:string ; """2004-12-22"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1321869"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/ifosfamide"""@eng ; skos:notation """CDR0000041094"""^^xsd:string ; skos:altLabel """CBDCA/IFF/VP-16"""@eng , """ICE"""@eng ; ; ; ; """4133"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280697"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/doxorubicin/verapamil/vincristine"""@eng ; skos:notation """CDR0000041095"""^^xsd:string ; skos:altLabel """DM/DOX/VCR/VPAM"""@eng ; ; ; ; ; """4134"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280698"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """finasteride"""@eng ; skos:notation """CDR0000041096"""^^xsd:string ; skos:altLabel """Uprosan"""@eng , """Prostide"""@eng , """Proscar"""@eng , """Finastid"""@eng , """Pro-Cure"""@eng , """MK-906"""@eng , """(5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide"""@eng , """MK 906"""@eng ; skos:definition """A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41096&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41096&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1099\" NCI Thesaurus)"""@eng ; ; """4136"""^^xsd:string ; """2006-07-03"""^^xsd:string ; """C1099"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0733735"""^^xsd:string ; umls:cui """C1831595"""^^xsd:string ; umls:cui """C0678149"""^^xsd:string ; umls:cui """C1517190"""^^xsd:string ; umls:cui """C1517192"""^^xsd:string ; umls:cui """C0060389"""^^xsd:string ; umls:cui """C1517189"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/tamoxifen/thiotepa"""@eng ; skos:notation """CDR0000041097"""^^xsd:string ; skos:altLabel """DOX/5-FU/TMX/TSPA"""@eng ; ; ; ; ; """4137"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280699"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amikacin/ceftazidime"""@eng ; skos:notation """CDR0000041090"""^^xsd:string ; skos:altLabel """AMIKA/CEFTA"""@eng ; ; ; """4129"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280693"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amikacin/ceftriaxone"""@eng ; skos:notation """CDR0000041091"""^^xsd:string ; skos:altLabel """AMIKA/CFTX"""@eng ; ; ; """4130"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280694"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lomustine/mitolactol/procarbazine/thioguanine"""@eng ; skos:notation """CDR0000041092"""^^xsd:string ; skos:altLabel """CCNU/DBD/PCB/TG"""@eng ; ; ; ; ; """4131"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280695"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim/thiotepa"""@eng ; skos:notation """CDR0000041093"""^^xsd:string ; skos:altLabel """GM-CSF/TSPA"""@eng ; ; ; """4132"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0214035"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/methotrexate/tamoxifen/thiotepa"""@eng ; skos:notation """CDR0000041098"""^^xsd:string ; skos:altLabel """5-FU/MTX/TMX/TSPA"""@eng ; ; ; ; ; """4138"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280700"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/sargramostim"""@eng ; skos:notation """CDR0000041099"""^^xsd:string ; skos:altLabel """CDDP/GM-CSF/VP-16"""@eng ; ; ; ; """4139"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280701"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-LET heavy ion therapy"""@eng ; skos:notation """CDR0000038993"""^^xsd:string ; skos:altLabel """therapy, high-LET heavy ion"""@eng ; ; rdfs:subClassOf ; """1551"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279017"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """parathyroid agent"""@eng ; skos:notation """CDR0000039295"""^^xsd:string ; rdfs:subClassOf ; """1928"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279173"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vasopressin"""@eng ; skos:notation """CDR0000039294"""^^xsd:string ; """1927"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1705480"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thyroid agent"""@eng ; skos:notation """CDR0000039297"""^^xsd:string ; rdfs:subClassOf ; """1930"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279175"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pituitary agent"""@eng ; skos:notation """CDR0000039296"""^^xsd:string ; rdfs:subClassOf ; """1929"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0279174"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """glucagon"""@eng ; skos:notation """CDR0000039291"""^^xsd:string ; """1924"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0017687"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diazoxide"""@eng ; skos:notation """CDR0000039290"""^^xsd:string ; skos:altLabel """SRG-95213"""@eng , """3-Methyl-7-chloro-1,2,4-benzothiadiazine 1,1-Dioxide"""@eng ; skos:definition """A benzothiadiazine derivate with antihypertensive and hyperglycemic activities. Diazoxide increases membrane permeability to potassium ions in vascular smooth muscle, thereby stabilizing the membrane action potential and preventing vascular smooth muscle contraction; this results in peripheral vasodilatation and decreases in peripheral vascular resistance. This agent also inhibits insulin release by interacting with ATP-sensitive potassium channels of pancreatic islet beta-cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39290&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39290&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C428\" NCI Thesaurus)"""@eng ; """1923"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """64198"""^^xsd:string ; """2006-07-05"""^^xsd:string ; """C428"""^^xsd:string ; """76130"""^^xsd:string ; umls:cui """C0012022"""^^xsd:string ; umls:cui """C1711242"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oxytocin"""@eng ; skos:notation """CDR0000039293"""^^xsd:string ; """1926"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0030095"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitonin"""@eng ; skos:notation """CDR0000039292"""^^xsd:string ; skos:altLabel """salmon calcitonin"""@eng , """Cibacalcin"""@eng , """Calcimar"""@eng , """calcitonin-salmon"""@eng , """calcitonin salmon"""@eng ; """1925"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0728730"""^^xsd:string ; umls:cui """C0073994"""^^xsd:string ; umls:cui """C0305641"""^^xsd:string ; umls:cui """C0006668"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """decitabine"""@eng ; skos:notation """CDR0000039299"""^^xsd:string ; skos:altLabel """Dacogen"""@eng , """DAC"""@eng , """2'-Deoxy-5-azacytidine"""@eng , """5-Azadeoxycytidine"""@eng , """Deoxyazacytidine"""@eng , """4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one"""@eng , """5-aza-dCyd"""@eng , """5-Aza-2-deoxycytidine"""@eng , """5-Aza-2'-deoxycytidine"""@eng , """5-Aza-2'deoxycytidine/Decitabine"""@eng , """Dezocitidine"""@eng ; skos:definition """A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39299&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39299&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C981\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; """1932"""^^xsd:string ; """127716"""^^xsd:string ; """C981"""^^xsd:string ; """2353-33-5"""^^xsd:string ; """2006-08-01"""^^xsd:string ; """50733"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1712036"""^^xsd:string ; umls:cui """C0049065"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """levothyroxine"""@eng ; skos:notation """CDR0000039298"""^^xsd:string ; """1931"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0040165"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """high-LET pion therapy"""@eng ; skos:notation """CDR0000038994"""^^xsd:string ; skos:altLabel """therapy, high-LET pion"""@eng ; ; rdfs:subClassOf ; """1552"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279018"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hydroxyurea/interferon alfa"""@eng ; skos:notation """CDR0000041542"""^^xsd:string ; skos:altLabel """HU/IFN-A"""@eng ; ; ; """4702"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338156"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indomethacin/interleukin-1-alpha/etoposide"""@eng ; skos:notation """CDR0000041543"""^^xsd:string ; skos:altLabel """IL-1A/Indomethacin/VP-16"""@eng ; ; ; ; """4703"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281172"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tazobactam sodium"""@eng ; skos:notation """CDR0000041540"""^^xsd:string ; skos:altLabel """TAZO"""@eng ; """Drug/agent"""^^xsd:string ; """C1242"""^^xsd:string ; """4700"""^^xsd:string ; """2006-11-21"""^^xsd:string ; umls:cui """C0075870"""^^xsd:string ; umls:cui """C0724700"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """muramyl tripeptide phosphatidylethanolamine liposome"""@eng ; skos:notation """CDR0000041541"""^^xsd:string ; skos:altLabel """MTP-PE Liposome"""@eng , """CGP 19835A Lipid"""@eng ; ; ; ; ; ; """4701"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0284547"""^^xsd:string ; umls:cui """C0281170"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aloe vera gel"""@eng ; skos:notation """CDR0000041546"""^^xsd:string ; skos:definition """Obtained as a preparation of leaf pulp from the parenchymal tissue of Aloe vera (Liliaceae) and containing carbohydrate polymers, such as glucomannans or pectic acid, and various vitamins and essential amino acids, as well as other organic and inorganic compounds. Aloe vera gel is used internally or externally for sunburn, skin problems, insect bites, ulcers, arthritis, constipation, and as an immune system enhancer. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41546&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41546&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1565\" NCI Thesaurus)"""@eng ; """4706"""^^xsd:string ; """C1565"""^^xsd:string ; """2007-01-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0974143"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amphotericin B/colistin sulfate/tobramycin"""@eng ; skos:notation """CDR0000041547"""^^xsd:string ; skos:altLabel """amphotericin B/colistin sulfate/TBM"""@eng ; ; ; ; """4707"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281175"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorhexidine"""@eng ; skos:notation """CDR0000041544"""^^xsd:string ; skos:definition """A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41544&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41544&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C364\" NCI Thesaurus)"""@eng ; """4704"""^^xsd:string ; """C364"""^^xsd:string ; """55-56-1"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0008196"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colistin sulfate"""@eng ; skos:notation """CDR0000041545"""^^xsd:string ; skos:altLabel """polymixin E"""@eng ; ; """4705"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0009316"""^^xsd:string ; umls:cui """C0009317"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """superior vena cava syndrome"""@eng ; skos:notation """CDR0000041548"""^^xsd:string ; rdfs:subClassOf ; """4708"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0038833"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antibody therapy"""@eng ; skos:notation """CDR0000041549"""^^xsd:string ; skos:altLabel """therapy, antibody"""@eng ; ; rdfs:subClassOf ; ; ; ; ; ; """4709"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281176"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavone acetic acid"""@eng ; skos:notation """CDR0000040152"""^^xsd:string ; skos:altLabel """FAA"""@eng , """LM 975"""@eng , """Flavone-8-Acetic Acid"""@eng , """4H-1-benzopyran-8-acetic Acid, 4-Oxo-2-phenyl"""@eng ; skos:definition """A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40152&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40152&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1101\" NCI Thesaurus)"""@eng ; ; """2939"""^^xsd:string ; """87626-55-9"""^^xsd:string ; """26886"""^^xsd:string ; """347512"""^^xsd:string ; """C1101"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0060441"""^^xsd:string ; umls:cui """C0126081"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """menogaril"""@eng ; skos:notation """CDR0000040153"""^^xsd:string ; skos:altLabel """MEN"""@eng , """[2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha)]-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione"""@eng , """7-(R)-O-methylnogarol"""@eng , """Menogarol"""@eng , """TUT-7"""@eng , """7-con-O-methylnogarol"""@eng , """7-con-O-methylnorgarol"""@eng , """U-52047"""@eng , """7-OMEN"""@eng ; skos:definition """A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin. Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40153&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40153&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1389\" NCI Thesaurus)"""@eng ; ; """2940"""^^xsd:string ; """269148"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """8806"""^^xsd:string ; """22519"""^^xsd:string ; """71628-96-1"""^^xsd:string ; """C1389"""^^xsd:string ; umls:cui """C1522553"""^^xsd:string ; umls:cui """C0127527"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estramustine/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000370053"""^^xsd:string ; skos:altLabel """EM/TAX/TOPO"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541241"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etanidazole/melphalan/prednisone"""@eng ; skos:notation """CDR0000040151"""^^xsd:string ; skos:altLabel """L-PAM/PRED/SR-2508"""@eng ; ; ; ; """2938"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279851"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/etoposide/thioguanine"""@eng ; skos:notation """CDR0000040156"""^^xsd:string ; skos:altLabel """ARA-C/DNR/TG/VP-16"""@eng , """V-TAD"""@eng ; ; ; ; ; """2943"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279854"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, breast cancer"""@eng ; skos:notation """CDR0000040157"""^^xsd:string ; skos:altLabel """breast cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2944"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279855"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040154"""^^xsd:string ; skos:altLabel """MACOP-B"""@eng , """BLEO/CTX/DOX/MTX/PRED/VCR"""@eng ; ; ; ; ; ; ; """2941"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279852"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/melphalan/teniposide"""@eng ; skos:notation """CDR0000040155"""^^xsd:string ; skos:altLabel """VAMP"""@eng , """CDDP/DOX/L-PAM/VM-26"""@eng ; ; ; ; ; """2942"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279853"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adrenocortical carcinoma"""@eng ; skos:notation """CDR0000040158"""^^xsd:string ; skos:altLabel """adrenocortical carcinoma cellular diagnosis"""@eng , """adrenal cortex cancer cellular diagnosis"""@eng , """adrenal cortical carcinoma cellular diagnosis"""@eng , """carcinoma, adrenocortical, cellular diagnosis"""@eng ; rdfs:subClassOf ; """2945"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279856"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/interleukin-2"""@eng ; skos:notation """CDR0000040159"""^^xsd:string ; skos:altLabel """CDDP/IL-2/VP-16"""@eng ; ; ; ; """2946"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279857"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood malignant germ cell tumor"""@eng ; skos:notation """CDR0000043498"""^^xsd:string ; skos:altLabel """recurrent germ cell tumor, childhood"""@eng , """germ cell tumor, recurrent, pediatric"""@eng , """recurrent germ cell tumor, pediatric"""@eng , """pediatric recurrent germ cell tumor"""@eng , """germ cell tumor, recurrent, childhood"""@eng ; rdfs:subClassOf ; """8728"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0886487"""^^xsd:string ; umls:cui """C0796666"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/GEM 231"""@eng ; skos:notation """CDR0000043499"""^^xsd:string ; skos:altLabel """GEM-231/TXT"""@eng ; ; ; """2003-10-29"""^^xsd:string ; """8729"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796667"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """proteolytic enzymes"""@eng ; skos:notation """CDR0000043492"""^^xsd:string ; skos:definition """Enzymes produced and secreted by the pancreas which aid in the proteolysis of proteins in the digestive tract. Pancreatic proteolytic enzymes include trypsin, chymotrypsin and carboxypeptidase; these enzymes are secreted as zymogens, inactive precursors of the enzymes, and are activated in the lumen of the digestive canal. Another proteolytic enzyme, enteropeptidase, is associated with the brush border of enterocytes; this enzyme catalyses the conversion of trypsinogen into trypsin which, in turn, can activate a number of other pancreatic zymogens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43492&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43492&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38728\" NCI Thesaurus)"""@eng ; """8722"""^^xsd:string ; """C38728"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; umls:cui """C0030940"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood extracranial germ cell tumor"""@eng ; skos:notation """CDR0000043493"""^^xsd:string ; skos:altLabel """extracranial germ cell tumor, childhood"""@eng , """extracranial germ cell tumor, pediatric"""@eng , """germ cell tumor, childhood, extracranial"""@eng , """germ cell tumor, extracranial, childhood"""@eng , """pediatric extracranial germ cell tumor"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """8723"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0796661"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/vaccinia-tyrosinase vaccine"""@eng ; skos:notation """CDR0000043490"""^^xsd:string ; skos:altLabel """IL-2/VACTYROS"""@eng ; ; ; """8719"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796659"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/cyclophosphamide/doxorubicin/paclitaxel"""@eng ; skos:notation """CDR0000043491"""^^xsd:string ; skos:altLabel """CTX/DOX/TAX/WR-2721"""@eng ; ; ; ; ; """8721"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796660"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood malignant ovarian germ cell tumor"""@eng ; skos:notation """CDR0000043496"""^^xsd:string ; skos:altLabel """ovarian germ cell tumor, childhood"""@eng , """germ cell tumor, ovarian, childhood"""@eng , """germ cell tumor, ovarian, pediatric"""@eng , """ovarian germ cell tumor, pediatric"""@eng , """pediatric ovarian germ cell tumor"""@eng ; rdfs:subClassOf ; """8726"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0886483"""^^xsd:string ; umls:cui """C0796664"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood extragonadal malignant germ cell tumor"""@eng ; skos:notation """CDR0000043497"""^^xsd:string ; skos:altLabel """extragonadal malignant germ cell tumor, pediatric"""@eng , """malignant germ cell tumor, extragonadal, pediatric"""@eng , """pediatric extragonadal malignant germ cell tumor"""@eng , """extragonadal malignant germ cell tumor, childhood"""@eng , """malignant germ cell tumor, extragonadal, childhood"""@eng ; rdfs:subClassOf ; """8727"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796665"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood mature and immature teratomas"""@eng ; skos:notation """CDR0000043494"""^^xsd:string ; skos:altLabel """mature and immature teratomas, pediatric"""@eng , """pediatric mature and immature teratomas"""@eng , """mature and immature teratomas, childhood"""@eng ; rdfs:subClassOf ; """8724"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796662"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood malignant testicular germ cell tumor"""@eng ; skos:notation """CDR0000043495"""^^xsd:string ; skos:altLabel """testicular germ cell tumor, pediatric"""@eng , """germ cell tumor, testicular, childhood"""@eng , """germ cell tumor, testicular, pediatric"""@eng , """testicular germ cell tumor, childhood"""@eng , """pediatric testicular germ cell tumor"""@eng ; rdfs:subClassOf ; """8725"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796663"""^^xsd:string ; umls:cui """C0886477"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bone marrow suppression"""@eng ; skos:notation """CDR0000041407"""^^xsd:string ; skos:altLabel """suppression, bone marrow"""@eng ; rdfs:subClassOf ; """4478"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280962"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urothelial toxicity attenuation"""@eng ; skos:notation """CDR0000041406"""^^xsd:string ; ; rdfs:subClassOf ; """4477"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280961"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cardiotoxicity attenuation"""@eng ; skos:notation """CDR0000041405"""^^xsd:string ; ; rdfs:subClassOf ; """4476"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280960"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chemoprotection"""@eng ; skos:notation """CDR0000041404"""^^xsd:string ; ; ; ; ; ; rdfs:subClassOf ; """4475"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0280959"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sexual dysfunction and infertility"""@eng ; skos:notation """CDR0000041403"""^^xsd:string ; skos:altLabel """dysfunction and infertility, sexual"""@eng ; rdfs:subClassOf ; """4474"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280958"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """psychosocial effects/treatment"""@eng ; skos:notation """CDR0000041402"""^^xsd:string ; skos:altLabel """psychosocial effects"""@eng , """treatment/psychosocial effects"""@eng , """effects, psychosocial"""@eng ; rdfs:subClassOf ; """4473"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280957"""^^xsd:string ; umls:tui """T080"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """poor vascular access"""@eng ; skos:notation """CDR0000041401"""^^xsd:string ; skos:altLabel """access, poor vascular"""@eng , """vascular access, poor"""@eng ; rdfs:subClassOf ; """4472"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280956"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """perioperative/postoperative complications"""@eng ; skos:notation """CDR0000041400"""^^xsd:string ; skos:altLabel """complications, perioperative/postoperative"""@eng , """complications, postoperative/perioperative"""@eng ; rdfs:subClassOf ; """4471"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280955"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """elsamitrucin"""@eng ; skos:notation """CDR0000041409"""^^xsd:string ; skos:altLabel """BMY-28090"""@eng , """BMY 28090"""@eng , """Benzo(h)(1)benzopyrano(5,4,3-cde)(1)ebnzopyran-5,12-dione,10((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl"""@eng , """BMY28090"""@eng , """10-O-Elsaminosylelsarosylchartarin"""@eng , """elsamicin A"""@eng ; skos:definition """A heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21. Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41409&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41409&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1080\" NCI Thesaurus)"""@eng ; """4480"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1080"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C0950684"""^^xsd:string ; umls:cui """C0059041"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thrombocytopenia"""@eng ; skos:notation """CDR0000041408"""^^xsd:string ; rdfs:subClassOf ; """4479"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0040034"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soblidotin"""@eng ; skos:notation """CDR0000302644"""^^xsd:string ; skos:altLabel """TZT1027"""@eng , """TZT-1027"""@eng ; skos:definition """A dolastatin-10 derivative. Soblidotin inhibits tubulin polymerization, resulting in cell cycle arrest and induction of apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=302644&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=302644&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26672\" NCI Thesaurus)"""@eng ; ; """2003-04-23"""^^xsd:string ; """C26672"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C0538648"""^^xsd:string ; umls:cui """C1328702"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aerosolized liposomal 9-nitro-20 (S) camptothecin"""@eng ; skos:notation """CDR0000473242"""^^xsd:string ; skos:altLabel """L9NC"""@eng , """aerosolized liposomal 9-nitrocamptothecin"""@eng ; skos:definition """An aerosolized liposomal preparation of a water-insoluble derivative of camptothecin with potential antineoplastic activity. 9-nitro-20 (S)-camptothecin and its active metabolite 9-aminocamptothecin (9-AC) selectively stabilize topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. This agent is formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 micrometer mass median aerodynamic diameter. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473242&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=473242&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61071\" NCI Thesaurus)"""@eng ; """2006-07-21"""^^xsd:string ; """C61071"""^^xsd:string ; """2006-03-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831774"""^^xsd:string ; umls:cui """C1831773"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ABI-007/carboplatin/trastuzumab"""@eng ; skos:notation """CDR0000373802"""^^xsd:string ; skos:altLabel """ABI 007/CBDCA/MOAB HER2"""@eng ; ; ; ; """2004-05-28"""^^xsd:string ; """2004-05-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541290"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/vincristine"""@eng ; skos:notation """CDR0000042019"""^^xsd:string ; skos:altLabel """DM/VCR"""@eng ; ; ; """5245"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281561"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclosporine/methotrexate"""@eng ; skos:notation """CDR0000042018"""^^xsd:string ; skos:altLabel """CYSP/MTX"""@eng ; ; ; """5244"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281560"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/milodistim/mitoxantrone"""@eng ; skos:notation """CDR0000042015"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/PIXY321"""@eng ; ; ; ; """5241"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281557"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/filgrastim"""@eng ; skos:notation """CDR0000042014"""^^xsd:string ; skos:altLabel """CTX/G-CSF/VP-16"""@eng ; ; ; ; """5240"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281556"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/PSC 833"""@eng ; skos:notation """CDR0000042017"""^^xsd:string ; skos:altLabel """PSC-833/TAX"""@eng ; ; ; """2003-10-28"""^^xsd:string ; """5243"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281559"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/filgrastim/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000042016"""^^xsd:string ; skos:altLabel """ARA-C/BLEO/CTX/DOX/G-CSF/MTX/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; ; ; """5242"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338183"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciprofloxacin/cisplatin/etoposide"""@eng ; skos:notation """CDR0000042011"""^^xsd:string ; skos:altLabel """CDDP/CPFX/VP-16"""@eng ; ; ; ; """5236"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281553"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000042010"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/VP-16"""@eng ; ; ; ; """5235"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281552"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/interleukin-1-alpha"""@eng ; skos:notation """CDR0000042013"""^^xsd:string ; skos:altLabel """DTIC/IL-1A"""@eng ; ; ; """5239"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281555"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ciprofloxacin/cisplatin/etoposide/filgrastim"""@eng ; skos:notation """CDR0000042012"""^^xsd:string ; skos:altLabel """CDDP/CPFX/G-CSF/VP-16"""@eng ; ; ; ; ; """5237"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281554"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/temozolomide/vincristine"""@eng ; skos:notation """CDR0000445605"""^^xsd:string ; skos:altLabel """CPT-11/TMZ/VCR"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-23"""^^xsd:string ; """2005-08-24"""^^xsd:string ; umls:cui """C1831721"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphoma"""@eng ; skos:notation """CDR0000041429"""^^xsd:string ; rdfs:subClassOf ; """450"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0024299"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III non-small cell lung cancer"""@eng ; skos:notation """CDR0000041428"""^^xsd:string ; skos:altLabel """nonsmall cell lung cancer, stage III"""@eng , """non-oat cell lung cancer, stage III"""@eng , """stage III NSCLC"""@eng , """non-small cell lung cancer, stage III"""@eng , """stage III nonsmall cell lung cancer"""@eng , """lung cancer, non-small cell, stage III"""@eng , """lung cancer, nonsmall cell, stage III"""@eng , """lung cancer, non-oat cell, stage III"""@eng , """NSCLC, stage III"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """45"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278506"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/mitolactol"""@eng ; skos:notation """CDR0000042177"""^^xsd:string ; skos:altLabel """BCNU/DBD"""@eng ; ; ; """5416"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281689"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/idarubicin/ifosfamide/methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042174"""^^xsd:string ; skos:altLabel """DM/IDA/IFF/MTX/TG/VCR"""@eng ; ; ; ; ; ; ; """5413"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281687"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042175"""^^xsd:string ; skos:altLabel """MTX/TG/VCR"""@eng ; ; ; ; """5414"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281688"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/idarubicin/ifosfamide/methotrexate/pegaspargase/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042172"""^^xsd:string ; skos:altLabel """ARA-C/DM/IDA/IFF/MTX/PEG-ASP/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; ; ; """5411"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281685"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/dexamethasone/etoposide/methotrexate/pegaspargase/thioguanine/vincristine"""@eng ; skos:notation """CDR0000042173"""^^xsd:string ; skos:altLabel """ARA-C/DM/MTX/PEG-ASP/TG/VCR/VP-16"""@eng ; ; ; ; ; ; ; ; """5412"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281686"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """parathyroid cancer"""@eng ; skos:notation """CDR0000042170"""^^xsd:string ; skos:altLabel """carcinoma of the parathyroid"""@eng , """cancer of the parathyroid"""@eng , """Parathyroid cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """541"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0687150"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/etoposide/ifosfamide/methotrexate/pegaspargase/vincristine"""@eng ; skos:notation """CDR0000042171"""^^xsd:string ; skos:altLabel """DM/IFF/MTX/PEG-ASP/VCR/VP-16"""@eng ; ; ; ; ; ; ; """5410"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281684"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/mitoxantrone"""@eng ; skos:notation """CDR0000042178"""^^xsd:string ; skos:altLabel """CDDP/CTX/DHAD"""@eng ; ; ; ; """5417"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281690"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/monoclonal antibody Ch14.18/monoclonal antibody R24"""@eng ; skos:notation """CDR0000042179"""^^xsd:string ; skos:altLabel """IL-2/MOAB Ch14.18/MOAB R24"""@eng ; ; ; ; """5418"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281691"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/docetaxel/irinotecan"""@eng ; skos:notation """CDR0000288842"""^^xsd:string ; skos:altLabel """CPT-11/SC-58635/TXT"""@eng ; ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327925"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """exemestane/trastuzumab"""@eng ; skos:notation """CDR0000288843"""^^xsd:string ; skos:altLabel """MOAB HER2/PNU 155971"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327926"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/ixabepilone"""@eng ; skos:notation """CDR0000288840"""^^xsd:string ; skos:altLabel """BMS 247550/CDDP"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2004-01-08"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327923"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/epirubicin"""@eng ; skos:notation """CDR0000288841"""^^xsd:string ; skos:altLabel """EPI/SC-58635"""@eng ; ; ; """2003-03-24"""^^xsd:string ; """2003-03-03"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327924"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """coxsackievirus A21"""@eng ; skos:notation """CDR0000486330"""^^xsd:string ; skos:altLabel """CVA21"""@eng ; skos:definition """A naturally occurring enterovirus with potential antitumor activity. Upon intratumoral administration, coxsackievirus A21 targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are both overexpressed on certain malignant cells. After entering the cells, coxsackievirus A21 replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486330&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486330&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61493\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2006-10-11"""^^xsd:string ; """C61493"""^^xsd:string ; """2006-05-19"""^^xsd:string ; umls:cui """C1440507"""^^xsd:string ; umls:tui """T005"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AVN944"""@eng ; skos:notation """CDR0000486333"""^^xsd:string ; skos:altLabel """AVN-944"""@eng ; skos:definition """An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis. Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486333&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486333&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49181\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C49181"""^^xsd:string ; """2006-05-19"""^^xsd:string ; umls:cui """C1706677"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """electric field therapy"""@eng ; skos:notation """CDR0000524079"""^^xsd:string ; """2006-11-30"""^^xsd:string ; """2006-12-01"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C1831995"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pirfenidone"""@eng ; skos:notation """CDR0000038334"""^^xsd:string ; skos:altLabel """Deskar"""@eng ; skos:definition """An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38334&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38334&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2635\" NCI Thesaurus)"""@eng ; """10953"""^^xsd:string ; """53179-13-8"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C2635"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0936003"""^^xsd:string ; umls:cui """C0298067"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV adenoid cystic carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040714"""^^xsd:string ; skos:altLabel """adenoid cystic carcinoma of the oral cavity, stage IV"""@eng , """oral cavity adenoid cystic carcinoma, stage IV"""@eng , """adenoid cystic carcinoma of the oral cavity, metastatic"""@eng , """oral cavity adenoid cystic carcinoma, metastatic"""@eng , """metastatic adenoid cystic carcinoma of the oral cavity"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3653"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280362"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent squamous cell carcinoma of the lip and oral cavity"""@eng ; skos:notation """CDR0000040715"""^^xsd:string ; skos:altLabel """squamous cell carcinoma of the lip and oral cavity, recurrent"""@eng , """oral cavity and lip squamous cell carcinoma, recurrent"""@eng , """lip and oral cavity squamous cell carcinoma, recurrent"""@eng , """epidermoid carcinoma of the lip and oral cavity, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3654"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280363"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent basal cell carcinoma of the lip"""@eng ; skos:notation """CDR0000040716"""^^xsd:string ; skos:altLabel """lip basal cell carcinoma, recurrent"""@eng , """basal cell carcinoma of the lip, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3655"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280364"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent verrucous carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040717"""^^xsd:string ; skos:altLabel """verrucous carcinoma of the oral cavity, recurrent"""@eng , """oral cavity verrucous carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3656"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280365"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV squamous cell carcinoma of the lip and oral cavity"""@eng ; skos:notation """CDR0000040710"""^^xsd:string ; skos:altLabel """oral cavity and lip squamous cell carcinoma, stage IV"""@eng , """lip and oral cavity squamous cell carcinoma, metastatic"""@eng , """lip and oral cavity squamous cell carcinoma, stage IV"""@eng , """squamous cell carcinoma of the lip and oral cavity, stage IV"""@eng , """metastatic squamous cell carcinoma of the lip and oral cavity"""@eng , """oral cavity and lip squamous cell carcinoma, metastatic"""@eng , """squamous cell carcinoma of the lip and oral cavity, metastatic"""@eng , """epidermoid carcinoma of the lip and oral cavity, stage IV"""@eng , """epidermoid carcinoma of the lip and oral cavity, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3649"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280358"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV basal cell carcinoma of the lip"""@eng ; skos:notation """CDR0000040711"""^^xsd:string ; skos:altLabel """metastatic basal cell carcinoma of the lip"""@eng , """basal cell carcinoma of the lip, stage IV"""@eng , """lip basal cell carcinoma, stage IV"""@eng , """lip basal cell carcinoma, metastatic"""@eng , """basal cell carcinoma of the lip, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3650"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280359"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV verrucous carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040712"""^^xsd:string ; skos:altLabel """verrucous carcinoma of the oral cavity, stage IV"""@eng , """oral cavity verrucous carcinoma, metastatic"""@eng , """metastatic verrucous carcinoma of the oral cavity"""@eng , """verrucous carcinoma of the oral cavity, metastatic"""@eng , """oral cavity verrucous carcinoma, stage IV"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3651"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280360"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV mucoepidermoid carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040713"""^^xsd:string ; skos:altLabel """oral cavity mucoepidermoid carcinoma, stage IV"""@eng , """oral cavity mucoepidermoid carcinoma, metastatic"""@eng , """metastatic mucoepidermoid carcinoma of the oral cavity"""@eng , """mucoepidermoid carcinoma of the oral cavity, stage IV"""@eng , """mucoepidermoid carcinoma of the oral cavity, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3652"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280361"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent mucoepidermoid carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040718"""^^xsd:string ; skos:altLabel """oral cavity mucoepidermoid carcinoma, recurrent"""@eng , """mucoepidermoid carcinoma of the oral cavity, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3657"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280366"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent adenoid cystic carcinoma of the oral cavity"""@eng ; skos:notation """CDR0000040719"""^^xsd:string ; skos:altLabel """adenoid cystic carcinoma of the oral cavity, recurrent"""@eng , """oral cavity adenoid cystic carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """lip and oral cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3658"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280367"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lobular breast carcinoma in situ"""@eng ; skos:notation """CDR0000039848"""^^xsd:string ; skos:altLabel """lobular breast carcinoma, in situ"""@eng , """LCIS of the breast"""@eng , """lobular breast cancer in situ"""@eng , """lobular cancer in situ of the breast"""@eng , """lobular carcinoma in situ"""@eng , """lobular in situ breast carcinoma"""@eng , """in situ lobular breast carcinoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2529"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279563"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """invasive lobular breast carcinoma with predominant in situ component"""@eng ; skos:notation """CDR0000039849"""^^xsd:string ; skos:altLabel """lobular invasive breast carcinoma with predominant in situ component"""@eng ; rdfs:subClassOf ; """2530"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279564"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mucinous ductal breast carcinoma"""@eng ; skos:notation """CDR0000039840"""^^xsd:string ; skos:altLabel """ductal colloid breast carcinoma"""@eng , """ductal mucinous breast carcinoma"""@eng , """colloid ductal breast carcinoma"""@eng ; rdfs:subClassOf ; """2519"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279555"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """invasive ductal breast carcinoma with predominant intraductal component"""@eng ; skos:notation """CDR0000039841"""^^xsd:string ; skos:altLabel """ductal invasive breast carcinoma with predominant intraductal component"""@eng ; rdfs:subClassOf ; """2520"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279556"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenosquamous cell lung cancer"""@eng ; skos:notation """CDR0000039842"""^^xsd:string ; skos:altLabel """epidermoid and adenocarcinoma of the lung, combined"""@eng , """adenocarcinoma and squamous cell of the lung, combined"""@eng , """adenocarcinoma and epidermoid of the lung, combined"""@eng , """non-oat cell lung cancer, adenosquamous cell"""@eng , """squamous cell and adenocarcinoma of the lung, combined"""@eng , """lung cancer, adenosquamous cell"""@eng ; rdfs:subClassOf ; """2521"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279557"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """invasive ductal breast carcinoma"""@eng ; skos:notation """CDR0000039843"""^^xsd:string ; skos:altLabel """ductal invasive breast carcinoma"""@eng ; rdfs:subClassOf ; """2522"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1134719"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """comedo ductal breast carcinoma"""@eng ; skos:notation """CDR0000039844"""^^xsd:string ; skos:altLabel """ductal comedo breast carcinoma"""@eng ; rdfs:subClassOf ; """2523"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279559"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """papillary ductal breast carcinoma"""@eng ; skos:notation """CDR0000039845"""^^xsd:string ; skos:altLabel """ductal papillary breast carcinoma"""@eng ; rdfs:subClassOf ; """2525"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279560"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tubular ductal breast carcinoma"""@eng ; skos:notation """CDR0000039846"""^^xsd:string ; skos:altLabel """ductal tubular breast carcinoma"""@eng ; rdfs:subClassOf ; """2527"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279561"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lobular breast carcinoma"""@eng ; skos:notation """CDR0000039847"""^^xsd:string ; rdfs:subClassOf ; """2528"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206692"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/cyclophosphamide/etoposide/thalidomide"""@eng ; skos:notation """CDR0000257824"""^^xsd:string ; skos:altLabel """CTX/SC-58635/THAL/VP-16"""@eng ; ; ; ; ; """2002-09-11"""^^xsd:string ; """11465"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327787"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/staphylococcal enterotoxin B"""@eng ; skos:notation """CDR0000037995"""^^xsd:string ; skos:altLabel """IL-2/SEB"""@eng ; ; ; """10488"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879542"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/lurtotecan liposome"""@eng ; skos:notation """CDR0000037996"""^^xsd:string ; skos:altLabel """CDDP/NX211"""@eng ; ; ; """10490"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879543"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dexamethasone/mitoxantrone"""@eng ; skos:notation """CDR0000037997"""^^xsd:string ; skos:altLabel """CTX/DHAD/DM"""@eng ; ; ; ; """10492"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879544"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tipifarnib/trastuzumab"""@eng ; skos:notation """CDR0000037990"""^^xsd:string ; skos:altLabel """MOAB HER2/R115777"""@eng ; ; ; """2002-09-11"""^^xsd:string ; """10419"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879522"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000037991"""^^xsd:string ; skos:altLabel """NHL, lymphoblastic stage I childhood"""@eng , """pediatric lymphoblastic non-Hodgkin's lymphoma, stage I"""@eng , """non-Hodgkin's lymphoma, lymphoblastic stage I childhood"""@eng , """lymphoblastic stage I non-Hodgkin's lymphoma, childhood"""@eng , """stage I lymphoblastic childhood lymphoma"""@eng , """childhood non-Hodgkin's lymphoma, lymphoblastic stage I"""@eng , """lymphoma, non-Hodgkin's, lymphoblastic stage I childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1045"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278735"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000037992"""^^xsd:string ; skos:altLabel """lymphoblastic stage II non-Hodgkin's lymphoma, childhood"""@eng , """lymphoma, non-Hodgkin's, lymphoblastic stage II childhood"""@eng , """non-Hodgkin's lymphoma, lymphoblastic stage II childhood"""@eng , """pediatric lymphoblastic non-Hodgkin's lymphoma, stage II"""@eng , """NHL, lymphoblastic stage II childhood"""@eng , """stage II lymphoblastic childhood lymphoma"""@eng , """childhood non-Hodgkin's lymphoma, lymphoblastic stage II"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1046"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278736"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III childhood lymphoblastic lymphoma"""@eng ; skos:notation """CDR0000037993"""^^xsd:string ; skos:altLabel """pediatric lymphoblastic non-Hodgkin's lymphoma, stage III"""@eng , """childhood non-Hodgkin's lymphoma, lymphoblastic stage III"""@eng , """lymphoma, non-Hodgkin's, lymphoblastic stage III childhood"""@eng , """NHL, lymphoblastic stage III childhood"""@eng , """stage III lymphoblastic childhood lymphoma"""@eng , """lymphoblastic stage III non-Hodgkin's lymphoma, childhood"""@eng , """non-Hodgkin's lymphoma, lymphoblastic stage III childhood"""@eng ; rdfs:subClassOf ; """childhood non-Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1047"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278737"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized Ewing's sarcoma/primitive neuroectodermal tumor"""@eng ; skos:notation """CDR0000038713"""^^xsd:string ; skos:altLabel """localized Ewing's sarcoma/PNET"""@eng , """Ewing's sarcoma, localized"""@eng ; rdfs:subClassOf ; """114"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796547"""^^xsd:string ; umls:cui """C0863029"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hormone therapy"""@eng ; skos:notation """CDR0000038712"""^^xsd:string ; skos:altLabel """therapy, hormone"""@eng , """therapy, hormonal"""@eng , """hormonal therapy"""@eng ; ; ; ; rdfs:subClassOf ; ; ; ; ; ; ; ; ; ; ; ; ; """1139"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0279025"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ginger"""@eng ; skos:notation """CDR0000038711"""^^xsd:string ; skos:definition """A rhizome herb isolated from the plant Zingiber officinale with potential antineoplastic activity. Ginger contains a number of different phenolic compounds, some of which have displayed antineoplastic, anti-inflammatory, and antioxidant activities. This agent also exhibits antiemetic properties. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38711&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38711&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2691\" NCI Thesaurus)"""@eng ; """11369"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2691"""^^xsd:string ; umls:cui """C0939895"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/Hypericum perforatum"""@eng ; skos:notation """CDR0000038710"""^^xsd:string ; skos:altLabel """HyP/TXT"""@eng ; ; ; """11368"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134709"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/gefitinib/gemcitabine"""@eng ; skos:notation """CDR0000037998"""^^xsd:string ; skos:altLabel """CDDP/dFdC/ZD 1839"""@eng ; ; ; ; """2002-10-10"""^^xsd:string ; """10493"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879545"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/dexamethasone/mitoxantrone"""@eng ; skos:notation """CDR0000037999"""^^xsd:string ; skos:altLabel """ARA-C/CTX/DHAD/DM"""@eng ; ; ; ; ; """10494"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879546"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous bone marrow transplantation"""@eng ; skos:notation """CDR0000038715"""^^xsd:string ; skos:altLabel """transplantation, autologous bone marrow"""@eng , """ABMT"""@eng , """bone marrow transplantation, autologous"""@eng ; ; rdfs:subClassOf ; """1141"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0194037"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """steroid therapy"""@eng ; skos:notation """CDR0000038714"""^^xsd:string ; skos:altLabel """therapy, steroid"""@eng , """corticosteroid therapy"""@eng ; ; rdfs:subClassOf ; """1140"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0149783"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thrombolytic agent"""@eng ; skos:notation """CDR0000040439"""^^xsd:string ; rdfs:subClassOf ; """3308"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0016018"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """skin and mucous membrane antifungal agent"""@eng ; skos:notation """CDR0000040438"""^^xsd:string ; rdfs:subClassOf ; """3307"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280086"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amino acid injection"""@eng ; skos:notation """CDR0000040431"""^^xsd:string ; rdfs:subClassOf ; """3300"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280081"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III gastric cancer"""@eng ; skos:notation """CDR0000040430"""^^xsd:string ; skos:altLabel """stomach cancer, stage III"""@eng , """gastric cancer, stage III"""@eng ; rdfs:subClassOf ; """gastric cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """33"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278497"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diuretic"""@eng ; skos:notation """CDR0000040433"""^^xsd:string ; rdfs:subClassOf ; """3302"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0012798"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """caloric agent"""@eng ; skos:notation """CDR0000040432"""^^xsd:string ; rdfs:subClassOf ; """3301"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280082"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """unclassified therapeutic agent"""@eng ; skos:notation """CDR0000040435"""^^xsd:string ; """3304"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280084"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """electrolytic, caloric, and water balance agent"""@eng ; skos:notation """CDR0000040434"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3303"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280083"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cell stimulant and proliferant"""@eng ; skos:notation """CDR0000040437"""^^xsd:string ; rdfs:subClassOf ; """3306"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280085"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """uricosuric agent"""@eng ; skos:notation """CDR0000040436"""^^xsd:string ; rdfs:subClassOf ; """3305"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0041983"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexamethasone/epoetin alfa"""@eng ; skos:notation """CDR0000304395"""^^xsd:string ; skos:altLabel """DM/EPO"""@eng ; ; ; """2003-04-23"""^^xsd:string ; """2003-04-21"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327965"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anorexia"""@eng ; skos:notation """CDR0000041397"""^^xsd:string ; rdfs:subClassOf ; """4468"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0003123"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """malnutrition"""@eng ; skos:notation """CDR0000041396"""^^xsd:string ; rdfs:subClassOf ; """4467"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; """2006-03-03"""^^xsd:string ; umls:cui """C0162429"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nausea and vomiting"""@eng ; skos:notation """CDR0000041395"""^^xsd:string ; skos:altLabel """vomiting and nausea"""@eng , """anticipatory nausea and vomiting"""@eng ; rdfs:subClassOf ; """4466"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0027498"""^^xsd:string ; umls:cui """C0279036"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """long-term effects secondary to cancer therapy in children"""@eng ; skos:notation """CDR0000041394"""^^xsd:string ; skos:altLabel """long term effects secondary to cancer therapy in children"""@eng , """cancer therapy in children, long-term effects secondary to"""@eng , """cancer therapy in children, long term effects secondary to"""@eng , """effects secondary to cancer therapy in children, long term"""@eng , """effects secondary to cancer therapy in children, long-term"""@eng ; rdfs:subClassOf ; """4465"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0280954"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """infection"""@eng ; skos:notation """CDR0000041393"""^^xsd:string ; rdfs:subClassOf ; """4464"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C3714514"""^^xsd:string ; umls:tui """T046"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypoglycemia"""@eng ; skos:notation """CDR0000041392"""^^xsd:string ; rdfs:subClassOf ; """4463"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0020615"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hypercalcemia"""@eng ; skos:notation """CDR0000041391"""^^xsd:string ; rdfs:subClassOf ; """4462"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0020437"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fatigue"""@eng ; skos:notation """CDR0000041390"""^^xsd:string ; rdfs:subClassOf ; """4461"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0015672"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pain"""@eng ; skos:notation """CDR0000041399"""^^xsd:string ; rdfs:subClassOf ; """4470"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0030193"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cachexia"""@eng ; skos:notation """CDR0000041398"""^^xsd:string ; rdfs:subClassOf ; """4469"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0006625"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """risedronate"""@eng ; skos:notation """CDR0000256445"""^^xsd:string ; skos:altLabel """Risedronate Sodium"""@eng , """RISE"""@eng , """Actonel"""@eng , """NE-58095"""@eng ; skos:definition """A synthetic pyridinyl bisphosphonate agent. Risedronate binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256445&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256445&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1528\" NCI Thesaurus)"""@eng ; ; ; """11395"""^^xsd:string ; """2006-05-05"""^^xsd:string ; """C1528"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """115436-72-1"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0246719"""^^xsd:string ; umls:cui """C0068472"""^^xsd:string ; umls:cui """C1996201"""^^xsd:string ; umls:cui """C0166025"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cephalosporin agent"""@eng ; skos:notation """CDR0000040386"""^^xsd:string ; rdfs:subClassOf ; """3247"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280048"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium carbonate/cholecalciferol/conjugated estrogens"""@eng ; skos:notation """CDR0000256447"""^^xsd:string ; skos:altLabel """CACO3/EST/VIT-D"""@eng ; ; ; ; """2002-07-16"""^^xsd:string ; """11397"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327747"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antihelminthic agent"""@eng ; skos:notation """CDR0000040384"""^^xsd:string ; rdfs:subClassOf ; """2002-10-30"""^^xsd:string ; """3245"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003158"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-infective agent"""@eng ; skos:notation """CDR0000040383"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3244"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003204"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antihistamine"""@eng ; skos:notation """CDR0000040382"""^^xsd:string ; """3243"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0003360"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hormone and synthetic substitute"""@eng ; skos:notation """CDR0000040381"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """3242"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280046"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """podophyllin derivative"""@eng ; skos:notation """CDR0000040380"""^^xsd:string ; rdfs:subClassOf ; """3241"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280045"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/sirolimus/tacrolimus"""@eng ; skos:notation """CDR0000380452"""^^xsd:string ; skos:altLabel """FK506/MTX/SLM"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541585"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """modafinil"""@eng ; skos:notation """CDR0000256449"""^^xsd:string ; skos:altLabel """Provigil"""@eng ; skos:definition """A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine. This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256449&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256449&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26661\" NCI Thesaurus)"""@eng ; """11399"""^^xsd:string ; """C26661"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-05-10"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0066677"""^^xsd:string ; umls:cui """C0722882"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcium carbonate/cholecalciferol/conjugated estrogens/risedronate"""@eng ; skos:notation """CDR0000256448"""^^xsd:string ; skos:altLabel """CACO3/EST/RISE/VIT-D"""@eng ; ; ; ; ; """2002-07-16"""^^xsd:string ; """11398"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327748"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antibiotic with bacteriostatic action"""@eng ; skos:notation """CDR0000040389"""^^xsd:string ; rdfs:subClassOf ; """3250"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280050"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """extended spectrum penicillin"""@eng ; skos:notation """CDR0000040388"""^^xsd:string ; """3249"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0280049"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/leucovorin calcium/methotrexate"""@eng ; skos:notation """CDR0000270386"""^^xsd:string ; skos:altLabel """CF/CTX/MTX/VP-16"""@eng ; ; ; ; ; """2003-01-26"""^^xsd:string ; """2003-01-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327867"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """calcitriol/zoledronate"""@eng ; skos:notation """CDR0000256190"""^^xsd:string ; skos:altLabel """CALTROL/ZOLE"""@eng ; ; ; """2002-07-16"""^^xsd:string ; """11370"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327735"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/doxorubicin/oblimersen"""@eng ; skos:notation """CDR0000315653"""^^xsd:string ; skos:altLabel """DOX/G3139/TXT"""@eng ; ; ; ; """2003-06-23"""^^xsd:string ; """2003-06-13"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327995"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/carboplatin"""@eng ; skos:notation """CDR0000040857"""^^xsd:string ; skos:altLabel """CBDCA/WR-2721"""@eng ; ; ; """3892"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """poor prognosis metastatic gestational trophoblastic tumor"""@eng ; skos:notation """CDR0000040856"""^^xsd:string ; skos:altLabel """trophoblastic tumor, metastatic, poor prognosis"""@eng , """gestational trophoblastic tumor, poor prognosis, metastatic"""@eng , """poor prognosis metastatic GTT"""@eng , """metastatic GTT, poor prognosis"""@eng , """GTT, metastatic, poor prognosis"""@eng , """gestational trophoblastic tumor, metastatic, poor prognosis"""@eng , """GTT, poor prognosis, metastatic"""@eng ; rdfs:subClassOf ; """gestational trophoblastic tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3891"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280481"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cetuximab/irinotecan"""@eng ; skos:notation """CDR0000351910"""^^xsd:string ; skos:altLabel """CPT-11/MOAB C225/MOAB VEGF"""@eng ; ; ; ; """2004-01-23"""^^xsd:string ; """2004-01-05"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328137"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood oligodendroglioma"""@eng ; skos:notation """CDR0000040850"""^^xsd:string ; skos:altLabel """pediatric oligodendroglioma"""@eng , """pediatric brain tumor, oligodendroglioma"""@eng , """oligodendroglioma, pediatric"""@eng , """childhood CNS tumor, oligodendroglioma"""@eng , """central nervous system tumor, oligodendroglioma, childhood"""@eng , """childhood brain tumor, oligodendroglioma"""@eng , """CNS tumor, childhood oligodendroglioma"""@eng , """pediatric CNS tumor, oligodendroglioma"""@eng , """CNS tumor, oligodendroglioma, childhood"""@eng , """brain tumor, childhood oligodendroglioma"""@eng , """CNS tumor, pediatric oligodendroglioma"""@eng , """oligodendroglioma, childhood"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3883"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280475"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/triacetyluridine"""@eng ; skos:notation """CDR0000037820"""^^xsd:string ; skos:altLabel """CF/5-FU/TAU"""@eng ; ; ; ; """10210"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879400"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/paclitaxel/ZD6474"""@eng ; skos:notation """CDR0000350208"""^^xsd:string ; skos:altLabel """CBDCA/TAX/ZD-6474"""@eng ; ; ; ; """2003-12-23"""^^xsd:string ; """2003-12-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328130"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lerisetron"""@eng ; skos:notation """CDR0000037821"""^^xsd:string ; """10211"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0758799"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/leucovorin calcium"""@eng ; skos:notation """CDR0000037822"""^^xsd:string ; skos:altLabel """ARA-C/CF"""@eng ; ; ; """10212"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879401"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sildenafil"""@eng ; skos:notation """CDR0000269137"""^^xsd:string ; skos:altLabel """Viagra"""@eng , """Sildenafil Citrate"""@eng ; skos:definition """The citrate salt of a pyrazolopyrimidinone derivative structurally related to zaprinast. Sildenafil selectively inhibits cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase, resulting in vasodilation in the corpus cavernosum of the penis and penile erection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269137&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269137&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26670\" NCI Thesaurus)"""@eng ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26670"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0663448"""^^xsd:string ; umls:cui """C0724693"""^^xsd:string ; umls:cui """C0529793"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """COL18A1"""@eng ; skos:notation """CDR0000037823"""^^xsd:string ; """10213"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """C18046"""^^xsd:string ; umls:cui """C0251815"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """marijuana/morphine"""@eng ; skos:notation """CDR0000269132"""^^xsd:string ; skos:altLabel """MARI/MORPH"""@eng ; ; ; """2002-11-24"""^^xsd:string ; """2002-11-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327843"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """marijuana"""@eng ; skos:notation """CDR0000269131"""^^xsd:string ; skos:altLabel """cannabis"""@eng ; skos:definition """Any part of, or extract from, the female hemp plant Cannabis sativa. Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties. This agent has potential use for treating cancer pain and cachexia. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269131&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269131&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26659\" NCI Thesaurus)"""@eng ; ; """2002-11-24"""^^xsd:string ; """2006-12-19"""^^xsd:string ; """134452"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26659"""^^xsd:string ; umls:cui """C0024808"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hexyl 5-aminolevulinate"""@eng ; skos:notation """CDR0000269130"""^^xsd:string ; skos:altLabel """P-1206"""@eng , """HAL"""@eng , """hexaminolevulinate"""@eng , """HexvixR"""@eng , """Hexvix"""@eng ; skos:definition """The hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, hexyl 5-aminolevulinate induces the endogenous production of the photosensitizer protoporphyrin IX (PPIX) which accumulates selectively in tumor tissue. When exposed to specific wavelengths of light, PPIX is activated and, depending on the wavelength and/or intensity of light, either fluoresces, thereby allowing tumor imaging, or induces tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269130&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269130&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26654\" NCI Thesaurus)"""@eng ; """2002-11-24"""^^xsd:string ; """2006-07-10"""^^xsd:string ; """C26654"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1327842"""^^xsd:string ; umls:cui """C1512427"""^^xsd:string ; umls:cui """C1328694"""^^xsd:string ; umls:cui """C1327841"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """captopril"""@eng ; skos:notation """CDR0000037824"""^^xsd:string ; skos:altLabel """Capoten"""@eng , """CPT"""@eng , """(S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline"""@eng ; skos:definition """A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion. This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37824&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37824&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C340\" NCI Thesaurus)"""@eng ; ; """10214"""^^xsd:string ; """C340"""^^xsd:string ; """62571-86-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-30"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591224"""^^xsd:string ; umls:cui """C0006938"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acetyldinaline"""@eng ; skos:notation """CDR0000037825"""^^xsd:string ; skos:altLabel """CI-994"""@eng , """CI 994"""@eng , """CI994"""@eng ; ; """C2202"""^^xsd:string ; """10215"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-12-04"""^^xsd:string ; umls:cui """C0217598"""^^xsd:string ; umls:cui """C0217595"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood acute myeloid leukemia and other myeloid malignancies"""@eng ; skos:notation """CDR0000039079"""^^xsd:string ; skos:altLabel """pediatric leukemia, acute myeloid untreated"""@eng , """untreated childhood AML"""@eng , """childhood leukemia, acute myeloid untreated"""@eng , """childhood acute nonlymphocytic leukemia, untreated"""@eng , """acute nonlymphocytic leukemia, untreated childhood"""@eng , """pediatric acute myeloid leukemia, untreated"""@eng , """AML, untreated childhood"""@eng , """myeloid leukemia, untreated childhood acute"""@eng , """childhood leukemia, acute nonlymphocytic untreated"""@eng , """nonlymphocytic leukemia, untreated childhood acute"""@eng , """childhood AML, untreated"""@eng , """untreated pediatric acute myeloid leukemia"""@eng , """leukemia, untreated childhood acute nonlymphocytic"""@eng , """pediatric leukemia, acute nonlymphocytic untreated"""@eng , """untreated pediatric acute nonlymphocytic leukemia"""@eng , """childhood acute myeloid leukemia, untreated"""@eng , """ANLL, untreated childhood"""@eng , """untreated childhood acute nonlymphocytic leukemia"""@eng , """ANLL, untreated pediatric"""@eng , """acute myeloid leukemia, untreated childhood"""@eng , """pediatric acute nonlymphocytic leukemia, untreated"""@eng , """AML, untreated pediatric"""@eng , """leukemia, untreated childhood acute myeloid"""@eng ; rdfs:subClassOf ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1665"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279090"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """neoplastic syndrome"""@eng ; skos:notation """CDR0000475629"""^^xsd:string ; skos:altLabel """Neoplastic syndrome"""@eng ; rdfs:subClassOf ; """Cancer diagnosis"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """2006-03-24"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; umls:cui """C1882062"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated adult acute myeloid leukemia"""@eng ; skos:notation """CDR0000039078"""^^xsd:string ; skos:altLabel """ANLL, untreated adult"""@eng , """leukemia, untreated adult acute myeloid"""@eng , """adult acute myelogenous leukemia, untreated"""@eng , """AML, untreated adult"""@eng , """untreated adult AML"""@eng , """adult acute myeloid leukemia, untreated"""@eng , """leukemia, untreated adult acute myelogenous"""@eng , """acute myelogenous leukemia, adult untreated"""@eng , """adult acute nonlymphocytic leukemia, untreated"""@eng , """untreated adult acute nonlymphocytic leukemia"""@eng , """myelogenous leukemia, untreated adult acute"""@eng , """leukemia, untreated adult acute nonlymphocytic"""@eng , """acute nonlymphocytic leukemia, adult untreated"""@eng , """untreated adult ANLL"""@eng , """adult leukemia, acute myelogenous untreated"""@eng , """nonlymphocytic leukemia, untreated adult acute"""@eng , """myeloid leukemia, untreated adult acute"""@eng , """untreated adult acute myelogenous leukemia"""@eng , """adult leukemia, acute myeloid untreated"""@eng , """acute myeloid leukemia, adult untreated"""@eng , """adult AML, untreated"""@eng , """adult leukemia, acute nonlymphocytic untreated"""@eng ; rdfs:subClassOf ; """adult acute myeloid leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1664"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279089"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melanoma helper peptide vaccine/Montanide ISA-51/multi-epitope melanoma peptide vaccine"""@eng ; skos:notation """CDR0000436055"""^^xsd:string ; skos:altLabel """ISA-51/MHP VAC/MULTI-EP MP VAC"""@eng ; ; ; """2005-06-25"""^^xsd:string ; """2005-06-06"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831640"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """blastic phase chronic myelogenous leukemia"""@eng ; skos:notation """CDR0000039071"""^^xsd:string ; skos:altLabel """myelogenous leukemia, blastic phase chronic"""@eng , """chronic myelocytic leukemia, blastic phase"""@eng , """chronic myelogenous leukemia, blastic phase"""@eng , """granulocytic leukemia, blastic phase chronic"""@eng , """blastic phase CML"""@eng , """CGL, blastic phase"""@eng , """CML, blastic phase"""@eng , """leukemia, blastic phase chronic myelogenous"""@eng , """myelocytic leukemia, blastic phase chronic"""@eng , """chronic granulocytic leukemia, blastic phase"""@eng , """blastic phase CGL"""@eng ; rdfs:subClassOf ; """chronic myeloproliferative disorders"""^^xsd:string ; """chronic myelogenous leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1657"""^^xsd:string ; """2004-12-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0005699"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/vincristine"""@eng ; skos:notation """CDR0000043531"""^^xsd:string ; skos:altLabel """CPT-11/VCR"""@eng ; ; ; """8786"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796694"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vatalanib"""@eng ; skos:notation """CDR0000043530"""^^xsd:string ; skos:altLabel """PTK787/ZK-222584"""@eng , """PTK787/ZK222584"""@eng , """PTK787"""@eng , """PTK787/ZK 222584"""@eng , """1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)"""@eng , """CGP-79787"""@eng , """1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate"""@eng , """PTK-787"""@eng , """ZK 222584"""@eng , """CGP79787D"""@eng ; skos:definition """An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43530&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43530&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1868\" NCI Thesaurus)"""@eng ; ; ; ; ; """8779"""^^xsd:string ; """212142-18-2"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1868"""^^xsd:string ; """2006-09-28"""^^xsd:string ; """719335"""^^xsd:string ; umls:cui """C2700408"""^^xsd:string ; umls:cui """C1524078"""^^xsd:string ; umls:cui """C0912413"""^^xsd:string ; umls:cui """C1533714"""^^xsd:string ; umls:cui """C0912586"""^^xsd:string ; umls:cui """C0796692"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indole-3-carbinol"""@eng ; skos:notation """CDR0000038058"""^^xsd:string ; skos:altLabel """I3C"""@eng ; skos:definition """A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38058&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38058&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1135\" NCI Thesaurus)"""@eng ; """10594"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C1135"""^^xsd:string ; umls:cui """C0063491"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rituximab/vinorelbine"""@eng ; skos:notation """CDR0000043532"""^^xsd:string ; skos:altLabel """MOAB IDEC-C2B8/VNB"""@eng ; ; ; """8787"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796695"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RevM10/polAS gene"""@eng ; skos:notation """CDR0000043535"""^^xsd:string ; """8790"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796698"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """RevM10 gene"""@eng ; skos:notation """CDR0000043534"""^^xsd:string ; skos:definition """RevM10 is a dominant-negative mutant of HIV-1 Rev gene, which encodes a RNA-binding protein involving in nuclear trafficking of unspliced viral mRNAs. Due to the fact that Rev is essential for HIV-1 replication makes it an attractive target for antiviral approaches. Based on the notion of intracellular immunization, in vitro studies that introducing RevM10 gene into stem cells have demonstrated its ability to combat HIV-1 infection in human hematopoietic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43534&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43534&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C18318\" NCI Thesaurus)"""@eng ; """8789"""^^xsd:string ; """C18318"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796697"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexrazoxane/doxorubicin/ifosfamide"""@eng ; skos:notation """CDR0000043537"""^^xsd:string ; skos:altLabel """ADR-529/DOX/IFF"""@eng ; ; ; ; """8792"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796700"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dexrazoxane/doxorubicin"""@eng ; skos:notation """CDR0000043536"""^^xsd:string ; skos:altLabel """ADR-529/CDDP/DOX"""@eng ; ; ; ; """8791"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796699"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/ranpirnase"""@eng ; skos:notation """CDR0000043539"""^^xsd:string ; skos:altLabel """DOX/P30"""@eng ; ; ; """2003-08-12"""^^xsd:string ; """8794"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0879256"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epidemic Kaposi's sarcoma"""@eng ; skos:notation """CDR0000039075"""^^xsd:string ; skos:altLabel """acquired immune deficiency syndrome related Kaposi's sarcoma"""@eng , """AIDS-related Kaposi's sarcoma"""@eng , """sarcoma, Kaposi's, AIDS related"""@eng , """Kaposi's sarcoma, AIDS related"""@eng , """sarcoma, multiple hemorrhagic, AIDS related"""@eng , """AIDS-associated Kaposi's sarcoma"""@eng , """Kaposi's sarcoma, epidemic"""@eng , """AIDS related multiple hemorrhagic sarcoma"""@eng , """AIDS related Kaposi's sarcoma"""@eng , """multiple hemorrhagic sarcoma, AIDS related"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Kaposi's sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1661"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0276535"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunosuppressive treatment related Kaposi's sarcoma"""@eng ; skos:notation """CDR0000039074"""^^xsd:string ; skos:altLabel """multiple hemorrhagic sarcoma, immunosuppressive treatment related"""@eng , """sarcoma, multiple hemorrhagic, immunosuppressive treatment related"""@eng , """sarcoma, immunosuppressive treatment related Kaposi's"""@eng , """sarcoma, Kaposi's, immunosuppressive treatment related"""@eng , """Kaposi's sarcoma, immunosuppressive treatment related"""@eng ; rdfs:subClassOf ; """Kaposi's sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1660"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279085"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent Kaposi's sarcoma"""@eng ; skos:notation """CDR0000039076"""^^xsd:string ; skos:altLabel """Kaposi's sarcoma, recurrent"""@eng , """multiple hemorrhagic sarcoma, recurrent"""@eng , """sarcoma, Kaposi's, recurrent"""@eng , """recurrent multiple hemorrhagic sarcoma"""@eng , """sarcoma, multiple hemorrhagic, recurrent"""@eng ; rdfs:subClassOf ; """Kaposi's sarcoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1662"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279087"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dactinomycin/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040949"""^^xsd:string ; skos:altLabel """VACAR"""@eng , """VACA"""@eng , """CY-VA-DACT"""@eng , """CTX/DACT/DOX/VCR"""@eng ; ; ; ; ; """3988"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0077966"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/lomustine/methotrexate"""@eng ; skos:notation """CDR0000040948"""^^xsd:string ; skos:altLabel """CCM"""@eng , """CMCC"""@eng , """CCNU/CTX/MTX"""@eng , """CMC"""@eng ; ; ; ; """3987"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0065772"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000040941"""^^xsd:string ; skos:altLabel """CFPMV"""@eng , """VPCMF"""@eng , """CTX/5-FU/MTX/PRED/VCR"""@eng , """CMFVP"""@eng ; ; ; ; ; ; """3980"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0055987"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/vincristine"""@eng ; skos:notation """CDR0000040940"""^^xsd:string ; skos:altLabel """EPOC"""@eng , """VPC-E"""@eng , """CDDP/CTX/VCR/VP-16"""@eng , """COPE"""@eng ; ; ; ; ; """3979"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280558"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040943"""^^xsd:string ; skos:altLabel """CTX/5-FU/MTX/VCR"""@eng , """CMFV"""@eng , """COMF"""@eng ; ; ; ; ; """3982"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056159"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000040942"""^^xsd:string ; skos:altLabel """PATCO"""@eng , """T-COAP"""@eng , """ARA-C/CTX/PRED/TG/VCR"""@eng ; ; ; ; ; ; """3981"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280560"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/vincristine"""@eng ; skos:notation """CDR0000040945"""^^xsd:string ; skos:altLabel """CTX/5-FU/VCR"""@eng , """VCF"""@eng , """COF"""@eng ; ; ; ; """3984"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056079"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/cytarabine/prednisone/vincristine"""@eng ; skos:notation """CDR0000040944"""^^xsd:string ; skos:altLabel """ARA-C/CTX/PRED/VCR"""@eng , """VPCA"""@eng , """COAP"""@eng ; ; ; ; ; """3983"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056019"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dacarbazine/vincristine"""@eng ; skos:notation """CDR0000040947"""^^xsd:string ; skos:altLabel """CDV"""@eng , """COD"""@eng , """CTX/DTIC/VCR"""@eng ; ; ; ; """3986"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0056632"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/dacarbazine/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040946"""^^xsd:string ; skos:altLabel """CY-VA-DIC"""@eng , """VAdrC-D"""@eng , """CYVADIC"""@eng , """CTX/DOX/DTIC/VCR"""@eng ; ; ; ; ; """3985"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057010"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/methylprednisolone/pixantrone/rituximab"""@eng ; skos:notation """CDR0000322250"""^^xsd:string ; skos:altLabel """ARA-C/BBR 2778/CDDP/MePRDL/MOAB IDEC-C2B8"""@eng ; ; ; ; ; ; """2003-07-26"""^^xsd:string ; """2003-07-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328021"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """buthionine sulfoximine"""@eng ; skos:notation """CDR0000039123"""^^xsd:string ; skos:altLabel """d,l-Buthionine-s,r-sulfoximine"""@eng , """Buthionine Sulphoximine"""@eng , """2-Amino-4-(S-butylsulfonimidoyl) Butanoic Acid"""@eng , """S-(n-Butyl)homocysteine Sulfoximine"""@eng , """L-Buthionine Sulfoximine"""@eng , """Butanoic Acid, 2-Amino-4-(S-butylsulfonimidoyl)-"""@eng , """BSO"""@eng , """S-(3-Amino-3-carboxypropyl)-S-butylsulfoximine"""@eng ; skos:definition """A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthetase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39123&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39123&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1029\" NCI Thesaurus)"""@eng ; ; """1713"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """32981"""^^xsd:string ; """326231"""^^xsd:string ; """2006-07-27"""^^xsd:string ; """C1029"""^^xsd:string ; """5072-26-4"""^^xsd:string ; umls:cui """C0054252"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/octreotide"""@eng ; skos:notation """CDR0000039122"""^^xsd:string ; skos:altLabel """CDDP/DOX/SSTN"""@eng ; ; ; ; """1712"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279127"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """medroxyprogesterone/tamoxifen"""@eng ; skos:notation """CDR0000039121"""^^xsd:string ; skos:altLabel """MPA/TMX"""@eng ; ; ; """1711"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279126"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/dacarbazine/doxorubicin/etoposide/vincristine"""@eng ; skos:notation """CDR0000039120"""^^xsd:string ; skos:altLabel """CDDP/CTX/DOX/DTIC/VCR/VP-16"""@eng ; ; ; ; ; ; ; """1710"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279125"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prior radiation therapy"""@eng ; skos:notation """CDR0000039127"""^^xsd:string ; """1741"""^^xsd:string ; umls:cui """C0279134"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """central nervous system involvement/metastases"""@eng ; skos:notation """CDR0000039126"""^^xsd:string ; skos:altLabel """metastases, CNS"""@eng , """CNS involvement/metastases"""@eng , """involvement, CNS"""@eng , """CNS metastases"""@eng ; """1722"""^^xsd:string ; umls:cui """C0686377"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/octreotide/streptozocin"""@eng ; skos:notation """CDR0000039125"""^^xsd:string ; skos:altLabel """FUDR/SSTN/SZC"""@eng ; ; ; ; """1715"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279129"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/streptozocin"""@eng ; skos:notation """CDR0000039124"""^^xsd:string ; skos:altLabel """FUDR/SZC"""@eng ; ; ; """1714"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279128"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """acetaminophen"""@eng ; skos:notation """CDR0000039129"""^^xsd:string ; skos:altLabel """Tylenol"""@eng , """paracetamol"""@eng , """ACMP"""@eng , """4-hydroxyacetanilide"""@eng ; ; ; """1750"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C198"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0000970"""^^xsd:string ; umls:cui """C0699142"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flurocitabine"""@eng ; skos:notation """CDR0000039128"""^^xsd:string ; skos:altLabel """AAFC"""@eng ; """1749"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0049176"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/dexamethasone/etoposide/gemcitabine"""@eng ; skos:notation """CDR0000043140"""^^xsd:string ; skos:altLabel """CDDP/CTX/dFdC/DM/VP-16"""@eng ; ; ; ; ; ; """7581"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796323"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """irinotecan/oxaliplatin"""@eng ; skos:notation """CDR0000043141"""^^xsd:string ; skos:altLabel """CPT-11/L-OHP"""@eng ; ; ; """7582"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796324"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """polifeprosan 20 with carmustine implant"""@eng ; skos:notation """CDR0000043142"""^^xsd:string ; skos:altLabel """Gliadel wafer"""@eng , """Gliadel"""@eng ; skos:definition """A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine. As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43142&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43142&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2487\" NCI Thesaurus)"""@eng ; ; ; """7583"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """714372"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """C2487"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0720676"""^^xsd:string ; umls:cui """C1171407"""^^xsd:string ; umls:cui """C0796325"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T200"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/floxuridine/paclitaxel"""@eng ; skos:notation """CDR0000043143"""^^xsd:string ; skos:altLabel """CDDP/FUDR/TAX"""@eng ; ; ; ; """7584"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796326"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """L-778,123"""@eng ; skos:notation """CDR0000043144"""^^xsd:string ; skos:altLabel """L 778,123"""@eng , """L778,123"""@eng , """L-778123"""@eng ; ; """2003-10-28"""^^xsd:string ; """7585"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796327"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/dexamethasone/etoposide"""@eng ; skos:notation """CDR0000043145"""^^xsd:string ; skos:altLabel """CDDP/CTX/DM/VP-16"""@eng ; ; ; ; ; """7586"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796328"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 monoclonal antibody 81C6"""@eng ; skos:notation """CDR0000043146"""^^xsd:string ; skos:altLabel """I 131 Monoclonal Antibody 81C6"""@eng , """iodine I 131 MOAB 81C6"""@eng , """81C6"""@eng ; skos:definition """A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic properties. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43146&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43146&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2488\" NCI Thesaurus)"""@eng ; """7587"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2488"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C0796330"""^^xsd:string ; umls:cui """C0796329"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 123 monoclonal antibody 81C6"""@eng ; skos:notation """CDR0000043147"""^^xsd:string ; skos:altLabel """81C6"""@eng , """iodine I 123 MOAB 81C6"""@eng ; """7588"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796330"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """astatine At 211 monoclonal antibody 81C6"""@eng ; skos:notation """CDR0000043148"""^^xsd:string ; skos:altLabel """astatine At 211 MOAB 81C6"""@eng ; """7589"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796331"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000043149"""^^xsd:string ; skos:altLabel """rhabdomyosarcoma, childhood"""@eng , """sarcoma, childhood rhabdomyosarcoma"""@eng , """Rhabdomyosarcoma, child"""@eng , """pediatric rhabdomyosarcoma"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """759"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0220611"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CC-401"""@eng ; skos:notation """CDR0000453550"""^^xsd:string ; skos:definition """A second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. Based on the chemistry of SP600125, another anthrapyrazolone inhibitor of JNK, CC-401 competitively binds the ATP binding site of JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of transcription factor c-Jun; decreased transcription activity of c-Jun; and a variety of cellular effects including decreased cellular proliferation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453550&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453550&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49095\" NCI Thesaurus)"""@eng ; """C49095"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-10-24"""^^xsd:string ; """2006-07-31"""^^xsd:string ; umls:cui """C1707079"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alvimopan"""@eng ; skos:notation """CDR0000453551"""^^xsd:string ; skos:altLabel """Entereg"""@eng , """LY-246376"""@eng , """ADL8-2698"""@eng ; skos:definition """A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons andthe immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opiod-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453551&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=453551&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49096\" NCI Thesaurus)"""@eng ; """C49096"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2005-10-24"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1706785"""^^xsd:string ; umls:cui """C0963856"""^^xsd:string ; umls:cui """C1508751"""^^xsd:string ; umls:cui """C1508750"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG-162"""@eng ; skos:notation """CDR0000390339"""^^xsd:string ; """2006-10-09"""^^xsd:string ; """2004-09-25"""^^xsd:string ; umls:cui """C1530450"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """natural killer cell therapy"""@eng ; skos:notation """CDR0000474286"""^^xsd:string ; ; rdfs:subClassOf ; """Cancer therapy modality"""^^xsd:string ; """2006-03-16"""^^xsd:string ; """2006-03-17"""^^xsd:string ; umls:cui """C1831784"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """paclitaxel/R101933"""@eng ; skos:notation """CDR0000038528"""^^xsd:string ; skos:altLabel """R-101933/TAX"""@eng ; ; ; """11151"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134557"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Chinese herbs"""@eng ; skos:notation """CDR0000038529"""^^xsd:string ; skos:altLabel """CHIHERB"""@eng , """herbs, Chinese"""@eng ; ; """11152"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134558"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/ovarian cancer peptide vaccine/sargramostim/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000436113"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/OC-PEP-VAC/TET TOX PEP VAC"""@eng ; ; ; ; """2005-06-07"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-06-25"""^^xsd:string ; umls:cui """C1831644"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bortezomib/carboplatin"""@eng ; skos:notation """CDR0000038525"""^^xsd:string ; skos:altLabel """CBDCA/PS-341"""@eng ; ; ; """2002-11-19"""^^xsd:string ; """11148"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134555"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laniquidar"""@eng ; skos:notation """CDR0000038526"""^^xsd:string ; skos:altLabel """R101933"""@eng , """R-101933"""@eng ; ; ; """11149"""^^xsd:string ; """C28698"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-11-22"""^^xsd:string ; umls:cui """C3495495"""^^xsd:string ; umls:cui """C0916124"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/R101933"""@eng ; skos:notation """CDR0000038527"""^^xsd:string ; skos:altLabel """R-101933/TXT"""@eng ; ; ; """11150"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134556"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/filgrastim/prednisone/rituximab/vincristine"""@eng ; skos:notation """CDR0000038520"""^^xsd:string ; skos:altLabel """CTX/DOX/G-CSF/MOAB IDEC-C2B8/PRED/VCR"""@eng ; ; ; ; ; ; ; """11143"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134550"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/gemcitabine"""@eng ; skos:notation """CDR0000038521"""^^xsd:string ; skos:altLabel """dFdC/MOAB VEGF"""@eng ; ; ; """11144"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134551"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/gemtuzumab ozogamicin/mitoxantrone"""@eng ; skos:notation """CDR0000038522"""^^xsd:string ; skos:altLabel """ARA-C/CMA-676/DHAD"""@eng ; ; ; ; """11145"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134552"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """asparaginase/cytarabine/gemtuzumab ozogamicin"""@eng ; skos:notation """CDR0000038523"""^^xsd:string ; skos:altLabel """ARA-C/ASP/CMA-676"""@eng ; ; ; ; """11146"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134553"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biopsies"""@eng ; skos:notation """CDR0000042815"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """6614"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0005558"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """laparoscopy"""@eng ; skos:notation """CDR0000042814"""^^xsd:string ; rdfs:subClassOf ; """6613"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0031150"""^^xsd:string ; umls:tui """T058"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ultrasonography"""@eng ; skos:notation """CDR0000042817"""^^xsd:string ; rdfs:subClassOf ; """6616"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0041618"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endoscopic biopsy"""@eng ; skos:notation """CDR0000042816"""^^xsd:string ; rdfs:subClassOf ; """6615"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0184980"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hepatitis A vaccine"""@eng ; skos:notation """CDR0000442110"""^^xsd:string ; skos:altLabel """Vaqta"""@eng , """Havrix"""@eng ; skos:definition """An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=442110&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=442110&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29090\" NCI Thesaurus)"""@eng ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """C29090"""^^xsd:string ; """2005-08-05"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-25"""^^xsd:string ; umls:cui """C0700881"""^^xsd:string ; umls:cui """C0379473"""^^xsd:string ; umls:cui """C0795623"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim plasmid DNA pancreatic tumor cell vaccine"""@eng ; skos:notation """CDR0000042810"""^^xsd:string ; skos:altLabel """GM-CSF plasmid DNA pancreatic tumor cell vaccine"""@eng ; skos:definition """A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42810&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42810&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2445\" NCI Thesaurus)"""@eng ; """6609"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2445"""^^xsd:string ; umls:cui """C0677758"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """docetaxel/estramustine"""@eng ; skos:notation """CDR0000042813"""^^xsd:string ; skos:altLabel """EM/TXT"""@eng ; ; ; """6612"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677761"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amifostine/ciprofloxacin/dexamethasone/pentoxifylline"""@eng ; skos:notation """CDR0000042812"""^^xsd:string ; skos:altLabel """CPFX/DM/PTX/WR-2721"""@eng ; ; ; ; ; """6611"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677760"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sentinel node biopsy"""@eng ; skos:notation """CDR0000042819"""^^xsd:string ; rdfs:subClassOf ; """6618"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0796693"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """technetium Tc 99m sulfur colloid"""@eng ; skos:notation """CDR0000042818"""^^xsd:string ; skos:altLabel """Tc-99m SC"""@eng , """Tc 99m Sulfur Colloid"""@eng ; skos:definition """A gamma-emitting colloid used in scintillation scanning of the reticuloendothelial system (RES). After intravenous administration, technetium Tc 99m sulfur colloid is phagocytized by the reticuloendothelial system and concentrated in the liver, spleen, and bone marrow; detection/localization of phagocytized gamma ray-emitting colloid is performed with a gamma-ray scintillation camera. Scintillation scanning using technetium Tc 99m colloid sulfur helps determine the distribution and function of the RES and the extent to which tumor involves the RES. The RES includes cells types that can phagocytize and sequester inert particles and vital dyes; RES cell types include macrophages or macrophage precursors, specialized endothelial cells lining the sinusoids of the liver, spleen, and bone marrow, and reticular cells of lymphatic tissue and of bone marrow. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42818&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42818&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C856\" NCI Thesaurus)"""@eng ; ; """6617"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C856"""^^xsd:string ; """2006-09-26"""^^xsd:string ; umls:cui """C0039419"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T197"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ingenol 3-angelate"""@eng ; skos:notation """CDR0000432941"""^^xsd:string ; skos:altLabel """3-ingenyl angelate"""@eng , """I3A"""@eng , """PEP005"""@eng ; skos:definition """A selective small-molecule activator of protein kinase C (PKC) isolated from the plant Euphorbia peplus with potential antineoplastic activity. Ingenol 3-angelate (I3A) activates various protein kinase C (PKC) isoforms, thereby inducing apoptosis in some tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes including proliferation, differentiation, and apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=432941&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=432941&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48398\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-05-06"""^^xsd:string ; """C48398"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C1456762"""^^xsd:string ; umls:cui """C1452152"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 124 iododeoxyuridine"""@eng ; skos:notation """CDR0000428586"""^^xsd:string ; skos:altLabel """I-124 iododeoxyuridine"""@eng ; skos:definition """A radiopharmaceutical comprised of the thymidine analog, 5-iodo-2-deoxyuridine (idoxuridine), labeled with the positron emitter iodine I 124. After incorporation into tumor cell DNA, positron emission tomography (PET) is used to image iodine I 124 localized to tumor cells for determining and monitoring tumor burden. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428586&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=428586&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48399\" NCI Thesaurus)"""@eng ; """2005-04-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48399"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C1541554"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thyroxine"""@eng ; skos:notation """CDR0000528273"""^^xsd:string ; skos:altLabel """T4"""@eng ; skos:definition """A hormone synthesized and secreted by the thyroid gland containing four iodine atoms and is converted to triiodothyronine (T3) in the body, influencing metabolism and organ function. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=528273&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=528273&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2302\" NCI Thesaurus)"""@eng ; """2006-12-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2302"""^^xsd:string ; umls:cui """C0040165"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sinomenine"""@eng ; skos:notation """CDR0000529346"""^^xsd:string ; skos:altLabel """Cocculine"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0074568"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """BLP25 liposome vaccine"""@eng ; skos:notation """CDR0000529341"""^^xsd:string ; skos:altLabel """BLP25"""@eng , """Stimuvax"""@eng , """BP1-7-KLH"""@eng , """L-BLP25"""@eng ; skos:definition """A liposome-encapsulated peptide vaccine consists of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic property. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein, which is overexpressed on many tumor cells. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1 expression tumor cells, thereby results in inhibiting tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=529341&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=529341&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2195\" NCI Thesaurus)"""@eng ; """2007-01-03"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; """C2195"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1832016"""^^xsd:string ; umls:cui """C1832017"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """E2F1 pathway activator ARQ 171"""@eng ; skos:notation """CDR0000529342"""^^xsd:string ; skos:altLabel """ARQ 171"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1832018"""^^xsd:string ; umls:cui """C1832019"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trofosfamide"""@eng ; skos:notation """CDR0000039725"""^^xsd:string ; skos:altLabel """A-4828"""@eng , """N,N,3-tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide"""@eng , """trofosfamid"""@eng , """TFF"""@eng , """Ixoten"""@eng , """Genoxal Trofosfamida"""@eng ; skos:definition """An orally bioavailable oxazaphosphorine prodrug with antineoplastic activity. Trofosfamide (TFF) is metabolized predominantly to the cyclophosphamide analogue ifosfamide (IFO), which is then metabolized by liver cytochrome P450s to the active isophosphoramide mustard (IPM). IPM alkylates DNA to form DNA-DNA cross-links, which may result in inhibition of DNA, RNA and protein synthesis, and tumor cell apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39725&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39725&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1268\" NCI Thesaurus)"""@eng ; """2387"""^^xsd:string ; """C1268"""^^xsd:string ; """2006-07-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0124273"""^^xsd:string ; umls:cui """C0149248"""^^xsd:string ; umls:cui """C0077375"""^^xsd:string ; umls:cui """C1519657"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trimethoprim-sulfamethoxazole"""@eng ; skos:notation """CDR0000039724"""^^xsd:string ; skos:altLabel """Bactrim"""@eng , """Eslectin"""@eng , """Centran"""@eng , """Cotrimoxazole"""@eng , """Septra"""@eng , """Centrin"""@eng , """TMP-SMX"""@eng , """Insozalin"""@eng , """Trimezole"""@eng , """SMZ-TMP"""@eng , """Trimedin"""@eng , """Cotrim"""@eng , """co-trimoxazole"""@eng ; skos:definition """A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as co-trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthetase. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39724&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39724&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C909\" NCI Thesaurus)"""@eng ; """2006-09-28"""^^xsd:string ; """C909"""^^xsd:string ; """2386"""^^xsd:string ; """618652"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """8064-90-2"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0699584"""^^xsd:string ; umls:cui """C0591139"""^^xsd:string ; umls:cui """C0041044"""^^xsd:string ; umls:cui """C0699595"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tobramycin sulfate"""@eng ; skos:notation """CDR0000039727"""^^xsd:string ; skos:altLabel """TBM"""@eng ; ; """C893"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2389"""^^xsd:string ; """2006-11-29"""^^xsd:string ; umls:cui """C0040341"""^^xsd:string ; umls:cui """C0027519"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trioxifene"""@eng ; skos:notation """CDR0000039726"""^^xsd:string ; skos:altLabel """trioxifene mesylate"""@eng ; """2388"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0146868"""^^xsd:string ; umls:cui """C0077238"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """iodine I 131 liothyronine"""@eng ; skos:notation """CDR0000039721"""^^xsd:string ; skos:altLabel """liothyronine I 131"""@eng ; """2383"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-02-17"""^^xsd:string ; umls:cui """C0338103"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """treosulfan"""@eng ; skos:notation """CDR0000039720"""^^xsd:string ; skos:altLabel """Ovastat"""@eng , """tresulfon"""@eng , """Treosulphan"""@eng , """L-Threitol 1,4-dimethanesulfonate"""@eng , """Dihydroxybusulfan"""@eng , """(S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate"""@eng ; skos:definition """A prodrug belongs to sulfonate compound family with antineoplastic activity. Treosulfan alkylates DNA, causes DNA-DNA crosslinks and DNA strand breaks, thereby inhibiting DNA replication. This agent's proapoptotic effect might be mediated, at least in part, via protein kinase C signaling pathway. Due to its myeloablative and immunosuppressive effects, its use in conditioning regimens prior to allogeneic stem cell treatment (SCT) has been proposed. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39720&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39720&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1257\" NCI Thesaurus)"""@eng ; """2382"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """299-75-2"""^^xsd:string ; """2006-02-16"""^^xsd:string ; """C1257"""^^xsd:string ; """94160"""^^xsd:string ; """39069"""^^xsd:string ; """39070"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1519641"""^^xsd:string ; umls:cui """C0076959"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """triciribine phosphate"""@eng ; skos:notation """CDR0000039723"""^^xsd:string ; skos:altLabel """tricycloside phosphate"""@eng , """TCN-P"""@eng , """tricyclic nucleoside 5'-phosphate"""@eng ; """Drug/agent"""^^xsd:string ; """2385"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """C1262"""^^xsd:string ; umls:cui """C0077070"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """teroxirone"""@eng ; skos:notation """CDR0000039722"""^^xsd:string ; skos:altLabel """Henkel's Compound"""@eng , """alpha-1,3,5-triglycidyl-s-triazinetrione"""@eng , """alpha-triglycidyl isocyanurate"""@eng , """alpha-TGI"""@eng ; skos:definition """A triazene triepoxide with antineoplastic activity. Teroxine alkylates and cross-links DNA, thereby inhibiting DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39722&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39722&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2320\" NCI Thesaurus)"""@eng ; """2384"""^^xsd:string ; """296934"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """59653-73-5 (alpha)"""^^xsd:string ; """19670"""^^xsd:string ; """C2320"""^^xsd:string ; """2451-62-9"""^^xsd:string ; """2006-12-18"""^^xsd:string ; umls:cui """C0043891"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """urokinase"""@eng ; skos:notation """CDR0000039729"""^^xsd:string ; skos:altLabel """Abbokinase"""@eng , """Breokinase"""@eng ; """2391"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0813160"""^^xsd:string ; umls:cui """C0701941"""^^xsd:string ; umls:cui """C0042071"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tubercidin"""@eng ; skos:notation """CDR0000039728"""^^xsd:string ; skos:altLabel """U-10071"""@eng , """TBC"""@eng , """7-deazaadenosine"""@eng , """7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine"""@eng , """4-amino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine"""@eng ; skos:definition """An antibiotic and adenosine analog isolated from the bacterium Streptomyces tubercidicus with potential antineoplastic activity. Tubercidin is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis. This agent also exhibits antifungal and antiviral activities. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39728&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39728&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C911\" NCI Thesaurus)"""@eng ; """2390"""^^xsd:string ; """2006-12-18"""^^xsd:string ; """69-33-0"""^^xsd:string ; """56408"""^^xsd:string ; """C911"""^^xsd:string ; """1804"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0041286"""^^xsd:string ; umls:cui """C0733535"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/PKC412"""@eng ; skos:notation """CDR0000391013"""^^xsd:string ; skos:altLabel """ARA-C/DNR/PKC 412"""@eng ; ; ; """2004-09-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-16"""^^xsd:string ; umls:cui """C1541470"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/PKC412"""@eng ; skos:notation """CDR0000391015"""^^xsd:string ; skos:altLabel """ARA-C/PKC 412"""@eng ; ; """2004-09-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2006-08-16"""^^xsd:string ; umls:cui """C1541471"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """localized resectable neuroblastoma"""@eng ; skos:notation """CDR0000043708"""^^xsd:string ; skos:altLabel """neuroblastoma, localized resectable"""@eng ; rdfs:subClassOf ; """neuroblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """957"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278691"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """regional neuroblastoma"""@eng ; skos:notation """CDR0000043709"""^^xsd:string ; skos:altLabel """neuroblastoma, regional"""@eng ; rdfs:subClassOf ; """neuroblastoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """959"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278692"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I ovarian epithelial cancer"""@eng ; skos:notation """CDR0000043702"""^^xsd:string ; skos:altLabel """stage I ovary cancer"""@eng , """ovarian carcinoma, stage I"""@eng , """ovarian cancer, stage I"""@eng , """ovary cancer, stage I"""@eng , """ovarian epithelial cancer, stage I"""@eng , """stage I ovarian carcinoma"""@eng , """stage I ovarian cancer"""@eng ; rdfs:subClassOf ; """ovarian epithelial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """951"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278685"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II ovarian epithelial cancer"""@eng ; skos:notation """CDR0000043703"""^^xsd:string ; skos:altLabel """stage II ovary cancer"""@eng , """stage II ovarian carcinoma"""@eng , """ovarian cancer, stage II"""@eng , """ovarian epithelial cancer, stage II"""@eng , """stage II ovarian cancer"""@eng , """ovarian carcinoma, stage II"""@eng , """ovary cancer, stage II"""@eng ; rdfs:subClassOf ; """ovarian epithelial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """952"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278686"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIA anal cancer"""@eng ; skos:notation """CDR0000043700"""^^xsd:string ; skos:altLabel """anus cancer, stage IIIA"""@eng , """anal cancer, stage IIIA"""@eng , """stage IIIA anus cancer"""@eng ; rdfs:subClassOf ; """anal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """95"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278563"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian epithelial cancer"""@eng ; skos:notation """CDR0000043701"""^^xsd:string ; skos:altLabel """carcinoma, ovarian epithelial"""@eng , """carcinoma, ovarian"""@eng , """Ovarian epithelial cancer"""@eng , """ovarian cancer"""@eng , """ovary cancer"""@eng , """epithelial ovarian carcinoma"""@eng , """ovarian epithelial carcinoma"""@eng , """ovarian carcinoma"""@eng , """epithelial ovarian cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2002-10-15"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """950"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1140680"""^^xsd:string ; umls:cui """C0677886"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent ovarian epithelial cancer"""@eng ; skos:notation """CDR0000043706"""^^xsd:string ; skos:altLabel """recurrent ovarian carcinoma"""@eng , """recurrent ovarian cancer"""@eng , """ovarian epithelial cancer, recurrent"""@eng , """recurrent ovary cancer"""@eng , """ovarian carcinoma, recurrent"""@eng , """ovarian cancer, recurrent"""@eng , """ovary cancer, recurrent"""@eng ; rdfs:subClassOf ; """ovarian epithelial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """955"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278689"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent childhood brain tumor"""@eng ; skos:notation """CDR0000043707"""^^xsd:string ; skos:altLabel """recurrent, CNS tumor, childhood"""@eng , """recurrent pediatric brain tumor"""@eng , """recurrent childhood CNS tumor"""@eng , """CNS tumor, recurrent childhood"""@eng , """brain tumor, childhood, recurrent"""@eng , """pediatric brain tumor, recurrent"""@eng , """brain tumor, pediatric, recurrent"""@eng , """recurrent brain tumor, childhood"""@eng , """recurrent pediatric CNS tumor"""@eng , """pediatric CNS tumor, recurrent"""@eng , """brain tumor, recurrent, childhood"""@eng , """CNS tumor, pediatric, recurrent"""@eng , """CNS tumor, childhood, recurrent"""@eng , """childhood brain tumor, recurrent"""@eng , """childhood CNS tumor, recurrent"""@eng ; rdfs:subClassOf ; """childhood brain tumor"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """956"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278690"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/cytarabine/idarubicin"""@eng ; skos:notation """CDR0000038427"""^^xsd:string ; skos:altLabel """ARA-C/IDA/MOAB VEGF"""@eng ; ; ; ; """11044"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134480"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV ovarian epithelial cancer"""@eng ; skos:notation """CDR0000043705"""^^xsd:string ; skos:altLabel """ovary cancer, stage IV"""@eng , """metastatic ovary cancer"""@eng , """ovarian cancer, metastatic"""@eng , """ovarian carcinoma, metastatic"""@eng , """metastatic ovarian epithelial cancer"""@eng , """ovarian epithelial cancer, stage IV"""@eng , """metastatic ovarian cancer"""@eng , """stage IV ovarian cancer"""@eng , """stage IV ovarian carcinoma"""@eng , """ovarian carcinoma, stage IV"""@eng , """ovary cancer, metastatic"""@eng , """ovarian epithelial cancer, metastatic"""@eng , """ovarian cancer, stage IV"""@eng , """metastatic ovarian carcinoma"""@eng , """stage IV ovary cancer"""@eng ; rdfs:subClassOf ; """ovarian epithelial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """954"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278688"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colorectal cancer prevention"""@eng ; skos:notation """CDR0000041568"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4731"""^^xsd:string ; umls:cui """C0281190"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """head and neck cancer prevention"""@eng ; skos:notation """CDR0000041569"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4732"""^^xsd:string ; umls:cui """C0281191"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast cancer screening"""@eng ; skos:notation """CDR0000041560"""^^xsd:string ; skos:altLabel """early detection of breast cancer"""@eng , """breast cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4723"""^^xsd:string ; umls:cui """C0281182"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """SNS-032"""@eng ; skos:notation """CDR0000488948"""^^xsd:string ; skos:altLabel """BMS-387032"""@eng ; """2006-09-18"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62523"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1451099"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """oral cancer screening"""@eng ; skos:notation """CDR0000041562"""^^xsd:string ; skos:altLabel """early detection for oral cancer"""@eng , """oral cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4725"""^^xsd:string ; umls:cui """C0281184"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """topoisomerase II alpha"""@eng ; skos:notation """CDR0000464377"""^^xsd:string ; skos:altLabel """Topoisomerase (DNA) II Alpha 170kDa Gene"""@eng , """TOP2A"""@eng , """TOP2A Gene"""@eng , """topo II alpha"""@eng ; skos:definition """This gene plays a role in DNA replication, chromosome recombination and the regulation of the DNA topology during transcription. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464377&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464377&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26592\" NCI Thesaurus)"""@eng ; """C26592"""^^xsd:string ; """Gene"""^^xsd:string ; """2006-01-25"""^^xsd:string ; umls:cui """C1336657"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prostate cancer screening"""@eng ; skos:notation """CDR0000041564"""^^xsd:string ; skos:altLabel """early detection of prostate cancer"""@eng , """prostate cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4727"""^^xsd:string ; umls:cui """C0281186"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """early detection of cervical cancer"""@eng ; skos:notation """CDR0000041565"""^^xsd:string ; skos:altLabel """cervical cancer screening"""@eng , """cervical cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4728"""^^xsd:string ; umls:cui """C0281187"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """testicular cancer screening"""@eng ; skos:notation """CDR0000041566"""^^xsd:string ; skos:altLabel """early detection of testicular cancer"""@eng , """testicular cancer early detection"""@eng ; """2002-10-17"""^^xsd:string ; """4729"""^^xsd:string ; umls:cui """C0281188"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """breast cancer prevention"""@eng ; skos:notation """CDR0000041567"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4730"""^^xsd:string ; umls:cui """C0281189"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, melanoma"""@eng ; skos:notation """CDR0000040178"""^^xsd:string ; skos:altLabel """melanoma, cutaneous, cellular diagnosis"""@eng , """cutaneous melanoma cellular diagnosis"""@eng , """melanoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2968"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279875"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, anal cancer"""@eng ; skos:notation """CDR0000040179"""^^xsd:string ; skos:altLabel """anus cancer cellular diagnosis"""@eng , """anal cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2969"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279876"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, metastatic squamous neck cancer with occult primary"""@eng ; skos:notation """CDR0000040170"""^^xsd:string ; skos:altLabel """metastatic squamous neck cancer with occult primary cellular diagnosis"""@eng ; rdfs:subClassOf ; """2959"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279868"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """estrogen"""@eng ; skos:notation """CDR0000040171"""^^xsd:string ; rdfs:subClassOf ; """296"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0014939"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T125"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, testicular cancer"""@eng ; skos:notation """CDR0000040172"""^^xsd:string ; skos:altLabel """testicular cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2960"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279869"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adult primary liver cancer"""@eng ; skos:notation """CDR0000040173"""^^xsd:string ; skos:altLabel """adult primary liver cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2962"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279870"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """probenecid/10-propargyl-10-deaxaaminopterin"""@eng ; skos:notation """CDR0000038426"""^^xsd:string ; skos:altLabel """PDX/PROB"""@eng ; ; ; """11043"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134479"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, adult soft tissue sarcoma"""@eng ; skos:notation """CDR0000040175"""^^xsd:string ; skos:altLabel """adult soft tissue sarcoma cellular diagnosis"""@eng ; rdfs:subClassOf ; """2964"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279872"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, nasopharyngeal cancer"""@eng ; skos:notation """CDR0000040176"""^^xsd:string ; skos:altLabel """nasopharynx cancer cellular diagnosis"""@eng , """nasopharyngeal cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2965"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279873"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, vulvar cancer"""@eng ; skos:notation """CDR0000040177"""^^xsd:string ; skos:altLabel """vulvar cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2966"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279874"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/fluorouracil/menogaril"""@eng ; skos:notation """CDR0000038894"""^^xsd:string ; skos:altLabel """CTX/5-FU/MEN"""@eng ; ; ; ; """1388"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278934"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage, uterine sarcoma"""@eng ; skos:notation """CDR0000038895"""^^xsd:string ; skos:altLabel """uterine sarcoma, stage"""@eng ; rdfs:subClassOf ; """1389"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278935"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """no measurable or evaluable disease"""@eng ; skos:notation """CDR0000038896"""^^xsd:string ; """1390"""^^xsd:string ; umls:cui """C0278936"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """no evidence of disease after surgery"""@eng ; skos:notation """CDR0000038897"""^^xsd:string ; """1391"""^^xsd:string ; umls:cui """C0278937"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/pirarubicin"""@eng ; skos:notation """CDR0000038890"""^^xsd:string ; skos:altLabel """DTIC/THP-DOX"""@eng ; ; ; """1384"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338081"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/doxorubicin/methylprednisolone"""@eng ; skos:notation """CDR0000038891"""^^xsd:string ; skos:altLabel """A-SHAP"""@eng , """ARA-C/CDDP/DOX/MePRDL"""@eng , """ASHAP"""@eng ; ; ; ; ; """1385"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0296911"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000038892"""^^xsd:string ; skos:altLabel """CDDP/CF/5-FU"""@eng ; ; ; ; """1386"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0070493"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mercaptopurine/methotrexate/pentostatin"""@eng ; skos:notation """CDR0000038893"""^^xsd:string ; skos:altLabel """DCF/MP/MTX"""@eng ; ; ; ; """1387"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278933"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gross residual disease after surgery"""@eng ; skos:notation """CDR0000038898"""^^xsd:string ; skos:altLabel """residual cancer present, gross or microscopic"""@eng ; """1392"""^^xsd:string ; umls:cui """C0278938"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """microscopic residual disease after surgery"""@eng ; skos:notation """CDR0000038899"""^^xsd:string ; """1393"""^^xsd:string ; umls:cui """C0278939"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/oxaliplatin"""@eng ; skos:notation """CDR0000440879"""^^xsd:string ; skos:altLabel """L-OHP/rhuMAb VEGF"""@eng ; ; ; """2005-07-12"""^^xsd:string ; """2005-07-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831677"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cyclophosphamide/etoposide/filgrastim"""@eng ; skos:notation """CDR0000042039"""^^xsd:string ; skos:altLabel """CDDP/CTX/G-CSF/VP-16"""@eng ; ; ; ; ; """5268"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281578"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/prednisolone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000042038"""^^xsd:string ; skos:altLabel """CLB/PCB/PRDL/VBL"""@eng ; ; ; ; ; """5267"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281577"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant tissue plasminogen activator"""@eng ; skos:notation """CDR0000042033"""^^xsd:string ; skos:altLabel """Activase"""@eng , """t-PA"""@eng , """rt-PA"""@eng ; skos:definition """A recombinant therapeutic agent which is chemically identical to or similar to endogenous tissue plasminogen activator (tPA). tPA is a serine protease which converts plasminogen to plasmin, a fibrinolytic enzyme. Upon administration, recombinant tPA increases plasmin enzymatic activity, resulting in hyperfibrinolysis and potential dissolution of a thrombus or embolism. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42033&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42033&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C39607\" NCI Thesaurus)"""@eng ; ; """C39607"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5262"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0701942"""^^xsd:string ; umls:cui """C0032143"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """DAB389 epidermal growth factor"""@eng ; skos:notation """CDR0000042032"""^^xsd:string ; skos:altLabel """DAB389 EGF"""@eng , """DAB389EGF"""@eng , """DAB389-EGF"""@eng ; skos:definition """A recombinant fusion protein composed of the diphtheria toxin with the receptor-binding domain replaced by human epidermal growth factor (EGF). When administered, EGF binds to the endothelial cell growth factor receptor, EGFR, which is upregulated in many solid tumors. After binding to the EGF receptor, the agent is internalized by the cell, where the diphtheria toxin moiety exerts its cytotoxic effect, inhibiting protein synthesis through ADP-ribosylation of elongation factor 2. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42032&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42032&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2383\" NCI Thesaurus)"""@eng ; """5261"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """C2383"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0281573"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/sargramostim"""@eng ; skos:notation """CDR0000042031"""^^xsd:string ; skos:altLabel """ARA-C/GM-CSF/IDA"""@eng ; ; ; ; """5260"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281572"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/mitoxantrone/sargramostim"""@eng ; skos:notation """CDR0000042030"""^^xsd:string ; skos:altLabel """ARA-C/DHAD/GM-CSF"""@eng ; ; ; ; """5258"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281571"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/doxorubicin/etoposide/prednisolone/vincristine"""@eng ; skos:notation """CDR0000042037"""^^xsd:string ; skos:altLabel """BLEO/DOX/PRDL/VCR/VP-16"""@eng ; ; ; ; ; ; """5266"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281576"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """veno-occlusive disease"""@eng ; skos:notation """CDR0000042036"""^^xsd:string ; rdfs:subClassOf ; """5265"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0948441"""^^xsd:string ; umls:tui """T047"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """thrombolytic therapy"""@eng ; skos:notation """CDR0000042035"""^^xsd:string ; skos:altLabel """therapy, thrombolytic"""@eng ; ; rdfs:subClassOf ; """5264"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0040044"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminocamptothecin/filgrastim"""@eng ; skos:notation """CDR0000042034"""^^xsd:string ; skos:altLabel """9-AC/G-CSF"""@eng ; ; ; """5263"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281574"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """vertebroplasty"""@eng ; skos:notation """CDR0000481374"""^^xsd:string ; """2006-04-17"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C1303192"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """endoscopy"""@eng ; skos:notation """CDR0000481371"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """Diagnostic test/procedure"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """2006-04-17"""^^xsd:string ; umls:cui """C0014245"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tirapazamine"""@eng ; skos:notation """CDR0000042158"""^^xsd:string ; skos:altLabel """WIN 59075"""@eng , """SR 4233"""@eng , """SR4233"""@eng , """WIN-59075"""@eng , """SR-4233"""@eng , """Tirazone"""@eng ; skos:definition """A benzotriazine di-N-oxide with potential antineoplastic activity. Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42158&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42158&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1464\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """5398"""^^xsd:string ; """27314-97-2"""^^xsd:string ; """46525"""^^xsd:string ; """130181"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1464"""^^xsd:string ; """2006-09-27"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0935950"""^^xsd:string ; umls:cui """C0878536"""^^xsd:string ; umls:cui """C0878535"""^^xsd:string ; umls:cui """C0208407"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/tirapazamine"""@eng ; skos:notation """CDR0000042159"""^^xsd:string ; skos:altLabel """CDDP/SR-4233"""@eng ; ; ; """5399"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281676"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/paclitaxel"""@eng ; skos:notation """CDR0000042154"""^^xsd:string ; skos:altLabel """CDDP/DOX/TAX"""@eng ; ; ; ; """5394"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281672"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/doxorubicin/filgrastim/paclitaxel"""@eng ; skos:notation """CDR0000042155"""^^xsd:string ; skos:altLabel """CDDP/DOX/G-CSF/TAX"""@eng ; ; ; ; ; """5395"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281673"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/mitoxantrone/sargramostim"""@eng ; skos:notation """CDR0000042156"""^^xsd:string ; skos:altLabel """DHAD/GM-CSF/VP-16"""@eng ; ; ; ; """5396"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281674"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/novobiocin"""@eng ; skos:notation """CDR0000042157"""^^xsd:string ; skos:altLabel """NBC/VP-16"""@eng ; ; ; """5397"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281675"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dexverapamil/vinblastine"""@eng ; skos:notation """CDR0000042150"""^^xsd:string ; skos:altLabel """R-VPAM/VBL"""@eng ; ; ; """5389"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281668"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/docetaxel/fluorouracil/leucovorin calcium"""@eng ; skos:notation """CDR0000042151"""^^xsd:string ; skos:altLabel """CDDP/CF/5-FU/TXT"""@eng ; ; ; ; ; """5390"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281669"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """disaccharide tripeptide glycerol dipalmitoyl"""@eng ; skos:notation """CDR0000042152"""^^xsd:string ; skos:altLabel """ImmTher"""@eng , """DTP-GDP"""@eng ; ; """TRD"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """5392"""^^xsd:string ; """2006-11-27"""^^xsd:string ; """C1575"""^^xsd:string ; umls:cui """C0641098"""^^xsd:string ; umls:cui """C0281671"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-12"""@eng ; skos:notation """CDR0000042153"""^^xsd:string ; skos:altLabel """Cytotoxic Lymphocyte Maturation Factor"""@eng , """Natural Killer Cell Stimulatory Factor"""@eng , """Ro 24-7472"""@eng , """interleukin 12"""@eng , """IL-12"""@eng , """Recombinant Interleukin-12"""@eng , """Recombinant human interleukin-12 (IL-12) cytokine"""@eng ; skos:definition """A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity. Recombinant interleukin-12 binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42153&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42153&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1380\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """5393"""^^xsd:string ; """6123"""^^xsd:string ; """8748"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """6419"""^^xsd:string ; """672423"""^^xsd:string ; """187348-17-0"""^^xsd:string ; """C1380"""^^xsd:string ; """6798"""^^xsd:string ; """7103"""^^xsd:string ; """2006-08-28"""^^xsd:string ; umls:cui """C0123759"""^^xsd:string ; umls:cui """C1328728"""^^xsd:string ; umls:cui """C1524115"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lapatinib ditosylate"""@eng ; skos:notation """CDR0000269659"""^^xsd:string ; skos:altLabel """GW-572016"""@eng , """Lapatinib"""@eng , """lapatinib"""@eng , """Tykerb"""@eng , """GSK572016"""@eng , """GW2016"""@eng ; skos:definition """The ditosylate salt of a synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269659&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269659&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26653\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """2006-08-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C26653"""^^xsd:string ; """2002-12-21"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1504917"""^^xsd:string ; umls:cui """C1173538"""^^xsd:string ; umls:cui """C1708163"""^^xsd:string ; umls:cui """C1384663"""^^xsd:string ; umls:cui """C1721362"""^^xsd:string ; umls:cui """C1506770"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intraoperative radiotherapy"""@eng ; skos:notation """CDR0000042320"""^^xsd:string ; skos:altLabel """radiotherapy, intraoperative"""@eng ; ; rdfs:subClassOf ; """5568"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0338240"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000269304"""^^xsd:string ; skos:altLabel """CBDCA/CTX/DOX/VP-16"""@eng ; ; ; ; ; """2002-12-04"""^^xsd:string ; """2002-12-02"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327850"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imipenem-cilastatin sodium"""@eng ; skos:notation """CDR0000040786"""^^xsd:string ; skos:altLabel """imipenem cilastatin sodium"""@eng , """Primaxin"""@eng ; """3750"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0733696"""^^xsd:string ; umls:cui """C0145617"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon gamma/tumor necrosis factor"""@eng ; skos:notation """CDR0000040884"""^^xsd:string ; skos:altLabel """IFN-G/TNF"""@eng ; ; ; """3922"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280507"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interleukin-2/lymphokine-activated killer cells"""@eng ; skos:notation """CDR0000040885"""^^xsd:string ; skos:altLabel """IL-2/LAK"""@eng ; ; ; """3923"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280508"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """brequinar"""@eng ; skos:notation """CDR0000040886"""^^xsd:string ; skos:altLabel """Bipenquinate"""@eng , """6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic Acid"""@eng ; skos:definition """A synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40886&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40886&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1560\" NCI Thesaurus)"""@eng ; ; """3924"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1560"""^^xsd:string ; """2006-12-28"""^^xsd:string ; """96187-53-0"""^^xsd:string ; umls:cui """C0280509"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """edatrexate"""@eng ; skos:notation """CDR0000040887"""^^xsd:string ; skos:altLabel """EDAM"""@eng , """CGP-30694"""@eng , """10-EdAM"""@eng , """N-[4-[1-[(2,4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic Acid"""@eng , """10-Ethyl-10-deaza-aminopterin"""@eng ; skos:definition """A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40887&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40887&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C958\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; """3925"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """33873"""^^xsd:string ; """C958"""^^xsd:string ; """626715"""^^xsd:string ; """80576-83-6"""^^xsd:string ; umls:cui """C1527327"""^^xsd:string ; umls:cui """C0044667"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """flavone acetic acid/interleukin-2"""@eng ; skos:notation """CDR0000040880"""^^xsd:string ; skos:altLabel """FAA/IL-2"""@eng ; ; ; """3918"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280503"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/PALA"""@eng ; skos:notation """CDR0000040881"""^^xsd:string ; skos:altLabel """5-FU/PALA"""@eng ; ; ; """3919"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280504"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ifosfamide/mitoxantrone"""@eng ; skos:notation """CDR0000040882"""^^xsd:string ; skos:altLabel """DHAD/IFF"""@eng ; ; ; """3920"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280505"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/interferon gamma"""@eng ; skos:notation """CDR0000040883"""^^xsd:string ; skos:altLabel """IFN-A/IFN-G"""@eng ; ; ; """3921"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338119"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mifepristone"""@eng ; skos:notation """CDR0000040888"""^^xsd:string ; skos:altLabel """RU-486"""@eng , """RU-38486"""@eng , """11 Beta-[4-(N,N-dimethylamino)phenyl]-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one"""@eng , """RU 486"""@eng , """11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) Estra-4,9- dien-3-one"""@eng , """Mifegyne"""@eng , """(aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one"""@eng , """Mifeprex"""@eng , """RU486"""@eng ; skos:definition """A synthetic compound with antiprogesterone properties. Mifepristone competitively binds to the progesterone receptor, leading to changes in the endometrial blood supply. This agent also exhibits antiglucocorticoid and weak antiandrogenic activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40888&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40888&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C655\" NCI Thesaurus)"""@eng ; """3926"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """84371-65-3"""^^xsd:string ; """2006-05-09"""^^xsd:string ; """652104"""^^xsd:string ; """C655"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591786"""^^xsd:string ; umls:cui """C0939382"""^^xsd:string ; umls:cui """C0026088"""^^xsd:string ; umls:cui """C0701303"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040889"""^^xsd:string ; skos:altLabel """ABO"""@eng , """VBM"""@eng , """BLEO/MTX/VCR"""@eng , """VBM-L"""@eng ; ; ; ; """3927"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078140"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/imatinib mesylate"""@eng ; skos:notation """CDR0000318798"""^^xsd:string ; skos:altLabel """17-AAG/STI571"""@eng ; ; ; """2003-07-26"""^^xsd:string ; """2004-02-20"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328008"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mast cell leukemia"""@eng ; skos:notation """CDR0000466588"""^^xsd:string ; rdfs:subClassOf ; """Cancer diagnosis"""^^xsd:string ; """2006-01-25"""^^xsd:string ; """2006-01-24"""^^xsd:string ; umls:cui """C0023461"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040772"""^^xsd:string ; skos:altLabel """metastatic esthesioneuroblastoma of the paranasal sinus and nasal cavity"""@eng , """nasal cavity and paranasal sinus esthesioneuroblastoma, metastatic"""@eng , """esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage IV"""@eng , """nasal cavity and paranasal sinus esthesioneuroblastoma, stage IV"""@eng , """paranasal sinus and nasal cavity esthesioneuroblastoma, metastatic"""@eng , """paranasal sinus and nasal cavity esthesioneuroblastoma, stage IV"""@eng , """esthesioneuroblastoma of the paranasal sinus and nasal cavity, metastatic"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3731"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280418"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040773"""^^xsd:string ; skos:altLabel """paranasal sinus and nasal cavity squamous cell carcinoma, recurrent"""@eng , """squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent"""@eng , """epidermoid carcinoma of the paranasal sinus and nasal cavity, recurrent"""@eng , """nasal cavity and paranasal sinus squamous cell carcinoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3732"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280419"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV inverted papilloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040770"""^^xsd:string ; skos:altLabel """inverted papilloma of the paranasal sinus and nasal cavity, stage IV"""@eng , """inverted papilloma of the paranasal sinus and nasal cavity, metastatic"""@eng , """paranasal sinus and nasal cavity inverted papilloma, metastatic"""@eng , """metastatic inverted papilloma of the paranasal sinus and nasal cavity"""@eng , """nasal cavity and paranasal sinus inverted papilloma, stage IV"""@eng , """nasal cavity and paranasal sinus inverted papilloma, metastatic"""@eng , """paranasal sinus and nasal cavity inverted papilloma, stage IV"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Clinical Trials--CancerType"""^^xsd:string ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """3726"""^^xsd:string ; """Cancer stage"""^^xsd:string ; """2006-11-28"""^^xsd:string ; umls:cui """C0280416"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV midline lethal granuloma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040771"""^^xsd:string ; skos:altLabel """midline lethal granuloma of the paranasal sinus and nasal cavity, metastatic"""@eng , """paranasal sinus and nasal cavity midline lethal granuloma, stage IV"""@eng , """nasal cavity and paranasal sinus midline lethal granuloma, metastatic"""@eng , """metastatic midline lethal granuloma of the paranasal sinus and nasal cavity"""@eng , """midline lethal granuloma of the paranasal sinus and nasal cavity, stage IV"""@eng , """paranasal sinus and nasal cavity midline lethal granuloma, metastatic"""@eng , """nasal cavity and paranasal sinus midline lethal granuloma, stage IV"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3729"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280417"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity"""@eng ; skos:notation """CDR0000040776"""^^xsd:string ; skos:altLabel """nasal cavity and paranasal sinus esthesioneuroblastoma, recurrent"""@eng , """esthesioneuroblastoma of the paranasal sinus and nasal cavity, recurrent"""@eng , """paranasal sinus and nasal cavity esthesioneuroblastoma, recurrent"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """paranasal sinus and nasal cavity cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3738"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280422"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult T-cell leukemia/lymphoma"""@eng ; skos:notation """CDR0000040777"""^^xsd:string ; skos:altLabel """adult T-cell leukemia/lymphoma, stage I"""@eng , """stage I HTLV-I associated adult T-cell leukemia/lymphoma"""@eng , """HTLV-I associated adult T-cell leukemia/lymphoma, stage I"""@eng ; rdfs:subClassOf ; """adult T-cell leukemia/lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """3739"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0280423"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """clarithromycin/omeprazole/tinidazole"""@eng ; skos:notation """CDR0000043289"""^^xsd:string ; skos:altLabel """CLARITH/OMEP/TDZ"""@eng ; ; ; ; """7802"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796443"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tinidazole"""@eng ; skos:notation """CDR0000043288"""^^xsd:string ; skos:altLabel """TDZ"""@eng , """Fasigyn"""@eng , """Tindamax"""@eng , """Simplotan"""@eng ; skos:definition """A 5-nitroimidazole derivative with antiprotozoal property. Although the mechanism of action has not been fully elucidated, it has been suggested that tinidazole is metabolized and yields nitrite anions and metronidazole. Metronidazole's nitro group in turn is reduced via the parasite ferredoxin, thereby generating a series of free nitro radicals including nitro anions. Toxicity is achieved via depletion of sulfhydryl groups and DNA strand breaks with multiple hits having an additive effect and ultimately leading to cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43288&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43288&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C890\" NCI Thesaurus)"""@eng ; ; """7801"""^^xsd:string ; """C890"""^^xsd:string ; """19387-91-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0040263"""^^xsd:string ; umls:cui """C2350048"""^^xsd:string ; umls:cui """C0591480"""^^xsd:string ; umls:cui """C1601334"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/methylprednisolone"""@eng ; skos:notation """CDR0000043287"""^^xsd:string ; skos:altLabel """DOX/MePRDL"""@eng ; ; ; """7800"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796442"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I rectal cancer"""@eng ; skos:notation """CDR0000043286"""^^xsd:string ; skos:altLabel """rectal cancer, stage I"""@eng , """rectum cancer, stage I"""@eng , """Dukes A rectal cancer"""@eng , """stage I rectum cancer"""@eng , """rectum cancer, Dukes A"""@eng , """rectal cancer, Dukes A"""@eng ; rdfs:subClassOf ; """rectal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """78"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278535"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/tretinoin liposome"""@eng ; skos:notation """CDR0000043285"""^^xsd:string ; skos:altLabel """IFN-A/L-ATRA"""@eng ; ; ; """7799"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796441"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/gemcitabine/interferon alfa/interleukin-2"""@eng ; skos:notation """CDR0000043284"""^^xsd:string ; skos:altLabel """dFdC/5-FU/IFN-A/IL-2"""@eng ; ; ; ; ; """7798"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796440"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soft tissue sarcoma, adult, stage IIC"""@eng ; skos:notation """CDR0000043283"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, stage IIC"""@eng , """adult soft tissue sarcoma, stage IIC"""@eng ; """2004-06-10"""^^xsd:string ; """7797"""^^xsd:string ; umls:cui """C0796439"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soft tissue sarcoma, adult, stage IIB"""@eng ; skos:notation """CDR0000043282"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, stage IIB"""@eng , """adult soft tissue sarcoma, stage IIB"""@eng ; """2004-06-10"""^^xsd:string ; """7796"""^^xsd:string ; umls:cui """C0796438"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """soft tissue sarcoma, adult, stage IIA"""@eng ; skos:notation """CDR0000043281"""^^xsd:string ; skos:altLabel """sarcoma, adult soft tissue, stage IIA"""@eng , """adult soft tissue sarcoma, stage IIA"""@eng ; """2004-06-10"""^^xsd:string ; """7795"""^^xsd:string ; umls:cui """C0796437"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/THERATOPE STn-KLH vaccine"""@eng ; skos:notation """CDR0000043280"""^^xsd:string ; skos:altLabel """CTX/THERATOPE"""@eng ; ; ; """7794"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796436"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """filgrastim/interferon alfa"""@eng ; skos:notation """CDR0000041829"""^^xsd:string ; skos:altLabel """G-CSF/IFN-A"""@eng ; ; ; """5013"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338170"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """olsalazine"""@eng ; skos:notation """CDR0000041828"""^^xsd:string ; skos:altLabel """azodisalicylate"""@eng ; """5012"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0069454"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/topotecan"""@eng ; skos:notation """CDR0000041825"""^^xsd:string ; skos:altLabel """DOX/TOPO"""@eng ; ; ; """5009"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281396"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/interferon alfa"""@eng ; skos:notation """CDR0000041824"""^^xsd:string ; skos:altLabel """BU/IFN-A"""@eng ; ; ; """5008"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338169"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phenylbutyrate"""@eng ; skos:notation """CDR0000041827"""^^xsd:string ; skos:altLabel """Buphenyl"""@eng , """4-Phenylbutyric Acid, Sodium Salt"""@eng , """PBA"""@eng , """Sodium 4-Phenylbutyrate"""@eng , """4-Phenylbutyrate"""@eng , """Sodium Phenylbutyrate"""@eng , """Phenylbutyrate Sodium"""@eng ; skos:definition """An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41827&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41827&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1440\" NCI Thesaurus)"""@eng ; ; ; ; ; """5011"""^^xsd:string ; """657802"""^^xsd:string ; """C1440"""^^xsd:string ; """1716-12-7"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """50386"""^^xsd:string ; """46624"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0281398"""^^xsd:string ; umls:cui """C0719042"""^^xsd:string ; umls:cui """C0718066"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/zidovudine"""@eng ; skos:notation """CDR0000041826"""^^xsd:string ; skos:altLabel """MTX/ZDV"""@eng ; ; ; """5010"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281397"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """floxuridine/mitomycin"""@eng ; skos:notation """CDR0000041821"""^^xsd:string ; skos:altLabel """FUDR/MITO"""@eng ; ; ; """5005"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281392"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/mitoxantrone"""@eng ; skos:notation """CDR0000041820"""^^xsd:string ; skos:altLabel """BU/CTX/DHAD"""@eng ; ; ; ; """5004"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281391"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related diffuse small cleaved cell lymphoma"""@eng ; skos:notation """CDR0000041823"""^^xsd:string ; skos:altLabel """diffuse small cleaved cell lymphoma, AIDS-related"""@eng , """AIDS-associated diffuse small cleaved cell lymphoma"""@eng ; rdfs:subClassOf ; """5007"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281394"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AIDS-related diffuse mixed cell lymphoma"""@eng ; skos:notation """CDR0000041822"""^^xsd:string ; skos:altLabel """AIDS-associated diffuse mixed cell lymphoma"""@eng , """diffuse mixed cell lymphoma, AIDS-related"""@eng ; rdfs:subClassOf ; """5006"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281393"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I bladder cancer"""@eng ; skos:notation """CDR0000038771"""^^xsd:string ; skos:altLabel """bladder cancer, stage I"""@eng , """stage I carcinoma of the bladder"""@eng , """stage A bladder cancer"""@eng , """stage A carcinoma of the bladder"""@eng , """carcinoma of the bladder, stage I"""@eng , """bladder cancer, stage A"""@eng , """stage A cancer of the bladder"""@eng , """carcinoma of the bladder, stage A"""@eng , """cancer of the bladder, stage A"""@eng , """stage I cancer of the bladder"""@eng , """cancer of the bladder, stage I"""@eng ; rdfs:subClassOf ; """bladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1213"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278822"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IVA cervical cancer"""@eng ; skos:notation """CDR0000038770"""^^xsd:string ; skos:altLabel """cancer of the cervix, stage IVA"""@eng , """cervical cancer, stage IVA"""@eng , """cervix cancer, stage IVA"""@eng , """stage IVA cervix cancer"""@eng , """uterine cervix cancer, stage IVA"""@eng , """uterine cervical cancer, stage IVA"""@eng , """stage IVA cancer of the cervix"""@eng , """stage IVA uterine cervix cancer"""@eng , """stage IVA carcinoma of the cervix"""@eng , """carcinoma of the cervix, stage IVA"""@eng ; rdfs:subClassOf ; """cervical cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """121"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278589"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage III bladder cancer"""@eng ; skos:notation """CDR0000038773"""^^xsd:string ; skos:altLabel """cancer of the bladder, stage III"""@eng , """bladder cancer, stage III"""@eng , """stage III cancer of the bladder"""@eng , """stage III carcinoma of the bladder"""@eng , """carcinoma of the bladder, stage III"""@eng ; rdfs:subClassOf ; """bladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1216"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278824"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II bladder cancer"""@eng ; skos:notation """CDR0000038772"""^^xsd:string ; skos:altLabel """bladder cancer, stage II"""@eng , """stage B1 cancer of the bladder"""@eng , """bladder cancer, stage B1"""@eng , """stage II cancer of the bladder"""@eng , """cancer of the bladder, stage B1"""@eng , """stage B1 carcinoma of the bladder"""@eng , """stage II carcinoma of the bladder"""@eng , """cancer of the bladder, stage II"""@eng , """carcinoma of the bladder, stage B1"""@eng , """carcinoma of the bladder, stage II"""@eng ; rdfs:subClassOf ; """bladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1214"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278823"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pirarubicin"""@eng ; skos:notation """CDR0000038775"""^^xsd:string ; skos:altLabel """4'-O-Tetrahydropyranyl Doxorubicin"""@eng , """(2\"R)-4'-O-Tetrahydropyranyladriamycin"""@eng , """THP-Doxorubicin"""@eng , """Therarubicin"""@eng , """Tetrahydropyranyl-Doxorubicin"""@eng , """(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-3-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione"""@eng , """THP-Adriamycin"""@eng , """THP"""@eng , """THP-ADM"""@eng , """Theprubicine"""@eng , """[8S-[8Alpha,10alpha(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione"""@eng , """THP-DOX"""@eng , """Pinorubicin"""@eng , """theprubicin"""@eng , """Tepirubicin"""@eng , """1609RB"""@eng ; skos:definition """An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38775&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38775&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1197\" NCI Thesaurus)"""@eng ; ; ; """1219"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """72496-41-4"""^^xsd:string ; """C1197"""^^xsd:string ; """333054"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0071126"""^^xsd:string ; umls:cui """C0950476"""^^xsd:string ; umls:cui """C1519094"""^^xsd:string ; umls:cui """C1519093"""^^xsd:string ; umls:cui """C1524054"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent bladder cancer"""@eng ; skos:notation """CDR0000038774"""^^xsd:string ; skos:altLabel """carcinoma of the bladder, recurrent"""@eng , """recurrent cancer of the bladder"""@eng , """cancer of the bladder, recurrent"""@eng , """recurrent carcinoma of the bladder"""@eng , """bladder cancer, recurrent"""@eng ; rdfs:subClassOf ; """bladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1218"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278827"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IV bladder cancer"""@eng ; skos:notation """CDR0000038777"""^^xsd:string ; skos:altLabel """cancer of the bladder, metastatic"""@eng , """stage IV cancer of the bladder"""@eng , """carcinoma of the bladder, stage IV"""@eng , """cancer of the bladder, stage IV"""@eng , """metastatic cancer of the bladder"""@eng , """carcinoma of the bladder, metastatic"""@eng , """stage IV carcinoma of the bladder"""@eng , """bladder cancer, metastatic"""@eng , """metastatic bladder cancer"""@eng , """bladder cancer, stage IV"""@eng , """metastatic carcinoma of the bladder"""@eng ; rdfs:subClassOf ; """bladder cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1220"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278828"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent Ewing's sarcoma/primitive neuroectodermal tumor"""@eng ; skos:notation """CDR0000038776"""^^xsd:string ; skos:altLabel """Ewing's sarcoma, recurrent"""@eng , """recurrent Ewing's sarcoma/PNET"""@eng ; rdfs:subClassOf ; """122"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0796549"""^^xsd:string ; umls:cui """C0278590"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage II testicular cancer"""@eng ; skos:notation """CDR0000038779"""^^xsd:string ; skos:altLabel """carcinoma of the testis, stage II"""@eng , """cancer of the testis, stage II"""@eng , """stage II testis cancer"""@eng , """testicular cancer, stage II"""@eng , """stage II cancer of the testis"""@eng , """stage II carcinoma of the testis"""@eng , """testicle cancer, stage II"""@eng , """testis cancer, stage II"""@eng ; rdfs:subClassOf ; """testicular cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1226"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278832"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I testicular cancer"""@eng ; skos:notation """CDR0000038778"""^^xsd:string ; skos:altLabel """testicle cancer, stage I"""@eng , """cancer of the testis, stage I"""@eng , """carcinoma of the testis, stage I"""@eng , """testicular cancer, stage I"""@eng , """stage I testis cancer"""@eng , """stage I cancer of the testis"""@eng , """testis cancer, stage I"""@eng , """stage I carcinoma of the testis"""@eng ; rdfs:subClassOf ; """testicular cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1225"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278831"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melanoma helper peptide vaccine"""@eng ; skos:notation """CDR0000341633"""^^xsd:string ; skos:altLabel """MHP VAC"""@eng ; skos:definition """A multivalent vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=341633&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=341633&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38700\" NCI Thesaurus)"""@eng ; ; ; ; ; """2003-10-25"""^^xsd:string ; """C38700"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-29"""^^xsd:string ; umls:cui """C1328093"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """multi-epitope melanoma peptide vaccine"""@eng ; skos:notation """CDR0000341632"""^^xsd:string ; skos:altLabel """MULTI-EP MP VAC"""@eng ; skos:definition """A peptide cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=341632&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=341632&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38695\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """2003-10-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-31"""^^xsd:string ; """C38695"""^^xsd:string ; umls:cui """C1328092"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/multi-epitope melanoma peptide vaccine/sargramostim/tetanus toxoid helper peptide vaccine"""@eng ; skos:notation """CDR0000341635"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/MULTI-EP MP VAC/TET TOX PEP VAC"""@eng ; ; ; ; """Drug/agent combination"""^^xsd:string ; """2003-10-22"""^^xsd:string ; """2003-10-25"""^^xsd:string ; umls:cui """C1832056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Montanide ISA-51/multi-epitope melanoma peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000341634"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/MULTI-EP MP VAC"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328094"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melanoma helper peptide vaccine/Montanide ISA-51/sargramostim"""@eng ; skos:notation """CDR0000341637"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/MHP VAC"""@eng ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328097"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """melanoma helper peptide vaccine/Montanide ISA-51/multi-epitope melanoma peptide vaccine/sargramostim"""@eng ; skos:notation """CDR0000341636"""^^xsd:string ; skos:altLabel """GM-CSF/ISA-51/MHP VAC/MULTI-EP MP VAC"""@eng ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-22"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328096"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/dacarbazine/doxorubicin/vincristine"""@eng ; skos:notation """CDR0000040417"""^^xsd:string ; skos:altLabel """BLEO/DOX/DTIC/VCR"""@eng , """ABOD"""@eng ; ; ; ; ; """3285"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0050379"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prednisolone/vincristine"""@eng ; skos:notation """CDR0000040416"""^^xsd:string ; skos:altLabel """PRDL/VCR"""@eng ; ; ; """3284"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0078413"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/etoposide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040415"""^^xsd:string ; skos:altLabel """ECMV"""@eng , """CTX/MTX/VCR/VP-16"""@eng ; ; ; ; ; """3283"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0208707"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """etoposide/ifosfamide"""@eng ; skos:notation """CDR0000040414"""^^xsd:string ; skos:altLabel """IFF/VP-16"""@eng , """EIM"""@eng ; ; ; """3281"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280068"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040413"""^^xsd:string ; skos:altLabel """VMV-VAC"""@eng , """CTX/DOX/MTX/VCR/VP-16"""@eng ; ; ; ; ; ; """3279"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0054553"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/daunorubicin/prednisone/thioguanine/vincristine"""@eng ; skos:notation """CDR0000040412"""^^xsd:string ; skos:altLabel """DATVP"""@eng , """ARA-C/DNR/PRED/TG/VCR"""@eng ; ; ; ; ; ; """3278"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0057152"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/mitomycin"""@eng ; skos:notation """CDR0000040411"""^^xsd:string ; skos:altLabel """DOX/MITO/VP-16"""@eng , """VAM"""@eng ; ; ; ; """3277"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280065"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/mercaptopurine"""@eng ; skos:notation """CDR0000040410"""^^xsd:string ; skos:altLabel """BCNU/MP"""@eng ; ; ; """3273"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280064"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """catumaxomab"""@eng ; skos:notation """CDR0000487002"""^^xsd:string ; """2006-06-02"""^^xsd:string ; """C62445"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-18"""^^xsd:string ; umls:cui """C1831854"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorambucil/prednisone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000040419"""^^xsd:string ; skos:altLabel """CLB/PCB/PRED/VBL"""@eng , """ChlVPP"""@eng ; ; ; ; ; """3287"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280073"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/methotrexate/vincristine"""@eng ; skos:notation """CDR0000040418"""^^xsd:string ; skos:altLabel """CTX/MTX/VCR"""@eng , """COM"""@eng ; ; ; ; """3286"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066480"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/EKB-569"""@eng ; skos:notation """CDR0000378087"""^^xsd:string ; skos:altLabel """EKB 569/SC-58635"""@eng ; ; ; """2004-07-23"""^^xsd:string ; """2004-06-28"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541450"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMT2003"""@eng ; skos:notation """CDR0000489244"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-06-09"""^^xsd:string ; umls:cui """C1831883"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cetuximab/docetaxel/irinotecan"""@eng ; skos:notation """CDR0000256467"""^^xsd:string ; skos:altLabel """CPT-11/MOAB C225/TXT"""@eng ; ; ; ; """2002-07-16"""^^xsd:string ; """11375"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327751"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I pancreatic cancer"""@eng ; skos:notation """CDR0000042468"""^^xsd:string ; skos:altLabel """stage I pancreas cancer"""@eng , """pancreas cancer, stage I"""@eng , """pancreatic cancer, stage I"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """59"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C1167720"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """plasmapheresis"""@eng ; skos:notation """CDR0000042469"""^^xsd:string ; skos:altLabel """therapeutic plasmapheresis"""@eng , """plasma exchange"""@eng , """therapeutic plasma exchange"""@eng ; """590"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0032134"""^^xsd:string ; umls:cui """C0032113"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/fluorouracil/gemcitabine/leucovorin calcium"""@eng ; skos:notation """CDR0000378334"""^^xsd:string ; skos:altLabel """CF/dFdC/5-FU/SC-58635"""@eng ; ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541452"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous dendritic cells/trastuzumab/vinorelbine"""@eng ; skos:notation """CDR0000378335"""^^xsd:string ; skos:altLabel """ADC/MOAB HER2/VNB"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541453"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/capecitabine/docetaxel"""@eng ; skos:notation """CDR0000378336"""^^xsd:string ; skos:altLabel """CAPE/MOAB VEGF/TXT"""@eng ; ; ; ; """2004-07-23"""^^xsd:string ; """2004-07-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541454"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant interferon alpha-2a"""@eng ; skos:notation """CDR0000467189"""^^xsd:string ; skos:altLabel """Interferon alfa 2a"""@eng , """Alferon"""@eng , """Recombinant Interferon Alfa-2a"""@eng , """IFN-Alpha 2"""@eng , """Roceron"""@eng , """Roceron-A"""@eng , """Roferon-A"""@eng , """Laroferon"""@eng , """rHuIFN-a 2a"""@eng , """IFN alpha-2A"""@eng , """Alpha 2 Interferon"""@eng , """Interferon Alfa"""@eng ; skos:definition """A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli. Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04) Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467189&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467189&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1952\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """4747"""^^xsd:string ; """2006-03-03"""^^xsd:string ; """C1952"""^^xsd:string ; """1913"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """377523"""^^xsd:string ; """367982"""^^xsd:string ; """76543-88-9"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1512831"""^^xsd:string ; umls:cui """C1512833"""^^xsd:string ; umls:cui """C1512832"""^^xsd:string ; umls:cui """C1622507"""^^xsd:string ; umls:cui """C0021734"""^^xsd:string ; umls:cui """C0699179"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recombinant bispecific single-chain antibody rM28"""@eng ; skos:notation """CDR0000467183"""^^xsd:string ; skos:definition """A recombinant, bispecific, single chain antibody directed against both the T-cell surface-associated costimulatory molecule CD28 and a melanoma-associated proteoglycan (MAPG) with potential antitumor activity. By targeting both CD28 and MAPG, recombinant bispecific single-chain antibody rM28 enhances cytotoxic T-cell recognition of melanoma cells, which may result in immune effector cell-mediated tumor cell death and a decrease in distant metastases. This agent appears to have a long serum half-life secondary to the formation of dimers. When activated, CD28 facilitates interactions between T-cells and other immune effector cells resulting in cytotoxic T-lymphocyte responses; MAPG is a surface antigen expressed on the majority of melanomas, including primary cutaneous, ocular and metastatic melanomas. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467183&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467183&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C60882\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """C60882"""^^xsd:string ; """2006-07-17"""^^xsd:string ; """2006-02-21"""^^xsd:string ; umls:cui """C1831730"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """herba scutellaria barbata"""@eng ; skos:notation """CDR0000467184"""^^xsd:string ; skos:definition """A Chinese herb isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba Scutellaria barbata has been shown to induce apoptosis of ovarian and breast tumor cells in vitro. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467184&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=467184&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2661\" NCI Thesaurus)"""@eng ; """2006-10-02"""^^xsd:string ; """2006-02-21"""^^xsd:string ; """C2661"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1134548"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """HER-2-neu, CEA peptides/GM-CSF, Montanide ISA-51 vaccine"""@eng ; skos:notation """CDR0000442901"""^^xsd:string ; skos:definition """A vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic properties. HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. The GM-CSF adjuvant stimulates the proliferation of monocytes and monocyte differentiation into macrophages and dendritic cells, immunohematopoietic elements with important antitumoral functions. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=442901&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=442901&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48392\" NCI Thesaurus)"""@eng ; """2005-08-24"""^^xsd:string ; """C48392"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-07-20"""^^xsd:string ; umls:cui """C1708269"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/PI-88"""@eng ; skos:notation """CDR0000442900"""^^xsd:string ; skos:altLabel """DTIC/PI 88"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-08-05"""^^xsd:string ; """2005-08-03"""^^xsd:string ; umls:cui """C1831697"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIB non-small cell lung cancer"""@eng ; skos:notation """CDR0000038939"""^^xsd:string ; skos:altLabel """stage IIIB NSCLC"""@eng , """non-oat cell lung cancer, stage IIIB"""@eng , """stage IIIB nonsmall cell lung cancer"""@eng , """nonsmall cell lung cancer, stage IIIB"""@eng , """lung cancer, non-small cell, stage IIIB"""@eng , """NSCLC, stage IIIB"""@eng , """lung cancer, nonsmall cell, stage IIIB"""@eng , """non-small cell lung cancer, stage IIIB"""@eng , """lung cancer, non-oat cell, stage IIIB"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1448"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278984"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage IIIA non-small cell lung cancer"""@eng ; skos:notation """CDR0000038938"""^^xsd:string ; skos:altLabel """non-oat cell lung cancer, stage IIIA"""@eng , """nonsmall cell lung cancer, stage IIIA"""@eng , """lung cancer, non-small cell, stage IIIA"""@eng , """stage IIIA NSCLC"""@eng , """NSCLC, stage IIIA"""@eng , """non-small cell lung cancer, stage IIIA"""@eng , """lung cancer, non-oat cell, stage IIIA"""@eng , """lung cancer, nonsmall cell, stage IIIA"""@eng , """stage IIIA nonsmall cell lung cancer"""@eng ; rdfs:subClassOf ; """non-small cell lung cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1447"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278983"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """goldenrod"""@eng ; skos:notation """CDR0000459961"""^^xsd:string ; skos:definition """A group of North American weedy herbs belonging to the genus Solidago (family Asteraceae) with potential chemopreventive activities. Goldenrod may also possess anti-inflammatory, antiseptic properties, diuretic and antifungal properties, and may relieve chemotherapy-induced side-effects. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459961&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459961&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52191\" NCI Thesaurus)"""@eng ; """Drug/agent"""^^xsd:string ; """2005-12-22"""^^xsd:string ; """2006-08-07"""^^xsd:string ; """C52191"""^^xsd:string ; umls:cui """C0771937"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/PHY906"""@eng ; skos:notation """CDR0000357578"""^^xsd:string ; skos:altLabel """CAPE/PHY-906"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328235"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """angiostatin/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000357573"""^^xsd:string ; skos:altLabel """ANGIOSTAT/CBDCA/TAX"""@eng ; ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328234"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """angiostatin"""@eng ; skos:notation """CDR0000357572"""^^xsd:string ; skos:altLabel """PLG"""@eng , """Kringles 1-4 of Plasminogen"""@eng ; skos:definition """Encoded by human PLG Gene (Plasminogen Family) and expressed in the kidney, angiostatin is an angiogenesis inhibitor present in plasma and other extracellular fluids that blocks neovascularization and mediates suppression of metastases. Containing at least three kringles, angiostatin is a 38-kD internal (serine protease) proteolytic fragment of plasminogen. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357572&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=357572&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C17910\" NCI Thesaurus)"""@eng ; ; """2004-02-20"""^^xsd:string ; """C17910"""^^xsd:string ; """2006-12-20"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C3887700"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PHY906"""@eng ; skos:notation """CDR0000357577"""^^xsd:string ; skos:altLabel """PHY-906"""@eng ; ; ; """2004-02-20"""^^xsd:string ; """2004-02-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1260030"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent pancreatic cancer"""@eng ; skos:notation """CDR0000042949"""^^xsd:string ; skos:altLabel """pancreatic cancer, recurrent"""@eng , """pancreas cancer, recurrent"""@eng , """recurrent pancreas cancer"""@eng ; rdfs:subClassOf ; """pancreatic cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """71"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854777"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """p53 gene"""@eng ; skos:notation """CDR0000042948"""^^xsd:string ; rdfs:subClassOf ; """7041"""^^xsd:string ; """Gene"""^^xsd:string ; umls:cui """C0079419"""^^xsd:string ; umls:tui """T028"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fludarabine/mitoxantrone/rituximab"""@eng ; skos:notation """CDR0000445106"""^^xsd:string ; skos:altLabel """DHAD/FAMP/MOAB IDEC-C2B8"""@eng ; ; ; ; """2005-08-11"""^^xsd:string ; """2005-08-12"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831702"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """hormonal changes"""@eng ; skos:notation """CDR0000038438"""^^xsd:string ; rdfs:subClassOf ; """11055"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C1134488"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bevacizumab/temsirolimus"""@eng ; skos:notation """CDR0000430566"""^^xsd:string ; skos:altLabel """CCI-779/MOAB VEGF"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-04-23"""^^xsd:string ; """2005-05-05"""^^xsd:string ; umls:cui """C1541565"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """juvenile myelomonocytic leukemia"""@eng ; skos:notation """CDR0000038439"""^^xsd:string ; skos:altLabel """myelomonocytic leukemia, juvenile"""@eng , """JMML"""@eng , """juvenile chronic myeloid leukemia"""@eng , """juvenile chronic myelogenous leukemia"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """2003-10-06"""^^xsd:string ; """myelodysplastic/myeloproliferative diseases"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """11056"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0349639"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CP-461"""@eng ; skos:notation """CDR0000354217"""^^xsd:string ; skos:altLabel """CP461"""@eng ; """2004-01-23"""^^xsd:string ; """2004-01-21"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1101538"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """poly IC"""@eng ; skos:notation """CDR0000039558"""^^xsd:string ; skos:altLabel """poly I-poly C"""@eng , """poly I:C"""@eng , """Polyinosinic-polycytidylic Acid"""@eng , """polyinosinic acid-polycytidylic acid"""@eng , """5'-Inosinic Acid, Homopolymer Complex with 5'-Cytidylic Acid Homopolymer"""@eng , """polyinosinic acid.polycytidylic acid"""@eng , """polyinosate.polycytidylate"""@eng , """polyinosate-polycytidylate"""@eng , """poly (I).poly (C)"""@eng , """poly (rI). poly (rC)"""@eng , """poly (I)-poly (C)"""@eng , """poly (rI)- poly (rC)"""@eng , """poly I.poly C"""@eng ; skos:definition """A synthetic polyinosinic-polycytidylic acid double-stranded RNA. Poly IC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the number and tumoricidal activities of various immunohematopoietic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39558&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39558&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C758\" NCI Thesaurus)"""@eng ; """2207"""^^xsd:string ; """C758"""^^xsd:string ; """397"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """128576"""^^xsd:string ; """24939-03-5"""^^xsd:string ; umls:cui """C0032414"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """poly ICLC"""@eng ; skos:notation """CDR0000039559"""^^xsd:string ; skos:altLabel """Poly I:PolyC with Poly-1-Lysine Stabilizer"""@eng , """Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose"""@eng , """poly I:poly C with poly-1-lysine stabilizer"""@eng , """Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose"""@eng , """stabilized polyriboinosinic/polyribocytidylic acid"""@eng ; skos:definition """A synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA. Poly ICLC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the tumoricidal activities of various immunohematopoietic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39559&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39559&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1198\" NCI Thesaurus)"""@eng ; ; ; """2208"""^^xsd:string ; """39200"""^^xsd:string ; """2006-09-11"""^^xsd:string ; """59789-29-6"""^^xsd:string ; """301463"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """1908"""^^xsd:string ; """C1198"""^^xsd:string ; umls:cui """C0071359"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piperazinedione"""@eng ; skos:notation """CDR0000039556"""^^xsd:string ; skos:altLabel """Merck Compound 593A;"""@eng , """2, 5-piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride"""@eng , """2,5-piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3.alpha.(2S*,5R*),6.alpha.(2S*,5R*)]]- (9CI)"""@eng , """compound 593A"""@eng , """593A"""@eng , """PZD dihydrochloride, 3,6-bis(5-chloro-2-piperidinyl)-, dihydrochloride"""@eng , """PZD"""@eng ; skos:definition """A crystalline antibiotic, fermentation product of actinomycetes with alkylating activity. Piperazinedione alkylates DNA molecules, thereby prevents completion of DNA replication leading to cell cycle arrest. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39556&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39556&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1401\" NCI Thesaurus)"""@eng ; """2205"""^^xsd:string ; """10158"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """C1401"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """135758"""^^xsd:string ; """41109-80-2"""^^xsd:string ; umls:cui """C0137098"""^^xsd:string ; umls:cui """C0098709"""^^xsd:string ; umls:cui """C0888240"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """poly AU"""@eng ; skos:notation """CDR0000039557"""^^xsd:string ; skos:altLabel """poly A:U"""@eng , """Polyadenylic Polyuridylic Acid"""@eng ; skos:definition """A synthetic polyadenylic-polyuridylic acid double-stranded RNA. Poly AU may stimulate the release of cytotoxic cytokines and, by inducing the production of interferon, may increase the number and tumoricidal activities of various immunohematopoietic cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39557&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39557&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C757\" NCI Thesaurus)"""@eng ; """2206"""^^xsd:string ; """C757"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2655"""^^xsd:string ; """24936-38-7"""^^xsd:string ; umls:cui """C0032402"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """phosphorus P32"""@eng ; skos:notation """CDR0000039554"""^^xsd:string ; skos:altLabel """P32"""@eng , """32-P"""@eng ; skos:definition """A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39554&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39554&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1698\" NCI Thesaurus)"""@eng ; """2203"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1698"""^^xsd:string ; """2006-07-20"""^^xsd:string ; umls:cui """C0851287"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:tui """T196"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """piperacillin sodium"""@eng ; skos:notation """CDR0000039555"""^^xsd:string ; skos:altLabel """Pipracil"""@eng , """T-1220"""@eng , """CL 227,193"""@eng ; ; """2204"""^^xsd:string ; """C749"""^^xsd:string ; """2006-11-28"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700463"""^^xsd:string ; umls:cui """C0008877"""^^xsd:string ; umls:cui """C0701912"""^^xsd:string ; umls:cui """C0701913"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peplomycin"""@eng ; skos:notation """CDR0000039552"""^^xsd:string ; skos:altLabel """PEP"""@eng , """n1-[3[[(S)-alpha-methylbenzyl]amino]propyl]bleomycinamide"""@eng , """pepleomycin"""@eng , """(S)-n1-[3-[(1-phenylethyl)amino]propyl]bleomycinamide"""@eng ; skos:definition """A semisynthetic analog of Bleomycin, a mixture of several basic glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus. Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA. This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39552&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39552&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1399\" NCI Thesaurus)"""@eng ; """2201"""^^xsd:string ; """68247-85-8"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1399"""^^xsd:string ; """276382"""^^xsd:string ; umls:cui """C0135981"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pentamethylmelamine"""@eng ; skos:notation """CDR0000039553"""^^xsd:string ; skos:altLabel """Melamine"""@eng , """N,N,N',N',N\"-pentamethyl-1,3,5-triazine"""@eng , """Pentamethylmelamine Monohydrochloride"""@eng , """PMM"""@eng , """1,3,5-Triazine-2,4,6-triamine, N,N,N',N', N''-pentamethyl-, monohydrochloride (9CI)"""@eng , """Pentamethylmelamine MonoHCl"""@eng , """melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride"""@eng ; skos:definition """A principal metabolite of hexamethylmelamine with antineoplastic activity. Pentamethylmelamine alkylates DNA and other macromolecules and forms DNA intrastrand and DNA-protein crosslinks, thereby preventing DNA replication. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39553&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39553&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1189\" NCI Thesaurus)"""@eng ; """2202"""^^xsd:string ; """14585"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """118742"""^^xsd:string ; """C1189"""^^xsd:string ; """16268-62-5"""^^xsd:string ; umls:cui """C0890530"""^^xsd:string ; umls:cui """C0065896"""^^xsd:string ; umls:cui """C0070302"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anal cancer"""@eng ; skos:notation """CDR0000039550"""^^xsd:string ; skos:altLabel """Anal cancer"""@eng , """anus cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """22"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279637"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """penberol"""@eng ; skos:notation """CDR0000039551"""^^xsd:string ; """2200"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0070218"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytologic sampling"""@eng ; skos:notation """CDR0000038623"""^^xsd:string ; ; rdfs:subClassOf ; """11251"""^^xsd:string ; """2006-04-21"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; umls:cui """C1524035"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """methotrexate/prednisone"""@eng ; skos:notation """CDR0000043519"""^^xsd:string ; skos:altLabel """MTX/PRED"""@eng ; ; ; """8763"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796682"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gp100 antigen/incomplete Freund's adjuvant/sargramostim/tyrosinase peptide"""@eng ; skos:notation """CDR0000043518"""^^xsd:string ; skos:altLabel """GM-CSF/gp100/IFA/TYRP"""@eng ; ; ; ; ; """8762"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796681"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CRL 1005/gp100 antigen/incomplete Freund's adjuvant/tyrosinase peptide"""@eng ; skos:notation """CDR0000043517"""^^xsd:string ; skos:altLabel """CRL 1005/gp100/IFA/TYRP"""@eng ; ; ; ; ; """8761"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0796680"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """microscopy"""@eng ; skos:notation """CDR0000043516"""^^xsd:string ; rdfs:subClassOf owl:Thing ; """8760"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0026018"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """electron microscopy"""@eng ; skos:notation """CDR0000043515"""^^xsd:string ; skos:altLabel """EM"""@eng , """microscopy, electron"""@eng ; rdfs:subClassOf ; """8759"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0026019"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pancreatic enzymes"""@eng ; skos:notation """CDR0000043514"""^^xsd:string ; skos:altLabel """Pancrecarb"""@eng , """pancrelipase"""@eng ; """8754"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0920330"""^^xsd:string ; umls:cui """C0917975"""^^xsd:string ; umls:cui """C0770343"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T126"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stereotactic radiosurgery"""@eng ; skos:notation """CDR0000043513"""^^xsd:string ; ; rdfs:subClassOf ; """8751"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0085203"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody MN-14"""@eng ; skos:notation """CDR0000043512"""^^xsd:string ; skos:altLabel """In 111 monoclonal antibody MN-14"""@eng , """In111 MOAB MN-14"""@eng , """In 111 MOAB MN-14"""@eng , """indium In 111 MOAB MN-14"""@eng ; """8749"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0879254"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """yttrium Y 90 monoclonal antibody MN-14"""@eng ; skos:notation """CDR0000043511"""^^xsd:string ; skos:altLabel """Y 90 MoAb MN-14"""@eng , """MOAB MN-14, yttrium Y 90"""@eng , """Y90 monoclonal antibody MN-14"""@eng , """Y90 MOAB MN-14"""@eng , """Y 90 Monoclonal Antibody MN-14"""@eng , """monoclonal antibody MN-14, yttrium Y 90"""@eng , """yttrium Y 90 MOAB MN-14"""@eng ; skos:definition """A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Y 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43511&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43511&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2249\" NCI Thesaurus)"""@eng ; """8748"""^^xsd:string ; """C2249"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-28"""^^xsd:string ; umls:cui """C0879253"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indium In 111 monoclonal antibody Lym-1"""@eng ; skos:notation """CDR0000043510"""^^xsd:string ; skos:altLabel """In111 MOAB Lym-1"""@eng , """In 111 monoclonal antibody Lym-1"""@eng , """In 111 MOAB Lym-1"""@eng , """indium In 111 MOAB Lym-1"""@eng ; """8747"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0796676"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluoxymesterone/thiotepa/vinblastine"""@eng ; skos:notation """CDR0000040979"""^^xsd:string ; skos:altLabel """DOX/FXM/TSPA/VBL"""@eng , """TsAVbH"""@eng , """VATH"""@eng ; ; ; ; """4017"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0075860"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000040967"""^^xsd:string ; skos:altLabel """MIFA"""@eng , """DOX/5-FU/MITO"""@eng , """DMF"""@eng , """FAM"""@eng ; ; ; ; """4004"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0060056"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000040966"""^^xsd:string ; skos:altLabel """DOX/5-FU/MTX"""@eng , """MEFA"""@eng , """FAMTX"""@eng ; ; ; ; """4003"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0051571"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/fluorouracil"""@eng ; skos:notation """CDR0000040965"""^^xsd:string ; skos:altLabel """FA"""@eng , """AFA"""@eng , """DOX/5-FU"""@eng ; ; ; """4002"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280580"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/procarbazine/vincristine"""@eng ; skos:notation """CDR0000040964"""^^xsd:string ; skos:altLabel """DOX/PCB/VCR/VP-16"""@eng , """VAPE"""@eng , """APVV"""@eng ; ; ; ; ; """4001"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0291011"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/etoposide/methotrexate"""@eng ; skos:notation """CDR0000040963"""^^xsd:string ; skos:altLabel """EMCC (EMC2)"""@eng , """MACE"""@eng , """CEM"""@eng , """ARA-C/MTX/VP-16"""@eng ; ; ; ; """4000"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0280578"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small cell lung cancer"""@eng ; skos:notation """CDR0000040962"""^^xsd:string ; skos:altLabel """oat cell lung cancer"""@eng , """SCLC"""@eng , """Lung cancer, small cell"""@eng , """lung cancer, small cell"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """40"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0149925"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I adult Hodgkin's lymphoma"""@eng ; skos:notation """CDR0000040961"""^^xsd:string ; skos:altLabel """adult HD, stage I"""@eng , """lymphoma, stage I adult Hodgkin's"""@eng , """Hodgkin's lymphoma, stage I, adult"""@eng , """stage I adult Hodgkin's disease"""@eng , """stage I adult HD"""@eng , """Hodgkin's disease, stage I, adult"""@eng , """adult Hodgkin's disease, stage I"""@eng , """HD, stage I, adult"""@eng , """HD, adult, stage I"""@eng ; rdfs:subClassOf ; """2003-01-09"""^^xsd:string ; """adult Hodgkin's lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278470"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/etoposide"""@eng ; skos:notation """CDR0000040960"""^^xsd:string ; skos:altLabel """CDE"""@eng , """ACE-II"""@eng , """CED"""@eng , """ACE"""@eng , """CAVP"""@eng , """CTX/DOX/VP-16"""@eng , """CAVP-16"""@eng , """AVE"""@eng , """CAE"""@eng ; ; ; ; """3999"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0108844"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """epithelial mesothelioma"""@eng ; skos:notation """CDR0000039969"""^^xsd:string ; skos:altLabel """mesothelial sarcoma, epithelial"""@eng , """mesothelioma, epithelial"""@eng , """sarcoma, mesothelial, epithelial"""@eng ; rdfs:subClassOf ; """2674"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0862312"""^^xsd:string ; umls:cui """C0279678"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """peritoneal cavity cancer"""@eng ; skos:notation """CDR0000040969"""^^xsd:string ; skos:altLabel """Peritoneal cavity cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4006"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0153467"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fallopian tube cancer"""@eng ; skos:notation """CDR0000040968"""^^xsd:string ; skos:altLabel """cancer of the fallopian tube"""@eng , """Fallopian tube cancer"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4005"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0238122"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pamidronate"""@eng ; skos:notation """CDR0000039149"""^^xsd:string ; skos:altLabel """Aminomux"""@eng , """Aredia"""@eng , """aminohydroxypropylidene diphosphonate"""@eng , """Pamidronate Disodium"""@eng , """GCP-23339A"""@eng , """APD"""@eng ; skos:definition """A synthetic bisphosphonate agent. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39149&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39149&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1345\" NCI Thesaurus)"""@eng ; ; ; ; ; ; """1769"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """57248-88-1"""^^xsd:string ; """C1345"""^^xsd:string ; """720699"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1518864"""^^xsd:string ; umls:cui """C0043603"""^^xsd:string ; umls:cui """C1522026"""^^xsd:string ; umls:cui """C0104018"""^^xsd:string ; umls:cui """C0356588"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anguidine"""@eng ; skos:notation """CDR0000039148"""^^xsd:string ; skos:altLabel """3.Alpha,4.Beta, 15-triol, 12, 13-epoxy-,4, 15-diacetate (8CI)"""@eng , """4.Beta, 15-diacetoxy-3.alpha-hydroxy-12, 13-epoxytrichothec-9-ene"""@eng , """Trichothec-9-ene-3,4, 15-triol, 12,13-epoxy-, 4,15-diacetate"""@eng , """diacetoxyscirpenol"""@eng , """DAS"""@eng , """Trichothec-9-ene-3, 4, 15-triol, 12, 13-epoxy-, 4, 15-diacetate (3.alpha, 4.beta)-(9CI)"""@eng , """MM 4462"""@eng , """Anguidin"""@eng , """4, 15-Diacetoxyscirpen-3-ol"""@eng ; skos:definition """A trichothecene mycotoxin and potent teratogen. Anguidine inhibits initiation of protein synthesis, resulting in the death of rapidly proliferating cells. Anguidine also has been shown to both potentiate and protect against the cytotoxic effects of other drugs. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39148&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39148&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1068\" NCI Thesaurus)"""@eng ; """1768"""^^xsd:string ; """C1068"""^^xsd:string ; """2270-40-8"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """11309"""^^xsd:string ; """177378"""^^xsd:string ; """141537"""^^xsd:string ; """2006-12-27"""^^xsd:string ; umls:cui """C1524016"""^^xsd:string ; umls:cui """C0057671"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """annual screening"""@eng ; skos:notation """CDR0000038620"""^^xsd:string ; ; rdfs:subClassOf ; """11248"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134631"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminopterin"""@eng ; skos:notation """CDR0000039141"""^^xsd:string ; skos:altLabel """4-Aminopteroylglutamic Acid"""@eng , """APGA"""@eng , """Aminopterin Sodium"""@eng , """4-Aminofolic Acid"""@eng , """Aminopteroylglutamic Acid"""@eng ; skos:definition """A synthetic derivative of pterins with antineoplastic and immunosuppressive properties. As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39141&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39141&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C235\" NCI Thesaurus)"""@eng ; ; """1761"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C235"""^^xsd:string ; """54-62-6"""^^xsd:string ; """739"""^^xsd:string ; umls:cui """C0002583"""^^xsd:string ; umls:cui """C0282048"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T131"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminoglutethimide"""@eng ; skos:notation """CDR0000039140"""^^xsd:string ; skos:altLabel """Cytadren"""@eng , """AGT"""@eng , """Elipten"""@eng , """AG"""@eng ; ; ; ; ; ; ; ; """1760"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0002555"""^^xsd:string ; umls:cui """C0591920"""^^xsd:string ; umls:cui """C0701949"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amphotericin B deoxycholate"""@eng ; skos:notation """CDR0000039143"""^^xsd:string ; skos:altLabel """Fungizone"""@eng , """amphotericin-B"""@eng , """amphotericin B"""@eng ; skos:definition """The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, resulting in depolarization of the membrane; alterations in cell membrane permeability and leakage of important intracellular components; and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39143&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39143&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62201\" NCI Thesaurus)"""@eng ; ; ; """2006-08-07"""^^xsd:string ; """1763"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C62201"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0002679"""^^xsd:string ; umls:cui """C0051761"""^^xsd:string ; umls:cui """C0812405"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amsacrine"""@eng ; skos:notation """CDR0000039142"""^^xsd:string ; skos:altLabel """acridinyl anisidide"""@eng , """Amsidine"""@eng , """4'-(9-Acridinylamino)methane-sulfon-m-anisidide"""@eng , """m-AMSA"""@eng , """SN-11841"""@eng , """AMSA"""@eng , """Lamasine"""@eng , """Amekrin"""@eng , """N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide"""@eng , """Amsidyl"""@eng , """Cain's Acridine"""@eng , """CI-880"""@eng , """Amsa P-D"""@eng ; skos:definition """An aminoacridine derivative with potent antineoplastic properties. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39142&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39142&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C240\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """1762"""^^xsd:string ; """249992"""^^xsd:string ; """51264-14-3"""^^xsd:string ; """2006-07-26"""^^xsd:string ; """C240"""^^xsd:string ; """13750"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0591085"""^^xsd:string ; umls:cui """C0919345"""^^xsd:string ; umls:cui """C1523988"""^^xsd:string ; umls:cui """C0002699"""^^xsd:string ; umls:cui """C1510879"""^^xsd:string ; umls:cui """C1510878"""^^xsd:string ; umls:cui """C0878034"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """amikacin sulfate"""@eng ; skos:notation """CDR0000039145"""^^xsd:string ; skos:altLabel """AMIKA"""@eng , """Amikin"""@eng ; ; ; """1765"""^^xsd:string ; """2006-11-30"""^^xsd:string ; """C230"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0700949"""^^xsd:string ; umls:cui """C0002499"""^^xsd:string ; umls:cui """C0002501"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aminothiadiazole"""@eng ; skos:notation """CDR0000039144"""^^xsd:string ; skos:altLabel """ATDA"""@eng , """Amino 134-Thiadiazole"""@eng , """2-Amino-1,3,4-thiadiazole"""@eng , """1,3, 4-Thiadiazol-2-amine (9CI)"""@eng , """1,3,4-Thiadiazole, 2-Amino"""@eng , """1,3, 4-Thiadiazole, 2-Amino- (8CI)"""@eng , """2-Aminothiadiazole"""@eng , """A-TD"""@eng , """2-Amino-1-thia-3,4-diazole"""@eng , """FDA 0084"""@eng ; skos:definition """A synthetic derivative of nicotinamide adenine dinucleotide (NAD). Aminothiadiazole competitively inhibits inosine 5-monophosphate dehydrogenase, thereby disrupting the regulation of cell proliferation and differentiation in a number of cells. This agent is also a selective human adenosine A3 receptor antagonist. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39144&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39144&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1335\" NCI Thesaurus)"""@eng ; """1764"""^^xsd:string ; """4005-51-0"""^^xsd:string ; """11820"""^^xsd:string ; """C1335"""^^xsd:string ; """2006-12-11"""^^xsd:string ; """4728"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1522018"""^^xsd:string ; umls:cui """C0092419"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ametantrone"""@eng ; skos:notation """CDR0000039147"""^^xsd:string ; """1767"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0102923"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """aniline mustard"""@eng ; skos:notation """CDR0000039146"""^^xsd:string ; skos:altLabel """SK 592"""@eng , """TL 476"""@eng , """N,N-bis(2-chloroethyl)benzenamine"""@eng , """beta, beta'-dichlorodiethylaniline"""@eng , """Benzenamine, N, N-bis(2-chloroethyl)-(9CI)"""@eng , """Lymphoquin"""@eng , """Lymphochin"""@eng , """N,N-bis(2-chloroethyl)aniline"""@eng , """Lymphocin"""@eng , """A 14489"""@eng , """mesylerythrol"""@eng , """CB 1074"""@eng , """phenylbis[2-chloroethylamine]"""@eng ; skos:definition """An alkylating mustard with antineoplastic activity. Aniline mustard forms covalent linkages with nucleophilic centers, resulting in depurination, base miscoding and strand scission, and crosslinking of DNA strands, all of which contribute to its cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39146&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39146&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C249\" NCI Thesaurus)"""@eng ; """1766"""^^xsd:string ; """5886"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """553-27-5"""^^xsd:string ; """C249"""^^xsd:string ; """18429"""^^xsd:string ; umls:cui """C1522675"""^^xsd:string ; umls:cui """C1522676"""^^xsd:string ; umls:cui """C1522677"""^^xsd:string ; umls:cui """C0003040"""^^xsd:string ; umls:cui """C1142666"""^^xsd:string ; umls:cui """C1522678"""^^xsd:string ; umls:cui """C0878245"""^^xsd:string ; umls:cui """C0878246"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Sialyl Tn antigen"""@eng ; skos:notation """CDR0000041616"""^^xsd:string ; skos:altLabel """STn antigen"""@eng ; ; ; """4778"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0074480"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chamomile"""@eng ; skos:notation """CDR0000041614"""^^xsd:string ; skos:definition """The flower-heads of either the plant Anthemis nobilis or the plant Matricaria chamomilla. Chamomile has a warm aromatic odour and a very bitter taste and contains volatile oils which are a mixture of butyl and amyl angelates and valerates. Due to its coumarin constituents, large doses may interfere with coagulation. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41614&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41614&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1045\" NCI Thesaurus)"""@eng ; """4776"""^^xsd:string ; """C1045"""^^xsd:string ; """83244"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0439963"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """milodistim"""@eng ; skos:notation """CDR0000041615"""^^xsd:string ; skos:altLabel """Granulocyte-Macrophage Colony Stimulating Factor/Interleukin-3 Fusion Protein"""@eng , """GM-CSF/IL3 Fusion Protein"""@eng , """PIXY321"""@eng , """GM-CSF/IL-3 Fusion Protein"""@eng , """pixykine"""@eng ; skos:definition """A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines. This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41615&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41615&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1477\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; """4777"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """645014"""^^xsd:string ; """4341"""^^xsd:string ; """C1477"""^^xsd:string ; umls:cui """C0211169"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/interleukin-1-alpha"""@eng ; skos:notation """CDR0000041612"""^^xsd:string ; skos:altLabel """CTX/IL-1A"""@eng ; ; ; """4774"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281229"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboxyamidotriazole"""@eng ; skos:notation """CDR0000041613"""^^xsd:string ; skos:altLabel """1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4(4-chlorobenzoyl)phenyl)methyl)"""@eng , """5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide"""@eng , """L651582"""@eng , """carboxyamido-triazole"""@eng , """carboxyaminoimidazole"""@eng , """CAI"""@eng ; skos:definition """An orally-active agent with potential antineoplastic activity. Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis. This agent may also inhibit tumor cell growth, invasion and metastasis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41613&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41613&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1141\" NCI Thesaurus)"""@eng ; ; ; """4775"""^^xsd:string ; """38583"""^^xsd:string ; """609974"""^^xsd:string ; """99519-84-3"""^^xsd:string ; """2006-07-30"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1141"""^^xsd:string ; umls:cui """C0064494"""^^xsd:string ; umls:cui """C0286394"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide/vincristine"""@eng ; skos:notation """CDR0000041610"""^^xsd:string ; skos:altLabel """CBDCA/CTX/VCR/VP-16"""@eng ; ; ; ; ; """4772"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281227"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/carmustine/tamoxifen"""@eng ; skos:notation """CDR0000041611"""^^xsd:string ; skos:altLabel """BCNU/CBDCA/TMX"""@eng ; ; ; ; """4773"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281228"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """prolymphocytic leukemia"""@eng ; skos:notation """CDR0000041618"""^^xsd:string ; skos:altLabel """Prolymphocytic leukemia"""@eng , """leukemia, prolymphocytic"""@eng ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """4780"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0023486"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """diarrhea"""@eng ; skos:notation """CDR0000041619"""^^xsd:string ; rdfs:subClassOf ; """2002-11-20"""^^xsd:string ; """4781"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0011991"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """antisurvivin antisense oligonucleotide LY2181308"""@eng ; skos:notation """CDR0000532253"""^^xsd:string ; skos:altLabel """LY2181308"""@eng ; """2007-01-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1832051"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """colonoscopic studies"""@eng ; skos:notation """CDR0000038626"""^^xsd:string ; ; rdfs:subClassOf ; """11254"""^^xsd:string ; """Screening intervention/procedure"""^^xsd:string ; """2006-04-21"""^^xsd:string ; umls:cui """C1134637"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alpha fetoprotein plasmid DNA vaccine/sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant"""@eng ; skos:notation """CDR0000390315"""^^xsd:string ; skos:altLabel """phAFP/phGM-CSF HCC"""@eng ; ; ; """2004-09-25"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2004-08-31"""^^xsd:string ; umls:cui """C1541365"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alpha fetoprotein adenoviral vector vaccine"""@eng ; skos:notation """CDR0000390311"""^^xsd:string ; skos:altLabel """AdVhAFP"""@eng ; skos:definition """A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=390311&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=390311&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48372\" NCI Thesaurus)"""@eng ; """2004-09-25"""^^xsd:string ; """C48372"""^^xsd:string ; """2004-08-23"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541362"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alpha fetoprotein plasmid DNA vaccine"""@eng ; skos:notation """CDR0000390312"""^^xsd:string ; skos:altLabel """phAFP"""@eng ; skos:definition """A vaccine consisting of plasmid DNA encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=390312&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=390312&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48373\" NCI Thesaurus)"""@eng ; ; """2004-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C48373"""^^xsd:string ; """2006-07-26"""^^xsd:string ; umls:cui """C1541363"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant"""@eng ; skos:notation """CDR0000390313"""^^xsd:string ; skos:altLabel """GM-CSF plasmid DNA hepatocellular carcinoma vaccine adjuvant"""@eng , """phGM-CSF HCC"""@eng ; skos:definition """A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (granulocyte-macrophage colony-stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered hepatocellular carcinoma vaccine. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=390313&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=390313&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48420\" NCI Thesaurus)"""@eng ; ; """2004-09-25"""^^xsd:string ; """C48420"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1541364"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PC-SPES"""@eng ; skos:notation """CDR0000404383"""^^xsd:string ; """2004-11-22"""^^xsd:string ; """2004-11-01"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0756934"""^^xsd:string ; umls:tui """T123"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboxyamidotriazole/paclitaxel"""@eng ; skos:notation """CDR0000042135"""^^xsd:string ; skos:altLabel """CAI/TAX"""@eng ; ; ; """5372"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281656"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/SB-715992"""@eng ; skos:notation """CDR0000443088"""^^xsd:string ; skos:altLabel """CAPE/SB 715992"""@eng ; ; ; """2005-08-04"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-08-05"""^^xsd:string ; umls:cui """C1831699"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """sapacitabine"""@eng ; skos:notation """CDR0000513165"""^^xsd:string ; skos:altLabel """CYC682"""@eng ; """2006-10-14"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1831966"""^^xsd:string ; umls:cui """C0764827"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult astrocytic tumors"""@eng ; skos:notation """CDR0000430658"""^^xsd:string ; skos:altLabel """Brain tumor, adult: Astrocytic tumors"""@eng ; rdfs:subClassOf ; """2005-04-23"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2005-04-25"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1332183"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult ependymal tumors"""@eng ; skos:notation """CDR0000430659"""^^xsd:string ; skos:altLabel """Brain tumor, adult: Ependymal tumors"""@eng ; rdfs:subClassOf ; """2005-04-23"""^^xsd:string ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """2005-04-25"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C1541566"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/erlotinib"""@eng ; skos:notation """CDR0000038548"""^^xsd:string ; skos:altLabel """CDDP/OSI774"""@eng ; ; ; """11175"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134575"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """NB1011"""@eng ; skos:notation """CDR0000038549"""^^xsd:string ; skos:altLabel """Thymectacin"""@eng , """NB101.1"""@eng ; skos:definition """A novel small molecule, and a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine with antitumor property. NB1011 is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis and its over-expression is associated with many solid tumors. This agent is different from the current TS-targeted drugs, which require inhibition of TS to be effective, while cytotoxicity of NB1011 depends upon activation by TS and is independent of tumor suppressor p53. Although the mechanism of action is unclear, NB1011 appears to induce expressions of bax (pro-apoptotic Bcl-2 family member), p21 and GADD45, both are involving in check point control of cell cycle. Activation of these genes results in deregulation of cell cycle and leads to apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38549&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38549&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1882\" NCI Thesaurus)"""@eng ; """11176"""^^xsd:string ; """C1882"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1135140"""^^xsd:string ; umls:cui """C0964443"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """rF-B7.1 vaccine"""@eng ; skos:notation """CDR0000038542"""^^xsd:string ; skos:altLabel """recombinant fowlpox-B7.1 vaccine"""@eng ; skos:definition """A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the stimulatory molecule transgene B7-1. Recombinant fowlpox-B7.1 (rF-B7.1) vaccine may enhance antigen presentation and activate antitumoral cytotoxic T-cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38542&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38542&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2666\" NCI Thesaurus)"""@eng ; """11169"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """679008"""^^xsd:string ; """2006-09-25"""^^xsd:string ; """C2666"""^^xsd:string ; umls:cui """C1134569"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fowlpox-TRICOM vaccine"""@eng ; skos:notation """CDR0000038543"""^^xsd:string ; skos:altLabel """rF-TRICOM (B7.1.iCAM1-LFA3-Fowlpox)"""@eng , """Recombinant Fowlpox-TRICOM Vaccine"""@eng , """rF-TRICOM"""@eng ; skos:definition """A cancer vaccine comprised of a recombinant fowlpox virus vector encoding TRICOM. TRICOM is comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3) that may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38543&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38543&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2667\" NCI Thesaurus)"""@eng ; ; """11170"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """9888"""^^xsd:string ; """710658"""^^xsd:string ; """9710"""^^xsd:string ; """C2667"""^^xsd:string ; """2006-08-07"""^^xsd:string ; umls:cui """C1134570"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """anti-thymocyte globulin/cyclophosphamide/fludarabine/methylprednisolone"""@eng ; skos:notation """CDR0000038540"""^^xsd:string ; skos:altLabel """ATG/CTX/FAMP/MePRDL"""@eng ; ; ; ; ; """11167"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134567"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/gemcitabine"""@eng ; skos:notation """CDR0000038541"""^^xsd:string ; skos:altLabel """CAPE/dFdC"""@eng ; ; ; """11168"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134568"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/monoclonal antibody Ch14.18"""@eng ; skos:notation """CDR0000038546"""^^xsd:string ; skos:altLabel """13-CRA/MOAB Ch14.18"""@eng ; ; ; """11173"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134573"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AG-858/imatinib mesylate"""@eng ; skos:notation """CDR0000334951"""^^xsd:string ; skos:altLabel """AG858/STI571"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-24"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328059"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """autologous lymphocytes/fluorouracil/pegylated interferon alfa/sargramostim"""@eng ; skos:notation """CDR0000038544"""^^xsd:string ; skos:altLabel """AL/5-FU/GM-CSF/PEG-IFNA"""@eng ; ; ; ; ; """11171"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134571"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/docetaxel"""@eng ; skos:notation """CDR0000038545"""^^xsd:string ; skos:altLabel """SC-58635/TXT"""@eng ; ; ; """11172"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1134572"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """biological markers"""@eng ; skos:notation """CDR0000042832"""^^xsd:string ; """6630"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0005516"""^^xsd:string ; umls:tui """T201"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """streptozocin"""@eng ; skos:notation """CDR0000042831"""^^xsd:string ; skos:altLabel """2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose"""@eng , """streptozotocin"""@eng , """SZC"""@eng , """U-9889"""@eng , """Zanosar"""@eng , """2-deoxy-2-[[(methylnitrosamino)-carbonyl]amino]-D-glucopyranose"""@eng , """SZN"""@eng , """STZ"""@eng ; skos:definition """A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes. Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis. Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations. Unlike other nitrosoureas, streptozocin causes little myelosuppression. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42831&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42831&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C845\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; """663"""^^xsd:string ; """2006-09-26"""^^xsd:string ; """3859"""^^xsd:string ; """18883-66-4"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """85998"""^^xsd:string ; """C845"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0038432"""^^xsd:string ; umls:cui """C0724450"""^^xsd:string ; umls:cui """C0729061"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorophotometry"""@eng ; skos:notation """CDR0000042830"""^^xsd:string ; rdfs:subClassOf ; """6629"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0016353"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/raltitrexed"""@eng ; skos:notation """CDR0000042837"""^^xsd:string ; skos:altLabel """5-FU/ICI D1694"""@eng ; ; ; """6636"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0677774"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """immunoenzyme techniques"""@eng ; skos:notation """CDR0000042836"""^^xsd:string ; rdfs:subClassOf ; """6635"""^^xsd:string ; """Diagnostic test/procedure"""^^xsd:string ; umls:cui """C0021002"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody E2.3"""@eng ; skos:notation """CDR0000042835"""^^xsd:string ; skos:altLabel """E2.3"""@eng , """MOAB E2.3"""@eng , """Anti-Transferrin MOAB E2.3"""@eng ; skos:definition """A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2.3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42835&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42835&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2448\" NCI Thesaurus)"""@eng ; """6634"""^^xsd:string ; """644262"""^^xsd:string ; """C2448"""^^xsd:string ; """7237"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0677773"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """monoclonal antibody A27.15"""@eng ; skos:notation """CDR0000042834"""^^xsd:string ; skos:altLabel """ANTI-TRANSFERRIN MOAB 27.15"""@eng , """MOAB A27.15"""@eng , """A27.15"""@eng ; skos:definition """A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42834&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42834&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2447\" NCI Thesaurus)"""@eng ; """6633"""^^xsd:string ; """644261"""^^xsd:string ; """C2447"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """7237"""^^xsd:string ; umls:cui """C0677772"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """capecitabine/carboplatin"""@eng ; skos:notation """CDR0000433521"""^^xsd:string ; skos:altLabel """CAPE/CBDCA"""@eng ; ; ; """2005-05-23"""^^xsd:string ; """2005-05-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831621"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """isotretinoin/temozolomide/thalidomide"""@eng ; skos:notation """CDR0000433523"""^^xsd:string ; skos:altLabel """13-CRA/THAL/TMZ"""@eng ; ; ; ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; """2005-05-17"""^^xsd:string ; umls:cui """C1831623"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/temozolomide"""@eng ; skos:notation """CDR0000433522"""^^xsd:string ; skos:altLabel """SC-58635/TMZ"""@eng ; ; ; """2005-05-17"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831622"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/isotretinoin/temozolomide/thalidomide"""@eng ; skos:notation """CDR0000433525"""^^xsd:string ; skos:altLabel """13-CRA/SC-58635/THAL/TMZ"""@eng ; ; ; ; ; """2005-05-17"""^^xsd:string ; """2005-05-23"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831625"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/isotretinoin/temozolomide"""@eng ; skos:notation """CDR0000433524"""^^xsd:string ; skos:altLabel """13-CRA/SC-58635/TMZ"""@eng ; ; ; ; """2005-05-23"""^^xsd:string ; """2005-05-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1831624"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """tiacumicin B"""@eng ; skos:notation """CDR0000530629"""^^xsd:string ; skos:altLabel """diffimicin"""@eng , """OPT-80"""@eng , """PAR-101"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-16"""^^xsd:string ; umls:cui """C1832032"""^^xsd:string ; umls:cui """C1453661"""^^xsd:string ; umls:cui """C0125918"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KW-0761"""@eng ; skos:notation """CDR0000500479"""^^xsd:string ; """2006-09-21"""^^xsd:string ; """C62510"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-08-06"""^^xsd:string ; umls:cui """C1831941"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """celecoxib/paclitaxel"""@eng ; skos:notation """CDR0000368789"""^^xsd:string ; skos:altLabel """SC-58635/TAX"""@eng ; ; ; """2004-05-28"""^^xsd:string ; """2004-04-29"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541233"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GVAX lung cancer vaccine"""@eng ; skos:notation """CDR0000346435"""^^xsd:string ; skos:altLabel """CG8123"""@eng , """CG8123 vaccine"""@eng , """CG8123V"""@eng , """GVAX Autologous Lung Cancer Vaccine"""@eng ; skos:definition """An autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine. GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function and may augment host antitumoral immunity. For safety, cells are irradiated prior to vaccination. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346435&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=346435&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1979\" NCI Thesaurus)"""@eng ; ; """2003-11-20"""^^xsd:string ; """2004-03-23"""^^xsd:string ; """C1979"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1328108"""^^xsd:string ; umls:cui """C1527120"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """CDK inhibitor P276-00"""@eng ; skos:notation """CDR0000529362"""^^xsd:string ; skos:altLabel """P276-00"""@eng ; """Drug/agent"""^^xsd:string ; """2007-01-05"""^^xsd:string ; umls:cui """C1832023"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """forodesine hydrochloride"""@eng ; skos:notation """CDR0000301648"""^^xsd:string ; skos:altLabel """forodesine"""@eng , """immucillin-H"""@eng , """BCX-1777"""@eng ; skos:definition """The hydrochloride salt of the synthetic high-affinity transition-state analogue forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes. A transition state analogue is a substrate designed to mimic the properties or the geometry of the transition state of reaction. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301648&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301648&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26655\" NCI Thesaurus)"""@eng ; """2006-08-02"""^^xsd:string ; """C26655"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2003-04-23"""^^xsd:string ; umls:cui """C1997549"""^^xsd:string ; umls:cui """C1175653"""^^xsd:string ; umls:cui """C0676720"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """EP-2101"""@eng ; skos:notation """CDR0000301640"""^^xsd:string ; skos:altLabel """EP2101"""@eng ; skos:definition """A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. EP-2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301640&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=301640&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26645\" NCI Thesaurus)"""@eng ; ; """2003-04-23"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """C26645"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C1327951"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """streptonigrin"""@eng ; skos:notation """CDR0000039703"""^^xsd:string ; skos:altLabel """5-Amino-6-(70-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic Acid"""@eng , """Rufocromomycin"""@eng , """STN"""@eng , """nigrin"""@eng , """BA-163"""@eng , """5-Amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic Acid"""@eng , """Bruneomycin"""@eng , """PC-501"""@eng ; skos:definition """An aminoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces flocculus. Streptonigrin complexes with DNA and topoisomerase II, resulting in DNA cleavage and inhibition of DNA replication and RNA synthesis. This agent also acts as a reverse transcriptase inhibitor and causes free radical-mediated cellular damage. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39703&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39703&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C844\" NCI Thesaurus)"""@eng ; """2363"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """45383"""^^xsd:string ; """2006-12-15"""^^xsd:string ; """83950"""^^xsd:string ; """3930-19-6"""^^xsd:string ; """925"""^^xsd:string ; """C844"""^^xsd:string ; umls:cui """C0878534"""^^xsd:string ; umls:cui """C0878531"""^^xsd:string ; umls:cui """C0878533"""^^xsd:string ; umls:cui """C0038427"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T195"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/prednisone/vincristine"""@eng ; skos:notation """CDR0000039702"""^^xsd:string ; skos:altLabel """BOP"""@eng , """BLEO/PRED/VCR"""@eng ; ; ; ; """2358"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279482"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/dacarbazine/vinblastine"""@eng ; skos:notation """CDR0000039701"""^^xsd:string ; skos:altLabel """BVDD"""@eng , """BLEO/CDDP/DTIC/VBL"""@eng ; ; ; ; ; """2357"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279481"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cyclophosphamide/dactinomycin"""@eng ; skos:notation """CDR0000039700"""^^xsd:string ; skos:altLabel """BCD"""@eng , """BLEO/CTX/DACT"""@eng ; ; ; ; """2356"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0053048"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dronabinol"""@eng ; skos:notation """CDR0000039707"""^^xsd:string ; skos:altLabel """Abbott 40566"""@eng , """delta 9-tetrahydrocannabinol"""@eng , """SP-104"""@eng , """delta-9-tetrahydrocannabinol"""@eng , """cannabinol"""@eng , """tetrahydrocannabinol"""@eng , """Marinol"""@eng , """THC"""@eng ; skos:definition """A synthetic form of delta-9-tetrahydrocannabinol, a psychoactive substance found in Cannabis sativa. Dronabinol acts directly on the appetite and vomiting control centers in the brain to stimulate appetite and prevent emesis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39707&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39707&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C867\" NCI Thesaurus)"""@eng ; ; """2369"""^^xsd:string ; """2006-05-19"""^^xsd:string ; """C867"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0728767"""^^xsd:string ; umls:cui """C0740167"""^^xsd:string ; umls:cui """C0006865"""^^xsd:string ; umls:cui """C0039663"""^^xsd:string ; umls:cui """C0740168"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/mitomycin/vinblastine"""@eng ; skos:notation """CDR0000039706"""^^xsd:string ; skos:altLabel """HMM/MITO/VBL"""@eng , """HMVlb"""@eng ; ; ; ; """2367"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0291012"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cyclophosphamide/fluorouracil/methotrexate"""@eng ; skos:notation """CDR0000039705"""^^xsd:string ; skos:altLabel """CTX/5-FU/HMM/MTX"""@eng , """HEXA-CAF"""@eng ; ; ; ; ; """2365"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0062594"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/cisplatin"""@eng ; skos:notation """CDR0000039704"""^^xsd:string ; skos:altLabel """HP"""@eng , """CDDP/HMM"""@eng ; ; ; """2364"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279483"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carmustine/cisplatin/cyclophosphamide/cytarabine/hydroxyurea/methylprednisolone/procarbazine/vincristine"""@eng ; skos:notation """CDR0000039709"""^^xsd:string ; skos:altLabel """ARA-C/BCNU/CDDP/CTX/HU/MePRDL/PCB/VCR"""@eng ; ; ; ; ; ; ; ; ; """2371"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279487"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """altretamine/doxorubicin/fluorouracil/mitomycin"""@eng ; skos:notation """CDR0000039708"""^^xsd:string ; skos:altLabel """DOX/5-FU/HMM/MITO"""@eng , """HEXA-FAM"""@eng ; ; ; ; ; """2370"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279486"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ibandronate"""@eng ; skos:notation """CDR0000365963"""^^xsd:string ; skos:altLabel """Boniva"""@eng , """Bondronate"""@eng , """ibandronic acid"""@eng ; skos:definition """A synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=365963&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=365963&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1670\" NCI Thesaurus)"""@eng ; """2004-04-23"""^^xsd:string ; """2006-05-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C1670"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0379200"""^^xsd:string ; umls:cui """C0379199"""^^xsd:string ; umls:cui """C0918019"""^^xsd:string ; umls:cui """C1541222"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/celecoxib/gemcitabine/zileuton"""@eng ; skos:notation """CDR0000335286"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/SC-58635/ZLT"""@eng ; ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328066"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/gemcitabine/zileuton"""@eng ; skos:notation """CDR0000335285"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/ZLT"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328065"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/celecoxib/gemcitabine"""@eng ; skos:notation """CDR0000335284"""^^xsd:string ; skos:altLabel """CBDCA/dFdC/SC-58635"""@eng ; ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328064"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """imatinib mesylate/PEG-interferon alfa-2a"""@eng ; skos:notation """CDR0000335282"""^^xsd:string ; skos:altLabel """PEG-IFNA2a/STI571"""@eng ; ; ; """2003-09-24"""^^xsd:string ; """2003-09-16"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328063"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-interferon alfa-2a"""@eng ; skos:notation """CDR0000335280"""^^xsd:string ; skos:altLabel """pegylated interferon alfa-2a"""@eng , """PEG-IFNA2a"""@eng , """PEGASYS"""@eng ; skos:definition """A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=335280&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=335280&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C33987\" NCI Thesaurus)"""@eng ; ; """2003-09-24"""^^xsd:string ; """2006-09-08"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C33987"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1176430"""^^xsd:string ; umls:cui """C0391001"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """alemtuzumab/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine"""@eng ; skos:notation """CDR0000340973"""^^xsd:string ; skos:altLabel """CTX/DOX/MOAB CD52/PRED/VCR/VP-16"""@eng ; ; ; ; ; ; ; """2003-10-25"""^^xsd:string ; """2003-10-14"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1328084"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adenocarcinoma of the stomach"""@eng ; skos:notation """CDR0000043720"""^^xsd:string ; skos:altLabel """stomach, adenocarcinoma of the"""@eng , """gastric cancer, adenocarcinoma"""@eng , """stomach cancer, adenocarcinoma"""@eng ; rdfs:subClassOf ; """969"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278701"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent esophageal cancer"""@eng ; skos:notation """CDR0000043721"""^^xsd:string ; skos:altLabel """esophageal cancer, recurrent"""@eng , """esophagus cancer, recurrent"""@eng ; rdfs:subClassOf ; """esophageal cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """97"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0854761"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood hepatoblastoma"""@eng ; skos:notation """CDR0000043722"""^^xsd:string ; skos:altLabel """hepatoblastoma, childhood"""@eng , """pediatric hepatoblastoma"""@eng ; rdfs:subClassOf ; """970"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0206624"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mechlorethamine/prednisone/procarbazine/vinblastine"""@eng ; skos:notation """CDR0000043723"""^^xsd:string ; skos:altLabel """MVPP"""@eng , """NM/PCB/PRED/VBL"""@eng ; ; ; ; ; """977"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0066986"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood cancer"""@eng ; skos:notation """CDR0000043724"""^^xsd:string ; skos:altLabel """cancer, childhood"""@eng , """pediatric cancer"""@eng ; rdfs:subClassOf ; """978"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0278704"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000043725"""^^xsd:string ; skos:altLabel """Sezary syndrome"""@eng , """T-cell lymphoma, cutaneous"""@eng , """CTCL"""@eng , """mycosis fungoides/Sezary syndrome"""@eng , """lymphoma, cutaneous T-cell"""@eng , """mycosis fungoides"""@eng , """T cell lymphoma, cutaneous"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """98"""^^xsd:string ; """2004-10-25"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0026948"""^^xsd:string ; umls:cui """C0862196"""^^xsd:string ; umls:cui """C0036920"""^^xsd:string ; umls:cui """C0079773"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/mercaptopurine/methotrexate/prednisone/vincristine"""@eng ; skos:notation """CDR0000043726"""^^xsd:string ; skos:altLabel """CTX/MP/MTX/PRED/VCR"""@eng , """COMMP"""@eng ; ; ; ; ; ; """981"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278705"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """semustine"""@eng ; skos:notation """CDR0000043727"""^^xsd:string ; skos:altLabel """methyl-CCNU"""@eng , """methyl CCNU"""@eng , """CCNU, methyl-"""@eng , """MeCCNU"""@eng , """MCCNU"""@eng ; skos:definition """A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43727&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43727&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C827\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; """987"""^^xsd:string ; """2006-02-17"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C827"""^^xsd:string ; umls:cui """C0036637"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """busulfan/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000043728"""^^xsd:string ; skos:altLabel """BU/CTX/VP-16"""@eng ; ; ; ; """989"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0278706"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """stage I cutaneous T-cell lymphoma"""@eng ; skos:notation """CDR0000043729"""^^xsd:string ; skos:altLabel """cutaneous T-cell lymphoma, stage I"""@eng , """mycosis fungoides/Sezary syndrome, stage I"""@eng , """stage I mycosis fungoides/Sezary syndrome"""@eng ; rdfs:subClassOf ; """cutaneous T-cell lymphoma"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """99"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278566"""^^xsd:string ; umls:cui """C0862211"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/leucovorin calcium/methylmercaptopurine riboside/PALA"""@eng ; skos:notation """CDR0000041586"""^^xsd:string ; skos:altLabel """CF/5-FU/MMPR/PALA"""@eng ; ; ; ; ; """4748"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281205"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer prevention"""@eng ; skos:notation """CDR0000041587"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """4750"""^^xsd:string ; umls:cui """C0281206"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """interferon alfa/megestrol/tamoxifen"""@eng ; skos:notation """CDR0000041584"""^^xsd:string ; skos:altLabel """IFN-A/MEG/TMX"""@eng ; ; ; ; """4746"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338159"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/leucovorin calcium/mitomycin"""@eng ; skos:notation """CDR0000041585"""^^xsd:string ; skos:altLabel """CF/5-FU/IFN-A/MITO"""@eng ; ; ; ; ; """4747"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338160"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cytarabine/idarubicin"""@eng ; skos:notation """CDR0000041582"""^^xsd:string ; skos:altLabel """ARA-C/CBDCA/IDA"""@eng ; ; ; ; """4744"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281201"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/bleomycin/epirubicin/prednisone/vincristine"""@eng ; skos:notation """CDR0000041583"""^^xsd:string ; skos:altLabel """BLEO/CTX/EPI/PRED/VCR"""@eng ; ; ; ; ; ; """4745"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0296247"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/etoposide/interferon alfa/mitoxantrone"""@eng ; skos:notation """CDR0000041580"""^^xsd:string ; skos:altLabel """CBDCA/DHAD/IFN-A/VP-16"""@eng ; ; ; ; ; """4742"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338158"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cytarabine/idarubicin/interleukin-3"""@eng ; skos:notation """CDR0000041581"""^^xsd:string ; skos:altLabel """ARA-C/IDA/IL-3"""@eng ; ; ; ; """4743"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281200"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer prevention intervention"""@eng ; skos:notation """CDR0000041588"""^^xsd:string ; rdfs:subClassOf owl:Thing ; ; ; ; ; ; """4751"""^^xsd:string ; """2004-05-26"""^^xsd:string ; """Preventative intervention/procedure"""^^xsd:string ; umls:cui """C0281207"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """GM2-KLH vaccine"""@eng ; skos:notation """CDR0000041589"""^^xsd:string ; skos:altLabel """GM2-KLH"""@eng , """GM2-KLH ganglioside"""@eng , """KLH-conjugated GM2 Ganglioside Vaccine"""@eng ; skos:definition """A cancer vaccine consisting of GM2 ganglioside, a melanoma-specific antigen, conjugated with the immunostimulant keyhole limpet hemocyanin. Vaccination with GM2-KLH vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against GM2 ganglioside-expressing melanoma cells, resulting in tumor growth inhibition. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41589&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41589&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2376\" NCI Thesaurus)"""@eng ; ; ; """4752"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """C2376"""^^xsd:string ; """2006-08-07"""^^xsd:string ; umls:cui """C0281208"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, childhood acute myeloid leukemia"""@eng ; skos:notation """CDR0000040196"""^^xsd:string ; skos:altLabel """childhood acute nonlymphocytic leukemia cellular diagnosis"""@eng , """childhood AML cellular diagnosis"""@eng , """pediatric ANLL cellular diagnosis"""@eng , """pediatric acute nonlymphocytic leukemia cellular diagnosis"""@eng , """cellular diagnosis, childhood acute nonlymphocytic leukemia"""@eng , """pediatric AML cellular diagnosis"""@eng , """childhood ANLL cellular diagnosis"""@eng ; rdfs:subClassOf ; """2988"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279892"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa/PALA"""@eng ; skos:notation """CDR0000040197"""^^xsd:string ; skos:altLabel """5-FU/IFN-A/PALA"""@eng ; ; ; ; """2989"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338107"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000040194"""^^xsd:string ; skos:altLabel """cellular diagnosis, childhood acute lymphocytic leukemia"""@eng , """childhood acute lymphocytic leukemia cellular diagnosis"""@eng , """childhood ALL cellular diagnosis"""@eng ; rdfs:subClassOf ; """2986"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279890"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """doxorubicin/etoposide/prednisone"""@eng ; skos:notation """CDR0000040195"""^^xsd:string ; skos:altLabel """DOX/PRED/VP-16"""@eng ; ; ; ; """2987"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279891"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, cervical cancer"""@eng ; skos:notation """CDR0000040192"""^^xsd:string ; skos:altLabel """cervical cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2984"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279888"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, gastric cancer"""@eng ; skos:notation """CDR0000040193"""^^xsd:string ; skos:altLabel """gastric cancer cellular diagnosis"""@eng , """stomach cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2985"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279889"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, ovarian epithelial cancer"""@eng ; skos:notation """CDR0000040190"""^^xsd:string ; skos:altLabel """ovarian epithelial cancer cellular diagnosis"""@eng , """cellular diagnosis, ovarian cancer"""@eng , """ovarian cancer cellular diagnosis"""@eng , """ovary cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2981"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279887"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """didox"""@eng ; skos:notation """CDR0000040191"""^^xsd:string ; """2983"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0094556"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """trifluoperazine/vinblastine"""@eng ; skos:notation """CDR0000040198"""^^xsd:string ; skos:altLabel """TFPZ/VBL"""@eng ; ; ; """2990"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279894"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cellular diagnosis, childhood liver cancer"""@eng ; skos:notation """CDR0000040199"""^^xsd:string ; skos:altLabel """childhood liver cancer cellular diagnosis"""@eng ; rdfs:subClassOf ; """2991"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279895"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """AMG 706/carboplatin/paclitaxel"""@eng ; skos:notation """CDR0000407529"""^^xsd:string ; skos:altLabel """AMG-706/CBDCA/TAX"""@eng ; ; ; ; """2004-11-19"""^^xsd:string ; """2004-11-17"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1541415"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cancer risk, genetic testing"""@eng ; skos:notation """CDR0000042589"""^^xsd:string ; skos:altLabel """genetic testing"""@eng ; """2003-06-19"""^^xsd:string ; """6287"""^^xsd:string ; umls:cui """C0393006"""^^xsd:string ; umls:tui """T059"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """chlorodihydroxypyridine/potassium oxonate/tegafur"""@eng ; skos:notation """CDR0000042588"""^^xsd:string ; skos:altLabel """CDHP/FT/Oxo"""@eng , """S-1"""@eng ; ; ; ; """6276"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393005"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """releasing hormone antagonist therapy"""@eng ; skos:notation """CDR0000481379"""^^xsd:string ; rdfs:subClassOf ; """2006-04-20"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; """2006-04-17"""^^xsd:string ; umls:cui """C1831806"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """lymphadenectomy"""@eng ; skos:notation """CDR0000481378"""^^xsd:string ; rdfs:subClassOf ; """2006-04-17"""^^xsd:string ; """2006-04-20"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0024203"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000042583"""^^xsd:string ; skos:altLabel """CDDP/TAX/TOPO"""@eng ; ; ; ; """6269"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393001"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/paclitaxel/topotecan"""@eng ; skos:notation """CDR0000042582"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/TAX/TOPO"""@eng ; ; ; ; ; """6268"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0393000"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """KRN5500"""@eng ; skos:notation """CDR0000042581"""^^xsd:string ; skos:altLabel """(6-[4-Deoxy-4-(2E, 4E)-tetradecadienoylglycyl] amino-L-glycero - beta-L-mannoheptopyranosyl] amino-9H-purine)"""@eng ; skos:definition """A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus. KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions. This agent also induces cell differentiation and caspase-dependent apoptosis. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42581&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42581&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1614\" NCI Thesaurus)"""@eng ; """6267"""^^xsd:string ; """650426"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """51682"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C1614"""^^xsd:string ; umls:cui """C0294829"""^^xsd:string ; umls:cui """C1527054"""^^xsd:string ; umls:tui """T114"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leukocyte interleukin"""@eng ; skos:notation """CDR0000042580"""^^xsd:string ; skos:altLabel """LI"""@eng ; """6266"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0392999"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """gimeracil"""@eng ; skos:notation """CDR0000042587"""^^xsd:string ; skos:altLabel """CDHP"""@eng , """chlorodihydroxypyridine"""@eng , """5-Chloro-2,4-dihydroxypyridinediol"""@eng ; skos:definition """A pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhibiting the enzyme dihydropyrimidine dehydrogenase causing decreased degradation of the fluoropyrimidines. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42587&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42587&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2416\" NCI Thesaurus)"""@eng ; ; """Drug/agent"""^^xsd:string ; """2007-01-24"""^^xsd:string ; """6275"""^^xsd:string ; """C2416"""^^xsd:string ; umls:cui """C0535459"""^^xsd:string ; umls:cui """C0393004"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """potassium oxonate"""@eng ; skos:notation """CDR0000042586"""^^xsd:string ; skos:altLabel """oxonate potassium"""@eng , """Oxo"""@eng ; ; """6274"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393003"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carcinoembryonic antigen peptide 1"""@eng ; skos:notation """CDR0000042585"""^^xsd:string ; skos:altLabel """CEA Peptide 9-mer"""@eng , """CAP-1"""@eng , """Carcinoembryonic Antigen Peptide-1"""@eng , """Carcinoembryonic Peptide-1"""@eng , """CEA Peptide 1"""@eng ; skos:definition """A nine amino acid peptide fragment of carcinoembryonic antigen (CEA), a protein that is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung. Autologous vaccination with activated autologous dendritic cells (DC) or peripheral blood mononuclear cells (PBMC) which have been exposed to CEA peptide 1 in vitro may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing CEA, thereby inhibiting tumor growth. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42585&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42585&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2414\" NCI Thesaurus)"""@eng ; ; """672683"""^^xsd:string ; """6843"""^^xsd:string ; """C2414"""^^xsd:string ; """2006-12-27"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0393002"""^^xsd:string ; umls:tui """T116"""^^xsd:string ; umls:tui """T129"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """leucovorin calcium"""@eng ; skos:notation """CDR0000042584"""^^xsd:string ; skos:altLabel """folinate calcium"""@eng , """Leucovorin"""@eng , """Dalisol"""@eng , """Cehafolin"""@eng , """Imo"""@eng , """Foliben"""@eng , """Folix"""@eng , """Calcium (6S)-Folinate"""@eng , """Rescufolin"""@eng , """5-Formyl-5,6,7,8-tetrahydrofolic Acid"""@eng , """Folaxin"""@eng , """Folaren"""@eng , """calcium leucovorin"""@eng , """Calfolex"""@eng , """Folinoral"""@eng , """LV"""@eng , """Citrec"""@eng , """Wellcovorin"""@eng , """5-Formyl Tetrahydrofolate"""@eng , """N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid"""@eng , """citrovorum factor"""@eng , """Tonofolin"""@eng , """Calinat"""@eng , """Disintox"""@eng , """Calcifolin"""@eng , """Adinepar"""@eng , """CF"""@eng , """N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid"""@eng , """Lederfolat"""@eng , """Lederfolin"""@eng , """Flynoken A"""@eng , """Cromatonbic Folinico"""@eng , """calcium folinate"""@eng , """Divical"""@eng , """5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid"""@eng , """Ecofol"""@eng , """Folidan"""@eng , """FOLI-cell"""@eng , """Rescuvolin"""@eng , """folinic acid"""@eng , """Foliplus"""@eng , """Folinic Acid Calcium Salt Pentahydrate"""@eng , """Citofolin"""@eng , """Folinvit"""@eng , """Leucosar"""@eng , """Folidar"""@eng , """Emovis"""@eng , """CFR"""@eng , """Folinac"""@eng ; skos:definition """An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs. Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42584&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42584&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C607\" NCI Thesaurus)"""@eng ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """627"""^^xsd:string ; """3590"""^^xsd:string ; """4292"""^^xsd:string ; """1492-18-8"""^^xsd:string ; """27275"""^^xsd:string ; """2006-08-28"""^^xsd:string ; """C607"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1517788"""^^xsd:string ; umls:cui """C1517789"""^^xsd:string ; umls:cui """C1517804"""^^xsd:string ; umls:cui """C1517803"""^^xsd:string ; umls:cui """C1517802"""^^xsd:string ; umls:cui """C1517801"""^^xsd:string ; umls:cui """C1517800"""^^xsd:string ; umls:cui """C1517780"""^^xsd:string ; umls:cui """C1517781"""^^xsd:string ; umls:cui """C1517782"""^^xsd:string ; umls:cui """C1517783"""^^xsd:string ; umls:cui """C1517784"""^^xsd:string ; umls:cui """C1517785"""^^xsd:string ; umls:cui """C1517786"""^^xsd:string ; umls:cui """C1517787"""^^xsd:string ; umls:cui """C0591716"""^^xsd:string ; umls:cui """C1517775"""^^xsd:string ; umls:cui """C1517777"""^^xsd:string ; umls:cui """C1517776"""^^xsd:string ; umls:cui """C0023413"""^^xsd:string ; umls:cui """C1517779"""^^xsd:string ; umls:cui """C1517778"""^^xsd:string ; umls:cui """C0701377"""^^xsd:string ; umls:cui """C1517799"""^^xsd:string ; umls:cui """C1517798"""^^xsd:string ; umls:cui """C1517793"""^^xsd:string ; umls:cui """C1517792"""^^xsd:string ; umls:cui """C1517791"""^^xsd:string ; umls:cui """C1517790"""^^xsd:string ; umls:cui """C1517797"""^^xsd:string ; umls:cui """C1517796"""^^xsd:string ; umls:cui """C1517795"""^^xsd:string ; umls:cui """C1517794"""^^xsd:string ; umls:cui """C0731033"""^^xsd:string ; umls:cui """C1177012"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:tui """T127"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """targeted fusion protein therapy"""@eng ; skos:notation """CDR0000042051"""^^xsd:string ; ; rdfs:subClassOf ; """5281"""^^xsd:string ; """Cancer therapy modality"""^^xsd:string ; umls:cui """C0281589"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quality-of-life assessment"""@eng ; skos:notation """CDR0000042050"""^^xsd:string ; skos:altLabel """quality of life assessment"""@eng ; ; rdfs:subClassOf ; """5280"""^^xsd:string ; """Supportive care modality"""^^xsd:string ; umls:cui """C0281588"""^^xsd:string ; umls:tui """T060"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dacarbazine/doxorubicin/filgrastim/ifosfamide"""@eng ; skos:notation """CDR0000042053"""^^xsd:string ; skos:altLabel """DOX/DTIC/G-CSF/IFF"""@eng ; ; ; ; ; """5283"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281590"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """quality of life"""@eng ; skos:notation """CDR0000042052"""^^xsd:string ; skos:altLabel """quality-of-life"""@eng ; rdfs:subClassOf ; """5282"""^^xsd:string ; """Secondary related condition"""^^xsd:string ; umls:cui """C0518214"""^^xsd:string ; umls:tui """T184"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bleomycin/cisplatin/etoposide/mitomycin"""@eng ; skos:notation """CDR0000042055"""^^xsd:string ; skos:altLabel """BLEO/CDDP/MITO/VP-16"""@eng ; ; ; ; ; """5285"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281592"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/pentoxifylline"""@eng ; skos:notation """CDR0000042054"""^^xsd:string ; skos:altLabel """CBDCA/PTX"""@eng ; ; ; """5284"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281591"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """Hodgkin's lymphoma during pregnancy"""@eng ; skos:notation """CDR0000042057"""^^xsd:string ; skos:altLabel """Hodgkin's disease during pregnancy"""@eng , """pregnancy, Hodgkin's disease during"""@eng , """HD during pregnancy"""@eng ; rdfs:subClassOf ; """2003-01-14"""^^xsd:string ; """5289"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281594"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mitoxantrone/paclitaxel"""@eng ; skos:notation """CDR0000042056"""^^xsd:string ; skos:altLabel """DHAD/TAX"""@eng ; ; ; """5287"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281593"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/tumor necrosis factor"""@eng ; skos:notation """CDR0000042059"""^^xsd:string ; skos:altLabel """CDDP/TNF"""@eng ; ; ; """5292"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281596"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bispecific antibody 520C9xH22/interferon gamma"""@eng ; skos:notation """CDR0000042058"""^^xsd:string ; skos:altLabel """BsAb 520C9xH22/IFN-G"""@eng ; ; ; """5291"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281595"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """17-N-allylamino-17-demethoxygeldanamycin/irinotecan"""@eng ; skos:notation """CDR0000438762"""^^xsd:string ; skos:altLabel """17-AAG/CPT-11"""@eng ; ; ; """Drug/agent combination"""^^xsd:string ; """2005-06-27"""^^xsd:string ; """2005-07-23"""^^xsd:string ; umls:cui """C1831662"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent endometrial cancer"""@eng ; skos:notation """CDR0000038743"""^^xsd:string ; skos:altLabel """endometrial carcinoma, recurrent"""@eng , """cancer of the endometrium, recurrent"""@eng , """recurrent uterine cancer"""@eng , """uterine cancer, recurrent"""@eng , """endometrial cancer, recurrent"""@eng , """carcinoma of the endometrium, recurrent"""@eng , """recurrent cancer of the endometrium"""@eng , """recurrent carcinoma of the endometrium"""@eng ; rdfs:subClassOf ; """endometrial cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1182"""^^xsd:string ; """2004-10-21"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278802"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """mixed childhood rhabdomyosarcoma"""@eng ; skos:notation """CDR0000039900"""^^xsd:string ; skos:altLabel """mixed type childhood rhabdomyosarcoma"""@eng , """childhood rhabdomyosarcoma, mixed"""@eng , """rhabdomyosarcoma, mixed childhood"""@eng , """mixed cell type childhood rhabdomyosarcoma"""@eng , """rhabdomyosarcoma, childhood mixed"""@eng , """rhabdomyosarcoma, pediatric mixed"""@eng , """mixed type pediatric rhabdomyosarcoma"""@eng , """mixed cell type pediatric rhabdomyosarcoma"""@eng , """pediatric rhabdomyosarcoma, mixed"""@eng , """mixed pediatric rhabdomyosarcoma"""@eng ; rdfs:subClassOf ; """2581"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0279615"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """ovarian cancer prevention"""@eng ; skos:notation """CDR0000042138"""^^xsd:string ; """2002-10-17"""^^xsd:string ; """5375"""^^xsd:string ; umls:cui """C0281659"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/dacarbazine/interferon alfa/interleukin-2/tamoxifen/tumor infiltrating lymphocytes"""@eng ; skos:notation """CDR0000042139"""^^xsd:string ; skos:altLabel """CDDP/DTIC/IFN-A/IL-2/TIL/TMX"""@eng ; ; ; ; ; ; ; """5376"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338188"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/pyrazoloacridine"""@eng ; skos:notation """CDR0000042132"""^^xsd:string ; skos:altLabel """CDDP/PZA"""@eng ; ; ; """5368"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281654"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/filgrastim/pyrazoloacridine"""@eng ; skos:notation """CDR0000042133"""^^xsd:string ; skos:altLabel """CDDP/G-CSF/PZA"""@eng ; ; ; ; """5369"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281655"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """verteporfin"""@eng ; skos:notation """CDR0000042130"""^^xsd:string ; skos:altLabel """Benzoporphyrin Derivative Monoacid Ring A"""@eng , """Visudyne"""@eng , """BPD-MA"""@eng ; skos:definition """A synthetic light-activated agent with photodynamic activity. Upon systemic administration, verteporfin accumulates in neovessels in the eye and, once stimulated by nonthermal red light in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to neovascular endothelium and blood vessel occlusion. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42130&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42130&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1014\" NCI Thesaurus)"""@eng ; """5366"""^^xsd:string ; """C1014"""^^xsd:string ; """2006-08-02"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """129497-78-5"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C0876212"""^^xsd:string ; umls:cui """C0387288"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/filgrastim"""@eng ; skos:notation """CDR0000042131"""^^xsd:string ; skos:altLabel """CBDCA/CTX/G-CSF"""@eng ; ; ; ; """5367"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281653"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cyclophosphamide/doxorubicin/methylprednisolone/vincristine"""@eng ; skos:notation """CDR0000042136"""^^xsd:string ; skos:altLabel """CTX/DOX/MePRDL/VCR"""@eng ; ; ; ; ; """5373"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281657"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """intraocular lymphoma"""@eng ; skos:notation """CDR0000042137"""^^xsd:string ; skos:altLabel """Intraocular lymphoma"""@eng , """IOL"""@eng , """lymphoma, intraocular"""@eng ; rdfs:subClassOf ; rdfs:subClassOf ; """Disease/diagnosis"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """5374"""^^xsd:string ; """Cancer diagnosis"""^^xsd:string ; umls:cui """C0281658"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """nitrosourea"""@eng ; skos:notation """CDR0000042134"""^^xsd:string ; rdfs:subClassOf ; rdfs:subClassOf ; """537"""^^xsd:string ; """Drug/agent category"""^^xsd:string ; umls:cui """C0028210"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """PEG-camptothecin"""@eng ; skos:notation """CDR0000372793"""^^xsd:string ; skos:altLabel """Prothecan®"""@eng , """Pegamotecan"""@eng , """Prothecan![REGISTERED SIGN]!"""@eng ; """2004-05-28"""^^xsd:string ; """2004-05-19"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """TRD"""^^xsd:string ; """TRD"""^^xsd:string ; umls:cui """C1174776"""^^xsd:string ; umls:cui """C0758797"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small intestine adenocarcinoma"""@eng ; skos:notation """CDR0000038744"""^^xsd:string ; skos:altLabel """adenocarcinoma, small intestine"""@eng , """small bowel adenocarcinoma"""@eng ; rdfs:subClassOf ; """small intestine cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1183"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278803"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """pixantrone"""@eng ; skos:notation """CDR0000269678"""^^xsd:string ; skos:altLabel """BBR 2778"""@eng ; skos:definition """A synthetic noncardiotoxic aza-anthracenedione analogue. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. Check for \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269678&idtype=1\" active clinical trials or \"http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269678&idtype=1&closed=1\" closed clinical trials using this agent. (\"http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26663\" NCI Thesaurus)"""@eng ; ; ; ; ; """2002-12-21"""^^xsd:string ; """C26663"""^^xsd:string ; """Drug/agent"""^^xsd:string ; """2006-09-11"""^^xsd:string ; umls:cui """C0288748"""^^xsd:string ; umls:cui """C0253355"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T121"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """cisplatin/cytarabine/methylprednisolone/pixantrone"""@eng ; skos:notation """CDR0000269679"""^^xsd:string ; skos:altLabel """ARA-C/BBR 2778/CDDP/MePRDL"""@eng ; ; ; ; ; """2002-12-21"""^^xsd:string ; """2002-12-15"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C1327856"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """small intestine lymphoma"""@eng ; skos:notation """CDR0000038745"""^^xsd:string ; skos:altLabel """lymphoma, small intestine"""@eng , """small bowel lymphoma"""@eng ; rdfs:subClassOf ; """small intestine cancer"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1184"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0278805"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bromocriptine/flutamide/leuprolide"""@eng ; skos:notation """CDR0000041519"""^^xsd:string ; skos:altLabel """BRCR/FLUT/LEUP"""@eng ; ; ; ; """4675"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281148"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """bromocriptine/flutamide"""@eng ; skos:notation """CDR0000041518"""^^xsd:string ; skos:altLabel """BRCR/FLUT"""@eng ; ; ; """4674"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0281147"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """dinitrofluorobenzene"""@eng ; skos:notation """CDR0000039223"""^^xsd:string ; skos:altLabel """DNFB"""@eng ; """1845"""^^xsd:string ; """Drug/agent"""^^xsd:string ; umls:cui """C0012463"""^^xsd:string ; umls:tui """T109"""^^xsd:string ; umls:tui """T130"""^^xsd:string ; umls:hasSTY ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute lymphoblastic leukemia in remission"""@eng ; skos:notation """CDR0000039084"""^^xsd:string ; skos:altLabel """remission, adult acute lymphocytic leukemia"""@eng , """lymphocytic leukemia in remission, adult acute"""@eng , """adult ALL in remission"""@eng , """acute lymphocytic leukemia in remission, adult"""@eng , """adult acute lymphocytic leukemia in remission"""@eng , """ALL in remission, adult"""@eng , """leukemia in remission, adult acute leukemia"""@eng ; rdfs:subClassOf ; """adult acute lymphoblastic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1672"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279095"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute myeloid leukemia in remission"""@eng ; skos:notation """CDR0000039085"""^^xsd:string ; skos:altLabel """myeloid leukemia in remission, childhood"""@eng , """pediatric leukemia, acute nonlymphocytic in remission"""@eng , """childhood acute nonlymphocytic leukemia in remission"""@eng , """remission, childhood nonlymphocytic acute leukemia"""@eng , """pediatric AML in remission"""@eng , """nonlymphocytic leukemia in remission, childhood"""@eng , """pediatric ANLL in remission"""@eng , """childhood leukemia, acute myeloid in remission"""@eng , """childhood leukemia, acute nonlymphocytic in remission"""@eng , """pediatric leukemia, acute myeloid in remission"""@eng , """AML, pediatric in remission"""@eng , """remission, childhood myeloid acute leukemia"""@eng , """ANLL, pediatric in remission"""@eng , """acute myeloid leukemia in remission, childhood"""@eng , """childhood AML in remission"""@eng , """acute nonlymphocytic leukemia in remission, childhood"""@eng , """pediatric acute nonlymphocytic leukemia in remission"""@eng , """pediatric acute myeloid leukemia in remission"""@eng , """childhood ANLL in remission"""@eng , """ANLL, childhood in remission"""@eng , """AML, childhood in remission"""@eng ; rdfs:subClassOf ; """childhood acute myeloid leukemia/other myeloid malignancies"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1673"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279096"""^^xsd:string ; umls:cui """C1377717"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """childhood acute lymphoblastic leukemia in remission"""@eng ; skos:notation """CDR0000039086"""^^xsd:string ; skos:altLabel """remission, childhood acute lymphocytic leukemia"""@eng , """acute lymphocytic leukemia in remission, childhood"""@eng , """leukemia in remission, childhood acute leukemia"""@eng , """childhood acute lymphocytic leukemia in remission"""@eng , """pediatric ALL in remission"""@eng , """childhood ALL in remission"""@eng , """lymphocytic leukemia in remission, childhood acute"""@eng , """pediatric acute lymphocytic leukemia in remission"""@eng , """ALL in remission, childhood"""@eng ; rdfs:subClassOf ; """childhood acute lymphoblastic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1674"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279097"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """fluorouracil/interferon alfa"""@eng ; skos:notation """CDR0000039087"""^^xsd:string ; skos:altLabel """5-FU/IFN-A"""@eng ; ; ; """1675"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0338085"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated childhood acute lymphoblastic leukemia"""@eng ; skos:notation """CDR0000039080"""^^xsd:string ; skos:altLabel """leukemia, untreated childhood acute lymphocytic"""@eng , """pediatric acute lymphocytic leukemia, untreated"""@eng , """untreated childhood ALL"""@eng , """lymphocytic leukemia, untreated childhood acute"""@eng , """acute lymphocytic leukemia, untreated childhood"""@eng , """childhood acute lymphocytic leukemia, untreated"""@eng , """untreated pediatric acute lymphocytic leukemia"""@eng , """untreated childhood acute lymphocytic leukemia"""@eng , """ALL, untreated childhood"""@eng ; rdfs:subClassOf ; """childhood acute lymphoblastic leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1666"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279091"""^^xsd:string ; umls:tui """T033"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """indomethacin/interleukin-1-alpha"""@eng ; skos:notation """CDR0000039081"""^^xsd:string ; skos:altLabel """IL-1A/Indomethacin"""@eng ; ; ; """1669"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279092"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """carboplatin/cyclophosphamide/etoposide"""@eng ; skos:notation """CDR0000039082"""^^xsd:string ; skos:altLabel """CBDCA/CTX/VP-16"""@eng ; ; ; ; """1670"""^^xsd:string ; """Drug/agent combination"""^^xsd:string ; umls:cui """C0279093"""^^xsd:string ; umls:tui """T061"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """adult acute myeloid leukemia in remission"""@eng ; skos:notation """CDR0000039083"""^^xsd:string ; skos:altLabel """adult acute nonlymphocytic leukemia in remission"""@eng , """adult leukemia, acute myelogenous in remission"""@eng , """adult leukemia, acute myeloid in remission"""@eng , """myelogenous leukemia in remission, adult acute"""@eng , """adult acute myelogenous leukemia in remission"""@eng , """myeloid leukemia in remission, adult acute"""@eng , """adult AML in remission"""@eng , """ANLL in remission, adult"""@eng , """remission, adult acute myeloid leukemia"""@eng , """remission, adult acute nonlymphocytic leukemia"""@eng , """AML in remission, adult"""@eng , """adult ANLL in remission"""@eng , """adult leukemia, acute nonlymphocytic in remission"""@eng , """nonlymphocytic leukemia in remission, adult acute"""@eng , """remission, adult acute myelogenous leukemia"""@eng ; rdfs:subClassOf ; """adult acute myeloid leukemia"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1671"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279094"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """untreated metastatic squamous neck cancer with occult primary"""@eng ; skos:notation """CDR0000039088"""^^xsd:string ; skos:altLabel """metastatic squamous neck cancer with occult primary, untreated"""@eng , """occult primary cancer metastatic squamous to neck, untreated"""@eng , """neck cancer, untreated metastatic squamous with occult primary"""@eng ; rdfs:subClassOf ; """metastatic squamous neck cancer with occult primary"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1677"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279099"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:Class ; skos:prefLabel """recurrent metastatic squamous neck cancer with occult primary"""@eng ; skos:notation """CDR0000039089"""^^xsd:string ; skos:altLabel """neck cancer, recurrent metastatic squamous with occult primary"""@eng , """occult primary cancer metastatic squamous to neck, recurrent"""@eng , """metastatic squamous neck cancer with occult primary, recurrent"""@eng ; rdfs:subClassOf ; """metastatic squamous neck cancer with occult primary"""^^xsd:string ; """Clinical Trials--CancerType"""^^xsd:string ; """1678"""^^xsd:string ; """Cancer stage"""^^xsd:string ; umls:cui """C0279100"""^^xsd:string ; umls:tui """T191"""^^xsd:string ; umls:hasSTY ; . a owl:DatatypeProperty ; rdfs:label """PXC"""; rdfs:comment """PDQ Protocol Exclusion Criteria - terms with type \"exclusion criteria,\" which may be indexed on protocol records to identify conditions that exclude a patient from eligibility. """ . a owl:ObjectProperty ; rdfs:label """Associated disease"""; rdfs:comment """Inverse of associated_genetic_condition""" . a owl:ObjectProperty ; rdfs:label """Associated genetic condition"""; rdfs:comment """Inverse of associated_disease""" . a owl:DatatypeProperty ; rdfs:label """MENU PARENT"""; rdfs:comment """Link information to Term Menu parent. This may not always be the same as the TermParent. Element will not exist for top level menus, e.g. cancer.""" . a owl:DatatypeProperty ; rdfs:label """ORIG STY"""; rdfs:comment """Original semantic type""" . a owl:DatatypeProperty ; rdfs:label """IND Code"""; rdfs:comment """IND Code""" . umls:hasSTY a owl:ObjectProperty ; rdfs:label """Semantic type UMLS property"""; rdfs:comment """Semantic type UMLS property""" . a owl:DatatypeProperty ; rdfs:label """CAS Registry"""; rdfs:comment """CAS Registry""" . a owl:DatatypeProperty ; rdfs:label """Legacy PDQ ID"""; rdfs:comment """Legacy PDQ ID""" . a owl:DatatypeProperty ; rdfs:label """NSC Code"""; rdfs:comment """NSC Code""" . a owl:DatatypeProperty ; rdfs:label """DATE FIRST PUBLISHED"""; rdfs:comment """Date first published""" . a owl:DatatypeProperty ; rdfs:label """MENU TYPE"""; rdfs:comment """Values are Clinical Trials--Cancer Type, Clinical Trials--Drug, or Cancer Information.""" . a owl:DatatypeProperty ; rdfs:label """Date last modified"""; rdfs:comment """Date last modified""" . a owl:DatatypeProperty ; rdfs:label """Lower Level Term"""; rdfs:comment """Lower Level Term""" . a owl:ObjectProperty ; rdfs:label """Component of"""; rdfs:comment """Inverse of has_component""" . a owl:DatatypeProperty ; rdfs:label """NCI ID"""; rdfs:comment """NCI thesaurus concept id""" . a owl:ObjectProperty ; rdfs:label """Has component"""; rdfs:comment """Inverse of component_of""" . a owl:Class ; skos:notation "T116"^^xsd:string ; skos:prefLabel "Amino Acid, Peptide, or Protein"@en . a owl:Class ; skos:notation "T121"^^xsd:string ; skos:prefLabel "Pharmacologic Substance"@en . a owl:Class ; skos:notation "T130"^^xsd:string ; skos:prefLabel "Indicator, Reagent, or Diagnostic Aid"@en . a owl:Class ; skos:notation "T109"^^xsd:string ; skos:prefLabel "Organic Chemical"@en . a owl:Class ; skos:notation "T126"^^xsd:string ; skos:prefLabel "Enzyme"@en . a owl:Class ; skos:notation "T123"^^xsd:string ; skos:prefLabel "Biologically Active Substance"@en . a owl:Class ; skos:notation "T131"^^xsd:string ; skos:prefLabel "Hazardous or Poisonous Substance"@en . a owl:Class ; skos:notation "T125"^^xsd:string ; skos:prefLabel "Hormone"@en . a owl:Class ; skos:notation "T114"^^xsd:string ; skos:prefLabel "Nucleic Acid, Nucleoside, or Nucleotide"@en . a owl:Class ; skos:notation "T127"^^xsd:string ; skos:prefLabel "Vitamin"@en . a owl:Class ; skos:notation "T195"^^xsd:string ; skos:prefLabel "Antibiotic"@en . a owl:Class ; skos:notation "T129"^^xsd:string ; skos:prefLabel "Immunologic Factor"@en . a owl:Class ; skos:notation "T024"^^xsd:string ; skos:prefLabel "Tissue"@en . a owl:Class ; skos:notation "T073"^^xsd:string ; skos:prefLabel "Manufactured Object"@en . a owl:Class ; skos:notation "T081"^^xsd:string ; skos:prefLabel "Quantitative Concept"@en . a owl:Class ; skos:notation "T170"^^xsd:string ; skos:prefLabel "Intellectual Product"@en . a owl:Class ; skos:notation "T029"^^xsd:string ; skos:prefLabel "Body Location or Region"@en . a owl:Class ; skos:notation "T184"^^xsd:string ; skos:prefLabel "Sign or Symptom"@en . a owl:Class ; skos:notation "T033"^^xsd:string ; skos:prefLabel "Finding"@en . a owl:Class ; skos:notation "T191"^^xsd:string ; skos:prefLabel "Neoplastic Process"@en . a owl:Class ; skos:notation "T023"^^xsd:string ; skos:prefLabel "Body Part, Organ, or Organ Component"@en . a owl:Class ; skos:notation "T005"^^xsd:string ; skos:prefLabel "Virus"@en . a owl:Class ; skos:notation "T047"^^xsd:string ; skos:prefLabel "Disease or Syndrome"@en . a owl:Class ; skos:notation "T019"^^xsd:string ; skos:prefLabel "Congenital Abnormality"@en . a owl:Class ; skos:notation "T169"^^xsd:string ; skos:prefLabel "Functional Concept"@en . a owl:Class ; skos:notation "T190"^^xsd:string ; skos:prefLabel "Anatomical Abnormality"@en . a owl:Class ; skos:notation "T037"^^xsd:string ; skos:prefLabel "Injury or Poisoning"@en . a owl:Class ; skos:notation "T022"^^xsd:string ; skos:prefLabel "Body System"@en . a owl:Class ; skos:notation "T018"^^xsd:string ; skos:prefLabel "Embryonic Structure"@en . a owl:Class ; skos:notation "T046"^^xsd:string ; skos:prefLabel "Pathologic Function"@en . a owl:Class ; skos:notation "T101"^^xsd:string ; skos:prefLabel "Patient or Disabled Group"@en . a owl:Class ; skos:notation "T093"^^xsd:string ; skos:prefLabel "Health Care Related Organization"@en . a owl:Class ; skos:notation "T089"^^xsd:string ; skos:prefLabel "Regulation or Law"@en . a owl:Class ; skos:notation "T061"^^xsd:string ; skos:prefLabel "Therapeutic or Preventive Procedure"@en . a owl:Class ; skos:notation "T062"^^xsd:string ; skos:prefLabel "Research Activity"@en . a owl:Class ; skos:notation "T041"^^xsd:string ; skos:prefLabel "Mental Process"@en . a owl:Class ; skos:notation "T055"^^xsd:string ; skos:prefLabel "Individual Behavior"@en . a owl:Class ; skos:notation "T004"^^xsd:string ; skos:prefLabel "Fungus"@en . a owl:Class ; skos:notation "T060"^^xsd:string ; skos:prefLabel "Diagnostic Procedure"@en . a owl:Class ; skos:notation "T070"^^xsd:string ; skos:prefLabel "Natural Phenomenon or Process"@en . a owl:Class ; skos:notation "T197"^^xsd:string ; skos:prefLabel "Inorganic Chemical"@en . a owl:Class ; skos:notation "T057"^^xsd:string ; skos:prefLabel "Occupational Activity"@en . a owl:Class ; skos:notation "T083"^^xsd:string ; skos:prefLabel "Geographic Area"@en . a owl:Class ; skos:notation "T074"^^xsd:string ; skos:prefLabel "Medical Device"@en . a owl:Class ; skos:notation "T002"^^xsd:string ; skos:prefLabel "Plant"@en . a owl:Class ; skos:notation "T065"^^xsd:string ; skos:prefLabel "Educational Activity"@en . a owl:Class ; skos:notation "T092"^^xsd:string ; skos:prefLabel "Organization"@en . a owl:Class ; skos:notation "T204"^^xsd:string ; skos:prefLabel "Eukaryote"@en . a owl:Class ; skos:notation "T025"^^xsd:string ; skos:prefLabel "Cell"@en . a owl:Class ; skos:notation "T196"^^xsd:string ; skos:prefLabel "Element, Ion, or Isotope"@en . a owl:Class ; skos:notation "T067"^^xsd:string ; skos:prefLabel "Phenomenon or Process"@en . a owl:Class ; skos:notation "T080"^^xsd:string ; skos:prefLabel "Qualitative Concept"@en . a owl:Class ; skos:notation "T102"^^xsd:string ; skos:prefLabel "Group Attribute"@en . a owl:Class ; skos:notation "T098"^^xsd:string ; skos:prefLabel "Population Group"@en . a owl:Class ; skos:notation "T051"^^xsd:string ; skos:prefLabel "Event"@en . a owl:Class ; skos:notation "T040"^^xsd:string ; skos:prefLabel "Organism Function"@en . a owl:Class ; skos:notation "T034"^^xsd:string ; skos:prefLabel "Laboratory or Test Result"@en . a owl:Class ; skos:notation "T201"^^xsd:string ; skos:prefLabel "Clinical Attribute"@en . a owl:Class ; skos:notation "T097"^^xsd:string ; skos:prefLabel "Professional or Occupational Group"@en . a owl:Class ; skos:notation "T064"^^xsd:string ; skos:prefLabel "Governmental or Regulatory Activity"@en . a owl:Class ; skos:notation "T054"^^xsd:string ; skos:prefLabel "Social Behavior"@en . a owl:Class ; skos:notation "T007"^^xsd:string ; skos:prefLabel "Bacterium"@en . a owl:Class ; skos:notation "T044"^^xsd:string ; skos:prefLabel "Molecular Function"@en . a owl:Class ; skos:notation "T053"^^xsd:string ; skos:prefLabel "Behavior"@en . a owl:Class ; skos:notation "T069"^^xsd:string ; skos:prefLabel "Environmental Effect of Humans"@en . a owl:Class ; skos:notation "T039"^^xsd:string ; skos:prefLabel "Physiologic Function"@en . a owl:Class ; skos:notation "T103"^^xsd:string ; skos:prefLabel "Chemical"@en . a owl:Class ; skos:notation "T122"^^xsd:string ; skos:prefLabel "Biomedical or Dental Material"@en . a owl:Class ; skos:notation "T015"^^xsd:string ; skos:prefLabel "Mammal"@en . a owl:Class ; skos:notation "T020"^^xsd:string ; skos:prefLabel "Acquired Abnormality"@en . a owl:Class ; skos:notation "T030"^^xsd:string ; skos:prefLabel "Body Space or Junction"@en . a owl:Class ; skos:notation "T026"^^xsd:string ; skos:prefLabel "Cell Component"@en . a owl:Class ; skos:notation "T043"^^xsd:string ; skos:prefLabel "Cell Function"@en . a owl:Class ; skos:notation "T059"^^xsd:string ; skos:prefLabel "Laboratory Procedure"@en . a owl:Class ; skos:notation "T052"^^xsd:string ; skos:prefLabel "Activity"@en . a owl:Class ; skos:notation "T056"^^xsd:string ; skos:prefLabel "Daily or Recreational Activity"@en . a owl:Class ; skos:notation "T079"^^xsd:string ; skos:prefLabel "Temporal Concept"@en . a owl:Class ; skos:notation "T091"^^xsd:string ; skos:prefLabel "Biomedical Occupation or Discipline"@en . a owl:Class ; skos:notation "T042"^^xsd:string ; skos:prefLabel "Organ or Tissue Function"@en . a owl:Class ; skos:notation "T192"^^xsd:string ; skos:prefLabel "Receptor"@en . a owl:Class ; skos:notation "T031"^^xsd:string ; skos:prefLabel "Body Substance"@en . a owl:Class ; skos:notation "T048"^^xsd:string ; skos:prefLabel "Mental or Behavioral Dysfunction"@en . a owl:Class ; skos:notation "T058"^^xsd:string ; skos:prefLabel "Health Care Activity"@en . a owl:Class ; skos:notation "T120"^^xsd:string ; skos:prefLabel "Chemical Viewed Functionally"@en . a owl:Class ; skos:notation "T100"^^xsd:string ; skos:prefLabel "Age Group"@en . a owl:Class ; skos:notation "T171"^^xsd:string ; skos:prefLabel "Language"@en . a owl:Class ; skos:notation "T032"^^xsd:string ; skos:prefLabel "Organism Attribute"@en . a owl:Class ; skos:notation "T095"^^xsd:string ; skos:prefLabel "Self-help or Relief Organization"@en . a owl:Class ; skos:notation "T078"^^xsd:string ; skos:prefLabel "Idea or Concept"@en . a owl:Class ; skos:notation "T090"^^xsd:string ; skos:prefLabel "Occupation or Discipline"@en . a owl:Class ; skos:notation "T167"^^xsd:string ; skos:prefLabel "Substance"@en . a owl:Class ; skos:notation "T068"^^xsd:string ; skos:prefLabel "Human-caused Phenomenon or Process"@en . a owl:Class ; skos:notation "T168"^^xsd:string ; skos:prefLabel "Food"@en . a owl:Class ; skos:notation "T028"^^xsd:string ; skos:prefLabel "Gene or Genome"@en . a owl:Class ; skos:notation "T014"^^xsd:string ; skos:prefLabel "Reptile"@en . a owl:Class ; skos:notation "T050"^^xsd:string ; skos:prefLabel "Experimental Model of Disease"@en . a owl:Class ; skos:notation "T045"^^xsd:string ; skos:prefLabel "Genetic Function"@en . a owl:Class ; skos:notation "T104"^^xsd:string ; skos:prefLabel "Chemical Viewed Structurally"@en . a owl:Class ; skos:notation "T011"^^xsd:string ; skos:prefLabel "Amphibian"@en . a owl:Class ; skos:notation "T013"^^xsd:string ; skos:prefLabel "Fish"@en . a owl:Class ; skos:notation "T094"^^xsd:string ; skos:prefLabel "Professional Society"@en . a owl:Class ; skos:notation "T087"^^xsd:string ; skos:prefLabel "Amino Acid Sequence"@en . a owl:Class ; skos:notation "T066"^^xsd:string ; skos:prefLabel "Machine Activity"@en . a owl:Class ; skos:notation "T185"^^xsd:string ; skos:prefLabel "Classification"@en . a owl:Class ; skos:notation "T049"^^xsd:string ; skos:prefLabel "Cell or Molecular Dysfunction"@en . a owl:Class ; skos:notation "T008"^^xsd:string ; skos:prefLabel "Animal"@en . a owl:Class ; skos:notation "T038"^^xsd:string ; skos:prefLabel "Biologic Function"@en . a owl:Class ; skos:notation "T194"^^xsd:string ; skos:prefLabel "Archaeon"@en . a owl:Class ; skos:notation "T086"^^xsd:string ; skos:prefLabel "Nucleotide Sequence"@en . a owl:Class ; skos:notation "T012"^^xsd:string ; skos:prefLabel "Bird"@en . a owl:Class ; skos:notation "T063"^^xsd:string ; skos:prefLabel "Molecular Biology Research Technique"@en . a owl:Class ; skos:notation "T017"^^xsd:string ; skos:prefLabel "Anatomical Structure"@en . a owl:Class ; skos:notation "T082"^^xsd:string ; skos:prefLabel "Spatial Concept"@en . a owl:Class ; skos:notation "T088"^^xsd:string ; skos:prefLabel "Carbohydrate Sequence"@en . a owl:Class ; skos:notation "T099"^^xsd:string ; skos:prefLabel "Family Group"@en . a owl:Class ; skos:notation "T001"^^xsd:string ; skos:prefLabel "Organism"@en . a owl:Class ; skos:notation "T096"^^xsd:string ; skos:prefLabel "Group"@en . a owl:Class ; skos:notation "T075"^^xsd:string ; skos:prefLabel "Research Device"@en . a owl:Class ; skos:notation "T072"^^xsd:string ; skos:prefLabel "Physical Object"@en . a owl:Class ; skos:notation "T071"^^xsd:string ; skos:prefLabel "Entity"@en . a owl:Class ; skos:notation "T200"^^xsd:string ; skos:prefLabel "Clinical Drug"@en . a owl:Class ; skos:notation "T085"^^xsd:string ; skos:prefLabel "Molecular Sequence"@en . a owl:Class ; skos:notation "T077"^^xsd:string ; skos:prefLabel "Conceptual Entity"@en . a owl:Class ; skos:notation "T010"^^xsd:string ; skos:prefLabel "Vertebrate"@en . a owl:Class ; skos:notation "T016"^^xsd:string ; skos:prefLabel "Human"@en . a owl:Class ; skos:notation "T021"^^xsd:string ; skos:prefLabel "Fully Formed Anatomical Structure"@en . a owl:Class ; skos:notation "T203"^^xsd:string ; skos:prefLabel "Drug Delivery Device"@en . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf . rdfs:subClassOf .